,pubmed_id,title,abstract,keywords,journal,publication_date,authors,methods,conclusions,results,copyrights,doi,xml
0,38262525,Potential therapeutic effects of Chinese herbal medicine in postpartum depression: Mechanisms and future directions.,"Postpartum depression (PPD) is a common psychiatric disorder in women after childbirth. Per data from epidemiologic studies, PPD affects about 5%-26.32% of postpartum mothers worldwide. Biological factors underlying this condition are multiple and complex and have received extensive inquiries for the roles they play in PPD. Chinese herbal medicine (CHM), which is widely used as a complementary and alternative therapy for neurological disorders, possesses multi-component, multi-target, multi-access, and low side effect therapeutic characteristics. CHM has already shown efficacy in the treatment of PPD, and a lot more research exploring the mechanisms of its potential therapeutic effects is being conducted.
This review provides an in-depth and comprehensive overview of the underlying mechanisms of PPD, as well as samples the progress made in researching the potential role of CHM in treating the disorder.
Literature was searched comprehensively in scholarly electronic databases, including PubMed, Web of Science, Scopus, CNKI and WanFang DATA, using the search terms ""postpartum depression"", ""genetic"", ""hormone"", ""immune"", ""neuroinflammation"", ""inflammation"", ""neurotransmitter"", ""neurogenesis"", ""brain-gut axis"", ""traditional Chinese medicine"", ""Chinese herbal medicine"", ""herb"", and an assorted combination of these terms.
PPD is closely associated with genetics, as well as with the hormones, immune inflammatory, and neurotransmitter systems, neurogenesis, and gut microbes, and these biological factors often interact and work together to cause PPD. For example, inflammatory factors could suppress the production of the neurotransmitter serotonin by inducing the regulation of tryptophan-kynurenine in the direction of neurotoxicity. Many CHM constituents improve anxiety- and depression-like behaviors by interfering with the above-mentioned mechanisms and have shown decent efficacy clinically against PPD. For example, Shen-Qi-Jie-Yu-Fang invigorates the neuroendocrine system by boosting the hormone levels of hypothalamic pituitary adrenal (HPA) and hypothalamic pituitary gonadal (HPG) axes, regulating the imbalance of Treg/T-helper cells (Th) 17 and Th1/Th2, and modulating neurotransmitter system to play antidepressant roles. The Shenguiren Mixture interferes with the extracellular signal-regulated kinase (ERK) pathway to enhance the number, morphology and apoptosis of neurons in the hippocampus of PPD rats. Other herbal extracts and active ingredients of CHM, such as Paeoniflorin, hypericin, timosaponin B-III and more, also manage depression by remedying the neuroendocrine system and reducing neuroinflammation.
The pathogenesis of PPD is complex and diverse, with the main pathogenesis not clear. Still, CHM constituents, like Shen-Qi-Jie-Yu-Fang, the Shenguiren Mixture, Paeoniflorin, hypericin and other Chinese Medicinal Formulae, active monomers and Crude extracts, treats PPD through multifaceted interventions. Therefore, developing more CHM components for the treatment of PPD is an essential step forward.","['Brain-gut axis', 'Chinese herbal medicine', 'Hormone', 'Inflammation', 'Neurotransmitter', 'Postpartum depression']",Journal of ethnopharmacology,2024-01-24,"[{'lastname': 'Xie', 'firstname': 'Hongxiao', 'initials': 'H', 'affiliation': 'State Key Laboratory of Southwestern Chinese Medicine Resources, School of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, 611137, PR China. Electronic address: xiehongxiao1106@163.com.'}, {'lastname': 'Xie', 'firstname': 'Zhiqiang', 'initials': 'Z', 'affiliation': 'State Key Laboratory of Southwestern Chinese Medicine Resources, School of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, 611137, PR China. Electronic address: Xiezhiqiang2408@163.com.'}, {'lastname': 'Luan', 'firstname': 'Fei', 'initials': 'F', 'affiliation': 'Shaanxi Province Key Laboratory of New Drugs and Chinese Medicine Foundation Research, Pharmacy College, Shaanxi University of Chinese Medicine, Xianyang, 712046, PR China. Electronic address: luanfeiren@163.com.'}, {'lastname': 'Zeng', 'firstname': 'Jiuseng', 'initials': 'J', 'affiliation': 'State Key Laboratory of Southwestern Chinese Medicine Resources, School of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, 611137, PR China. Electronic address: zengjiuseng@163.com.'}, {'lastname': 'Zhang', 'firstname': 'Xiumeng', 'initials': 'X', 'affiliation': 'State Key Laboratory of Southwestern Chinese Medicine Resources, School of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, 611137, PR China. Electronic address: zhangxiumeng@stu.cdutcm.edu.cn.'}, {'lastname': 'Chen', 'firstname': 'Li', 'initials': 'L', 'affiliation': 'State Key Laboratory of Southwestern Chinese Medicine Resources, School of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, 611137, PR China; Department of Pharmacy, Clinical Medical College and the First Affiliated Hospital of Chengdu Medical College, Chengdu, 610500, PR China. Electronic address: cyfy1219@163.com.'}, {'lastname': 'Zeng', 'firstname': 'Nan', 'initials': 'N', 'affiliation': 'State Key Laboratory of Southwestern Chinese Medicine Resources, School of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, 611137, PR China. Electronic address: 19932015@cdutcm.edu.cn.'}, {'lastname': 'Liu', 'firstname': 'Rong', 'initials': 'R', 'affiliation': 'State Key Laboratory of Southwestern Chinese Medicine Resources, School of Pharmacy, Chengdu University of Traditional Chinese Medicine, Chengdu, Sichuan, 611137, PR China. Electronic address: liurong_1116@163.com.'}]",,,"PPD is closely associated with genetics, as well as with the hormones, immune inflammatory, and neurotransmitter systems, neurogenesis, and gut microbes, and these biological factors often interact and work together to cause PPD. For example, inflammatory factors could suppress the production of the neurotransmitter serotonin by inducing the regulation of tryptophan-kynurenine in the direction of neurotoxicity. Many CHM constituents improve anxiety- and depression-like behaviors by interfering with the above-mentioned mechanisms and have shown decent efficacy clinically against PPD. For example, Shen-Qi-Jie-Yu-Fang invigorates the neuroendocrine system by boosting the hormone levels of hypothalamic pituitary adrenal (HPA) and hypothalamic pituitary gonadal (HPG) axes, regulating the imbalance of Treg/T-helper cells (Th) 17 and Th1/Th2, and modulating neurotransmitter system to play antidepressant roles. The Shenguiren Mixture interferes with the extracellular signal-regulated kinase (ERK) pathway to enhance the number, morphology and apoptosis of neurons in the hippocampus of PPD rats. Other herbal extracts and active ingredients of CHM, such as Paeoniflorin, hypericin, timosaponin B-III and more, also manage depression by remedying the neuroendocrine system and reducing neuroinflammation.",Copyright © 2024 Elsevier B.V. All rights reserved.,10.1016/j.jep.2024.117785,<Element 'PubmedArticle' at 0x7f05d8547f90>
1,"38257323
28904554
37797461
30901660
25792098
30417354
31910378
27722705
30205181
32094454
34067450
26795198
37761214
34716790
21749363
28861479
26870049
31156677
31525639
16540272
18060039
20698820
33000946
33722296
28120229
35163863
24144733
8598388
10386984
16192374
8784259
12887920
17487181
11596125
25110235
21360445
21527731
23393609
24360280
28602351
35215252
12684452
12796468
14597556
23867926
20037584
23812099
23254930
26939933
23708142
23623698
23150934
26933222
18701698
21148344
17891167
9974178
9526841
7556170
16387640
19074027
15371507
11916961
16452678
15390091
12667658
15385435
28653665
26271952
33383145
30418525
33978927
25601726
34053085
20153076
18848818
19565660
24999220
21785434
18574142
28624443
19900555
16672367
19052649
24600449
19910459
28087250
20196794
27038180
24778118
20929960
20600638
17140265
12858038
30152161
21175579
29986533
25252936
23204985
35956911
15837565
12598628
16389547
17592514
28973916
28230072
31748505
32387338
31831863
22971837
24727978
29338785
27430371
28853159
31686510
30056123
31084246
12378695
22940001
23941747
10594923
33669787
19476340
1753786
9458003
26065766
19774507
24455984
20937617
32091871
32858172
9721036
10331283
32116073
32417167
31438532
32284791
29992185
25857324
26590655
27918106
27696789
36551898
31559333
25171128
34569961
26904161
31187844
30687364
23478312
24634659
27303261
31104297
19896326
30258398
30250104
29940172
18053325
32269529
30689342
20393458
23108550
29751921
25479151",The Neurotherapeutic Arsenal in ,"Cannabis, renowned for its historical medicinal use, harbours various bioactive compounds-cannabinoids, terpenes, and flavonoids. While major cannabinoids like delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) have received extensive scrutiny for their pharmacological properties, emerging evidence underscores the collaborative interactions among these constituents, suggesting a collective therapeutic potential. This comprehensive review explores the intricate relationships and synergies between cannabinoids, terpenes, and flavonoids in cannabis. Cannabinoids, pivotal in cannabis's bioactivity, exhibit well-documented analgesic, anti-inflammatory, and neuroprotective effects. Terpenes, aromatic compounds imbuing distinct flavours, not only contribute to cannabis's sensory profile but also modulate cannabinoid effects through diverse molecular mechanisms. Flavonoids, another cannabis component, demonstrate anti-inflammatory, antioxidant, and neuroprotective properties, particularly relevant to neuroinflammation. The entourage hypothesis posits that combined cannabinoid, terpene, and flavonoid action yields synergistic or additive effects, surpassing individual compound efficacy. Recognizing the nuanced interactions is crucial for unravelling cannabis's complete therapeutic potential. Tailoring treatments based on the holistic composition of cannabis strains allows optimization of therapeutic outcomes while minimizing potential side effects. This review underscores the imperative to delve into the intricate roles of cannabinoids, terpenes, and flavonoids, offering promising prospects for innovative therapeutic interventions and advocating continued research to unlock cannabis's full therapeutic potential within the realm of natural plant-based medicine.","['Cannabis sativa', 'cannabinoids', 'entourage effects', 'flavonoids', 'neuroinflammatory', 'neuroprotective diseases', 'phytochemicals', 'synergistic effects', 'terpenes']","Molecules (Basel, Switzerland)",2024-01-23,"[{'lastname': 'Al-Khazaleh', 'firstname': 'Ahmad K', 'initials': 'AK', 'affiliation': 'NICM Health Research Institute, Western Sydney University, Penrith, NSW 2751, Australia.'}, {'lastname': 'Zhou', 'firstname': 'Xian', 'initials': 'X', 'affiliation': 'NICM Health Research Institute, Western Sydney University, Penrith, NSW 2751, Australia.'}, {'lastname': 'Bhuyan', 'firstname': 'Deep Jyoti', 'initials': 'DJ', 'affiliation': 'NICM Health Research Institute, Western Sydney University, Penrith, NSW 2751, Australia.\nSchool of Science, Western Sydney University, Penrith, NSW 2751, Australia.'}, {'lastname': 'Münch', 'firstname': 'Gerald W', 'initials': 'GW', 'affiliation': 'NICM Health Research Institute, Western Sydney University, Penrith, NSW 2751, Australia.\nPharmacology Unit, School of Medicine, Western Sydney University, Penrith, NSW 2751, Australia.'}, {'lastname': 'Al-Dalabeeh', 'firstname': 'Elaf Adel', 'initials': 'EA', 'affiliation': 'Department of Biological Sciences, School of Science, University of Jordan, Amman 11942, Jordan.'}, {'lastname': 'Jaye', 'firstname': 'Kayla', 'initials': 'K', 'affiliation': 'NICM Health Research Institute, Western Sydney University, Penrith, NSW 2751, Australia.'}, {'lastname': 'Chang', 'firstname': 'Dennis', 'initials': 'D', 'affiliation': 'NICM Health Research Institute, Western Sydney University, Penrith, NSW 2751, Australia.'}]",,,,,"10.3390/molecules29020410
10.1155/2017/3574012
10.1016/j.biopha.2023.115596
10.1016/j.phymed.2019.152889
10.1016/S1474-4422(15)70016-5
10.1002/jcp.27725
10.1016/j.cub.2019.10.039
10.1039/C6NP00074F
10.1016/j.jep.2018.09.004
10.1038/s41598-020-60172-6
10.3390/agronomy13030931
10.1007/s10681-004-4811-6
10.3390/ijms22115479
10.3390/foods12183505
10.1016/j.tifs.2020.10.004
10.1007/s00394-021-02711-z
10.1111/j.1476-5381.2011.01238.x
10.1016/j.cropro.2018.11.003
10.1089/can.2015.29003.ebr
10.1007/s12229-015-9157-3
10.1007/s00334-019-00731-8
10.3389/fpls.2016.00019
10.1007/s12229-015-9158-2
10.3389/fpls.2019.00614
10.1016/j.drugpo.2019.09.001
10.1016/j.jep.2006.02.001
10.1016/j.cnr.2006.09.006
10.2174/138161210793176572
10.1021/acs.jnatprod.0c00241
10.1186/s42238-021-00062-4
10.3390/molecules27030604
10.1016/j.neures.2013.10.004
10.1016/0165-5728(95)00148-4
10.1046/j.1471-4159.1999.0730309.x
10.1523/JNEUROSCI.2868-05.2005
10.1016/0165-5728(96)00056-2
10.1016/S0092-8674(03)00521-X
10.1038/nprot.2006.327
10.1002/glia.1106
10.1016/j.brainres.2014.07.050
10.1152/physrev.00011.2010
10.1371/journal.pone.0056293
10.1016/j.cell.2013.11.030
10.1016/j.cell.2017.05.018
10.3390/ph15020140
10.1523/JNEUROSCI.23-07-02665.2003
10.1084/jem.20021546
10.1096/fj.03-0364fje
10.1038/ni.2668
10.1038/ni.1836
10.1038/ni.2639
10.1038/nature11729
10.1186/s13024-016-0088-1
10.1038/nn.3435
10.1016/j.neuron.2013.04.014
10.1056/NEJMoa1211851
10.1073/pnas.1600852113
10.1523/JNEUROSCI.0616-08.2008
10.1126/science.1197623
10.1038/sj.bjp.0707458
10.1006/nbdi.1998.0221
10.1016/S0165-5728(97)00181-1
10.1111/j.1432-1033.1995.tb20780.x
10.1016/j.neuron.2005.11.027
10.1523/JNEUROSCI.0847-08.2008
10.1523/JNEUROSCI.2419-04.2004
10.1074/jbc.M110813200
10.1523/JNEUROSCI.3101-05.2006
10.1002/glia.20108
10.1016/S0165-5728(03)00045-6
10.1096/fj.04-2190fje
10.1038/npp.2017.130
10.1007/s13311-015-0374-6
10.1016/j.bbi.2020.12.024
10.1093/ecco-jcc/jjy185
10.1007/s12079-021-00622-6
10.1007/s11481-015-9584-2
10.1111/imm.13378
10.1016/j.imbio.2009.12.006
10.1016/j.bcp.2008.09.014
10.1002/glia.20907
10.1016/j.pbb.2014.06.025
10.1038/nn.2874
10.1073/pnas.0803601105
10.1016/j.taap.2017.06.016
10.1016/j.nbd.2009.10.023
10.1073/pnas.0511232103
10.3389/fimmu.2014.00058
10.1074/jbc.M109.069294
10.1016/j.yebeh.2016.11.016
10.1111/j.1528-1167.2010.02523.x
10.1007/s00109-016-1404-5
10.1128/IAI.01666-14
10.1093/brain/awq278
10.1016/j.neuroscience.2010.06.056
10.1021/mp060066m
10.1097/00001756-200305060-00007
10.1111/head.13345
10.1016/j.procbio.2021.08.025
10.1111/j.1476-5381.2010.01166.x
10.3390/ijms19071992
10.1007/s13311-014-0304-z
10.2174/157015912800604515
10.3390/molecules27154961
10.1016/j.nbd.2004.11.009
10.1523/JNEUROSCI.23-04-01398.2003
10.1007/s00109-005-0025-1
10.1038/sj.bjp.0707337
10.1073/pnas.1711351114
10.1038/npp.2017.40
10.1038/s41398-019-0654-8
10.1016/j.nbd.2020.104892
10.1038/s41582-019-0284-z
10.1007/s11481-012-9399-3
10.1371/journal.pone.0094733
10.1186/s12974-018-1060-5
10.1038/srep29789
10.1111/bph.14019
10.1021/acs.jnatprod.9b00600
10.1016/j.neuropharm.2018.07.029
10.1177/0269881119844184
10.1053/ejpn.2002.0612
10.1016/j.neuropharm.2012.08.010
10.1016/j.neuint.2013.08.002
10.1002/(SICI)1098-1136(20000101)29:1<58::AID-GLIA6>3.0.CO;2-W
10.1007/978-3-030-31269-5_15
10.3390/molecules26041107
10.1016/j.fbio.2022.101951
10.1021/np800740m
10.1016/0378-8741(91)90187-I
10.1016/S0300-483X(97)00144-3
10.1002/ffj.2002
10.1016/j.foodchem.2007.11.046
10.1055/s-0029-1186085
10.1021/np400828x
10.1177/0269881110385594
10.1021/acschemneuro.0c00075
10.1016/j.fitote.2020.104712
10.1016/S0014-2999(98)00392-6
10.1039/a703973e
10.1080/17512433.2020.1721281
10.1016/j.tplants.2020.04.007
10.3390/molecules24173031
10.18632/oncotarget.27528
10.1089/can.2018.0010
10.1111/bph.13159
10.1016/j.msard.2015.08.001
10.1002/jcb.25815
10.1002/cam4.816
10.3390/biomedicines10123142
10.1089/can.2019.0016
10.1159/000362689
10.3233/JAD-210735
10.1155/2016/2986796
10.1039/C9NP00011A
10.3389/fpls.2018.01969
10.3233/JAD-130050
10.3389/fphar.2014.00037
10.3389/fnins.2016.00243
10.1007/s12035-019-1637-8
10.1016/j.jpainsymman.2009.06.008
10.3389/fneur.2018.00759
10.1038/s41598-018-32651-4
10.1016/j.bcp.2018.06.025
10.1211/jpp.59.12.0005
10.3389/fphar.2020.00359
10.1021/acschemneuro.8b00651
10.1038/npp.2010.19
10.1098/rstb.2011.0388
10.1016/j.foodchem.2018.04.078
10.1016/j.phanu.2014.05.001
10.1155/2014/754693",<Element 'PubmedArticle' at 0x7f05da841040>
2,"38250049
34614409
29424317
9737646
3075276
7575771
32737252
31144547
20704527
31389309
31727409
33808030
28614708
28153798
30404008
31495690
19144836
22201683
30140371
36915539
34407830
36223777
34841227
32188837
17587760
28683288
15382020
18279013
25497089
24107256
18832722
28949382
25874616
17965192
33472023
9729044
23356264
24657242
16596808
10776745
31549442
31577260
27616557
34430820
24560969
27932556
30563192
33024813
32449761
29705240
9687370
33208407
32504036
31927141
32795415
30500539
31056798
31959954
31086327
36328744",Palmitoylation of PKCδ by ZDHHC5 in hypothalamic microglia presents as a therapeutic target for fatty liver disease.,"The hypothalamus plays a fundamental role in controlling lipid metabolism through neuroendocrine signals. However, there are currently no available drug targets in the hypothalamus that can effectively improve human lipid metabolism. In this study, we found that the antimalarial drug artemether (ART) significantly improved lipid metabolism by specifically inhibiting microglial activation in the hypothalamus of high-fat diet-induced mice. Mechanically, ART protects the thyrotropin-releasing hormone (TRH) neurons surrounding microglial cells from inflammatory damage and promotes the release of TRH into the peripheral circulation. As a result, TRH stimulates the synthesis of thyroid hormone (TH), leading to a significant improvement in hepatic lipid disorders. Subsequently, we employed a biotin-labeled ART chemical probe to identify the direct cellular target in microglial cells as protein kinase Cδ (PKCδ). Importantly, ART directly targeted PKCδ to inhibit its palmitoylation modification by blocking the binding of zinc finger DHHC-type palmitoyltransferase 5 (ZDHHC5), which resulted in the inhibition of downstream neuroinflammation signaling. In vivo, hypothalamic microglia-specific PKCδ knockdown markedly impaired ART-dependent neuroendocrine regulation and lipid metabolism improvement in mice. Furthermore, single-cell transcriptomics analysis in human brain tissues revealed that the level of PKCδ in microglia positively correlated with individuals who had hyperlipemia, thereby highlighting a clinical translational value. Collectively, these data suggest that the palmitoylation of microglial PKCδ in the hypothalamus plays a role in modulating peripheral lipid metabolism through hypothalamus-liver communication, and provides a promising therapeutic target for fatty liver diseases.","['artemether', 'hepatic lipid metabolism', 'hypothalamic microglia', 'palmitoylation modification', 'protein kinase Cδ (PKCδ)']",Theranostics,2024-01-22,"[{'lastname': 'Wang', 'firstname': 'Yan-Hang', 'initials': 'YH', 'affiliation': 'State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing 100191, China.'}, {'lastname': 'Chen', 'firstname': 'Xin', 'initials': 'X', 'affiliation': 'Department of Neurosurgery, Peking University Third Hospital, Beijing 100191, China.'}, {'lastname': 'Bai', 'firstname': 'Yi-Zhen', 'initials': 'YZ', 'affiliation': 'State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing 100191, China.'}, {'lastname': 'Gao', 'firstname': 'Peng', 'initials': 'P', 'affiliation': 'State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing 100191, China.'}, {'lastname': 'Yang', 'firstname': 'Zhuo', 'initials': 'Z', 'affiliation': 'State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing 100191, China.'}, {'lastname': 'Guo', 'firstname': 'Qiang', 'initials': 'Q', 'affiliation': 'State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing 100191, China.'}, {'lastname': 'Lu', 'firstname': 'Ying-Yuan', 'initials': 'YY', 'affiliation': 'State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing 100191, China.'}, {'lastname': 'Zheng', 'firstname': 'Jiao', 'initials': 'J', 'affiliation': 'School of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing 100102, China.'}, {'lastname': 'Liu', 'firstname': 'Dan', 'initials': 'D', 'affiliation': 'Proteomics Laboratory, Medical and Healthy Analytical Center, Peking University Health Science Center, Beijing 100191, China.'}, {'lastname': 'Yang', 'firstname': 'Jun', 'initials': 'J', 'affiliation': 'Department of Neurosurgery, Peking University Third Hospital, Beijing 100191, China.'}, {'lastname': 'Tu', 'firstname': 'Peng-Fei', 'initials': 'PF', 'affiliation': 'State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing 100191, China.'}, {'lastname': 'Zeng', 'firstname': 'Ke-Wu', 'initials': 'KW', 'affiliation': 'State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing 100191, China.'}]",,,,© The author(s).,10.7150/thno.89602,<Element 'PubmedArticle' at 0x7f05de1e4c20>
3,"38246956
29754747
7920638
30334074
29985474
22784036
23477989
15379294
16981857
27443609
31097468
33560670
29275859
22018233
28930663
11704183
23460719
26285177
9037091
34854884
9343467
19595937
28874832
16906128
11796757
30627643
25991443
18045930
15081593
12515896
12700177
36307876
35440664
30291623
35618840
34127866
29892276
36721148
36755206
37315112
3828426",Early modulation of the gut microbiome by female sex hormones alters amyloid pathology and microglial function.,"It is well-established that women are disproportionately affected by Alzheimer's disease. The mechanisms underlying this sex-specific disparity are not fully understood, but several factors that are often associated-including interactions of sex hormones, genetic factors, and the gut microbiome-likely contribute to the disease's etiology. Here, we have examined the role of sex hormones and the gut microbiome in mediating Aβ amyloidosis and neuroinflammation in APPPS1-21 mice. We report that postnatal gut microbiome perturbation in female APPPS1-21 mice leads to an elevation in levels of circulating estradiol. Early stage ovariectomy (OVX) leads to a reduction of plasma estradiol that is correlated with a significant alteration of gut microbiome composition and reduction in Aβ pathology. On the other hand, supplementation of OVX-treated animals with estradiol restores Aβ burden and influences gut microbiome composition. The reduction of Aβ pathology with OVX is paralleled by diminished levels of plaque-associated microglia that acquire a neurodegenerative phenotype (MGnD-type) while estradiol supplementation of OVX-treated animals leads to a restoration of activated microglia around plaques. In summary, our investigation elucidates the complex interplay between sex-specific hormonal modulations, gut microbiome dynamics, metabolic perturbations, and microglial functionality in the pathogenesis of Alzheimer's disease.",[],Scientific reports,2024-01-22,"[{'lastname': 'Saha', 'firstname': 'Piyali', 'initials': 'P', 'affiliation': 'Department of Neurobiology, The University of Chicago, Chicago, IL, USA.'}, {'lastname': 'Weigle', 'firstname': 'Ian Q', 'initials': 'IQ', 'affiliation': 'Department of Neurobiology, The University of Chicago, Chicago, IL, USA.'}, {'lastname': 'Slimmon', 'firstname': 'Nicholas', 'initials': 'N', 'affiliation': 'School of Biomedical Sciences, UT Southwestern Medical Center, Dallas, TX, USA.'}, {'lastname': 'Poli', 'firstname': 'Pedro Blauth', 'initials': 'PB', 'affiliation': 'Department of Neurobiology, The University of Chicago, Chicago, IL, USA.'}, {'lastname': 'Patel', 'firstname': 'Priyam', 'initials': 'P', 'affiliation': 'Center for Genetic Medicine, Northwestern University, Chicago, IL, USA.'}, {'lastname': 'Zhang', 'firstname': 'Xiaoqiong', 'initials': 'X', 'affiliation': 'Department of Neurobiology, The University of Chicago, Chicago, IL, USA.'}, {'lastname': 'Cao', 'firstname': 'Yajun', 'initials': 'Y', 'affiliation': 'Genomic Facility, The University of Chicago, Chicago, IL, USA.'}, {'lastname': 'Michalkiewicz', 'firstname': 'Julia', 'initials': 'J', 'affiliation': 'Department of Physiology and Biophysics, The University of Illinois, Chicago, IL, USA.'}, {'lastname': 'Gomm', 'firstname': 'Ashley', 'initials': 'A', 'affiliation': 'Department of Neurology, Harvard Medical School, Boston, MA, USA.'}, {'lastname': 'Zhang', 'firstname': 'Can', 'initials': 'C', 'affiliation': 'Department of Neurology, Harvard Medical School, Boston, MA, USA.'}, {'lastname': 'Tanzi', 'firstname': 'Rudolph E', 'initials': 'RE', 'affiliation': 'Department of Neurology, Harvard Medical School, Boston, MA, USA.'}, {'lastname': 'Dylla', 'firstname': 'Nicholas', 'initials': 'N', 'affiliation': 'Duchossois Family Institute, The University of Chicago, Chicago, IL, USA.'}, {'lastname': 'Al-Hendy', 'firstname': 'Ayman', 'initials': 'A', 'affiliation': 'Department of Obstetrics and Gynecology, The University of Chicago, Chicago, IL, USA.'}, {'lastname': 'Sisodia', 'firstname': 'Sangram S', 'initials': 'SS', 'affiliation': 'Department of Neurobiology, The University of Chicago, Chicago, IL, USA. ssisodia@bsd.uchicago.edu.'}]",,,,© 2024. The Author(s).,"10.1038/s41598-024-52246-6
10.1016/j.neurobiolaging.2018.04.004
10.1038/ng0694-180
10.1007/s00401-018-1920-1
10.1038/s41582-018-0032-9
10.1056/NEJMoa1202753
10.1016/S1474-4422(13)70044-9
10.3949/ccjm.71.Suppl_2.S4
10.1111/j.1528-1167.2006.00672.x
10.1038/srep30028
10.1084/jem.20182386
10.1097/WCO.0000000000000911
10.1016/j.cell.2017.11.042
10.1016/j.chom.2011.10.003
10.1016/j.immuni.2017.08.008
10.1210/er.2012-1055
10.1016/j.lfs.2015.08.004
10.1073/pnas.94.4.1550
10.1084/jem.20200895
10.1001/jama.1997.03550160069041
10.1016/j.jalz.2007.04.381
10.1038/s41598-017-11047-w
10.1038/sj.embor.7400784
10.1046/j.0022-3042.2001.00690.x
10.1038/nrn3880
10.1523/JNEUROSCI.2718-07.2007
10.1016/j.expneurol.2004.01.015
10.3233/JAD-2002-4601
10.1210/er.2001-0016
10.1186/s13293-022-00466-8
10.1038/s41467-022-29903-3
10.1002/cne.24551
10.1038/s41386-022-01349-7
10.1038/s41684-021-00777-0
10.3389/fmicb.2018.01085
10.1186/s13024-023-00595-7
10.30802/AALAS-JAALAS-22-000068
10.1126/scitranslmed.abo2984
10.1095/biolreprod35.5.1088",<Element 'PubmedArticle' at 0x7f05de21ce50>
4,38242042,Essential oil of Pterocarpus santalinus L. alleviates behavioral impairments in social defeat stress-exposed mice by regulating neurotransmission and neuroinflammation.,"Pterocarpus santalinus L. essential oil (PSEO) is traditionally employed for treating fever and mental aberrations. We aim to explore the antidepressant potential of intranasal PSEO in social defeat stress (SDS)-expose mice and identify its mechanisms and components.
PSEO components were analyzed using gas chromatography-mass spectrometry (GC-MS). C57BL/6 mice underwent a 10-day SDS with intranasal PSEO (10, 20 mg/kg) for 21 days. Efficacy was evaluated through changes in behaviors and serum corticosterone (CORT), hippocampal neurotransmitter, and inflammatory cytokine levels. In vitro effects were examined using primary hippocampal neurons, PC12 and BV2 cells.
GC-MS identified 22 volatile compounds in PSEO, and (+)-ledene (16.7%), cedrol (13.5%), and isoaromadendrene epoxide (7.0%) as major components. PSEO (20 mg/kg) significantly reversed SDS-induced social withdrawal, increased open-area explorations in the open field test (OFT) and elevated plus maze (EPM) test, and reduced immobility time in the tail suspension test (TST) and forced swimming test (FST). PSEO downregulated serum CORT and hippocampal interleukin (IL)-1β, IL-6, and tumor necrosis factor (TNF)-α levels, while increasing hippocampal gamma-aminobutyric acid (GABA), norepinephrine (NE), and serotonin (5-HT) levels. PSEO (0.1, 1, 10 µg/mL) reduced neurotoxicity and neuroinflammation in PC12 and BV2 cells, respectively. PSEO (10 µg/mL) enhanced glutamic acid decarboxylase 6 (GAD6)- and GABA B receptor 1 (GABABR1)-positive puncta in the hippocampal neurons and FM1-43 fluorescence intensity.
Intranasal PSEO exhibited antidepressant-like effects on SDS-exposed mice, potentially through modulating stress hormone, neurotransmission, and neuroinflammation. Further investigation into the pharmacokinetics, bioavailability, and mechanisms of (+)-ledene, cedrol, and isoaromadendrene epoxide is needed.","['Depression', 'Essential oil', 'Intranasal administration', 'Pterocarpus santalinus L.', 'Red sandalwood', 'Stress resilience']",Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie,2024-01-20,"[{'lastname': 'Nguyen', 'firstname': 'Ly Thi Huong', 'initials': 'LTH', 'affiliation': 'Department of Physiology, Dongguk University College of Korean Medicine, Gyeongju 38066, Republic of Korea; Department of Pathology, University of Alabama at Birmingham, Birmingham, AL 35294, USA.'}, {'lastname': 'Nguyen', 'firstname': 'Nhi Phuc Khanh', 'initials': 'NPK', 'affiliation': 'Department of Physiology, Dongguk University College of Korean Medicine, Gyeongju 38066, Republic of Korea.'}, {'lastname': 'Tran', 'firstname': 'Khoa Nguyen', 'initials': 'KN', 'affiliation': 'Department of Physiology, Dongguk University College of Korean Medicine, Gyeongju 38066, Republic of Korea.'}, {'lastname': 'Choi', 'firstname': 'Ho Jin', 'initials': 'HJ', 'affiliation': 'Department of Anatomy, Dongguk University College of Medicine, and Medical Institute of Dongguk University, Gyeongju, Republic of Korea.'}, {'lastname': 'Moon', 'firstname': 'Il Soo', 'initials': 'IS', 'affiliation': 'Department of Anatomy, Dongguk University College of Medicine, Gyeongju 38066, Republic of Korea.'}, {'lastname': 'Shin', 'firstname': 'Heung-Mook', 'initials': 'HM', 'affiliation': 'Department of Physiology, Dongguk University College of Korean Medicine, Gyeongju 38066, Republic of Korea.'}, {'lastname': 'Yang', 'firstname': 'In-Jun', 'initials': 'IJ', 'affiliation': 'Department of Physiology, Dongguk University College of Korean Medicine, Gyeongju 38066, Republic of Korea. Electronic address: injuny@dongguk.ac.kr.'}]",,"Intranasal PSEO exhibited antidepressant-like effects on SDS-exposed mice, potentially through modulating stress hormone, neurotransmission, and neuroinflammation. Further investigation into the pharmacokinetics, bioavailability, and mechanisms of (+)-ledene, cedrol, and isoaromadendrene epoxide is needed.","GC-MS identified 22 volatile compounds in PSEO, and (+)-ledene (16.7%), cedrol (13.5%), and isoaromadendrene epoxide (7.0%) as major components. PSEO (20 mg/kg) significantly reversed SDS-induced social withdrawal, increased open-area explorations in the open field test (OFT) and elevated plus maze (EPM) test, and reduced immobility time in the tail suspension test (TST) and forced swimming test (FST). PSEO downregulated serum CORT and hippocampal interleukin (IL)-1β, IL-6, and tumor necrosis factor (TNF)-α levels, while increasing hippocampal gamma-aminobutyric acid (GABA), norepinephrine (NE), and serotonin (5-HT) levels. PSEO (0.1, 1, 10 µg/mL) reduced neurotoxicity and neuroinflammation in PC12 and BV2 cells, respectively. PSEO (10 µg/mL) enhanced glutamic acid decarboxylase 6 (GAD6)- and GABA B receptor 1 (GABABR1)-positive puncta in the hippocampal neurons and FM1-43 fluorescence intensity.",Copyright © 2024. Published by Elsevier Masson SAS.,10.1016/j.biopha.2024.116164,<Element 'PubmedArticle' at 0x7f05d843b630>
5,"38225412
31713152
35309625
34418564
36359390
29498103
32706187
36432051
25858697
25401971
32375205
27499754
26676145
31192707
27238369
22527998
15033929
31600601
23340221
31327964
34202842
28648359
33428242
35326182
25301688
29255243
29077529
36307249
32327687
29602294
31638842
21951153
26740407
28703738
24509309
22212051
34069523
32157560
32784556
32729676
37774554
29352484
32825327
29854017
30215696
23971978
29907977
33441154
25930714
24995391
29898451
25454643
31726890
26359987
29104591
15964511
30611799
29497878
34658636
37777162
26004526
22804755
35334234
37521462
26036976
30862067
35248827
25991443
25612238
21486366
31209782
37881313
34455956
29729237
34769277
32806490
37445309
35437700
36632077
24342563
32673435
21184755
34100322
33635478
34440122
29973144
31640239
28192673
18289173
19221418
31666560
32998479
32941923
35185525
25236562
21407167
31333809
35881170
23995234
22725668
31664453
31614181
23621307
20878262
28400813
36611925
31831203
22952551
22982225
23698762
29759891
37429996
31742766
35607703
35008896
31773776
34087957
28554133
34177671
22739839
21741988
29138117
29425728
23402899
33020940
29242522
37097427
36015107
31330909
27500468
29495303
21600349
23528889
21163446
34202125
26654775
23985544
31763180
28419991
35606613
36049659
30756405
20964710
22245784
24959861
16179266
33546386
33957167
26985725
34679663
17198536
27999288
29385085
35682631
35219702
23952810
33081671
28503116
27180068
33014290
28664509
29441009
27121187
35893061
31795242
26310973
29653348
31185581
25713608
15230863
17401652
27645169
33165196
34929236
17014688
25248807
24315928
28293167
25401748
35455066
25752877
27047496
31757938
30459555
34267535",Modulation of neural circuits by melatonin in neurodegenerative and neuropsychiatric disorders.,"Neurodegenerative and neuropsychiatric disorders are two broad categories of neurological disorders characterized by progressive impairments in movement and cognitive functions within the central and peripheral nervous systems, and have emerged as a significant cause of mortality. Oxidative stress, neuroinflammation, and neurotransmitter imbalances are recognized as prominent pathogenic factors contributing to cognitive deficits and neurobehavioral anomalies. Consequently, preventing neurodegenerative and neuropsychiatric diseases has surfaced as a pivotal challenge in contemporary public health. This review explores the investigation of neurodegenerative and neuropsychiatric disorders using both synthetic and natural bioactive compounds. A central focus lies on melatonin, a neuroregulatory hormone secreted by the pineal gland in response to light-dark cycles. Melatonin, an amphiphilic molecule, assumes multifaceted roles, including scavenging free radicals, modulating energy metabolism, and synchronizing circadian rhythms. Noteworthy for its robust antioxidant and antiapoptotic properties, melatonin exhibits diverse neuroprotective effects. The inherent attributes of melatonin position it as a potential key player in the pathophysiology of neurological disorders. Preclinical and clinical studies have demonstrated melatonin's efficacy in alleviating neuropathological symptoms across neurodegenerative and neuropsychiatric conditions (depression, schizophrenia, bipolar disorder, and autism spectrum disorder). The documented neuroprotective prowess of melatonin introduces novel therapeutic avenues for addressing neurodegenerative and psychiatric disorders. This comprehensive review encompasses many of melatonin's applications in treating diverse brain disorders. Despite the strides made, realizing melatonin's full neuroprotective potential necessitates further rigorous clinical investigations. By unravelling the extended neuroprotective benefits of melatonin, future studies promise to deepen our understanding and augment the therapeutic implications against neurological deficits.","['Anti-inflammatory', 'Antioxidant', 'Melatonin', 'Neurodegenerative diseases', 'Neuropsychiatric diseases']",Naunyn-Schmiedeberg's archives of pharmacology,2024-01-16,"[{'lastname': 'Giri', 'firstname': 'Aditi', 'initials': 'A', 'affiliation': 'Division of Neuroscience, Department of Pharmacology, ISF College of Pharmacy Moga, Punjab, India.'}, {'lastname': 'Mehan', 'firstname': 'Sidharth', 'initials': 'S', 'affiliation': 'Division of Neuroscience, Department of Pharmacology, ISF College of Pharmacy Moga, Punjab, India. sidh.mehan@gmail.com.\nIK Gujral Punjab Technical University, Jalandhar, Punjab, 144603, India. sidh.mehan@gmail.com.'}, {'lastname': 'Khan', 'firstname': 'Zuber', 'initials': 'Z', 'affiliation': 'Division of Neuroscience, Department of Pharmacology, ISF College of Pharmacy Moga, Punjab, India.\nIK Gujral Punjab Technical University, Jalandhar, Punjab, 144603, India.'}, {'lastname': 'Das Gupta', 'firstname': 'Ghanshyam', 'initials': 'G', 'affiliation': 'Department of Pharmaceutics, ISF College of Pharmacy, Moga, Punjab, India.'}, {'lastname': 'Narula', 'firstname': 'Acharan S', 'initials': 'AS', 'affiliation': 'Narula Research, LLC, 107 Boulder Bluff, Chapel Hill, NC, 27516, USA.'}, {'lastname': 'Kalfin', 'firstname': 'Reni', 'initials': 'R', 'affiliation': 'Institute of Neurobiology, Bulgarian Academy of Sciences, Acad. G. Bonchev St., Block 23, Sofia, 1113, Bulgaria.\nDepartment of Healthcare, South-West University ""NeofitRilski"", Ivan Mihailov St. 66, Blagoevgrad, 2700, Bulgaria.'}]",,,,"© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.","10.1007/s00210-023-02939-y
10.1007/s12031-019-01425-6
10.4103/jfmpc.jfmpc_1839_21
10.1016/j.phrs.2021.105839
10.3390/biomedicines10112866
10.1002/jnr.24220
10.31083/j.jin.2020.02.32
10.3390/molecules27227951
10.1111/jpi.12238
10.1111/jpi.12194
10.1111/jpi.12667
10.3389/fimmu.2016.00278
10.1152/physrev.00007.2015
10.1111/jpi.12442
10.1080/17446651.2019.1631158
10.1111/aas.12747
10.1007/s11011-012-9307-9
10.1096/fj.03-1031fje
10.1016/j.arcmed.2019.08.005
10.1016/j.ejphar.2013.01.007
10.3389/fendo.2019.00391
10.3389/fimmu.2019.01511
10.3390/antiox10071020
10.14715/cmb/2021.67.3.13
10.1016/j.smrv.2016.06.005
10.1007/s00406-016-0711-8
10.1002/mus.27168
10.3390/antiox11030532
10.1016/j.brainres.2014.09.068
10.1016/j.physbeh.2015.06.040
10.1038/s41598-017-18016-3
10.1080/00207454.2017.1398156
10.1016/j.npep.2022.102296
10.1038/s41598-020-63986-6
10.1556/2060.105.2018.1.1
10.1016/j.jstrokecerebrovasdis.2021.105864
10.1016/j.parkreldis.2016.05.012
10.1080/14656566.2019.1674283
10.1016/j.comppsych.2016.03.005
10.1111/j.1600-079X.2011.00962.x
10.1016/j.schres.2018.08.018
10.1016/j.brainres.2015.12.03
10.1096/fj.14-265678
10.3390/ijms18071439
10.1016/j.bbr.2014.01.048
10.1111/j.1600-079X.2011.00945.x
10.3390/ijms22105343
10.1007/s10974-020-09578-3
10.3390/biom10081158
10.1111/jcmm.15654
10.1016/j.jneuroim.2023.578200
10.1111/jpi.12470
10.3390/biom10091211
10.1155/2016/6842568
10.1155/2018/1849794
10.1210/er.2018-00084
10.1503/jpn.130009
10.1111/jpi.12515
10.1186/s13024-021-00424-9
10.1016/j.jns.2015.03.040
10.1016/j.clineuro.2020.105878
10.1177/1759091420981204
10.1016/j.cophys.2019.12.015
10.1016/j.neuint.2014.06.015
10.1159/000489470
10.1038/s41572-021-00248-3
10.3233/adr-190125
10.1016/j.jns.2014.10.009
10.1080/13813455.2019.1684954
10.1016/j.msard.2022.103520
10.1093/hmg/dds227
10.1016/j.cell.2015.08.025
10.1155/2017/1835195
10.1016/j.freeradbiomed.2005.03.007
10.1016/j.pnpbp.2022.110626
10.1007/s00213-016-4272-3
10.1111/jpi.12421.10.1111/jpi.12421
10.1089/rej.2015.1704
10.1016/j.neubiorev.2018.12.025
10.1007/s10571-018-0580-y
10.29399/npa.27467
10.1016/j.bcp.2023.115831
10.1016/j.ejphar.2015.05.032
10.1111/j.1600-079x.2012.01023.x
10.1016/S1474-4422(21)00414-2
10.1101/cshperspect.a024117
10.1016/j.jaac.2017.09.414
10.3389/fphar.2023.1218506
10.1016/j.neurol.2019.07.025
10.2174/1567202612666150603130235
10.1016/j.jstrokecerebrovasdis.2016.07.023
10.1100/2012/640389
10.3390/ijms20051223
10.1016/j.redox.2022.102251
10.1038/nrn3880
10.1111/jpi.12210
10.1111/j.1600-079x.2011.00871.x
10.1007/s12035-019-01660-3
10.3389/fneur.2023.1265789
10.2174/1574884716666210726110021
10.1016/j.amjmed.2018.04.009
10.1155/2021/5577541
10.3390/ijms222111847
10.1002/mds.26003
10.1177/2167702614521188
10.1007/s10072-018-3585-x
10.1590/s1516-31802012000300006
10.3390/biomedicines8080284
10.3390/jcm12134274
10.1007/s12035-022-02819-1
10.12793/tcp.2022.30.e21
10.1186/s12974-014-0218-z
10.1016/j.neuroscience.2013
10.1111/apa.15485
10.1016/j.expneurol.2010.12.0
10.1080/07420528.2021.1930028
10.1007/s11011-021-00691-x
10.3390/biomedicines9080918
10.4088/JCP.10m06347yel
10.1186/s12868-018-0439-7
10.3390/brainsci9100285
10.1139/apnm-2016-0677
10.1111/j.1600-079X.2007.00510.x
10.3233/JAD-2009-0949
10.1146/annurev-pharmtox-010814-124742
10.1038/s41598-019-52058-z
10.1155/2015/504678
10.3390/ijms21197174
10.1016/j.pnpbp.2020.110109
10.1155/2018/9286458
10.3389/fnagi.2022.784314
10.1007/7854_2010_51
10.1055/a-0656-6643
10.1016/j.ejbas.2016.07.001
10.1007/s00228-022-03363-6
10.1007/s10803-011-1418-3
10.3171/2018.3.JNS172274
10.1111/febs.15716
10.1038/ni.2695
10.1111/j.1600-079X.2012.01014.x
10.1001/jamapsychiatry.2019.3360
10.1016/j.neulet.2019.134539
10.1586/ern.13.39
10.1007/s12031-010-9454-6
10.4103/1673-5374.200812
10.4103/ijp.IJP_11_18
10.4103/1673-5374.270316
10.2147/DNND.S247153
10.1038/s41398-021-01464-x
10.1111/bcp.12092
10.1016/j.pnpbp.2011.11.003
10.3390/cells12010131
10.1111/nyas.14436
10.1016/j.euroneuro.2019.11.0
10.1172/JCI45691
10.1016/j.mrfmmm.2012.08.006
10.1016/j.pnpbp.2020.110162
10.3390/ijms14059037
10.1016/j.smrv.2018.03.007
10.1007/s10787-023-01271-4
10.1111/jpi.12624
10.1007/s11481-018-9824-3
10.1155/2022/4759963
10.3390/ijms23010471
10.1111/jpi.12627
10.1007/s12640-012-9331-x
10.1016/j.pharep.2016.04.003
10.1002/brb3.2227
10.1016/j.biopha.2017.05.094
10.3389/fpsyt.2021.688890
10.1007/s12640-012-9337-4
10.1177/1074248416660622
10.1155/2019/9626715
10.1016/j.pbb.2011.06.026
10.1016/j.lfs.2017.11.016
10.1016/j.phrs.2018.01.018
10.1016/j.neurobiolaging.2012.12.010
10.1111/jpi.12699
10.1038/nrneurol.2017.162
10.1007/s10522-023-10034-1
10.1080/10715762.2020.1774575
10.1038/s41440-018-0066-9
10.1177/09603271211013456
10.3390/ph15080959
10.3390/cells8070760
10.1016/j.comptc.2017.11.017
10.1111/jpi.12360
10.3390/molecules23020509
10.1016/j.bbrc.2022.03.025
10.1016/j.pcl.2011.03.009
10.3390/ijms14046597
10.1016/b978-0-12-405933-7.00018-4
10.1016/S1474-4422(10)70245-3
10.3390/ijms22136841
10.2174/1381612822666151214104624
10.1517/13543784.2012.681045
10.1254/jphs.13r01sr
10.1093/gerona/glz079
10.1016/j.neuro.2023.08.001
10.1016/j.toxrep.2019.10.019
10.1016/j.phyplu.2021.100051
10.1159/000454681
10.1007/s12035-022-02875-7
10.1016/j.bbr.2022.114083
10.1111/nyas.14005
10.1111/j.1600-079X.2010.00819.x
10.1016/j.mce.2012.01.004
10.1016/j.bbr.2014.06.030
10.1007/BF03033887
10.2147/cpt.s44802
10.3390/diagnostics11020231
10.1016/j.neubiorev.2021.04.034
10.3892/mmr.2016.4991
10.3390/antiox10101528
10.1111/j.1600-079X.2006.00407.x
10.3390/ijms17122124
10.3390/molecules23020301
10.1016/j.physbeh.2018.02.034
10.3390/ijms23115954
10.1016/j.bcp.2022.114980
10.1111/jpi.12081
10.2174/1389450121666201020155010
10.2174/1570159x1466616122812
10.1007/s11910-016-0664-3
10.18632/oncotarget.27754
10.1007/s11357-017-9981-y
10.3389/fnagi.2018.00004
10.2174/0929867323666160428105849
10.3390/genes13081324
10.3390/ijms20236004
10.1007/s12035-015-9404-y
10.1111/bph.14197
10.1016/j.psychres.2018.03.089
10.3390/ijms20112818
10.1001/jamaneurol.2013.6239
10.1038/nrdp.2018.8
10.1016/j.phrs.2018.06.011
10.1007/s00018-014-1659-3
10.1111/j.1600-079X.2004.00130.x
10.1007/s11064-007-9308-y
10.1002/gps.4571
10.26355/eurrev_201904_17723
10.1186/s13024-020-00376-6
10.1097/WNR.0000000000001554
10.1016/j.bbr.2021.113724
10.1111/j.1600-079X.2006.00377.x
10.2174/1381612822666151214125657
10.1192/bjp.bp.111.096321
10.1016/j.nlm.2013.11.016(RetractionpublishedNeurobiolLearnMem.2015Dec;126:87)
10.3389/fnmol.2017.00049
10.1177/09603271221084276
10.1016/j.freeradbiomed.2012.04.033
10.1111/jpi.12193
10.3390/life12040574
10.1177/1179573520907397.PMID:32165850;PMCID:PMC7050025
10.1111/jpc.12868
10.1016/j.mad.2016.02.003
10.4062/biomolther.2017.071
10.3389/fpls.2016.00197
10.1038/s12276-019-0273-8
10.3389/fncel.2018.00306
10.2147/JIR.S317672
10.1111/j.1600-079X.2004.00136.x",<Element 'PubmedArticle' at 0x7f05d84374a0>
6,"38187564
9048584
9247129
15668595
11113299
19803851
15539556
17666595
16735636
28944165
12525723
24048848
12867518
11514077
16725270
2054668
1353794
24112361
31364065
21285321
25205317
20442496
29311911
27870425
32210745
24042430
12771112
29526116
15213207
30814803
27707975
8030628
12771113
24508665
30298180
23100399
34948039
30728170
33488324
21518944
16837643
29952604
32670182
32365920
18369406
19258710
27127533
19326447
22566700
35360070
20212170
23684970
31335040
17983964
34642852
30265334
36626981
18558852
30664247
11144355
10964943
23217743
9657148
20152113
19451621
23902637
18047785
10936173
23818240
10822011
15634231
12533840
26109339
32707231
22296764
26733801
31840000
11741335
17374692
28039038
11739094
15279908
9795757
16461929
15271873
15389572
18434428
15018811
18336945
27872704
17726140
15514030
34302919
26598706
36815939
34335629
22525735
12387745
23401502
9241047
23104886
24227677
25516281
22722343
21493656
35246015
22954632
28072409
33237311
12525261
26476454",Modulation of neural gene networks by estradiol in old rhesus macaque females.,"The postmenopausal decrease in circulating estradiol (E2) levels has been shown to contribute to several adverse physiological and psychiatric effects. To elucidate the molecular effects of E2 on the brain, we examined differential gene expression and DNA methylation (DNAm) patterns in the nonhuman primate brain following ovariectomy (Ov) and subsequent E2 treatment. We identified several dysregulated molecular networks, including MAPK signaling and dopaminergic synapse response, that are associated with ovariectomy and shared across two different brain areas, the occipital cortex (OC) and prefrontal cortex (PFC). The finding that hypomethylation (","['Aging', 'DNA methylation', 'Estradiol', 'Occipital Cortex', 'Ovariectomy', 'Prefrontal Cortex', 'RNA-Seq']",bioRxiv : the preprint server for biology,2024-01-08,"[{'lastname': 'Cervera-Juanes', 'firstname': 'Rita', 'initials': 'R', 'affiliation': 'Department of Translational Neuroscience, Atrium Health Wake Forest Baptist, Winston-Salem, NC 27157.\nCenter for Precision Medicine, Atrium Health Wake Forest Baptist, Winston-Salem, NC 27157.'}, {'lastname': 'Zimmerman', 'firstname': 'Kip D', 'initials': 'KD', 'affiliation': 'Center for Precision Medicine, Atrium Health Wake Forest Baptist, Winston-Salem, NC 27157.\nDepartment of Internal Medicine, Atrium Health Wake Forest Baptist, Winston-Salem, NC 27157.'}, {'lastname': 'Wilhelm', 'firstname': 'Larry', 'initials': 'L', 'affiliation': 'Department of Translational Neuroscience, Atrium Health Wake Forest Baptist, Winston-Salem, NC 27157.'}, {'lastname': 'Zhu', 'firstname': 'Dongqin', 'initials': 'D', 'affiliation': 'Department of Translational Neuroscience, Atrium Health Wake Forest Baptist, Winston-Salem, NC 27157.'}, {'lastname': 'Bodie', 'firstname': 'Jessica', 'initials': 'J', 'affiliation': 'Department of Translational Neuroscience, Atrium Health Wake Forest Baptist, Winston-Salem, NC 27157.'}, {'lastname': 'Kohama', 'firstname': 'Steven G', 'initials': 'SG', 'affiliation': 'Division of Neuroscience, Oregon National Primate Research Center, Beaverton, Oregon, USA.'}, {'lastname': 'Urbanski', 'firstname': 'Henryk F', 'initials': 'HF', 'affiliation': 'Division of Neuroscience, Oregon National Primate Research Center, Beaverton, Oregon, USA.\nDivision of Reproductive & Developmental Sciences, Oregon National Primate Research Center, Beaverton, Oregon, USA.\nDepartment of Behavioral Neuroscience, Oregon Health & Science University, Portland, Oregon, USA.'}]",,,,,"10.1101/2023.12.18.572105
10.1210/endo.138.3.4979
10.1016/s0014-5793(97)00413-4
10.1097/00042192-200512010-00005
10.1016/s0306-4522(00)00410-3
10.2217/17455057.3.2.173
10.1210/en.2004-1064
10.1097/01.AOG.0000270153.59102.40
10.2105/AJPH.2005.066936
10.1007/s40675-017-0084-1
10.1212/wnl.60.1.82
10.1523/JNEUROSCI.1716-13.2013
10.1523/JNEUROSCI.23-15-06338.2003
10.1016/s0304-3940(01)02083-3
10.1016/j.neuroscience.2006.03.075
10.1016/0006-8993(91)91057-8
10.1523/JNEUROSCI.12-08-03217.1992
10.1111/jne.12108
10.1007/s13311-019-00766-9
10.1210/en.2010-1273
10.1016/j.yhbeh.2014.08.011
10.3233/JAD-2010-100501
10.3389/fnagi.2017.00430
10.1002/jnr.23827
10.3389/fnins.2020.00157
10.1093/epirev/mxt008
10.1001/jama.289.20.2651
10.1080/13697137.2018.1439915
10.1001/jama.291.24.2959
10.1007/s13224-019-01202-w
10.1523/JNEUROSCI.0909-16.2016
10.1093/oxfordjournals.aje.a117244
10.1001/jama.289.20.2663
10.1016/j.mce.2014.01.020
10.14283/jpad.2018.34
10.1212/WNL.0b013e318271f823
10.3390/ijms222413242
10.1523/JNEUROSCI.1970-18.2019
10.5114/pm.2020.101941
10.1001/archinternmed.2011.121
10.1095/biolreprod.106.051839
10.1037/bne0000259
10.3389/fneur.2020.00539
10.3390/ijms21093177
10.2174/138920206779315737
10.1159/000201107
10.1186/s12986-016-0090-1
10.1002/jnr.22068
10.1074/jbc.M112.351262
10.3389/fendo.2022.783823
10.1073/pnas.0910578107
10.1016/j.jphysparis.2013.05.001
10.1016/j.nic.2007.07.005
10.1007/s11357-021-00453-8
10.1093/jmcb/mjy020
10.1016/j.jbc.2023.102885
10.1146/annurev.neuro.31.061307.090711
10.1111/jnc.14665
10.1016/s0896-6273(00)00124-0
10.1523/JNEUROSCI.20-17-06374.2000
10.1016/j.neuron.2012.10.012
10.1016/s0092-8674(00)81459-2
10.1016/j.neuron.2009.12.007
10.1073/pnas.0812937106
10.1186/1478-811X-11-52
10.5483/bmbrep.2007.40.6.899
10.1046/j.1471-4159.2000.0750934.x
10.1007/s12672-013-0151-0
10.1016/s0960-0760(00)00037-6
10.1111/j.1365-2990.2004.00603.x
10.1002/path.1283
10.1152/physrev.00036.2014
10.1016/j.phrs.2020.105090
10.1101/cshperspect.a006049
10.3389/fnmol.2015.00077
10.1038/s41392-019-0091-4
10.1006/bbrc.2001.6121
10.1152/ajpendo.00666.2006
10.1016/j.neuroscience.2016.12.025
10.1152/ajpendo.2002.282.1.E139
10.1016/j.mce.2004.06.002
10.1139/cjpp-76-4-463
10.1677/jme.1.01825
10.1210/en.2004-0806
10.1002/jcp.20166
10.1677/JME-07-0156
10.1016/s1567-133x(00)00002-8
10.1016/j.neures.2008.01.018
10.1152/ajpendo.00425.2007
10.1210/me.2004-0267
10.1016/j.canlet.2021.07.027
10.1073/pnas.1422015112
10.1515/tnsci-2022-0272
10.3389/fimmu.2021.712632
10.1038/nrendo.2012.65
10.1016/s1074-7613(02)00423-5
10.1101/2022.09.19.508592
10.20517/2347-8659.2020.09
10.1073/pnas.1300313110
10.1095/biolreprod57.2.335
10.1093/bioinformatics/bts635
10.1093/bioinformatics/btt656
10.1186/s13059-014-0550-8
10.1101/gr.133744.111
10.1093/bioinformatics/btr167
10.1080/15592294.2022.2044127
10.1093/bioinformatics/bts545
10.1038/tp.2016.266
10.1093/nar/gkaa1074
10.1186/1471-2105-4-2
10.1093/nar/gkv1070",<Element 'PubmedArticle' at 0x7f05db661220>
7,"38178204
29754747
26482651
9409336
30010124
31129153
27546235
36136224
30089221
29151590
30184509
29924994
33609158
31951107
32840654
33606969
28602351
31018141
33402227
35388616
37774678
31042697
34239132
29608177
25867923
24658644
28569836
31974247
28991892
32832661
31061481
30944313
34557778
26771021
31873194
31113487
34112929
32989152
29865057
2011243
1759558
17568013
17035694
31960376
24742461
11240026
34760339
34131105
34276705
27770558
32070869
34385585
33257666
31373067
27345837
27998929
32259484
36527260
36419137
36747024
28228558
36002854
25178113
31841110
33414510
15613448
18348297
28930663
29346778
29416036
33892622
35004893
31249304
27799308
34991657
34220439
29590624
2535151
32655126
9143685
33479171
36543959
14676303
32686767
26119982
35399207
26200012
35189551
34938728
34429650
22654870
11159828
25883987
30326622
20709693
30124174
28628103
28031488
30127720
20418886
32365920
10754536
33522914
36420620
32511104
36348357
29861287
37087770
33301878
35576680
35476452
36883688
34746703
24728269
3302117
28720143
1484388
36672249
16148231
32727504
26465210
27033053
36624497
21118977
34373577
31942999
9407129
34472467
32610143",Identification of female-enriched and disease-associated microglia (FDAMic) contributes to sexual dimorphism in late-onset Alzheimer's disease.,"Late-onset Alzheimer's disease (LOAD) is the most common form of dementia; it disproportionally affects women in terms of both incidence rates and severity of progression. The cellular and molecular mechanisms underlying this clinical phenomenon remain elusive and ill-defined.
In-depth analyses were performed with multiple human LOAD single-nucleus transcriptome datasets to thoroughly characterize cell populations in the cerebral cortex. ROSMAP bulk human brain tissue transcriptome and DNA methylome datasets were also included for validation. Detailed assessments of microglial cell subpopulations and their relevance to sex-biased changes at the tissue level were performed. Clinical trait associations, cell evolutionary trajectories, and transcription regulon analyses were conducted.
The relative numbers of functionally defective microglia were aberrantly increased uniquely among affected females. Substratification of the microglia into different subtypes according to their transcriptomic signatures identified a group of female-enriched and disease-associated microglia (FDAMic), the numbers of which were positively associated with disease severity. Phenotypically, these cells exhibit transcriptomic signatures that support active proliferation, MHC class II autoantigen presentation and amyloid-β binding, but they are also likely defective in phagocytosis. FDAMic are likely evolved from female activated response microglia (ARMic) with an APOE4 background and compromised estrogen receptor (ER) signaling that is deemed to be active among most subtypes of microglia.
This study offered important insights at both the cellular and molecular levels into how ER signaling affects microglial heterogeneity and function. FDAMic are associated with more advanced pathologies and severe trends of cognitive decline. Their emergence could, at least in part, explain the phenomenon of greater penetrance of the APOE4 genotype found in females. The biases of FDAMic emergence toward female sex and APOE4 status may also explain why hormone replacement therapy is more effective in APOE4 carriers. The pathologic nature of FDAMic suggests that selective modulations of these cells may help to regain brain neuroimmune homeostasis, serving as a new target for future drug development.","['Bioinformatics', 'Estrogen receptor signaling', 'Late-onset Alzheimer’s disease', 'Microglia', 'Sex dimorphism']",Journal of neuroinflammation,2024-01-05,"[{'lastname': 'Wu', 'firstname': 'Deng', 'initials': 'D', 'affiliation': 'School of Life Sciences, Faculty of Science, The Chinese University of Hong Kong, Hong Kong SAR, 999077, China.'}, {'lastname': 'Bi', 'firstname': 'Xiaoman', 'initials': 'X', 'affiliation': 'Key Laboratory of Tropical Translational Medicine of Ministry of Education, College of Biomedical Information and Engineering, Hainan Medical University, Haikou, 571199, China.'}, {'lastname': 'Chow', 'firstname': 'Kim Hei-Man', 'initials': 'KH', 'affiliation': 'School of Life Sciences, Faculty of Science, The Chinese University of Hong Kong, Hong Kong SAR, 999077, China. heimanchow@cuhk.edu.hk.\nGerald Choa Neuroscience Institute, The Chinese University of Hong Kong, Hong Kong SAR, 999077, China. heimanchow@cuhk.edu.hk.\nNexus of Rare Neurodegenerative Diseases, The Chinese University of Hong Kong, Hong Kong SAR, 999077, China. heimanchow@cuhk.edu.hk.'}]",,"This study offered important insights at both the cellular and molecular levels into how ER signaling affects microglial heterogeneity and function. FDAMic are associated with more advanced pathologies and severe trends of cognitive decline. Their emergence could, at least in part, explain the phenomenon of greater penetrance of the APOE4 genotype found in females. The biases of FDAMic emergence toward female sex and APOE4 status may also explain why hormone replacement therapy is more effective in APOE4 carriers. The pathologic nature of FDAMic suggests that selective modulations of these cells may help to regain brain neuroimmune homeostasis, serving as a new target for future drug development.","The relative numbers of functionally defective microglia were aberrantly increased uniquely among affected females. Substratification of the microglia into different subtypes according to their transcriptomic signatures identified a group of female-enriched and disease-associated microglia (FDAMic), the numbers of which were positively associated with disease severity. Phenotypically, these cells exhibit transcriptomic signatures that support active proliferation, MHC class II autoantigen presentation and amyloid-β binding, but they are also likely defective in phagocytosis. FDAMic are likely evolved from female activated response microglia (ARMic) with an APOE4 background and compromised estrogen receptor (ER) signaling that is deemed to be active among most subtypes of microglia.",© 2023. The Author(s).,"10.1186/s12974-023-02987-4
10.1016/j.neurobiolaging.2018.04.004
10.1186/s13073-015-0232-5
10.1212/WNL.49.6.1498
10.3233/JAD-180141
10.1016/j.brainres.2019.05.031
10.1038/nri.2016.90
10.1007/s11357-022-00664-7
10.1146/annurev-cellbio-100616-060509
10.1038/nri.2017.125
10.1016/j.celrep.2018.08.001
10.1016/j.celrep.2018.05.048
10.1007/s00401-021-02263-w
10.15252/emmm.201910606
10.1007/s00401-020-02200-3
10.1016/j.neuron.2021.01.027
10.1016/j.cell.2017.05.018
10.1016/j.celrep.2019.03.099
10.1186/s40478-020-01099-x
10.1111/acel.13606
10.1016/j.cell.2023.08.037
10.1038/s41586-019-1195-2
10.1038/s41588-021-00894-z
10.1038/nbt.4091
10.1038/nbt.3192
10.1038/nbt.2859
10.1038/ncomms15599
10.1126/science.aax0249
10.1038/nmeth.4463
10.1126/sciadv.aba2619
10.1038/s41587-019-0114-2
10.1038/s41467-019-09234-6
10.1016/j.cels.2015.12.004
10.1038/s41593-019-0560-7
10.1186/s40478-019-0729-z
10.1038/s42003-021-02259-y
10.1073/pnas.2008762117
10.3233/JAD-179939
10.1212/WNL.41.4.479
10.1007/BF00308809
10.1212/01.wnl.0000271090.28148.24
10.1159/000096129
10.1007/978-1-0716-0301-7_7
10.1016/j.neuron.2014.02.040
10.1016/S0165-5728(01)00240-5
10.1016/j.omtn.2021.08.030
10.1038/s41419-021-03899-y
10.3389/fimmu.2021.711633
10.1002/hep.28873
10.1016/j.cca.2020.02.008
10.1038/s41598-021-96006-2
10.1038/s41467-020-19737-2
10.15252/embj.2019101997
10.1016/j.stem.2016.05.010
10.1016/j.cell.2020.03.021
10.1002/glia.24314
10.1186/s13024-022-00577-1
10.4049/jimmunol.1602057
10.1186/s13024-022-00552-w
10.1186/s12974-014-0145-z
10.1038/s41418-020-00706-7
10.1677/erc.1.00777
10.1002/cncr.23440
10.1016/j.immuni.2017.08.008
10.1016/j.celrep.2017.12.066
10.1038/s41467-018-02926-5
10.1186/s11689-021-09358-1
10.3389/fcvm.2021.778674
10.1038/s41467-019-10643-w
10.4049/jimmunol.1600642
10.1186/s13041-021-00892-6
10.3389/fnins.2021.682247
10.1016/j.celrep.2018.03.011
10.12659/MSMBR.924124
10.1146/annurev.immunol.15.1.155
10.1038/s41590-022-01374-0
10.1084/jem.20030714
10.1038/s41422-020-0374-x
10.1002/stem.2086
10.1097/BS9.0000000000000059
10.1016/j.immuni.2015.07.003
10.1016/j.redox.2022.102265
10.3389/fcell.2021.697748
10.2147/CMAR.S311650
10.3389/fendo.2012.00052
10.1210/endo.142.2.7982
10.1155/2015/916585
10.3390/ijms19103173
10.1093/bioinformatics/btq466
10.1186/s13024-018-0277-1
10.1038/nn.4587
10.1073/pnas.1612195114
10.3389/fncel.2018.00206
10.1038/nm.2122
10.3390/ijms21093177
10.1016/S1043-2760(00)00248-4
10.1186/s12905-020-01164-6
10.1111/jne.13209
10.18632/aging.103405
10.1186/s13024-022-00574-4
10.1016/j.neuron.2018.05.008
10.1016/j.jstrokecerebrovasdis.2023.107132
10.1016/j.nbd.2020.105217
10.1016/j.bbrc.2022.04.120
10.1126/sciadv.abf2017
10.1111/acel.13810
10.1016/j.isci.2021.103238
10.1038/nn.3697
10.1016/0022-510X(87)90218-8
10.1186/s12974-017-0915-5
10.1002/jnr.490330407
10.3390/cells12020314
10.1523/JNEUROSCI.1808-05.2005
10.1186/s12964-020-00578-x
10.1038/ncomms9623
10.2174/1567205013666160401115127
10.1186/s13195-022-01121-5
10.1038/s41388-021-01985-1
10.1093/hmg/ddz320
10.1074/jbc.272.52.33360
10.4103/1673-5374.322452
10.1016/j.celrep.2020.107843",<Element 'PubmedArticle' at 0x7f05dd964b80>
8,38176933,Neuroinflammation in the Brain and Role of Intestinal Microbiota: An Overview of the Players.,"Great interest is aimed at understanding the inflammatory responses at the level of the central nervous system (CNS), referred to as neuroinflammatory. The environment and the duration of the inflammatory responses are essential factors for comprehending the biochemical and pathophysiological consequences induced by the inflammatory state. Specific inducers of inflammation associated with neurodegenerative disorders can activate inflammatory processes and produce mediators that potentiate neurodegeneration. Immune responders in the brain include microglial cells, astrocytes, and mast cells. A number of human pathologies are recognized to have an inflammatory component, including disorders related to brain function. Emerging evidence also attributes an important role to intestinal microorganisms in disorders related to brain function. In the gut-brain axis, the intestinal microbiota produce a variety of molecules and neurotransmitters, transform primary bile acids into secondary bile, and synthesize short-chain fatty acids. Communication within the gut-brain axis occurs through several pathways, including the immune system, the enteric nervous system, the vagus nerve, and the production of microbial metabolites. The CNS responds to this input from the gut by modulating the activity of the autonomic nervous system and the hypothalamic-pituitary-adrenal axis, which manages adrenocortical hormones. In this perspective, gut microbiota may influence neural function by influencing microglia, astroglia, and mast cells. Conversely, the relationship between neurons, microglia and synaptic alteration may also involve gut microbiota. The purpose of this review is to provide a concise overview of the mechanisms involved in communication between intestinal microbiota and the brain and how this contributes to the management of neuroinflammation.","['astrocyte', 'butyrate', 'gut', 'intestinal microbiota', 'lipopolysaccharide', 'mast cells', 'microglia', 'neuroinflammation']",Journal of integrative neuroscience,2024-01-05,"[{'lastname': 'Cavaliere', 'firstname': 'Gina', 'initials': 'G', 'affiliation': 'Department of Pharmaceutical Sciences, University of Perugia, 06123 Perugia, Italy.'}, {'lastname': 'Traina', 'firstname': 'Giovanna', 'initials': 'G', 'affiliation': 'Department of Pharmaceutical Sciences, University of Perugia, 06123 Perugia, Italy.'}]",,,,© 2023 The Author(s). Published by IMR Press.,10.31083/j.jin2206148,<Element 'PubmedArticle' at 0x7f05dd853d60>
9,"38105928
28855298
23123774
28189098
22407616
27792185
20045412
16457782
11522260
19236618
17490624
24140504
17188118
27886414
24744379
23569914
19548052
16723122
11151029
17889834
29853846
23680701
18395385
9391032
21334417
22335772
18436709
23373710
12616644
9626714
25981499
24688074
35976285
25666307
19498050
20118615
28437734
24336428
18675469
29934859
27247802
23062861
15694227
4863731
24661762
23332522
24621065
22020230
37112604
36668728
18655800
26365466
23612048
19151710
19022375
25079084
26786147
29290042
23611177","Anxiolytic and antidepressant like effects of Zamzam water in STZ-induced diabetic rats, targeting oxidative stress, neuroinflammation, BDNF/ERK/CREP pathway with modulation of hypothalamo-pituitary-adrenal axis.","Recent studies have reported a strong relationship between diabetes and anxiety- and depression-like behaviors; however, there is a lack of information on the underlying pathophysiology. Alkaline Zamzam water (ZW), which is rich in several trace elements, has neuroprotective properties. This study aimed to investigate the anxiolytic and antidepressant effects of ZW against diabetes-induced behavioral changes and shed light on the possible underlying mechanisms.
Forty-eight rats were divided into four experimental groups (
ZW significantly decreased the immobility time in the FST, indicating an antidepressant effect (
Our results suggested a neuroprotective effect of ZW against diabetes-induced anxiety- and depression-like behaviors and explored the underlying mechanisms. These findings suggest a promising therapeutic strategy for patients with diabetes who experience anxiety and depression.","['Zamzam water', 'anxiety', 'depression', 'diabetes', 'neuroinflammation', 'oxidative stress']",Frontiers in neuroscience,2023-12-18,"[{'lastname': 'Taha', 'firstname': 'Medhat', 'initials': 'M', 'affiliation': 'Department of Anatomy and Embryology, Faculty of Medicine, Mansoura University, Mansoura, Egypt.\nDepartment of Anatomy, Al-Qunfudah Medical College, Umm Al-Qura University, Al-Qunfudah, Saudi Arabia.'}, {'lastname': 'Mahmoud', 'firstname': 'Mohamed Ezzat', 'initials': 'ME', 'affiliation': 'Histology Department, Damietta Faculty of Medicine, Al-Azhar University, Damietta, Egypt.'}, {'lastname': 'Al-Kushi', 'firstname': 'Abdullah G', 'initials': 'AG', 'affiliation': 'Department of Human Anatomy, Faculty of Medicine, Umm Al-Qura University, Makkah, Makkah, Saudi Arabia.'}, {'lastname': 'Sarhan', 'firstname': 'Anas', 'initials': 'A', 'affiliation': 'Department of Internal Medicine, College of Medicine, Umm Al-Qura University, Makkah, Saudi Arabia.'}, {'lastname': 'Abdelbagi', 'firstname': 'Omer', 'initials': 'O', 'affiliation': 'Department of Pathology, Qunfudah Faculty of Medicine, Umm-Al-Qura University, Al-Qunfudah, Saudi Arabia.'}, {'lastname': 'Baokbah', 'firstname': 'Tourki A S', 'initials': 'TAS', 'affiliation': 'Department of Medical Emergency Services, College of Health Sciences-AlQunfudah, Umm Al-Qura University, Al-Qunfudah, Saudi Arabia.'}, {'lastname': 'Babateen', 'firstname': 'Omar', 'initials': 'O', 'affiliation': 'Department of Physiology, Faculty of Medicine, Umm Al-Qura University, Makkah, Makkah, Saudi Arabia.'}, {'lastname': 'El-Shenbaby', 'firstname': 'Ibrahim', 'initials': 'I', 'affiliation': 'Clinical Pharmacology Department, Faculty of Medicine, Mansoura University, Mansoura, Egypt.'}, {'lastname': 'Qusty', 'firstname': 'Naeem F', 'initials': 'NF', 'affiliation': 'Medical Laboratories Department, Faculty of Applied Medical Sciences, Umm Al-Qura University, Makkah, Saudi Arabia.'}, {'lastname': 'Elazab', 'firstname': 'Sara T', 'initials': 'ST', 'affiliation': 'Department of Pharmacology, Faculty of Veterinary Medicine, Mansoura University, Mansoura, Egypt.'}]",,Our results suggested a neuroprotective effect of ZW against diabetes-induced anxiety- and depression-like behaviors and explored the underlying mechanisms. These findings suggest a promising therapeutic strategy for patients with diabetes who experience anxiety and depression.,"ZW significantly decreased the immobility time in the FST, indicating an antidepressant effect (","Copyright © 2023 Taha, Mahmoud, Al-Kushi, Sarhan, Abdelbagi, Baokbah, Babateen, El-Shenbaby, Qusty and Elazab.","10.3389/fnins.2023.1265134
10.5897/JMPR12.740
10.1152/jn.00945.2016
10.1016/j.neulet.2012.10.045
10.1016/j.pharep.2016.12.004
10.1124/pr.111.005108
10.3390/nu8110679
10.4172/2155-6156.1000249
10.2478/s13380-012-0027-8
10.1016/j.expneurol.2009.12.022
10.1016/j.biopsych.2005
10.1016/s0006-3223(01)01083-6
10.1111/j.1464-5491.2008.02648.x
10.1016/j.brainres.2007.03.088
10.1016/j.bbr.2013.10.011
10.1016/j.jpsychores.2006.07.009
10.1111/ejn.13486
10.1126/science.1249240
10.1016/S2221-1691(12)60023-9
10.1007/s12640-009-9072-7
10.1016/j.bcp.2006.04.011
10.1590/s0100-879x2001000100007
10.1016/j.biopsych.2007.07.016
10.1155/2018/6589608
10.1016/j.neubiorev.2013.03.010
10.1016/j.exger.2008.02.007
10.1073/pnas.94.25.13386
10.1016/j.neulet.2011.02.030
10.1111/j.1476-5381.2012.01902.x
10.1210/er.2007-0034
10.3109/13880209.2012.749924
10.1002/jbt.10058
10.1017/s0033291798006680
10.2174/1573399811666150515125349
10.1093/infdis/jiu194
10.1590/1519-6984.262815
10.1016/j.physbeh.2015.02.015
10.1373/clinchem.2009.123752
10.1254/jphs.09292sc
10.1016/j.diabres.2017.03.024
10.1097/PSY.0000000000000009
10.1016/j.tins.2008.06.006
10.1007/s11011-018-0264-9
10.1155/2016/3760702
10.1016/S0165-0327(12)70004-6
10.1016/j.pnpbp.2004.11.003
10.1016/j.dsx.2013.06.010
10.1016/j.jpsychores.2012.11.013
10.1179/1476830513Y.0000000105
10.1016/j.neubiorev.2011.10.001
10.3390/toxics11040377
10.3390/toxics11010002
10.1016/j.physbeh.2008.06.017
10.1016/j.bbadis.2015.09.003
10.1038/tp.2013.27
10.1038/nn.2257
10.1016/j.bbadis.2008.10.013
10.1503/jpn.130169
10.2174/1570159x14666160119094646
10.1007/s11011-017-0179-x
10.1503/jpn.120228",<Element 'PubmedArticle' at 0x7f05ddd6f630>
10,"38069238
28282816
34225945
26577509
30718450
28409113
32571909
32390807
30295682
26964832
37599881
12629196
11069610
12077209
12133566
15793577
33328933
20080543
11784803
18059435
29951186
20237128
29097256
17426909
33331023
25554999
31823457
37238920
32150310
32648088
16375977
30914249
35513230
36292973
18325597
23399912
36051635
24937095
28134302
37204300
32567027
18076877
18951894
27917870
37270842
14692699
12694386
16519665
16460881
21855627
24755486
24486959
7700568
33182554
32726685
27733389
30865890
25883554
16760179
23897970
24702642
25002731
15709959
17543357
20948519
19926299
17869482
28965353
36402246
32512130
29054677
24933336
29035710
26206409
24798553
26999434
27652978
30001736
29807534
12493072
26819917
31295526
31751573
37945922
18595767
26454750
35027835
22056623
24161357",Deep-Brain Subthalamic Nucleus Stimulation Enhances Food-Related Motivation by Influencing Neuroinflammation and Anxiety Levels in a Rat Model of Early-Stage Parkinson's Disease.,"Deep-brain subthalamic nucleus stimulation (DBS-STN) has become a well-established therapeutic option for advanced Parkinson's disease (PD). While the motor benefits of DBS-STN are widely acknowledged, the neuropsychiatric effects are still being investigated. Beyond its immediate effects on neuronal circuits, emerging research suggests that DBS-STN might also modulate the peripheral inflammation and neuroinflammation. In this work, we assessed the effects of DBS-STN on food-related motivation, food intake pattern, and the level of anxiety and compared them with markers of cellular and immune activation in nigrostriatal and mesolimbic areas in rats with the 6-OHDA model of early PD. To evaluate the potential mechanism of observed effects, we also measured corticosterone concentration in plasma and leukocyte distribution in peripheral blood. We found that DBS-STN applied during neurodegeneration has beneficial effects on food intake pattern and motivation and reduces anxiety. These behavioral effects occur with reduced percentages of IL-6-labeled cells in the ventral tegmental area and substantia nigra pars compacta in the stimulated brain hemisphere. At the same brain structures, the cFos cell activations were confirmed. Simultaneously, the corticosterone plasma concentration was elevated, and the peripheral blood lymphocytes were reduced after DBS-STN. We believe that comprehending the relationship between the effects of DBS-STN on inflammation and its therapeutic results is essential for optimizing DBS therapy in PD.","['6-hydroxydopamine', 'Parkinson’s disease', 'anxiety', 'cFos protein', 'corticosterone', 'food-related motivation', 'interleukin-6', 'lymphocytes', 'subthalamic nucleus deep-brain stimulation']",International journal of molecular sciences,2023-12-09,"[{'lastname': 'Grembecka', 'firstname': 'Beata', 'initials': 'B', 'affiliation': 'Department of Animal and Human Physiology, Faculty of Biology, University of Gdańsk, Wita Stwosza 59, 80-308 Gdańsk, Poland.'}, {'lastname': 'Majkutewicz', 'firstname': 'Irena', 'initials': 'I', 'affiliation': 'Department of Animal and Human Physiology, Faculty of Biology, University of Gdańsk, Wita Stwosza 59, 80-308 Gdańsk, Poland.'}, {'lastname': 'Harackiewicz', 'firstname': 'Oliwia', 'initials': 'O', 'affiliation': 'Department of Animal and Human Physiology, Faculty of Biology, University of Gdańsk, Wita Stwosza 59, 80-308 Gdańsk, Poland.'}, {'lastname': 'Wrona', 'firstname': 'Danuta', 'initials': 'D', 'affiliation': 'Department of Animal and Human Physiology, Faculty of Biology, University of Gdańsk, Wita Stwosza 59, 80-308 Gdańsk, Poland.'}]",,,,,"10.3390/ijms242316916
10.3233/JPD-179007
10.1016/B978-0-12-820107-7.00026-4
10.1007/s11065-015-9306-9
10.1038/s41398-019-0404-y
10.1016/j.nicl.2017.03.011
10.1073/pnas.2004914117
10.3389/fnana.2020.00013
10.21307/ane-2018-023
10.1038/emm.2016.4
10.3389/fpsyt.2023.1264669
10.1523/JNEUROSCI.23-05-01916.2003
10.1046/j.1460-9568.2000.00296.x
10.1523/JNEUROSCI.22-12-05137.2002
10.1016/S0304-3940(02)00463-9
10.1088/1755-1315/714/2/022065
10.1038/nn1429
10.3389/fnhum.2020.578564
10.1073/pnas.0908189107
10.1523/JNEUROSCI.22-02-00562.2002
10.1038/sj.npp.1301653
10.1155/2018/9756468
10.1093/brain/awq032
10.1016/j.pnpbp.2017.10.022
10.1007/s00415-006-0510-7
10.1002/mds.28390
10.1016/j.psyneuen.2014.12.001
10.1111/obr.12955
10.3390/biomedicines11051248
10.1111/ejn.14720
10.1007/s11481-020-09934-7
10.1016/j.jneuroim.2005.10.017
10.1016/j.brainres.2019.03.028
10.1016/j.nbd.2022.105744
10.3390/ijms232012116
10.1016/j.jneumeth.2008.01.015
10.1038/mp.2013.3
10.3389/fnbeh.2022.940672
10.1038/tp.2014.43
10.1038/srep41589
10.7554/eLife.83971
10.1007/s12264-020-00533-3
10.1016/j.expneurol.2007.10.020
10.1016/j.expneurol.2008.09.017
10.1038/npp.2016.270
10.1097/WNR.0000000000001917
10.1093/jnen/62.12.1228
10.1046/j.1471-4159.2003.01665.x
10.1111/j.1460-9568.2006.04638.x
10.1016/j.neuroscience.2005.12.034
10.1016/j.jchemneu.2011.08.003
10.1016/j.neuroscience.2014.04.016
10.1016/j.neuro.2014.01.006
10.1016/0304-3940(94)90508-8
10.3390/ijms21228421
10.1016/j.bbi.2020.07.035
10.1152/ajpregu.00426.2016
10.1016/j.celrep.2019.02.044
10.3389/fnana.2015.00032
10.1080/02841860500401167
10.1200/JCO.2012.44.4661
10.1089/jpm.2013.0324
10.1200/JCO.2013.54.3926
10.1146/annurev.physiol.67.040403.120816
10.1016/j.physbeh.2007.04.011
10.1038/oby.2010.241
10.1016/j.tem.2009.10.004
10.1016/j.nut.2007.08.008
10.1111/ejn.13730
10.1016/j.neuropharm.2022.109344
10.1016/j.pnpbp.2020.110000
10.1016/j.biopsych.2017.08.013
10.1016/j.pbb.2014.06.003
10.1016/j.psyneuen.2017.09.023
10.1016/j.nbd.2015.07.010
10.1007/s12026-014-8517-0
10.1002/mds.26563
10.1038/srep33738
10.1186/s12974-018-1248-8
10.1186/s12974-018-1206-5
10.1186/cc1820
10.15171/apb.2015.063
10.1016/j.exger.2019.110653
10.1016/j.ejphar.2019.172814
10.1038/s41598-023-46576-0
10.1016/j.parkreldis.2008.04.015
10.1007/s11481-015-9632-y
10.2147/JIR.S342280
10.1016/j.brainresbull.2011.10.014
10.1016/j.brainresbull.2013.10.002",<Element 'PubmedArticle' at 0x7f05ddd898b0>
11,"37994952
29677475
22521375
19162013
8152586
17569888
30206482
25935397
34327481
36893777
35309046
22429119
18585782
22827472
22958438
23458610
15854152
21551268
23316343
18326552
21081794
10948091
18443753
20870012
1717781
19127280
24343120
19553933
19648480
21624097
34707513
22307669
11120695
11922892
15023878
29544870
15536110
24327952
20404913
10611369
34910246
28606950
20195267
28775014
16704560
26202709
27283279
17569877
25505871
26777746
23465244
18694565
24237608
28101763
20814009
18234752
3352695
23810896
20170788
15703419
27708278
16477490
11701591
36409823
26786114
24763468
24345399
10512901
26179566
25052322
23632982
26184616
21075756
22236222
22871677
12451014
24643411
24963567
15956123
30025574
27956440
15148057
34674004
20717123
26101368
34754227
28886155
34381674
21778438
27908798
33348925
14744438
23641832
22252325
20029200
30988767
33253676
30923543
30116504
27748656
28479899
37414611
31412906",The Brain-Heart Axis: Neuroinflammatory Interactions in Cardiovascular Disease.,"The role of neuroimmune modulation and inflammation in cardiovascular disease has been historically underappreciated. Physiological connections between the heart and brain, termed the heart-brain axis (HBA), are bidirectional, occur through a complex network of autonomic nerves/hormones and cytokines, and play important roles in common disorders.
At the molecular level, advances in the past two decades reveal complex crosstalk mediated by the sympathetic and parasympathetic nervous systems, the renin-angiotensin aldosterone and hypothalamus-pituitary axes, microRNA, and cytokines. Afferent pathways amplify proinflammatory signals via the hypothalamus and brainstem to the periphery, promoting neurogenic inflammation. At the organ level, while stress-mediated cardiomyopathy is the prototypical disorder of the HBA, cardiac dysfunction can result from a myriad of neurologic insults including stroke and spinal injury. Atrial fibrillation is not necessarily a causative factor for cardioembolic stroke, but a manifestation of an abnormal atrial substrate, which can lead to the development of stroke independent of AF. Central and peripheral neurogenic proinflammatory factors have major roles in the HBA, manifesting as complex bi-directional relationships in common conditions such as stroke, arrhythmia, and cardiomyopathy.","['Arrhythmia-related stroke', 'Cardiometabolic syndrome', 'Cardiovascular neurogenic aging', 'Heart brain axis', 'Neuroinflammatory interactions', 'Stress cardiomyopathy']",Current cardiology reports,2023-11-23,"[{'lastname': 'Hu', 'firstname': 'Jiun-Ruey', 'initials': 'JR', 'affiliation': 'Section of Cardiovascular Medicine, Yale School of Medicine, 789 Howard Ave, New Haven, CT, 06519, USA.'}, {'lastname': 'Abdullah', 'firstname': 'Ahmed', 'initials': 'A', 'affiliation': 'Section of Cardiovascular Medicine, Yale School of Medicine, 789 Howard Ave, New Haven, CT, 06519, USA.'}, {'lastname': 'Nanna', 'firstname': 'Michael G', 'initials': 'MG', 'affiliation': 'Section of Cardiovascular Medicine, Yale School of Medicine, 789 Howard Ave, New Haven, CT, 06519, USA.'}, {'lastname': 'Soufer', 'firstname': 'Robert', 'initials': 'R', 'affiliation': 'Section of Cardiovascular Medicine, Yale School of Medicine, 789 Howard Ave, New Haven, CT, 06519, USA. Robert.Soufer@yale.edu.\nVA Connecticut Healthcare System, 950 Campbell Ave, -111B, West Haven, CT, 06516, USA. Robert.Soufer@yale.edu.'}]",,,,© 2023. This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply.,"10.1007/s11886-023-01990-8
10.1146/annurev-immunol-042617-053158
10.1016/j.ijcard.2012.03.165
10.1016/j.expneurol.2008.12.014
10.1016/0304-3940(93)90873-j
10.1161/CIRCRESAHA.107.148940
10.15420/cfr.2018.14.2
10.1186/s12974-015-0306-8
10.1016/j.ajpc.2020.100130
10.1016/S0140-6736(23)00215-5
10.3389/fphys.2022.837723
10.1089/ars.2012.4585
10.1016/j.neubiorev.2008.05.020
10.1042/CS20120078
10.1186/1742-2094-9-212
10.1016/j.pharmthera.2013.02.005
10.1111/j.1440-1681.2005.04205.x
10.1113/expphysiol.2010.052332
10.1155/2012/242786
10.1113/expphysiol.2007.041814
10.1161/01.hyp.36.2.282
10.1007/s00109-008-0324-4
10.1016/j.neuroscience.2010.09.029
10.1097/00005344-199108000-00006
10.1038/jcbfm.2008.158
10.1161/HYPERTENSIONAHA.113.01743
10.1038/clpt.2009.117
10.1113/expphysiol.2008.045948
10.1111/j.1748-1716.2011.02313.x
10.3389/fphys.2021.746494
10.1152/ajpheart.00722.2011
10.1161/01.cir.102.25.3060
10.1016/s0008-6363(01)00503-x
10.1161/01.CIR.0000124490.27666.B2
10.1016/j.jacc.2018.03.002
10.1001/jama.292.18.2237
10.1016/j.molmet.2013.09.005
10.1371/journal.pone.0010099
10.1073/pnas.96.26.15239
10.1007/s00018-021-04019-x
10.1161/circulationaha.116.027121
10.1038/nrcardio.2010.16
10.1161/circresaha.117.311170
10.1111/j.1365-2796.2006.01639.x
10.1111/ijs.12573
10.5853/jos.2015.01697
10.1161/strokeaha.106.471813
10.3389/fncel.2014.00389
10.1016/j.jcrc.2015.12.005
10.1016/j.ijcard.2013.01.160
10.1016/j.devcel.2008.07.002
10.1186/1471-2377-13-178
10.1007/s12975-017-0520-z
10.1161/strokeaha.110.584995
10.1056/nejmoa0707427
10.1056/nejm198804213181601
10.1016/j.jacc.2013.05.070
10.1016/j.jacc.2009.07.073
10.1056/nejmoa043046
10.1038/nrcardio.2016.163
10.1007/s10286-006-0278-y
10.1093/brain/124.12.2361
10.3171/FOC.2008.25.11.E13
10.1111/jgs.18120
10.1161/strokeaha.115.012004
10.1161/circresaha.114.302240
10.1161/circulationaha.113.005119
10.1161/01.str.30.10.2019
10.1002/ana.24482
10.1161/strokeaha.114.006364
10.1161/strokeaha.113.001118
10.1016/j.jacc.2015.05.018
10.1093/cvr/cvq357
10.1056/NEJMoa1105575
10.1161/strokeaha.112.667865
10.1161/01.cir.0000039327.11661.16
10.1161/strokeaha.114.004800
10.1056/nejmoa1313600
10.1161/circulationaha.104.512806
10.1016/j.jacc.2018.04.071
10.7861/clinmedicine.16-6-s43
10.1152/ajpheart.01072.2003
10.1007/s00109-021-02154-3
10.1038/jcbfm.2010.140
10.1177/0003319715591751
10.2147/ijgm.S329398
10.1371/journal.pone.0184244
10.5334/gh.934
10.1161/STR.0b013e3182299496
10.1016/j.brainresbull.2016.11.008
10.3390/ijms21249655
10.1016/s0092-8674(04)00045-5
10.1186/1755-8794-6-16
10.1373/clinchem.2011.173823
10.1159/000268088
10.3892/etm.2019.7398
10.1016/j.ahj.2020.11.011
10.11909/j.issn.1671-5411.2019.02.008
10.15171/jcvtr.2018.11
10.1097/aln.0000000000001378
10.4314/ahs.v16i4.23
10.1016/j.carrev.2023.06.010
10.1186/s13063-019-3586-y",<Element 'PubmedArticle' at 0x7f05dd035590>
12,"37969663
32528949
28062563
31375134
35937069
28256516
33195128
0
14597658
12882332
19447561
20079433
27908981",Neurological potency of native plants from sub-Himalayan West Bengal through reverse pharmacology.,"Neurodegenerative diseases, such as Alzheimer's disease (AD), Parkinson's disease (PD), and epilepsy, pose a growing global health challenge due to an aging population. These conditions share common processes, including protein accumulation, oxidative stress, and neuro-inflammation, making their treatment complex and costly. Network pharmacology, an innovative approach integrating systems biology and computational biology, offers insights into multi-target formulations and the repurposing of existing medications for neurodegenerative diseases. We shortlisted 730 bioactive compounds from 25 traditional Himalayan plants, assessed their drug-like properties using ADME criteria, and predicted their potential target proteins through reverse docking and pharmacophore mapping. Our study identified 287 compounds with high gastrointestinal absorption and good blood-brain barrier permeability. These compounds were subjected to target prediction, yielding a list of 171 potential target proteins. Functional annotation and pathway enrichment analysis highlighted their involvement in steroid hormone-related pathways, MAPK signaling, FOXO signaling, TNF signaling, VEGF signaling, and neurotrophin signaling. Importantly, one plant, ","['Neurological potency', 'native plants', 'reverse pharmacology', 'sub-Himalayan West Bengal']",Bioinformation,2023-11-16,"[{'lastname': 'Tshering Dhendup', 'firstname': 'Lepcha', 'initials': 'L', 'affiliation': 'Molecular Genetics Laboratory, Department of Botany, University of North Bengal, Raja Rammohanpur, Siliguri-734013, India.'}, {'lastname': 'Sutapa', 'firstname': 'Datta', 'initials': 'D', 'affiliation': 'Molecular Genetics Laboratory, Department of Botany, University of North Bengal, Raja Rammohanpur, Siliguri-734013, India.'}, {'lastname': 'Lee', 'firstname': 'Joongku', 'initials': 'J', 'affiliation': 'Department of Environmental and Forest Resources, Chungnam National University, Daehak-ro, Yuseong-gu, Daejeon, Republic of Korea.'}, {'lastname': 'Mohammad', 'firstname': 'Ajmal Ali', 'initials': 'AA', 'affiliation': 'Department of Botany and Microbiology, College of Sciences,King Saud University, Riyadh 11451, Saudi Arabia.'}, {'lastname': 'Sen', 'firstname': 'Arnab', 'initials': 'A', 'affiliation': 'Molecular Genetics Laboratory, Department of Botany, University of North Bengal, Raja Rammohanpur, Siliguri-734013, India.\nBioinformatics Facility Centre, University of North Bengal, Raja Rammohanpur, Siliguri-734013, India.\nBiswa Bangla Genome Centre, University of North Bengal, Raja Rammohanpur, Siliguri-734013, India.'}]",,,,© 2023 Biomedical Informatics.,"10.6026/97320630019995
10.15406/japlr.2018.07.00230
10.22271/PLANTS.2021.V9.I4A.1307
10.15482/USDA.ADC/1239279",<Element 'PubmedArticle' at 0x7f05db574ef0>
13,"37958929
1673054
29653606
17015225
15036808
36555399
34638637
17023659
25492944
20971753
31119452
36449413
33720637
35542991
37095250
35921451
31059641
35653060
33839324
36129998
35790708
30696107
31507408
34083109
15831717
28226226
31862977
26861995
33369790
34890221
32733433
23953759
33922383
33127097
33712570
31727856
20195797
23644076
21110971
28099414
37081238
34290887
27604565
19795409
35039149
36244875
30326935
21204008
22781549
23239020
18378771
21785136
19556463
23830905
16862116
17458552
27114033
32866962
33502028
31604244
25975230
29315334
30739198
24943344
35379992
29151590
34742308
32044129
32535152
28122877
31960800
22747919
25261995
36883644
15562429
32179883
32380523
24117616
32778130
31448566
26436904
30258234
37452321
25833819
21148344
12933918
23930978
26448863
24411104
26124111
28435163
30820047
28714976
27943641
21460841
26687838
31413141
31462511
10858277
28728022
25186741
22509390
22859297
16862115
26248158
1542665
18359860
34898994
24383743
21393509
34185706
25169730
18568075
12526812
21645236
21820214
33539798
21092856
36827976
30448285
31600775
31291241
27789271
26370502
28541286
31398187
29036611
30922528
30783219
16950801
28404863
30707188
30707189
36138153
18565828
19625741
31701892
18184915
31039256
21047645
29378861
28073925
24804730
20967127
35079633
37397563
36781744
20026663
30180904
23931993
17469117
17963732
35697880
32790644
28778989
27770818
28379303
32937039
34450028
25575133
28070672
32973454
28837568
18977398
30362531
24012002
30862089
36602862
30112957
28473694
25022663
20522652
23041626
28438992
21813674
28453791
22733568
37519899
19860916
20946666
23706646
21933710
27778404
24336722
20737593
29149899
8062819
21159977
27356620
37322482
26611584
30710128
34502086
11844847
14747386
12686654
16738662
31692592
36980592
11179018",Targeting Progranulin as an Immuno-Neurology Therapeutic Approach.,"Immuno-neurology is an emerging therapeutic strategy for dementia and neurodegeneration designed to address immune surveillance failure in the brain. Microglia, as central nervous system (CNS)-resident myeloid cells, routinely perform surveillance of the brain and support neuronal function. Loss-of-function (LOF) mutations causing decreased levels of progranulin (PGRN), an immune regulatory protein, lead to dysfunctional microglia and are associated with multiple neurodegenerative diseases, including frontotemporal dementia caused by the progranulin gene (","['PGRN', 'frontotemporal dementia', 'immuno-neurology', 'neuroimmunology', 'neuroinflammation']",International journal of molecular sciences,2023-11-14,"[{'lastname': 'Boylan', 'firstname': 'Maria A', 'initials': 'MA', 'affiliation': 'Alector, Inc., 131 Oyster Point Blvd, Suite 600, South San Francisco, CA 94080, USA.'}, {'lastname': 'Pincetic', 'firstname': 'Andrew', 'initials': 'A', 'affiliation': 'Alector, Inc., 131 Oyster Point Blvd, Suite 600, South San Francisco, CA 94080, USA.'}, {'lastname': 'Romano', 'firstname': 'Gary', 'initials': 'G', 'affiliation': 'Alector, Inc., 131 Oyster Point Blvd, Suite 600, South San Francisco, CA 94080, USA.'}, {'lastname': 'Tatton', 'firstname': 'Nadine', 'initials': 'N', 'affiliation': 'Alector, Inc., 131 Oyster Point Blvd, Suite 600, South San Francisco, CA 94080, USA.'}, {'lastname': 'Kenkare-Mitra', 'firstname': 'Sara', 'initials': 'S', 'affiliation': 'Alector, Inc., 131 Oyster Point Blvd, Suite 600, South San Francisco, CA 94080, USA.'}, {'lastname': 'Rosenthal', 'firstname': 'Arnon', 'initials': 'A', 'affiliation': 'Alector, Inc., 131 Oyster Point Blvd, Suite 600, South San Francisco, CA 94080, USA.'}]",,,,,"10.3390/ijms242115946
10.1016/0896-6273(91)90052-2
10.1016/j.jalz.2018.02.018
10.1016/j.neuron.2006.09.026
10.1016/j.tig.2004.01.008
10.3390/ijms232415755
10.3390/ijms221910298
10.1126/science.1134108
10.1177/1073858414561795
10.1136/jnnp.2010.212225
10.1007/s00415-019-09363-4
10.1056/NEJMoa2212948
10.1056/NEJMoa2100708
10.14283/jpad.2022.30
10.1038/s41591-023-02326-3
10.1056/NEJMoa2202867
10.1056/NEJMoa1900907
10.1007/s13311-022-01247-2
10.1016/j.ymthe.2021.04.008
10.1056/NEJMoa2204705
10.1007/s13311-022-01260-5
10.3390/ijms20030558
10.3389/fphar.2019.00840
10.1016/j.biopha.2021.111703
10.1126/science.1110647
10.1146/annurev-immunol-051116-052358
10.1038/s41467-019-13812-z
10.1093/jb/mvw009
10.1002/glia.23961
10.1126/sciadv.abk1131
10.3389/fimmu.2020.01024
10.1111/acel.12149
10.3390/ijms22094402
10.1016/j.tins.2020.10.002
10.1038/s41467-021-21823-y
10.1126/science.aay0793
10.1007/s12035-010-8106-8
10.1016/j.pharmthera.2013.04.013
10.1016/j.expneurol.2010.11.014
10.1038/nature21029
10.1007/s00018-023-04775-y
10.1042/NS20210008
10.1038/npp.2016.185
10.1002/bies.200900086
10.1016/j.tips.2021.11.015
10.1016/j.tcb.2022.09.006
10.1186/s13024-018-0288-y
10.1007/s13238-010-0067-1
10.1186/1750-1326-7-33
10.1007/s12035-012-8380-8
10.1083/jcb.200712039
10.1093/nar/gkr593
10.1126/science.1174447
10.1016/j.neuroscience.2013.06.049
10.1038/nature05016
10.1007/s00401-007-0223-8
10.1016/j.cell.2016.04.001
10.1038/s41586-020-2709-7
10.1002/ana.26032
10.1126/science.aav7188
10.1038/srep10042
10.1007/s00401-019-01962-9
10.1016/S1474-4422(14)70065-1
10.1038/s41588-022-01024-z
10.1038/nri.2017.125
10.1186/s12974-021-02309-6
10.1016/j.tins.2020.01.003
10.1016/j.nbd.2020.104962
10.1093/brain/aww349
10.1186/1742-2094-9-155
10.1038/nm.3672
10.1093/brain/awad078
10.1002/ana.20332
10.1093/brain/awaa033
10.1093/brain/awaa088
10.1111/nan.12092
10.1186/s12974-020-01907-0
10.1002/acn3.50875
10.1038/nn.4132
10.1038/s41593-018-0242-x
10.1186/s12974-023-02853-3
10.1093/brain/awv081
10.1126/science.1197623
10.1136/jnnp.74.9.1200
10.3109/00207454.2013.833510
10.1186/s40035-015-0041-1
10.1016/j.tins.2013.11.006
10.1073/pnas.1510329112
10.1038/nrn.2017.36
10.1038/s41588-019-0358-2
10.1038/ng.3916
10.1002/ajmg.b.32499
10.1038/ng.801
10.1016/j.neuron.2015.11.013
10.1126/scitranslmed.aau2291
10.1126/scitranslmed.aav6221
10.1177/002215540004800713
10.1016/j.neuron.2017.06.026
10.1523/JNEUROSCI.1860-14.2014
10.1371/journal.pone.0035115
10.1074/jbc.R112.399170
10.1038/nature05017
10.1371/journal.pone.0133749
10.1073/pnas.89.5.1715
10.1110/ps.073295308
10.2147/JIR.S339254
10.1111/imm.12241
10.1126/science.1199214
10.1172/JCI144016
10.1136/annrheumdis-2014-205779
10.1101/2023.04.06.535844
10.1016/S0092-8674(02)01141-8
10.1111/j.1582-4934.2011.01350.x
10.1016/j.neurobiolaging.2011.06.017
10.1016/j.brainres.2021.147312
10.1016/j.neuron.2010.09.034
10.1016/j.stemcr.2023.01.012
10.1016/j.nbd.2018.11.011
10.1093/hmg/ddz229
10.1371/journal.pone.0212382
10.1016/j.ebiom.2016.10.010
10.1083/jcb.201502029
10.1038/ncomms15277
10.1371/journal.pgen.1008295
10.1093/hmg/ddx364
10.1016/j.braindev.2019.03.004
10.1038/s41582-019-0138-8
10.1093/hmg/ddl241
10.1126/scitranslmed.aah5642
10.1212/CON.0000000000000698
10.1212/CON.0000000000000699
10.1038/s41591-022-01942-9
10.1212/01.wnl.0000319688.89790.7a
10.3233/JAD-2009-1170
10.1016/S1474-4422(19)30320-5
10.1212/01.wnl.0000289191.54852.75
10.1093/brain/awz099
10.1016/j.jns.2010.10.009
10.1523/JNEUROSCI.3081-17.2018
10.1093/hmg/ddx011
10.1371/journal.pone.0097032
10.1371/journal.pone.0013368
10.1002/btm2.10258
10.1016/j.gendis.2022.05.031
10.1007/s13311-023-01348-6
10.1084/jem.20091568
10.1186/s13024-018-0281-5
10.1016/j.neuron.2013.07.033
10.1002/ana.21154
10.1016/j.brainres.2007.09.048
10.1007/s00401-022-02444-1
10.1172/JCI139741
10.1084/jem.20160999
10.1186/s13024-016-0132-1
10.1093/brain/awx060
10.1002/acn3.51165
10.1016/j.cell.2021.08.002
10.1097/NEN.0000000000000158
10.1007/s00401-017-1668-z
10.3389/fncel.2020.00260
10.1371/journal.pone.0182896
10.1016/j.bbamcr.2008.09.018
10.1002/jcp.27588
10.1016/j.neuron.2013.06.046
10.3390/cells8030230
10.1172/JCI164919
10.1080/13554794.2018.1506039
10.1038/s41598-017-01587-6
10.1186/s40478-014-0078-x
10.2353/ajpath.2010.090915
10.1172/JCI63113
10.1101/2023.07.14.549089
10.1073/pnas.1700477114
10.1523/JNEUROSCI.6244-10.2011
10.1093/hmg/ddx162
10.1002/path.4043
10.1016/j.isci.2023.107247
10.1186/1471-2202-10-130
10.1186/1750-1326-5-41
10.1016/j.neurobiolaging.2013.04.022
10.1016/j.nbd.2011.08.029
10.1002/glia.23091
10.1523/JNEUROSCI.4318-13.2013
10.1002/cne.22430
10.1186/s12974-017-1000-9
10.1002/j.1460-2075.1994.tb06648.x
10.1523/JNEUROSCI.4067-10.2010
10.1038/ncomms11992
10.1186/s12967-023-04251-y
10.1038/s41573-019-0012-9
10.3390/ijms22179181
10.1056/NEJMoa011931
10.1097/01.ASN.0000107561.59698.42
10.1093/ndt/gfg182
10.1038/nature04818
10.1159/000500804
10.3390/cancers15061706
10.1086/318809",<Element 'PubmedArticle' at 0x7f05db57a270>
14,37914124,Probiotic Lactobacillus rhamnosus alleviates the neurotoxicity of microcystin-LR in zebrafish (Danio rerio) through the gut-brain axis.,"Microcystin-LR (MCLR) is one of the most toxic cyanobacterial toxins and is harmful to the central nervous system of fish. Probiotic additives can improve neuroendocrine function in fish. Although both MCLR and probiotics aim at the nervous system, whether they interact with each other and the mechanisms remain unexplored. In the present study, 4-month-old zebrafish were exposed to 0, 2.2, and 22 μg/L of MCLR for 28 days with or without the probiotic L. rhamnosus. We found that MCLR exposure could inhibit the swimming speed of zebrafish, while the presence of L. rhamnosus mitigated this abnormality. To elucidate the mechanism of how L. rhamnosus alleviates MCLR-induced neurotoxicity, we examined the bioaccumulation of MCLR, changes in neurotransmitters, immune biochemical indicators, and hormone content of the hypothalamic-pituitary-interrenal (HPI) axis in zebrafish along the gut-brain axis. Our results showed L. rhamnosus could reverse the abnormal swimming behavior and eventually alleviate neurotoxicity in zebrafish by modulating intestinal and brain neural signaling, neuroinflammation, and HPI axis responses. This study provides implications for the application of probiotics in the aquaculture industry.","['Gut-brain axis', 'HPI axis', 'MCLR', 'Neurotransmitter', 'Probiotic']",The Science of the total environment,2023-11-02,"[{'lastname': 'Luan', 'firstname': 'Ning', 'initials': 'N', 'affiliation': 'College of Fisheries, Huazhong Agricultural University, Wuhan 430070, China.'}, {'lastname': 'Zuo', 'firstname': 'Junli', 'initials': 'J', 'affiliation': 'College of Fisheries, Huazhong Agricultural University, Wuhan 430070, China.'}, {'lastname': 'Niu', 'firstname': 'Qianping', 'initials': 'Q', 'affiliation': 'College of Fisheries, Huazhong Agricultural University, Wuhan 430070, China.'}, {'lastname': 'Yan', 'firstname': 'Wei', 'initials': 'W', 'affiliation': 'Institute of Quality Standard and Testing Technology for Agro-Products, Hubei Academy of Agricultural Sciences, Hubei Key Laboratory of Nutritional Quality and Safety of Agro-products, Wuhan 430064, Hubei, China.'}, {'lastname': 'Hung', 'firstname': 'Tien-Chieh', 'initials': 'TC', 'affiliation': 'Department of Biological and Agricultural Engineering, University of California-Davis, Davis, CA 95616, USA.'}, {'lastname': 'Liu', 'firstname': 'Haoling', 'initials': 'H', 'affiliation': 'College of Fisheries, Huazhong Agricultural University, Wuhan 430070, China.'}, {'lastname': 'Wu', 'firstname': 'Qin', 'initials': 'Q', 'affiliation': 'Hubei Key Laboratory of Edible Wild Plants Conservation and Utilization, Huangshi Key Laboratory of Lake Biodiversity and Environmental Conservation, Hubei Normal University, Huangshi, Hubei Province 435002, China.'}, {'lastname': 'Wang', 'firstname': 'Guoao', 'initials': 'G', 'affiliation': 'College of Fisheries, Huazhong Agricultural University, Wuhan 430070, China.'}, {'lastname': 'Deng', 'firstname': 'Ping', 'initials': 'P', 'affiliation': ""Study and practical demonstratiministryon on regime shifts and optimization of ecosystem after ecological restoration project 'turning fishpond to wetland' in Chenhu Lake, Wuhan Academy of Agricultural Sciences, Wuhan 430056, China.""}, {'lastname': 'Ma', 'firstname': 'Xufa', 'initials': 'X', 'affiliation': 'College of Fisheries, Huazhong Agricultural University, Wuhan 430070, China.'}, {'lastname': 'Qin', 'firstname': 'Jianhui', 'initials': 'J', 'affiliation': 'College of Fisheries, Huazhong Agricultural University, Wuhan 430070, China.'}, {'lastname': 'Li', 'firstname': 'Guangyu', 'initials': 'G', 'affiliation': 'College of Fisheries, Huazhong Agricultural University, Wuhan 430070, China. Electronic address: liguangyu@mail.hzau.edu.cn.'}]",,,,Copyright © 2023. Published by Elsevier B.V.,10.1016/j.scitotenv.2023.168058,<Element 'PubmedArticle' at 0x7f05da962ef0>
15,37907134,Repurposing and clinical attributes of antidiabetic drugs for the treatment of neurodegenerative disorders.,"The risk of neurodegeneration was found to be increased among people with type 2 diabetes mellitus (T2DM). Brain disorders like Alzheimer's disease, Parkinson's disease, Huntington's disease, Amyotrophic lateral sclerosis, and others are considered neurodegenerative diseases and can be characterized by progressive loss of neurons. The deficiency of insulin, impaired signaling, and its resistance lead to alteration in the neuronal functioning of the brain. Insulin degrading enzyme (IDE) plays a significant role in the amyloid β metabolism, aggregation, and deposition of misfolded proteins in the brain's hippocampal and cortical neuronal regions. The insulin signaling via IP3 activation upregulates the IDE and could be a promising approach to regulate neurodegeneration. The repurposing of existing antidiabetic drugs such as Metformin, DPP-4 inhibitors, thiazolidinediones, glucagon-like peptides (GLP-1), sodium-glucose co-transport-2 (SGCT-2) inhibitors, and insulin could be an alternative and effective strategy to treat neurodegeneration via modulating insulin signaling, insulin resistance, IDE activity, oxidative stress, mitochondrial dysfunction, serum lipid profile and neuroinflammation in the brain. Antidiabetic medications reduce the risk of neuroinflammation, oxidative stress, and Aβ deposition by enhancing their clearance rate. The downregulation of IDE alters the degradation of Aβ monomers in the Tg2576 APP mice. Also, the treatment with metformin activated the AMPK pathway and suppressed mTOR and BACE-1 protein expression in the APP/PS1-induced mice model. Thus, the primary intention of this review is to explore the link between T2DM and neurodegenerative disorders, and the possible role of various antidiabetic drugs in the management of neurodegenerative disorders.","['AMPK/mTOR/BACE1', 'Antidiabetic drugs', 'Insulin degrading enzyme (IDE)', 'Insulin resistance', 'Neurodegenerative disorders', 'Oxidative stress']",European journal of pharmacology,2023-11-01,"[{'lastname': 'Birajdar', 'firstname': 'Swapnali Vasant', 'initials': 'SV', 'affiliation': 'Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research (NIPER) Raebareli, Lucknow, 226002, Uttar Pradesh, India.'}, {'lastname': 'Mazahir', 'firstname': 'Farhan', 'initials': 'F', 'affiliation': 'Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research (NIPER) Raebareli, Lucknow, 226002, Uttar Pradesh, India.'}, {'lastname': 'Alam', 'firstname': 'Md Imtiyaz', 'initials': 'MI', 'affiliation': 'Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research (NIPER) Raebareli, Lucknow, 226002, Uttar Pradesh, India.'}, {'lastname': 'Kumar', 'firstname': 'Amit', 'initials': 'A', 'affiliation': 'Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research (NIPER) Raebareli, Lucknow, 226002, Uttar Pradesh, India.'}, {'lastname': 'Yadav', 'firstname': 'Awesh K', 'initials': 'AK', 'affiliation': 'Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research (NIPER) Raebareli, Lucknow, 226002, Uttar Pradesh, India. Electronic address: awesh.yadav@niperraebareli.edu.in.'}]",,,,Copyright © 2023 Elsevier B.V. All rights reserved.,10.1016/j.ejphar.2023.176117,<Element 'PubmedArticle' at 0x7f05ddabbf90>
16,37884161,GV1001 modulates neuroinflammation and improves memory and behavior through the activation of gonadotropin-releasing hormone receptors in a triple transgenic Alzheimer's disease mouse model.,"GV1001 protects neural cells from amyloid-β (Aβ) toxicity and other stressors in in vitro studies and demonstrates clinically beneficial effects in patients with moderate to severe Alzheimer's disease (AD). Here, we investigated the protective effects and mechanism of action of GV1001 in triple transgenic AD (3xTg-AD) mice. We found that GV1001 improved memory and cognition in middle- and old-aged 3xTg-AD mice. Additionally, it reduced Aβ oligomer and phospho-tau (Ser202 and Thr205) levels in the brain, and mitigated neuroinflammation by promoting a neuroprotective microglial and astrocyte phenotype while diminishing the neurotoxic ones. In vitro, GV1001 bound to gonadotropin releasing hormone receptors (GnRHRs) with high affinity. Levels of cyclic adenosine monophosphate, a direct downstream effector of activated GnRHRs, increased after GV1001 treatment. Furthermore, inhibition of GnRHRs blocked GV1001-induced effects. Thus, GV1001 might improve cognitive and memory functions of 3xTg-AD mice by suppressing neuroinflammation and reducing Aβ oligomers levels and phospho-tau by activating GnRHRs and their downstream signaling pathways.","['3xTg-AD mice', 'Alzheimer’s disease', 'GV1001', 'Gonadotropin-releasing hormone receptors', 'Neuroinflammation']","Brain, behavior, and immunity",2023-10-27,"[{'lastname': 'Park', 'firstname': 'Hyunhee', 'initials': 'H', 'affiliation': 'Department of Neurology, Hanyang University Guri Hospital, Hanyang University College of Medicine, 153, Gyeongchun-ro, Guri-si, Gyeonggi-do 11923, South Korea.'}, {'lastname': 'Kwon', 'firstname': 'Hyuk Sung', 'initials': 'HS', 'affiliation': 'Department of Neurology, Hanyang University Guri Hospital, Hanyang University College of Medicine, 153, Gyeongchun-ro, Guri-si, Gyeonggi-do 11923, South Korea.'}, {'lastname': 'Lee', 'firstname': 'Kyu-Yong', 'initials': 'KY', 'affiliation': 'Department of Neurology, Hanyang University Guri Hospital, Hanyang University College of Medicine, 153, Gyeongchun-ro, Guri-si, Gyeonggi-do 11923, South Korea.'}, {'lastname': 'Kim', 'firstname': 'Ye Eun', 'initials': 'YE', 'affiliation': 'Department of Neurology, Hanyang University Guri Hospital, Hanyang University College of Medicine, 153, Gyeongchun-ro, Guri-si, Gyeonggi-do 11923, South Korea.'}, {'lastname': 'Son', 'firstname': 'Jeong-Woo', 'initials': 'JW', 'affiliation': 'Department of Neurology, Hanyang University Guri Hospital, Hanyang University College of Medicine, 153, Gyeongchun-ro, Guri-si, Gyeonggi-do 11923, South Korea.'}, {'lastname': 'Choi', 'firstname': 'Na-Young', 'initials': 'NY', 'affiliation': 'Department of Neurology, Hanyang University Guri Hospital, Hanyang University College of Medicine, 153, Gyeongchun-ro, Guri-si, Gyeonggi-do 11923, South Korea.'}, {'lastname': 'Lee', 'firstname': 'Eun Ji', 'initials': 'EJ', 'affiliation': 'Department of Neurology, Hanyang University Guri Hospital, Hanyang University College of Medicine, 153, Gyeongchun-ro, Guri-si, Gyeonggi-do 11923, South Korea.'}, {'lastname': 'Han', 'firstname': 'Myung-Hoon', 'initials': 'MH', 'affiliation': 'Department of Neurosurgery, Hanyang University Guri Hospital, Hanyang University College of Medicine, 153, Gyeongchun-ro, Guri-si, Gyeonggi-do 11923, South Korea.'}, {'lastname': 'Park', 'firstname': 'Dong Woo', 'initials': 'DW', 'affiliation': 'Department of Radiology, Hanyang University Guri Hospital, Hanyang University College of Medicine, 153, Gyeongchun-ro, Guri-si, Gyeonggi-do 11923, South Korea.'}, {'lastname': 'Kim', 'firstname': 'Sangjae', 'initials': 'S', 'affiliation': 'Teloid Inc., 3580 Wilshire Boulevard, Suite 900-31, Los Angeles, CA 90010, USA. Electronic address: chiron@gemvax.com.'}, {'lastname': 'Koh', 'firstname': 'Seong-Ho', 'initials': 'SH', 'affiliation': 'Department of Neurology, Hanyang University Guri Hospital, Hanyang University College of Medicine, 153, Gyeongchun-ro, Guri-si, Gyeonggi-do 11923, South Korea; Department of Translational Medicine, Hanyang University Graduate School of Biomedical Science & Engineering, Seoul 04763, South Korea. Electronic address: ksh213@hanyang.ac.kr.'}]",,,,Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved.,10.1016/j.bbi.2023.10.021,<Element 'PubmedArticle' at 0x7f05ddaaaae0>
17,37865165,Melatonin Protects Injured Spinal Cord Neurons From Apoptosis by Inhibiting Mitochondrial Damage via the SIRT1/Drp1 Signaling Pathway.,"Spinal cord injuries (SCIs) often result in limited prospects for recovery and a high incidence of disability. Melatonin (Mel), a hormone, is acknowledged for its neuroprotective attributes. Mel was examined in this study to discover if it alleviates SCIs via the sirtuin1/dynamin-related protein1 (SIRT1/Drp1) signaling pathway. SCIs were simulated in mice by inducing cord contusion at the T9-T10 vertebrae and causing inflammation in primary spinal neurons using lipopolysaccharide (LPS). The findings of our study demonstrated that Mel treatment effectively promoted neuromotor recovery through multiple mechanisms, including the reduction of neuronal death, suppression of astrocyte and microglia activation, and attenuation of neuroinflammation. Moreover, Mel therapy significantly upregulated the expression of SIRT1 in both spinal cord tissues and spinal neurons of mice. Additionally, Mel exhibited the potential to mitigate neuronal mitochondrial dysfunction by modulating the levels of Drp1 and TOMM20, thereby addressing the underlying factors contributing to this dysfunction. Furthermore, when SIRT1 was downregulated, it reversed the positive effects of Mel. Overall, our present study suggests that Mel has the capacity to modulate the SIRT1/Drp1 pathway, thereby ameliorating mitochondrial dysfunction, attenuating inflammation and apoptosis, and enhancing neural function subsequent to SCIs.","['Apoptosis', 'Dynamin-related protein 1', 'Melatonin', 'Mitochondria', 'Sirtuin 1', 'Spinal cord injury']",Neuroscience,2023-10-22,"[{'lastname': 'Zhong', 'firstname': 'Guibin', 'initials': 'G', 'affiliation': 'Department of Orthopaedics, Baoshan Branch, Ren Ji Hospital, School of Medicine Shanghai Jiao Tong University, No.1058, Huan Zhen Bei Road, Shanghai 200444, China; Department of Orthopaedics, Ren Ji Hospital, School of Medicine Shanghai Jiao Tong University, Shanghai 200127, China.'}, {'lastname': 'Yang', 'firstname': 'Yanqiu', 'initials': 'Y', 'affiliation': 'Department of Orthopaedics, Baoshan Branch, Ren Ji Hospital, School of Medicine Shanghai Jiao Tong University, No.1058, Huan Zhen Bei Road, Shanghai 200444, China.'}, {'lastname': 'Feng', 'firstname': 'Daming', 'initials': 'D', 'affiliation': 'Department of Orthopaedics, Baoshan Branch, Ren Ji Hospital, School of Medicine Shanghai Jiao Tong University, No.1058, Huan Zhen Bei Road, Shanghai 200444, China.'}, {'lastname': 'Wei', 'firstname': 'Ke', 'initials': 'K', 'affiliation': 'Department of Orthopaedics, Baoshan Branch, Ren Ji Hospital, School of Medicine Shanghai Jiao Tong University, No.1058, Huan Zhen Bei Road, Shanghai 200444, China.'}, {'lastname': 'Chen', 'firstname': 'Junling', 'initials': 'J', 'affiliation': 'Department of Orthopaedics, Baoshan Branch, Ren Ji Hospital, School of Medicine Shanghai Jiao Tong University, No.1058, Huan Zhen Bei Road, Shanghai 200444, China.'}, {'lastname': 'Chen', 'firstname': 'Jianwei', 'initials': 'J', 'affiliation': 'Department of Orthopaedics, Ren Ji Hospital, School of Medicine Shanghai Jiao Tong University, Shanghai 200127, China.'}, {'lastname': 'Deng', 'firstname': 'Chao', 'initials': 'C', 'affiliation': 'Department of Spine Surgery and Orthopaedics, Xiangya Hospital, Central South University, No.87, Xiangya Road, Kaifu District, Changsha 410008, China. Electronic address: dengchao0816@126.com.'}]",,,,Copyright © 2023 The Authors. Published by Elsevier Ltd.. All rights reserved.,10.1016/j.neuroscience.2023.10.010,<Element 'PubmedArticle' at 0x7f05ddabd1d0>
18,"37830561
19829367
10735278
36918389
33667416
2655627
63862
1673054
1763432
1736183
19282288
19503072
27179961
1745413
1370967
33318676
25792098
30795987
26871627
35978311
34433707
32963694
34267346
29562533
24664866
35395415
28059794
29162310
2278545
32221697
37197654
30784608
13524162
10922518
9122257
37008911
17111043
37453419
37343447
9065537
30221596
23562431
33157321
35444256
31300657
36056211
36533129
33597769
10858586
36012242
23983897
31375134
35069578
11818174
25533482
31086184
35026701
32823544
22397651
32829072
9467682",Hydrocortisone Mitigates Alzheimer's-Related Cognitive Decline through Modulating Oxidative Stress and Neuroinflammation.,"Alzheimer's disease (AD), an age-related degenerative disorder, is characterized by β-amyloid deposition, abnormal phosphorylation of tau proteins, synaptic dysfunction, neuroinflammation, and oxidative stress. Despite extensive research, there are no medications or therapeutic interventions to completely treat and reverse AD. Herein, we explore the potential of hydrocortisone (HC), a natural and endogenous glucocorticoid known to have potent anti-inflammatory properties, in an Aβ","['Alzheimer’s disease', 'glial activation', 'hydrocortisone', 'neuroinflammation', 'oxidative stress']",Cells,2023-10-13,"[{'lastname': 'Li', 'firstname': 'Jinran', 'initials': 'J', 'affiliation': 'Jiangsu Provincial Key Laboratory of Drug Metabolism and Pharmacokinetics, China Pharmaceutical University, 639 Longmian Avenue, Nanjing 211166, China.\nState Key Laboratory of Natural Medicines, China Pharmaceutical University, 639 Longmian Avenue, Nanjing 211166, China.'}, {'lastname': 'Chen', 'firstname': 'Long', 'initials': 'L', 'affiliation': 'Jiangsu Provincial Key Laboratory of Drug Metabolism and Pharmacokinetics, China Pharmaceutical University, 639 Longmian Avenue, Nanjing 211166, China.\nState Key Laboratory of Natural Medicines, China Pharmaceutical University, 639 Longmian Avenue, Nanjing 211166, China.'}, {'lastname': 'Liu', 'firstname': 'Sai', 'initials': 'S', 'affiliation': 'Jiangsu Provincial Key Laboratory of Drug Metabolism and Pharmacokinetics, China Pharmaceutical University, 639 Longmian Avenue, Nanjing 211166, China.\nState Key Laboratory of Natural Medicines, China Pharmaceutical University, 639 Longmian Avenue, Nanjing 211166, China.'}, {'lastname': 'Sun', 'firstname': 'Yuan', 'initials': 'Y', 'affiliation': 'Jiangsu Provincial Key Laboratory of Drug Metabolism and Pharmacokinetics, China Pharmaceutical University, 639 Longmian Avenue, Nanjing 211166, China.\nState Key Laboratory of Natural Medicines, China Pharmaceutical University, 639 Longmian Avenue, Nanjing 211166, China.'}, {'lastname': 'Zhen', 'firstname': 'Le', 'initials': 'L', 'affiliation': 'Jiangsu Provincial Key Laboratory of Drug Metabolism and Pharmacokinetics, China Pharmaceutical University, 639 Longmian Avenue, Nanjing 211166, China.\nState Key Laboratory of Natural Medicines, China Pharmaceutical University, 639 Longmian Avenue, Nanjing 211166, China.'}, {'lastname': 'Zhu', 'firstname': 'Zheying', 'initials': 'Z', 'affiliation': 'School of Pharmacy, The University of Nottingham, Nottingham NG7 2RD, UK.'}, {'lastname': 'Wang', 'firstname': 'Guangji', 'initials': 'G', 'affiliation': 'Jiangsu Provincial Key Laboratory of Drug Metabolism and Pharmacokinetics, China Pharmaceutical University, 639 Longmian Avenue, Nanjing 211166, China.\nState Key Laboratory of Natural Medicines, China Pharmaceutical University, 639 Longmian Avenue, Nanjing 211166, China.'}, {'lastname': 'Li', 'firstname': 'Xinuo', 'initials': 'X', 'affiliation': 'Jiangsu Provincial Key Laboratory of Drug Metabolism and Pharmacokinetics, China Pharmaceutical University, 639 Longmian Avenue, Nanjing 211166, China.\nState Key Laboratory of Natural Medicines, China Pharmaceutical University, 639 Longmian Avenue, Nanjing 211166, China.'}]",,,,,"10.3390/cells12192348
10.1038/461895a
10.1007/s100480050011
10.1002/alz.13016
10.1016/S0140-6736(20)32205-4
10.1146/annurev.pu.10.050189.000555
10.1016/S0140-6736(76)91936-X
10.1016/0896-6273(91)90052-2
10.1016/0165-6147(91)90609-V
10.1212/WNL.42.2.447
10.1074/jbc.M808759200
10.1038/ncb1901
10.1016/j.jalz.2016.02.010
10.1016/0304-3940(91)90490-K
10.1038/s41582-020-00435-y
10.1016/S1474-4422(15)70016-5
10.1016/S1474-4422(18)30490-3
10.1016/j.cell.2015.12.056
10.1186/s12974-022-02565-0
10.1248/bpb.b21-00381
10.1155/2020/4754195
10.1038/s41401-021-00702-8
10.3233/JAD-170732
10.1007/s12264-013-1423-y
10.1016/j.arr.2022.101619
10.3233/JAD-161088
10.1016/j.tem.2017.10.010
10.1056/NEJM199005173222001
10.1007/s00213-020-05503-1
10.3389/fimmu.2023.1192940
10.1016/j.ccc.2018.11.005
10.1210/endo-62-4-455
10.1016/S0361-9230(00)00275-6
10.1073/pnas.94.6.2687
10.3389/fendo.2023.1107780
10.1371/journal.pctr.0010033
10.1016/j.neuron.2023.06.013
10.1016/j.redox.2023.102785
10.1212/WNL.48.3.626
10.1056/NEJMoa1800722
10.1016/j.jalz.2012.11.012
10.1016/j.arr.2020.101208
10.1038/s41380-022-01565-z
10.1038/s41467-019-10910-w
10.1038/s41583-022-00624-2
10.3389/fnmol.2022.1037912
10.1038/s41436-020-01075-9
10.1016/S0197-4580(00)00124-X
10.3390/ijms23168972
10.1155/2013/316523
10.1186/s13024-019-0333-5
10.3389/fimmu.2021.796867
10.1016/S0306-4530(01)00061-0
10.1016/j.neuron.2014.11.018
10.1038/s41467-019-10116-0
10.1016/j.redox.2022.102229
10.3390/antiox9080743
10.1056/NEJMoa1106668
10.1016/j.psychres.2020.113409
10.2165/00002512-199812010-00001",<Element 'PubmedArticle' at 0x7f05ddad0d10>
19,37786968,Melatonin prevents EAAC1 deletion-induced retinal ganglion cell degeneration by inhibiting apoptosis and senescence.,"Normal tension glaucoma (NTG) is referred to as a progressive degenerative disorder of the retinal ganglion cells (RGCs), resulting in nonreversible visual defects, despite intraocular pressure levels within the statistically normal range. Current therapeutic strategies for NTG yield limited benefits. Excitatory amino acid carrier 1 (EAAC1) knockout (EAAC1","['EAAC1', 'apoptosis', 'melatonin', 'normal tension glaucoma', 'oxidative stress', 'retinal ganglion cells', 'senescence']",Journal of pineal research,2023-10-03,"[{'lastname': 'Hu', 'firstname': 'Chenyang', 'initials': 'C', 'affiliation': 'State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangdong Provincial Key Laboratory of Ophthalmology and Visual Science, Guangzhou, China.'}, {'lastname': 'Feng', 'firstname': 'Yanlin', 'initials': 'Y', 'affiliation': 'State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangdong Provincial Key Laboratory of Ophthalmology and Visual Science, Guangzhou, China.'}, {'lastname': 'Huang', 'firstname': 'Guangyi', 'initials': 'G', 'affiliation': ""Guangxi Key Laboratory of Eye Health & Guangxi Health Commission Key Laboratory of Ophthalmology and Related Systemic Diseases Artificial Intelligence Screening Technology, Department of Ophthalmology, The People's Hospital of Guangxi Zhuang Autonomous Region, Institute of Ophthalmic Diseases, Guangxi Academy of Medical Sciences, Nanning, China.""}, {'lastname': 'Cui', 'firstname': 'Kaixuan', 'initials': 'K', 'affiliation': 'State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangdong Provincial Key Laboratory of Ophthalmology and Visual Science, Guangzhou, China.'}, {'lastname': 'Fan', 'firstname': 'Matthew', 'initials': 'M', 'affiliation': 'Yale College, Yale University, New Haven, Connecticut, USA.'}, {'lastname': 'Xiang', 'firstname': 'Wu', 'initials': 'W', 'affiliation': 'State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangdong Provincial Key Laboratory of Ophthalmology and Visual Science, Guangzhou, China.'}, {'lastname': 'Shi', 'firstname': 'Yuxun', 'initials': 'Y', 'affiliation': 'State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangdong Provincial Key Laboratory of Ophthalmology and Visual Science, Guangzhou, China.'}, {'lastname': 'Ye', 'firstname': 'Dan', 'initials': 'D', 'affiliation': 'State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangdong Provincial Key Laboratory of Ophthalmology and Visual Science, Guangzhou, China.'}, {'lastname': 'Ye', 'firstname': 'Huiwen', 'initials': 'H', 'affiliation': 'State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangdong Provincial Key Laboratory of Ophthalmology and Visual Science, Guangzhou, China.'}, {'lastname': 'Bai', 'firstname': 'Xue', 'initials': 'X', 'affiliation': 'State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangdong Provincial Key Laboratory of Ophthalmology and Visual Science, Guangzhou, China.'}, {'lastname': 'Xu', 'firstname': 'Fan', 'initials': 'F', 'affiliation': ""Guangxi Key Laboratory of Eye Health & Guangxi Health Commission Key Laboratory of Ophthalmology and Related Systemic Diseases Artificial Intelligence Screening Technology, Department of Ophthalmology, The People's Hospital of Guangxi Zhuang Autonomous Region, Institute of Ophthalmic Diseases, Guangxi Academy of Medical Sciences, Nanning, China.""}, {'lastname': 'Xu', 'firstname': 'Yue', 'initials': 'Y', 'affiliation': 'State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangdong Provincial Key Laboratory of Ophthalmology and Visual Science, Guangzhou, China.'}, {'lastname': 'Huang', 'firstname': 'Jingjing', 'initials': 'J', 'affiliation': 'State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-sen University, Guangdong Provincial Key Laboratory of Ophthalmology and Visual Science, Guangzhou, China.'}]",,,,© 2023 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.,10.1111/jpi.12916,<Element 'PubmedArticle' at 0x7f05def08950>
20,"37712419
10199429
9153163
17135285
25205317
28846921
29847771
28093732
31310807
25957002
30714337
34582594
34334233
29804835
32869747
32320644
17567808
20012068
27027288
22553043
28099414
11755001
22593014
31840043
25907614
24211851
27015313
12036302
32530565
22558197
11533224
31429156
8421494
4985058
20457765
7791901
33848615
34233151
35283239
11773440
24962572
29249556
19716793
36472247
31332839
33014432
29437957
22289043
15082697
24445074
28033587
26985039
22492045
21645039
9393880
32686212
34161122
33436375
26337722
11483993
26643508
32442584
19377485",PJA1 mediates the effects of astrocytic GPR30 on learning and memory in female mice.,"Hormone replacement therapy (HRT) is not recommended for treating learning and memory decline in menopausal women because it exerts adverse effects by activating classic estrogen receptors ERα and ERβ. The membrane estrogen receptor G protein-coupled receptor 30 (GPR30) has been reported to be involved in memory modulation; however, the underlying mechanisms are poorly understood. Here, we found that GPR30 deletion in astrocytes, but not in neurons, impaired learning and memory in female mice. Astrocytic GPR30 depletion induced A1 phenotype transition, impairing neuronal function. Further exploration revealed that Praja1 (PJA1), a RING ubiquitin ligase, mediated the effects of astrocytic GPR30 on learning and memory by binding to Serpina3n, which is a molecular marker of neuroinflammation in astrocytes. GPR30 positively modulated PJA1 expression through the CREB signaling pathway in cultured murine and human astrocytes. Additionally, the mRNA levels of GPR30 and PJA1 were reduced in exosomes isolated from postmenopausal women while Serpina3n levels were increased in the plasma. Together, our findings suggest a key role for astrocytic GPR30 in the learning and memory abilities of female mice and identify GPR30/PJA1/Serpina3n as potential therapeutic targets for learning and memory loss in peri- and postmenopausal women.","['Inflammation', 'Memory', 'Neuroscience', 'Pharmacology']",The Journal of clinical investigation,2023-09-15,"[{'lastname': 'Wang', 'firstname': 'Xinshang', 'initials': 'X', 'affiliation': 'Department of Pharmacology, School of Pharmacy and.'}, {'lastname': 'Jiang', 'firstname': 'Yongli', 'initials': 'Y', 'affiliation': ""Precision Pharmacy & Drug Development Center, Department of Pharmacy, Tangdu Hospital, Fourth Military Medical University, Xi'an, China.""}, {'lastname': 'Feng', 'firstname': 'Ban', 'initials': 'B', 'affiliation': 'Department of Pharmacology, School of Pharmacy and.'}, {'lastname': 'Ma', 'firstname': 'Xue', 'initials': 'X', 'affiliation': 'Department of Pharmacology, School of Pharmacy and.'}, {'lastname': 'Zhang', 'firstname': 'Kun', 'initials': 'K', 'affiliation': 'Department of Pharmacology, School of Pharmacy and.'}, {'lastname': 'Yang', 'firstname': 'Fan', 'initials': 'F', 'affiliation': 'Department of Pharmacology, School of Pharmacy and.'}, {'lastname': 'Liu', 'firstname': 'Zhenguo', 'initials': 'Z', 'affiliation': ""Department of Pharmacy, Northwest Women's and Children's Hospital, Xi'an, China.""}, {'lastname': 'Yang', 'firstname': 'Le', 'initials': 'L', 'affiliation': ""Precision Pharmacy & Drug Development Center, Department of Pharmacy, Tangdu Hospital, Fourth Military Medical University, Xi'an, China.""}, {'lastname': 'Yue', 'firstname': 'Jiao', 'initials': 'J', 'affiliation': 'Department of Pharmacology, School of Pharmacy and.'}, {'lastname': 'Lu', 'firstname': 'Liang', 'initials': 'L', 'affiliation': 'Department of Pharmacology, School of Pharmacy and.'}, {'lastname': 'Song', 'firstname': 'Dake', 'initials': 'D', 'affiliation': 'Department of Pharmacology, School of Pharmacy and.'}, {'lastname': 'Guo', 'firstname': 'Qingjuan', 'initials': 'Q', 'affiliation': 'Department of Pharmacology, School of Pharmacy and.'}, {'lastname': 'Qi', 'firstname': 'Jingyu', 'initials': 'J', 'affiliation': 'Department of Pharmacology, School of Pharmacy and.'}, {'lastname': 'Li', 'firstname': 'Xubo', 'initials': 'X', 'affiliation': 'Department of Pharmacology, School of Pharmacy and.'}, {'lastname': 'Wang', 'firstname': 'Min', 'initials': 'M', 'affiliation': 'Department of Pharmacology, School of Pharmacy and.'}, {'lastname': 'Zhang', 'firstname': 'Huinan', 'initials': 'H', 'affiliation': ""Department of Health Management, Tangdu Hospital, Fourth Military Medical University, Xi'an, China.""}, {'lastname': 'Huang', 'firstname': 'Jing', 'initials': 'J', 'affiliation': ""Department of Health Management, Tangdu Hospital, Fourth Military Medical University, Xi'an, China.""}, {'lastname': 'Zhao', 'firstname': 'Minggao', 'initials': 'M', 'affiliation': ""Precision Pharmacy & Drug Development Center, Department of Pharmacy, Tangdu Hospital, Fourth Military Medical University, Xi'an, China.""}, {'lastname': 'Liu', 'firstname': 'Shuibing', 'initials': 'S', 'affiliation': 'Department of Pharmacology, School of Pharmacy and.'}]",,,,,"10.1172/JCI165812
10.1001/jama.281.13.1197
10.1212/WNL.48.5_Suppl_7.21S
10.1093/humupd/dml042
10.1016/j.yhbeh.2014.08.011
10.1016/j.psyneuen.2017.08.013
10.1016/j.yhbeh.2018.05.019
10.1016/j.semcancer.2019.07.006
10.1016/j.psyneuen.2015.04.002
10.1111/cns.13108
10.1002/glia.24099
10.1016/j.tins.2021.07.004
10.1016/j.cell.2018.05.002
10.1016/j.neuron.2020.03.025
10.1523/JNEUROSCI.1419-07.2007
10.1007/s00401-009-0619-8
10.1038/nature17623
10.1523/JNEUROSCI.6221-11.2012
10.1038/nature21029
10.1016/S0197-4580(01)00302-5
10.1002/glia.22354
10.1038/s41531-019-0101-9
10.1038/nrm3982
10.1016/j.pneurobio.2013.10.004
10.1016/j.cell.2016.03.003
10.1006/geno.2002.6770
10.1002/acn3.51093
10.1371/journal.pone.0035678
10.1101/lm.39401
10.1002/glia.23697
10.1038/361031a0
10.1002/aja.1001270402
10.1083/jcb.201003008
10.1038/375682a0
10.1016/j.brainresbull.2021.04.005
10.1016/j.neuron.2021.06.012
10.1016/j.pneurobio.2022.102264
10.1210/mend.16.1.0758
10.1074/jbc.M114.566893
10.1016/j.jneuroim.2017.12.005
10.1016/j.molcel.2009.06.028
10.15252/embj.2022112372
10.1111/jpi.12596
10.1038/s41420-020-00325-8
10.1073/pnas.1800165115
10.1037/a0026660
10.1001/jama.291.14.1775
10.1016/j.bbr.2014.01.006
10.1016/j.psyneuen.2016.11.019
10.1523/JNEUROSCI.0257-15.2016
10.1523/JNEUROSCI.5828-11.2012
10.1111/j.1440-1681.2011.05549.x
10.1038/sj.onc.1201405
10.1111/neup.12694
10.1091/mbc.E20-11-0747
10.1212/NXI.0000000000000941
10.1186/s12974-015-0376-7
10.1038/35085068
10.1002/ptr.5538
10.1016/j.physbeh.2020.112891
10.1038/nmeth.1322",<Element 'PubmedArticle' at 0x7f05def2aa40>
21,"37708021
10788637
27396334
27174389
33811144
15937014
37310190
23177956
33091338
27477017
33301712
7488853
15378039
22878719
23817549
27021171
32296311
25104383
33609483
24097352
30110598
22443509
20087360
17995907
22330314
32029359
16289526
30318409
22593071
33229572
25556836
28167837
37643621
27749828
20188652
36624279
36416886
28666633
21034768
11449264
14622888
17097864
30038278
1540675
10195184
26354921
29247159
25278859
36282913
27013676
35210417
26612957
35221922
24440415
33108272
32101169
23995447
26196895
24358266
37708021
37708021
28384469
26909035
25201983
23868258
25147504
32143831
24035827
28816240
22176721
17274017
21253357
30122374
31000656",Top-down input modulates visual context processing through an interneuron-specific circuit.,"Visual stimuli that deviate from the current context elicit augmented responses in the primary visual cortex (V1). These heightened responses, known as ""deviance detection,"" require local inhibition in the V1 and top-down input from the anterior cingulate area (ACa). Here, we investigated the mechanisms by which the ACa and V1 interact to support deviance detection. Local field potential recordings in mice during an oddball paradigm showed that ACa-V1 synchrony peaks in the theta/alpha band (≈10 Hz). Two-photon imaging in the V1 revealed that mainly pyramidal neurons exhibited deviance detection, while contextually redundant stimuli increased vasoactive intestinal peptide (VIP)-positive interneuron (VIP) activity and decreased somatostatin-positive interneuron (SST) activity. Optogenetic drive of ACa-V1 inputs at 10 Hz activated V1-VIPs but inhibited V1-SSTs, mirroring the dynamics present during the oddball paradigm. Chemogenetic inhibition of V1-VIPs disrupted Aca-V1 synchrony and deviance detection in the V1. These results outline temporal and interneuron-specific mechanisms of top-down modulation that support visual context processing.","['CP: Neuroscience', 'cortex', 'interneurons', 'mismatch negativity', 'oscillations', 'predictive coding', 'schizophrenia']",Cell reports,2023-09-14,"[{'lastname': 'Bastos', 'firstname': 'Georgia', 'initials': 'G', 'affiliation': 'Neuroscience Institute, Georgia State University, Petit Science Center, 100 Piedmont Ave, Atlanta, GA 30303, USA; Center for Neuroinflammation and Cardiometabolic Diseases, Georgia State University, Petit Science Center, 100 Piedmont Ave, Atlanta, GA 30303, USA.'}, {'lastname': 'Holmes', 'firstname': 'Jacob T', 'initials': 'JT', 'affiliation': 'Neuroscience Institute, Georgia State University, Petit Science Center, 100 Piedmont Ave, Atlanta, GA 30303, USA.'}, {'lastname': 'Ross', 'firstname': 'Jordan M', 'initials': 'JM', 'affiliation': 'Neuroscience Institute, Georgia State University, Petit Science Center, 100 Piedmont Ave, Atlanta, GA 30303, USA; Center for Behavioral Neuroscience, Georgia State University, Petit Science Center, 100 Piedmont Ave, Atlanta, GA 30303, USA.'}, {'lastname': 'Rader', 'firstname': 'Anna M', 'initials': 'AM', 'affiliation': 'Neuroscience Institute, Georgia State University, Petit Science Center, 100 Piedmont Ave, Atlanta, GA 30303, USA; Center for Neuroinflammation and Cardiometabolic Diseases, Georgia State University, Petit Science Center, 100 Piedmont Ave, Atlanta, GA 30303, USA.'}, {'lastname': 'Gallimore', 'firstname': 'Connor G', 'initials': 'CG', 'affiliation': 'Neuroscience Institute, Georgia State University, Petit Science Center, 100 Piedmont Ave, Atlanta, GA 30303, USA.'}, {'lastname': 'Wargo', 'firstname': 'Joseph A', 'initials': 'JA', 'affiliation': 'Neuroscience Institute, Georgia State University, Petit Science Center, 100 Piedmont Ave, Atlanta, GA 30303, USA.'}, {'lastname': 'Peterka', 'firstname': 'Darcy S', 'initials': 'DS', 'affiliation': 'Mortimer B. Zuckerman Mind Brain Behavior Institute, Columbia University, New York, NY 10027, USA.'}, {'lastname': 'Hamm', 'firstname': 'Jordan P', 'initials': 'JP', 'affiliation': 'Neuroscience Institute, Georgia State University, Petit Science Center, 100 Piedmont Ave, Atlanta, GA 30303, USA; Center for Neuroinflammation and Cardiometabolic Diseases, Georgia State University, Petit Science Center, 100 Piedmont Ave, Atlanta, GA 30303, USA; Center for Behavioral Neuroscience, Georgia State University, Petit Science Center, 100 Piedmont Ave, Atlanta, GA 30303, USA. Electronic address: jhamm1@gsu.edu.'}]",,,,Copyright © 2023 The Author(s). Published by Elsevier Inc. All rights reserved.,"10.1016/j.celrep.2023.113133
10.1016/s0042-6989(99)00234-5
10.1016/j.celrep.2016.06.037
10.1016/j.cortex.2016.03.017
10.1073/pnas.2026179118
10.1098/rstb.2005.1622
10.1093/cercor/bhad215
10.1016/j.neuron.2012.10.038
10.1016/J.NEURON.2020.09.024
10.1016/j.neuron.2016.06.033
10.1016/j.neuron.2020.11.013
10.1016/0959-4388(95)80012-3
10.1038/nrn1519
10.1038/nature11312
10.1038/nn.3446
10.1016/j.neuron.2016.02.037
10.3389/fncir.2020.00013
10.1126/science.1254126
10.1016/j.neuron.2021.02.001
10.1038/nature12676
10.1016/j.neures.2018.07.004
10.1146/annurev-neuro-062111-150444
10.1038/nrn2774
10.1111/j.1469-8986.2007.00624.x
10.1016/J.NEUROIMAGE.2012.01.125
10.1016/J.TICS.2019.12.006
10.1016/J.COGBRAINRES.2005.09.015
10.1016/j.neuron.2018.09.029
10.1523/JNEUROSCI.5198-11.2012
10.1073/pnas.2014868117
10.1016/j.neuron.2014.12.018
10.1038/mp.2017.3
10.1016/j.cub.2023.08.002
10.1038/nn.4417
10.1016/j.neuron.2010.01.033
10.1038/s41593-022-01227-x
10.7554/eLife.78815
10.1016/j.schres.2017.06.023
10.1016/j.pbiomolbio.2010.10.004
10.1038/35084005
10.1016/j.neunet.2003.06.005
10.1016/j.jphysparis.2006.10.001
10.1038/s41593-018-0200-7
10.1007/BF00198477
10.1038/4580
10.1523/JNEUROSCI.2240-15.2015
10.1038/s41467-017-02038-6
10.3389/fnhum.2014.00666
10.1073/pnas.2205264119
10.1523/JNEUROSCI.3646-15.2016
10.1038/s41467-022-28635-8
10.1126/science.aac9462
10.3389/fncel.2022.811484
10.1016/j.conb.2013.12.015
10.7554/eLife.55130
10.7554/eLife.50340
10.1073/pnas.1313287110
10.1101/2023.02.14.528085
10.1016/j.biopsycho.2015.07.006
10.1371/journal.pone.0083255
10.5281/zenodo.8273225
10.5281/zenodo.8335415
10.1016/j.neuron.2017.03.019
10.3389/fninf.2016.00006
10.1073/pnas.1406077111
10.1038/nature12354
10.3389/fncir.2014.00092
10.1016/j.biopsych.2020.01.004
10.1016/j.neuroscience.2013.08.065
10.1038/NPP.2017.176
10.1111/j.1469-8986.2011.01327.x
10.1002/hbm.20342
10.1155/2011/156869
10.2307/1912791
10.1016/j.neuron.2018.07.031
10.1126/science.aav7893",<Element 'PubmedArticle' at 0x7f05deac7220>
22,37640149,The exploration of neuroinflammatory mechanism by which CRHR2 deficiency induced anxiety disorder.,"Inflammation stimulates the hypothalamic-pituitary adrenal (HPA) axis and triggers glial neuroinflammatory phenotypes, which reduces monoamine neurotransmitters by activating indoleamine 2,3-dioxygenase enzyme. These changes can induce psychiatric diseases, including anxiety. Corticotropin releasing hormone receptor 2 (CRHR2) in the HPA axis is involved in the etiology of anxiety. Omega(n)-3 polyunsaturated fatty acids (PUFAs) can attenuate anxiety through anti-inflammation and HPA axis modulation. However, the underlying molecular mechanism by CRHR2 modulates anxiety and its correlation with neuroinflammation remain unclear. Here, we first constructed a crhr2 zebrafish mutant line, and evaluated anxiety-like behaviors, gene expression associated with the HPA axis, neuroinflammatory response, neurotransmitters, and PUFAs profile in crhr2","['Anxiety disorder', 'HPA axis', 'Neuroinflammation', 'Zebrafish', 'crhr2']",Progress in neuro-psychopharmacology & biological psychiatry,2023-08-29,"[{'lastname': 'Deng', 'firstname': 'Shuyi', 'initials': 'S', 'affiliation': 'Research Institute for Marine Drugs and Nutrition, College of Food Science and Technology, Guangdong Ocean University, Zhanjiang 524088, China.'}, {'lastname': 'Guo', 'firstname': 'Anqi', 'initials': 'A', 'affiliation': 'The Affiliated Kangning Hospital of Wenzhou Medical University, Zhejiang Provincial Clinical Research Center for Mental Disorders, Wenzhou, Zhejiang 325000, China.'}, {'lastname': 'Huang', 'firstname': 'Zhengwei', 'initials': 'Z', 'affiliation': 'The Affiliated Kangning Hospital of Wenzhou Medical University, Zhejiang Provincial Clinical Research Center for Mental Disorders, Wenzhou, Zhejiang 325000, China.'}, {'lastname': 'Guan', 'firstname': 'Kaiyu', 'initials': 'K', 'affiliation': ""Wenzhou Seventh People's Hospital, Wenzhou, Zhejiang 325000, China.""}, {'lastname': 'Zhu', 'firstname': 'Ya', 'initials': 'Y', 'affiliation': 'The Affiliated Kangning Hospital of Wenzhou Medical University, Zhejiang Provincial Clinical Research Center for Mental Disorders, Wenzhou, Zhejiang 325000, China; State Key Laboratory of Freshwater Ecology and Biotechnology, Hubei Hongshan Laboratory, The Innovation Academy of Seed Design, University of Chinese Academy of Sciences, Institute of Hydrobiology, Chinese Academy of Sciences, Wuhan, China.'}, {'lastname': 'Chan', 'firstname': 'Cheekai', 'initials': 'C', 'affiliation': 'College of Science and Technology, Wenzhou-Kean University, Zhejiang 325000, China.'}, {'lastname': 'Gui', 'firstname': 'Jianfang', 'initials': 'J', 'affiliation': 'State Key Laboratory of Freshwater Ecology and Biotechnology, Hubei Hongshan Laboratory, The Innovation Academy of Seed Design, University of Chinese Academy of Sciences, Institute of Hydrobiology, Chinese Academy of Sciences, Wuhan, China.'}, {'lastname': 'Song', 'firstname': 'Cai', 'initials': 'C', 'affiliation': 'Research Institute for Marine Drugs and Nutrition, College of Food Science and Technology, Guangdong Ocean University, Zhanjiang 524088, China. Electronic address: cai.song@dal.ca.'}, {'lastname': 'Li', 'firstname': 'Xi', 'initials': 'X', 'affiliation': 'The Affiliated Kangning Hospital of Wenzhou Medical University, Zhejiang Provincial Clinical Research Center for Mental Disorders, Wenzhou, Zhejiang 325000, China. Electronic address: xili@wmu.edu.cn.'}]",,,,Copyright © 2023. Published by Elsevier Inc.,10.1016/j.pnpbp.2023.110844,<Element 'PubmedArticle' at 0x7f05d9576e50>
23,"37569815
36918389
34998485
21044778
30689575
36449413
35542991
18570697
22237023
27452313
24114836
23593248
23018146
24120943
23470775
30617325
30388754
37137892
33281355
30550785
24023786
25576856
25382002
33625721
29587291
31365569
26074767
27333343
32396989
33359670
24298283
30190379
33768561
25920499
26142757
24398403
12112469
33935687
27725121
24506871
28085671
27669446
33493316
26869037
34118939
25257172
29758300
34551326
31507373
26039451
36503597
29441009
32812023
32677986
31072403
29488822
31391333
35691251
36203845
28219696
35094663
27211556
28394923
26520898
25338001
35392928
28819546
28059794
16805774
24933428
32668682
31228811
35793739
19372765
32973488
29992181
27123241
12684028
27964992
32823544
31533339
30844383
32561386
29414191
33318676
30210663
28226226
28886007
33562601
28099414
33239064
21148344
25598354
19014446
35504553
31281225
36225200
32582833
36118704
31564456",Move Your Body toward Healthy Aging: Potential Neuroprotective Mechanisms of Irisin in Alzheimer's Disease.,"Alzheimer's disease (AD) is the leading cause of dementia in older adults, having a significant global burden and increasing prevalence. Current treatments for AD only provide symptomatic relief and do not cure the disease. Physical activity has been extensively studied as a potential preventive measure against cognitive decline and AD. Recent research has identified a hormone called irisin, which is produced during exercise, that has shown promising effects on cognitive function. Irisin acts on the brain by promoting neuroprotection by enhancing the growth and survival of neurons. It also plays a role in metabolism, energy regulation, and glucose homeostasis. Furthermore, irisin has been found to modulate autophagy, which is a cellular process involved in the clearance of protein aggregates, which are a hallmark of AD. Additionally, irisin has been shown to protect against cell death, apoptosis, oxidative stress, and neuroinflammation, all of which are implicated in AD pathogenesis. However, further research is needed to fully understand the mechanisms and therapeutic potential of irisin in AD. Despite the current gaps in knowledge, irisin holds promise as a potential therapeutic target for slowing cognitive decline and improving quality of life in AD patients.","['Alzheimer’s disease', 'apoptosis', 'autophagy', 'cell death', 'exercise', 'irisin', 'neuroinflammation', 'neuroprotection', 'oxidative stress']",International journal of molecular sciences,2023-08-12,"[{'lastname': 'Bellettini-Santos', 'firstname': 'Tatiani', 'initials': 'T', 'affiliation': 'Graduate Program of Research and Extension (CEPEG), University Center of Espirito Santo, Espírito Santo 29703-858, Brazil.'}, {'lastname': 'Batista-Silva', 'firstname': 'Hemily', 'initials': 'H', 'affiliation': 'Graduate Program of Research and Extension (CEPEG), University Center of Espirito Santo, Espírito Santo 29703-858, Brazil.'}, {'lastname': 'Marcolongo-Pereira', 'firstname': 'Clairton', 'initials': 'C', 'affiliation': 'Graduate Program of Research and Extension (CEPEG), University Center of Espirito Santo, Espírito Santo 29703-858, Brazil.'}, {'lastname': 'Quintela-Castro', 'firstname': 'Fernanda Cristina de Abreu', 'initials': 'FCA', 'affiliation': 'Graduate Program of Research and Extension (CEPEG), University Center of Espirito Santo, Espírito Santo 29703-858, Brazil.'}, {'lastname': 'Barcelos', 'firstname': 'Rafael Mazioli', 'initials': 'RM', 'affiliation': 'Graduate Program of Research and Extension (CEPEG), University Center of Espirito Santo, Espírito Santo 29703-858, Brazil.'}, {'lastname': 'Chiepe', 'firstname': 'Kelly Cristina Mota Braga', 'initials': 'KCMB', 'affiliation': 'Graduate Program of Research and Extension (CEPEG), University Center of Espirito Santo, Espírito Santo 29703-858, Brazil.'}, {'lastname': 'Rossoni', 'firstname': 'Joamyr Victor', 'initials': 'JV', 'affiliation': 'Graduate Program of Research and Extension (CEPEG), University Center of Espirito Santo, Espírito Santo 29703-858, Brazil.'}, {'lastname': 'Passamani-Ambrosio', 'firstname': 'Roberta', 'initials': 'R', 'affiliation': 'Graduate Program of Research and Extension (CEPEG), University Center of Espirito Santo, Espírito Santo 29703-858, Brazil.'}, {'lastname': 'da Silva', 'firstname': 'Bruno Spalenza', 'initials': 'BS', 'affiliation': 'Graduate Program of Research and Extension (CEPEG), University Center of Espirito Santo, Espírito Santo 29703-858, Brazil.'}, {'lastname': 'Chiarelli-Neto', 'firstname': 'Orlando', 'initials': 'O', 'affiliation': 'Graduate Program of Research and Extension (CEPEG), University Center of Espirito Santo, Espírito Santo 29703-858, Brazil.'}, {'lastname': 'Garcez', 'firstname': 'Michelle Lima', 'initials': 'ML', 'affiliation': 'Graduate Program of Research and Extension (CEPEG), University Center of Espirito Santo, Espírito Santo 29703-858, Brazil.'}]",,,,,"10.3390/ijms241512440
10.1002/alz.13016
10.1016/S2468-2667(21)00249-8
10.1016/j.jalz.2009.09.004
10.3233/JAD-180766
10.1056/NEJMoa2212948
10.14283/jpad.2022.30
10.1017/S0033291708003681
10.1038/nature10777
10.1016/j.biocel.2016.07.022
10.1074/jbc.M113.516641
10.1371/journal.pone.0060563
10.1016/j.metabol.2012.09.002
10.1016/j.cmet.2013.09.008
10.1016/j.neuroscience.2013.02.050
10.1038/s41591-018-0275-4
10.3390/jcm7110407
10.14202/vetworld.2020.2191-2196
10.1016/j.cell.2018.10.025
10.1371/journal.pone.0072858
10.1016/j.mce.2014.12.027
10.1111/apha.12421
10.1007/s13300-021-01023-z
10.1159/000488422
10.1371/journal.pone.0226344
10.3389/fncel.2015.00191
10.1111/jnc.15039
10.1016/j.lfs.2020.118954
10.1155/2013/746281
10.1126/science.aan8821
10.1111/nan.12711
10.1007/s12020-015-0607-9
10.1016/j.npep.2015.06.004
10.1152/ajpendo.00308.2013
10.1002/dvdy.10099
10.3389/fnagi.2021.649929
10.1186/1753-6561-6-S3-O23
10.1016/j.jneuroim.2016.08.007
10.1016/j.cmet.2013.12.017
10.1515/hmbci-2016-0048
10.1249/MSS.0000000000001095
10.1210/endrev/bnab003
10.1007/s11064-016-1844-x
10.1186/s12993-021-00179-9
10.1038/cdd.2014.150
10.1016/j.neulet.2018.05.017
10.1016/j.arr.2021.101464
10.3389/fnmol.2019.00203
10.1016/j.cmet.2015.05.016
10.1017/erm.2022.41
10.3389/fnagi.2018.00004
10.1093/brain/awaa223
10.1186/s13024-020-00391-7
10.1186/s12929-019-0524-y
10.1152/physrev.00011.2017
10.1172/jci.insight.128834
10.1016/j.conb.2022.102575
10.3389/fpsyt.2022.967683
10.1016/j.peptides.2017.02.003
10.1080/13510002.2022.2031516
10.1016/j.ebiom.2016.02.041
10.1371/journal.pone.0175498
10.1016/j.atherosclerosis.2015.10.020
10.1371/journal.pone.0110273
10.1186/s12974-022-02438-6
10.1155/2017/8416763
10.3233/JAD-161088
10.1111/j.1471-4159.2006.03907.x
10.3390/molecules25143191
10.1016/j.ejmech.2019.06.010
10.1016/j.arr.2022.101680
10.4161/cam.3.1.7402
10.3389/fnagi.2020.00252
10.1016/j.ynstr.2018.05.003
10.3892/br.2016.630
10.1016/S0014-4886(02)00059-6
10.1016/j.mad.2016.12.003
10.3390/antiox9080743
10.3390/genes10090720
10.1016/j.pcad.2019.02.007
10.1016/j.arr.2020.101108
10.1016/j.phrs.2018.01.012
10.1038/s41582-020-00435-y
10.1146/annurev-immunol-051116-052358
10.1038/nm.4397
10.3390/ijms22041605
10.1038/nature21029
10.1186/s40035-020-00221-2
10.1126/science.1197623
10.1007/s12035-014-9070-5
10.1186/1742-2094-5-51
10.1016/j.arr.2022.101637
10.1155/2019/1567179
10.3389/fendo.2022.962968
10.1002/dad2.12034
10.3389/fnagi.2022.965190
10.1016/j.cell.2019.09.001",<Element 'PubmedArticle' at 0x7f05d957ef40>
24,"37566177
2856104
30980716
11402341
29626214
24084075
20398732
25227506
22673229
3527687
25228100
27571131
32150310
19174491
24806746
36277478
26384616
26539077
9191978
24565565
8006678
26349009
31726042
29890290
26305887
27459932
24530653
23613579
24642683
24744759
31078691
32485293
23051934
33326799
36517583
34968684
34033211
29393419
23000619
11846609
23946308
31635851
36437722
30210286
1688879
34396578
31116973
10935546
24196358
20407281
35157987
33745919
32369774
23384835
29162310
35777263
19317179
20573451
27443914
34048845
24700466
24712483
28676747","Stress-induced Neuroinflammation of the Spinal Cord is Restrained by Cort113176 (Dazucorilant), A Specific Glucocorticoid Receptor Modulator.","Glucocorticoids exert antiinflammatory, antiproliferative and immunosupressive effects. Paradoxically they may also enhance inflammation particularly in the nervous system, as shown in Cushing´ syndrome and neurodegenerative disorders of humans and models of human diseases. .""The Wobbler mouse model of amyotrophic lateral sclerosis shows hypercorticoidism and neuroinflammation which subsided by treatment with the glucocorticoid receptor (GR) modulator Dazucorilant (CORT113176). This effect suggests that GR mediates the chronic glucocorticoid unwanted effects. We now tested this hypothesis using a chronic stress model resembling the condition of the Wobbler mouse Male NFR/NFR mice remained as controls or were subjected to a restraining / rotation stress protocol for 3 weeks, with a group of stressed mice receiving CORT113176 also for 3 weeks. We determined the mRNAS or reactive protein for the proinflamatory factors HMGB1, TLR4, NFkB, TNFα, markers of astrogliosis (GFAP, SOX9 and acquaporin 4), of microgliosis (Iba, CD11b, P2RY12 purinergic receptor) as well as serum IL1β and corticosterone. We showed that chronic stress produced high levels of serum corticosterone and IL1β, decreased body and spleen weight, produced microgliosis and astrogliosis and increased proinflammatory mediators. In stressed mice, modulation of the GR with CORT113176 reduced Iba + microgliosis, CD11b and P2RY12 mRNAs, immunoreactive HMGB1 + cells, GFAP + astrogliosis, SOX9 and acquaporin expression and TLR4 and NFkB mRNAs vs. stress-only mice. The effects of CORT113176 indicate that glucocorticoids are probably involved in neuroinflammation. Thus, modulation of the GR would become useful to dampen the inflammatory component of neurodegenerative disorders.","['Cort113176', 'Glucocorticoid receptor modulators', 'Glucocorticoids', 'Neuroinflammation', 'Stress']",Molecular neurobiology,2023-08-11,"[{'lastname': 'Meyer', 'firstname': 'Maria', 'initials': 'M', 'affiliation': 'Laboratory of Neuroendocrine Biochemistry, Instituto de Biologia y Medicina Experimental-CONICET, Buenos Aires, Argentina.'}, {'lastname': 'Meijer', 'firstname': 'Onno', 'initials': 'O', 'affiliation': 'Dept. of Medicine, Division of Endocrinology, Leiden University Medical Center, Leiden, The Netherlands.'}, {'lastname': 'Hunt', 'firstname': 'Hazel', 'initials': 'H', 'affiliation': 'Corcept Therapeutics, Menlo Park, Ca, USA.'}, {'lastname': 'Belanoff', 'firstname': 'Joseph', 'initials': 'J', 'affiliation': 'Corcept Therapeutics, Menlo Park, Ca, USA.'}, {'lastname': 'Lima', 'firstname': 'Analia', 'initials': 'A', 'affiliation': 'Laboratory of Neuroendocrine Biochemistry, Instituto de Biologia y Medicina Experimental-CONICET, Buenos Aires, Argentina.'}, {'lastname': 'de Kloet', 'firstname': 'E Ronald', 'initials': 'ER', 'affiliation': 'Dept. of Medicine, Division of Endocrinology, Leiden University Medical Center, Leiden, The Netherlands.'}, {'lastname': 'Gonzalez Deniselle', 'firstname': 'Maria Claudia', 'initials': 'MC', 'affiliation': 'Laboratory of Neuroendocrine Biochemistry, Instituto de Biologia y Medicina Experimental-CONICET, Buenos Aires, Argentina.\nDept. of Physiology, Faculty of Medicine, University of Buenos Aires, Buenos Aires, Argentina.'}, {'lastname': 'De Nicola', 'firstname': 'Alejandro F', 'initials': 'AF', 'affiliation': 'Laboratory of Neuroendocrine Biochemistry, Instituto de Biologia y Medicina Experimental-CONICET, Buenos Aires, Argentina. alejandrodenicola@gmail.com.\nDept. of Human Biochemiistry, Faculty of Medicine, University of Buenos Aires, Buenos Aires, Argentina. alejandrodenicola@gmail.com.'}]",,,,"© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.","10.1007/s12035-023-03554-x
10.1016/0896-6273(88)90136-5
10.1210/en.2018-00819
10.1038/sj.onc.1204388
10.1038/s41467-018-03780-1
10.1016/j.jaci.2013.09.007
10.1016/j.mce.2010.04.005
10.1159/000362724
10.1016/j.yfrne.2018.02.003
10.3389/fendo.2016.00078
10.1210/en.2012-1020
10.1210/edrv-7-3-284
10.1159/000367849
10.1210/en.2016-1244
10.1038/nrendo.2016.170
10.1111/ejn.14720
10.1210/jc.2008-2543
10.1055/s-0034-1371891
10.1136/bmjno-2022-000344
10.1016/j.jns.2015.09.011
10.3389/fnins.2015.00381
10.1016/s0960-0760(96)00193-8
10.1016/j.jsbmb.2014.02.007
10.1186/s12974-015-0435-0
10.1007/BF01181559
10.1016/j.neuroscience.2015.09.007
10.1016/j.brainres.2019.146551
10.1016/j.neuroscience.2018.05.042
10.1210/en.2015-1390
10.1016/j.neurobiolaging.2016.05.018
10.1016/j.yhbeh.2014.02.002
10.1073/pnas.1219411110
10.1371/journal.pone.0091248
10.1016/j.ando.2018.03.004
10.1523/JNEUROSCI.0733-19.2019
10.3389/fimmu.2014.00136
10.1016/j.bbi.2019.05.014
10.1016/j.bbi.2020.05.063
10.1159/000342092
10.55782/ane-2008-1682
10.1016/j.expneurol.2020.113556
10.1038/s41386-022-01519-7
10.1016/j.phrs.2021.106045
10.1002/iub.2510
10.3892/mmr.2018.8485
10.1016/j.neuroscience.2012.09.032
10.1006/meth.2001.1262
10.1212/WNL.0b013e3182a4a577
10.1016/j.tins.2019.09.004
10.2174/1567202619666220829110111
10.3389/fnins.2018.00622
10.1016/0165-5728(90)90088-5
10.1002/glia.24071
10.1016/j.celrep.2019.04.094
10.1210/mend.14.8.0506
10.1210/en.2013-1473
10.1159/000292019
10.1016/j.brainresbull.2022.02.008
10.1016/j.expneurol.2021.113703
10.1530/JOE-19-0486
10.1210/en.2012-2045
10.1016/j.tem.2017.10.010
10.1523/JNEUROSCI.0303-09.2010
10.1016/j.intimp.2022.108972
10.1515/revneuro.2008.19.6.395
10.1016/j.pain.2010.05.031
10.1016/j.it.2016.06.006
10.1016/j.neuint.2021.105080
10.1523/JNEUROSCI.3199-16.2017
10.1074/jbc.M113.534594
10.1111/cns.12267
10.3389/fnhum.2017.00316",<Element 'PubmedArticle' at 0x7f05d8900db0>
25,37483155,Luteolin/ZnO nanoparticles attenuate neuroinflammation associated with diabetes via regulating MicroRNA-124 by targeting C/EBPA.,"The most prevalent brain-specific microRNA, MicroRNA-124, exhibits anti-inflammatory properties. Luteolin nano-formulation with Zn oxide in the form of L/ZnO NPs may boost anti-diabetic properties; however, its beneficial effect on miRNAs is yet unknown in diabetes. The effectiveness of L/ZnONPs supplements in preventing diabetic neurodegeneration by modulating inflammatory responses in a diabetic model was investigated.
A diabetic rat model was induced by a high-fat diet and streptozotocin (30 mg/kg I.P.). Plasma glucose, insulin, and HOMR-IR levels, as well as cytokines, lipid peroxidation, GSH/GSSG, and glucose transporter 1, were determined along with the tight junction proteins occludin (OCLN) and zona occludens 1 (ZO-1). Moreover, the expressions of brain CCAAT/enhancer-binding protein (C/EBPA mRNA), miR-124, glial fibrillary acidic protein (GFAP), and NF-kBp65 were measured alongside the histological investigation.
The results revealed that L/ZnO NPs were able to diminish lipid peroxidation, increase the activity of antioxidant enzymes, and reduce inflammation under oxidative stress. Consequently, it was able to reduce hyperglycemia, elevate insulin levels, and improve insulin resistance. Besides, L/ZnO NPs upregulate miR-124, reduce C/EBPA mRNA, increase BCl-2, and inhibit apoptosis. The results indicate that diabetes raises BBB permeability via tight junction protein decline, which is restored following L/ZnO NPs treatment. Luteolin/ZnO NPs regulate miR-124 and microglia polarization by targeting C/EBPA and are expected to alleviate inflammatory injury via modulation of the redox-sensitive signal transduction pathways. Luteolin/ZnO NPs have a novel target for the protection of the BBB and the prevention of neurological complications in diabetes.","['Luteolin/ZnO NPs', 'blood brain-barrier', 'diabetes', 'miR-124']",Environmental toxicology,2023-07-24,"[{'lastname': 'Moustafa', 'firstname': 'Enas M', 'initials': 'EM', 'affiliation': 'Radiation Biology, National Center for Radiation Research and Technology, Egyptian Atomic Energy Authority, Cairo, Egypt.'}, {'lastname': 'Moawed', 'firstname': 'Fatma S M', 'initials': 'FSM', 'affiliation': 'Health radiation research, National Center for Radiation Research and Technology, Egyptian Atomic Energy Authority, Cairo, Egypt.'}, {'lastname': 'Elmaghraby', 'firstname': 'Dina F', 'initials': 'DF', 'affiliation': 'Health radiation research, National Center for Radiation Research and Technology, Egyptian Atomic Energy Authority, Cairo, Egypt.'}]",,,"The results revealed that L/ZnO NPs were able to diminish lipid peroxidation, increase the activity of antioxidant enzymes, and reduce inflammation under oxidative stress. Consequently, it was able to reduce hyperglycemia, elevate insulin levels, and improve insulin resistance. Besides, L/ZnO NPs upregulate miR-124, reduce C/EBPA mRNA, increase BCl-2, and inhibit apoptosis. The results indicate that diabetes raises BBB permeability via tight junction protein decline, which is restored following L/ZnO NPs treatment. Luteolin/ZnO NPs regulate miR-124 and microglia polarization by targeting C/EBPA and are expected to alleviate inflammatory injury via modulation of the redox-sensitive signal transduction pathways. Luteolin/ZnO NPs have a novel target for the protection of the BBB and the prevention of neurological complications in diabetes.",© 2023 Wiley Periodicals LLC.,10.1002/tox.23903,<Element 'PubmedArticle' at 0x7f05dc9f8090>
26,"37458892
23843821
16310183
11212630
24352431
24582164
30261413
19368863
23295186
27506119
23743171
26074748
7870899
27335516
32707436
18346997
26385432
26785346
31022822
29311911
31956630","Administration of α-lipoic acid and silymarin attenuates aggression by modulating endocrine, oxidative stress and inflammatory pathways in mice.","Aggression, a highly prevalent behavior among all the psychological disorders having strong association with psychiatric imbalance, neuroendocrine changes and neurological disturbances (including oxidative stress & neuroinflammation) require both pharmacological and non-pharmacological treatments. Focusing the preclinical neuroendocrine determinants of aggression, this interventional study was designed to elucidate the curative effect of antioxidants on aggression in male mice. Adult albino male mice (n = 140) randomly divided into two main treatment groups for α-lipoic acid (ALA) and silymarin with 5 subgroups (n = 10) for each curative study, namely control, disease (aggression-induced), standard (diazepam, 2.5 mg/kg), low dose (100 mg/kg) and high dose (200 mg/kg) treatment groups of selected antioxidants. Resident-intruder paradigm and levodopa (L-dopa 375 mg/kg, p.o.) induced models were used for aggression. Effect of antioxidant treatment (i.e., 21 days bid) on aggression was assessed by evaluating the changes in aggressive behavior, oxidative stress biomarkers superoxide dismutase, catalase, glutathione, nitrite and malondialdehyde (SOD, CAT, GSH, nitrite & MDA), neurotransmitters (dopamine, nor-adrenaline and serotonin), pro-inflammatory cytokines tumor necrosis factor-α and interleukin- 6 (TNF-α & IL-6) along with serum testosterone examination. This study showed potential ameliorative effect on aggressive behavior with both low (100 mg/kg) and high (200 mg/kg) doses of antioxidants (ALA & silymarin). Resident-intruder or L-dopa induced aggression in male mice was more significantly tuned with ALA treatment than silymarin via down regulating both oxidative stress and inflammatory biomarkers. ALA also exhibited notable effects in managing aggression-induced disturbances on plasma testosterone levels. In conclusion, ALA is more effective than silymarin in attenuating aggression in mice.","['Aggression', 'Animals behavior', 'Neuroinflammation', 'Oxidative stress', 'Silymarin', 'α-Lipoic acid']",Metabolic brain disease,2023-07-17,"[{'lastname': 'Karim', 'firstname': 'Adnan', 'initials': 'A', 'affiliation': 'Riphah Institute of Pharmaceutical Sciences, Riphah International University, Lahore, Pakistan.'}, {'lastname': 'Anwar', 'firstname': 'Fareeha', 'initials': 'F', 'affiliation': 'Riphah Institute of Pharmaceutical Sciences, Riphah International University, Lahore, Pakistan. fareeha.anwar@riphah.edu.pk.'}, {'lastname': 'Saleem', 'firstname': 'Uzma', 'initials': 'U', 'affiliation': 'Department of Pharmacology, Faculty of Pharmaceutical Sciences, Government College University, Faisalabad, Pakistan. uzma95@gmail.com.'}, {'lastname': 'Fatima', 'firstname': 'Saniya', 'initials': 'S', 'affiliation': 'Riphah Institute of Pharmaceutical Sciences, Riphah International University, Lahore, Pakistan.'}, {'lastname': 'Ismail', 'firstname': 'Tariq', 'initials': 'T', 'affiliation': 'Department of Pharmacy, COMSAT University, Abbottabad, Pakistan.'}, {'lastname': 'Obaidullah', 'firstname': 'Ahmad J', 'initials': 'AJ', 'affiliation': 'Department of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, Riyadh, 11451, Saudi Arabia.'}, {'lastname': 'Khayat', 'firstname': 'Rana O', 'initials': 'RO', 'affiliation': 'Department of Biology, College of Applied Sciences, Umm Al-Qura University, Makkah, 21955, Saudi Arabia.'}, {'lastname': 'Alqahtani', 'firstname': 'Moneerah J', 'initials': 'MJ', 'affiliation': 'Department of Pharmacognosy, College of Pharmacy, King Saud University, Riyadh, 11451, Saudi Arabia.'}, {'lastname': 'Alsharif', 'firstname': 'Ifat', 'initials': 'I', 'affiliation': 'Department of Biology, Jamoum University College, Umm Al-Qura University, Makkah, 21955, Saudi Arabia.'}, {'lastname': 'Khan', 'firstname': 'Haroon', 'initials': 'H', 'affiliation': 'Department of Pharmacy, Abdul Wali Khan University, Mardan, Pakistan.'}, {'lastname': 'Vargas-De-La-Cruz', 'firstname': 'Celia', 'initials': 'C', 'affiliation': 'Department of Pharmacology, Bromatology, Toxicology, Faculty of Pharmacy and Biochemistry, Universidad Nacional Mayor de San Marcos, Jr. Puno 1002, Lima, 15001, Peru.\nE-Health Research Center, Universidad de Ciencias Y Humanidades, Lima, 15001, Peru.'}, {'lastname': 'Shah', 'firstname': 'Muhammad Ajmal', 'initials': 'MA', 'affiliation': 'Department of Pharmacy, Hazara University, Mansehra, Pakistan. ajmalshah@hu.edu.pk.'}]",,,,"© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.","10.1007/s11011-023-01258-8
10.4236/ojas.2014.42010
10.1155/2015/542542
10.5812/ijem.3661
10.1016/j.ejphar.2005.09.065
10.1037/0033-295X.108.1.273
10.1001/jamapsychiatry.2013.3297
10.1016/j.biopsych.2014.01.014
10.1016/j.jpsychires.2018.09.004
10.1007/s10826-011-9461-4
10.1016/j.neulet.2009.03.065
10.1016/S0302-4598(98)00072-5
10.1016/j.neubiorev.2005.01.005
10.1016/j.brainres.2012.12.041
10.1016/j.taap.2017.11.012
10.5530/jyp.2016.2.6
10.2174/138161212803523554
10.1016/j.ijbiomac.2016.08.012
10.1016/j.lfs.2013.05.020
10.3922/j.psns.2014.4.20
10.1080/13880200490519712
10.2174/1570159X13666141210221434
10.1007/BF02246950
10.4103/0253-7176.183087
10.1016/j.biopha.2020.110473
10.1176/appi.ajp.2008.07111774
10.1111/jnc.13371
10.3390/antiox4010204
10.1186/1742-2094-10-73
10.3390/geriatrics1040029
10.3389/fnagi.2017.00430
10.4103/jrpp.JRPP_18_100",<Element 'PubmedArticle' at 0x7f05dca06680>
27,"37446324
25345893
30962497
26990767
32581717
32756342
25835737
28192415
31760920
34225588
22041296
19286276
19647070
28752628
28890366
15910976
33832414
16597735
20943909
24485491
14718388
24607701
18838174
17203472
31734263
30688267
18753690
1480349
31392674
37331704
34855115
34225592",Ambiguous Contribution of Glucocorticosteroids to Acute Neuroinflammation in the Hippocampus of Rat.,"Effects of modulation of glucocorticoid and mineralocorticoid receptors (GR and MR, respectively) on acute neuroinflammatory response were studied in the dorsal (DH) and ventral (VH) parts of the hippocampus of male Wistar rats. Local neuroinflammatory response was induced by administration of bacterial lipopolysaccharide (LPS) to the DH. The modulation of GR and MR was performed by dexamethasone (GR activation), mifepristone, and spironolactone (GR and MR inhibition, respectively). Experimental drugs were delivered to the dentate gyrus of the DH bilaterally by stereotaxic injections. Dexamethasone, mifepristone, and spironolactone were administered either alone (basal conditions) or in combination with LPS (neuroinflammatory conditions). Changes in expression levels of neuroinflammation-related genes and morphology of microglia 3 days after intrahippocampal administration of above substances were assessed. Dexamethasone alone induced a weak proinflammatory response in the hippocampal tissue, while neither mifepristone nor spironolactone showed significant effects. During LPS-induced neuroinflammation, GR activation suppressed expression of selected inflammatory genes, though it did not prevent appearance of activated forms of microglia. In contrast to GR activation, GR or MR inhibition had virtually no influence on LPS-induced inflammatory response. The results suggest glucocorticosteroids ambiguously modulate specific aspects of neuroinflammatory response in the hippocampus of rats at molecular and cellular levels.","['bacterial lipopolysaccharide', 'dexamethasone', 'glucocorticosteroids', 'hippocampus', 'microglia', 'mifepristone', 'neuroinflammation', 'spironolactone']",International journal of molecular sciences,2023-07-14,"[{'lastname': ""Tret'yakova"", 'firstname': 'Liya V', 'initials': 'LV', 'affiliation': 'Institute of Higher Nervous Activity and Neurophysiology, Russian Academy of Sciences, 117485 Moscow, Russia.'}, {'lastname': 'Kvichansky', 'firstname': 'Alexey A', 'initials': 'AA', 'affiliation': 'Institute of Higher Nervous Activity and Neurophysiology, Russian Academy of Sciences, 117485 Moscow, Russia.'}, {'lastname': 'Barkovskaya', 'firstname': 'Ekaterina S', 'initials': 'ES', 'affiliation': 'Institute of Higher Nervous Activity and Neurophysiology, Russian Academy of Sciences, 117485 Moscow, Russia.'}, {'lastname': 'Manolova', 'firstname': 'Anna O', 'initials': 'AO', 'affiliation': 'Institute of Higher Nervous Activity and Neurophysiology, Russian Academy of Sciences, 117485 Moscow, Russia.'}, {'lastname': 'Bolshakov', 'firstname': 'Alexey P', 'initials': 'AP', 'affiliation': 'Institute of Higher Nervous Activity and Neurophysiology, Russian Academy of Sciences, 117485 Moscow, Russia.'}, {'lastname': 'Gulyaeva', 'firstname': 'Natalia V', 'initials': 'NV', 'affiliation': 'Institute of Higher Nervous Activity and Neurophysiology, Russian Academy of Sciences, 117485 Moscow, Russia.\nResearch and Clinical Center for Neuropsychiatry of Moscow Healthcare Department, 115419 Moscow, Russia.'}]",,,,,"10.3390/ijms241311147
10.1111/bpa.12198
10.1038/s41598-019-42286-8
10.1111/jnc.13607
10.3389/fncel.2020.00142
10.3390/antiox9080693
10.1177/0023677215570087
10.1038/nri.2017.1
10.1134/S0006297919110087
10.1134/S0006297921060031
10.1016/j.bbi.2011.10.005
10.1016/j.neurobiolaging.2009.01.012
10.1016/j.bbi.2009.07.008
10.1111/cei.13018
10.1016/j.neuropharm.2017.09.009
10.1016/j.jneumeth.2004.11.002
10.1134/S0006297921020048
10.1523/JNEUROSCI.4398-05.2006
10.1523/JNEUROSCI.0303-09.2010
10.1016/j.psyneuen.2013.11.006
10.1134/S1819712421330011
10.1096/fj.03-0328com
10.1016/j.neuint.2014.02.008
10.1016/j.jneuroim.2008.08.015
10.1002/glia.20467
10.1016/j.bbr.2019.112360
10.4103/1673-5374.249229
10.1177/1087057108322155
10.1016/S0149-7634(05)80194-0
10.1007/978-1-4939-9658-2_2
10.1134/S0006297923050012
10.1007/s12035-021-02668-4
10.1134/S0006297921060079",<Element 'PubmedArticle' at 0x7f05d95a4590>
28,37354708,Oxytocin as neuro-hormone and neuro-regulator exert neuroprotective properties: A mechanistic graphical review.,"Neurodegeneration is progressive cell loss in specific neuronal populations, often resulting in clinical consequences with significant medical, societal, and economic implications. Because of its antioxidant, anti-inflammatory, and anti-apoptotic properties, oxytocin has been proposed as a potential neuroprotective and neurobehavioral therapeutic agent, including modulating mood disturbances and cognitive enchantment.
Literature searches were conducted using the following databases Web of Science, PubMed, Elsevier Science Direct, Google Scholar, the Core Collection, and Cochrane from January 2000 to February 2023 for articles dealing with oxytocin neuroprotective properties in preventing or treating neurodegenerative disorders and diseases with a focus on oxidative stress, inflammation, and apoptosis/cell death.
The neuroprotective effects of oxytocin appears to be mediated by its anti-inflammatory properties, inhibition of neuro inflammation, activation of several antioxidant enzymes, inhibition of oxidative stress and free radical formation, activation of free radical scavengers, prevent of mitochondrial dysfunction, and inhibition of apoptosis.
Oxytocin acts as a neuroprotective agent by preventing neuro-apoptosis, neuro-inflammation, and neuronal oxidative stress, and by restoring mitochondrial function.","['Mitochondria', 'Neuro-apoptosis', 'Neuro-inflammation', 'Neurodegeneration', 'Neuroprotective', 'Oxytocin', 'and Neuronal oxidative stress']",Neuropeptides,2023-06-25,"[{'lastname': 'Kamrani-Sharif', 'firstname': 'Roya', 'initials': 'R', 'affiliation': 'Chronic Respiratory Disease Research Center (CRDRC), National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran.'}, {'lastname': 'Hayes', 'firstname': 'A Wallace', 'initials': 'AW', 'affiliation': 'University of South Florida College of Public Health, Tampa, FL, USA; Institute for Integrative Toxicology, Michigan State University, East Lansing, MI, USA.'}, {'lastname': 'Gholami', 'firstname': 'Mina', 'initials': 'M', 'affiliation': 'Chronic Respiratory Disease Research Center (CRDRC), National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran.'}, {'lastname': 'Salehirad', 'firstname': 'Mahsa', 'initials': 'M', 'affiliation': 'Cognitive and Neuroscience Research Center (CNRC), Amir-Almomenin Hospital, Tehran Medical Sciences, Islamic Azad University, Tehran, Iran.'}, {'lastname': 'Allahverdikhani', 'firstname': 'Maryam', 'initials': 'M', 'affiliation': 'Chronic Respiratory Disease Research Center (CRDRC), National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran.'}, {'lastname': 'Motaghinejad', 'firstname': 'Majid', 'initials': 'M', 'affiliation': 'Chronic Respiratory Disease Research Center (CRDRC), National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran. Electronic address: Dr.motaghinejad6@gmail.com.'}, {'lastname': 'Emanuele', 'firstname': 'Enzo', 'initials': 'E', 'affiliation': '2E Science, Robbio (PV), Italy.'}]",,"Oxytocin acts as a neuroprotective agent by preventing neuro-apoptosis, neuro-inflammation, and neuronal oxidative stress, and by restoring mitochondrial function.","The neuroprotective effects of oxytocin appears to be mediated by its anti-inflammatory properties, inhibition of neuro inflammation, activation of several antioxidant enzymes, inhibition of oxidative stress and free radical formation, activation of free radical scavengers, prevent of mitochondrial dysfunction, and inhibition of apoptosis.",Copyright © 2023 Elsevier Ltd. All rights reserved.,10.1016/j.npep.2023.102352,<Element 'PubmedArticle' at 0x7f05d95cf680>
29,"37326113
34017166
32582615
32568969
32469251
32411652
32188484
32497297
32225176
32558150
32665054
32275288
35261766
32100124
32538857
32691236
32616524
32610334
32519164
32132184
32142651
19321428
32291526
32255491
32507883
27469342
29237475
22246130
32582574
34635561
34795449
33010584
27956226
35676404
32560707
32524732
21507086
16930683
18266940
19232537
31681264
28766273
22209870
30441762
32510581
32354293
32292903
32873575
32439389
32386441
34672382
34746909
34619336
35624943
35333613
35785029
33850105
19416735
32370112
26109716
20404154
22685434
29480460
35625558
33462852
17466957
23180053
35458506
15188374
21836070
30032246
15798185
33031735
34333238
35364273
21745355
21484412
32432918
21536991
32007576
31440144
32389847
32584474
33129007
34404919
33463909
34759703
34748905
34630027
34158806
26122294
23795744
15024130
27825818
24675030
20091232
29416029
26621682",Estrogens as a Possible Therapeutic Strategy for the Management of Neuroinflammation and Neuroprotection in COVID-19.,"The Coronavirus disease 2019 (COVID-19) affects several tissues, including the central and peripheral nervous system. It has also been related to signs and symptoms that suggest neuroinflammation with possible effects in the short, medium, and long term. Estrogens could have a positive impact on the management of the disease, not only due to its already known immunomodulator effect, but also activating other pathways that may be important in the pathophysiology of COVID-19, such as the regulation of the virus receptor and its metabolites. In addition, they can have a positive effect on neuroinflammation secondary to pathologies other than COVID-19. The aim of this study is to analyze the molecular mechanisms that link estrogens with their possible therapeutic effect for neuroinflammation related to COVID-19. Advanced searches were performed in scientific databases as Pub- Med, ProQuest, EBSCO, the Science Citation index, and clinical trials. Estrogens have been shown to participate in the immune modulation of the response to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). In addition to this mechanism, we propose that estrogens can regulate the expression and activity of the Angiotensin-converting enzyme 2 (ACE2), reestablishing its cytoprotective function, which may be limited by its interaction with SARS-CoV-2. In this proposal, estrogens and estrogenic compounds could increase the synthesis of Angiotensin-(1-7) (Ang-(1-7)) that acts through the Mas receptor (MasR) in cells that are being attacked by the virus. Estrogens can be a promising, accessible, and low-cost treatment for neuroprotection and neuroinflammation in patients with COVID-19, due to its direct immunomodulatory capacity in decreasing cytokine storm and increasing cytoprotective capacity of the axis ACE2/Ang (1-7)/MasR.","['ACE2', 'Ang (1-7)', 'COVID-19', 'Estrogens', 'SARS-CoV-2', 'neuroinflammation', 'neuroprotection']",Current neuropharmacology,2023-06-16,"[{'lastname': 'Bandala', 'firstname': 'Cindy', 'initials': 'C', 'affiliation': 'Higher School of Medicine, National Polytechnic Institute, Mexico City, 11340, Mexico.'}, {'lastname': 'Cárdenas-Rodríguez', 'firstname': 'Noemí', 'initials': 'N', 'affiliation': 'Higher School of Medicine, National Polytechnic Institute, Mexico City, 11340, Mexico.\nNeuroscience Laboratory, National Institute of Pediatrics, Mexico City, 04530, Mexico.'}, {'lastname': 'Reyes-Long', 'firstname': 'Samuel', 'initials': 'S', 'affiliation': 'Basic Neurosciences, National Institute of Rehabilitation LGII, Mexico City, 14389, Mexico.'}, {'lastname': 'Cortés-Algara', 'firstname': 'Alfredo', 'initials': 'A', 'affiliation': 'Higher School of Medicine, National Polytechnic Institute, Mexico City, 11340, Mexico.\nDepartment of Robotic Surgery and Laparoscopy in Gynecology, Centro Médico Nacional 20 de Noviembre, Mexico City, CP, Mexico.'}, {'lastname': 'Contreras-García', 'firstname': 'Itzel Jatziri', 'initials': 'IJ', 'affiliation': 'Neuroscience Laboratory, National Institute of Pediatrics, Mexico City, 04530, Mexico.'}, {'lastname': 'Cruz-Hernández', 'firstname': 'Teresita Rocío', 'initials': 'TR', 'affiliation': 'Higher School of Medicine, National Polytechnic Institute, Mexico City, 11340, Mexico.'}, {'lastname': 'Alfaro-Rodriguez', 'firstname': 'Alfonso', 'initials': 'A', 'affiliation': 'Basic Neurosciences, National Institute of Rehabilitation LGII, Mexico City, 14389, Mexico.'}, {'lastname': 'Cortes-Altamirano', 'firstname': 'José Luis', 'initials': 'JL', 'affiliation': 'Neurociencias básicas, Instituto Nacional de Rehabilitación LGII, Mexico City, 14389, Mexico.\nResearch Department, Ecatepec Valley State University, Valle de Anahuac, Ecatepec, 55210, Mexico State, Mexico.'}, {'lastname': 'Perez-Santos', 'firstname': 'Martín', 'initials': 'M', 'affiliation': 'Directorate of Innovation and Knowledge Transfer, Meritorious Autonomous University of Puebla, 72570, Puebla, Mexico.'}, {'lastname': 'Anaya-Ruiz', 'firstname': 'Maricruz', 'initials': 'M', 'affiliation': 'Cell Biology Laboratory, Oriente Biomedical Research Center, Mexican Social Security Institute, Metepec, 74360, Puebla, Mexico.'}, {'lastname': 'Lara-Padilla', 'firstname': 'Eleazar', 'initials': 'E', 'affiliation': 'Higher School of Medicine, National Polytechnic Institute, Mexico City, 11340, Mexico.'}]",,,,"Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.","10.2174/1570159X21666230616103850
10.1101/2020.05.27.120105
10.3389/fpubh.2020.00264
10.1097/JCMA.0000000000000375
10.1080/13625187.2020.1766017
10.3389/fpubh.2020.00152
10.1186/s13054-020-2833-7
10.1002/jmv.26137
10.1038/s41586-020-2180-5
10.1111/acel.13168
10.1017/cjn.2020.146
10.1001/jamaneurol.2020.1127
10.1016/j.amsu.2022.103440
10.1007/s00415-020-09773-9
10.3233/JAD-200581
10.1007/s00415-020-10067-3
10.1136/svn-2020-000431
10.1159/000508991
10.1007/s11239-020-02172-x
10.1126/science.abb2762
10.1016/j.cell.2020.02.052
10.1073/pnas.0809524106
10.1007/s11886-020-01291-4
10.1042/CS20200363
10.1042/CS20200492
10.2174/1389450117666160727142401
10.1186/s13054-017-1882-z
10.1007/s00109-012-0859-2
10.3389/fcimb.2020.00317
10.1212/WNL.0000000000012930
10.1038/s41582-021-00593-7
10.1016/j.msard.2020.102535
10.1016/j.yhbeh.2016.11.017
10.1038/s41598-022-13585-4
10.1186/s13054-020-03086-z
10.1111/andr.12836
10.1111/j.1365-2826.2011.02141.x
10.1016/j.yfrne.2006.06.002
10.1111/j.1365-2826.2008.01667.x
10.1016/j.bbi.2009.02.005
10.3389/fimmu.2019.02317
10.1007/s13311-017-0562-7
10.1016/j.yfrne.2011.12.001
10.3390/ijms19113589
10.1002/ijgo.13265
10.1080/14767058.2020.1759541
10.1016/j.ajogmf.2020.100118
10.1136/bmj.m3320
10.1016/j.ajog.2020.05.031
10.1111/aogs.13901
10.1002/uog.24797
10.1016/j.lanepe.2021.100242
10.1016/j.tcm.2021.09.009
10.1016/j.maturitas.2021.08.026
10.3390/brainsci12050556
10.1089/jwh.2021.0411
10.20953/1726-1678-2022-1-85-90
10.1155/2022/9534163
10.1038/s41420-021-00464-6
10.1016/j.yfrne.2009.04.011
10.3390/ijms21093219
10.1212/WNL.0000000000001776
10.1073/pnas.0910627107
10.3389/fphys.2012.00165
10.1007/s11906-018-0810-1
10.1023/A:1009757416302
10.3390/biom12050629
10.1111/jne.12935
10.1016/j.cardiores.2007.03.023
10.1007/s11906-012-0319-y
10.3390/v14040776
10.1002/art.20309
10.1161/ATVBAHA.111.235176
10.1210/en.2018-00486
10.1128/MCB.25.8.2957-2968.2005
10.1016/S1474-4422(20)30308-2
10.1016/j.ebiom.2021.103512
10.1016/j.nbd.2022.105715
10.1186/2042-6410-2-7
10.1007/s00395-011-0174-z
10.1152/ajplung.00153.2020
10.1161/HYPERTENSIONAHA.110.167650
10.1016/j.lfs.2020.117388
10.3389/fncel.2019.00363
10.1016/j.ijid.2020.05.002
10.1002/rmv.2119
10.1016/j.mehy.2020.110354
10.1038/s41418-021-00844-6
10.14814/phy2.14707
10.4103/jmh.JMH_57_21
10.1016/j.neures.2021.11.001
10.3389/fnins.2021.742065
10.1155/2021/9999146
10.1016/j.yhbeh.2015.06.010
10.1111/jne.12068
10.1073/pnas.0306948101
10.1016/j.mam.2016.10.004
10.1016/j.brainres.2014.03.020
10.1007/s10495-009-0436-5
10.1038/s41419-017-0260-8
10.1016/S1474-4422(15)00322-1",<Element 'PubmedArticle' at 0x7f05d95d71d0>
30,37321333,Ambient particulate matter (PM,Exposure to ambient particulate matter (PM,"['Air Pollution', 'Fine Particulate matter', 'Gut-Brain axis', 'Hippocampus', 'Melatonin', 'Neurodegeneration', 'Olfactory bulb']",Environmental toxicology and pharmacology,2023-06-16,"[{'lastname': 'Panda', 'firstname': 'Samir Ranjan', 'initials': 'SR', 'affiliation': 'Department of Pharmacology and Toxicology, National Institute of Pharmaceutical Education and Research (NIPER), Guwahati, Assam 781101, India.'}, {'lastname': 'Chaudhari', 'firstname': 'Vishal Balu', 'initials': 'VB', 'affiliation': 'Department of Pharmacology and Toxicology, National Institute of Pharmaceutical Education and Research (NIPER), Guwahati, Assam 781101, India.'}, {'lastname': 'Ahmed', 'firstname': 'Sahabuddin', 'initials': 'S', 'affiliation': 'Department of Pharmacology and Toxicology, National Institute of Pharmaceutical Education and Research (NIPER), Guwahati, Assam 781101, India; Department of Psychiatry, Yale University School of Medicine, 300 George Street, Suite 15 901, New Haven, CT 06511, USA.'}, {'lastname': 'Kwatra', 'firstname': 'Mohit', 'initials': 'M', 'affiliation': 'Department of Pharmacology and Toxicology, National Institute of Pharmaceutical Education and Research (NIPER), Guwahati, Assam 781101, India; Neuroregeneration and Stem Cell Programs, Institute for Cell Engineering, The John Hopkins University School of Medicine, Baltimore, MD, 21205, USA.'}, {'lastname': 'Jala', 'firstname': 'Aishwarya', 'initials': 'A', 'affiliation': 'Department of Pharmaceutical Analysis, National Institute of Pharmaceutical Education and Research, Guwahati, Assam 781101, India.'}, {'lastname': 'Ponneganti', 'firstname': 'Srikanth', 'initials': 'S', 'affiliation': 'Department of Pharmaceutical Analysis, National Institute of Pharmaceutical Education and Research, Guwahati, Assam 781101, India.'}, {'lastname': 'Pawar', 'firstname': 'Sharad D', 'initials': 'SD', 'affiliation': 'Regional Ayurveda Institute for Fundamental Research, Pune, Maharashtra, India.'}, {'lastname': 'Borkar', 'firstname': 'Roshan M', 'initials': 'RM', 'affiliation': 'Department of Pharmaceutical Analysis, National Institute of Pharmaceutical Education and Research, Guwahati, Assam 781101, India.'}, {'lastname': 'Sharma', 'firstname': 'Pawan', 'initials': 'P', 'affiliation': 'Center for Translational Medicine, Division of Pulmonary, Allergy and Critical Care Medicine, Jane & Leonard Korman Respiratory Institute, Sidney Kimmel Medical College, Thomas Jefferson University, Philadelphia, PA 19107, USA. Electronic address: Pawan.Sharma@jefferson.edu.'}, {'lastname': 'Naidu', 'firstname': 'V G M', 'initials': 'VGM', 'affiliation': 'Department of Pharmacology and Toxicology, National Institute of Pharmaceutical Education and Research (NIPER), Guwahati, Assam 781101, India. Electronic address: vgmnaidu@gmail.com.'}]",,,,Copyright © 2023 Elsevier B.V. All rights reserved.,10.1016/j.etap.2023.104183,<Element 'PubmedArticle' at 0x7f05d93f3860>
31,37302429,"Melatonin modulates the aggravation of pyroptosis, necroptosis, and neuroinflammation following cerebral ischemia and reperfusion injury in obese rats.","Obesity is well-established as a common comorbidity in ischemic stroke. The increasing evidence has revealed that it also associates with the exacerbation of brain pathologies, resulting in increasingly severe neurological outcomes following cerebral ischemia and reperfusion (I/R) damage. Mechanistically, pyroptosis and necroptosis are novel forms of regulated death that relate to the propagation of inflammatory signals in case of cerebral I/R. Previous studies noted that pyroptotic and necroptotic signaling were exacerbated in I/R brain of obese animals and led to the promotion of brain tissue injury. This study aimed to investigate the roles of melatonin on pyroptosis, necroptosis, and pro-inflammatory pathways occurring in the I/R brain of obese rats. Male Wistar rats were given a high-fat diet for 16 weeks to induce the obese condition, and then were divided into 4 groups: Sham-operated, I/R treated with vehicle, I/R treated with melatonin (10 mg/kg), and I/R treated with glycyrrhizic acid (10 mg/kg). All drugs were administered via intraperitoneal injection at the onset of reperfusion. The development of neurological deficits, cerebral infarction, histological changes, neuronal death, and glial cell hyperactivation were investigated. This study revealed that melatonin effectively improved these detrimental parameters. Furthermore, the processes of pyroptosis, necroptosis, and inflammation were all diminished by melatonin treatment. A summary of the findings is that melatonin effectively reduces ischemic brain pathology and thereby improves post-stroke outcomes in obese rats by modulating pyroptosis, necroptosis, and inflammation.","['Inflammation', 'Ischemic stroke', 'Melatonin', 'Necroptosis', 'Obesity', 'Pyroptosis', 'Reperfusion injury']",Biochimica et biophysica acta. Molecular basis of disease,2023-06-12,"[{'lastname': 'Yawoot', 'firstname': 'Nuttapong', 'initials': 'N', 'affiliation': 'Department of Physiology, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand; Graduate School, Chiang Mai University, Chiang Mai 50200, Thailand.'}, {'lastname': 'Sengking', 'firstname': 'Jirakhamon', 'initials': 'J', 'affiliation': 'Department of Anatomy, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand.'}, {'lastname': 'Govitrapong', 'firstname': 'Piyarat', 'initials': 'P', 'affiliation': 'Chulabhorn Graduate Institute, Kamphaeng Phet 6 Road, Lak Si, Bangkok 10210, Thailand.'}, {'lastname': 'Tocharus', 'firstname': 'Chainarong', 'initials': 'C', 'affiliation': 'Department of Anatomy, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand.'}, {'lastname': 'Tocharus', 'firstname': 'Jiraporn', 'initials': 'J', 'affiliation': 'Department of Physiology, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand; Functional Food Research Center for Well-being, Chiang Mai University, Chiang Mai, Thailand. Electronic address: jiraporn.tocharus@cmu.ac.th.'}]",,,,Copyright © 2023 Elsevier B.V. All rights reserved.,10.1016/j.bbadis.2023.166785,<Element 'PubmedArticle' at 0x7f05d940cd60>
32,37301531,Melatonin regulates microglial polarization and protects against ischemic stroke-induced brain injury in mice.,"Ischemic stroke is a leading cause of mortality and morbidity worldwide, with neuroinflammation playing a key role in its pathophysiology. Microglia, the primary immune cells in the brain, undergo rapid activation and phenotypic polarization, which are crucial for regulating neuroinflammatory responses following ischemic stroke. Melatonin is a promising neuroprotective agent that can regulate microglial polarization in central nervous system (CNS) diseases. However, the specific mechanism underlying the neuroprotective effects of melatonin against ischemic stroke-induced brain injury by modulating microglial polarization after ischemic stroke remains poorly understood. To investigate this mechanism, we used the transient middle cerebral artery occlusion/reperfusion (tMCAO/R) model in C57BL/6 mice to induce ischemic stroke and administered intraperitoneal melatonin (20 mg/kg) or an equivalent volume of vehicle daily after reperfusion. Our results demonstrated that melatonin treatment reduced the infarct volume, prevented neuronal loss and apoptosis, and improved neurological deficits after ischemic stroke. Furthermore, melatonin attenuated microglial activation and reactive astrogliosis, while promoting the polarization of microglia toward M2 phenotype via signal transducer and activator of transcription 1/6 (STAT1/6) pathways. Collectively, these findings suggest that melatonin exerts neuroprotective effects against ischemic stroke-induced brain injury by modulating microglial polarization toward M2 phenotype and has the potential as a promising candidate for the treatment of ischemic stroke.","['Ischemic stroke', 'Melatonin', 'Microglial polarization', 'Neuroinflammation', 'Neuroprotection']",Experimental neurology,2023-06-11,"[{'lastname': 'Li', 'firstname': 'Donghai', 'initials': 'D', 'affiliation': 'Gansu Key Laboratory of Biomonitoring and Bioremediation for Environmental Pollution, School of Life Sciences, Lanzhou University, Lanzhou 730000, PR China.'}, {'lastname': 'He', 'firstname': 'Tianpeng', 'initials': 'T', 'affiliation': 'First Department of Critical Care Medicine, Gansu Provincial Hospital, Lanzhou 730000, PR China.'}, {'lastname': 'Zhang', 'firstname': 'Yue', 'initials': 'Y', 'affiliation': 'Gansu Key Laboratory of Biomonitoring and Bioremediation for Environmental Pollution, School of Life Sciences, Lanzhou University, Lanzhou 730000, PR China.'}, {'lastname': 'Liu', 'firstname': 'Junru', 'initials': 'J', 'affiliation': 'Gansu Key Laboratory of Biomonitoring and Bioremediation for Environmental Pollution, School of Life Sciences, Lanzhou University, Lanzhou 730000, PR China.'}, {'lastname': 'Zhao', 'firstname': 'Haiyu', 'initials': 'H', 'affiliation': 'Gansu Key Laboratory of Biomonitoring and Bioremediation for Environmental Pollution, School of Life Sciences, Lanzhou University, Lanzhou 730000, PR China.'}, {'lastname': 'Wang', 'firstname': 'Dongliang', 'initials': 'D', 'affiliation': 'First Department of Critical Care Medicine, Gansu Provincial Hospital, Lanzhou 730000, PR China.'}, {'lastname': 'Wang', 'firstname': 'Quanchao', 'initials': 'Q', 'affiliation': 'First Department of Critical Care Medicine, Gansu Provincial Hospital, Lanzhou 730000, PR China.'}, {'lastname': 'Yuan', 'firstname': 'Yuan', 'initials': 'Y', 'affiliation': 'First Department of Critical Care Medicine, Gansu Provincial Hospital, Lanzhou 730000, PR China. Electronic address: lanzhouyy@163.com.'}, {'lastname': 'Zhang', 'firstname': 'Shengxiang', 'initials': 'S', 'affiliation': 'Gansu Key Laboratory of Biomonitoring and Bioremediation for Environmental Pollution, School of Life Sciences, Lanzhou University, Lanzhou 730000, PR China. Electronic address: sxzhang@lzu.edu.cn.'}]",,,,Copyright © 2023 Elsevier Inc. All rights reserved.,10.1016/j.expneurol.2023.114464,<Element 'PubmedArticle' at 0x7f05d940adb0>
33,37269608,"Protective effect of Prolactin releasing peptide against 1,2-diacetylbenzene -induced neuroinflammation.","Prolactin-releasing peptide (PrRP) has been investigated as a potential therapeutic for diabetes by the effect of food intake reduction, increasing leptin signaling, and insulin tolerance. Recent studies focused on its synaptogenesis and protective effects against neurodegeneration. Whereas 1,2-diacetylbenzene (DAB), a common metabolite of a neurotoxicant 1,2-diethyl benzene, causes memory impairment and neurotoxicity partly through the inflammatory process. Our present study assessed the effect of PrRP in microglia and its action in balancing the inflammation to protect against DAB. We observed that PrRP modulated NADPH oxidase - regulated NLRP3 inflammasome and PRL signaling pathways differently between physical and toxic conditions in microglia.","['1,2-diacetylbenzene', 'NADPH oxidase', 'Neuroinflammation', 'Prolactin-releasing peptide']",Neuropeptides,2023-06-04,"[{'lastname': 'Hoang', 'firstname': 'Ngoc Minh Hong', 'initials': 'NMH', 'affiliation': 'Department of Pharmacy, College of Pharmacy and Research Institute of Life and Pharmaceutical Sciences, Sunchon National University, Suncheon, Jeonnam 57922, Republic of Korea.'}, {'lastname': 'Jo', 'firstname': 'Wonhee', 'initials': 'W', 'affiliation': 'Department of Pharmacy, College of Pharmacy and Research Institute of Life and Pharmaceutical Sciences, Sunchon National University, Suncheon, Jeonnam 57922, Republic of Korea.'}, {'lastname': 'Kim', 'firstname': 'Min-Sun', 'initials': 'MS', 'affiliation': 'Department of Pharmacy, College of Pharmacy and Research Institute of Life and Pharmaceutical Sciences, Sunchon National University, Suncheon, Jeonnam 57922, Republic of Korea. Electronic address: minsun@scnu.ac.kr.'}]",,,,Copyright © 2023. Published by Elsevier Ltd.,10.1016/j.npep.2023.102349,<Element 'PubmedArticle' at 0x7f05d93ec310>
34,"37269487
29871791
33879872
28282810
28632413
35216503
28078647
26873369
30972606
28622738
33826115
34040513
18556236
21411503
25454317
22432112
29866628
23375873
32536688
23160735
32333549
24622783
31001792
36094778
36834679
32538869
31990459
31620350
29974394
32854858
34774622
30614757
35343207
27149468
19570816
25752913
31535659
36751811
31000697
24990317
32356200
32147679
29805536
29032011
26330275
30069457
26010513
29781786
33568987
32358323
29378454
30428473
12925848
25580570
32247373
25897356",DPP-4 inhibitors and type 2 diabetes mellitus in Parkinson's disease: a mutual relationship.,"Parkinson's disease (PD) usually occurs due to the degeneration of dopaminergic neurons in the substantia nigra (SN). Management of PD is restricted to symptomatic improvement. Consequently, a novel treatment for managing motor and non-motor symptoms in PD is necessary. Abundant findings support the protection of dipeptidyl peptidase 4 (DPP-4) inhibitors in PD. Consequently, this study aims to reveal the mechanism of DPP-4 inhibitors in managing PD. DPP-4 inhibitors are oral anti-diabetic agents approved for managing type 2 diabetes mellitus (T2DM). T2DM is linked with an increased chance of the occurrence of PD. Extended usage of DPP-4 inhibitors in T2DM patients may attenuate the development of PD by inhibiting inflammatory and apoptotic pathways. Thus, DPP-4 inhibitors like sitagliptin could be a promising treatment against PD neuropathology via anti-inflammatory, antioxidant, and anti-apoptotic impacts. DPP-4 inhibitors, by increasing endogenous GLP-1, can also reduce memory impairment in PD. In conclusion, the direct effects of DPP-4 inhibitors or indirect effects through increasing circulating GLP-1 levels could be an effective therapeutic strategy in treating PD patients through modulation of neuroinflammation, oxidative stress, mitochondrial dysfunction, and neurogenesis.","['DPP-4 inhibitor', 'Inflammation', 'Parkinson’s disease', 'Sitagliptin']",Pharmacological reports : PR,2023-06-03,"[{'lastname': 'Alrouji', 'firstname': 'Mohammed', 'initials': 'M', 'affiliation': 'Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, Shaqra University, Shaqra, 11961, Saudi Arabia.'}, {'lastname': 'Al-Kuraishy', 'firstname': 'Hayder M', 'initials': 'HM', 'affiliation': 'Department of Clinical Pharmacology and Medicine, College of Medicine, ALmustansiriyia University, Baghdad, Iraq.'}, {'lastname': 'Al-Buhadily', 'firstname': 'Ali K', 'initials': 'AK', 'affiliation': 'Department of Clinical Pharmacology and Medicine, College of Medicine, ALmustansiriyia University, Baghdad, Iraq.'}, {'lastname': 'Al-Gareeb', 'firstname': 'Ali I', 'initials': 'AI', 'affiliation': 'Department of Clinical Pharmacology and Medicine, College of Medicine, ALmustansiriyia University, Baghdad, Iraq.'}, {'lastname': 'Elekhnawy', 'firstname': 'Engy', 'initials': 'E', 'affiliation': 'Pharmaceutical Microbiology Department, Faculty of Pharmacy, Tanta University, Tanta, 31527, Egypt. engy.ali@pharm.tanta.edu.eg.'}, {'lastname': 'Batiha', 'firstname': 'Gaber El-Saber', 'initials': 'GE', 'affiliation': 'Department of Pharmacology and Therapeutics, Faculty of Veterinary Medicine, Damanhour University, Damanhour, 22511, AL Beheira, Egypt. gaberbatha@gmail.com.'}]",,,,© 2023. The Author(s) under exclusive licence to Maj Institute of Pharmacology Polish Academy of Sciences.,"10.1007/s43440-023-00500-5
10.1007/s10787-022-01125-5
10.1016/j.parkreldis.2018.05.027
10.1016/j.neurobiolaging.2019.11.006
10.1007/s11357-020-00192-2
10.1038/s41582-021-00486-9
10.3233/JPD-179001
10.1007/s12010-022-04155-5
10.4155/fmc-2017-0016
10.3390/ijms23042388
10.1007/s10787-022-01078-9
10.1007/s40265-016-0686-9
10.1007/s40264-016-0399-8
10.1007/s11033-019-04806-7
10.1177/1060028017698496
10.1007/s42770-021-00485-4
10.3389/fphar.2021.570835
10.1016/j.parkreldis.2008.04.036
10.1186/s43042-021-00170-z
10.1097/MD.0000000000005921
10.2337/dc10-1333
10.1016/j.parkreldis.2014.10.008
10.2337/dc11-1511
10.1016/j.parkreldis.2018.05.026
10.1016/j.molmed.2013.01.002
10.1038/s41380-020-0804-7
10.1007/s00210-022-02346-9
10.1007/s11357-012-9491-x
10.3233/JPD-191900
10.1016/j.biopha.2022.113673
10.1515/revneuro-2013-0050
10.1007/s13668-019-0276-z
10.1007/s11033-022-07822-2
10.1002/mds.28124
10.1007/s10787-022-01070-3
10.1016/j.neuroscience.2014.04.006
10.3390/ijms24043264
10.1186/s40001-022-00818-5
10.3233/JPD-202085
10.17219/acem/112058
10.3389/fendo.2021.694893
10.4103/IJCIIS.IJCIIS_40_19
10.1186/1750-1326-9-30
10.1007/s12035-018-1195-5
10.1016/bs.irn.2020.02.010
10.1007/s10787-017-0331-6
10.1016/j.lfs.2021.120132
10.1089/mdr.2018.0235
10.4103/ijp.IJP_384_20
10.3389/fmed.2022.866343
10.1016/j.neuropharm.2014.10.007
10.1186/s43042-022-00252-6
10.1002/mds.26734
10.1097/MD.0000000000003549
10.1002/mds.28075
10.1677/JOE-09-0132
10.1111/jnc.13087
10.1155/2018/6091014
10.4103/1673-5374.264470
10.1038/s41419-019-1571-8
10.1007/s12035-014-8787-5
10.1007/s00401-020-02157-3
10.1093/abbs/gmz156
10.1016/j.neuint.2017.10.006
10.1016/j.neuropharm.2021.108662
10.1021/acschemneuro.8b00356
10.1007/s12031-015-0647-x
10.21037/atm.2018.04.41
10.1111/cns.12404
10.1080/01616412.2018.1474840
10.3389/fnagi.2020.606927
10.1097/PSY.0000000000000796
10.1007/s13311-019-00805-5
10.1080/1061186X.2018.1433682
10.1159/000494435
10.1155/2020/8493916
10.1038/nm919
10.1111/dom.12432
10.1016/bs.pbr.2019.10.008
10.1016/j.neuropharm.2019.107668
10.4239/wjd.v6.i3.456",<Element 'PubmedArticle' at 0x7f05d93f61d0>
35,"37259303
28150045
28780180
28332488
27720003
27055126
24607323
29649433
33450279
27751556
27401947
29178365
26595228
32561452
27959620
24471431
3399080
8819134
10192776
8843599
7700568
8015728
11124893
14513261
17447416
15668962
20082990
15791003
28226226
19246476
11087781
11248594
12777365
15026515
16533144
22935408
24976103
27105081
26708712
10875828
17098842
22687345
15740829
16151602
29523394
22237822
17586327
25179495
28054129
25440010
15184606
34426982
16930735
15251260
11424955
34555366
23407936
24607811
24871624
6370082
6163211
29924994
15363566
27549867
18038216
26006269
33731174
28982631
35935876
30184509
33004513
36090351
27870450
31171460
22182318
25432430
22919059
33766745
23211561
34250902
31392674
31371505
35024696
12213134
1312193
32755645
12531513
29572096",Three-Dimensional Analysis of Sex- and Gonadal Status- Dependent Microglial Activation in a Mouse Model of Parkinson's Disease.,"Parkinson's disease (PD) is characterized by neurodegeneration and neuroinflammation. PD prevalence and incidence are higher in men than in women and modulation of gonadal hormones could have an impact on the disease course. This was investigated in male and female gonadectomized (GDX) and SHAM operated (SHAM) mice. Dutasteride (DUT), a 5α-reductase inhibitor, was administered to these mice for 10 days to modulate their gonadal sex hormones. On the fifth day of DUT treatment, mice received 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) to model PD. We have previously shown in these mice the toxic effect of MPTP in SHAM and GDX males and in GDX females on dopamine markers and astrogliosis whereas SHAM females were protected by their female sex hormones. In SHAM males, DUT protected against MPTP toxicity. In the present study, microglial density and the number of doublets, representative of a microglial proliferation, were increased by the MPTP lesion only in male mice and prevented by DUT in SHAM males. A three-dimensional morphological microglial analysis showed that MPTP changed microglial morphology from quiescent to activated only in male mice and was not prevented by DUT. In conclusion, microgliosis can be modulated by sex hormone-dependent and independent factors in a mice model of PD.","['Parkinson’s disease', 'dutasteride', 'microglial activation', 'microglial morphology', 'sex differences']","Pharmaceuticals (Basel, Switzerland)",2023-06-01,"[{'lastname': 'Isenbrandt', 'firstname': 'Amandine', 'initials': 'A', 'affiliation': 'Centre de Recherche du CHU de Québec, Axe Neurosciences, 2705, Boulevard Laurier, Québec, QC G1V 4G2, Canada.\nFaculté de Pharmacie, Pavillon Ferdinand-Vandry, Université Laval, 1050, Avenue de la Médecine, Québec, QC G1V 0A6, Canada.'}, {'lastname': 'Coulombe', 'firstname': 'Katherine', 'initials': 'K', 'affiliation': 'Centre de Recherche du CHU de Québec, Axe Neurosciences, 2705, Boulevard Laurier, Québec, QC G1V 4G2, Canada.'}, {'lastname': 'Morissette', 'firstname': 'Marc', 'initials': 'M', 'affiliation': 'Centre de Recherche du CHU de Québec, Axe Neurosciences, 2705, Boulevard Laurier, Québec, QC G1V 4G2, Canada.'}, {'lastname': 'Bourque', 'firstname': 'Mélanie', 'initials': 'M', 'affiliation': 'Centre de Recherche du CHU de Québec, Axe Neurosciences, 2705, Boulevard Laurier, Québec, QC G1V 4G2, Canada.'}, {'lastname': 'Lamontagne-Proulx', 'firstname': 'Jérôme', 'initials': 'J', 'affiliation': 'Centre de Recherche du CHU de Québec, Axe Neurosciences, 2705, Boulevard Laurier, Québec, QC G1V 4G2, Canada.'}, {'lastname': 'Di Paolo', 'firstname': 'Thérèse', 'initials': 'T', 'affiliation': 'Centre de Recherche du CHU de Québec, Axe Neurosciences, 2705, Boulevard Laurier, Québec, QC G1V 4G2, Canada.\nFaculté de Pharmacie, Pavillon Ferdinand-Vandry, Université Laval, 1050, Avenue de la Médecine, Québec, QC G1V 0A6, Canada.'}, {'lastname': 'Soulet', 'firstname': 'Denis', 'initials': 'D', 'affiliation': 'Centre de Recherche du CHU de Québec, Axe Neurosciences, 2705, Boulevard Laurier, Québec, QC G1V 4G2, Canada.\nFaculté de Pharmacie, Pavillon Ferdinand-Vandry, Université Laval, 1050, Avenue de la Médecine, Québec, QC G1V 0A6, Canada.'}]",,,,,"10.3390/ph16020152
10.1007/s00702-017-1686-y
10.1016/j.parkreldis.2017.07.033
10.1038/nrdp.2017.13
10.1016/j.ncl.2016.06.012
10.1371/journal.pone.0151841
10.1016/j.yfrne.2014.02.002
10.1016/j.neuropharm.2018.04.005
10.1016/j.ejphar.2021.173862
10.1016/S1474-4422(16)30230-7
10.1111/jnc.13691
10.1002/mds.27216
10.1517/14656566.2015.1111336
10.1016/j.neulet.2020.135164
10.1146/annurev-physiol-022516-034406
10.1146/annurev-immunol-032713-120240
10.1212/WNL.38.8.1285
10.1006/neur.1996.0020
10.1006/exnr.1998.6993
10.1016/0166-2236(96)10049-7
10.1016/0304-3940(94)90508-8
10.1016/0304-3940(94)90746-3
10.1006/mcne.2000.0914
10.1007/s00401-003-0766-2
10.1007/978-3-211-33328-0_7
10.1002/ana.20338
10.1016/S1353-8020(09)70814-4
10.1096/fj.04-2751com
10.1146/annurev-immunol-051116-052358
10.1136/jnnp.2008.168211
10.1212/WNL.55.9.1358
10.1016/S1353-8020(00)00029-8
10.1093/aje/kwg068
10.1136/jnnp.2003.020982
10.1586/14737175.6.3.407
10.1016/j.jns.2012.07.026
10.1002/mds.25945
10.1159/000445751
10.1016/j.neubiorev.2015.09.024
10.1136/bmj.321.7252.21
10.1136/jnnp.2006.103788
10.1016/j.yhbeh.2012.05.013
10.1016/j.biopsycho.2004.11.009
10.1007/s00415-005-0835-7
10.1016/j.parkreldis.2018.02.047
10.1007/s00415-011-6392-3
10.1016/j.disamonth.2007.02.002
10.1016/j.parkreldis.2014.08.003
10.1007/s00415-016-8384-9
10.1016/j.pjnns.2014.08.004
10.1212/WNL.62.11.2010
10.1002/mds.28760
10.1016/j.bbr.2006.07.004
10.1016/j.pbb.2004.04.022
10.1023/A:1007117424491
10.1016/j.neuropharm.2021.108784
10.1523/JNEUROSCI.1268-12.2013
10.1016/j.jsbmb.2014.02.018
10.1177/1073858414536468
10.1146/annurev.ne.07.030184.002213
10.1126/science.6163211
10.1016/j.celrep.2018.05.048
10.1016/j.eururo.2004.05.008
10.4103/0378-6323.188652
10.1007/s00018-007-7403-5
10.1016/j.neuropharm.2015.05.015
10.1186/s12974-021-02124-z
10.1016/j.jsbmb.2017.09.021
10.3389/fphar.2022.898067
10.1016/j.celrep.2018.08.001
10.1126/science.abb8587
10.3389/fpsyt.2022.945548
10.1002/jnr.23821
10.1016/j.molmed.2019.05.001
10.1111/j.1471-4159.2011.07630.x
10.1016/j.neurobiolaging.2014.10.028
10.1210/en.2012-1458
10.1016/j.mad.2021.111473
10.1016/j.neuroscience.2012.11.039
10.7554/eLife.61173
10.1007/978-1-4939-9658-2_2
10.1073/pnas.1900406116
10.1089/andro.2021.0011
10.1046/j.1365-2826.2002.00833.x
10.1016/0024-3205(92)90204-3
10.1016/j.bbi.2020.07.044
10.1016/S0169-328X(02)00459-X
10.1016/j.freeradbiomed.2018.03.036",<Element 'PubmedArticle' at 0x7f05df36b6d0>
36,37257334,"Regulation of COX-2 expression by selected trace elements and heavy metals: Health implications, and changes in neuronal plasticity. A review.","Trace elements or trace metals are essential components of enzymes, proteins, hormones and play a key role in biochemical processes, cell growth and differentiation, as well as in neurotransmission, affecting human physiology. In nature there are also heavy metals that exhibit toxic effects on the human body, including the brain. The importance of trace elements has been established in neurodegenerative disorders, schizophrenia, depression among others. In parallel, an important regulatory element in the above diseases is cyclooxygenase-2 (COX-2), a modulator of the arachidonic acid (AA) pathway, and a cause of neuroinflammation, and glutamate (Glu) dysregulation, affecting calcium (Ca) metabolism in cells. This review presents the effects of major trace elements and heavy metals on COX-2 expression. Calcium (Ca), zinc (Zn), cadmium (Cd), vanadium (V), nickel (Ni), copper (Cu), and iron (Fe) can potentially increase COX-2 expression, inducing neuroinflammation and Glu excitotoxicity; while magnesium (Mg), lithium (Li), and selenium (Se) can potentially decrease COX-2 expression. The associated mechanisms are described in the article.","['COX-2', 'COX-2 expression', 'Heavy metals', 'Synaptic plasticity', 'Trace elements']",Journal of trace elements in medicine and biology : organ of the Society for Minerals and Trace Elements (GMS),2023-06-01,"[{'lastname': 'Stachowicz', 'firstname': 'Katarzyna', 'initials': 'K', 'affiliation': 'Department of Neurobiology, Maj Institute of Pharmacology, Polish Academy of Sciences, Smętna 12, 31-343 Kraków, Poland. Electronic address: stachow@if-pan.krakow.pl.'}]",,,,Copyright © 2023 Elsevier GmbH. All rights reserved.,10.1016/j.jtemb.2023.127226,<Element 'PubmedArticle' at 0x7f05de36d3b0>
37,"37256192
32513838
28076784
26774208
28539349
22492304
19362559
30210563
34544431
29179585
31053149
18073775
28484229
28648389
28848398
27466339
34740365
22408275
22632257
15798185
16920082
26109339
3050629
24184399
18477398
18814846
20881118
12646294
26111720
27546235
29686672
26696821
22457705
8103633
2089275
24871624
29669582
489711
33642362
25984561
26774527
20351193
27604565
30477578
33065974
34488804
19693001
32161729
19179442
30061743
11205708
35140249
21439964
31920505
30239762
22387107
34918084
25742564
24309634
8843881
31068886
22898545
12878732
18522863
32554430
27317566
22778213
27196727
23507975
21350248
29351316
30626393
29939190
30962497",Ovariectomy in mice primes hippocampal microglia to exacerbate behavioral sickness responses.,"Estrogens are a group of steroid hormones that promote the development and maintenance of the female reproductive system and secondary sex characteristics. Estrogens also modulate immune responses; estrogen loss at menopause increases the risk of inflammatory disorders. Elevated inflammatory responses in the brain can lead to affective behavioral changes, which are characteristic of menopause. Thus, here we examined whether loss of estrogens sensitizes microglia, the primary innate immune cell of the brain, leading to changes in affective behaviors. To test this question, adult C57BL/6 mice underwent an ovariectomy to remove endogenous estrogens and then received estradiol hormone replacement or vehicle. After a one-month recovery, mice received an immune challenge with lipopolysaccharide (LPS) or vehicle control treatment and underwent behavioral testing. Ovariectomized, saline-treated mice exhibited reduced social investigation compared to sham-operated mice. Furthermore, ovariectomized mice that received LPS exhibited an exacerbated decrease in sucrose preference, which was ameliorated by estradiol replacement. These results indicate that ovariectomy modulates affective behaviors at baseline and in response to an inflammatory challenge. Ovariectomy-related behavioral changes were associated with downregulation of ","['Anxiety', 'Estrogen', 'Hippocampus', 'Lipopolysaccharide', 'Microglia', 'Neuroinflammation', 'Ovariectomy', 'Sickness']","Brain, behavior, & immunity - health",2023-05-31,"[{'lastname': 'Sanchez', 'firstname': 'Kevin', 'initials': 'K', 'affiliation': 'Division of Pharmacology & Toxicology, College of Pharmacy, The University of Texas at Austin, Austin, TX, 78712, USA.'}, {'lastname': 'Wu', 'firstname': 'Sienna L', 'initials': 'SL', 'affiliation': 'Division of Pharmacology & Toxicology, College of Pharmacy, The University of Texas at Austin, Austin, TX, 78712, USA.'}, {'lastname': 'Kakkar', 'firstname': 'Reha', 'initials': 'R', 'affiliation': 'Division of Pharmacology & Toxicology, College of Pharmacy, The University of Texas at Austin, Austin, TX, 78712, USA.'}, {'lastname': 'Darling', 'firstname': 'Jeffrey S', 'initials': 'JS', 'affiliation': 'Division of Pharmacology & Toxicology, College of Pharmacy, The University of Texas at Austin, Austin, TX, 78712, USA.'}, {'lastname': 'Harper', 'firstname': 'Claire S', 'initials': 'CS', 'affiliation': 'Division of Pharmacology & Toxicology, College of Pharmacy, The University of Texas at Austin, Austin, TX, 78712, USA.'}, {'lastname': 'Fonken', 'firstname': 'Laura K', 'initials': 'LK', 'affiliation': 'Division of Pharmacology & Toxicology, College of Pharmacy, The University of Texas at Austin, Austin, TX, 78712, USA.'}]",,,,© 2023 The Authors.,10.1016/j.bbih.2023.100638,<Element 'PubmedArticle' at 0x7f05de334220>
38,"37240884
29062283
16423810
23407534
7797535
10497171
11375776
11108715
15694400
35751804
23482593
34224692
25854704
11159842
31699241
3999625
8134300
1720895
33604214
9827010
9011748
7723628
11086825
9439929
11879796
11595209
16470617
6537520
36918976
24503654
12626363
12456385
6682781
8483807
32210273
20482322
25773046
20796031
10499494
8770894
12559132
18459453
11818570
19401215
28890271
10526330
9003022
10856302
16023614
11602681
11013069
12098667
10854439
11861531
19857544
17394159
16871538
18495420
18770870
16361065
12815752
15073536
17207559
20696160
22159128
26338326
18700839
23060860
21382418
22081168
24828191
26943721
24806578
35460461
26943719
33542968
29520810
27186861
30261328
31552607
35155969
19755524
25916761
24397607
31168854
26742935
26771703
22160326
23560281
31621051
27670574
36245251
32661948",Parathyroid Hormone (PTH)-Related Peptides Family: An Intriguing Role in the Central Nervous System.,"Parathyroid Hormone (PTH) plays a crucial role in the maintenance of calcium homeostasis directly acting on bone and kidneys and indirectly on the intestine. However, a large family of PTH-related peptides exists that exerts other physiological effects on different tissues and organs, such as the Central Nervous System (CNS). In humans, PTH-related peptides are Parathyroid Hormone (PTH), PTH-like hormones (PTHrP and PTHLH), and tuberoinfundibular peptide of 39 (TIP39 or PTH2). With different affinities, these ligands can bind parathyroid receptor type 1 (PTH1R) and type 2 (PTH2R), which are part of the type II G-protein-coupled-receptors (GPCRs) family. The PTH/PTHrP/PTH1R system has been found to be expressed in many areas of the brain (hippocampus, amygdala, hypothalamus, caudate nucleus, corpus callosum, subthalamic nucleus, thalamus, substantia nigra, cerebellum), and literature data suggest the system exercises a protective action against neuroinflammation and neurodegeneration, with positive effects on memory and hyperalgesia. TIP39 is a small peptide belonging to the PTH-related family with a high affinity for PTH2R in the CNS. The TIP39/PTH2R system has been proposed to mediate many regulatory and functional roles in the brain and to modulate auditory, nociceptive, and sexual maturation functions. This review aims to summarize the knowledge of PTH-related peptides distribution and functions in the CNS and to highlight the gaps that still need to be filled.","['PTH', 'PTH receptors', 'PTH1R', 'PTH2R', 'PTHrP', 'TIP39']",Journal of personalized medicine,2023-05-27,"[{'lastname': 'Dettori', 'firstname': 'Cristina', 'initials': 'C', 'affiliation': 'Biochemistry Laboratory, Department of Pathology, University of Pisa, 56126 Pisa, Italy.'}, {'lastname': 'Ronca', 'firstname': 'Francesca', 'initials': 'F', 'affiliation': 'Biochemistry Laboratory, Department of Pathology, University of Pisa, 56126 Pisa, Italy.'}, {'lastname': 'Scalese', 'firstname': 'Marco', 'initials': 'M', 'affiliation': 'Institute of Clinical Physiology, National Council of Research, 56126 Pisa, Italy.'}, {'lastname': 'Saponaro', 'firstname': 'Federica', 'initials': 'F', 'affiliation': 'Biochemistry Laboratory, Department of Pathology, University of Pisa, 56126 Pisa, Italy.'}]",,,,,"10.3390/jpm13050714
10.3389/fphys.2017.00776
10.1677/joe.1.06057
10.1038/nature11896
10.1074/jbc.270.26.15455
10.1074/jbc.274.40.28185
10.2174/1381612013397825
10.1074/jbc.M009395200
10.1016/j.bbrc.2004.11.069
10.1007/s40618-022-01822-6
10.1530/EJE-12-0946
10.1016/j.bcp.2021.114669
10.1016/j.coph.2015.03.005
10.1210/endo.142.2.7945
10.1016/j.tem.2019.07.011
10.1007/BF01733667
10.1016/0196-9781(93)90174-F
10.1016/0306-4530(91)90017-N
10.7759/cureus.12679
10.1016/S0742-8413(98)00010-3
10.1016/0169-328X(95)00253-O
10.1016/0169-328X(94)00222-Z
10.1007/s007010070072
10.1055/s-0029-1211775
10.1016/S0006-8993(01)03407-2
10.1016/S0006-8993(01)02850-5
10.1002/glia.20319
10.1016/0031-9384(84)90228-2
10.1186/s13195-023-01202-z
10.1371/journal.pone.0087284
10.1152/ajpregu.00001.2003
10.1152/ajpregu.00436.2002
10.1016/0014-2999(83)90403-X
10.1016/0196-9781(93)90041-E
10.1038/s41598-020-62045-4
10.1185/03007995.2010.488516
10.1007/s00774-014-0646-y
10.1111/j.1601-183X.2010.00643.x
10.1210/endo.140.10.7040
10.1210/endo.137.7.8770894
10.1016/S0028-3908(02)00335-0
10.1073/pnas.042416199
10.1016/j.neuroscience.2009.04.054
10.1016/j.physbeh.2017.09.005
10.1038/14724
10.1210/endo.138.2.5031
10.1016/S0021-9258(19)61508-5
10.1016/j.bbamem.2005.06.003
10.1006/frne.2000.0203
10.1677/joe.0.1740095
10.1016/S0021-9258(19)61507-3
10.1210/endo.143.3.8698
10.1016/j.pneurobio.2009.10.017
10.1002/cne.21330
10.1002/cne.21063
10.1016/j.jchemneu.2008.04.001
10.1002/cne.21829
10.1016/j.neuroscience.2005.11.010
10.1002/cne.10739
10.1097/00001756-200404090-00030
10.1016/j.peptides.2006.12.002
10.1016/j.expneurol.2010.08.004
10.1523/JNEUROSCI.2619-11.2011
10.1523/JNEUROSCI.1736-15.2015
10.1111/j.1601-183X.2008.00432.x
10.3389/fendo.2012.00121
10.1016/j.bbr.2011.02.043
10.1007/s00429-011-0357-2
10.1038/nature13307
10.1210/jc.2015-3909
10.1002/jbmr.2273
10.1007/s40618-022-01800-y
10.1210/jc.2015-3907
10.1210/jendso/bvab003
10.1111/cen.13593
10.1210/jc.2016-1477
10.1016/j.bone.2018.09.017
10.1007/s40271-019-00388-5
10.1210/jendso/bvac002
10.1677/ERC-09-0147
10.1016/j.ando.2015.03.015
10.1586/14737167.2014.873702
10.1111/cen.14045
10.1007/s40618-015-0423-3
10.1210/jc.2015-3094
10.1007/s00423-011-0885-5
10.1001/2013.jamasurg.316
10.1007/s40618-019-01128-0
10.1177/000313481608200948
10.1002/jbmr.4677
10.1007/s40618-020-01355-w",<Element 'PubmedArticle' at 0x7f05db4d14a0>
39,37196734,Impact of sex on neuroimmune contributions to Parkinson's disease.,"Parkinson's disease (PD) is the second most common neurodegenerative disorder after Alzheimer's disease. Inflammation has been observed in both the idiopathic and familial forms of PD. Importantly, PD is reported more often in men than in women, men having at least 1.5- fold higher risk to develop PD than women. This review summarizes the impact of biological sex and sex hormones on the neuroimmune contributions to PD and its investigation in animal models of PD. Innate and peripheral immune systems participate in the brain neuroinflammation of PD patients and is reproduced in neurotoxin, genetic and α-synuclein based models of PD. Microglia and astrocytes are the main cells of the innate immune system in the central nervous system and are the first to react to restore homeostasis in the brain. Analysis of serum immunoprofiles in female and male control and PD patients show that a great proportion of these markers differ between males and females. The relationship between cerebrospinal fluid inflammatory markers and PD clinical characteristics or PD biomarkers shows sex differences. Conversely, in animal models of PD, sex differences in inflammation are well documented and the beneficial effects of endogenous and exogenous estrogenic modulation in inflammation have been reported. Targeting neuroinflammation in PD is an emerging therapeutic option but gonadal drugs have not yet been investigated in this respect, thus offering new opportunities for sex specific treatments.","['Astrocyte', 'Glia', 'Inflammation', 'Microglia', 'Parkinson', 'Sex']",Brain research bulletin,2023-05-18,"[{'lastname': 'Bourque', 'firstname': 'Mélanie', 'initials': 'M', 'affiliation': 'Centre de Recherche du CHU de Québec, Axe Neurosciences, 2705, Boulevard Laurier, Québec, Québec G1V4G2, Canada. Electronic address: melanie.bourque@crchudequebec.ulaval.ca.'}, {'lastname': 'Morissette', 'firstname': 'Marc', 'initials': 'M', 'affiliation': 'Centre de Recherche du CHU de Québec, Axe Neurosciences, 2705, Boulevard Laurier, Québec, Québec G1V4G2, Canada. Electronic address: marc.morissette@crchudequebec.ulaval.ca.'}, {'lastname': 'Soulet', 'firstname': 'Denis', 'initials': 'D', 'affiliation': 'Centre de Recherche du CHU de Québec, Axe Neurosciences, 2705, Boulevard Laurier, Québec, Québec G1V4G2, Canada; Faculté de Pharmacie, Pavillon Ferdinand-Vandry, 1050, avenue de la Médecine, Université Laval, Québec, Québec G1V 0A6, Canada. Electronic address: denis.soulet@crchudequebec.ulaval.ca.'}, {'lastname': 'Di Paolo', 'firstname': 'Thérèse', 'initials': 'T', 'affiliation': 'Centre de Recherche du CHU de Québec, Axe Neurosciences, 2705, Boulevard Laurier, Québec, Québec G1V4G2, Canada; Faculté de Pharmacie, Pavillon Ferdinand-Vandry, 1050, avenue de la Médecine, Université Laval, Québec, Québec G1V 0A6, Canada. Electronic address: therese.dipaolo@crchudequebec.ulaval.ca.'}]",,,,Copyright © 2023 The Authors. Published by Elsevier Inc. All rights reserved.,10.1016/j.brainresbull.2023.110668,<Element 'PubmedArticle' at 0x7f05dc6c28b0>
40,"37180115
34911748
30214637
32826385
27637676
32507747
19246690
34320814
18722812
32641445
32030203
20489177
36598387
21160056
36526331
35175851
25276492
35936502
21917808
36293143
35379747
15452117
15772666
15001666
15322528
18573200
17116881
20035840
25404174
17166174
19265047
31281524
32292498
25205317
32450779
19368068
33042259
15082146
33897900
32865008
34473429
31036290
35964426
33204331
34221544
34525359
34162400
35173738
30387323
26860504
29600006
32513838
19536048
35264400
22561337
35882433
31338213
12426043
35724494
20870014
21969914
21565615
11245665
16469811
27127723
33085047
29653184
16013043
11014219
11579140
14702112
15748951
31709121
4032384
32407868
11874493
14632195
10490972
15188374
17947704
9763529
10455066
12852833
33664865
34815787
32863942
21911834
32197947
19919699
15798185
15143155
18319556
20351193
17553937
16953563
35589416
28900508
29675290
32940147
32706336
15350818
16478916
10077336
10203109
27592181
16797503
15353495
21836070
35832091
34341701
28382159
16005526
15142882
15603918
16825664
17673296
27620506
29288569
16676326
21317386
23731522
32899616
21726119
29621182
30728170
33158962
33747172
34829553
33427560
24323337
12771114
22172623
15345733
22306563
22581460
17573984
21790340
20601871
20670199
27256671
22011208
12117397
30654116
33537101
31055232",Immunomodulatory role of estrogen in ischemic stroke: neuroinflammation and effect of sex.,"Although estrogen is predominantly related to the maintenance of reproductive functioning in females, it mediates various physiological effects in nearly all tissues, especially the central nervous system. Clinical trials have revealed that estrogen, especially 17β-estradiol, can attenuate cerebral damage caused by an ischemic stroke. One mechanism underlying this effect of 17β-estradiol is by modulating the responses of immune cells, indicating its utility as a novel therapeutic strategy for ischemic stroke. The present review summarizes the effect of sex on ischemic stroke progression, the role of estrogen as an immunomodulator in immune reactions, and the potential clinical value of estrogen replacement therapy. The data presented here will help better understand the immunomodulatory function of estrogen and may provide a basis for its novel therapeutic use in ischemic stroke.","['17β-estradiol', 'estrogen', 'immunomodulation', 'ischemic stroke', 'neuroinflammation', 'neuroprotection', 'therapy']",Frontiers in immunology,2023-05-14,"[{'lastname': 'Zhong', 'firstname': 'Xiaojun', 'initials': 'X', 'affiliation': 'Department of Neurosurgery, Zhejiang Rongjun Hospital, Jiaxing, China.'}, {'lastname': 'Sun', 'firstname': 'Yulin', 'initials': 'Y', 'affiliation': 'Department of Neurosurgery, Zhejiang Rongjun Hospital, Jiaxing, China.'}, {'lastname': 'Lu', 'firstname': 'Yajun', 'initials': 'Y', 'affiliation': ""Department of Internal Medicine, Sunto Women & Children's Hospital, Jiaxing, China.""}, {'lastname': 'Xu', 'firstname': 'Lei', 'initials': 'L', 'affiliation': 'Department of Neurology, Zhejiang Rongjun Hospital, Jiaxing, China.'}]",,,,"Copyright © 2023 Zhong, Sun, Lu and Xu.","10.3389/fimmu.2023.1164258
10.1212/wnl.0000000000013115
10.7150/thno.25674
10.1136/svn-2020-000457
10.1016/s0140-6736(16)30962-x
10.1136/practneurol-2020-002557
10.1161/strokeaha.108.541128
10.1161/strokeaha.121.034480
10.1016/s1474-4422(08)70193-5
10.1136/svn-2020-000351
10.1136/svn-2019-000268
10.1161/strokeaha.109.575043
10.1161/CIR.0b013e3182009701
10.1136/svn-2022-001907
10.1161/circresaha.121.319915
10.14336/ad.2014.0500340
10.3389/fncel.2022.917181
10.1523/jneurosci.0621-11.2011
10.3390/ijms232012288
10.4049/jimmunol.2101099
10.1074/jbc.M406543200
10.1038/nature03479
10.1210/me.2003-0441
10.1038/nrn1494
10.1186/1479-5876-6-33
10.1073/pnas.0606528103
10.1016/j.neuroscience.2009.12.041
10.1111/cns.12346
10.1111/j.1471-4159.2006.04269.x
10.1161/strokeaha.108.538686
10.7150/thno.30814
10.7150/thno.42982
10.1016/j.yhbeh.2014.08.011
10.1161/circresaha.119.316453
10.1097/JNN.0b013e31819345f8
10.7150/thno.47037
10.1016/j.neulet.2004.01.075
10.7150/thno.56331
10.1152/ajpendo.00071.2020
10.1002/brb3.2316
10.1016/bs.apcsb.2019.01.001
10.1016/j.ejmech.2022.114658
10.7150/thno.51573
10.14336/ad.2021.0311
10.1016/j.celrep.2021.109693
10.1186/s12974-021-02170-7
10.3389/fimmu.2022.828447
10.1111/cns.13081
10.1007/s12975-016-0455-9
10.1136/svn-2017-000123
10.1124/jpet.119.264598
10.1097/SHK.0b013e3181b0ebcb
10.1136/svn-2021-001224
10.1016/j.yhbeh.2012.04.007
10.1136/svn-2022-001659
10.1136/svn-2018-000196
10.1016/s0006-8993(02)03475-3
10.1016/j.jpsychires.2022.06.026
10.1016/j.neuroscience.2010.09.033
10.4061/2011/251517
10.1016/j.cell.2011.03.050
10.1523/jneurosci.21-06-01809.2001
10.1210/en.2005-1330
10.1002/brb3.449
10.1007/s12035-020-02171-2
10.1016/j.bbadis.2018.04.006
10.1002/jnr.20583
10.1210/endo.141.10.7693
10.1046/j.1471-4159.2001.00511.x
10.1172/jci18336
10.1016/j.jneuroim.2004.12.016
10.1136/svn-2018-000180
10.1016/0165-0378(85)90027-0
10.1016/j.jsbmb.2020.105667
10.1046/j.0022-202x.2002.01672.x
10.1046/j.1523-1747.2003.12487.x
10.1002/art.20309
10.4049/jimmunol.179.9.6284
10.1161/01.atv.18.10.1575
10.1161/01.res.85.4.377
10.7150/thno.53749
10.7150/thno.65203
10.7150/thno.44394
10.1182/blood-2011-03-340281
10.1016/j.redox.2020.101482
10.1186/1479-5876-7-97
10.1128/mcb.25.8.2957-2968.2005
10.1210/me.2004-0098
10.2152/jmi.55.133
10.4049/jimmunol.0903463
10.1152/ajpcell.00092.2007
10.2119/2006-00030.Zheng
10.1016/j.jaci.2022.03.028
10.7150/thno.19979
10.14336/ad.2017.0602
10.1177/1545968320948607
10.7554/eLife.57274
10.1016/j.lfs.2004.04.035
10.1189/jlb.1005596
10.1016/s0306-4522(98)00340-6
10.1002/(sici)1096-8652(199904)60:4<312::aid-ajh13>3.0.co;2-k
10.1016/j.aquatox.2016.08.015
10.1016/j.cardiores.2006.05.015
10.1161/01.Cir.0000142050.19488.C7
10.1161/atvbaha.111.235176
10.7150/thno.72760
10.14336/ad.2021.0119
10.7150/thno.17558
10.1016/j.jneuroim.2005.04.026
10.1182/blood-2003-10-3380
10.1016/j.toxlet.2004.09.016
10.1101/gr.5217506
10.1016/j.molimm.2007.06.148
10.1016/j.intimp.2016.09.001
10.1111/cea.13081
10.1002/jnr.20881
10.4049/jimmunol.1001322
10.1016/j.coph.2013.05.007
10.3390/ijms21186454
10.3109/09513590.2010.507281
10.3390/ijms19041091
10.1523/jneurosci.1970-18.2019
10.1523/jneurosci.0888-20.2020
10.3892/etm.2021.9850
10.3390/antiox10111682
10.1080/21688370.2020.1865760
10.1007/s12975-012-0230-5
10.1001/jama.289.20.2673
10.1016/s1474-4422(11)70269-1
10.1093/gerona/59.8.m827
10.1093/aje/kwr343
10.1210/en.2011-1859
10.1016/j.jclinepi.2006.10.012
10.2217/whe.11.42
10.1097/MOH.0b013e32833c07bc
10.3109/13697137.2010.507111
10.1161/strokeaha.116.013052
10.1089/jwh.2011.2839
10.1001/jama.288.3.321
10.1016/j.neuint.2019.01.012
10.7150/thno.55241
10.1016/j.intimp.2019.04.048",<Element 'PubmedArticle' at 0x7f05dc6a7270>
41,"37106402
26250739
9682040
21401856
28627518
28864494
30222193
30984115
31001255
29056235
35508809
31391585
34605719
31644905
31474999
33790911
31444265
20065129
20610493
20126412
17561269
30671056
34136095
31604244
25853560
32271876
34054852
30561547
35967338
24897084
26683605
23237963
33133091
35522918
27626663
35790914
35185927
34223649
23307939
16619256
29666308
32632016
26621681
23104886
28263959
28961746
27924034
23175756
16632515
33015620
19910308
25605792
21118553
25576597
27851915
24485249
33237311
14597658
22455463
25765347",Prominent epigenetic and transcriptomic changes in CD4,"Multiple sclerosis (MS) is a neuroinflammatory disease in which pregnancy leads to a temporary amelioration in disease activity as indicated by the profound decrease in relapses rate during the 3rd trimester of pregnancy. CD4
Women with MS and healthy controls were longitudinally sampled before, during (1st, 2nd and 3rd trimesters) and after pregnancy. DNA methylation array and RNA sequencing were performed on paired CD4
Both DNA methylation and RNA sequencing revealed a prominent regulation, mostly peaking in the 3rd trimester and reversing post-partum, thus mirroring the clinical course with improvement followed by a worsening in disease activity. This rebound pattern was found to represent a general adaptation of the maternal immune system, with only minor differences between MS and controls. By using a network-based approach, we highlighted several genes at the core of this pregnancy-induced regulation, which were found to be enriched for genes and pathways previously reported to be involved in MS. Moreover, these pathways were enriched for in vitro stimulated genes and pregnancy hormones targets.
This study represents, to our knowledge, the first in-depth investigation of the methylation and expression changes in peripheral CD4","['CD4+', 'CD8+', 'Methylation', 'Modules', 'Multiple sclerosis', 'Networks', 'Pregnancy', 'T cells', 'Transcriptomics']",Journal of neuroinflammation,2023-04-28,"[{'lastname': 'Zenere', 'firstname': 'Alberto', 'initials': 'A', 'affiliation': 'Division of Automatic Control, Department of Electrical Engineering, Linköping University, Linköping, Sweden.'}, {'lastname': 'Hellberg', 'firstname': 'Sandra', 'initials': 'S', 'affiliation': 'Bioinformatics, Department of Physics, Chemistry and Biology, Linköping University, Linköping, Sweden. sandra.hellberg@liu.se.'}, {'lastname': 'Papapavlou Lingehed', 'firstname': 'Georgia', 'initials': 'G', 'affiliation': 'Division of Inflammation and Infection, Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden.'}, {'lastname': 'Svenvik', 'firstname': 'Maria', 'initials': 'M', 'affiliation': 'Division of Inflammation and Infection, Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden.\nDepartment of Obstetrics and Gynecology, Region Kalmar County, Kalmar, Sweden.'}, {'lastname': 'Mellergård', 'firstname': 'Johan', 'initials': 'J', 'affiliation': 'Department of Neurology, Linköping University, Linköping, Sweden.\nDepartment of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden.'}, {'lastname': 'Dahle', 'firstname': 'Charlotte', 'initials': 'C', 'affiliation': 'Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden.\nDepartment of Clinical Immunology and Transfusion Medicine, Linköping University, Linköping, Sweden.'}, {'lastname': 'Vrethem', 'firstname': 'Magnus', 'initials': 'M', 'affiliation': 'Department of Neurology, Linköping University, Linköping, Sweden.\nDepartment of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden.'}, {'lastname': 'Raffetseder', 'firstname': 'Johanna', 'initials': 'J', 'affiliation': 'Division of Inflammation and Infection, Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden.'}, {'lastname': 'Khademi', 'firstname': 'Mohsen', 'initials': 'M', 'affiliation': 'Neuroimmunology Unit, Department of Clinical Neuroscience, Center for Molecular Medicine, Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden.'}, {'lastname': 'Olsson', 'firstname': 'Tomas', 'initials': 'T', 'affiliation': 'Neuroimmunology Unit, Department of Clinical Neuroscience, Center for Molecular Medicine, Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden.'}, {'lastname': 'Blomberg', 'firstname': 'Marie', 'initials': 'M', 'affiliation': 'Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden.\nDepartment of Obstetrics and Gynecology, Linköping University, Linköping, Sweden.'}, {'lastname': 'Jenmalm', 'firstname': 'Maria C', 'initials': 'MC', 'affiliation': 'Division of Inflammation and Infection, Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden.'}, {'lastname': 'Altafini', 'firstname': 'Claudio', 'initials': 'C', 'affiliation': 'Division of Automatic Control, Department of Electrical Engineering, Linköping University, Linköping, Sweden.'}, {'lastname': 'Gustafsson', 'firstname': 'Mika', 'initials': 'M', 'affiliation': 'Bioinformatics, Department of Physics, Chemistry and Biology, Linköping University, Linköping, Sweden. mika.gustafsson@liu.se.'}, {'lastname': 'Ernerudh', 'firstname': 'Jan', 'initials': 'J', 'affiliation': 'Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden.\nDepartment of Clinical Immunology and Transfusion Medicine, Linköping University, Linköping, Sweden.'}]",,"This study represents, to our knowledge, the first in-depth investigation of the methylation and expression changes in peripheral CD4","Both DNA methylation and RNA sequencing revealed a prominent regulation, mostly peaking in the 3rd trimester and reversing post-partum, thus mirroring the clinical course with improvement followed by a worsening in disease activity. This rebound pattern was found to represent a general adaptation of the maternal immune system, with only minor differences between MS and controls. By using a network-based approach, we highlighted several genes at the core of this pregnancy-induced regulation, which were found to be enriched for genes and pathways previously reported to be involved in MS. Moreover, these pathways were enriched for in vitro stimulated genes and pregnancy hormones targets.",© 2023. The Author(s).,"10.1186/s12974-023-02781-2
10.1038/nri3871
10.1056/NEJM199807303390501
10.1111/j.1471-0528.2011.02931.x
10.1038/nri.2017.64
10.1126/sciimmunol.aan2946
10.1111/imm.13004
10.3389/fendo.2019.00198
10.3389/fimmu.2019.00625
10.1016/j.placenta.2017.09.003
10.1038/s41586-019-1467-x
10.1016/j.celrep.2019.09.025
10.3389/fimmu.2019.01935
10.3389/fimmu.2021.642038
10.4049/jimmunol.1900611
10.1001/archneurol.2009.304
10.1177/1352458510373939
10.1371/journal.pone.0008962
10.1016/j.jneuroim.2007.05.008
10.3389/fimmu.2018.03075
10.1016/j.csbj.2021.05.015
10.1126/science.aav7188
10.1371/journal.pcbi.1004120
10.1093/bioinformatics/btaa235
10.3389/fimmu.2021.672168
10.1093/bioinformatics/bty537
10.3389/fimmu.2022.930947
10.1056/NEJMra1213566
10.1371/journal.pone.0145204
10.1038/nri3361
10.3389/fimmu.2020.575197
10.1002/ctm2.821
10.1016/j.celrep.2016.08.036
10.1186/s12014-022-09361-1
10.3389/fimmu.2022.835625
10.1002/eji.202049144
10.1189/jlb.1012491
10.1002/jcb.20858
10.1126/scisignal.aap9415
10.1073/pnas.2002266117
10.1016/S1474-4422(15)00348-8
10.1093/bioinformatics/bts635
10.1038/nmeth.4197
10.1093/bioinformatics/btx513
10.1093/bioinformatics/bts680
10.1093/nargab/lqaa078
10.1093/bioinformatics/btp616
10.1093/nar/gkv007
10.1186/1471-2105-11-587
10.1016/j.immuni.2016.10.022
10.1186/gb-2014-15-2-r29
10.1093/nar/gkaa1074
10.1101/gr.1239303
10.1089/omi.2011.0118
10.1093/bioinformatics/btv145",<Element 'PubmedArticle' at 0x7f05db7f7ea0>
42,37094770,Systemic treatment with GnRH agonist produces antidepressant-like effects in LPS induced depression male mouse model.,"Gonadotropin-releasing hormone (GnRH) is at the head of the neuroendocrine reproductive axis. However, the non-reproductive functions of GnRH expressed in various tissues, including hippocampus, are still not known. Here, we unveil a previously unknown effect of GnRH, which mediates depression-like behaviors through the modulation of microglia function during immune challenge. Specifically, we found that either systemic treatment with GnRH agonist or over-expression of endogenous hippocampal GnRH via viral tool abolished the depression-like behavior after LPS challenges in mice. And the anti-depressant of GnRH was dependent on the hippocampal GnRHR signaling, since antagonizing GnRHR by drug treatment or by hippocampal GnRHR knockdown could block the antidepressant-effect of GnRH agonist. Interestingly, we found that the peripheral GnRH treatment prevented the microglia activation mediated inflammation in the hippocampus of mice. In light of the research findings presented here, we propose that, at least in the hippocampus, GnRH appears to act on GnRHR to regulate higher order non-reproductive functions associated with the microglia mediated neuroinflammation. These findings also provide insights into the function and cross-talk of GnRH, a known neuropeptide hormone, in neuro-immune response.","['Depression', 'GnRH', 'Hppocampus', 'Microglia', 'Neuroinflammation']",Neuropharmacology,2023-04-25,"[{'lastname': 'Xu', 'firstname': 'Yang', 'initials': 'Y', 'affiliation': 'Institute of Neuroscience, Hengyang Medical School, University of South China, Hengyang, 421001, Hunan, China.'}, {'lastname': 'Li', 'firstname': 'Wei', 'initials': 'W', 'affiliation': 'Department of Human Anatomy, Hengyang Medical School, University of South China, Hengyang, 421001, Hunan, China.'}, {'lastname': 'Shi', 'firstname': 'Mengmeng', 'initials': 'M', 'affiliation': 'Department of Human Anatomy, Hengyang Medical School, University of South China, Hengyang, 421001, Hunan, China.'}, {'lastname': 'Xu', 'firstname': 'Xiaofan', 'initials': 'X', 'affiliation': 'Department of Human Anatomy, Hengyang Medical School, University of South China, Hengyang, 421001, Hunan, China.'}, {'lastname': 'Guo', 'firstname': 'Dongmin', 'initials': 'D', 'affiliation': 'Department of Human Anatomy, Hengyang Medical School, University of South China, Hengyang, 421001, Hunan, China.'}, {'lastname': 'Liu', 'firstname': 'Zhenghai', 'initials': 'Z', 'affiliation': 'Department of Human Anatomy, Hengyang Medical School, University of South China, Hengyang, 421001, Hunan, China.'}, {'lastname': 'Chen', 'firstname': 'Ling', 'initials': 'L', 'affiliation': 'Department of Metabolism and Endocrinology, The First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, 421001, Hunan, China.'}, {'lastname': 'Zhong', 'firstname': 'Xiaolin', 'initials': 'X', 'affiliation': 'Department of Metabolism and Endocrinology, The First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, 421001, Hunan, China. Electronic address: zhxl20130623@163.com.'}, {'lastname': 'Cao', 'firstname': 'Wenyu', 'initials': 'W', 'affiliation': 'Department of Human Anatomy, Hengyang Medical School, University of South China, Hengyang, 421001, Hunan, China. Electronic address: marksman0@163.com.'}]",,,,Copyright © 2023 Elsevier Ltd. All rights reserved.,10.1016/j.neuropharm.2023.109560,<Element 'PubmedArticle' at 0x7f05dcd9b180>
43,"37030549
29487568
27065166
23629538
31939479
28389277
27208894
23485579
36327147
26940385
23590874
22851280
23785317
29460051
24517230
33792539
15833590
9344566
21756906
27072946
33152340
31470413
31366244
30737388
31479305
32229232
32317389
33069692
33972988
33769619
35395079
35803590
35779583
28462074
36633824
1673916
10521563
19115393
15090034
23792323
12586785
26268661
1791834
23349524
36099517
24751572
24316468
34562435
29459441
25237935
21490921
23939786
24699247
21098272
30377664
26470014
28524175
22201683
31182869
36543864
26275221
20625432
35568227
27508869",Central growth hormone action regulates neuroglial and proinflammatory markers in the hypothalamus of male mice.,"Growth hormone (GH) action in specific neuronal populations regulates neuroendocrine responses, metabolism, and behavior. However, the potential role of central GH action on glial function is less understood. The present study aims to determine how the hypothalamic expression of several neuroglial markers is affected by central GH action in male mice. The dwarf GH- and insulin-like growth factor-1 (IGF-1)-deficient Ghrhr","['Astrocyte', 'Cytokine', 'GH', 'IGF-1', 'Microglia', 'Neuroinflammation']",Neuroscience letters,2023-04-09,"[{'lastname': 'Wasinski', 'firstname': 'Frederick', 'initials': 'F', 'affiliation': 'Department of Neurology and Neurosurgery, Universidade Federal de Sao Paulo, Sao Paulo, SP 04039-032, Brazil.'}, {'lastname': 'Tavares', 'firstname': 'Mariana R', 'initials': 'MR', 'affiliation': 'Department of Physiology and Biophysics, Instituto de Ciencias Biomedicas, Universidade de Sao Paulo, Sao Paulo, SP 05508-000, Brazil.'}, {'lastname': 'Gusmao', 'firstname': 'Daniela O', 'initials': 'DO', 'affiliation': 'Department of Physiology and Biophysics, Instituto de Ciencias Biomedicas, Universidade de Sao Paulo, Sao Paulo, SP 05508-000, Brazil.'}, {'lastname': 'List', 'firstname': 'Edward O', 'initials': 'EO', 'affiliation': 'Edison Biotechnology Institute and Heritage College of Osteopathic Medicine, Ohio University, Athens, OH 45701, USA.'}, {'lastname': 'Kopchick', 'firstname': 'John J', 'initials': 'JJ', 'affiliation': 'Edison Biotechnology Institute and Heritage College of Osteopathic Medicine, Ohio University, Athens, OH 45701, USA.'}, {'lastname': 'Alves', 'firstname': 'Guilherme A', 'initials': 'GA', 'affiliation': 'Department of Anatomy, Instituto de Ciencias Biomedicas, Universidade de Sao Paulo, Sao Paulo, SP 05508-900, Brazil.'}, {'lastname': 'Frazao', 'firstname': 'Renata', 'initials': 'R', 'affiliation': 'Department of Anatomy, Instituto de Ciencias Biomedicas, Universidade de Sao Paulo, Sao Paulo, SP 05508-900, Brazil.'}, {'lastname': 'Donato', 'firstname': 'Jose', 'initials': 'J', 'affiliation': 'Department of Physiology and Biophysics, Instituto de Ciencias Biomedicas, Universidade de Sao Paulo, Sao Paulo, SP 05508-000, Brazil. Electronic address: jdonato@icb.usp.br.'}]",,,,Copyright © 2023 Elsevier B.V. All rights reserved.,"10.1016/j.neulet.2023.137236
10.3389/fendo.2018.00035
10.1002/cphy.c150002
10.1038/nrendo.2013.78
10.20945/2359-399700000018
10.1016/j.yhbeh.2017.04.001
10.1093/gerona/glw088
10.1172/JCI64595
10.1530/JOE-22-0159
10.1016/bs.pmbts.2015.10.014
10.1016/i.pnpbp.2013.04.005
10.1007/s11357-012-9460-4
10.3389/fnbeh.2013.00066
10.1007/s00429-018-1627-z
10.1210/en.2013-2086
10.7554/eLife.67267
10.1016/j.brainresbull.2005.01.012
10.1006/exnr.1997.6629
10.1016/i.expneurol.2011.06.014
10.1007/s00429-016-1221-1
10.1016/i.brainres.2020.147189
10.1530/JOE-19-0242
10.1096/fi.201901315R
10.1038/s41467-019-08607-1
10.1152/aipendo.00229.2019
10.1016/i.neuroscience.2020.03.037
10.1523/JNEUROSCI.2531-19.2020
10.1016/i.peptides.2020.170426
10.1210/endocr/bqab097
10.1111/ine.12957
10.1210/endocr/bqac045
10.1210/endocr/bqac103
10.1016/i.brainres.2022.147995
10.1016/j.molmet.2017.03.001
10.1007/s11357-023-00726-4
10.1016/0742-8413(91)90200-D
10.1016/s0165-3806(99)00081-4
10.1002/glia.20829
10.1111/j.0953-816X.2004.03308.x
10.1530/JOE-13-0053
10.1210/en.2002-220667
10.1111/acel.12382
10.1210/mend-5-12-1845
10.1210/me.2012-1330
10.1210/endocr/bqac151
10.1016/j.brainres.2014.04.018
10.1016/i.neuroscience.2013.11.050
10.1016/j.lfs.2021.119970
10.1530/EJE-18-0018
10.1210/en.2014-1367
10.1371/journal.pone.0018535
10.1002/cne.23451
10.1371/journal.pone.0090381
10.1073/pnas.1016485107
10.1002/btm2.10109
10.1002/glia.22930
10.1038/nrneurol.2017.69
10.1172/JCI59660
10.1038/s41593-019-0418-z
10.1038/s41598-022-26671-4
10.1371/iournal.pone.0135502
10.1371/iournal.pone.0011443
10.1016/i.lfs.2022.120636
10.1016/i.cmet.2016.07.017",<Element 'PubmedArticle' at 0x7f05dcd71e00>
44,36990415,Tuning the aggregation behavior of human insulin in the presence of luteolin: An in vitro and in silico approach.,"Protein misfolding and related formation of amyloid fibrils are associated with several conformational diseases, such as Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease (HD), prion diseases, and Diabetes mellitus, Type 2 (DM-II). Several molecules including antibiotics, polyphenols, flavonoids, anthraquinones, and other small molecules are implicated to modulate amyloid assembly. The stabilization of the native forms of the polypeptides and prevention of their misfolding and aggregation are of clinical and biotechnological importance. Among the natural flavonoids, luteolin is of great importance because of its therapeutic role against neuroinflammation. Herein, we have explored the inhibitory effect of luteolin (LUT) on aggregation of a model protein, human insulin (HI). To understand the molecular mechanism of the inhibition of aggregation of HI by LUT, we employed molecular simulation, UV-Vis, fluorescence, and circular dichroism (CD) spectroscopies along with the dynamic light scattering (DLS). The analysis of the tuning of the HI aggregation process by luteolin revealed that interaction of HI with LUT resulted in the decrease in binding of the various fluorescent dyes, such as thioflavin T (ThT) and 8-anilinonaphthalene-1-sulfonic acid (ANS) to this protein. Retention of the native-like CD spectra and resistance to the aggregation in the presence of LUT has confirmed the aggregation inhibitory potential of LUT. The maximum inhibitory effect was found at the protein-to-drug ratio of 1:12, and no significant change was observed beyond this concentration.","['Aggregation', ""Alzheimer's disease"", 'Human insulin', 'Misfolding', 'Simulation conformational diseases']",International journal of biological macromolecules,2023-03-30,"[{'lastname': 'Ali', 'firstname': 'Syed Moasfar', 'initials': 'SM', 'affiliation': 'Interdisciplinary Biotechnology Unit, Aligarh Muslim University, Aligarh, UP, India.'}, {'lastname': 'Nabi', 'firstname': 'Faisal', 'initials': 'F', 'affiliation': 'Interdisciplinary Biotechnology Unit, Aligarh Muslim University, Aligarh, UP, India.'}, {'lastname': 'Furkan', 'firstname': 'Mohammad', 'initials': 'M', 'affiliation': 'Department of Biochemistry, Aligarh Muslim University, Aligarh, UP, India.'}, {'lastname': 'Hisamuddin', 'firstname': 'Malik', 'initials': 'M', 'affiliation': 'Interdisciplinary Biotechnology Unit, Aligarh Muslim University, Aligarh, UP, India.'}, {'lastname': 'Malik', 'firstname': 'Sadia', 'initials': 'S', 'affiliation': 'Interdisciplinary Biotechnology Unit, Aligarh Muslim University, Aligarh, UP, India.'}, {'lastname': 'Zakariya', 'firstname': 'Syed Mohammad', 'initials': 'SM', 'affiliation': 'Interdisciplinary Biotechnology Unit, Aligarh Muslim University, Aligarh, UP, India.'}, {'lastname': 'Rizvi', 'firstname': 'Irum', 'initials': 'I', 'affiliation': 'Interdisciplinary Biotechnology Unit, Aligarh Muslim University, Aligarh, UP, India.'}, {'lastname': 'Uversky', 'firstname': 'Vladimir N', 'initials': 'VN', 'affiliation': 'Department of Molecular Medicine and Byrd Alzheimer\'s Research Institute, Morsani College of Medicine, University of South Florida, Tampa, FL 33620, USA; Laboratory of New Methods in Biology, Institute for Biological Instrumentation of the Russian Academy of Sciences, Federal Research Center ""Pushchino Scientific Center for Biological Research of the Russian Academy of Sciences"", Pushchino, Moscow region 142290, Russia.'}, {'lastname': 'Khan', 'firstname': 'Rizwan H', 'initials': 'RH', 'affiliation': 'Interdisciplinary Biotechnology Unit, Aligarh Muslim University, Aligarh, UP, India. Electronic address: rizwanhkhan1@gmail.com.'}]",,,,Copyright © 2023 Elsevier B.V. All rights reserved.,10.1016/j.ijbiomac.2023.124219,<Element 'PubmedArticle' at 0x7f05d84b39f0>
45,"36982488
19679277
33488984
21726199
27873462
25744672
18333761
32471464
18979198
31083583
35764292
19777353
26514204
30215696
27698681
25587567
26435711
25599452
21244359
22010042
16153306
24571249
36180687
1323736
22245784
36065903
29247550
21629741
17982102
25836422
15082137
22589599
19079295
16020519
14907713
5964963
13650640
6536823
7561867
28601083
10976232
24422
10969143",Modulation of Melatonin in Pain Behaviors Associated with Oxidative Stress and Neuroinflammation Responses in an Animal Model of Central Post-Stroke Pain.,"Central post-stroke pain is a severe persistent pain disease that affects 12% of stroke survivors (CPSP). These patients may have a cognitive impairment, depression, and sleep apnea, which leave them open to misdiagnosis and mistreatment. However, there has been little research on whether the neurohormone melatonin can effectively reduce pain in CPSP conditions. In the present study, we labeled melatonin receptors in various brain regions of rats. Later, we established a CPSP animal model by intra-thalamic collagenase lesions. After a rehabilitation period of three weeks, melatonin was administered using different doses (i.e., 30 mg/kg, 60 mg/kg, 120 mg/kg) for the following three weeks. Mechanical allodynia, thermal hyperalgesia, and cold allodynia behavioral tests were performed. Immediately after behavioral parameters were tested, animals were sacrificed, and the thalamus and cortex were isolated for biochemical (mitochondrial complexes/enzyme assays and LPO, GSH levels) and neuroinflammatory (TNF-α, IL-1β, IL-6) assessments. The results show that melatonin receptors were abundant in VPM/VPL regions. The thalamic lesion significantly induced pain behaviors in the mechanical, thermal planters, and cold allodynia tests. A significant decrease in mitochondrial chain complexes (C-I, II, III, IV) and enzymes (SOD, CAT, Gpx, SDH) was observed after the thalamic lesion. While there were significant increases in reactive oxygen species levels, including increases in LPO, the levels of reduced GSH were decreased in both the cortex and thalamus. Proinflammatory infiltration was noticed after the thalamic lesion, as there was a significant elevation in levels of TNF-α, IL-1β, and IL-6. Administration of melatonin has been shown to reverse the injury effect dose-dependently. Moreover, a significant increase in C-I, IV, SOD, CAT, and Gpx levels occurred in the CPSP group. Proinflammatory cytokines were significantly reduced by melatonin treatments. Melatonin seems to mediate its actions through MT1 receptors by preserving mitochondrial homeostasis, reducing free radical generation, enhancing mitochondrial glutathione levels, safeguarding the proton potential in the mitochondrial ETC by stimulating complex I and IV activities, and protecting the neuronal damage. In summary, exogenous melatonin can ameliorate pain behaviors in CPSP. The present findings may provide a novel neuromodulatory treatment in the clinical aspects of CPSP.","['central poststroke pain', 'inflammation', 'melatonin', 'mitochondrial dysfunction', 'neuromodulation']",International journal of molecular sciences,2023-03-30,"[{'lastname': 'Kaur', 'firstname': 'Tavleen', 'initials': 'T', 'affiliation': 'Taiwan International Graduate Program in Interdisciplinary Neuroscience, National Yang-Ming Chiao Tung University and Academia Sinica, Taipei 11529, Taiwan.\nDivision of Neuroscience, Institute of Biomedical Sciences, Academia Sinica, Taipei 11529, Taiwan.'}, {'lastname': 'Huang', 'firstname': 'Andrew Chih-Wei', 'initials': 'AC', 'affiliation': 'Department of Psychology, Fo Guang University, Yilan County 26247, Taiwan.'}, {'lastname': 'Shyu', 'firstname': 'Bai-Chuang', 'initials': 'BC', 'affiliation': 'Division of Neuroscience, Institute of Biomedical Sciences, Academia Sinica, Taipei 11529, Taiwan.'}]",,,,,"10.3390/ijms24065413
10.1016/S1474-4422(09)70176-0
10.4314/mmj.v32i3.5
10.1042/BJ20110162
10.1111/cns.12655
10.1146/annurev.neuro.30.051606.094302
10.1186/s13024-020-00376-6
10.1007/s11064-008-9865-8
10.3390/biology8020038
10.1016/j.nbd.2022.105803
10.1007/s11154-009-9120-x
10.1146/annurev-pharmtox-010814-124742
10.1210/er.2018-00084
10.3892/etm.2016.3565
10.1155/2014/586270
10.1155/2015/384750
10.1097/01.j.pain.0000460311.71572.5f
10.2174/156802611794863517
10.1177/1756285611406166
10.1186/1743-7075-2-22
10.1111/jpi.12128
10.1016/0024-3205(92)90237-J
10.1016/j.mce.2012.01.004
10.1177/17448069221127180
10.1111/jpi.12463
10.4061/2011/326320
10.4049/jimmunol.179.10.7101
10.1016/j.nbd.2015.02.028
10.1016/j.pain.2004.01.029
10.1038/aps.2008.14
10.1152/ajpregu.00834.2004
10.1016/S0021-9258(19)52451-6
10.1042/bj0990667
10.1016/0003-9861(59)90090-6
10.1016/0160-5402(84)90059-7
10.1046/j.1471-4159.1995.65041698.x
10.1134/S0006297917060104
10.1083/jcb.32.2.415
10.1016/0003-9861(78)90479-4
10.1016/S0014-2999(00)00421-0",<Element 'PubmedArticle' at 0x7f05d84c64f0>
46,"36966972
27976413
10858586
30336991
12498988
24101490
23891880
24684963
25818503
31332738
29751000
34217798
34864001
32197779
18650918
25130621
35353392
14610053
18096503
23217738
33085920
18670616
26888301
18682568
15302527
23040807
20855465
20479749
26109933
28638858
35142686
36254984
16099392
24267894
23122958
21256197
12741992
15363397
29097192
30067909
36460464
31831863
27599555
23558985
32322464
2848184
1470919
25524120
15100161
12136125
12505697
21501147
22053353
32867595
23924692
12509806
3377450
8395053
7565624
28751457
24973119
29756563
20797687
23796481
12810767
3955067
12741983
12843414
31913777
35713704
20147530
11976704
30059673
10779390
26565024
28213089
2405648
18297102
15233753
29531087
33939165
17267577
19575681
19365736
7944079
25792098
15817521
1992016
2308954
24845457
23912944
25298214
10785538
17202425
15973410
15975032
3601007
28826534
12037135
1700516
15464149
6092901
2869405
35136958
18297109
11852973
26223500
12764049
28910616
30354159
20216546
19307565
33786823
19126760
9341166
11470505
22524785
25166905
30152284
18096504
31562623
19144193
14965328
11402053
10931854
12049940
33239064
20491633
35173313
33171143
27630175
23818695
29348400
27775008
21696217
19029917
19635411
21406188
18064422
32980261
24510751
21035522
25474204
16596779
18426493
32285169
31151929
24844690
20657592
31251974
2165569
27189876
27716676
23208308
4910003
7605349
6046550
6039537
25315390
22804774
5879214
11972360
16534113
15453089
29722963
3969219
26244281
17360910
21459826
34117788
30697147
23142242
7689702
24102242
22270809
22969151
22021672
17704824
27077495
17021169
26668358
24747340
21940435
15729296
16364651
11586361
28373073
28826718
16402100
26408156
25927213
14595399
34516291
22813736
29759062
7993636
26278494
8606472
19648913
36283077
27540165
29842858
32203086
21508345
16611855
18250160
15975510
2825898
16957004
16484297
17539917
30664773
21418147
26216043
20729846
24849924
30295758
34943962
28901776
21418185
25466252
33905617
28186177
11879109
30522932
26541090
17349697
36638804
9285589
16678907
7575630
32483456
26403860
36268116
30538288
22526684
20159446
35246670
12846993
29171003
1249056
11818462
27715315
16732431
32867595
16224028
9597150
26362942
26212325
26779719
33093652
18093517
28975471
24897085
25796567
33174475
29940242
11516401
11279497
11976437
23459929
33892818
21049984
24571856
30946940
18537667
30381825
16672646
17270732
34577139
18952573
18534982
28733897
25378159
25492114
25131612
24476943
34831202
36481187
36481187
36717883",Inhibiting degradation of 2-arachidonoylglycerol as a therapeutic strategy for neurodegenerative diseases.,"Endocannabinoids are endogenous lipid signaling mediators that participate in a variety of physiological and pathological processes. 2-Arachidonoylglycerol (2-AG) is the most abundant endocannabinoid and is a full agonist of G-protein-coupled cannabinoid receptors (CB1R and CB2R), which are targets of Δ","['2-Arachidonoylglycerol', 'Alzheimer’s disease', 'Endocannabinoid', 'Monoacylglycerol lipase', 'Neurodegenerative disease', 'Traumatic brain injury']",Pharmacology & therapeutics,2023-03-27,"[{'lastname': 'Chen', 'firstname': 'Chu', 'initials': 'C', 'affiliation': 'Department of Cellular and Integrative Physiology, Center for Biomedical Neuroscience, Joe R. and Teresa Lozano Long School of Medicine, University of Texas Health San Antonio, San Antonio, TX 78229, USA. Electronic address: chenc7@uthscsa.edu.'}]",,,,Copyright © 2023 The Author(s). Published by Elsevier Inc. All rights reserved.,10.1016/j.pharmthera.2023.108394,<Element 'PubmedArticle' at 0x7f05dcba3540>
47,"36890518
30818749
32887786
34280844
32720161
33469815
9545219
11304551
15365096
15365095
34874976
16260389
34822299
31460832
34450312
34589903
33912676
17589370
31809361
35771903
21830069
21463073
27561826
25378491
31114576
25389027
29194121
29471387
20874519
34954656
29160817
34914498
34267388
32058974
32630206
25452565
26267216
29514950
23618408
25260700
23975260
12759259
30872089
33472520
34261550
27400930
30260742
31917687
27796300
33918416
26402097
10903839
30031156
19222525
25445488
27598965
31870404
25676386
21215273
23522044
20798282
33285203
27010449
21063504
31337416
32804309
16260391
23768491
19929218
32378435
34564703
30031609
33584204
33875655
26019222
25036707
32326963
19056987
32747434
10521561
27518089
32047899
20160352
27922192
29187192
35107690
23752207
28100738
32813239
27133395
25666611
34069576
27765578
30189584
14706866
28600357
31825083
33829028
30120222
29057986
25586559
33054518
35082169
33101496
33874858
30409105
30543777
33431578
32690600
33332005
31349929
31274535
35288604
20201849
17404045
28029694
30463579
32029532
33411137
32183416
21874328
32792944
29354290
32068119
27434582
30352948
31208526
11923437
16635249
19110265
25398949
31030641
12212784
33193190
35370963
26273688
34258318
35728041
33024047
35451695
35044528
31506009
28798125
27690502",Cannabinoids modulate the microbiota-gut-brain axis in HIV/SIV infection by reducing neuroinflammation and dysbiosis while concurrently elevating endocannabinoid and indole-3-propionate levels.,"Although the advent of combination anti-retroviral therapy (cART) has transformed HIV into a manageable chronic disease, an estimated 30-50% of people living with HIV (PLWH) exhibit cognitive and motor deficits collectively known as HIV-associated neurocognitive disorders (HAND). A key driver of HAND neuropathology is chronic neuroinflammation, where proinflammatory mediators produced by activated microglia and macrophages are thought to inflict neuronal injury and loss. Moreover, the dysregulation of the microbiota-gut-brain axis (MGBA) in PLWH, consequent to gastrointestinal dysfunction and dysbiosis, can lead to neuroinflammation and persistent cognitive impairment, which underscores the need for new interventions.
We performed RNA-seq and microRNA profiling in basal ganglia (BG), metabolomics (plasma) and shotgun metagenomic sequencing (colon contents) in uninfected and SIV-infected rhesus macaques (RMs) administered vehicle (VEH/SIV) or delta-9-tetrahydrocannabinol (THC) (THC/SIV).
Long-term, low-dose THC reduced neuroinflammation and dysbiosis and significantly increased plasma endocannabinoid, endocannabinoid-like, glycerophospholipid and indole-3-propionate levels in chronically SIV-infected RMs. Chronic THC potently blocked the upregulation of genes associated with type-I interferon responses (NLRC5, CCL2, CXCL10, IRF1, IRF7, STAT2, BST2), excitotoxicity (SLC7A11), and enhanced protein expression of WFS1 (endoplasmic reticulum stress) and CRYM (oxidative stress) in BG. Additionally, THC successfully countered miR-142-3p-mediated suppression of WFS1 protein expression via a cannabinoid receptor-1-mediated mechanism in HCN2 neuronal cells. Most importantly, THC significantly increased the relative abundance of Firmicutes and Clostridia including indole-3-propionate (C. botulinum, C. paraputrificum, and C. cadaveris) and butyrate (C. butyricum, Faecalibacterium prausnitzii and Butyricicoccus pullicaecorum) producers in colonic contents.
This study demonstrates the potential of long-term, low-dose THC to positively modulate the MGBA by reducing neuroinflammation, enhancing endocannabinoid levels and promoting the growth of gut bacterial species that produce neuroprotective metabolites, like indole-3-propionate. The findings from this study may benefit not only PLWH on cART, but also those with no access to cART and more importantly, those who fail to suppress the virus under cART.","['Clostridia', 'Endocannabinoids', 'Indole-3-propionate', 'Microbiome', 'Microbiota–gut–brain axis', 'Neuroinflammation', 'Rhesus macaque', 'SIV', 'THC', 'Type-I interferon']",Journal of neuroinflammation,2023-03-09,"[{'lastname': 'McDew-White', 'firstname': 'Marina', 'initials': 'M', 'affiliation': 'Southwest National Primate Research Center, Texas Biomedical Research Institute, 8715 West Military Drive, San Antonio, TX, 78227-5302, USA.'}, {'lastname': 'Lee', 'firstname': 'Eunhee', 'initials': 'E', 'affiliation': 'Southwest National Primate Research Center, Texas Biomedical Research Institute, 8715 West Military Drive, San Antonio, TX, 78227-5302, USA.'}, {'lastname': 'Premadasa', 'firstname': 'Lakmini S', 'initials': 'LS', 'affiliation': 'Southwest National Primate Research Center, Texas Biomedical Research Institute, 8715 West Military Drive, San Antonio, TX, 78227-5302, USA.'}, {'lastname': 'Alvarez', 'firstname': 'Xavier', 'initials': 'X', 'affiliation': 'Southwest National Primate Research Center, Texas Biomedical Research Institute, 8715 West Military Drive, San Antonio, TX, 78227-5302, USA.'}, {'lastname': 'Okeoma', 'firstname': 'Chioma M', 'initials': 'CM', 'affiliation': 'Department of Pathology, Microbiology, and Immunology, New York Medical College, Valhalla, NY, 10595-1524, USA.'}, {'lastname': 'Mohan', 'firstname': 'Mahesh', 'initials': 'M', 'affiliation': 'Southwest National Primate Research Center, Texas Biomedical Research Institute, 8715 West Military Drive, San Antonio, TX, 78227-5302, USA. mmohan@txbiomed.org.'}]",,"This study demonstrates the potential of long-term, low-dose THC to positively modulate the MGBA by reducing neuroinflammation, enhancing endocannabinoid levels and promoting the growth of gut bacterial species that produce neuroprotective metabolites, like indole-3-propionate. The findings from this study may benefit not only PLWH on cART, but also those with no access to cART and more importantly, those who fail to suppress the virus under cART.","Long-term, low-dose THC reduced neuroinflammation and dysbiosis and significantly increased plasma endocannabinoid, endocannabinoid-like, glycerophospholipid and indole-3-propionate levels in chronically SIV-infected RMs. Chronic THC potently blocked the upregulation of genes associated with type-I interferon responses (NLRC5, CCL2, CXCL10, IRF1, IRF7, STAT2, BST2), excitotoxicity (SLC7A11), and enhanced protein expression of WFS1 (endoplasmic reticulum stress) and CRYM (oxidative stress) in BG. Additionally, THC successfully countered miR-142-3p-mediated suppression of WFS1 protein expression via a cannabinoid receptor-1-mediated mechanism in HCN2 neuronal cells. Most importantly, THC significantly increased the relative abundance of Firmicutes and Clostridia including indole-3-propionate (C. botulinum, C. paraputrificum, and C. cadaveris) and butyrate (C. butyricum, Faecalibacterium prausnitzii and Butyricicoccus pullicaecorum) producers in colonic contents.",© 2023. The Author(s).,"10.1186/s12974-023-02729-6
10.3390/v11030200
10.1212/WNL.0000000000010752
10.1016/j.jneuroim.2021.577649
10.1007/7854_2020_131
10.1007/s11904-020-00537-8
10.1126/science.280.5362.427
10.1084/jem.193.8.905
10.1084/jem.20040874
10.1084/jem.20041196
10.1371/journal.ppat.1010105
10.1126/science.abi6087
10.1152/physrev.00018.2018
10.1016/j.phrs.2021.105840
10.1016/j.bbih.2020.100168
10.1089/can.2020.0037
10.1097/QAI.0b013e31811ed205
10.1097/QAI.0000000000002211
10.1126/science.abp9960
10.1007/s11481-011-9301-8
10.1037/a0023000
10.1111/nmo.12931
10.1128/JVI.01754-14
10.3389/fimmu.2019.00914
10.1111/dar.12223
10.1097/QAD.0000000000001704
10.1093/cid/cix1116
10.1089/aid.2010.0218
10.1016/j.ebiom.2021.103769
10.3390/nu9111269
10.1126/science.abf6099
10.1038/d41586-021-01894-z
10.1016/j.isci.2020.100866
10.3390/v12070713
10.4049/jimmunol.1401447
10.7554/eLife.05005
10.4049/jimmunol.1701148
10.1186/gb-2013-14-4-r36
10.1093/bioinformatics/btu638
10.1038/nprot.2013.099
10.1016/S0002-9440(10)64336-2
10.1016/j.bbi.2019.03.011
10.1089/aid.2020.0203
10.1017/S1355617720001447
10.1007/s13365-016-0466-z
10.1089/vim.2018.0085
10.1172/JCI133737
10.1038/ncomms12849
10.3390/cells10040798
10.3233/JAD-150318
10.1006/geno.2000.6228
10.1016/j.nbd.2018.07.019
10.1111/j.1440-169X.2009.01088.x
10.1016/j.neuropharm.2014.10.026
10.1038/tp.2016.129
10.1186/s13041-019-0537-1
10.1007/s00401-015-1394-3
10.1016/j.neuropharm.2010.12.029
10.1016/j.neuron.2013.01.017
10.1126/science.1195227
10.1016/j.neuropharm.2020.108425
10.1210/en.2016-1055
10.1007/s12079-010-0095-x
10.1186/s12967-019-1993-1
10.1007/s13365-020-00861-0
10.1007/BF03033825
10.1016/j.chom.2013.05.006
10.1089/neu.2009.0955
10.1080/14728222.2020.1766445
10.1038/s41398-021-01618-x
10.1016/j.bbrc.2018.07.043
10.3389/fncel.2020.544285
10.1038/s41467-021-22399-3
10.1126/scitranslmed.aaa8103
10.1172/JCI71886
10.1186/s12974-020-01809-1
10.1126/science.1164022
10.1242/dev.185140
10.1016/S0165-3806(99)00092-9
10.1007/s11064-016-2015-9
10.1093/alcalc/agaa007
10.1172/JCI39678
10.1002/jcb.25825
10.1186/s12916-017-0974-6
10.1007/s10571-022-01200-z
10.1096/fj.13-232678
10.1523/JNEUROSCI.0851-16.2016
10.1007/s12035-020-02054-6
10.1053/j.gastro.2016.04.015
10.1074/jbc.M114.618447
10.3390/ijerph18105429
10.1016/j.brainres.2016.10.011
10.3390/molecules23092257
10.1016/j.brainres.2003.09.079
10.1074/jbc.M116.773861
10.1093/advances/nmz127
10.3389/fmed.2021.648259
10.1038/s41467-018-05470-4
10.1038/s41598-017-13722-4
10.1038/mi.2014.128
10.1080/19490976.2020.1826748
10.1136/gutjnl-2021-325989
10.3892/ol.2020.12190
10.1080/19490976.2021.1907272
10.1080/19490976.2018.1534513
10.1016/j.chom.2018.11.006
10.1136/gutjnl-2020-323020
10.1007/978-3-030-57369-0_6
10.1016/bs.irn.2019.06.012
10.1097/QAD.0000000000002300
10.1038/s41598-022-08364-0
10.1111/j.1749-6632.2009.05277.x
10.1196/annals.1397.036
10.1111/jnc.13940
10.1186/s12974-018-1354-7
10.1523/JNEUROSCI.2516-19.2020
10.1007/s10067-020-05526-1
10.3390/pharmaceutics12030265
10.1007/s00401-011-0865-4
10.3389/fphar.2020.01097
10.1038/cddiscovery.2017.61
10.1016/j.phrs.2020.104702
10.1371/journal.pbio.1002511
10.1126/scisignal.aaq1380
10.1016/bs.irn.2019.04.003
10.1523/JNEUROSCI.22-07-02718.2002
10.1111/j.1471-4159.2006.03750.x
10.1016/j.jpsychires.2008.11.006
10.1093/hmg/ddu571
10.1080/19490976.2019.1586038
10.1007/s12031-002-0036-0
10.3389/fmicb.2020.575586
10.3389/fendo.2022.841703
10.1002/acn3.214
10.1093/ofid/ofab288
10.1093/ajcn/nqac170
10.1128/mSystems.00313-20
10.1007/s00726-022-03161-5
10.1007/s00018-021-04060-w
10.1146/annurev-pharmtox-010919-023628
10.1126/science.aam9949
10.1037/pha0000081",<Element 'PubmedArticle' at 0x7f05dbc816d0>
48,36868399,Chronic administration of catalase inhibitor attenuates hypertension in renovascular hypertensive rats.,"Reactive oxygen species like hydrogen peroxide (H
Male Holtzman rats with a clip occluding partially the left renal artery and chronic sc injections of ATZ were used.
Subcutaneous injections of ATZ (600 mg/kg of body weight/day) for 9 days in 2K1C rats reduced arterial pressure (137 ± 8, vs. saline: 182 ± 8 mmHg). ATZ also reduced the sympathetic modulation and enhanced the parasympathetic modulation of pulse interval, reducing the sympatho-vagal balance. Additionally, ATZ reduced mRNA expression for interleukins 6 and IL-1β, tumor necrosis factor-α, AT1 receptor (0.77 ± 0.06, vs. saline: 1.47 ± 0.26 fold change), NOX 2 (0.85 ± 0.13, vs. saline: 1.75 ± 0.15 fold change) and the marker of microglial activation, CD 11 (0.47 ± 0.07, vs. saline, 1.34 ± 0.15 fold change) in the hypothalamus of 2K1C rats. Daily water and food intake and renal excretion were only slightly modified by ATZ.
The results suggest that the increase of endogenous H","['Angiotensin II', 'Autonomic modulation', 'Catalase inhibitor', 'Hydrogen peroxide', 'Hypertension', 'Neuro-inflammation', 'Sympathetic activity']",Life sciences,2023-03-04,"[{'lastname': 'Lauar', 'firstname': 'Mariana R', 'initials': 'MR', 'affiliation': 'Department of Physiology and Pathology, School of Dentistry, São Paulo State University, UNESP, Araraquara, SP, Brazil.'}, {'lastname': 'Colombari', 'firstname': 'Débora S A', 'initials': 'DSA', 'affiliation': 'Department of Physiology and Pathology, School of Dentistry, São Paulo State University, UNESP, Araraquara, SP, Brazil.'}, {'lastname': 'De Paula', 'firstname': 'Patrícia M', 'initials': 'PM', 'affiliation': 'Department of Physiology and Pathology, School of Dentistry, São Paulo State University, UNESP, Araraquara, SP, Brazil.'}, {'lastname': 'Colombari', 'firstname': 'Eduardo', 'initials': 'E', 'affiliation': 'Department of Physiology and Pathology, School of Dentistry, São Paulo State University, UNESP, Araraquara, SP, Brazil.'}, {'lastname': 'Andrade', 'firstname': 'Carina A F', 'initials': 'CAF', 'affiliation': 'Department of Physiology and Pathology, School of Dentistry, São Paulo State University, UNESP, Araraquara, SP, Brazil.'}, {'lastname': 'De Luca', 'firstname': 'Laurival A', 'initials': 'LA', 'affiliation': 'Department of Physiology and Pathology, School of Dentistry, São Paulo State University, UNESP, Araraquara, SP, Brazil.'}, {'lastname': 'Menani', 'firstname': 'José V', 'initials': 'JV', 'affiliation': 'Department of Physiology and Pathology, School of Dentistry, São Paulo State University, UNESP, Araraquara, SP, Brazil. Electronic address: jv.menani@unesp.br.'}]",,,,Copyright © 2023 Elsevier Inc. All rights reserved.,10.1016/j.lfs.2023.121538,<Element 'PubmedArticle' at 0x7f05dc8eccc0>
49,"36785617
30287051
30584159
25904081
27338524
26511768
33848468
25506674
35022304
34951063
25258329
31584222
21375602
29272304
12112469
22237023
29455364
18468820
24273936
32632847
32647952
33945146
20570453
24140093
18337619
28500919
27508394
20454844
33989733
35391661
32418186
33909265
34179744
33205039
36094176
24120563
31637623
18457924
18424396
32575116
26764391
30869825
33493316
36092796
18070024
36044549
32257109
30617325
30550785
16116614
27708076
34655501
35313950
30250260
32739015
34601135
31414194
26601726
32582833
24120943
34087277
33998558
28480165",Could exercise hormone irisin be a therapeutic agent against Parkinson's and other neurodegenerative diseases?,"Parkinson's disease (PD) is the second most common neurodegenerative disease after Alzheimer's disease (AD). The pathologic hallmarks of the disease are the loss of dopaminergic neurons of substantia nigra pars compacta and the presence of intraneuronal alpha synuclein (a-syn) aggregates. Clinical features of PD include motor symptoms such as bradykinesia, rigidity, tremors, postural instability, and gait impairment, and non-motor symptoms such as constipation, orthostatic hypotension, REM sleep disorder, depression and dementia. Currently, there is no disease-modifying therapy for PD. Several human studies have shown that exercise reduces progression of motor symptoms, improves performance on cognitive tasks, and slows functional deterioration. However, regular exercise may not always be feasible in PD patients. Irisin is an exercise-induced myokine involved in metabolism modulation and body fat reduction, but it also crosses the blood-brain barrier and may mediate some of the benefits of exercise in brain function. Recent evidence has shown that irisin could be therapeutically promising in PD as an ""exercise-mimicking"" intervention. Exogenous irisin administration decreases brain a-syn pathology and loss of dopaminergic neurons, while it improves motor outcomes in preclinical models. Several other neurodegenerative disorders such as AD share common underlying pathogenetic mechanisms with PD such as protein misfolding and aggregation, neuroinflammation, brain metabolic abnormalities, and neuronal loss. Therefore, investigation of irisin as a disease-modifying therapy could be promising for PD and other neurodegenerative disorders including AD.","['Adipokine', 'Alzheimer’s disease', 'Exercise', 'Irisin', 'Myokine', 'Neurodegenerative disorders', 'Parkinson’s disease']",Metabolism open,2023-02-15,"[{'lastname': 'Avgerinos', 'firstname': 'Konstantinos I', 'initials': 'KI', 'affiliation': 'Department of Neurology, Wayne State University, Detroit, MI, USA.'}, {'lastname': 'Liu', 'firstname': 'Junli', 'initials': 'J', 'affiliation': ""Shanghai Jiao Tong University School of Medicine, Shanghai Jiao Tong University Affiliated 6th People's Hospital, Shanghai Diabetes Institute, Shanghai, China.""}, {'lastname': 'Dalamaga', 'firstname': 'Maria', 'initials': 'M', 'affiliation': 'Department of Biologic Chemistry, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece.'}]",,,,© 2023 The Authors.,10.1016/j.metop.2023.100233,<Element 'PubmedArticle' at 0x7f05dc8f9f40>
50,36745405,The Endocannabinoid System as a Potential Therapeutic Target for HIV-1-Associated Neurocognitive Disorder.,,"['2-arachidonoylglycerol', 'HIV-associated neurocognitive disorders', 'N-arachidonylethanolamine', 'cannabinoid receptors', 'endocannabinoid system']",Cannabis and cannabinoid research,2023-02-07,"[{'lastname': 'Chu', 'firstname': 'Liuxi', 'initials': 'L', 'affiliation': 'Department of Brain and Learning Science, School of Biological Science and Medical Engineering, Southeast University, Nanjing, China.\nKey Laboratory of Child Development and Learning Science (Southeast University), Ministry of Education, Nanjing, China.\nDepartment of Child Development and Education, Research Center for Learning Science, Southeast University, Nanjing, China.'}, {'lastname': 'Shu', 'firstname': 'Zheng', 'initials': 'Z', 'affiliation': 'Clinical Nutrition Department, The Third Affiliated Hospital of Shandong First Medical University, Jinan, China.'}, {'lastname': 'Gu', 'firstname': 'Xinpei', 'initials': 'X', 'affiliation': 'Department of Human Anatomy, Shandong First Medical University and Shandong Academy of Medical Sciences, Taian, China.'}, {'lastname': 'Wu', 'firstname': 'Yan', 'initials': 'Y', 'affiliation': 'Department of Brain and Learning Science, School of Biological Science and Medical Engineering, Southeast University, Nanjing, China.\nKey Laboratory of Child Development and Learning Science (Southeast University), Ministry of Education, Nanjing, China.\nDepartment of Child Development and Education, Research Center for Learning Science, Southeast University, Nanjing, China.'}, {'lastname': 'Yang', 'firstname': 'Jin', 'initials': 'J', 'affiliation': 'Department of Child Development and Education, Research Center for Learning Science, Southeast University, Nanjing, China.\nDepartment of Child and Adolescent Hygienics, School of Public Health, Southeast University, Nanjing, China.'}, {'lastname': 'Deng', 'firstname': 'Huihua', 'initials': 'H', 'affiliation': 'Department of Brain and Learning Science, School of Biological Science and Medical Engineering, Southeast University, Nanjing, China.\nKey Laboratory of Child Development and Learning Science (Southeast University), Ministry of Education, Nanjing, China.\nDepartment of Child Development and Education, Research Center for Learning Science, Southeast University, Nanjing, China.'}]",,,,,10.1089/can.2022.0267,<Element 'PubmedArticle' at 0x7f05d8829db0>
51,36744980,[Oxytocin: a new target for neuroprotection?].,"Every year, 30 million infants worldwide are delivered after intra-uterine growth restriction (IUGR) and 15 million are born preterm. These two conditions are the leading causes of ante-/perinatal stress and brain injury responsible for neurocognitive and behavioral disorders affecting more than 9 million children each year. Most pharmacological candidates to prevent perinatal brain damage have failed to demonstrate substantial benefits. In contrast, environment enrichment based on developmental care, skin-to-skin contact and vocal/music exposure appear to exert positive effects on brain structure and function. However, mechanisms underlying these effects remain unknown. There is strong evidence that an adverse environment during pregnancy and the neonatal period can influence hormonal responses of the newborn with long-lasting neurobehavioral consequences in infancy and adulthood. In particular, excessive cortisol release in response to perinatal stress associated with prematurity or IUGR is recognized to induce brain-programming effects and neuroinflammation, a key predictor of subsequent neurological impairments. These deleterious effects are known to be balanced by oxytocin (OT), a neuropeptide released by the hypothalamus, which plays a role during the perinatal period and in social behavior. In addition, preclinical studies suggest that OT is able to regulate the central inflammatory response to injury in the adult brain. Using a rodent model of IUGR associated with developing white matter damage, we recently reported that carbetocin, a brain permeable OT receptor (OTR) agonist, induced a significant reduction of activated microglia, the primary immune cells of the brain. Moreover, this reduced microglia reactivity was associated with long-term neuroprotection. These findings make OT a promising candidate for neonatal neuroprotection through neuroinflammation regulation. However, the mechanisms linking endogenous OT and central inflammation response to injury have not yet been established. Further studies are needed to assess the protective role of OT in the developing brain through modulation of microglial activation, a key feature of brain injury observed in infants born preterm or growth-restricted. They are expected to have several impacts in the near future not only for improving knowledge of microglial cell physiology and reactivity during brain development, but also to design clinical trials testing interventions associated with endogenous OT release as a relevant strategy to alleviate neuroinflammation in neonates.
Ocytocine  : une nouvelle cible de neuroprotection ?
Chaque année, dans le monde, 30 millions de nouveau-nés naissent après un retard de croissance intra-utérin (RCIU) et 15 millions naissent prématurément. Ces deux conditions sont les principales causes de stress anté-/périnatal et de lésions cérébrales responsables de troubles neurocognitifs et comportementaux chez plus de 9 millions d’enfants chaque année. La plupart des stratégies pharmacologiques visant à prévenir les lésions cérébrales périnatales n’ont pas réussi à démontrer des bénéfices cliniques substantiels. En revanche, l’enrichissement de l’environnement basé sur les soins de développement, le contact peau à peau et l’exposition vocale/musicale semblent avoir des effets positifs sur la structure et la fonctionnalité du cerveau. Toutefois, les mécanismes qui sous-tendent ces effets restent inconnus. De nombreuses évidences montrent qu’un environnement défavorable pendant la grossesse et la période néonatale peut influencer les réponses hormonales du nouveau-né et avoir des conséquences neurocomportementales durables pendant la petite enfance et à l’âge adulte. L’ocytocine (OT), un neuropeptide libéré par l’hypothalamus, joue un rôle pendant la période périnatale dans l’attachement parents-enfant et dans le comportement social. En outre, des études précliniques suggèrent que l’OT est capable de réguler la réponse inflammatoire centrale aux lésions dans le cerveau adulte. Ces données font de l’OT un candidat prometteur pour la neuroprotection néonatale par la régulation de la neuro-inflammation.","['brain lesions', 'lésions cérébrales', 'microglia', 'microglie', 'neuroprotection', 'nouveau-né prématuré', 'ocytocine', 'oxytocin', 'preterm infants']",Biologie aujourd'hui,2023-02-07,"[{'lastname': 'Baud', 'firstname': 'Olivier', 'initials': 'O', 'affiliation': 'Laboratoire du développement, Université de Genève, Genève, Suisse - Inserm U1141, Université Paris Cité, 75019 Paris, France - Service de Soins Intensifs Pédiatriques et Néonatologie, Hôpitaux Universitaires de Genève, 30 boulevard de Cluse, 1205 Genève, Suisse.'}, {'lastname': 'Knoop', 'firstname': 'Marit', 'initials': 'M', 'affiliation': 'Laboratoire du développement, Université de Genève, Genève, Suisse.'}, {'lastname': 'Jacquens', 'firstname': 'Alice', 'initials': 'A', 'affiliation': 'Laboratoire du développement, Université de Genève, Genève, Suisse - Inserm U1141, Université Paris Cité, 75019 Paris, France.'}, {'lastname': 'Possovre', 'firstname': 'Marie-Laure', 'initials': 'ML', 'affiliation': 'Laboratoire du développement, Université de Genève, Genève, Suisse.'}]",,,,"© Société de Biologie, 2023.
© Société de Biologie, 2023.",10.1051/jbio/2022012,<Element 'PubmedArticle' at 0x7f05d8839860>
52,36736846,The neuroprotective effects of estrogen and estrogenic compounds in spinal cord injury.,"Spinal cord injury (SCI) occurs when the spinal cord is damaged from either a traumatic event or disease. SCI is characterised by multiple injury phases that affect the transmission of sensory and motor signals and lead to temporary or long-term functional deficits. There are few treatments for SCI. Estrogens and estrogenic compounds, however, may effectively mitigate the effects of SCI and therefore represent viable treatment options. This review systematically examines the pre-clinical literature on estrogen and estrogenic compound neuroprotection after SCI. Several estrogens were examined by the included studies: estrogen, estradiol benzoate, Premarin, isopsoralen, genistein, and selective estrogen receptor modulators. Across these pharmacotherapies, we find significant evidence that estrogens indeed offer protection against myriad pathophysiological effects of SCI and lead to improvements in functional outcomes, including locomotion. A STRING functional network analysis of proteins modulated by estrogen after SCI demonstrated that estrogen simultaneously upregulates known neuroprotective pathways, such as HIF-1, and downregulates pro-inflammatory pathways, including IL-17. These findings highlight the strong therapeutic potential of estrogen and estrogenic compounds after SCI.","['Estrogen', 'Estrogenic compounds', 'Neuroprotection', 'Spinal cord injury']",Neuroscience and biobehavioral reviews,2023-02-04,"[{'lastname': 'Shvetcov', 'firstname': 'Artur', 'initials': 'A', 'affiliation': 'Black Dog Institute, Sydney, Australia; School of Psychiatry, Faculty of Medicine, University of New South Wales, Sydney, Australia.'}, {'lastname': 'Ruitenberg', 'firstname': 'Marc J', 'initials': 'MJ', 'affiliation': 'School of Biomedical Sciences, Faculty of Medicine, The University of Queensland, Brisbane, Australia.'}, {'lastname': 'Delerue', 'firstname': 'Fabien', 'initials': 'F', 'affiliation': 'Dementia Research Centre, Macquarie Medical School, Faculty of Medicine, Health and Human Sciences, Macquarie University, Sydney, Australia.'}, {'lastname': 'Gold', 'firstname': 'Wendy A', 'initials': 'WA', 'affiliation': ""School of Medical Sciences, Faculty of Medicine Health, The University of Sydney, Sydney, Australia; Molecular Neurobiology Research Laboratory, Kids Research, Children's Hospital at Westmead and the Children's Medical Research Institute, Westmead, Australia; Kids Neuroscience Centre, Kids Research, Children's Hospital at Westmead, Westmead, Australia.""}, {'lastname': 'Brown', 'firstname': 'David A', 'initials': 'DA', 'affiliation': 'Neuroinflammation Research Group, Centre for Immunology and Allergy Research, Westmead Institute for Medical Research, Sydney, Australia; Department of Immunopathology, Institute for Clinical Pathology and Medical Research-New South Wales Health Pathology, Westmead Hospital, Sydney, Australia; Westmead Clinical School, Faculty of Medicine and Health, The University of Sydney, Sydney, Australia.'}, {'lastname': 'Finney', 'firstname': 'Caitlin A', 'initials': 'CA', 'affiliation': 'School of Medical Sciences, Faculty of Medicine Health, The University of Sydney, Sydney, Australia; Neuroinflammation Research Group, Centre for Immunology and Allergy Research, Westmead Institute for Medical Research, Sydney, Australia. Electronic address: caitlin.finney@wimr.org.au.'}]",,,,Copyright © 2023 The Authors. Published by Elsevier Ltd.. All rights reserved.,10.1016/j.neubiorev.2023.105074,<Element 'PubmedArticle' at 0x7f05d882a310>
53,36657372,Calcitriol modulate post-ischemic TLR signaling pathway in ischemic stroke patients.,"Neuroinflammation is a significant contributor to post-ischemic neuronal death after stroke, and Toll-Like Receptors (TLRs) are one of the essential mediators in many inflammatory pathways. TLRs activate the nuclear factor kappa β (NF-kβ), which promotes the expression of various pro-inflammatory genes such as interleukin (IL-1β) and IL-6. 1,25(OH)2D3, also known as calcitriol, is an active form of vitamin D3 that acts as a neurosteroid compound with anti-inflammatory properties. This study aimed to determine the modulatory effects of calcitriol hormone on post-ischemic immunity response.
Neurological tests and conventional blood factors were evaluated in patients with stroke symptoms upon arrival (n = 38) to confirm the stroke. A blood sample was taken from each stroke patient immediately upon admission and again after 24 h. The experimental group was given 10 μg calcitriol orally. The gene expression levels of TLR4, TLR2, NF-kβ, IL-1β, and IL-6 pro-inflammatory factors were measured using real-time PCR. The protein expression of TLR4 and NF-kβ markers was assessed using the flow cytometry technique.
TLR4, NF-kβ, and pro-inflammatory factors IL-1β and IL-6 expression increased significantly after an ischemic stroke, and calcitriol could modulate the TLR4/NF-kβ signaling pathway 24 h after ischemia.
Calcitriol may be considered a protective reagent after ischemia by reducing the TLR4/NF-kB activation cascade and probably plays a beneficial role in reducing and improving ischemic stroke patients' symptoms.
Iranian Registry of Clinical Trials identifier: IRCT2017012532174N1.","['Calcitriol', 'Inflammation', 'Ischemia', 'NF-kβ', 'Stroke', 'TLR']",Journal of neuroimmunology,2023-01-20,"[{'lastname': 'Tajalli-Nezhad', 'firstname': 'Saeedeh', 'initials': 'S', 'affiliation': 'Anatomical Sciences Research Center, Institute for Basic Sciences, Kashan University of Medical Sciences, Kashan, Iran.'}, {'lastname': 'Mohammadi', 'firstname': 'Salimeh', 'initials': 'S', 'affiliation': 'Anatomical Sciences Research Center, Institute for Basic Sciences, Kashan University of Medical Sciences, Kashan, Iran.'}, {'lastname': 'Atlasi', 'firstname': 'Mohammad Ali', 'initials': 'MA', 'affiliation': 'Anatomical Sciences Research Center, Institute for Basic Sciences, Kashan University of Medical Sciences, Kashan, Iran.'}, {'lastname': 'Kheiran', 'firstname': 'Mahdi', 'initials': 'M', 'affiliation': 'Department of Neurology, Faculty of Medicine, Kashan University of Medical Sciences, Kashan, Iran.'}, {'lastname': 'Moghadam', 'firstname': 'Sepideh Etehadi', 'initials': 'SE', 'affiliation': 'Anatomical Sciences Research Center, Institute for Basic Sciences, Kashan University of Medical Sciences, Kashan, Iran.'}, {'lastname': 'Naderian', 'firstname': 'Homayoun', 'initials': 'H', 'affiliation': 'Anatomical Sciences Research Center, Institute for Basic Sciences, Kashan University of Medical Sciences, Kashan, Iran. Electronic address: ho.naderian@gmail.com.'}, {'lastname': 'Azami Tameh', 'firstname': 'Abolfazl', 'initials': 'A', 'affiliation': 'Anatomical Sciences Research Center, Institute for Basic Sciences, Kashan University of Medical Sciences, Kashan, Iran.'}]",,,"TLR4, NF-kβ, and pro-inflammatory factors IL-1β and IL-6 expression increased significantly after an ischemic stroke, and calcitriol could modulate the TLR4/NF-kβ signaling pathway 24 h after ischemia.",Copyright © 2022. Published by Elsevier B.V.,10.1016/j.jneuroim.2022.578013,<Element 'PubmedArticle' at 0x7f05dc8c2720>
54,"36650223
24150027
31884930
32094295
27659865
9622311
29897824
31587509
27339196
22614768
27110744
30952098
31491842
29382531
24745331
23295602
25040340
30178867
24792896
31897506
16574244
20597104
24827941
23346385
27270170
35149272
18687466
31295432
21769868
33436885
19359373
11136866
12623943
17904985
17916368
27500458
30009813
31933528
29317289
34616312
31293442
15821434
9228382
27546235
30360757
10869545
32092384
2174942
25545166
15451190
25983078
28974495
32762557
15528396
32116567
33713657
21999375
27250735
15375302
29124510
34668428
33798633
16896185
23488800
11304516
12548089
11062339
24647709
34324867
18382194
23181751
30595084
23602334
23223087
12635709
15085068
24733557
25656942
26536032
27186102",The renin-angiotensin system modulates endotoxic postconditioning of exacerbated renal vasoconstriction in preeclamptic offspring.,"We recently reported exacerbated endotoxic signs of neuroinflammation and autonomic defects in offspring of preeclamptic (PE) dams. Here, we investigated whether PE programming similarly modifies hemodynamic and renal vasoconstrictor responsiveness to endotoxemia in PE offspring and whether this interaction is modulated by gestational angiotensin 1-7 (Ang1-7). Preeclampsia was induced by gestational treatment with L-NAME. Adult offspring was challenged with lipopolysaccharides (LPS, 5 mg/kg) and systolic blood pressure (SBP) and renal vasoconstrictions were assessed 4 h later. Male, but not female, offspring of PE rats exhibited SBP elevations that were blunted by LPS. Renal vasoconstrictions induced by angiotensin II (Ang II), but not phenylephrine, were intensified in perfused kidneys of either sex. LPS blunted the heightened Ang II responses in male, but not female, kidneys. While renal expressions of AT1-receptors and angiotensin converting enzyme (ACE) were increased in PE offspring of both sexes, ACE2 was upregulated in female offspring only. These molecular effects were diminished by LPS in male offspring. Gestational Ang1-7 caused sex-unrelated attenuation of phenylephrine vasoconstrictions and preferentially downregulated Ang II responses and AT1-receptor and nuclear factor-kB (NFkB) expressions in females. Together, endotoxemia and Ang1-7 offset in sexually-related manners imbalances in renal vasoconstriction and AT1/ACE/ACE2 signaling in PE offspring.",[],Scientific reports,2023-01-18,"[{'lastname': 'Morgaan', 'firstname': 'Hagar A', 'initials': 'HA', 'affiliation': 'Department of Pharmacology and Toxicology, Faculty of Pharmacy, Alexandria University, Alazarita, Alexandria, 21521, Egypt.'}, {'lastname': 'Sallam', 'firstname': 'Marwa Y', 'initials': 'MY', 'affiliation': 'Department of Pharmacology and Toxicology, Faculty of Pharmacy, Alexandria University, Alazarita, Alexandria, 21521, Egypt.'}, {'lastname': 'El-Gowelli', 'firstname': 'Hanan M', 'initials': 'HM', 'affiliation': 'Department of Pharmacology and Toxicology, Faculty of Pharmacy, Alexandria University, Alazarita, Alexandria, 21521, Egypt.'}, {'lastname': 'El-Gowilly', 'firstname': 'Sahar M', 'initials': 'SM', 'affiliation': 'Department of Pharmacology and Toxicology, Faculty of Pharmacy, Alexandria University, Alazarita, Alexandria, 21521, Egypt. sahar.elgowilly@alexu.edu.eg.'}, {'lastname': 'El-Mas', 'firstname': 'Mahmoud M', 'initials': 'MM', 'affiliation': 'Department of Pharmacology and Toxicology, Faculty of Pharmacy, Alexandria University, Alazarita, Alexandria, 21521, Egypt.\nDepartment of Pharmacology and Toxicology, Faculty of Medicine, Kuwait University, Kuwait City, Kuwait.'}]",,,,© 2023. The Author(s).,"10.1038/s41598-023-27923-7
10.2174/1573396316666191224092405
10.1124/jpet.119.264192
10.1016/j.earlhumdev.2016.09.007
10.1016/s0301-2115(98)00060-8
10.1152/ajpregu.00218.2017
10.1002/ar.24270
10.1542/peds.2011-3093
10.1097/FJC.0000000000000400
10.1016/j.intimp.2019.03.043
10.3390/ijms20184341
10.1016/j.ejphar.2018.01.051
10.1016/j.immuni.2014.04.001
10.6061/clinics/2012(12)18
10.26355/eurrev_201808_15742
10.1016/j.vph.2014.04.005
10.1007/s00011-019-01309-w
10.1016/j.jri.2006.01.004
10.1002/emmm.201000080
10.1042/CS20130450
10.1155/2012/739274
10.1172/jci83918
10.1016/j.preghy.2022.01.011
10.1016/j.placenta.2008.06.011
10.1016/j.abb.2019.07.006
10.1002/jcp.22940
10.1038/s41598-020-79902-x
10.1113/jphysiol.2009.170407
10.1111/j.1469-7793.2001.0141m.x
10.1161/01.HYP.0000053448.95913.3D
10.1016/j.ajog.2007.06.064
10.1016/j.lfs.2007.09.006
10.1016/j.intimp.2016.07.023
10.1016/j.ejphar.2018.07.008
10.1016/j.jsps.2019.11.014
10.1016/j.brainres.2018.01.003
10.3389/fphys.2021.745285
10.3389/fphys.2019.00771
10.1097/01.fjc.0000157438.72483.ae
10.1378/chest.112.1.235
10.1038/nri.2016.90
10.1186/s40779-018-0182-5
10.1016/s0008-6363(00)00075-4
10.1016/j.taap.2020.114928
10.1097/00004872-199010000-00004
10.1002/jcla.21819
10.1016/j.placenta.2004.02.011
10.1038/srep09723
10.1161/JAHA.117.006630
10.1152/ajpheart.00202.2020
10.1152/ajpregu.00178.2004
10.3389/fncel.2020.00026
10.1016/j.expneurol.2021.113691
10.1186/1742-2094-8-140
10.1038/srep27091
10.1161/01.STR.0000143450.04438.ae
10.1007/s11255-017-1735-3
10.1152/ajpregu.00211.2021
10.1016/j.mce.2021.111254
10.1152/ajprenal.00139.2006
10.1111/bph.12159
10.1161/01.hyp.37.4.1141
10.1097/00005344-200302000-00017
10.1016/s0167-0115(00)00164-6
10.1152/ajprenal.00042.2014
10.1016/j.bcp.2021.114703
10.1097/CCM.0b013e318168ccd5
10.3109/0886022x.2012.744040
10.1177/1933719118813200
10.1016/j.placenta.2013.03.008
10.1038/jhh.2012.55
10.1097/00005344-200404000-00012
10.1371/journal.pone.0095079
10.1016/j.taap.2015.01.018
10.1371/journal.pone.0142303
10.2147/JEP.S14342",<Element 'PubmedArticle' at 0x7f05dc8ccb30>
55,36640481,Prevention of suicide by clozapine in mental disorders: systematic review.,"Previous research has investigated the efficacy of clozapine in reducing suicidality in patients with schizophrenia and schizoaffective disorder. We aimed to systematically review published evidence, including studies concerning clozapine administration to treat: (a) refractory suicidality in other mental disorders, including bipolar disorder and borderline and other personality disorders; and (b) refractory cases of non-suicidal self-injury.
We performed a PUBMED-search (last day: July 17, 2022) of English-language studies, combining the keywords ""clozapine"", ""suicidality"", and ""suicide"" with various psychopathological terms (e.g. ""schizophrenia""). All duplications were eliminated.
Fifty-one studies were eligible for inclusion in the review. Most studies suggest a superior anti-suicide effect of clozapine in schizophrenia/schizoaffective disorder, compared to other antipsychotics, or no antipsychotic therapy, which is not due to the close monitoring of patients for blood dyscrasias. No consensus exists as to whether other antipsychotic drugs share this effect. Discontinuation of clozapine is associated with increases in suicidality. Reductions in refractory suicidality/NSSI are observed in clozapine-treated patients with bipolar disorder or borderline personality disorder, but the evidence is limited. Potential biological underpinnings of the anti-suicide effect of clozapine include its unique profile of modulation of brain neurotransmitters; its non-selectivity for neurotransmitter receptors; specific genetic and hormonal factors; effects on neuroinflammation; and ability to elicit epileptiform activity.
The superior anti-suicide effect of clozapine in schizophrenia/schizoaffective disorder patients is well established. It may have a role in severe and refractory cases of suicidality and non-suicidal self-injury in patients with bipolar disorder or borderline personality disorder, but the level and quality of supporting evidence is limited.","['Clozapine', 'Self-injury', 'Suicidality', 'Suicide prevention']",European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology,2023-01-15,"[{'lastname': 'Masdrakis', 'firstname': 'Vasilios G', 'initials': 'VG', 'affiliation': 'National and Kapodistrian University of Athens, School of Medicine, First Department of Psychiatry, Eginition Hospital, 74 Vas. Sofias Avenue, 11528 Athens, Greece.'}, {'lastname': 'Baldwin', 'firstname': 'David S', 'initials': 'DS', 'affiliation': 'University Department of Psychiatry, Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, United Kingdom; University Department of Psychiatry and Mental Health, University of Cape Town, Cape Town, South Africa. Electronic address: D.S.Baldwin@soton.ac.uk.'}]","We performed a PUBMED-search (last day: July 17, 2022) of English-language studies, combining the keywords ""clozapine"", ""suicidality"", and ""suicide"" with various psychopathological terms (e.g. ""schizophrenia""). All duplications were eliminated.","The superior anti-suicide effect of clozapine in schizophrenia/schizoaffective disorder patients is well established. It may have a role in severe and refractory cases of suicidality and non-suicidal self-injury in patients with bipolar disorder or borderline personality disorder, but the level and quality of supporting evidence is limited.","Fifty-one studies were eligible for inclusion in the review. Most studies suggest a superior anti-suicide effect of clozapine in schizophrenia/schizoaffective disorder, compared to other antipsychotics, or no antipsychotic therapy, which is not due to the close monitoring of patients for blood dyscrasias. No consensus exists as to whether other antipsychotic drugs share this effect. Discontinuation of clozapine is associated with increases in suicidality. Reductions in refractory suicidality/NSSI are observed in clozapine-treated patients with bipolar disorder or borderline personality disorder, but the evidence is limited. Potential biological underpinnings of the anti-suicide effect of clozapine include its unique profile of modulation of brain neurotransmitters; its non-selectivity for neurotransmitter receptors; specific genetic and hormonal factors; effects on neuroinflammation; and ability to elicit epileptiform activity.",Copyright © 2022. Published by Elsevier B.V.,10.1016/j.euroneuro.2022.12.011,<Element 'PubmedArticle' at 0x7f05dbf26090>
56,36587502,"The GLP-1 receptor agonist exenatide ameliorates neuroinflammation, locomotor activity, and anxiety-like behavior in mice with diet-induced obesity through the modulation of microglial M2 polarization and downregulation of SR-A4.","Obesity is associated with multiple comorbidities, such as metabolic abnormalities and cognitive dysfunction. Moreover, accumulating evidence indicates that neurodegenerative disorders are associated with chronic neuroinflammation. GLP-1 receptor agonists (RAs) have been extensively studied as a treatment for type 2 diabetes. Emerging evidence has demonstrated a protective effect of GLP-1 RAs on neurodegenerative disease, which is independent of its glucose-lowering effects. In this study, we aimed to examine the effects of a long-acting GLP-1 RA, exenatide, on high-fat diet (HFD)-induced neuroinflammation and related brain function impairment. First, mice treated with exenatide exhibited significantly reduced HFD-increased body weight and blood glucose. In an open field test, exenatide treatment ameliorated the reduction in local motor activity and anxiety in HFD-fed mice. Moreover, HFD induced astrogliosis, microgliosis, and upregulation of IL-1β, IL-6 and TNF-α in hippocampus and cortex. Exenatide treatment reduced HFD-induced astrogliosis and IL-1β and TNF-α expressions. Moreover, exenatide increased phosphor-ERK and M2-type microglia marker arginase-1 expression in the hippocampus and cortex. In addition, we found that scavenger receptor-A4 protein expression was induced by HFD and was subsequently inhibited by exenatide. SR-A4 knockout reversed the locomotor activity impairment but not the anxiety behavior caused by HFD consumption. SR-A4 knockout also reduced HFD-induced neuroinflammation, as shown by the reduced expression of GFAP and IBA-1 compared with that in wild-type control mice. These results demonstrate that exenatide decreases HFD-increased neuroinflammation and promotes anti-inflammatory M2 differentiation. The inhibition of SR-A4 by exenatide exerts anti-inflammatory activity.","['Exenatide', 'Neuroinflammation', 'Obesity', 'SR-A4', 'T2DM']",International immunopharmacology,2023-01-02,"[{'lastname': 'Lin', 'firstname': 'Ming-Hong', 'initials': 'MH', 'affiliation': 'Department of Microbiology and Immunology, School of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung 807, Taiwan; Graduate Institute of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung 807, Taiwan; M.Sc. Program in Tropical Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung 807, Taiwan; Department of Medical Research, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung 807, Taiwan. Electronic address: mhlin@kmu.edu.tw.'}, {'lastname': 'Cheng', 'firstname': 'Po-Ching', 'initials': 'PC', 'affiliation': 'Department of Molecular Parasitology and Tropical Diseases, School of Medicine, College of Medicine, Taipei Medical University, Taipei 110, Taiwan; Center for International Tropical Medicine, School of Medicine, College of Medicine, Taipei Medical University, Taipei 110, Taiwan. Electronic address: bonjovi@tmu.edu.tw.'}, {'lastname': 'Hsiao', 'firstname': 'Pi-Jung', 'initials': 'PJ', 'affiliation': 'Division of Endocrinology and Metabolism, E-Da Hospital, I-Shou University, Kaohsiung, Taiwan; School of Medicine, College of Medicine, I-Shou University, Kaohsiung, Taiwan. Electronic address: pjhsiao101@isu.edu.tw.'}, {'lastname': 'Chen', 'firstname': 'Szu-Chia', 'initials': 'SC', 'affiliation': 'Department of Internal Medicine, Kaohsiung Municipal Siaogang Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan; Division of Nephrology, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan; Research Center for Environmental Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan. Electronic address: chensc@kmu.edu.tw.'}, {'lastname': 'Hung', 'firstname': 'Chih-Hsing', 'initials': 'CH', 'affiliation': 'Research Center for Environmental Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan; Department of Pediatrics, School of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan; Department of Pediatrics, Kaohsiung Municipal Siaogang Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan. Electronic address: 1086066@kmuh.org.tw.'}, {'lastname': 'Kuo', 'firstname': 'Chao-Hung', 'initials': 'CH', 'affiliation': 'Department of Internal Medicine, Kaohsiung Municipal Siaogang Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan; Division of Gastroenterology, Department of Internal Medicine, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan. Electronic address: jhkao@kmu.edu.tw.'}, {'lastname': 'Huang', 'firstname': 'Shau-Ku', 'initials': 'SK', 'affiliation': 'National Institute of Environmental Health Sciences, National Health Research Institutes, Miaoli County 350, Taiwan; Department of Medicine, Division of Allergy and Clinical Immunology, Johns Hopkins University School of Medicine, Baltimore, MD 21205, USA. Electronic address: skhuang@nhri.org.tw.'}, {'lastname': 'Clair Chiou', 'firstname': 'Hsin-Ying', 'initials': 'HY', 'affiliation': 'Center of Teaching and Research, Kaohsiung Municipal Siaogang Hospital, Kaohsiung Medical University, Kaohsiung 812, Taiwan; Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung 807, Taiwan; Department of Applied Chemistry, National Chi Nan University, Nantou, Taiwan. Electronic address: 1086093@mail.kmuh.org.tw.'}]",,,,Copyright © 2022 The Authors. Published by Elsevier B.V. All rights reserved.,10.1016/j.intimp.2022.109653,<Element 'PubmedArticle' at 0x7f05dbf60e00>
57,36566971,Melatonin alleviates BDE-209-induced cognitive impairment and hippocampal neuroinflammation by modulating microglia polarization via SIRT1-mediated HMGB1/TLR4/NF-κB pathway.,"Polybrominated diphenyl ethers (PBDEs) are persistent environmental contaminants with developmental neurotoxicity, the mechanism of which remains obscure. The present study aimed to evaluate cognitive deficits and microglia-originated neuroinflammation in the hippocampus of offspring rats exposed to BDE-209 (30 and 100 mg/kg) during perinatal period. Compared to the control, BDE-209-treated rats showed significant longer escape latency and less platform crossings in tests of Morris water maze. Besides obvious hippocampal neuron damage, increased microglial activation and pro-inflammatory markers (CD86, TNFα, and IL-1β), meanwhile, decreased anti-inflammatory molecules (CD206, IL-10, and Arg1) were induced by BDE-209. Furthermore, we investigated the neuroprotection of melatonin against BDE-209 and whether through sirtuin 1 (SIRT1). Consistent with restored SIRT1 activity, enhanced deacetylation of HMGB1 and inhibited cytoplasmic translocation of HMGB1, reduced expression of proteins involved in TLR4-NF-κB pathway and nuclear transfer of phosphorylated-NF-κB p65, and ultimately suppressed microglial activation and improved spatial memory were observed in 10 mg/kg melatonin-pretreated rats, compared with BDE-209-exposed alone. These results demonstrated that melatonin ameliorated BDE-209-caused cognitive impairment partially through shifting microglia polarization towards anti-inflammatory phenotype in a SIRT1-dependent manner, suggesting a potential mechanism for prevention.","['Decabromodiphenyl ether', 'Melatonin', 'Microglia', 'Sirtuin 1', 'Spatial memory']",Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association,2022-12-26,"[{'lastname': 'Wu', 'firstname': 'Jie', 'initials': 'J', 'affiliation': 'Department of Occupational and Environmental Health, School of Public Health, Jinzhou Medical University, Jinzhou, Liaoning, PR China. Electronic address: wujie@jzmu.edu.cn.'}, {'lastname': 'Hao', 'firstname': 'Ziwen', 'initials': 'Z', 'affiliation': 'Department of Occupational and Environmental Health, School of Public Health, Jinzhou Medical University, Jinzhou, Liaoning, PR China.'}, {'lastname': 'Wang', 'firstname': 'Ying', 'initials': 'Y', 'affiliation': 'Department of Occupational and Environmental Health, School of Public Health, Jinzhou Medical University, Jinzhou, Liaoning, PR China.'}, {'lastname': 'Yan', 'firstname': 'Dongying', 'initials': 'D', 'affiliation': 'Department of Occupational and Environmental Health, School of Public Health, Jinzhou Medical University, Jinzhou, Liaoning, PR China.'}, {'lastname': 'Meng', 'firstname': 'Jia', 'initials': 'J', 'affiliation': 'Department of Occupational and Environmental Health, School of Public Health, Jinzhou Medical University, Jinzhou, Liaoning, PR China.'}, {'lastname': 'Ma', 'firstname': 'Honglin', 'initials': 'H', 'affiliation': 'Department of Health Statistics, School of Public Health, Jinzhou Medical University, Jinzhou, Liaoning, PR China.'}]",,,,Copyright © 2022 Elsevier Ltd. All rights reserved.,10.1016/j.fct.2022.113561,<Element 'PubmedArticle' at 0x7f05dbf552c0>
58,36566969,Pleiotrophin deficiency protects against high-fat diet-induced neuroinflammation: Implications for brain mitochondrial dysfunction and aberrant protein aggregation.,"Metabolic Syndrome (MetS) is a risk factor for the development of neurodegenerative diseases. Neuroinflammation associated with MetS may contribute significantly to neurodegeneration. Pleiotrophin (PTN) is a neurotrophic factor that modulates neuroinflammation and is a key player in regulating energy metabolism and thermogenesis, suggesting that PTN could be important in the connection between MetS and neuroinflammation. We have now used a high-fat diet (HFD)-induced obesity model in Ptn","['Metabolic syndrome', 'Neuroinflammation', 'Pleiotrophin', 'Ptprz1']",Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association,2022-12-26,"[{'lastname': 'Cañeque-Rufo', 'firstname': 'Héctor', 'initials': 'H', 'affiliation': 'Departamento de Química y Bioquímica, Facultad de Farmacia, Universidad San Pablo-CEU, CEU Universities, Urbanización Montepríncipe, 28660, Boadilla del Monte, Madrid, Spain; Departamento de Ciencias Farmacéuticas y de la Salud, Facultad de Farmacia, Universidad San Pablo-CEU, CEU Universities, Urbanización Montepríncipe, 28660, Boadilla del Monte, Madrid, Spain.'}, {'lastname': 'Sánchez-Alonso', 'firstname': 'María Gracia', 'initials': 'MG', 'affiliation': 'Departamento de Química y Bioquímica, Facultad de Farmacia, Universidad San Pablo-CEU, CEU Universities, Urbanización Montepríncipe, 28660, Boadilla del Monte, Madrid, Spain.'}, {'lastname': 'Zuccaro', 'firstname': 'Agata', 'initials': 'A', 'affiliation': 'Departamento de Química y Bioquímica, Facultad de Farmacia, Universidad San Pablo-CEU, CEU Universities, Urbanización Montepríncipe, 28660, Boadilla del Monte, Madrid, Spain.'}, {'lastname': 'Sevillano', 'firstname': 'Julio', 'initials': 'J', 'affiliation': 'Departamento de Química y Bioquímica, Facultad de Farmacia, Universidad San Pablo-CEU, CEU Universities, Urbanización Montepríncipe, 28660, Boadilla del Monte, Madrid, Spain.'}, {'lastname': 'Ramos-Álvarez', 'firstname': 'María Del Pilar', 'initials': 'MDP', 'affiliation': 'Departamento de Química y Bioquímica, Facultad de Farmacia, Universidad San Pablo-CEU, CEU Universities, Urbanización Montepríncipe, 28660, Boadilla del Monte, Madrid, Spain.'}, {'lastname': 'Herradón', 'firstname': 'Gonzalo', 'initials': 'G', 'affiliation': 'Departamento de Ciencias Farmacéuticas y de la Salud, Facultad de Farmacia, Universidad San Pablo-CEU, CEU Universities, Urbanización Montepríncipe, 28660, Boadilla del Monte, Madrid, Spain. Electronic address: herradon@ceu.es.'}]",,,,Copyright © 2022 Elsevier Ltd. All rights reserved.,10.1016/j.fct.2022.113578,<Element 'PubmedArticle' at 0x7f05dbf3d5e0>
59,"36547092
10422759
10567694
7461607
11528470
12604792
29537336
35207461
12728244
21161321
25449422
18647349
35921971
15976302
16537498
12024206
16279936
15066905
35327666
36077245
34829877
35410604
7759949
9761684
20677202
35207535
30253862
14978236
16113687
18559922
17054399
22122547
20412858
25708536
22132188
18826963
33412090
30553543
30172578
19006379
24852280
19667192
24902717
25685780
25434589
26730729
33072073
31525509
30995914
26477583
27989680
31408628
25884014
33802771
34215801
27140692
23372791
27609223
31474981
26798205
32508669
34970418
27703142
33404134
25831128
34396166",Non-Peptide Agonists and Antagonists of the Prokineticin Receptors.,"The prokineticin family comprises a group of secreted peptides that can be classified as chemokines based on their structural features and chemotactic and immunomodulatory functions. Prokineticins (PKs) bind with high affinity to two G protein-coupled receptors (GPCRs). Prokineticin receptor 1 (PKR1) and prokineticin receptor 2 (PKR2) are involved in a variety of physiological functions such as angiogenesis and neurogenesis, hematopoiesis, the control of hypothalamic hormone secretion, the regulation of circadian rhythm and the modulation of complex behaviors such as feeding and drinking. Dysregulation of the system leads to an inflammatory process that is the substrate for many pathological conditions such as cancer, pain, neuroinflammation and neurodegenerative diseases such as Alzheimer's and Parkinson's disease. The use of PKR's antagonists reduces PK2/PKRs upregulation triggered by various inflammatory processes, suggesting that a pharmacological blockade of PKRs may be a successful strategy to treat inflammatory/neuroinflammatory diseases, at least in rodents. Under certain circumstances, the PK system exhibits protective/neuroprotective effects, so PKR agonists have also been developed to modulate the prokineticin system.","['PKRs agonists', 'PKRs antagonists', 'orthosteric and allosteric ligands', 'prokineticin receptors', 'prokineticis', 'triazine-compounds']",Current issues in molecular biology,2022-12-23,"[{'lastname': 'Lattanzi', 'firstname': 'Roberta', 'initials': 'R', 'affiliation': 'Department of Physiology and Pharmacology ""Vittorio Erspamer"", Sapienza University of Rome, Piazzale Aldo Moro 5, I-00185 Rome, Italy.'}, {'lastname': 'Miele', 'firstname': 'Rossella', 'initials': 'R', 'affiliation': 'Department of Biochemical Sciences ""A. Rossi Fanelli"", CNR-Institute of Molecular Biology and Pathology, Sapienza University of Rome, Piazzale Aldo Moro 5, I-00185 Rome, Italy.'}]",,,,,"10.3390/cimb44120431
10.1016/S0014-2999(99)00229-0
10.1016/S0014-5793(99)01459-3
10.1515/bchm2.1980.361.2.1787
10.1038/35091000
10.1073/pnas.0337667100
10.1152/physrev.00012.2017
10.3390/life12020172
10.1038/sj.embor.embor830
10.1007/s00018-010-0601-6
10.1016/j.mce.2014.10.024
10.1111/j.1742-4658.2008.06559.x
10.1016/j.canlet.2022.215838
10.1126/science.1112103
10.1073/pnas.0508881103
10.1016/j.bbadva.2021.100028
10.1038/417405a
10.1111/j.1742-4658.2005.04984.x
10.1038/sj.bjp.0705686
10.3390/biom12030474
10.3390/ijms23179853
10.36118/pharmadvances.2022.30
10.3390/biomedicines9111648
10.2174/1570159X20666220411084612
10.1002/jlb.57.5.703
10.1006/jmbi.1998.2057
10.1002/cbic.201000330
10.3390/life12020248
10.1016/j.npep.2018.06.005
10.1124/mol.65.3.582
10.1038/sj.bjp.0706376
10.1210/jc.2007-2654
10.1371/journal.pgen.0020175
10.1111/j.1476-5381.2011.01797.x
10.1016/j.pep.2010.04.012
10.1038/icb.2015.15
10.1371/journal.pone.0027990
10.1093/hmg/ddn318
10.1016/j.bbamem.2020.183549
10.1016/j.npep.2018.11.006
10.1016/j.tcm.2018.08.007
10.1021/jm800854e
10.1016/j.ejmech.2014.05.030
10.1073/pnas.0903720106
10.1111/bph.12793
10.1155/2015/301292
10.1016/j.phrs.2014.11.004
10.1371/journal.pone.0146259
10.3389/fimmu.2020.02119
10.1016/j.bbi.2019.09.012
10.1186/s12974-019-1461-0
10.1038/srep15301
10.1016/j.neuropharm.2016.12.012
10.1016/j.neuropharm.2019.107739
10.1212/NXI.0000000000000095
10.3390/biomedicines9030309
10.1038/s41598-021-93102-1
10.1016/j.neuropharm.2016.04.043
10.1371/journal.pone.0054916
10.1186/s12891-016-1243-0
10.3389/fimmu.2019.01872
10.1155/2015/289519
10.3389/fphys.2020.00425
10.1155/2021/6779559
10.1038/ncomms12932
10.1002/mds.28458
10.1371/journal.pone.0121027
10.1016/j.jaccao.2019.06.003",<Element 'PubmedArticle' at 0x7f05dbf253b0>
60,36512265,The Interaction Between NF-κB and Estrogen in Alzheimer's Disease.,"Post-menopausal women are at a higher risk of developing Alzheimer's disease (AD) than males. The higher rates of AD in women are associated with the sharp decline in the estrogen levels after menopause. Estrogen has been shown to downregulate inflammatory cytokines in the central nervous system (CNS), which has a neuroprotective role against neurodegenerative diseases including AD. Sustained neuroinflammation is associated with neurodegeneration and contributes to AD. Nuclear factor kappa-B (NF-κB) is a transcription factor involved with the modulation of inflammation and interacts with estrogen to influence the progression of AD. Application of 17β-estradiol (E2) has been shown to inhibit NF-κB, thereby reducing transcription of NF-κB target genes. Despite accumulating evidence showing that estrogens have beneficial effects in pre-clinical AD studies, there are mixed results with hormone replacement therapy in clinical trials. Furthering our understanding of how NF-κB interacts with estrogen and alters the progression of neurodegenerative disorders including AD, should be beneficial and result in the development of novel therapeutics.","['ApoE4', 'Dementia', 'Estrogen', 'Inflammation', 'NF-κB', 'Neurodegeneration', 'Nrf2']",Molecular neurobiology,2022-12-14,"[{'lastname': 'Mishra', 'firstname': 'Pranav', 'initials': 'P', 'affiliation': 'Division of Neurodegenerative Disorders, St. Boniface Hospital Research, Winnipeg, MB, Canada.\nDepartment of Pharmacology & Therapeutics, College of Medicine, University of Manitoba, Winnipeg, MB, Canada.'}, {'lastname': 'Davies', 'firstname': 'Don A', 'initials': 'DA', 'affiliation': 'Department of Biology, York University, Toronto, ON, Canada.'}, {'lastname': 'Albensi', 'firstname': 'Benedict C', 'initials': 'BC', 'affiliation': 'Division of Neurodegenerative Disorders, St. Boniface Hospital Research, Winnipeg, MB, Canada. balbensi@sbrc.ca.\nDepartment of Pharmacology & Therapeutics, College of Medicine, University of Manitoba, Winnipeg, MB, Canada. balbensi@sbrc.ca.\nDepartment of Pharmaceutical Sciences, College of Pharmacy, Nova Southeastern University, Fort Lauderdale, FL, USA. balbensi@sbrc.ca.'}]",,,,"© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.",10.1007/s12035-022-03152-3,<Element 'PubmedArticle' at 0x7f05dad3b310>
61,"36499189
6161310
9354811
11574888
24817841
11403935
6371818
2710333
6355911
19490084
18626069
21618891
34225942
27167463
29374538
1343594
26945087
15470136
34335160
21324537
4401996
9443563
25820671
1704419
25902865
34083254
9737201
31110471
15374459
20620164
25973435
3412497
28596586
2005590
7452304
2238092
7126249
15834447
1530666
1404819
1673209
10598795
80107
7535897
10593199
10833057
23965627
25980587
24595131
8205482
24445575
10720638
31046146
12663858
16290886
26120961
11181507
19619143
24805361
15256495
9266010
11245665
25080336
2866055
1346769
8103457
11717346
12710989
29420932
11164999
29228949
26081150
8971733
12049940
33666139
15790419
19827792
19575469
28795565
35726253",An In Vivo Definition of Brain Histamine Dynamics Reveals Critical Neuromodulatory Roles for This Elusive Messenger.,"Histamine is well known for mediating peripheral inflammation; however, this amine is also found in high concentrations in the brain where its roles are much less known. In vivo chemical dynamics are difficult to measure, thus fundamental aspects of histamine's neurochemistry remain undefined. In this work, we undertake the first in-depth characterization of real time in vivo histamine dynamics using fast electrochemical tools. We find that histamine release is sensitive to pharmacological manipulation at the level of synthesis, packaging, autoreceptors and metabolism. We find two breakthrough aspects of histamine modulation. First, differences in H3 receptor regulation between sexes show that histamine release in female mice is much more tightly regulated than in male mice under H3 or inflammatory drug challenge. We hypothesize that this finding may contribute to hormone-mediated neuroprotection mechanisms in female mice. Second, a high dose of a commonly available antihistamine, the H1 receptor inverse agonist diphenhydramine, rapidly decreases serotonin levels. This finding highlights the sheer significance of pharmaceuticals on neuromodulation. Our study opens the path to better understanding and treating histamine related disorders of the brain (such as neuroinflammation), emphasizing that sex and modulation (of serotonin) are critical factors to consider when studying/designing new histamine targeting therapeutics.","['FSCV', 'inflammation', 'sex differences', 'thioperamide', 'voltammetry']",International journal of molecular sciences,2022-12-12,"[{'lastname': 'Berger', 'firstname': 'Shane N', 'initials': 'SN', 'affiliation': 'Department of Chemistry and Biochemistry, University of South Carolina, Columbia, SC 29208, USA.'}, {'lastname': 'Baumberger', 'firstname': 'Beatrice', 'initials': 'B', 'affiliation': 'Department of Bioengineering, Imperial College London, London SW7 2AZ, UK.'}, {'lastname': 'Samaranayake', 'firstname': 'Srimal', 'initials': 'S', 'affiliation': 'Department of Chemistry and Biochemistry, University of South Carolina, Columbia, SC 29208, USA.'}, {'lastname': 'Hersey', 'firstname': 'Melinda', 'initials': 'M', 'affiliation': 'Department of Chemistry and Biochemistry, University of South Carolina, Columbia, SC 29208, USA.\nDepartment of Physiology, Pharmacology & Neuroscience, University of South Carolina School of Medicine, Columbia, SC 29209, USA.'}, {'lastname': 'Mena', 'firstname': 'Sergio', 'initials': 'S', 'affiliation': 'Department of Bioengineering, Imperial College London, London SW7 2AZ, UK.'}, {'lastname': 'Bain', 'firstname': 'Ian', 'initials': 'I', 'affiliation': 'Department of Chemistry and Biochemistry, University of South Carolina, Columbia, SC 29208, USA.'}, {'lastname': 'Duncan', 'firstname': 'William', 'initials': 'W', 'affiliation': 'Department of Mathematics, Montana State University, Bozeman, MT 59717, USA.'}, {'lastname': 'Reed', 'firstname': 'Michael C', 'initials': 'MC', 'affiliation': 'Department of Mathematics, Duke University, Durham, NC 27710, USA.'}, {'lastname': 'Nijhout', 'firstname': 'H Frederik', 'initials': 'HF', 'affiliation': 'Department of Biology, Duke University, Durham, NC 27708, USA.'}, {'lastname': 'Best', 'firstname': 'Janet', 'initials': 'J', 'affiliation': 'Department of Mathematics, Ohio State University, Columbus, OH 43210, USA.'}, {'lastname': 'Hashemi', 'firstname': 'Parastoo', 'initials': 'P', 'affiliation': 'Department of Chemistry and Biochemistry, University of South Carolina, Columbia, SC 29208, USA.\nDepartment of Bioengineering, Imperial College London, London SW7 2AZ, UK.'}]",,,,,"10.3390/ijms232314862
10.1038/289186a0
10.1152/physrev.1997.77.4.1033
10.1038/35096564
10.3389/fncel.2014.00120
10.1016/S0304-3940(01)01835-3
10.1073/pnas.81.8.2572
10.1016/0306-4522(89)90007-9
10.1016/0304-3940(83)90308-7
10.1111/j.1460-9568.2009.06765.x
10.1152/physrev.00043.2007
10.1007/978-1-4419-8056-4_10
10.1016/B978-0-12-820107-7.00023-9
10.1111/jnc.13659
10.1016/j.neuroscience.2018.01.027
10.1016/S0928-4257(05)80002-6
10.1124/jpet.115.230771
10.1523/JNEUROSCI.2690-04.2004
10.3389/fnins.2021.680214
10.1016/j.tips.2011.01.003
10.1111/j.1471-4159.1972.tb01459.x
10.1016/S0091-3057(97)00395-X
10.1007/s12031-015-0536-3
10.1111/j.1471-4159.1991.tb01990.x
10.1039/C5AN00313J
10.1523/JNEUROSCI.2618-20.2021
10.1021/ac9819640
10.3389/fnins.2019.00362
10.1016/0167-4943(91)90002-8
10.1016/j.neubiorev.2010.07.002
10.1155/2015/351829
10.1007/BF00182737
10.1038/s41598-017-02981-w
10.1111/j.1471-4159.1980.tb07858.x
10.1016/0165-6147(90)90181-7
10.1016/0006-2952(82)90531-7
10.1358/mf.2005.27.3.890872
10.1016/0006-2952(92)90133-4
10.1001/jama.1992.03490180055026
10.1016/0140-6736(91)92656-M
10.1007/s002109900097
10.1007/BF01968614
10.1007/BF00169363
10.1016/S0091-3057(99)00143-4
10.1089/neu.2000.17.367
10.1038/nature12479
10.1016/j.cbi.2015.05.007
10.1371/journal.pone.0090013
10.1016/0006-8993(94)91742-6
10.1038/ncomms4125
10.1016/S0014-2999(00)00060-1
10.1111/bph.14696
10.1073/pnas.0730053100
10.1016/S1550-8579(05)80042-7
10.1038/nn.4053
10.1210/endo.142.3.8033
10.1111/j.1471-4159.2009.06272.x
10.1371/journal.pone.0096232
10.1210/en.2004-0619
10.1111/j.1600-0897.1997.tb00275.x
10.1523/JNEUROSCI.21-06-01809.2001
10.1371/journal.pone.0103969
10.2165/00003088-198510060-00002
10.1136/gut.33.1.118
10.1016/0014-2999(93)90263-H
10.1523/JNEUROSCI.21-23-09134.2001
10.1016/S0306-4522(03)00005-8
10.1016/j.neuron.2018.01.006
10.1016/S0301-0082(00)00039-3
10.1186/s12976-017-0070-9
10.1007/s12035-015-9280-5
10.1007/BF00166899
10.1016/S0959-4388(02)00328-8
10.1080/15563650.2021.1891244
10.1186/1471-2210-5-8
10.1021/ac9018846
10.1002/0471142301.nsa04is48
10.1021/acs.analchem.7b01257
10.1021/acsmeasuresciau.1c00003",<Element 'PubmedArticle' at 0x7f05dccdde50>
62,"36497156
24625129
29779863
27839855
23885233
33639200
24621110
22334391
19081519
24646278
29908311
27242451
33446672
25438043
27490664
28008304
25569693
26493779
25105752
26519107
31001173
35717524
34378804
22908052
29017336
30335622
34453088
28520141
11274341
31104950
22325206
21719680
33589833
33686187
35178519
32161366
25767437
28812269
10700590
34218479
30057594
28899620
28135005
16429122
26009761
24464043
32038171
17956324
17000015
28812263
22375852
24863032
32313029
22031440
35347267
8815448
24376405
26001309
27624619
28864972
8815448
1320828
22723669
33990685
20876615
26763721
25910577
34713517
33219219
33994964
12781996
118862
23583307
23616543
7643957
29259158
16033890
23102690
293752
32795469
26948889
36389241
35606144
29222469
29279308
35811321
30737392
26881105
28912554
25644702
27052180
17170309
30186114
28962859
26668400
18579733
30108475
20371820
21068836
15821089
20349187
17028368
29907917
34835975
17180163
27187682
35153675
36327895
7413519
34742308
32765501
21684291
32733433
32438751
25459361
29763840
29096641
34827545
25599930
30356897
34290367
35842075
30506969
21796662
31665242
28925578
33022295
27075756
30098544
25959200
31279535
31629288
31125917
19772883
22782459
26208985
28238116
32485136
32719333
35870680
19807846
28860967
28099414
34413515
11754214
12106888
34315403
18077694
31159306
18940936
28049625
26926566
15013563
18420947
29162434
35510352
30259418
34177557
28805558
30275444
33761343
18404425
25524407
34293712
26884166
30471926
30606613
35260865
25186741
21960564
33095507
24025838
36064593
28607170
19228979
31038917",The Role of Oxytocin in Abnormal Brain Development: Effect on Glial Cells and Neuroinflammation.,"The neonatal period is critical for brain development and determinant for long-term brain trajectory. Yet, this time concurs with a sensitivity and risk for numerous brain injuries following perinatal complications such as preterm birth. Brain injury in premature infants leads to a complex amalgam of primary destructive diseases and secondary maturational and trophic disturbances and, as a consequence, to long-term neurocognitive and behavioral problems. Neuroinflammation is an important common factor in these complications, which contributes to the adverse effects on brain development. Mediating this inflammatory response forms a key therapeutic target in protecting the vulnerable developing brain when complications arise. The neuropeptide oxytocin (OT) plays an important role in the perinatal period, and its importance for lactation and social bonding in early life are well-recognized. Yet, novel functions of OT for the developing brain are increasingly emerging. In particular, OT seems able to modulate glial activity in neuroinflammatory states, but the exact mechanisms underlying this connection are largely unknown. The current review provides an overview of the oxytocinergic system and its early life development across rodent and human. Moreover, we cover the most up-to-date understanding of the role of OT in neonatal brain development and the potential neuroprotective effects it holds when adverse neural events arise in association with neuroinflammation. A detailed assessment of the underlying mechanisms between OT treatment and astrocyte and microglia reactivity is given, as well as a focus on the amygdala, a brain region of crucial importance for socio-emotional behavior, particularly in infants born preterm.","['amygdala', 'astrocytes', 'developing brain', 'microglia', 'neuroinflammation', 'neuroprotection', 'oxytocin']",Cells,2022-12-12,"[{'lastname': 'Knoop', 'firstname': 'Marit', 'initials': 'M', 'affiliation': 'Laboratory of Child Growth and Development, University of Geneva, 1205 Geneva, Switzerland.'}, {'lastname': 'Possovre', 'firstname': 'Marie-Laure', 'initials': 'ML', 'affiliation': 'Laboratory of Child Growth and Development, University of Geneva, 1205 Geneva, Switzerland.'}, {'lastname': 'Jacquens', 'firstname': 'Alice', 'initials': 'A', 'affiliation': 'Faculty of Medicine, Université Paris Cité, Inserm, NeuroDiderot, 75019 Paris, France.'}, {'lastname': 'Charlet', 'firstname': 'Alexandre', 'initials': 'A', 'affiliation': 'Centre National de la Recherche Scientifique, Institute of Cellular and Integrative Neuroscience, University of Strasbourg, INCI UPR3212, 67000 Strasbourg, France.'}, {'lastname': 'Baud', 'firstname': 'Olivier', 'initials': 'O', 'affiliation': ""Laboratory of Child Growth and Development, University of Geneva, 1205 Geneva, Switzerland.\nFaculty of Medicine, Université Paris Cité, Inserm, NeuroDiderot, 75019 Paris, France.\nDivision of Neonatology and Pediatric Intensive Care, Children's University Hospital of Geneva, 1205 Geneva, Switzerland.""}, {'lastname': 'Darbon', 'firstname': 'Pascal', 'initials': 'P', 'affiliation': 'Centre National de la Recherche Scientifique, Institute of Cellular and Integrative Neuroscience, University of Strasbourg, INCI UPR3212, 67000 Strasbourg, France.'}]",,,,,"10.3390/cells11233899
10.1186/1742-4755-10-S1-S2
10.1016/j.bpobgyn.2018.04.003
10.1016/S0140-6736(16)31593-8
10.3389/fnins.2013.00123
10.1016/j.brainres.2021.147389
10.1111/dmcn.12430
10.1002/ana.22620
10.1016/S1474-4422(08)70294-1
10.1042/BST20130284
10.1016/j.neuroimage.2018.06.034
10.3389/fnana.2016.00055
10.1038/s41598-020-79446-0
10.1371/journal.pone.0113975
10.1016/j.earlhumdev.2016.07.010
10.3389/fnins.2016.00560
10.1080/09297049.2014.994486
10.1080/09297049.2015.1099619
10.1016/j.earlhumdev.2014.07.008
10.1111/apa.13254
10.3389/fpsyg.2019.00715
10.1002/imhj.21938
10.1891/0730-0832.31.5.311
10.1177/1099800417735633
10.1097/ANC.0000000000000558
10.1038/s41598-021-96840-4
10.1002/imhj.20298
10.1152/physrev.2001.81.2.629
10.1016/j.neuron.2019.04.029
10.1016/j.neuron.2011.11.030
10.1126/science.1201043
10.1038/s41593-021-00800-0
10.1038/s41598-021-84906-2
10.1093/braincomms/fcac009
10.1038/s41386-020-0653-8
10.1007/BF00341151
10.1021/ja01641a004
10.3389/fnana.2014.00164
10.1016/S0006-8993(99)02418-X
10.1111/jne.13004
10.1155/2018/4864107
10.1016/j.tips.2017.08.005
10.1002/cphy.c160007
10.1038/nrn1845
10.1098/rstb.2014.0182
10.1038/nn.3634
10.3389/fncel.2019.00570
10.1042/BST0351252
10.1016/j.bbr.2006.08.025
10.1007/7854_2017_6
10.1111/j.1365-2826.2012.02303.x
10.1038/npp.2014.120
10.1038/s41467-020-15659-1
10.1038/nature10523
10.1038/s41386-022-01305-5
10.1016/0168-0102(95)01003-3
10.3389/fnbeh.2013.00195
10.1016/j.biopsych.2015.04.013
10.1007/s12079-016-0353-7
10.1007/7854_2017_7
10.1111/j.1749-6632.1992.tb34343.x
10.1152/jn.00077.2012
10.1038/s42003-021-02110-4
10.1093/hmg/ddq424
10.1111/jne.12364
10.1016/j.yhbeh.2015.04.006
10.1111/jne.13049
10.1038/s41467-020-19569-0
10.3389/fnsys.2021.655110
10.1016/S0014-4886(03)00032-3
10.1016/0378-3782(79)90022-7
10.1016/j.pneurobio.2013.04.001
10.1523/JNEUROSCI.5746-12.2013
10.1007/BF01694533
10.1038/s41467-017-02174-z
10.1523/JNEUROSCI.1342-05.2005
10.1016/j.psyneuen.2012.09.018
10.1073/pnas.76.12.6661
10.1016/j.yhbeh.2020.104840
10.1016/j.neuron.2016.01.041
10.3389/fnins.2022.1044736
10.1523/JNEUROSCI.0307-22.2022
10.1038/s41467-017-02173-0
10.1523/JNEUROSCI.1896-17.2017
10.1186/s12929-022-00834-x
10.1038/s41467-019-08503-8
10.1155/2016/3276383
10.1038/s41467-017-00675-5
10.1534/genetics.114.173963
10.1016/j.celrep.2016.03.013
10.1126/science.1133212
10.3389/fncel.2018.00254
10.1016/j.bbrc.2017.09.143
10.1073/pnas.1514761112
10.1523/JNEUROSCI.4572-07.2008
10.3389/fnins.2018.00512
10.1523/JNEUROSCI.5538-09.2010
10.1038/nature09553
10.1126/science.1105636
10.1007/s00381-010-1125-y
10.1385/NMM:8:4:435
10.1007/s11910-018-0862-2
10.3390/nu13113719
10.1038/nrn2038
10.1002/cne.24040
10.3389/fncel.2021.811061
10.1016/j.neuron.2022.10.020
10.1016/S0344-0338(80)80271-8
10.1186/s12974-021-02309-6
10.3389/fimmu.2020.01416
10.1016/j.lfs.2011.05.011
10.3389/fimmu.2020.01024
10.3390/jcm9051534
10.1016/j.pediatrneurol.2014.10.005
10.1016/j.cyto.2018.05.004
10.1186/s12974-017-0981-8
10.3390/brainsci11111545
10.1016/j.biopsych.2014.11.010
10.3389/fncel.2018.00355
10.1038/s41380-021-01227-6
10.1016/j.pnpbp.2022.110600
10.1002/glia.23546
10.1002/ana.22489
10.1093/brain/awz319
10.1002/glia.23216
10.1016/j.peptides.2020.170398
10.1186/s12974-016-0541-7
10.1016/j.biopha.2018.07.148
10.1272/jnms.82.92
10.1016/j.biopsych.2019.04.037
10.1016/j.jneuroim.2019.577066
10.1016/j.jpsychires.2019.05.019
10.1016/j.pnpbp.2009.09.012
10.1007/s00213-012-2796-8
10.1016/j.psychres.2015.07.043
10.1007/s12264-017-0103-8
10.1016/j.neuron.2020.05.014
10.1038/s41467-020-17514-9
10.1016/j.pneurobio.2022.102328
10.1111/j.1365-2826.2009.01922.x
10.3389/fnmol.2017.00262
10.1038/nature21029
10.1038/s41593-021-00905-6
10.1002/glia.10029
10.1016/S0165-0378(02)00038-4
10.1186/s10194-021-01299-3
10.1523/JNEUROSCI.4119-07.2007
10.3390/cells8060527
10.1152/ajpendo.90718.2008
10.1152/ajpendo.00346.2016
10.1016/j.bbrc.2016.02.109
10.1016/S0197-4580(03)00126-X
10.1161/STROKEAHA.108.516401
10.1016/j.ejphar.2017.11.018
10.1021/acsami.2c00007
10.1007/s12640-018-9962-7
10.3389/fnagi.2021.682633
10.1038/s41467-018-06224-y
10.1016/j.celrep.2021.108882
10.1007/s11302-006-9043-x
10.1016/j.neulet.2014.12.026
10.1016/j.intimp.2021.107975
10.1073/pnas.1525528113
10.1016/j.immuni.2018.11.004
10.1016/j.neuron.2018.12.006
10.1038/s41593-022-01022-8
10.1523/JNEUROSCI.1860-14.2014
10.1161/STROKEAHA.111.628008
10.1002/glia.23918
10.1038/nature12518
10.1038/s42003-022-03879-8
10.1523/JNEUROSCI.0659-17.2017
10.1523/JNEUROSCI.5593-08.2009
10.1021/acschemneuro.8b00665",<Element 'PubmedArticle' at 0x7f05dba31310>
63,36403520,Thiadiazine-thione derivatives ameliorate STZ-induced diabetic neuropathy by regulating insulin and neuroinflammatory signaling.,"Diabetes Mellitus is accompanied by chronic hyperglycemia, inflammation, and related molecular processes, which leads to diabetic neuropathy. In this work, we tested Thiadiazine-thione (TDT) synthetic derivatives TDT1 and TDT2 against streptozotocin (STZ)-induced diabetic neuropathy. Sprague Dawley's rats, SH-SY5Y neuronal and BV2 microglial cells were employed in this work, followed by behavioral, biochemical, and morphological studies utilizing RT-qPCR, ELISA, Immunoblotting, immunohistochemistry, Immunofluorescence, and in silico analyses. TDT1 and TDT2 abolished STZ-induced allodynia and hyperalgesia. Next, we examined IRS1/PI3K/AKT signaling to assess TDT1 and TDT2's impact on diabetic neuropathy. STZ downregulated IRS1, PI3K, AKT mRNA and protein expression in rat spinal cord and SH-SY5Y neuronal cells. TDT1 and TDT2 improved IRS1, PI3k, and AKT mRNA and protein expression. STZ elevated GSK3β mRNA and protein expression in vivo and in vitro, whereas TDT1 and TDT2 mitigated it. STZ increased the expression of inflammatory mediators such as p-NF-κB, TNF-α, and COX-2 in rat spinal cord lysates. TDT1 and TDT2 co-treatment with STZ decreased inflammatory cytokine expression by ameliorating astrocytosis (revealed by increased GFAP) and microgliosis (indicated by increased Iba1). TDT1 and TDT2 reduced STZ-induced JNK, Iba1, and COX-2 upregulation in BV2 microglial cells validating our in vivo findings. In silico molecular docking and MD simulations analyses suggested that TDT1 and TDT2 have IRS binding affinity, however, both compounds had an identical binding affinity, but distinct interaction pattern with IRS protein residues. Overall, these findings demonstrate that TDT derivatives mitigated STZ-induced neuropathy through modulating the insulin and inflammatory signaling pathways.","['Diabetic neuropathy', 'Insulin receptor substrate (IRS)', 'Neuroinflammation', 'PI3KT/AKT', 'Thiadiazine-Thione']",International immunopharmacology,2022-11-21,"[{'lastname': 'Qureshi', 'firstname': 'Sonia', 'initials': 'S', 'affiliation': 'Department of Pharmacy, University of Peshawar, Peshawar, 25120, Pakistan; Krembil Research Institute, University Health Network, M5G 1L7, Toronto, Ontario, Canada.'}, {'lastname': 'Ali', 'firstname': 'Gowhar', 'initials': 'G', 'affiliation': 'Department of Pharmacy, University of Peshawar, Peshawar, 25120, Pakistan. Electronic address: gowhar_ali@uop.edu.pk.'}, {'lastname': 'Muhammad', 'firstname': 'Tahir', 'initials': 'T', 'affiliation': 'Molecular Neuropsychiatry and Development (MiND) Lab, Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, ON, Canada; Institute of Medical Science, University of Toronto, Toronto, ON, Canada.'}, {'lastname': 'Idrees', 'firstname': 'Muhammad', 'initials': 'M', 'affiliation': 'Division of Applied Life Science (BK21 Four), Gyeongsang National University, Jinju 52828, Gyeongnam Province, Republic of Korea; Institute of Agriculture and Life Science, Gyeongsang National University, Gyeongnam Province, Republic of Korea.'}, {'lastname': 'Ullah', 'firstname': 'Sultan', 'initials': 'S', 'affiliation': 'Department of Molecular Medicine, UF Scripps Biomedical Research, Jupiter, FL, 33458, USA.'}, {'lastname': 'Ali Khan', 'firstname': 'Salman', 'initials': 'S', 'affiliation': 'H.E.J. Research Institute of Chemistry, International Center for Chemical and Biological Sciences, University of Karachi, Karachi, Pakistan; Dr. Panjwani Center for Molecular Medicine and Drug Research, International Center for Chemical and Biological Sciences, University of Karachi, Karachi, Pakistan.'}, {'lastname': 'Ullah', 'firstname': 'Rahim', 'initials': 'R', 'affiliation': 'Department of Pharmacy, University of Peshawar, Peshawar, 25120, Pakistan.'}, {'lastname': 'Khan', 'firstname': 'Rasool', 'initials': 'R', 'affiliation': 'Institute of chemical sciences, University of Peshawar, Peshawar, Pakistan.'}, {'lastname': 'Ul-Haq', 'firstname': 'Zaheer', 'initials': 'Z', 'affiliation': 'Dr. Panjwani Center for Molecular Medicine and Drug Research, International Center for Chemical and Biological Sciences, University of Karachi, Karachi, Pakistan; Institute of chemical sciences, University of Peshawar, Peshawar, Pakistan.'}, {'lastname': 'Haseeb Mohsin', 'firstname': 'Abdul', 'initials': 'A', 'affiliation': 'Institute of chemical sciences, University of Peshawar, Peshawar, Pakistan.'}, {'lastname': 'Kong', 'firstname': 'Il-Keun', 'initials': 'IK', 'affiliation': 'Division of Applied Life Science (BK21 Four), Gyeongsang National University, Jinju 52828, Gyeongnam Province, Republic of Korea; Institute of Agriculture and Life Science, Gyeongsang National University, Gyeongnam Province, Republic of Korea; The Kingkong Co. Ltd., Gyeongsang National University, Jinju 52828, Gyeongnam Province, Republic of Korea.'}]",,,,Copyright © 2022 Elsevier B.V. All rights reserved.,10.1016/j.intimp.2022.109421,<Element 'PubmedArticle' at 0x7f05d854def0>
64,"36374861
10599761
26132277
17764626
205798
10574963
6323631
10460236
22956272
20444434
21745566
31276749
31801553
29804228
31382613
21935365
32390823
29463061
29473514
20182019
19777393
25575908
19946431
12457784
24247674
32236312
23336971
27176073
23225498
29233204
26836174
12759183
18579197
29176000
28683595
29961403
21932040
29372547
29545166
0
32043072
7951753
32730766
22895667
29515352
15094074
2249648
11445137
12006603
29217283
12125099
12711007
15637289
17112620
16046118
12446608
18093597
31281852
30483737
31635074
31792284
31574510
28441890
28747485
32627720
32851076
30616171
33758546
24202444
34408615
17229572
34102194
31799688
24670389
29950970
23874448
26851642
15919790
30451830
7698218
31084577
30409076
19615978
30579679
27997893
26198568
31904546
24269557
21679297
27833613
26995317",Vitamin D and rosuvastatin alleviate type-II diabetes-induced cognitive dysfunction by modulating neuroinflammation and canonical/noncanonical Wnt/β-catenin signaling.,"Type-II diabetes mellitus (T2DM) is a major risk factor for cognitive impairment. Protecting the brain environment against inflammation, and neurodegeneration, as well as preservation of the BBB veracity through modulating the crosstalk between insulin/AKT/GSK-3β and Wnt/β-catenin signaling, might introduce novel therapeutic targets.
This study aimed at exploring the possible neuroprotective potential of vitamin D3 (VitD) and/or rosuvastatin (RSV) in T2DM-induced cognitive deficits.
T2DM was induced by a high-fat sucrose diet and a single streptozotocin (STZ) dose. Diabetic rats were allocated into a diabetic control and three groups treated with RSV (15 mg/kg/day, PO), VitD (500 IU/kg/day, PO), or their combination.
Administration of VitD and/or RSV mitigated T2DM-induced metabolic abnormalities and restored the balance between the anti-inflammatory, IL 27 and the proinflammatory, IL 23 levels in the hippocampus. In addition, they markedly activated both the canonical and noncanonical Wnt/β-catenin cassettes with stimulation of their downstream molecular targets. VitD and/or RSV upregulated insulin and α7 nicotinic acetylcholine (α7nACh) receptors gene expression, as well as blood-brain barrier integrity markers including Annexin A1, claudin 3, and VE-cadherin. Also, they obliterated hippocampal ApoE-4 content, Tau hyperphosphorylation, and Aβ deposition. These biochemical changes were reflected as improved behavioral performance in Morris water maze and novel object recognition tests and restored hippocampal histological profile.
The current findings have accentuated the neuroprotective potential of VitD and RSV and provide new incentives to expand their use in T2DM-induced cognitive and memory decline. This study also suggests a superior benefit of combining both treatments over either drug alone.",[],PloS one,2022-11-15,"[{'lastname': 'Muneeb', 'firstname': 'Muhammad', 'initials': 'M', 'affiliation': 'Department of Pharmacology, Toxicology, and Biochemistry, Faculty of Pharmacy, Future University in Egypt, Cairo, Egypt.'}, {'lastname': 'Mansou', 'firstname': 'Suzan M', 'initials': 'SM', 'affiliation': 'Department of Pharmacology, Toxicology, and Biochemistry, Faculty of Pharmacy, Future University in Egypt, Cairo, Egypt.\nDepartment of Pharmacology and Toxicology, Faculty of Pharmacy, Cairo University, Cairo, Egypt.'}, {'lastname': 'Saleh', 'firstname': 'Samira', 'initials': 'S', 'affiliation': 'Department of Pharmacology and Toxicology, Faculty of Pharmacy, Cairo University, Cairo, Egypt.'}, {'lastname': 'Mohammed', 'firstname': 'Reham A', 'initials': 'RA', 'affiliation': 'Department of Pharmacology and Toxicology, Faculty of Pharmacy, Cairo University, Cairo, Egypt.'}]",,The current findings have accentuated the neuroprotective potential of VitD and RSV and provide new incentives to expand their use in T2DM-induced cognitive and memory decline. This study also suggests a superior benefit of combining both treatments over either drug alone.,"Administration of VitD and/or RSV mitigated T2DM-induced metabolic abnormalities and restored the balance between the anti-inflammatory, IL 27 and the proinflammatory, IL 23 levels in the hippocampus. In addition, they markedly activated both the canonical and noncanonical Wnt/β-catenin cassettes with stimulation of their downstream molecular targets. VitD and/or RSV upregulated insulin and α7 nicotinic acetylcholine (α7nACh) receptors gene expression, as well as blood-brain barrier integrity markers including Annexin A1, claudin 3, and VE-cadherin. Also, they obliterated hippocampal ApoE-4 content, Tau hyperphosphorylation, and Aβ deposition. These biochemical changes were reflected as improved behavioral performance in Morris water maze and novel object recognition tests and restored hippocampal histological profile.","Copyright: © 2022 Muneeb et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.","10.1371/journal.pone.0277457
10.1212/wnl.53.9.1937
10.1111/nyas.12807
10.1007/s11910-007-0058-7
10.1038/272827a0
10.1074/jbc.274.49.34893
10.1111/j.1471-4159.1984.tb02795.x
10.1523/JNEUROSCI.19-17-07300.1999
10.1007/s12035-012-8339-9
10.1016/j.arr.2010.04.007
10.1016/j.bbadis.2011.06.011
10.1016/j.mcn.2019.103390
10.1002/alz.047353
10.1186/s13041-019-0525-5
10.1007/s12035-018-1103-z
10.3390/cells8080826
10.1371/journal.pone.0023914
10.3389/fnagi.2020.00105
10.3390/genes9020109
10.2174/1570159X16666180222164809
10.3233/JAD-2010-091570
10.1007/s11606-014-3115-3
10.3238/arztebl.2009.0664
10.1016/j.jacl.2014.02.067
10.20945/2359-3997000000214
10.1111/nan.12020
10.3233/JAD-150943
10.1002/ana.23738
10.1007/978-3-319-73742-3_7
10.1017/S0029665117004153
10.3233/JAD-150811
10.1016/s0304-3940(03)00303-3
10.1016/j.mam.2008.05.001.Vitamin
10.1042/BSR20171184
10.1080/1028415X.2017.1348436
10.1080/13510002.2018.1492774
10.1007/s12031-011-9644-x
10.1007/s12035-017-0863-1
10.1016/j.neubiorev.2018.03.010
10.1385/0-89603-268-X:9
10.1016/S1474-4422(20)30231-3
10.1161/ATVBAHA.112.252759
10.3389/fnins.2018.00073
10.1016/j.ejphar.2004.02.045
10.1210/endo-127-6-3234
10.1016/s0149-7634(01)00016-1
10.1016/j.neuropharm.2017.12.001
10.1016/S0960-0760(03)00032-3
10.1210/en.2004-1322
10.1016/j.diabres.2006.10.007
10.1016/j.jsbmb.2005.06.002
10.1210/en.2002-220449
10.1016/j.atherosclerosis.2007.11.003
10.1155/2019/7894950
10.3892/mmr.2018.9666
10.3390/nu11102525
10.1038/s41598-019-54557-5
10.1159/000503105
10.1177/0960327117705431
10.3945/jn.117.249953.The
10.1080/01616412.2020.1787624
10.1155/2020/4864017
10.1016/j.intimp.2018.12.061
10.2147/CMAR.S289819
10.1016/j.jtumed.2021.01.012
10.1016/j.jsbmb.2006.11.018
10.26502/jcsct.5079068
10.1016/j.lfs.2021.119697
10.26355/eurrev_201911_19586
10.1038/srep04493
10.3389/fnins.2018.00383
10.1371/journal.pone.0067802
10.1111/jnc.13569
10.2337/diabetes.54.6.1692
10.1038/s41467-018-07302-x
10.1096/fj.201802750RR
10.1080/21688370.2018.1540904
10.1016/j.bbrc.2009.07.057
10.1016/j.npep.2018.12.003
10.1159/000453197
10.1007/s12035-015-9344-6
10.1016/j.nlm.2019.107154
10.1016/j.ajpath.2013.10.010
10.1111/j.1601-183X.2011.00711.x
10.3389/fimmu.2016.00460
10.1016/j.bbi.2016.03.010",<Element 'PubmedArticle' at 0x7f05d8523ae0>
65,"36362220
12597862
30201764
11549663
20012068
33381011
25239737
15788704
10604470
31784044
21524673
29576534
12130749
28552455
30874792
11162448
20497419
15232612
23071554
29845448
24381790
17983863
21903149
26042199
21219177
20720512
24727365
34939700
27303049
12663466
19384567
25785032
22159999
31306657
18523304
29599941
31447640
30177523
11057670
20584998
15339247
12970297
20587751
25607843
20826561
15855322
23900445
29197160
26569220
32710901
30129476
33714946
29057768
26033219
28232667
33333485
26542050
27337340
32959884
29151590
25800044
25035950
23454862
31062335
25385337
35016495
24327949
32508567
22201683
35681242
30524228
35742824
16600402
16460274
26016745
30578932
28697569
28504110
28592656
31758009
28507516
31178685
21371747
1941102
22355802
32320406
30309945
30833177
20948643
33582568
31835423
34305953
30628018
21565248
28782532
31780940
32859774
21389984
19463757
33838250
11274343
30116300
21605050
21949705
22908267
33154069
30065032
28469442
26090621
12447443
22476196
25111866
20351014
26079709
25792098
21718498
19740737
25309797
19382238
15507538
23565247
23506735
30339715
16491079
19349094
30949921
28380673
20930280
30443455
25173805
1933245
31077796
9278044
31787891
29626177
32736085
31862977
20028343
26872221
29277488
24009547
12068076
16233968",The Interplay between Ghrelin and Microglia in Neuroinflammation: Implications for Obesity and Neurodegenerative Diseases.,"Numerous studies have shown that microglia are capable of producing a wide range of chemokines to promote inflammatory processes within the central nervous system (CNS). These cells share many phenotypical and functional characteristics with macrophages, suggesting that microglia participate in innate immune responses in the brain. Neuroinflammation induces neurometabolic alterations and increases in energy consumption. Microglia may constitute an important therapeutic target in neuroinflammation. Recent research has attempted to clarify the role of Ghre signaling in microglia on the regulation of energy balance, obesity, neuroinflammation and the occurrence of neurodegenerative diseases. These studies strongly suggest that Ghre modulates microglia activity and thus affects the pathophysiology of neurodegenerative diseases. This review aims to summarize what is known from the current literature on the way in which Ghre modulates microglial activity during neuroinflammation and their impact on neurometabolic alterations in neurodegenerative diseases. Understanding the role of Ghre in microglial activation/inhibition regulation could provide promising strategies for downregulating neuroinflammation and consequently for diminishing negative neurological outcomes.","['Alzheimer’s disease', 'Ghrelin', 'Ghrelin receptor', 'Parkinson’s disease', 'inflammation', 'microglia', 'neurodegenerative diseases', 'neuroinflammation']",International journal of molecular sciences,2022-11-12,"[{'lastname': 'Russo', 'firstname': 'Cristina', 'initials': 'C', 'affiliation': 'Section of Pathology, Department of Biomedical and Biotechnological Sciences, School of Medicine, University of Catania, 95123 Catania, Italy.'}, {'lastname': 'Valle', 'firstname': 'Maria Stella', 'initials': 'MS', 'affiliation': 'Laboratory of Neuro-Biomechanics, Department of Biomedical and Biotechnological Sciences, School of Medicine, University of Catania, 95123 Catania, Italy.\nSection of Physiology, Department of Biomedical and Biotechnological Sciences, University of Catania, 95123 Catania, Italy.'}, {'lastname': 'Russo', 'firstname': 'Antonella', 'initials': 'A', 'affiliation': 'Section of Physiology, Department of Biomedical and Biotechnological Sciences, University of Catania, 95123 Catania, Italy.'}, {'lastname': 'Malaguarnera', 'firstname': 'Lucia', 'initials': 'L', 'affiliation': 'Section of Pathology, Department of Biomedical and Biotechnological Sciences, School of Medicine, University of Catania, 95123 Catania, Italy.'}]",,,,,"10.3390/ijms232113432
10.1016/S0896-6273(03)00063-1
10.1523/JNEUROSCI.0789-18.2018
10.1210/jcem.86.9.7866
10.1007/s00401-009-0619-8
10.3389/fnins.2020.614828
10.1016/j.jalz.2014.06.016
10.1152/physrev.00012.2004
10.1038/45230
10.1016/j.npep.2019.101997
10.1016/j.peptides.2011.04.010
10.1016/j.cmet.2018.02.008
10.1124/jpet.102.034827
10.1016/j.neulet.2017.05.049
10.1210/en.2019-00074
10.1006/bbrc.2000.4039
10.1111/j.1440-1681.2010.05409.x
10.1172/JCI21134
10.1371/journal.pone.0046321
10.1007/s00221-018-5298-z
10.1155/2013/518909
10.1016/j.mce.2011.08.034
10.1016/j.molmet.2015.03.005
10.1146/annurev-immunol-031210-101322
10.1097/SHK.0b013e3181f48a37
10.1016/j.bbi.2014.04.001
10.1096/fj.202101297R
10.1042/CS20160077
10.2337/diabetes.52.4.948
10.1007/s12640-009-9037-x
10.1152/ajpheart.00390.2010
10.1016/j.lfs.2019.116654
10.4049/jimmunol.180.12.8369
10.1155/2018/1564748
10.3389/fnins.2019.00828
10.1042/BSR20181061
10.1038/35038090
10.2337/db10-0504
10.1530/eje.0.151s067
10.1210/jc.2002-021940
10.1152/ajpendo.00414.2009
10.1172/JCI73688
10.1210/en.2010-0556
10.2337/diabetes.54.5.1371
10.1038/ijo.2013.140
10.1002/dneu.22562
10.3390/ijms161125990
10.1016/j.brainres.2020.147023
10.1016/S1474-4422(18)30238-2
10.18632/aging.202805
10.1507/endocrj.EJ17-0281
10.1007/s12035-015-9227-x
10.1038/nrendo.2016.222
10.1016/j.npep.2020.102112
10.1016/j.tem.2015.09.010
10.1038/nature18283
10.1093/hmg/ddaa209
10.1038/nri.2017.125
10.1111/bph.13139
10.1016/j.immuni.2014.06.008
10.1016/j.bbi.2013.02.005
10.1007/s12264-019-00388-3
10.1038/nrneurol.2014.207
10.4081/ejh.2022.3350
10.1016/j.molmet.2013.08.003
10.3389/fnins.2020.00444
10.1172/JCI59660
10.1186/s12974-022-02519-6
10.3389/fnins.2018.00846
10.3390/ijms23126380
10.1016/j.regpep.2006.02.005
10.1146/annurev.physiol.68.040504.094635
10.1530/JOE-15-0139
10.1016/j.bbi.2018.12.008
10.3233/JAD-170248
10.1016/S1474-4422(17)30084-4
10.1242/dmm.026609
10.1038/s41598-019-53578-4
10.3389/fnagi.2017.00115
10.3389/fnins.2019.00513
10.1016/S0140-6736(10)61349-9
10.1523/JNEUROSCI.11-11-03679.1991
10.1101/cshperspect.a009399
10.1371/journal.pone.0231720
10.1126/science.aat0473
10.1016/j.it.2019.02.001
10.3410/B1-42
10.1016/j.neurobiolaging.2021.01.011
10.3390/biom9120850
10.3389/fimmu.2021.714340
10.1007/s11064-018-02714-z
10.1016/j.mce.2011.04.019
10.1016/j.lfs.2017.08.004
10.3389/fphar.2019.01320
10.4103/1673-5374.290881
10.1038/nature09788
10.1016/j.peptides.2009.03.001
10.1016/j.bbi.2021.04.001
10.1152/physrev.2001.81.2.741
10.1177/1756286418791107
10.2174/156720511796391818
10.1371/journal.pone.0024325
10.1073/pnas.1205847109
10.2337/db20-0231
10.2337/db18-0451
10.1177/1178626417703995
10.1038/srep11452
10.1038/nature01137
10.1172/JCI57256
10.1097/MCO.0000000000000101
10.1677/JOE-10-0040
10.1016/j.nbd.2015.06.002
10.1016/S1474-4422(15)70016-5
10.1186/1750-1326-6-45
10.1074/jbc.M109.045104
10.3803/EnM.2014.29.3.371
10.1002/jnr.22088
10.1152/ajpendo.00196.2004
10.1371/journal.pone.0060437
10.1016/j.neuroscience.2013.02.062
10.1111/jnc.14615
10.1038/nn1656
10.1016/j.neurobiolaging.2009.02.025
10.1007/s13668-019-0271-4
10.1111/jne.12476
10.3233/JAD-2010-101263
10.7759/cureus.3285
10.1016/j.nbd.2014.08.026
10.1093/brain/114.5.2283
10.1016/j.semcdb.2019.05.004
10.1038/42166
10.3389/fnagi.2019.00302
10.1212/WNL.0000000000005475
10.1016/j.nbd.2020.105028
10.1038/s41467-019-13812-z
10.1111/j.1600-0404.2009.01185.x
10.1111/jnc.13576
10.1016/j.neuropharm.2017.12.027
10.3389/fnins.2013.00148
10.1046/j.1471-4159.2002.00928.x
10.1016/j.exger.2005.09.003",<Element 'PubmedArticle' at 0x7f05db6e1220>
66,36334782,Resveratrol exerts anxiolytic-like effects through anti-inflammatory and antioxidant activities in rats exposed to chronic social isolation.,"Emerging evidence has confirmed resveratrol's (RES) antioxidant, anti-inflammatory, and antidepressant effects. The beneficial effects of RES were confirmed for several emotional and cognitive deficits. This research aimed to assess the impacts of RES on behavior and hippocampal levels of anti-inflammatory and pro-inflammatory factors in rats exposed to chronic social isolation (SI) stress, which is known to induce mental disorders such as depressive-like behavior. The animals were treated by RES (20, 40, or 80 mg/kg/intraperitoneally) for 28 days following a 28-day exposure to stress. Behavioral tests, including the forced swim test (FST), open-field test (OFT), tail suspension test (TST), and sucrose preference test (SPT), assessed depressive symptoms. Finally, the animals were sacrificed, and molecular studies (qPCR and ELISA) were performed. Exposure of animals to SI dramatically increased the immobility of animals in TST and FST, enhanced the time spent in the open-field peripheral zone of the OFT, and reduced the sucrose preference rate. In addition, SI increased serum levels of corticosterone and hippocampal content of MDA, whereas it reduced hippocampal SOD and CAT activities. Moreover, SI upregulated the expression of IL-10, IL-18, and IL-1β and downregulated the expression of TGF-β in the hippocampus. RES treatment (40 & 80 mg/kg) significantly improved the behavioral alterations through the modulation of neuroinflammation and oxidative stress. The 20 mg/kg RES dose was inefficient for treating SI-induced depressive-like behavior. These results indicated that RES attenuated depressive-like behavior in prolonged stressed animals. These properties might be associated with RES-mediated improvements in serum corticosterone and hippocampal inflammatory and oxidative stress biomarkers.","['Cytokines', 'Depressive-like behavior', 'Neuroinflammation', 'Resveratrol', 'Social Isolation']",Behavioural brain research,2022-11-06,"[{'lastname': 'Baghaei Naeini', 'firstname': 'Farinaz', 'initials': 'F', 'affiliation': 'Faculty of Veterinary Medicine, Science and Research Branch, Islamic Azad University, Tehran, Islamic Republic of Iran.'}, {'lastname': 'Hassanpour', 'firstname': 'Shahin', 'initials': 'S', 'affiliation': 'Division of Physiology, Department of Basic Sciences, Faculty of Veterinary Medicine, Science and Research Branch, Islamic Azad University, Tehran, Islamic Republic of Iran. Electronic address: hassanpour.shahin@gmail.com.'}, {'lastname': 'Asghari', 'firstname': 'Ahmad', 'initials': 'A', 'affiliation': 'Department of Clinical Sciences, Faculty of Veterinary Medicine, Science and Research Branch, Islamic Azad University, Tehran, Islamic Republic of Iran.'}]",,,,Copyright © 2022 Elsevier B.V. All rights reserved.,10.1016/j.bbr.2022.114201,<Element 'PubmedArticle' at 0x7f05d85a96d0>
67,"36317290
19567371
12391160
26056061
28502781
23627753
26276664
35011684
11313722
21980503
26699485
34589820
23620290
26271538
20649850
27883893
29428549
28319043
23707790
17169985
28087238
30689226
30355700
22125095
25433170
27568094
26799851
23756047
22832853
32741824
27769714
22184247
19849801
30464573
19190255
30792350
20081528
33483691
14998915
30366905
29180230
23033538
34158177
22170608
30282019
25958077
24189141
23426900
26812118
25146427
28382017
29439024
24270424
19141540
20106676
31005044
23845513
31316402
29560886
23180795
22822164
28760748
30602137
20080870
23152603
31314053
34807912
27889895
19840546
29288075
22895791
27764084
21965677
30338290
19684579
20471965
29234010
24929192
18643788
29643512
30740047
21525267
26901093
16768357
17574218
16249183
27485028
30522007","Circadian Clock, Glucocorticoids and NF-κB Signaling in Neuroinflammation- Implicating Glucocorticoid Induced Leucine Zipper as a Molecular Link.","Inflammation including neuroinflammation is considered a protective response and is directed to repair, regenerate, and restore damaged tissues in the central nervous system. Persistent inflammation due to chronic stress, age related accrual of free radicals, subclinical infections or other factors lead to reduced survival and increased neuronal death. Circadian abnormalities secondary to altered sleep/wake cycles is one of the earliest signs of neurodegenerative diseases. Brain specific or global deficiency of core circadian trans-activator brain and muscle ARNT (Arylhydrocarbon Receptor Nuclear Translocator)-like protein 1 (BMAL1) or that of the transrepressor REV-ERBα, impaired neural function and cognitive performance in rodents. Consistently, transcripts of inflammatory cytokines and host immune responses have been shown to exhibit diurnal variation, in parallel with the disruption of the circadian rhythm. Glucocorticoids that exhibit both a circadian rhythm similar to that of the core clock transactivator BMAL1 and tissue specific ultradian rhythm are critical in the control of neuroinflammation and re-establishment of homeostasis. It is widely accepted that the glucocorticoids suppress nuclear factor-kappa B (NF-κB) mediated transactivation and suppress inflammation. Recent mechanistic elucidations suggest that the core clock components also modulate NF-κB mediated transactivation in the brain and peripheral tissues. In this review we discuss evidence for interactions between the circadian clock components, glucocorticoids and NF-κB signaling responses in the brain and propose glucocorticoid induced leucine zipper (GILZ) encoded by Tsc22d3, as a molecular link that connect all three pathways in the maintenance of CNS homeostasis as well as in the pathogenesis of neuroinflammation-neurodegeneration.","['CLOCK', 'GILZ', 'NF-κB p65', 'glucocorticoids']",ASN neuro,2022-11-02,"[{'lastname': 'Srinivasan', 'firstname': 'Mythily', 'initials': 'M', 'affiliation': 'Department of Oral Pathology, Medicine and Radiology, Indiana University School of Dentistry, Indiana University Purdue University at Indianapolis, Indiana, USA.\nProvaidya LLC, 10668Indiana Center for Biomedical Innovation, Indianapolis, Indiana, USA.'}, {'lastname': 'Walker', 'firstname': 'Chandler', 'initials': 'C', 'affiliation': 'Department of Oral Pathology, Medicine and Radiology, Indiana University School of Dentistry, Indiana University Purdue University at Indianapolis, Indiana, USA.\nDepartment of Biomedical Sciences and Comprehensive Care, Indiana University School of Dentistry, Indiana University Purdue University at Indianapolis, Indiana, USA.'}]",,,,,"10.1177/17590914221120190
10.1096/fj.09-134684
10.1128/MCB.22.22.7929-7941.2002
10.14814/phy2.12382
10.1016/j.yfrne.2017.05.001
10.2174/15672050113109990004
10.1182/blood-2015-03-631580
10.3390/cells11010122
10.1038/sj.cdd.4400798
10.1371/journal.pone.0025612
10.1073/pnas.1508249112
10.1016/j.bbih.2021.100337
10.1093/nar/gkt307
10.1177/0748730415598608
10.1111/j.1365-2826.2010.02051.x
10.1016/j.jalz.2016.10.003
10.1016/j.yfrne.2018.02.003
10.1172/JCI88886
10.1016/j.mce.2013.05.012
10.1093/nar/gkl1080
10.1016/j.immuni.2016.12.011
10.1111/ejn.14358
10.1212/WNL.0000000000006549
10.1007/s13311-011-0084-7
10.1016/j.bbi.2014.11.009
10.1016/j.neurobiolaging.2016.07.019
10.1016/j.psyneuen.2016.01.006
10.1016/j.conb.2013.05.002
10.1038/tp.2012.14
10.3233/JAD-200331
10.1016/j.mce.2016.10.019
10.1073/pnas.1106750109
10.1111/j.1467-789X.2009.00661.x
10.2147/JIR.S140188
10.1152/ajpendo.90946.2008
10.1073/pnas.1812405116
10.1097/CCM.0b013e3181cd131c
10.1038/s41380-021-01016-1
10.1093/brain/awh129
10.1101/gad.319228.118
10.1016/j.pnpbp.2017.11.020
10.1126/scisignal.2003333
10.1016/j.mam.2021.100984
10.1038/nature10700
10.1016/j.yhbeh.2015.04.020
10.1210/en.2013-1531
10.3892/mmr.2013.1331
10.1016/j.bbi.2016.01.018
10.1111/cns.12315
10.3389/fneur.2017.00099
10.1126/science.aao0318
10.1172/JCI70317
10.1096/fj.08-117697
10.1016/j.tem.2009.12.011
10.1016/j.psyneuen.2019.04.015
10.1016/j.psyneuen.2013.06.020
10.3389/fpsyt.2019.00423
10.1016/j.bpsc.2016.08.006
10.1093/nar/gks1161
10.1210/en.2012-1484
10.1530/EC-17-0160
10.1016/j.psyneuen.2018.12.234
10.1210/en.2009-1119
10.1093/abbs/gmz070
10.1371/journal.pgen.1009933
10.1007/s12035-016-0297-1
10.1016/j.neuron.2009.09.032
10.1016/j.yfrne.2017.12.005
10.1073/pnas.1206274109
10.1371/journal.pone.0160314
10.1074/jbc.M111.279257
10.1016/j.trci.2018.04.004
10.1038/ncb1922
10.1016/j.brainres.2010.05.013
10.1038/s41467-017-02111-0
10.1016/j.bbi.2014.06.002
10.1111/j.1471-4159.2008.05575.x
10.1038/s41586-018-0023-4
10.3389/fnagi.2018.00432
10.1523/JNEUROSCI.0450-11.2011
10.1210/en.2015-1884
10.1162/jocn.2006.18.4.508.
10.1016/j.brainres.2007.05.024
10.1074/jbc.M509600200
10.1080/07420528.2016.1211668
10.1016/j.psyneuen.2018.11.033",<Element 'PubmedArticle' at 0x7f05d85bf130>
68,"36289122
34251921
34376800
28156186
29862891
16091003
27346372
18281277
25481643
34744609
34151801
34234508
36179318
28146081
20919643
20607622
34244137
35327165
32424203
32554188
18204095
30909396
24273690
34531642
31527435
31527435
34175020
19897276
16507786
28875857
31383928
34894211
31196177
31330799
34019663
27336782
26546682
33170805
27689343
33396940
21508345
29739677
21546914
31798939
30611497
31374939
30268024
33945534
27979317
34986597
17981741
35715809
33449145
35700359
26090402",Isoflavone consumption reduces inflammation through modulation of phenylalanine and lipid metabolism.,"Phytoestrogens found in soy, fruits, peanuts, and other legumes, have been identified as metabolites capable of providing beneficial effects in multiple pathological conditions due to their ability to mimic endogenous estrogen. Interestingly, the health-promoting effects of some phytoestrogens, such as isoflavones, are dependent on the presence of specific gut bacteria. Specifically, gut bacteria can metabolize isoflavones into equol, which has a higher affinity for endogenous estrogen receptors compared to dietary isoflavones. We have previously shown that patients with multiple sclerosis (MS), a neuroinflammatory disease, lack gut bacteria that are able to metabolize phytoestrogen. Further, we have validated the importance of both isoflavones and phytoestrogen-metabolizing gut bacteria in disease protection utilizing an animal model of MS. Specifically, we have shown that an isoflavone-rich diet can protect from neuroinflammatory diseases, and that protection was dependent on the ability of gut bacteria to metabolize isoflavones into equol. Additionally, mice on a diet with isoflavones showed an anti-inflammatory response compared to the mice on a diet lacking isoflavones. However, it is unknown how isoflavones and/or equol mediates their protective effects, especially their effects on host metabolite levels.
In this study, we utilized untargeted metabolomics to identify metabolites found in plasma that were modulated by the presence of dietary isoflavones.
We found that the consumption of isoflavones increased anti-inflammatory monounsaturated fatty acids and beneficial polyunsaturated fatty acids while reducing pro-inflammatory glycerophospholipids, sphingolipids, phenylalanine metabolism, and arachidonic acid derivatives.
Isoflavone consumption alters the systemic metabolic landscape through concurrent increases in monounsaturated fatty acids and beneficial polyunsaturated fatty acids plus reduction in pro-inflammatory metabolites and pathways. This highlights a potential mechanism by which an isoflavone diet may modulate immune-mediated disease.","['Inflammation', 'Isoflavone', 'Metabolites', 'Multiple sclerosis', 'Phytoestrogen', 'Untargeted metabolomics']",Metabolomics : Official journal of the Metabolomic Society,2022-10-27,"[{'lastname': 'Shrode', 'firstname': 'Rachel L', 'initials': 'RL', 'affiliation': 'Department of Informatics, University of Iowa, Iowa City, IA, 52242, USA.'}, {'lastname': 'Cady', 'firstname': 'Nicole', 'initials': 'N', 'affiliation': 'Department of Pathology, Carver College of Medicine, University of Iowa, Iowa City, IA, 52242, USA.\nDepartment of Microbiology and Immunology, University of Michigan, Ann Arbor, MI, 48109, USA.'}, {'lastname': 'Jensen', 'firstname': 'Samantha N', 'initials': 'SN', 'affiliation': 'Interdisciplinary Graduate Program in Immunology, University of Iowa, Iowa City, IA, 52242, USA.\nDivision of Gastroenterology, Joan and Sanford I. Weill Department of Medicine, Weill Cornell Medicine, Cornell University, New York, NY, USA.\nJill Roberts Institute for Research in Inflammatory Bowel Disease, Weill Cornell Medicine, Cornell University, New York, NY, USA.'}, {'lastname': 'Borcherding', 'firstname': 'Nicholas', 'initials': 'N', 'affiliation': 'Department of Pathology and Immunology, School of Medicine, Washington University, St. Louis, MO, 63110, USA.'}, {'lastname': 'Mangalam', 'firstname': 'Ashutosh K', 'initials': 'AK', 'affiliation': 'Department of Informatics, University of Iowa, Iowa City, IA, 52242, USA. ashutosh-mangalam@uiowa.edu.\nDepartment of Pathology, Carver College of Medicine, University of Iowa, Iowa City, IA, 52242, USA. ashutosh-mangalam@uiowa.edu.\nInterdisciplinary Graduate Program in Immunology, University of Iowa, Iowa City, IA, 52242, USA. ashutosh-mangalam@uiowa.edu.\nIowa Institute for Oral Health Research, College of Dentistry, University of Iowa, Iowa City, IA, 52242, USA. ashutosh-mangalam@uiowa.edu.'}]",,Isoflavone consumption alters the systemic metabolic landscape through concurrent increases in monounsaturated fatty acids and beneficial polyunsaturated fatty acids plus reduction in pro-inflammatory metabolites and pathways. This highlights a potential mechanism by which an isoflavone diet may modulate immune-mediated disease.,"We found that the consumption of isoflavones increased anti-inflammatory monounsaturated fatty acids and beneficial polyunsaturated fatty acids while reducing pro-inflammatory glycerophospholipids, sphingolipids, phenylalanine metabolism, and arachidonic acid derivatives.",© 2022. This is a U.S. Government work and not under copyright protection in the US; foreign copyright protection may apply.,"10.1007/s11306-022-01944-1
10.1080/10408398.2021.1946006
10.1038/s41598-021-95923-6
10.1177/1352458517691150
10.1177/1352458518779925
10.1207/s15327914nc5201_6
10.1038/srep28484
10.1074/jbc.M708700200
10.1007/s11130-014-0455-4
10.3389/fnins.2021.738220
10.3233/JAD-210283
10.2147/JIR.S316262
10.1080/19490976.2022.2127446
10.3390/TOXINS9020052
10.1007/s12017-010-8128-4
10.3390/ani12060768
10.1038/s41467-020-16274-w
10.1016/j.isci.2020.101226
10.1194/jlr.R700019-JLR200
10.3390/molecules24061139
10.1080/08905436.2012.670832
10.4172/2155-9899.1000150
10.4103/injr.injr_210_20
10.3390/NU11092231
10.3390/nu11092231
10.1016/S0140-6736(21)00244-0
10.1016/j.imbio.2009.09.004
10.1152/physiolgenomics.00155.2005
10.2174/1573406413666170906123857
10.1038/s41598-019-47906-x
10.1093/brain/awab320
10.1186/s40168-019-0704-8
10.3390/nu11071660
10.1093/nar/gkab382
10.1371/journal.pone.0157513
10.1074/jbc.M115.679068
10.1172/JCI138519
10.1002/mnfr.201600120
10.3390/ijms22010330
10.1161/ATVBAHA.110.207449
10.1016/j.numecd.2018.03.007
10.1038/nri2974
10.1177/2055217319888767
10.1016/j.foodchem.2018.12.019
10.3390/molecules24152809
10.1016/j.jpba.2018.09.025
10.1371/journal.pgen.1009557
10.1016/j.tips.2016.10.006
10.21105/joss.01686
10.1093/nar/gkab1062
10.2741/2873
10.1186/s12974-022-02502-1
10.1007/s00018-020-03733-2
10.1073/pnas.2123265119
10.1155/2015/354671",<Element 'PubmedArticle' at 0x7f05dcaeef40>
69,36280440,HLDF-6 peptides exhibit neuroprotective effects in the experimental model of preclinical Parkinson's disease.,"The mechanisms of the neuroprotective action of the hexapeptides HLDF-6 encoded by the amino acid sequence 41-46 of Human Leukemia Differentiation Factor and its homoserine derivative HLDF-6H were studied in an experimental 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced model of Parkinson's disease (PD). C57Bl/6 mice received two intraperitoneal injections of 18 mg/kg MPTP-HCl, with an interval of 2 hours. MPTP-induced motor dysfunction was assessed using horizontal grid test. Our data show that chronic intranasal administration of peptides (3 weeks, 300 μg/kg/day) restored normal levels of dopamine and improved its turnover rates in the striatum. Furthermore, peptide administration increased serum estradiol levels and led to a significant improvement in motor functions in MPTP-treated mice. Additionally, peptide treatment increased the levels of mRNA encoding neurotrophin BDNF, but normalized the levels of mRNA encoding the inflammatory mediators TGFβ1, IL1β and IFNγ in the brain. Collectively, our behavioral and biochemical studies demonstrate that HLDF-6 peptides have a therapeutic potential for treating PD. We propose that HLDF-6 peptides may exert their neuroprotective mechanism, at least in part, by normalizing estradiol levels and modulating the expression of key factors involved in neurotrophic support and neuroinflammation.","[""Models of Parkinson's disease"", 'Neuroprotectors', 'Neurotrophic factors', 'Peptide HLDF-6', 'Test “Horizontal grid”']",Neuropeptides,2022-10-25,"[{'lastname': 'Zolotarev', 'firstname': 'Yurii A', 'initials': 'YA', 'affiliation': 'Institute of Molecular Genetics of National Research Center «Kurchatov Institute», Moscow, Russia. Electronic address: zolya@img.ras.ru.'}, {'lastname': 'Shram', 'firstname': 'Stanislav I', 'initials': 'SI', 'affiliation': 'Institute of Molecular Genetics of National Research Center «Kurchatov Institute», Moscow, Russia.'}, {'lastname': 'Dadayan', 'firstname': 'Aleksandr K', 'initials': 'AK', 'affiliation': 'Institute of Molecular Genetics of National Research Center «Kurchatov Institute», Moscow, Russia.'}, {'lastname': 'Dolotov', 'firstname': 'Oleg V', 'initials': 'OV', 'affiliation': 'Institute of Molecular Genetics of National Research Center «Kurchatov Institute», Moscow, Russia; Faculty of Biology, Lomonosov Moscow State University, Moscow, Russia.'}, {'lastname': 'Markov', 'firstname': 'Dmitriy D', 'initials': 'DD', 'affiliation': 'Institute of Molecular Genetics of National Research Center «Kurchatov Institute», Moscow, Russia.'}, {'lastname': 'Nagaev', 'firstname': 'Igor Yu', 'initials': 'IY', 'affiliation': 'Institute of Molecular Genetics of National Research Center «Kurchatov Institute», Moscow, Russia.'}, {'lastname': 'Kudrin', 'firstname': 'Vladimir S', 'initials': 'VS', 'affiliation': 'Zakusov Research Institute of Pharmacology, Moscow, Russia.'}, {'lastname': 'Narkevich', 'firstname': 'Viktor B', 'initials': 'VB', 'affiliation': 'Zakusov Research Institute of Pharmacology, Moscow, Russia.'}, {'lastname': 'Sokolov', 'firstname': 'Oleg Yu', 'initials': 'OY', 'affiliation': 'Mental Health Research Center, Moscow, Russia.'}, {'lastname': 'Kost', 'firstname': 'Natalya V', 'initials': 'NV', 'affiliation': 'Mental Health Research Center, Moscow, Russia.'}]",,,,Copyright © 2022. Published by Elsevier Ltd.,10.1016/j.npep.2022.102287,<Element 'PubmedArticle' at 0x7f05dc390b80>
70,"36261694
30267518
31612411
31553356
28819746
31847639
29173244
26217190
11098417
28867937
32273610
32631403
33975150
33739881
34302872
35044840
35811001
29185059
26183690
30878016
9364620
30336151
34639019
2864480
3923523
559941
15910803
13539004
33417225
32143600
35044840
32194190
23201176
25603858
27663583
26522512
27756905
26315757
33600831
34639204
29958998
22155655
15121188
27686571
18374609
30316917
27374162
23843538
33215390
23430475
27235079
32513972
1400118
24776635
17462789
10409573
23372143",Resistance Training Modulates Hippocampal Neuroinflammation and Protects Anxiety-Depression-like Dyad Induced by an Emotional Single Prolonged Stress Model.,"Stress is a triggering factor for anxious and depressive phenotypes. Exercise is known for its action on the central nervous system. This study aimed to evaluate the role of resistance exercise in an anxiety-depression-like dyad in a model of stress. Male Swiss mice (35-day-old) were exercised, three times a week for 4 weeks on nonconsecutive days. The resistance exercise consisted of climbing a 1-m-high ladder 15 times. After mice were subjected to an emotional single prolonged stress (Esps) protocol. Seven days later, they were subjected to anxiety and depression predictive behavioral tests. The results showed that exercised mice gain less weight than sedentary from weeks 3 to 5. Resistance exercise was effective against an increase in immobility time in the forced swim test and tail suspension test and a decrease in grooming time of mice subjected to Esps. Resistance exercise protected against the decrease in the percentage of open arms time and open arm entries, and the increase in the anxiety index in Esps mice. Four-week resistance exercise did not elicit an antidepressant/anxiolytic phenotype in non-stressed mice. Esps did not alter plasma corticosterone levels but increased the hippocampal glucocorticoid receptor content in mice. Resistance exercise protected against the decrease in hippocampal levels of tropomyosin kinase B (TRκB), the p-Akt/Akt, and the p-mTOR/mTOR ratios of Esps mice. Resistance exercise proved to be effective in decreasing hippocampal neuroinflammation in Esps mice. Resistance exercise protected against the increase in the hippocampal Akt/mTOR pathway and neuroinflammation, and anxiety/depression-like dyad in Esps exposed mice.","['Anxiety', 'Depression', 'Neuroinflammation', 'Resistance exercise', 'Stress']",Molecular neurobiology,2022-10-20,"[{'lastname': 'Jung', 'firstname': 'Juliano Ten Kathen', 'initials': 'JTK', 'affiliation': 'Laboratory of Synthesis, Reactivity, Pharmacological and Toxicological Evaluation of Organochalcogen Compounds, Department of Biochemistry and Molecular Biology, Center of Natural and Exact Sciences, Federal University of Santa Maria, Santa Maria, RS, 97105-900, Brazil.'}, {'lastname': 'Marques', 'firstname': 'Luiza Souza', 'initials': 'LS', 'affiliation': 'Laboratory of Synthesis, Reactivity, Pharmacological and Toxicological Evaluation of Organochalcogen Compounds, Department of Biochemistry and Molecular Biology, Center of Natural and Exact Sciences, Federal University of Santa Maria, Santa Maria, RS, 97105-900, Brazil.'}, {'lastname': 'Zborowski', 'firstname': 'Vanessa Angonesi', 'initials': 'VA', 'affiliation': 'Laboratory of Synthesis, Reactivity, Pharmacological and Toxicological Evaluation of Organochalcogen Compounds, Department of Biochemistry and Molecular Biology, Center of Natural and Exact Sciences, Federal University of Santa Maria, Santa Maria, RS, 97105-900, Brazil.'}, {'lastname': 'Silva', 'firstname': 'Guilherme Lutz', 'initials': 'GL', 'affiliation': 'Laboratory of Synthesis, Reactivity, Pharmacological and Toxicological Evaluation of Organochalcogen Compounds, Department of Biochemistry and Molecular Biology, Center of Natural and Exact Sciences, Federal University of Santa Maria, Santa Maria, RS, 97105-900, Brazil.'}, {'lastname': 'Nogueira', 'firstname': 'Cristina Wayne', 'initials': 'CW', 'affiliation': 'Laboratory of Synthesis, Reactivity, Pharmacological and Toxicological Evaluation of Organochalcogen Compounds, Department of Biochemistry and Molecular Biology, Center of Natural and Exact Sciences, Federal University of Santa Maria, Santa Maria, RS, 97105-900, Brazil.'}, {'lastname': 'Zeni', 'firstname': 'Gilson', 'initials': 'G', 'affiliation': 'Laboratory of Synthesis, Reactivity, Pharmacological and Toxicological Evaluation of Organochalcogen Compounds, Department of Biochemistry and Molecular Biology, Center of Natural and Exact Sciences, Federal University of Santa Maria, Santa Maria, RS, 97105-900, Brazil. gzeni@ufsm.br.'}]",,,,"© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.","10.1007/s12035-022-03069-x
10.24869/psyd.20s18.273
10.1007/S11033-019-05129-3
10.1007/S40279-017-0769-0
10.1080/00207454.2019.1679809
10.1017/S0033291717003336
10.1038/s41591-020-0863-y
10.1186/S12992-020-00589-W/TABLES/2
10.1089/JMF.2020.4766/ASSET/IMAGES/LARGE/JMF.2020.4766_FIGURE7.JPEG
10.1016/J.BBR.2021.113486
10.1016/J.BBR.2022.114004
10.1016/J.EXGER.2015.07.006
10.1016/S0306-4530(97)00045-0
10.1016/j.neuropharm.2018.10.019
10.1016/0165-0270(85)90031-7
10.1007/BF00428203
10.1038/266730a0
10.1016/j.ejphar.2005.03.029
10.1016/S0021-9258(18)70434-1
10.1016/J.BBR.2020.112591
10.1016/J.NEURES.2012.11.001
10.1093/ijnp/pyv006
10.1007/S12640-016-9673-X
10.1038/srep16024
10.1016/J.BRAINRES.2021.147373
10.1016/J.NEUROSCIENCE.2011.11.029
10.1016/J.MCN.2004.01.006
10.1016/j.nlm.2008.02.005
10.1016/J.BRAINRESBULL.2018.10.004
10.1016/J.BBR.2016.06.057
10.1523/JNEUROSCI.3541-12.2013
10.1007/S12035-020-02213-9/FIGURES/9
10.1007/s00441-013-1581-2
10.1097/00004583-199209000-00013
10.1038/nmeth.2935
10.1016/J.APPET.2007.03.007
10.1152/jappl.1999.87.1.183
10.1152/JAPPLPHYSIOL.01161.2012",<Element 'PubmedArticle' at 0x7f05dc370450>
71,36251234,Activation of Angiotensin-converting Enzyme 2 Protects Against Lipopolysaccharide-induced Glial Activation by Modulating Angiotensin-converting Enzyme 2/Angiotensin (1-7)/Mas Receptor Axis.,"Neuroinflammation is associated with activation of glial cells and pro-inflammatory arm of the central Renin Angiotensin System (RAS) namely, Angiotensin-Converting Enzyme/Angiotensin II/Angiotensin Type 1 Receptor (ACE/Ang II/AT1R) axis. Apart from this, another axis of RAS also exists, Angiotensin-Converting Enzyme 2/Angiotensin (1-7)/Mas Receptor (ACE2/Ang (1-7)/MasR), which counters ACE/Ang II/AT1R axis by showing anti-inflammatory properties. However, the role of ACE2/Ang (1-7)/MasR axis has not been explored in glial activation and neuroinflammation. Hence, the present study tries to unveil the role of ACE2/Ang (1-7)/MasR axis in lipopolysaccharide (LPS)-induced neuroinflammation using diminazene aceturate (DIZE), an ACE2 activator, in astroglial (C6) and microglial (BV2) cells as well as male SD rats. We found that ACE2 activation efficiently prevented LPS-induced changes by decreasing glial activation, inflammatory signaling, cell migration, ROS generation via upregulation of ACE2/Ang (1-7)/MasR signaling. In addition, activation of ACE2/Ang (1-7)/MasR axis by DIZE significantly suppressed the pro-inflammatory ACE/Ang II/AT1R axis by reducing Ang II level in neuroinflammatory conditions induced by LPS in both in vitro and in vivo. ACE2/Ang (1-7)/MasR axis activation further decreased mitochondrial depolarization and apoptosis, hence providing neuroprotection. Furthermore, to validate that the beneficial effect of the ACE2 activator was indeed through MasR, a selective MasR antagonist (A779) was used that significantly blocked the anti-inflammatory effect of ACE2 activation by DIZE. Hence, our study demonstrated that ACE2 activation imparted neuroprotection by enhancing ACE2/Ang (1-7)/MasR signaling which in turn decreased glial activation, neuroinflammation, and apoptosis and improved mitochondrial health.","['Angiotensin-Converting Enzyme 2', 'Glial activation', 'Mas receptor', 'Neuroinflammation', 'Renin Angiotensin System']",Molecular neurobiology,2022-10-18,"[{'lastname': 'Tiwari', 'firstname': 'Priya', 'initials': 'P', 'affiliation': 'Division of Pharmacology, CSIR- Central Drug Research Institute, Lucknow-226031, Uttar Pradesh, India.\nAcademy of Scientific and Innovative Research (AcSIR), Ghaziabad-201002, India.'}, {'lastname': 'Tiwari', 'firstname': 'Virendra', 'initials': 'V', 'affiliation': 'Division of Neuroscience and Ageing Biology, CSIR- Central Drug Research Institute, Lucknow-226031, Uttar Pradesh, India.\nAcademy of Scientific and Innovative Research (AcSIR), Ghaziabad-201002, India.'}, {'lastname': 'Gupta', 'firstname': 'Shivangi', 'initials': 'S', 'affiliation': 'Division of Neuroscience and Ageing Biology, CSIR- Central Drug Research Institute, Lucknow-226031, Uttar Pradesh, India.\nAcademy of Scientific and Innovative Research (AcSIR), Ghaziabad-201002, India.'}, {'lastname': 'Shukla', 'firstname': 'Shubha', 'initials': 'S', 'affiliation': 'Division of Neuroscience and Ageing Biology, CSIR- Central Drug Research Institute, Lucknow-226031, Uttar Pradesh, India.\nAcademy of Scientific and Innovative Research (AcSIR), Ghaziabad-201002, India.'}, {'lastname': 'Hanif', 'firstname': 'Kashif', 'initials': 'K', 'affiliation': 'Division of Pharmacology, CSIR- Central Drug Research Institute, Lucknow-226031, Uttar Pradesh, India. k_hanif@cdri.res.in.\nAcademy of Scientific and Innovative Research (AcSIR), Ghaziabad-201002, India. k_hanif@cdri.res.in.'}]",,,,"© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.","10.1007/s12035-022-03061-5
10.1016/j.exer.2019.05.020
10.3389/fnagi.2017.00129
10.1016/j.sjbs.2020.01.026
10.1016/j.neurobiolaging.2014.01.017
10.1007/s12035-015-9584-5
10.1007/s12035-017-0450-5
10.1021/acschemneuro.5b00274
10.1161/HYPERTENSIONAHA.114.04691
10.1111/j.1471-4159.2008.05723.x
10.1007/s00424-016-1875-9
10.1016/j.lfs.2016.09.006
10.1016/j.redox.2019.101295
10.1371/journal.pone.0048696
10.1167/iovs.14-13883
10.1161/HYPERTENSIONAHA.113.01337
10.1164/rccm.201205-0880OC
10.1038/srep08209
10.1161/HYPERTENSIONAHA.115.05185
10.1016/j.bbi.2014.12.003
10.18632/aging.103544
10.1007/s00401-019-02098-6
10.1111/j.1476-5381.2012.02105.x
10.2174/0929866527666191223143230
10.1016/j.bbi.2016.09.021
10.1186/s12974-018-1308-0
10.1111/1440-1681.13368
10.1016/j.biopha.2018.10.201
10.1016/j.biopha.2018.08.136
10.1097/FBP.0000000000000516
10.1016/B978-0-12-416618-9.00013-3
10.1007/s12035-018-1272-9
10.4049/jimmunol.179.10.7101
10.1007/s11010-020-03780-0
10.1186/s12974-017-0839-0
10.1177/039463201202500204
10.1016/j.phrs.2019.04.029
10.3389/fphar.2019.00318
10.2174/0929866527666191218091823
10.1007/s11906-014-0512-2
10.2147/DDDT.S252351
10.2119/molmed.2015.00022
10.1038/s41374-019-0289-7
10.1155/2012/169649
10.1152/ajprenal.00477.2006
10.1016/j.lfs.2020.117749
10.3389/fncel.2019.00263
10.1016/j.bbih.2020.100127
10.3389/fncel.2020.00209
10.1007/s00210-018-1523-3
10.1074/jbc.M513646200
10.3892/ijmm.2017.3252
10.1038/srep27911
10.1186/s12974-016-0489-7
10.3389/fncel.2017.00024
10.1186/s13046-019-1156-5
10.26355/eurrev_202004_20867
10.1016/j.brainres.2014.01.013
10.1016/j.sjbs.2014.04.003
10.2174/0929866522666151013130550
10.1111/jsm.12757
10.3892/mmr.2017.7152
10.1007/s12035-016-9857-7
10.1016/j.jneuroim.2010.07.023
10.1161/01.hyp.37.1.72
10.1161/01.hyp.27.3.523
10.1155/2020/6137521
10.3389/fncel.2018.00114
10.1016/j.neures.2006.06.005
10.1111/jcmm.14780
10.1093/qjmed/hcz206
10.1186/s12974-019-1689-8
10.4049/jimmunol.1102157
10.1155/2020/4213541
10.1016/j.bbrc.2017.11.055
10.3969/j.issn.1673-5374.2013.21.009
10.1097/MAJ.0000000000000506
10.1007/s11064-014-1460-6
10.1007/s10735-021-10011-3",<Element 'PubmedArticle' at 0x7f05db49ad10>
72,36244214,A high sucrose diet modifies brain oxylipins in a sex-dependent manner.,"Oxylipins have been implicated in many biological processes and diseases. Dysregulation of cerebral lipid homeostasis and altered lipid metabolites have been associated with the onset and progression of dementia. Although most dietary interventions have focused on modulation of dietary fats, the impact of a high sucrose diet on the brain oxylipin profile is unknown.
Male and female C57BL/6J mice were fed a high sucrose diet (HSD, 34%) in comparison to a control low sucrose diet (LSD, 12%) for 12 weeks beginning at 20 weeks of age. The profile of 53 free oxylipins was then measured in brain by ultra-high performance liquid chromatography tandem mass spectrometry. Serum glucose and insulin were measured enzymatically. We first assessed whether there were any effects of the diet on the brain oxylipin profile, then assessed for sex differences.
There were no differences in fasting serum glucose between the sexes for mice fed a HSD or in fasting serum insulin levels for mice on either diet. The HSD altered the brain oxylipin profile in both sexes in distinctly different patterns: there was a reduction in three oxylipins (by 47-61%) and an increase in one oxylipin (16%) all downstream of lipoxygenase enzymes in males and a reduction in eight oxylipins (by 14-94%) mostly downstream of cyclooxygenase activity in females. 9-oxo-ODE and 6-trans-LTB4 were most influential in the separation of the oxylipin profiles by diet in male mice, whereas 5-HEPE and 12-HEPE were most influential in the separation by diet in female mice. Oxylipins 9‑hydroxy-eicosatetraenoic acid (HETE), 11-HETE, and 15-HETE were higher in the brains of females, regardless of diet.
A HSD substantially changes brain oxylipins in a distinctly sexually dimorphic manner. Results are discussed in terms of potential mechanisms and links to metabolic disease. Sex and diet effects on brain oxylipin composition may provide future targets for the management of neuroinflammatory diseases, such as dementia.","['Brain', 'Dementia', 'High sucrose diet', 'Oxylipin', 'Sex differences']","Prostaglandins, leukotrienes, and essential fatty acids",2022-10-17,"[{'lastname': 'Norman', 'firstname': 'Jennifer E', 'initials': 'JE', 'affiliation': 'Division of Cardiovascular Medicine, Department of Internal Medicine, University of California, Davis, The Grove 1258, One Shields Avenue, Davis, CA 95616, USA. Electronic address: jenorman@ucdavis.edu.'}, {'lastname': 'Nuthikattu', 'firstname': 'Saivageethi', 'initials': 'S', 'affiliation': 'Division of Cardiovascular Medicine, Department of Internal Medicine, University of California, Davis, The Grove 1258, One Shields Avenue, Davis, CA 95616, USA.'}, {'lastname': 'Milenkovic', 'firstname': 'Dragan', 'initials': 'D', 'affiliation': 'Department of Nutrition, University of California, Davis, Meyer Hall 3143, One Shields Avenue, Davis, CA 95616, USA.'}, {'lastname': 'Rutledge', 'firstname': 'John C', 'initials': 'JC', 'affiliation': 'Division of Cardiovascular Medicine, Department of Internal Medicine, University of California, Davis, The Grove 1258, One Shields Avenue, Davis, CA 95616, USA.'}, {'lastname': 'Villablanca', 'firstname': 'Amparo C', 'initials': 'AC', 'affiliation': 'Division of Cardiovascular Medicine, Department of Internal Medicine, University of California, Davis, The Grove 1258, One Shields Avenue, Davis, CA 95616, USA.'}]",,"A HSD substantially changes brain oxylipins in a distinctly sexually dimorphic manner. Results are discussed in terms of potential mechanisms and links to metabolic disease. Sex and diet effects on brain oxylipin composition may provide future targets for the management of neuroinflammatory diseases, such as dementia.","There were no differences in fasting serum glucose between the sexes for mice fed a HSD or in fasting serum insulin levels for mice on either diet. The HSD altered the brain oxylipin profile in both sexes in distinctly different patterns: there was a reduction in three oxylipins (by 47-61%) and an increase in one oxylipin (16%) all downstream of lipoxygenase enzymes in males and a reduction in eight oxylipins (by 14-94%) mostly downstream of cyclooxygenase activity in females. 9-oxo-ODE and 6-trans-LTB4 were most influential in the separation of the oxylipin profiles by diet in male mice, whereas 5-HEPE and 12-HEPE were most influential in the separation by diet in female mice. Oxylipins 9‑hydroxy-eicosatetraenoic acid (HETE), 11-HETE, and 15-HETE were higher in the brains of females, regardless of diet.",Copyright © 2022. Published by Elsevier Ltd.,10.1016/j.plefa.2022.102506,<Element 'PubmedArticle' at 0x7f05db474810>
73,"36232883
21978149
24787343
24577438
20581331
17965656
29535781
26867125
34390739
28750350
30571942
15044630
25176008
1321574
18426493
15927245
14706563
11583811
20073408
18495297
18703042
23628488
24460677
27434506
34941749
34822611
9696476
28886007
23470532
25800044
32194554
33907040
31590042
33241000
25572198
22126967
10371588
21741621
22025055
24140886
19857996
35090951
19103881
19476641
16307586
12606768
28154473
25637536
25443294
29079445
35755780
35909222
35743229
12531232
9269686
12120094
8796867
32206297
25575710
24512946
28888771
11958852
21771590
28917977
6893963
7936715
942051
35656322
6877845",Crotalphine Modulates Microglia M1/M2 Phenotypes and Induces Spinal Analgesia Mediated by Opioid-Cannabinoid Systems.,"Pain is a worldwide public health problem and its treatment is still a challenge since clinically available drugs do not completely reverse chronic painful states or induce undesirable effects. Crotalphine is a 14 amino acids synthetic peptide that induces a potent and long-lasting analgesic effect on acute and chronic pain models, peripherally mediated by the endogenous release of dynorphin A and the desensitization of the transient receptor potential ankyrin 1 (TRPA1) receptor. However, the effects of crotalphine on the central nervous system (CNS) and the signaling pathway have not been investigated. Thus, the central effect of crotalphine was evaluated on the partial sciatic nerve ligation (PSNL)-induced chronic neuropathic pain model. Crotalphine (100 µg/kg, p.o.)-induced analgesia on the 14th day after surgery lasting up to 24 h after administration. This effect was prevented by intrathecal administration of CB1 (AM251) or CB2 (AM630) cannabinoid receptor antagonists. Besides that, crotalphine-induced analgesia was reversed by CTOP, nor-BNI, and naltrindole, antagonists of ","['M2 polarization', 'chronic pain', 'endogenous opioid release', 'glial cells', 'neuroimmune modulation', 'neuropathic pain']",International journal of molecular sciences,2022-10-15,"[{'lastname': 'Lopes', 'firstname': 'Flavia S R', 'initials': 'FSR', 'affiliation': 'Laboratory of Pain and Signaling, Butantan Institute, São Paulo 05503-900, Brazil.'}, {'lastname': 'Giardini', 'firstname': 'Aline C', 'initials': 'AC', 'affiliation': 'Laboratory of Pain and Signaling, Butantan Institute, São Paulo 05503-900, Brazil.'}, {'lastname': ""Sant'Anna"", 'firstname': 'Morena B', 'initials': 'MB', 'affiliation': 'Laboratory of Pain and Signaling, Butantan Institute, São Paulo 05503-900, Brazil.'}, {'lastname': 'Kimura', 'firstname': 'Louise F', 'initials': 'LF', 'affiliation': 'Laboratory of Pain and Signaling, Butantan Institute, São Paulo 05503-900, Brazil.'}, {'lastname': 'Bufalo', 'firstname': 'Michelle C', 'initials': 'MC', 'affiliation': 'Laboratory of Pain and Signaling, Butantan Institute, São Paulo 05503-900, Brazil.\nCenter of Excellence in New Target Discovery (CENTD), Instituto Butantan, São Paulo 05503-900, Brazil.'}, {'lastname': 'Vigerelli', 'firstname': 'Hugo', 'initials': 'H', 'affiliation': 'Center of Excellence in New Target Discovery (CENTD), Instituto Butantan, São Paulo 05503-900, Brazil.'}, {'lastname': 'Zambelli', 'firstname': 'Vanessa O', 'initials': 'VO', 'affiliation': 'Laboratory of Pain and Signaling, Butantan Institute, São Paulo 05503-900, Brazil.'}, {'lastname': 'Picolo', 'firstname': 'Gisele', 'initials': 'G', 'affiliation': 'Laboratory of Pain and Signaling, Butantan Institute, São Paulo 05503-900, Brazil.'}]",,,,,"10.3390/ijms231911571
10.1186/1471-2458-11-770
10.1016/j.pmr.2014.01.007
10.1038/nri3621
10.1177/1073858409360822
10.1038/nn1992
10.1155/2018/8179013
10.1111/bcpt.12567
10.1016/j.bcp.2021.114727
10.1016/j.intimp.2017.07.019
10.1016/j.neuron.2018.11.009
10.1124/mol.65.4.999
10.1111/bph.12895
10.1111/j.1749-6632.1992.tb25954.x
10.1111/j.1365-2826.2008.01671.x
10.1016/j.pbb.2005.01.021
10.1016/j.lfs.2003.09.038
10.1016/S0165-6147(00)01799-5
10.5055/jom.2009.0034
10.1016/j.peptides.2008.04.003
10.1016/j.ejphar.2008.07.053
10.1016/j.pbb.2013.04.012
10.1111/bph.12488
10.1097/j.pain.0000000000000669
10.3390/toxins13120912
10.3390/toxins13110827
10.1016/S0304-3959(98)00045-1
10.1038/nm.4397
10.1038/cddis.2013.54
10.1111/bph.13139
10.3389/fimmu.2020.00300
10.4103/1673-5374.313050
10.1016/j.molimm.2019.09.020
10.21037/atm-20-5838
10.1016/j.mayocp.2014.09.010
10.1097/FBP.0b013e32834eafbc
10.1016/S0140-6736(99)01307-0
10.1016/j.brainres.2011.06.022
10.1038/nri3086
10.1016/j.lfs.2013.10.005
10.1016/j.coph.2009.09.009
10.1016/j.neubiorev.2022.104544
10.1084/jem.20081880
10.1186/1744-8069-5-25
10.1111/j.1460-9568.2005.04451.x
10.1124/mol.63.3.607
10.1155/2017/5048616
10.1016/j.bbrc.2015.01.073
10.1016/j.neurobiolaging.2014.09.019
10.1016/j.bbi.2017.10.021
10.3389/fncel.2022.863836
10.1111/imr.13121
10.3390/ijms23126788
10.1016/S0301-0082(02)00128-4
10.1016/S1357-4310(97)01077-0
10.1038/nrd725
10.1016/1357-4310(96)88720-X
10.1186/s13578-020-00387-2
10.1016/S1474-4422(14)70251-0
10.1016/j.peptides.2013.10.012
10.1016/j.peptides.2017.08.009
10.1016/S0304-3940(02)00109-X
10.1016/j.ejphar.2011.06.057
10.1016/j.jep.2017.09.011
10.1016/0014-2999(80)90515-4
10.1016/0304-3959(94)90013-2
10.1016/0003-2697(76)90527-3
10.3389/fgene.2022.845747
10.1016/0304-3959(83)90201-4",<Element 'PubmedArticle' at 0x7f05db49bea0>
74,36200160,"The Protective Role of L-carnitine on Psychosocial Stress-induced Changes in Gene Expression and Protein Levels of Matrix Metalloproteinases, Serum Corticosterone in a Rat Model.","Psychosocial stress (STS) is a common stress in modern societies. Chronic STS is associated with the impairment of a broad range of cognitive functions in humans and with prolonged abnormalities in memory. Matrix metalloproteinases (MMPs), a protein family of zinccontaining endopeptidases, are essential in neuro-inflammation and involved in neurodegenerative diseases. L-Car possessed neuroprotective, antioxidant, and anti-inflammatory properties and was shown to modulate MMPs.
The current study aimed to examine the protective effect of L-Carnitine (L-CAR) on STSinduced changes in serum corticosterone levels, MMP-2, -9, and -12 protein and mRNA expression in the hippocampus as a possible mechanism for L-CAR protective effect on STS-induced memory impairment.
The chronic STS and L-CAR (300 mg/kg/day, i.p) were simultaneously administered for 6 weeks to adult male Wistar rats. Serum corticosterone and protein levels of MMP-2, -9 and -12 were evaluated using ELISA. Real-Time PCR techniques were used to determine the mRNA levels of MMP-2, -9 and -12 in the hippocampus.
The findings showed that serum corticosterone levels and MMP-2 and -9 protein levels were significantly increased (
STS induced elevations in corticosterone and MMP-2 and -9 levels in the hippocampus. L-CAR, on the other hand, exhibited protective effects against the STS-induced changes in MMP-2 and -9.","['Gene', 'Hippocampus', 'L-carnitine', 'Metalloproteinases', 'Psychosocial stress', 'corticosterone', 'expression']",CNS & neurological disorders drug targets,2022-10-07,"[{'lastname': ""Rababa'h"", 'firstname': 'Suzie Y', 'initials': 'SY', 'affiliation': 'Department of Biological Sciences, School of Science, The University of Jordan, Amman 11942, Jordan.\nDepartment of Medical Science, Irbid Faculty, Al-Balqa Applied University (BAU), Irbid 21110, Jordan.'}, {'lastname': 'Alzoubi', 'firstname': 'Karem H', 'initials': 'KH', 'affiliation': 'Department of Pharmacy Practice and Pharmacotherapeutics, University of Sharjah, Sharjah, UAE.\nDepartment of Clinical Pharmacy, Jordan University of Science and Technology, Irbid 22110, Jordan.'}, {'lastname': 'Hammad', 'firstname': 'Hana', 'initials': 'H', 'affiliation': 'Department of Biological Sciences, School of Science, The University of Jordan, Amman 11942, Jordan.'}, {'lastname': 'AlQuraan', 'firstname': 'Laiali', 'initials': 'L', 'affiliation': 'Department of Biology, Yarmouk University, Irbid 21163, Jordan.'}, {'lastname': ""Rababa'h"", 'firstname': 'Abeer M', 'initials': 'AM', 'affiliation': 'Department of Clinical Pharmacy, Jordan University of Science and Technology, Irbid 22110, Jordan.'}]",,"STS induced elevations in corticosterone and MMP-2 and -9 levels in the hippocampus. L-CAR, on the other hand, exhibited protective effects against the STS-induced changes in MMP-2 and -9.",The findings showed that serum corticosterone levels and MMP-2 and -9 protein levels were significantly increased (,"Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.",10.2174/1871527322666221005130026,<Element 'PubmedArticle' at 0x7f05db7a3bd0>
75,36191807,Protective role of IGF-1 and GLP-1 signaling activation in neurological dysfunctions.,"Insulin-like growth factor-1 (IGF-1), a pleiotropic polypeptide, plays an essential role in CNS development and maturation. Glucagon-like peptide-1 (GLP-1) is an endogenous incretin hormone that regulates blood glucose levels and fatty acid oxidation in the brain. GLP-1 also exhibits similar functions and growth factor-like properties to IGF-1, which is likely how it exerts its neuroprotective effects. Recent preclinical and clinical evidence indicate that IGF-1 and GLP-1, apart from regulating growth and development, prevent neuronal death mediated by amyloidogenesis, cerebral glucose deprivation, neuroinflammation and apoptosis through modulation of PI3/Akt kinase, mammalian target of rapamycin (mTOR) and mitogen-activated protein kinase (MAPK/ERK). IGF-1 resistance and GLP-1 deficiency impair protective cellular signaling mechanisms, contributing to the progression of neurodegenerative diseases. Over the past decades, IGF-1 and GLP-1 have emerged as an essential component of the neuronal system and as potential therapeutic targets for several neurodegenerative and neuropsychiatric dysfunctions. There is substantial evidence that IGF-1 and GLP-1 analogues penetrate the blood-brain barrier (BBB) and exhibit neuroprotective functions, including synaptic formation, neuronal plasticity, protein synthesis, and autophagy. Conclusively, this review represents the therapeutic potential of IGF-1 and GLP-1 signaling target activators in ameliorating neurological disorders.","['GLP-1', 'IGF-1', 'Neurodegeneration', 'Neurological dysfunctions', 'Neuroprotection']",Neuroscience and biobehavioral reviews,2022-10-04,"[{'lastname': 'Bhalla', 'firstname': 'Sonalika', 'initials': 'S', 'affiliation': 'Neuropharmacology Division, Department of Pharmacology, ISF College of Pharmacy, Moga, Punjab, India.'}, {'lastname': 'Mehan', 'firstname': 'Sidharth', 'initials': 'S', 'affiliation': 'Neuropharmacology Division, Department of Pharmacology, ISF College of Pharmacy, Moga, Punjab, India. Electronic address: sidharthmehan@isfcp.org.'}, {'lastname': 'Khan', 'firstname': 'Andleeb', 'initials': 'A', 'affiliation': 'Department of Pharmacology and Toxicology, College of Pharmacy, Jazan University, Jazan 45142, Saudi Arabia. Electronic address: ankhan@jazanu.edu.sa.'}, {'lastname': 'Rehman', 'firstname': 'Muneeb U', 'initials': 'MU', 'affiliation': 'Department of Clinical Pharmacy, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia.'}]",,,,Copyright © 2022 Elsevier Ltd. All rights reserved.,10.1016/j.neubiorev.2022.104896,<Element 'PubmedArticle' at 0x7f05db7d25e0>
76,36182043,Melatonin ameliorates lipopolysaccharide induced brain inflammation through modulation of oxidative status and diminution of cytokine rush in Danio rerio.,"Lipopolysaccharide (LPS) is known to induce inﬂammation and immunonomodulation in a piscine model of Danio rerio. Present study aimed to explore the ability of melatonin in attenuating LPS-induced oxidative damages using this model. In LPS-exposed fish, activation of stress marker MDA was observed in brain with corresponding augmentation of multiple pro-inflammatory cytokines (IL1β, IL6, IL10 and TNFα). In addition, it also showed marked increase in the levels of heat shock factor (HSF) and heat shock proteins (HSPs) in association with transcription factors (NF-kB and NRF2) and mitogen-activated protein kinases (MAPKs). The changes in the levels of these mediators are highly correlated with the induction of pro-inflammatory cytokines. In melatonin-treated fishes, significant amelioration of oxidative stress was observed with reduced levels of MDA and pro-inflammatory cytokines. Melatonin also modulated expression of HSPs that facilitated the brain to overcome inflammation-induced stress by directly initiating NFkB/NRF2 translocation. In summary, melatonin effectively functions to reduce stress induced inflammatory signalling through modulation of oxidative stress and protects the brain from the neuropathological insult.","['Cytokines', 'Inflammation', 'Lipopolysaccharide', 'Melatonin', 'Molecular chaperones']",Environmental toxicology and pharmacology,2022-10-02,"[{'lastname': 'Moniruzzaman', 'firstname': 'Mahammed', 'initials': 'M', 'affiliation': 'Department of Zoology, University of Calcutta, Kolkata 700019, India.'}, {'lastname': 'Maiti', 'firstname': 'Arpan Kumar', 'initials': 'AK', 'affiliation': 'Department of Zoology, University of North Bengal, Darjeeling 734013, India.'}, {'lastname': 'Chakraborty', 'firstname': 'Suman Bhusan', 'initials': 'SB', 'affiliation': 'Department of Zoology, University of Calcutta, Kolkata 700019, India.'}, {'lastname': 'Saha', 'firstname': 'Ishita', 'initials': 'I', 'affiliation': 'Department of Physiology, Medical College and Hospital, Kolkata, India.'}, {'lastname': 'Saha', 'firstname': 'Nimai Chandra', 'initials': 'NC', 'affiliation': ""Fisheries and Ecotoxicology Research Laboratory Vice Chancellor's Research Group, Department of Zoology, The University of Burdwan, Purba bardhaman, Burdwan 713104, West Bengal, India. Electronic address: fishtoxicology.bu@gmail.com.""}]",,,,Copyright © 2022 Elsevier B.V. All rights reserved.,10.1016/j.etap.2022.103983,<Element 'PubmedArticle' at 0x7f05da8e56d0>
77,36179902,Neuroprotective effect of Biochanin a against Bisphenol A-induced prenatal neurotoxicity in zebrafish by modulating oxidative stress and locomotory defects.,"Exogenous toxicants cause oxidative stress and damage to brain cells, resulting in inflammation. Neuroinflammation is important in the pathobiology of various neurological illnesses, including Alzheimer's disease (AD). In this context, Bisphenol A (BPA), a common toxin, causes oxidative damage and has been linked to neurological problems. An O-methylated isoflavone known as Biochanin A (5,7-dihydroxy-4'-methoxy-isoflavone, BCA) is considered to be a phytoestrogen, which is abundant in some legume plants and soy which have preventive effects against cancer, osteoporosis, menopausal symptoms and oxidative stress. However, the mechanism by which BCA protected the prenatal neurological stress are not known. So that, in this study we investigated the BCA neuroprotective effect against BPA-induced neuroinflammation in zebrafish embryo models. For this study, fertilized zebrafish embryos are exposed to BPA (1 µM) with or without BCA. Our finding suggested that BCA co-exposure prevented the depletion of antioxidant defense enzymes by BPA and reduced the production of intracellular ROS production, superoxide anion (O","['Biochanin', 'Bisphenol', 'Neuroprotection', 'Neurotoxicity', 'Oxidative stress']",Neuroscience letters,2022-10-01,"[{'lastname': 'Haridevamuthu', 'firstname': 'B', 'initials': 'B', 'affiliation': 'Department of Biotechnology, College of Science and Humanities, SRM Institute of Science and Technology, Kattankulathur 603 203, Chennai, Tamil Nadu, India.'}, {'lastname': 'Guru', 'firstname': 'Ajay', 'initials': 'A', 'affiliation': 'Department of Conservative Dentistry and Endodontics, Saveetha Dental College and Hospitals, SIMATS, Chennai 600 077, Tamil Nadu, India.'}, {'lastname': 'Murugan', 'firstname': 'Raghul', 'initials': 'R', 'affiliation': 'Department of Biotechnology, College of Science and Humanities, SRM Institute of Science and Technology, Kattankulathur 603 203, Chennai, Tamil Nadu, India.'}, {'lastname': 'Sudhakaran', 'firstname': 'Gokul', 'initials': 'G', 'affiliation': 'Department of Biotechnology, College of Science and Humanities, SRM Institute of Science and Technology, Kattankulathur 603 203, Chennai, Tamil Nadu, India.'}, {'lastname': 'Pachaiappan', 'firstname': 'Raman', 'initials': 'R', 'affiliation': 'Department of Biotechnology, School of Bioengineering, College of Engineering and Technology, SRM Institute of Science and Technology, Kattankulathur 603 203, Chennai, Tamil Nadu, India.'}, {'lastname': 'Almutairi', 'firstname': 'Mikhlid H', 'initials': 'MH', 'affiliation': 'Department of Zoology, College of Science, King Saud University, P.O. Box: 2455, Riyadh 11451, Saudi Arabia.'}, {'lastname': 'Almutairi', 'firstname': 'Bader O', 'initials': 'BO', 'affiliation': 'Department of Zoology, College of Science, King Saud University, P.O. Box: 2455, Riyadh 11451, Saudi Arabia.'}, {'lastname': 'Juliet', 'firstname': 'Annie', 'initials': 'A', 'affiliation': 'Institute for Cellular and Molecular Biology, The University of Texas at Austin, University Station A4800, Austin TX 78712, USA.'}, {'lastname': 'Arockiaraj', 'firstname': 'Jesu', 'initials': 'J', 'affiliation': 'Department of Biotechnology, College of Science and Humanities, SRM Institute of Science and Technology, Kattankulathur 603 203, Chennai, Tamil Nadu, India. Electronic address: jesuaroa@srmist.edu.in.'}]",,,,Copyright © 2022 Elsevier B.V. All rights reserved.,10.1016/j.neulet.2022.136889,<Element 'PubmedArticle' at 0x7f05da8ea3b0>
78,"36153399
35025605
30873027
30679040
31862243
23630570
27540379
31616242
31653831
479903
28155867
32505212
16008534
28117398
30962427
27561251
20856166
17641465
30459766
26359987
35038645
29526318
26130320
34307460
16988050
17200195
23973746
33290962
30186285
30478397
9379342
17594069
19637229
32604956
31434983
33708223
34373202
21763768
33281456
22251552
34127024
24089628
22084596
18362914
29408249
18516065
29040756
28469467
22393127
20133677
22340513
25779966
26582988
11328886
12184808
31127785",Melatonin ameliorates disease severity in a mouse model of multiple sclerosis by modulating the kynurenine pathway.,"Melatonin (MT), a neurohormone with immunomodulatory properties, is one of the metabolites produced in the brain from tryptophan (TRP) that has already strong links with the neuropathogenesis of Multiple sclerosis (MS). However, the exact molecular mechanisms behind that are not fully understood. There is some evidence showing that MS and MT are interconnected via different pathways: Relapses of MS has a direct correlation with a low level of MT secretion and a growing body of evidence suggest that MT be therapeutic in Experimental Autoimmune Encephalomyelitis (EAE, a recognise animal model of MS) severity. Previous studies have demonstrated that the kynurenine pathway (KP), the main pathway of TRP catabolism, plays a key role in the pathogenesis of MS in humans and in EAE. The present study aimed to investigate whether MT can improve clinical signs in the EAE model by modulating the KP. C57BL/6 mice were induced with EAE and received different doses of MT. Then the onset and severity of EAE clinical symptoms were recorded. Two biological factors, aryl hydrocarbon receptor (AhR) and NAD",[],Scientific reports,2022-09-25,"[{'lastname': 'Jand', 'firstname': 'Yahya', 'initials': 'Y', 'affiliation': 'Department of Pharmacology, School of Medicine, Tehran University of Medical Sciences, P.O. Box 13145-784, Tehran, Iran.'}, {'lastname': 'Ghahremani', 'firstname': 'Mohammad Hossein', 'initials': 'MH', 'affiliation': 'Department of Pharmacology and Toxicology, Faculty of Pharmacy, University of Medical Sciences, Tehran, Iran.'}, {'lastname': 'Ghanbari', 'firstname': 'Amir', 'initials': 'A', 'affiliation': 'Cellular and Molecular Research Center, Yasuj University of Medical Sciences, Yasuj, Iran.'}, {'lastname': 'Ejtemaei-Mehr', 'firstname': 'Shahram', 'initials': 'S', 'affiliation': 'Department of Pharmacology, School of Medicine, Tehran University of Medical Sciences, P.O. Box 13145-784, Tehran, Iran.'}, {'lastname': 'Guillemin', 'firstname': 'Gilles J', 'initials': 'GJ', 'affiliation': 'Neuroinflammation Group, Faculty of Medicine and Health Sciences, Macquarie University, Sydney, NSW, Australia.'}, {'lastname': 'Ghazi-Khansari', 'firstname': 'Mahmoud', 'initials': 'M', 'affiliation': 'Department of Pharmacology, School of Medicine, Tehran University of Medical Sciences, P.O. Box 13145-784, Tehran, Iran. ghazikha@tums.ac.ir.'}]",,,,© 2022. The Author(s).,"10.1038/s41598-022-20164-0
10.1126/science.abj8222
10.3389/fphar.2019.00147
10.1016/j.molmed.2019.11.003
10.1371/journal.pone.0059749
10.3389/fimmu.2016.00246
10.3389/fnins.2019.01013
10.1038/s41467-019-12776-4
10.1136/jnnp.42.7.640
10.1038/srep41473
10.1186/s12974-020-01844-y
10.1111/j.1600-0404.2005.00442.x
10.1038/srep41271
10.1038/s41419-019-1556-7
10.1002/bies.201600018
10.1203/PDR.0b013e3181fcb40b
10.1269/jrr.06070
10.3389/fimmu.2018.02484
10.1016/j.cell.2015.08.025
10.1016/j.msard.2022.103520
10.1016/j.nrl.2018.01.007
10.1016/j.bbi.2015.06.021
10.3389/fmolb.2021.703532
10.1523/jneurosci.2116-06.2006
10.2353/ajpath.2007.060683
10.1016/j.brainres.2013.08.025
10.1016/j.intimp.2020.107092
10.3389/fimmu.2018.01914
10.1038/s41590-018-0255-3
10.1111/j.1600-079x.1997.tb00330.x
10.1007/s00109-007-0229-7
10.1002/eji.200939535
10.3390/cells9061564
10.1038/s41598-019-48635-x
10.3389/fimmu.2021.636081
10.1016/j.molmed.2021.07.006
10.1016/j.ntt.2011.07.002
10.1177/1178646920970902
10.1111/j.1742-4658.2012.08493.x
10.1186/s12974-021-02175-2
10.1155/2013/104024
10.4137/ijtr.s4294
10.1038/nature06881
10.1016/j.phrs.2018.01.022
10.1038/cr.2008.63
10.1093/toxsci/kfx215
10.1177/1178646917691738
10.1084/jem.20110698
10.1073/pnas.0912531107
10.1179/1351000212y.0000000001
10.1016/j.neuroscience.2015.03.016
10.3389/fnagi.2015.00196
10.1093/nar/29.9.e45
10.1186/gb-2002-3-7-research0034
10.3233/jad-190049",<Element 'PubmedArticle' at 0x7f05da903180>
79,36150527,Anandamide and other N-acylethanolamines: A class of signaling lipids with therapeutic opportunities.,"N-acylethanolamines (NAEs), including N-palmitoylethanolamine (PEA), N-oleoylethanolamine (OEA), N-arachidonoylethanolamine (AEA, anandamide), N-docosahexaenoylethanolamine (DHEA, synaptamide) and their oxygenated metabolites are a lipid messenger family with numerous functions in health and disease, including inflammation, anxiety and energy metabolism. The NAEs exert their signaling role through activation of various G protein-coupled receptors (cannabinoid CB",[],Progress in lipid research,2022-09-24,"[{'lastname': 'Mock', 'firstname': 'Elliot D', 'initials': 'ED', 'affiliation': 'Department of Molecular Physiology, Leiden Institute of Chemistry, Leiden University and Oncode Institute, Einsteinweg 55, Leiden 2333 CC, The Netherlands.'}, {'lastname': 'Gagestein', 'firstname': 'Berend', 'initials': 'B', 'affiliation': 'Department of Molecular Physiology, Leiden Institute of Chemistry, Leiden University and Oncode Institute, Einsteinweg 55, Leiden 2333 CC, The Netherlands.'}, {'lastname': 'van der Stelt', 'firstname': 'Mario', 'initials': 'M', 'affiliation': 'Department of Molecular Physiology, Leiden Institute of Chemistry, Leiden University and Oncode Institute, Einsteinweg 55, Leiden 2333 CC, The Netherlands. Electronic address: m.van.der.stelt@chem.leidenuniv.nl.'}]",,,,Copyright © 2022 The Authors. Published by Elsevier Ltd.. All rights reserved.,10.1016/j.plipres.2022.101194,<Element 'PubmedArticle' at 0x7f05dd00a0e0>
80,36126456,Protein tyrosine phosphatase 1B (PTP1B) as a potential therapeutic target for neurological disorders.,"Protein tyrosine phosphatase 1B (PTP1B) is a typical member of the PTP family, considered a direct negative regulator of several receptor and receptor-associated tyrosine kinases. This widely localized enzyme has been involved in the pathophysiology of several diseases. More recently, PTP1B has attracted attention in the field of neuroscience, since its activation in brain cells can lead to schizophrenia-like behaviour deficits, anxiety-like effects, neurodegeneration, neuroinflammation and depression. Conversely, PTP1B inhibition has been shown to prevent microglial activation, thus exerting a potent anti-inflammatory effect and has also shown potential to increase the cognitive process through the stimulation of hippocampal insulin, leptin and BDNF/TrkB receptors. Notwithstanding, most research on the clinical efficacy of targeting PTP1B has been developed in the field of obesity and type 2 diabetes mellitus (TD2M). However, despite the link existing between these metabolic alterations and neurodegeneration, no clinical trials assessing the neurological advantages of PTP1B inhibition have been performed yet. Preclinical studies, though, have provided strong evidence that targeting PTP1B could allow to reach different pathophysiological mechanisms at once. herefore, specific interventions or trials should be designed to modulate PTP1B activity in brain, since it is a promising strategy to decelerate or prevent neurodegeneration in aged individuals, among other neurological diseases. The present paper fails to include all neurological conditions in which PTP1B could have a role; instead, it focuses on those which have been related to metabolic alterations and neurodegenerative processes. Moreover, only preclinical data is discussed, since clinical studies on the potential of PTP1B inhibition for treating neurological diseases are still required.","['Alzheimer’s disease', 'Insulin receptor', 'Neurodegenerative diseases', 'Neuroinflammation', 'Neurological disorders', 'PTP1B', 'Type 2 diabetes']",Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie,2022-09-21,"[{'lastname': 'Olloquequi', 'firstname': 'Jordi', 'initials': 'J', 'affiliation': 'Department of Biochemistry and Physiology, Faculty of Pharmacy and Food Sciences, Universitat de Barcelona, Spain; Institute of Biomedical Sciences, Faculty of Health Sciences, Universidad Autónoma de Chile, Talca, Chile.'}, {'lastname': 'Cano', 'firstname': 'Amanda', 'initials': 'A', 'affiliation': 'Biomedical Research Networking Centre in Neurodegenerative Diseases (CIBERNED), Madrid, Spain; Department of Pharmacy, Pharmaceutical Technology and Physical Chemistry, Faculty of Pharmacy and Food Sciences, Universitat de Barcelona, Spain; Ace Alzheimer Center Barcelona - International University of Catalunya (UIC), Barcelona, Spain; Institute of Nanoscience and Nanotechnology (IN2UB), Universitat de Barcelona, Barcelona, Spain. Electronic address: acano@fundacioace.org.'}, {'lastname': 'Sanchez-López', 'firstname': 'Elena', 'initials': 'E', 'affiliation': 'Biomedical Research Networking Centre in Neurodegenerative Diseases (CIBERNED), Madrid, Spain; Department of Pharmacy, Pharmaceutical Technology and Physical Chemistry, Faculty of Pharmacy and Food Sciences, Universitat de Barcelona, Spain; Institute of Nanoscience and Nanotechnology (IN2UB), Universitat de Barcelona, Barcelona, Spain; Unit of Synthesis and Biomedical Applications of Peptides, IQAC-CSIC, 08034 Barcelona, Spain.'}, {'lastname': 'Carrasco', 'firstname': 'Marina', 'initials': 'M', 'affiliation': 'Biomedical Research Networking Centre in Neurodegenerative Diseases (CIBERNED), Madrid, Spain; Department of Pharmacology, Toxicology and Therapeutic Chemistry, Faculty of Pharmacy and Food Sciences, Universitat de Barcelona, Spain; Institut de Neurociències (UBNeuro), Universitat de Barcelona, Spain; Department of Biochemistry and Biotechnology, Rovira i Virgili University, Spain Unit of Biochemistry and Pharmacology, Faculty of Medicine and Health Sciences, Universitat Rovira i Virgili, Reus, 43201 Reus, Tarragona, Spain.'}, {'lastname': 'Verdaguer', 'firstname': 'Ester', 'initials': 'E', 'affiliation': 'Biomedical Research Networking Centre in Neurodegenerative Diseases (CIBERNED), Madrid, Spain; Institut de Neurociències (UBNeuro), Universitat de Barcelona, Spain; Department of Cellular Biology, Physiology and Immunology, Faculty of Biology, Universitat de Barcelona, Spain.'}, {'lastname': 'Fortuna', 'firstname': 'Ana', 'initials': 'A', 'affiliation': 'Laboratory of Pharmacology, Faculty of Pharmacy, University of Coimbra, Coimbra, Portugal; CIBIT/ICNAS - Coimbra Institute for Biomedical Imaging and Translational Research, University of Coimbra, Coimbra, Portugal.'}, {'lastname': 'Folch', 'firstname': 'Jaume', 'initials': 'J', 'affiliation': 'Biomedical Research Networking Centre in Neurodegenerative Diseases (CIBERNED), Madrid, Spain; Department of Biochemistry and Biotechnology, Rovira i Virgili University, Spain Unit of Biochemistry and Pharmacology, Faculty of Medicine and Health Sciences, Universitat Rovira i Virgili, Reus, 43201 Reus, Tarragona, Spain.'}, {'lastname': 'Bulló', 'firstname': 'Mònica', 'initials': 'M', 'affiliation': 'Department of Biochemistry and Biotechnology, Rovira i Virgili University, Spain Unit of Biochemistry and Pharmacology, Faculty of Medicine and Health Sciences, Universitat Rovira i Virgili, Reus, 43201 Reus, Tarragona, Spain; Institute of Health Pere Virgili-IISPV, Nutrition and Metabolic Disorders Research Group, 43204 Reus, Spain; CIBER Physiology of Obesity and Nutrition (CIBEROBN), Carlos III Health Institute, 28029 Madrid, Spain.'}, {'lastname': 'Auladell', 'firstname': 'Carme', 'initials': 'C', 'affiliation': 'Biomedical Research Networking Centre in Neurodegenerative Diseases (CIBERNED), Madrid, Spain; Institut de Neurociències (UBNeuro), Universitat de Barcelona, Spain; Department of Cellular Biology, Physiology and Immunology, Faculty of Biology, Universitat de Barcelona, Spain.'}, {'lastname': 'Camins', 'firstname': 'Antoni', 'initials': 'A', 'affiliation': 'Biomedical Research Networking Centre in Neurodegenerative Diseases (CIBERNED), Madrid, Spain; Department of Pharmacology, Toxicology and Therapeutic Chemistry, Faculty of Pharmacy and Food Sciences, Universitat de Barcelona, Spain; Institut de Neurociències (UBNeuro), Universitat de Barcelona, Spain. Electronic address: camins@ub.edu.'}, {'lastname': 'Ettcheto', 'firstname': 'Miren', 'initials': 'M', 'affiliation': 'Biomedical Research Networking Centre in Neurodegenerative Diseases (CIBERNED), Madrid, Spain; Department of Pharmacology, Toxicology and Therapeutic Chemistry, Faculty of Pharmacy and Food Sciences, Universitat de Barcelona, Spain; Institut de Neurociències (UBNeuro), Universitat de Barcelona, Spain. Electronic address: camins@ub.edu.'}]",,,,Copyright © 2022 The Authors. Published by Elsevier Masson SAS.. All rights reserved.,10.1016/j.biopha.2022.113709,<Element 'PubmedArticle' at 0x7f05dd0150e0>
81,"36096938
8866743
8871581
29672222
22932723
31274535
30652349
20874519
31490211
31437433
23763417
18838257
23432167
23603301
26527689
26264599
25973575
33036231
23593167
19262134
14582906
17641064
19295339
21645191
15908444
25407601
20052414
15326289
19442504
27536982
19498381
24838567
26205405
28338013
25880110
30111566
27960084
27882942
21609964
21423178
19011622
32731547
21235781
29081809
26891626
27596437
25484139
31676584
31484431
25135977
25135971
22246184
9475112
11106300
31114576
25378491
21463073
33019624
23962915
21876528
32872253
32155736
25977294
30011310
28636962
14998513
21481949
12125082
32323731
10869418
12555203
9133389
8406676
1750503
22551810
22156527
32525948
28552341
30818064
11011004
15285795
12672692
25715649
19137005
10706289
11081512
33785041
30238933
29408500
22586040
27145859
29571804
33446221
28692534
25836593
7188352
12843275
15579139
29082467
21228813
29337138
23667114
22610069
30626732
26126865
28660234
25828099
17103184
15495269
16796601
10674496
20482831
8528734
2295799
33293383
8780406
16893496
10216000
9225683
26538832
10822329
11413325
11598182
12639246
12742664
22093090
10640747
14607932
10731151
17589370
22133305
25933422
23963694
28456895
26937033
21830069
24400995
26607731
25389027
29194121
28276820
27561826
27792038
25199471
24969296
24356243
19857521
28870605
17158026
11315551
15233755
10350552
25896633
29892066
31530090
16825202",Chronic delta-9-tetrahydrocannabinol (THC) treatment counteracts SIV-induced modulation of proinflammatory microRNA cargo in basal ganglia-derived extracellular vesicles.,"Early invasion of the central nervous system (CNS) by human immunodeficiency virus (HIV) (Gray et al. in Brain Pathol 6:1-15, 1996; An et al. in Ann Neurol 40:611-6172, 1996), results in neuroinflammation, potentially through extracellular vesicles (EVs) and their micro RNAs (miRNA) cargoes (Sharma et al. in FASEB J 32:5174-5185, 2018; Hu et al. in Cell Death Dis 3:e381, 2012). Although the basal ganglia (BG) is a major target and reservoir of HIV in the CNS (Chaganti et al. in Aids 33:1843-1852, 2019; Mintzopoulos et al. in Magn Reson Med 81:2896-2904, 2019), whether BG produces EVs and the effect of HIV and/or the phytocannabinoid-delta-9-tetrahydrocannabinol (THC) on BG-EVs and HIV neuropathogenesis remain unknown.
We used the simian immunodeficiency virus (SIV) model of HIV and THC treatment in rhesus macaques (Molina et al. in AIDS Res Hum Retroviruses 27:585-592, 2011) to demonstrate for the first time that BG contains EVs (BG-EVs), and that BG-EVs cargo and function are modulated by SIV and THC. We also used primary astrocytes from the brains of wild type (WT) and CX3CR1
Significant changes in BG-EV-associated miRNA specific to SIV infection and THC treatment were observed. BG-EVs from SIV-infected rhesus macaques (SIV EVs) contained 11 significantly downregulated miRNAs. Remarkably, intervention with THC led to significant upregulation of 37 miRNAs in BG-EVs (SIV-THC EVs). Most of these miRNAs are predicted to regulate pathways related to inflammation/immune regulation, TLR signaling, Neurotrophin TRK receptor signaling, and cell death/response. BG-EVs activated WT and CX3CR1
Our findings reveal a role for BG-EVs as a vehicle with potential to disseminate HIV- and THC-induced changes within the CNS.","['Astrocytes', 'Basal ganglia', 'CX3CR1', 'Extracellular vesicles', 'Neuroinflammation', 'THC']",Journal of neuroinflammation,2022-09-13,"[{'lastname': 'Kaddour', 'firstname': 'Hussein', 'initials': 'H', 'affiliation': 'Department of Pharmacology, Stony Brook University Renaissance School of Medicine, Stony Brook, NY, 11794-8651, USA.\nRegeneron Pharmaceuticals, Inc., Tarrytown, NY, 10591, USA.'}, {'lastname': 'McDew-White', 'firstname': 'Marina', 'initials': 'M', 'affiliation': 'Host Pathogen Interaction Program, Southwest National Primate Research Center, Texas Biomedical Research Institute, San Antonio, TX, 78227-5302, USA.'}, {'lastname': 'Madeira', 'firstname': 'Miguel M', 'initials': 'MM', 'affiliation': 'Department of Pharmacology, Stony Brook University Renaissance School of Medicine, Stony Brook, NY, 11794-8651, USA.'}, {'lastname': 'Tranquille', 'firstname': 'Malik A', 'initials': 'MA', 'affiliation': 'Department of Pharmacology, Stony Brook University Renaissance School of Medicine, Stony Brook, NY, 11794-8651, USA.'}, {'lastname': 'Tsirka', 'firstname': 'Stella E', 'initials': 'SE', 'affiliation': 'Department of Pharmacology, Stony Brook University Renaissance School of Medicine, Stony Brook, NY, 11794-8651, USA.'}, {'lastname': 'Mohan', 'firstname': 'Mahesh', 'initials': 'M', 'affiliation': 'Host Pathogen Interaction Program, Southwest National Primate Research Center, Texas Biomedical Research Institute, San Antonio, TX, 78227-5302, USA. mmohan@txbbiomed.org.'}, {'lastname': 'Okeoma', 'firstname': 'Chioma M', 'initials': 'CM', 'affiliation': 'Department of Pharmacology, Stony Brook University Renaissance School of Medicine, Stony Brook, NY, 11794-8651, USA. cokeoma@nymc.edu.\nDepartment of Pathology, Microbiology, and Immunology, New York Medical College, Valhalla, NY, 10595-1524, USA. cokeoma@nymc.edu.'}]",,,"Significant changes in BG-EV-associated miRNA specific to SIV infection and THC treatment were observed. BG-EVs from SIV-infected rhesus macaques (SIV EVs) contained 11 significantly downregulated miRNAs. Remarkably, intervention with THC led to significant upregulation of 37 miRNAs in BG-EVs (SIV-THC EVs). Most of these miRNAs are predicted to regulate pathways related to inflammation/immune regulation, TLR signaling, Neurotrophin TRK receptor signaling, and cell death/response. BG-EVs activated WT and CX3CR1",© 2022. The Author(s).,"10.1186/s12974-022-02586-9
10.1111/j.1750-3639.1996.tb00775.x
10.1002/ana.410400411
10.1096/fj.201701558R
10.1038/cddis.2012.114
10.1097/QAD.0000000000002300
10.1002/mrm.27635
10.1089/aid.2010.0218
10.1097/QAD.0000000000002296
10.1016/j.neuropharm.2019.107740
10.2105/AJPH.2012.301162
10.1016/j.etp.2008.08.001
10.1016/j.imlet.2013.04.003
10.1074/jbc.M115.694133
10.1186/s12967-015-0623-9
10.1038/srep09991
10.1371/journal.pone.0060122
10.4161/cam.1.3.5114
10.1183/09031936.03.00041703
10.4049/jimmunol.179.3.1969
10.1097/QAI.0b013e3181900129
10.1111/j.1600-0854.2011.01225.x
10.1093/intimm/dxh267
10.1186/s12977-014-0102-z
10.1371/journal.pone.0008577
10.1073/pnas.0403453101
10.1016/j.ceb.2009.03.007
10.1097/QAD.0000000000001236
10.1038/nri2567
10.1093/nar/gku347
10.3390/v7072810
10.1038/srep45034
10.1016/j.virol.2015.03.040
10.1016/j.ccell.2016.10.009
10.1038/cddis.2016.336
10.1093/nar/gkr254
10.1038/ncb2210
10.1038/ncb1800
10.3390/ijms21155361
10.1186/1479-5876-9-9
10.1155/2017/1719050
10.1038/nrn.2015.29
10.15252/emmm.201606271
10.1002/cbin.10401
10.1074/mcp.RA119.001594
10.3390/cells8091027
10.1098/rstb.2013.0510
10.1038/emboj.2011.489
10.3109/13550289709031186
10.1177/026988110001400305
10.3389/fimmu.2019.00914
10.1128/JVI.01754-14
10.1037/a0023000
10.3390/v12101117
10.3390/cancers12092448
10.3390/molecules25051188
10.1093/nar/gkv403
10.1371/journal.pone.0200602
10.1016/j.immuni.2017.06.006
10.1016/j.micinf.2003.11.006
10.1016/j.jneuroim.2011.03.005
10.1002/jnr.10304
10.1073/pnas.090017497
10.1002/glia.10181
10.1523/JNEUROSCI.17-10-03664.1997
10.1002/glia.440080203
10.1093/infdis/jis326
10.1128/JVI.06266-11
10.1371/journal.ppat.1008381
10.1016/j.mcn.2017.05.009
10.1016/j.nbd.2019.02.020
10.1016/S0006-8993(00)02725-6
10.1186/1742-2094-1-7
10.1101/gad.1074403
10.15252/embj.201489504
10.1038/nmeth.1294
10.1038/35002607
10.1038/35040556
10.1186/s13000-021-01089-0
10.12659/MSM.909093
10.1016/j.brainres.2018.01.032
10.4049/jimmunol.1101196
10.1038/srep25341
10.1016/j.ejrad.2018.01.025
10.1186/s13046-020-01813-6
10.1097/QAD.0000000000001595
10.1016/j.jconrel.2015.03.033
10.1002/j.1460-2075.1982.tb01207.x
10.1523/JNEUROSCI.23-13-05715.2003
10.1111/j.1460-9568.2004.03764.x
10.1007/s12031-017-0994-x
10.1038/gene.2010.53
10.1016/j.cmet.2017.12.007
10.4049/jimmunol.1202496
10.1038/nn.3113
10.1074/jbc.RA119.007389
10.1038/jcbfm.2015.154
10.1038/ncomms7716
10.1007/s00427-006-0116-1
10.1002/path.1645
10.1111/j.1365-2362.2006.01657.x
10.1097/00001756-200002070-00037
10.1186/1742-2094-7-30
10.1097/00042560-199601010-00008
10.1046/j.1365-2990.1999.00167.x
10.1002/ana.410420108
10.1155/2015/620581
10.3109/13550280009013159
10.1128/JVI.75.14.6572-6583.2001
10.1091/mbc.12.10.2934
10.1089/088922203762688612
10.1016/S0165-5728(03)00117-6
10.1186/1750-1326-6-78
10.4049/jimmunol.164.3.1333
10.4049/jimmunol.171.10.5305
10.1126/science.287.5461.2274
10.1097/QAI.0b013e31811ed205
10.1016/j.brainres.2011.11.001
10.1371/journal.pone.0125088
10.1007/s13181-013-0325-8
10.1007/s10461-017-1782-x
10.1128/JVI.00189-16
10.1007/s11481-011-9301-8
10.1089/aid.2013.0182
10.1007/s11481-015-9645-6
10.1111/dar.12223
10.1097/QAD.0000000000001704
10.1080/17474124.2017.1292851
10.1111/nmo.12931
10.1097/MEG.0000000000000779
10.1038/ajg.2014.245
10.1159/000358155
10.1159/000356512
10.1016/j.antiviral.2009.10.016
10.1016/j.neures.2017.08.009
10.1016/j.bbi.2006.10.007
10.1007/s002210000630
10.1111/j.1460-9568.2004.03514.x
10.1016/S0006-8993(99)01326-8
10.1007/s10753-015-0168-3
10.1038/s41591-018-0051-5
10.1080/15384101.2019.1667189
10.1093/brain/awl165",<Element 'PubmedArticle' at 0x7f05dcff99a0>
82,"36078099
30479916
27147970
28979667
29998371
18980476
27957787
18790013
25278785
31997824
23477737
34948371
18059979
17662717
17071951
8989657
29311826
25266700
15115592
15037862
28672950
29130941
25939377
31843491
34685763
12794745
22824323
30705270
27220367
20085927
16374800
33578421
33745920
11406187
30206190
30471926
33085226
34132743
35149686
35232960
29196042
26582736
21674586
24722853
19158301
9219976
15763246
15992367
10931531
4378090
26377802
25902336
15684769
24583148
27153777
25972240
26796989
17912625
21806470
26122134
17111361
22154967
24972324
19878566
16038625
23317037
24975034
18572364
21559863
22968128
19036970
16129904
25473931
29051850
22842524
18029549
16918386
12675973
18971481
20849956
14753477
27764754
25243650
15217394
20457564
24166720
19441883
26790672
18438913
27736748
29957379
19444307
32710081
11923434
25017893
15084655
17439492
11378514
12429857
27309476
27306339
27965141
25309797
18634597
19620309
25788907
28041951
22745823
25190142
18191837
22902590
18408713
24561219
23403365
19670441
8534265
21138398
32164967
32676138
20440299
26722386
18974065
29055745
26791582
21151161
27573340
1731369
19831872
15009633
20817464
23236036
27847197
28482882
20400636
29159201
27509306
21251802
17703359
19469692
27563878
28085005
24220051
12600901
24344836
24866054
16633368
20954833
27909916
24685114
20382225
33358981
29860396
22920456
28330471",Inflammation: A Target for Treatment in Spinal Cord Injury.,"Spinal cord injury (SCI) is a significant cause of disability, and treatment alternatives that generate beneficial outcomes and have no side effects are urgently needed. SCI may be treatable if intervention is initiated promptly. Therefore, several treatment proposals are currently being evaluated. Inflammation is part of a complex physiological response to injury or harmful stimuli induced by mechanical, chemical, or immunological agents. Neuroinflammation is one of the principal secondary changes following SCI and plays a crucial role in modulating the pathological progression of acute and chronic SCI. This review describes the main inflammatory events occurring after SCI and discusses recently proposed potential treatments and therapeutic agents that regulate inflammation after insult in animal models.","['cytokines', 'hormonal therapy', 'macrophages', 'microglia', 'natural compounds', 'neutrophils', 'pharmaceuticals', 'spinal cord']",Cells,2022-09-10,"[{'lastname': 'Freyermuth-Trujillo', 'firstname': 'Ximena', 'initials': 'X', 'affiliation': 'Unidad de Investigación Médica en Enfermedades Neurológicas, Hospital de Especialidades Dr. Bernardo Sepúlveda, Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Mexico City CP 06720, Mexico.\nPosgrado en Ciencias Biológicas, Universidad Nacional Autónoma de México, Mexico City CP 04510, Mexico.'}, {'lastname': 'Segura-Uribe', 'firstname': 'Julia J', 'initials': 'JJ', 'affiliation': 'Subdirección de Gestión de la Investigación, Hospital Infantil de México Federico Gómez, Secretaría de Salud, Mexico City CP 06720, Mexico.'}, {'lastname': 'Salgado-Ceballos', 'firstname': 'Hermelinda', 'initials': 'H', 'affiliation': 'Unidad de Investigación Médica en Enfermedades Neurológicas, Hospital de Especialidades Dr. Bernardo Sepúlveda, Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Mexico City CP 06720, Mexico.'}, {'lastname': 'Orozco-Barrios', 'firstname': 'Carlos E', 'initials': 'CE', 'affiliation': 'CONACyT-Unidad de Investigación Médica en Enfermedades Neurológicas, Hospital de Especialidades Dr. Bernardo Sepúlveda, Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Mexico City CP 06720, Mexico.'}, {'lastname': 'Coyoy-Salgado', 'firstname': 'Angélica', 'initials': 'A', 'affiliation': 'CONACyT-Unidad de Investigación Médica en Enfermedades Neurológicas, Hospital de Especialidades Dr. Bernardo Sepúlveda, Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Mexico City CP 06720, Mexico.'}]",,,,,"10.3390/cells11172692
10.1002/advs.201800529
10.3389/fncel.2016.00098
10.1007/s10143-018-1008-3
10.3171/FOC.2008.25.11.E2
10.1111/jcmm.13034
10.1016/j.neuroscience.2008.08.021
10.2147/CLEP.S68889
10.4103/1673-5374.274348
10.1016/j.immuni.2013.02.012
10.3390/ijms222413577
10.1016/j.cnr.2006.09.007
10.1016/j.expneurol.2007.06.009
10.1093/brain/awl296
10.1002/(sici)1096-9861(19970120)377:33.0.co;2-s
10.3389/fncel.2017.00391
10.1038/sc.2014.158
10.1089/089771504323004575
10.1038/sj.sc.3101603
10.3892/etm.2017.4505
10.1159/000484460
10.1111/bph.13179
10.1016/B978-0-12-804214-4.00008-7
10.1016/j.expneurol.2019.113143
10.3390/cells10102783
10.1002/cne.10736
10.1186/1742-2094-9-178
10.1038/s41467-019-08446-0
10.1186/s12974-016-0581-z
10.1093/brain/awp322
10.1002/cne.20827
10.1093/brain/awaa360
10.1016/j.expneurol.2021.113704
10.1016/s0028-3908(01)00019-3
10.15252/embr.201846171
10.1016/j.immuni.2018.11.004
10.1002/iid3.362
10.1084/jem.20210040
10.1038/s41467-022-28473-8
10.1038/s41392-022-00885-4
10.1016/j.jconrel.2017.11.044
10.1016/j.nano.2015.10.011
10.1002/ana.22421
10.1007/s10875-014-0021-8
10.1523/JNEUROSCI.4918-08.2009
10.1016/s0306-4522(97)00011-0
10.1016/j.ejphar.2005.01.033
10.1111/j.1471-4159.2005.03280.x
10.1002/1097-4547(20000815)61:43.0.CO;2-W
10.1016/0005-2744(71)90281-6
10.1186/s12974-015-0391-8
10.1016/j.taap.2015.04.004
10.1089/neu.2004.21.1778
10.1016/j.intimp.2014.02.017
10.1016/j.lfs.2016.05.004
10.1007/s12035-015-9203-5
10.1080/1028415X.2015.1103460
10.1007/s10571-007-9219-0
10.1089/neu.2011.1922
10.1016/j.intimp.2015.06.015
10.1002/cne.21149
10.1016/j.jep.2011.11.040
10.1016/j.molimm.2014.05.019
10.1186/1477-3155-7-8
10.1111/j.1745-7254.2005.00152.x
10.1186/1742-2094-10-6
10.1002/jnr.23429
10.1016/j.jvs.2008.04.011
10.1007/s10753-011-9341-5
10.1016/j.jpain.2012.06.007
10.1523/JNEUROSCI.3512-08.2008
10.1385/CRIAI:28:3:197
10.1039/C4FO00761A
10.1002/advs.201700034
10.1016/j.brainres.2012.07.037
10.1124/jpet.107.127746
10.2174/156720206778018776
10.1089/08977150360547116
10.1523/JNEUROSCI.3708-08.2008
10.1016/j.mcn.2010.09.001
10.1007/978-3-7091-0651-8_85
10.1016/j.biopha.2016.10.007
10.1055/s-0034-1389950
10.1111/j.0953-816X.2004.03441.x
10.1101/cshperspect.a001651
10.1007/s10072-013-1566-7
10.1089/jir.2008.0027
10.1007/s12035-016-9709-5
10.1002/jnr.21658
10.1242/dmm.025833
10.1016/j.jneuroim.2018.05.007
10.1038/nri2550
10.1038/s41467-020-17564-z
10.1523/JNEUROSCI.22-07-02690.2002
10.1016/j.expneurol.2014.04.023
10.1523/JNEUROSCI.0406-04.2004
10.1111/j.1460-9568.2007.05458.x
10.1016/s1471-4914(01)01993-1
10.1073/pnas.232565399
10.1016/j.neuropharm.2016.12.007
10.3803/EnM.2014.29.3.371
10.1017/S1740925X05000037
10.4049/jimmunol.0803362
10.4103/1673-5374.150640
10.1016/j.steroids.2016.12.011
10.1371/journal.pone.0039751
10.1038/cdd.2014.134
10.1016/j.expneurol.2007.11.025
10.1016/j.jconrel.2012.07.044
10.1038/nchembio.83
10.1016/j.neuroscience.2014.02.007
10.1016/j.neures.2013.01.004
10.1002/ana.21673
10.1016/0006-2952(95)02110-8
10.3109/00207454.2010.537415
10.1016/bs.podrm.2019.10.006
10.1155/2019/3642491
10.1016/j.nutres.2004.07.005
10.1038/sc.2010.45
10.1093/carcin/bgn244
10.1016/j.phrs.2017.10.008
10.3109/10799893.2015.1049358
10.1038/aps.2010.181
10.3892/mmr.2016.5651
10.1152/physrev.1992.72.1.101
10.1089/neu.2009.1044
10.1046/j.1471-4159.2003.02240.x
10.1016/j.jocn.2010.04.027
10.1136/bmj.e8346
10.1016/j.brainres.2016.11.015
10.1186/s12951-017-0272-7
10.1242/jeb.035162
10.1016/j.omtm.2017.10.001
10.1590/1414-431x20165319
10.1016/j.colsurfb.2010.12.034
10.1007/s11064-007-9426-6
10.1089/neu.2008.0725
10.3390/ijms17091380
10.1088/1741-2552/aa596b
10.1097/MOT.0000000000000026
10.1161/01.CIR.0000057525.13182.24
10.1186/1742-2094-10-155
10.3109/10715762.2014.927578
10.1097/01.fjc.0000167010.98177.78
10.3109/10715762.2010.526604
10.1007/s10103-016-2120-7
10.1111/cns.12258
10.1016/j.nbd.2010.04.003
10.1016/j.bbi.2020.12.013
10.1093/brain/awy128
10.1016/j.apmr.2012.04.032
10.1186/s12984-017-0232-3",<Element 'PubmedArticle' at 0x7f05dbb2ac70>
83,"36071461
27261683
16324087
28784102
9633736
31590282
31877873
22537481
31832624
21667161
27304890
22086365
23357160
31180581
10869055
18562509
30303037
29275977
10589540
27366236
27604620
16099294
23768729
12070050
15541283
11430999
26977423
20182574
35055321
26779181
21795588
16670296
30244922
24835393
22547654
29420590
28002679
30377816
32727835",Immunoadsorption versus double-dose methylprednisolone in refractory multiple sclerosis relapses.,"Intravenous methylprednisolone is the standard treatment for a multiple sclerosis relapse; however, this fails to improve symptoms in up to one quarter of patients. Immunoadsorption is an accepted treatment for refractory relapses, but prospective comparator-controlled studies are missing.
In this observational study, patients with steroid-refractory acute multiple sclerosis relapses receiving either six courses of tryptophan-immunoadsorption or double-dose methylprednisolone therapy were analysed. Outcomes were evaluated at discharge and three months later. Immune profiling of blood lymphocytes and proteomic analysis were performed by multi-parameter flow cytometry and Olink analysis, respectively (NCT04450030).
42 patients were enrolled (methylprednisolone: 26 patients; immunoadsorption: 16 patients). For determination of the primary outcome, treatment response was stratified according to relative function system score changes (""full/best"" vs. ""average"" vs. ""worse/none""). Upon discharge, the adjusted odds ratio for any treatment response (""full/best"" + ""average"" vs. ""worse/none"") was 10.697 favouring immunoadsorption (p = 0.005 compared to methylprednisolone). At follow-up, the adjusted odds ratio for the best treatment response (""full/best"" vs. ""average"" + ""worse/none"") was 103.236 favouring IA patients (p = 0.001 compared to methylprednisolone). Similar results were observed regarding evoked potentials and quality of life outcomes, as well as serum neurofilament light-chain levels. Flow cytometry revealed a profound reduction of B cell subsets following immunoadsorption, which was closely correlated to clinical outcomes, whereas methylprednisolone had a minimal effect on B cell populations. Immunoadsorption treatment skewed the blood cytokine network, reduced levels of B cell-related cytokines and reduced immunoglobulin levels as well as levels of certain coagulation factors.
Immunoadsorption demonstrated favourable outcomes compared to double-dose methylprednisolone. Outcome differences were significant at discharge and follow-up. Further analyses identified modulation of B cell function as a potential mechanism of action for immunoadsorption, as reduction of B cell subsets correlated with clinical improvement.","['Immunoadsorption', 'Intravenous methylprednisolone', 'Multiple sclerosis', 'Relapse', 'Steroids']",Journal of neuroinflammation,2022-09-08,"[{'lastname': 'Pfeuffer', 'firstname': 'Steffen', 'initials': 'S', 'affiliation': 'Department of Neurology and Institute of Translational Neurology, University Hospital Muenster, Albert-Schweitzer-Campus 1, 48149, Muenster, Germany.'}, {'lastname': 'Rolfes', 'firstname': 'Leoni', 'initials': 'L', 'affiliation': 'Department of Neurology and Institute of Translational Neurology, University Hospital Muenster, Albert-Schweitzer-Campus 1, 48149, Muenster, Germany.\nDepartment of Neurology, University Hospital Duesseldorf, Duesseldorf, Germany.'}, {'lastname': 'Wirth', 'firstname': 'Timo', 'initials': 'T', 'affiliation': 'Department of Neurology and Institute of Translational Neurology, University Hospital Muenster, Albert-Schweitzer-Campus 1, 48149, Muenster, Germany.'}, {'lastname': 'Steffen', 'firstname': 'Falk', 'initials': 'F', 'affiliation': 'Department of Neurology, University Hospital Mainz, Mainz, Germany.'}, {'lastname': 'Pawlitzki', 'firstname': 'Marc', 'initials': 'M', 'affiliation': 'Department of Neurology and Institute of Translational Neurology, University Hospital Muenster, Albert-Schweitzer-Campus 1, 48149, Muenster, Germany.\nDepartment of Neurology, University Hospital Duesseldorf, Duesseldorf, Germany.'}, {'lastname': 'Schulte-Mecklenbeck', 'firstname': 'Andreas', 'initials': 'A', 'affiliation': 'Department of Neurology and Institute of Translational Neurology, University Hospital Muenster, Albert-Schweitzer-Campus 1, 48149, Muenster, Germany.'}, {'lastname': 'Gross', 'firstname': 'Catharina C', 'initials': 'CC', 'affiliation': 'Department of Neurology and Institute of Translational Neurology, University Hospital Muenster, Albert-Schweitzer-Campus 1, 48149, Muenster, Germany.'}, {'lastname': 'Brand', 'firstname': 'Marcus', 'initials': 'M', 'affiliation': 'Medical Department D - Nephrology, University Hospital Muenster, Muenster, Germany.'}, {'lastname': 'Bittner', 'firstname': 'Stefan', 'initials': 'S', 'affiliation': 'Department of Neurology, University Hospital Mainz, Mainz, Germany.'}, {'lastname': 'Ruck', 'firstname': 'Tobias', 'initials': 'T', 'affiliation': 'Department of Neurology and Institute of Translational Neurology, University Hospital Muenster, Albert-Schweitzer-Campus 1, 48149, Muenster, Germany.\nDepartment of Neurology, University Hospital Duesseldorf, Duesseldorf, Germany.'}, {'lastname': 'Klotz', 'firstname': 'Luisa', 'initials': 'L', 'affiliation': 'Department of Neurology and Institute of Translational Neurology, University Hospital Muenster, Albert-Schweitzer-Campus 1, 48149, Muenster, Germany.'}, {'lastname': 'Wiendl', 'firstname': 'Heinz', 'initials': 'H', 'affiliation': 'Department of Neurology and Institute of Translational Neurology, University Hospital Muenster, Albert-Schweitzer-Campus 1, 48149, Muenster, Germany. Heinz.wiendl@ukmuenster.de.'}, {'lastname': 'Meuth', 'firstname': 'Sven G', 'initials': 'SG', 'affiliation': 'Department of Neurology and Institute of Translational Neurology, University Hospital Muenster, Albert-Schweitzer-Campus 1, 48149, Muenster, Germany. Sven.Meuth@uni-duesseldorf.de.\nDepartment of Neurology, University Hospital Duesseldorf, Duesseldorf, Germany. Sven.Meuth@uni-duesseldorf.de.'}]",,,"42 patients were enrolled (methylprednisolone: 26 patients; immunoadsorption: 16 patients). For determination of the primary outcome, treatment response was stratified according to relative function system score changes (""full/best"" vs. ""average"" vs. ""worse/none""). Upon discharge, the adjusted odds ratio for any treatment response (""full/best"" + ""average"" vs. ""worse/none"") was 10.697 favouring immunoadsorption (p = 0.005 compared to methylprednisolone). At follow-up, the adjusted odds ratio for the best treatment response (""full/best"" vs. ""average"" + ""worse/none"") was 103.236 favouring IA patients (p = 0.001 compared to methylprednisolone). Similar results were observed regarding evoked potentials and quality of life outcomes, as well as serum neurofilament light-chain levels. Flow cytometry revealed a profound reduction of B cell subsets following immunoadsorption, which was closely correlated to clinical outcomes, whereas methylprednisolone had a minimal effect on B cell populations. Immunoadsorption treatment skewed the blood cytokine network, reduced levels of B cell-related cytokines and reduced immunoglobulin levels as well as levels of certain coagulation factors.",© 2022. The Author(s).,"10.1186/s12974-022-02583-y
10.1111/j.1468-1331.2005.01352.x
10.1186/s12883-017-0927-x
10.1212/WNL.50.6.1833
10.3390/jcm8101623
10.3390/jcm9010035
10.1186/1742-2094-9-80
10.1016/j.eclinm.2019.10.017
10.1007/s00115-011-3324-5
10.1159/000447059
10.1159/000332397
10.1016/j.atherosclerosissup.2012.10.025
10.1093/brain/123.7.1431
10.1177/1352458507085758
10.1016/S1474-4422(17)30470-2
10.1002/1531-8249(199912)46:6<878::AID-ANA10>3.0.CO;2-Q
10.1177/1756285616637046
10.1007/s00415-016-8277-y
10.1016/S0140-6736(05)67102-4
10.1016/j.jneuroim.2013.05.010
10.1182/blood-2002-01-0128
10.1016/j.jim.2004.07.006
10.1016/S0165-5728(01)00330-7
10.1212/NXI.0000000000000207
10.4103/0972-2327.58283
10.3390/jpm12010006
10.3389/fimmu.2015.00170
10.1126/scitranslmed.3002400
10.4049/jimmunol.176.10.5890
10.1016/j.jneuroim.2018.09.001
10.4049/jimmunol.1300749
10.1084/jem.20111675
10.1371/journal.pone.0192516
10.1056/NEJMoa1601277
10.1007/s00415-018-9092-4
10.1212/WNL.0000000000010380",<Element 'PubmedArticle' at 0x7f05df6fd270>
84,36070663,Perillyl alcohol attenuates chronic restraint stress aggravated dextran sulfate sodium-induced ulcerative colitis by modulating TLR4/NF-κB and JAK2/STAT3 signaling pathways.,"Ulcerative colitis (UC) is the most prevalent chronic inflammatory immune bowel disease. The modernization of lifestyle accompanied by the stress to cope with the competition has resulted in a new range of complications where stress became a critical contributing factor for many diseases, including UC. Hence there is an urgent need to develop a dual role in curtailing both systemic and neuroinflammation. Perillyl alcohol (POH) is a natural essential oil found in lavender, peppermint, cherries etc and has been widely studied for its strong anti-inflammatory, antioxidant and anti-stress properties.
POH regulates the various inflammatory signaling cascades involved in chronic inflammation by inhibiting farnesyltransferase  enzyme. Several studies reported that POH could inhibit the phosphorylation of  NF-κB, STAT3 and promote the endogenous antioxidant enzymes like Nrf2 via farnesyltransferase enzyme inhibition.  Also, the effects of POH against UC is not known yet. Thus, this study aims to explore the anti-ulcerative properties of POH on stress aggravated ulcerative colitis in C57BL/6 mice.
Ulcerative colitis was induced by duel exposure of chronic restraint stress (day 1 to day 28) and 2.5% dextran sulphate sodium (day8 to day14) in mice. POH treatment 100 and 200 mg/kg was administred from day14 ti day28 following oral route of administration. Disease activity index, colonoscopy, western blot analysis and histological analysis, neurotransmitter analysis and Gene expression studies were perofomerd to asses the anti-colitis effects of POH.
The treatment reversed the oxidative stress and inflammatory response by inhibiting TLR4/NF-kB pathway, and IL-6/JAK2/STAT3 pathway in both isolated mice colons and brains. The inhibition of these pathways resulted in a decrease in pro-inflammatory cytokines like IL-6, IL-1β and TNF-α. The treatment improved the physiological and histological changes with decreased ulcerations as examined by colonic endoscopy and Haematoxylin and Eosin staining. The treatment also improved the behavior response as it increased mobility time which was reduced by chronic restrained stress. This was due to increased satiety neurotransmitters like dopamine and serotonin and decreased cortisol in mice brains.
These results infer that POH has significant anti-colitis activity on chronic restraint stress aggravated DSS-induced UC in mice.","['Perillyl alcohol', 'anti-inflammatory', 'chronic restraint stress', 'dextran sulfate sodium', 'neuroinflammation', 'ulcerative colitis']",Phytomedicine : international journal of phytotherapy and phytopharmacology,2022-09-08,"[{'lastname': 'Puppala', 'firstname': 'Eswara Rao', 'initials': 'ER', 'affiliation': 'Department of Pharmacology and Toxicology, National Institute of Pharmaceutical Education and Research (NIPER)-Guwahati, Assam, India, 781101.'}, {'lastname': 'Aochenlar', 'firstname': 'Sunepjungla L', 'initials': 'SL', 'affiliation': 'Department of Pharmacology and Toxicology, National Institute of Pharmaceutical Education and Research (NIPER)-Guwahati, Assam, India, 781101.'}, {'lastname': 'Shantanu', 'firstname': 'P A', 'initials': 'PA', 'affiliation': 'Department of Pharmacology and Toxicology, National Institute of Pharmaceutical Education and Research (NIPER)-Guwahati, Assam, India, 781101.'}, {'lastname': 'Ahmed', 'firstname': 'Sahabuddin', 'initials': 'S', 'affiliation': 'Department of Pharmacology and Toxicology, National Institute of Pharmaceutical Education and Research (NIPER)-Guwahati, Assam, India, 781101.'}, {'lastname': 'Jannu', 'firstname': 'Arun Kumar', 'initials': 'AK', 'affiliation': 'Department of Pharmacology and Toxicology, National Institute of Pharmaceutical Education and Research (NIPER)-Guwahati, Assam, India, 781101.'}, {'lastname': 'Jala', 'firstname': 'Aishwarya', 'initials': 'A', 'affiliation': 'Department of Pharmaceutical Analysis, National Institute of Pharmaceutical Education and Research (NIPER)-Guwahati, Assam, India, 781101.'}, {'lastname': 'Yalamarthi', 'firstname': 'Sai Sudha', 'initials': 'SS', 'affiliation': 'Department of Pharmacology and Toxicology, National Institute of Pharmaceutical Education and Research (NIPER)-Guwahati, Assam, India, 781101.'}, {'lastname': 'Borkar', 'firstname': 'Roshan M', 'initials': 'RM', 'affiliation': 'Department of Pharmaceutical Analysis, National Institute of Pharmaceutical Education and Research (NIPER)-Guwahati, Assam, India, 781101.'}, {'lastname': 'Tripathi', 'firstname': 'Dinesh Mani', 'initials': 'DM', 'affiliation': 'Department of Molecular and Cellular Medicine, Institute of Liver and Biliary sciences (ILBS), New Delhi, Delhi 110070.'}, {'lastname': 'Naidu', 'firstname': 'V G M', 'initials': 'VGM', 'affiliation': 'Department of Pharmacology and Toxicology, National Institute of Pharmaceutical Education and Research (NIPER)-Guwahati, Assam, India, 781101. Electronic address: vgmnaidu@gmail.com.'}]",,These results infer that POH has significant anti-colitis activity on chronic restraint stress aggravated DSS-induced UC in mice.,"The treatment reversed the oxidative stress and inflammatory response by inhibiting TLR4/NF-kB pathway, and IL-6/JAK2/STAT3 pathway in both isolated mice colons and brains. The inhibition of these pathways resulted in a decrease in pro-inflammatory cytokines like IL-6, IL-1β and TNF-α. The treatment improved the physiological and histological changes with decreased ulcerations as examined by colonic endoscopy and Haematoxylin and Eosin staining. The treatment also improved the behavior response as it increased mobility time which was reduced by chronic restrained stress. This was due to increased satiety neurotransmitters like dopamine and serotonin and decreased cortisol in mice brains.",Copyright © 2022 Elsevier GmbH. All rights reserved.,10.1016/j.phymed.2022.154415,<Element 'PubmedArticle' at 0x7f05da9b3e50>
85,"36009055
28716255
20070435
27054030
14643375
15037694
1789684
12399581
26555572
21645391
26718584
27662322
31925823
32485235
8421494
21606570
30372679
23423358
25295005
34385602
28713250
35713198
27929004
35314851
27840659
30498753
29062035
28959956
20581818
22805374
32538836
20533377
32273328
11493163
10436342
8740626
21073671
15633942
34373529
27438089
29315334
23543794
27844039
25716012
17882012
15619128
12165466
24962261
27889895
34140881
30530995
24217521
23686809
24927875
29163013
27333343
16896307
28165465
22521461
31016348
14755726
1347673
15056468
17346749
28302159
24844438
30288203
27539936
26965148
15465922
17876300
19386271
12360213
21255263
22414817
22912680
25106636
18263732
25205418
28807673
30354245
27488130
28779174
28336953
33802689
24312564
14517174
26490328
27084583
28957663
30417826
27829687
25768340
23834189
33347668
23844686
24246048
27701827
26295827
23880066
31396087
35625595
22405189
23394526
25210802
28939905
35740258
25801844
25765918
29576849
26260027
30970677
8096161
30266286
32033363
35686025
28861501
32471239
22998138
26929355
26820462
32623398
33441154
31835422
33297460
32946657",Synaptic Effects of Palmitoylethanolamide in Neurodegenerative Disorders.,"Increasing evidence strongly supports the key role of neuroinflammation in the pathophysiology of neurodegenerative diseases, such as Alzheimer's disease, frontotemporal dementia, and amyotrophic lateral sclerosis. Neuroinflammation may alter synaptic transmission contributing to the progression of neurodegeneration, as largely documented in animal models and in patients' studies. In the last few years, palmitoylethanolamide (PEA), an endogenous lipid mediator, and its new composite, which is a formulation constituted of PEA and the well-recognized antioxidant flavonoid luteolin (Lut) subjected to an ultra-micronization process (co-ultraPEALut), has been identified as a potential therapeutic agent in different disorders by exerting potential beneficial effects on neurodegeneration and neuroinflammation by modulating synaptic transmission. In this review, we will show the potential therapeutic effects of PEA in animal models and in patients affected by neurodegenerative disorders.","['Alzheimer’s disease', 'PEA', 'amyotrophic lateral sclerosis', 'endocannabinoids', 'frontotemporal dementia', 'neurodegeneration', 'neuroinflammation', 'synaptic plasticity', 'transcranial magnetic stimulation']",Biomolecules,2022-08-27,"[{'lastname': 'Assogna', 'firstname': 'Martina', 'initials': 'M', 'affiliation': 'Department of Clinical and Behavioural Neurology, Santa Lucia Foundation IRCCS, 00179 Rome, Italy.\nMemory Clinic, Department of Systems Medicine, University of Tor Vergata, 00133 Rome, Italy.'}, {'lastname': 'Di Lorenzo', 'firstname': 'Francesco', 'initials': 'F', 'affiliation': 'Department of Clinical and Behavioural Neurology, Santa Lucia Foundation IRCCS, 00179 Rome, Italy.'}, {'lastname': 'Martorana', 'firstname': 'Alessandro', 'initials': 'A', 'affiliation': 'Department of Clinical and Behavioural Neurology, Santa Lucia Foundation IRCCS, 00179 Rome, Italy.\nMemory Clinic, Department of Systems Medicine, University of Tor Vergata, 00133 Rome, Italy.'}, {'lastname': 'Koch', 'firstname': 'Giacomo', 'initials': 'G', 'affiliation': 'Department of Clinical and Behavioural Neurology, Santa Lucia Foundation IRCCS, 00179 Rome, Italy.\nDepartment of Neuroscience and Rehabilitation, University of Ferrara, 44121 Ferrara, Italy.'}]",,,,,"10.3390/biom12081161
10.1016/j.jns.2017.06.030
10.1111/j.1582-4934.2010.01010.x
10.1186/s40035-016-0054-4
10.1016/j.neurobiolaging.2003.08.002
10.1212/01.WNL.0000115115.98960.37
10.1002/ana.410300410
10.1126/science.1074069
10.1111/cns.12476
10.1186/1750-1326-6-39
10.1016/j.jalz.2015.10.009
10.3233/JAD-160763
10.1002/ana.25677
10.1016/j.brs.2020.05.013
10.1038/361031a0
10.3233/JAD-2011-110116
10.3233/JAD-180503
10.3389/fnagi.2013.00002
10.3389/fnagi.2014.00254
10.1038/s41380-021-01257-0
10.3389/fnsys.2017.00048
10.1002/ana.26444
10.1038/nature20587
10.1038/s42003-022-03169-3
10.1111/cen3.12307
10.1155/2018/3087475
10.1038/s41598-017-14204-3
10.1038/nature24016
10.1038/nn.2583
10.1186/1756-6606-5-25
10.3233/JAD-191250
10.1002/jnr.22392
10.1136/jnnp-2019-322493
10.1001/archneur.58.8.1233
10.1159/000051214
10.1159/000106867
10.1111/j.1365-2990.2010.01150.x
10.1177/153331750401900606
10.1038/s41598-021-95499-1
10.1002/ana.24731
10.1371/journal.pmed.1002487
10.1136/jnnp-2012-304644
10.1212/NXI.0000000000000301
10.1007/s11910-015-0531-7
10.1097/nen.0b013e31812503e1
10.1007/s00401-004-0919-y
10.1016/S0896-6273(02)00794-8
10.1038/nri3705
10.1007/s12035-016-0297-1
10.3389/fncel.2021.660693
10.4103/1673-5374.244782
10.1038/nrneurol.2013.221
10.1002/ana.23937
10.1016/j.tins.2014.05.006
10.3389/fnins.2017.00609
10.1111/jnc.13713
10.1097/01.jnen.0000228202.35163.c4
10.1038/srep41765
10.1016/j.nbd.2012.03.036
10.1007/s00018-019-03111-7
10.1002/ana.10805
10.1016/j.nbd.2003.12.012
10.1016/j.jns.2007.01.057
10.1186/s40478-017-0424-x
10.1016/j.phrs.2014.05.006
10.1186/s41232-018-0086-5
10.1111/bph.13580
10.1016/j.plipres.2016.02.002
10.1124/mol.104.006353
10.1038/sj.bjp.0707464
10.1016/j.ejphar.2009.04.022
10.1038/nri912
10.1111/j.1582-4934.2011.01267.x
10.1038/npp.2012.25
10.1371/journal.pone.0041880
10.2174/1871527313666140806124322
10.1073/pnas.0711278105
10.1111/bph.12907
10.1016/j.neuropharm.2017.08.017
10.1161/ATVBAHA.118.311185
10.2174/1570159X14666160729155441
10.1038/s41598-017-07519-8
10.1038/s41598-017-00342-1
10.3390/ijms22063054
10.1371/journal.pone.0081618
10.1038/sj.bjp.0705467
10.1093/brain/awv297
10.1016/j.brainres.2016.04.022
10.1016/j.neuron.2017.09.003
10.7554/eLife.37703
10.1038/nrn.2016.141
10.3390/ijms16035555
10.2174/09298673113209990155
10.1002/biof.1703
10.2174/18715273113129990084
10.1186/ar4382
10.1111/cns.12648
10.2174/1871527314666150821102823
10.1186/1742-2094-10-91
10.3389/fphar.2019.00821
10.3390/biom12050667
10.1186/1742-2094-9-49
10.2174/1871527311312010011
10.1038/cddis.2014.376
10.1038/s41598-017-12529-7
10.3390/biomedicines10061236
10.2174/1871527314666150317224155
10.3233/JAD-143039
10.1155/2018/4720532
10.1186/s13041-015-0139-5
10.3390/ijms20071757
10.1016/0361-9230(93)90278-J
10.1016/j.nbd.2018.09.023
10.3390/jcm9020428
10.3389/fnagi.2022.890855
10.1089/can.2016.0030
10.3390/ijms21113802
10.2174/1871527311201070933
10.1073/pnas.1600251113
10.1007/s40520-016-0533-6
10.1186/s13024-021-00424-9
10.3390/biomedicines7040097
10.3390/ijms21239318
10.1002/alz.12189",<Element 'PubmedArticle' at 0x7f05da9a3b80>
86,35994946,The role of damage associated molecular pattern molecules (DAMPs) and permeability of the blood-brain barrier in depression and neuroinflammation.,"Depression is a heterogeneous mental disorder characterized by feelings of sadness and loss of interest that render the subject unable to handle basic daily activities such as sleeping, eating, or working. Neurobiological traits leading to depression include genetic background, early life abuse, life stressors, and systemic and central inflammatory profiles. Several clinical and preclinical reports documented that depression shows an increase in pro-inflammatory markers such as interleukin (IL-)1β, IL-6, IL-12, tumor necrosis factor (TNF), and interferon (IFN)-γ; and a decrease in anti-inflammatory IL-4, IL-10, and transforming growth factor (TGF)-β species. Inflammatory activation may trigger and maintain depression. Dynamic crosstalk between the peripheral immune system and the central nervous system (CNS) such as activated endothelial cells, monocytes, monocyte-derived dendritic cells, macrophages, T cells, and microglia has been proposed as a leading cause of neuroinflammation. Notably, pro-inflammatory cytokines disrupt the hypothalamic-pituitary-adrenal (HPA) axis and serotonergic, noradrenergic, dopaminergic, and glutamatergic neurotransmission. While still under investigation, peripheral cytokines can engage brain pathways and affect the central synthesis of HPA hormones and neurotransmitters through several mechanisms such as activation of the vagus nerve, increasing the permeability of the blood-brain barrier (BBB), altered cytokines transport systems, and engaging toll-like receptors (TLRs) by pathogen-associated molecular patterns (PAMPs) or damage-associated molecular patterns (DAMPs). However, physiological mechanisms that favor time-dependent central inflammation before or during illness are not totally understood. This review will provide preclinical and clinical evidence of DAMPs and the BBB permeability as contributors to depression and neuroinflammation. We will also discuss pharmacologic approaches that could potentially modulate DAMPs and BBB permeability for future interventions against major depression.","['Blood-brain barrier', 'Cytokines', 'DAMPs', 'Depression', 'Neuroinflammation']",Journal of neuroimmunology,2022-08-23,"[{'lastname': 'Serna-Rodríguez', 'firstname': 'María Fernanda', 'initials': 'MF', 'affiliation': 'Universidad Autónoma de Nuevo León, Facultad de Medicina, Departamento de Bioquímica y Medicina Molecular. Monterrey CP. 64460, Nuevo Leon, Mexico.'}, {'lastname': 'Bernal-Vega', 'firstname': 'Sofía', 'initials': 'S', 'affiliation': 'Universidad Autónoma de Nuevo León, Facultad de Medicina, Departamento de Bioquímica y Medicina Molecular. Monterrey CP. 64460, Nuevo Leon, Mexico.'}, {'lastname': 'de la Barquera', 'firstname': 'José Alfonso Ontiveros-Sánchez', 'initials': 'JAO', 'affiliation': 'Universidad Autónoma de Nuevo León, Facultad de Medicina Monterrey, Departamento de Psiquiatría, Monterrey CP. 64460, Nuevo Leon, Mexico.'}, {'lastname': 'Camacho-Morales', 'firstname': 'Alberto', 'initials': 'A', 'affiliation': 'Universidad Autónoma de Nuevo León, Facultad de Medicina, Departamento de Bioquímica y Medicina Molecular. Monterrey CP. 64460, Nuevo Leon, Mexico. Electronic address: alberto.camachomr@uanl.edu.mx.'}, {'lastname': 'Pérez-Maya', 'firstname': 'Antonio Alí', 'initials': 'AA', 'affiliation': 'Universidad Autónoma de Nuevo León, Facultad de Medicina, Departamento de Bioquímica y Medicina Molecular. Monterrey CP. 64460, Nuevo Leon, Mexico. Electronic address: antonio.perezmy@uanl.edu.mx.'}]",,,,Copyright © 2022 Elsevier B.V. All rights reserved.,10.1016/j.jneuroim.2022.577951,<Element 'PubmedArticle' at 0x7f05df2eb4a0>
87,"35993563
22271773
29525523
33449828
29930550
22405489
28432781
30442190
25882713
25844311
31803117
22053153
12490959
22543257
28479263
26101331
24513875
26222786
19451634
17604598
22898545
16554740
12017552
18522863
31036290
23348042
18601693
21320576
25222701
30042117
29524268
31947687
19131570
21595115
210930
1540948
34322676
25633981
31019214
23007862
32190339
21933867
34797509
28680060
21530561
6690267
17616732
17584823
24782009
32710274
10782364
17932880
8636351
27530684
27067638
4815174
25223867
1954167
3986816
16675129
31108169
32486326
6429184
32542593
35286462
15919741
15932928
31575604
12699330
24305803
22940545
22492304
30679700
19373617
14960294
16135578
25102452
17036362
22776268
27558905
32574226
30951973
26640615
31996464
25907742
25263255
12175700
26503700
35440664
30728170",Ovarian status modulates endocrine and neuroinflammatory responses to a murine mammary tumor.,"Patients with breast cancer have increased circulating inflammatory markers and mammary tumors increase neuroinflammation in rodent models. Menopausal status is not only important in the context of breast cancer as circulating estrogen influences tumor progression, but also because estrogen is anti-inflammatory and an essential modulator of endocrine function in the brain and body. Here, we manipulated ""menopause"" status (ovary-intact and ovariectomized) in an estrogen receptor (ER)+ mouse mammary tumor model to determine the extent to which ovarian status modulates: ","['brain', 'breast cancer', 'cytokines', 'estrogen', 'tumor resection']","American journal of physiology. Regulatory, integrative and comparative physiology",2022-08-23,"[{'lastname': 'Strehle', 'firstname': 'Lindsay D', 'initials': 'LD', 'affiliation': 'Institute for Behavioral Medicine Research, The Ohio State University, Columbus, Ohio.'}, {'lastname': 'Russart', 'firstname': 'Kathryn L G', 'initials': 'KLG', 'affiliation': 'Institute for Behavioral Medicine Research, The Ohio State University, Columbus, Ohio.\nComprehensive Cancer Center, The Ohio State University, Columbus, Ohio.'}, {'lastname': 'Burch', 'firstname': 'Valerie A', 'initials': 'VA', 'affiliation': 'Institute for Behavioral Medicine Research, The Ohio State University, Columbus, Ohio.'}, {'lastname': 'Grant', 'firstname': 'Corena V', 'initials': 'CV', 'affiliation': 'Institute for Behavioral Medicine Research, The Ohio State University, Columbus, Ohio.'}, {'lastname': 'Pyter', 'firstname': 'Leah M', 'initials': 'LM', 'affiliation': 'Institute for Behavioral Medicine Research, The Ohio State University, Columbus, Ohio.\nComprehensive Cancer Center, The Ohio State University, Columbus, Ohio.\nDepartment of Psychiatry and Behavioral Health, The Ohio State University, Columbus, Ohio.\nDepartment of Neuroscience, The Ohio State University, Columbus, Ohio.'}]",,,,,"10.1152/ajpregu.00124.2022
10.1093/jnci/djr541
10.1016/j.psym.2018.01.007
10.1200/OP.20.00793
10.3389/fimmu.2018.01195
10.1186/1756-9966-31-20
10.1111/psyp.12874
10.1186/s13058-018-1062-3
10.1093/jnci/djv099
10.1016/j.nicl.2015.02.005
10.3389/fpsyg.2019.02584
10.3389/fnhum.2011.00122
10.1038/nature01322
10.1016/j.bbi.2012.04.003
10.1016/j.bbr.2017.05.011
10.1093/jnci/djv131
10.1016/j.bbi.2013.10.022
10.1016/j.bbr.2015.07.040
10.1073/pnas.0811949106
10.1016/j.bbi.2007.05.005
10.1016/j.bbr.2012.07.038
10.1038/sj.npp.1301067
10.1210/rp.57.1.357
10.1016/j.yfrne.2008.04.001
10.1016/bs.apcsb.2019.01.001
10.1016/j.molmed.2012.12.007
10.1111/j.1365-2826.2008.01713.x
10.1016/j.neuroscience.2011.02.012
10.1016/j.psyneuen.2014.07.025
10.1530/JOE-18-0108
10.1111/jne.12590
10.3390/ijms21020529
10.1210/en.2008-1595
10.1016/j.cpnec.2020.100002
10.1242/dmm.017830
10.1038/s41598-019-42880-w
10.3791/4389
10.1186/s40738-020-00074-3
10.1210/en.2011-1501
10.1007/s12020-021-02931-7
10.1038/s41598-017-04946-5
10.1016/j.physbeh.2011.04.014
10.1210/endo-114-1-108
10.1530/REP-06-0302
10.1093/humupd/dmm009
10.1007/978-1-4939-0659-8_7
10.1007/s00441-020-03258-x
10.1210/edrv.21.2.0394
10.1002/cncr.23071
10.1210/jcem.81.4.8636351
10.5483/bmbrep.2016.49.9.141
10.1530/JME-15-0310
10.1210/jcem-38-3-476
10.1016/j.yfrne.2014.08.005
10.1016/0960-0760(91)90026-2
10.1016/j.bbcan.2006.03.001
10.1016/j.bbi.2019.05.028
10.3390/ijms21113943
10.1210/jcem-59-2-328
10.1007/s12035-020-01960-z
10.1007/s00726-022-03139-3
10.1210/en.2005-0488
10.1210/en.2005-0337
10.1523/ENEURO.0275-19.2019
10.1002/hipo.10075
10.1523/JNEUROSCI.3878-13.2013
10.1016/j.yfrne.2012.08.001
10.1210/en.2011-1925
10.1038/s41598-018-37334-8
10.1080/10673220902899706
10.1016/j.biopsych.2003.08.011
10.1097/01.AOG.0000175834.77215.2e
10.1016/j.bbi.2014.07.013
10.1002/cncr.22294
10.1016/j.bbi.2012.06.011
10.1080/09513590.2016.1214257
10.1371/journal.pone.0235174
10.1016/j.jnutbio.2019.02.012
10.1155/2016/5719291
10.1126/scitranslmed.aau5956
10.1016/j.bbr.2015.04.017
10.1017/S1092852914000480
10.1016/s0024-3205(02)01853-2
10.1186/s12905-015-0251-9
10.1038/s41467-022-29903-3
10.1523/JNEUROSCI.1970-18.2019",<Element 'PubmedArticle' at 0x7f05df2c1a40>
88,"35966795
16288292
28469276
34410631
27393312
16095999
35767131
35488997
30644041
27794564
27648105
25328885
16263144
19321148
26525379
30233288
10822371
30065258
21742017
9046563
9799621
19588079
23866011
24246855
21620960
11113299
22216827
26555354
29403626
11403979
33811472
10617621
22085882
32351180
11255426
27856395
12490568
26404616
23715379
26834422
12486194
10368772
23840215
24205314
25280667
27146164
10629355
34108509
21639804
12719730
34354441
20207238
32781196
22035196
33137454
31606849
30285727
33831465
31701036
11402335
8700549
33309979
25225489
21145432
25653146
24059066
27073471
24556222
32664974
9496988
31357227",Dietary Supplementation With ,"The midlife transition period in women marks the progressive flattening of neurological health along with increased adiposity, dyslipidemia, frailty, and inflammatory responses mainly attributed to the gradual decline in estrogen levels. Conflicting reports of hormone replacement therapy (HRT) necessitate the exploration of novel therapeutic interventions using bioactive natural products having the least toxicity and a holistic mode of action for the preservation of metabolic homeodynamics with aging in women. The present study was planned to investigate the effects of aging and/or a high-fat diet (HFD) on cognitive impairments and anxiety and further their management by dietary supplement with the ","['Tinospora cordifolia', 'anxiety', 'cognitive impairments', 'memory', 'menopause', 'synaptic plasticity']",Frontiers in aging neuroscience,2022-08-16,"[{'lastname': 'Bhandari', 'firstname': 'Anmol', 'initials': 'A', 'affiliation': 'Department of Biotechnology, Guru Nanak Dev University, Amritsar, India.'}, {'lastname': 'Sunkaria', 'firstname': 'Aditya', 'initials': 'A', 'affiliation': 'Department of Biotechnology, Guru Nanak Dev University, Amritsar, India.'}, {'lastname': 'Kaur', 'firstname': 'Gurcharan', 'initials': 'G', 'affiliation': 'Department of Biotechnology, Guru Nanak Dev University, Amritsar, India.'}]",,,,"Copyright © 2022 Bhandari, Sunkaria and Kaur.","10.3389/fnagi.2022.944144
10.1038/sj.onc.1209085
10.1038/nrn.2017.45
10.1007/s12017-021-08683-x
10.1007/s00401-016-1595-4
10.1016/S0065-230X(05)94002-5
10.1007/s10522-022-09975-w
10.1007/s10522-022-09962-1
10.1007/s12017-018-08521-7
10.18632/aging.101078
10.1155/2016/9232593
10.1155/2014/492141
10.1016/j.physbeh.2005.09.004
10.1016/j.physbeh.2009.03.016
10.1016/j.plefa.2015.10.003
10.1038/sj.onc.1203566
10.1016/j.neuroscience.2011.06.072
10.1146/annurev.psych.48.1.339
10.1006/hbeh.1998.1451
10.1007/s12011-009-8439-1
10.2174/18746098112059990036
10.1016/j.yfrne.2013.11.001
10.1016/j.cellsig.2011.05.004
10.1016/s0306-4522(00)00410-3
10.1016/j.biopsych.2015.09.011
10.19082/5826
10.1016/s0306-4530(01)00013-0
10.1002/brb3.2139
10.1074/jbc.275.1.322
10.1016/j.bbr.2011.10.047
10.2174/1389201021666200430114547
10.1001/jama.285.11.1489
10.1016/S2215-0366(16)30358-3
10.1124/jpet.102.035048
10.1152/japplphysiol.00299.2015
10.1097/GME.0b013e3182960cf8
10.4103/0975-9476.157953
10.1523/JNEUROSCI.22-24-10985.2002
10.1210/edrv.20.3.0365
10.1155/2013/209812
10.1371/journal.pone.0078764
10.1007/s12035-014-8892-5
10.1038/srep25564
10.1159/000017206
10.1038/s41598-021-90084-y
10.1515/RNS.2011.031
10.1038/ni0503-410
10.1016/j.sjbs.2021.04.056
10.1016/j.ajog.2009.07.061
10.1016/j.yfrne.2020.100861
10.1186/1472-6882-11-102
10.1016/j.neuint.2020.104891
10.1007/s12017-019-08566-2
10.1186/s12906-018-2330-6
10.1016/j.jep.2021.114054
10.1016/j.heliyon.2019.e02437
10.1038/sj.onc.1204383
10.1016/j.neuint.2020.104937
10.3389/fpsyg.2014.00925
10.1016/j.arr.2010.11.002
10.3892/ijmm.2015.2091
10.3892/etm.2016.3074
10.1016/j.jep.2014.01.031
10.1186/s12974-020-01887-1
10.1001/jama.279.9.688
10.1111/1440-1681.13149",<Element 'PubmedArticle' at 0x7f05dbb71540>
89,35961539,"The effect of glucagon like peptide-1 receptor agonist on behavioral despair and anxiety-like behavior in ovariectomized rats: Modulation of BDNF/CREB, Nrf2 and lipocalin 2.","Ovariectomized (OVX) rodents show behavioral despair and anxiety-like behaviors. Glucagon-like peptide-1 receptor agonists (GLP-1RA) possess neuroprotective effects by reducing oxidative stress and neuroinflammation, thereby preventing synaptic loss. The objective of the present study is to evaluate the effect of GLP-1RA, namely liraglutide, on emotional behaviors, and to identify the level of oxidative stress, neuroinflammation, and BDNF signaling in the hippocampus of OVX rats. Forty female young Wistar rats were divided into 5 groups: Control, Control+liraglutide treated, OVX, OVX+fluoxetine, and OVX+liraglutide (150 µg/kg for 15 days, sc). Open field test and elevated plus-maze test were used to evaluate behaviors that are suggestive of anxiety. A forced swimming test was used to evaluate behavioral despair. At the end of the experiments, blood glucose level and body weight gain were measured. The levels of BDNF, CREB, Nrf2, and lipocalin 2 in the hippocampal tissue were measured by ELISA. Malondialdehyde (MDA) and glutathione levels were also evaluated. Statistical analysis was conducted through ANOVA and Bonferroni tests. Seven weeks post-OVX rats exhibited high anxiety related behavior and behavioral despair in comparison with the control groups. These behavioral changes were associated with increased lipocalin 2 and MDA levels in rats. Moreover, BDNF, CREB, and Nrf2 levels decreased significantly in the hippocampus of OVX rats. Liraglutide treatment limited the reduction of BDNF and Nrf2 levels in the hippocampus, maintaining them at the control levels. Liraglutide treatment also prevented the symptoms of behavioral despair and anxiety related behavior. As the main finding of the study GLP-1RA reduced behavioral despair and anxiety level and this may be related to the preservation of BDNF/Nrf2 levels and the decrease in oxidative stress and lipocalin 2 levels in the hippocampus.","['BDNF', 'Behavioral despair', 'GLP-1', 'Lipocalin 2', 'Ovariectomy']",Behavioural brain research,2022-08-13,"[{'lastname': 'Sağlam', 'firstname': 'Candan', 'initials': 'C', 'affiliation': 'Zonguldak Bülent Ecevit University, Health Sciences Institute, Department of Physiology, Zonguldak, Turkey.'}, {'lastname': 'Turan', 'firstname': 'İnci', 'initials': 'İ', 'affiliation': 'Zonguldak Bülent Ecevit University, Faculty of Medicine, Department of Physiology, Zonguldak, Turkey.'}, {'lastname': 'Özaçmak', 'firstname': 'Hale Sayan', 'initials': 'HS', 'affiliation': 'Zonguldak Bülent Ecevit University, Faculty of Medicine, Department of Physiology, Zonguldak, Turkey. Electronic address: hale.sozacmak@beun.edu.tr.'}]",,,,Copyright © 2022 Elsevier B.V. All rights reserved.,10.1016/j.bbr.2022.114053,<Element 'PubmedArticle' at 0x7f05dca5b720>
90,35924434,Therapeutic potential of progesterone in spinal cord injury-induced neuropathic pain: At the crossroads between neuroinflammation and N-methyl-D-aspartate receptor.,"In recent decades, an area of active research has supported the notion that progesterone promotes a wide range of remarkable protective actions in experimental models of nervous system trauma or disease, and has also provided a strong basis for considering this steroid as a promising molecule for modulating the complex maladaptive changes that lead to neuropathic pain, especially after spinal cord injury. In this review, we intend to give the readers a brief appraisal of the main mechanisms underlying the increased excitability of the spinal circuit in the pain pathway after trauma, with particular emphasis on those mediated by the activation of resident glial cells, the subsequent release of proinflammatory cytokines and their impact on N-methyl-D-aspartate receptor function. We then summarize the available preclinical data pointing to progesterone as a valuable repurposing molecule for blocking critical cellular and molecular events that occur in the dorsal horn of the injured spinal cord and are related to the development of chronic pain. Since the treatment and management of neuropathic pain after spinal injury remains challenging, the potential therapeutic value of progesterone opens new traslational perspectives to prevent central pain.","['N-methyl-D-aspartate receptor', 'neuroinflammation', 'neuropathic pain', 'progesterone', 'spinal cord injury']",Journal of neuroendocrinology,2022-08-05,"[{'lastname': 'Ferreyra', 'firstname': 'Sol', 'initials': 'S', 'affiliation': 'Instituto de Biología y Medicina Experimental, Laboratorio de Nocicepción y Dolor Neuropático, CONICET, Buenos Aires, Argentina.'}, {'lastname': 'González', 'firstname': 'Susana', 'initials': 'S', 'affiliation': 'Instituto de Biología y Medicina Experimental, Laboratorio de Nocicepción y Dolor Neuropático, CONICET, Buenos Aires, Argentina.\nUniversidad de Buenos Aires, Facultad de Medicina, Departamento de Bioquímica Humana, Buenos Aires, Argentina.'}]",,,,© 2022 British Society for Neuroendocrinology.,10.1111/jne.13181,<Element 'PubmedArticle' at 0x7f05dca44090>
91,"35897423
29718780
34834756
1967820
17467679
32627322
29457959
34428995
35178585
28884474
26114596
23303913
23077140
31095280
9717719
11264981
34153214
34830081
34806144
35101444
27142780
32974183
9392419
34667945
35525811
31199480
23059950
34021815
32933108
17094036
33291255
31244054
23065638
11521206
8811180
8621375
1992464
2052607
29282289
22048229
28235469
29424242
33224889
24027568
15955538
11309191
16477080
23901157
35628237
35585236
33479604
32139507
30773935
16507758
21984972
22407328
31989383
24390573
28553321
31474985
32582214
34539662
28501347
27377765
30797829
25107911
27499643
26048578
34937577
33146995
19077110
33369790
32819809
35635133
30258234
30423423
28226226
29742058
35805174
11189454
15967158
30459026
35563576
35662183
35089425
21619866
12191486
20303873
31036962
24758928
21124315
23502856
23994495
19505385
18604209
21760595
11256882
34638552
27270400
34635190
26997483
19464372
32722471
33901180
22759742
24287904
29768139
27009539
11051212
34068578
31635164
21280176
35645423
35321818
34129891
33538259
30030365
33479824
33305107
30847826
27499294
33667628",Prenylation Defects and Oxidative Stress Trigger the Main Consequences of Neuroinflammation Linked to Mevalonate Pathway Deregulation.,"The cholesterol biosynthesis represents a crucial metabolic pathway for cellular homeostasis. The end products of this pathway are sterols, such as cholesterol, which are essential components of cell membranes, precursors of steroid hormones, bile acids, and other molecules such as ubiquinone. Furthermore, some intermediates of this metabolic system perform biological activity in specific cellular compartments, such as isoprenoid molecules that can modulate different signal proteins through the prenylation process. The defects of prenylation represent one of the main causes that promote the activation of inflammation. In particular, this mechanism, in association with oxidative stress, induces a dysfunction of the mitochondrial activity. The purpose of this review is to describe the pleiotropic role of prenylation in neuroinflammation and to highlight the consequence of the defects of prenylation.","['cholesterol', 'neuroinflammation', 'oxidative stress', 'prenylation']",International journal of environmental research and public health,2022-07-29,"[{'lastname': 'Pisanti', 'firstname': 'Simona', 'initials': 'S', 'affiliation': ""Department of Medicine, Surgery and Dentistry 'Scuola Medica Salernitana', University of Salerno, 84081 Baronissi, Italy.""}, {'lastname': 'Rimondi', 'firstname': 'Erika', 'initials': 'E', 'affiliation': 'Department of Translational Medicine, University of Ferrara, 44121 Ferrara, Italy.\nLTTA Centre, University of Ferrara, 44121 Ferrara, Italy.'}, {'lastname': 'Pozza', 'firstname': 'Elena', 'initials': 'E', 'affiliation': 'Department of Translational Medicine, University of Ferrara, 44121 Ferrara, Italy.'}, {'lastname': 'Melloni', 'firstname': 'Elisabetta', 'initials': 'E', 'affiliation': 'Department of Translational Medicine, University of Ferrara, 44121 Ferrara, Italy.\nLTTA Centre, University of Ferrara, 44121 Ferrara, Italy.'}, {'lastname': 'Zauli', 'firstname': 'Enrico', 'initials': 'E', 'affiliation': 'Department of Translational Medicine, University of Ferrara, 44121 Ferrara, Italy.'}, {'lastname': 'Bifulco', 'firstname': 'Maurizio', 'initials': 'M', 'affiliation': 'Department of Molecular Medicine and Medical Biotechnologies, University of Naples ""Federico II"", 80131 Naples, Italy.'}, {'lastname': 'Martinelli', 'firstname': 'Rosanna', 'initials': 'R', 'affiliation': ""Department of Medicine, Surgery and Dentistry 'Scuola Medica Salernitana', University of Salerno, 84081 Baronissi, Italy.""}, {'lastname': 'Marcuzzi', 'firstname': 'Annalisa', 'initials': 'A', 'affiliation': 'Department of Translational Medicine, University of Ferrara, 44121 Ferrara, Italy.'}]",,,,,"10.3390/ijerph19159061
10.1080/10409238.2018.1458070
10.3390/plants10112393
10.1038/343425a0
10.1016/j.clinbiochem.2007.03.016
10.1111/jebm.12406
10.1080/09168451.2018.1433020
10.1080/10409238.2021.1957668
10.1007/s11274-022-03242-3
10.1002/ijc.31036
10.7554/eLife.07999
10.1152/physrev.00033.2011
10.1161/ATVBAHA.112.300134
10.1093/cvr/cvz127
10.1097/00041433-200104000-00003
10.1146/annurev-biochem-081820-101010
10.3390/ijms222212198
10.1007/s11011-021-00877-3
10.1016/j.jbc.2022.101652
10.1186/s12969-016-0091-7
10.3389/fonc.2020.01510
10.1016/S0022-2275(20)34935-X
10.1016/j.isci.2021.103180
10.1016/j.ymgme.2022.04.006
10.1093/cvr/cvz155
10.1002/ajmg.c.31343
10.1007/s10072-021-05337-5
10.3390/ijms21186695
10.1007/s11064-006-9190-z
10.3390/ijms21239299
10.1021/acschemneuro.9b00248
10.1242/dmm.010124
10.1055/s-2001-16618
10.1146/annurev.bi.65.070196.001325
10.1074/jbc.271.10.5289
10.1073/pnas.88.3.732
10.1073/pnas.88.12.5302
10.1074/jbc.M117.805770
10.1038/clpt.2011.215
10.1016/j.bbamem.2017.02.012
10.1080/10409238.2018.1431606
10.3389/fonc.2020.595034
10.3389/fimmu.2013.00239
10.1016/j.lfs.2005.05.017
10.1242/jcs.114.9.1603
10.1194/jlr.R600002-JLR200
10.3390/ijms23105424
10.1038/s41586-022-04729-7
10.1039/C9MD00442D
10.1074/jbc.REV119.008897
10.1080/10409238.2019.1568964
10.1096/fj.05-4044lsf
10.1007/s00345-012-0844-y
10.1007/s12035-020-01870-0
10.1007/s12035-013-8627-z
10.3389/fimmu.2019.01900
10.3389/fimmu.2020.01150
10.3389/fimmu.2021.724991
10.1016/j.jaci.2017.02.033
10.1038/icb.2016.58
10.1016/j.jaci.2019.02.013
10.1074/jbc.M114.571810
10.1186/s12974-015-0332-6
10.1186/s12974-021-02334-5
10.1021/acschemneuro.0c00427
10.1111/j.1365-2990.2008.01005.x
10.1002/glia.23961
10.1016/j.it.2020.07.006
10.1177/17590914221104566
10.1038/s41593-018-0242-x
10.1016/j.neuint.2018.11.006
10.1146/annurev-immunol-051116-052358
10.3390/cells11132091
10.1379/1466-1268(2000)005<0471:FATHSR>2.0.CO;2
10.1016/j.prostaglandins.2005.01.001
10.3390/ijms23095188
10.1007/s00018-021-04090-4
10.1016/j.bpa.2010.11.001
10.1016/S1097-2765(02)00599-3
10.1016/j.cell.2010.01.040
10.1038/s41577-019-0165-0
10.3390/ijms15046843
10.1038/nature09663
10.1038/ni.2550
10.1016/j.bbagen.2013.08.014
10.1177/039463200902200208
10.1038/ni.1636
10.1038/cdd.2011.96
10.1023/A:1009616228304
10.3390/ijms221910211
10.1038/ni.3487
10.1186/s41232-021-00181-8
10.1016/j.cell.2016.02.023
10.1016/j.nbd.2009.05.005
10.3390/metabo10080304
10.1371/journal.pbio.3001134
10.1016/j.ijdevneu.2012.06.002
10.3390/ijms141223274
10.1056/NEJMoa1706314
10.1038/nrrheum.2015.179
10.18388/abp.2000_4027
10.3390/antiox10050755
10.3390/ijms20205195
10.1002/iub.413
10.5114/reum.2022.114108
10.1016/j.ejphar.2022.174906
10.1016/j.mad.2021.111521
10.1016/j.jacc.2020.12.009
10.1007/s00467-020-04914-8
10.1016/j.ekir.2020.09.044
10.1007/s12311-019-01011-x
10.1016/j.molcel.2016.06.030
10.1016/j.freeradbiomed.2021.02.039",<Element 'PubmedArticle' at 0x7f05dbdea900>
92,"35818443
29662059
21750622
19197266
29306945
22370490
21130297
22794138
17126865
21894327
29202274
25322288
22111586
30195065
25867960
23406749
30416662
32871086
18675469
33209030
24582593
29688389
30529362
25486982
20021321
32763585
16939974
21223646
22840395
22472057
22036797
16876135
20724638",Red Raspberry Extract Decreases Depression-Like Behavior in Rats by Modulating Neuroinflammation and Oxidative Stress.,"Red raspberry serves as a proven natural product to produce anti-inflammatory, antioxidant, and anticancer functions, but limited findings are available on its effects on depression. This study, by using a chronic unpredictable mild stress- (CUMS-) induced depression model, thus investigated the effects and underlying mechanism of red raspberry extract (RRE) on depressive behavior, inflammation, and oxidative stress.
Different treatments were given after random grouping of Sprague-Dawley rats, including no intervention (control), CUMS induction, and CUMS+different concentrations of RRE, and subsequently, depression-like behavior tests were performed. HE staining was designed to observe the pathological damage of the hippocampal tissue in rats. The levels of oxidative stress, endocrine hormones, and inflammatory factors were determined by biochemical assay and ELISA, and gene expression (mRNA and protein) in the hippocampal tissue by qRT-PCR and Western blot.
On completion of CUMS treatment, the rats showed severe depression-like behavior, with obvious hippocampal tissue damage, oxidative inflammatory response, and endocrine imbalance. Importantly, RRE treatment significantly improved such depression-like behavior and attenuated histopathological damage in CUMS rats when reducing inflammation and oxidative stress and endocrine imbalance with upregulation of glutathione (GSH), superoxide dismutase (SOD), and interleukin- (IL-) 10 and downregulation of adrenocorticotropic hormone (ACTH), corticosterone (CORT), malondialdehyde (MDA), IL-1
By regulating neuroinflammation, oxidative stress response, endocrine level, and BDNF/TrkB level, RRE showed potential efficacy in alleviating depression-like behavior and histopathological damage of hippocampal tissue in CUMS rats by regulating the GSK3",[],BioMed research international,2022-07-13,"[{'lastname': 'Chen', 'firstname': 'Yanhua', 'initials': 'Y', 'affiliation': 'Mental Health Center, General Hospital of Ningxia Medical University, Yinchuan, Ningxia 750001, China.'}, {'lastname': 'Yang', 'firstname': 'Xia', 'initials': 'X', 'affiliation': 'Information Center, Health Commission of Ningxia Hui Autonomous Region, Yinchuan, Ningxia 750002, China.'}, {'lastname': 'Li', 'firstname': 'Hui', 'initials': 'H', 'affiliation': 'Minkang Hospital Department of Civil Affairs of Ningxia, Yinchuan, Ningxia 750011, China.'}, {'lastname': 'Fang', 'firstname': 'Jianqun', 'initials': 'J', 'affiliation': 'Mental Health Center, General Hospital of Ningxia Medical University, Yinchuan, Ningxia 750001, China.'}]",,"By regulating neuroinflammation, oxidative stress response, endocrine level, and BDNF/TrkB level, RRE showed potential efficacy in alleviating depression-like behavior and histopathological damage of hippocampal tissue in CUMS rats by regulating the GSK3","On completion of CUMS treatment, the rats showed severe depression-like behavior, with obvious hippocampal tissue damage, oxidative inflammatory response, and endocrine imbalance. Importantly, RRE treatment significantly improved such depression-like behavior and attenuated histopathological damage in CUMS rats when reducing inflammation and oxidative stress and endocrine imbalance with upregulation of glutathione (GSH), superoxide dismutase (SOD), and interleukin- (IL-) 10 and downregulation of adrenocorticotropic hormone (ACTH), corticosterone (CORT), malondialdehyde (MDA), IL-1",Copyright © 2022 Yanhua Chen et al.,"10.1155/2022/9943598
10.1038/s41467-018-03819-3
10.2147/NDT.S19617
10.1038/oby.2008.647
10.1159/000481515
10.1016/j.psc.2011.12.001
10.1016/j.nutres.2010.10.004
10.1089/ars.2012.4581
10.1016/j.phytochem.2006.10.014
10.1039/c1fo10047e
10.1016/j.jnutbio.2017.10.012
10.1039/C4FO00376D
10.1021/jf203456w
10.1016/j.biocel.2018.09.003
10.3791/52587
10.1016/S1734-1140(12)70936-2
10.1080/15384101.2020.1810401
10.1016/j.tins.2008.06.006
10.2147/NDT.S251152
10.1016/j.lfs.2014.02.014
10.1093/ijnp/pyy040
10.1016/j.neubiorev.2018.12.002
10.1038/mp.2014.163
10.1586/ern.09.144
10.1016/j.jpsychires.2020.06.010
10.1098/rstb.2006.1894
10.1503/jpn.100048
10.1016/j.celrep.2012.06.010
10.1016/j.brainresbull.2012.03.004
10.1016/j.jad.2011.09.024
10.1016/j.biopsych.2006.04.036
10.1126/science.1190287",<Element 'PubmedArticle' at 0x7f05ddc21590>
93,35750198,Microglial polarization differentially affects neuronal vulnerability to the β-amyloid protein: Modulation by melatonin.,"Microglial cells play a central but yet debated role in neuroinflammatory events occurring in Alzheimer's disease (AD). We here explored how microglial features are modulated by melatonin following β-amyloid (Aβ42)-induced activation and examined the cross-talk with Aβ-challenged neuronal cells. Human microglial HMC3 cells were exposed to Aβ42 (200 nM) in the presence of melatonin (MEL; 1 μM) added since the beginning (MELco) or after a 72 h-exposure to Aβ42 (MELpost). In both conditions, MEL favored an anti-inflammatory activation and rescued SIRT1 and BDNF expression/release. Caspase-1 up-regulation and phospho-ERK induction following a prolonged exposure to Aβ42 were prevented by MEL. In addition, MEL partially restored proteasome functionality that was altered by long-term Aβ42 treatment, re-establishing both 20S and 26S chymotrypsin-like activity. Differentiated neuronal-like SH-SY5Y cells were exposed to Aβ42 (200 nM for 24 h) in basal medium or in the presence of conditioned medium (CM) collected from microglia exposed for different times to Aβ42 alone or in combination with MELco or MELpost. Aβ42 significantly reduced pre-synaptic proteins synaptophysin and VAMP2 and mean neuritic length. These effects were prevented by CM from anti-inflammatory microglia (Aβ42 for 6 h), or from MELco and MELpost microglia, but the reduction of neuritic length was not rescued when the SIRT1 inhibitor EX527 was added. In conclusion, our data add to the concept that melatonin shows a promising anti-inflammatory action on microglia that is retained even after pro-inflammatory activation, involving modulation of proteasome function and translating into neuroprotective microglial effects.","['HMC3 microglial cell line', 'Immunoproteasome', 'Neuritic length', 'Neuroinflammation', 'SIRT1', 'Synaptic proteins']",Biochemical pharmacology,2022-06-25,"[{'lastname': 'Merlo', 'firstname': 'Sara', 'initials': 'S', 'affiliation': 'Department of Biomedical and Biotechnological Sciences, Section of Pharmacology, University of Catania, Via Santa Sofia 97, 95123 Catania, Italy. Electronic address: sara_merlo@hotmail.com.'}, {'lastname': 'Caruso', 'firstname': 'Grazia Ilaria', 'initials': 'GI', 'affiliation': 'Department of Biomedical and Biotechnological Sciences, Section of Pharmacology, University of Catania, Via Santa Sofia 97, 95123 Catania, Italy. Electronic address: grazia.caruso@outlook.it.'}, {'lastname': 'Bonfili', 'firstname': 'Laura', 'initials': 'L', 'affiliation': 'School of Biosciences and Veterinary Medicine, University of Camerino, via Gentile III da Varano, 62032 Camerino, MC, Italy. Electronic address: laura.bonfili@unicam.it.'}, {'lastname': 'Spampinato', 'firstname': 'Simona Federica', 'initials': 'SF', 'affiliation': 'Department of Scienza e Tecnologia del Farmaco, University of Turin, Via P. Giuria 13, Turin 10125, Italy. Electronic address: simonafederica.spampinato@unito.it.'}, {'lastname': 'Costantino', 'firstname': 'Giuseppe', 'initials': 'G', 'affiliation': 'Department of Biomedical and Biotechnological Sciences, Section of Pharmacology, University of Catania, Via Santa Sofia 97, 95123 Catania, Italy. Electronic address: giuseppe.costantino@unifg.it.'}, {'lastname': 'Eleuteri', 'firstname': 'Anna Maria', 'initials': 'AM', 'affiliation': 'School of Biosciences and Veterinary Medicine, University of Camerino, via Gentile III da Varano, 62032 Camerino, MC, Italy. Electronic address: annamaria.eleuteri@unicam.it.'}, {'lastname': 'Sortino', 'firstname': 'Maria Angela', 'initials': 'MA', 'affiliation': 'Department of Biomedical and Biotechnological Sciences, Section of Pharmacology, University of Catania, Via Santa Sofia 97, 95123 Catania, Italy. Electronic address: msortino@unict.it.'}]",,,,Copyright © 2022 Elsevier Inc. All rights reserved.,10.1016/j.bcp.2022.115151,<Element 'PubmedArticle' at 0x7f05ddbf5ea0>
94,"35705992
14744257
10601667
28830762
17375137
25557223
22204802
32188569
32487735
19789384
30572023
30314566
28162807
31931229
34331656
28434951
15916629
9430796
11506126
15241581
22337491
15109509
14659512
14630714
29356757
30830471
10648719
30298965
16495007
27153520
31489921
32948219
1686211
22235389
18853426
28135239
32896638
16616418
8891603
25716783
22886732
17151600
11064361
7708757",Superior control of inflammatory pain by corticotropin-releasing factor receptor 1 via opioid peptides in distinct pain-relevant brain areas.,"Under inflammatory conditions, the activation of corticotropin-releasing factor (CRF) receptor has been shown to inhibit pain through opioid peptide release from immune cells or neurons. CRF's effects on human and animal pain modulation depend, however, on the distribution of its receptor subtypes 1 and 2 (CRF-R1 and CRF-R2) along the neuraxis of pain transmission. The objective of this study is to investigate the respective role of each CRF receptor subtype on centrally administered CRF-induced antinociception during inflammatory pain.
The present study investigated the role of intracerebroventricular (i.c.v.) CRF receptor agonists on nociception and the contribution of cerebral CRF-R1 and/or CRF-R2 subtypes in an animal model of Freund's complete adjuvant (FCA)-induced hind paw inflammation. Methods used included behavioral experiments, immunofluorescence confocal analysis, and reverse transcriptase-polymerase chain reaction.
Intracerebroventricular, but systemically inactive, doses of CRF elicited potent, dose-dependent antinociceptive effects in inflammatory pain which were significantly antagonized by i.c.v. CRF-R1-selective antagonist NBI 27914 (by approximately 60%) but less by CRF-R2-selective antagonist K41498 (by only 20%). In line with these findings, i.c.v. administration of CRF-R1 agonist stressin I produced superior control of inflammatory pain over CRF-R2 agonist urocortin-2. Intriguingly, i.c.v. opioid antagonist naloxone significantly reversed the CRF as well as CRF-R1 agonist-elicited pain inhibition. Consistent with existing evidence of high CRF concentrations in brain areas such as the thalamus, hypothalamus, locus coeruleus, and periaqueductal gray following its i.c.v. administration, double-immunofluorescence confocal microscopy demonstrated primarily CRF-R1-positive neurons that expressed opioid peptides in these pain-relevant brain areas. Finally, PCR analysis confirmed the predominant expression of the CRF-R1 over CRF-R2 in representative brain areas such as the hypothalamus.
Taken together, these findings suggest that CRF-R1 in opioid-peptide-containing brain areas plays an important role in the modulation of inflammatory pain and may be a useful therapeutic target for inflammatory pain control.","['Brain', 'Corticotropin-releasing factor', 'Immunofluorescence', 'Inflammatory pain', 'Opioid peptide']",Journal of neuroinflammation,2022-06-16,"[{'lastname': 'Mousa', 'firstname': 'Shaaban A', 'initials': 'SA', 'affiliation': 'Department of Anesthesiology and Operative Intensive Care Medicine, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität Zu Berlin, and Berlin Institute of Health, Charité Campus Benjamin Franklin, Hindenburgdamm 30, 12203, Berlin, Germany. shaaban.mousa@charite.de.'}, {'lastname': 'Khalefa', 'firstname': 'Baled I', 'initials': 'BI', 'affiliation': 'Department of Anesthesiology and Operative Intensive Care Medicine, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität Zu Berlin, and Berlin Institute of Health, Charité Campus Benjamin Franklin, Hindenburgdamm 30, 12203, Berlin, Germany.\nZoology Department, Faculty of Science, AL-Zintan University, Alzintan, Libya.'}, {'lastname': 'Shaqura', 'firstname': 'Mohammed', 'initials': 'M', 'affiliation': 'Department of Anesthesiology and Operative Intensive Care Medicine, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität Zu Berlin, and Berlin Institute of Health, Charité Campus Benjamin Franklin, Hindenburgdamm 30, 12203, Berlin, Germany.'}, {'lastname': 'Al-Madol', 'firstname': 'Mohammed', 'initials': 'M', 'affiliation': None}, {'lastname': 'Treskatsch', 'firstname': 'Sascha', 'initials': 'S', 'affiliation': 'Department of Anesthesiology and Operative Intensive Care Medicine, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität Zu Berlin, and Berlin Institute of Health, Charité Campus Benjamin Franklin, Hindenburgdamm 30, 12203, Berlin, Germany.'}, {'lastname': 'Schäfer', 'firstname': 'Michael', 'initials': 'M', 'affiliation': 'Department of Anesthesiology and Operative Intensive Care Medicine, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität Zu Berlin, and Berlin Institute of Health, Charité Campus Benjamin Franklin, Hindenburgdamm 30, 12203, Berlin, Germany.'}]",,"Taken together, these findings suggest that CRF-R1 in opioid-peptide-containing brain areas plays an important role in the modulation of inflammatory pain and may be a useful therapeutic target for inflammatory pain control.","Intracerebroventricular, but systemically inactive, doses of CRF elicited potent, dose-dependent antinociceptive effects in inflammatory pain which were significantly antagonized by i.c.v. CRF-R1-selective antagonist NBI 27914 (by approximately 60%) but less by CRF-R2-selective antagonist K41498 (by only 20%). In line with these findings, i.c.v. administration of CRF-R1 agonist stressin I produced superior control of inflammatory pain over CRF-R2 agonist urocortin-2. Intriguingly, i.c.v. opioid antagonist naloxone significantly reversed the CRF as well as CRF-R1 agonist-elicited pain inhibition. Consistent with existing evidence of high CRF concentrations in brain areas such as the thalamus, hypothalamus, locus coeruleus, and periaqueductal gray following its i.c.v. administration, double-immunofluorescence confocal microscopy demonstrated primarily CRF-R1-positive neurons that expressed opioid peptides in these pain-relevant brain areas. Finally, PCR analysis confirmed the predominant expression of the CRF-R1 over CRF-R2 in representative brain areas such as the hypothalamus.",© 2022. The Author(s).,"10.1186/s12974-022-02498-8
10.1146/annurev.pharmtox.44.101802.121410
10.1016/S0304-3959(99)00193-1
10.1016/j.expneurol.2017.08.010
10.1038/sj.npp.1301393
10.1111/nmo.12495
10.1016/j.neuropharm.2020.108052
10.1124/mol.120.119388
10.1152/physrev.00005.2009
10.1016/j.nbd.2018.12.005
10.1016/bs.pbr.2018.07.002
10.1016/j.neuron.2017.01.008
10.1016/j.jpain.2020.01.001
10.1007/s12035-021-02481-z
10.1016/j.taap.2017.04.021
10.1111/j.1365-2982.2005.00648.x
10.1046/j.1365-2982.1997.d01-63.x
10.1097/00000542-200108000-00036
10.1007/s00210-004-0942-5
10.1002/j.1532-2149.2011.00070.x
10.1016/j.pain.2003.12.008
10.1016/S0304-3959(03)00302-6
10.1210/en.2003-1287
10.1097/ALN.0000000000002087
10.1007/s11926-019-0813-1
10.1523/JNEUROSCI.20-03-01142.2000
10.1111/nmo.13489
10.1016/j.pain.2005.12.024
10.1016/j.psyneuen.2016.04.021
10.1186/s13041-020-00669-3
10.1016/0006-8993(91)91535-9
10.1007/s10517-011-1195-1
10.1002/cne.21848
10.1038/nn.4491
10.1016/j.jpain.2020.08.002
10.1016/j.pain.2006.02.027
10.1016/0014-2999(96)00440-2
10.1002/cne.23082
10.1038/nature05453
10.1002/1096-9861(20001211)428:2<191::AID-CNE1>3.0.CO;2-U
10.1073/pnas.92.7.2969",<Element 'PubmedArticle' at 0x7f05ddbf44f0>
95,35660757,Demystifying the dual role of the angiotensin system in neuropathic pain.,"Neuropathic Pain is caused by damage to a nerve or disease of the somatosensory nervous system. Apart from the blood pressure regulating actions of angiotensin ligands, studies have shown that it also modulates neuropathic pain. In the animal models including surgical, chemotherapeutic, and retroviral-induced neuropathic pain, an increase in the levels of angiotensin II has been identified and it has been proposed that an increase in angiotensin II may participate in the induction of neuropathic pain. The pain-inducing actions of the angiotensin system are primarily due to the activation of AT","['AT(1) receptor', 'AT(2) receptor', 'Angiotensin (1–7)', 'Angiotensin II', 'Neuropathic pain', 'Pain']",Neuropeptides,2022-06-07,"[{'lastname': 'Kaur', 'firstname': 'Sahibpreet', 'initials': 'S', 'affiliation': 'Department of Pharmaceutical Sciences and Drug Research, Punjabi University Patiala, Patiala 147002, India.'}, {'lastname': 'Bali', 'firstname': 'Anjana', 'initials': 'A', 'affiliation': 'Department of Pharmacology, Central University of Punjab, Bathinda, India. Electronic address: anjana.bali@cup.edu.in.'}, {'lastname': 'Singh', 'firstname': 'Nirmal', 'initials': 'N', 'affiliation': 'Department of Pharmaceutical Sciences and Drug Research, Punjabi University Patiala, Patiala 147002, India.'}, {'lastname': 'Jaggi', 'firstname': 'Amteshwar Singh', 'initials': 'AS', 'affiliation': 'Department of Pharmaceutical Sciences and Drug Research, Punjabi University Patiala, Patiala 147002, India. Electronic address: amteshwarjaggi@yahoo.co.in.'}]",,,,Copyright © 2022 Elsevier Ltd. All rights reserved.,10.1016/j.npep.2022.102260,<Element 'PubmedArticle' at 0x7f05db792f40>
96,"35648353
29671019
30612672
30997025
27825853
30505169
34521354
32394729
13967893
28791538
30758795
34421241
5707208
30706423
29080524
16186112
30013308
34664771
12080361
402499
32153214
33855084
29557751
31853270
23821590
34199189
33545766
18110453
22833841
30680205
31136753
25792098
30312649
34036312
33488353
29688418
25134454
31331528
33933775
32775714
28413320
30406177
14034603
20148699
24351827
24861936
32163746
11846609
27100828
31299621
32215265
32581807
6751596
24376630
29504497
36810
19706731
31934821
13458125
2424556
29867445
31956306
32528016
32572985
29244763
25381574
22605562
32994730
28790390
31781332
26797684
33232435
33140083
25047101",Nattokinase attenuates bisphenol A or gamma irradiation-mediated hepatic and neural toxicity by activation of Nrf2 and suppression of inflammatory mediators in rats.,"Nattokinase (NK), a protease enzyme produced by Bacillus subtilis, has various biological effects such as lipid-lowering activity, antihypertensive, antiplatelet/anticoagulant, and neuroprotective effects. Exposure to environmental toxicants such as bisphenol A (BPA) or γ-radiation (IR) causes multi-organ toxicity through several mechanisms such as impairment of oxidative status, signaling pathways, and hepatic and neuronal functions as well as disruption of the inflammatory responses. Therefore, this study is designed to evaluate the ameliorative effect of NK against BPA- or IR-induced liver and brain damage in rats. Serum ammonia level and liver function tests were measured in addition to brain oxidative stress markers, amyloid-beta, tau protein, and neuroinflammatory mediators. Moreover, relative quantification of brain nuclear factor-erythroid 2-related factor-2 (Nrf2)/heme oxygenase-1 (HO-1) genes, as well as apoptotic markers in brain tissue, was carried out in addition to histopathological examination. The results showed that NK improved liver functions, impaired oxidative status, the cholinergic deficits, and minified the misfolded proteins aggregates. Furthermore, NK alleviated the neuroinflammation via modulating NF-κB/Nrf2/HO-1 pathway and glial cell activation in addition to their antiapoptotic effect. Collectively, the current results revealed the protective effect of NK against hepatic and neurotoxicity derived from BPA or IR.","['Bisphenol A', 'Gamma irradiation', 'Inflammatory response', 'NF-κB/Nrf2/HO-1', 'Nattokinase', 'Oxidative stress']",Environmental science and pollution research international,2022-06-02,"[{'lastname': 'Elbakry', 'firstname': 'Mustafa M M', 'initials': 'MMM', 'affiliation': 'Biochemistry Department, Faculty of Science, Ain Shams University, Cairo, Egypt.'}, {'lastname': 'Mansour', 'firstname': 'Somaya Z', 'initials': 'SZ', 'affiliation': 'Radiation Biology Research, National Center for Radiation Research and Technology, Egyptian Atomic Energy Authority, Nasr City, Cairo, 11787, Egypt.'}, {'lastname': 'Helal', 'firstname': 'Hamed', 'initials': 'H', 'affiliation': 'Zoology Department, Faculty of Science, Al-Azhar University, Cairo, Egypt.'}, {'lastname': 'Ahmed', 'firstname': 'Esraa S A', 'initials': 'ESA', 'affiliation': 'Radiation Biology Research, National Center for Radiation Research and Technology, Egyptian Atomic Energy Authority, Nasr City, Cairo, 11787, Egypt. esraa.tamim@yahoo.com.'}]",,,,© 2022. The Author(s).,"10.1007/s11356-022-21126-9
10.1007/s00210-018-1497-1
10.1016/j.jtherbio.2018.12.013
10.1039/c8tx00312b
10.1016/j.bbadis.2016.11.005
10.1016/j.sjbs.2018.07.002
10.1186/s12199-021-01010-7
10.1177/0960327120921440
10.3233/NUA-150051
10.1007/s10787-017-0381-9
10.1007/s11356-019-04487-6
10.4103/ijoem.IJOEM_198_20
10.1007/s40265-018-1017-0
10.1016/j.redox.2017.10.014
10.1074/jbc.M505733200
10.1177/1177271918785130
10.1002/tox.23384
10.1038/sj.bmt.1703568
10.1258/002367777780959175
10.1111/j.1365-2559.1990.tb00755.x
10.1177/0960327120909882
10.1155/2021/8843218
10.2174/1570163815666180320111937
10.3892/etm.2019.8193
10.1177/0960327112467040
10.3390/nu13062031
10.21037/apm-20-2284
10.1016/S0021-9258(18)57021-6
10.3389/fonc.2012.00073
10.3892/mco.2018.1790
10.1016/j.lfs.2019.05.067
10.1016/S1474-4422(15)70016-5
10.1016/j.fct.2018.09.078
10.1167/iovs.62.6.25
10.3389/fnins.2020.613225
10.18869/acadpub.ijrr.17.2.229
10.1186/s41936-018-0015-9
10.1016/j.nutres.2014.07.010
10.1016/j.jtherbio.2019.04.012
10.1016/j.scitotenv.2021.147384
10.1016/j.heliyon.2020.e04499
10.1016/j.jgr.2016.02.006
10.1016/j.trci.2018.06.014
10.24099/vet.arhiv.0438
10.3109/09553000903419346
10.3390/ijms141224438
10.1111/jnc.12769
10.1016/j.biopha.2020.110074
10.1006/meth.2001.1262
10.1007/s00018-016-2223-0
10.1016/j.envres.2019.108575
10.22088/IJMCM.BUMS.8.2.141
10.3389/fphar.2020.00852
10.1093/clinchem/28.10.2007
10.1371/journal.pone.0083049
10.1080/09553002.2018.1440092
10.1016/j.egyr.2019.11.011
10.1016/0003-2697(79)90738-3
10.1124/mol.109.058180
10.1089/jmf.2019.0183
10.1093/ajcp/28.1.56
10.1016/0006-8993(86)90399-9
10.3389/fnagi.2018.00134
10.3389/fnagi.2019.00357
10.1038/s41598-020-65229-0
10.1111/jfbc.13326
10.3390/ijms18122726
10.1007/s12035-014-8940-1
10.1002/jnr.23073
10.1016/j.sjbs.2020.06.020
10.6227/jfda.2012200317
10.1038/s41598-017-07544-7
10.1155/2019/3010342
10.1007/s12035-015-9628-x
10.1039/d0fo02349c
10.1093/jrr/rraa093
10.1007/s10753-014-9971-5",<Element 'PubmedArticle' at 0x7f05db782180>
97,"35642214
26644079
20638485
10683423
27959620
20048196
30318562
26324508
28826800
33842566
27568995
24381729
18026097
30108586
15831717
27714685
24889886
14980203
15601948
21778362
15890528
19193879
25002752
21804537
27459405
24669294
32023447
31585077
32259484
30539780
20547972
22958438
26056339
25963715
26874752
24324037
27155147
16940209
27113409
9809195
17519130
29351470
22526255
25302502
22387113
32532282
6132853
29038201
1655143
1317760
20074796
32087235
26374897
25047746
25732305
34489683
25568124
31924219
28698257
23608137
31421410
25811788
23441900
26637556
34610452
28143587
25870193
35113664
30612527
28222814
26715471
31923755
26254332
24561814
20156424
15148057
24794248
22591793
16242142
32566102
24879505
25524407
21487505
30353660
30978539
27184295
26344664
25446007
28320099
28164443
32963707",Microglia-Mediated Neuroinflammation: A Potential Target for the Treatment of Cardiovascular Diseases.,"Microglia are tissue-resident macrophages of the central nervous system (CNS). In the CNS, microglia play an important role in the monitoring and intervention of synaptic and neuron-level activities. Interventions targeting microglia have been shown to improve the prognosis of various neurological diseases. Recently, studies have observed the activation of microglia in different cardiovascular diseases. In addition, different approaches that regulate the activity of microglia have been shown to modulate the incidence and progression of cardiovascular diseases. The change in autonomic nervous system activity after neuroinflammation may be a potential intermediate link between microglia and cardiovascular diseases. Here, in this review, we will discuss recent updates on the regulatory role of microglia in hypertension, myocardial infarction and ischemia/reperfusion injury. We propose that microglia serve as neuroimmune modulators and potential targets for cardiovascular diseases.","['autonomic nervous system', 'central-peripheral crosstalk', 'neuroimmune', 'sympathetic nervous system']",Journal of inflammation research,2022-06-02,"[{'lastname': 'Wang', 'firstname': 'Menglong', 'initials': 'M', 'affiliation': ""Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan, 430060, People's Republic of China.\nCardiovascular Research Institute, Wuhan University, Wuhan, 430060, People's Republic of China.\nHubei Key Laboratory of Cardiology, Wuhan, 430060, People's Republic of China.""}, {'lastname': 'Pan', 'firstname': 'Wei', 'initials': 'W', 'affiliation': ""Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan, 430060, People's Republic of China.\nCardiovascular Research Institute, Wuhan University, Wuhan, 430060, People's Republic of China.\nHubei Key Laboratory of Cardiology, Wuhan, 430060, People's Republic of China.""}, {'lastname': 'Xu', 'firstname': 'Yao', 'initials': 'Y', 'affiliation': ""Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan, 430060, People's Republic of China.\nCardiovascular Research Institute, Wuhan University, Wuhan, 430060, People's Republic of China.\nHubei Key Laboratory of Cardiology, Wuhan, 430060, People's Republic of China.""}, {'lastname': 'Zhang', 'firstname': 'Jishou', 'initials': 'J', 'affiliation': ""Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan, 430060, People's Republic of China.\nCardiovascular Research Institute, Wuhan University, Wuhan, 430060, People's Republic of China.\nHubei Key Laboratory of Cardiology, Wuhan, 430060, People's Republic of China.""}, {'lastname': 'Wan', 'firstname': 'Jun', 'initials': 'J', 'affiliation': ""Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan, 430060, People's Republic of China.\nCardiovascular Research Institute, Wuhan University, Wuhan, 430060, People's Republic of China.\nHubei Key Laboratory of Cardiology, Wuhan, 430060, People's Republic of China.""}, {'lastname': 'Jiang', 'firstname': 'Hong', 'initials': 'H', 'affiliation': ""Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan, 430060, People's Republic of China.\nCardiovascular Research Institute, Wuhan University, Wuhan, 430060, People's Republic of China.\nHubei Key Laboratory of Cardiology, Wuhan, 430060, People's Republic of China.""}]",,,,© 2022 Wang et al.,"10.2147/JIR.S350109
10.1016/j.resp.2015.11.015
10.1016/j.biocel.2010.07.005
10.1016/S0306-4522(99)00538-2
10.1146/annurev-physiol-022516-034406
10.1161/HYPERTENSIONAHA.109.142042
10.1007/s12264-018-0298-3
10.1161/HYPERTENSIONAHA.115.03624
10.1016/j.ijcard.2017.08.011
10.3389/fcvm.2021.668387
10.1016/j.autneu.2016.08.014
10.12703/P5-53
10.1038/nn2014
10.3389/fimmu.2018.01753
10.1126/science.1110647
10.1186/1742-2094-11-98
10.1016/S0896-6273(04)00069-8
10.1523/JNEUROSCI.2251-04.2004
10.1126/science.1202529
10.1016/j.mcn.2005.03.005
10.1523/JNEUROSCI.5505-08.2009
10.1084/jem.20132477
10.1038/nn.2887
10.1038/nn.4338
10.12703/P6-13
10.1016/j.celrep.2020.01.010
10.1016/j.cell.2019.08.053
10.1016/j.cell.2020.03.021
10.1016/j.cyto.2018.07.003
10.1161/HYPERTENSIONAHA.110.150409
10.1186/1742-2094-9-212
10.1161/HYPERTENSIONAHA.115.05333
10.1161/CIRCRESAHA.117.305853
10.1016/j.jjcc.2016.01.004
10.1161/HYPERTENSIONAHA.113.02429
10.1016/j.neuroscience.2016.04.044
10.1016/j.pharmthera.2016.04.006
10.1111/j.1440-1681.1998.tb02303.x
10.1007/s11906-007-0041-3
10.1152/ajpheart.00616.2017
10.1161/HYPERTENSIONAHA.111.190108
10.1371/journal.pone.0092937
10.1016/j.neuroscience.2012.02.018
10.1016/0306-3623(83)90001-0
10.1161/HYPERTENSIONAHA.117.09744
10.1111/j.1476-5381.1991.tb12341.x
10.1042/cs0820513
10.1016/j.npep.2009.12.011
10.1016/j.phrs.2020.104715
10.1074/jbc.M115.677286
10.1038/npp.2014.164
10.1084/jem.20142322
10.3389/fnagi.2021.716917
10.1523/JNEUROSCI.3561-14.2015
10.1186/s12974-019-1673-3
10.1161/STROKEAHA.117.017370
10.1016/j.psyneuen.2013.03.017
10.1016/j.redox.2019.101295
10.1371/journal.pone.0122850
10.2174/1389203711314010006
10.1152/ajpheart.00247.2015
10.1016/j.phrs.2021.105877
10.1186/s40168-016-0222-x
10.1161/HYPERTENSIONAHA.115.05315
10.1161/CIRCRESAHA.121.319816
10.1161/CIRCRESAHA.118.313882
10.1017/S0954422416000275
10.1186/s12967-015-0759-7
10.1016/j.jnutbio.2019.108318
10.1152/ajpheart.00349.2015
10.1249/MSS.0000000000000307
10.1016/j.brainres.2010.02.028
10.1152/ajpheart.01072.2003
10.1016/j.autneu.2014.03.007
10.1016/j.autneu.2012.04.004
10.1016/j.yjmcc.2005.09.002
10.1155/2020/7956274
10.1007/s00380-014-0527-2
10.1016/j.neulet.2014.12.026
10.4161/self.1.4.13736
10.1111/jcmm.13890
10.1016/j.redox.2019.101186
10.1016/j.neures.2016.05.002
10.1179/1743132815Y.0000000090
10.1016/j.brainres.2014.10.005
10.1016/j.biopha.2017.03.024
10.1002/jbio.201600244
10.1155/2020/9343160",<Element 'PubmedArticle' at 0x7f05da240b30>
98,"35624485
503201
8580448
25545035
30242884
33432588
32685016
26735612
26359987
26130320
23661536
20811163
16777578
30356688
30218573
31420466
25716996
31545975
22933083
34600916
11722621
32380695
23899494
31937929
21871655
21708926
24460899
24553808
21517957
8609593
21893693
19069959
12114284
2318959
30648758
18507659
2496815
10484950
25546814
17014688
11200779
26292662
26130320
29679979
28099758
23551402
26465239
30891627
30853312
33106495
28684304
28152213
25612066
16021634
15230868
32520581
26797926
9138098
12603316
26465080
23617726
23415911
29749372
25003952
24389582
32902872
27562847
28990401
31152156
17081104
18510923
12370347
15100259
32566089","Melatonin, an endogenous hormone, modulates Th17 cells via the reactive-oxygen species/TXNIP/HIF-1α axis to alleviate autoimmune uveitis.","Melatonin, an indoleamine produced by the pineal gland, plays a pivotal role in maintaining circadian rhythm homeostasis. Recently, the strong antioxidant and anti-inflammatory properties of melatonin have attracted attention of researchers. We evaluated the therapeutic efficacy of melatonin in experimental autoimmune uveitis (EAU), which is a representative animal model of human autoimmune uveitis.
EAU was induced in mice via immunization with the peptide interphotoreceptor retinoid binding protein 1-20 (IRBP
Melatonin treatment resulted in notable attenuation of ocular inflammation in EAU mice, evidenced by decreasing optic disc edema, few signs of retinal vasculitis, and minimal retinal and choroidal infiltrates. Mechanistic studies revealed that melatonin restricted the proliferation of peripheral Th1 and Th17 cells by suppressing their transcription factors and potentiated Treg cells. In vitro studies corroborated that melatonin restrained the polarization of retina-specific T cells towards Th17 and Th1 cells in addition to enhancing the proportion of Treg cells. Pretreatment of retina-specific T cells with melatonin failed to induce EAU in naïve recipients. Furthermore, the ROS/ TXNIP/ HIF-1α pathway was shown to mediate the therapeutic effect of melatonin in EAU.
Melatonin regulates autoimmune T cells by restraining effector T cells and facilitating Treg generation, indicating that melatonin could be a hopeful treatment alternative for autoimmune uveitis.","['Experimental autoimmune uveitis', 'HIF-1α', 'Melatonin', 'Reactive-oxygen species', 'TXNIP', 'Th17/Treg']",Journal of neuroinflammation,2022-05-28,"[{'lastname': 'Huang', 'firstname': 'Jun', 'initials': 'J', 'affiliation': 'State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Guangdong Provincial Key Laboratoryof Ophthalmologyand VisualScience, Sun Yat-Sen University, Guangzhou, 510060, China.'}, {'lastname': 'Li', 'firstname': 'Zhuang', 'initials': 'Z', 'affiliation': 'State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Guangdong Provincial Key Laboratoryof Ophthalmologyand VisualScience, Sun Yat-Sen University, Guangzhou, 510060, China.'}, {'lastname': 'Hu', 'firstname': 'Yunwei', 'initials': 'Y', 'affiliation': 'State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Guangdong Provincial Key Laboratoryof Ophthalmologyand VisualScience, Sun Yat-Sen University, Guangzhou, 510060, China.'}, {'lastname': 'Li', 'firstname': 'Zuoyi', 'initials': 'Z', 'affiliation': 'State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Guangdong Provincial Key Laboratoryof Ophthalmologyand VisualScience, Sun Yat-Sen University, Guangzhou, 510060, China.'}, {'lastname': 'Xie', 'firstname': 'Yanyan', 'initials': 'Y', 'affiliation': 'State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Guangdong Provincial Key Laboratoryof Ophthalmologyand VisualScience, Sun Yat-Sen University, Guangzhou, 510060, China.'}, {'lastname': 'Huang', 'firstname': 'Haixiang', 'initials': 'H', 'affiliation': 'State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Guangdong Provincial Key Laboratoryof Ophthalmologyand VisualScience, Sun Yat-Sen University, Guangzhou, 510060, China.'}, {'lastname': 'Chen', 'firstname': 'Qian', 'initials': 'Q', 'affiliation': 'State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Guangdong Provincial Key Laboratoryof Ophthalmologyand VisualScience, Sun Yat-Sen University, Guangzhou, 510060, China.'}, {'lastname': 'Chen', 'firstname': 'Guanyu', 'initials': 'G', 'affiliation': 'State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Guangdong Provincial Key Laboratoryof Ophthalmologyand VisualScience, Sun Yat-Sen University, Guangzhou, 510060, China.'}, {'lastname': 'Zhu', 'firstname': 'Wenjie', 'initials': 'W', 'affiliation': 'State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Guangdong Provincial Key Laboratoryof Ophthalmologyand VisualScience, Sun Yat-Sen University, Guangzhou, 510060, China.'}, {'lastname': 'Chen', 'firstname': 'Yuxi', 'initials': 'Y', 'affiliation': 'State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Guangdong Provincial Key Laboratoryof Ophthalmologyand VisualScience, Sun Yat-Sen University, Guangzhou, 510060, China.'}, {'lastname': 'Su', 'firstname': 'Wenru', 'initials': 'W', 'affiliation': 'State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Guangdong Provincial Key Laboratoryof Ophthalmologyand VisualScience, Sun Yat-Sen University, Guangzhou, 510060, China.'}, {'lastname': 'Chen', 'firstname': 'Xiaoqing', 'initials': 'X', 'affiliation': 'State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Guangdong Provincial Key Laboratoryof Ophthalmologyand VisualScience, Sun Yat-Sen University, Guangzhou, 510060, China. chenxiaoqing@gzzoc.com.'}, {'lastname': 'Liang', 'firstname': 'Dan', 'initials': 'D', 'affiliation': 'State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Guangdong Provincial Key Laboratoryof Ophthalmologyand VisualScience, Sun Yat-Sen University, Guangzhou, 510060, China. liangdan@gzzoc.com.'}]",,,"Melatonin treatment resulted in notable attenuation of ocular inflammation in EAU mice, evidenced by decreasing optic disc edema, few signs of retinal vasculitis, and minimal retinal and choroidal infiltrates. Mechanistic studies revealed that melatonin restricted the proliferation of peripheral Th1 and Th17 cells by suppressing their transcription factors and potentiated Treg cells. In vitro studies corroborated that melatonin restrained the polarization of retina-specific T cells towards Th17 and Th1 cells in addition to enhancing the proportion of Treg cells. Pretreatment of retina-specific T cells with melatonin failed to induce EAU in naïve recipients. Furthermore, the ROS/ TXNIP/ HIF-1α pathway was shown to mediate the therapeutic effect of melatonin in EAU.",© 2022. The Author(s).,"10.1186/s12974-022-02477-z
10.1038/282301a0
10.1097/00001756-199510010-00033
10.1111/jpi.12204
10.1111/jpi.12525
10.1002/jcp.30269
10.7150/thno.45862
10.1016/j.intimp.2015.12.020
10.1016/j.cell.2015.08.025
10.1016/j.bbi.2015.06.021
10.5301/ejo.5000278
10.1172/JCI42440
10.1016/j.berh.2006.03.008
10.3389/fimmu.2018.02304
10.1002/eji.201747029
10.4049/jimmunol.1801306
10.4049/jimmunol.1402650
10.1016/j.bcp.2019.113645
10.1007/978-1-60761-720-4_22
10.1016/j.bcp.2021.114793
10.1034/j.1600-065X.2001.1820102.x
10.3390/ijms21093291
10.1016/j.freeradbiomed.2013.07.036
10.1038/s41401-019-0335-4
10.1016/j.cell.2011.07.033
10.1084/jem.20110278
10.1111/jne.12134
10.1007/s00429-014-0719-7
10.1111/j.1600-079X.2011.00856.x
10.1111/j.1600-079X.1995.tb00168.x
10.3923/pjbs.2007.1471.1476
10.1111/j.1749-6632.2002.tb04227.x
10.1016/0165-5728(90)90139-E
10.1111/jpi.12560
10.1111/j.1365-2125.2008.03181.x
10.1136/bmj.298.6675.705
10.1111/jpi.12203
10.1111/j.1600-079X.2006.00377.x
10.1023/A:1026552405042
10.1111/jpi.12270
10.1016/j.bbi.2015.06.021
10.1186/s12974-018-1157-x
10.1111/jpi.12389
10.1111/jpi.12054
10.1111/jpi.12287
10.1007/s00281-019-00733-8
10.1016/j.jaut.2019.02.006
10.1038/s41467-020-18961-0
10.1016/j.bcp.2017.06.136
10.1111/jpi.12394
10.1111/jpi.12208
10.1002/jcp.20461
10.1111/j.1600-079X.2004.00135.x
10.1111/jpi.12312
10.1002/(SICI)1097-4644(19970601)65:3<430::AID-JCB12>3.0.CO;2-J
10.1046/j.1432-1033.2003.03430.x
10.1517/14728222.2016.1091882
10.3109/08830185.2012.755176
10.1016/j.immuni.2012.10.020
10.1038/s41467-018-04274-w
10.1016/j.jhep.2014.06.032
10.1038/ncomms3958
10.1002/eji.202048851
10.1007/s11481-016-9702-9
10.1089/ars.2017.7357
10.1038/s41385-019-0177-x
10.1016/j.cell.2008.05.009
10.4049/jimmunol.169.8.4183
10.4049/jimmunol.172.9.5213",<Element 'PubmedArticle' at 0x7f05d8501950>
99,"35574174
18395582
27900828
31078196
22764360
24701496
19105683
19402278
12892987
29986177
33968873
33156860
33240729
33430265
19402804
12409855
22242652
22611222
26351969
8514462
7739706
10530636
23744611
27378473
11191167
19622211
1897330
3140572
15229203
16135578
22336820
27923181
32730861
15198787
29072794
17579609
22814368
17085022
12215085
32268180
10809171
18374402
7970453
2011161
23739217
22296075
33297719
33641380
31649968
2422758
15895085
19272715
7962316
9351749
24846476
10700721
9435325
15950994
26272051
15708482
25459890
28319848
34597899
16724185
21600269
30177236
33049432
30452945
22394303
11152912
24776841
28619476
28278440
32435663
30790145
17599809
28044059
34035477
30356121
32695026
27268465
22865231
16723122
15118249
19150053
29133955
19223611
24717337
28760971
25035435
16403011
27135720
32526539
33444909
31364524
25110962
20084389
33919885
33530988
31154571
20933336
25200490
20156515
27488628
25560580
20385066
7515592
32217347
31630609
26851553
26226414
28199198
23978486
17182282
18769373
12689771
15677881
16355225
10393886
15813942
1446611
18524541
1966304
9626129
17040565
24044974
22939998
11331087
2546650
8799552
31357135
26601989
30840651
33965699
32936329
34488087
32033286
32103961
33271293
33404701
32984973
33477613
30293199
34999294
25647070
21775045
32845159
31788825
30783069
32522750
31987230
31780016
31464546
30918875
31104056
31624297
30880352",Recent advances in understanding/management of premenstrual dysphoric disorder/premenstrual syndrome.,"Premenstrual syndrome (PMS) and premenstrual dysphoric disorder (PMDD) are common disorders of the luteal phase of the menstrual cycle and are characterized by moderate to severe physical, affective, or behavioral symptoms that impair daily activities and quality of life. PMS and PMDD have recently raised great interest in the research community for their considerable global prevalence. The etiology of PMS/PMDD is complex. Ovarian reproductive steroids (estradiol and progesterone) are considered pathogenetic effectors, but the key feature seems to be an altered sensitivity of the GABAergic central inhibitory system to allopregnanolone, a neurosteroid derived from progesterone produced after ovulation. Also, a reduced availability of serotonin seems to be involved. New insights point to a role for genetic and epigenetic modifications of hormonal and neurotransmitter pathways, and inflammation is the potential link between peripheral and neurological integrated responses to stressors. Thus, new therapeutic approaches to PMS/PMDD include inhibition of progesterone receptors in the brain (i.e., with ulipristal acetate), reduced conversion of progesterone to its metabolite allopregnanolone with dutasteride, and possible modulation of the action of allopregnanolone on the brain GABAergic system with sepranolone. Further research is needed to better understand the interaction between peripheral inflammatory molecules (cytokines, interleukins, C-reactive protein, and reactive oxygen species) and the brain neurotransmitter systems in women with PMS/PMDD. If confirmed, neuroinflammation could lead both to develop targeted anti-inflammatory therapies and to define prevention strategies for the associated chronic inflammatory risk in PMS/PMDD. Finally, the observed association between premenstrual disorders and psychological diseases may guide prompt and adequate interventions to achieve a better quality of life.","['Premenstrual syndrome', 'allopregnanolone', 'depression', 'inflammation', 'neurosteroids', 'premenstrual dysphoric disorder', 'prevention', 'progesterone', 'therapeutic strategies']",Faculty reviews,2022-05-17,"[{'lastname': 'Tiranini', 'firstname': 'Lara', 'initials': 'L', 'affiliation': 'Research Center for Reproductive Medicine, Gynecological Endocrinology and Menopause, IRCCS San Matteo Foundation, Pavia, Italy.\nDepartment of Clinical, Surgical, Diagnostic and Pediatric Sciences, University of Pavia, Pavia, Italy.'}, {'lastname': 'Nappi', 'firstname': 'Rossella E', 'initials': 'RE', 'affiliation': 'Research Center for Reproductive Medicine, Gynecological Endocrinology and Menopause, IRCCS San Matteo Foundation, Pavia, Italy.\nDepartment of Clinical, Surgical, Diagnostic and Pediatric Sciences, University of Pavia, Pavia, Italy.'}]",,,,Copyright: © 2022 Nappi RE et al.,"10.12703/r/11-11
10.1016/S0140-6736(08)60527-9
10.1111/1471-0528.14260
10.1016/j.mcna.2019.02.007
10.1176/appi.ajp.2012.11081302
10.7860/JCDR/2014/8024.4021
10.1089/jwh.2008.0932
10.1016/s0306-4530(03)00098-2
10.1016/j.psychres.2018.06.005
10.3389/fpubh.2021.596128
10.1371/journal.pone.0241702
10.7759/cureus.11595
10.3390/healthcare9010056
10.1586/erp.09.14
10.1080/07399332.2011.610530
10.1258/mi.2012.012014
10.1001/jamapsychiatry.2015.1472
10.2190/J2W0-RTGD-NYKK-FF77
10.1056/NEJM199506083322301
10.1001/archpsyc.56.10.932
10.1002/14651858.CD001396.pub3
10.1007/s00737-016-0631-7
10.3109/01674820009085589
10.1783/147118909788708147
10.1530/acta.0.1250132
10.3109/00016348809004191
10.1093/humrep/deh354
10.1097/01.AOG.0000175834.77215.2e
10.1002/14651858.CD006586.pub4
10.1016/j.psyneuen.2016.11.033
10.1016/j.yfrne.2020.100856
10.1111/j.1471-0528.2004.00135.x
10.1111/jne.12553
10.1038/sj.mp.4002030
10.1016/j.yhbeh.2012.07.005
10.1016/j.pscychresns.2006.05.002
10.1001/archpsyc.59.9.851
10.1016/j.yfrne.2020.100838
10.1016/s0024-3205(00)00497-5
10.1016/j.yfrne.2008.02.001
10.1056/NEJM199104253241705
10.1093/humrep/det247
10.1056/NEJMoa1103182
10.1176/appi.ajp.2020.20030286
10.1176/appi.ajp.2020.20121793
10.1016/j.ynstr.2019.100196
10.1126/science.2422758
10.1038/nn1469
10.1016/j.psyneuen.2009.02.003
10.1210/jcem.79.5.7962316
10.1016/S0029-7844(97)00417-1
10.1007/s00213-014-3599-x
10.1530/eje.0.1420269
10.1056/NEJM199801223380401
10.1016/j.neuropharm.2005.04.026
10.1038/npp.2015.246
10.1016/j.neuroscience.2004.11.010
10.1016/j.psyneuen.2014.10.025
10.1016/j.psyneuen.2017.02.031
10.1016/j.psyneuen.2021.105426
10.1007/s00213-006-0417-0
10.1016/j.neuroscience.2011.03.061
10.1016/S0140-6736(18)31551-4
10.1016/j.jad.2020.09.130
10.1016/j.biopsycho.2018.10.014
10.3109/09513590.2012.651932
10.1016/s0029-7844(00)01112-1
10.1159/000358838
10.1016/S0140-6736(17)31264-3
10.1016/j.psyneuen.2017.02.012
10.1016/j.ynstr.2020.100212
10.1007/s40263-019-00605-7
10.1016/j.biopsych.2006.12.019
10.1038/mp.2016.229
10.1038/s41380-021-01144-8
10.1038/s41380-018-0274-3
10.3389/fpsyt.2020.00572
10.1089/jwh.2016.5937
10.1007/s11154-012-9223-7
10.1016/j.bcp.2006.04.011
10.1262/jrd.50.215
10.1016/j.biopsych.2008.11.029
10.1038/mp.2017.205
10.2337/dc08-1979
10.1515/cclm-2014-0011
10.1073/pnas.1710519114
10.1093/humrep/deu170
10.1111/j.1365-2362.2006.01591.x
10.1089/jwh.2015.5529
10.1016/j.jpsychores.2020.110158
10.1016/j.jpsychores.2020.110355
10.1017/neu.2019.30
10.3109/01443615.2014.948399
10.1007/s00404-009-1347-y
10.3390/antiox10040604
10.1186/s12905-021-01187-7
10.1007/s12011-019-01757-9
10.1016/j.psyneuen.2010.08.006
10.1016/j.jtemb.2014.07.019
10.1016/j.pnpbp.2010.02.010
10.1523/JNEUROSCI.3393-15.2016
10.1016/j.pharep.2014.08.006
10.1152/ajpregu.1994.266.5.R1711
10.1016/j.jad.2020.03.033
10.1177/2053369119875386
10.1016/j.bbi.2016.02.001
10.1016/j.autrev.2015.07.011
10.2741/4539
10.1016/j.pneurobio.2013.07.005
10.1016/j.coph.2006.11.005
10.1038/ncpneuro0883
10.1016/S0166-2236(03)00068-7
10.1159/000083657
10.1038/nature04223
10.1073/pnas.96.14.7714
10.1111/j.1460-9568.2005.03959.x
10.1210/endo.131.6.1446611
10.1016/j.eplepsyres.2008.04.013
10.1016/0306-4530(90)90072-h
10.1210/jcem.83.6.4899
10.1186/1744-8069-2-32
10.1016/j.pnpbp.2013.09.005
10.1016/j.neuropharm.2012.08.012
10.1016/s0006-3223(00)01044-1
10.1016/0006-8993(89)90938-4
10.1111/j.1476-5381.1996.tb15476.x
10.1016/j.psyneuen.2019.104372
10.1093/aje/kwv159
10.1371/journal.pone.0212557
10.1016/j.genhosppsych.2021.04.009
10.1007/s00737-020-01054-8
10.1016/j.jad.2021.08.082
10.3390/ijerph17030988
10.2147/NDT.S202881
10.1016/j.jpag.2020.11.019
10.1007/s00737-020-01094-0
10.1111/ppc.12628
10.3390/ijerph18020781
10.1007/s00737-018-0916-0
10.1016/j.psychres.2021.114381
10.1007/s00737-015-0505-4
10.1016/j.ejogrb.2011.06.041
10.1080/13548506.2020.1810718
10.1111/ppc.12460
10.1159/000496237
10.3399/bjgpopen20X101032
10.1016/j.ctim.2019.102272
10.1016/j.ctim.2019.08.024
10.1089/jwh.2019.7770
10.5468/ogs.2019.62.2.73
10.1159/000500016
10.1038/s41598-019-51498-x
10.1007/s12011-019-01672-z",<Element 'PubmedArticle' at 0x7f05dc2c52c0>
100,35562014,Biochanin A as a modulator of the inflammatory response: An updated overview and therapeutic potential.,"Uncontrolled inflammation and failure to resolve the inflammatory response are crucial factors involved in the progress of inflammatory diseases. Current therapeutic strategies aimed at controlling excessive inflammation are effective in some cases, though they may be accompanied by severe side effects, such as immunosuppression. Phytochemicals as a therapeutic alternative can have a fundamental impact on the different stages of inflammation and its resolution. Biochanin A (BCA) is an isoflavone known for its wide range of pharmacological properties, especially its marked anti-inflammatory effects. Recent studies have provided evidence of BCA's abilities to activate events essential for resolving inflammation. In this review, we summarize the most recent findings from pre-clinical studies of the pharmacological effects of BCA on the complex signaling network associated with the onset and resolution of inflammation and BCA's potential protective functionality in several models of inflammatory diseases, such as arthritis, pulmonary disease, neuroinflammation, and metabolic disease.","['17-β-estradiol (PubChem CID: 5757)', 'Anti-inflammation', 'Baicalin (PubChem CID: 64982)', 'Biochanin A', 'Biochanin A (PubChem CID: 5280373)', 'Catechin (PubChem CID: 9064)', 'Daidzein (PubChem CID: 5281708)', 'Genistein (PubChem CID: 5280961)', 'Inflammation', 'Inflammation Resolution', 'Phytotherapy', 'Wogonin (PubChem CID: 5281703)', 'cAMP (PubChem CID: 6076)']",Pharmacological research,2022-05-14,"[{'lastname': 'Felix', 'firstname': 'Franciel Batista', 'initials': 'FB', 'affiliation': 'Department of Morphology, Institute of Biological Sciences, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil.'}, {'lastname': 'Vago', 'firstname': 'Juliana Priscila', 'initials': 'JP', 'affiliation': 'Experimental Rheumatology, Department of Rheumatology, Radboud Institute for Molecular Life Sciences, Radboud University Medical Center, Nijmegen, The Netherlands.'}, {'lastname': 'Beltrami', 'firstname': 'Vinícius Amorim', 'initials': 'VA', 'affiliation': 'Department of Morphology, Institute of Biological Sciences, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil.'}, {'lastname': 'Araújo', 'firstname': 'Jessica Maria Dantas', 'initials': 'JMD', 'affiliation': 'Cell Migration Laboratory, Department of Physiology, Universidade Federal de Sergipe, São Cristovão, Brazil.'}, {'lastname': 'Grespan', 'firstname': 'Renata', 'initials': 'R', 'affiliation': 'Cell Migration Laboratory, Department of Physiology, Universidade Federal de Sergipe, São Cristovão, Brazil.'}, {'lastname': 'Teixeira', 'firstname': 'Mauro Martins', 'initials': 'MM', 'affiliation': 'Department of Biochemistry and Immunology, Institute of Biological Sciences, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil.'}, {'lastname': 'Pinho', 'firstname': 'Vanessa', 'initials': 'V', 'affiliation': 'Department of Morphology, Institute of Biological Sciences, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil. Electronic address: vpinho@icb.ufmg.br.'}]",,,,Copyright © 2022 Elsevier Ltd. All rights reserved.,10.1016/j.phrs.2022.106246,<Element 'PubmedArticle' at 0x7f05daa4def0>
101,"35547876
25651787
30787125
31805526
29632055
29248428
23874095
32297442
28112552
32138535
34150784
26217082
24344728
31855257
30805077
26738499
25657670
33976542
33488793
24830939
32305573
24066010
31008843
26556766
27613370
31256014
28068938
27013473
29735975
25481535
33255279
29034548
31775332
30904013
29088102
29315282
25254060
28069044
24157984
32514290
30798684
25449310
25579196
32378261
28270726
24787745
31635295
30906450
26386034
26680224
28449490
25152759
21425582
19873920
17828268
26159389
26925806
34552585
23081701
22020068
32943934
33456484
31312613
32292489
24228059
29018212
34355266
11357145
27148472
29939325
18836471
31839752
34629905
34290337
34729102
33574698
34983587
35178106
31833790
29234451
33178318
22365541
34281592
22837036
22710756
34992414
29115896
30100992
27330845
21703296
24947870
30186550
26886752
25922060
34439331
34371713
34199874
33684727
34055878
24562381
32791039
34646018
34400883
34112755
27295554
28445461
29332937
28371798",Clinical Efficacy and Potential Mechanisms of Acupoint Stimulation Combined With Chemotherapy in Combating Cancer: A Review and Prospects.,"Although chemotherapy is the first-line treatment strategy for a variety of tumors, its side effects have limited its efficacy. This review summarizes the progress on the use of acupoint stimulation to combat chemotherapy-associated side effects, including chemotherapy-induced peripheral neuropathy (CIPN), cognitive impairment (CICI), and gastrointestinal toxicity (GI), as well as myelosuppression and immunosuppression. It was found that acupoint stimulation attenuated CIPN and GI by modulating the 5-hydroxytryptamine system in dorsal root ganglia, the dorsal horn of the spinal cord, and the duodenum by reducing oxidative stress and neuroinflammation. Acupoint stimulation also alleviated GI by activating vagal activity in the nucleus tractus solitarius and promoting the secretion of gastrointestinal neuropeptide hormones. Acupoint stimulation restored both bone marrow hematopoiesis and immune function to combat cancer. In addition, the combination of acupoint stimulation and chemotherapy could inhibit tumor growth by promoting tumor cell apoptosis and the enrichment of chemotherapeutic agents in tumor tissue and by modulating the tumor immune microenvironment and normalizing the vasculature. Multiple evidence also indicates that neuroimmune regulation may be involved in the effects of acupoint stimulation. In conclusion, the evidence suggests that acupoint stimulation can alleviate the side effects of chemotherapy and can also assist chemotherapeutic agents in inhibiting tumor growth, which expands the clinical application of acupoint stimulation in cancer treatment. However, more high-quality clinical studies are needed to confirm the clinical value of acupoint stimulation.","['acupoint stimulation', 'acupuncture', 'cancer', 'chemotherapy', 'neuroimmune']",Frontiers in oncology,2022-05-14,"[{'lastname': 'Li', 'firstname': 'Shanshan', 'initials': 'S', 'affiliation': 'Research Center of Experimental Acupuncture Science, Tianjin University of Traditional Chinese Medicine, Tianjin, China.'}, {'lastname': 'Zhao', 'firstname': 'Suhong', 'initials': 'S', 'affiliation': 'Research Center of Experimental Acupuncture Science, Tianjin University of Traditional Chinese Medicine, Tianjin, China.'}, {'lastname': 'Guo', 'firstname': 'Yi', 'initials': 'Y', 'affiliation': 'Research Center of Experimental Acupuncture Science, Tianjin University of Traditional Chinese Medicine, Tianjin, China.\nSchool of Traditional Chinese Medicine, Tianjin University of Traditional Chinese Medicine, Tianjin, China.\nNational Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion, Tianjin, China.'}, {'lastname': 'Yang', 'firstname': 'Yuanzhen', 'initials': 'Y', 'affiliation': 'Research Center of Experimental Acupuncture Science, Tianjin University of Traditional Chinese Medicine, Tianjin, China.'}, {'lastname': 'Huang', 'firstname': 'Jin', 'initials': 'J', 'affiliation': 'Research Center of Experimental Acupuncture Science, Tianjin University of Traditional Chinese Medicine, Tianjin, China.'}, {'lastname': 'Wang', 'firstname': 'Jiaqi', 'initials': 'J', 'affiliation': 'Research Center of Experimental Acupuncture Science, Tianjin University of Traditional Chinese Medicine, Tianjin, China.'}, {'lastname': 'Lu', 'firstname': 'Shanshan', 'initials': 'S', 'affiliation': 'Research Center of Experimental Acupuncture Science, Tianjin University of Traditional Chinese Medicine, Tianjin, China.'}, {'lastname': 'Wang', 'firstname': 'Bin', 'initials': 'B', 'affiliation': ""Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin, China.""}, {'lastname': 'Chai', 'firstname': 'Chao', 'initials': 'C', 'affiliation': 'Department of Radiology, Tianjin Institute of Imaging Medicine, Tianjin First Central Hospital, School of Medicine, Nankai University, Tianjin, China.'}, {'lastname': 'Xu', 'firstname': 'Zhifang', 'initials': 'Z', 'affiliation': 'Research Center of Experimental Acupuncture Science, Tianjin University of Traditional Chinese Medicine, Tianjin, China.\nNational Clinical Research Center for Chinese Medicine Acupuncture and Moxibustion, Tianjin, China.\nSchool of Acupuncture and Moxibustion and Tuina, Tianjin University of Traditional Chinese Medicine, Tianjin, China.'}, {'lastname': 'Chin', 'firstname': 'Yenlie', 'initials': 'Y', 'affiliation': ""Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin's Clinical Research Center for Cancer, Tianjin, China.""}]",,,,"Copyright © 2022 Li, Zhao, Guo, Yang, Huang, Wang, Lu, Wang, Chai, Xu and Chin.","10.3389/fonc.2022.864046
10.3322/caac.21262
10.6004/jnccn.2019.0059
10.6004/jnccn.2018.0021
10.1016/j.ymthe.2017.11.011
10.2147/IJN.S46327
10.1634/theoncologist.2019-0489
10.1089/acm.2016.0155
10.1142/S0192415X20500135
10.3389/fmed.2021.586900
10.3748/wjg.v21.i27.8304
10.1186/1472-6882-13-362
10.1001/jamaoncol.2019.5233
10.1089/acu.2018.1316
10.1007/s10103-015-1845-z
10.3969/j.issn.1673-5374.2012.18.003
10.2147/CIA.S309082
10.3892/etm.2021.9615
10.1016/j.ctrv.2014.04.004
10.1016/j.bbi.2020.04.035
10.1155/2013/349653
10.1097/j.pain.0000000000001540
10.1016/j.ygyno.2015.11.011
10.1136/acupmed-2016-011112
10.1136/bmjspcare-2018-001542
10.1186/s12885-016-3037-z
10.1007/s10549-016-3759-2
10.12659/MSM.909712
10.1186/1472-6882-14-471
10.3390/toxins12120737
10.1002/ejp.1132
10.3390/ijms20235917
10.33549/physiolres.934084
10.3390/toxins9110351
10.1155/2014/860631
10.1186/s40880-016-0176-1
10.1016/j.ejphar.2013.09.073
10.1186/s13020-020-00333-x
10.1177/1043454218810140
10.1016/j.ygyno.2014.10.025
10.1007/s11655-014-2009-x
10.1111/ner.13158
10.3747/co.24.3296
10.1017/S1478951514000248
10.3390/biom9100624
10.3892/etm.2019.7250
10.1136/acupmed-2015-010833
10.21037/jtd.2017.03.12
10.1155/2014/217397
10.1038/ni1509
10.1016/j.jim.2015.07.001
10.1038/srep22373
10.3389/fimmu.2021.714244
10.1007/s10555-012-9397-1
10.1038/cmi.2011.47
10.2147/CMAR.S249797
10.1155/2020/3170803
10.3389/fonc.2019.00576
10.1186/s13020-020-00315-z
10.1155/2013/387169
10.1038/s41598-017-11213-0
10.1007/s00262-021-03013-3
10.1038/35077241
10.3389/fonc.2016.00066
10.1093/intimm/dxy042
10.1038/onc.2008.271
10.7150/ijms.38521
10.2147/CLEP.S324193
10.1038/s41598-021-94466-0
10.7150/jca.55803
10.2147/JPR.S292657
10.1186/s13020-021-00558-4
10.1155/2022/5572869
10.1177/1534735419886662
10.1155/2017/9854893
10.1155/2020/5691468
10.1016/j.neuron.2012.02.008
10.1186/s13020-021-00466-7
10.1038/nn.3155
10.1016/S1474-4422(12)70134-5
10.2147/JIR.S341581
10.1080/10428194.2017.1397662
10.18632/oncotarget.25718
10.14336/AD.2015.1022
10.1016/j.pbb.2011.06.015
10.1007/s00210-014-1008-y
10.1155/2018/9125601
10.1007/s10571-016-0344-5
10.1093/annonc/mdv206
10.3390/cancers13164177
10.3390/pharmaceutics13071021
10.3390/cells10061386
10.1016/j.autneu.2021.102793
10.3389/fmolb.2021.647647
10.1038/nm.3479
10.1016/j.neuron.2020.07.015
10.1038/s41586-021-04001-4
10.7150/ijms.61525
10.1038/s41467-021-23164-2
10.1038/ncb3371
10.1038/nature22311
10.1038/nri.2017.145
10.1038/nature21724",<Element 'PubmedArticle' at 0x7f05daa42ae0>
102,35533351,Angiotensin-Converting Enzyme 2 Activation Mitigates Behavioral Deficits and Neuroinflammatory Burden in 6-OHDA Induced Experimental Models of Parkinson's Disease.,"Hypertension is reported to cause major brain disorders including Parkinson's disease (PD), apart from cardiovascular and chronic kidney disorders. Considering this, for the first time, we explored the effect of modulation of the ACE2/Ang (1-7)/MasR axis using diminazene aceturate (DIZE), an ACE2 activator, in 6-hydroxydopamine (6-OHDA) induced PD model. We found that DIZE treatment improved neuromuscular coordination and locomotor deficits in the 6-OHDA induced PD rat model. Further, the DIZE-mediated activation of ACE2 led to increased tyrosine hydroxylase (TH) and dopamine transporters (DAT) expression in the rat brain, indicating the protection of dopaminergic (DAergic) neurons from 6-OHDA induced neurotoxicity. Moreover, 6-OHDA induced activation of glial cells (astrocytes and microglia) and release of neuroinflammatory mediators were attenuated by DIZE treatment in both ","['ACE2', 'DIZE', 'Parkinson’s disease', 'neuroinflammation']",ACS chemical neuroscience,2022-05-10,"[{'lastname': 'Gupta', 'firstname': 'Shivangi', 'initials': 'S', 'affiliation': 'Division of Neuroscience and Ageing Biology, CSIR-Central Drug Research Institute, Lucknow 226031, U.P., India.\nAcademy of Scientific and Innovative Research (AcSIR), Ghaziabad 201002, U.P., India.'}, {'lastname': 'Tiwari', 'firstname': 'Virendra', 'initials': 'V', 'affiliation': 'Division of Neuroscience and Ageing Biology, CSIR-Central Drug Research Institute, Lucknow 226031, U.P., India.\nAcademy of Scientific and Innovative Research (AcSIR), Ghaziabad 201002, U.P., India.'}, {'lastname': 'Tiwari', 'firstname': 'Priya', 'initials': 'P', 'affiliation': 'Division of Pharmacology, CSIR-Central Drug Research Institute, Lucknow 226031, U.P., India.\nAcademy of Scientific and Innovative Research (AcSIR), Ghaziabad 201002, U.P., India.'}, {'lastname': 'Parul', 'firstname': None, 'initials': None, 'affiliation': 'Division of Neuroscience and Ageing Biology, CSIR-Central Drug Research Institute, Lucknow 226031, U.P., India.'}, {'lastname': 'Mishra', 'firstname': 'Akanksha', 'initials': 'A', 'affiliation': 'Division of Neuroscience and Ageing Biology, CSIR-Central Drug Research Institute, Lucknow 226031, U.P., India.\nAcademy of Scientific and Innovative Research (AcSIR), Ghaziabad 201002, U.P., India.'}, {'lastname': 'Hanif', 'firstname': 'Kashif', 'initials': 'K', 'affiliation': 'Division of Pharmacology, CSIR-Central Drug Research Institute, Lucknow 226031, U.P., India.\nAcademy of Scientific and Innovative Research (AcSIR), Ghaziabad 201002, U.P., India.'}, {'lastname': 'Shukla', 'firstname': 'Shubha', 'initials': 'S', 'affiliation': 'Division of Neuroscience and Ageing Biology, CSIR-Central Drug Research Institute, Lucknow 226031, U.P., India.\nAcademy of Scientific and Innovative Research (AcSIR), Ghaziabad 201002, U.P., India.'}]",,,,,10.1021/acschemneuro.1c00797,<Element 'PubmedArticle' at 0x7f05dcde9a90>
103,"35505051
30833511",Progranulin Promotes Functional Recovery in Rats with Acute Spinal Cord Injury via Autophagy-Induced Anti-inflammatory Microglial Polarization.,"Since microglia-associated neuroinflammation plays a critical role in the progression of acute spinal cord injury, modulation of microglial activation has been suggested as a potential therapeutic strategy. Progranulin has been reported to exert neuroprotective effects by attenuating neuroinflammation, but whether these effects are due to the modulation of microglial polarization and the underlying mechanism remain unclear. Here, we investigated the effect of progranulin on microglial polarization and analyzed the crosstalk between microglial autophagy and polarization. We found that progranulin could reduce proinflammatory cytokine production at the lesion site and promote locomotor functional recovery after acute spinal cord injury. In vitro, we found that progranulin could activate microglia to acquire an anti-inflammatory phenotype and express IL-10. Moreover, progranulin-mediated enhancement of anti-inflammatory microglial polarization was attributed to the protection of lysosomal function and the enhancement of autophagic flux. Above all, progranulin exerts anti-inflammatory effects by protecting lysosomal function to enhance microglial autophagy, induce M2 microglial polarization, and ultimately improve neurological function after acute spinal cord injury. These results suggest that targeting the autophagy-lysosomal pathway to modulate microglial polarization and reduce neuroinflammation is a potential treatment for spinal cord injury.","['Autophagy-lysosomal pathway', 'M2 microglial polarization', 'Progranulin', 'Spinal cord injury']",Molecular neurobiology,2022-05-04,"[{'lastname': 'Shi', 'firstname': 'Qiang', 'initials': 'Q', 'affiliation': ""Department of Orthopedic Surgery, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, 200233, China.""}, {'lastname': 'Wu', 'firstname': 'Yinghao', 'initials': 'Y', 'affiliation': ""Department of Orthopedic Surgery, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, 200233, China.""}, {'lastname': 'Zhang', 'firstname': 'Baokun', 'initials': 'B', 'affiliation': ""Department of Orthopedic Surgery, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, 200233, China.""}, {'lastname': 'Wu', 'firstname': 'Shengting', 'initials': 'S', 'affiliation': ""Department of Orthopedic Surgery, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, 200233, China.""}, {'lastname': 'Wang', 'firstname': 'Xin', 'initials': 'X', 'affiliation': ""Department of Orthopedic Surgery, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, 200233, China.""}, {'lastname': 'Lin', 'firstname': 'Fangqi', 'initials': 'F', 'affiliation': ""Department of Orthopedic Surgery, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, 200233, China.""}, {'lastname': 'Zhang', 'firstname': 'Guowang', 'initials': 'G', 'affiliation': ""Department of Orthopedic Surgery, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, 200233, China.""}, {'lastname': 'Lian', 'firstname': 'Xiaofeng', 'initials': 'X', 'affiliation': ""Department of Orthopedic Surgery, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, 200233, China.""}, {'lastname': 'Xu', 'firstname': 'Jianguang', 'initials': 'J', 'affiliation': ""Department of Orthopedic Surgery, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, 200233, China. xjgn6spine@126.com.""}]",,,,"© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.","10.1007/s12035-022-02836-0
10.1089/neu.2018.6362
10.1093/brain/awl296
10.1186/s12974-020-1726-7
10.1002/glia.23041
10.1126/science.1199214
10.1038/nature05016
10.1186/s13024-021-00472-1
10.1186/s12974-021-02203-1
10.1016/j.neuron.2010.09.034
10.1007/s00401-017-1668-z
10.1038/nm.3672
10.1371/journal.pone.0182896
10.3389/fncel.2020.00260
10.1038/nrn.2016.51
10.7150/thno.46566
10.3389/fcell.2021.761273
10.1186/s12974-019-1630-1
10.1172/JCI63113
10.1038/cddis.2014.527
10.1007/s00401-009-0616-y
10.1186/s13287-021-02401-x
10.1089/neu.1995.12.1
10.1016/j.bbi.2019.04.016
10.1038/s41419-019-1764-1
10.1038/s41419-018-0469-1
10.1186/s12974-018-1183-8
10.1016/j.bbi.2015.04.008
10.1038/s41419-017-0236-8
10.1126/science.1205992
10.1007/s10571-020-00856-9
10.3389/fcell.2020.616590
10.1186/s13024-018-0281-5",<Element 'PubmedArticle' at 0x7f05dcde39f0>
104,35504318,Night shift hormone: How does melatonin affect depression?,"Melatonin is the main hormone secreted by the pineal gland that modulates the circadian rhythm and mood. Previous studies have shown the therapeutic effects of melatonin, or its important analogue, agomelatine, on depression. In this review study, we aimed to discuss the potential mechanisms of melatonin involved in the treatment of depression. It was noted that disrupted circadian rhythm can lead to depressive state, and melatonin via regulating circadian rhythm shows a therapeutic effect. It was also noted that melatonin induces antidepressant effects via promoting antioxidant system and neurogenesis, and suppressing oxidative stress, neuroinflammation, and apoptosis. The interaction effect between melatonin or agomelatine and serotonergic signaling has a significant effect on depression. It was noted that the psychotropic effects of agomelatine are induced by the synergistic interaction between melatonin and 5-HT","['Agomelatine', 'Circadian rhythm', 'Depression', 'Inflammation', 'Melatonin']",Physiology & behavior,2022-05-04,"[{'lastname': 'Kholghi', 'firstname': 'Gita', 'initials': 'G', 'affiliation': 'Department of Psychology, Faculty of Human Sciences, Tonekabon Branch, Islamic Azad University, Tonekabon, Iran.'}, {'lastname': 'Eskandari', 'firstname': 'Maliheh', 'initials': 'M', 'affiliation': 'Faculty of Basic Sciences, Central Tehran Branch, Islamic Azad University, Tehran, Iran.'}, {'lastname': 'Shokouhi Qare Saadlou', 'firstname': 'Mohammad-Saleh', 'initials': 'MS', 'affiliation': 'Department of Psychology, Faculty of Humanities, Sirjan Branch, Islamic Azad University, Sirjan, Iran.'}, {'lastname': 'Zarrindast', 'firstname': 'Mohammad-Reza', 'initials': 'MR', 'affiliation': 'Department of Pharmacology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.'}, {'lastname': 'Vaseghi', 'firstname': 'Salar', 'initials': 'S', 'affiliation': 'Medicinal Plants Research Center, Institute of Medicinal Plants, ACECR, Karaj, Iran. Electronic address: vaseghi@imp.ac.ir.'}]",,,,Copyright © 2022. Published by Elsevier Inc.,10.1016/j.physbeh.2022.113835,<Element 'PubmedArticle' at 0x7f05dce12cc0>
105,35476966,MicroRNA modulation is a potential molecular mechanism for neuroprotective effects of intranasal insulin administration in amyloid βeta oligomer induced Alzheimer's like rat model.,"Substantial evidence indicates that imbalance in the expression of miR-132-3p, miR-181b-5p, miR-125b-5p, miR-26a-5p, miR-124-3p, miR-146a-5p, miR-29a-3p, and miR-30a-5p in the AD brain are associated with amyloid-beta (Aβ) aggregation, tau pathology, neuroinflammation, and synaptic dysfunction, the major pathological hallmarks of Alzheimer's disease)AD(. Several studies have reported that intranasal insulin administration ameliorates memory in AD patients and animal models. However, the underlying molecular mechanisms are not yet completely elucidated. Therefore, the aim of this study was to determine whether insulin is involved in regulating the expression of AD-related microRNAs. Pursuing this objective, we first investigated the therapeutic effect of intranasal insulin on Aβ oligomer (AβO)-induced memory impairment in male rats using the Morris water maze task. Then, molecular and histological changes in response to AβO and/or insulin time course were assessed in the extracted hippocampi on days 1, 14, and 21 of the study using congo red staining, western blot and quantitative real-time PCR analyses. We observed memory impairment, Aβ aggregation, tau hyper-phosphorylation, neuroinflammation, insulin signaling dys-regulation, and down-regulation of miR-26a, miR-124, miR-29a, miR-181b, miR-125b, miR-132, and miR-146a in the hippocampus of AβO-exposed rats 21 days after AβO injection. Intranasal insulin treatment ameliorated memory impairment and concomitantly increased miR-132, miR-181b, and miR-125b expression, attenuated tau phosphorylation levels, Aβ aggregation, and neuroinflammation, and regulated the insulin signaling as well. In conclusion, our study suggest that the neuroprotective effects of insulin on memory observed in AD-like rats could be partially due to the restoration of miR-132, miR-181b, and miR-125b expression in the brain.","[""Alzheimer's disease"", 'Intranasal insulin treatment', 'Soluble amyloid-beta oligomer', 'microRNA']",Experimental gerontology,2022-04-28,"[{'lastname': 'Bazrgar', 'firstname': 'Maryam', 'initials': 'M', 'affiliation': 'Neuroscience Research Center, Shahid Beheshti University of Medical Science, Tehran, Iran.'}, {'lastname': 'Khodabakhsh', 'firstname': 'Pariya', 'initials': 'P', 'affiliation': 'Department of Pharmacology, Shahid Beheshti University of Medical Science, Tehran, Iran.'}, {'lastname': 'Dargahi', 'firstname': 'Leila', 'initials': 'L', 'affiliation': 'Neurobiology Research Center, Shahid Beheshti University of Medical Science, Tehran, Iran.'}, {'lastname': 'Mohagheghi', 'firstname': 'Fatemeh', 'initials': 'F', 'affiliation': 'Institute of Experimental Hematology, Center for Translational Cancer Research (TranslaTUM), School of Medicine, Technical University of Munich, Munich, Germany.'}, {'lastname': 'Ahmadiani', 'firstname': 'Abolhassan', 'initials': 'A', 'affiliation': 'Neuroscience Research Center, Shahid Beheshti University of Medical Science, Tehran, Iran. Electronic address: aahmadiani@yahoo.com.'}]",,,,Copyright © 2022 Elsevier Inc. All rights reserved.,10.1016/j.exger.2022.111812,<Element 'PubmedArticle' at 0x7f05dcdfd040>
106,35469820,Palmitoylethanolamide ameliorates neuroinflammation via modulating PPAR-α to promote the functional outcome after intracerebral hemorrhage.,"Intracerebral hemorrhage is a type of acute cerebrovascular disease that remains one of the main causes of death and disability. After the onset of ICH, different types of severe pathophysiological changes can cause great damage to brain tissue, including neuroinflammation. Our study demonstrated the effect of PEA on modulating microglia phenotype and neuroinflammation, as well as the possible underlying mechanisms after ICH for the first time. The phenotypic transformation of microglia and simulation of neuroinflammation after ICH in vitro was induced by hemoglobin on BV2 cells. Additionally, the experiment in vivo model was induced by collagenase injection in mice. The role of PEA on hematoma clearance was also discussed. Western blot, ELISA and immunofluorescence staining were used to determine the phenotypic polarization of microglia and neuroinflammation. In order to evaluate the role of PPAR-α in the anti-inflammatory effect of PEA after ICH, the PPAR-α antagonist GW6471 was utilized. Behavior tests examined the effect of PEA on improving neuronal function. Our results showed that PEA can ameliorate neuroinflammation by inhibiting upregulation of NF-κB, IL-1β and TNF-α, both in vivo and in vitro. Additionally, PEA can improve motor function in ICH mice and promotes hematoma clearance. At the same time, PEA can increase the levels of PPAR-α in the nucleus. Hence, PPAR-α antagonists can reverse the protective effects of PEA on neuroinflammation. These results suggest that PEA is involved in microglia polarization, attenuating the activation of neuroinflammation, as well as improving motor function after ICH. This, at least in part, may contribute to the involvement of PPAR-α modulation of NF-κB.","['Intracerebral hemorrhage', 'NF-kB', 'Neuroinflammation', 'PPAR-α', 'Palmitoylethanolamide']",Neuroscience letters,2022-04-27,"[{'lastname': 'Zhou', 'firstname': 'Guoyang', 'initials': 'G', 'affiliation': 'Department of Neurosurgery, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.'}, {'lastname': 'Fu', 'firstname': 'Xiongjie', 'initials': 'X', 'affiliation': 'Department of Neurosurgery, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.'}, {'lastname': 'Wang', 'firstname': 'Liang', 'initials': 'L', 'affiliation': 'Department of Neurosurgery, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.'}, {'lastname': 'Cao', 'firstname': 'Yang', 'initials': 'Y', 'affiliation': 'Department of Neurosurgery, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.'}, {'lastname': 'Zhuang', 'firstname': 'JianFeng', 'initials': 'J', 'affiliation': 'Department of Neurosurgery, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.'}, {'lastname': 'Hu', 'firstname': 'Junwen', 'initials': 'J', 'affiliation': 'Department of Neurosurgery, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.'}, {'lastname': 'Li', 'firstname': 'Yin', 'initials': 'Y', 'affiliation': 'Department of Neurosurgery, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.'}, {'lastname': 'Xu', 'firstname': 'Chaoran', 'initials': 'C', 'affiliation': 'Department of Neurosurgery, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.'}, {'lastname': 'Gao', 'firstname': 'Shiqi', 'initials': 'S', 'affiliation': 'Department of Neurosurgery, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.'}, {'lastname': 'Shao', 'firstname': 'Anwen', 'initials': 'A', 'affiliation': 'Department of Neurosurgery, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China. Electronic address: 21118116@zju.edu.cn.'}, {'lastname': 'Wang', 'firstname': 'Lin', 'initials': 'L', 'affiliation': 'Department of Neurosurgery, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China. Electronic address: dr_wang@zju.edu.cn.'}]",,,,Copyright © 2022 The Authors. Published by Elsevier B.V. All rights reserved.,10.1016/j.neulet.2022.136648,<Element 'PubmedArticle' at 0x7f05dce08c70>
107,35437979,Corticosterone potentiates ochratoxin A-induced microglial activation.,"Microglial activation in the central nervous system (CNS) has been associated with brain damage and neurodegenerative disorders. Ochratoxin A (OTA) is a mycotoxin that occurs naturally in food and feed and has been associated with neurotoxicity, while corticosteroids are CNS' physiological function modulators. This study examined how OTA affected microglia activation and how corticosteroids influenced microglial neuroinflammation. Murine microglial cells (BV-2) were stimulated by OTA, and the potentiation effects on OTA-induced inflammation were determined by corticosterone pre-treatment. Expressions of pro-inflammatory mediators including tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β), interleukin-6 (IL-6), and inducible nitric oxide synthase (iNOS) were determined. Phosphorylation of mitogen-activated protein kinases (MAPKs) was analyzed by western blotting. OTA significantly increased the mRNA expression of IL-6, TNF-α, IL-1β, and iNOS and also elevated IL-6 and NO levels. Corticosterone pre-treatment enhanced the neuroinflammatory response to OTA in a mineralocorticoid receptor (MR)-dependent mechanism, which is associated with increases in extracellular signal-regulated kinase (ERK) and p38 MAPK activation. In response to OTA, microglial cells produced pro-inflammatory cytokines and NO, while corticosterone increased OTA-induced ERK and p38 MAPK phosphorylation via MR. Findings indicated the direct role of OTA in microglia activation and neuroinflammatory response and suggested that low corticosterone concentrations in the brain exacerbated neurodegeneration.","['corticosterone', 'microglia', 'mitogen-activated protein kinases', 'neuroinflammation', 'ochratoxin A']",Biomolecular concepts,2022-04-20,"[{'lastname': 'Chansawhang', 'firstname': 'Anchana', 'initials': 'A', 'affiliation': 'The Center for Veterinary Diagnosis, Faculty of Veterinary Science, Mahidol University, Salaya, Phutthamonthon, Nakhon Pathom 73170, Thailand.'}, {'lastname': 'Phochantachinda', 'firstname': 'Sataporn', 'initials': 'S', 'affiliation': 'Prasu-Arthorn Animal Hospital, Faculty of Veterinary Science, Mahidol University, Salaya, Phutthamonthon, Nakhon Pathom 73170, Thailand.'}, {'lastname': 'Temviriyanukul', 'firstname': 'Piya', 'initials': 'P', 'affiliation': 'Institute of Nutrition, Mahidol University, Salaya, Phutthamonthon, Nakhon Pathom 73170, Thailand.'}, {'lastname': 'Chantong', 'firstname': 'Boonrat', 'initials': 'B', 'affiliation': 'Department of Pre-clinical and Applied Animal Science, Faculty of Veterinary Science, Mahidol University, Salaya, Phutthamonthon, Nakhon Pathom 73170, Thailand.'}]",,,,"© 2022 Anchana Chansawhang et al., published by De Gruyter.",10.1515/bmc-2022-0017,<Element 'PubmedArticle' at 0x7f05de6e6720>
108,35384793,A single dose of ketamine cannot prevent protracted stress-induced anhedonia and neuroinflammation in rats.,"Worldwide, millions of people suffer from treatment-resistant depression. Ketamine, a glutamatergic receptor antagonist, can have a rapid antidepressant effect even in treatment-resistant patients. A proposed mechanism for the antidepressant effect of ketamine is the reduction of neuroinflammation. To further explore this hypothesis, we investigated whether a single dose of ketamine can modulate protracted neuroinflammation in a repeated social defeat (RSD) stress rat model, which resembles features of depression. To this end, male animals exposed to RSD were injected with ketamine (20 mg/kg) or vehicle. A combination of behavioral analyses and PET scans of the inflammatory marker TSPO in the brain were performed. Rats submitted to RSD showed anhedonia-like behavior in the sucrose preference test, decreased weight gain, and increased TSPO levels in the insular and entorhinal cortices, as observed by [","['Neuroinflammation', 'ketamine', 'major depressive disorder', 'positron emission tomography', 'repeated social defeat']","Stress (Amsterdam, Netherlands)",2022-04-07,"[{'lastname': 'Moraga-Amaro', 'firstname': 'Rodrigo', 'initials': 'R', 'affiliation': 'Department of Nuclear Medicine and Medical Imaging, University Medical Center Groningen, University of Groningen, Groningen, GZ, The Netherlands.'}, {'lastname': 'Guerrin', 'firstname': 'Cyprien G J', 'initials': 'CGJ', 'affiliation': 'Department of Nuclear Medicine and Medical Imaging, University Medical Center Groningen, University of Groningen, Groningen, GZ, The Netherlands.'}, {'lastname': 'Reali Nazario', 'firstname': 'Luiza', 'initials': 'L', 'affiliation': 'Department of Nuclear Medicine and Medical Imaging, University Medical Center Groningen, University of Groningen, Groningen, GZ, The Netherlands.'}, {'lastname': 'Lima Giacobbo', 'firstname': 'Bruno', 'initials': 'B', 'affiliation': 'Department of Nuclear Medicine and Medical Imaging, University Medical Center Groningen, University of Groningen, Groningen, GZ, The Netherlands.'}, {'lastname': 'J O Dierckx', 'firstname': 'Rudi A', 'initials': 'RA', 'affiliation': 'Department of Nuclear Medicine and Medical Imaging, University Medical Center Groningen, University of Groningen, Groningen, GZ, The Netherlands.'}, {'lastname': 'Stehberg', 'firstname': 'Jimmy', 'initials': 'J', 'affiliation': 'Laboratorio de Neurobiología, Instituto de Ciencias Biomédicas, Facultad de Medicina y Facultad de Ciencias de la Vida, Universidad Andrés Bello, Santiago, Chile.'}, {'lastname': 'de Vries', 'firstname': 'Erik F J', 'initials': 'EFJ', 'affiliation': 'Department of Nuclear Medicine and Medical Imaging, University Medical Center Groningen, University of Groningen, Groningen, GZ, The Netherlands.'}, {'lastname': 'Doorduin', 'firstname': 'Janine', 'initials': 'J', 'affiliation': 'Department of Nuclear Medicine and Medical Imaging, University Medical Center Groningen, University of Groningen, Groningen, GZ, The Netherlands.'}]",,,,,10.1080/10253890.2022.2045269,<Element 'PubmedArticle' at 0x7f05de6ed360>
109,35362178,Progranulin deficiency promotes persistent neuroinflammation and causes regional pathology in the hippocampus following traumatic brain injury.,"Traumatic brain injury (TBI) can be progressive and can lead to the development of a long-term complication termed chronic traumatic encephalopathy. The mechanisms underlying the progressive changes are still unknown; however, studies have suggested that microglia-mediated neuroinflammation in response to TBI may play a fundamental role. This study aimed to determine whether progranulin (PGRN), a major modulator of microglial activity, plays a role in the progressive damage following TBI. PGRN-deficient and wild-type mice were subjected to controlled cortical impact and were observed neuropathologically after 3 days, 7 days, and 5 months. Compared to sham and wild-type mice, the PGRN-deficient mice showed overall stronger microgliosis and astrocytosis. The astrocytosis involved broader areas than the microgliosis and was more prominent in the basal ganglia, hippocampus, and internal capsule in PGRN-deficient mice. Ongoing neuronal death was uniquely observed in the hippocampal CA3 region of PGRN-deficient mice at 5 months after TBI, accompanying the regional chronic microgliosis and astrocytosis involving the CA3 commissural pathway. In addition, there was M1 microglial polarization in the pericontusional area with activated TLR4/MyD88/NF-κB signaling; however, the hippocampus showed only mild M1 polarization 7 days after TBI. Lastly, Morris water maze tests showed PGRN-deficient mice had poorer spatial learning and memory 5 months after TBI than wild-type or sham mice. The data indicated the PGRN deficiency caused TBI progression by promoting persistent microgliosis with microglial polarization and astrocytosis, as well as regional pathology in the hippocampus. The study suggests that PGRN should be evaluated as a potential therapy for TBI.","['astrocyte', 'hippocampus', 'microglia', 'neuroinflammation', 'progranulin', 'traumatic brain injury']",Glia,2022-04-02,"[{'lastname': 'Zheng', 'firstname': 'Xiaojing', 'initials': 'X', 'affiliation': ""Laboratory of Gene Therapy, Department of Biochemistry, College of Life Sciences, Shaanxi Normal University, Xi'an, Shaanxi, China.""}, {'lastname': 'Mi', 'firstname': 'Tiantian', 'initials': 'T', 'affiliation': ""Laboratory of Gene Therapy, Department of Biochemistry, College of Life Sciences, Shaanxi Normal University, Xi'an, Shaanxi, China.""}, {'lastname': 'Wang', 'firstname': 'Rong', 'initials': 'R', 'affiliation': ""Laboratory of Gene Therapy, Department of Biochemistry, College of Life Sciences, Shaanxi Normal University, Xi'an, Shaanxi, China.""}, {'lastname': 'Zhang', 'firstname': 'Zihan', 'initials': 'Z', 'affiliation': ""Laboratory of Gene Therapy, Department of Biochemistry, College of Life Sciences, Shaanxi Normal University, Xi'an, Shaanxi, China.""}, {'lastname': 'Li', 'firstname': 'Wenyan', 'initials': 'W', 'affiliation': ""Laboratory of Gene Therapy, Department of Biochemistry, College of Life Sciences, Shaanxi Normal University, Xi'an, Shaanxi, China.""}, {'lastname': 'Zhao', 'firstname': 'Junli', 'initials': 'J', 'affiliation': ""Laboratory of Gene Therapy, Department of Biochemistry, College of Life Sciences, Shaanxi Normal University, Xi'an, Shaanxi, China.""}, {'lastname': 'Yang', 'firstname': 'Peiyan', 'initials': 'P', 'affiliation': ""Laboratory of Gene Therapy, Department of Biochemistry, College of Life Sciences, Shaanxi Normal University, Xi'an, Shaanxi, China.""}, {'lastname': 'Xia', 'firstname': 'Haibin', 'initials': 'H', 'affiliation': ""Laboratory of Gene Therapy, Department of Biochemistry, College of Life Sciences, Shaanxi Normal University, Xi'an, Shaanxi, China.""}, {'lastname': 'Mao', 'firstname': 'Qinwen', 'initials': 'Q', 'affiliation': 'Department of Pathology, University of Utah, Salt Lake City, Utah, USA.'}]",,,,© 2022 Wiley Periodicals LLC.,10.1002/glia.24175,<Element 'PubmedArticle' at 0x7f05de6cb7c0>
110,"35355991
31857931
30679040
19233038
19608392
26311235
20070435
31063129
29955526
27987059
30873027
29739849
23968560
9839535
24865588
19891905
11520894
14614276
26130320
26735612
27562847
29061489
29193274
29497878
29450696
29526318
32582799
27696474
9396042
17118492
24726946
28538669
17560727
9090295
28578430
18501024
25959295
6752894
17275978
11757963
17398118
16644118
16320723
26637184
28657129
28549068",PDK4 Inhibition Ameliorates Melatonin Therapy by Modulating Cerebral Metabolism and Remyelination in an EAE Demyelinating Mouse Model of Multiple Sclerosis.,"We recently showed that melatonin ameliorates the severity of experimental autoimmune encephalomyelitis (EAE), an animal model of MS. However, efficiency of melatonin therapy was associated with side effects, manifested by slowing down of remyelination, through increasing the inhibitory effects of brain pyruvate dehydrogenase kinase-4 (PDK-4) on pyruvate dehydrogenase complex (PDC), a key enzyme in fatty acid (FA) synthesis during remyelination. In this study, we investigated the metabolic profile of FA synthesis using combination therapy of melatonin and diisopropylamine dichloroacetate (DADA), a PDK4 inhibitor, in EAE mice. Disease progression was monitored by recording the disability scores. Immunological, oligodendrogenesis and metabolic factors were also evaluated. Results showed that combination therapy of melatonin and DADA significantly reduced EAE disability scores, compared to melatonin, whereas DADA alone did not have any effect. In addition, co-therapy inhibited pro-inflammatory while increasing anti-inflammatory cytokines, significantly better than melatonin alone. Moreover, administration of combination drugs recovered the declined expression of oligodendrocytic markers in EAE, more potently than melatonin. Furthermore, co-therapy affected cerebral energy metabolism by significantly reducing lactate levels while increasing N-acetylaspartate (NAA) and 3-hydroxy-3-methyl-glutaryl-coenzyme-A reductase (HMGCR) levels. Finally, while melatonin increased lactate and PDK4 expression levels and greatly reduced PDC activity, co-therapy significantly restored PDC function while reducing the lactate levels. In summary, administration of melatonin with DADA increased the efficiency of melatonin treatment by eliminating the inhibitory effects of PDK4 on PDC's function, a critical step for proper FA synthesis during remyelination.","['PDC', 'PDK4', 'diisopropylamine dichloroacetate', 'experimental autoimmune encephalomyelitis (EAE)', 'fatty acids', 'melatonin', 'multiple scleorsis (MS)', 'neuroinflammation']",Frontiers in immunology,2022-04-01,"[{'lastname': 'Ghareghani', 'firstname': 'Majid', 'initials': 'M', 'affiliation': 'Neuroscience Axis, Research Center of CHU de Québec-Université Laval, Quebec City, QC, Canada.\nDepartment of Molecular Medicine, Faculty of Medicine, Université Laval, Quebec City, QC, Canada.'}, {'lastname': 'Farhadi', 'firstname': 'Zahra', 'initials': 'Z', 'affiliation': 'Cellular and Molecular Research Center, Yasuj University of Medical Sciences, Yasuj, Iran.'}, {'lastname': 'Rivest', 'firstname': 'Serge', 'initials': 'S', 'affiliation': 'Neuroscience Axis, Research Center of CHU de Québec-Université Laval, Quebec City, QC, Canada.\nDepartment of Molecular Medicine, Faculty of Medicine, Université Laval, Quebec City, QC, Canada.'}, {'lastname': 'Zibara', 'firstname': 'Kazem', 'initials': 'K', 'affiliation': 'PRASE and Biology Department, Faculty of Sciences-I, Lebanese University, Beirut, Lebanon.'}]",,,,"Copyright © 2022 Ghareghani, Farhadi, Rivest and Zibara.","10.3389/fimmu.2022.862316
10.9740/mhc.2019.11.349
10.1016/S1474-4422(18)30443-5
10.1016/S1474-4422(09)70043-2
10.1016/j.plefa.2009.06.003
10.1186/s12883-015-0411-4
10.1111/j.1582-4934.2010.01010.x
10.7554/eLife.44702
10.9740/mhc.2017.09.213
10.1007/s10571-016-0450-4
10.3389/fphar.2019.00147
10.1074/jbc.RA118.002838
10.1016/j.jneuroim.2013.07.016
10.1016/S0024-3205(99)80008-3
10.1371/journal.pone.0098032
10.1007/s11940-009-0046-0
10.1046/j.1471-4159.2001.00456.x
10.4142/jvs.2001.2.2.85
10.1016/j.bbi.2015.06.021
10.1016/j.intimp.2015.12.020
10.1007/s11481-016-9702-9
10.1016/j.steroids.2017.10.006
10.1111/fcp.12337
10.1007/s10571-018-0580-y
10.1007/s12031-017-1022-x
10.1016/j.nrl.2018.01.007
10.1111/1440-1681.12678
10.1159/000164122
10.1016/j.neuint.2006.09.001
10.1016/j.bbadis.2014.04.005
10.3390/ijms18061126
10.1016/j.neuroscience.2007.05.002
10.1007/978-1-4615-5901-6_7
10.1038/s41598-017-02638-8
10.1186/1742-2094-5-20
10.1111/bpa.12266
10.1080/01635588109513714
10.1016/j.pneurobio.2006.12.003
10.1007/s004150170052
10.1016/j.neuroimage.2007.02.036
10.1016/j.neulet.2006.03.042
10.1191/1352458505ms1234oa
10.1186/s40478-015-0261-8
10.1002/glia.23184
10.1371/journal.pbio.1002605",<Element 'PubmedArticle' at 0x7f05db073400>
111,"35355989
28723321
30659573
23406828
9595997
20595669
24323051
22534672
28215029
20947837
33069252
31964292
3895589
24291544
11958426
34630043
32171298
21773873
22556195
28298035
24194732
17878513
20597104
10642292
28528561
23692861
15549174
23092879
31245374
24389733
22527880
31427727
25766951
12623931
34685735
24842292
29203630
4296696
4332505
12676175
17493693
30953113
29543776
9344632
24184051
31853042
12459472
24697296
10557335
31786978
1438983
12483279
34024117
11937178
33059037
27761230
11818364
28364024
24508710
22920387
24090950
21685445
22817481
29663576
24102099
30296700
26540167
24487246
24440367
25941346
10535331
11533142
27285537
28226226
25302502
28515690
11596123
22152301
29858771
33672482
32998969
32362228
32488543
30354809
28385651
29987762
25160895
24184050
30103772
25534368
29122524
33178092
31421410
30622315
29684446
31751621
33642985
28884281
28476949
29684507
33572986
34529881
33658918
15550614
27693730
15544836
18287217
20713916
12874086
12865311
23812385
24858844
26538819
17470467
24827941
20868737
19748527
18190523
23583926
34333284
29667931
26448556
34654436
31669235
30816157
30958350
30709867
31037999
29428223
28054808
27681328
26264508
24012919
34759348
10510333
19046046
10915812
8248986
12573992
17208987
24877125
24799613
23386129
18026570
21789389
11304515
11463766
11677365
18628782
7709776
16915120
16888270
14705720
15003298
30312372
33114359
33105809
21645240
24163134
25222828
26851244
25125015
29850820
25297539
11927520
20816713
27730696
27872279
15284177
9931106
15951342
19920106
28877748
31901211
7902657
33685320",Angiotensin-(1-7) as a Potential Therapeutic Strategy for Delayed Cerebral Ischemia in Subarachnoid Hemorrhage.,"Aneurysmal subarachnoid hemorrhage (SAH) is a substantial cause of mortality and morbidity worldwide. Moreover, survivors after the initial bleeding are often subject to secondary brain injuries and delayed cerebral ischemia, further increasing the risk of a poor outcome. In recent years, the renin-angiotensin system (RAS) has been proposed as a target pathway for therapeutic interventions after brain injury. The RAS is a complex system of biochemical reactions critical for several systemic functions, namely, inflammation, vascular tone, endothelial activation, water balance, fibrosis, and apoptosis. The RAS system is classically divided into a pro-inflammatory axis, mediated by angiotensin (Ang)-II and its specific receptor AT","['acute brain injury', 'anoxic injury', 'delayed cerebral ischemia (DCI)', 'renin–angiotensin system (RAS)', 'subarachnoid hemorrhage (SAH)']",Frontiers in immunology,2022-04-01,"[{'lastname': 'Annoni', 'firstname': 'Filippo', 'initials': 'F', 'affiliation': 'Laboratory of Acute Brain Injury and Therapeutic Strategies, Department of Neuroscience, Mario Negri Institute for Pharmacological Research IRCCS, Milan, Italy.\nDepartment of Intensive Care, Erasme Hospital, Free University of Brussels, Anderlecht, Belgium.'}, {'lastname': 'Moro', 'firstname': 'Federico', 'initials': 'F', 'affiliation': 'Laboratory of Acute Brain Injury and Therapeutic Strategies, Department of Neuroscience, Mario Negri Institute for Pharmacological Research IRCCS, Milan, Italy.'}, {'lastname': 'Caruso', 'firstname': 'Enrico', 'initials': 'E', 'affiliation': ""Laboratory of Acute Brain Injury and Therapeutic Strategies, Department of Neuroscience, Mario Negri Institute for Pharmacological Research IRCCS, Milan, Italy.\nNeuroscience Intensive Care Unit, Department of Anesthesia and Critical Care, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.""}, {'lastname': 'Zoerle', 'firstname': 'Tommaso', 'initials': 'T', 'affiliation': ""Neuroscience Intensive Care Unit, Department of Anesthesia and Critical Care, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.\nDepartment of Pathophysiology and Transplantation, University of Milan, Milan, Italy.""}, {'lastname': 'Taccone', 'firstname': 'Fabio Silvio', 'initials': 'FS', 'affiliation': 'Department of Intensive Care, Erasme Hospital, Free University of Brussels, Anderlecht, Belgium.'}, {'lastname': 'Zanier', 'firstname': 'Elisa R', 'initials': 'ER', 'affiliation': 'Laboratory of Acute Brain Injury and Therapeutic Strategies, Department of Neuroscience, Mario Negri Institute for Pharmacological Research IRCCS, Milan, Italy.'}]",,,,"Copyright © 2022 Annoni, Moro, Caruso, Zoerle, Taccone and Zanier.","10.3389/fimmu.2022.841692
10.1056/NEJMcp1605827
10.1001/jamaneurol.2019.0006
10.1159/000346087
10.1212/WNL.50.5.1413
10.1161/STROKEAHA.110.581975
10.1038/nrneurol.2013.246
10.1038/jcbfm.2012.57
10.1007/s10143-017-0827-y
10.1161/STROKEAHA.110.597443
10.1186/s13054-020-03342-2
10.1161/STROKEAHA.119.025997
10.1161/01.STR.16.4.562
10.1016/j.pneurobio.2013.11.003
10.1179/016164102101199783
10.3389/fncel.2021.739506
10.1007/978-3-7091-0353-1_1
10.1186/s13054-020-2825-7
10.1007/s12028-011-9605-9
10.1161/STR.0b013e3182587839
10.3171/2016.10.JNS162227
10.3389/fendo.2013.00161
10.1124/pr.59.3.3
10.1002/emmm.201000080
10.1161/01.HYP.35.1.155
10.1056/NEJMoa1704154
10.1016/j.peptides.2013.04.014
10.1007/s00018-004-4246-1
10.1530/JOE-12-0341
10.3389/fmed.2019.00107
10.1097/01.mnh.0000441052.44406.92
10.1007/s00109-012-0894-z
10.1038/s41569-019-0244-8
10.1016/j.jacc.2015.01.033
10.1161/01.HYP.0000054215.71691.16
10.3390/cells10102755
10.3109/10641955.2014.911884
10.1161/HYPERTENSIONAHA.117.10406
10.1016/0006-8993(71)90137-5
10.1016/S1357-2725(02)00306-0
10.1016/j.regpep.2007.03.006
10.1007/s00216-019-01771-9
10.3390/ijms19030876
10.1006/frne.1997.0155
10.1016/j.expneurol.2013.10.013
10.1038/s41440-019-0374-8
10.1016/S0014-5793(02)03640-2
10.1042/CS20130396
10.1073/pnas.96.23.13415
10.1161/HYPERTENSIONAHA.119.12675
10.1016/0167-0115(92)90527-2
10.1007/s00441-002-0655-3
10.1161/STR.0000000000000375
10.1016/S0140-6736(02)08089-3
10.1016/j.cellsig.2020.109809
10.1186/s13231-016-0022-1
10.1096/fj.01-0601com
10.1161/STROKEAHA.116.016269
10.1016/j.neuropharm.2014.01.044
10.1186/2040-7378-4-16
10.1016/j.npep.2013.09.002
10.1113/expphysiol.2011.058578
10.1111/j.1476-5381.2012.02105.x
10.1113/EP086957
10.1042/CS20130324
10.1016/j.redox.2018.09.022
10.1371/journal.pone.0142087
10.1113/expphysiol.2013.076836
10.1016/j.neuropharm.2014.01.004
10.1161/HYPERTENSIONAHA.115.05185
10.1016/S0361-9230(99)00089-1
10.1111/j.1469-7793.2001.00533.x
10.3171/2016.4.JNS16409
10.1146/annurev-immunol-051116-052358
10.1371/journal.pone.0092937
10.3389/fnagi.2017.00129
10.1002/glia.1104
10.1016/j.cmet.2011.08.016
10.1007/s11064-018-2557-0
10.3390/ph14020166
10.1126/scitranslmed.aaz2541
10.1161/HYPERTENSIONAHA.119.14431
10.1007/s10787-020-00724-4
10.1161/HYPERTENSIONAHA.118.11775
10.1016/j.bbi.2017.04.001
10.1007/s13311-018-0646-z
10.1016/j.expneurol.2014.08.019
10.1016/j.expneurol.2013.10.014
10.1186/s12974-018-1262-x
10.1016/j.jstrokecerebrovasdis.2014.09.037
10.1016/S1474-4422(17)30371-X
10.3389/fneur.2020.00992
10.1016/j.redox.2019.101295
10.1038/s41440-018-0190-6
10.1016/j.lfs.2018.04.033
10.1016/j.neuint.2019.104604
10.3389/fnins.2021.628403
10.1007/s12035-017-0754-5
10.1523/JNEUROSCI.0329-17.2017
10.1016/j.neuroscience.2018.04.012
10.3390/ijms22031356
10.1111/acel.13480
10.3389/fnagi.2021.624387
10.1152/ajpregu.00595.2004
10.1016/j.yfrne.2016.09.003
10.1016/j.regpep.2004.06.021
10.1152/ajpregu.00864.2007
10.1161/HYPERTENSIONAHA.110.153668
10.1161/01.HYP.0000085220.53285.11
10.1210/en.2003-0009
10.1152/ajpheart.00193.2013
10.1152/ajpheart.01012.2013
10.1155/2015/720141
10.1136/jnnp.2007.117655
10.1042/CS20130450
10.1016/j.bbi.2010.09.015
10.1016/j.regpep.2009.09.001
10.1111/j.1460-9568.2007.06014.x
10.1016/j.neuropharm.2013.03.025
10.1016/j.redox.2021.102078
10.18632/aging.101419
10.1111/jnc.13386
10.1186/s12974-021-02281-1
10.1016/j.bcp.2019.113681
10.1038/s41598-019-39102-8
10.3233/JAD-181000
10.1124/jpet.118.254854
10.1089/neu.2019.6376
10.1016/j.bcp.2018.01.047
10.1037/bne0000182
10.1152/ajpregu.00467.2015
10.1016/j.vph.2015.08.007
10.1016/j.freeradbiomed.2013.08.183
10.1038/s41577-021-00634-8
10.1172/JCI7886
10.3171/2008.8.JNS08789
10.1016/S0006-8993(00)02482-3
10.1161/01.STR.24.12.2041
10.1152/ajpheart.01145.2002
10.1152/ajpheart.01245.2006
10.1155/2014/640329
10.1161/HYPERTENSIONAHA.114.03415
10.1182/blood-2012-09-459156
10.2119/2007-00073.Fraga-Silva
10.1590/S1807-59322011000500021
10.1161/01.HYP.37.4.1136
10.1161/01.HYP.38.1.90
10.1097/00004872-200111000-00010
10.1038/jcbfm.2008.74
10.1007/BF01401464
10.1227/01.NEU.0000227519.27569.45
10.1161/01.STR.0000236841.16055.0f
10.3171/jns.2003.99.6.0953
10.1016/j.clineuro.2004.01.006
10.1093/ageing/afy169
10.3390/ijms21217904
10.3390/ijms21217840
10.1111/j.1582-4934.2011.01354.x
10.1093/hmg/ddt514
10.1042/CS20140215
10.1242/dmm.023390
10.1016/j.ijcard.2014.07.279
10.1093/eurheartj/ehy077
10.1186/s40001-014-0054-8
10.1161/01.CIR.0000013847.07035.B9
10.1016/j.peptides.2010.08.024
10.1113/EP085884
10.1073/pnas.1612668113
10.1093/carcin/bgh236
10.1161/01.HYP.33.1.207
10.1152/ajpheart.00941.2004
10.1158/1078-0432.CCR-09-1957
10.1186/s13054-017-1823-x
10.1111/1440-1681.13251
10.1016/0001-706X(93)90092-P
10.1080/01480545.2021.1894741",<Element 'PubmedArticle' at 0x7f05db07c590>
112,"35348977
32668062
29928190
32717399
32848594
26923778
33513867
32178222
29712997
19630576
27869327
32166165
31785168
27911858
28948971
20937274
28430869
32194944
30774631
33691249
23805233
32441783
30588079
33385878
32538857
32291463
32228035
25550769
29075178
33285234
33536545
31986264
32076399
32365642
30678080
29773951
30649612
32546655
23514317
33174962
32399719
33662680
27844095
32192578
32469400
22797452
31174279
33328588
32437679
32125452
29467654
34563872
29512466
32767095
28382917
31371719
34537482
15283741
33124941
31477683
32223077
32732883
22353665
32235786
32150310
32298803
31616477
15123501
30664971
33369818
30397195
27269743
32534467
32166013
32075877
32725449
28646910
33420763",Therapeutic Potential of the Purinergic System in Major Depressive Disorder Associated with COVID-19.,"Neuroinflammation is closely related to the development of depression, since the latter is caused, among other factors, by inflammatory processes, mainly related to the activation of microglia and expression of specific genes, which occurs during the neuroinflammatory process. Thus, COVID-19 is an important risk factor for the development of depression, since in addition to generating the feeling of stress, which also increases the activity of the immune system, it is also the cause of pathological processes and physiological ones that lead to the development of neuroinflammation, microglial activation, gene expression dysfunction and decreased concentration of available serotonin. That said, drugs are being used to combat COVID-19 to reduce the oxidative stress presented in the disease. Thus, tramadol and fluoxetine are highlighted as drugs used, however, although they present some positive results, such as the reduction of pro-inflammatory cytokines, they are also associated with negative effects such as dependence, pulmonary, cardiac and brain impairment. From this, the purinergic system is highlighted in the literature as a possible therapeutic target. This is because its mechanisms are related to the regulation of microglia, astrocytes and the physiology of important neurotransmitters and hormones. Added to this, there is a modulation of inflammatory activity, especially with regard to the P2X7 receptors of this system. The latter is an important target for the treatment of depression and COVID-19, since positive results were obtained through the genetic exclusion of this receptor and the use of selective antagonists.","['Major depression disorder', 'Neuroinflammation', 'Purinergic signaling']",Cellular and molecular neurobiology,2022-03-30,"[{'lastname': 'Simões', 'firstname': 'Júlia Leão Batista', 'initials': 'JLB', 'affiliation': 'Medical School, Federal University of Fronteira Sul, Chapecó, SC, Brazil.'}, {'lastname': 'Galvan', 'firstname': 'Agatha Carina Leite', 'initials': 'ACL', 'affiliation': 'Nursing School, Federal University of Fronteira Sul, Chapecó, SC, Brazil.'}, {'lastname': 'da Silva', 'firstname': 'Eduarda Luiza Maciel', 'initials': 'ELM', 'affiliation': 'Nursing School, Federal University of Fronteira Sul, Chapecó, SC, Brazil.'}, {'lastname': 'Ignácio', 'firstname': 'Zuleide Maria', 'initials': 'ZM', 'affiliation': 'Graduate Program in Medical Sciences, Federal University of Fronteira Sul, Chapecó, SC, Brazil.'}, {'lastname': 'Bagatini', 'firstname': 'Margarete Dulce', 'initials': 'MD', 'affiliation': 'Graduate Program in Medical Sciences, Federal University of Fronteira Sul, Chapecó, SC, Brazil. margaretebagatini@yahoo.com.br.'}]",,,,"© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.","10.1007/s10571-022-01215-6
10.1111/ene.14442
10.3389/fnins.2018.00386
10.1016/J.BBI.2020.07.026
10.3389/FNMOL.2020.00124
10.21451/1984-3143-AR823
10.2174/1570159X14666160229114755
10.3390/PH14020097
10.3390/brainsci10030160
10.1038/s41380-018-0057-x
10.1146/ANNUREV.MED.60.042307.110802
10.1002/JBMR.3045
10.1177/2398212818817494
10.1111/ejn.14631
10.18632/ONCOTARGET.13689
10.1038/mp.2017.188
10.1016/J.FEBSLET.2010.10.001
10.1093/BRAIN/AWX085
10.12688/f1000research.22457.2
10.3389/FIMMU.2019.00119
10.1016/J.BIOPHA.2021.111437
10.1371/JOURNAL.PONE.0066547
10.1111/BPH.15138
10.2147/JPR.S184782
10.1016/J.MEHY.2020.110468
10.3233/JAD-200581
10.1007/S00134-020-06033-2
10.1164/RCCM.202003-0817LE
10.3389/FNMOL.2017.00325
10.1016/J.PHRS.2020.105363
10.1038/S41380-021-01021-4
10.1016/S0140-6736(20)30183-5
10.3389/FNMOL.2019.00331
10.3390/cells9051108
10.3390/ijms20030485
10.2147/JIR.S141033
10.1007/S00441-018-02987-4
10.1212/WNL.0000000000010111
10.1146/ANNUREV-PUBLHEALTH-031912-114409
10.1590/0037-8682-0504-2020
10.1007/s12640-020-00219-8
10.1016/J.BIOPHA.2021.111430
10.1007/S00213-016-4483-7
10.1016/S0140-6736(20)30628-0
10.4103/1687-4315.205828
10.1001/JAMANEUROL.2020.2125
10.1001/JAMA.2012.5669
10.3390/IJMS20112778
10.1038/S41380-020-00965-3
10.1016/S2215-0366(20)30203-0
10.1007/S00134-020-05991-X
10.3389/FPHAR.2018.00052
10.1016/J.REDOX.2021.102137
10.2174/1570159X16666180302120322
10.1007/S00011-020-01389-Z
10.2807/1560-7917.ES.2017.22.13.30494
10.1038/S41419-019-1813-9
10.1016/J.INTIMP.2021.108150
10.1111/J.1600-0447.2004.00335.X
10.1152/PHYSREV.00035.2020
10.1038/s41398-019-0548-9
10.1111/APHA.13473
10.1038/s41398-020-00949-5
10.1159/000334586
10.3390/ijms21062194
10.1111/EJN.14720
10.1016/j.bbi.2020.04.027
10.3389/FGENE.2019.00898
10.1192/BJP.184.5.386
10.1016/j.pnpbp.2019.01.006
10.1111/ENE.14703
10.1038/s41398-018-0276-6
10.1080/15622975.2016.1197423
10.1002/JLB.3COVR0520-272R
10.1186/S13578-020-00388-1
10.1126/science.aax0902
10.1007/s10072-020-04575-3
10.1186/S13041-017-0306-Y
10.24272/J.ISSN.2095-8137.2020.294",<Element 'PubmedArticle' at 0x7f05dc5c4680>
113,"35327616
27540165
24699227
28226226
26354893
26745839
26509334
30016687
25779633
26499989
10662535
31513776
26600009
26205628
20153425
19665809
19063914
11739531
21565615
26708712
12777709
12422368
16253392
27549171
11150483
15148390
16407456
17192562
21541365
23074265
18771935
11743142
10593612
9626133
15390121
20060904
31980574
11070493
28894299
19845386
27618740
28082899
29473218
30817930
24585880
23190582
27299736
32526552
20147251
22871921
22743772
21376707
1550679
15289442
21482827
22762015
27477018
29518356
31019284
25904803
34201844
27555812
19461673
30496700
30277599
24316888
33986301
31564456
32044947
23977697
16411894
12528312
11735609
29651949
8053664
9701676
24285878
23303920
30918278
30006508
29208634
28567989
27716798
28602351
28930663
29775591
30266932
23150934
30206190","ENT-A010, a Novel Steroid Derivative, Displays Neuroprotective Functions and Modulates Microglial Responses.","Tackling neurodegeneration and neuroinflammation is particularly challenging due to the complexity of central nervous system (CNS) disorders, as well as the limited drug accessibility to the brain. The activation of tropomyosin-related kinase A (TRKA) receptor signaling by the nerve growth factor (NGF) or the neurosteroid dehydroepiandrosterone (DHEA) may combat neurodegeneration and regulate microglial function. In the present study, we synthesized a C-17-spiro-cyclopropyl DHEA derivative (ENT-A010), which was capable of activating TRKA. ENT-A010 protected PC12 cells against serum starvation-induced cell death, dorsal root ganglia (DRG) neurons against NGF deprivation-induced apoptosis and hippocampal neurons against Aβ-induced apoptosis. In addition, ENT-A010 pretreatment partially restored homeostatic features of microglia in the hippocampus of lipopolysaccharide (LPS)-treated mice, enhanced Aβ phagocytosis, and increased ","['Aβ', 'DHEA', 'ENT-A010', 'hippocampus', 'microglia', 'neuroprotection', 'phagocytosis', 'ΤRKA']",Biomolecules,2022-03-26,"[{'lastname': 'Yilmaz', 'firstname': 'Canelif', 'initials': 'C', 'affiliation': 'Institute of Clinical Chemistry and Laboratory Medicine, University Clinic Carl Gustav Carus, Technische Universität Dresden, 01307 Dresden, Germany.'}, {'lastname': 'Rogdakis', 'firstname': 'Thanasis', 'initials': 'T', 'affiliation': 'Pharmacology Department, Faculty of Medicine, University of Crete, 71003 Heraklion, Greece.\nInstitute of Molecular Biology and Biotechnology, Foundation for Research and Technology Hellas, 71003 Heraklion, Greece.'}, {'lastname': 'Latorrata', 'firstname': 'Alessia', 'initials': 'A', 'affiliation': 'Institute of Chemical Biology, National Hellenic Research Foundation, 11635 Athens, Greece.'}, {'lastname': 'Thanou', 'firstname': 'Evangelia', 'initials': 'E', 'affiliation': 'Center for Neurogenomics and Cognitive Research, Department of Molecular and Cellular Neurobiology, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, 1081 HV Amsterdam, The Netherlands.'}, {'lastname': 'Karadima', 'firstname': 'Eleftheria', 'initials': 'E', 'affiliation': 'Institute of Clinical Chemistry and Laboratory Medicine, University Clinic Carl Gustav Carus, Technische Universität Dresden, 01307 Dresden, Germany.'}, {'lastname': 'Papadimitriou', 'firstname': 'Eleni', 'initials': 'E', 'affiliation': 'Pharmacology Department, Faculty of Medicine, University of Crete, 71003 Heraklion, Greece.\nInstitute of Molecular Biology and Biotechnology, Foundation for Research and Technology Hellas, 71003 Heraklion, Greece.'}, {'lastname': 'Siapi', 'firstname': 'Eleni', 'initials': 'E', 'affiliation': 'Institute of Chemical Biology, National Hellenic Research Foundation, 11635 Athens, Greece.'}, {'lastname': 'Li', 'firstname': 'Ka Wan', 'initials': 'KW', 'affiliation': 'Center for Neurogenomics and Cognitive Research, Department of Molecular and Cellular Neurobiology, Amsterdam Neuroscience, Vrije Universiteit Amsterdam, 1081 HV Amsterdam, The Netherlands.'}, {'lastname': 'Katsila', 'firstname': 'Theodora', 'initials': 'T', 'affiliation': 'Institute of Chemical Biology, National Hellenic Research Foundation, 11635 Athens, Greece.'}, {'lastname': 'Calogeropoulou', 'firstname': 'Theodora', 'initials': 'T', 'affiliation': 'Institute of Chemical Biology, National Hellenic Research Foundation, 11635 Athens, Greece.'}, {'lastname': 'Charalampopoulos', 'firstname': 'Ioannis', 'initials': 'I', 'affiliation': 'Pharmacology Department, Faculty of Medicine, University of Crete, 71003 Heraklion, Greece.\nInstitute of Molecular Biology and Biotechnology, Foundation for Research and Technology Hellas, 71003 Heraklion, Greece.'}, {'lastname': 'Alexaki', 'firstname': 'Vasileia Ismini', 'initials': 'VI', 'affiliation': 'Institute of Clinical Chemistry and Laboratory Medicine, University Clinic Carl Gustav Carus, Technische Universität Dresden, 01307 Dresden, Germany.'}]",,,,,"10.3390/biom12030424
10.1126/science.aag2590
10.1016/j.neuroscience.2014.03.045
10.1146/annurev-immunol-051116-052358
10.1101/cshperspect.a020560
10.1016/j.conb.2015.12.004
10.1111/jnc.13411
10.1016/j.neuint.2018.07.003
10.1084/jem.20141656
10.1186/s12883-015-0478-y
10.1006/frne.1999.0188
10.1016/j.yfrne.2019.100788
10.1016/j.psyneuen.2015.11.005
10.1016/j.psychres.2015.05.093
10.1016/j.jsbmb.2010.02.007
10.1016/j.archger.2009.07.001
10.1016/j.yfrne.2008.11.002
10.4049/jimmunol.167.12.7094
10.1016/j.cell.2011.03.050
10.1016/j.neubiorev.2015.09.024
10.1385/ENDO:21:1:97
10.1002/syn.10145
10.1016/j.neurobiolaging.2005.09.028
10.4049/jimmunol.1601038
10.1016/S0006-8993(00)03077-8
10.1073/pnas.0306631101
10.1096/fj.05-5078fje
10.1196/annals.1366.003
10.1371/journal.pbio.1001051
10.1126/scisignal.2003387
10.1016/j.tem.2008.07.004
10.1177/153537020122601113
10.1016/S0736-5748(99)00067-2
10.1210/jcem.83.6.4876
10.1002/glia.20070
10.1016/j.jsbmb.2009.12.016
10.4049/jimmunol.1900746
10.1002/1097-4547(20001115)62:4<503::AID-JNR4>3.0.CO;2-A
10.1038/mp.2017.167
10.1021/jm900468p
10.1016/j.neuropharm.2016.09.007
10.3389/fphar.2016.00512
10.1002/glia.23312
10.1016/j.yexcr.2019.02.023
10.4049/jimmunol.1300825
10.1186/1479-5876-10-239
10.1021/acs.jmedchem.6b00472
10.1016/j.ejmech.2020.112327
10.1101/pdb.prot5275
10.3791/3634
10.1038/nmeth.2019
10.1016/j.brainres.2011.02.078
10.1016/j.tet.2008.04.079
10.1016/0896-6273(92)90284-K
10.1096/fj.04-1495fje
10.1074/jbc.M111.234674
10.1101/cshperspect.a006338
10.1016/j.neuron.2016.06.015
10.1016/j.neuron.2018.01.031
10.1038/s41577-019-0167-y
10.1523/JNEUROSCI.4586-14.2015
10.3390/cells10071584
10.3389/fnhum.2016.00398
10.1038/nri2565
10.1096/fj.201801539R
10.1002/glia.23507
10.1038/nn.3599
10.1038/s41572-021-00269-y
10.1016/j.cell.2019.09.001
10.1001/jama.2019.22360
10.1038/nrd4024
10.1042/CS20050161
10.2165/00003088-200140120-00003
10.2174/1570159X16666180412092859
10.1002/ana.410360221
10.1159/000017069
10.1523/JNEUROSCI.1310-13.2013
10.1523/JNEUROSCI.0399-12.2013
10.1038/s41598-019-41654-8
10.1038/s41598-018-28633-1
10.2337/db17-0391
10.1002/glia.23170
10.1371/journal.pone.0164103
10.1016/j.cell.2017.05.018
10.1016/j.immuni.2017.08.008
10.1016/j.cell.2018.05.003
10.1038/s41582-018-0072-1
10.1056/NEJMoa1211851
10.15252/embr.201846171",<Element 'PubmedArticle' at 0x7f05df798d10>
114,"35272592
33181336
32600224
32714148
32276177
18626751
19401906
24924665
26845551
23100112
25780797
21979541
19383333
22408567
29681985
30386046
25416634
20638808
5699301
26042591
22833841
9848278
14612506
19929420
29867445
16549835
25897156
20841389
14745018
19602591
29661831
22442308
30992459
24024169
24898155
7720680
11923430
16934233
23079626
28330762
19959011
15260139
30259694
12423981
2702569
11803584
21920857
18448270
24418214
20421690
27830812
31191244
18093566
12695498
29281123
32630301
30201914
12947383
10727772
2573657
30654525
31405050
11525876
28352155
31602419
20556625
11245785
23125894
9252331
33711400
21825020
29156207
28460188
30116051
22737387
24710536
25784053
26210990
27000151
28731040
17244559
19249650
23802883
15280047
16341280
22005465
28167240
1825655
21980554
29921816
19230774
26296072
19747726
10980192
10908611
24910594
27852777
20547131
30733602
28683268
24946960
1973430
1409597
8184014
11358802
9426173
30013647
12094016
31036290
19179659
8769313
9058381
8650195
9242648
2826895
2118104
15947175
11861030
23276634
20392807
11040417
18253054
21829222
22422988
30059692
29129748
10759025
17200459
10531067
18250332
17936613
19596521
18297067
20977477
1353794
9252035
12270495
20732393
15389604
18992727
15246826
17543470
19125376
11290370
8551343
17803971
22681685
19207809
20709161
17671090
24127579
23038752
26940882
26871469
24780430
24040270
24829769
21704159
19189968
20456002
14504383
15994367
17889838
12153491
34299239
18354059
10566973
30968314
22242402
22538356
20351193
29158945
26733801
31143184
17138646
15482376
22723832
17785421
22209870
20403194
19234228
19664827
23804112
30420555
19335068
28186560
19861400
17849004
28714586
26158518
24785256
31526167
24972010
31078693
22860116
28419990
17194963
8909345
11736875
8190445
22034440
11795355
10668686
10851363
10697060
19890493
14927905
9191758
8064097
10199429
32210745
8528351
8649552
8019704
10408542
10202604
18558855
12325070
14634144
7200210
28835399
10540020
29352052
11486708
12943695
29289555
20044983
26397227
29688418
30368985
28888167
27232147
25159739
30173659
24722566
29939076
1384778
22947921
30173659
33762910
26891883
24004276
19457130
20630763
23886572
27554391
10976942
20385012
25852154
20967847
30485399
18823033
32822707
22291649
25651298
22415355
25206782
24124281
9751507
28157652
32991785
11014220
18202548
24451142
18061364
19656855
20234037
35158804
34610415
29200866
14673006
9347981
17239878
16421506
3139181
8388207
8422201
12117397
19458604
20446769
17882254
10820432
26543490
14600281
15839380
17640948
2967196
24498895
27862176
25381162
22020114
29674603
31516880
23107780
26634789
24746691
29881683
30227240
26035622
35646537
33331798
32081636
32823300
15244259
17088055
20924976
20924975
14635262
17378522
19433340
25653923
12589938
23327692
29051735
19889614
29913427
21932171
31092862
22799344
18645020
29739490
29593542
26339345
31431131
26832795
31817453
25127034
22572619
18457947
29951338
23325100
17289903
24019253
23768371
25934092
28353647
19577453
30228287
29286333
31621765
28839227
31448633
25088993
32551573
19411863
21111586
23749762
24397737
29389559
20013881
19353300
24355881
31002890
24480042
18177995
24012889
24260594
30433834
33704934
25715966
27863380
31763216
22771294
23249859",Targeting Estrogen Signaling in the Radiation-induced Neurodegeneration: A Possible Role of Phytoestrogens.,"Radiation for medical use is a well-established therapeutic method with an excellent prognosis rate for various cancer treatments. Unfortunately, a high dose of radiation therapy comes with its own share of side effects, causing radiation-induced non-specific cellular toxicity; consequently, a large percentage of treated patients suffer from chronic effects during the treatment and even after the post-treatment. Accumulating data evidenced that radiation exposure to the brain can alter the diverse cognitive-related signaling and cause progressive neurodegeneration in patients because of elevated oxidative stress, neuroinflammation, and loss of neurogenesis. Epidemiological studies suggested the beneficial effect of hormonal therapy using estrogen in slowing down the progression of various neuropathologies. Despite its primary function as a sex hormone, estrogen is also renowned for its neuroprotective activity and could manage radiation-induced side effects as it regulates many hallmarks of neurodegenerations. Thus, treatment with estrogen and estrogen-like molecules or modulators, including phytoestrogens, might be a potential approach capable of neuroprotection in radiation-induced brain degeneration. This review summarized the molecular mechanisms of radiation effects and estrogen signaling in the manifestation of neurodegeneration and highlighted the current evidence on the phytoestrogen mediated protective effect against radiationinduced brain injury. This existing knowledge points towards a new area to expand to identify the possible alternative therapy that can be taken with radiation therapy as adjuvants to improve patients' quality of life with compromised cognitive function.","['Radiation', 'brain', 'estrogen', 'neurodegeneration', 'phytoestrogen', 'radiation therapy']",Current neuropharmacology,2022-03-12,"[{'lastname': 'Mitra', 'firstname': 'Sarmistha', 'initials': 'S', 'affiliation': 'Department of Anatomy, Dongguk University College of Medicine, Gyeongju 38066, Republic of Korea.'}, {'lastname': 'Dash', 'firstname': 'Raju', 'initials': 'R', 'affiliation': 'Department of Anatomy, Dongguk University College of Medicine, Gyeongju 38066, Republic of Korea.'}, {'lastname': 'Sohel', 'firstname': 'Md', 'initials': 'M', 'affiliation': 'Department of Biochemistry and Molecular Biology, Mawlana Bhashani Science and Technology University, Santosh, Tangail-1902, Bangladesh.'}, {'lastname': 'Chowdhury', 'firstname': 'Apusi', 'initials': 'A', 'affiliation': 'Department of Pharmaceutical Science, North-South University, Dhaka-12 29, Bangladesh.'}, {'lastname': 'Munni', 'firstname': 'Yeasmin Akter', 'initials': 'YA', 'affiliation': 'Department of Anatomy, Dongguk University College of Medicine, Gyeongju 38066, Republic of Korea.'}, {'lastname': 'Ali', 'firstname': 'Md Chayan', 'initials': 'MC', 'affiliation': 'Department of Immunology, Genetics and Pathology, Science for Life Laboratory, Uppsala University, Uppsala SE-751 08, Sweden.'}, {'lastname': 'Hannan', 'firstname': 'Md Abdul', 'initials': 'MA', 'affiliation': 'Department of Biochemistry and Molecular Biology, Bangladesh Agricultural University, Mymensingh-2202, Bangladesh.'}, {'lastname': 'Islam', 'firstname': 'Md Tofazzal', 'initials': 'MT', 'affiliation': 'Institute of Biotechnology and Genetic Engineering (IBGE), Bangabandhu Sheikh Mujibur Rahman Agricultural University (BSMRAU), Gazipur, Bangladesh.'}, {'lastname': 'Moon', 'firstname': 'Il Soo', 'initials': 'IS', 'affiliation': 'Department of Anatomy, Dongguk University College of Medicine, Gyeongju 38066, Republic of Korea.'}]",,,,"Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.","10.2174/1570159X20666220310115004
10.1016/j.arr.2020.101209
10.2174/1381612826666200628022812
10.3389/fnmol.2020.00116
10.1016/j.phymed.2020.153201
10.1007/s11095-008-9661-9
10.1080/09553000902883836
10.1016/j.jalz.2014.04.009
10.2174/1568026616666160204122449
10.1007/s00411-012-0436-7
10.5339/gcsp.2014.57
10.1097/HP.0b013e3182259a71
10.1016/j.nima.2006.01.123
10.1016/j.precisioneng.2019.06.007
10.1016/j.molonc.2008.04.001
10.7150/ijms.3635
10.1155/2018/8324696
10.4103/ijnm.IJNM_56_18
10.1007/s00259-014-2957-6
10.1016/j.ejrad.2010.06.031
10.1080/00039896.1968.10665350
10.1371/journal.pone.0128316
10.3389/fonc.2012.00073
10.1080/095530098141177
10.1667/RR1617.1
10.3389/fnagi.2018.00134
10.1200/JCO.2005.03.3001
10.1200/JCO.2014.58.4508
10.1158/1055-9965.EPI-10-0658
10.1073/pnas.0308319100
10.1158/0008-5472.CAN-09-0506
10.1158/0008-5472.CAN-17-3470
10.1158/1535-7163.MCT-11-0960
10.1038/s41598-019-42313-8
10.1016/j.redox.2013.05.003
10.1001/jamapsychiatry.2014.250
10.1210/endo.136.5.7720680
10.1523/JNEUROSCI.22-07-02650.2002
10.1016/j.brainres.2006.07.064
10.1016/j.neuroscience.2012.10.019
10.1016/j.neuro.2017.03.005
10.1016/j.nic.2009.08.014
10.1023/B:NERV.0000026649.68781.8e
10.1002/cam4.1784
10.1016/S0140-6736(02)11398-5
10.1002/1097-0142(19890515)63:10<1962:AID-CNCR2820631016>3.0.CO;2-V
10.2176/nmc.41.590
10.3174/ajnr.A2643
10.1016/j.ijrobp.2008.03.009
10.1186/1471-2377-14-10
10.3233/JAD-2010-100498
10.1038/nature20411
10.3389/fnmol.2019.00132
10.1016/S1474-4422(07)70327-7
10.1083/jcb.200207030
10.1002/1873-3468.12956
10.3390/md18070347
10.3390/ijerph15091971
10.1038/sj.onc.1206663
10.1016/S0300-9084(00)00062-6
10.1080/09553008914551841
10.3390/cells8010059
10.3390/ijms20163896
10.1016/S0531-5565(01)00139-5
10.2147/DDDT.S130514
10.1016/j.cotox.2018.12.007
10.1007/s00726-010-0646-8
10.1016/S0005-2728(00)00252-8
10.1155/2012/919832
10.1074/jbc.272.33.20313
10.1016/j.neuint.2021.105011
10.1101/cshperspect.a010454
10.1016/j.beha.2017.09.001
10.1146/annurev-biochem-061516-044908
10.1038/nrd.2018.109
10.3390/cells1040926
10.1146/annurev-biochem-060614-033955
10.1007/s00401-015-1462-8
10.1007/s10495-016-1225-6
10.1038/nrneurol.2017.99
10.1016/j.nec.2006.10.010
10.1016/j.semradonc.2008.12.003
10.1089/ars.2012.5134
10.1016/j.febslet.2004.06.078
10.1016/j.bbrc.2011.10.006
10.1016/j.phrs.2017.02.003
10.1016/S0021-9258(20)64351-4
10.4161/cib.4.3.15019
10.3390/biom8020042
10.1016/j.molmed.2009.01.001
10.1016/j.redox.2015.08.010
10.1016/j.ceca.2009.08.005
10.1074/jbc.M002361200
10.1523/JNEUROSCI.20-15-05715.2000
10.3389/fncel.2014.00147
10.1523/JNEUROSCI.1081-16.2016
10.1016/j.neuron.2010.04.029
10.1038/s41580-019-0101-y
10.1016/j.neuron.2017.05.026
10.1016/B978-0-12-801944-3.00006-0
10.1016/j.tcb.2014.05.003
10.1080/09553009014551481
10.1073/pnas.89.19.9005
10.2307/3578688
10.1023/A:1018566431912
10.3892/ol.2018.8968
10.1177/153537020222700716
10.1016/bs.apcsb.2019.01.001
10.1161/CIRCRESAHA.108.190892
10.1016/0014-5793(96)00782-X
10.1073/pnas.93.12.5925
10.1074/jbc.272.32.19858
10.1016/0022-4731(87)90288-3
10.1002/j.1460-2075.1990.tb07469.x
10.1126/science.1112062
10.1016/S0008-6363(01)00473-4
10.1016/j.steroids.2012.12.006
10.1124/pr.109.002071
10.1016/S0301-0082(00)00025-3
10.1159/000111559
10.1038/nrm3168
10.1158/0008-5472.CAN-11-3213
10.1016/j.bbamcr.2018.07.018
10.1016/j.jchemneu.2017.11.008
10.1007/s001090000077
10.1124/mi.6.6.5
10.1126/science.286.5440.790
10.1073/pnas.0711324105
10.1016/j.jsbmb.2007.09.011
10.1016/j.psyneuen.2009.06.003
10.1038/nn2057
10.1111/j.1471-4159.2010.07038.x
10.1523/JNEUROSCI.12-08-03217.1992
10.1016/S0006-8993(97)00449-6
10.1016/S0006-8993(02)03158-X
10.1016/j.neuroscience.2010.08.019
10.1002/neu.20043
10.1016/j.brainres.2008.10.015
10.1016/j.expneurol.2004.01.014
10.1016/j.neuroscience.2007.04.037
10.1080/00207450802330959
10.1016/S0014-2999(01)00880-9
10.1523/JNEUROSCI.16-02-00595.1996
10.1016/j.brainres.2007.06.092
10.1016/j.neuron.2012.03.035
10.1111/j.1365-2826.2009.01838.x
10.1016/j.neuroscience.2010.08.012
10.1101/gad.1553007
10.1073/pnas.1315319110
10.1096/fj.12-212290
10.1038/emm.2015.115
10.18632/oncotarget.7276
10.1016/j.neuint.2014.04.011
10.1371/journal.pone.0074522
10.5812/ircmj.13954
10.1016/j.jsbmb.2011.06.008
10.1074/jbc.M808246200
10.1111/j.1471-4159.2010.06770.x
10.1073/pnas.2032621100
10.1124/mol.105.014662
10.1016/j.brainres.2007.08.036
10.1046/j.1471-4159.2002.01000.x
10.3390/ijms22147620
10.1124/jpet.107.134072
10.1097/00004647-199911000-00011
10.1007/s00401-019-02009-9
10.1159/000338409
10.4049/jimmunol.0903463
10.1038/sigtrans.2017.23
10.3389/fnmol.2015.00077
10.3389/fimmu.2019.01043
10.1210/en.2006-1137
10.1111/j.1472-8206.2004.00284.x
10.1371/journal.pone.0036890
10.1073/pnas.0703783104
10.1016/j.yfrne.2011.12.001
10.1186/1471-2172-11-20
10.4049/jimmunol.0803205
10.1016/j.jneuroim.2009.06.023
10.1523/JNEUROSCI.0886-13.2013
10.1101/cshperspect.a034066
10.1517/14728220902832697
10.1093/hmg/ddx049
10.1093/jb/mvp166
10.1371/journal.pone.0000874
10.1111/jcmm.13280
10.1038/cddis.2015.181
10.1158/1535-7163.MCT-13-1066
10.1177/0300060519871373
10.1080/15257770.2014.885045
10.1016/j.jsbmb.2019.105380
10.1371/journal.pone.0042339
10.1159/000475433
10.1097/01.gme.0000230347.28616.1c
10.1111/j.1532-5415.1996.tb01400.x
10.1046/j.0306-5251.2001.01492.x
10.1097/00006250-199406000-00017
10.31887/DCNS.2002.4.2/ddubal
10.1111/j.1749-6632.2001.tb04023.x
10.1212/WNL.54.2.295
10.1212/WNL.54.11.2061
10.1001/jama.283.8.1007
10.1177/1756285608100427
10.1093/geronj/7.2.228
10.1212/WNL.48.6.1517
10.1111/j.1532-5415.1994.tb06580.x
10.1001/jama.281.13.1197
10.3389/fnins.2020.00157
10.1507/endocrj.41.361
10.1212/WNL.46.6.1580
10.1515/REVNEURO.1994.5.1.27
10.1212/WNL.53.1.91
10.1097/00002826-199903000-00005
10.1146/annurev.neuro.30.051606.094313
10.1002/ana.10301
10.1212/WNL.32.5.547
10.1212/WNL.0000000000004390
10.1016/S0022-510X(99)00234-8
10.1634/theoncologist.2017-0423
10.1081/CNV-100104293
10.1016/S0960-0760(03)00207-3
10.1016/j.pharmthera.2017.12.012
10.1016/j.brainres.2009.12.055
10.32725/jab.2009.020
10.18632/oncotarget.5191
10.1093/jrr/rry032
10.1002/jbt.22242
10.1016/j.jphotobiol.2017.08.034
10.12816/0033118
10.1016/j.jphotobiol.2016.04.031
10.1016/j.pbb.2014.08.005
10.2174/1874471011666180831101459
10.3390/ijms15045928
10.1080/09553002.2018.1492755
10.1159/000342208
10.2174/1874471011666180831101459
10.1159/000109348
10.3389/fncel.2021.636176
10.1016/j.pneurobio.2015.12.008
10.1089/neu.2013.3108
10.1111/j.1471-4159.2009.06077.x
10.1016/j.jocn.2010.01.049
10.1016/j.brainresbull.2013.07.007
10.1038/srep31599
10.1097/00001756-200008210-00014
10.1186/1471-2377-10-23
10.1093/qjmed/hcv072
10.1002/pon.1860
10.1002/cncr.31858
10.1002/cncr.23853
10.1016/j.yfrne.2020.100869
10.3389/fphar.2011.00094
10.18502/tim.v6i3.7314
10.1371/journal.pone.0117020
10.1007/s12031-012-9737-1
10.4103/1673-5374.135328
10.4103/0973-1296.117824
10.1210/endo.139.10.6216
10.1016/j.biopha.2017.01.081
10.1002/jbt.22634
10.1210/endo.141.10.7721
10.1254/jphs.FP0071206
10.3390/ijms15011625
10.1016/j.cdp.2007.10.018
10.3945/jn.109.109785
10.1080/07315724.2009.10718116
10.3390/cancers14030539
10.1016/j.canlet.2021.09.043
10.2147/OTT.S142154
10.1523/JNEUROSCI.23-36-11420.2003
10.3171/jns.1997.87.5.0724
10.1016/j.yhbeh.2006.12.002
10.1038/sj.jcbfm.9600278
10.1136/bmj.297.6647.519
10.1001/archinte.1993.00410100035005
10.1001/archinte.1993.00410010097008
10.1001/jama.288.3.321
10.1038/jcbfm.2009.66
10.1089/ars.2009.3074
10.1038/nrn2214
10.1002/(SICI)1097-4547(20000601)60:5<613::AID-JNR6>3.0.CO;2-8
10.1186/s12979-015-0046-8
10.1093/toxsci/kfh007
10.1080/10408440590917062
10.1210/er.2007-0001
10.1016/S0015-0282(16)59945-2
10.1186/1742-4933-10-41
10.1002/jnr.23986
10.1007/s12079-014-0253-7
10.1016/j.mam.2011.10.007
10.3390/ph4050726
10.1186/alzrt146
10.2174/1567201813666151202195437
10.1016/j.ijpharm.2014.04.039
10.1016/j.apsb.2018.03.004
10.1016/j.ijpharm.2018.09.031
10.1586/14737175.2015.1044981
10.1016/j.apsb.2021.10.027
10.1016/j.ijantimicag.2020.105924
10.1055/s-0040-1701984
10.1016/j.jsbmb.2006.09.017
10.1080/01635581.2010.509841
10.1080/01635581.2010.509839
10.1002/jat.904
10.1080/09553000601132642
10.1016/j.radonc.2009.04.005
10.3389/fonc.2014.00381
10.1016/S0960-0760(02)00230-3
10.1517/14728222.2013.756869
10.3389/fphar.2017.00699
10.1093/annonc/mdp499
10.1016/j.intimp.2018.06.016
10.1055/s-0031-1286306
10.1038/s41598-019-43768-5
10.1158/1535-7163.MCT-07-2350
10.3727/096504018X15228018559434
10.3389/fphar.2018.00220
10.1080/21655979.2019.1657327
10.1158/1535-7163.MCT-15-0606
10.3390/cancers11121947
10.1371/journal.pone.0104459
10.1016/j.jss.2012.04.027
10.1016/j.jsbmb.2008.03.032
10.20892/j.issn.2095-3941.2018.0012
10.3390/molecules18011122
10.1158/1078-0432.CCR-06-1651
10.1177/1087057113502673
10.1016/j.foodchem.2013.03.053
10.1016/j.jsbmb.2015.04.019
10.3390/ijms18040729
10.1016/j.phymed.2009.05.015
10.1038/s41598-018-32438-7
10.3390/molecules23010074
10.1039/C9FO01721F
10.1038/s41598-017-09933-4
10.1080/01635581.2019.1654529
10.1016/j.bbrc.2014.07.115
10.1021/acs.jafc.0c03202
10.4161/cbt.8.6.7582
10.1016/j.phymed.2010.10.013
10.1177/1933719113492213
10.1111/cas.12349
10.1016/j.jfda.2017.03.009
10.1002/mnfr.200900111
10.1007/s10616-009-9191-2
10.1159/000356612
10.1016/j.gene.2019.04.005
10.1016/j.fct.2014.01.040
10.1016/j.mce.2007.11.020
10.1016/j.neuro.2013.08.012
10.1080/00207454.2018.1545772
10.1002/brb3.2100
10.3109/13880209.2014.962057
10.18632/oncotarget.13338
10.1016/j.ejphar.2012.06.037
10.3390/ijerph9124732",<Element 'PubmedArticle' at 0x7f05ddd39090>
115,"35237767
24381049
34221542
20738443
32673700
34443519
1935809
8246142
9284088
9582259
30741691
18491044
20422475
18353507
19835562
19413310
21524253
25017241
1617402
8915907
17027094
26237701
18328580
15985713
18506634
21514338
1312085
29701556
19109992
18511649
21114961
18405376
32807782
7632881
29395804
15518895
10066755
14578481
31449829
32057796
1649637
8795075
9726637
1522236
8156912
7714762
30295667
19306379
30989485
20129497
24760409
25585137
30709867
19657303
1483839
11175907
18423411
26157795
1171714
20613859
23648414
18515209
32157248
16401644
17574305
9730914
11193883
22342206
26125201
17582655
22300099
24576160
27712117
17313456
21118955
23127847
23564451
25083019
30003140
8095427
11253364
22668124
11281773
2803320
2383262
21157320
16022590
29038483
33536635
15589520
12182949
26612670
8951643
21341976
8028478
16075406
25698233
21593432
15084446
15518897
29107653
1325033
1321043
11566141
24702469
24899763
24416145
29789012
30398389
31677290
33319441
10526883
31309675
10100920
19285088
20029451
10590302
21956442
1319331
16750350
21530028
11978642
34236893
1327769
11972030
16009465
19805477
29464574
1383635
14959888
11786210
28705763
21122475
29939190
21840512
24291725
12690116
21871613",Design and Synthesis of Brain Penetrant Glycopeptide Analogues of PACAP With Neuroprotective Potential for Traumatic Brain Injury and Parkinsonism.,"There is an unmet clinical need for curative therapies to treat neurodegenerative disorders. Most mainstay treatments currently on the market only alleviate specific symptoms and do not reverse disease progression. The Pituitary adenylate cyclase-activating polypeptide (PACAP), an endogenous neuropeptide hormone, has been extensively studied as a potential regenerative therapeutic. PACAP is widely distributed in the central nervous system (CNS) and exerts its neuroprotective and neurotrophic effects ","['6-hydroxydopamine', 'PAC1', 'VPAC1/VPAC2 receptors', 'blood-brain barrier', 'neurodegeneration', 'neuroinflammation']",Frontiers in drug discovery,2022-03-04,"[{'lastname': 'Apostol', 'firstname': 'Christopher R', 'initials': 'CR', 'affiliation': 'Department of Chemistry and Biochemistry, BIO5, The University of Arizona, Tucson, AZ, United States.'}, {'lastname': 'Bernard', 'firstname': 'Kelsey', 'initials': 'K', 'affiliation': 'Graduate Interdisciplinary Program in Physiological Sciences, The University of Arizona, Tucson, AZ, United States.'}, {'lastname': 'Tanguturi', 'firstname': 'Parthasaradhireddy', 'initials': 'P', 'affiliation': 'Department of Pharmacology, College of Medicine, The University of Arizona, Tucson, AZ, United States.'}, {'lastname': 'Molnar', 'firstname': 'Gabriella', 'initials': 'G', 'affiliation': 'Department of Pharmacology, College of Medicine, The University of Arizona, Tucson, AZ, United States.'}, {'lastname': 'Bartlett', 'firstname': 'Mitchell J', 'initials': 'MJ', 'affiliation': 'Department of Neurology, College of Medicine, The University of Arizona, Tucson, AZ, United States.'}, {'lastname': 'Szabò', 'firstname': 'Lajos', 'initials': 'L', 'affiliation': 'Department of Chemistry and Biochemistry, BIO5, The University of Arizona, Tucson, AZ, United States.'}, {'lastname': 'Liu', 'firstname': 'Chenxi', 'initials': 'C', 'affiliation': 'Department of Chemistry and Biochemistry, BIO5, The University of Arizona, Tucson, AZ, United States.'}, {'lastname': 'Ortiz', 'firstname': 'J Bryce', 'initials': 'JB', 'affiliation': ""Barrow Neurological Institute at Phoenix Children's Hospital, The University of Arizona College of Medicine-Phoenix, Phoenix, AZ, United States.\nDepartment of Child Health, The University of Arizona College of Medicine-Phoenix, Phoenix, AZ, United States.\nPhoenix Veteran Affairs Health Care System, Phoenix, AZ, United States.""}, {'lastname': 'Saber', 'firstname': 'Maha', 'initials': 'M', 'affiliation': ""Barrow Neurological Institute at Phoenix Children's Hospital, The University of Arizona College of Medicine-Phoenix, Phoenix, AZ, United States.\nDepartment of Child Health, The University of Arizona College of Medicine-Phoenix, Phoenix, AZ, United States.""}, {'lastname': 'Giordano', 'firstname': 'Katherine R', 'initials': 'KR', 'affiliation': ""Barrow Neurological Institute at Phoenix Children's Hospital, The University of Arizona College of Medicine-Phoenix, Phoenix, AZ, United States.\nDepartment of Child Health, The University of Arizona College of Medicine-Phoenix, Phoenix, AZ, United States.\nPhoenix Veteran Affairs Health Care System, Phoenix, AZ, United States.""}, {'lastname': 'Green', 'firstname': 'Tabitha R F', 'initials': 'TRF', 'affiliation': 'Department of Child Health, The University of Arizona College of Medicine-Phoenix, Phoenix, AZ, United States.'}, {'lastname': 'Melvin', 'firstname': 'James', 'initials': 'J', 'affiliation': 'Department of Child Health, The University of Arizona College of Medicine-Phoenix, Phoenix, AZ, United States.\nDepartment of Biological Sciences, University of Bath, Bath, United Kingdom.'}, {'lastname': 'Morrison', 'firstname': 'Helena W', 'initials': 'HW', 'affiliation': 'College of Nursing, University of Arizona, Tucson, AZ, United States.'}, {'lastname': 'Madhavan', 'firstname': 'Lalitha', 'initials': 'L', 'affiliation': 'Graduate Interdisciplinary Program in Physiological Sciences, The University of Arizona, Tucson, AZ, United States.\nDepartment of Neurology, College of Medicine, The University of Arizona, Tucson, AZ, United States.'}, {'lastname': 'Rowe', 'firstname': 'Rachel K', 'initials': 'RK', 'affiliation': ""Barrow Neurological Institute at Phoenix Children's Hospital, The University of Arizona College of Medicine-Phoenix, Phoenix, AZ, United States.\nDepartment of Child Health, The University of Arizona College of Medicine-Phoenix, Phoenix, AZ, United States.\nDepartment of Integrative Physiology, University of Colorado Boulder, Boulder, CO, United States.""}, {'lastname': 'Streicher', 'firstname': 'John M', 'initials': 'JM', 'affiliation': 'Department of Pharmacology, College of Medicine, The University of Arizona, Tucson, AZ, United States.'}, {'lastname': 'Heien', 'firstname': 'Michael L', 'initials': 'ML', 'affiliation': 'Department of Chemistry and Biochemistry, BIO5, The University of Arizona, Tucson, AZ, United States.'}, {'lastname': 'Falk', 'firstname': 'Torsten', 'initials': 'T', 'affiliation': 'Graduate Interdisciplinary Program in Physiological Sciences, The University of Arizona, Tucson, AZ, United States.\nDepartment of Pharmacology, College of Medicine, The University of Arizona, Tucson, AZ, United States.\nDepartment of Neurology, College of Medicine, The University of Arizona, Tucson, AZ, United States.'}, {'lastname': 'Polt', 'firstname': 'Robin', 'initials': 'R', 'affiliation': 'Department of Chemistry and Biochemistry, BIO5, The University of Arizona, Tucson, AZ, United States.'}]",,,,,"10.3389/fddsv.2021.818003
10.3390/ijms15010309
10.14336/AD.2021.0511
10.1111/j.1582-4934.2010.01164.x
10.1007/978-1-60327-185-1_32
10.1016/j.peptides.2020.170369
10.3390/molecules26164932
10.1210/endo-129-5-2787
10.1016/S0024-3205(97)00597-3
10.1006/exnr.1998.6786
10.3233/JPD-181525
10.1007/s12031-008-9075-5
10.1007/s12640-010-9186-y
10.1016/j.peptides.2008.01.022
10.2174/092986709789712899
10.1021/jm900291j
10.2174/138161211795589337
10.1016/j.peptides.2014.07.001
10.1007/s10989-008-9154-z
10.1016/0006-8993(92)90557-P
10.1089/neu.1996.13.557
10.1016/j.regpep.2006.06.016
10.2217/rme.15.32
10.1016/j.bbr.2008.01.012
10.1007/s12031-008-9087-1
10.1016/j.peptides.2011.04.003
10.1016/s0021-9258(18)42737-8
10.3171/2017.10.JNS17352
10.1016/j.pharmthera.2008.11.006
10.1124/jpet.108.138180
10.1039/c39940000853
10.1016/j.bcp.2010.11.015
10.1186/1475-925X-7-14
10.1038/s41467-020-17933-8
10.1016/j.tetasy.2004.11.038
10.1002/bip.360370504
10.1016/j.bmc.2018.01.012
10.1016/j.regpep.2004.05.014
10.1074/jbc.274.11.7011
10.1113/jphysiol.2003.053835
10.1016/j.peptides.2019.170134
10.1016/j.expneurol.2020.113242
10.1016/0005-2736(91)90193-C
10.1016/0167-0115(96)00010-9
10.1016/S0014-2999(98)00435-X
10.1097/00006254-199303000-00022
10.1210/endo.134.5.8156912
10.3791/58513
10.1002/msj.20104
10.1016/S0040-4039(00)91681-2
10.1007/s40263-019-00630-6
10.1016/j.nurt.2009.10.021
10.1007/s00221-014-3948-3
10.1016/j.bbi.2015.01.001
10.1124/jpet.118.254854
10.1249/MSS.0b013e31819fcd1b
10.1111/j.1399-3011.1992.tb00324.x
10.1038/84159
10.1016/j.freeradbiomed.2008.03.011
10.3389/fchem.2015.00040
10.1016/0006-8993(75)90233-4
10.1371/journal.pbio.1000412
10.1016/j.bbagen.2013.04.038
10.1007/BF03033558
10.1038/s41594-020-0386-8
10.1096/fj.05-4812fje
10.1016/j.peptides.2007.04.026
10.1007/BF00117955
10.1124/mol.54.3.547
10.1111/j.1749-6632.2000.tb06954.x
10.1016/j.carres.2012.01.008
10.1021/acs.jmedchem.5b00014
10.1016/j.peptides.2007.05.002
10.4155/fmc.11.195
10.1021/jm400879w
10.1080/02699052.2016.1193628
10.1111/j.1747-0285.2007.00462.x
10.1124/jpet.110.172866
10.1016/j.neulet.2012.10.029
10.1074/jbc.M112.434597
10.5665/sleep.3936
10.1038/s41531-018-0058-0
10.1016/0006-8993(93)90241-E
10.1038/35040009
10.2165/11634020-000000000-00000
10.1021/jo005712m
10.1016/0006-291X(89)91757-
10.1016/0006-291X(90)92140-U
10.1097/MED.0b013e328342568a
10.1146/annurev.neuro.28.061604.135718
10.1038/s41598-017-13581-z
10.1038/s41573-020-00135-8
10.1016/j.expneurol.2004.09.013
10.1016/S0196-9781(02)00085-2
10.1039/c5cs00680e
10.1002/(SICI)1096-9861(19961209)376:2<278:AID-CNE9>3.0.CO;2-0
10.1089/neu.2010.1499
10.1016/0169-328X(94)90222-4
10.1002/med.20039
10.1016/j.peptides.2015.01.009
10.1096/fj.10-180133
10.1016/j.bbr.2003.09.007
10.1016/j.regpep.2004.05.016
10.1016/j.peptides.2017.10.013
10.1111/j.1432-1033.1992.tb17043.x
10.1016/S0091-3057
10.3109/02699052.2014.888768
10.5665/sleep.3582
10.1371/journal.pone.0082507
10.1186/s12974-018-1200-y
10.1089/neu.2018.5980
10.1111/ejn.14611
10.1002/jnr.24771
10.1002/(sici)1099-1387(199909)5:9<403:aid-psc213>3.0.co;2-s
10.1002/psc.3193
10.1016/s0167-0115(98)00147-5
10.1016/j.lfs.2009.02.025
10.1038/jcbfm.2009.262
10.1016/S0005-2736(99)00200-X
10.1038/npp.2011.212
10.1016/j.tet.2011.08.046
10.1210/endo.131.1.1319331
10.1016/j.euroneuro.2006.04.009
10.1016/j.bjoms.2011.03.004
10.2337/diabetes.51.5.1453
10.1146/annurev-neuro-100720-034518
10.1111/j.1432-1033.1992.tb17252.x
10.1073/pnas.082112699
10.1016/j.peptides.2005.05.015
10.1124/pr.109.001370.283
10.1007/s13311-017-0596-x
10.1097/00005344-199220010-00011
10.1002/psc.484
10.1016/S0196-9781(01)00537-X
10.1016/0040-4039(95)00667-2
10.1021/ja961509q
10.1016/j.jmb.2017.06.022
10.3791/57648
10.1016/j.brainres.2011.07.038
10.1016/j.neuroscience.2013.11.038
10.1074/jbc.M212355200
10.1016/j.brainres.2011.07.056",<Element 'PubmedArticle' at 0x7f05dd1c8090>
116,35143834,"Raloxifene, a cannabinoid type-2 receptor inverse agonist, mitigates visual deficits and pathology and modulates microglia after ocular blast.","Visual deficits after ocular blast injury (OBI) are common, but pharmacological approaches to improve long-term outcomes have not been identified. Blast forces frequently damage the retina and optic nerves, and work on experimental animals has shown the pro-inflammatory actions of microglia can further exacerbate such injuries. Cannabinoid type-2 receptor (CB2) inverse agonists specifically target activated microglia, biasing them away from the harmful pro-inflammatory M1 state toward the helpful reparative M2 state. We previously found that treating mice with CB2 inverse agonists after traumatic brain injury, produced by either focal cranial air blast or dorsal cranial impact, greatly attenuated the visual deficits and pathology that otherwise resulted. Here we examined the consequences of single and repeat OBI and the benefit provided by raloxifene, an FDA-approved estrogen receptor drug that possesses noteworthy CB2 inverse agonism. After single OBI, although the amplitudes of the A- and B-waves of the electroretinogram and pupil light response appeared to be normal, the mice showed hints of deficits in contrast sensitivity and visual acuity, a trend toward optic nerve axon loss, and significantly increased light aversion, which were reversed by 2 weeks of daily treatment with raloxifene. Mice subjected to repeat OBI (5 blasts spaced 1 min apart), exhibited more severe visual deficits, including decreases in contrast sensitivity, visual acuity, the amplitudes of the A- and B-waves of the electroretinogram, light aversion, and resting pupil diameter (i.e. hyperconstriction), accompanied by the loss of photoreceptor cells and optic nerve axons, nearly all of which were mitigated by raloxifene. Interestingly, optic nerve axon abundance was strongly correlated with contrast sensitivity and visual acuity across all groups of experimental mice in the repeat OBI study, suggesting optic nerve axon loss with repeat OBI and its attenuation with raloxifene are associated with the extent of these two deficits while photoreceptor abundance was highly correlated with A-wave amplitude and resting pupil size, suggesting a prominent role for photoreceptors in these two deficits. Quantitative PCR (qPCR) showed levels of M1-type microglial markers (e.g. iNOS, IL1β, TNFα, and CD32) in retina, optic nerve, and thalamus were increased 3 days after repeat OBI. With raloxifene treatment, the overall expression of M1 markers was more similar to that in sham mice. Raloxifene treatment was also associated with the elevation of IL10 transcripts in all three tissues compared to repeat OBI alone, but the results for the three other M2 microglial markers we examined were more varied. Taken together, the qPCR results suggest that raloxifene benefit for visual function and pathology was associated with a lessening of the pro-inflammatory actions of microglia. The benefit we find for raloxifene following OBI provides a strong basis for phase-2 efficacy testing in human clinical trials for treating ocular injury.","['CB2 receptors', 'Inflammatory responses', 'Microglia', 'Mouse model', 'Neuroinflammation', 'Ocular injury', 'Raloxifene', 'Visual deficits']",Experimental eye research,2022-02-11,"[{'lastname': 'Honig', 'firstname': 'Marcia G', 'initials': 'MG', 'affiliation': 'Department of Anatomy and Neurobiology(,) the University of Tennessee Health Science Center, Memphis, TN, 38163, USA.'}, {'lastname': 'Del Mar', 'firstname': 'Nobel A', 'initials': 'NA', 'affiliation': 'Department of Anatomy and Neurobiology(,) the University of Tennessee Health Science Center, Memphis, TN, 38163, USA.'}, {'lastname': 'Henderson', 'firstname': 'Desmond L', 'initials': 'DL', 'affiliation': 'Department of Anatomy and Neurobiology(,) the University of Tennessee Health Science Center, Memphis, TN, 38163, USA.'}, {'lastname': ""O'Neal"", 'firstname': 'Dylan', 'initials': 'D', 'affiliation': 'Department of Anatomy and Neurobiology(,) the University of Tennessee Health Science Center, Memphis, TN, 38163, USA.'}, {'lastname': 'Yammanur', 'firstname': 'Meghna', 'initials': 'M', 'affiliation': 'Department of Anatomy and Neurobiology(,) the University of Tennessee Health Science Center, Memphis, TN, 38163, USA.'}, {'lastname': 'Cox', 'firstname': 'Rachel', 'initials': 'R', 'affiliation': 'Department of Anatomy and Neurobiology(,) the University of Tennessee Health Science Center, Memphis, TN, 38163, USA.'}, {'lastname': 'Li', 'firstname': 'Chunyan', 'initials': 'C', 'affiliation': 'Department of Anatomy and Neurobiology(,) the University of Tennessee Health Science Center, Memphis, TN, 38163, USA.'}, {'lastname': 'Perry', 'firstname': 'Aaron M', 'initials': 'AM', 'affiliation': 'Department of Anatomy and Neurobiology(,) the University of Tennessee Health Science Center, Memphis, TN, 38163, USA.'}, {'lastname': 'Moore', 'firstname': 'Bob M', 'initials': 'BM', 'affiliation': 'Department of Pharmaceutical Sciences, The University of Tennessee Health Science Center, Memphis, TN, 38163, USA.'}, {'lastname': 'Reiner', 'firstname': 'Anton', 'initials': 'A', 'affiliation': 'Department of Anatomy and Neurobiology(,) the University of Tennessee Health Science Center, Memphis, TN, 38163, USA; Department of Ophthalmology, The University of Tennessee Health Science Center, Memphis, TN, 38163, USA. Electronic address: areiner@uthsc.edu.'}]",,,,Copyright © 2022 The Authors. Published by Elsevier Ltd.. All rights reserved.,10.1016/j.exer.2022.108966,<Element 'PubmedArticle' at 0x7f05da517a90>
117,35134437,"Linagliptin attenuates thioacetamide-induced hepatic encephalopathy in rats: Modulation of C/EBP-β and CX3CL1/Fractalkine, neuro-inflammation, oxidative stress and behavioral defects.","The degree of neuroinflammation is correlated mainly with cognitive and motor dysfunctions associated with hepatic encephalopathy (HE). The current study was conducted to explore the possible protective potential of the antidiabetic drug; linagliptin (LNG; 10 or 20 mg/kg) against HE induced by thioacetamide (TAA) in rats. Animals received two consecutive intraperitoneal injections of TAA (200 mg/kg) on alternate days. Neurobehavioral tests were performed 24 h after the last injection, and rats were sacrificed 24 h later (48 h). The higher LNG dose more effectively protected against TAA-induced changes. Administration of LNG for 15 days before TAA notably mitigated TAA-induced acute liver injury and HE, as verified by the marked improvement in motor coordination, locomotor activity, and cognition function. LNG maintained both brain and liver weight indices and retracted the hyperammonemia with a prominent suppression in liver transaminases. This was accompanied by an evident modulation of hepatic and hippocampal oxidative stress markers; GSH and MDA. LNG attenuated both liver and hippocampal pro-inflammatory cytokine; IL-1β while augmented the anti-inflammatory one; IL-10. It noticeably reduced hepatic and hippocampal COX-2 and TNF-α and maintained hepatic and brain architectures. It also induced a marked decrease in the inflammation-regulated transcription factor, C/EBP-β, with a profound increase in hippocampi's anti-inflammatory chemokine, CX3CL1/Fractalkine. LNG modulated TAA-induced disturbances in hippocampal amino acids; glutamate, and GABA with a significant increase in hippocampal BDNF. In conclusion, the regulatory effect of LNG on neuroinflammatory signaling underlines its neuroprotective effect against progressive encephalopathy accompanying acute liver injury.","['C/EBP-β', 'CX3CL1/Fractalkine', 'Hepatic encephalopathy', 'Linagliptin', 'Neuroinflammation', 'Thioacetamide']",Life sciences,2022-02-09,"[{'lastname': 'Hussien', 'firstname': 'Yosra A', 'initials': 'YA', 'affiliation': 'Pharmacology Department, Medical Research and Clinical Institute - National Research Centre, Giza, Egypt.'}, {'lastname': 'Mansour', 'firstname': 'Dina F', 'initials': 'DF', 'affiliation': 'Pharmacology Department, Medical Research and Clinical Institute - National Research Centre, Giza, Egypt.'}, {'lastname': 'Nada', 'firstname': 'Somaia A', 'initials': 'SA', 'affiliation': 'Pharmacology Department, Medical Research and Clinical Institute - National Research Centre, Giza, Egypt.'}, {'lastname': 'Abd El-Rahman', 'firstname': 'Sahar S', 'initials': 'SS', 'affiliation': 'Pathology Department, Faculty of Veterinary Medicine, Cairo University, Giza, Egypt.'}, {'lastname': 'Abdelsalam', 'firstname': 'Rania M', 'initials': 'RM', 'affiliation': 'Pharmacology and Toxicology Department, Faculty of Pharmacy, Cairo University, Cairo, Egypt; Biology Department, School of Pharmacy, New Giza University, Giza, Egypt.'}, {'lastname': 'Attia', 'firstname': 'Amina S', 'initials': 'AS', 'affiliation': 'Pharmacology and Toxicology Department, Faculty of Pharmacy, Cairo University, Cairo, Egypt.'}, {'lastname': 'El-Tanbouly', 'firstname': 'Dalia M', 'initials': 'DM', 'affiliation': 'Pharmacology and Toxicology Department, Faculty of Pharmacy, Cairo University, Cairo, Egypt. Electronic address: dalia.eltanbouly@pharma.cu.edu.eg.'}]",,,,Copyright © 2022 Elsevier Inc. All rights reserved.,10.1016/j.lfs.2022.120378,<Element 'PubmedArticle' at 0x7f05dba07b30>
118,"35092416
25842176
20530481
30381462
33210737
29170064
28430636
31384158
32044330
19865538
32838138
17096118
33297311
28433610
21199929
32382056
15232408
27609416
22653878
28889264
26904161
24012887
23743621
29677557
20578959
29531225
23911207
25038992
29908950
27380314
14579013
15772423
29439952
26359712
25126045
10882337
22824324
23274086
22964087
15345661
19497963
32093309
27062895
23376469
21354197
30746344
29441810
22135851
22860094
21217689
24421402
22411250
25635583
22666051
18691157
17404154
26056385
31205544
23908111
26913202
18178738
11803456
32411652
31905923
21836061
19357782
10940438
27322774
25708945
27096809
11102464
31052559
29729330
25812084
29731617
19643039
28637359
4026939
25965560
32487820
31351988
26656916
18440321
14984433
9714608
17884997
31835890
28803777
16891303
11579088
28954597
0
20716914
25210784
34714861
22744335
8661009
30693042
26825389
32032646
33374313
20381198
19071155
14636952
19091699
14592851
24657077
23125205
16822964
26608647
9443862
11146649
22441669
22570791
30397533
21867409
30641857
19474728
19654933
15544923
16970920
17292903
18020951
27012165
22534874
16822965
29199478
17122353
19840942
30802459
33348669
30241945
18347034
28108734
15301672
18695162
17652427
30863482
24100645
31338708
21626386
21368884
22666600
30977447
32090497
21053390
20861927",Insights into the role of paraoxonase 2 in human pathophysiology.,"Paraoxonase 2 (PON2) is a ubiquitously expressed intracellular enzyme that is known to have a protective role from oxidative stress. Clinical studies have also demonstrated the significance of PON2 in the manifestation of cardiovascular and several other diseases, and hence, it is considered an important biomarker. Recent findings of its expression in brain tissue suggest its potential protective effect on oxidative stress and neuroinflammation. Polymorphisms of PON2 in humans are a risk factor in many pathological conditions, suggesting a possible mechanism of its anti-oxidative property probably through lactonase activity. However, exogenous factors may also modulate the expression and activity of PON2. Hence, this review aims to report the mechanism by which PON2 expression is regulated and its role in oxidative stress disorders such as neurodegeneration and tumor formation. The role of PON2 owing to its lactonase activity in bacterial infectious diseases and association of PON2 polymorphism with pathological conditions are also highlighted.",[],Journal of biosciences,2022-01-30,"[{'lastname': 'Parween', 'firstname': 'Fauzia', 'initials': 'F', 'affiliation': 'Faculty of Life Sciences and Biotechnology, South Asian University, New Delhi, India.'}, {'lastname': 'Gupta', 'firstname': 'Rinkoo Devi', 'initials': 'RD', 'affiliation': None}]",,,,,"10.1007/s12038-021-00234-7
10.1093/eep/dvv003",<Element 'PubmedArticle' at 0x7f05db9fa590>
119,"35079029
32840331
33783469
32730766
29377010
15750214
29476033
28852028
26159205
27726055
6384211
12101028
32568367
34101779
19578713
27327500
30406177
29427657
30630955
29874566
31083442
31575996
26311408
23332364
24190781
25510382
22539931
19487648
29653606
17188367
30711675
34160128
29958802
30389931
27664933
19513308
23335631
28279120
22815714
28634890
26280014
32801037
28003243
34122046
25882245
22129253
18390924
23136554
19828948
24760020
20721349
21238488
26675645
20692646
29599291
28086917
33961966
30827953
33679687
31135596
18799497
26932603
32038141
31139684
28587659
22119648
28050342
9236948
1572948
20683186",Intranasal insulin modulates cerebrospinal fluid markers of neuroinflammation in mild cognitive impairment and Alzheimer's disease: a randomized trial.,"Intranasal insulin (INI) has shown promise as a treatment for Alzheimer's disease (AD) in pilot clinical trials. In a recent phase 2 trial, participants with mild cognitive impairment (MCI) or AD who were treated with INI with one of two delivery devices showed improved cerebral spinal fluid (CSF) biomarker profiles and slower symptom progression compared with placebo. In the cohort which showed benefit, we measured changes in CSF markers of inflammation, immune function and vascular integrity and assessed their relationship with changes in cognition, brain volume, and CSF amyloid and tau concentrations. The insulin-treated group had increased CSF interferon-γ (p = 0.032) and eotaxin (p = 0.049), and reduced interleukin-6 (p = 0.048) over the 12 month trial compared to placebo. Trends were observed for increased CSF macrophage-derived chemokine for the placebo group (p = 0.083), and increased interleukin-2 in the insulin-treated group (p = 0.093). Insulin-treated and placebo groups showed strikingly different patterns of associations between changes in CSF immune/inflammatory/vascular markers and changes in cognition, brain volume, and amyloid and tau concentrations. In summary, INI treatment altered the typical progression of markers of inflammation and immune function seen in AD, suggesting that INI may promote a compensatory immune response associated with therapeutic benefit.",[],Scientific reports,2022-01-27,"[{'lastname': 'Kellar', 'firstname': 'Derek', 'initials': 'D', 'affiliation': 'Department of Internal Medicine-Geriatrics, Wake Forest School of Medicine, Winston-Salem, NC, USA.'}, {'lastname': 'Register', 'firstname': 'Thomas', 'initials': 'T', 'affiliation': 'Department of Internal Medicine-Geriatrics, Wake Forest School of Medicine, Winston-Salem, NC, USA.'}, {'lastname': 'Lockhart', 'firstname': 'Samuel N', 'initials': 'SN', 'affiliation': 'Department of Internal Medicine-Geriatrics, Wake Forest School of Medicine, Winston-Salem, NC, USA.'}, {'lastname': 'Aisen', 'firstname': 'Paul', 'initials': 'P', 'affiliation': ""Alzheimer's Therapeutic Research Institute, University of Southern California, San Diego, USA.""}, {'lastname': 'Raman', 'firstname': 'Rema', 'initials': 'R', 'affiliation': ""Alzheimer's Therapeutic Research Institute, University of Southern California, San Diego, USA.""}, {'lastname': 'Rissman', 'firstname': 'Robert A', 'initials': 'RA', 'affiliation': ""Alzheimer's Therapeutic Research Institute, University of Southern California, San Diego, USA.\nDepartment of Neurosciences, University of California, San Diego, La Jolla, USA.""}, {'lastname': 'Brewer', 'firstname': 'James', 'initials': 'J', 'affiliation': ""Alzheimer's Therapeutic Research Institute, University of Southern California, San Diego, USA.\nDepartment of Neurosciences, University of California, San Diego, La Jolla, USA.""}, {'lastname': 'Craft', 'firstname': 'Suzanne', 'initials': 'S', 'affiliation': 'Department of Internal Medicine-Geriatrics, Wake Forest School of Medicine, Winston-Salem, NC, USA. suzcraft@wakehealth.edu.'}]",,,,© 2022. The Author(s).,"10.1038/s41598-022-05165-3
10.37765/ajmc.2020.88482
10.1001/jama.2021.3854
10.1016/S1474-4422(20)30231-3
10.1038/nrneurol.2017.185
10.3233/JAD-2005-7106
10.1212/WNL.0000000000005214
10.1038/s41598-017-09577-4
10.2174/1567205012666150710104428
10.1007/s11481-016-9708-3
10.1016/S0021-9258(20)71260-3
10.1016/s0165-3806(02)00355-3
10.1001/jamaneurol.2020.1840
10.14283/jpad.2021.14
10.1100/tsw.2009.72
10.1038/ncomms11934
10.1016/j.trci.2018.06.014
10.1016/j.neuroscience.2018.01.059
10.1136/jnnp-2018-319148
10.1016/j.cmet.2018.05.011
10.3390/jcm8050651
10.1016/j.nbd.2015.08.014
10.1016/S1474-4422(12)70291-0
10.1007/s11910-013-0415-7
10.1016/j.jalz.2014.10.008
10.3389/fneur.2012.00064
10.1212/WNL.0b013e3181a82634
10.1016/j.jalz.2018.02.018
10.1016/j.jneuroim.2006.10.023
10.1016/j.neurobiolaging.2018.12.019
10.1002/alz.12399
10.1016/j.immuni.2018.05.005
10.1038/s41467-018-07053-9
10.1016/j.clim.2016.09.010
10.3988/jcn.2008.4.2.84
10.1073/pnas.1211270110
10.1080/10799893.2017.1298132
10.1371/journal.pone.0039794
10.1007/s12975-017-0545-3
10.1212/NXI.0000000000000138
10.1016/j.autrev.2020.102645
10.1093/brain/awx109
10.1038/nri3823
10.1056/NEJMoa1105143
10.1096/fj.08-105866
10.7150/ijbs.4679
10.1159/000245156
10.1371/journal.pone.0095995
10.4061/2010/606802
10.1016/j.brainresrev.2011.01.002
10.1159/000439214
10.1016/j.biopsych.2010.06.012
10.1074/jbc.RA118.001848
10.1186/s12974-016-0779-0
10.1016/j.pnpbp.2021.110343
10.1515/bmc-2019-0002
10.3389/fimmu.2020.587229
10.1097/MOL.0000000000000616
10.1177/1538574408322755
10.1007/s00401-016-1551-3
10.3389/fnins.2019.01436
10.1002/acn3.763
10.1186/s13195-017-0266-6
10.1016/j.neuroimage.2011.11.032
10.1016/j.nicl.2016.05.017
10.1097/00002093-199700112-00003
10.1080/01688639208402827
10.1097/WAD.0b013e3181cfc78b",<Element 'PubmedArticle' at 0x7f05ddcd9c70>
120,35066437,Involvement of nitric oxide pathway in the acute anticonvulsant effect of salmon calcitonin in rats.,"Epilepsy is a chronic neurological disease that is thought to affect up to 1% of the world's population. Evidence suggests that salmon calcitonin (sCT) has positive effects on epileptic seizures and epileptogenesis. However, it remains unknown that whether nitric oxide (NO) pathway contributed to this antiepileptic effect of sCT. We have used the pentylenetetrazole (PTZ)-induced seizure rat model to identify the effect of sCT on seizure score, seizure-induced cognitive deficit, and the NO pathway in the brain. We found that sCT increases the first myoclonic jerk (FMJ), decreased Racine's convulsion scale (RCS), and abates seizure-induced cognitive impairment. We further demonstrated that sCT attenuated the abnormal increase of NO in the brain. These results revealed that sCT exerts an antiepileptic effect by modulating the NO pathway in the brain.","['Neuroinflammation', 'Nitric oxide', 'Pentylenetetrazole', 'Rat', 'Salmon calcitonin']",Epilepsy research,2022-01-24,"[{'lastname': 'Filiz', 'firstname': 'Ahmet Kemal', 'initials': 'AK', 'affiliation': 'Department of Medical Physiology, Faculty of Medicine, Sivas Cumhuriyet University, Sivas, Turkey.'}, {'lastname': 'Karabulut', 'firstname': 'Sebahattin', 'initials': 'S', 'affiliation': 'Department of Medical Services and Techniques, Vocational School of Health Services, Sivas Cumhuriyet University, Sivas, Turkey. Electronic address: sbkarabulut@cumhuriyet.edu.tr.'}]",,,,Copyright © 2022 Elsevier B.V. All rights reserved.,10.1016/j.eplepsyres.2022.106864,<Element 'PubmedArticle' at 0x7f05ddec43b0>
121,"35002238
30581865
23922765
25580634
33014280
24104186
29454288
31338194
16037678
28931086
30121663
22529470
16490412
21134315
15688079
21277252
26344956
20459382
17109029
16198318
17996695
32264352
25996565
24758520
26143603
30295993
26801915
19596036
30545058
31194753
32922005
31616508
36810
7181105
6727660
4400444
13650640
6066618
3239770
942051
11076082
13726518
16119198
15850843
2203796
11846609
12685545
34234429
32606692
30718708
29284460
30288038
17664013
11673642
16852575
14583345
24204137
29138567
32455953
30369869
15266352
32318662
24405689
33064168
32199213
19100996
27960139
27525050
32273940
33014280
33047361
27785741
30014352
28463572
32748421
21925195
31398773
31941442
28352129
30526621
29849495
30221667
17997286
25429836
28694433
15322334
32150824
18690111
28656300
12849929
31193976
30772427
33086080
31619074
12558963
8794045
31857128
31197433
31332714
11494410
28800278
24932776
33434624
33084015","Neuroprotective Efficiency of Prodigiosins Conjugated with Selenium Nanoparticles in Rats Exposed to Chronic Unpredictable Mild Stress is Mediated Through Antioxidative, Anti-Inflammatory, Anti-Apoptotic, and Neuromodulatory Activities.","Depression is a mood disorder accompanied by intensive molecular and neurochemical alterations. Currently, available antidepressant therapies are not fully effective and are often accompanied by several adverse impacts. Accordingly, the ultimate goal of this investigation was to clarify the possible antidepressant effects of prodigiosins (PDGs) loaded with selenium nanoparticles (PDGs-SeNPs) in chronic unpredictable mild stress (CUMS)-induced depression-like behavior in rats.
Sixty Sprague Dawley rats were randomly allocated into six groups: control, CUMS group (depression model), fluoxetine (Flu, 10 mg/kg)+CUMS, PDGs+CUMS (300 mg/kg), sodium selenite (Na
PDGs-SeNPs administration prevented oxidative insults in hippocampal tissue, as demonstrated by decreased oxidant levels (nitric oxide and malondialdehyde) and elevated innate antioxidants (glutathione, glutathione peroxidase, glutathione reductase, superoxide dismutase, and catalase), in addition to the upregulated expression of nuclear factor erythroid 2-related factor 2 and heme oxygenase-1 in rats exposed to CUMS. Additionally, PDGs-SeNPs administration suppressed neuroinflammation in hippocampal tissue, as determined by the decreased production of pro-inflammatory cytokines (tumor necrosis factor-alpha, interleukin-1β, and interleukin-6), increased anti-inflammatory cytokine interleukin-10, and decreased inflammatory mediators (prostaglandin E2, cyclooxygenase-2, and nuclear factor kappa B). Moreover, PDGs-SeNPs administration in stressed rats inhibited neuronal loss and the development of hippocampal apoptosis through enhanced levels of B cell lymphoma 2 and decreased levels of caspase 3 and Bcl-2-associated X protein. Interestingly, PDGs-SeNPs administration improved hormonal levels typically disrupted by CUMS exposure and significantly modulated hippocampal levels of monoamines, brain-derived neurotrophic factor, monoamine oxidase, and acetylcholinesterase activities, in addition to upregulating the immunoreactivity of glial fibrillary acidic protein in CUMS model rats.
PDGs-SeNPs may serve as a prospective antidepressant candidate due to their potent antioxidant, anti-inflammatory, and neuroprotective potential.","['apoptosis', 'chronic unpredictable mild stress', 'neurochemical markers', 'neuroinflammation', 'oxidative stress', 'prodigiosin-loaded selenium nanoparticles']",International journal of nanomedicine,2022-01-11,"[{'lastname': 'Albrakati', 'firstname': 'Ashraf', 'initials': 'A', 'affiliation': 'Department of Human Anatomy, College of Medicine, Taif University, Taif, Saudi Arabia.'}, {'lastname': 'Alsharif', 'firstname': 'Khalaf F', 'initials': 'KF', 'affiliation': 'Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, Taif University, Taif, Saudi Arabia.'}, {'lastname': 'Al Omairi', 'firstname': 'Naif E', 'initials': 'NE', 'affiliation': 'Department of Internal Medicine, College of Medicine, Taif University, Taif, Saudi Arabia.'}, {'lastname': 'Alsanie', 'firstname': 'Walaa F', 'initials': 'WF', 'affiliation': 'Department of Clinical Laboratory Sciences, College of Applied Medical Sciences, Taif University, Taif, Saudi Arabia.'}, {'lastname': 'Almalki', 'firstname': 'Abdulraheem S A', 'initials': 'ASA', 'affiliation': 'Department of Chemistry, Faculty of Science, Taif University, Taif, Saudi Arabia.'}, {'lastname': 'Abd Elmageed', 'firstname': 'Zakaria Y', 'initials': 'ZY', 'affiliation': 'Department of Pharmacology, Edward via College of Osteopathic Medicine, University of Louisiana at Monroe, Monroe, LA, USA.'}, {'lastname': 'Elshopakey', 'firstname': 'Gehad E', 'initials': 'GE', 'affiliation': 'Department of Clinical Pathology, Faculty of Veterinary Medicine, Mansoura University, Mansoura, Egypt.'}, {'lastname': 'Lokman', 'firstname': 'Maha S', 'initials': 'MS', 'affiliation': 'Biology Department, College of Science and Humanities, Prince Sattam bin Abdul Aziz University, Alkharj, Saudi Arabia.\nDepartment of Zoology and Entomology, Faculty of Science, Helwan University, Cairo, Egypt.'}, {'lastname': 'Bauomy', 'firstname': 'Amira A', 'initials': 'AA', 'affiliation': 'Department of Science Laboratories, College of Science and Arts, Qassim University, ArRassAl-Qassim, Saudi Arabia.'}, {'lastname': 'Abdel Moneim', 'firstname': 'Ahmed E', 'initials': 'AE', 'affiliation': 'Department of Zoology and Entomology, Faculty of Science, Helwan University, Cairo, Egypt.'}, {'lastname': 'Kassab', 'firstname': 'Rami B', 'initials': 'RB', 'affiliation': 'Department of Zoology and Entomology, Faculty of Science, Helwan University, Cairo, Egypt.\nBiology Department, Faculty of Science and Arts, Al Baha University, Al Makhwah Branch, Al Baha, Saudi Arabia.'}]",,"PDGs-SeNPs may serve as a prospective antidepressant candidate due to their potent antioxidant, anti-inflammatory, and neuroprotective potential.","PDGs-SeNPs administration prevented oxidative insults in hippocampal tissue, as demonstrated by decreased oxidant levels (nitric oxide and malondialdehyde) and elevated innate antioxidants (glutathione, glutathione peroxidase, glutathione reductase, superoxide dismutase, and catalase), in addition to the upregulated expression of nuclear factor erythroid 2-related factor 2 and heme oxygenase-1 in rats exposed to CUMS. Additionally, PDGs-SeNPs administration suppressed neuroinflammation in hippocampal tissue, as determined by the decreased production of pro-inflammatory cytokines (tumor necrosis factor-alpha, interleukin-1β, and interleukin-6), increased anti-inflammatory cytokine interleukin-10, and decreased inflammatory mediators (prostaglandin E2, cyclooxygenase-2, and nuclear factor kappa B). Moreover, PDGs-SeNPs administration in stressed rats inhibited neuronal loss and the development of hippocampal apoptosis through enhanced levels of B cell lymphoma 2 and decreased levels of caspase 3 and Bcl-2-associated X protein. Interestingly, PDGs-SeNPs administration improved hormonal levels typically disrupted by CUMS exposure and significantly modulated hippocampal levels of monoamines, brain-derived neurotrophic factor, monoamine oxidase, and acetylcholinesterase activities, in addition to upregulating the immunoreactivity of glial fibrillary acidic protein in CUMS model rats.",© 2021 Albrakati et al.,"10.2147/IJN.S323436
10.1155/2018/7383869
10.1371/journal.pone.0069637
10.1111/imm.12443
10.1155/2020/9268083
10.1016/j.pnpbp.2013.09.017
10.1016/j.biopha.2018.01.137
10.3892/br.2019.1226
10.1159/000087097
10.1371/journal.pone.0185129
10.1159/000492684
10.4103/0253-7613.93843
10.1016/j.nurx.2005.12.007
10.1017/S0033291710002291
10.1038/nrd1634
10.1016/j.jbiosc.2010.12.026
10.1007/s13197-015-1740-4
10.2174/092986710791331103
10.1038/nrmicro1531
10.1016/j.bcp.2005.08.017
10.1016/j.intimp.2007.09.002
10.1039/C6TB02952C
10.1039/C5MT00075K
10.1021/am501341u
10.1016/j.actbio.2015.06.035
10.1002/jbm.a.36493
10.1007/s00253-016-7300-7
10.1016/j.pnpbp.2009.07.002
10.3390/pharmaceutics10040270
10.1371/journal.pone.0216737
10.2147/IJN.S259134
10.3892/etm.2019.8018
10.1080/24750573.2018.1426694
10.1016/0003-2697(79)90738-3
10.1016/0003-2697(82)90118-X
10.1016/S0006-291X(72)80218-3
10.1016/0003-9861(59)90090-6
10.1016/0003-2697(88)90564-7
10.1016/0003-2697(76)90527-3
10.1016/S0378-4347(00)00348-0
10.1016/0006-2952(61)90145-9
10.1080/14756360400026212
10.1016/j.ecl.2005.01.002
10.1210/jcem-71-3-553
10.1006/meth.2001.1262
10.1046/j.1440-1827.2002.01410.x
10.2147/IJN.S306186
10.2147/IJN.S247426
10.1038/s41598-018-38085-2
10.1186/s12906-016-1505-2
10.2147/IJN.S153758
10.1016/j.jinorgbio.2007.06.021
10.1002/biof.5520150103
10.1021/jp051328n
10.1016/S0891-5849(03)00428-3
10.2147/IJN.S43691
10.2147/NDT.S150028
10.3390/biom10050801
10.3389/fnmol.2018.00377
10.1038/sj.npp.1300532
10.1002/ame2.12107
10.1017/S1461145713001661
10.1016/j.ecoenv.2020.110479
10.1016/j.jpsychires.2008.11.002
10.1016/j.psyneuen.2016.11.031
10.1155/2016/2153745
10.1155/2020/2325391
10.1155/2020/9268083
10.1111/jfbc.13505
10.1007/s12011-016-0876-z
10.1007/s10534-018-0128-0
10.1080/17512433.2017.1324781
10.1111/jfbc.13413
10.1016/j.taap.2011.08.027
10.1002/mnfr.201900243
10.1186/s12868-020-0551-3
10.1038/s41598-016-0028-x
10.1186/s12974-018-1377-0
10.1155/2018/7834381
10.3892/mmr.2018.9431
10.1016/j.bbadis.2007.09.004
10.1007/s12032-014-0366-0
10.1002/biof.5520200205
10.3390/ijms21051769
10.1097/FBP.0b013e32830cd80f
10.3892/mmr.2017.6807
10.1016/S0022-3956(03)00050-5
10.1016/j.gendis.2018.05.005
10.1016/j.bbr.2019.02.025
10.1016/j.phrs.2020.105252
10.1177/0960327119880589
10.1046/j.1471-4159.2003.01531.x
10.1016/S0959-4388(96)80010-9
10.1016/j.jep.2019.112487
10.1007/s00213-019-05287-z
10.1007/s12640-019-00086-y
10.1002/glia.1084
10.1080/10520295.2017.1323276
10.1016/j.fitote.2014.06.007
10.1016/j.brainresbull.2021.01.005
10.5603/FM.a2020.0117",<Element 'PubmedArticle' at 0x7f05ddeb0ae0>
122,34974121,Gut microbiota modulation by prednisolone in a rat kindling model of pentylenetetrazol (PTZ)-induced seizure.,"The gut microbiota is a complex community composed by several microorganisms that interact in the maintenance of homeostasis and contribute to physiological processes, including brain function. The relationship of the taxonomic composition of the gut microbiota with neurological diseases such as autism, Parkinson's, Alzheimer's, anxiety, and depression is widely recognized. The immune system is an important intermediary between the gut microbiota and the central nervous system, being one of the communication routes of the gut-brain axis. Although the complexity of the relationship between inflammation and epilepsy has not yet been elucidated, inflammatory processes are similar in many ways to the consequences of dysbiosis and contribute to disease progression. This study aimed to analyze the taxonomic composition of the gut microbiota of rats treated with prednisolone in a kindling model of epilepsy. Male Wistar rats (90 days, n = 24) divided into four experimental groups: sodium chloride solution 0.9 g%, diazepam 2 mg/kg, prednisolone 1 mg/kg, and prednisolone 5 mg/kg administered intraperitoneally (i.p.) for 14 days. The kindling model was induced by pentylenetetrazole (PTZ) 25 mg/kg i.p. on alternate days. The taxonomic profile was established by applying metagenomic DNA sequencing. There was no change in alpha diversity, and the composition of the gut microbiota between prednisolone and diazepam was similar. The significant increase in Verrucomicrobia, Saccharibacteria, and Actinobacteria may be related to the protective activity against seizures and inflammatory processes that cause some cases of epilepsy. Further studies are needed to investigate the functional influence that these species have on epilepsy and the inflammatory processes that trigger it.","['Bacterial community composition', 'Epilepsy', 'Metagenomic analysis', 'Neuroinflammation']",Microbial pathogenesis,2022-01-03,"[{'lastname': 'de Lima', 'firstname': 'Amanda Muliterno Domingues Lourenço', 'initials': 'AMDL', 'affiliation': 'Programa de Pós-Graduação em Microbiologia Agrícola e do Ambiente, Universidade Federal do Rio Grande do Sul, Instituto de Ciências Básicas da Saúde, Rua Sarmento Leite 500, Porto Alegre, RS, Brazil.'}, {'lastname': 'de Lima Rosa', 'firstname': 'Gabriel', 'initials': 'G', 'affiliation': 'Programa de Pós-Graduação em Ciências Biológicas: Fisiologia, Universidade Federal do Rio Grande do Sul, Instituto de Ciências Básicas da Saúde, Rua Sarmento Leite 500, Porto Alegre, RS, Brazil.'}, {'lastname': 'Müller Guzzo', 'firstname': 'Edson Fernando', 'initials': 'EF', 'affiliation': 'Programa de Pós-Graduação em Ciências Biológicas: Fisiologia, Universidade Federal do Rio Grande do Sul, Instituto de Ciências Básicas da Saúde, Rua Sarmento Leite 500, Porto Alegre, RS, Brazil.'}, {'lastname': 'Padilha', 'firstname': 'Rafael Bremm', 'initials': 'RB', 'affiliation': 'Departamento de Microbiologia, Imunologia e Parasitologia, Universidade Federal do Rio Grande do Sul, Instituto de Ciências Básicas da Saúde, Rua Sarmento Leite 500, Porto Alegre, RS, Brazil.'}, {'lastname': 'Costa da Silva', 'firstname': 'Rodrigo', 'initials': 'R', 'affiliation': 'Departamento de Microbiologia, Imunologia e Parasitologia, Universidade Federal do Rio Grande do Sul, Instituto de Ciências Básicas da Saúde, Rua Sarmento Leite 500, Porto Alegre, RS, Brazil.'}, {'lastname': 'Silveira', 'firstname': 'Alexandre Kleber', 'initials': 'AK', 'affiliation': 'Programa de Pós-Graduação em Ciências Biológicas: Bioquímica, Universidade Federal do Rio Grande do Sul, Instituto de Ciências Básicas da Saúde, Rua Ramiro Barcelos 2.600 - Annex, Porto Alegre, RS, Brazil.'}, {'lastname': 'de Lima Morales', 'firstname': 'Daiana', 'initials': 'D', 'affiliation': 'Laboratório de Pesquisa em Resistência Bacteriana, Hospital de Clínicas de Porto Alegre, Rua Ramiro Barcelos 2.350, Porto Alegre, RS, Brazil.'}, {'lastname': 'Conci de Araujo', 'firstname': 'Milena', 'initials': 'M', 'affiliation': 'Departamento de Microbiologia, Imunologia e Parasitologia, Universidade Federal do Rio Grande do Sul, Instituto de Ciências Básicas da Saúde, Rua Sarmento Leite 500, Porto Alegre, RS, Brazil.'}, {'lastname': 'Fonseca Moreira', 'firstname': 'José Claudio', 'initials': 'JC', 'affiliation': 'Programa de Pós-Graduação em Ciências Biológicas: Bioquímica, Universidade Federal do Rio Grande do Sul, Instituto de Ciências Básicas da Saúde, Rua Ramiro Barcelos 2.600 - Annex, Porto Alegre, RS, Brazil.'}, {'lastname': 'Barth', 'firstname': 'Afonso Luís', 'initials': 'AL', 'affiliation': 'Laboratório de Pesquisa em Resistência Bacteriana, Hospital de Clínicas de Porto Alegre, Rua Ramiro Barcelos 2.350, Porto Alegre, RS, Brazil.'}, {'lastname': 'Coitinho', 'firstname': 'Adriana Simon', 'initials': 'AS', 'affiliation': 'Programa de Pós-Graduação em Ciências Biológicas: Fisiologia, Universidade Federal do Rio Grande do Sul, Instituto de Ciências Básicas da Saúde, Rua Sarmento Leite 500, Porto Alegre, RS, Brazil; Departamento de Microbiologia, Imunologia e Parasitologia, Universidade Federal do Rio Grande do Sul, Instituto de Ciências Básicas da Saúde, Rua Sarmento Leite 500, Porto Alegre, RS, Brazil; Programa de Pós-Graduação em Ciências Biológicas: Farmacologia e Terapêutica, Universidade Federal do Rio Grande do Sul, Instituto de Ciências Básicas da Saúde, Rua Sarmento Leite 500, Porto Alegre, RS, Brazil. Electronic address: adriana.simon@ufrgs.br.'}, {'lastname': 'Van Der Sand', 'firstname': 'Sueli Teresinha', 'initials': 'ST', 'affiliation': 'Programa de Pós-Graduação em Microbiologia Agrícola e do Ambiente, Universidade Federal do Rio Grande do Sul, Instituto de Ciências Básicas da Saúde, Rua Sarmento Leite 500, Porto Alegre, RS, Brazil; Departamento de Microbiologia, Imunologia e Parasitologia, Universidade Federal do Rio Grande do Sul, Instituto de Ciências Básicas da Saúde, Rua Sarmento Leite 500, Porto Alegre, RS, Brazil.'}]",,,,Copyright © 2021 Elsevier Ltd. All rights reserved.,10.1016/j.micpath.2021.105376,<Element 'PubmedArticle' at 0x7f05dd288310>
123,"34964935
5688821
20482507
21397005
29118713
20554880
20616986
24963825
19298844
2027923
12766626
14568308
22371267
21850445
16214024
16469931
30091823
26465707
21266194
25001278
21468623
24806691
12622662
12669179
2266207
7475034
15753199
24370534
8986003
20682194
17482248
12669176
15274050
11797060
16249907
15496936
30271332
23206318
16205917
17164819
31147611
26002627
17570346
29321525
23240885
27435872
29066224
13889428
10832905
5066093
30062672
17766316
33328476
3834917
17079660
16876134
20493211
23071333
8837929
27749004
18631323
17159992
27457669
32647898
18190912
22526537
5104623
1871131
25331895
26676983
22926005
26403083
27053215
22941108
24275014
11797057
21631540
22885872
25899790
26576941
15830234
8577373
25567426
29897293
27273552
27481050
9046559
8300981
7793438
12578436
21527731
15322726
9348352
21316391
18923511
22666364
16952998
16524701
33941861
23064228
23332316
28253539
10923760
23647151
31085604
21307935
9287218
26992696
18162074
19913200
17393141
18374518
20089372
22486245
29056427
15893820
31465790
25084048
17705061
4303377
28419649
21262339
27627910
12614627
25934706
18641974
26820641
30089884
7643193
108702
7199758
18789966
35974246
10536021
11781502
4139949
26686767
31782169
19273843
22630795
28150369
27717041
29696309
30450381
29052618
31255250
34281710
14751279
18445218
24589296
25242256
27720487
17624999
11493581
17284196
30421483
28755749
8894850
489776
6115346
1898494
18417174
20211641
28092660
28229112
24917195
12063074
25701613
8467387
25596319
29052632
15642607
11141034
15537886
25219790
19068224
26183165
17591544
26404708
8296886
7192876
27109623
21025115
1377716
15652255
27312404
26549324
21638221
25178816
25493956
29675581
9989425
11988580
18671810
30153753
11797055
18991954
18563062
26044636
14660155
19342616
10529820
28265716
23488992
14623958
8711018
21276964
12118257
18422836
21143244
24411803
8793094
9151353
8511216
7892426
27822501
18855803
16554744
20438754
12394282
11438355
28858691
32437827
11505038
17207096
14625373
28941277
30759387
19485563
5535207
8229752
4702273
23966702
24439304
2057508
14637229
31493767
11566046
23294766
24456850",Neurobiological Bases of Alcohol Consumption After Social Stress.,"The urge to seek and consume excessive alcohol is intensified by prior experiences with social stress, and this cascade can be modeled under systematically controlled laboratory conditions in rodents and non-human primates. Adaptive coping with intermittent episodes of social defeat stress often transitions to maladaptive responses to traumatic continuous stress, and alcohol consumption may become part of coping responses. At the circuit level, the neural pathways subserving stress coping intersect with those for alcohol consumption. Increasingly discrete regions and connections within the prefrontal cortex, the ventral and dorsal striatum, thalamic and hypothalamic nuclei, tegmental areas as well as brain stem structures begin to be identified as critical for reacting to and coping with social stress while seeking and consuming alcohol. Several candidate molecules that modulate signals within these neural connections have been targeted in order to reduce excessive drinking and relapse. In spite of some early clinical failures, neuropeptides such as CRF, opioids, or oxytocin continue to be examined for their role in attenuating stress-escalated drinking. Recent work has focused on neural sites of action for peptides and steroids, most likely in neuroinflammatory processes as a result of interactive effects of episodic social stress and excessive alcohol seeking and drinking.","['Alcohol', 'CRF', 'Consumption', 'Coping', 'Hypothalamus', 'Neuroinflammation', 'Opioid', 'Oxytocin', 'Prefrontal cortex', 'Seeking', 'Self-administration', 'Striatum', 'Tegmentum']",Current topics in behavioral neurosciences,2021-12-30,"[{'lastname': 'Miczek', 'firstname': 'Klaus A', 'initials': 'KA', 'affiliation': 'Department of Psychology, Tufts University, Medford, MA, USA. klaus.miczek@tufts.edu.\nDepartment of Neuroscience, Tufts University, Boston, MA, USA. klaus.miczek@tufts.edu.'}, {'lastname': 'DiLeo', 'firstname': 'Alyssa', 'initials': 'A', 'affiliation': 'Department of Neuroscience, Tufts University, Boston, MA, USA.'}, {'lastname': 'Newman', 'firstname': 'Emily L', 'initials': 'EL', 'affiliation': 'Department of Psychiatry, Harvard Medical School, Belmont, MA, USA.'}, {'lastname': 'Akdilek', 'firstname': 'Naz', 'initials': 'N', 'affiliation': 'Department of Psychology, Tufts University, Medford, MA, USA.'}, {'lastname': 'Covington', 'firstname': 'Herbert E', 'initials': 'HE', 'affiliation': 'Department of Psychology, Tufts University, Medford, MA, USA.'}]",,,,"© 2021. The Author(s), under exclusive license to Springer Nature Switzerland AG.","10.1007/7854_2021_273
10.1016/j.biopsych.2021.05.022",<Element 'PubmedArticle' at 0x7f05dd2854f0>
124,34923495,Chronic Glucocorticoids Consumption Triggers and Worsens Experimental Alzheimer's Disease-Like Pathology by Detrimental Immune Modulations.,"Among the risk factors identified in the sporadic forms of Alzheimer's disease (AD), environmental and lifestyle elements are of growing interest. Clinical observations suggest that stressful events can anticipate AD onset, while stress-related disorders can promote AD. Here, we tested the hypothesis that a chronic treatment with glucocorticoids is sufficient to trigger or exacerbate AD molecular hallmarks.
We first validated a rat model of experimental chronic glucocorticoids (GC) consumption (corticosterone [CORT] in drinking water for 4 weeks). Then, to evaluate the consequences of chronic GC consumption on the onset of amyloid-β (Aβ) toxicity, animals chronically treated with GC were intracerebroventricularly injected with an oligomeric solution of Aβ25-35 (oAβ) (acute model of AD). We evaluated AD-related cognitive deficits and pathogenic mechanisms, with a special emphasis on neuroinflammatory markers.
Chronic CORT consumption caused the inhibition of the nonamyloidogenic pathways, the impairment of Aβ clearance processes and the induction of amyloidogenic pathways in the hippocampus. The principal enzymes involved in glucocorticoid receptor activation and Tau phosphorylation were upregulated. Importantly, the AD-like phenotype triggered by chronic CORT was analogous to the one caused by oAβ. These molecular commonalities across models were independent from inflammation, as chronic CORT was immunosuppressive while oAβ was pro-inflammatory. When chronic CORT consumption anticipated the induction of the oAβ pathology, we found a potentiation of neuroinflammatory processes associated with an exacerbation of synaptic and memory deficits but also an aggravation of AD-related hallmarks.
This study unravels new functional outcomes identifying chronic CORT consumption as a main risk factor for AD and suggests that glucocorticoid-based therapies should be prescribed with caution in populations with AD risk.","['Alzheimer’s disease', 'Amyloid toxicity', 'Chronic glucocorticoids consumption', 'Memory deficits', 'Neuroinflammation']",Neuroendocrinology,2021-12-20,"[{'lastname': 'Canet', 'firstname': 'Geoffrey', 'initials': 'G', 'affiliation': 'Molecular Mechanisms in Neurodegenerative Dementia (MMDN) Laboratory, University of Montpellier, EPHE, INSERM, Montpellier, France.'}, {'lastname': 'Zussy', 'firstname': 'Charleine', 'initials': 'C', 'affiliation': 'Molecular Mechanisms in Neurodegenerative Dementia (MMDN) Laboratory, University of Montpellier, EPHE, INSERM, Montpellier, France.'}, {'lastname': 'Hernandez', 'firstname': 'Célia', 'initials': 'C', 'affiliation': 'Molecular Mechanisms in Neurodegenerative Dementia (MMDN) Laboratory, University of Montpellier, EPHE, INSERM, Montpellier, France.'}, {'lastname': 'Chevallier', 'firstname': 'Nathalie', 'initials': 'N', 'affiliation': 'Molecular Mechanisms in Neurodegenerative Dementia (MMDN) Laboratory, University of Montpellier, EPHE, INSERM, Montpellier, France.'}, {'lastname': 'Marchi', 'firstname': 'Nicola', 'initials': 'N', 'affiliation': 'Department of Neuroscience, Laboratory of Cerebrovascular and Glia Research, Institute of Functional Genomics, UMR CNRS-5203, INSERM-U1191, University of Montpellier, Montpellier, France.'}, {'lastname': 'Desrumaux', 'firstname': 'Catherine', 'initials': 'C', 'affiliation': 'Molecular Mechanisms in Neurodegenerative Dementia (MMDN) Laboratory, University of Montpellier, EPHE, INSERM, Montpellier, France.'}, {'lastname': 'Givalois', 'firstname': 'Laurent', 'initials': 'L', 'affiliation': 'Molecular Mechanisms in Neurodegenerative Dementia (MMDN) Laboratory, University of Montpellier, EPHE, INSERM, Montpellier, France.\nDepartment of Psychiatry and Neurosciences, Faculty of Medicine, Laval University, CR-CHUQ, P-9717, Québec, Québec, Canada.'}]",,,"Chronic CORT consumption caused the inhibition of the nonamyloidogenic pathways, the impairment of Aβ clearance processes and the induction of amyloidogenic pathways in the hippocampus. The principal enzymes involved in glucocorticoid receptor activation and Tau phosphorylation were upregulated. Importantly, the AD-like phenotype triggered by chronic CORT was analogous to the one caused by oAβ. These molecular commonalities across models were independent from inflammation, as chronic CORT was immunosuppressive while oAβ was pro-inflammatory. When chronic CORT consumption anticipated the induction of the oAβ pathology, we found a potentiation of neuroinflammatory processes associated with an exacerbation of synaptic and memory deficits but also an aggravation of AD-related hallmarks.","© 2021 S. Karger AG, Basel.",10.1159/000521559,<Element 'PubmedArticle' at 0x7f05da13def0>
125,34826653,New insights and therapeutic opportunities for progranulin-deficient frontotemporal dementia.,"Frontotemporal dementia (FTD) is the second most common form of dementia. It affects the frontal and temporal lobes of the brain and has a highly heterogeneous clinical representation with patients presenting with a wide range of behavioral, language, and executive dysfunctions. Etiology of FTD is complex and consists of both familial and sporadic cases. Heterozygous mutations in the GRN gene, resulting in GRN haploinsufficiency, cause progranulin (PGRN)-deficient FTD characterized with cytoplasmic mislocalization of TAR DNA-binding protein 43 kDa (TDP-43) aggregates. GRN codes for PGRN, a secreted protein that is also localized in the endolysosomes and plays a critical role in regulating lysosomal homeostasis. How PGRN deficiency modulates immunity and causes TDP-43 pathology and FTD-related neurodegeneration remains an active area of intense investigation. In the current review, we discuss some of the significant progress made in the past two years that links PGRN deficiency with microglial-associated neuroinflammation, TDP-43 pathology, and lysosomal dysfunction. We also review the opportunities and challenges toward developing therapies and biomarkers to treat PGRN-deficient FTD.",[],Current opinion in neurobiology,2021-11-27,"[{'lastname': 'Amin', 'firstname': 'Sadaf', 'initials': 'S', 'affiliation': ""Helen and Robert Appel Alzheimer's Disease Research Institute, Brain and Mind Research Institute, Weill Cornell Medicine, New York, NY, 10021, USA.""}, {'lastname': 'Carling', 'firstname': 'Gillian', 'initials': 'G', 'affiliation': ""Helen and Robert Appel Alzheimer's Disease Research Institute, Brain and Mind Research Institute, Weill Cornell Medicine, New York, NY, 10021, USA; Neuroscience Graduate Program, Weill Cornell Medicine, New York, NY, 10021, USA.""}, {'lastname': 'Gan', 'firstname': 'Li', 'initials': 'L', 'affiliation': ""Helen and Robert Appel Alzheimer's Disease Research Institute, Brain and Mind Research Institute, Weill Cornell Medicine, New York, NY, 10021, USA. Electronic address: lig2033@med.cornell.edu.""}]",,,,Copyright © 2021 The Authors. Published by Elsevier Ltd.. All rights reserved.,10.1016/j.conb.2021.10.001,<Element 'PubmedArticle' at 0x7f05da151220>
126,"34797509
1540948",A novel targeted approach to delineate a role for estrogen receptor-β in ameliorating murine mammary tumor-associated neuroinflammation.,"Circulating estrogens in breast cancer patients and survivors are often extremely low due to menopause and estrogen-reducing cancer treatments. Simultaneously, circulating inflammatory markers, and inflammatory proteins in brains of rodent tumor models, can be elevated and correlate with debilitating neurological and psychological comorbidities. Because estrogen has anti-inflammatory properties in the brain, we hypothesized that mammary tumor-induced neuroinflammation is driven, in part, by reduced brain estrogen signaling.
An ovariectomized mouse model of postmenopausal breast cancer utilizing the ERα-positive 67NR mammary tumor cell line was used for these experiments. A novel, orally bioavailable, and brain penetrant ERβ agonist was administered daily via oral gavage. Following treatment, estrogen-responsive genes were measured in brain regions. Central and circulating inflammatory markers were measured via RT-qPCR and a multiplex cytokine array, respectively.
We present novel findings that peripheral mammary tumors alter estrogen signaling genes including receptors and aromatase in the hypothalamus, hippocampus, and frontal cortex. Mammary tumors induced peripheral and central inflammation, however, pharmacological ERβ activation was not sufficient to reduce this inflammation.
Data presented here suggest that compensating for low circulating estrogen with ERβ brain activation is not sufficient to attenuate mammary tumor-induced neuroinflammation, and is therefore not a likely candidate for the treatment of behavioral symptoms in patients. The novel finding that mammary tumors alter estrogen signaling-related genes is a clinically relevant advancement to the understanding of how peripheral tumor biology modulates neurobiology. This is necessary to predict and prevent behavioral comorbidities (e.g., cognitive impairment) prevalent in cancer patients and survivors.","['Breast cancer', 'Cytokines', 'Hippocampus', 'Hypothalamus–pituitary–gonadal axis', 'Neuroendocrinology']",Endocrine,2021-11-20,"[{'lastname': 'Grant', 'firstname': 'Corena V', 'initials': 'CV', 'affiliation': 'Institute for Behavioral Medicine Research, The Ohio State University, Columbus, OH, USA.\nDepartment of Psychiatry and Behavioral Health, The Ohio State University, Columbus, OH, USA.'}, {'lastname': 'Russart', 'firstname': 'Kathryn L G', 'initials': 'KLG', 'affiliation': 'Institute for Behavioral Medicine Research, The Ohio State University, Columbus, OH, USA.\nComprehensive Cancer Center, The Ohio State University, Columbus, OH, USA.\nMinnesota State University Moorhead, Moorhead, MN, USA.'}, {'lastname': 'Pyter', 'firstname': 'Leah M', 'initials': 'LM', 'affiliation': 'Institute for Behavioral Medicine Research, The Ohio State University, Columbus, OH, USA. leah.pyter@osumc.edu.\nDepartment of Psychiatry and Behavioral Health, The Ohio State University, Columbus, OH, USA. leah.pyter@osumc.edu.\nComprehensive Cancer Center, The Ohio State University, Columbus, OH, USA. leah.pyter@osumc.edu.'}]",,,"We present novel findings that peripheral mammary tumors alter estrogen signaling genes including receptors and aromatase in the hypothalamus, hippocampus, and frontal cortex. Mammary tumors induced peripheral and central inflammation, however, pharmacological ERβ activation was not sufficient to reduce this inflammation.","© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.",10.1007/s12020-021-02931-7,<Element 'PubmedArticle' at 0x7f05da15a1d0>
127,"34672414
10973318
12374492
31324898
28940143
30232458
30541895
30783092
23821583
24006291
27830577
19238804
23024434
34093114
22955882
33476396
26100750
27621438
25454592
9822755
24472706
17853446
9630473
16917819
23840908
28231463
10517961
16014733
15924864
7346592
15282280
11394998
24806676
19725248
20160349
22470463
21102981
26668381
24708924
29755322
25861024
19687452
11055430
12946023
24394344
25771509
25892508
28035899
30894198
32539736
19328847
6731185
26648474
30225986
19725250
15306250",Histamine in murine narcolepsy: What do genetic and immune models tell us?,"An increased number of histaminergic neurons, identified by labeling histidine-decarboxylase (HDC) its synthesis enzyme, was unexpectedly found in patients with narcolepsy type 1 (NT1). In quest for enlightenment, we evaluate whether an increase in HDC cell number and expression level would be detected in mouse models of the disease, in order to provide proof of concepts reveling possible mechanisms of compensation for the loss of orexin neurons, and/or of induced expression as a consequence of local neuroinflammation, a state that likely accompanies NT1. To further explore the compensatory hypothesis, we also study the noradrenergic wake-promoting system. Immunohistochemistry for HDC, orexin, and melanin-concentrating hormone (MCH) was used to count neurons. Quantitative-PCR of HDC, orexin, MCH, and tyrosine-hydroxylase was performed to evaluate levels of mRNA expression in the hypothalamus or the dorsal pons. Both quantifications were achieved in genetic and neuroinflammatory models of narcolepsy with major orexin impairment, namely the orexin-deficient (Orex-KO) and orexin-hemagglutinin (Orex-HA) mice respectively. The number of HDC neurons and mRNA expression level were unchanged in Orex-KO mice compared to controls. Similarly, we found no change in tyrosine-hydroxylase mRNA expression in the dorsal pons between groups. Further, despite the presence of protracted local neuroinflammation as witnessed by the presence of reactive microglia, we found no change in the number of neurons nor the expression of HDC in Orex-HA mice compared to controls. Importantly, no correlation was found in all conditions between HDC and orexin. Our findings indicate that, in mice, the expression of histamine and noradrenalin, two wake-promoting systems, are not modulated by orexin level whether the lack of orexin is constitutive or induced at adult age, showing thus no compensation. They also show no recruitment of histamine by local neuroinflammation. Further studies will be needed to further define the role of histamine in the pathophysiology of NT1.","['hypocretin', 'hypothalamus', 'orexin', 'sleep']","Brain pathology (Zurich, Switzerland)",2021-10-22,"[{'lastname': 'Melzi', 'firstname': 'Silvia', 'initials': 'S', 'affiliation': 'Sleep Team, Center for Research in Neuroscience of LYON, CNRS UMR5292, INSERM U1028, University of Lyon1, Bron, France.'}, {'lastname': 'Morel', 'firstname': 'Anne-Laure', 'initials': 'AL', 'affiliation': 'Sleep Team, Center for Research in Neuroscience of LYON, CNRS UMR5292, INSERM U1028, University of Lyon1, Bron, France.'}, {'lastname': 'Scoté-Blachon', 'firstname': 'Céline', 'initials': 'C', 'affiliation': 'Functional Neurogenetics platform, Center for Research in Neuroscience of LYON, CNRS UMR5292, INSERM U1028, University of Lyon1, Bron, France.'}, {'lastname': 'Liblau', 'firstname': 'Roland', 'initials': 'R', 'affiliation': 'Toulouse Institute for Infectious and Inflammatory diseases, Centre National de la Recherche Scientifique, Institut National de la Santé et de la Recherche Médicale, UPS, University of Toulouse, Toulouse, France.'}, {'lastname': 'Dauvilliers', 'firstname': 'Yves', 'initials': 'Y', 'affiliation': 'National Reference Centre for Orphan Diseases, Narcolepsy - Rare hypersomnia, Sleep Unit, Department of Neurology, CHU Montpellier, Institute for Neuroscience of Montpellier INM, INSERM U1298, University of Montpellier, Montpellier, France.'}, {'lastname': 'Peyron', 'firstname': 'Christelle', 'initials': 'C', 'affiliation': 'Sleep Team, Center for Research in Neuroscience of LYON, CNRS UMR5292, INSERM U1028, University of Lyon1, Bron, France.'}]",,,,© 2021 The Authors. Brain Pathology published by John Wiley & Sons Ltd on behalf of International Society of Neuropathology.,"10.1111/bpa.13027
10.1038/s41586-018-0540-1
10.1371/journal.pone.0069123
10.1523/jneurosci.1783-04.2004",<Element 'PubmedArticle' at 0x7f05daad6950>
128,"34646382
24561705
11672421
24467911
26299059
33379862
29533978
20590555
19087195
25524120
26212325
22821058
29440474
25475659
29148769
29498843
27279908
29738910
26155312
16822554
18374421
22875916
37614
19020019
23908068
29177913
8428373
8813082
30941587
18273070
31267316
29246630
19794397
26483037
15371507
10557349
24372209
19807907
31719236
23848221
3069970
23994458
21050275
19274089
17409230
27424778
10716884
29694958","Neuroprotective effects of minocycline and KML29, a potent inhibitor of monoacylglycerol lipase, in an experimental stroke model: a small-animal positron emission tomography study.","Hypoxia caused by ischemia induces acidosis and neuroexcitotoxicity, resulting in neuronal death in the central nervous system (CNS). Monoacylglycerol lipase (MAGL) is a modulator of 2-arachidonoylglycerol (2-AG), which is involved in retrograde inhibition of glutamate release in the endocannabinoid system. In the present study, we used positron emission tomography (PET) to monitor MAGL-positive neurons and neuroinflammation in the brains of ischemic rats. Additionally, we performed PET imaging to evaluate the neuroprotective effects of an MAGL inhibitor in an ischemic injury model. ","['KML29', 'MAGL', 'Minocycline', 'PET', 'TSPO']",Theranostics,2021-10-15,"[{'lastname': 'Yamasaki', 'firstname': 'Tomoteru', 'initials': 'T', 'affiliation': 'Department of Advanced Nuclear Medicine Sciences, Institute of Quantum Medical Sciences, National Institutes for Quantum and Radiological Science and Technology, 4-9-1 Anagawa, Inage-ku, Chiba 263-8555, Japan.'}, {'lastname': 'Hatori', 'firstname': 'Akiko', 'initials': 'A', 'affiliation': 'Department of Advanced Nuclear Medicine Sciences, Institute of Quantum Medical Sciences, National Institutes for Quantum and Radiological Science and Technology, 4-9-1 Anagawa, Inage-ku, Chiba 263-8555, Japan.'}, {'lastname': 'Zhang', 'firstname': 'Yiding', 'initials': 'Y', 'affiliation': 'Department of Advanced Nuclear Medicine Sciences, Institute of Quantum Medical Sciences, National Institutes for Quantum and Radiological Science and Technology, 4-9-1 Anagawa, Inage-ku, Chiba 263-8555, Japan.'}, {'lastname': 'Mori', 'firstname': 'Wakana', 'initials': 'W', 'affiliation': 'Department of Advanced Nuclear Medicine Sciences, Institute of Quantum Medical Sciences, National Institutes for Quantum and Radiological Science and Technology, 4-9-1 Anagawa, Inage-ku, Chiba 263-8555, Japan.'}, {'lastname': 'Kurihara', 'firstname': 'Yusuke', 'initials': 'Y', 'affiliation': 'Department of Advanced Nuclear Medicine Sciences, Institute of Quantum Medical Sciences, National Institutes for Quantum and Radiological Science and Technology, 4-9-1 Anagawa, Inage-ku, Chiba 263-8555, Japan.\nSHI Accelerator Service Co., 1-17-6 Osaki, Shinagawa-ku, Tokyo 141-0032, Japan.'}, {'lastname': 'Ogawa', 'firstname': 'Masanao', 'initials': 'M', 'affiliation': 'Department of Advanced Nuclear Medicine Sciences, Institute of Quantum Medical Sciences, National Institutes for Quantum and Radiological Science and Technology, 4-9-1 Anagawa, Inage-ku, Chiba 263-8555, Japan.\nSHI Accelerator Service Co., 1-17-6 Osaki, Shinagawa-ku, Tokyo 141-0032, Japan.'}, {'lastname': 'Wakizaka', 'firstname': 'Hidekatsu', 'initials': 'H', 'affiliation': 'Department of Advanced Nuclear Medicine Sciences, Institute of Quantum Medical Sciences, National Institutes for Quantum and Radiological Science and Technology, 4-9-1 Anagawa, Inage-ku, Chiba 263-8555, Japan.'}, {'lastname': 'Rong', 'firstname': 'Jian', 'initials': 'J', 'affiliation': 'Division of Nuclear Medicine and Molecular Imaging, Massachusetts General Hospital, and Department of Radiology, Harvard Medical School, Boston, Massachusetts 02114, United States.'}, {'lastname': 'Wang', 'firstname': 'Lu', 'initials': 'L', 'affiliation': 'Center of Cyclotron and PET Radiopharmaceuticals, Department of Nuclear Medicine and PET/CT-MRI Center, The First Affiliated Hospital of Jinan University, 613 West Huangpu Road, Tianhe District, Guangzhou 510630, China.'}, {'lastname': 'Liang', 'firstname': 'Steven', 'initials': 'S', 'affiliation': 'Division of Nuclear Medicine and Molecular Imaging, Massachusetts General Hospital, and Department of Radiology, Harvard Medical School, Boston, Massachusetts 02114, United States.'}, {'lastname': 'Zhang', 'firstname': 'Ming-Rong', 'initials': 'MR', 'affiliation': 'Department of Advanced Nuclear Medicine Sciences, Institute of Quantum Medical Sciences, National Institutes for Quantum and Radiological Science and Technology, 4-9-1 Anagawa, Inage-ku, Chiba 263-8555, Japan.'}]",,,,© The author(s).,10.7150/thno.64320,<Element 'PubmedArticle' at 0x7f05daacd6d0>
129,"34642455
11931738
28645024
27046319
27514302
26830195
18923511
30776369
27277867
22137156
20015486
26776095
23338678
27679767
22859832
30611121
32645628
32562769
28467722
28768533
25786173
20368511
17051205
28263786
29937410
22688349
32661510
22778410
30843204
32375205
33261639
11083834
29386977
30984168
22424226
20357764
30948709
26937618
33526073
28078988
21718299
26424427
22130479
22633396
22778410
19188531
25541493
29988087
32174477
31068207
28469251
31176703
17827403
30115912",Anti-depressive-like behaviors of APN KO mice involve Trkb/BDNF signaling related neuroinflammatory changes.,"Major depression disorder is a severe mental illness often linked with metabolic disorders. Adiponectin is an adipocyte-secreted circulatory hormone with antidiabetic and glucose/lipid modulation capacities. Studies have demonstrated the pathophysiological roles of adiponectin involved in various neurological disorders, including depression. However, the underlying mechanisms are poorly understood. Here we showed that adiponectin deprivation enhanced antidepressive-like behaviors in the LPS-induced model of depression. APN KO mice displayed increased cytokines (both pro and anti-inflammatory), accompanied by an impaired expression of adiponectin receptors (mRNA/protein level) and decreasing IBA-1 level in the cortex and primary microglia of LPS treated APN KO mice. Further, LPS-treatment significantly reduced p-NFκB expression in the microglia of APN KO mice. However, the Bay11-7082 treatment recovered p-NFκB expression in the cortex of APN KO mice in the presence of LPS. Interestingly, the antidepressant potentials of APN KO mice were abolished by TrkB antagonist K252a, IKK inhibitor Bay11-7082, and AdipoRon suggesting crosstalk between TrkB/BDNF signaling and NFκB in depression. Furthermore, the effects of Bay11-7082 were abolished by a TrkB/BDNF activator (7,8-DHF), indicating a critical role of TrkB/BDNF signaling. Taken together, these findings showed that dysregulated neuroinflammatory status and BDNF signaling might underlie the antidepressive-like behaviors of APN KO mice. NFκB elicited BDNF changes may be accountable for the pathogenesis of LPS induced depression, where APN might present an alternative therapeutic target for depressive disorders.",[],Molecular psychiatry,2021-10-14,"[{'lastname': 'Li', 'firstname': 'Weifen', 'initials': 'W', 'affiliation': 'State Key Laboratory of Chemical Oncogenomics, School of Chemical Biology and Biotechnology, Peking University Shenzhen Graduate School, Shenzhen, 518055, China.'}, {'lastname': 'Ali', 'firstname': 'Tahir', 'initials': 'T', 'affiliation': 'State Key Laboratory of Chemical Oncogenomics, School of Chemical Biology and Biotechnology, Peking University Shenzhen Graduate School, Shenzhen, 518055, China.'}, {'lastname': 'Zheng', 'firstname': 'Chengyou', 'initials': 'C', 'affiliation': 'State Key Laboratory of Chemical Oncogenomics, School of Chemical Biology and Biotechnology, Peking University Shenzhen Graduate School, Shenzhen, 518055, China.'}, {'lastname': 'He', 'firstname': 'Kaiwu', 'initials': 'K', 'affiliation': 'State Key Laboratory of Chemical Oncogenomics, School of Chemical Biology and Biotechnology, Peking University Shenzhen Graduate School, Shenzhen, 518055, China.'}, {'lastname': 'Liu', 'firstname': 'Zizhen', 'initials': 'Z', 'affiliation': 'State Key Laboratory of Chemical Oncogenomics, School of Chemical Biology and Biotechnology, Peking University Shenzhen Graduate School, Shenzhen, 518055, China.'}, {'lastname': 'Shah', 'firstname': 'Fawad Ali', 'initials': 'FA', 'affiliation': 'State Key Laboratory of Chemical Oncogenomics, School of Chemical Biology and Biotechnology, Peking University Shenzhen Graduate School, Shenzhen, 518055, China.\nRiphah Institute of Pharmaceutical Sciences Riphah International University Islamabad, Islamabad, Pakistan.'}, {'lastname': 'Li', 'firstname': 'Ningning', 'initials': 'N', 'affiliation': 'Department of Neurology, Affiliated ZhongDa Hospital, School of Medicine, Southeast University, Nanjing, China.\nTomas Lindahl Nobel Laureate Laboratory, Precision Medicine Research Centre, The Seventh Affiliated Hospital of Sun Yat-sen University, Shenzhen, 518107, China.'}, {'lastname': 'Yu', 'firstname': 'Zhi-Jian', 'initials': 'ZJ', 'affiliation': 'Department of Infectious Diseases and Shenzhen key laboratory for endogenous infections, the 6th Affiliated Hospital of Shenzhen University Health Science Center. No 89, Taoyuan Road, Nanshan District, Shenzhen, 518052, China. yuzhijiansmu@163.com.'}, {'lastname': 'Li', 'firstname': 'Shupeng', 'initials': 'S', 'affiliation': 'State Key Laboratory of Chemical Oncogenomics, School of Chemical Biology and Biotechnology, Peking University Shenzhen Graduate School, Shenzhen, 518055, China. lisp@pku.edu.cn.\nCampbell Research Institute, Centre for Addiction and Mental Health, Toronto, ON, Canada. lisp@pku.edu.cn.\nDepartment of Psychiatry, University of Toronto, Toronto, ON, Canada. lisp@pku.edu.cn.'}]",,,,"© 2021. The Author(s), under exclusive licence to Springer Nature Limited.","10.1038/s41380-021-01327-3
10.1016/S0896-6273(02)00653-0
10.1016/j.jad.2017.06.011
10.1016/j.ajp.2017.01.025
10.4088/JCP.13097tx3c
10.1016/j.psc.2016.04.002
10.1186/s12893-016-0120-y
10.1038/nature07455
10.1016/j.ejphar.2019.02.024
10.1038/nrn.2016.69
10.1016/j.biopsych.2011.10.025
10.1016/j.biopsych.2009.09.033
10.1016/j.molmed.2015.12.003
10.1007/s11064-012-0967-y
10.1016/0889-1591(88)90028-1
10.5498/wjp.v6.i3.283
10.1189/jlb.0512265
10.1016/j.redox.2018.101093
10.1016/j.intimp.2020.106729
10.1016/j.biocel.2020.105794
10.1089/ars.2017.7099
10.1016/j.bbadis.2020.165752
10.1186/s12974-017-0928-0
10.1016/j.immuni.2015.02.002
10.1001/archgenpsychiatry.2010.22
10.1038/nature05292
10.1016/j.bbi.2017.03.002
10.1016/j.cyto.2018.06.012
10.1007/s00125-012-2598-x
10.1038/s42255-019-0041-z
10.1073/pnas.1202835109
10.1111/jpi.12667
10.1016/j.bbr.2017.05.064
10.1186/s12974-020-02015-9
10.1111/j.1745-7270.2007.00261.x
10.1128/IAI.68.12.7087-7093.2000
10.1111/cns.12588
10.1016/j.bbi.2020.11.008
10.3389/fimmu.2019.00545
10.1016/j.cell.2012.02.035
10.1038/nature08991
10.1038/s41467-019-09562-7
10.1038/nm.4050
10.1186/s12974-021-02091-5
10.2174/1381612823666170111141915
10.1111/j.1476-5381.2011.01560.x
10.1016/j.jpsychires.2015.09.001
10.1016/j.psyneuen.2011.11.002
10.1016/j.jpsychires.2012.04.028
10.1073/pnas.1202835109
10.1097/PSY.0b013e3181907c1b
10.1017/S0033291717002483
10.1016/j.biopsych.2014.10.014
10.1016/j.euroneuro.2015.06.007
10.1111/acps.12698
10.1038/s41380-018-0076-7
10.1016/j.jad.2020.03.022
10.1186/s12974-019-1474-8
10.1038/s41598-017-01600-y
10.1016/j.neuroscience.2019.05.060
10.2337/db07-0510
10.1016/j.beem.2013.09.003
10.1038/s41398-018-0210-y",<Element 'PubmedArticle' at 0x7f05de40d770>
130,"34639186
33174475
25263833
19901245
27934854
26362895
24072725
31161863
30429274
18037931
25412623
26688099
10965234
26250739
31810488
30362156
21840891
33636613
33779783
33620411
34228301
29440323
29410647
28002688
19847908
18272891
23045237
30632834
27351487
32154570
26531700
28285710
31636528
31753762
26022934
31636637
33927692
18177270
20536390
17283229
31736971
22948153
24397980
16306350
30219158
28641765
31129285
22426759
20714168
30196837
30300462
30321074
33486671
19538214
29910742
8548812
19136996
23343052
33369280
16212539
19922787
17617622
15324935
24098530
26856937
15788534
24215402
25809135
24008588
31563075
25505980
17904647
12799033
25097618
28823971
16269354
11209052
24404511
21545576
24606903
19754671
15843582
16039994
14733921
26634156
33863926
23932723
24047472
28071854
33915177
25548799
25637017
21752353
22768214
26363224
18794339
24977972
33097973
19558533
15604363
21694775
33513808
18802071
17237424
29412160
33713324
18241674
26293846
31299236
28248533
19304942
28444107
30235451
25951933
14597097
31255353
30122837
28441629
33268480
33731174
34112929
30915034
24665910
30813240
29205099
21364526
12660880
20601896
26276791
27792289
23640763
27514756
31922310
31902083
32132650
11342605
11465089
24576482
30814586
32638449
34392775
23916894
28091609
24780498
30690681
29773580
24217159
19864606
32477131
32302063
22490786
28528966
30820847
19936064
33563078
31040784
32413735
33845103
25278489
26391329
30709405
22992073
30171200
32622513
18678605
32920091
27239035",Adipokines as Immune Cell Modulators in Multiple Sclerosis.,"Multiple sclerosis (MS), a chronic inflammatory and demyelinating disease of the central nervous system (CNS), is a major clinical and societal problem, which has a tremendous impact on the life of patients and their proxies. Current immunomodulatory and anti-inflammatory therapies prove to be relatively effective; however, they fail to concomitantly stop ongoing neurological deterioration and do not reverse acquired disability. The proportion to which genetic and environmental factors contribute to the etiology of MS is still incompletely understood; however, a recent association between MS etiology and obesity was shown, with obesity greatly increasing the risk of developing MS. An altered balance of adipokines, which are white adipose tissue (WAT) hormones, plays an important role in the low-grade chronic inflammation during obesity by their pervasive modification of local and systemic inflammation. Vice versa, inflammatory factors secreted by immune cells affect adipokine function. To explore the role of adipokines in MS pathology, we will here review the reciprocal effects of adipokines and immune cells and summarize alterations in adipokine levels in MS patient cohorts. Finally, we will discuss proof-of-concept studies demonstrating the therapeutic potential of adipokines to target both neuroinflammation and neurodegeneration processes in MS.","['adipokines', 'demyelination', 'immunology', 'multiple sclerosis', 'neurodegeneration', 'neuroinflammation', 'obesity']",International journal of molecular sciences,2021-10-14,"[{'lastname': 'Rijnsburger', 'firstname': 'Merel', 'initials': 'M', 'affiliation': 'Department of Molecular Cell Biology and Immunology, MS Center Amsterdam, Amsterdam Neuroscience, Amsterdam UMC, Vrije Universiteit Amsterdam, de Boelelaan 1108, 1181 HZ Amsterdam, The Netherlands.'}, {'lastname': 'Djuric', 'firstname': 'Niek', 'initials': 'N', 'affiliation': 'Department of Molecular Cell Biology and Immunology, MS Center Amsterdam, Amsterdam Neuroscience, Amsterdam UMC, Vrije Universiteit Amsterdam, de Boelelaan 1108, 1181 HZ Amsterdam, The Netherlands.'}, {'lastname': 'Mulder', 'firstname': 'Inge A', 'initials': 'IA', 'affiliation': 'Department of Biomedical Engineering and Physics, Amsterdam UMC, University of Amsterdam, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands.'}, {'lastname': 'de Vries', 'firstname': 'Helga E', 'initials': 'HE', 'affiliation': 'Department of Molecular Cell Biology and Immunology, MS Center Amsterdam, Amsterdam Neuroscience, Amsterdam UMC, Vrije Universiteit Amsterdam, de Boelelaan 1108, 1181 HZ Amsterdam, The Netherlands.'}]",,,,,"10.3390/ijms221910845
10.1177/1352458520970841
10.1016/j.orcp.2014.01.002
10.1212/WNL.0b013e3181c0d6e0
10.1038/nrneurol.2016.187
10.1177/1352458515603798
10.1177/1352458513507357
10.1177/1352458519853473
10.1212/WNL.0000000000006644
10.1038/ncprheum0674
10.2337/db14-0758
10.1016/j.exppara.2015.12.002
10.1159/000026458
10.1038/nri3871
10.1186/s12974-019-1650-x
10.1002/ana.25365
10.1093/brain/awr182
10.1016/j.msard.2021.102845
10.1007/s00401-021-02293-4
10.1001/jama.2020.26858
10.1007/s40263-021-00822-z
10.1101/cshperspect.a029249
10.3389/fneur.2018.00005
10.1056/NEJMoa1606468
10.1002/ana.21867
10.1056/NEJMoa0706383
10.1038/nrneurol.2012.203
10.1080/14712598.2019.1568407
10.1371/journal.pmed.1002053
10.5603/EP.a2020.0008
10.1016/j.jneuroim.2015.09.008
10.1016/j.cellimm.2017.03.001
10.3389/fnins.2019.01026
10.1016/S1474-4422(19)30356-4
10.1016/j.tips.2015.04.014
10.3389/fimmu.2019.02312
10.3389/fendo.2021.639757
10.1042/BJ20071492
10.1515/bc.2010.104
10.1677/JOE-06-0047
10.3389/fimmu.2019.02555
10.1074/jbc.M112.409516
10.1161/CIRCRESAHA.114.302439
10.2337/diabetes.54.12.3358
10.1016/j.amjms.2018.03.008
10.1016/j.msard.2017.04.006
10.1016/j.jneuroim.2019.576968
10.5114/ninp.2012.27211
10.1159/000317393
10.1016/j.jneuroim.2018.07.011
10.1111/ene.13822
10.1080/08820139.2018.1528270
10.1007/s12035-021-02287-z
10.1111/j.1468-1331.2009.02701.x
10.3389/fphys.2018.00640
10.1016/0092-8674(95)90151-5
10.1038/ijo.2008.232
10.1186/1742-4933-10-3
10.1002/acn3.51291
10.1007/s10541-005-0193-1
10.1016/j.bbi.2009.11.003
10.4049/jimmunol.179.2.1292
10.1111/cen3.12092
10.1016/j.jaut.2004.05.007
10.1371/annotation/6de84c11-73f5-4ee4-aec7-ca83072401a4
10.1016/j.msard.2015.10.002
10.1073/pnas.0408995102
10.1186/1471-2377-13-172
10.1007/s11011-015-9665-1
10.1159/000353567
10.1016/j.msard.2019.101409
10.1155/2014/486282
10.1016/j.jneuroim.2007.08.008
10.1016/S0165-5728(03)00154-1
10.1016/j.clim.2017.08.011
10.1016/j.peptides.2005.03.037
10.1073/pnas.98.2.502
10.4093/dmj.2013.37.6.404
10.1111/j.1476-5381.2011.01369.x
10.1016/j.cmet.2014.01.013
10.1111/j.1582-4934.2009.00899.x
10.4049/jimmunol.174.9.5789
10.1016/j.bbrc.2005.06.202
10.1016/j.bbrc.2003.12.104
10.1155/2015/371734
10.1038/s41598-021-87235-6
10.1016/j.jbspin.2013.07.013
10.3109/10641963.2013.827697
10.1002/oby.21735
10.1016/j.pharmthera.2021.107879
10.1007/s00011-014-0792-7
10.4049/jimmunol.1402166
10.1016/j.cellimm.2011.06.016
10.1371/journal.pone.0040043
10.1016/j.mce.2015.09.002
10.1084/jem.20080300
10.1007/s10072-020-04847-y
10.1111/j.1365-2265.2009.03664.x
10.1126/science.1097243
10.1371/journal.pone.0020287
10.3390/ijms22031235
10.4049/jimmunol.181.7.4685
10.4049/jimmunol.178.3.1748
10.1016/j.micpath.2018.02.002
10.1007/s11064-021-03267-4
10.1016/j.bbamcr.2008.01.004
10.1111/jcmm.12657
10.1016/j.lfs.2019.116645
10.33549/physiolres.933349
10.1152/ajpheart.01341.2008
10.4236/mri.2014.32007
10.1159/000493653
10.1007/s11427-015-4861-0
10.1016/j.jneuroim.2003.08.029
10.1016/j.npep.2019.101938
10.4103/aian.AIAN_377_17
10.1016/j.redox.2017.04.012
10.4049/jimmunol.2000490
10.1186/s12974-021-02124-z
10.1038/s42003-021-02259-y
10.3389/fendo.2019.00137
10.1111/jdv.12451
10.3390/nu11020454
10.1080/21623945.2017.1402151
10.1038/ijo.2011.20
10.1055/s-2002-38241
10.2310/JIM.0b013e3181ec5db2
10.1093/ajh/hpv136
10.1111/bpa.12454
10.1002/eji.201242836
10.1007/s12035-016-0036-7
10.1111/cpr.12759
10.1007/s12975-019-00768-x
10.1038/s41380-020-0701-0
10.4049/jimmunol.166.10.5909
10.1002/1521-4141(200105)31:5<1324::AID-IMMU1324>3.0.CO;2-Y
10.1016/j.bbi.2014.02.003
10.1038/s41598-019-39230-1
10.1111/ejn.14896
10.1080/10495398.2021.1920424
10.1016/j.bbi.2013.07.176
10.1038/srep40397
10.1016/j.nbd.2014.04.012
10.1007/s11064-019-02726-3
10.1530/JOE-18-0096
10.1038/nrcardio.2013.139-c1
10.4049/jimmunol.0803435
10.3389/fphar.2020.00656
10.1002/acn3.51044
10.1186/1742-2094-9-66
10.1016/j.neuroscience.2017.05.022
10.1007/s12975-019-00692-0
10.1371/journal.pone.0007897
10.1177/0271678x21992625
10.3389/fphar.2019.00395
10.1016/j.intimp.2020.106546
10.1016/j.bbr.2021.113290
10.1016/j.peptides.2014.09.016
10.1177/1759091415605114
10.1186/s12974-019-1406-7
10.1056/NEJMoa1114287
10.1038/s41582-018-0058-z
10.1016/j.jaut.2020.102510
10.1189/jlb.0208133
10.1016/j.jnutbio.2020.108493
10.1016/j.celrep.2016.05.009",<Element 'PubmedArticle' at 0x7f05de41a180>
131,"34623401
27039345
29654072
27451102
20595940
17183542
31991411
27196727
25228013
17615392
28514502
28465157
15705806
20478441
10330493
29133394
11826265
28241485
18374335
26456904
11240308
22989628
16122717
15101093
12697714
17570500
25700604
31877966
28643774
27889472
33400952
31847265
12828421
32387645
19420011
17120292
18401595
25222701
19596521
20100545
25993604
12657692
12657693
11168553
20875808
11116225
16127691
17803971
23861392
12670715
10036289
33192257
8248223
11074057
32703416
11891272
15642619
23401502
24191028
21555578
11978836
22209870
33557413
19450619
17035515
10942479
11386980
32456504
14960294
31976839
33719785
23770320
20368517
23625334
18724263
20226402
20689282
31479034
16421627
12771112
29981391
17116000
30878503
9717719
9874807
20826654
16763553
31059772
19168586
21489984
30395175
28213512
25453744
21353593
23874659
26141492
30686764
28169841
33706960
33016923
17975326
30104506
8290098
15939846
32646017
17261779
23180279
11378248
12957499
12927764
15070964
12819990
26837465
20732393
31012223
18276750
11955468
16538187
10765041
25061285
22451324
19189968
29550215
22070562
11226319
23948892
31332160
20557567
12535954
9619148
17412603
34335180
19410597
32210745
10227628
10494997
30381823
18063054
10891861
15567427
21420980
29266208
15219649
18980828
29149179
22401913
27716751
30481522
29924994",Estrogen receptors and the aging brain.,"The female sex hormone estrogen has been ascribed potent neuroprotective properties. It signals by binding and activating estrogen receptors that, depending on receptor subtype and upstream or downstream effectors, can mediate gene transcription and rapid non-genomic actions. In this way, estrogen receptors in the brain participate in modulating neural differentiation, proliferation, neuroinflammation, cholesterol metabolism, synaptic plasticity, and behavior. Circulating sex hormones decrease in the course of aging, more rapidly at menopause in women, and slower in men. This review will discuss what this drop entails in terms of modulating neuroprotection and resilience in the aging brain downstream of spatiotemporal estrogen receptor alpha (ERα) and beta (ERβ) signaling, as well as in terms of the sex differences observed in Alzheimer's disease (AD) and Parkinson's disease (PD). In addition, controversies related to ER expression in the brain will be discussed. Understanding the spatiotemporal signaling of sex hormones in the brain can lead to more personalized prevention strategies or therapies combating neurodegenerative diseases.","['Ageing', ""Alzheimer's disease"", 'Estrogen receptor', ""Parkinson's disease"", 'Sex differences', 'Sex hormones']",Essays in biochemistry,2021-10-09,"[{'lastname': 'Maioli', 'firstname': 'Silvia', 'initials': 'S', 'affiliation': 'Division of Neurogeriatrics, Department of Neurobiology, Care Sciences and Society, Center for Alzheimer Research, Karolinska Institutet, 171 77 Stockholm, Sweden.'}, {'lastname': 'Leander', 'firstname': 'Karin', 'initials': 'K', 'affiliation': 'Institute of Environmental Medicine, Karolinska Institutet, 171 77 Stockholm, Sweden.'}, {'lastname': 'Nilsson', 'firstname': 'Per', 'initials': 'P', 'affiliation': 'Division of Neurogeriatrics, Department of Neurobiology, Care Sciences and Society, Center for Alzheimer Research, Karolinska Institutet, 171 77 Stockholm, Sweden.'}, {'lastname': 'Nalvarte', 'firstname': 'Ivan', 'initials': 'I', 'affiliation': 'Department of Biosciences and Nutrition, Karolinska Institutet, 141 57 Huddinge, Sweden.'}]",,,,© 2021 The Author(s).,"10.1042/EBC20200162
10.1530/JOE-18-0129
10.1002/cne.21240
10.1159/000506162
10.1210/er.2016-1007
10.1007/s10072-014-1937-8
10.1152/physrev.00026.2006
10.1111/jne.12488
10.1016/j.jsbmb.2017.04.012
10.1126/science.1106943
10.1016/S0079-6123(08)81013-8
10.1016/S0925-4773(98)00223-8
10.1073/pnas.1714094114
10.1146/annurev.physiol.64.081601.142703
10.3390/brainsci7030024
10.1016/j.yhbeh.2008.01.013
10.1016/j.yfrne.2015.10.001
10.1016/S0301-0082(00)00059-9
10.1210/en.2012-1550
10.1016/j.brainres.2005.06.073
10.1002/cne.20128
10.1210/en.2002-221069
10.1002/cne.21419
10.1016/j.mce.2015.02.013
10.3390/ijms21010115
10.1038/ncomms15840
10.1016/j.mce.2016.11.016
10.1016/j.mce.2020.111145
10.3390/ijms20246312
10.1046/j.0022-7722.2003.00042.x
10.1016/j.neuroscience.2020.04.047
10.1677/JOE-09-0066
10.1002/cne.21193
10.1007/s00441-008-0606-8
10.1016/j.psyneuen.2014.07.025
10.1016/j.psyneuen.2009.06.003
10.1016/j.bbagen.2010.01.006
10.1016/j.yhbeh.2015.05.004
10.1523/JNEUROSCI.23-06-02333.2003
10.1523/JNEUROSCI.23-06-02340.2003
10.1046/j.0953-816x.2000.01409.x
10.1016/j.brainres.2010.09.069
10.1002/1096-9861(20010115)429:3<355::AID-CNE1>3.0.CO;2-#
10.1002/cne.20724
10.1016/j.brainres.2007.06.092
10.1074/jbc.M113.467837
10.1016/S0169-328X(03)00088-3
10.1152/jn.1999.81.2.925
10.3389/fnins.2020.572511
10.1073/pnas.90.23.11162
10.1016/S0006-8993(00)02993-0
10.1016/j.bbrc.2020.06.063
10.1073/pnas.012032699
10.1016/j.physbeh.2004.11.002
10.1073/pnas.1300313110
10.1073/pnas.1311763110
10.1073/pnas.1103833108
10.1523/JNEUROSCI.22-09-03608.2002
10.1016/j.yfrne.2011.12.001
10.3390/ijms22041589
10.1016/j.yfrne.2009.04.016
10.1523/JNEUROSCI.3369-06.2006
10.1067/mob.2000.106004
10.1001/archpsyc.58.6.529
10.1176/appi.ajp.2020.19080848
10.1016/j.biopsych.2003.08.011
10.2174/1570159X18666200123165652
10.1080/13697137.2021.1892627
10.1016/j.jsbmb.2013.06.001
10.1001/archgenpsychiatry.2010.30
10.1007/s00404-013-2865-1
10.1097/gme.0b013e318174f155
10.1016/j.jmig.2009.12.016
10.1159/000314681
10.1097/GME.0000000000001415
10.1358/dnp.2005.18.9.948450
10.1001/jama.289.20.2651
10.1016/j.pneurobio.2018.06.007
10.1111/j.1365-2796.2006.01725.x
10.1016/j.jsbmb.2019.03.003
10.1016/S0022-2275(20)32188-X
10.1073/pnas.96.1.266
10.1523/JNEUROSCI.1898-10.2010
10.1038/sj.emboj.7601181
10.1016/j.reprotox.2019.04.007
10.1093/carcin/bgp029
10.1074/jbc.M111.227082
10.1093/cercor/bhy274
10.1084/jem.20160534
10.1016/j.bbr.2014.10.018
10.1016/j.tem.2011.01.003
10.1371/journal.pone.0068534
10.1093/brain/awv166
10.1016/j.stem.2018.12.013
10.1101/2021.04.23.441050
10.1016/j.jalz.2019.01.010
10.1097/WAD.0000000000000187
10.1016/bs.vh.2020.12.020
10.3233/JAD-200982
10.1159/000109998
10.3390/brainsci8080154
10.1212/WNL.44.1.90
10.1001/archpsyc.62.6.685
10.3390/ijms21134812
10.1196/annals.1386.036
10.1007/s12035-012-8377-3
10.1016/S0197-4580(00)00255-4
10.1016/S0014-4886(03)00138-9
10.1016/S0197-4580(03)00009-5
10.1210/jc.2003-030862
10.1007/s00401-003-0720-3
10.1038/srep20352
10.1016/j.neuroscience.2010.08.019
10.1111/acel.12961
10.1210/en.2007-1346
10.1016/S0006-3223(01)01289-6
10.1097/01.ypg.0000194445.27555.71
10.1159/000017224
10.2147/CIA.S65921
10.3233/JAD-2012-120283
10.1074/jbc.M808246200
10.1016/j.bbabio.2018.03.006
10.1111/j.1365-2826.2011.02251.x
10.1073/pnas.041617498
10.3233/JAD-122341
10.1038/s41419-019-1786-8
10.1111/j.1755-5949.2010.00163.x
10.1016/S0306-4522(02)00578-X
10.1016/j.nbd.2007.02.009
10.3389/fnmol.2021.657064
10.1016/j.yfrne.2009.04.014
10.3389/fnins.2020.00157
10.1212/WNL.52.7.1417
10.1016/S0091-3057(99)00091-X
10.1111/bph.14531
10.1016/j.brainresrev.2007.10.011
10.1002/1098-2396(20000915)37:4<245::AID-SYN1>3.0.CO;2-5
10.1016/j.neuropharm.2004.08.020
10.1016/j.lfs.2011.03.010
10.1002/jcp.26412
10.1016/j.psyneuen.2003.08.010
10.1016/j.biopha.2008.09.007
10.1371/journal.pmed.1002445
10.1016/S1470-2045(12)70075-X
10.1038/nrendo.2016.164
10.1016/j.yfrne.2018.11.003
10.1016/j.celrep.2018.05.048",<Element 'PubmedArticle' at 0x7f05dbf1eb80>
132,"34589812
29804835
30406198
10975906
19318467
15295027
10322493
23943137
11271408
20018408
32999463
28216088
17950926
23339575
17470522
16646155
23219473
23554175
32745992
10762353
18073775
25151944
33232758
15339653
25979764
17024679
28755863
18805467
31235930
17976923
19171181
30184509
20300101
11256079
11144361
26404713
22159118
11870871
30635056
30108482
6289442
11553304
25017883
23599891
27546235
27870401
23183882
29324460
32291137
29857518
22497984
11182095
30728170
29669258
22025910
24051097
10845078
11121525
20506473
17006898
14704216
18364018
32615087
33837868
26937008
20934505
7911978
25834045
34488804
16316783
22466658
17678962
24933434
25810524
22072675
14597099
21382557
21745355
9636227
28363835
7972026
15788779
9180080
23356992
7190730
30083579
27870428
31473031
27337340
20847426
14507968
32297671
30209204
27375619
1353794
16918306
24013012
30214058
19918929
14638938
32725944
20970492
32912598
22153080
10652441
11282163","Three's Company: Neuroimmune activation, sex, and memory at the tripartite synapse.","The neuroimmune system is required for normal cognitive functions such as learning and memory in addition to its critical role in detecting and responding to invading pathogens and injury. Understanding the functional convergence of neurons, astrocytes, and microglia at the synapse, particularly in the hippocampus, is key to understanding the nuances of such diverse roles. In the healthy brain, communication between all three cells is important for regulating neuronal activation and synaptic plasticity mechanisms, and during neuroinflammation, the activity and functions of all three cells can produce and be modulated by inflammatory cytokines. An important remaining component to this system is the conclusive evidence of sex differences in hippocampal plasticity mechanisms, hormone modulation of synaptic plasticity, functional properties of hippocampal neurons, and in neuroimmune activation. Sex as a biological variable here is necessary to consider given sex differences in the prevalence of memory-related disorders such as Alzheimer's disease and Post-Traumatic Stress disorder, both of which present with neuroimmune dysregulation. To make meaningful progress towards a deeper understanding of sex biases in memory-related disease prevalence, I propose that the next chapter of psychoneuroimmune research must focus on the signal integration and transduction at the synapse between experience-dependent plasticity mechanisms, neuroimmune activation, and the influence of biological sex.","['Astrocytes', 'Memory', 'Microglia', 'Neuroimmune', 'Sex differences', 'Tripartite synapse']","Brain, behavior, & immunity - health",2021-10-01,"[{'lastname': 'Posillico', 'firstname': 'Caitlin K', 'initials': 'CK', 'affiliation': 'Psychology Department, University of Michigan, Ann Arbor, 48109, USA.'}]",,,,© 2021 The Author.,"10.1016/j.bbih.2021.100326
10.1016/j.cell.2018.05.002
10.1523/ENEURO.0088-18.2018
10.1002/1098-1136(200010)32:1%3c1::AID-GLIA10%3e3.0.CO;2-W
10.1101/lm.918309
10.1523/JNEUROSCI.0473-04.2004
10.1016/S0166-2236(98)01349-6
10.1007/s12640-013-9417-0
10.1007/s002130000590
10.1016/j.neurobiolaging.2009.11.022
10.1038/s41586-020-2777-8
10.1016/j.bbi.2017.02.006
10.1016/j.tins.2007.08.007
10.1186/1756-6606-6-5
10.1677/JOE-07-0017
10.1016/j.jphysparis.2005.12.008
10.1016/j.psyneuen.2012.11.007
10.1002/hipo.22129
10.1016/j.ebiom.2020.102919
10.1046/j.1460-9568.2000.00011.x
10.1038/nrn2297
10.1016/J.NLM.2014.08.008
10.1016/j.neuint.2020.104921
10.1016/j.neuron.2004.08.011
10.1016/j.euroneuro.2015.04.020
10.1002/hipo.20230
10.1016/j.physbeh.2017.07.028
10.1016/j.neuroscience.2008.08.043
10.1038/s41593-019-0427-y
10.1016/J.PSYNEUEN.2007.09.004
10.1016/J.NEUROSCIENCE.2009.01.009
10.1016/j.celrep.2018.08.001
10.1038/nrn2803
10.1038/35058528
10.1016/S0896-6273(00)00130-6
10.1038/nn.4113
10.1523/JNEUROSCI.4067-11.2011
10.1002/glia.10037
10.1186/s13293-019-0219-9
10.3389/fnmol.2018.00266
10.1126/science.6289442
10.1046/j.0953-816X.2001.01664.x
10.1016/j.expneurol.2014.01.001
10.7554/eLife.00362
10.1038/nri.2016.90
10.1002/jnr.23864
10.1038/nrneurol.2012.236
10.1097/YCO.0000000000000401
10.1016/j.jaut.2020.102452
10.3390/jcm7060132
10.1016/j.psyneuen.2012.02.018
10.1016/S0896-6273(01)00194-5
10.1523/JNEUROSCI.1970-18.2019
10.1016/j.yhbeh.2018.04.007
10.3389/fncel.2011.00022
10.1101/lm.028357.112
10.1146/annurev.neuro.23.1.649
10.1016/S0006-8993(00)02877-8
10.1002/cne.22361
10.1002/glia.20367
10.1093/cercor/bhg118
10.1111/j.1460-9568.2008.06109.x
10.1016/j.cell.2020.05.050
10.1007/s11064-021-03317-x
10.1523/JNEUROSCI.4437-15.2016
10.1016/J.BBI.2010.10.003
10.1038/369744a0
10.1523/JNEUROSCI.4255-14.2015
10.1101/2020.11.23.394742
10.1007/978-1-4614-4729-0_3
10.1016/J.IT.2005.11.006
10.1172/JCI58644
10.1016/S0074-7742(07)82010-1
10.1016/j.bbi.2014.04.009
10.1523/JNEUROSCI.4485-14.2015
10.1523/JNEUROSCI.3667-11.2011
10.1016/J.JNEUROIM.2003.08.030
10.1016/j.neuron.2011.02.003
10.1186/2042-6410-2-7
10.1073/PNAS.95.13.7778
10.1101/378257
10.1016/j.neuroimage.2017.03.051
10.1073/pnas.91.23.11158
10.1523/JNEUROSCI.4486-04.2005
10.1126/science.276.5319.1699
10.1186/1756-6606-6-6
10.1126/science.7190730
10.1016/j.cobeha.2018.04.005
10.1002/jnr.23921
10.1016/j.tins.2019.07.009
10.1038/nature18283
10.3233/JAD-2010-101089
10.1523/jneurosci.23-25-08692.2003
10.1111/bjh.16659
10.1523/JNEUROSCI.0801-18.2018
10.3389/fimmu.2016.00219
10.1523/jneurosci.12-08-03217.1992
10.1146/annurev.pharmtox.47.120505.105219
10.1016/j.bbr.2013.08.048
10.1038/s41386-018-0208-4
10.1002/da.20629
10.1073/pnas.2431073100
10.1111/acel.13182
10.1016/J.BBI.2010.10.015
10.1016/j.jpsychires.2020.06.022
10.1016/j.cell.2011.11.029
10.1002/(SICI)1098-1136(20000215)29:4
10.1016/S0165-5728(01)00259-4",<Element 'PubmedArticle' at 0x7f05dec09630>
133,"34585328
28434651
25517926
26678483
16492984
26837375
23743468
20970492
19914034
30636629
19109548
25593138
29665077
29114096
19428957
26655283
31226122
29895784
30919486
31033013
24826922
31325156
28475125
31207928
28404943
30055549
31296240
31031659
31442321
27314810
28288671
31728577
29636575
29867352
25632141
11319769
19685288
23825548
26238505
27896432
14960598
20564349
25892207
26672764
12932205
32334833
31622511
12416551
15087099
11598321
31288048
30817119
28255166
28708259
28994117
29088788
28480587
19771167
20136703
24416646",Melatonin Reduces Neuroinflammation and Improves Axonal Hypomyelination by Modulating M1/M2 Microglia Polarization via JAK2-STAT3-Telomerase Pathway in Postnatal Rats Exposed to Lipopolysaccharide.,"Microglia activation and associated inflammation are implicated in the periventricular white matter damage (PWMD) in septic postnatal rats. This study investigated whether melatonin would mitigate inflammation and alleviate the axonal hypomyelination in the corpus callosum in septic postnatal rats. We further explored if this might be related to the modulation of microglial polarization from M1 phenotype to M2 through the JAK2/STAT3/telomerase pathway. We reported here that indeed melatonin not only can it reduce the neurobehavioral disturbances in LPS-injected rats, but it can also dampen microglia-mediated inflammation. Thus, in LPS + melatonin group, the expression of proinflammatory mediators in M1 phenotype microglia was downregulated. As opposed to this, M2 microglia were increased which was accompanied by upregulated expression of anti-inflammatory mediators along with telomerase reverse transcriptase or melatonin receptor 1(MT1). In parallel to this was decreased NG2 expression but increased expression of myelin and neurofilament proteins. Melatonin can improve hypomyelination which was confirmed by electron microscopy. In vitro in primary microglia stimulated by LPS, melatonin decreased the expression of proinflammatory mediators significantly; but it increased the expression of anti-inflammatory mediators. Additionally, the expression levels of p-JAK2 and p-STAT3 were significantly elevated in microglia after melatonin treatment. Remarkably, the effect of melatonin on LPS-treated microglia was blocked by melatonin receptor, JAK2, STAT3 and telomerase reverse transcriptase inhibitors, respectively. Taken together, it is concluded that melatonin can attenuate PWMD through shifting M1 microglia towards M2 via MT1/JAK2/STAT3/telomerase pathway. The results suggest a new therapeutic strategy whereby melatonin may be adopted to convert microglial polarization from M1 to M2 phenotype that would ultimately contribute to the attenuation of PWMD.","['Axonal hypomyelination', 'JAK2', 'Melatonin', 'Microglial polarization', 'Periventricular white matter damage', 'STAT3', 'Telomerase reverse transcriptase']",Molecular neurobiology,2021-09-30,"[{'lastname': 'Zhou', 'firstname': 'Qiuping', 'initials': 'Q', 'affiliation': ""Department of Critical Care Medicine, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, 510080, China.\nSchool of Medicine, South China University of Technology, Guangzhou, 510006, China.""}, {'lastname': 'Lin', 'firstname': 'Lanfen', 'initials': 'L', 'affiliation': 'Department of Critical Care Medicine, Guangdong Second Provincial General Hospital, Guangzhou, 510317, Guangdong, China.'}, {'lastname': 'Li', 'firstname': 'Haiyan', 'initials': 'H', 'affiliation': ""Department of Critical Care Medicine, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, 510080, China.""}, {'lastname': 'Wang', 'firstname': 'Huifang', 'initials': 'H', 'affiliation': ""Department of Critical Care Medicine, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, 510080, China.\nThe Second School of Clinical Medicine, Southern Medical University, Guangzhou, 510515, China.""}, {'lastname': 'Jiang', 'firstname': 'Shuqi', 'initials': 'S', 'affiliation': ""Department of Critical Care Medicine, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, 510080, China.\nSchool of Medicine, South China University of Technology, Guangzhou, 510006, China.""}, {'lastname': 'Huang', 'firstname': 'Peixian', 'initials': 'P', 'affiliation': ""Department of Critical Care Medicine, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, 510080, China.\nSchool of Medicine, South China University of Technology, Guangzhou, 510006, China.""}, {'lastname': 'Lin', 'firstname': 'Qiongyu', 'initials': 'Q', 'affiliation': ""Department of Critical Care Medicine, Jieyang People's Hospital, Jieyang, 522000, Guangdong, China.""}, {'lastname': 'Chen', 'firstname': 'Xuan', 'initials': 'X', 'affiliation': ""Department of Critical Care Medicine, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, 510080, China.\nShantou University Medical College (FCS), Shantou, 515063, China.""}, {'lastname': 'Deng', 'firstname': 'Yiyu', 'initials': 'Y', 'affiliation': ""Department of Critical Care Medicine, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, 510080, China. yiyudeng666@163.com.\nSchool of Medicine, South China University of Technology, Guangzhou, 510006, China. yiyudeng666@163.com.""}]",,,,© 2021. The Author(s).,"10.1007/s12035-021-02568-7
10.1016/S0140-6736(17)31002-4
10.1089/jir.2014.0119
10.1002/glia.22950
10.1203/01.pdr.0000199905.08848.55
10.1136/practneurol-2015-001184
10.1097/AOG.0b013e318297f37f
10.1016/j.bbi.2010.10.015
10.1016/j.jcrc.2009.10.001
10.1186/s13195-018-0461-0
10.1161/STROKEAHA.108.521906
10.1161/STROKEAHA.114.007145
10.1002/glia.23336
10.1161/STROKEAHA.117.018505
10.1016/j.pneurobio.2009.01.003
10.1016/j.pneurobio.2015.11.002
10.1371/journal.pbio.3000330
10.3390/ijms19061743
10.1111/jpi.12572
10.1111/jpi.12583
10.1002/ddr.21177
10.1007/s11064-019-02838-w
10.3390/ijms18050988
10.3390/nu11061343
10.18632/oncotarget.15780(2017)
10.1615/JEnvironPatholToxicolOncol.2018025666
10.1186/s13024-019-0330-8
10.3389/fpsyt.2019.00221
10.1111/jpi.12606
10.1111/bph.13536
10.1186/s12974-017-0805-x
10.1007/s00018-019-03369-x
10.1038/d41586-018-02684-w
10.3389/fnmol.2018.00160
10.1523/JNEUROSCI.2925-14.2015
10.1002/jnr.1073
10.1007/s11064-009-0044-3
10.1371/journal.pone.0066602
10.1111/acel.12370
10.1007/s00406-016-0750-1
10.1523/JNEUROSCI.4082-03.2004
10.1002/jnr.22450
10.1016/j.neurobiolaging.2015.03.008
10.18632/oncotarget.6407
10.1034/j.1600-079x.2003.00077.x
10.1016/j.bbrc.2020.04.058
10.1111/bpa.12798
10.1046/j.1440-1789.2002.00438.x
10.1016/j.pediatrneurol.2003.10.001
10.1159/000046144
10.1016/j.neulet.2019.134364
10.1021/acschemneuro.9b00051
10.1038/emm.2016.159
10.1111/jpi.12434
10.1111/jphp.12830
10.18632/oncotarget.20382
10.1111/jpi.12417
10.1371/journal.pone.0007128
10.1111/j.1600-079X.2009.00740.x
10.4161/jkst.25256",<Element 'PubmedArticle' at 0x7f05dc71cae0>
134,"34576325
27243427
30890425
28150045
28054129
34236893
25637088
32674727
33400183
33229744
33820460
29803225
33803482
32824367
22247890
10529898
16378501
27352979
25007880
22434581
15711583
18060014
17317294
11330046
18068127
17981503
9013583
11755111
26632493
22685301
27514452
25450819
18313368
16942889
20533901
15855325
17387142
12486128
24814435
17766440
17361034
12082115
11375435
18059282
17903364
16960755
28948004
17264754
30400386
18054742
17569578
17394460
16539667
17965419
17167171
17433295
15574741
18384649
32170673
18464922
19007323
30897356
28332488
32390826
27610264
32438686
27105081
19188574
31282427
15048890
27080380
29473513
33168089
31484320
28598856
21269927
23220449
25681453
25984676
26528949
18803967
8848182
10214746
29764354
29288112
26899237
10665491
7217993
12666100
16224497
10471497
15228595
15054084
20506312
16352719
19297401
19025767
17385668
23251494
27539639
33443131
25909088
24477431
25573151
23258538
33357211
33573368
19847896
22574684
3487318
33905061
12846968
27827408
34065042
30026688
15841414
10329595
33101584
33946349
15252205
16934505
27960106
30954070
19296921
24437518
11137760
20455864
12504866
12095645
12531866
15854758
20697033
19505575
21684337
20844148
25197640
15349860
9560156
25611507
31188151
9046040
9207126
8888015
10688892
12079401
17196747
15791003
26113789
2154550
1471869
1658241
10514096
2861548
18245082
24942732
27280685
12153485
14690537
20650633
23085103
21603186
21819568
31132685
28356907
17254027
18207323
17976742
18205920
21839812
27535749
16360119
17266988
32703610
24635117
33210212
17196944
24593945
30273550
10961664
33052479
32564332
33652920
12349958
33160981
28178069
29885451
30222980
17055439
17805244
16407166
17433296
34070609
34139465
32580329
32215168
33800548
20926834
20178833
21376232
21508222
21984601
17051205
8209872
11761476
11359079
12205639
27055126
17620489
7783862
15331239
19013262
25217056
29298853
33390888
32580456
10819950
11319241
11456310
11087780
16407551
30155737
24590499
32230811
24262162
16678972
15214505
17157992
16360152
15248294",Elucidating the Neuroprotective Role of PPARs in Parkinson's Disease: A Neoteric and Prospective Target.,"One of the utmost frequently emerging neurodegenerative diseases, Parkinson's disease (PD) must be comprehended through the forfeit of dopamine (DA)-generating nerve cells in the substantia nigra pars compacta (SN-PC). The etiology and pathogenesis underlying the emergence of PD is still obscure. However, expanding corroboration encourages the involvement of genetic and environmental factors in the etiology of PD. The destruction of numerous cellular components, namely oxidative stress, ubiquitin-proteasome system (UPS) dysfunction, autophagy-lysosome system dysfunction, neuroinflammation and programmed cell death, and mitochondrial dysfunction partake in the pathogenesis of PD. Present-day pharmacotherapy can alleviate the manifestations, but no therapy has been demonstrated to cease disease progression. Peroxisome proliferator-activated receptors (PPARs) are ligand-directed transcription factors pertaining to the class of nuclear hormone receptors (NHR), and are implicated in the modulation of mitochondrial operation, inflammation, wound healing, redox equilibrium, and metabolism of blood sugar and lipids. Numerous PPAR agonists have been recognized to safeguard nerve cells from oxidative destruction, inflammation, and programmed cell death in PD and other neurodegenerative diseases. Additionally, various investigations suggest that regular administration of PPAR-activating non-steroidal anti-inflammatory drugs (NSAIDs) (ibuprofen, indomethacin), and leukotriene receptor antagonists (montelukast) were related to the de-escalated evolution of neurodegenerative diseases. The present review elucidates the emerging evidence enlightening the neuroprotective outcomes of PPAR agonists in in vivo and in vitro models experiencing PD. Existing articles up to the present were procured through PubMed, MEDLINE, etc., utilizing specific keywords spotlighted in this review. Furthermore, the authors aim to provide insight into the neuroprotective actions of PPAR agonists by outlining the pharmacological mechanism. As a conclusion, PPAR agonists exhibit neuroprotection through modulating the expression of a group of genes implicated in cellular survival pathways, and may be a propitious target in the therapy of incapacitating neurodegenerative diseases like PD.","['Parkinson’s disease', 'mitochondrial dysfunction', 'neurodegenerative diseases', 'neuroprotection', 'oxidative stress', 'peroxisome proliferator-activated receptors']",International journal of molecular sciences,2021-09-29,"[{'lastname': 'Behl', 'firstname': 'Tapan', 'initials': 'T', 'affiliation': 'Chitkara College of Pharmacy, Chitkara University, Punjab 140401, India.'}, {'lastname': 'Madaan', 'firstname': 'Piyush', 'initials': 'P', 'affiliation': 'Chitkara College of Pharmacy, Chitkara University, Punjab 140401, India.'}, {'lastname': 'Sehgal', 'firstname': 'Aayush', 'initials': 'A', 'affiliation': 'Chitkara College of Pharmacy, Chitkara University, Punjab 140401, India.'}, {'lastname': 'Singh', 'firstname': 'Sukhbir', 'initials': 'S', 'affiliation': 'Chitkara College of Pharmacy, Chitkara University, Punjab 140401, India.'}, {'lastname': 'Sharma', 'firstname': 'Neelam', 'initials': 'N', 'affiliation': 'Chitkara College of Pharmacy, Chitkara University, Punjab 140401, India.'}, {'lastname': 'Bhatia', 'firstname': 'Saurabh', 'initials': 'S', 'affiliation': 'Natural & Medical Sciences Research Centre, University of Nizwa, Birkat Al Mauz 616, Nizwa P.O. Box 33, Oman.\nSchool of Health Science, University of Petroleum and Energy Studies, Dehradun 248007, India.'}, {'lastname': 'Al-Harrasi', 'firstname': 'Ahmed', 'initials': 'A', 'affiliation': 'Natural & Medical Sciences Research Centre, University of Nizwa, Birkat Al Mauz 616, Nizwa P.O. Box 33, Oman.'}, {'lastname': 'Chigurupati', 'firstname': 'Sridevi', 'initials': 'S', 'affiliation': 'Department of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, Qassim University, Buraydah 52571, Saudi Arabia.'}, {'lastname': 'Alrashdi', 'firstname': 'Ibrahim', 'initials': 'I', 'affiliation': 'Translational and Clinical Research Institute, Newcastle University, Newcastle-upon-Tyne NE1 7RU, UK.'}, {'lastname': 'Bungau', 'firstname': 'Simona Gabriela', 'initials': 'SG', 'affiliation': 'Department of Pharmacy, Faculty of Medicine and Pharmacy, University of Oradea, 410028 Oradea, Romania.\nDoctoral School of Biological and Biomedical Sciences, University of Oradea, 410073 Oradea, Romania.'}]",,,,,"10.3390/ijms221810161
10.1097/NHH.0000000000000398
10.1016/j.amjmed.2019.03.001
10.1007/s00702-017-1686-y
10.1007/s00415-016-8384-9
10.1146/annurev-neuro-100720-034518
10.1016/j.ejphar.2015.01.030
10.2174/0929867327666200716113136
10.1007/s12640-020-00323-9
10.4103/1673-5374.297072
10.52711/0974-360X.2021.00688
10.1080/03602532.2021.1903488
10.1186/s12974-018-1179-4
10.3390/ijms22052782
10.3390/ijms21165895
10.4103/2231-4040.90879
10.2174/092986705774462905
10.1016/j.freeradbiomed.2016.06.023
10.1007/s11064-014-1377-0
10.1007/s12035-012-8259-8
10.1038/sj.ijo.0802905
10.1155/2007/29275
10.1016/j.bbalip.2007.01.007
10.1385/CBB:32:1-3:187
10.1016/j.febslet.2007.11.081
10.1016/j.it.2007.09.003
10.1074/jbc.272.6.3406
10.1016/S0006-2952(01)00822-X
10.1016/j.ejphar.2015.11.004
10.1074/jbc.M112.374041
10.1016/j.bbrc.2016.08.043
10.1016/j.dsx.2014.09.015
10.1016/j.arr.2008.01.001
10.1016/j.tem.2006.08.005
10.1042/bse0470069
10.2337/diabetes.54.5.1392
10.1124/mol.106.033845
10.1074/jbc.M208132200
10.1016/j.drudis.2014.05.001
10.1073/pnas.0707189104
10.3233/JAD-2007-11108
10.1074/jbc.M204279200
10.1146/annurev.nutr.21.1.193
10.1038/nm1672
10.1007/s11064-006-9138-3
10.18632/oncotarget.19610
10.1097/CAD.0b013e328011e67d
10.3390/ijms19113464
10.1016/j.beem.2007.09.004
10.1016/j.bbalip.2007.04.016
10.1111/j.1471-4159.2006.04376.x
10.1111/j.1471-4159.2006.03758.x
10.1074/jbc.M700447200
10.1124/jpet.106.113472
10.1016/j.expneurol.2007.02.009
10.1523/JNEUROSCI.3987-04.2004
10.1111/j.1471-4159.2008.05388.x
10.1007/s11064-020-02993-5
10.1155/2008/418765
10.1517/14728220802515400
10.20517/2347-8659.2020.58
10.1016/j.neuron.2019.03.004
10.1038/nrdp.2017.13
10.3389/fphar.2020.00356
10.1155/2016/1720621
10.3390/biology9050103
10.1159/000445751
10.1212/01.wnl.0000341769.50075.bb
10.3233/JPD-191683
10.1002/ana.20017
10.2174/1570159X16666180222165418
10.1186/s40478-020-01062-w
10.3390/jcm8091377
10.3233/JPD-171092
10.1289/ehp.1002839
10.1016/j.taap.2012.11.016
10.1212/WNL.0000000000001362
10.1097/MD.0000000000000869
10.1097/JNN.0000000000000162
10.1016/j.metabol.2008.07.015
10.1212/WNL.45.12.2143
10.1212/WNL.52.6.1214
10.5694/mja17.01074
10.1016/j.arr.2017.12.007
10.2174/1389203717666160217143721
10.1002/1531-8249(200002)47:2<201::AID-ANA10>3.0.CO;2-F
10.1016/0022-510X(81)90032-0
10.1002/ana.10512
10.1038/nrn1788
10.1038/12647
10.1111/j.1471-4159.2004.02485.x
10.1096/fj.03-0338rev
10.1002/humu.21277
10.1073/pnas.0508052102
10.1093/hmg/ddp012
10.1002/jnr.21949
10.1002/humu.20507
10.1371/journal.pone.0051308
10.1038/srep31380
10.1002/acn3.177
10.1093/brain/awt367
10.1016/j.pneurobio.2014.12.001
10.1074/jbc.M112.402123
10.3390/ijms22031413
10.1002/ana.21717
10.3109/10408444.2012.680431
10.1016/0006-291X(86)91210-6
10.1007/s11356-021-14127-7
10.1038/srep36669
10.3390/ijms22095010
10.3389/fnmol.2018.00236
10.1007/s00401-004-0937-9
10.1016/S0002-9440(10)65396-5
10.1155/2020/2360872
10.3390/ijms22094771
10.1073/pnas.0404161101
10.1016/j.niox.2006.07.003
10.1016/j.neurobiolaging.2016.11.008
10.1186/s12883-019-1286-6
10.1016/S1474-4422(09)70062-6
10.1089/ars.2013.5802
10.1016/S0304-3940(00)01701-8
10.2174/156720510792231766
10.1006/exnr.2002.8050
10.1016/S0304-3940(02)00296-3
10.1172/JCI200317575
10.1016/j.neulet.2005.01.024
10.1001/archneurol.2010.198
10.1016/j.nbd.2009.05.023
10.1016/j.nbd.2011.05.022
10.1523/JNEUROSCI.1920-10.2010
10.1155/2014/371256
10.1002/ana.20256
10.1038/33416
10.1016/j.neuron.2014.12.007
10.1097/WCO.0000000000000715
10.1073/pnas.94.14.7531
10.1016/0304-3940(96)12961-X
10.1073/pnas.040556597
10.1006/nbdi.2002.0494
10.1016/j.neulet.2006.12.003
10.1096/fj.04-2751com
10.5607/en.2015.24.2.103
10.1111/j.1471-4159.1990.tb02325.x
10.1002/ana.410320612
10.1016/0022-510X(91)90311-T
10.1002/1531-8249(199910)46:4<598::AID-ANA7>3.0.CO;2-F
10.1016/0024-3205(85)90146-8
10.1074/jbc.M710012200
10.1074/jbc.M113.545749
10.1126/scitranslmed.aaf3634
10.1046/j.1471-4159.2002.00990.x
10.1046/j.1471-4159.2003.02210.x
10.1016/j.bmcl.2010.06.128
10.1016/j.expneurol.2012.08.012
10.4061/2011/689181
10.1186/1742-2094-8-91
10.1016/j.pharep.2018.11.005
10.1155/2017/4089214
10.1111/j.1471-4159.2006.04327.x
10.1016/j.neulet.2007.12.019
10.1016/j.jneuroim.2007.09.029
10.1186/1742-2094-5-4
10.1016/j.neuroscience.2011.07.046
10.1186/s40478-016-0346-z
10.1016/j.bbrc.2005.11.177
10.1016/j.jns.2006.11.020
10.1016/j.mam.2020.100871
10.2174/1567202611666140318114037
10.1007/s12017-020-08629-9
10.1016/j.brainres.2006.12.011
10.1016/j.pnpbp.2014.02.009
10.1016/j.brainres.2018.09.036
10.1016/S0304-3940(00)01294-5
10.1007/s10787-020-00764-w
10.1007/s11481-020-09925-8
10.3390/pathogens10030268
10.1016/S1567-5769(02)00078-4
10.1016/j.neuropharm.2020.108378
10.1097/WNR.0000000000000740
10.1016/j.neulet.2018.05.052
10.1016/j.taap.2018.09.012
10.1016/j.cell.2006.09.024
10.1038/ncpneuro0586
10.1073/pnas.0503839103
10.1016/j.expneurol.2007.02.008
10.3390/ijms22115606
10.1016/j.clnu.2021.05.011
10.3390/ijms21124424
10.1155/2020/1452696
10.3390/ijms22073487
10.1126/scitranslmed.3001059
10.1016/j.neulet.2010.02.034
10.1016/j.cell.2011.02.010
10.1523/JNEUROSCI.4441-10.2011
10.1007/s00018-011-0850-z
10.1038/nature05292
10.1093/oxfordjournals.aje.a116960
10.1002/ana.10028
10.1159/000054770
10.1002/ana.10277
10.1001/archneur.64.7.990
10.1212/WNL.45.6.1041
10.1016/j.tins.2004.06.008
10.1016/j.bbapap.2008.09.026
10.1212/WNL.0000000000000879
10.1212/WNL.0000000000004898
10.3389/fnins.2020.602697
10.3390/nu12061860
10.1001/jama.283.20.2674
10.1523/JNEUROSCI.21-10-j0001.2001
10.1002/ana.1052
10.1212/WNL.55.9.1350
10.1523/JNEUROSCI.3008-05.2006
10.1007/s00415-018-9032-3
10.1002/mds.25863
10.3390/ijms21072316
10.1016/S1353-8020(13)70030-0
10.1016/j.neuroscience.2006.03.027
10.1023/B:MEBR.0000027416.13070.c3
10.1016/j.neuroscience.2006.10.042
10.1016/j.expneurol.2005.11.004
10.1002/jnr.20162",<Element 'PubmedArticle' at 0x7f05dc71ae00>
135,34555366,Effect of sex and gonadectomy on brain MPTP toxicity and response to dutasteride treatment in mice.,"The main neuropathological feature of Parkinson's disease (PD) is degeneration of dopamine (DA) neurons in the substantia nigra (SN); PD prevalence is higher in men, suggesting a role of sex hormones in neuroprotection. This study sought the effects of sex hormones in the brain in a mouse model of PD and modulation of steroid metabolism/synthesis with the 5α-reductase inhibitor dutasteride shown to protect 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) male mice. Male and female mice were gonadectomized (GDX) or SHAM operated. They were treated with vehicle or dutasteride (5 mg/kg) for 10 days and administered a low dose of MPTP (5.5 mg/kg) or saline on the 5th day to model early PD; brains were collected thereafter. Striatal measures of the active metabolite 1-methyl-4-phenylpyridinium (MPP","['Dutasteride', 'Gonadectomy', 'MPTP', ""Parkinson's disease"", 'Sex']",Neuropharmacology,2021-09-24,"[{'lastname': 'Isenbrandt', 'firstname': 'Amandine', 'initials': 'A', 'affiliation': 'Centre de Recherche du CHU de Québec, Axe Neurosciences, 2705, Boulevard Laurier, Québec, (Québec), G1V4G2, Canada; Faculté de Pharmacie, Pavillon Ferdinand-Vandry, 1050, avenue de la Médecine, Université Laval, Québec, (Québec) G1V 0A6, Canada.'}, {'lastname': 'Morissette', 'firstname': 'Marc', 'initials': 'M', 'affiliation': 'Centre de Recherche du CHU de Québec, Axe Neurosciences, 2705, Boulevard Laurier, Québec, (Québec), G1V4G2, Canada.'}, {'lastname': 'Bourque', 'firstname': 'Mélanie', 'initials': 'M', 'affiliation': 'Centre de Recherche du CHU de Québec, Axe Neurosciences, 2705, Boulevard Laurier, Québec, (Québec), G1V4G2, Canada.'}, {'lastname': 'Lamontagne-Proulx', 'firstname': 'Jérôme', 'initials': 'J', 'affiliation': 'Centre de Recherche du CHU de Québec, Axe Neurosciences, 2705, Boulevard Laurier, Québec, (Québec), G1V4G2, Canada; Faculté de Pharmacie, Pavillon Ferdinand-Vandry, 1050, avenue de la Médecine, Université Laval, Québec, (Québec) G1V 0A6, Canada.'}, {'lastname': 'Coulombe', 'firstname': 'Katherine', 'initials': 'K', 'affiliation': 'Centre de Recherche du CHU de Québec, Axe Neurosciences, 2705, Boulevard Laurier, Québec, (Québec), G1V4G2, Canada.'}, {'lastname': 'Soulet', 'firstname': 'Denis', 'initials': 'D', 'affiliation': 'Centre de Recherche du CHU de Québec, Axe Neurosciences, 2705, Boulevard Laurier, Québec, (Québec), G1V4G2, Canada; Faculté de Pharmacie, Pavillon Ferdinand-Vandry, 1050, avenue de la Médecine, Université Laval, Québec, (Québec) G1V 0A6, Canada.'}, {'lastname': 'Di Paolo', 'firstname': 'Thérèse', 'initials': 'T', 'affiliation': 'Centre de Recherche du CHU de Québec, Axe Neurosciences, 2705, Boulevard Laurier, Québec, (Québec), G1V4G2, Canada; Faculté de Pharmacie, Pavillon Ferdinand-Vandry, 1050, avenue de la Médecine, Université Laval, Québec, (Québec) G1V 0A6, Canada. Electronic address: therese.dipaolo@crchul.ulaval.ca.'}]",,,,Copyright © 2021. Published by Elsevier Ltd.,10.1016/j.neuropharm.2021.108784,<Element 'PubmedArticle' at 0x7f05df90d040>
136,34543901,Prenatal exposure to paraquat and nanoscaled TiO,"Nanopesticides are innovative pesticides involving engineered nanomaterials in their formulation to increase the efficiency of plant protection products, while mitigating their environmental impact. Despite the predicted growth of the nanopesticide use, no data is available on their inhalation toxicity and the potential cocktail effects between their components. In particular, the neurodevelopmental toxicity caused by prenatal exposures might have long lasting consequences. In the present study, we repeatedly exposed gestating mice in a whole-body exposure chamber to three aerosols, involving the paraquat herbicide, nanoscaled titanium dioxide particles (nTiO","['Aerosol toxicology', 'Nano-TiO2', 'Nanopesticides', 'Neurodevelopment', 'Paraquat']",Chemosphere,2021-09-21,"[{'lastname': 'Hamdaoui', 'firstname': 'Quentin', 'initials': 'Q', 'affiliation': ""IGFL, Functional Genomics of Thyroid Hormone Signaling Group, Lyon, France; Laboratoire National de Métrologie et D'essais (LNE), Paris, France.""}, {'lastname': 'Zekri', 'firstname': 'Yanis', 'initials': 'Y', 'affiliation': 'IGFL, Functional Genomics of Thyroid Hormone Signaling Group, Lyon, France.'}, {'lastname': 'Richard', 'firstname': 'Sabine', 'initials': 'S', 'affiliation': 'IGFL, Functional Genomics of Thyroid Hormone Signaling Group, Lyon, France.'}, {'lastname': 'Aubert', 'firstname': 'Denise', 'initials': 'D', 'affiliation': 'IGFL, Functional Genomics of Thyroid Hormone Signaling Group, Lyon, France.'}, {'lastname': 'Guyot', 'firstname': 'Romain', 'initials': 'R', 'affiliation': 'IGFL, Functional Genomics of Thyroid Hormone Signaling Group, Lyon, France.'}, {'lastname': 'Markossian', 'firstname': 'Suzy', 'initials': 'S', 'affiliation': 'IGFL, Functional Genomics of Thyroid Hormone Signaling Group, Lyon, France.'}, {'lastname': 'Gauthier', 'firstname': 'Karine', 'initials': 'K', 'affiliation': 'IGFL, Functional Genomics of Thyroid Hormone Signaling Group, Lyon, France.'}, {'lastname': 'Gaie-Levrel', 'firstname': 'François', 'initials': 'F', 'affiliation': ""Laboratoire National de Métrologie et D'essais (LNE), Paris, France.""}, {'lastname': 'Bencsik', 'firstname': 'Anna', 'initials': 'A', 'affiliation': 'Université Claude Bernard Lyon 1, ANSES, Laboratoire de Lyon, France.'}, {'lastname': 'Flamant', 'firstname': 'Frédéric', 'initials': 'F', 'affiliation': 'IGFL, Functional Genomics of Thyroid Hormone Signaling Group, Lyon, France. Electronic address: Frederic.flamant@ens-lyon.fr.'}]",,,,Copyright © 2021 The Authors. Published by Elsevier Ltd.. All rights reserved.,10.1016/j.chemosphere.2021.132253,<Element 'PubmedArticle' at 0x7f05df91b860>
137,"34529881
29119534
30443713
28147245
31421410
28058465
31982938
25169902
31001119
27235347
30966861
28249679
29733881
29212498
29667931
29516284
30236277
31876243
30523761
26984939
30374682
29102406
27127546
30296700
31039397
28894507
29652517
31669235
26306439
29433734
29351514
30541633
29929978
31815636
25598354
26862037
22497526
30818124
26767952
29943092
25919885
23095236
30551030
31356776",Activation of angiotensin-converting enzyme 2/angiotensin (1-7)/mas receptor axis triggers autophagy and suppresses microglia proinflammatory polarization via forkhead box class O1 signaling.,"Brain renin-angiotensin (Ang) system (RAS) is implicated in neuroinflammation, a major characteristic of aging process. Angiotensin (Ang) II, produced by angiotensin-converting enzyme (ACE), activates immune system via angiotensin type 1 receptor (AT1), whereas Ang(1-7), generated by ACE2, binds with Mas receptor (MasR) to restrain excessive inflammatory response. Therefore, the present study aims to explore the relationship between RAS and neuroinflammation. We found that repeated lipopolysaccharide (LPS) treatment shifted the balance between ACE/Ang II/AT1 and ACE2/Ang(1-7)/MasR axis to the deleterious side and treatment with either MasR agonist, AVE0991 (AVE) or ACE2 activator, diminazene aceturate, exhibited strong neuroprotective actions. Mechanically, activation of ACE2/Ang(1-7)/MasR axis triggered the Forkhead box class O1 (FOXO1)-autophagy pathway and induced superoxide dismutase (SOD) and catalase (CAT), the FOXO1-targeted antioxidant enzymes. Meanwhile, knockdown of MasR or FOXO1 in BV2 cells, or using the selective FOXO1 inhibitor, AS1842856, in animals, suppressed FOXO1 translocation and compromised the autophagic process induced by MasR activation. We further used chloroquine (CQ) to block autophagy and showed that suppressing either FOXO1 or autophagy abrogated the anti-inflammatory action of AVE. Likewise, Ang(1-7) also induced FOXO1 signaling and autophagic flux following LPS treatment in BV2 cells. Cotreatment with AS1842856 or CQ all led to autophagic inhibition and thereby abolished Ang(1-7)-induced remission on NLRP3 inflammasome activation caused by LPS exposure, shifting the microglial polarization from M1 to M2 phenotype. Collectively, these results firstly illustrated the mechanism of ACE2/Ang(1-7)/MasR axis in neuroinflammation, strongly indicating the involvement of FOXO1-mediated autophagy in the neuroimmune-modulating effects triggered by MasR activation.","['FOXO1', 'autophagy', 'neuroinflammation', 'renin-angiotensin system']",Aging cell,2021-09-17,"[{'lastname': 'Dang', 'firstname': 'Ruili', 'initials': 'R', 'affiliation': ""Institute of Clinical Pharmacy and Pharmacology, Jining First People's Hospital, Jining Medical University, Jining, China.""}, {'lastname': 'Yang', 'firstname': 'Mengqi', 'initials': 'M', 'affiliation': ""Institute of Clinical Pharmacy and Pharmacology, Jining First People's Hospital, Jining Medical University, Jining, China.""}, {'lastname': 'Cui', 'firstname': 'Changmeng', 'initials': 'C', 'affiliation': 'Department of Neurosurgery, Affiliated Hospital of Jining Medical University, Jining, China.'}, {'lastname': 'Wang', 'firstname': 'Changshui', 'initials': 'C', 'affiliation': 'Department of Neurosurgery, Affiliated Hospital of Jining Medical University, Jining, China.'}, {'lastname': 'Zhang', 'firstname': 'Wenyuan', 'initials': 'W', 'affiliation': 'Department of Pharmacy, Zhongshan Affiliated Hospital of Zhongshan University, Zhongshan, China.'}, {'lastname': 'Geng', 'firstname': 'Chunmei', 'initials': 'C', 'affiliation': ""Institute of Clinical Pharmacy and Pharmacology, Jining First People's Hospital, Jining Medical University, Jining, China.""}, {'lastname': 'Han', 'firstname': 'Wenxiu', 'initials': 'W', 'affiliation': ""Institute of Clinical Pharmacy and Pharmacology, Jining First People's Hospital, Jining Medical University, Jining, China.""}, {'lastname': 'Jiang', 'firstname': 'Pei', 'initials': 'P', 'affiliation': ""Institute of Clinical Pharmacy and Pharmacology, Jining First People's Hospital, Jining Medical University, Jining, China.""}]",,,,© 2021 The Authors. Aging Cell published by Anatomical Society and John Wiley & Sons Ltd.,"10.1111/acel.13480
10.1007/s12035-017-0812-z
10.1007/s11064-018-2679-4
10.1016/j.neuroscience.2017.01.027
10.1016/j.redox.2019.101295
10.1007/s00394-016-1373-z
10.1007/s00401-019-02098-6
10.1186/s13041-014-0056-z
10.3389/fphar.2019.00318
10.1016/j.jneuroim.2016.04.006
10.1080/15548627.2019.1596481
10.1016/j.molimm.2017.02.013
10.1016/j.neubiorev.2018.05.005
10.1186/s12974-017-1013-4
10.18632/aging.101419
10.1007/s12035-018-0966-3
10.1016/j.neuron.2018.09.011
10.1080/15548627.2019.1703354
10.1080/15548627.2018.1556946
10.1161/CIRCULATIONAHA.115.017443
10.1007/s00109-018-1704-z
10.1016/j.tig.2017.10.002
10.1155/2016/2183026
10.1016/j.redox.2018.09.022
10.1016/j.phrs.2019.04.029
10.1155/2017/3494289
10.1165/rcmb.2017-0284OC
10.1016/j.bcp.2019.113681
10.1007/s13311-015-0385-3
10.1016/bs.ctdb.2017.10.002
10.1152/physrev.00023.2016
10.1186/s12974-018-1385-0
10.1074/jbc.RA118.001880
10.1186/s12974-019-1668-0
10.1007/s12035-014-9070-5
10.1186/s12974-016-0489-7
10.1021/pr3001755
10.1016/j.redox.2019.101148
10.1016/j.neuropharm.2015.12.026
10.1007/s00213-018-4949-x
10.1080/15548627.2015.1023981
10.1111/cns.12015
10.1016/j.intimp.2018.12.012
10.1016/j.abb.2019.07.026",<Element 'PubmedArticle' at 0x7f05df9278b0>
138,"34515549
25385447
11935076
28082670
26705676
21439035
24251393
26347470
30250261
30523362
29377008
22048062
27327500
30643288
27793855
31645758
26311408
27821575
30505270
31557051
30692517
12468796
11875310
11104736
30564547
24757379
23381040
28617071
32663219
17126954
28476949
17406392
16319316
21549843
16215960
10467296
25126069
8126267
20851191
24151012
29976930
11906227
7915604
24319654
23748408
28854435
26770594
27641495
31358646
28960176
15483113
27301939
19268311
26271106
29581224
25471394
18173961
22506129
23459792
27447807
30678702
31324021
24623839
23792680
28039950
25843438
24926076
22958818
8532116
2905385
31662427
31212931
28069927",A functional cerebral endothelium is necessary to protect against cognitive decline.,"A vascular insult occurring early in disease onset may initiate cognitive decline leading to dementia, while pharmacological and lifestyle interventions can prevent this progression. Mice with a selective, tamoxifen-inducible deletion of NF-κB essential modulator (Nemo) in brain endothelial cells were studied as a model of vascular cognitive impairment. Groups included Nemo","['Cerebral endothelium', 'NF-κB essential modulator', 'physical exercise', 'simvastatin', 'vascular cognitive impairment']",Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism,2021-09-14,"[{'lastname': 'Trigiani', 'firstname': 'Lianne J', 'initials': 'LJ', 'affiliation': 'Laboratory of Cerebrovascular Research, Montreal Neurological Institute, McGill University, Montréal, Canada.'}, {'lastname': 'Bourourou', 'firstname': 'Miled', 'initials': 'M', 'affiliation': 'Laboratory of Cerebrovascular Research, Montreal Neurological Institute, McGill University, Montréal, Canada.'}, {'lastname': 'Lacalle-Aurioles', 'firstname': 'María', 'initials': 'M', 'affiliation': 'Laboratory of Cerebrovascular Research, Montreal Neurological Institute, McGill University, Montréal, Canada.'}, {'lastname': 'Lecrux', 'firstname': 'Clotilde', 'initials': 'C', 'affiliation': 'Laboratory of Cerebrovascular Research, Montreal Neurological Institute, McGill University, Montréal, Canada.'}, {'lastname': 'Hynes', 'firstname': 'Amy', 'initials': 'A', 'affiliation': 'Laboratory of Cerebrovascular Research, Montreal Neurological Institute, McGill University, Montréal, Canada.'}, {'lastname': 'Spring', 'firstname': 'Shoshana', 'initials': 'S', 'affiliation': 'Mouse Imaging Centre (MICe), Hospital for Sick Children, Toronto, Canada.'}, {'lastname': 'Fernandes', 'firstname': 'Darren J', 'initials': 'DJ', 'affiliation': 'Mouse Imaging Centre (MICe), Hospital for Sick Children, Toronto, Canada.'}, {'lastname': 'Sled', 'firstname': 'John G', 'initials': 'JG', 'affiliation': 'Mouse Imaging Centre (MICe), Hospital for Sick Children, Toronto, Canada.'}, {'lastname': 'Lesage', 'firstname': 'Frédéric', 'initials': 'F', 'affiliation': 'Biomedical Engineering Institute, École Polytechnique de Montréal, Montréal, Canada.'}, {'lastname': 'Schwaninger', 'firstname': 'Markus', 'initials': 'M', 'affiliation': 'Institute for Experimental and Clinical Pharmacology and Toxicology, University of Lübeck, Lübeck, Germany.'}, {'lastname': 'Hamel', 'firstname': 'Edith', 'initials': 'E', 'affiliation': 'Laboratory of Cerebrovascular Research, Montreal Neurological Institute, McGill University, Montréal, Canada.'}]",,,,,10.1177/0271678X211045438,<Element 'PubmedArticle' at 0x7f05df7cdbd0>
139,34508923,Potentiation of microglial endocannabinoid signaling alleviates neuroinflammation in Alzheimer's disease.,Alzheimer's disease (AD) isaprogressive neurodegenerative disorder characterized by chronic inflammation due to the presence of neurotoxic Aβ and tau proteins. Increased microglial activation and inflated immune response are the other factors to be considered in AD pathology. Microglial cells own biochemical machinery that synthesizes and release endocannabinoids. The exploitation of therapeutic actions of endocannabinoid system has newly emerged in the field of Alzheimer's disease. The activation of cannabinoid receptors/ cannabinoid system modulates inflammatory responses. This review assesses the association between the microglial endocannabinoid system and neuroinflammation in AD. The data supporting the anti-inflammatory role of pharmacological agents modulating cannabinoid system are also reviewed.,"[""Alzheimer's disease"", 'CB(1)R', 'CB(2)R', 'Endocannabinoid', 'Microglia', 'Neuroinflammation']",Neuropeptides,2021-09-12,"[{'lastname': 'Rapaka', 'firstname': 'Deepthi', 'initials': 'D', 'affiliation': 'A.U. College of Pharmaceutical Sciences, Andhra University, Visakhapatnam 530003, India. Electronic address: deepthirapaka7@gmail.com.'}, {'lastname': 'Bitra', 'firstname': 'Veera Raghavulu', 'initials': 'VR', 'affiliation': 'School of Pharmacy, University of Botswana, P/Bag-0022, Gaborone, Botswana.'}, {'lastname': 'Challa', 'firstname': 'Siva Reddy', 'initials': 'SR', 'affiliation': 'Department of Cancer Biology and Pharmacology, University of Illinois College of Medicine, Peoria, IL 61614, USA.'}, {'lastname': 'Adiukwu', 'firstname': 'Paul C', 'initials': 'PC', 'affiliation': 'School of Pharmacy, University of Botswana, P/Bag-0022, Gaborone, Botswana.'}]",,,,Copyright © 2021 Elsevier Ltd. All rights reserved.,10.1016/j.npep.2021.102196,<Element 'PubmedArticle' at 0x7f05df7f9630>
140,34505250,Neurotoxicity and neuroinflammatory effects of bisphenol A in male rats: the neuroprotective role of grape seed proanthocyanidins.,"Exposure to bisphenol A (BPA) contributes to neurological disorders, but the underlying mechanisms are still not completely understood. We studied the neurotoxic effect of BPA and how it promotes inflammation and alteration in the neurotransmission synthesis, release, and transmission. This study was also designed to investigate the neuroprotective effect of grape seed proanthocyanidins (GSPE) against BPA-induced neurotoxicity in rats. Rats were equally divided into 4 groups with 7 rats in each: control group, BPA group, GSPE + BPA group, and GSPE group. Rats were orally treated with their respective doses (50 mg BPA/kg BW and/or 200 mg GSPE/kg BW) daily for 70 days. BPA elicits significant elevation in malondialdehyde (MDA) and nitric oxide (NO) associated with a significant reduction in glutathione (GSH), total thiols, glutathione peroxidase (GPx), superoxide dismutase (SOD), and glutathione-S-transferase (GST). BPA exposure results in increased dopamine and serotonin levels, elevation in acetylcholinesterase (AChE) activity, and reduction in Na/K-ATPase and total ATPase activities in the brain. Also, BPA induces upregulation in the gene expression of the inflammatory markers, tumor necrosis factor-α (TNF-α) and cyclooxygenase-2 (COX-2), and in the tumor suppressor and pro-oxidant p53 protein. The pretreatment with GSPE attenuates or ameliorate all the oxidative and neurotoxic parameters induced by BPA. Our results suggest that GSPE has a promising role in modulating BPA-induced neuroinflammation and neurotoxicity and its antioxidant and free radical scavenging activities may in part be responsible for such effects.","['Bisphenol A', 'COX-2', 'Grape seed proanthocyanidins', 'Na/K-ATPase', 'Oxidative stress', 'TNF-α']",Environmental science and pollution research international,2021-09-11,"[{'lastname': 'Abdou', 'firstname': 'Heba M', 'initials': 'HM', 'affiliation': 'Department of Zoology, Faculty of Science, Alexandria University, Alexandria, 21561, Egypt.'}, {'lastname': 'Abd Elkader', 'firstname': 'Heba-Tallah Abd Elrahim', 'initials': 'HAE', 'affiliation': 'Zoology, Biological and Geological Sciences Department, Faculty of Education, Alexandria University, Alexandria, Egypt.'}, {'lastname': 'El-Gendy', 'firstname': 'Amel H', 'initials': 'AH', 'affiliation': 'Department of Zoology, Faculty of Science, Alexandria University, Alexandria, 21561, Egypt.'}, {'lastname': 'Eweda', 'firstname': 'Saber Mohamed', 'initials': 'SM', 'affiliation': 'Department of Biochemistry, Faculty of Science, Alexandria University, Alexandria, 21561, Egypt. seweda@taibahu.edu.sa.\nMedical Laboratories Technology Department, College of Applied Medical Sciences, Taibah University, Madinah, Kingdom of Saudi Arabia. seweda@taibahu.edu.sa.'}]",,,,"© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.",10.1007/s11356-021-16311-1,<Element 'PubmedArticle' at 0x7f05df804b80>
141,"34464488
17914061
24631008
22898369
19535598
15293278
16585053
18247124
24156898
13880724
16830939
17556771
32554630
26447583
11222864
19472057
32102916
11209067
32687963
19837255
21135382
27090351
15846771
24836381
22633805
26279231
30333162
32322820
33822880
29058572
29471387
17517438
24715492
30368974
30239074
20874519
11102668
23274186
871500
20036831
24367482
26850792
22713908
24990428
30094159
32954330
29342238
16552102
9136207
9282479
33059048
33836267
30215685
28714584
29672678
32044438
23840428
19462243",Cannabis use impacts pre-stimulus neural activity in the visual cortices of people with HIV.,"People with HIV (PWH) use cannabis at a higher rate than the general population, but the influence on neural activity is not well characterized. Cannabis use among PWH may have a beneficial effect, as neuroinflammation is known to be a critical problem in PWH and cannabis use has been associated with a reduction in proinflammatory markers. Thus, it is important to understand the net impact of cannabis use on brain and cognitive function in PWH. In this study, we collected magnetoencephalographic (MEG) brain imaging data on 81 participants split across four demographically matched groups (i.e., PWH using cannabis, controls using cannabis, non-using PWH, and non-using controls). Participants completed a visuospatial processing task during MEG. Time-frequency resolved voxel time series were extracted to identify the dynamics of oscillatory and pre-stimulus baseline neural activity. Our results indicated strong theta (4-8 Hz), alpha (10-16 Hz), and gamma (62-72 Hz) visual oscillations in parietal-occipital brain regions across all participants. PWH exhibited significant behavioral deficits in visuospatial processing, as well as reduced theta oscillations and elevated pre-stimulus gamma activity in visual cortices, all of which replicate prior work. Strikingly, chronic cannabis use was associated with a significant reduction in pre-stimulus gamma activity in the visual cortices, such that PWH no longer statistically differed from controls. These results provide initial evidence that cannabis use may normalize some neural aberrations in PWH. This study fills an important gap in understanding the impact of cannabis use on brain and cognitive function in PWH.","['MEG', 'gamma', 'magnetoencephalography', 'neural oscillations', 'neurocognitive decline', 'visuospatial processing']",Human brain mapping,2021-09-01,"[{'lastname': 'Christopher-Hayes', 'firstname': 'Nicholas J', 'initials': 'NJ', 'affiliation': 'Institute for Human Neuroscience, Boys Town National Research Hospital, Boys Town, Nebraska, USA.'}, {'lastname': 'Lew', 'firstname': 'Brandon J', 'initials': 'BJ', 'affiliation': 'Institute for Human Neuroscience, Boys Town National Research Hospital, Boys Town, Nebraska, USA.\nCollege of Medicine, University of Nebraska Medical Center (UNMC), Omaha, Nebraska, USA.'}, {'lastname': 'Wiesman', 'firstname': 'Alex I', 'initials': 'AI', 'affiliation': 'Institute for Human Neuroscience, Boys Town National Research Hospital, Boys Town, Nebraska, USA.\nCollege of Medicine, University of Nebraska Medical Center (UNMC), Omaha, Nebraska, USA.\nMontreal Neurological Institute, McGill University, Montréal, Quebec, Canada.'}, {'lastname': 'Schantell', 'firstname': 'Mikki', 'initials': 'M', 'affiliation': 'Institute for Human Neuroscience, Boys Town National Research Hospital, Boys Town, Nebraska, USA.\nCollege of Medicine, University of Nebraska Medical Center (UNMC), Omaha, Nebraska, USA.'}, {'lastname': ""O'Neill"", 'firstname': 'Jennifer', 'initials': 'J', 'affiliation': 'Department of Internal Medicine, Division of Infectious Diseases, UNMC, Omaha, Nebraska, USA.'}, {'lastname': 'May', 'firstname': 'Pamela E', 'initials': 'PE', 'affiliation': 'Department of Neurological Sciences, UNMC, Omaha, Nebraska, USA.'}, {'lastname': 'Swindells', 'firstname': 'Susan', 'initials': 'S', 'affiliation': 'Department of Internal Medicine, Division of Infectious Diseases, UNMC, Omaha, Nebraska, USA.'}, {'lastname': 'Wilson', 'firstname': 'Tony W', 'initials': 'TW', 'affiliation': 'Institute for Human Neuroscience, Boys Town National Research Hospital, Boys Town, Nebraska, USA.\nCollege of Medicine, University of Nebraska Medical Center (UNMC), Omaha, Nebraska, USA.'}]",,,,© 2021 The Authors. Human Brain Mapping published by Wiley Periodicals LLC.,"10.1002/hbm.25634
10.1212/01.WNL.0000287431.88658.8b
10.1016/j.clinph.2014.01.024
10.1016/j.clinph.2012.06.002
10.1523/JNEUROSCI.0113-09.2009
10.1002/ana.20190
10.1093/brain/awl064
10.1007/s11481-007-9092-0
10.1016/S1473-3099(13)70269-X
10.1109/TBME.2006.873752
10.1093/cercor/bhm073
10.1212/NXI.0000000000000809
10.1214/088342304000000396
10.1016/j.neuron.2015.09.034
10.1126/science.1055465
10.1007/s11065-009-9095-0
10.1212/NXI.0000000000000690
10.1073/pnas.98.2.694
10.1016/j.pnpbp.2020.110040
10.1212/WNL.0b013e318200d727
10.1016/j.neuroimage.2016.04.032
10.1002/hbm.20102
10.1016/j.tins.2014.04.001
10.1016/j.cub.2012.03.054
10.1016/j.cub.2015.07.048
10.1212/WNL.0000000000006504
10.1093/braincomms/fcaa015
10.1093/cercor/bhab045
10.1080/08897077.2017.1391925
10.1093/cid/cix1116
10.1016/j.jneumeth.2007.03.024
10.1055/s-0034-1372346
10.30770/2572-1852-104.4.32
10.1002/hbm.24405
10.1111/adb.12678
10.1089/aid.2010.0218
10.1016/S0167-8760(00)00171-9
10.1016/j.neuroimage.2012.12.038
10.1371/journal.pone.0081355
10.25080/Majora-92bf1922-011
10.1016/B978-0-12-800213-1.00080-8
10.1016/j.biopsych.2015.12.011
10.1038/npp.2012.65
10.1038/npp.2014.166
10.1016/j.nicl.2018.07.009
10.1093/braincomms/fcaa080
10.1093/cercor/bhx349
10.1088/0031-9155/51/7/008
10.1007/BF02534144
10.1109/10.623056
10.1016/j.neuroimage.2020.117448
10.1016/j.neuroimage.2021.118024
10.1093/cercor/bhy220
10.1002/hbm.23720
10.1093/brain/awy097
10.1016/j.neuroimage.2020.116610
10.1371/journal.pone.0066241
10.1007/s11065-009-9102-5",<Element 'PubmedArticle' at 0x7f05df759e50>
142,"34445575
24751956
9523521
34211157
21677747
32103191
26255561
21921917
17361131
24062746
30027368
33253681
31848474
31923399
21763243
32888429
26264347
18152861
13260656
13182220
30288077
23301732
33071933
29769726
26919462
29710331
29788069
29785965
30309751
28170377
10202534
27878439
33933908
16143121
23027881
22552994
17894769
23980911
29767705
33983615
32093531
31807751
24490959
33633540
31546668
31980808
21351207
23935379
28586827
18587394
21102463
33174662
26237551
28352666
19139628
20602997
18849966
24089213
11385577
11425413
27090875
20711177
31701892
21833088
31063848
20584104
31079293
31123415
30225764
25184418
7637860
32152479
27112528
26635804
27435372
20722067
22080974
22031325
23814609
31498131
30576008
28843021
31041582
26367776
27176462
27352007
27346372
28893994
28893978
33077601
27652609
27912057
23939304
31316206
24753353
31254094
31255487
28706993
29979986
33093662
26030851
20660719
27158906
30120222
32640190
28648659
26805875
31196984
31268562
25575570
31235952
28138136
26488817
28262351
28096541
32848245
33220232
32160524
18035408
11731781
18983967
23642363
22761314
23995685
24277810
26644564
26005811
27476966
26573335
32527923
28445465
28504681
33333020
30911172
26863197
19575677
29802404
31383635
27980341
30737492
21151107
31924806
24936470
22082986
27869805
33431859
32249832
18808327
25428410
21480343
27676432
30948332
19329995
32103122
29520026
31352002
31754092
25307862
29467166
25123931
26395928
33087876
25007816
31591580
32401820
29658944",The Gut-Brain Axis in Inflammatory Bowel Disease-Current and Future Perspectives.,"The gut-brain axis is a bidirectional communication system driven by neural, hormonal, metabolic, immunological, and microbial signals. Signaling events from the gut can modulate brain function and recent evidence suggests that the gut-brain axis may play a pivotal role in linking gastrointestinal and neurological diseases. Accordingly, accumulating evidence has suggested a link between inflammatory bowel diseases (IBDs) and neurodegenerative, as well as neuroinflammatory diseases. In this context, clinical, epidemiological and experimental data have demonstrated that IBD predisposes a person to pathologies of the central nervous system (CNS). Likewise, a number of neurological disorders are associated with changes in the intestinal environment, which are indicative for disease-mediated gut-brain inter-organ communication. Although this axis was identified more than 20 years ago, the sequence of events and underlying molecular mechanisms are poorly defined. The emergence of precision medicine has uncovered the need to take into account non-intestinal symptoms in the context of IBD that could offer the opportunity to tailor therapies to individual patients. The aim of this review is to highlight recent findings supporting the clinical and biological link between the gut and brain, as well as its clinical significance for IBD as well as neurodegeneration and neuroinflammation. Finally, we focus on novel human-specific preclinical models that will help uncover disease mechanisms to better understand and modulate the function of this complex system.","['IBD', 'MS', 'PD', 'ex vivo organ models', 'gut-brain axis']",International journal of molecular sciences,2021-08-28,"[{'lastname': 'Günther', 'firstname': 'Claudia', 'initials': 'C', 'affiliation': 'Department of Medicine 1, Friedrich-Alexander-University Erlangen-Nürnberg, 91054 Erlangen, Germany.'}, {'lastname': 'Rothhammer', 'firstname': 'Veit', 'initials': 'V', 'affiliation': 'Department of Neurology, Friedrich-Alexander-University Erlangen-Nürnberg, 91054 Erlangen, Germany.'}, {'lastname': 'Karow', 'firstname': 'Marisa', 'initials': 'M', 'affiliation': 'Institute of Biochemistry, Friedrich-Alexander-University Erlangen-Nürnberg, 91054 Erlangen, Germany.'}, {'lastname': 'Neurath', 'firstname': 'Markus', 'initials': 'M', 'affiliation': 'Department of Medicine 1, Friedrich-Alexander-University Erlangen-Nürnberg, 91054 Erlangen, Germany.'}, {'lastname': 'Winner', 'firstname': 'Beate', 'initials': 'B', 'affiliation': 'Department of Stem Cell Biology, Friedrich-Alexander-University Erlangen-Nürnberg, 91054 Erlangen, Germany.'}]",,,,,"10.3390/ijms22168870
10.1038/nri3661
10.1007/s002689900401
10.1038/s41575-021-00473-x
10.1038/nature10209
10.1038/s41586-020-2025-2
10.1053/j.gastro.2015.08.001
10.1038/nature10400
10.1038/nature05698
10.3389/fimmu.2013.00280
10.1007/s12328-018-0886-9
10.1053/j.gastro.2020.09.056
10.1038/s41575-019-0248-1
10.1016/j.cell.2019.12.016
10.1053/j.gastro.2011.07.002
10.1016/j.cell.2020.08.003
10.1053/j.gastro.2015.05.063
10.1136/bmj.2.4947.1041
10.1136/bmj.2.4884.375
10.2147/JIR.S174982
10.1056/NEJMcp1113996
10.3389/fneur.2020.01041
10.1038/s41586-018-0119-x
10.1097/MIB.0000000000000735
10.1001/jamaneurol.2018.0605
10.1093/ibd/izy190
10.1136/gutjnl-2017-315666
10.1016/j.dld.2018.09.017
10.1038/nm.4269
10.1146/annurev.neuro.22.1.123
10.1007/s00415-016-8340-8
10.1016/j.msard.2021.102942
10.1053/j.gastro.2005.06.022
10.1177/1352458512461393
10.1002/ibd.23011
10.1111/j.1445-5994.2007.01452.x
10.2174/13894501113146660206
10.1093/ecco-jcc/jjy060
10.1007/s40265-021-01528-8
10.1080/14712598.2020.1732919
10.1093/ibd/izz174
10.1586/1744666X.2014.885381
10.3389/fnins.2021.639140
10.3390/cells8101124
10.1038/s41582-019-0301-2
10.1002/ibd.21651
10.2147/TACG.S33966
10.1001/jamaneurol.2017.0469
10.1038/ng.175
10.1038/ng.717
10.1111/cpr.12958
10.1038/ni.3233
10.1172/jci.insight.91917
10.4161/auto.5.2.7560
10.1016/j.cell.2010.05.009
10.1038/nature07416
10.1038/nature12599
10.1038/35079114
10.1016/S0140-6736(00)05063-7
10.1111/jnc.13593
10.1038/ng.642
10.1016/S1474-4422(19)30320-5
10.1016/j.bbi.2019.05.007
10.1111/j.1471-4159.2010.06879.x
10.1007/s12017-019-08539-5
10.2147/JIR.S196552
10.1007/s12264-018-0288-5
10.1371/journal.pone.0106335
10.1016/0306-4522(95)00067-S
10.1038/s41575-020-0271-2
10.1016/j.ydbio.2016.04.016
10.3389/fimmu.2015.00590
10.1038/nrgastro.2016.107
10.1002/ibd.21422
10.1007/s00535-011-0495-6
10.1038/nature10554
10.1177/1756283X13482996
10.3233/JPD-191711
10.1002/mds.27581
10.1002/mds.27105
10.1007/s00415-019-09320-1
10.1371/journal.pone.0137429
10.1111/ene.13026
10.1038/ncomms12015
10.1038/srep28484
10.1073/pnas.1711233114
10.1073/pnas.1711235114
10.1073/pnas.2002817117
10.1186/s12883-016-0703-3
10.1016/j.cell.2016.11.018
10.3233/JPD-2011-11041
10.1038/s41586-019-1405-y
10.1002/mds.25882
10.1007/s00401-019-02040-w
10.1016/j.neuron.2019.05.035
10.1126/sciadv.1700492
10.1016/j.stem.2018.06.015
10.1038/s41579-020-00460-0
10.1038/nn.4030
10.1073/pnas.1000082107
10.1038/nm.4106
10.1038/s41467-018-05470-4
10.1016/j.cell.2020.06.022
10.1016/j.cell.2017.05.034
10.3390/nu8010056
10.1126/science.aau6323
10.1111/nyas.14138
10.1053/j.gastro.2014.12.036
10.1038/s41590-019-0415-0
10.1038/nri.2016.144
10.1016/j.immuni.2015.09.007
10.1016/j.cell.2017.02.009
10.1038/nrgastro.2016.191
10.1038/s41586-020-2634-9
10.1016/j.immuni.2020.10.014
10.1016/j.immuni.2020.02.009
10.1016/j.cell.2007.11.019
10.1038/nbt1201-1129
10.1016/j.stem.2008.09.002
10.1016/j.stem.2013.04.009
10.1073/pnas.1202944109
10.1038/nature12517
10.1073/pnas.1315710110
10.1073/pnas.1520760112
10.1038/nmeth.3415
10.1016/j.stem.2016.07.005
10.1038/ncomms9896
10.1126/science.aaz5626
10.1038/nature22330
10.1038/nmeth.4304
10.1016/j.cell.2020.11.017
10.1038/s41596-019-0141-y
10.1038/nature16951
10.1146/annurev.cellbio.042308.113344
10.1038/s41556-018-0105-4
10.1242/dmm.039347
10.1038/nrd.2016.245
10.1038/s41576-019-0100-z
10.1038/nature09691
10.1038/s41467-019-13916-6
10.1016/j.stemcr.2014.05.001
10.1038/nprot.2011.410
10.1038/nm.4233
10.1038/s41467-020-20351-5
10.1038/s41598-020-63151-z
10.1146/annurev.physiol.010908.163145
10.1177/0300985814559404
10.1002/hep.24252
10.1016/j.devcel.2016.08.014
10.1016/j.dld.2019.02.020
10.1038/nature07935
10.1038/s12276-020-0386-0
10.1038/s41385-018-0011-x
10.1053/j.gastro.2019.07.031
10.1038/s41419-019-2115-y
10.1053/j.gastro.2014.09.042
10.1136/gutjnl-2017-314540
10.1136/gutjnl-2014-307650
10.2217/rme.15.70
10.1038/s41418-020-00630-w
10.1136/gutjnl-2013-306651
10.1038/s41592-019-0586-5
10.1371/journal.pbio.3000705
10.1038/nbt.4127",<Element 'PubmedArticle' at 0x7f05df6b4540>
143,"34443519
30003140
29701556
28154096
21956442
21530028
15285801
19296921
27916979
27540165
28844606
24638131
17180163
11972030
20422475
15518895
15518897
21514338
17027094
16401644
31284862
15985713
19805477
22266723
24359917
25698233
21114961
21524253
19413310
1321043
1325033
8795075
31401178
14578481
8246142
25805003
33536635
28720325
23726889
32673700
24379782
28660018
26157795
23127847
33374986
18511649
24576160
30709867
17313456
22300099
22342206
26612670
10526883",Synthesis and In Vitro Characterization of Glycopeptide Drug Candidates Related to PACAP,"The search for efficacious treatment of neurodegenerative and progressive neuroinflammatory diseases continues, as current therapies are unable to halt or reverse disease progression. PACAP represents one potential therapeutic that provides neuroprotection effects on neurons, and also modulates inflammatory responses and circulation within the brain. However, PACAP is a relatively long peptide hormone that is not trivial to synthesize. Based on previous observations that the shortened isoform PACAP","['Alzheimer’s', 'Parkinson’s', 'glycopeptide', 'glycosylation', 'stroke']","Molecules (Basel, Switzerland)",2021-08-28,"[{'lastname': 'Apostol', 'firstname': 'Christopher R', 'initials': 'CR', 'affiliation': 'Department of Chemistry and Biochemistry, BIO5, The University of Arizona, 1306 E. University Blvd, Tucson, AZ 85721, USA.'}, {'lastname': 'Tanguturi', 'firstname': 'Parthasaradhireddy', 'initials': 'P', 'affiliation': 'Department of Pharmacology, College of Medicine, The University of Arizona, 1501 N. Campbell Ave, Tucson, AZ 85724, USA.'}, {'lastname': 'Szabò', 'firstname': 'Lajos Z', 'initials': 'LZ', 'affiliation': 'Department of Chemistry and Biochemistry, BIO5, The University of Arizona, 1306 E. University Blvd, Tucson, AZ 85721, USA.'}, {'lastname': 'Varela', 'firstname': 'Daniel', 'initials': 'D', 'affiliation': 'Facultat de Quìmica Tarragona, Universitat Rovera I Virgili, 43007 Barcelona, Spain.'}, {'lastname': 'Gilmartin', 'firstname': 'Thiago', 'initials': 'T', 'affiliation': 'Facultat de Quìmica Tarragona, Universitat Rovera I Virgili, 43007 Barcelona, Spain.'}, {'lastname': 'Streicher', 'firstname': 'John M', 'initials': 'JM', 'affiliation': 'Department of Pharmacology, College of Medicine, The University of Arizona, 1501 N. Campbell Ave, Tucson, AZ 85724, USA.'}, {'lastname': 'Polt', 'firstname': 'Robin', 'initials': 'R', 'affiliation': 'Department of Chemistry and Biochemistry, BIO5, The University of Arizona, 1306 E. University Blvd, Tucson, AZ 85721, USA.'}]",,,,,"10.3390/molecules26164932
10.1038/s41531-018-0058-0
10.1016/j.jalz.2017.02.001
10.3171/2017.10.JNS17352
10.1161/CIRCRESAHA.116.308413
10.1038/npp.2011.212
10.1016/j.bjoms.2011.03.004
10.1186/1742-2094-1-14
10.1016/S1474-4422(09)70062-6
10.1038/nri.2016.123
10.1126/science.aag2590
10.1016/j.expneurol.2017.08.013
10.1038/nrneurol.2014.38
10.1038/nrn2038
10.1073/pnas.082112699
10.1007/s12640-010-9186-y
10.1016/j.regpep.2004.05.014
10.1016/j.regpep.2004.05.016
10.1016/j.peptides.2011.04.003
10.1016/j.regpep.2006.06.016
10.1096/fj.05-4812fje
10.2174/1568026619666190709092647
10.1124/pr.109.001370
10.1038/aps.2011.170
10.1016/j.tips.2013.11.001
10.1016/j.peptides.2015.01.009
10.1016/j.bcp.2010.11.015
10.2174/138161211795589337
10.1021/jm900291j
10.1111/j.1432-1033.1992.tb17043.x
10.1016/0167-0115(96)00010-9
10.1016/j.bbagen.2019.08.003
10.1113/jphysiol.2003.053835
10.1016/j.peptides.2015.03.010
10.1038/s41573-020-00135-8
10.1016/j.bmc.2017.06.052
10.1016/j.drudis.2013.05.011
10.1016/j.peptides.2020.170369
10.3389/fphar.2013.00155
10.1039/C5SC04392A
10.3389/fchem.2015.00040
10.1016/j.neulet.2012.10.029
10.3390/ijms22010020
10.1124/jpet.108.138180
10.1021/jm400879w
10.1124/jpet.118.254854
10.1111/j.1747-0285.2007.00462.x
10.4155/fmc.11.195
10.1016/b978-0-12-812218-1.00003-8
10.1016/j.carres.2012.01.008
10.1039/C5CS00680E
10.1039/C39940000853
10.1016/j.tet.2011.08.046
10.1016/0040-4039(94)88360-2
10.1007/s10989-008-9154-z
10.1002/(SICI)1099-1387(199909)5:9<403::AID-PSC213>3.0.CO;2-S",<Element 'PubmedArticle' at 0x7f05df6587c0>
144,34428482,"Melatonin rescues the mice brain against cisplatin-induced neurodegeneration, an insight into antioxidant and anti-inflammatory effects.","Herein, we evaluated the neuroprotective effect of melatonin against cisplatin-induced oxidative damage, neuroinflammation, and synaptic dysfunction in mice. Cisplatin was administered at a dose of 2 mg/kg for eleven consecutive days to induce symptoms of cognitive impairment and neurodegeneration, while melatonin was administered at a 20 mg/kg dose for thirty consecutive days. We used various experimental techniques such as western blotting, immunofluorescence analysis, and oxidative stress marker assays to support our notion. Moreover, for cognitive impairment, we conducted behavioral analyses such as Morris Water Maze (MWM) and Y-Maze tests. The results indicated that melatonin attenuated oxidative stress by upregulating the expression of NF-E2-related factor-2 (Nrf2) dependent anti-oxidative protein levels. Similarly, melatonin positively modulated the expression of Sirt1 (a member of the sirtuin family), Phospho-AMPKα (Thr172), peroxisome proliferator-activated receptor (PPARγ), PPAR gamma coactivator 1 alpha (PGC-1α) coupled to downregulation of neuroinflammatory mediators and markers such as nuclear factor kappa-B (NF-κB), tumor necrosis factor-alpha (TNF-α), and interleukin-1 beta (IL-1β). Moreover, melatonin significantly upregulated the expression of synaptic markers such as postsynaptic density protein -95 (PSD-95), synaptosomal-associated protein 23 (SNAP-23), and synaptophysin compared to the cisplatin alone group. Furthermore, the results of behavior tests suggested that melatonin significantly improved the cognitive functions of the cisplatin injected mice.","['Chemotherapy', 'Cisplatin', 'Melatonin', 'Neurodegeneration']",Neurotoxicology,2021-08-25,"[{'lastname': 'Zakria', 'firstname': 'Muhammad', 'initials': 'M', 'affiliation': 'Institute of Basic Medical Sciences, Khyber Medical Univesity Peshawar Pakistan, Pakistan. Electronic address: Zakria.ibms@kmu.edu.pk.'}, {'lastname': 'Ahmad', 'firstname': 'Nasir', 'initials': 'N', 'affiliation': 'Institute of Basic Medical Sciences, Khyber Medical Univesity Peshawar Pakistan, Pakistan. Electronic address: Nasirwazir40@yahoo.com.'}, {'lastname': 'Al Kury', 'firstname': 'Lina Tariq', 'initials': 'LT', 'affiliation': 'College of Natural and Health Sciences, Zayed University, Abu Dhabi 49153, United Arab Emirates. Electronic address: Lina.AlKury@zu.ac.ae.'}, {'lastname': 'Alattar', 'firstname': 'Abdullah', 'initials': 'A', 'affiliation': 'Department of Pharmacology and Toxicology, Faculty of Pharmacy, University of Tabuk, Tabuk 71421, Saudi Arabia. Electronic address: Aalattar@ut.edu.sa.'}, {'lastname': 'Uddin', 'firstname': 'Zia', 'initials': 'Z', 'affiliation': 'Department of Pharmacy, COMSATS University Islamabad, Abbottaad campus Abbottabad, Pakistan. Electronic address: ziauddin@cuiatd.edu.pk.'}, {'lastname': 'Siraj', 'firstname': 'Sami', 'initials': 'S', 'affiliation': 'Institute of Basic Medical Sciences, Khyber Medical Univesity Peshawar Pakistan, Pakistan. Electronic address: Samisiraj.ibms@kmu.edu.pk.'}, {'lastname': 'Ullah', 'firstname': 'Shakir', 'initials': 'S', 'affiliation': 'Institute of Basic Medical Sciences, Khyber Medical Univesity Peshawar Pakistan, Pakistan. Electronic address: shakir.ibms@kmu.edu.pk.'}, {'lastname': 'Alshaman', 'firstname': 'Reem', 'initials': 'R', 'affiliation': 'Department of Pharmacology and Toxicology, Faculty of Pharmacy, University of Tabuk, Tabuk 71421, Saudi Arabia.'}, {'lastname': 'Khan', 'firstname': 'Muhammad Imran', 'initials': 'MI', 'affiliation': 'Riphah Institute of Pharmaceutical Sciences, Riphah International University, Islamabad 44000, Pakistan.'}, {'lastname': 'Shah', 'firstname': 'Fawad Ali', 'initials': 'FA', 'affiliation': 'Riphah Institute of Pharmaceutical Sciences, Riphah International University, Islamabad 44000, Pakistan. Electronic address: fawad.shah@riphah.edu.pk.'}]",,,,Copyright © 2021. Published by Elsevier B.V.,10.1016/j.neuro.2021.08.010,<Element 'PubmedArticle' at 0x7f05df60b0e0>
145,"34418603
28332488
26217195
21689593
20495568
15003389
12596253
24642597
25445849
24529663
26993302
33673334
21733157
28575743
24667322
25100745
30389571
23719809
29217683
17917122
23170013
21798010
18085551
10773220
30250265
9870933
21270887
24667322
1846582
22903618
31035004
29721549
16261549
18222006
23296790
11591459
20359499
26675822
29480526
22743091
11591459
12971891
32828969
29362479
28303016
12666096
29393357
8139611
29183391
29629441
22540427
30601141
30219247
31727879
33383658
11050436
20078222
30745181
33239287
32296300
29364506
22354563
21856379
23294312
26812787
31964153
33762743
28123558
29115830
32763437
32079324
25975984
21403858
30080657
23665395
31680826
17267597
31358653
22019741
30965670
25702135
20639120
30744070
31937935
27263112
26269525
24726895
27784786
32075092
27889578
31590432
19672298
31053723
27520881
26408528
32108853
10646524
32642868
32912509
19276553",Insulin-like growth factor II prevents oxidative and neuronal damage in cellular and mice models of Parkinson's disease.,"Oxidative distress and mitochondrial dysfunction, are key factors involved in the pathophysiology of Parkinson's disease (PD). The pleiotropic hormone insulin-like growth factor II (IGF-II) has shown neuroprotective and antioxidant effects in some neurodegenerative diseases. In this work, we demonstrate the protective effect of IGF-II against the damage induced by 1-methyl-4-phenylpyridinium (MPP+) in neuronal dopaminergic cell cultures and a mouse model of progressive PD. In the neuronal model, IGF-II counteracts the oxidative distress produced by MPP + protecting dopaminergic neurons. Improved mitochondrial function, increased nuclear factor (erythroid-derived 2)-like2 (NRF2) nuclear translocation along with NRF2-dependent upregulation of antioxidative enzymes, and modulation of mammalian target of rapamycin (mTOR) signalling pathway were identified as mechanisms leading to neuroprotection and the survival of dopaminergic cells. The neuroprotective effect of IGF-II against MPP + -neurotoxicity on dopaminergic neurons depends on the specific IGF-II receptor (IGF-IIr). In the mouse model, IGF-II prevents behavioural dysfunction and dopaminergic nigrostriatal pathway degeneration and mitigates neuroinflammation induced by MPP+. Our work demonstrates that hampering oxidative stress and normalising mitochondrial function through the interaction of IGF-II with its specific IGF-IIr are neuroprotective in both neuronal and mouse models. Thus, the modulation of the IGF-II/IGF-IIr signalling pathway may be a useful therapeutic approach for the prevention and treatment of PD.","['Insulin like growth factor-II', 'Mitochondria', 'Neuroprotection', 'Oxidative distress', ""Parkinson's disease""]",Redox biology,2021-08-22,"[{'lastname': 'Martín-Montañez', 'firstname': 'Elisa', 'initials': 'E', 'affiliation': 'Departamento de Farmacología y Pediatría, Facultad de Medicina, Instituto de Investigación Biomédica de Málaga (IBIMA), Universidad de Málaga (UMA), Malaga, 29010, Spain.'}, {'lastname': 'Valverde', 'firstname': 'Nadia', 'initials': 'N', 'affiliation': 'Departamento de Farmacología y Pediatría, Facultad de Medicina, Instituto de Investigación Biomédica de Málaga (IBIMA), Universidad de Málaga (UMA), Malaga, 29010, Spain; Departamento de Fisiología Humana, Facultad de Medicina, Instituto de Investigación Biomédica de Málaga (IBIMA), Universidad de Málaga (UMA), Malaga, 29010, Spain.'}, {'lastname': 'Ladrón de Guevara-Miranda', 'firstname': 'David', 'initials': 'D', 'affiliation': 'Departamento de Psicobiología y Metodología de las Ciencias del Comportamiento, Facultad de Psicología, Instituto de Investigación Biomédica de Málaga (IBIMA), Universidad de Málaga (UMA), Malaga, 29010, Spain.'}, {'lastname': 'Lara', 'firstname': 'Estrella', 'initials': 'E', 'affiliation': 'Departamento de Fisiología Humana, Facultad de Medicina, Instituto de Investigación Biomédica de Málaga (IBIMA), Universidad de Málaga (UMA), Malaga, 29010, Spain.'}, {'lastname': 'Romero-Zerbo', 'firstname': 'Yanina S', 'initials': 'YS', 'affiliation': 'Departamento de Fisiología Humana, Facultad de Medicina, Instituto de Investigación Biomédica de Málaga (IBIMA), Universidad de Málaga (UMA), Malaga, 29010, Spain.'}, {'lastname': 'Millon', 'firstname': 'Carmelo', 'initials': 'C', 'affiliation': 'Departamento de Fisiología Humana, Facultad de Medicina, Instituto de Investigación Biomédica de Málaga (IBIMA), Universidad de Málaga (UMA), Malaga, 29010, Spain.'}, {'lastname': 'Boraldi', 'firstname': 'Federica', 'initials': 'F', 'affiliation': 'Dipartimento di Scienze della Vita. Patologia Generale.Universita di Modena e Reggio Emilia. 41125, Italy.'}, {'lastname': 'Ávila-Gámiz', 'firstname': 'Fabiola', 'initials': 'F', 'affiliation': 'Departamento de Psicobiología y Metodología de las Ciencias del Comportamiento, Facultad de Psicología, Instituto de Investigación Biomédica de Málaga (IBIMA), Universidad de Málaga (UMA), Malaga, 29010, Spain.'}, {'lastname': 'Pérez-Cano', 'firstname': 'Ana M', 'initials': 'AM', 'affiliation': 'Departamento de Psicobiología y Metodología de las Ciencias del Comportamiento, Facultad de Psicología, Instituto de Investigación Biomédica de Málaga (IBIMA), Universidad de Málaga (UMA), Malaga, 29010, Spain.'}, {'lastname': 'Garrido-Gil', 'firstname': 'Pablo', 'initials': 'P', 'affiliation': 'Centro de Investigación en Medicina Molecular y Enfermedades Crónicas (CiMUS) y Centro de Investigación en Red de Enfermedades Neurodegenerativas (CIBERNED-Madrid). Universidad de Santiago de Compostela, 15782 Spain.'}, {'lastname': 'Labandeira-Garcia', 'firstname': 'Jose Luis', 'initials': 'JL', 'affiliation': 'Centro de Investigación en Medicina Molecular y Enfermedades Crónicas (CiMUS) y Centro de Investigación en Red de Enfermedades Neurodegenerativas (CIBERNED-Madrid). Universidad de Santiago de Compostela, 15782 Spain.'}, {'lastname': 'Santin', 'firstname': 'Luis J', 'initials': 'LJ', 'affiliation': 'Departamento de Psicobiología y Metodología de las Ciencias del Comportamiento, Facultad de Psicología, Instituto de Investigación Biomédica de Málaga (IBIMA), Universidad de Málaga (UMA), Malaga, 29010, Spain.'}, {'lastname': 'Pavia', 'firstname': 'Jose', 'initials': 'J', 'affiliation': 'Departamento de Farmacología y Pediatría, Facultad de Medicina, Instituto de Investigación Biomédica de Málaga (IBIMA), Universidad de Málaga (UMA), Malaga, 29010, Spain. Electronic address: pavia@uma.es.'}, {'lastname': 'Garcia-Fernandez', 'firstname': 'Maria', 'initials': 'M', 'affiliation': 'Departamento de Fisiología Humana, Facultad de Medicina, Instituto de Investigación Biomédica de Málaga (IBIMA), Universidad de Málaga (UMA), Malaga, 29010, Spain. Electronic address: igf@uma.es.'}]",,,,Copyright © 2021 The Authors. Published by Elsevier B.V. All rights reserved.,"10.1016/j.redox.2021.102095
10.1038/nrdp.2017.13
10.3389/fnana.2015.00091
10.1016/j.neuron.2011.06.003
10.1038/nm.2165
10.1016/j.brainresrev.2003.11.002
10.1002/cne.10578
10.1038/npp.2014.69
10.1038/nrendo.2014.208
10.1016/j.euroneuro.2014.01.020
10.1007/s12035-016-9849-7
10.3390/ijms22041849
10.1186/1479-5876-9-103
10.1016/j.redox.2017.05.012
10.1016/J.BBADIS.2014.03.010
10.15252/emmm.201404228
10.1016/j.neures.2018.10.012
10.1523/JNEUROSCI.2700-12.2013
10.1523/JNEUROSCI.2010-17.2017
10.1007/s12035-007-0021-2
10.1212/WNL.0b013e3182752eef
10.1186/1479-5876-9-123
10.4314/tjpr.v14i7.10
10.1002/ajmg.b.30633
10.1016/S0006-8993(00)02153-3
10.1038/s41593-018-0236-8
10.1523/JNEUROSCI.19-01-00010.1999
10.1038/nature09667
10.1016/j.bbadis.2014.03.010
10.1210/endo-128-2-1201
10.1210/en.2012-1139
10.1016/j.freeradbiomed.2019.04.022
10.20455/ros.2016.865
10.1002/path.1867
10.1016/j.jneumeth.2007.12.004
10.1007/978-1-62703-251-3_17
10.1016/S0306-4522(01)00295-0
10.1016/j.jneumeth.2010.03.026
10.1038/nrn.2015.8
10.1111/adb.12612
10.1016/j.neurobiolaging.2012.06.001
10.1016/s0306-4522(01)00295-0
10.1016/S0896-6273(03)00568-3
10.1016/j.mito.2020.08.003
10.1038/s41418-017-0012-4
10.1038/nrn.2017.25
10.1002/ana.10483
10.3892/ijmm.2018.3406
10.1002/mds.870090115
10.1186/s13041-017-0340-9
10.1039/C8CC01639A
10.1089/ars.2012.4640
10.1172/JCI120848
10.1016/j.pneurobio.2018.09.003
10.1038/s41419-019-2091-2
10.3390/cells10010034
10.1016/S0968-0004(00)01674-1
10.1146/annurev.pathol.4.110807.092314
10.1016/j.cmet.2019.01.006
10.1126/sciadv.abb7389
10.3389/fnins.2020.00213
10.1002/1873-3468.12989
10.1002/jnr.23000
10.1016/j.bbagen.2011.08.007
10.1146/annurev-pharmtox-011112-140320
10.1515/hsz-2015-0295
10.1177/1759091419899782
10.1038/s41418-021-00767-2
10.3892/OL.2016.5383
10.1021/ACSCHEMNEURO.7B00247
10.1016/J.FCT.2020.111644
10.3390/BIOM10020320
10.1016/j.freeradbiomed.2015.04.036
10.4061/2011/314082
10.1016/j.bj.2018.02.005
10.1016/j.freeradbiomed.2013.05.001
10.3389/fnins.2019.01091
10.1073/pnas.0610978104
10.1523/JNEUROSCI.0625-19.2019
10.1016/j.tox.2011.10.007
10.3390/molecules24071377
10.1007/s12031-015-0516-7
10.1016/j.cellsig.2010.05.015
10.3390/ijms20030728
10.1038/s41580-019-0199-y
10.1007/s12017-016-8417-7
10.1152/physrev.00038.2014
10.1016/j.cellsig.2014.04.009
10.1074/jbc.M116.760249
10.3390/cells9020441
10.1016/j.neuroscience.2016.11.017
10.3390/cells8101207
10.1371/journal.pone.0006606
10.1038/s41467-019-09786-7
10.1111/ejn.13357
10.1124/pr.114.010397
10.1042/BCJ20190676
10.1046/j.1471-4159.2000.740721.x
10.1007/s00401-020-02183-1
10.1016/j.jstrokecerebrovasdis.2020.105128
10.3233/JAD-2009-0995",<Element 'PubmedArticle' at 0x7f05df61b0e0>
146,"34411281
31710717
21323872
18192510
29645315
25626735
21824982
16741123
21475703
21750563
18054961
28489068
29981425
9718088
29520785
25539830
7992831
23949222
27773938
10496266
32788256
15263088
25568329
30531847
28596251
27054329
31019997
28602351
12055133
25707796
27494181
28930663
20200508
10896869
27733491
32662875
29608146
31849093
21097551
12362410
30630957
23311642
31144522
21607987
32663219
7846037
8446170
22632442
27637961
28855891
18688283
28683286
26984187
32699414
19833869
12802201
24582471
17673516
10884437
27052383
23007189",The feeding behaviour of Amyotrophic Lateral Sclerosis mouse models is modulated by the Ca,"Amyotrophic lateral sclerosis (ALS) patients exhibit dysfunctional energy metabolism and weight loss, which is negatively correlated with survival, together with neuroinflammation. However, the possible contribution of neuroinflammation to deregulations of feeding behaviour in ALS has not been studied in detail. We here investigated if microglial K
hSOD1
We found that treatment of hSOD1
Using ALS mouse models, we describe defects in the hypothalamic melanocortin system that affect appetite control. These results reveal a new regulatory role for K","['CSF', 'hypothalamus feeding behaviour', 'ion channels', 'microglia', 'neurodegenerative disease', 'neuroinflammation']",British journal of pharmacology,2021-08-20,"[{'lastname': 'Cocozza', 'firstname': 'Germana', 'initials': 'G', 'affiliation': 'Instituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Neuromed, Pozzilli, Italy.'}, {'lastname': 'Garofalo', 'firstname': 'Stefano', 'initials': 'S', 'affiliation': 'Department of Physiology and Pharmacology, Sapienza University of Rome, Rome, Italy.'}, {'lastname': 'Morotti', 'firstname': 'Marta', 'initials': 'M', 'affiliation': 'Department of Physiology and Pharmacology, Sapienza University of Rome, Rome, Italy.'}, {'lastname': 'Chece', 'firstname': 'Giuseppina', 'initials': 'G', 'affiliation': 'Department of Physiology and Pharmacology, Sapienza University of Rome, Rome, Italy.'}, {'lastname': 'Grimaldi', 'firstname': 'Alfonso', 'initials': 'A', 'affiliation': 'Center for Life Nanoscience, Istituto Italiano di Tecnologia@Sapienza, Rome, Italy.'}, {'lastname': 'Lecce', 'firstname': 'Mario', 'initials': 'M', 'affiliation': 'Department of Molecular Medicine, Sapienza University of Rome, Rome, Italy.'}, {'lastname': 'Scavizzi', 'firstname': 'Ferdinando', 'initials': 'F', 'affiliation': 'EMMA CNR, Monterotondo, Italy.'}, {'lastname': 'Menghini', 'firstname': 'Rossella', 'initials': 'R', 'affiliation': 'Department of Systems Medicine, Tor Vergata University of Rome, Rome, Italy.'}, {'lastname': 'Casagrande', 'firstname': 'Viviana', 'initials': 'V', 'affiliation': 'Department of Systems Medicine, Tor Vergata University of Rome, Rome, Italy.'}, {'lastname': 'Federici', 'firstname': 'Massimo', 'initials': 'M', 'affiliation': 'Department of Systems Medicine, Tor Vergata University of Rome, Rome, Italy.'}, {'lastname': 'Raspa', 'firstname': 'Marcello', 'initials': 'M', 'affiliation': 'EMMA CNR, Monterotondo, Italy.'}, {'lastname': 'Wulff', 'firstname': 'Heike', 'initials': 'H', 'affiliation': 'Department of Pharmacology, University of California, Davis, Davis, California, USA.'}, {'lastname': 'Limatola', 'firstname': 'Cristina', 'initials': 'C', 'affiliation': 'Instituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Neuromed, Pozzilli, Italy.\nDepartment of Physiology and Pharmacology, Sapienza University of Rome, Rome, Italy.'}]",,,,© 2021 The Authors. British Journal of Pharmacology published by John Wiley & Sons Ltd on behalf of British Pharmacological Society.,"10.1111/bph.15665
10.1111/j.1365-2141.2010.08520.x
10.1182/blood-2007-08-110098
10.1111/jne.12598
10.2337/db14-0093
10.1177/0269881111408458
10.1126/science.1123511
10.1007/s13539-010-0015-1
10.1038/jcbfm.2011.101
10.1016/j.jns.2007.10.024
10.1016/j.bbi.2018.07.002
10.1016/S0024-3205(98)00322-1
10.1111/bph.14153
10.1186/s40478-014-0171-1
10.1038/ijo.2016.183
10.1212/WNL.53.5.1059
10.1136/jnnp-2020-323372
10.1073/pnas.0402026101
10.15252/embr.201439668
10.1136/jnnp-2017-315795
10.1038/sj.bjp.0704767
10.1038/nature14260
10.1038/npp.2010.26
10.1152/ajpregu.2000.279.1.R93
10.15252/embr.201541499
10.1111/bph.15178
10.1002/ana.25661
10.1002/mus.10191
10.1136/jnnp-2018-319611
10.1080/21678421.2019.1621346
10.1002/mus.22114
10.1371/journal.pbio.3000410
10.1073/pnas.92.3.689
10.3109/17482968.2012.678366
10.1016/B978-0-12-802973-2.00013-6
10.3389/fendo.2017.00197
10.1172/JCI30836
10.1093/brain/aww004
10.1038/s41586-020-2527-y
10.1073/pnas.0908767106
10.1016/S0140-6736(14)60222-1
10.1210/en.2007-0394
10.1073/pnas.97.14.8151
10.1038/nrn.2016.24
10.1038/nn.3211",<Element 'PubmedArticle' at 0x7f05df5dc680>
147,"34409198
460932
10491980
17177754
8783314
17590272
24105754
21796057
20068448
24500412
10846153
19712899
26525230
16698416
24237004
9884866
31343465
18456219
12764087
30761997
16093381
24752199
20103545
22699129
23881791
29178038
23216170
10561444
9350845
27069626
20961685
31079836
18615140
32221089
29794783
20364022
25822923
23578860
29052225
30124544
17543812
26869374
23390475
26650425
31491863
26966331
29392204
28767509
29026331
31626143
25790453
30726237
19542791
12421200
18952472
25985024
28681962
28366128
28233180
28035535
31234188
27974040
28220542
29899036
31534227
24798884
25415497
26432952
24956966
30650376
31573550
31469291
28356427
29397391
27814521
26822992
29409054
30489316
25146375
22972295
31460832
24997031
29380303
31123355
31552496
31653850
31551115
10401557
26324094
18268332
19400724
22365541
32807072
28486769
28714953
31889131
29872383
30705252
14581119
30267869
26930255
28629511
16105890
28265110
27729657
26793178
25888704
23618829
31063849
31974315
30925514
30925707
27793219
30883471
23225871
31809997
32115044
24948120
27793571
17943118
19686699
29292393
18304834
20404851
32305572
23872358
20576919
18027846
21393555
28155242
25846205
33392418
27195116
30915065
19807780
25637492
22684624
21981302
29903615
15475622
20332520
20003079
18194152
27406353
29619131
26045134
25910186
27102666
31785713
23157347
22978429
25073649
27749354
21799397
21773855
25209095
22546966",Postoperative pain and the gut microbiome.,"In excess of 300 million surgical procedures are undertaken worldwide each year. Despite recognition of the prevalence of postoperative pain, and improvements in pain management techniques, poorly controlled postoperative pain remains a major unresolved challenge globally. An estimated 71% and 51% of patients experience moderate to severe pain after surgery in in-patient and outpatient settings, respectively. Inadequately controlled pain after surgery is associated with significant perioperative morbidity including myocardial infarction and pulmonary complications. As many as 20-56% of patients develop chronic pain after commonly performed procedures such as hernia repair, hysterectomy, and thoracotomy. Traditional analgesics and interventions are often ineffective or partially effective in the treatment of postoperative pain, resulting in a chronic pain condition with related socio-economic impacts and reduced quality of life for the patient. Such chronic pain which occurs after surgery is referred to as Persistent Post-Surgical Pain (PPSP). The complex ecosystem that is the gastrointestinal microbiota (including bacteria, fungi, viruses, phage) plays essential roles in the maintenance of the healthy state of the host. A disruption to the balance of this microbiome has been implicated not only in gastrointestinal disease but also neurological disorders including chronic pain. The influence of the gut microbiome is well documented in the context of visceral pain from the gastrointestinal tract while a greater understanding is emerging of the impact on inflammatory pain and neuropathic pain (both of which can occur during the perioperative period). The gut microbiome is an essential source for driving immune maturation and maintaining appropriate immune response. Given that inflammatory processes have been implicated in postoperative pain, aberrant microbiome profiles may play a role in the development of this type of pain. Furthermore, the microorganisms in our gut produce metabolites, neurotransmitters, and neuromodulators which interact with their receptors to regulate peripheral and central sensitisation associated with chronic pain. Microbiota-derived mediators can also regulate neuroinflammation, which is associated with activation of microglia as well as infiltration by immune cells, known to modulate the development and maintenance of central sensitisation. Moreover, risk factors for developing postoperative pain include anxiety, depression, and increased stress response. These central nervous system-related disorders have been associated with an altered gut microbiome and microbiome targeted intervention studies indicate improvements. Females are more likely to suffer from postoperative pain. As gonadal hormones are associated with a differential microbiome and pre-clinical studies show that male microbiome confers protection from inflammatory pain, it is possible that the composition of the microbiome and its by-products contribute to the increased risk for the development of postoperative pain. Very little evidence exists relating the microbiome to somatic pain. Here we discuss the potential role of the gut microbiome in the aetiology and pathophysiology of postoperative pain in the context of other somatic pain syndromes and what is known about microbe-neuron interactions. Investigations are needed to determine the specific role of the gut microbiome in this type of pain which may help inform the development of preventative interventions as well as management strategies to improve patient outcome.","['Microbiome', 'Microbiome-gut-brain axis', 'Post surgical pain', 'Postoperative pain', 'Stress']","Neurobiology of pain (Cambridge, Mass.)",2021-08-20,"[{'lastname': 'Brenner', 'firstname': 'David', 'initials': 'D', 'affiliation': 'Department of Anesthesia and Intensive Care Medicine, Cork University Hospital and University College Cork, Ireland.'}, {'lastname': 'Shorten', 'firstname': 'George D', 'initials': 'GD', 'affiliation': 'Department of Anesthesia and Intensive Care Medicine, Cork University Hospital and University College Cork, Ireland.'}, {'lastname': ""O'Mahony"", 'firstname': 'Siobhain M', 'initials': 'SM', 'affiliation': 'APC Microbiome Ireland, University College Cork, Cork, Ireland.\nDepartment of Anatomy and Neuroscience, University College Cork, Cork, Ireland.'}]",,,,© 2021 Published by Elsevier Inc.,10.1016/j.ynpai.2021.100070,<Element 'PubmedArticle' at 0x7f05df5916d0>
148,"34341712
12476342
28259169
30548343
20729991
14670989
26470014
19345186
11750861
14611864
24704258
10662535
31513776
30618719
30400090
26540080
20811568
15295589
12214075
33239064
31855379
32823921
29748506
32241688
28623000
31580307
31982474
32810649
27877121
29931997
28886007
30319362
3614616
12788335
31715222
10737694
32848613
23884544
11596125
25800044
28862638
31093687
26067058
30459555
27825853
31429127
24638131
20303880
30249283
24760020
32391019
18564425
17684513
26931456
23492769
12601160
27528245
28716963
16038625
7739519
25224917
29710717
26790758
21753171
25833819
23486975
20864679
28372330
33240722
32829453
28643167
25411471
30066368
25589730
27776263
26869995
31544208
15344917
15814846
31050045
32646017
16319920
21514366
20488256
12414884
15374110
20153425
19665809
10664834
2570275
19428144
16365303
25206601
29179999
32276438
30900203
33069760
33114450
27697052
17569208
32953558
19966973
31560864
30669068
31137655
33160067
26059355
31376068
8741021
22086747
25506211
25114079
26268332
20104449
26819725
32153388
31016201
28086917
26362286
28940752
12873849
25446949
22932777
11395173
17982894
30958356
33287198
32771949
18097616
23717092
18580589
32806490
33050575
27840992
29064461
26401779
27048893
16353824
30223002
30642737
30569089
32928279
31488882
28642806
23493529
30995776
26035622
17569224
18417733
30477087
15545088
21291975
22470237
12434011
12631693
21575276
19260079
30096397
9795834
21258872
16624639
9883965
23911887
29324687
29864481
25218903
26551702
12447370
28594115
22185664
30717203
27560534
19132916
21048386
7622446
21331635
12469318
28991199
23815956
32795898
32838181
33268824
29614679
32813239
30796934
32059690
31831363
33187212
32949638",Promising Intervention Approaches to Potentially Resolve Neuroinflammation And Steroid Hormones Alterations in Alzheimer's Disease and Its Neuropsychiatric Symptoms.,"Neuroinflammation is a biological process by which the central nervous system responds to stimuli/injuries affecting its homeostasis. So far as this reactive response becomes exacerbated and uncontrolled, it can lead to neurodegeneration, compromising the cognitive and neuropsychiatric domains. Parallelly, modifications in the hypothalamic signaling of neuroprotective hormones linked also to the inflammatory responses of microglia and astrocytes can exacerbate these processes. To complicate the picture, modulations in the gut microbiota (GM) can induce changes in neuroinflammation, altering cognitive and neuropsychiatric functioning. We conducted a web-based search on PubMed. We described studies regarding the cross-talk among microglia and astrocytes in the neuroinflammation processes, along with the role played by the steroid hormones, and how this can reflect on cognitive decline/neurodegeneration, in particular on Alzheimer's Disease (AD) and its neuropsychiatric manifestations. We propose and support the huge literature showing the potentiality of complementary/alternative therapeutic approaches (nutraceuticals) targeting the sustained inflammatory response, the dysregulation of hypothalamic system and the GM composition. NF-κB and Keap1/Nrf2 are the main molecular targets on which a list of nutraceuticals can modulate the altered processes. Since there are some limitations, we propose a new intervention natural treatment in terms of Oxygen-ozone (O","['Alzheimer’s Disease', 'Keap1/Nrf2', 'NF-κB', 'Neuroinflammation', 'Nutraceuticals', 'Oxygen-Ozone Therapy', 'Steroid hormones']",Aging and disease,2021-08-04,"[{'lastname': 'Scassellati', 'firstname': 'Catia', 'initials': 'C', 'affiliation': '1Biological Psychiatry Unit, IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy.'}, {'lastname': 'Galoforo', 'firstname': 'Antonio Carlo', 'initials': 'AC', 'affiliation': '2Oxygen-Ozone Therapy Scientific Society (SIOOT), Gorle, Italy.\n3University of Pavia, Pavia, Italy.'}, {'lastname': 'Esposito', 'firstname': 'Ciro', 'initials': 'C', 'affiliation': '4Department of Internal Medicine and Therapeutics, University of Pavia, Italy.\n5Nephrology and dialysis unit, ICS S. Maugeri SPA SB Hospital, Pavia, Italy.\n6P.D. High School in Geriatrics, University of Pavia, Italy.'}, {'lastname': 'Ciani', 'firstname': 'Miriam', 'initials': 'M', 'affiliation': '7Molecular Markers Laboratory, IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy.'}, {'lastname': 'Ricevuti', 'firstname': 'Giovanni', 'initials': 'G', 'affiliation': '6P.D. High School in Geriatrics, University of Pavia, Italy.\n8Department of Drug Sciences, University of Pavia, Italy.\n9St. Camillus Medical University, Rome, Italy.'}, {'lastname': 'Bonvicini', 'firstname': 'Cristian', 'initials': 'C', 'affiliation': '7Molecular Markers Laboratory, IRCCS Istituto Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy.'}]",,,,copyright: © 2021 Scassellati et al.,"10.14336/AD.2021.0122
10.3390/nu12113458",<Element 'PubmedArticle' at 0x7f05df5554a0>
149,34333040,Adiponectin ameliorates hypoperfusive cognitive deficits by boosting a neuroprotective microglial response.,"Vascular cognitive impairment and dementia (VaD) is the second most common type of dementia caused by chronic vascular hypoperfusion. Adiponectin, one of the cytokines produced by adipocytes (adipocytokine), plays a role in CNS pathologies, but its specific function in VaD is unknown. Here, transcriptomic analyses on human brain tissues showed downregulation of adipocytokine/PPAR signaling in VaD patients, with prominent upregulation of pro-inflammatory responses. Using the murine asymmetric common carotid artery stenosis (ACAS) model, we discovered that the adiponectin/PPARγ axis is essential in reducing chronic hypoperfusion-induced cognitive deficits via modulation of microglial function. Adiponectin levels in the plasma increased early after VaD induction, but decreased in the cerebrospinal fluid in the late phase of VaD. Adiponectin deficiency worsened hippocampus-dependent cognitive deficits, exacerbated neuroinflammation and microglia/macrophage activation, and amplified neuronal loss, but these behavioral and histological outcomes were rescued by adipoRon, a small molecule agonist of the adiponectin receptors. AdipoRon boosted PPARγ expression and inhibited pro-inflammatory microglial responses in vitro, thereby protecting ischemic neurons in primary microglia-neuron cocultures. Microglia/macrophage-specific knockout of PPARγ abolished the neuroprotective effects of adipoRon. Collectively, these data confirm the importance of adiponectin/PPARγ signaling in maintaining cognitive functions in chronic hypoperfusion-induced dementia, and thus provide novel therapeutic targets for VaD.","['Adiponectin', 'Cognitive deficits', 'Microglia', 'Neuroinflammation', 'PPARγ', 'Vascular dementia']",Progress in neurobiology,2021-08-02,"[{'lastname': 'Miao', 'firstname': 'Wanying', 'initials': 'W', 'affiliation': 'Pittsburgh Institute of Brain Disorders & Recovery and Department of Neurology, University of Pittsburgh, Pittsburgh, PA, 15213, USA.'}, {'lastname': 'Jiang', 'firstname': 'Liyuan', 'initials': 'L', 'affiliation': 'Pittsburgh Institute of Brain Disorders & Recovery and Department of Neurology, University of Pittsburgh, Pittsburgh, PA, 15213, USA.'}, {'lastname': 'Xu', 'firstname': 'Fei', 'initials': 'F', 'affiliation': 'Pittsburgh Institute of Brain Disorders & Recovery and Department of Neurology, University of Pittsburgh, Pittsburgh, PA, 15213, USA; Geriatric Research, Education and Clinical Center, Veterans Affairs Pittsburgh Health Care System, Pittsburgh, PA, 15261, USA.'}, {'lastname': 'Lyu', 'firstname': 'Junxuan', 'initials': 'J', 'affiliation': 'Pittsburgh Institute of Brain Disorders & Recovery and Department of Neurology, University of Pittsburgh, Pittsburgh, PA, 15213, USA.'}, {'lastname': 'Jiang', 'firstname': 'Xiaoyan', 'initials': 'X', 'affiliation': 'Pittsburgh Institute of Brain Disorders & Recovery and Department of Neurology, University of Pittsburgh, Pittsburgh, PA, 15213, USA; Geriatric Research, Education and Clinical Center, Veterans Affairs Pittsburgh Health Care System, Pittsburgh, PA, 15261, USA.'}, {'lastname': 'He', 'firstname': 'Maxine', 'initials': 'M', 'affiliation': 'Pittsburgh Institute of Brain Disorders & Recovery and Department of Neurology, University of Pittsburgh, Pittsburgh, PA, 15213, USA.'}, {'lastname': 'Liu', 'firstname': 'Yaan', 'initials': 'Y', 'affiliation': 'Pittsburgh Institute of Brain Disorders & Recovery and Department of Neurology, University of Pittsburgh, Pittsburgh, PA, 15213, USA.'}, {'lastname': 'Yang', 'firstname': 'Tuo', 'initials': 'T', 'affiliation': 'Pittsburgh Institute of Brain Disorders & Recovery and Department of Neurology, University of Pittsburgh, Pittsburgh, PA, 15213, USA; Geriatric Research, Education and Clinical Center, Veterans Affairs Pittsburgh Health Care System, Pittsburgh, PA, 15261, USA.'}, {'lastname': 'Leak', 'firstname': 'Rehana K', 'initials': 'RK', 'affiliation': 'Graduate School of Pharmaceutical Sciences, Duquesne University, Pittsburgh, PA, 15282, USA.'}, {'lastname': 'Stetler', 'firstname': 'R Anne', 'initials': 'RA', 'affiliation': 'Pittsburgh Institute of Brain Disorders & Recovery and Department of Neurology, University of Pittsburgh, Pittsburgh, PA, 15213, USA; Geriatric Research, Education and Clinical Center, Veterans Affairs Pittsburgh Health Care System, Pittsburgh, PA, 15261, USA.'}, {'lastname': 'Chen', 'firstname': 'Jun', 'initials': 'J', 'affiliation': 'Pittsburgh Institute of Brain Disorders & Recovery and Department of Neurology, University of Pittsburgh, Pittsburgh, PA, 15213, USA; Geriatric Research, Education and Clinical Center, Veterans Affairs Pittsburgh Health Care System, Pittsburgh, PA, 15261, USA. Electronic address: chenj2@upmc.edu.'}, {'lastname': 'Hu', 'firstname': 'Xiaoming', 'initials': 'X', 'affiliation': 'Pittsburgh Institute of Brain Disorders & Recovery and Department of Neurology, University of Pittsburgh, Pittsburgh, PA, 15213, USA; Geriatric Research, Education and Clinical Center, Veterans Affairs Pittsburgh Health Care System, Pittsburgh, PA, 15261, USA. Electronic address: hux2@upmc.edu.'}]",,,,Copyright © 2021 Elsevier Ltd. All rights reserved.,10.1016/j.pneurobio.2021.102125,<Element 'PubmedArticle' at 0x7f05df51d950>
150,"34299330
10572156
17286590
8705846
7886816
7986484
33192310
10850730
15895084
15681802
12379913
12488575
30910443
31831863
15543349
25347455
15894331
14657172
15728830
29454025
23515018
22248049
14757702
21546126
29579222
22813736
26362942
31121907
23644076
11021405
18686032
19840553
32234529
27470986
16322748
16949823
25339865
25800044
32941933
33027950
12478284
12511873
26408161
29962346
31979368
20468046
22388959
21187088
21461357
34063708
28963903
16834756
16343349
28336953
19476641
22321194
22970888
17217969
21778362
29563239
33847763
33154976
26336035
31915009
25989853
31922322
16859761
14744429
23707391
10066831
29888765
29246246
18000012
28334226
29158718
17200137
16513651
11789671
26086345
29560022
32117037
28877953
23949608
25619654
26402623
24937045
30098312
17543306
28825114
6832887
11846609",Fatty Acid Amide Hydrolase (FAAH) Inhibition Modulates Amyloid-Beta-Induced Microglia Polarization.,"The ability of endocannabinoid (eCB) to change functional microglial phenotype can be explored as a possible target for therapeutic intervention. Since the inhibition of fatty acid amide hydrolase (FAAH), the main catabolic enzyme of anandamide (AEA), may provide beneficial effects in mice model of Alzheimer's disease (AD)-like pathology, we aimed at determining whether the FAAH inhibitor URB597 might target microglia polarization and alter the cytoskeleton reorganization induced by the amyloid-β peptide (Aβ). The morphological evaluation showed that Aβ treatment increased the surface area of BV-2 cells, which acquired a flat and polygonal morphology. URB597 treatment partially rescued the control phenotype of BV-2 cells when co-incubated with Aβ. Moreover, URB597 reduced both the increase of Rho protein activation in Aβ-treated BV-2 cells and the Aβ-induced migration of BV-2 cells, while an increase of Cdc42 protein activation was observed in all samples. URB597 also increased the number of BV-2 cells involved in phagocytosis. URB597 treatment induced the polarization of microglial cells towards an anti-inflammatory phenotype, as demonstrated by the decreased expression of iNOS and pro-inflammatory cytokines along with the parallel increase of Arg-1 and anti-inflammatory cytokines. Taken together, these data suggest that FAAH inhibition promotes cytoskeleton reorganization, regulates phagocytosis and cell migration processes, thus driving microglial polarization towards an anti-inflammatory phenotype.","['M1/M2 phenotypes', 'N-arachidonoylethanolamine (AEA)', 'URB597', 'actin cytoskeleton', 'cell migration', 'fatty acid amide hydrolase (FAAH)', 'microglia', 'neuroinflammation']",International journal of molecular sciences,2021-07-25,"[{'lastname': 'Grieco', 'firstname': 'Maddalena', 'initials': 'M', 'affiliation': 'Department of Biochemical Sciences, Sapienza University of Rome, Piazzale Aldo Moro 5, 00185 Rome, Italy.'}, {'lastname': 'De Caris', 'firstname': 'Maria Giovanna', 'initials': 'MG', 'affiliation': 'Department of Experimental Medicine, Sapienza University of Rome, Viale Regina Elena 324, 00161 Rome, Italy.'}, {'lastname': 'Maggi', 'firstname': 'Elisa', 'initials': 'E', 'affiliation': 'Department of Medico-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Corso della Repubblica 79, 04100 Latina, Italy.'}, {'lastname': 'Armeli', 'firstname': 'Federica', 'initials': 'F', 'affiliation': 'Department of Medico-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Corso della Repubblica 79, 04100 Latina, Italy.'}, {'lastname': 'Coccurello', 'firstname': 'Roberto', 'initials': 'R', 'affiliation': 'Fondazione Santa Lucia IRCCS, Preclinical Neuroscience, Via del Fosso di Fiorano 64, 00143 Rome, Italy.\nInstitute for Complex Systems (ISC), C.N.R., Via dei Taurini 19, 00185 Rome, Italy.'}, {'lastname': 'Bisogno', 'firstname': 'Tiziana', 'initials': 'T', 'affiliation': 'Endocannabinoid Research Group, Institute of Translational Pharmacology, CNR, Via Fosso del Cavaliere 100, 00133 Rome, Italy.'}, {'lastname': ""D'Erme"", 'firstname': 'Maria', 'initials': 'M', 'affiliation': 'Department of Biochemical Sciences, Sapienza University of Rome, Piazzale Aldo Moro 5, 00185 Rome, Italy.'}, {'lastname': 'Maccarrone', 'firstname': 'Mauro', 'initials': 'M', 'affiliation': ""Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, Via Vetoio snc, 67100 L'Aquila, Italy.\nEuropean Center for Brain Research/Santa Lucia Foundation IRCCS, Via del Fosso di Fiorano 64, 00143 Rome, Italy.""}, {'lastname': 'Mancini', 'firstname': 'Patrizia', 'initials': 'P', 'affiliation': 'Department of Experimental Medicine, Sapienza University of Rome, Viale Regina Elena 324, 00161 Rome, Italy.'}, {'lastname': 'Businaro', 'firstname': 'Rita', 'initials': 'R', 'affiliation': 'Department of Medico-Surgical Sciences and Biotechnologies, Sapienza University of Rome, Corso della Repubblica 79, 04100 Latina, Italy.'}]",,,,,"10.3390/ijms22147711
10.1056/NEJM199911253412207
10.1111/j.1471-4159.2006.04426.x
10.1038/nm0896-850
10.1016/0165-6147(94)90057-4
10.1097/00002093-199408030-00001
10.3389/fncel.2020.563446
10.1097/00002093-200000001-00008
10.1038/nn1472
10.1196/annals.1332.006
10.1002/glia.10153
10.1155/S1110724302203010
10.1016/S1474-4422(19)30032-8
10.1038/s41582-019-0284-z
10.1055/s-0037-1614296
10.3390/molecules191117078
10.1016/j.jns.2005.03.002
10.1523/JNEUROSCI.23-35-11136.2003
10.1523/JNEUROSCI.4540-04.2005
10.1016/j.phrs.2018.02.009
10.3233/JAD-130137
10.1186/1742-2094-9-8
10.1038/sj.bjp.0705667
10.1016/j.neurobiolaging.2011.03.012
10.1093/ijnp/pyy033
10.1016/j.celrep.2012.05.001
10.1016/j.neurobiolaging.2015.08.003
10.3390/cells8050491
10.1016/j.pharmthera.2013.04.013
10.1111/j.1348-0421.2000.tb02556.x
10.1007/s11064-008-9776-8
10.1016/j.neuron.2009.08.039
10.1016/j.ejphar.2020.173090
10.1002/glia.23041
10.1038/nri1733
10.1016/j.tcb.2006.08.006
10.3389/fncel.2014.00314
10.1111/bph.13139
10.1016/j.neuroscience.2020.09.024
10.3390/ijms21197354
10.1038/nature01148
10.1038/nri978
10.1007/978-3-319-20825-1_6
10.2174/1570159X16666180702144644
10.3390/ijms21030747
10.1002/glia.20983
10.1038/nn.3053
10.1016/j.febslet.2010.12.032
10.4061/2011/925050
10.3390/ijms22094850
10.1016/j.eplepsyres.2017.09.017
10.1111/j.1527-3458.2006.00021.x
10.1186/1742-2094-2-29
10.1038/s41598-017-00342-1
10.1186/1744-8069-5-25
10.1111/j.1476-5381.2012.01889.x
10.1111/j.1476-5381.2012.02208.x
10.1016/j.neuropharm.2006.11.009
10.1126/science.1202529
10.1523/JNEUROSCI.1136-17.2017
10.1007/s00018-021-03810-0
10.20517/2347-8659.2020.02
10.1016/j.bbi.2015.08.023
10.1186/s12974-019-1694-y
10.1007/s00429-015-1067-y
10.1002/glia.23782
10.1016/j.tins.2006.07.001
10.1016/S0092-8674(04)00003-0
10.1016/j.cellsig.2013.05.023
10.1128/MMBR.63.1.54-105.1999
10.1016/j.isci.2018.01.004
10.1186/s13195-017-0320-4
10.1093/brain/awm260
10.1093/cercor/bhw309
10.1016/j.jsps.2017.05.002
10.1242/jcs.03323
10.1074/jbc.M510871200
10.1016/S1567-5769(01)00147-3
10.1016/j.bbi.2015.06.002
10.1186/s13020-018-0173-1
10.3389/fneur.2020.00087
10.1189/jlb.2AB0116-009RR
10.1007/s12031-013-0063-z
10.1016/j.neuron.2014.12.068
10.3233/JAD-142832
10.1016/j.neuropharm.2014.06.006
10.1016/j.bcp.2018.08.005
10.1016/j.febslet.2007.05.037
10.1007/s00210-017-1417-9
10.1111/j.1399-3011.1983.tb03085.x
10.1006/meth.2001.1262",<Element 'PubmedArticle' at 0x7f05df529ef0>
151,34280460,"Metformin reduces oxandrolone- induced depression-like behavior in rats via modulating the expression of IL-1β, IL-6, IL-10 and TNF-α.","Oxandrolone (OXA) is an androgen and anabolic steroid (AAS) that is used to reverse weight loss associated with some medical conditions. One of the side effects of OXA is its potential to induce depressive symptoms. Growing evidence suggested that neuroinflammation and cytokines play crucial roles in sickness behavioral and associated mood disturbances. Previous studies showed that metformin attenuated neuroinflammation. This study investigated the potential protective role of metformin against OXA-induced depression-like behavior and neuroinflammation. Twenty- four Wistar male rats were randomly grouped into four groups: the control group (Control) received only vehicle; the oxandrolone group (OXA) received oxandrolone (0.28 mg/kg, i.p); the metformin group (MET) received metformin (100 mg/kg, i.p); and the oxandrolone / metformin group (OXA + MET) received both oxandrolone (0.28 mg/kg, i.p) and metformin (100 mg/kg, i.p). These treatments were administered for fourteen consecutive days. Behavioral tests to measure depression-like behavior were conducted before and after treatments. qRT-PCR was used to measure the relative expression of proinflammatory and anti-inflammatory cytokines in the hippocampus and hypothalamus. The results showed that oxandrolone induced depression-like behavior and dysregulated pro-/anti-inflammatory cytokines, while metformin attenuated these effects. These findings suggest that metformin is a potential treatment to reverse the depressive effects induced by oxandrolone that involve neuroinflammatory effects.","['Depression-like behavioral', 'Metformin', 'Neuroinflammation', 'Oxandrolone']",Behavioural brain research,2021-07-20,"[{'lastname': 'Hammad', 'firstname': 'Alaa M', 'initials': 'AM', 'affiliation': 'Department of Pharmacy, College of Pharmacy, Al-Zaytoonah University of Jordan, Amman, Jordan. Electronic address: alaa.hammad@zuj.edu.jo.'}, {'lastname': 'Ibrahim', 'firstname': 'Yasmeen A', 'initials': 'YA', 'affiliation': 'Department of Pharmacy, College of Pharmacy, Al-Zaytoonah University of Jordan, Amman, Jordan.'}, {'lastname': 'Khdair', 'firstname': 'Sawsan I', 'initials': 'SI', 'affiliation': 'Department of Pharmacy, College of Pharmacy, Al-Zaytoonah University of Jordan, Amman, Jordan.'}, {'lastname': 'Hall', 'firstname': 'F Scott', 'initials': 'FS', 'affiliation': 'Department of Pharmacology and Experimental Therapeutics, College of Pharmacy and Pharmaceutical Sciences, University of Toledo, Toledo, OH, USA.'}, {'lastname': 'Alfaraj', 'firstname': 'Malek', 'initials': 'M', 'affiliation': 'Department of Pharmacy, College of Pharmacy, Al-Zaytoonah University of Jordan, Amman, Jordan.'}, {'lastname': 'Jarrar', 'firstname': 'Yazan', 'initials': 'Y', 'affiliation': 'Department of Pharmacy, College of Pharmacy, Al-Zaytoonah University of Jordan, Amman, Jordan.'}, {'lastname': 'Abed', 'firstname': 'Abdulqader Fadhil', 'initials': 'AF', 'affiliation': 'Department of Pharmacy, College of Pharmacy, Al-Zaytoonah University of Jordan, Amman, Jordan.'}]",,,,Copyright © 2021 Elsevier B.V. All rights reserved.,10.1016/j.bbr.2021.113475,<Element 'PubmedArticle' at 0x7f05df4ab680>
152,"34275474
23146889
22201683
26208455
25497089
24914942
18267068
26016745
18854155
28683286
27903745
17681884
15364058
18787108
20102710
27175610
24366864
27086950
31917347
30935076
12379902
24166765
32275331
12532159
20576518
20349136
25898198
31534953
16876587
12508119
16056392
23459752
25626735
25456138
28377875
26306651
19144836
17956294
28489068
27986987
25646713
27773938",C1q/TNF-related protein 4 restores leptin sensitivity by downregulating NF-κB signaling and microglial activation.,"C1qTNF-related protein 4 (CTRP4) acts in the hypothalamus to modulate food intake in diet-induced obese mice and has been shown to exert an anti-inflammatory effect on macrophages. Since high-fat diet-induced microglial activation and hypothalamic inflammation impair leptin signaling and increase food intake, we aimed to explore the potential connection between the anorexigenic effect of CTRP4 and the suppression of hypothalamic inflammation in mice with DIO.
Using an adenovirus-mediated hypothalamic CTRP4 overexpression model, we investigated the impact of CTRP4 on food intake and the hypothalamic leptin signaling pathway in diet-induced obese mice. Furthermore, central and plasma proinflammatory cytokines, including TNF-α and IL-6, were measured by Western blotting and ELISA. Changes in the hypothalamic NF-κB signaling cascade and microglial activation were also examined in vivo. In addition, NF-κB signaling and proinflammatory factors were investigated in BV-2 cells after CTRP4 intervention.
We found that food intake was decreased, while leptin signaling was significantly improved in mice with DIO after CTRP4 overexpression. Central and peripheral TNF-α and IL-6 levels were reduced by central Ad-CTRP4 administration. Hypothalamic NF-κB signaling and microglial activation were also significantly suppressed in vivo. In addition, NF-κB signaling was inhibited in BV-2 cells following CTRP4 intervention, which was consistent with the decreased production of TNF-α and IL-6.
Our data indicate that CTRP4 reverses leptin resistance by inhibiting NF-κB-dependent microglial activation and hypothalamic inflammation.","['CTRP4', 'Diet-induced obesity', 'Leptin signaling', 'Microglial activation', 'NF-κB signaling']",Journal of neuroinflammation,2021-07-20,"[{'lastname': 'Ye', 'firstname': 'Liu', 'initials': 'L', 'affiliation': 'Department of Rehabilitation, The Second Affiliated Hospital of Chongqing Medical University, 76 Linjiang Road, Yuzhong District, Chongqing, 400010, China.'}, {'lastname': 'Jia', 'firstname': 'Gongwei', 'initials': 'G', 'affiliation': 'Department of Rehabilitation, The Second Affiliated Hospital of Chongqing Medical University, 76 Linjiang Road, Yuzhong District, Chongqing, 400010, China.'}, {'lastname': 'Li', 'firstname': 'Yuejie', 'initials': 'Y', 'affiliation': 'Department of Rehabilitation, The Second Affiliated Hospital of Chongqing Medical University, 76 Linjiang Road, Yuzhong District, Chongqing, 400010, China.'}, {'lastname': 'Wang', 'firstname': 'Ying', 'initials': 'Y', 'affiliation': 'Department of Rehabilitation, The Second Affiliated Hospital of Chongqing Medical University, 76 Linjiang Road, Yuzhong District, Chongqing, 400010, China.'}, {'lastname': 'Chen', 'firstname': 'Hong', 'initials': 'H', 'affiliation': 'Department of Orthopedics, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.'}, {'lastname': 'Yu', 'firstname': 'Lehua', 'initials': 'L', 'affiliation': 'Department of Rehabilitation, The Second Affiliated Hospital of Chongqing Medical University, 76 Linjiang Road, Yuzhong District, Chongqing, 400010, China.'}, {'lastname': 'Wu', 'firstname': 'Dandong', 'initials': 'D', 'affiliation': 'Department of Rehabilitation, The Second Affiliated Hospital of Chongqing Medical University, 76 Linjiang Road, Yuzhong District, Chongqing, 400010, China. facia2010@126.com.'}]",,,"We found that food intake was decreased, while leptin signaling was significantly improved in mice with DIO after CTRP4 overexpression. Central and peripheral TNF-α and IL-6 levels were reduced by central Ad-CTRP4 administration. Hypothalamic NF-κB signaling and microglial activation were also significantly suppressed in vivo. In addition, NF-κB signaling was inhibited in BV-2 cells following CTRP4 intervention, which was consistent with the decreased production of TNF-α and IL-6.",© 2021. The Author(s).,"10.1186/s12974-021-02167-2
10.1038/embor.2012.174
10.1172/JCI59660
10.1016/j.bbrc.2015.07.097
10.1016/j.celrep.2014.11.018
10.1210/en.2014-1121
10.1016/j.cell.2008.01.020
10.1530/JOE-15-0139
10.1016/j.cell.2008.07.043
10.1016/j.cmet.2017.05.015
10.2337/db16-0586
10.1016/j.it.2007.07.003
10.1016/j.it.2004.08.006
10.1096/fj.08-114991
10.1016/j.atherosclerosis.2016.04.024
10.1074/jbc.M113.506956
10.1038/cmi.2016.16
10.1016/j.neuroscience.2019.12.039
10.3390/nu11040752
10.1002/glia.10161
10.1002/glia.22580
10.1096/fj.201901836RR
10.1038/sj.ijo.0802187
10.1007/s10495-010-0495-7
10.1038/ni.3153
10.1016/S0079-6123(06)53022-5
10.1038/nature01339
10.1038/nrd1797
10.1113/jphysiol.2012.249268
10.2337/db14-0093
10.1016/j.celrep.2014.10.045
10.1016/j.molmet.2017.01.010
10.1016/j.neulet.2015.08.033
10.1523/JNEUROSCI.2760-08.2009
10.1042/BST0351127
10.1038/ncomms15143
10.1007/s00125-016-4181-3
10.1210/en.2014-1849
10.1038/ijo.2016.183",<Element 'PubmedArticle' at 0x7f05df43b9f0>
153,34274445,Coupling of GPR30 mediated neurogenesis and protection with astroglial Aromatase-STAT3 signaling in rat hippocampus after global cerebral ischemia.,"Our previous study revealed that G-protein-coupled estrogen receptor-30 (GPR30) agonist G1 serves as a viable alternative neuroprotectant of 17β-estradiol (E2) to attenuate neuroinflammation and improve cognitive function after global cerebral ischemia (GCI). Aromatase, the key enzyme of E2 biosynthesis, is widely expressed in animal and human brain, and its expression and activity are mediated by selective estrogen receptor modulators. In the present study, we explored the long-term protective and reparative effects of G1 in ovariectomized rats after GCI. We used the aromatase inhibitor letrozole to elucidate whether G1 and brain-derived E2 together induce beneficial effects. Our results showed that G1 administration for 28 days a) significantly increased neurogenesis in the hippocampal sub-granular zone and CA1 regions; b) declined CA1 neuronal impairment in a long-term fashion; c) enhanced expression of synaptic proteins and cognitive function; d) and prevented reactive astrocytes loss, wherein aromatase and brain-derived estrogen levels were markedly increased. Additionally, expression and activation of transducer and activator of transcription 3 (STAT3) were increased in CA1 astrocytes of G1-treated animals. Letrozole abolished all of the observed benefits of G1. Our results suggest that GPR30 activation mediates long-term neuroprotection and neurogenesis in the hippocampus following GCI, with potential mechanism coupling with the activation of astroglial aromatase-STAT3 signaling.","['Aromatase', 'Astroglial', 'G protein coupled receptor 30', 'Global cerebral ischemia', 'Neurogenesis', 'Signal transducer and activator of transcription 3']",Molecular and cellular endocrinology,2021-07-19,"[{'lastname': 'Wang', 'firstname': 'Lu', 'initials': 'L', 'affiliation': 'School of Public Health of North China University of Science and Technology, Tangshan, Hebei, 063210, China; Dementia and Dyscognitive Key Lab, Tangshan, Hebei, 063000, China; International Science & Technology Cooperation Base of Geriatric Medicine, Tangshan, Hebei, 063000, China.'}, {'lastname': 'Liu', 'firstname': 'Jiahao', 'initials': 'J', 'affiliation': 'School of Public Health of North China University of Science and Technology, Tangshan, Hebei, 063210, China; Dementia and Dyscognitive Key Lab, Tangshan, Hebei, 063000, China; International Science & Technology Cooperation Base of Geriatric Medicine, Tangshan, Hebei, 063000, China.'}, {'lastname': 'Xu', 'firstname': 'Jing', 'initials': 'J', 'affiliation': 'Dementia and Dyscognitive Key Lab, Tangshan, Hebei, 063000, China; International Science & Technology Cooperation Base of Geriatric Medicine, Tangshan, Hebei, 063000, China; School of Basic Medical Sciences, North China University of Science and Technology, Tangshan, Hebei, 063210, China.'}, {'lastname': 'Zhang', 'firstname': 'Wenli', 'initials': 'W', 'affiliation': 'School of Public Health of North China University of Science and Technology, Tangshan, Hebei, 063210, China; Dementia and Dyscognitive Key Lab, Tangshan, Hebei, 063000, China; International Science & Technology Cooperation Base of Geriatric Medicine, Tangshan, Hebei, 063000, China.'}, {'lastname': 'Wang', 'firstname': 'Ruimin', 'initials': 'R', 'affiliation': 'School of Public Health of North China University of Science and Technology, Tangshan, Hebei, 063210, China; Dementia and Dyscognitive Key Lab, Tangshan, Hebei, 063000, China; International Science & Technology Cooperation Base of Geriatric Medicine, Tangshan, Hebei, 063000, China; School of Basic Medical Sciences, North China University of Science and Technology, Tangshan, Hebei, 063210, China. Electronic address: ruimin-wang@163.com.'}]",,,,Copyright © 2021 Elsevier B.V. All rights reserved.,10.1016/j.mce.2021.111394,<Element 'PubmedArticle' at 0x7f05df462720>
154,34225933,Central and peripheral release of oxytocin: Relevance of neuroendocrine and neurotransmitter actions for physiology and behavior.,"The hypothalamic neuropeptide oxytocin (OT) is critically involved in the modulation of socio-emotional behavior, sexual competence, and pain perception and anticipation. While intracellular signaling of OT and its receptor (OTR), as well as the functional connectivity of hypothalamic and extra-hypothalamic OT projections, have been recently explored, it remains elusive how one single molecule has pleotropic effects from cell proliferation all the way to modulation of complex cognitive processes. Moreover, there are astonishing species-dependent differences in the way OT regulates various sensory modalities such as touch, olfaction, and vision, which can be explained by differences in OTR expression in brain regions processing sensory information. Recent research highlights a small subpopulation of OT-synthesizing cells, namely, parvocellular cells, which merely constitute 1% of the total number of OT cells but act as ""master cells' that regulate the activity of the entire OT system. In this chapter, we summarize the latest advances in the field of OT research with a particular focus on differences between rodents, monkeys and humans and highlight the main differences between OT and its ""sister"" peptide arginine-vasopressin, which often exerts opposite effects on physiology and behavior.","['Arginine–vasopressin', 'Axonal release', 'Glutamate', 'Magnocellular neurons', 'Oxytocin', 'Oxytocin receptor', 'Parvocellular neurons', 'Primates', 'Rodents', 'Somatodendritic release']",Handbook of clinical neurology,2021-07-07,"[{'lastname': 'Althammer', 'firstname': 'Ferdinand', 'initials': 'F', 'affiliation': 'Neuroscience Department, Center for Neuroinflammation and Cardiometabolic Diseases, Georgia State University, Atlanta, GA, United States.'}, {'lastname': 'Eliava', 'firstname': 'Marina', 'initials': 'M', 'affiliation': 'Department of Neuropeptide Research in Psychiatry, Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany.'}, {'lastname': 'Grinevich', 'firstname': 'Valery', 'initials': 'V', 'affiliation': 'Department of Neuropeptide Research in Psychiatry, Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany. Electronic address: valery.grinevich@zi-mannheim.de.'}]",,,,Copyright © 2021 Elsevier B.V. All rights reserved.,10.1016/B978-0-12-820107-7.00003-3,<Element 'PubmedArticle' at 0x7f05df46fb30>
155,34218479,The multiple faces of the oxytocin and vasopressin systems in the brain.,"Classically, hypothalamic neuroendocrine cells that synthesise oxytocin and vasopressin were categorised in two major cell types: the magnocellular and parvocellular neurones. It was assumed that magnocellular neurones project exclusively to the pituitary gland where they release oxytocin and vasopressin into the systemic circulation. The parvocellular neurones, on the other hand, project within the brain to regulate discrete brain circuitries and behaviours. Within the last few years, it has become evident that the classical view of these projections is outdated. It is now clear that oxytocin and vasopressin in the brain are released extrasynaptically from dendrites and from varicosities in distant axons. The peptides act principally to modulate information transfer through conventional synapses (such as glutamate synapses) by actions at respective receptors that may be preferentially localised to synaptic regions (on either side of the synapse) to alter the 'gain' of conventional synapses.","['anatomy', 'axonal release', 'magnocellular', 'oxytocin', 'parvocellular', 'projections', 'somato-dendritic release', 'vasopressin']",Journal of neuroendocrinology,2021-07-05,"[{'lastname': 'Grinevich', 'firstname': 'Valery', 'initials': 'V', 'affiliation': 'Department of Neuropeptide Research in Psychiatry, Central Institute of Mental Health, University of Heidelberg, Mannheim, Germany.\nCentre for Neuroinflammation and Cardiometabolic Diseases, Georgia State University, Atlanta, GA, USA.'}, {'lastname': 'Ludwig', 'firstname': 'Mike', 'initials': 'M', 'affiliation': 'Centre for Discovery Brain Sciences, University of Edinburgh, Edinburgh, UK.\nCentre for Neuroendocrinology, Department of Immunology, University of Pretoria, Pretoria, South Africa.'}]",,,,© 2021 British Society for Neuroendocrinology.,10.1111/jne.13004,<Element 'PubmedArticle' at 0x7f05df3f87c0>
156,34082316,Bisphenol A impairs cognitive function and 5-HT metabolism in adult male mice by modulating the microbiota-gut-brain axis.,"Bisphenol A (BPA) has been found to promote hepatotoxicity, reproductive toxicity, and developmental toxicity. However, the neurotoxicity and mechanism of BPA on cognitive function are still unclear. To that end, eight-week-old adult male and female C57BL/6J mice were exposed to 0.05, 0.5, 5, and 50 mg/kg BPA by dietary supplementation for 22 weeks. BPA exposure impaired learning and memory in male mice, associated with increased neuroinflammation and damaged blood-brain barrier. BPA exposure reduced the tight junctions in the colon, resulting in dysfunction of the gut barrier. The levels of neurotransmitters in the serum, hippocampus, and colon of male mice, including tryptophan, 5-hydroxytryptamine (5-HT) and 5-hydroxyindoleacetic acid, were all decreased by BPA, together with reduced expression of tryptophan and 5-HT metabolism-related genes. Cecal microbiota analysis revealed that the diversity and composition of the microbiota in male mice were markedly altered by BPA, leading to functional profile changes in the microbial community. These results suggest that the neurotoxicity of BPA in male mice may be partly regulated by the interactions of the microbiota-gut-brain axis. However, BPA has little effect on the cognitive function in female mice, which might be caused by the microbial differences and the role of estrogen receptors.","['Bisphenol A', 'Blood-brain barrier', 'Cognitive function', 'Gut barrier', 'Microbiota-gut-brain axis', 'Neurotransmitter']",Chemosphere,2021-06-04,"[{'lastname': 'Ni', 'firstname': 'Yinhua', 'initials': 'Y', 'affiliation': 'College of Biotechnology and Bioengineering, Zhejiang University of Technology, China.'}, {'lastname': 'Hu', 'firstname': 'Luting', 'initials': 'L', 'affiliation': 'College of Biotechnology and Bioengineering, Zhejiang University of Technology, China.'}, {'lastname': 'Yang', 'firstname': 'Song', 'initials': 'S', 'affiliation': 'College of Biotechnology and Bioengineering, Zhejiang University of Technology, China.'}, {'lastname': 'Ni', 'firstname': 'Liyang', 'initials': 'L', 'affiliation': 'College of Biotechnology and Bioengineering, Zhejiang University of Technology, China.'}, {'lastname': 'Ma', 'firstname': 'Lingyan', 'initials': 'L', 'affiliation': 'College of Biotechnology and Bioengineering, Zhejiang University of Technology, China.'}, {'lastname': 'Zhao', 'firstname': 'Yufeng', 'initials': 'Y', 'affiliation': 'College of Biotechnology and Bioengineering, Zhejiang University of Technology, China.'}, {'lastname': 'Zheng', 'firstname': 'Aqian', 'initials': 'A', 'affiliation': 'College of Biotechnology and Bioengineering, Zhejiang University of Technology, China.'}, {'lastname': 'Jin', 'firstname': 'Yuanxiang', 'initials': 'Y', 'affiliation': 'College of Biotechnology and Bioengineering, Zhejiang University of Technology, China.'}, {'lastname': 'Fu', 'firstname': 'Zhengwei', 'initials': 'Z', 'affiliation': 'College of Biotechnology and Bioengineering, Zhejiang University of Technology, China. Electronic address: azwfu@zjut.edu.cn.'}]",,,,Copyright © 2021 Elsevier Ltd. All rights reserved.,10.1016/j.chemosphere.2021.130952,<Element 'PubmedArticle' at 0x7f05df40b220>
157,"34069940
15387480
29743650
31806905
26194075
23044824
29630225
21327168
33114698
27150288
29470410
18029339
25027766
24904283
29576849
31396087
22414817
23394520
25210802
23206503
25205418
27539936
24066256
26491593
27220803
29486338
30927159
23667516
32106527
27924524
28325153
29676237
23449036
32560159
24032675
23964161
22772472
7724569
19625089
30505308
19933834
18657182
13211905
29311913
21601500
11301536
26283633
19909294
27720681
24423192
18181976
21255263
23394526
26706245
25046306
22884901
27701827
30177906
24948120
25164769
18602217
23394519
22558609
26604814
24804094
22084787
26334329
17459586
16880317
26233289
25974242
20176435
21601979
18417375
32150935
33265983
28321191
24082036
30953765
28215162
22410503
32718895
31426423
28161475
31514292
392005
22244572
28336953
15864274
26189369
20003352
23394523
20389049
20519886
19840548
25177273
12527815
30193877
25598150
12432941
18031566
19828304
22561833
22912680
29662433
27004851
19394765
18311684
25568124
26578323
25830558
29134359
27623929
30622429
28867303
31485978
31181700
23404369
23108549
31496832
30929760
15465922
17876302
11485574
18695637
19386271
21354467
23394524
23533304
27033477
28939471
30961531
30353868
15009009
18778570
32377286
28944048
24075089
23891544
17174824
23415738
30495997
30370434
20699160
24899825
24899883
26815246
20589688
24653755
28149655
20609564
23264838
32848762
18443635
16682240
12374520
22293240
16495392
21689421
33137899
26055231
9685157
23813098
24952959
16004597
11730234
12409811
8887208
27752983
24030935
28035017
20518645
2868515
14715039
23013520
34676324
31161980
33998849
33381640
30617517
9632753
30110239
32774241
30559589
12888546
16585410
21075236
17803017
28579842
29797753
26444713
21857095
20469800
26867484
26068727
29885369
21961415
29102992
21779318
15000462
29615912
29974228
33302446
23394528",Palmitoylethanolamide: A Natural Compound for Health Management.,"All nations which have undergone a nutrition transition have experienced increased frequency and falling latency of chronic degenerative diseases, which are largely driven by chronic inflammatory stress. Dietary supplementation is a valid strategy to reduce the risk and severity of such disorders. Palmitoylethanolamide (PEA) is an endocannabinoid-like lipid mediator with extensively documented anti-inflammatory, analgesic, antimicrobial, immunomodulatory and neuroprotective effects. It is well tolerated and devoid of side effects in animals and humans. PEA's actions on multiple molecular targets while modulating multiple inflammatory mediators provide therapeutic benefits in many applications, including immunity, brain health, allergy, pain modulation, joint health, sleep and recovery. PEA's poor oral bioavailability, a major obstacle in early research, has been overcome by advanced delivery systems now licensed as food supplements. This review summarizes the functionality of PEA, supporting its use as an important dietary supplement for lifestyle management.","['ALIAmides', 'bioactive lipids', 'dietotherapy', 'endocannbinoids', 'immunomodulation', 'immunomodulator', 'inflammation', 'lipid signaling', 'molecular mechanism', 'neuroinflammation', 'nutraceuticals', 'pain']",International journal of molecular sciences,2021-06-03,"[{'lastname': 'Clayton', 'firstname': 'Paul', 'initials': 'P', 'affiliation': 'Institute of Food, Brain and Behaviour, Beaver House, 23-28 Hythe Bridge Street, Oxford OX1 2EP, UK.'}, {'lastname': 'Hill', 'firstname': 'Mariko', 'initials': 'M', 'affiliation': 'Gencor Pacific Limited, Discovery Bay, Lantau Island, New Territories, Hong Kong, China.'}, {'lastname': 'Bogoda', 'firstname': 'Nathasha', 'initials': 'N', 'affiliation': 'Gencor Pacific Limited, Discovery Bay, Lantau Island, New Territories, Hong Kong, China.'}, {'lastname': 'Subah', 'firstname': 'Silma', 'initials': 'S', 'affiliation': 'Gencor Pacific Limited, Discovery Bay, Lantau Island, New Territories, Hong Kong, China.'}, {'lastname': 'Venkatesh', 'firstname': 'Ruchitha', 'initials': 'R', 'affiliation': 'School of Medicine, University of Hong Kong, Hong Kong, China.'}]",,,,,"10.3390/ijms22105305
10.1111/j.1753-4887.2004.tb00084.x
10.1038/s41576-018-0012-3
10.2147/RRCC.S16919
10.1038/s41591-019-0675-0
10.3803/EnM.2015.30.2.159
10.1038/embor.2012.142
10.4103/0973-1229.58817
10.3390/ijms21217942
10.1038/nrendo.2016.54
10.3390/nu10020248
10.1007/BF02877718
10.1186/1475-2891-13-72
10.3389/fncel.2014.00138
10.1155/2018/4720532
10.3389/fphar.2019.00821
10.1038/npp.2012.25
10.2174/1871527311312010010
10.1038/cddis.2014.376
10.23736/S0393-3660.17.03564-1
10.1016/j.neuropharm.2012.11.017
10.1111/bph.12907
10.1111/bph.13580
10.1155/2013/151028
10.4172/2167-0846.1000114
10.1155/2015/325061
10.1111/bcp.13020
10.1016/j.jad.2018.02.057
10.1007/s10787-019-00582-9
10.1371/journal.pone.0062741
10.3390/nu12030596
10.1007/s12035-016-0313-5
10.2174/1871527316666170321124949
10.2174/1871527317666180420143830
10.1007/s11552-011-9373-1
10.3390/vetsci7020078
10.1111/imm.12170
10.2147/JPR.S48653
10.1097/SHK.0b013e318267bbb9
10.1073/pnas.92.8.3376
10.1016/j.vetimm.2009.06.011
10.3389/fimmu.2018.02671
10.1128/IAI.01110-09
10.1111/j.1460-9568.2008.06377.x
10.1084/jem.100.5.425
10.3389/fphar.2017.00857
10.1016/j.tvjl.2011.04.002
10.1046/j.1365-3164.2001.00214.x
10.1111/vde.12250
10.1111/j.1398-9995.2009.02254.x
10.1016/j.ejphar.2016.10.005
10.1186/1746-6148-10-21
10.1111/j.1468-3083.2007.02351.x
10.1111/j.1582-4934.2011.01267.x
10.2174/1871527311312010011
10.1007/s12975-015-0440-8
10.1089/neu.2014.3460
10.1016/j.bbi.2012.07.021
10.1111/cns.12648
10.3389/fneur.2018.00674
10.1038/nrd4334
10.1186/s12974-014-0136-0
10.1016/j.pain.2008.06.003
10.2174/1871527311312010008
10.2147/JPR.S93106
10.1155/2014/849623
10.5402/2011/917350
10.1007/s40122-015-0038-6
10.1016/j.pain.2007.03.012
10.15436/2377-1348.16.019
10.1097/01.AOG.0000230214.26638.0c
10.1016/j.jpag.2014.12.011
10.1097/j.pain.0000000000000220
10.1016/j.ejogrb.2010.01.008
10.1016/j.ejogrb.2011.04.011
10.1016/j.joca.2008.03.002
10.3390/antiox9030216
10.3390/ijms21239103
10.3389/fphar.2017.00095
10.1136/gutjnl-2013-305005
10.1016/j.bbi.2019.04.006
10.2174/0929867324666170216113756
10.1016/j.jad.2012.02.023
10.1016/j.jiph.2020.07.001
10.3390/nu11081933
10.1016/j.bbi.2017.01.021
10.3390/nu11092175
10.1007/bf00560353
10.1016/j.jneuroim.2011.12.013
10.1038/s41598-017-00342-1
10.1038/nri1602
10.1038/cmi.2015.74
10.1186/cc8208
10.2174/1871527311312010013
10.1159/000312403
10.1159/000315947
10.1016/j.neuron.2009.09.033
10.3389/fncel.2014.00240
10.1124/mol.63.2.429
10.1016/j.bbi.2018.09.003
10.1111/bph.13084
10.1016/S0090-6980(02)00053-9
10.1111/j.1365-2222.2007.02886.x
10.1016/j.coi.2009.09.006
10.1038/nm.2755
10.1371/journal.pone.0041880
10.3389/fnins.2018.00145
10.1038/srep23481
10.1016/j.psyneuen.2009.03.013
10.1055/s-2007-993211
10.1523/JNEUROSCI.3561-14.2015
10.1038/srep16676
10.1007/s13311-017-0585-0
10.1096/fj.201500132
10.1155/2018/2037838
10.1016/j.euroneuro.2017.08.433
10.1007/s12325-019-01053-x
10.3390/biom9060223
10.1007/s00401-013-1092-y
10.1098/rstb.2011.0391
10.2147/IJWH.S204275
10.1016/j.bja.2019.02.019
10.1124/mol.104.006353
10.1038/sj.bjp.0707460
10.1042/bj3580249
10.1038/bjp.2008.324
10.1016/j.ejphar.2009.04.022
10.1016/j.bbi.2011.02.006
10.2174/1871527311312010009
10.1155/2013/328797
10.3399/bjgp16X684433
10.1016/j.amjmed.2017.09.005
10.1186/s10194-019-0985-0
10.1016/S1474-4422(18)30322-3
10.1111/j.1468-2982.2003.00644.x
10.1007/s11916-006-0042-y
10.1155/2020/3938640
10.12688/f1000research.11682.1
10.1016/j.jpag.2013.06.018
10.1016/j.ejogrb.2013.07.004
10.1016/j.jpag.2006.09.001
10.1016/j.ejogrb.2013.01.009
10.2105/AJPH.2018.304747
10.1007/s11914-018-0493-1
10.1016/j.cger.2010.03.002
10.4137/CMAMD.S14386
10.12816/0006075
10.1002/acr.20142
10.1038/boneres.2016.44
10.1016/j.ijom.2010.06.003
10.2174/1874312901206010320
10.3389/fphar.2020.01153
10.1016/j.ejpain.2006.02.013
10.1001/archinte.162.18.2113
10.6051/j.issn.2311-5106.2014.01.7
10.1186/ar3657
10.1056/NEJMoa052771
10.1186/1550-2783-8-8
10.11648/j.ijnfs.20211001.12
10.3390/ijms21218056
10.1007/s12035-015-9253-8
10.1038/28393
10.1007/s12035-013-8487-6
10.1016/j.drudis.2014.06.007
10.1517/13543784.14.6.695
10.1093/gerona/56.suppl_2.13
10.1097/00002060-200211001-00007
10.1080/02640419608727714
10.1007/s40279-016-0640-8
10.1002/mus.24077
10.1152/japplphysiol.00971.2016
10.1515/CCLM.2010.179
10.2165/00007256-198603010-00003
10.2165/00007256-200434010-00005
10.1007/BF03262309
10.1159/000489287
10.2174/1570159X17666190603171901
10.1089/can.2019.0078
10.1089/can.2019.0101
10.1186/s40798-018-0176-6
10.1128/MCB.18.7.3708
10.1080/17461391.2018.1505957
10.3389/fnmol.2020.00125
10.1101/lm.58503
10.1161/01.HYP.0000217362.34748.e0
10.1016/B978-0-444-53702-7.00007-5
10.5664/jcsm.26918
10.2147/NSS.S134864
10.1111/jsr.12710
10.1371/journal.pone.0140058
10.1016/S1734-1140(11)70596-5
10.1093/sleep/33.5.585
10.1016/j.jpain.2016.01.474
10.1038/npp.2015.166
10.1016/j.jpain.2018.05.008
10.1136/bmjopen-2017-017732
10.1371/journal.pone.0020766
10.36648/nutraceuticals.5.2.3
10.1081/PDT-120027417
10.3389/fphar.2018.00249
10.1007/s00394-018-1766-2
10.3390/pharmaceutics12121190
10.2174/1871527311312010007",<Element 'PubmedArticle' at 0x7f05df412ef0>
158,"33998879
27443914
32276639
25380660
26470014
28099414
25233945
27154981
31238091
31748578
29549313
22591363
24950453
15831717
27052459
22818222
30205834
24123203
22315714
29578037
1438191
29406582
8799208
9037082
28122624
25448601
27273074
26499082
27033548
16127449
23533304
19245367
23374874
26578886
20880511
27158245
28825114
22634229
27077495
19421417
25448777
23794089
7565624
20305287
29786066
17178196
29945070
20868672
18302763
26082912
21856425
24691121
24089194
29121947
28668091
18546601
16496359
16555295
16901708
15509551
23104886
25260700
30567491
25516281
15941488
17202159
25673868
19544418
31383729
2007861
1320057
15962507
26689571
26637429
30957015
27309350
27424778
28481360
25024347
24577515
15390091
11906286
11564411
29456837
11342663
31809361","The Cannabinoid Receptor Agonist, WIN-55212-2, Suppresses the Activation of Proinflammatory Genes Induced by Interleukin 1 Beta in Human Astrocytes.",,"['immunosuppression', 'inflammation', 'neurobiology', 'synthetic cannabinoids']",Cannabis and cannabinoid research,2021-05-18,"[{'lastname': 'Fields', 'firstname': 'Jerel Adam', 'initials': 'JA', 'affiliation': 'Department of Psychiatry and University of California San Diego, La Jolla, California, USA.'}, {'lastname': 'Swinton', 'firstname': 'Mary K', 'initials': 'MK', 'affiliation': 'Department of Psychiatry and University of California San Diego, La Jolla, California, USA.'}, {'lastname': 'Montilla-Perez', 'firstname': 'Patricia', 'initials': 'P', 'affiliation': 'Department of Medicine, University of California San Diego, La Jolla, California, USA.'}, {'lastname': 'Ricciardelli', 'firstname': 'Eugenia', 'initials': 'E', 'affiliation': 'Institute of Genomic Medicine, University of California San Diego, La Jolla, California, USA.'}, {'lastname': 'Telese', 'firstname': 'Francesca', 'initials': 'F', 'affiliation': 'Department of Medicine, University of California San Diego, La Jolla, California, USA.'}]",,,,,10.1089/can.2020.0128,<Element 'PubmedArticle' at 0x7f05df291cc0>
159,33962227,Ciprofloxacin and dexamethasone in combination attenuate S. aureus induced brain abscess via neuroendocrine-immune interaction of TLR-2 and glucocorticoid receptor leading to behavioral improvement.,"Staphylococcus aureus induced brain abscess is a critical health concern throughout the developing world. The conventional surgical intervention could not regulate the abscess-induced brain inflammation. Thus further study over the alternative therapeutic strategy for treating a brain abscess is of high priority. The resident glial cells recognize the invading S. aureus by their cell surface Toll-like receptor-2 (TLR-2). Glucocorticoid receptor (GR) was known for its immunosuppressive effects. In this study, an attempt had been taken to utilize the functional relationship or cross-talking between TLR-2 and GR during the pathogenesis of brain abscesses. Here, the combination of an antibiotic (i.e. ciprofloxacin) and dexamethasone was used to regulate the brain inflammation either in TLR-2 or GR blocking condition. We were also interested to figure out the possible impact of alternative therapy on behavioral impairments. The results indicated that combination treatment during TLR-2 blockade significantly reduced the bacterial burden and abscess area score in the infected brain. However, marked improvements were observed in anxiety, depression-like behavior, and motor co-ordination. The combination treatment after TLR-2 blocking effectively scavenged free radicals (H","['Brain abscess', 'Ciprofloxacin', 'Dexamethasone', 'Inflammation', 'Microglia', 'S. aureus']",International immunopharmacology,2021-05-08,"[{'lastname': 'Dey', 'firstname': 'Rajen', 'initials': 'R', 'affiliation': 'Department of Physiology, Immunology Laboratory, University of Calcutta, University Colleges of Science and Technology, Calcutta, West Bengal, India.'}, {'lastname': 'Bishayi', 'firstname': 'Biswadev', 'initials': 'B', 'affiliation': 'Department of Physiology, Immunology Laboratory, University of Calcutta, University Colleges of Science and Technology, Calcutta, West Bengal, India. Electronic address: bbphys@caluniv.ac.in.'}]",,,,Copyright © 2021 Elsevier B.V. All rights reserved.,10.1016/j.intimp.2021.107695,<Element 'PubmedArticle' at 0x7f05df1ff5e0>
160,"33942174
26902870
11568644
32480309
9367260
6204013
16022602
12898614
25380804
1486150
6436477
22872230
22296742
30976648
15147308
21554570
1504840
1352088
416887
25310993
1759558
21516512
12498954
22002422
30293197
8027519
11706109
17823269
632368
29038736
23157409
30809111
29895964
29297596
17151169
26050140
28211814
33608699
6890396
6320030
24849862
579535
34906346
851895
12176079
1322067
8381505
30267649
8910902
4040613
1726027
33313963
23801736
1449247
12823466
28974926
32875628
33207731
21813697
11296096
18372313
4052770
12675915
16452658
20231476
25792098
30568576
18358569
10545156
31634513
29050913
26150341
21440258
27597825
26365177
24990930
31173842
2325821
21129451
4009243
31785021
29285207
17229089
31793911
24704327
28109312
31177220
32383020
11882374
25905349
27574304
29107830
32249849
7753394
30546103
7560278
10690972
6155966
7069423
6707659
3160517
13679251
23383396
23796701
28708061
14745052
25766617
31416793
30954437
29161567
29797112
32429301
9822755
32943779
7170052
16029199
16528616
1260438
19506723
23706187
3840810
3453741
27022631
30028316
7631873
21782889
29272343
29101940
1410432
819466
23761387
2992284
19276542
12084879
27513978
24311996
17928156
22554955
29475564
17267521
23486878
31102663
23360840
23628478
32410936
23636330
27306266
30322903
22048062",The connections of Locus Coeruleus with hypothalamus: potential involvement in Alzheimer's disease.,"The hypothalamus and Locus Coeruleus (LC) share a variety of functions, as both of them take part in the regulation of the sleep/wake cycle and in the modulation of autonomic and homeostatic activities. Such a functional interplay takes place due to the dense and complex anatomical connections linking the two brain structures. In Alzheimer's disease (AD), the occurrence of endocrine, autonomic and sleep disturbances have been associated with the disruption of the hypothalamic network; at the same time, in this disease, the occurrence of LC degeneration is receiving growing attention for the potential roles it may have both from a pathophysiological and pathogenetic point of view. In this review, we summarize the current knowledge on the anatomical and functional connections between the LC and hypothalamus, to better understand whether the impairment of the former may be responsible for the pathological involvement of the latter, and whether the disruption of their interplay may concur to the pathophysiology of AD. Although only a few papers specifically explored this topic, intriguingly, some pre-clinical and post-mortem human studies showed that aberrant protein spreading and neuroinflammation may cause hypothalamus degeneration and that these pathological features may be linked to LC impairment. Moreover, experimental studies in rodents showed that LC plays a relevant role in modulating the hypothalamic sleep/wake cycle regulation or neuroendocrine and systemic hormones; in line with this, the degeneration of LC itself may partly explain the occurrence of hypothalamic-related symptoms in AD.","['Alzheimer’s disease', 'Autonomic system', 'Hypothalamus', 'Locus Coeruleus', 'Neurodegenerative disorders', 'Noradrenaline', 'Sleep']","Journal of neural transmission (Vienna, Austria : 1996)",2021-05-05,"[{'lastname': 'Giorgi', 'firstname': 'Filippo Sean', 'initials': 'FS', 'affiliation': 'Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Via Roma 55, 56126, Pisa, Italy.'}, {'lastname': 'Galgani', 'firstname': 'Alessandro', 'initials': 'A', 'affiliation': 'Neurology Unit, Pisa University Hospital, 56126, Pisa, Italy.'}, {'lastname': 'Puglisi-Allegra', 'firstname': 'Stefano', 'initials': 'S', 'affiliation': 'I.R.C.C.S. Neuromed, Via Atinense 18, 86077, Pozzilli, IS, Italy.'}, {'lastname': 'Busceti', 'firstname': 'Carla Letizia', 'initials': 'CL', 'affiliation': 'I.R.C.C.S. Neuromed, Via Atinense 18, 86077, Pozzilli, IS, Italy.'}, {'lastname': 'Fornai', 'firstname': 'Francesco', 'initials': 'F', 'affiliation': 'Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Via Roma 55, 56126, Pisa, Italy. francesco.fornai@med.unipi.it.\nI.R.C.C.S. Neuromed, Via Atinense 18, 86077, Pozzilli, IS, Italy. francesco.fornai@med.unipi.it.'}]",,,,,"10.1007/s00702-021-02338-8
10.1007/s12020-016-0897-6
10.1097/00001756-200110080-00023
10.1016/j.parkreldis.2020.05.013
10.1016/S0006-8993(97)00613-6
10.1111/j.1471-4159.1984.tb00913.x
10.1146/annurev.neuro.28.061604.135709
10.1002/cne.10783
10.1177/1533317514556876
10.1016/0006-3223(92)90132-J
10.1113/jphysiol.1984.sp015425
10.1038/jcbfm.2012.115
10.1016/j.smrv.2011.12.003
10.1016/j.dadm.2019.02.001
10.1111/j.0953-816X.2004.03366.x
10.1111/j.1365-2826.1992.tb00338.x
10.1016/S0006-8993(10)80045-9
10.1152/ajpgi.1992.262.6.g1121
10.1016/0006-8993(78)90861-2
10.3233/JAD-141626
10.1007/BF00308809
10.1007/s00401-011-0825-z
10.1016/S0197-4580(02)00065-9
10.1097/NEN.0b013e318232a379
10.1007/s12149-018-1305-5
10.1016/0165-1838(94)90160-0
10.1212/WNL.57.9.1669
10.1210/en.2007-0854
10.1002/cne.901780102
10.1155/2017/7829507
10.3109/08037051.2012.733508
10.3389/fnins.2019.00062
10.1038/s41582-018-0013-z
10.1002/mds.27186
10.1176/ajp.2006.163.12.2164
10.1016/S1474-4422(15)00006-X
10.3233/JAD-161266
10.1093/sleep/zsab040
10.1016/0006-8993(82)90062-2
10.1159/000123858
10.1016/S1474-4422(14)70090-0
10.1530/acta.0.0870055
10.1016/j.endinu.2020.10.011
10.1016/0006-8993(77)90214-1
10.1016/S0197-0186(02)00049-9
10.1152/ajpregu.1992.263.1.r39
10.1016/j.brainres.2018.09.033
10.1006/neur.1996.0032
10.1159/000124152
10.1016/S0079-6123(08)63815-7
10.1007/s11910-020-01087-7
10.1093/brain/awt152
10.1002/ana.410320510
10.1046/j.1460-9568.2003.02692.x
10.3389/fnana.2017.00080
10.1002/jnr.24718
10.3390/ijms21228630
10.1523/JNEUROSCI.2311-11.2011
10.1001/archpsyc.58.4.353
10.1093/brain/awn049
10.1016/0006-8993(85)91093-5
10.1046/j.1471-4159.2003.01694.x
10.1523/jneurosci.4236-05.2006
10.1073/pnas.0909586107
10.1016/S1474-4422(15)70016-5
10.3389/fncel.2018.00471
10.1016/j.neurobiolaging.2007.11.024
10.1002/(SICI)1096-9861(19991213)415:2<145::AID-CNE1>3.0.CO;2-2
10.1016/j.neuroscience.2019.09.006
10.1016/j.jagp.2017.09.019
10.1007/s00401-015-1458-4
10.1016/j.jns.2011.02.033
10.3389/fnagi.2016.00196
10.1016/j.cmet.2015.08.016
10.1523/JNEUROSCI.0872-14.2014
10.1016/j.exger.2019.06.001
10.1007/BF00969178
10.1016/j.neuroscience.2010.11.052
10.1523/jneurosci.05-06-01513.1985
10.1002/mds.27922
10.18632/oncotarget.22218
10.1111/j.1460-9568.2006.05223.x
10.1172/JCI130513
10.1016/j.neulet.2014.03.020
10.1186/s40478-017-0411-2
10.3233/JAD-190090
10.1007/s00401-020-02158-2
10.1016/S0306-4522(01)00551-6
10.1098/rstb.2015.0350
10.1016/j.neubiorev.2017.10.023
10.1038/s41467-020-15410-w
10.1016/0306-4522(94)00481-J
10.1038/s41583-018-0097-x
10.1002/cne.903580105
10.1212/WNL.54.4.833
10.1192/bjp.136.6.533
10.1136/jnnp.45.2.113
10.1136/jnnp.47.2.201
10.1016/S0361-9230(03)00190-4
10.1159/000350291
10.7554/eLife.18247
10.1212/WNL.62.2.188
10.1038/emm.2014.121
10.1016/j.jalz.2019.06.3916
10.1016/j.clinbiochem.2019.04.001
10.1016/j.cub.2017.10.026
10.1007/s00401-018-1856-5
10.3390/ijms21103523
10.1523/jneurosci.18-23-09996.1998
10.1038/s41583-020-0360-9
10.1016/0197-4580(82)90024-0
10.1111/j.1460-9568.2005.04197.x
10.1007/s11064-005-9015-5
10.1016/0006-8993(76)90637-5
10.2174/157015908785777229
10.1016/j.conb.2013.04.004
10.1002/cne.902410203
10.1097/00002093-198701000-00004
10.1523/ENEURO.0018-16.2016
10.4103/1673-5374.235019
10.1152/ajpheart.1995.269.1.h46
10.1016/j.neulet.2011.07.006
10.1093/brain/awx348
10.1016/j.mayocp.2017.09.007
10.1016/S0079-6123(08)62369-9
10.1002/cne.901670207
10.1177/0269881113490326
10.1152/ajpendo.1985.249.2.e219
10.3233/JAD-2009-0991
10.1212/WNL.58.12.1791
10.1016/j.jalz.2016.06.2362
10.3389/fnins.2013.00216
10.1016/j.neuroscience.2007.05.055
10.1016/j.yhbeh.2012.04.006
10.1016/j.tins.2018.01.010
10.1093/brain/awl388
10.1212/WNL.0b013e3182897103
10.1016/j.yfrne.2019.100764
10.2310/JIM.0b013e318280aafb
10.1016/j.brainres.2013.04.039
10.3389/fnins.2020.00334
10.1038/nature12143
10.5665/sleep.6030
10.1523/JNEUROSCI.0275-18.2018
10.1038/nrn3114",<Element 'PubmedArticle' at 0x7f05df20c540>
161,"33933884
18332428
22519425
26493934
28520755
33164782
9005273
11092441
31796256
11681848
12270692
12150792
21986894
23807240
24659961
25785457
26619911
29454881
31255677
31778892
28659758
25753028
28500787
32027960
24140745
27931520
31325531
28328972
31640184
32832901
15635761
27500468
24995391
29570621
29104591
28370493
26681113
24035904
27532817
18493929
21339903
27488632
23235463
27017423
10987894
10831703
19230625
15120596
21914840
30882065
25251486
30558870
30825590
30321200
28634886
32081703
28286177
30859209
26793076
30041011
31079872
26635522
28536851
12907793
20354534
21814201
22423117
29339150
31785168
30242884
25697044
29755640
31015277
22974247
25388914
26639408
28099758
20457564
27487766
30015062
22537289
25797440
28623429
19927149
16939974
9390517
17264839
21476939
32781737
11486487
17283607","Melatonin improves brain function in a model of chronic Gulf War Illness with modulation of oxidative stress, NLRP3 inflammasomes, and BDNF-ERK-CREB pathway in the hippocampus.","Persistent cognitive and mood dysfunction is the primary CNS symptom in veterans afflicted with Gulf War Illness (GWI). This study investigated the efficacy of melatonin (MEL) for improving cognitive and mood function with antioxidant, antiinflammatory, and pro-cognitive effects in a rat model of chronic GWI. Six months after exposure to GWI-related chemicals and stress, rats were treated with vehicle or MEL (5, 10, 20, 40, and 80 mg/kg) for eight weeks. Behavioral tests revealed cognitive and mood dysfunction in GWI rats receiving vehicle, which were associated with elevated oxidative stress, reduced NRF2, catalase and mitochondrial complex proteins, astrocyte hypertrophy, activated microglia with NLRP3 inflammasomes, elevated proinflammatory cytokines, waned neurogenesis, and synapse loss in the hippocampus. MEL at 10 mg/kg alleviated simple and associative recognition memory dysfunction and anhedonia, along with reduced oxidative stress, enhanced glutathione and complex III, and reduced NLRP3 inflammasomes, IL-18, TNF-α, and IFN-γ. MEL at 20 mg/kg also normalized NRF2 and catalase and increased microglial ramification. MEL at 40 mg/kg, in addition, reduced astrocyte hypertrophy, activated microglia, NF-kB-NLRP3-caspase-1 signaling, IL-1β, MCP-1, and MIP-1α. Moreover, MEL at 80 mg/kg activated the BDNF-ERK-CREB signaling pathway, enhanced neurogenesis and diminished synapse loss in the hippocampus, and improved a more complex hippocampus-dependent cognitive function. Thus, MEL therapy is efficacious for improving cognitive and mood function in a rat model of chronic GWI, and MEL's effect was dose-dependent. The study provides the first evidence of MEL's promise for alleviating neuroinflammation and cognitive and mood impairments in veterans with chronic GWI.","['Brain-derived neurotrophic factor', 'Cognitive and mood function', 'Inflammasomes', 'Mitochondria', 'Neurogenesis', 'Neuroinflammation', 'Oxidative stress', 'cAMP response element-binding protein']",Redox biology,2021-05-03,"[{'lastname': 'Madhu', 'firstname': 'Leelavathi N', 'initials': 'LN', 'affiliation': 'Institute for Regenerative Medicine, Department of Molecular and Cellular Medicine, Texas A&M University College of Medicine, College Station, TX, USA.'}, {'lastname': 'Kodali', 'firstname': 'Maheedhar', 'initials': 'M', 'affiliation': 'Institute for Regenerative Medicine, Department of Molecular and Cellular Medicine, Texas A&M University College of Medicine, College Station, TX, USA.'}, {'lastname': 'Attaluri', 'firstname': 'Sahithi', 'initials': 'S', 'affiliation': 'Institute for Regenerative Medicine, Department of Molecular and Cellular Medicine, Texas A&M University College of Medicine, College Station, TX, USA.'}, {'lastname': 'Shuai', 'firstname': 'Bing', 'initials': 'B', 'affiliation': 'Institute for Regenerative Medicine, Department of Molecular and Cellular Medicine, Texas A&M University College of Medicine, College Station, TX, USA.'}, {'lastname': 'Melissari', 'firstname': 'Laila', 'initials': 'L', 'affiliation': 'Institute for Regenerative Medicine, Department of Molecular and Cellular Medicine, Texas A&M University College of Medicine, College Station, TX, USA.'}, {'lastname': 'Rao', 'firstname': 'Xiaolan', 'initials': 'X', 'affiliation': 'Institute for Regenerative Medicine, Department of Molecular and Cellular Medicine, Texas A&M University College of Medicine, College Station, TX, USA.'}, {'lastname': 'Shetty', 'firstname': 'Ashok K', 'initials': 'AK', 'affiliation': 'Institute for Regenerative Medicine, Department of Molecular and Cellular Medicine, Texas A&M University College of Medicine, College Station, TX, USA. Electronic address: akskrs@tamu.edu.'}]",,,,Published by Elsevier B.V.,10.1016/j.redox.2021.101973,<Element 'PubmedArticle' at 0x7f05df1e49a0>
162,"33919499
28665792
29176705
25602622
32216846
24934179
11706102
21998651
16863675
19149568
14757702
26987641
32528345
28686542
33536055
30288203
33114698
19926854
15465922
21857095
11442148
9696473
11979732
26491593
27701827
29807317
30728928
30193877
29662433
31969800
23643692
26578900
29388323
32932826
32170673
31443337
28283808
32847616",Palmitoylethanolamide and Its Biobehavioral Correlates in Autism Spectrum Disorder: A Systematic Review of Human and Animal Evidence.,"Autism spectrum disorder (ASD) pathophysiology is not completely understood; however, altered inflammatory response and glutamate signaling have been reported, leading to the investigation of molecules targeting the immune-glutamatergic system in ASD treatment. Palmitoylethanolamide (PEA) is a naturally occurring saturated N-acylethanolamine that has proven to be effective in controlling inflammation, depression, epilepsy, and pain, possibly through a neuroprotective role against glutamate toxicity. Here, we systematically reviewed all human and animal studies examining PEA and its biobehavioral correlates in ASD. Studies indicate altered serum/brain levels of PEA and other endocannabinoids (ECBs)/acylethanolamines (AEs) in ASD. Altered PEA signaling response to social exposure and altered expression/activity of enzymes responsible for the synthesis and catalysis of ECBs/AEs, as well as downregulation of the peroxisome proliferator activated receptor-α (PPAR-α) and cannabinoid receptor target GPR55 mRNA brain expression, have been reported. Stress and exposure to exogenous cannabinoids may modulate ECBs/AEs levels and expression of candidate genes for neuropsychiatric disorders, with implications for ASD. Limited research suggests that PEA supplementation reduces overall autism severity by improving language and social and nonsocial behaviors. Potential neurobiological underpinnings include modulation of immune response, neuroinflammation, neurotrophy, apoptosis, neurogenesis, neuroplasticity, neurodegeneration, mitochondrial function, and microbiota activity, possibly through peroxisome proliferator-activated receptor-α (PPAR-α) activation.","['acylethanolamines', 'cannabinoids', 'child and adolescent neuropsychiatry', 'glutamate', 'immune response', 'inflammation', 'neurodevelopment', 'peroxisome proliferator-activated receptor-α', 'pervasive developmental disorder']",Nutrients,2021-05-01,"[{'lastname': 'Colizzi', 'firstname': 'Marco', 'initials': 'M', 'affiliation': ""Child and Adolescent Neuropsychiatry Unit, Maternal-Child Integrated Care Department, Integrated University Hospital of Verona, 37126 Verona, Italy.\nSection of Psychiatry, Department of Neurosciences, Biomedicine and Movement Sciences, University of Verona, 37134 Verona, Italy.\nDepartment of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London SE5 8AF, UK.""}, {'lastname': 'Bortoletto', 'firstname': 'Riccardo', 'initials': 'R', 'affiliation': 'Child and Adolescent Neuropsychiatry Unit, Maternal-Child Integrated Care Department, Integrated University Hospital of Verona, 37126 Verona, Italy.'}, {'lastname': 'Costa', 'firstname': 'Rosalia', 'initials': 'R', 'affiliation': 'Community Mental Health Team, Department of Mental Health, ASST Mantova, 46100 Mantua, Italy.'}, {'lastname': 'Zoccante', 'firstname': 'Leonardo', 'initials': 'L', 'affiliation': 'Child and Adolescent Neuropsychiatry Unit, Maternal-Child Integrated Care Department, Integrated University Hospital of Verona, 37126 Verona, Italy.'}]",,,,,"10.3390/nu13041346
10.1515/revneuro-2017-0015
10.1038/s41598-017-16440-z
10.1089/brain.2014.0324
10.1017/S0033291720000574
10.1007/s40474-018-0152-3
10.1038/mp.2014.59
10.1212/WNL.57.9.1618
10.1371/journal.pone.0025340
10.1016/j.pnpbp.2006.06.013
10.2174/092986709787002745
10.1038/sj.bjp.0705667
10.1016/j.neubiorev.2016.03.010
10.3389/fpsyg.2020.00833
10.1080/1028415X.2017.1347373
10.1186/s13229-021-00420-2
10.1186/s41232-018-0086-5
10.3390/ijms21217942
10.1073/pnas.0907417106
10.1124/mol.104.006353
10.1016/S1734-1140(11)70596-5
10.1046/j.1528-1157.2001.41499.x
10.1016/S0304-3959(98)00041-4
10.1155/2015/325061
10.1111/cns.12648
10.1016/j.jpsychires.2018.04.022
10.1186/s13229-019-0256-6
10.1016/j.bbi.2018.09.003
10.3389/fnins.2018.00145
10.3389/fnins.2019.01345
10.1016/j.bbr.2013.04.043
10.3389/fnana.2015.00141
10.1111/cns.12810
10.3390/brainsci10090631
10.1007/s11064-020-02993-5
10.3390/nu11091974
10.1007/s12264-017-0118-1
10.1186/s13229-020-00372-z",<Element 'PubmedArticle' at 0x7f05df153540>
163,"33909305
10680787
30914845
32685488
25891869
29742427
25040546
33069254
27215477
1929894
30232451
15144856
16492745
32013258
10571474
27887995
27799628
29627763
22832417
26886885
15629689
18411055
20732460
30899760
9153585
12615653
24089474
12042880
26973195
12753089
15659808
22450372
8180832
32461080
29559883
12794733
31382686
22377912
21480899
31708741
32467161
25253868
19631259
15059975
15550947
22743772
24692354
11413487
10759566
21618114
20422297
8029467
2775765
24098718
24020974
21558319
30510502
29970188
29311911
30936558
29614651",Disarranged neuroplastin environment upon aging and chronic stress recovery in female Sprague Dawley rats.,"Chronic stress produces long-term metabolic changes throughout the superfamily of nuclear receptors, potentially causing various pathologies. Sex hormones modulate the stress response and generate a sex-specific age-dependent metabolic imprint, especially distinct in the reproductive senescence of females. We monitored chronic stress recovery in two age groups of female Sprague Dawley rats to determine whether stress and/or aging structurally changed the glycolipid microenvironment, a milieu playing an important role in cognitive functions. Old females experienced memory impairment even at basal conditions, which was additionally amplified by stress. On the other hand, the memory of young females was not disrupted. Stress recovery was followed by a microglial decrease and an increase in astrocyte count in the hippocampal immune system. Since dysfunction of the brain immune system could contribute to disturbed synaptogenesis, we analyzed neuroplastin expression and the lipid environment. Neuroplastin microenvironments were explored by analyzing immunofluorescent stainings using a newly developed Python script method. Stress reorganized glycolipid microenvironment in the Cornu Ammonis 1 (CA1) and dentate gyrus (DG) hippocampal regions of old females but in a very different fashion, thus affecting neuroplasticity. The postulation of four possible neuroplastin environments pointed to the GD1a ganglioside enrichment during reproductive senescence of stressed females, as well as its high dispersion in both regions and to GD1a and GM1 loss in the CA1 region. A specific lipid environment might influence neuroplastin functionality and underlie synaptic dysfunction triggered by a combination of aging and chronic stress.","['GD1a', 'GM1', 'hippocampus', 'neurodegeneration', 'neuroinflammation', 'reproductive senescence']",The European journal of neuroscience,2021-04-29,"[{'lastname': 'Balog', 'firstname': 'Marta', 'initials': 'M', 'affiliation': 'Department of Medical Biology and Genetics, Faculty of Medicine, J. J. Strossmayer University of Osijek, Osijek, Croatia.'}, {'lastname': 'Blažetić', 'firstname': 'Senka', 'initials': 'S', 'affiliation': 'Department of Biology, J. J. Strossmayer University of Osijek, Osijek, Croatia.'}, {'lastname': 'Ivić', 'firstname': 'Vedrana', 'initials': 'V', 'affiliation': 'Department of Medical Biology and Genetics, Faculty of Medicine, J. J. Strossmayer University of Osijek, Osijek, Croatia.'}, {'lastname': 'Labak', 'firstname': 'Irena', 'initials': 'I', 'affiliation': 'Department of Biology, J. J. Strossmayer University of Osijek, Osijek, Croatia.'}, {'lastname': 'Krajnik', 'firstname': 'Bartosz', 'initials': 'B', 'affiliation': 'Department of Experimental Physics, Wroclaw University of Science and Technology, Wroclaw, Poland.'}, {'lastname': 'Marin', 'firstname': 'Raquel', 'initials': 'R', 'affiliation': 'Laboratory of Cellular Neurobiology, Department of Basic Medical Sciences, School of Health Sciences, Universidad de La Laguna, La Laguna, Spain.'}, {'lastname': 'Canerina-Amaro', 'firstname': 'Ana', 'initials': 'A', 'affiliation': 'Laboratory of Cellular Neurobiology, Department of Basic Medical Sciences, School of Health Sciences, Universidad de La Laguna, La Laguna, Spain.'}, {'lastname': 'de Pablo', 'firstname': 'Daniel Pereda', 'initials': 'DP', 'affiliation': 'Laboratory of Cellular Neurobiology, Department of Basic Medical Sciences, School of Health Sciences, Universidad de La Laguna, La Laguna, Spain.'}, {'lastname': 'Bardak', 'firstname': 'Ana', 'initials': 'A', 'affiliation': 'Department of Medical Biology and Genetics, Faculty of Medicine, J. J. Strossmayer University of Osijek, Osijek, Croatia.'}, {'lastname': 'Gaspar', 'firstname': 'Robert', 'initials': 'R', 'affiliation': 'Department of Pharmacology and Pharmacotherapy, Faculty of Medicine, Interdisciplinary Excellence Centre, University of Szeged, Szeged, Hungary.'}, {'lastname': 'Szűcs', 'firstname': 'Kálmán Ferenc', 'initials': 'KF', 'affiliation': 'Department of Pharmacology and Pharmacotherapy, Faculty of Medicine, Interdisciplinary Excellence Centre, University of Szeged, Szeged, Hungary.'}, {'lastname': 'Vari', 'firstname': 'Sandor G', 'initials': 'SG', 'affiliation': 'Cedars-Sinai Medical Center, International Research and Innovation in Medicine Program, Los Angeles, CA, USA.'}, {'lastname': 'Heffer', 'firstname': 'Marija', 'initials': 'M', 'affiliation': 'Department of Medical Biology and Genetics, Faculty of Medicine, J. J. Strossmayer University of Osijek, Osijek, Croatia.'}]",,,,© 2021 The Authors. European Journal of Neuroscience published by Federation of European Neuroscience Societies and John Wiley & Sons Ltd.,"10.1111/ejn.15256
10.1212/wnl.54.3.588
10.21315/mjms2018.25.4.3
10.1155/2020/4701563
10.3325/cmj.2015.56.104
10.1016/j.celrep.2018.04.021
10.1111/jnc.12816
10.1186/s13024-020-00408-1
10.1016/j.biopsych.2016.03.2107
10.1001/archneur.1991.00530220048018
10.1038/s41586-018-0543-y
10.1016/j.expneurol.2003.12.010
10.1073/pnas.0507313103
10.3390/ijms21030868
10.1037//0735-7044.113.5.902
10.1016/j.physbeh.2016.11.017
10.1530/rep-16-0117
10.1016/j.neurobiolaging.2018.02.022
10.1097/JGP.0b013e31825c0a14
10.1097/GME.0000000000000579
10.1016/j.bbalip.2004.10.002
10.1016/j.mcn.2008.02.010
10.1016/j.arr.2010.08.006
10.3389/fcell.2019.00027
10.1111/j.1460-9568.1997.tb01427.x
10.1093/brain/awg089
10.1523/JNEUROSCI.2588-13.2013
10.1038/nrn849
10.18097/pbmc20166201093
10.1046/j.1471-4159.2003.01770.x
10.1196/annals.1329.035
10.1590/S0100-879X2012007500044
10.1016/0006-8993(94)91778-7
10.1016/j.neubiorev.2020.05.010
10.3389/fnins.2018.00128
10.1002/cne.10719
10.3390/ijms20153810
10.1093/glycob/cws057
10.1111/j.1471-4159.2011.07269.x
10.3389/fnmol.2019.00258
10.1073/pnas.2004259117
10.1523/JNEUROSCI.1149-14.2014
10.1016/j.brainresbull.2009.07.012
10.1096/fj.03-1378fje
10.1038/nrn1555
10.1038/nmeth.2019
10.1152/physrev.00033.2013
10.1038/35036052
10.1073/pnas.080389297
10.1007/978-1-4419-7877-6_14
10.1007/s11357-010-9145-9
10.1016/s0079-6123(08)61965-2
10.1016/0005-2760(89)90175-6
10.1371/journal.pone.0075720
10.2174/13894501113149990208
10.1210/en.2011-0145
10.3389/fncel.2018.00424
10.1186/s13041-018-0381-8
10.3389/fnagi.2017.00430
10.1038/s41593-019-0372-9
10.3233/JAD-170879",<Element 'PubmedArticle' at 0x7f05df0f7810>
164,"33907944
1698365
28583427
27498238
25847097
25318094
1709015
10366638
21777430
10947836
20348922
25799897
26318793
26775912
16095726
30096299
11789671
18615177
16086683
22020035
16343349
27608434
26283212
24803745
29936569
25364907
26515747
29386992
23711022
10688601
30096314
22196138
30179651",CB2 receptors modulate seizure-induced expression of pro-inflammatory cytokines in the hippocampus but not neocortex.,"We compared neuroinflammatory responses induced by nonconvulsive and convulsive seizures and analyzed the role that may be played by cannabinoid CB2 receptors in the neuroinflammatory response induced by generalized tonic-clonic seizures (GTCS). Using quantitative PCR, we analyzed expression of interleukin-1b, CCL2, interleukin-6, tumor necrosis factor (TNF), transforming growth factor beta 1 (TGFb1), fractalkine, and cannabinoid receptor type 2 in the neocortex, dorsal and ventral hippocampus, cortical leptomeninges, dura mater, and spleen in 3 and 6 h after induction of GTCS by a high dose of pentylenetetrazole (PTZ, 70 mg/kg) and absence-like activity by a low dose of PTZ (30 mg/kg). The low dose of PTZ had no effect on the gene expression 3 and 6 h after PTZ injection. In 3 and 6 h after high PTZ dose, the expression of CCL2 and TNF increased in the neocortex. Both ventral and dorsal parts of the hippocampus responded to seizures by elevation of CCL2 expression 3 h after PTZ. Cortical leptomeninges but not dura mater also had elevated CCL2 level and decreased TGFb1 expression 3 h after GTCS. Activation of CB2 receptors by HU308 suppressed an inflammatory response only in the dorsal hippocampus but not neocortex. Suppression of CB2 receptors by AM630 potentiated expression of inflammatory cytokines also in the hippocampus but not in the neocortex. Thus, we showed that GTCS, but not the absence-like activity, provoke inflammatory response in the neocortex, dorsal and ventral hippocampus, and cortical leptomeninges. Modulation of CB2 receptors changes seizure-induced neuroinflammation only in the hippocampus but not neocortex.","['CB2 receptor', 'CCL2', 'Dorsal hippocampus', 'Neuroinflammation', 'Pentylenetetrazole', 'Ventral hippocampus']",Molecular neurobiology,2021-04-29,"[{'lastname': 'Karan', 'firstname': 'Anna A', 'initials': 'AA', 'affiliation': 'Institute of Higher Nervous Activity and Neurophysiology, Russian Academy of Sciences, Moscow, Russia.'}, {'lastname': 'Spivak', 'firstname': 'Yulia S', 'initials': 'YS', 'affiliation': 'Institute of Higher Nervous Activity and Neurophysiology, Russian Academy of Sciences, Moscow, Russia.'}, {'lastname': 'Gerasimov', 'firstname': 'Konstantin A', 'initials': 'KA', 'affiliation': 'Institute of Higher Nervous Activity and Neurophysiology, Russian Academy of Sciences, Moscow, Russia.'}, {'lastname': 'Suleymanova', 'firstname': 'Elena M', 'initials': 'EM', 'affiliation': 'Institute of Higher Nervous Activity and Neurophysiology, Russian Academy of Sciences, Moscow, Russia.'}, {'lastname': 'Volobueva', 'firstname': 'Maria N', 'initials': 'MN', 'affiliation': 'Institute of Higher Nervous Activity and Neurophysiology, Russian Academy of Sciences, Moscow, Russia.'}, {'lastname': 'Kvichansky', 'firstname': 'Alexey A', 'initials': 'AA', 'affiliation': 'Institute of Higher Nervous Activity and Neurophysiology, Russian Academy of Sciences, Moscow, Russia.'}, {'lastname': 'Vinogradova', 'firstname': 'Lyudmila V', 'initials': 'LV', 'affiliation': 'Institute of Higher Nervous Activity and Neurophysiology, Russian Academy of Sciences, Moscow, Russia.'}, {'lastname': 'Bolshakov', 'firstname': 'Alexey P', 'initials': 'AP', 'affiliation': 'Institute of Higher Nervous Activity and Neurophysiology, Russian Academy of Sciences, Moscow, Russia. al230679@yandex.ru.'}]",,,,"© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.","10.1007/s12035-021-02395-w
10.1016/j.neubiorev.2016.02.007
10.1038/nrneurol.2010.178
10.1016/0006-291X(90)91221-D
10.1016/j.ejphar.2017.05.013
10.1016/j.brainres.2016.07.046
10.1111/epi.12960
10.6061/clinics/2014(09)08
10.1016/S0006-291X(05)80225-6
10.1523/jneurosci.19-12-05054.1999
10.1186/1742-2094-8-84
10.12659/MSM.910352
10.1046/j.1460-9568.2000.00140.x
10.1016/j.bbi.2008.03.009
10.1016/j.braindev.2008.11.013
10.1038/nm.2127
10.1016/j.seizure.2015.01.009
10.1016/j.yebeh.2015.07.021
10.1016/j.it.2015.12.008
10.1016/j.jneuroim.2005.06.025
10.1016/j.neuron.2018.09.022
10.3389/fnins.2017.00030
10.1016/j.cell.2018.07.028
10.1016/S1567-5769(01)00147-3
10.2174/157015907780866884
10.1111/j.1471-4159.2005.03380.x
10.1161/STROKEAHA.111.631044
10.1186/1742-2094-2-29
10.1016/0013-4694(72)90177-0
10.1016/j.eplepsyres.2016.08.011
10.1016/j.neuro.2015.08.007
10.1155/2014/978678
10.3390/molecules24234239
10.1006/ebeh.2001.0193
10.1007/s11064-018-2583-y
10.1371/journal.pone.0111665
10.1002/glia.20983
10.1016/j.neuroscience.2015.10.041
10.3389/fnmol.2017.00429
10.1111/bph.12191
10.1016/S0167-4781(02)00341-X
10.3390/ijms21197183
10.1016/j.cell.2018.06.021
10.1186/1742-2094-8-182
10.1016/j.neulet.2018.08.052",<Element 'PubmedArticle' at 0x7f05df12aa40>
165,33852527,Cardiac and Brainstem Neuroinflammatory Pathways Account for Androgenic Incitement of Cardiovascular and Autonomic Manifestations in Endotoxic Male Rats.,"Inconsistent reports are available on the role of testosterone in end-organ damage caused by endotoxemia. Here, pharmacologic, surgical, and molecular studies were employed to assess the testosterone modulation of cardiovascular, autonomic, and peripheral and central inflammatory derangements caused by endotoxemia. Studies were performed in conscious male rats preinstrumented with femoral indwelling catheters for the measurement of blood pressure and subjected to castration or pharmacologic interventions that interrupt the biosynthetic cascade of testosterone. Compared with the effects of lipopolysaccharide (10 mg/kg intravenously) in sham operated rats, 2-week castration reduced the lipopolysaccharide-evoked (1) falls in blood pressure, (2) decreases in time- and frequency-domain indices of heart rate variability, (3) shifts in spectral measures of cardiac sympathovagal balance toward parasympathetic dominance, and (4) increases in protein expressions of toll-like receptor-4 and monocyte chemoattractant protein-1 in heart and medullary neurons of the nucleus tractus solitarius and rostral ventrolateral medulla. While the ameliorating actions of castration on endotoxic cardiovascular manifestations were maintained after testosterone replacement, the concomitant inflammatory signals were restored to near-sham levels. The favorable influences of castration on inflammatory and cardiovascular abnormalities of endotoxemia were replicated in intact rats pretreated with degarelix (gonadotropin-releasing hormone receptor blocker) or finasteride (5α-reductase inhibitor) but not formestane (aromatase inhibitor). The data signifies the importance of androgens and its biosynthetic enzymes in cardiovascular and autonomic insults induced by the endotoxic inflammatory response. Clinically, the interruption of testosterone biosynthesis could offer a potential strategy for endotoxemia management.",[],Journal of cardiovascular pharmacology,2021-04-15,"[{'lastname': 'Sallam', 'firstname': 'Marwa Y', 'initials': 'MY', 'affiliation': 'Department of Pharmacology and Toxicology, Faculty of Pharmacy, Alexandria University, Alexandria, Egypt ; and.'}, {'lastname': 'El-Gowilly', 'firstname': 'Sahar M', 'initials': 'SM', 'affiliation': 'Department of Pharmacology and Toxicology, Faculty of Pharmacy, Alexandria University, Alexandria, Egypt ; and.'}, {'lastname': 'El-Mas', 'firstname': 'Mahmoud M', 'initials': 'MM', 'affiliation': 'Department of Pharmacology and Toxicology, Faculty of Pharmacy, Alexandria University, Alexandria, Egypt ; and.\nDepartment of Pharmacology and Toxicology, Faculty of Medicine, Kuwait University, Kuwait City, Kuwait .'}]",,,,"Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.",10.1097/FJC.0000000000000993,<Element 'PubmedArticle' at 0x7f05df0cb720>
166,33848542,"Ghrelin attenuates depressive-like behavior, heart failure, and neuroinflammation in postmyocardial infarction rat model.","Depression after myocardial infarction (MI) and chronic heart failure (CHF) is a common condition that is resistant to anti-depressive drugs. Ghrelin (a peptide hormone) shows dual protective effects on heart and brain. Whether ghrelin treatment attenuated depression after MI was investigated. Coronary artery occlusion was performed to induce MI and subsequent CHF in rats. Ghrelin (100 μg/kg in 0.5 ml of saline) or vehicle (0.5 ml of saline) was injected subcutaneously twice a day for 4 weeks. At week 5, all the animals underwent behavioral assessments including sucrose preference test (SPT), elevated plus maze test (EPM), and open field test (OFT). After cardiac function analysis, brain tissues were processed to determine inflammatory cytokines and microglial activations in hippocampus. Results showed that ghrelin substantially improved cardiac dysfunction, infarction size, and cardiac remodeling and modulated the release of inflammatory cytokines and the increase of Iba-1 positive microglia and glial fibrillary acidic protein-positive astrocytes in the CA1 area of hippocampus. Behavioral tests revealed that this treatment remarkably increased sucrose preference and mobile times and numbers. These findings provided evidence that peripheral ghrelin administration inhibits depression-like behavior and neuroinflammation and thus could be a new approach for the treatment of CHF-associated depression.","['Chronic heart failure', 'Depressive-like behavior', 'Ghrelin', 'Myocardial infarction', 'Neuroinflammation']",European journal of pharmacology,2021-04-14,"[{'lastname': 'Sun', 'firstname': 'Nan', 'initials': 'N', 'affiliation': 'Department of Gerontology, First Affiliated Hospital of Wannan Medical College (Yijishan Hospital), Wuhu, 241001, PR China; Key Laboratory of Non-coding RNA Transformation Research of Anhui Higher Education Institution (First Affiliated Hospital of Wannan Medical College (Yijishan Hospital), Wuhu, Anhui, 241001, PR China.'}, {'lastname': 'Mei', 'firstname': 'Yong', 'initials': 'Y', 'affiliation': 'Department of Gerontology, First Affiliated Hospital of Wannan Medical College (Yijishan Hospital), Wuhu, 241001, PR China; Key Laboratory of Non-coding RNA Transformation Research of Anhui Higher Education Institution (First Affiliated Hospital of Wannan Medical College (Yijishan Hospital), Wuhu, Anhui, 241001, PR China.'}, {'lastname': 'Hu', 'firstname': 'Zhengtao', 'initials': 'Z', 'affiliation': 'Department of Gerontology, First Affiliated Hospital of Wannan Medical College (Yijishan Hospital), Wuhu, 241001, PR China.'}, {'lastname': 'Xing', 'firstname': 'Wen', 'initials': 'W', 'affiliation': 'Department of Gerontology, First Affiliated Hospital of Wannan Medical College (Yijishan Hospital), Wuhu, 241001, PR China.'}, {'lastname': 'Lv', 'firstname': 'Kun', 'initials': 'K', 'affiliation': 'Key Laboratory of Non-coding RNA Transformation Research of Anhui Higher Education Institution (First Affiliated Hospital of Wannan Medical College (Yijishan Hospital), Wuhu, Anhui, 241001, PR China.'}, {'lastname': 'Hu', 'firstname': 'Nengwei', 'initials': 'N', 'affiliation': 'Department of Gerontology, First Affiliated Hospital of Wannan Medical College (Yijishan Hospital), Wuhu, 241001, PR China; Department of Physiology and Neurobiology, Zhengzhou University School of Medicine, Zhengzhou, 450001, China; Department of Pharmacology & Therapeutics and Institute of Neuroscience, Trinity College, Dublin 2, Ireland.'}, {'lastname': 'Zhang', 'firstname': 'Ting', 'initials': 'T', 'affiliation': 'Department of Psychology, Wannan Medical College, Wuhu, 241001, PR China. Electronic address: springall@126.com.'}, {'lastname': 'Wang', 'firstname': 'Deguo', 'initials': 'D', 'affiliation': 'Department of Gerontology, First Affiliated Hospital of Wannan Medical College (Yijishan Hospital), Wuhu, 241001, PR China; Key Laboratory of Non-coding RNA Transformation Research of Anhui Higher Education Institution (First Affiliated Hospital of Wannan Medical College (Yijishan Hospital), Wuhu, Anhui, 241001, PR China. Electronic address: wangdeguo@wnmc.edu.cn.'}]",,,,Copyright © 2021 Elsevier B.V. All rights reserved.,10.1016/j.ejphar.2021.174096,<Element 'PubmedArticle' at 0x7f05df0e7400>
167,"33839686
23150934
23150908
29321225
15049507
26478868
25732305
25728668
24316888
18551625
28602351
27196974
31350575
30617257
31235932
29037207
28100745
30232263
28802038
28559417
19171755
24990881
25716838
30157425
28483841
29599291
29518356
16951310
31301936
25631124
31902528
27995897
26374899
26374897
27477018
25047746
29407460
29518357
28490631
32154671
26414614
26399658
29551131
31926038
28591653
31740814
27097852
28671693
28546318
19625651
31507408
12832465
12101269
17425404
30397336
24638131
29020624
31917687
31932797
26076170
26058841
26311074",MEK1/2 activity modulates TREM2 cell surface recruitment.,"Rare sequence variants in the microglial cell surface receptor TREM2 have been shown to increase the risk for Alzheimer's disease (AD). Disease-linked TREM2 mutations seem to confer a partial loss of function, and increasing TREM2 cell surface expression and thereby its function(s) might have therapeutic benefit in AD. However, druggable targets that could modulate microglial TREM2 surface expression are not known. To identify such targets, we conducted a screen of small molecule compounds with known pharmacology using human myeloid cells, searching for those that enhance TREM2 protein at the cell surface. Inhibitors of the kinases MEK1/2 displayed the strongest and most consistent increases in cell surface TREM2 protein, identifying a previously unreported pathway for TREM2 regulation. Unexpectedly, inhibitors of the downstream effector ERK kinases did not have the same effect, suggesting that noncanonical MEK signaling regulates TREM2 trafficking. In addition, siRNA knockdown experiments confirmed that decreased MEK1 and MEK2 were required for this recruitment. In iPSC-derived microglia, MEK inhibition increased cell surface TREM2 only modestly, so various cytokines were used to alter iPSC microglia phenotype, making cells more sensitive to MEK inhibitor-induced TREM2 recruitment. Of those tested, only IFN-gamma priming prior to MEK inhibitor treatment resulted in greater TREM2 recruitment. These data identify the first known mechanisms for increasing surface TREM2 protein and TREM2-regulated function in human myeloid cells and are the first to show a role for MEK1/MEK2 signaling in TREM2 activity.","['Alzheimer’s disease', 'MEK', 'TREM2', 'microglia', 'neurodegeneration', 'neuroinflammation', 'phagocytosis']",The Journal of biological chemistry,2021-04-12,"[{'lastname': 'Schapansky', 'firstname': 'Jason', 'initials': 'J', 'affiliation': 'AbbVie Inc, Cambridge Research Center, Cambridge, Massachusetts, USA. Electronic address: jason.schapansky@abbvie.com.'}, {'lastname': 'Grinberg', 'firstname': 'Yelena Y', 'initials': 'YY', 'affiliation': 'AbbVie Inc, Cambridge Research Center, Cambridge, Massachusetts, USA.'}, {'lastname': 'Osiecki', 'firstname': 'David M', 'initials': 'DM', 'affiliation': 'AbbVie Inc, Drug Discovery Science and Technology, North Chicago, Illinois, USA.'}, {'lastname': 'Freeman', 'firstname': 'Emily A', 'initials': 'EA', 'affiliation': 'AbbVie Inc, Cambridge Research Center, Cambridge, Massachusetts, USA.'}, {'lastname': 'Walker', 'firstname': 'Stephen G', 'initials': 'SG', 'affiliation': 'AbbVie Inc, Drug Discovery Science and Technology, North Chicago, Illinois, USA.'}, {'lastname': 'Karran', 'firstname': 'Eric', 'initials': 'E', 'affiliation': 'AbbVie Inc, Cambridge Research Center, Cambridge, Massachusetts, USA.'}, {'lastname': 'Gopalakrishnan', 'firstname': 'Sujatha M', 'initials': 'SM', 'affiliation': 'AbbVie Inc, Drug Discovery Science and Technology, North Chicago, Illinois, USA.'}, {'lastname': 'Talanian', 'firstname': 'Robert V', 'initials': 'RV', 'affiliation': 'AbbVie Inc, Cambridge Research Center, Cambridge, Massachusetts, USA.'}]",,,,Copyright © 2020 The Authors. Published by Elsevier Inc. All rights reserved.,10.1074/jbc.RA120.014352,<Element 'PubmedArticle' at 0x7f05df074950>
168,"33835385
29119534
32127770
25251017
30296528
30103772
11034867
21150913
2777795
27382003
21147255
32451494
19926873
23296919
29873596
26769658
4325865
16715653
17952409
2352643
11327634
25753301
29543776
31037999
22817481
23127917
29667931
29942452
10506522
12364355
12086708
15665034
26448556
24090950
7898715
12676175
21685445
22726823
31157856
27670907
17401654
31427727
19942928
18385968
25377425
12426214
1618166
16075377
22827472
21035950
31953528
22257799
28301451
31105549
21926585
29365370
24957202
24849663
19861350
32956721
26115674
22892395
12466309
30202571
17573392
15142685
17351125
18990443
24814023",Manifestation of renin angiotensin system modulation in traumatic brain injury.,"Traumatic brain injury (TBI) alters brain function and is a crucial public health concern worldwide. TBI triggers the release of inflammatory mediators (cytokines) that aggravate cerebral damage, thereby affecting clinical prognosis. The renin angiotensin system (RAS) plays a critical role in TBI pathophysiology. RAS is widely expressed in many organs including the brain. Modulation of the RAS in the brain via angiotensin type 1 (AT","['ANG II receptor antagonists', 'Angiotensin II receptor type 1', 'Angiotensin II receptor type 2', 'Neuroprotection', 'Renin angiotensin system', 'Traumatic brain injury']",Metabolic brain disease,2021-04-10,"[{'lastname': 'Mirzahosseini', 'firstname': 'Golnoush', 'initials': 'G', 'affiliation': 'Department of Anatomy and Neurobiology, University of Tennessee Health Science Center, College of Medicine, 855 Monroe Avenue, Wittenborg Building, Room-231, Memphis, TN, 38163, USA.\nPharmaceutical Sciences, University of Tennessee Health Science Center, Memphis, TN, 38163, USA.'}, {'lastname': 'Ismael', 'firstname': 'Saifudeen', 'initials': 'S', 'affiliation': 'Department of Anatomy and Neurobiology, University of Tennessee Health Science Center, College of Medicine, 855 Monroe Avenue, Wittenborg Building, Room-231, Memphis, TN, 38163, USA.'}, {'lastname': 'Ahmed', 'firstname': 'Heba A', 'initials': 'HA', 'affiliation': 'Department of Anatomy and Neurobiology, University of Tennessee Health Science Center, College of Medicine, 855 Monroe Avenue, Wittenborg Building, Room-231, Memphis, TN, 38163, USA.'}, {'lastname': 'Ishrat', 'firstname': 'Tauheed', 'initials': 'T', 'affiliation': 'Department of Anatomy and Neurobiology, University of Tennessee Health Science Center, College of Medicine, 855 Monroe Avenue, Wittenborg Building, Room-231, Memphis, TN, 38163, USA. tishrat@uthsc.edu.\nPharmaceutical Sciences, University of Tennessee Health Science Center, Memphis, TN, 38163, USA. tishrat@uthsc.edu.\nNeuroscience Institute, University of Tennessee Health Science Center, Memphis, TN, 38163, USA. tishrat@uthsc.edu.'}]",,,,"© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.","10.1007/s11011-021-00728-1
10.1016/j.drudis.2010.11.016
10.1016/0306-4522(90)90163-X
10.1111/j.1476-5381.2012.02105.x
10.18632/aging.101419
10.1016/j.npep.2013.09.002
10.1001/jamaneurol.2019.1313
10.1038/s41569-019-0244-8
10.1111/cns.12802
10.1016/j.npep.2008.09.005
10.1016/j.neuroscience.2014.04.060",<Element 'PubmedArticle' at 0x7f05df0a4950>
169,33813350,Neuroinflammation modulates the association of PGRN with cerebral amyloid-β burden.,"Progranulin (PGRN) and neuroinflammatory markers increased over the course of Alzheimer's disease (AD). We aimed to determine whether neuroinflammation could modulate the association of PGRN with amyloid pathologies. Baseline cerebrospinal fluid (CSF) PGRN and AD pathologies were measured for 965 participants, among whom 228 had measurements of CSF neuroinflammatory markers. Causal mediation analyses with 10,000 bootstrapped iterations were conducted to explore the mediation effects within the framework of A/T/N biomarker profile. Increased levels of CSF PGRN and inflammatory markers (sTNFR1, sTNFR2, TGF-β1, ICAM1, and VCAM1) were associated with T- or N-positive (TN+) profile, irrespective of the amyloid pathology. In TN+ group, CSF PGRN was associated with increased levels of these inflammatory markers and CSF amyloid-β","['Alzheimer', 'Amyloid', 'Cognition', 'Neuroinflammation', 'Progranulin', 'Tau']",Neurobiology of aging,2021-04-05,"[{'lastname': 'Xu', 'firstname': 'Wei', 'initials': 'W', 'affiliation': 'Department of Neurology, Qingdao Municipal Hospital, Qingdao University, Qingdao, China. Electronic address: 1037219730@qq.com.'}, {'lastname': 'Tan', 'firstname': 'Chen-Chen', 'initials': 'CC', 'affiliation': 'Department of Neurology, Qingdao Municipal Hospital, Qingdao University, Qingdao, China.'}, {'lastname': 'Cao', 'firstname': 'Xi-Peng', 'initials': 'XP', 'affiliation': 'Clinical Research Center, Qingdao Municipal Hospital, Qingdao, China.'}, {'lastname': 'Tan', 'firstname': 'Lan', 'initials': 'L', 'affiliation': 'Department of Neurology, Qingdao Municipal Hospital, Qingdao University, Qingdao, China.'}, {'lastname': None, 'firstname': None, 'initials': None, 'affiliation': None}]",,,,Copyright © 2021. Published by Elsevier Inc.,10.1016/j.neurobiolaging.2021.02.016,<Element 'PubmedArticle' at 0x7f05df04eb30>
170,"33802689
21527731
19302036
19864556
24844438
7724569
24927796
28336953
16146656
26714634
10725699
19382211
8808786
23626522
20876360
23357419
25404893
28932183
25237008
11983155
10837071
31982922
33260658
12037135
16086683
25637536
26965148
31396087
22229320
15465922
11485574
31077796
17180163
2089275
27459405
25598354
28280458
18435916
17569869
10751435
11772946
11342663
24813072
18804455
21382557
16547515
21835925
8819477
32496649
28848398
29038483
19447135
20461235",Palmitoylethanolamide Modulation of Microglia Activation: Characterization of Mechanisms of Action and Implication for Its Neuroprotective Effects.,"Palmitoylethanolamide (PEA) is an endogenous lipid produced on demand by neurons and glial cells that displays neuroprotective properties. It is well known that inflammation and neuronal damage are strictly related processes and that microglia play a pivotal role in their regulation. The aim of the present work was to assess whether PEA could exert its neuroprotective and anti-inflammatory effects through the modulation of microglia reactive phenotypes. In N9 microglial cells, the pre-incubation with PEA blunted the increase of M1 pro-inflammatory markers induced by lipopolysaccharide (LPS), concomitantly increasing those M2 anti-inflammatory markers. Images of microglial cells were processed to obtain a set of morphological parameters that highlighted the ability of PEA to inhibit the LPS-induced M1 polarization and suggested that PEA might induce the anti-inflammatory M2a phenotype. Functionally, PEA prevented Ca","['LPS', 'cannabinoid receptor', 'cytokines', 'electrophysiology', 'microglia', 'morphotypes', 'neuroinflammation', 'palmitoylethanolamide']",International journal of molecular sciences,2021-04-04,"[{'lastname': ""D'Aloia"", 'firstname': 'Alessia', 'initials': 'A', 'affiliation': 'Department of Biotechnology and Biosciences, University of Milano-Bicocca, 20126 Milano, Italy.'}, {'lastname': 'Molteni', 'firstname': 'Laura', 'initials': 'L', 'affiliation': 'School of Medicine and Surgery, University of Milano-Bicocca, 20900 Monza, Italy.'}, {'lastname': 'Gullo', 'firstname': 'Francesca', 'initials': 'F', 'affiliation': 'Department of Biotechnology and Biosciences, University of Milano-Bicocca, 20126 Milano, Italy.'}, {'lastname': 'Bresciani', 'firstname': 'Elena', 'initials': 'E', 'affiliation': 'School of Medicine and Surgery, University of Milano-Bicocca, 20900 Monza, Italy.'}, {'lastname': 'Artusa', 'firstname': 'Valentina', 'initials': 'V', 'affiliation': 'Department of Biotechnology and Biosciences, University of Milano-Bicocca, 20126 Milano, Italy.'}, {'lastname': 'Rizzi', 'firstname': 'Laura', 'initials': 'L', 'affiliation': 'School of Medicine and Surgery, University of Milano-Bicocca, 20900 Monza, Italy.'}, {'lastname': 'Ceriani', 'firstname': 'Michela', 'initials': 'M', 'affiliation': 'Department of Biotechnology and Biosciences, University of Milano-Bicocca, 20126 Milano, Italy.'}, {'lastname': 'Meanti', 'firstname': 'Ramona', 'initials': 'R', 'affiliation': 'School of Medicine and Surgery, University of Milano-Bicocca, 20900 Monza, Italy.'}, {'lastname': 'Lecchi', 'firstname': 'Marzia', 'initials': 'M', 'affiliation': 'Department of Biotechnology and Biosciences, University of Milano-Bicocca, 20126 Milano, Italy.'}, {'lastname': 'Coco', 'firstname': 'Silvia', 'initials': 'S', 'affiliation': 'School of Medicine and Surgery, University of Milano-Bicocca, 20900 Monza, Italy.'}, {'lastname': 'Costa', 'firstname': 'Barbara', 'initials': 'B', 'affiliation': 'Department of Biotechnology and Biosciences, University of Milano-Bicocca, 20126 Milano, Italy.'}, {'lastname': 'Torsello', 'firstname': 'Antonio', 'initials': 'A', 'affiliation': 'School of Medicine and Surgery, University of Milano-Bicocca, 20900 Monza, Italy.'}]",,,,,"10.3390/ijms22063054
10.1152/physrev.00011.2010
10.1146/annurev.immunol.021908.132528
10.1523/JNEUROSCI.3257-09.2009
10.1016/j.phrs.2014.05.006
10.1073/pnas.92.8.3376
10.1186/1742-2094-11-108
10.1038/s41598-017-00342-1
10.1016/j.jneuroim.2005.08.006
10.1186/s12974-015-0458-6
10.4049/jimmunol.164.7.3476
10.1002/glia.20874
10.1016/0197-0186(95)00141-7
10.13140/2.1.3576.6082
10.1007/BF02289263
10.3389/fncel.2013.00049
10.1085/jgp.201010476
10.1016/j.bbrc.2013.01.064
10.3389/fncel.2014.00361
10.3389/fnins.2017.00500
10.1016/j.intimp.2014.09.007
10.1016/S0092-8674(02)00703-1
10.1146/annurev.immunol.18.1.621
10.1007/s00228-019-02799-7
10.3390/ijms21239074
10.1124/pr.54.2.161
10.1111/j.1471-4159.2005.03380.x
10.1016/j.bbrc.2015.01.073
10.1016/j.plipres.2016.02.002
10.3389/fphar.2019.00821
10.2174/187152711799219307
10.1124/mol.104.006353
10.1042/bj3580249
10.1016/j.semcdb.2019.05.004
10.1038/nrn2038
10.1016/0306-4522(90)90229-W
10.1038/nn.4338
10.1007/s12035-014-9070-5
10.3389/fncel.2017.00041
10.1016/j.bbrc.2008.04.055
10.1126/science.1139111
10.1523/JNEUROSCI.20-08-02835.2000
10.1096/fj.01-0514fje
10.4049/jimmunol.166.10.6383
10.1016/j.jtbi.2014.04.024
10.1016/j.brainres.2008.08.085
10.1016/j.neuron.2011.02.003
10.1038/nature04671
10.1074/jbc.M111.280826
10.1002/sctm.19-0327
10.3389/fncel.2017.00235
10.1038/s41598-017-13581-z
10.1016/j.jneumeth.2009.05.003
10.3389/fncir.2010.00011",<Element 'PubmedArticle' at 0x7f05df05b900>
171,33739881,Pterostilbene Improves Stress-Related Behaviors and Partially Reverses Underlying Neuroinflammatory and Hormonal Changes in Stress-Challenged Mice.,"Pterostilbene is a natural compound contained in various dietary sources that has received tremendous attention due to its antioxidant properties with promising benefits in cancers and vascular diseases. Currently, little is known about pterostilbene-associated neuroimmune endocrine effects. We aimed to examine the efficacy of pterostilbene for improving stress-related behaviors, neuroinflammation, and hormonal changes in a mouse stress model. To evaluate the efficacy of oral administration of pterostilbene or vehicle for 16 days for improving behavior, inflammation, and hypothalamic-pituitary-adrenal (HPA) axis hyperactivity, mice were divided into a normal control group or one of five restraint stress groups-the vehicle group; the 20, 40, or 80 mg/[kg·day] pterostilbene treatment group; or the 20 mg/[kg·day] resveratrol treatment group. Open field and forced swimming tests were conducted. Hippocampal brain-derived neurotrophic factor (BDNF) levels, endocrine hormone levels, oxidative stress parameters, and histopathological features were assessed. Oral pterostilbene administration significantly increased the measured times in the open field and forced swimming tests, elevated the BDNF levels, decreased the inducible nitric oxide synthase and superoxide dismutase levels in the brain, and reduced the plasma adrenocorticotropic hormone and corticosterone levels. Compared with vehicle treatment, pterostilbene dose dependently increased the numbers of neurons and decreased the numbers of glial and tumor necrosis factor alpha-immunolabeled cells in the hypothalamus. These findings suggest that pterostilbene may effectively modulate stress-related abnormal behaviors, neuroinflammation, and HPA axis hyperactivity.","['brain-derived neurotrophic factor', 'hypothalamic–pituitary–adrenal axis', 'neuroinflammation', 'pterostilbene', 'stress']",Journal of medicinal food,2021-03-20,"[{'lastname': 'Park', 'firstname': 'Byoungjin', 'initials': 'B', 'affiliation': 'Department of Family Medicine, Yonsei University College of Medicine, Seoul, Korea.\nDepartment of Medicine, Yonsei University Graduate School of Medicine, Seoul, Korea.'}, {'lastname': 'Lee', 'firstname': 'Yong-Jae', 'initials': 'YJ', 'affiliation': 'Department of Family Medicine, Yonsei University College of Medicine, Seoul, Korea.\nDepartment of Family Medicine, Gangnam Severance Hospital, Seoul, Korea.'}]",,,,,10.1089/jmf.2020.4766,<Element 'PubmedArticle' at 0x7f05df009ef0>
172,"33673448
29897293
11274341
25951955
32360118
27603752
32142721
8474635
26563756
27453431
18475254
574618
3556459
28378414
24129263
29090683
16513365
15623810
9278951
28787642
26932552
29128108
27475769
24025838
32304701
26810371
1983356
19560473
18092152
23916423
32624295
17907843
26391743
8916071
19371575
22110618
25402719
22198308
30323276
26088685
31542987
29056153
2991800
2848611
1805228
1891073
24280016
3593487
23025690
28503120
23764194
28110822
27661192
31792646
30085292
23564179
30521833
30227143
27555382
30448423
14675803
33069753
4746051
19488073
19786032
14551424
23972943
23295405
26087679
18601710
28915381
32561672
31327473
29056427
29382712
25219790
29960725
24062592
8511216
26475995
22955569
11797060
15019428
7202847
8623006
26545443
31536736
17524488
33008543
17466428
20206227
20065289
17628337
12546654
12532089
18762788
23312823
11381138
22232675
21425881
25173629
26525751
30707932
19694905
29618006
30335249
19362123
23061525
11033344
22474371
32194233
31259292
29623033
29858554
30898126
29911261
26338335
26335886
26230646
32093522
15589266
22974560
21208748
24183103
27608360
27836673
26385109
21397619
29186377
26620251
25306217
29066224
28911267
32011013
24405552
25466833
24659430
32002925
22807189
24594871
20720535
21996304
28877512
28559206
24862297
24871703
30189345
26851698
27614769
26741286
30554861
29126982
31682854
30798402
24806691
28698920
28725939
33132187
32408137
33002518
29391155
28466092
18762212
17678505
18789966
26222297
26403083
26576941
25373870
31400490
27866932
28963257
27615433
28669546
31333427
32298668
30923836
26700240
26231584
30382728
32634745
26847047
30144331
26374627
27319971
26556046
30742670
25688351
21960564
27075756
28259722
30513893
30172802",Oxytocin Signaling as a Target to Block Social Defeat-Induced Increases in Drug Abuse Reward.,"There is huge scientific interest in the neuropeptide oxytocin (OXT) due to its putative capacity to modulate a wide spectrum of physiological and cognitive processes including motivation, learning, emotion, and the stress response. The present review seeks to increase the understanding of the role of OXT in an individual's vulnerability or resilience with regard to developing a substance use disorder. It places specific attention on the role of social stress as a risk factor of addiction, and explores the hypothesis that OXT constitutes a homeostatic response to stress that buffers against its negative impact. For this purpose, the review summarizes preclinical and clinical literature regarding the effects of OXT in different stages of the addiction cycle. The current literature affirms that a well-functioning oxytocinergic system has protective effects such as the modulation of the initial response to drugs of abuse, the attenuation of the development of dependence, the blunting of drug reinstatement and a general anti-stress effect. However, this system is dysregulated if there is continuous drug use or chronic exposure to stress. In this context, OXT is emerging as a promising pharmacotherapy to restore its natural beneficial effects in the organism and to help rebalance the functions of the addicted brain.","['animal models', 'corticotropin-releasing factor', 'drug addiction', 'human research', 'neuroinflammation', 'oxytocin', 'reward system', 'social stress']",International journal of molecular sciences,2021-03-07,"[{'lastname': 'Ferrer-Pérez', 'firstname': 'Carmen', 'initials': 'C', 'affiliation': 'Department of Psychology and Sociology, University of Zaragoza, C/Ciudad Escolar s/n, 44003 Teruel, Spain.'}, {'lastname': 'Reguilón', 'firstname': 'Marina D', 'initials': 'MD', 'affiliation': 'Unit of Research Psychobiology of Drug Dependence, Department of Psychobiology, Facultad de Psicología, Universitat de Valencia, Avda. Blasco Ibáñez, 21, 46010 Valencia, Spain.'}, {'lastname': 'Miñarro', 'firstname': 'José', 'initials': 'J', 'affiliation': 'Unit of Research Psychobiology of Drug Dependence, Department of Psychobiology, Facultad de Psicología, Universitat de Valencia, Avda. Blasco Ibáñez, 21, 46010 Valencia, Spain.'}, {'lastname': 'Rodríguez-Arias', 'firstname': 'Marta', 'initials': 'M', 'affiliation': 'Unit of Research Psychobiology of Drug Dependence, Department of Psychobiology, Facultad de Psicología, Universitat de Valencia, Avda. Blasco Ibáñez, 21, 46010 Valencia, Spain.'}]",,,,,"10.3390/ijms22052372
10.1152/physrev.00031.2017
10.1152/physrev.2001.81.2.629
10.1016/j.yfrne.2015.04.003
10.1016/j.tics.2020.03.008
10.1097/FBP.0000000000000258
10.1016/j.brainres.2020.146761
10.1016/0143-4179(93)90081-K
10.1111/jne.12337
10.1111/ejn.13348
10.1038/bjp.2008.132
10.1038/282746a0
10.1007/BF00236302
10.1111/bph.13757
10.1038/npp.2013.285
10.1038/npp.2017.257
10.1016/j.mcn.2006.01.008
10.1210/jc.2004-1593
10.1016/S0278-5846(97)00080-8
10.1016/j.psyneuen.2017.07.481
10.1007/s40263-016-0313-z
10.1016/j.tins.2017.10.003
10.1016/S2215-0366(16)00104-8
10.1038/nature12518
10.1016/j.neuropharm.2020.108091
10.1111/adb.12362
10.1097/00001756-199011000-00006
10.1016/j.neuropharm.2009.06.018
10.1007/s00210-007-0245-8
10.1016/j.pbb.2013.07.015
10.1016/j.euroneuro.2020.06.008
10.1037/0735-7044.121.5.1113
10.2174/1570159X13666150921112841
10.1159/000119305
10.1016/j.neuropharm.2009.01.010
10.1371/journal.pone.0027237
10.1111/adb.12197
10.1016/j.yhbeh.2011.12.001
10.1038/s41593-018-0246-6
10.1007/s11064-015-1637-7
10.1177/0269881119874414
10.1016/bs.irn.2017.08.003
10.1016/0028-3908(85)90026-7
10.1016/0006-8993(88)90401-5
10.1016/0091-3057(91)90549-H
10.1016/0143-4179(91)90073-R
10.1016/j.pbb.2013.11.019
10.1111/j.1530-0277.2012.01958.x
10.3109/16066359.2016.1173682
10.1016/j.psyneuen.2013.05.005
10.1016/j.biopsych.2016.11.011
10.1097/FBP.0000000000000260
10.1007/s00213-019-05392-z
10.1093/ntr/nty159
10.1007/s00213-013-3062-4
10.1016/j.pbb.2018.11.008
10.1016/j.neubiorev.2018.09.008
10.1038/npp.2016.167
10.1016/j.neuropharm.2018.11.011
10.1016/S0006-3223(03)00465-7
10.1016/j.yhbeh.2020.104875
10.1016/0002-9149(70)90796-4
10.1038/nrendo.2009.106
10.1016/j.yhbeh.2009.09.011
10.1126/science.1091062
10.1016/j.psyneuen.2013.07.021
10.1159/000343003
10.1038/nrn3881
10.1111/j.1365-2826.2008.01726.x
10.1016/j.psyneuen.2017.09.003
10.1523/JNEUROSCI.2568-19.2020
10.1016/j.biopsych.2019.05.020
10.1016/j.yhbeh.2017.10.007
10.1523/JNEUROSCI.2568-17.2018
10.1111/adb.12184
10.1016/j.psychres.2018.05.011
10.1093/schbul/sbt134
10.1016/0031-9384(93)90278-N
10.1016/j.neubiorev.2015.10.006
10.1007/s00213-012-2853-3
10.1007/s002130100858
10.1016/j.neubiorev.2003.11.005
10.1002/dev.420140203
10.1016/0031-9384(95)02043-8
10.1016/j.jneumeth.2015.10.012
10.1016/j.neuropharm.2019.107780
10.1016/j.brainresrev.2007.04.005
10.1016/B978-0-444-64123-6.00004-7
10.1016/j.bandc.2007.02.007
10.1016/j.biopsycho.2010.02.015
10.1182/blood-2009-06-224782
10.1016/j.mce.2007.05.018
10.1042/bst0310060
10.1067/mai.2003.97
10.1038/ncprheum0898
10.1016/j.tem.2012.11.005
10.1073/pnas.121455098
10.1073/pnas.1114122109
10.2165/11587790-000000000-00000
10.1016/j.biopsych.2014.07.021
10.1007/s40473-015-0044-3
10.1016/j.bbi.2019.01.021
10.1111/j.1471-4159.2009.06345.x
10.1093/ijnp/pyy038
10.7705/biomedica.v38i3.3688
10.1016/j.neuroscience.2009.03.084
10.1111/jnc.12055
10.1016/S0014-2999(00)00569-0
10.1073/pnas.1118355109
10.1016/j.bbi.2020.03.012
10.1210/js.2019-00053
10.3389/fnbeh.2018.00056
10.1111/jnc.14478
10.1186/s12929-019-0514-0
10.1007/s00441-018-2866-2
10.1523/JNEUROSCI.1345-14.2015
10.1016/j.yhbeh.2015.08.010
10.1080/17470919.2015.1070747
10.1080/10253890.2020.1733962
10.1016/j.yfrne.2004.09.001
10.1016/j.tins.2012.08.004
10.1016/j.psyneuen.2010.12.005
10.1016/j.biopsych.2013.09.017
10.1016/j.psyneuen.2016.08.029
10.1016/j.yfrne.2016.11.001
10.1016/j.psyneuen.2015.08.027
10.1016/j.physbeh.2011.03.007
10.1210/en.2017-00606
10.1016/j.biopsych.2015.10.007
10.1016/j.psyneuen.2014.09.009
10.1016/j.biopsych.2017.08.024
10.1080/10253890.2017.1376185
10.1111/ejn.14691
10.1016/j.jpsychires.2013.12.012
10.1016/j.jpsychires.2014.11.001
10.1002/hbm.22508
10.1007/978-981-32-9705-0_7
10.1002/da.21973
10.1038/npp.2014.53
10.1038/npp.2010.123
10.1017/S1461145711001489
10.1016/j.neuroimage.2017.08.079
10.1016/j.biopsycho.2017.05.015
10.1002/hbm.22553
10.1007/s00213-014-3631-1
10.1016/j.psyneuen.2018.08.025
10.1016/j.psyneuen.2016.01.020
10.1093/scan/nsw123
10.1038/npp.2016.1
10.1016/j.euroneuro.2018.12.002
10.1016/j.pnpbp.2017.11.002
10.1016/j.neuropharm.2019.107836
10.1007/s00213-019-05191-6
10.1523/JNEUROSCI.3942-13.2014
10.1007/s00213-017-4676-8
10.1007/s00213-017-4677-7
10.1016/j.neuropharm.2020.108368
10.1016/j.drugalcdep.2020.108004
10.1016/j.pnpbp.2020.110123
10.1016/j.ejphar.2018.01.052
10.1007/s00213-017-4612-y
10.1016/j.brainresrev.2008.08.002
10.1111/j.1369-1600.2007.00070.x
10.1016/j.pharmthera.2008.07.006
10.1590/2237-6089-2014-0034
10.1007/s00213-015-4082-z
10.1007/s00213-015-4144-2
10.1007/s00213-014-3796-7
10.1016/j.neuroscience.2019.07.046
10.1016/j.neures.2016.11.007
10.1126/science.aan4994
10.1002/cne.24116
10.1016/j.neuron.2017.06.003
10.3389/fnbeh.2019.00148
10.1016/j.physbeh.2020.112913
10.1007/s00213-019-05233-z
10.1007/s00213-015-4184-7
10.1016/j.psychres.2015.07.064
10.1037/pha0000232
10.1016/j.psyneuen.2020.104752
10.1007/s00213-016-4218-9
10.1111/ejn.14127
10.1111/adb.12301
10.1038/npp.2016.102
10.1371/journal.pone.0142195
10.1371/journal.pone.0212397
10.1155/2015/167235
10.1161/STROKEAHA.111.628008
10.1186/s12974-016-0541-7
10.1016/j.pnpbp.2017.02.022
10.3390/ijms19123848
10.1016/j.neubiorev.2018.08.014",<Element 'PubmedArticle' at 0x7f05df012950>
173,33592574,Systemic cellular immunity and neuroinflammation during acute flare-up in multiple sclerosis and neuromyelitis optica spectrum disorder patients.,"Twenty-seven treatment-naïve patients with relapsing-remitting multiple sclerosis (MS) and 13 with neuromyelitis optica spectrum disorder (NMOSD) were enrolled during a time of acute flare-up. Common cerebrospinal fluid (CSF) features were increased CD29- and/or CD45RO-positive helper T cells capable of propagating inflammation in the central nervous system (CNS). B cell activation in the CSF was unique to MS, while an increase in CD4","['Biomarker', 'Cerebrospinal fluid', 'Flow cytometry', 'Lymphocyte subset', 'Multiple sclerosis', 'Neuromyelitis optica spectrum disorder']",Journal of neuroimmunology,2021-02-17,"[{'lastname': 'Uchida', 'firstname': 'Nobuaki', 'initials': 'N', 'affiliation': 'Department of Neurology, Kanazawa Medical University, 1-1 Daigaku, Uchinada, Kahoku-gun, Ishikawa 920-0293, Japan.'}, {'lastname': 'Mori', 'firstname': 'Kentaro', 'initials': 'K', 'affiliation': 'Department of Neurology, Kanazawa Medical University, 1-1 Daigaku, Uchinada, Kahoku-gun, Ishikawa 920-0293, Japan.'}, {'lastname': 'Fujita-Nakata', 'firstname': 'Michiyo', 'initials': 'M', 'affiliation': 'Department of Neurology, Kanazawa Medical University, 1-1 Daigaku, Uchinada, Kahoku-gun, Ishikawa 920-0293, Japan.'}, {'lastname': 'Nakanishi', 'firstname': 'Megumi', 'initials': 'M', 'affiliation': 'Department of Neurology, Kanazawa Medical University, 1-1 Daigaku, Uchinada, Kahoku-gun, Ishikawa 920-0293, Japan.'}, {'lastname': 'Sanada', 'firstname': 'Mitsuru', 'initials': 'M', 'affiliation': 'Department of Neurology, Kanazawa Medical University, 1-1 Daigaku, Uchinada, Kahoku-gun, Ishikawa 920-0293, Japan.'}, {'lastname': 'Nagayama', 'firstname': 'Shigemi', 'initials': 'S', 'affiliation': 'Department of Neurology, Kanazawa Medical University, 1-1 Daigaku, Uchinada, Kahoku-gun, Ishikawa 920-0293, Japan.'}, {'lastname': 'Sugiyama', 'firstname': 'Hiroshi', 'initials': 'H', 'affiliation': 'Department of Neurology, National Hospital Organization Utano National Hospital, 8 Narutaki-Ondoyama-cho, Ukyo-ku, Kyoto 616-8255, Japan.'}, {'lastname': 'Matsui', 'firstname': 'Makoto', 'initials': 'M', 'affiliation': 'Department of Neurology, Kanazawa Medical University, 1-1 Daigaku, Uchinada, Kahoku-gun, Ishikawa 920-0293, Japan. Electronic address: veritasm@kanazawa-med.ac.jp.'}]",,,,Copyright © 2021 Elsevier B.V. All rights reserved.,10.1016/j.jneuroim.2021.577500,<Element 'PubmedArticle' at 0x7f05def892c0>
174,"33589833
19482229
22325206
28899620
26911697
19228979
11906204
15821089
21719680
30158853
15155061
21389985
31537912
28945222
32703230
21796121
18356275
16707796
28479102
29779943
23612301
10924808
29302197
29922743
26386304
25345612
20557424
18510735
15295027
15339653
31954621
27828941
31283899
16339042
21314846
28210958
24456263
29079367
31079836
26527193
26316036
19056987
21536893
12574405
12490528
23589582
16707789
17310248
15893573
18579739
16414552
17406592
19783992
32015543
25700174
32139688
31116972
21697385",Astrocytes mediate the effect of oxytocin in the central amygdala on neuronal activity and affective states in rodents.,"Oxytocin (OT) orchestrates social and emotional behaviors through modulation of neural circuits. In the central amygdala, the release of OT modulates inhibitory circuits and, thereby, suppresses fear responses and decreases anxiety levels. Using astrocyte-specific gain and loss of function and pharmacological approaches, we demonstrate that a morphologically distinct subpopulation of astrocytes expresses OT receptors and mediates anxiolytic and positive reinforcement effects of OT in the central amygdala of mice and rats. The involvement of astrocytes in OT signaling challenges the long-held dogma that OT acts exclusively on neurons and highlights astrocytes as essential components for modulation of emotional states under normal and chronic pain conditions.",[],Nature neuroscience,2021-02-17,"[{'lastname': 'Wahis', 'firstname': 'Jérôme', 'initials': 'J', 'affiliation': 'Centre National de la Recherche Scientifique, University of Strasbourg, Institute of Cellular and Integrative Neurosciences, Strasbourg, France.\nKU Leuven, Leuven Brain Institue, Department of Neurosciences, VIB-KU Leuven Center for Brain and Disease Research, Laboratory of Glia Biology, Leuven, Belgium.'}, {'lastname': 'Baudon', 'firstname': 'Angel', 'initials': 'A', 'affiliation': 'Centre National de la Recherche Scientifique, University of Strasbourg, Institute of Cellular and Integrative Neurosciences, Strasbourg, France.'}, {'lastname': 'Althammer', 'firstname': 'Ferdinand', 'initials': 'F', 'affiliation': 'Center for Neuroinflammation and Cardiometabolic Diseases, Georgia State University, Atlanta GA, USA.'}, {'lastname': 'Kerspern', 'firstname': 'Damien', 'initials': 'D', 'affiliation': 'Centre National de la Recherche Scientifique, University of Strasbourg, Institute of Cellular and Integrative Neurosciences, Strasbourg, France.'}, {'lastname': 'Goyon', 'firstname': 'Stéphanie', 'initials': 'S', 'affiliation': 'Centre National de la Recherche Scientifique, University of Strasbourg, Institute of Cellular and Integrative Neurosciences, Strasbourg, France.'}, {'lastname': 'Hagiwara', 'firstname': 'Daisuke', 'initials': 'D', 'affiliation': 'Department of Neuropeptide Research for Psychiatry, Central Institute of Mental Health, University of Heidelberg, Mannheim, Germany.'}, {'lastname': 'Lefevre', 'firstname': 'Arthur', 'initials': 'A', 'affiliation': 'Centre National de la Recherche Scientifique, University of Strasbourg, Institute of Cellular and Integrative Neurosciences, Strasbourg, France.\nDepartment of Neuropeptide Research for Psychiatry, Central Institute of Mental Health, University of Heidelberg, Mannheim, Germany.'}, {'lastname': 'Barteczko', 'firstname': 'Lara', 'initials': 'L', 'affiliation': 'Department of Neuropeptide Research for Psychiatry, Central Institute of Mental Health, University of Heidelberg, Mannheim, Germany.'}, {'lastname': 'Boury-Jamot', 'firstname': 'Benjamin', 'initials': 'B', 'affiliation': 'Center for Psychiatric Neurosciences, Hôpital de Cery, Lausanne University Hospital (CHUV), Lausanne, Switzerland.'}, {'lastname': 'Bellanger', 'firstname': 'Benjamin', 'initials': 'B', 'affiliation': 'Centre National de la Recherche Scientifique, University of Strasbourg, Institute of Cellular and Integrative Neurosciences, Strasbourg, France.'}, {'lastname': 'Abatis', 'firstname': 'Marios', 'initials': 'M', 'affiliation': 'Center for Psychiatric Neurosciences, Hôpital de Cery, Lausanne University Hospital (CHUV), Lausanne, Switzerland.'}, {'lastname': 'Da Silva Gouveia', 'firstname': 'Miriam', 'initials': 'M', 'affiliation': 'German Cancer Research Center (DKFZ), Heidelberg, Germany.'}, {'lastname': 'Benusiglio', 'firstname': 'Diego', 'initials': 'D', 'affiliation': 'Department of Neuropeptide Research for Psychiatry, Central Institute of Mental Health, University of Heidelberg, Mannheim, Germany.'}, {'lastname': 'Eliava', 'firstname': 'Marina', 'initials': 'M', 'affiliation': 'Department of Neuropeptide Research for Psychiatry, Central Institute of Mental Health, University of Heidelberg, Mannheim, Germany.'}, {'lastname': 'Rozov', 'firstname': 'Andrei', 'initials': 'A', 'affiliation': 'OpenLab of Neurobiology, Kazan Federal University, Kazan, Russia, Federal Center of Brain Research and Neurotechnologies, Moscow, Russia and Department of Physiology and Pathophysiology, University of Heidelberg, Heidelberg, Germany.'}, {'lastname': 'Weinsanto', 'firstname': 'Ivan', 'initials': 'I', 'affiliation': 'Centre National de la Recherche Scientifique, University of Strasbourg, Institute of Cellular and Integrative Neurosciences, Strasbourg, France.'}, {'lastname': 'Knobloch-Bollmann', 'firstname': 'Hanna Sophie', 'initials': 'HS', 'affiliation': 'Department of Molecular and Cellular Biology, Center for Brain Science, Harvard University, Cambridge MA, USA.\nGroup of Systemic and Cellular Neuroscience, Institute of Physiology, University of Freiburg, Freiburg, Germany.'}, {'lastname': 'Kirchner', 'firstname': 'Matthew K', 'initials': 'MK', 'affiliation': 'Center for Neuroinflammation and Cardiometabolic Diseases, Georgia State University, Atlanta GA, USA.'}, {'lastname': 'Roy', 'firstname': 'Ranjan K', 'initials': 'RK', 'affiliation': 'Center for Neuroinflammation and Cardiometabolic Diseases, Georgia State University, Atlanta GA, USA.'}, {'lastname': 'Wang', 'firstname': 'Hong', 'initials': 'H', 'affiliation': 'Department of Pharmacology, Heidelberg University, Heidelberg, Germany.\nThe Brain Cognition and Brain Disease Institute of Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Beijing, China.'}, {'lastname': 'Pertin', 'firstname': 'Marie', 'initials': 'M', 'affiliation': 'Pain center, Department of Anesthesiology, Lausanne University Hospital (CHUV), Lausanne, Switzerland.'}, {'lastname': 'Inquimbert', 'firstname': 'Perrine', 'initials': 'P', 'affiliation': 'Centre National de la Recherche Scientifique, University of Strasbourg, Institute of Cellular and Integrative Neurosciences, Strasbourg, France.'}, {'lastname': 'Pitzer', 'firstname': 'Claudia', 'initials': 'C', 'affiliation': 'Interdisciplinary Neurobehavioral Core (INBC), Ruprecht-Karls-Universität, Heidelberg, Germany.'}, {'lastname': 'Siemens', 'firstname': 'Jan', 'initials': 'J', 'affiliation': 'Department of Pharmacology, Heidelberg University, Heidelberg, Germany.'}, {'lastname': 'Goumon', 'firstname': 'Yannick', 'initials': 'Y', 'affiliation': 'Centre National de la Recherche Scientifique, University of Strasbourg, Institute of Cellular and Integrative Neurosciences, Strasbourg, France.'}, {'lastname': 'Boutrel', 'firstname': 'Benjamin', 'initials': 'B', 'affiliation': 'Center for Psychiatric Neurosciences, Hôpital de Cery, Lausanne University Hospital (CHUV), Lausanne, Switzerland.'}, {'lastname': 'Lamy', 'firstname': 'Christophe Maurice', 'initials': 'CM', 'affiliation': 'Division of Anatomy, Faculty of Medicine, University of Geneva, Geneva, Switzerland.'}, {'lastname': 'Decosterd', 'firstname': 'Isabelle', 'initials': 'I', 'affiliation': 'Pain center, Department of Anesthesiology, Lausanne University Hospital (CHUV), Lausanne, Switzerland.\nDepartment of Fundamental Neurosciences, Faculty of Biology and Medicine (FBM), University of Lausanne, Lausanne, Switzerland.'}, {'lastname': 'Chatton', 'firstname': 'Jean-Yves', 'initials': 'JY', 'affiliation': 'Pain center, Department of Anesthesiology, Lausanne University Hospital (CHUV), Lausanne, Switzerland.'}, {'lastname': 'Rouach', 'firstname': 'Nathalie', 'initials': 'N', 'affiliation': 'Neuroglial Interactions in Cerebral Physiopathology, Center for Interdisciplinary Research in Biology, Collège de France, Centre National de la Recherche Scientifique UMR 7241, Institut National de la Santé et de la Recherche Médicale U1050, Labex Memolife, PSL Research University, Paris, France.'}, {'lastname': 'Young', 'firstname': 'W Scott', 'initials': 'WS', 'affiliation': 'Section on Neural Gene Expression, National Institute of Mental Health, National Institutes of Health, Bethesda, MD, USA.'}, {'lastname': 'Stern', 'firstname': 'Javier E', 'initials': 'JE', 'affiliation': 'Center for Neuroinflammation and Cardiometabolic Diseases, Georgia State University, Atlanta GA, USA.'}, {'lastname': 'Poisbeau', 'firstname': 'Pierrick', 'initials': 'P', 'affiliation': 'Centre National de la Recherche Scientifique, University of Strasbourg, Institute of Cellular and Integrative Neurosciences, Strasbourg, France.'}, {'lastname': 'Stoop', 'firstname': 'Ron', 'initials': 'R', 'affiliation': 'Center for Psychiatric Neurosciences, Hôpital de Cery, Lausanne University Hospital (CHUV), Lausanne, Switzerland.'}, {'lastname': 'Darbon', 'firstname': 'Pascal', 'initials': 'P', 'affiliation': 'Centre National de la Recherche Scientifique, University of Strasbourg, Institute of Cellular and Integrative Neurosciences, Strasbourg, France.'}, {'lastname': 'Grinevich', 'firstname': 'Valery', 'initials': 'V', 'affiliation': 'Department of Neuropeptide Research for Psychiatry, Central Institute of Mental Health, University of Heidelberg, Mannheim, Germany. valery.grinevich@zi-mannheim.de.'}, {'lastname': 'Charlet', 'firstname': 'Alexandre', 'initials': 'A', 'affiliation': 'Centre National de la Recherche Scientifique, University of Strasbourg, Institute of Cellular and Integrative Neurosciences, Strasbourg, France. acharlet@unistra.fr.\nUniversity of Strasbourg Institute for Advanced Study (USIAS), Strasbourg, France. acharlet@unistra.fr.'}]",,,,,"10.1038/s41593-021-00800-0
10.1016/j.neuron.2011.11.030
10.1016/j.tips.2017.08.005
10.1523/JNEUROSCI.2409-15.2016
10.1523/JNEUROSCI.5593-08.2009
10.1006/frne.2001.0226
10.3389/fncel.2020.581075
10.1126/science.1105636
10.1126/science.1201043
10.3389/fnmol.2018.00246
10.1177/1073858403261077
10.1038/nature09820
10.1038/s41583-019-0218-1
10.1038/nn.4649
10.1186/s12974-020-01892-4
10.1038/nature10360
10.1210/en.2007-1710
10.1523/JNEUROSCI.0037-06.2006
10.1016/j.neuron.2017.04.021
10.1016/j.neuron.2018.04.034
10.3390/cells8060586
10.1038/ncomms2779
10.1016/S0304-3959(00)00276-1
10.1155/2017/8296501
10.1097/PR9.0000000000000651
10.1016/j.bbr.2015.09.021
10.2174/1381612820666141027111843
10.1186/1744-8069-4-19
10.1523/JNEUROSCI.0473-04.2004
10.1016/j.neuron.2004.08.011
10.1016/j.neuron.2019.12.026
10.1038/nature20145
10.3390/brainsci10030168
10.1146/annurev-neuro-070918-050443
10.1523/JNEUROSCI.3984-05.2005
10.1111/j.1460-9568.2010.07584.x
10.1007/s11064-017-2195-y
10.1111/cns.12223
10.1016/j.neures.2017.08.012
10.1016/j.bja.2019.03.023
10.1177/204946371000400103
10.1016/j.tins.2015.07.006
10.1126/science.1164022
10.1073/pnas.1016650108
10.1523/JNEUROSCI.23-03-00766.2003
10.1093/hmg/ddg001
10.1085/jgp.201210949
10.1523/JNEUROSCI.5255-05.2006
10.1038/nn1849
10.1016/j.neures.2005.02.004
10.1523/JNEUROSCI.1717-08.2008
10.3389/fendo.2013.00144
10.1016/j.jpain.2005.07.011
10.1038/nprot.2007.44
10.1038/nn.2407
10.1038/s41592-019-0686-2
10.1126/science.aaa1934
10.1038/s41467-019-14198-8
10.1016/j.celrep.2019.04.078
10.1523/JNEUROSCI.0127-11.2011",<Element 'PubmedArticle' at 0x7f05def97e50>
175,33573565,The Endocannabinoid System and Alcohol Dependence: Will Cannabinoid Receptor 2 Agonism be More Fruitful than Cannabinoid Receptor 1 Antagonism?,"Alcohol-use disorder (AUD) remains a major public health concern. In recent years, there has been a heightened interest in components of the endocannabinoid system for the treatment of AUD. Cannabinoid type 1 (CB1) receptors have been shown to modulate the rewarding effects of alcohol, reduce the abuse-related effects of alcohol, improve cognition, exhibit anti-inflammatory, and neuroprotective effects, which are all favorable properties of potential therapeutic candidates for the treatment of AUD. However, CB1 agonists have not been investigated for the treatment of AUD because they stimulate the motivational properties of alcohol, increase alcohol intake, and have the tendency to be abused. Preclinical data suggest significant potential for the use of CB1 antagonists to treat AUD; however, a clinical phase I/II trial with SR14716A (rimonabant), a CB1 receptor antagonist/inverse agonist showed that it produced serious neuropsychiatric adverse events such as anxiety, depression, and even suicidal ideation. This has redirected the field to focus on alternative components of the endocannabinoid system, including cannabinoid type 2 (CB2) receptor agonists as a potential therapeutic target for AUD. CB2 receptor agonists are of particular interest because they can modulate the reward pathway, reduce abuse-related effects of alcohol, reverse neuroinflammation, improve cognition, and exhibit anti-inflammatory and neuroprotective effects, without exhibiting the psychiatric side effects seen with CB1 antagonists. Accordingly, this article presents an overview of the studies reported in the literature that have investigated CB2 receptor agonists with regards to AUD and provides commentary as to whether this receptor is a worthy target for continued investigation.","['Alcohol-use disorder (AUD)', 'CB1 receptor', 'CB2 receptor', 'anti-inflammatory', 'endocannabinoid system', 'ethanol', 'neuroprotection.']",CNS & neurological disorders drug targets,2021-02-13,"[{'lastname': 'Oppong-Damoah', 'firstname': 'Aboagyewaah', 'initials': 'A', 'affiliation': 'Department of Pharmaceutical Sciences, Mercer University College of Pharmacy, Mercer University Health Sciences Center,United States.'}, {'lastname': 'Gannon', 'firstname': 'Brenda Marie', 'initials': 'BM', 'affiliation': 'Department of Pharmaceutical Sciences, Mercer University College of Pharmacy, Mercer University Health Sciences Center,United States.'}, {'lastname': 'Murnane', 'firstname': 'Kevin Sean', 'initials': 'KS', 'affiliation': 'Department of Pharmaceutical Sciences, Mercer University College of Pharmacy, Mercer University Health Sciences Center,United States.'}]",,,,"Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.",10.2174/1871527320666210211115007,<Element 'PubmedArticle' at 0x7f05def4dc70>
176,33568039,The Putative Adverse Effects of Bisphenol A on Autoimmune Diseases.,"Bisphenol A (BPA) is a monomer that is widely used in the manufacturing of polycarbonate plastics (including storage plastics and baby bottles) and is considered to be one of the most widely used synthetic compounds in the manufacturing industry. Exposure to BPA mainly occurs after oral ingestion and results from leaks into food and water from plastic containers. According to epidemiological data, exposure is widespread and estimated to occur in 90% of individuals. BPA exhibits pleiotropic and estrogen-like effects; thus, it is considered an endocrine-disrupting chemical. A growing body of evidence highlights the role of BPA in modulating immune responses and signaling pathways, which results in a proinflammatory response by enhancing the differential polarization of immune cells and cytokine production profile to one that is consistent with proinflammation. Indeed, epidemiological studies have uncovered associations between several autoimmune diseases and BPA exposure. Data from animal models provided consistent evidence, which highlighted the role of BPA in the pathogenesis, exacerbation, and perpetuation of various autoimmune phenomena including neuroinflammation in the context of multiple sclerosis, colitis in inflammatory bowel disease, nephritis in systemic lupus erythematosus, and insulitis in type 1 diabetes mellitus. Owing to the widespread use of BPA and its effects on immune system dysregulation, a call for careful assessment of patients' risks and public health measures are needed to limit exposure and subsequent deleterious effects. The purpose of this study is to explore the autoimmune triggering mechanisms and present the current literature supporting the role of BPA in the pathogenesis of autoimmune diseases.","['Bisphenol A', 'Multiple sclerosis', 'Systemic lupus erythematosus', 'autoimmunity', 'plastics', 'proinflammation']","Endocrine, metabolic & immune disorders drug targets",2021-02-12,"[{'lastname': 'Sharif', 'firstname': 'Kassem', 'initials': 'K', 'affiliation': ""Department of Medicine \\'B\\', Sheba Medical Centre, Ramat Gan, Israel.\nZabludowicz Center for Autoimmune Diseases, Sheba Medical Center, Tel-Hashomer, Israel.\nSackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel.""}, {'lastname': 'Kurnick', 'firstname': 'Adam', 'initials': 'A', 'affiliation': 'Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel.'}, {'lastname': 'Coplan', 'firstname': 'Louis', 'initials': 'L', 'affiliation': 'Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel.'}, {'lastname': 'Alexander', 'firstname': 'Matthew', 'initials': 'M', 'affiliation': 'Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel.'}, {'lastname': 'Watad', 'firstname': 'Abdulla', 'initials': 'A', 'affiliation': ""Department of Medicine \\'B\\', Sheba Medical Centre, Ramat Gan, Israel.\nZabludowicz Center for Autoimmune Diseases, Sheba Medical Center, Tel-Hashomer, Israel.\nSackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel.""}, {'lastname': 'Amital', 'firstname': 'Howard', 'initials': 'H', 'affiliation': ""Department of Medicine \\'B\\', Sheba Medical Centre, Ramat Gan, Israel.\nZabludowicz Center for Autoimmune Diseases, Sheba Medical Center, Tel-Hashomer, Israel.\nSackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel.""}, {'lastname': 'Shoenfeld', 'firstname': 'Yehuda', 'initials': 'Y', 'affiliation': 'Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, Tel-Hashomer, Israel.\nSackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel.\nI.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University), Moscow, Russia.'}]",,,,"Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.",10.2174/1871530321666210210154309,<Element 'PubmedArticle' at 0x7f05def5a400>
177,33539800,Androgenic modulation of arterial baroreceptor dysfunction and neuroinflammation in endotoxic male rats.,"Autonomic neuropathy contributes to cardiovascular derangements induced by endotoxemia. In this communication, we tested the hypothesis that androgenic hormones improve arterial baroreflex dysfunction and predisposing neuroinflammatory response caused by endotoxemia in male rats. Baroreflex curves relating changes in heart rate to increases or decreases in blood pressure evoked by phenylephrine (PE) and sodium nitroprusside (SNP), respectively, were constructed in conscious sham-operated, castrated, and testosterone-replaced castrated rats treated with or without lipopolysaccharide (LPS, 10 mg/kg i.v.). Slopes of baroreflex curves were taken as measures of baroreflex sensitivity (BRS). In sham rats, LPS significantly reduced reflex bradycardia (BRS","['Arterial baroreceptors', 'Castration', 'Endotoxemia', 'Gonadotropin-releasing hormone receptors', 'Neuroinflammation', 'Testosterone']",Brain research,2021-02-05,"[{'lastname': 'Sallam', 'firstname': 'Marwa Y', 'initials': 'MY', 'affiliation': 'Department of Pharmacology and Toxicology, Faculty of Pharmacy, Alexandria University Alexandria, Egypt.'}, {'lastname': 'El-Gowilly', 'firstname': 'Sahar M', 'initials': 'SM', 'affiliation': 'Department of Pharmacology and Toxicology, Faculty of Pharmacy, Alexandria University Alexandria, Egypt.'}, {'lastname': 'El-Mas', 'firstname': 'Mahmoud M', 'initials': 'MM', 'affiliation': 'Department of Pharmacology and Toxicology, Faculty of Pharmacy, Alexandria University Alexandria, Egypt; Department of Pharmacology and Toxicology, Faculty of Medicine, Kuwait University, Kuwait. Electronic address: mahmoud.elmas@ku.edu.kw.'}]",,,,Copyright © 2021 Elsevier B.V. All rights reserved.,10.1016/j.brainres.2021.147330,<Element 'PubmedArticle' at 0x7f05def66180>
178,"33494281
23993280
18188442
31261897
30496105
26851330
14585943
26388529
21741216
19150704
22845879
21047156
30104506
21603930
30658014
31446215
32581855
31333434
11181507
31371505
31077728
23938177
30402099
30922675
27856397
24444786
15308615
28673758
27240529
24686136
32109548
26524527
25188634
28445465
30529907
31036290
18369406
21538657
10658612
17570500
9388012
11240308
14993040
12697714
26190834
12351713
18424448
22001950
16112656
12353223
11955958
22901352
21277876
14662550
28987712
14601036
31207455
19002139
31740837
31043756
32528109
25056061
29700475
26949748
29704319
30610197
29022597
27668389
30545857
32015716
28936160
32116564
23644028
31039525
31906708
28617822
31318452
25018677
30582748
31678567
31130380
7938003
27013346
22186669
30883896
19624391
22510887
21975034
23111185
25446950
27839913
27800654
20368511
8530074
10457534
11285140
31019265
27539538
29768193
32084458
28239307
25484074
31644973
30575805
31225453
28780170
19289156
8879469
16996188
9728523
28696432
14499463
29844355
22070562
18577698
2837664
1373180
9418891
18445124
18048642
19457121
18753308
15912132
28202255
12777700
11835321
15730564
22554613
29550215
15464048
19150053
26359903
25792098
27351598
29867038
26435451
32499649
32174850
25789684
20176265
20123911
21641581
22704639
22717193
28619247
22193673
32116664
20966214
27959620
31585077
29426702
30679343
18534557
19837763
16920490
20234358
24703991
26348581
11126389
14984887
21310238
30547416
26674997
21443944
29084144
29049933
9553964
11596126
28989099
30940904
25339862
30206330
31036962
29680514
29867314
28732515
27870410
19265047
23994069
25573105
25889641
14720179
21564348
32554430
28401937
31182728
16054770
23652162
25293493
23407936
22182318
24871624
29472840
18444252
25586400
17030651
25643025
5319766
1978495
17259207
6111227
28289283
17688462
19922550
21449915
4461784
32625059
16946919
23557849
20042529
3059473
16594998
27449797
22834460
23964248
10518181
1654746
22899397
17669558
17959792
7492260
10628529
14684455
23027419
19523965
16759710
15803162
20556669
27615800
17419756
22298694
27148090
19538681
23371914
5289225
24577622
30459650
18669513
26984740
28942195
32066698
25750611
8818400
32848567
10368772
19049819
11889496
2880640
9030643
1353442
1353794
16725270
24112361
27272766
9502814
18297067
19828812
16510735
17615392
12128251
19383291
11085516
12370120
11850811
14612509
12959972
15079859
21774811
17180163
26491441
26719696
17950954
18938255
18772582
11923430
16020928
12008023
8823751
9559922
9106616
10869887
29078280
26143621
26997644
18035408
21368825
27075820
30664289
30127392
31787569
30897183
31338163
31391546
21490598
31540999
28277309
24523672
28586384
27737794
28824363
29535595
19807941
20616000
26687838
9690763
16938356
19279265
28736215
32502466
23995685
27118425
28283582
30617271
31168097
30573846
30963107
29196977
32597849
26005811
28817799
29658944
30301888
31474560
29024164
29321530
29395611
30741085",Using iPSC Models to Understand the Role of Estrogen in Neuron-Glia Interactions in Schizophrenia and Bipolar Disorder.,"Schizophrenia (SCZ) and bipolar disorder (BIP) are severe mental disorders with a considerable disease burden worldwide due to early age of onset, chronicity, and lack of efficient treatments or prevention strategies. Whilst our current knowledge is that SCZ and BIP are highly heritable and share common pathophysiological mechanisms associated with cellular signaling, neurotransmission, energy metabolism, and neuroinflammation, the development of novel therapies has been hampered by the unavailability of appropriate models to identify novel targetable pathomechanisms. Recent data suggest that neuron-glia interactions are disturbed in SCZ and BIP, and are modulated by estrogen (E2). However, most of the knowledge we have so far on the neuromodulatory effects of E2 came from studies on animal models and human cell lines, and may not accurately reflect many processes occurring exclusively in the human brain. Thus, here we highlight the advantages of using induced pluripotent stem cell (iPSC) models to revisit studies of mechanisms underlying beneficial effects of E2 in human brain cells. A better understanding of these mechanisms opens the opportunity to identify putative targets of novel therapeutic agents for SCZ and BIP. In this review, we first summarize the literature on the molecular mechanisms involved in SCZ and BIP pathology and the beneficial effects of E2 on neuron-glia interactions. Then, we briefly present the most recent developments in the iPSC field, emphasizing the potential of using patient-derived iPSCs as more relevant models to study the effects of E2 on neuron-glia interactions.","['bipolar disorder', 'brain organoids', 'drug target', 'estrogen', 'iPS cells', 'in vitro model', 'neuron–glia interactions', 'pathophysiological mechanisms', 'schizophrenia']",Cells,2021-01-27,"[{'lastname': 'Reis de Assis', 'firstname': 'Denis', 'initials': 'D', 'affiliation': 'NORMENT, Institute of Clinical Medicine, University of Oslo & Division of Mental Health and Addiction, Oslo University Hospital, 0450 Oslo, Norway.\nDepartment of Medical Genetics, Oslo University Hospital, 0450 Oslo, Norway.'}, {'lastname': 'Szabo', 'firstname': 'Attila', 'initials': 'A', 'affiliation': 'NORMENT, Institute of Clinical Medicine, University of Oslo & Division of Mental Health and Addiction, Oslo University Hospital, 0450 Oslo, Norway.\nDepartment of Medical Genetics, Oslo University Hospital, 0450 Oslo, Norway.'}, {'lastname': 'Requena Osete', 'firstname': 'Jordi', 'initials': 'J', 'affiliation': 'NORMENT, Institute of Clinical Medicine, University of Oslo & Division of Mental Health and Addiction, Oslo University Hospital, 0450 Oslo, Norway.\nDepartment of Medical Genetics, Oslo University Hospital, 0450 Oslo, Norway.'}, {'lastname': 'Puppo', 'firstname': 'Francesca', 'initials': 'F', 'affiliation': 'NORMENT, Institute of Clinical Medicine, University of Oslo & Division of Mental Health and Addiction, Oslo University Hospital, 0450 Oslo, Norway.\nDepartment of Neurosciences, University of California San Diego, La Jolla, CA 92093, USA.'}, {'lastname': ""O'Connell"", 'firstname': 'Kevin S', 'initials': 'KS', 'affiliation': 'NORMENT, Institute of Clinical Medicine, University of Oslo & Division of Mental Health and Addiction, Oslo University Hospital, 0450 Oslo, Norway.'}, {'lastname': 'A Akkouh', 'firstname': 'Ibrahim', 'initials': 'I', 'affiliation': 'NORMENT, Institute of Clinical Medicine, University of Oslo & Division of Mental Health and Addiction, Oslo University Hospital, 0450 Oslo, Norway.\nDepartment of Medical Genetics, Oslo University Hospital, 0450 Oslo, Norway.'}, {'lastname': 'Hughes', 'firstname': 'Timothy', 'initials': 'T', 'affiliation': 'NORMENT, Institute of Clinical Medicine, University of Oslo & Division of Mental Health and Addiction, Oslo University Hospital, 0450 Oslo, Norway.\nDepartment of Medical Genetics, Oslo University Hospital, 0450 Oslo, Norway.'}, {'lastname': 'Frei', 'firstname': 'Evgeniia', 'initials': 'E', 'affiliation': 'NORMENT, Institute of Clinical Medicine, University of Oslo & Division of Mental Health and Addiction, Oslo University Hospital, 0450 Oslo, Norway.\nDepartment of Medical Genetics, Oslo University Hospital, 0450 Oslo, Norway.'}, {'lastname': 'A Andreassen', 'firstname': 'Ole', 'initials': 'O', 'affiliation': 'NORMENT, Institute of Clinical Medicine, University of Oslo & Division of Mental Health and Addiction, Oslo University Hospital, 0450 Oslo, Norway.\nDivision of Mental Health and Addiction, Oslo University Hospital, 0372 Oslo, Norway.'}, {'lastname': 'Djurovic', 'firstname': 'Srdjan', 'initials': 'S', 'affiliation': 'NORMENT, Institute of Clinical Medicine, University of Oslo & Division of Mental Health and Addiction, Oslo University Hospital, 0450 Oslo, Norway.\nNORMENT, Department of Clinical Science, University of Bergen, 5020 Bergen, Norway.'}]",,,,,"10.3390/cells10020209
10.1016/S0140-6736(13)61611-6
10.3390/ijms20133207
10.1016/S0140-6736(18)32225-6
10.1016/S2215-0366(15)00505-2
10.1056/NEJMra035458
10.1016/S0140-6736(15)00241-X
10.1016/j.schres.2011.06.008
10.1016/S0140-6736(09)60072-6
10.1111/j.1365-2826.2012.02365.x
10.3109/09540261.2010.515205
10.3390/brainsci8080154
10.1007/s11154-011-9184-2
10.1111/bph.14584
10.1016/j.psychres.2019.112503
10.3389/fpsyt.2020.00313
10.3389/fnhum.2019.00224
10.1210/endo.142.3.8033
10.1073/pnas.1900406116
10.1016/j.neuropharm.2019.05.008
10.1016/j.schres.2013.07.033
10.1155/2018/9516592
10.1016/j.yfrne.2019.03.002
10.1016/S2215-0366(16)30348-0
10.1016/j.mce.2014.01.009
10.1210/en.2004-0973
10.1016/j.yfrne.2017.06.003
10.1038/mp.2016.89
10.1038/mp.2014.22
10.1016/j.bbi.2020.02.008
10.1038/nature15526
10.1038/nprot.2014.158
10.1038/nature22330
10.1016/j.psyneuen.2018.11.037
10.1016/bs.apcsb.2019.01.001
10.2174/138920206779315737
10.1002/hipo.20935
10.1016/S0306-4522(99)00443-1
10.1002/cne.21419
10.1002/(SICI)1096-9861(19971201)388:4<507::AID-CNE1>3.0.CO;2-6
10.1016/S0301-0082(00)00059-9
10.1196/annals.1286.006
10.1210/en.2002-221069
10.1016/j.mce.2015.07.016
10.1523/JNEUROSCI.22-19-08391.2002
10.1093/hmg/ddn130
10.1016/j.pnpbp.2011.09.012
10.1016/j.biopsych.2005.04.047
10.1002/cne.10393
10.1016/S0920-9964(01)00188-8
10.4088/JCP.11m07422
10.1016/j.neuropharm.2011.01.022
10.1001/archpsyc.60.12.1187
10.1016/j.biopsych.2017.08.017
10.1002/ajmg.c.20013
10.1016/j.psychres.2019.06.010
10.1038/mp.2008.126
10.1038/s41588-019-0512-x
10.1038/s41588-019-0397-8
10.1038/s41582-020-0364-0
10.1038/nature13595
10.1101/2020.09.12.20192922
10.1038/s41588-018-0090-3
10.1016/j.bpsc.2015.09.002
10.1002/ajmg.b.32634
10.1038/s41380-018-0332-x
10.1101/2020.09.17.20187054
10.1038/nature24277
10.1038/nn.4399
10.1126/science.aat8464
10.1126/science.aad6469
10.3389/fnins.2017.00493
10.3389/fncel.2020.00020
10.1016/j.gene.2013.04.014
10.1016/j.psyneuen.2019.04.011
10.1176/appi.ajp.2019.19030256
10.1371/journal.pone.0179020
10.1111/jnc.14829
10.1111/jnc.14654
10.1016/j.mcn.2019.103417
10.1016/j.cell.2019.04.001
10.1073/pnas.91.22.10625
10.1016/j.neuint.2016.03.014
10.1038/jcbfm.2011.175
10.1002/jnr.24411
10.1111/j.1399-5618.2009.00717.x
10.1038/nrn3229
10.3727/096368911X600957
10.1016/j.abb.2012.10.009
10.1016/j.neubiorev.2014.11.005
10.1016/j.schres.2016.10.037
10.1111/pcn.12476
10.1001/archgenpsychiatry.2010.22
10.1006/geno.1995.1234
10.1016/S0893-133X(99)00016-0
10.1017/S1461145799001649
10.1038/s41380-019-0423-3
10.1002/ddr.21332
10.1016/j.celrep.2018.04.045
10.1016/j.mad.2020.111216
10.23861/EJBM201631752
10.4161/15548627.2014.984274
10.1016/j.mehy.2019.109443
10.1038/s41386-018-0293-4
10.15698/cst2018.11.161
10.1016/j.neulet.2017.08.005
10.1016/j.neuroscience.2009.03.011
10.1016/0006-3223(95)00657-5
10.1016/j.pnpbp.2006.08.008
10.1038/mp.2017.133
10.1016/S0165-0173(03)00203-0
10.1038/s41419-018-0676-9
10.1111/j.1365-2826.2011.02251.x
10.1152/ajpendo.90407.2008
10.1210/mend-2-4-332
10.1111/j.1471-4159.1992.tb10070.x
10.1128/MCB.18.1.442
10.1111/j.1365-2826.2008.01747.x
10.1210/me.2007-0029
10.1111/j.1471-4159.2009.06133.x
10.1677/JME-08-0085
10.1038/sj.bjp.0706265
10.1016/j.brainres.2017.02.004
10.1385/ENDO:21:1:27
10.1002/jnr.10146
10.1186/1471-2202-6-13
10.1016/j.freeradbiomed.2012.03.005
10.1016/j.bbabio.2018.03.006
10.1016/j.ejphar.2004.07.040
10.1016/j.biopsych.2008.11.029
10.1016/S2215-0366(14)00122-9
10.1016/S1474-4422(15)70016-5
10.1038/tp.2016.77
10.3390/ph11020056
10.1016/j.jsbmb.2015.09.039
10.1038/s41586-020-2277-x
10.3389/fpsyt.2020.00071
10.1038/ni.3123
10.1016/j.jaci.2009.12.980
10.1176/appi.ajp.2009.09030361
10.1016/j.biopsych.2011.04.013
10.1016/j.schres.2012.05.023
10.1017/S0033291712000736
10.1016/j.bbi.2017.06.005
10.1176/appi.ajp.2011.11030516
10.3389/fphar.2019.01612
10.1126/science.1194637
10.1146/annurev-physiol-022516-034406
10.1016/j.cell.2019.08.053
10.1016/j.immuni.2018.01.011
10.1126/science.aat7554
10.1016/j.biopsych.2008.04.025
10.2967/jnumed.109.066647
10.1016/j.imbio.2006.05.007
10.1038/nrneurol.2010.17
10.1016/j.bbi.2014.03.016
10.1016/j.bbi.2015.09.004
10.1038/sj.mp.4000811
10.1016/S0920-9964(03)00181-6
10.1016/j.nbd.2011.01.025
10.1007/s12031-018-1236-6
10.1016/j.bbi.2015.12.003
10.1016/j.bbi.2011.03.013
10.3390/brainsci7110144
10.1016/j.jad.2017.10.027
10.1002/glia.1107
10.1016/j.pnpbp.2017.10.002
10.1038/s41380-019-0401-9
10.3389/fnins.2014.00315
10.1038/s41583-018-0055-7
10.1038/s41577-019-0165-0
10.1016/j.psychres.2018.04.036
10.3389/fnins.2018.00296
10.1186/s12974-017-0920-8
10.1002/jnr.23962
10.1161/STROKEAHA.108.538686
10.1016/j.expneurol.2013.08.011
10.1093/trstmh/tru167
10.1186/s12974-015-0251-6
10.1046/j.0305-1846.2003.00515.x
10.1111/j.1365-2826.2011.02156.x
10.1523/ENEURO.0505-19.2020
10.1038/mi.2017.35
10.1038/s41598-019-44448-0
10.1016/j.neuroscience.2005.05.023
10.1016/j.ejphar.2013.04.024
10.1007/s10863-014-9583-7
10.1523/JNEUROSCI.1268-12.2013
10.1111/j.1471-4159.2011.07630.x
10.1177/1073858414536468
10.3389/fnmol.2018.00013
10.1002/ajmg.b.30769
10.1177/0269881114563634
10.1016/j.cacc.2009.07.008
10.1001/archneur.63.10.1372
10.1037/a0038550
10.1176/ajp.122.5.509
10.1111/j.1600-0447.1990.tb05279.x
10.1177/0269881106073126
10.1176/ajp.138.4.460
10.1038/mp.2017.16
10.1111/j.1600-0447.2007.01058.x
10.1111/j.1399-5618.2009.00760.x
10.1111/j.1476-5381.2011.01386.x
10.1016/0022-3956(74)90064-8
10.3389/fnins.2020.00632
10.1016/B978-0-12-398270-4.00039-2
10.1016/j.mehy.2013.03.013
10.1124/jpet.109.162123
10.1093/schbul/14.2.297
10.1186/1471-2164-7-70
10.1016/j.biopsych.2016.05.005
10.1111/j.1399-5618.2012.01033.x
10.3389/fpsyt.2013.00087
10.1176/ajp.156.10.1646
10.1176/ajp.148.10.1301
10.1093/schbul/sbs075
10.1016/j.neuint.2007.06.019
10.1523/JNEUROSCI.2213-07.2007
10.1001/archpsyc.1995.03950240016004
10.1016/S0022-3956(99)00029-1
10.1196/annals.1300.020
10.1007/978-3-642-25758-2_10
10.1016/j.neuropharm.2009.06.002
10.1016/j.brainresrev.2006.04.001
10.1038/nrn1648
10.1007/s11920-010-0124-8
10.1038/srep33095
10.1111/j.1460-9568.2007.05462.x
10.1177/026988119500900109
10.3389/fpsyt.2016.00061
10.1111/j.1399-5618.2009.00706.x
10.1007/s40263-013-0039-0
10.1038/newbio234124a0
10.1007/s00441-014-1806-z
10.3389/fpsyt.2018.00544
10.1093/brain/awn133
10.1007/s12035-016-9833-2
10.1016/j.redox.2017.09.002
10.1038/s41398-020-0682-4
10.3389/fnins.2015.00037
10.1007/BF02088099
10.3389/fnins.2020.00796
10.1210/er.20.3.279
10.1016/j.neuroscience.2008.10.016
10.1007/s00213-001-0959-0
10.1016/0006-8993(87)90634-2
10.1523/JNEUROSCI.17-05-01848.1997
10.1210/endo.131.2.1353442
10.1523/JNEUROSCI.12-08-03217.1992
10.1016/j.neuroscience.2006.03.075
10.1111/jne.12108
10.1038/npp.2016.83
10.1523/JNEUROSCI.18-07-02550.1998
10.1038/nn2057
10.1523/JNEUROSCI.3059-09.2009
10.1523/JNEUROSCI.3440-05.2006
10.1152/physrev.00026.2006
10.1016/S0165-3806(02)00364-4
10.1016/j.molonc.2007.04.001
10.1677/jme.0.0290175
10.1038/sj.onc.1205113
10.1210/en.2003-0567
10.1002/jnr.20076
10.1186/1742-2094-8-82
10.1038/nrn2038
10.1155/2015/615356
10.2147/ndt.s76700
10.1016/j.neurobiolaging.2007.09.004
10.1016/j.nlm.2008.09.017
10.1159/000153899
10.1523/JNEUROSCI.22-07-02650.2002
10.1159/000087002
10.1016/S0169-328X(02)00134-1
10.1016/0304-3940(96)12760-9
10.1097/00001756-199803090-00006
10.1124/mol.51.4.535
10.1016/S0893-133X(00)00085-3
10.1073/pnas.1705075114
10.1016/j.yhbeh.2015.06.014
10.1016/j.stemcr.2016.02.008
10.1016/j.cell.2007.11.019
10.1038/nature09805
10.3727/096368916X691312
10.1002/stem.2966
10.1038/s41591-018-0140-5
10.1016/j.ebiom.2019.11.026
10.1371/journal.pone.0214156
10.1186/s40035-019-0161-0
10.1038/s41380-019-0468-3
10.1038/nature09915
10.1523/ENEURO.0403-18.2019
10.1016/j.schres.2016.10.012
10.3389/fncel.2014.00012
10.1371/journal.pone.0178533
10.1016/j.vascn.2016.10.001
10.3389/fnins.2017.00440
10.3389/fnins.2018.00094
10.1017/S1740925X09990317
10.1073/pnas.0914257107
10.1016/j.neuron.2015.11.013
10.1016/S0306-9877(98)90000-7
10.1016/j.tins.2006.08.004
10.1523/JNEUROSCI.4707-08.2009
10.1016/j.stem.2017.06.012
10.1016/j.stemcr.2020.05.003
10.1038/nature12517
10.1016/j.cell.2016.04.032
10.15252/embj.201694700
10.1038/s41380-018-0343-7
10.1038/s41586-019-1289-x
10.1038/s41592-018-0255-0
10.1038/s41531-019-0078-4
10.1007/s12311-017-0905-2
10.3791/61143
10.1038/nmeth.3415
10.1016/j.neuron.2017.07.035
10.1038/nbt.4127
10.1038/s41467-018-06684-2
10.1016/j.stem.2019.08.002
10.1111/jne.12547
10.1038/s41537-017-0043-3
10.1016/j.schres.2018.01.017
10.1177/0269881118822167",<Element 'PubmedArticle' at 0x7f05deeb1720>
179,"33467657
30092099
30670325
32032668
28534818
27743978
30470952
26150767
32714510
32643194
29674185
29573342
24074470
23541912
30305694
22964791
25917989
30149267
30600520
30093539
30420706
32779186
25080181
32772475
30518826
28635158
30086533
26279463
27315483
31051155
31539886
24071008
30650536
27519153
28595087
25212412
22633920
28259676
24791714
23454542
20538025
30025860
24223863
30414884
30735761
30004004
28532855
26872592
29401579
30136369
32494038
30611800
27776561
29940426
18675469
30874581
26239616
20220017
32887946
23928377
27326907
20124437
18286589
30714555
29632361
24024117
27903745
31495690
30009766
32659044
33257673
32181523
27158906
27629368
29903615
30522820
31903710
31735910
28323039
18635655
31665252
26785315
29279863
27307234
29977198
32269316
31682820
32510473
31754139
33232913
28785241
30425618
30837902
19606226
24266392
18982008
32163401
29324300
31417349
30776574
31130833
29870819
31661820
30732639
17005423
29970928
29490194
30816216
22217452
28700632
18848473
31186075
28599146
30826632
28960210
28442403
29991705
21980407
22162969
29031410
27090305
31493988
31574280
30173873
30367045
30429801
30559716
32393856
32117107
27503374
28724659
22836031
30763539",Mechanisms Underlying the Cognitive and Behavioural Effects of Maternal Obesity.,"The widespread consumption of 'western'-style diets along with sedentary lifestyles has led to a global epidemic of obesity. Epidemiological, clinical and preclinical evidence suggests that maternal obesity, overnutrition and unhealthy dietary patterns programs have lasting adverse effects on the physical and mental health of offspring. We review currently available preclinical and clinical evidence and summarise possible underlying neurobiological mechanisms by which maternal overnutrition may perturb offspring cognitive function, affective state and psychosocial behaviour, with a focus on (1) neuroinflammation; (2) disrupted neuronal circuities and connectivity; and (3) dysregulated brain hormones. We briefly summarise research implicating the gut microbiota in maternal obesity-induced changes to offspring behaviour. In animal models, maternal obesogenic diet consumption disrupts CNS homeostasis in offspring, which is critical for healthy neurodevelopment, by altering hypothalamic and hippocampal development and recruitment of glial cells, which subsequently dysregulates dopaminergic and serotonergic systems. The adverse effects of maternal obesogenic diets are also conferred through changes to hormones including leptin, insulin and oxytocin which interact with these brain regions and neuronal circuits. Furthermore, accumulating evidence suggests that the gut microbiome may directly and indirectly contribute to these maternal diet effects in both human and animal studies. As the specific pathways shaping abnormal behaviour in offspring in the context of maternal obesogenic diet exposure remain unknown, further investigations are needed to address this knowledge gap. Use of animal models permits investigation of changes in neuroinflammation, neurotransmitter activity and hormones across global brain network and sex differences, which could be directly and indirectly modulated by the gut microbiome.","['behaviour', 'cognition', 'gut microbiome', 'maternal obesity', 'metabolism', 'neuroinflammation']",Nutrients,2021-01-21,"[{'lastname': 'Hasebe', 'firstname': 'Kyoko', 'initials': 'K', 'affiliation': 'Department of Pharmacology, School of Medical Sciences, UNSW, Sydney, NSW 2052, Australia.'}, {'lastname': 'Kendig', 'firstname': 'Michael D', 'initials': 'MD', 'affiliation': 'Department of Pharmacology, School of Medical Sciences, UNSW, Sydney, NSW 2052, Australia.'}, {'lastname': 'Morris', 'firstname': 'Margaret J', 'initials': 'MJ', 'affiliation': 'Department of Pharmacology, School of Medical Sciences, UNSW, Sydney, NSW 2052, Australia.'}]",,,,,"10.3390/nu13010240
10.1371/journal.pone.0202183
10.1016/j.tics.2019.01.003
10.1016/j.neuroscience.2020.01.023
10.3390/ijms18051093
10.1016/S2213-8587(16)30107-3
10.1007/s00787-018-1259-0
10.3389/fnins.2015.00194
10.1038/s41367-020-0016-2
10.1002/pd.5784
10.1016/j.amepre.2018.02.020
10.1111/jcpp.12898
10.1016/j.jaac.2013.07.002
10.1016/j.clnu.2013.03.002
10.1038/s41390-018-0199-1
10.1038/ijo.2012.143
10.1542/peds.2014-3058
10.1016/j.earlhumdev.2018.08.005
10.1007/s10995-018-2691-y
10.1542/peds.2018-0776
10.1038/s41390-018-0229-z
10.1111/jcpp.13301
10.1017/S2040174412000578
10.1002/oby.22908
10.1038/s41366-018-0268-x
10.1111/mcn.12481
10.1016/j.psyneuen.2018.08.003
10.1159/000439087
10.1016/j.cell.2016.06.001
10.1016/j.expneurol.2019.04.018
10.26402/jpp.2019.3.07
10.1016/j.ijdevneu.2013.09.001
10.3390/ijms20020329
10.1016/j.bbi.2016.08.005
10.1016/j.psyneuen.2017.05.003
10.1186/s12974-014-0156-9
10.1016/j.bbr.2012.05.027
10.1016/j.bbr.2017.02.049
10.1016/j.neuroscience.2014.04.012
10.1016/j.neuroscience.2013.02.044
10.1016/j.neuint.2010.05.015
10.1016/j.neuroscience.2018.07.014
10.1371/journal.pone.0078876
10.1016/j.physbeh.2018.11.004
10.1016/j.bbr.2019.02.003
10.1016/j.ijdevneu.2018.07.001
10.1016/j.brainres.2017.05.022
10.1016/j.nlm.2016.02.004
10.1096/fj.201700783RR
10.1002/dneu.22635
10.1038/s41366-020-0609-4
10.1016/j.neubiorev.2018.12.023
10.1017/S0033291716002452
10.1016/j.psyneuen.2018.06.015
10.1016/j.tins.2008.06.006
10.1038/s41598-019-40844-8
10.3892/mmr.2015.4104
10.1523/JNEUROSCI.5560-09.2010
10.1038/s41579-020-0433-9
10.1210/en.2013-1059
10.1016/j.ijdevneu.2016.06.005
10.1096/fj.09-144014
10.1002/ajmg.b.30712
10.1017/S1092852918001499
10.1038/s41593-018-0128-y
10.1016/j.molmet.2012.07.001
10.2337/db16-0586
10.1016/j.cmet.2019.08.010
10.1016/j.brainres.2018.07.017
10.1002/glia.23882
10.1038/s41467-020-19861-z
10.1002/glia.23822
10.1038/nm.4106
10.1038/npp.2016.199
10.1016/j.brainres.2018.03.015
10.1016/j.neuron.2018.11.018
10.1002/brb3.1522
10.1038/s41380-019-0580-4
10.1016/j.ijdevneu.2017.03.004
10.1210/en.2008-0582
10.1093/cercor/bhz188
10.1016/j.appet.2016.01.023
10.1523/ENEURO.0392-17.2017
10.1523/JNEUROSCI.0840-16.2016
10.3389/fnhum.2018.00250
10.1038/s41583-020-0292-4
10.1016/j.neuroscience.2019.09.016
10.1172/JCI134412
10.1038/s41598-019-53652-x
10.1016/j.dcn.2020.100879
10.3389/fendo.2017.00164
10.3389/fnmol.2018.00389
10.3389/fpsyt.2019.00057
10.1371/journal.pone.0006259
10.1111/jnc.12623
10.1038/ijo.2008.213
10.1371/journal.pbio.3000296
10.1016/j.psyneuen.2017.12.023
10.3389/fnins.2019.00788
10.1016/j.psyneuen.2019.02.004
10.3389/fnins.2019.00378
10.1016/j.jad.2018.05.008
10.3390/nu11112589
10.1186/s13148-019-0612-6
10.1016/j.nlm.2006.08.007
10.1038/s41431-018-0201-8
10.1146/annurev-neuro-080317-061747
10.1038/s41598-019-39434-5
10.1016/j.tins.2011.11.004
10.1371/journal.pone.0180853
10.1016/j.immuni.2008.08.012
10.1017/neu.2019.17
10.1016/j.psyneuen.2017.04.018
10.1016/j.psyneuen.2019.02.013
10.1038/nrendo.2017.115
10.1016/j.neubiorev.2017.04.017
10.1038/s41598-018-28816-w
10.1371/journal.pone.0025261
10.3389/fphys.2011.00094
10.1016/j.biopsych.2017.08.014
10.1038/mp.2016.50
10.1016/j.tem.2019.07.021
10.1016/j.yfrne.2019.100797
10.1016/j.jpeds.2018.07.066
10.1038/s41467-018-06929-0
10.3389/fphys.2018.01534
10.3389/fendo.2018.00716
10.1038/s41564-020-0721-1
10.3389/fmicb.2020.00060
10.1186/s13073-016-0330-z
10.3945/ajcn.112.037382
10.1016/j.chom.2019.01.011",<Element 'PubmedArticle' at 0x7f05dedf1c20>
180,"33436875
25356029
26501334
25468277
9823766
17254389
1772595
23625200
28738878
18348728
30312858
20066090
25171873
19538289
19575462
25377781
27958326
27151512
28372972
15535449
19387917
15740474
16719565
16399915
25689247
30220589
31403699
31102830
28431971
23584113
16434116
31995340
31879281
21396387
11964313
28714001
20220055
21615563
24534266
22776046
31165005
28778220
24827618
30658727
28057718
19556362
18308862
12235072
17978317
15571755
25227506
24890666
30211234
30590091
28757259
10869505
2998738
3702410
17615391
27145013
7708216
12367511
20030625
17726474
22232675
30454835
26173414
30502657
29912589
32770049
28025202
20383131
11571135
29912385
23828941
20827291
21702898",Chronic stress and corticosterone exacerbate alcohol-induced tissue injury in the gut-liver-brain axis.,"Alcohol use disorders are associated with altered stress responses, but the impact of stress or stress hormones on alcohol-associated tissue injury remain unknown. We evaluated the effects of chronic restraint stress on alcohol-induced gut barrier dysfunction and liver damage in mice. To determine whether corticosterone is the stress hormone associated with the stress-induced effects, we evaluated the effect of chronic corticosterone treatment on alcoholic tissue injury at the Gut-Liver-Brain (GLB) axis. Chronic restraint stress synergized alcohol-induced epithelial tight junction disruption and mucosal barrier dysfunction in the mouse intestine. These effects of stress on the gut were reproduced by corticosterone treatment. Corticosterone synergized alcohol-induced expression of inflammatory cytokines and chemokines in the colonic mucosa, and it potentiated the alcohol-induced endotoxemia and systemic inflammation. Corticosterone also potentiated alcohol-induced liver damage and neuroinflammation. Metagenomic analyses of 16S RNA from fecal samples indicated that corticosterone modulates alcohol-induced changes in the diversity and abundance of gut microbiota. In Caco-2 cell monolayers, corticosterone dose-dependently potentiated ethanol and acetaldehyde-induced tight junction disruption and barrier dysfunction. These data indicate that chronic stress and corticosterone exacerbate alcohol-induced mucosal barrier dysfunction, endotoxemia, and systemic alcohol responses. Corticosterone-mediated promotion of alcohol-induced intestinal epithelial barrier dysfunction and modulation of gut microbiota may play a crucial role in the mechanism of stress-induced promotion of alcohol-associated tissue injury at the GLB axis.",[],Scientific reports,2021-01-14,"[{'lastname': 'Shukla', 'firstname': 'Pradeep K', 'initials': 'PK', 'affiliation': 'Department of Physiology, College of Medicine, University of Tennessee Health Science Center, 3 N Dunlap, Suite S303, Memphis, TN, 38163, USA.'}, {'lastname': 'Meena', 'firstname': 'Avtar S', 'initials': 'AS', 'affiliation': 'Department of Physiology, College of Medicine, University of Tennessee Health Science Center, 3 N Dunlap, Suite S303, Memphis, TN, 38163, USA.'}, {'lastname': 'Dalal', 'firstname': 'Kesha', 'initials': 'K', 'affiliation': 'Department of Physiology, College of Medicine, University of Tennessee Health Science Center, 3 N Dunlap, Suite S303, Memphis, TN, 38163, USA.'}, {'lastname': 'Canelas', 'firstname': 'Cherie', 'initials': 'C', 'affiliation': 'Department of Physiology, College of Medicine, University of Tennessee Health Science Center, 3 N Dunlap, Suite S303, Memphis, TN, 38163, USA.'}, {'lastname': 'Samak', 'firstname': 'Geetha', 'initials': 'G', 'affiliation': 'Department of Physiology, College of Medicine, University of Tennessee Health Science Center, 3 N Dunlap, Suite S303, Memphis, TN, 38163, USA.'}, {'lastname': 'Pierre', 'firstname': 'Joseph F', 'initials': 'JF', 'affiliation': 'Department of Pediatrics, College of Medicine, University of Tennessee Health Science Center, Memphis, TN, 38163, USA.'}, {'lastname': 'Rao', 'firstname': 'RadhaKrishna', 'initials': 'R', 'affiliation': 'Department of Physiology, College of Medicine, University of Tennessee Health Science Center, 3 N Dunlap, Suite S303, Memphis, TN, 38163, USA. rrao2@uthsc.edu.'}]",,,,,"10.1038/s41598-020-80637-y
10.3748/wjg.v20.i40.14660
10.3390/biom5042573
10.1016/j.alcohol.2014.07.018
10.1002/jlb.64.5.615
10.1177/09680519060120060501
10.1515/bchm3.1991.372.2.829
10.1189/jlb.1212659
10.1186/s12974-017-0918-2
10.1186/1742-2094-5-10
10.1016/j.alcohol.2018.04.004
10.1101/cshperspect.a002584
10.1016/j.semcdb.2014.08.011
10.1111/j.1749-6632.2009.04054.x
10.1002/hep.23009
10.1042/BJ20140450
10.1038/srep38899
10.1007/s00018-016-2260-8
10.1016/j.yexcr.2017.03.061
10.1055/s-0029-1214373
10.1111/j.1440-1746.2004.03508.x
10.1037/0033-2909.132.3.327
10.1196/annals.1322.038
10.1172/JCI76304
10.1016/j.alcohol.2018.03.009
10.1111/acer.14178
10.1016/j.copsyc.2019.04.003
10.1016/j.neuropharm.2017.04.028
10.1016/j.ijpsycho.2005.10.007
10.1530/EJE-19-0811
10.1136/gutjnl-2019-319720
10.1016/j.physbeh.2011.03.001
10.1182/blood.V99.9.3427
10.3892/mmr.2017.6983
10.1167/iovs.09-4492
10.1111/j.1365-2826.2011.02161.x
10.1016/j.jneuroim.2014.01.013
10.1111/j.1471-4159.2012.07864.x
10.14336/AD.2018.0707
10.1186/s12974-017-0930-6
10.5009/gnl.2014.8.3.237
10.1016/j.jhep.2018.10.019
10.1042/BCJ20160679
10.1152/ajpgi.00023.2009
10.1152/ajpgi.00014.2008
10.1136/gut.51.4.507
10.1192/bjp.bp.106.024877
10.1016/j.yfrne.2004.07.001
10.1159/000362724
10.1111/acer.12428
10.1155/2018/9671919
10.1016/j.pbb.2018.12.007
10.1016/j.expneurol.2017.07.016
10.1016/S0006-8993(00)02405-7
10.1210/endo-117-6-2505
10.1016/0022-4731(86)90063-4
10.1152/physrev.00041.2006
10.1210/en.2016-1123
10.1016/0306-4522(94)00386-J
10.1016/S0896-6273(02)00942-X
10.2174/1874467211003010012
10.1038/nn1971
10.1073/pnas.1114122109
10.1016/j.cld.2018.09.005
10.1111/acer.12777
10.1016/j.jnutbio.2018.10.016
10.1038/s41598-020-70461-9
10.1038/nmeth.f.303
10.1128/AEM.67.10.4399-4406.2001
10.1093/bioinformatics/bty482
10.1126/science.1237439
10.1038/ismej.2010.133
10.1186/gb-2011-12-6-r60",<Element 'PubmedArticle' at 0x7f05dedc4720>
181,"33251159
25416141
18615177
10882622
24148086
26824948
23085269
25744564
29095719
27899748
26362566
30500552
27534533
23865742
8193937
28484229
25896094
7882902
20417414
16343349
7724569
31139184
24819918
25058046
26463937
29746358
25867462
24722525
18562209
29754263
16601488
17148956
17371820
12379902
29151103
10658595
31532239
30799631
23386810
12744466
28788104
8454848
8958228
11522576
12788989
26376816
24491581
26119836
11110643
23248040
27105658
27597805
12717622
3508700
30971685
21734248
30131074
31351490
31061158
19884325
11801337
10197818
27445150
10469884
25015040
30959794
19476641
32471272
19890068
18236016
22024597
28045021
16864706
20468046
18584858
28992427
16720574
32117037
30967852
19525393
27402121
27062097
19386456
12857775
20526697
10366638
11109000
29939190
22020035",Adjuvant Cannabinoid Receptor Type 2 Agonist Modulates the Polarization of Microglia Towards a Non-Inflammatory Phenotype in Experimental Pneumococcal Meningitis.,"Microglia initiates and sustains the inflammatory reaction that drives the pathogenesis of pneumococcal meningitis. The expression of the G-protein cannabinoid receptor type 2 (CB2) in the brain is low, but is upregulated in glial cells during infection. Its activation down-regulates pro-inflammatory processes, driving microglia towards an anti-inflammatory phenotype. CB2 agonists are therefore therapeutic candidates in inflammatory conditions like pneumococcal meningitis. We evaluated the effects of JWH-133, a specific CB2 agonist on microglial cells, inflammation, and damage driven by 
Primary mixed glial cultures were stimulated with live or heat-inactivated 
JWH-133 attenuates microglial activation and downregulates the concentrations of pro-inflammatory mediators in pneumococcal infection ","['bacterial meningitis', 'brain damage', 'endocannabinoid system', 'microglia', 'neuro-inflammation']",Frontiers in cellular and infection microbiology,2020-12-01,"[{'lastname': 'Pan', 'firstname': 'Steven D', 'initials': 'SD', 'affiliation': 'Neuroinfection Laboratory, Institute for Infectious Diseases, University of Bern, Bern, Switzerland.'}, {'lastname': 'Grandgirard', 'firstname': 'Denis', 'initials': 'D', 'affiliation': 'Neuroinfection Laboratory, Institute for Infectious Diseases, University of Bern, Bern, Switzerland.'}, {'lastname': 'Leib', 'firstname': 'Stephen L', 'initials': 'SL', 'affiliation': 'Neuroinfection Laboratory, Institute for Infectious Diseases, University of Bern, Bern, Switzerland.'}]",,,,"Copyright © 2020 Pan, Grandgirard and Leib.","10.3389/fcimb.2020.588195
10.1186/s12974-014-0191-6
10.2174/157015907780866884
10.1086/315658
10.1111/bph.12478
10.1128/AAC.02429-15
10.1016/j.ejphar.2012.09.053
10.1007/s12035-015-9107-4
10.1097/QCO.0000000000000416
10.1161/STROKEAHA.116.014793
10.1002/14651858.CD004405.pub5
10.1016/j.lfs.2018.11.058
10.1038/emm.2015.100
10.1186/1471-2334-13-326
10.1016/0361-9230(94)90189-9
10.1038/s41598-017-01747-8
10.1016/j.jinf.2015.04.006
10.3109/01902149409031733
10.1016/S1473-3099(10)70048-7
10.1186/1742-2094-2-29
10.1073/pnas.92.8.3376
10.3389/fimmu.2019.01027
10.1016/j.jns.2014.04.034
10.1016/j.expneurol.2014.07.005
10.1007/978-3-319-18497-5_24
10.1097/CCM.0000000000003220
10.1016/j.jneuroim.2015.02.008
10.1177/1073858414530512
10.1016/j.mcn.2008.05.001
10.1007/s00011-018-1158-3
10.1097/01.mop.0000193292.09894.b7
10.1159/000096218
10.1128/AAC.01014-06
10.1002/glia.10161
10.1159/000481824
10.1016/S0968-0896(99)00219-9
10.1089/dna.2019.5024
10.1096/fj.201802524R
10.3389/fncel.2013.00003
10.1111/j.1750-3639.2003.tb00012.x
10.3390/ijms18081669
10.1172/JCI119084
10.1093/brain/124.9.1734
10.1203/01.PDR.0000079185.67878.72
10.1007/s12975-015-0425-7
10.1128/IAI.00073-14
10.2217/fmb.15.43
10.1086/317921
10.1007/s00134-012-2792-9
10.1016/j.jinf.2016.04.009
10.1155/2016/5831315
10.1086/374644
10.1016/0887-8994(86)90019-6
10.1038/s41467-019-09040-0
10.1128/CMR.00008-11
10.1186/s12974-018-1272-8
10.1186/s12974-019-1549-6
10.1128/AAC.00220-19
10.1096/fj.09-141275
10.1016/S0166-2236(00)02024-5
10.1097/00005072-199903000-00006
10.1523/JNEUROSCI.0554-16.2016
10.1007/s11481-014-9554-0
10.3390/molecules24071350
10.1186/1744-8069-5-25
10.3390/ijms21113809
10.1212/WNL.0b013e3181c55d2e
10.1007/s10787-007-0013-x
10.1016/j.brainresbull.2011.10.004
10.1038/ncomms13958
10.1203/01.pdr.0000227553.47378.9f
10.1002/glia.20983
10.1016/j.pbb.2008.05.010
10.1080/21505594.2017.1389369
10.1074/jbc.M600504200
10.3389/fneur.2020.00087
10.3389/fmicb.2019.00576
10.4049/jimmunol.0900203
10.1007/s00018-016-2300-4
10.1016/j.cmi.2016.01.007
10.1016/j.medmal.2009.02.033
10.1128/CMR.16.3.415-429.2003
10.1007/s12028-010-9387-5
10.1523/JNEUROSCI.19-12-05054.1999
10.1016/s0304-3940(00)01645-1
10.3791/57648
10.1161/STROKEAHA.111.631044",<Element 'PubmedArticle' at 0x7f05ded7b540>
182,"33210212
17919779
26864581
20932114
23507144
5473492
27702819
19615407
19043612
9607781
31519175
29895749
3077065
23468969
31884472
18384649
27818230
29885849
15664689
19124421
21371012
27302364
20696148
26806339
24635117
27802237
16873964
8089669
26642438
15254070
25237037
32198386
31578267
20624891
21685825
24679540
30086290
32772463
17956739
17392020
22606335
19009042
28581332
28581362
31336903
17167170
20054784
30140974
29687345
31073415
29160120
25784542
30927048
23056034
30820047
29565812
30562729
30373124
22150037
25592770
19596280
7981125
16581799
31404249
20176685
10866668
32143325
17451173
29503034
19389799
16098614
30705969
18036566
12056592
32422896
23364132
28603493
22117646
22135673
27025652
19874267
21617181
31341184
7402431
29036828
14676330
24874493
31939088
18725982
31410002
26836193
27525190
27881385
21382489
28975471
32375405
32192216
27283430
21970791
32170673
26108185
29690611
27996177
21449912
19633434
20705927","Recent Insights on the Role of PPAR-β/δ in Neuroinflammation and Neurodegeneration, and Its Potential Target for Therapy.","Peroxisome proliferator-activated receptor (PPAR) β/δ belongs to the family of hormone and lipid-activated nuclear receptors, which are involved in metabolism of long-chain fatty acids, cholesterol, and sphingolipids. Similar to PPAR-α and PPAR-γ, PPAR-β/δ also acts as a transcription factor activated by dietary lipids and endogenous ligands, such as long-chain saturated and polyunsaturated fatty acids, and selected lipid metabolic products, such as eicosanoids, leukotrienes, lipoxins, and hydroxyeicosatetraenoic acids. Together with other PPARs, PPAR-β/δ displays transcriptional activity through interaction with retinoid X receptor (RXR). In general, PPARs have been shown to regulate cell differentiation, proliferation, and development and significantly modulate glucose, lipid metabolism, mitochondrial function, and biogenesis. PPAR-β/δ appears to play a special role in inflammatory processes and due to its proangiogenic and anti-/pro-carcinogenic properties, this receptor has been considered as a therapeutic target for treating metabolic syndrome, dyslipidemia, carcinogenesis, and diabetes. Until now, most studies were carried out in the peripheral organs, and despite of its presence in brain cells and in different brain regions, its role in neurodegeneration and neuroinflammation remains poorly understood. This review is intended to describe recent insights on the impact of PPAR-β/δ and its novel agonists on neuroinflammation and neurodegenerative disorders, including Alzheimer's and Parkinson's, Huntington's diseases, multiple sclerosis, stroke, and traumatic injury. An important goal is to obtain new insights to better understand the dietary and pharmacological regulations of PPAR-β/δ and to find promising therapeutic strategies that could mitigate these neurological disorders.","['Agonists', ""Alzheimer's disease"", 'Hypoxia/ischemia', 'Lipid metabolism', 'Neurodegenerative disorders', 'Neuroprotection', 'PPAR delta']",Neuromolecular medicine,2020-11-20,"[{'lastname': 'Strosznajder', 'firstname': 'Anna K', 'initials': 'AK', 'affiliation': 'Faculty of Medicine, Medical University of Bialystok, 1 Kilinskiego st., 15-089, Białystok, Poland.'}, {'lastname': 'Wójtowicz', 'firstname': 'Sylwia', 'initials': 'S', 'affiliation': 'Department of Cellular Signaling, Mossakowski Medical Research Centre Polish Academy of Sciences, 5 Pawińskiego st., 02-106, Warsaw, Poland.'}, {'lastname': 'Jeżyna', 'firstname': 'Mieszko J', 'initials': 'MJ', 'affiliation': 'Faculty of Medicine, Medical University of Bialystok, 1 Kilinskiego st., 15-089, Białystok, Poland.'}, {'lastname': 'Sun', 'firstname': 'Grace Y', 'initials': 'GY', 'affiliation': 'Biochemistry Department, University of Missouri, Columbia, MO, 65211, USA.'}, {'lastname': 'Strosznajder', 'firstname': 'Joanna B', 'initials': 'JB', 'affiliation': 'Department of Cellular Signaling, Mossakowski Medical Research Centre Polish Academy of Sciences, 5 Pawińskiego st., 02-106, Warsaw, Poland. jstrosznajder@imdik.pan.pl.'}]",,,,,"10.1007/s12017-020-08629-9
10.1016/j.neuint.2007.08.012
10.1007/s11011-016-9800-7
10.2217/fca.10.86
10.1016/j.bbadis.2013.03.006
10.1016/0005-2760(70)90086-X
10.1158/1078-0432.CCR-16-0775
10.1016/j.pharmthera.2009.06.011
10.1155/2008/904251
10.1210/endo.139.6.6049
10.1186/s12974-019-1564-7
10.3390/ijms19061738
10.1007/BF02935632
10.1371/journal.pone.0057313
10.3233/JAD-190864
10.1111/j.1471-4159.2008.05388.x
10.1016/j.trsl.2016.10.004
10.1016/j.bbr.2018.06.005
10.1016/j.neuroscience.2004.09.043
10.1177/1753944708090924
10.1111/j.1476-5381.2011.01302.x
10.1016/S1474-4422(16)00127-7
10.1016/j.brainres.2010.07.096
10.1016/j.neuint.2016.01.005
10.2174/1567202611666140318114037
10.3233/JAD-160656
10.3233/JAD-2006-9209
10.1136/jnnp.57.9.1064
10.1038/nm.4003
10.1194/jlr.R400004-JLR200
10.1016/j.nbd.2014.09.001
10.1038/s41598-020-60996-2
10.4049/jimmunol.1801200
10.1084/jem.20091663
10.1097/BRS.0b013e3182276d88
10.1016/j.cell.2014.03.012
10.1016/j.neuropharm.2018.08.003
10.1002/jnr.24709
10.1016/j.cell.2007.09.012
10.1016/j.bbalip.2007.02.006
10.1371/journal.pone.0037097
10.1155/2008/780452
10.2217/fca-2016-0059
10.2217/fca-2017-0019
10.3390/molecules24142545
10.1124/jpet.106.115758
10.1007/s12035-018-1286-3
10.1007/s12035-018-1040-x
10.1155/2019/7809216
10.1177/0271678X17743876
10.2337/db15-0115
10.1007/s00011-019-01231-1
10.1155/2012/209794
10.1038/s41588-019-0358-2
10.3390/ijms19040949
10.1159/000495969
10.3390/ijms19113339
10.1056/NEJMoa1100648
10.1186/s12974-014-0229-9
10.1016/j.brainres.2009.06.087
10.1016/0960-0760(94)90089-2
10.1128/MCB.26.8.3266-3281.2006
10.3389/fnins.2019.00770
10.1124/jpet.110.165605
10.1128/mcb.20.14.5119-5128.2000
10.3390/ijms21051747
10.1002/nbm.1157
10.1016/j.neurobiolaging.2018.01.018
10.1189/jlb.0508284
10.1016/j.jneuroim.2005.07.006
10.13188/2376-922X.1000025
10.1016/j.febslet.2007.11.040
10.1007/s11745-002-0923-1
10.3390/cells9051215
10.1159/000346069
10.3389/fnagi.2017.00148
10.1089/ars.2011.4400
10.1155/2011/373560
10.15252/emmm.201606210
10.2174/156720509789207949
10.2337/db10-0704
10.1038/s41598-019-47057-z
10.1007/BF00964780
10.3233/JAD-170585
10.1073/pnas.0306981100
10.1016/0736-5748(85)90019-X
10.1007/s11064-020-02956-w
10.1155/2008/204514
10.2147/IJN.S200490
10.3233/JAD-151013
10.4172/2161-0460.1000238
10.1152/ajpheart.00155.2016
10.1016/j.bbadis.2011.02.014
10.1007/s10571-017-0554-5
10.3390/cells9051133
10.3390/ijms21062061
10.1038/srep27618
10.1186/1742-2094-8-127
10.1007/s11064-020-02993-5
10.1007/s12035-015-9294-z
10.3390/ijms19041260
10.1002/mc.22607
10.1111/j.1476-5381.2011.01383.x
10.4161/cbt.8.13.8691
10.1161/STROKEAHA.110.586081",<Element 'PubmedArticle' at 0x7f05ded338b0>
183,"33182586
30135715
24339095
31637009
28413986
26149638
30704681
29044639
28410659
28190529
27154981
31318452
24493463
25523424
28927263
12130773
26509334
29113750
23930978
26374885
20236740
31823879
31215291
23891616
31370154
21088297
26001206
22037458
27871880
29421190
30634016
25534025
29721854
17000034
21109419
27795733
31356828
31410002
26403946
28676747
19038405
28821953
22896675
32751955
32413299
26758846
32317025
27352979
24628287
29718324
29079362
31383635
30806304
25449403
31741224
20014009",Phytohormone Abscisic Acid Improves Memory Impairment and Reduces Neuroinflammation in 5xFAD Mice by Upregulation of LanC-Like Protein 2.,"Alzheimer's disease (AD), a type of dementia, is the most common neurodegenerative disease in the elderly. Neuroinflammation caused by deposition of amyloid β (Aβ) is one of the most important pathological causes in AD. The isoprenoid phytohormone abscisic acid (ABA) has recently been found in mammals and was shown to be an endogenous hormone, acting in stress conditions. Although ABA has been associated with anti-inflammatory effects and reduced cognitive impairment in several studies, the mechanisms of ABA in AD has not been ascertained clearly. To investigate the clearance of Aβ and anti-inflammatory effects of ABA, we used quantitative real-time polymerase chain reaction and immunoassay. ABA treatment inhibited Aβ deposition and neuroinflammation, thus resulting in improvement of memory impairment in 5xFAD mice. Interestingly, these effects were not associated with activation of peroxisome proliferator-activated receptor gamma, well known as a molecular target of ABA, but related with modulation of the LanC-like protein 2 (LANCL2), known as a receptor of ABA. Taken together, our results indicate that ABA reduced Aβ deposition, neuroinflammation, and memory impairment, which is the most characteristic pathology of AD, via the upregulation of LANCL2. These data suggest that ABA might be a candidate for therapeutics for AD treatment.","['Alzheimer’s disease', 'LanC-like protein 2', 'abscisic acid', 'amyloid beta', 'neuroinflammation']",International journal of molecular sciences,2020-11-14,"[{'lastname': 'Jeon', 'firstname': 'Seung Ho', 'initials': 'SH', 'affiliation': 'Department of Fundamental Pharmaceutical Science, Graduate School, Kyung Hee University, 26, Kyungheedae-ro, Dongdaemun-gu, Seoul 02447, Korea.'}, {'lastname': 'Kim', 'firstname': 'Namkwon', 'initials': 'N', 'affiliation': 'Department of Life and Nanopharmaceutical Sciences, Graduate School, Kyung Hee University, 26, Kyungheedae-ro, Dongdaemun-gu, Seoul 02447, Korea.'}, {'lastname': 'Ju', 'firstname': 'Yeon-Joo', 'initials': 'YJ', 'affiliation': 'Department of Fundamental Pharmaceutical Science, Graduate School, Kyung Hee University, 26, Kyungheedae-ro, Dongdaemun-gu, Seoul 02447, Korea.'}, {'lastname': 'Gee', 'firstname': 'Min Sung', 'initials': 'MS', 'affiliation': 'Department of Fundamental Pharmaceutical Science, Graduate School, Kyung Hee University, 26, Kyungheedae-ro, Dongdaemun-gu, Seoul 02447, Korea.'}, {'lastname': 'Lee', 'firstname': 'Danbi', 'initials': 'D', 'affiliation': 'Department of Life and Nanopharmaceutical Sciences, Graduate School, Kyung Hee University, 26, Kyungheedae-ro, Dongdaemun-gu, Seoul 02447, Korea.'}, {'lastname': 'Lee', 'firstname': 'Jong Kil', 'initials': 'JK', 'affiliation': 'Department of Fundamental Pharmaceutical Science, Graduate School, Kyung Hee University, 26, Kyungheedae-ro, Dongdaemun-gu, Seoul 02447, Korea.\nDepartment of Pharmacy, College of Pharmacy, Kyung Hee University, 26, Kyungheedae-ro, Dongdaemun-gu, Seoul 02447, Korea.'}]",,,,,"10.3390/ijms21228425
10.12688/f1000research.14506.1
10.1177/1471301213494511
10.1038/s41392-019-0063-8
10.2174/1567205014666170417111859
10.1016/j.npep.2015.06.008
10.1016/j.mcna.2018.10.009
10.1111/nan.12445
10.1016/j.ncl.2017.01.005
10.1016/j.tins.2017.01.002
10.1016/j.freeradbiomed.2016.04.200
10.1111/jnc.14829
10.1001/jamaneurol.2013.5847
10.2174/1567205012666141218140953
10.1126/science.1072994
10.1111/jnc.13411
10.1016/j.bbadis.2017.11.004
10.3109/00207454.2013.833510
10.1016/j.clnu.2010.02.009
10.4103/1673-5374.270307
10.1080/00207454.2019.1634067
10.1016/j.neuropharm.2013.06.032
10.3390/nu11081757
10.1074/jbc.M110.160077
10.3109/00207454.2015.1015722
10.1016/j.bbrc.2011.10.079
10.1016/j.bbalip.2016.11.005
10.1016/j.biocel.2018.02.003
10.1016/j.brainresbull.2019.01.004
10.1007/s00401-014-1375-y
10.1007/s12035-018-1091-z
10.1016/j.clnu.2006.07.008
10.1016/j.jnutbio.2010.06.011
10.1186/s12986-016-0137-3
10.1016/j.bbr.2019.112106
10.2147/IJN.S200490
10.1021/acs.biochem.5b00986
10.3389/fnhum.2017.00316
10.1016/j.jpsychires.2008.10.006
10.1007/s00415-017-8593-x
10.1126/scitranslmed.3003748
10.3390/brainsci10080503
10.1016/j.cell.2020.03.037
10.1523/JNEUROSCI.2117-15.2016
10.1186/s13195-020-00617-2
10.1016/j.freeradbiomed.2016.06.023
10.2174/1389450115666140313123714
10.1093/ibd/izy167
10.1016/j.tox.2017.10.013
10.1242/dmm.039347
10.2174/1381612825666190220161254
10.1016/j.physbeh.2014.11.053
10.1007/s13311-019-00792-7
10.1002/stem.277",<Element 'PubmedArticle' at 0x7f05ded00e50>
184,"33153085
28512250
26269668
28164854
28243438
31196177
30154767
19601958
32665271
31058161
21205640
29902436
24390308
29768180
30413188
31182571
30646475
28778332
23259758
30897366
21876150
30582442
30823925
27866330
32424166
29689727
25642988
32751379
28928632
30065211
29444202
22034141
19426951
31488882
12506200
11274343
29936690
32045774
30406177
15489351
22738186
30443602
27199545
31637009
31884474
30441866
28317487
8892349
15051507
26283900
23563705
30579367
29095058
27435372
11076898
30385457
29163522
29467611
26578870
16965193
12444809
29870432
29266221
30958695
29051531
31063846
29758946
31064831
28676754
30746447
32596386
28035935
32117315
28176819
28546539
30816709
29559675
31383855
26935478
17537972
30065258
32238175
32622920
14730714
29163474
31680937
28674485
28662669
30344525
31543810
22737039
20205644
26834588
15285801
27807399
30337243
31264132
23454862
29036812
29176977
25598354
30618635
30612527
31611796
20012068
29311817
30699952
31773453
27425887
28099097
20049146
21834767
31729450
26207229
28730967
21803157
28300826
31655606
31765662
22669487
31439031
26321641
27069796
28407483
17203472
29267402
27443609
19966296
30622185
29364839
15829582
22891247
23027540
26855788
31519175
26608623
31602221
27725817
24590859
25497784
30173208
30333729
29755842
29520228
28294067
24782763
26468932
28717130
29507776
21158978
23462987
30454039
19320056
31505546
30920075
31813629
31461505
30642737
30569089
32600151
28763509
29555333
19204158
25230996
28440854
1789684
26766547
6061736
25147107
8836976
18625458
23276384
30650523
27528626
32597927
29703936
31477562
31757576
30503509
22699611
27475754
29134359
31440436
25550694",Do the Bugs in Your Gut Eat Your Memories? Relationship between Gut Microbiota and Alzheimer's Disease.,"The human microbiota is composed of trillions of microbial cells inhabiting the oral cavity, skin, gastrointestinal (GI) tract, airways, and reproductive organs. The gut microbiota is composed of dynamic communities of microorganisms that communicate bidirectionally with the brain via cytokines, neurotransmitters, hormones, and secondary metabolites, known as the gut microbiota-brain axis. The gut microbiota-brain axis is suspected to be involved in the development of neurological diseases, including Alzheimer's disease (AD), Parkinson's disease, and Autism Spectrum Disorder. AD is an irreversible, neurodegenerative disease of the central nervous system (CNS), characterized by amyloid-β plaques, neurofibrillary tangles, and neuroinflammation. Microglia and astrocytes, the resident immune cells of the CNS, play an integral role in AD development, as neuroinflammation is a driving factor of disease severity. The gut microbiota-brain axis is a novel target for Alzheimer's disease therapeutics to modulate critical neuroimmune and metabolic pathways. Potential therapeutics include probiotics, prebiotics, fecal microbiota transplantation, and dietary intervention. This review summarizes our current understanding of the role of the gut microbiota-brain axis and neuroinflammation in the onset and development of Alzheimer's disease, limitations of current research, and potential for gut microbiota-brain axis targeted therapies.","['Alzheimer’s disease', 'astrocytes', 'gut microbiota–brain axis', 'microbiome', 'microglia', 'neuroinflammation']",Brain sciences,2020-11-07,"[{'lastname': 'Borsom', 'firstname': 'Emily M', 'initials': 'EM', 'affiliation': 'The Pathogen and Microbiome Institute, Center for Applied Microbiome Science, Northern Arizona University, Flagstaff, AZ 86011, USA.'}, {'lastname': 'Lee', 'firstname': 'Keehoon', 'initials': 'K', 'affiliation': 'The Pathogen and Microbiome Institute, Center for Applied Microbiome Science, Northern Arizona University, Flagstaff, AZ 86011, USA.'}, {'lastname': 'Cope', 'firstname': 'Emily K', 'initials': 'EK', 'affiliation': 'The Pathogen and Microbiome Institute, Center for Applied Microbiome Science, Northern Arizona University, Flagstaff, AZ 86011, USA.'}]",,,,,"10.3390/brainsci10110814
10.1042/BCJ20160510
10.3748/wjg.v21.i29.8787
10.1016/j.gtc.2016.09.007
10.1038/cti.2017.2
10.1186/s40168-019-0704-8
10.3389/fmicb.2018.01835
10.1111/j.1462-2920.2009.01982.x
10.1128/mBio.00886-20
10.3389/fnut.2019.00048
10.1126/science.1198469
10.1016/j.chom.2018.05.012
10.1038/nm.3444
10.1016/j.immuni.2018.04.022
10.1186/s12929-018-0483-8
10.1073/pnas.1904099116
10.5056/jnm18087
10.1016/j.maturitas.2017.06.025
10.1186/1479-5876-10-253
10.1073/pnas.1102999108
10.1161/CIRCRESAHA.118.313234
10.1186/s12974-019-1434-3
10.1007/s13238-016-0338-6
10.1038/s41598-020-65196-6
10.3233/JAD-171103
10.2174/1871527314666150202152436
10.3390/ijms21155407
10.3389/fnins.2017.00498
10.3390/ijms19082243
10.1093/brain/awy017
10.1002/alz.12068
10.1038/s41422-019-0216-x
10.1073/pnas.222681699
10.1152/physrev.2001.81.2.741
10.1007/s12035-018-1188-4
10.1016/j.jneuroim.2020.577185
10.1016/j.trci.2018.06.014
10.1111/j.1574-6941.2012.01437.x
10.1128/mSystems.00069-18
10.4137/EBO.S36436
10.1038/s41392-019-0063-8
10.3233/JAD-190872
10.3390/nu10111765
10.2174/1567205014666170317113606
10.1016/0197-4580(96)00104-2
10.1016/j.yexcr.2004.01.002
10.3389/fnins.2015.00259
10.1038/nm.3145
10.1186/s13195-018-0451-2
10.1080/14737175.2018.1400909
10.1038/nrgastro.2016.107
10.1136/gut.47.suppl_4.iv15
10.1084/jem.20180794
10.3389/fimmu.2017.01452
10.3389/fnins.2018.00049
10.3389/fnins.2015.00413
10.4088/JCP.v67n0801
10.4088/JCP.v63n1103
10.1097/YCT.0000000000000502
10.1111/jnc.14284
10.1096/fj.201900071R
10.1038/s41598-017-13601-y
10.1016/j.bbi.2019.05.008
10.3233/JAD-180176
10.1128/mBio.00632-19
10.3389/fnagi.2017.00195
10.1126/sciadv.aau3333
10.1155/2020/8456596
10.3233/JAD-160926
10.3389/fimmu.2020.00200
10.1038/srep41802
10.1038/s41598-017-02587-2
10.1021/acs.jafc.8b07313
10.1038/s41598-018-23261-1
10.1038/s41398-019-0525-3
10.3892/mmr.2016.4948
10.1523/JNEUROSCI.0176-07.2007
10.1038/s41569-018-0064-2
10.1186/s12974-020-01774-9
10.1016/j.nbd.2020.105008
10.1002/glia.10319
10.3389/fimmu.2017.01385
10.3389/fnagi.2019.00284
10.3389/fnmol.2017.00191
10.1186/s13024-017-0192-x
10.3389/fimmu.2018.02325
10.3389/fnagi.2019.00233
10.2217/fnl.12.6
10.2174/187152710791012071
10.3389/fnint.2015.00073
10.1186/1742-2094-1-14
10.1186/s12950-016-0140-5
10.1016/j.brs.2018.10.005
10.1007/s10787-019-00613-5
10.1016/j.bbi.2013.02.005
10.3233/JAD-170020
10.3389/fimmu.2017.01520
10.1007/s12035-014-9070-5
10.3389/fncel.2018.00488
10.1161/CIRCRESAHA.118.313882
10.3389/fphar.2019.01114
10.1007/s00401-009-0619-8
10.3389/fnmol.2017.00427
10.3390/ijms20030571
10.1007/s11357-019-00140-9
10.1016/j.nbd.2016.07.007
10.1148/radiol.2017164043
10.2174/138161211798220918
10.1038/s41598-019-53414-9
10.3978/j.issn.2305-5839.2015.03.49
10.2174/1570159X15666170720095240
10.1016/j.mcn.2011.07.006
10.1038/cddis.2017.93
10.1186/s12974-019-1561-x
10.1016/j.physbeh.2019.112745
10.1007/s10753-012-9484-z
10.1186/s40168-019-0733-3
10.1016/j.celrep.2015.08.004
10.7717/peerj.1854
10.1016/j.chom.2017.03.002
10.1002/glia.20467
10.1371/journal.ppat.1006654
10.1038/srep30028
10.1073/pnas.0908714107
10.1016/j.jalz.2006.05.861
10.1128/mBio.02279-18
10.3390/biom8010005
10.1073/pnas.0501814102
10.1074/jbc.M112.383737
10.1128/IAI.00911-12
10.1038/npjbiofilms.2015.19
10.1186/s12974-019-1564-7
10.1186/s12974-015-0434-1
10.3892/etm.2019.7943
10.3389/fmicb.2016.01544
10.1007/s11064-014-1266-6
10.1186/s12974-014-0202-7
10.1515/revneuro-2018-0024
10.3389/fncel.2018.00329
10.3389/fnagi.2018.00042
10.2174/1570159X15666170313122937
10.3389/fnagi.2014.00066
10.1038/srep15015
10.1038/s41598-017-05903-y
10.1038/s41541-018-0046-8
10.1111/j.1365-2796.2010.02315.x
10.1038/tp.2012.151
10.1186/s13195-018-0441-4
10.1016/j.nbd.2009.01.006
10.1093/brain/awz165
10.1111/jam.14264
10.1016/j.neurobiolaging.2019.11.004
10.1371/journal.pone.0221828
10.1016/j.clnu.2018.11.034
10.1177/0300060520925930
10.1016/j.tifs.2014.07.012
10.1371/journal.pone.0182048
10.1016/j.phrs.2018.03.012
10.1001/archneurol.2008.536
10.1212/WNL.0000000000000884
10.1111/jgs.14922
10.1002/ana.410300410
10.1111/nyas.12999
10.1172/JCI105650
10.3233/JAD-141074
10.1016/0022-510X(96)00033-0
10.1016/j.nurt.2008.05.004
10.1016/j.neurobiolaging.2012.11.023
10.3390/nu11010169
10.1096/fj.201600773R
10.1093/advances/nmaa073
10.1038/s41598-018-25190-5
10.1016/j.ebiom.2019.08.032
10.1016/j.neurobiolaging.2019.09.015
10.1016/j.chom.2018.11.003
10.1038/nature11053
10.1186/s12876-016-0498-0
10.1007/s13311-017-0585-0
10.7717/peerj.7502
10.4110/in.2014.14.6.277",<Element 'PubmedArticle' at 0x7f05decb3180>
185,"33125461
29782959
25271439
25770025
22043967
31199957
23436936
32380197
29182579
25169255
22182919
20005285
11516773
25387796
14766349
31077717
31275246
28215000
20828607
24990149
24434771
25656369
28032996
29091894
30618732
12433365
17565598
23603201
24117480
30018656
26773932
18759972
22959056
18992719
29988625
29158945
29669582
11846609
12194863
14907713
28004106
22745245
22053950
12433373
27307950
25446674
28832497
28090274
27033055
32866503
19758106
30532733
26984336
29079998
30405876
31022830
28188358
21558879
25286313
22253425
21084670
27509090
28406691
30257370
28109286
28875362
30590319
28450469",Alogliptin Attenuates Lipopolysaccharide-Induced Neuroinflammation in Mice Through Modulation of TLR4/MYD88/NF-κB and miRNA-155/SOCS-1 Signaling Pathways.,"Endotoxin-induced neuroinflammation plays a crucial role in the pathogenesis and progression of various neurodegenerative diseases. A growing body of evidence supports that incretin-acting drugs possess various neuroprotective effects that can improve learning and memory impairments in Alzheimer's disease models. Thus, the present study aimed to investigate whether alogliptin, a dipeptidyl peptidase-4 inhibitor, has neuroprotective effects against lipopolysaccharide (LPS)-induced neuroinflammation and cognitive impairment in mice as well as the potential mechanisms underlying these effects.
Mice were treated with alogliptin (20 mg/kg/d; p.o.) for 14 days, starting 1 day prior to intracerebroventricular LPS injection (8 μg/μL in 3 μL).
Alogliptin treatment alleviated LPS-induced cognitive impairment as assessed by Morris water maze and novel object recognition tests. Moreover, alogliptin reversed LPS-induced increases in toll-like receptor 4 and myeloid differentiation primary response 88 protein expression, nuclear factor-κB p65 content, and microRNA-155 gene expression. It also rescued LPS-induced decreases in suppressor of cytokine signaling gene expression, cyclic adenosine monophosphate (cAMP) content, and phosphorylated cAMP response element binding protein expression in the brain.
The present study sheds light on the potential neuroprotective effects of alogliptin against intracerebroventricular LPS-induced neuroinflammation and its associated memory impairment via inhibition of toll-like receptor 4/ myeloid differentiation primary response 88/ nuclear factor-κB signaling, modulation of microRNA-155/suppressor of cytokine signaling-1 expression, and enhancement of cAMP/phosphorylated cAMP response element binding protein signaling.","['Alogliptin', 'cognitive impairment', 'lipopolysaccharide', 'neuroinflammation']",The international journal of neuropsychopharmacology,2020-10-31,"[{'lastname': 'El-Sahar', 'firstname': 'Ayman E', 'initials': 'AE', 'affiliation': 'Department of Pharmacology and Toxicology, Faculty of Pharmacy, Cairo University, Cairo, Egypt.'}, {'lastname': 'Shiha', 'firstname': 'Nesma A', 'initials': 'NA', 'affiliation': 'Department of Pharmacology and Toxicology, Faculty of Pharmacy, Cairo University, Cairo, Egypt.'}, {'lastname': 'El Sayed', 'firstname': 'Nesrine S', 'initials': 'NS', 'affiliation': 'Department of Pharmacology and Toxicology, Faculty of Pharmacy, Cairo University, Cairo, Egypt.'}, {'lastname': 'Ahmed', 'firstname': 'Lamiaa A', 'initials': 'LA', 'affiliation': 'Department of Pharmacology and Toxicology, Faculty of Pharmacy, Cairo University, Cairo, Egypt.'}]",,"The present study sheds light on the potential neuroprotective effects of alogliptin against intracerebroventricular LPS-induced neuroinflammation and its associated memory impairment via inhibition of toll-like receptor 4/ myeloid differentiation primary response 88/ nuclear factor-κB signaling, modulation of microRNA-155/suppressor of cytokine signaling-1 expression, and enhancement of cAMP/phosphorylated cAMP response element binding protein signaling.","Alogliptin treatment alleviated LPS-induced cognitive impairment as assessed by Morris water maze and novel object recognition tests. Moreover, alogliptin reversed LPS-induced increases in toll-like receptor 4 and myeloid differentiation primary response 88 protein expression, nuclear factor-κB p65 content, and microRNA-155 gene expression. It also rescued LPS-induced decreases in suppressor of cytokine signaling gene expression, cyclic adenosine monophosphate (cAMP) content, and phosphorylated cAMP response element binding protein expression in the brain.",© The Author(s) 2020. Published by Oxford University Press on behalf of CINP.,10.1093/ijnp/pyaa078,<Element 'PubmedArticle' at 0x7f05deca6130>
186,33115994,[Ictal electroencephalography (EEG) activity and cerebral blood flow dynamics as potential pathological indicators: a case of anti-leucine-rich glioma-inactivated 1 protein (LGI1) encephalitis].,"A 29 year-old, right-handed woman was admitted to our hospital due to her headache with fever elevation lasting for two months followed by a prolonged loss of awareness with an involuntary movement in her left hand and mouth. This movement appeared very frequently, and the duration was very short, so called ""faciobrachial dystonic seizures (FBDS)"". Some of FBDS were followed by prolonged loss of awareness. Brain MRI fluid attenuated inversion recovery (FLAIR) image revealed high intensity lesion in the left mesial temporal lobe. Arterial spin labeling (ASL) image indicated hyper perfusion in this lesion and also the lateral temporal region. No ictal electroencephalography (EEG) change was observed before the onset of FBDS. FBDS was often followed by focal impaired awareness seizure (FIAS) in which ictal EEG showed rhythmic alpha activity arising from left mid-temporal region. This EEG seizure pattern was clearly visible in the time-frequency analysis. Given these clinical findings, along with an evidence of serum anti-leucine-rich glioma-inactivated 1 (LGI1) antibody positive, she was diagnosed with anti-LGI1 encephalitis. Immunotherapy (methylpredonisolone and intravenous immunoglobulin) with a multiple anti-epileptic drugs therapy (lacosamide, perampanel, and lamotrigine) was highly responsible to her symptoms. Although the high intensity lesion in FLAIR image still remained after the treatment, findings of ASL and EEG showed clear correlation to her cognitive function and seizures, respectively. Temporal change in ASL imaging suggested that the hyper perfusion in ASL during the acute stage could be provided by inflammation of the encephalitis its self and also the seizures activities (FBDS and FIAS). The pathophysiological indication of anti-LGI1 encephalitis was limited in terms of the therapeutic strategy, however, our findings collectively suggested that the combination analysis of EEG activity and cerebral blood flow dynamics (ASL) could be the potential candidate.","['anti-leucine-rich glioma-inactivated 1 antibody', 'density modulated spectral array', 'epilepsy', 'focal impaired awareness seizure', 'limbic encephalitis']",Rinsho shinkeigaku = Clinical neurology,2020-10-30,"[{'lastname': 'Ishibashi', 'firstname': 'Haruka', 'initials': 'H', 'affiliation': 'Department of Neurology, Hiroshima University Hospital.'}, {'lastname': 'Neshige', 'firstname': 'Shuichiro', 'initials': 'S', 'affiliation': 'Department of Neurology, Hiroshima University Hospital.\nEpilepsy Center, Hiroshima University.'}, {'lastname': 'Aoki', 'firstname': 'Shiro', 'initials': 'S', 'affiliation': 'Department of Neurology, Hiroshima University Hospital.'}, {'lastname': 'Ueno', 'firstname': 'Hiroki', 'initials': 'H', 'affiliation': 'Department of Neurology, Hiroshima University Hospital.\nEpilepsy Center, Hiroshima University.'}, {'lastname': 'Iida', 'firstname': 'Koji', 'initials': 'K', 'affiliation': 'Epilepsy Center, Hiroshima University.\nDepartment of Neurosurgery, Hiroshima University Hospital.'}, {'lastname': 'Maruyama', 'firstname': 'Hirofumi', 'initials': 'H', 'affiliation': 'Department of Neurology, Hiroshima University Hospital.\nEpilepsy Center, Hiroshima University.'}]",,,,,10.5692/clinicalneurol.cn-001460,<Element 'PubmedArticle' at 0x7f05dec50590>
187,33098686,Neuromodulatory effect of curcumin on catecholamine systems and inflammatory cytokines in ovariectomized female rats.,"Anti-inflammatory products may represent the future for depressive disorder therapies. Curcumin (CUR) is a polyphenol and an active component of the turmeric plant Curcuma longa. The aim of this study was to investigate the impact of CUR, as a natural anti-inflammatory agent, on neuro-inflammation related to depression and compare it with the effects of fluoxetine (FLX) and estradiol (E","['catecholamines', 'curcumin', 'cytokines', 'depression', 'estradiol', 'ovariectomy']",Clinical and experimental pharmacology & physiology,2020-10-25,"[{'lastname': 'Saied', 'firstname': 'Nashwa M', 'initials': 'NM', 'affiliation': 'Department of Hormone, National Organization for Drug Control and Research, Giza, Egypt.'}, {'lastname': 'Georgy', 'firstname': 'Gehan S', 'initials': 'GS', 'affiliation': 'Department of Pharmacology, National Organization for Drug Control and Research, Giza, Egypt.'}, {'lastname': 'Hussien', 'firstname': 'Rokaya M', 'initials': 'RM', 'affiliation': 'Department of Hormone, National Organization for Drug Control and Research, Giza, Egypt.'}, {'lastname': 'Hassan', 'firstname': 'Wafaa A', 'initials': 'WA', 'affiliation': 'Department of Hormone, National Organization for Drug Control and Research, Giza, Egypt.'}]",,,,"© 2020 John Wiley & Sons Australia, Ltd.",10.1111/1440-1681.13427,<Element 'PubmedArticle' at 0x7f05dec5b310>
188,33096292,Protection induced by estradiol benzoate in the MPP,"Previously, we have demonstrated that β-estradiol-3-benzoate (EB) has a protective effect on the neurodegenerative experimental model of Parkinson's disease. The protective effect is through the induction of the expression of paraoxonase-2 (PON2) in the striatum. PON2 has proven to have antioxidant and anti-inflammatory activity, this protein has a beneficial effect in MPP","['Antioxidants', 'MPP(+)', 'Neuroimmunology', 'Neuroinflammation', ""Parkinson's disease"", 'Proinflammatory cytokines', 'β-Estradiol-3-benzoate']",Journal of neuroimmunology,2020-10-24,"[{'lastname': 'Aguirre-Vidal', 'firstname': 'Yoshajandith', 'initials': 'Y', 'affiliation': 'Laboratorio de Neuroprotección, Facultad de Farmacia, Universidad Autónoma del Estado de Morelos, Cuernavaca, Morelos, Mexico.'}, {'lastname': 'Morales-Montor', 'firstname': 'Jorge', 'initials': 'J', 'affiliation': 'Departamento de Inmunología, Instituto de Investigaciones Biomédicas, Universidad Nacional Autónoma de México, Ciudad de México 04510, Mexico. Electronic address: jmontor66@biomedicas.unam.mx.'}, {'lastname': 'Gómez de León', 'firstname': 'Carmen T', 'initials': 'CT', 'affiliation': 'Departamento de Inmunología, Instituto de Investigaciones Biomédicas, Universidad Nacional Autónoma de México, Ciudad de México 04510, Mexico.'}, {'lastname': 'Ostoa-Saloma', 'firstname': 'Pedro', 'initials': 'P', 'affiliation': 'Departamento de Inmunología, Instituto de Investigaciones Biomédicas, Universidad Nacional Autónoma de México, Ciudad de México 04510, Mexico.'}, {'lastname': 'Díaz-Zaragoza', 'firstname': 'Mariana', 'initials': 'M', 'affiliation': 'Laboratorio de Sistemas Biológicos, Departamento de Ciencias de la Salud, Centro Universitario de los Valles, Universidad de Guadalajara, C.P. 46600 Ameca, Jalisco, Mexico.'}, {'lastname': 'Montes', 'firstname': 'Sergio', 'initials': 'S', 'affiliation': 'Departamento de Neuroquímica, Instituto Nacional de Neurología y Neurocirugía, ""Dr. Manuel Velasco Suárez"", Ciudad de México, Mexico.'}, {'lastname': 'Arteaga-Silva', 'firstname': 'Marcela', 'initials': 'M', 'affiliation': 'Departamento de Biología de la Reproducción, Universidad Autónoma Metropolitana-Iztapalapa, Ciudad de México, Mexico.'}, {'lastname': 'Monroy-Noyola', 'firstname': 'Antonio', 'initials': 'A', 'affiliation': 'Laboratorio de Neuroprotección, Facultad de Farmacia, Universidad Autónoma del Estado de Morelos, Cuernavaca, Morelos, Mexico. Electronic address: amonroy@uaem.mx.'}]",,,,Copyright © 2020 Elsevier B.V. All rights reserved.,10.1016/j.jneuroim.2020.577426,<Element 'PubmedArticle' at 0x7f05dec6f4a0>
189,33069753,Oxytocin reverses ethanol consumption and neuroinflammation induced by social defeat in male mice.,"Oxytocin (OXT) modulates social interactions, attenuates stressful responses and can decrease drug-seeking and taking behaviors. In previous studies, we observed that social defeat (SD) induced a long-lasting increase in ethanol intake and neuroinflammation in male mice. We also know that OXT blocks the increase in cocaine reward induced by SD. Therefore, in the present study we aimed to evaluate the effect of 1 mg/kg of OXT administered 30 min before each episode of SD on ethanol consumption and the neuroinflammatory response in adult male mice. Three weeks after the last SD, mice underwent oral ethanol self-administration (SA) procedure, and striatal levels of the two chemokines CX3CL1 and CXCL12 were measured after the last SD and at the end of the ethanol SA. OXT administration blocked the increase in voluntary ethanol consumption observed in defeated mice, although it did not affect motivation for ethanol. An increase in the striatal levels of CX3CL1 and CXCL12 was observed in defeated animals immediately after the last defeat and after the ethanol SA. However, defeated mice treated with OXT did not show this increase in the neuroinflammatory response. In conclusion, OXT treatment can be a powerful therapeutic target to reduce the negative effects of social stress on ethanol consumption and the neuroinflammatory process.","['Chemokines', 'Ethanol', 'Neuroinflammation', 'Oxytocin', 'Self-administration', 'Social defeat', 'Stress']",Hormones and behavior,2020-10-19,"[{'lastname': 'Reguilón', 'firstname': 'M D', 'initials': 'MD', 'affiliation': 'Department of Psychobiology, Facultad de Psicología, Universitat de Valencia, Avda. Blasco Ibáñez, 21, 46010 Valencia, Spain.'}, {'lastname': 'Ferrer-Pérez', 'firstname': 'C', 'initials': 'C', 'affiliation': 'Department of Psychobiology, Facultad de Psicología, Universitat de Valencia, Avda. Blasco Ibáñez, 21, 46010 Valencia, Spain.'}, {'lastname': 'Miñarro', 'firstname': 'J', 'initials': 'J', 'affiliation': 'Department of Psychobiology, Facultad de Psicología, Universitat de Valencia, Avda. Blasco Ibáñez, 21, 46010 Valencia, Spain.'}, {'lastname': 'Rodríguez-Arias', 'firstname': 'M', 'initials': 'M', 'affiliation': 'Department of Psychobiology, Facultad de Psicología, Universitat de Valencia, Avda. Blasco Ibáñez, 21, 46010 Valencia, Spain. Electronic address: marta.rodriguez@uv.es.'}]",,,,Copyright © 2020 Elsevier Inc. All rights reserved.,10.1016/j.yhbeh.2020.104875,<Element 'PubmedArticle' at 0x7f05debbe4f0>
190,"33050589
24798679
25874594
28611664
26055231
25164769
29615912
27227691
22845893
27083308
29618972
26251227
32150935
31396087
20152858
15655246
29567427
20736084
26857391
16845890
24952959
27539936
29382825
29576849
17712833
8900284
23425575
26310614
28499701
31103036
30962497
26639457
29046777
22515328
23520554
15317910
19386271
31263402
4748425
25106636
26134003
28990726
30229438",Synergic Therapeutic Potential of PEA-Um Treatment and NAAA Enzyme Silencing In the Management of Neuroinflammation.,"Inflammation is a key element in the pathobiology of neurodegenerative diseases and sees the involvement of different neuronal and non-neuronal cells as players able to respond to inflammatory signals of immune origin. Palmitoylethanolamide (PEA) is an endogenous potent anti-inflammatory agent, in which activity is regulated by N-acylethanolamine acid amidase (NAAA), that hydrolyzes saturated or monounsaturated fatty acid ethanolamides, such as PEA. In this research, an in vitro study was performed on different neuronal (SH-SY5Y) and non-neuronal cell lines (C6, BV-2, and Mo3.13) subjected to NAAA enzyme silencing and treated with PEA ultra-micronized (PEA-um) (1, 3, and 10 μM) to increase the amount of endogenous PEA available for counteract neuroinflammation provoked by stimulation with lipopolysaccharide (LPS) (1 μg/mL) and interferon gamma (INF-γ )(100 U/mL). Cell viability was performed by MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide) staining, suggesting a protective effect of PEA-um (3 and 10 μM) on all cell lines studied. Western Blot analysis for inflammatory markers (Inducible nitric oxide synthase (iNOS) and cyclooxygenase 2 (COX-2)) was carried out in control and NAAA-silenced cells, highlighting how the concomitant treatment of the neuronal and non-neuronal cells with PEA-um after NAAA genic downregulation is satisfactory to counteract neuroinflammation. These in vitro findings support the protective role of endogenous PEA availability in the neuronal field, bringing interesting information for a translational point of view.","['glioma', 'microglia', 'neuroblastoma', 'neuroinflammation', 'oligodendrocytes', 'palmitoylethanolamide']",International journal of molecular sciences,2020-10-15,"[{'lastname': 'Casili', 'firstname': 'Giovanna', 'initials': 'G', 'affiliation': 'Department of Chemical, Biological, Pharmaceutical and Environmental Sciences, University of Messina, 98165 Messina, Italy.'}, {'lastname': 'Lanza', 'firstname': 'Marika', 'initials': 'M', 'affiliation': 'Department of Chemical, Biological, Pharmaceutical and Environmental Sciences, University of Messina, 98165 Messina, Italy.'}, {'lastname': 'Campolo', 'firstname': 'Michela', 'initials': 'M', 'affiliation': 'Department of Chemical, Biological, Pharmaceutical and Environmental Sciences, University of Messina, 98165 Messina, Italy.'}, {'lastname': 'Siracusa', 'firstname': 'Rosalba', 'initials': 'R', 'affiliation': 'Department of Chemical, Biological, Pharmaceutical and Environmental Sciences, University of Messina, 98165 Messina, Italy.'}, {'lastname': 'Paterniti', 'firstname': 'Irene', 'initials': 'I', 'affiliation': 'Department of Chemical, Biological, Pharmaceutical and Environmental Sciences, University of Messina, 98165 Messina, Italy.'}, {'lastname': 'Ardizzone', 'firstname': 'Alessio', 'initials': 'A', 'affiliation': 'Department of Chemical, Biological, Pharmaceutical and Environmental Sciences, University of Messina, 98165 Messina, Italy.'}, {'lastname': 'Scuderi', 'firstname': 'Sarah Adriana', 'initials': 'SA', 'affiliation': 'Department of Chemical, Biological, Pharmaceutical and Environmental Sciences, University of Messina, 98165 Messina, Italy.'}, {'lastname': 'Cuzzocrea', 'firstname': 'Salvatore', 'initials': 'S', 'affiliation': 'Department of Chemical, Biological, Pharmaceutical and Environmental Sciences, University of Messina, 98165 Messina, Italy.\nDepartment of Pharmacological and Physiological Science, Saint Louis University, Saint Louis, MO 63103, USA.'}, {'lastname': 'Esposito', 'firstname': 'Emanuela', 'initials': 'E', 'affiliation': 'Department of Chemical, Biological, Pharmaceutical and Environmental Sciences, University of Messina, 98165 Messina, Italy.'}]",,,,,"10.3390/ijms21207486
10.1016/j.phrs.2014.04.011
10.1021/acschembio.5b00114
10.3389/fphar.2017.00308
10.1007/s12035-015-9253-8
10.1186/s12974-014-0136-0
10.3389/fphar.2018.00249
10.1097/j.pain.0000000000000623
10.1111/j.1526-4637.2012.01432.x
10.1016/j.phrs.2016.04.007
10.3389/fncel.2018.00072
10.1111/nyas.12855
10.3390/antiox9030216
10.3389/fphar.2019.00821
10.1016/j.plipres.2010.02.003
10.1074/jbc.M413473200
10.1016/j.drudis.2018.03.007
10.1016/j.bbalip.2010.08.010
10.1007/s13311-016-0420-z
10.1139/Y05-143
10.1016/j.drudis.2014.06.007
10.1111/bph.13580
10.1038/s41398-017-0076-4
10.1155/2018/4720532
10.1002/cbdv.200790159
10.1038/384083a0
10.1111/febs.12152
10.1038/srep13565
10.1016/j.molmed.2017.04.005
10.1186/s12974-019-1490-8
10.1038/s41598-019-42286-8
10.2174/1570159X14666151204122017
10.4097/kjae.2017.70.5.561
10.1021/jm300349j
10.1371/journal.pone.0059131
10.1124/pr.56.3.3
10.3389/fncel.2019.00263
10.2174/1871527313666140806124322
10.1101/cshperspect.a020537
10.1007/s12035-018-1347-7",<Element 'PubmedArticle' at 0x7f05debcc450>
191,33001012,An Agathokakological Tale of Δ,Δ,"['atherogenesis', 'epilepsy', 'neurodegenerative\ndiseases', 'neuroinflammation', 'tetrahydrocannabinol', 'Δ9-Tetrahydrocannabinol']",Current drug targets,2020-10-02,"[{'lastname': 'Mathew', 'firstname': 'Bijo', 'initials': 'B', 'affiliation': 'Department of Pharmaceutical Chemistry, Amrita School of Pharmacy, Amrita Vishwa Vidyapeetham, AIMS Health Sciences Campus, Kochi-682 041, India.'}, {'lastname': 'Harilal', 'firstname': 'Seetha', 'initials': 'S', 'affiliation': 'Department of Pharmacy, Kerala University of Health Sciences, Thrissur, Kerala, India.'}, {'lastname': 'Musa', 'firstname': 'Arafa', 'initials': 'A', 'affiliation': 'Department of Pharmacogonosy, College of Pharmacy, Jouf University, Sakaka, Al Jouf, 2014, Saudi Arabia.'}, {'lastname': 'Kumar', 'firstname': 'Rajesh', 'initials': 'R', 'affiliation': 'Department of Pharmacy, Kerala University of Health Sciences, Thrissur, Kerala, India.'}, {'lastname': 'Parambi', 'firstname': 'Della Grace Thomas', 'initials': 'DGT', 'affiliation': 'Department of Pharmaceutical Chemistry, College of Pharmacy, Jouf University, Sakaka, Al Jouf, 2014, Saudi Arabia.'}, {'lastname': 'Jose', 'firstname': 'Jobin', 'initials': 'J', 'affiliation': 'Department of Pharmaceutics, NGSM Institute of Pharmaceutical Science, NITTE Deemed to be University, Manglore, 575018, India.'}, {'lastname': 'Uddin', 'firstname': 'Md Sahab', 'initials': 'MS', 'affiliation': 'Department of Pharmacy, Southeast University, Dhaka, Bangladesh.'}, {'lastname': 'Shah', 'firstname': 'Muhammad Ajmal', 'initials': 'MA', 'affiliation': 'Department of Pharmacogonosy, Faculty of Pharmaceutical Sciences, Government College University, Faisalabad, Pakistan.'}, {'lastname': 'Behl', 'firstname': 'Tapan', 'initials': 'T', 'affiliation': 'Department of Pharmacology, Chitkara College of Pharmacy, Chitkara University, Punjab, India.'}, {'lastname': 'Unnikrishnan', 'firstname': 'Mazhuvancherry Kesavan', 'initials': 'MK', 'affiliation': 'Department of Pharmaceutical Chemistry, National College of Pharmacy, Calicut, India.'}]",,,,"Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.",10.2174/1389450121666201001123515,<Element 'PubmedArticle' at 0x7f05deb704a0>
192,32940168,Diabetic Theory in Anti-Alzheimer's Drug Research and Development. Part 2: Therapeutic Potential of cAMP-Specific Phosphodiesterase Inhibitors.,"Alzheimer's disease (AD) is one of the most prevalent age-related neurodegenerative disease that affects the cognition, behavior, and daily activities of individuals. Studies indicate that this disease is characterized by several pathological mechanisms, including the accumulation of amyloid-beta peptide, hyperphosphorylation of tau protein, impairment of cholinergic neurotransmission, and increase in inflammatory responses within the central nervous system. Chronic neuroinflammation associated with AD is closely related to disturbances in metabolic processes, including insulin release and glucose metabolism. As AD is also called type III diabetes, diverse compounds having antidiabetic effects have been investigated as potential drugs for its symptomatic and disease-modifying treatment. In addition to insulin and oral antidiabetic drugs, scientific attention has been paid to cyclic-3',5'-adenosine monophosphate (cAMP)-specific phosphodiesterase (PDE) inhibitors that can modulate the concentration of glucose and related hormones and exert beneficial effects on memory, mood, and emotional processing. In this review, we present the most recent reports focusing on the involvement of cAMP-specific PDE4, PDE7, and PDE8 in glycemic and inflammatory response controls as well as the potential utility of the PDE inhibitors in the treatment of AD. Besides the results of in vitro and in vivo studies, the review also presents recent reports from clinical trials.","[""Alzheimer's disease"", 'PDE inhibitor', 'anti-inflammatory activity', 'antidiabetic activity', 'cAMP', 'cognitive\nimpairment', 'neuroinflammation', 'phosphodiesterase']",Current medicinal chemistry,2020-09-18,"[{'lastname': 'Jankowska', 'firstname': 'Agnieszka', 'initials': 'A', 'affiliation': 'Jagiellonian University Medical College, Faculty of Pharmacy, Department of Medicinal Chemistry, 9 Medyczna Street, Krakow 30-688, Poland.'}, {'lastname': 'Pawłowski', 'firstname': 'Maciej', 'initials': 'M', 'affiliation': 'Jagiellonian University Medical College, Faculty of Pharmacy, Department of Medicinal Chemistry, 9 Medyczna Street, Krakow 30-688, Poland.'}, {'lastname': 'Chłoń-Rzepa', 'firstname': 'Grażyna', 'initials': 'G', 'affiliation': 'Jagiellonian University Medical College, Faculty of Pharmacy, Department of Medicinal Chemistry, 9 Medyczna Street, Krakow 30-688, Poland.'}]",,,,"Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.",10.2174/0929867327666200917125857,<Element 'PubmedArticle' at 0x7f05deb7b540>
193,32926927,Modulatory effect of methylsulfonylmethane against BPA/γ-radiation induced neurodegenerative alterations in rats: Influence of TREM-2/DAP-12/Syk pathway.,"Methylsulfonylmethane (MSM), is an organosulfur compound, has many health benefits. Bisphenol-A (BPA) and γ-radiation (R) are two risky environmental contaminants that human beings are exposed to in everyday life. This work aims at unveiling the modulatory role of MSM in combating BPA and R co-exposure induced neurodegenerative disorder (Alzheimer's (AD)-mimic neurotoxicity).
Female rats were randomly divided into five groups. One group was normal control and the other four groups were subjected to subacute BPA intoxication and/or exposed to fractionated weekly doses of R for 4 weeks and either untreated or treated with MSM concomitantly.
BPA and R co-exposure induced typical hallmarks of neurodegenerative disorders as revealed by tremendously elevated oxidative stress, extensive neuroinflammation (tumor necrosis factor -α and interleukin-1β), elevated AD markers (amyloid-beta (Aβ
Our data suggest that MSM afforded neuroprotection against BPA and R; supporting its potential application in the associated neurodegenerative disorders.","['Bisphenol-A', 'Methylsulfonylmethane', 'TREM-2/DAP-12/Syk', 'Tau', 'γ-Radiation']",Life sciences,2020-09-15,"[{'lastname': 'Abdel-Rafei', 'firstname': 'Mohamed K', 'initials': 'MK', 'affiliation': 'Radiation Biology Department, National Centre for Radiation Research and Technology (NCRRT), Atomic Energy Authority, Cairo, Egypt. Electronic address: mohamed.marawan2011@yahoo.com.'}, {'lastname': 'Thabet', 'firstname': 'Noura M', 'initials': 'NM', 'affiliation': 'Radiation Biology Department, National Centre for Radiation Research and Technology (NCRRT), Atomic Energy Authority, Cairo, Egypt.'}]",,,,Copyright © 2020 Elsevier Inc. All rights reserved.,10.1016/j.lfs.2020.118410,<Element 'PubmedArticle' at 0x7f05deb82630>
194,"32877641
10995835
23024660
9712653
23399917
17360345
29100013
30447904
4041882
7225864
30927700
17188374
29437957
20844121
16455686
20392936
16816139
23457258
30389916
29298904
31242408
24941947
18400866
20300101
16158066
19033363
19131956
2479932
21212780
14660786
22912745
24269023
23618408
3412648
3220981
21795548
25425556
18091557
31114916
28636962
15979211
12097911
25942042
31145508
12174384
14730584
22357963
26731444
28528956
30911133
22192775
9325368
17021169
27885812
28225752
27161528
26217191
22504537
24312364
30739077
29670519
29298905
30823575
26299571
25957904
14984406
27143698
24212671
22842902
7895052
30476243
21943598
25023312
23222703
20847426
17018022
30834305
11516401
21983279
20736051
30057205
11942415",Neuropeptides Modulate Local Astrocytes to Regulate Adult Hippocampal Neural Stem Cells.,"Neural stem cells (NSCs) in the dentate gyrus (DG) reside in a specialized local niche that supports their neurogenic proliferation to produce adult-born neurons throughout life. How local niche cells interact at the circuit level to ensure continuous neurogenesis from NSCs remains unknown. Here we report the role of endogenous neuropeptide cholecystokinin (CCK), released from dentate CCK interneurons, in regulating neurogenic niche cells and NSCs. Specifically, stimulating CCK release supports neurogenic proliferation of NSCs through a dominant astrocyte-mediated glutamatergic signaling cascade. In contrast, reducing dentate CCK induces reactive astrocytes, which correlates with decreased neurogenic proliferation of NSCs and upregulation of genes involved in immune processes. Our findings provide novel circuit-based information on how CCK acts on local astrocytes to regulate the key behavior of adult NSCs.","['adult neural stem cells', 'astrocytes', 'cholecystokinin', 'hippocampus', 'neurogenesis', 'neuroinflammation', 'neuropeptide']",Neuron,2020-09-03,"[{'lastname': 'Asrican', 'firstname': 'Brent', 'initials': 'B', 'affiliation': 'Department of Pharmacology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA; Neuroscience Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.'}, {'lastname': 'Wooten', 'firstname': 'Josh', 'initials': 'J', 'affiliation': 'Department of Pharmacology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA; Genetics and Molecular Biology Curriculum, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.'}, {'lastname': 'Li', 'firstname': 'Ya-Dong', 'initials': 'YD', 'affiliation': 'Department of Pharmacology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA; Neuroscience Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.'}, {'lastname': 'Quintanilla', 'firstname': 'Luis', 'initials': 'L', 'affiliation': 'Department of Pharmacology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA; Neuroscience Curriculum, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.'}, {'lastname': 'Zhang', 'firstname': 'Feiran', 'initials': 'F', 'affiliation': 'Department of Human Genetics, Emory University, Atlanta, GA 30322, USA.'}, {'lastname': 'Wander', 'firstname': 'Connor', 'initials': 'C', 'affiliation': 'Department of Pharmacology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA; Pharmacology Curriculum, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.'}, {'lastname': 'Bao', 'firstname': 'Hechen', 'initials': 'H', 'affiliation': 'Department of Pharmacology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA; Neuroscience Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.'}, {'lastname': 'Yeh', 'firstname': 'Chia-Yu', 'initials': 'CY', 'affiliation': 'Department of Pharmacology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA; Neuroscience Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.'}, {'lastname': 'Luo', 'firstname': 'Yan-Jia', 'initials': 'YJ', 'affiliation': 'Department of Pharmacology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA; Neuroscience Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.'}, {'lastname': 'Olsen', 'firstname': 'Reid', 'initials': 'R', 'affiliation': 'Department of Pharmacology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.'}, {'lastname': 'Lim', 'firstname': 'Szu-Aun', 'initials': 'SA', 'affiliation': 'Department of Pharmacology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.'}, {'lastname': 'Hu', 'firstname': 'Jessica', 'initials': 'J', 'affiliation': 'Department of Pharmacology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.'}, {'lastname': 'Jin', 'firstname': 'Peng', 'initials': 'P', 'affiliation': 'Department of Human Genetics, Emory University, Atlanta, GA 30322, USA.'}, {'lastname': 'Song', 'firstname': 'Juan', 'initials': 'J', 'affiliation': 'Department of Pharmacology, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA; Neuroscience Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA. Electronic address: juansong@email.unc.edu.'}]",,,,Copyright © 2020 Elsevier Inc. All rights reserved.,10.1016/j.neuron.2020.07.039,<Element 'PubmedArticle' at 0x7f05deb931d0>
195,"32849818
25935351
29340013
22240294
31099037
24582593
19756449
17571248
23108393
30057531
23303060
23650397
20399565
23760347
28779999
12480495
25277330
25793778
18369660
16289097
19606083
21368868
20351714
31565597
20919962
26176920
25575479
16612175
23475071
20186711
31539779
28848088
28078988
28403881
10051674
25330741
24890068
20428081
24603133
31926635
31163384
31540539
28358001
9626555
28325815
30712809
31153932
20015486
26937618
22826346
16631126
20193739
31195092
11832334
27188165
26585800
24507187
12374740
18925875
24727982
29128043
26143539
26065825
25444754
31632443
15813940
26524592
28376115
26404713
18570873
30718901
21647420
25738875
27479909
27457803
30496104
26008736
27477270
31231295
31234698
20515807
17945407
15893584
27528460
25133871
26347657
23467095
10548550
25322082
26010085
31663783
30063009
21946312
19584721
17015487
20021289
23012321
20530112
23506284
21638237
29961124
26708271
26480816
26506154
20558230
29033793
28246558
17289131
30995920
31446016
19461886
24318124
20138063
30655532
16585788
26307347
31101126
30694908
15342340
21655274
26043694
20856249
15023499
30200269
15209375
27385417
19067144
28293733
19548318
27908895
22654714
16630541
23069755
19126684
25309465
28852377
27089181
27629598
17509675
19631474
17142971
24565447
30371993
28479211
31975953
30524235
31316402
11096081
31612411
25553404
17579818
23960204
31281445
25871428
26992751
16415915
18208916
21930911
20080870
18489715
22516894
25200670
17762509
21814182
18209482
30083112
28912935
19748978
23581296
29788407
26115975
19088076
26462020
26908461
27771704
26344141
31992966
27221032
29700475
23467085
23063465
12417564
26548813
21415537
29484897
24265802
27502757
25034177
31595217
15268969
26604025
26293964
20406665",The Emerging Role of SGK1 (Serum- and Glucocorticoid-Regulated Kinase 1) in Major Depressive Disorder: Hypothesis and Mechanisms.,"Major depressive disorder (MDD) is a heterogeneous psychiatric disease characterized by persistent low mood, diminished interests, and impaired cognitive and social functions. The multifactorial etiology of MDD is still largely unknown because of the complex genetic and environmental interactions involved. Therefore, no established mechanism can explain all the aspects of the disease. In this light, an extensive research about the pathophysiology of MDD has been carried out. Several pathogenic hypotheses, such as monoamines deficiency and neurobiological alterations in the stress-responsive system, including the hypothalamic-pituitary-adrenal (HPA) axis and the immune system, have been proposed for MDD. Over time, remarkable studies, mainly on preclinical rodent models, linked the serum- and glucocorticoid-regulated kinase 1 (SGK1) to the main features of MDD. SGK1 is a serine/threonine kinase belonging to the AGK Kinase family. SGK1 is ubiquitously expressed, which plays a pivotal role in the hormonal regulation of several ion channels, carriers, pumps, and transcription factors or regulators. SGK1 expression is modulated by cell stress and hormones, including gluco- and mineralocorticoids. Compelling evidence suggests that increased SGK1 expression or function is related to the pathogenic stress hypothesis of major depression. Therefore, the first part of the present review highlights the putative role of SGK1 as a critical mediator in the dysregulation of the HPA axis, observed under chronic stress conditions, and its controversial role in the neuroinflammation as well. The second part depicts the negative regulation exerted by SGK1 in the expression of both the brain-derived neurotrophic factor (BDNF) and the vascular endothelial growth factor (VEGF), resulting in an anti-neurogenic activity. Finally, the review focuses on the antidepressant-like effects of anti-oxidative nutraceuticals in several preclinical model of depression, resulting from the restoration of the physiological expression and/or activity of SGK1, which leads to an increase in neurogenesis. In summary, the purpose of this review is a systematic analysis of literature depicting SGK1 as molecular junction of the complex mechanisms underlying the MDD in an effort to suggest the kinase as a potential biomarker and strategic target in modern molecular antidepressant therapy.","['SGK1', 'antidepressant', 'inflammation', 'major depressive disorder', 'neurodevelopment', 'neurogenesis', 'neurotrophins', 'stress']",Frontiers in genetics,2020-08-28,"[{'lastname': 'Dattilo', 'firstname': 'Vincenzo', 'initials': 'V', 'affiliation': 'Genetic Unit, IRCCS Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy.'}, {'lastname': 'Amato', 'firstname': 'Rosario', 'initials': 'R', 'affiliation': 'Department of Health Sciences, Magna Graecia University of Catanzaro, Catanzaro, Italy.\nMedical Genetics Unit, Mater Domini University Hospital, Catanzaro, Italy.'}, {'lastname': 'Perrotti', 'firstname': 'Nicola', 'initials': 'N', 'affiliation': 'Department of Health Sciences, Magna Graecia University of Catanzaro, Catanzaro, Italy.\nMedical Genetics Unit, Mater Domini University Hospital, Catanzaro, Italy.'}, {'lastname': 'Gennarelli', 'firstname': 'Massimo', 'initials': 'M', 'affiliation': 'Genetic Unit, IRCCS Centro San Giovanni di Dio Fatebenefratelli, Brescia, Italy.\nDepartment of Molecular and Translational Medicine, University of Brescia, Brescia, Italy.'}]",,,,"Copyright © 2020 Dattilo, Amato, Perrotti and Gennarelli.","10.3389/fgene.2020.00826
10.1016/j.jpsychores.2015.04.008
10.18632/oncotarget.22500
10.1186/1756-9966-31-4
10.1002/jcp.28816
10.1016/j.lfs.2014.02.014
10.1007/s00109-009-0525-5
10.1007/s00109-007-0205-2
10.1038/onc.2012.470
10.3389/fnbeh.2018.00141
10.1038/npp.2012.253
10.1073/pnas.1300886110
10.1016/j.psyneuen.2010.03.007
10.1001/jamapsychiatry.2013.1111
10.1016/j.bbi.2017.08.001
10.1016/S0889-1591(02)00021-1
10.1016/j.ajp.2014.09.001
10.1080/15592294.2015.1017199
10.1007/s00424-008-0483-8
10.1016/j.febslet.2005.10.040
10.1038/npp.2009.75
10.1038/cddis.2010.60
10.1038/mp.2010.38
10.7759/cureus.5189
10.3109/08977194.2010.518616
10.1038/nature14659
10.1007/s12264-014-1486-4
10.1097/01.yco.0000194371.47685.f2
10.1007/s00018-013-1283-7
10.1002/dneu.20758
10.1016/j.ejmech.2019.111675
10.1159/000480328
10.2174/1381612823666170111141915
10.1186/s13041-017-0295-x
10.1073/pnas.96.5.2514
10.1038/mp.2014.136
10.1002/wps.20128
10.3390/molecules15042814
10.1159/000358636
10.1016/j.biopsych.2019.10.015
10.1016/j.tranon.2019.05.008
10.3390/molecules24183396
10.1038/srep45361
10.1210/edrv.19.3.0331
10.1126/scisignal.aaj1549
10.1016/j.biopsych.2018.12.014
10.1016/j.steroids.2019.05.011
10.1016/j.biopsych.2009.09.033
10.1038/nm.4050
10.1098/rstb.2011.0357
10.1016/j.biopsych.2006.02.013
10.1016/j.neulet.2010.02.063
10.1016/j.bbi.2019.06.015
10.1152/ajpcell.00408.2001
10.1186/s12864-016-2713-3
10.1038/nrn4023
10.1016/j.neuron.2014.01.027
10.1093/emboj/cdf551
10.1042/BJ20081668
10.1126/science.1252304
10.1016/j.biopsych.2017.09.023
10.1016/j.psyneuen.2015.06.015
10.1016/j.bbi.2015.06.001
10.1016/j.pharmthera.2014.10.002
10.3389/fgene.2019.00921
10.1111/j.1460-9568.2005.03951.x
10.1172/JCI81151
10.1371/journal.pone.0175075
10.1038/nn.4113
10.1016/j.molcel.2008.04.027
10.1038/s41593-018-0326-7
10.1371/journal.pone.0020198
10.1371/journal.pone.0118530
10.1038/ng.3623
10.1016/j.bbrc.2016.07.094
10.1016/S0140-6736(18)32279-7
10.1038/mp.2015.57
10.1016/j.celrep.2016.06.101
10.3389/fneur.2019.00515
10.1080/15548627.2019.1630222
10.2741/e195
10.1016/j.pnpbp.2007.09.008
10.1016/j.molbrainres.2004.12.020
10.1038/mp.2016.120
10.1007/978-1-4614-6434-1_174-1
10.1001/jamapsychiatry.2014.1332
10.3389/fphys.2015.00230
10.1038/nature11868
10.1042/0264-6021:3440189
10.1001/jamapsychiatry.2014.1611
10.1371/journal.pone.0127643
10.1080/14656566.2019.1683161
10.1016/j.kjms.2018.02.004
10.1016/j.febslet.2011.09.010
10.1097/MNH.0b013e32832f125e
10.1152/physrev.00050.2005
10.1517/13543770903365209
10.1096/fj.12-218230
10.1113/jphysiol.2010.190926
10.1517/13543784.2013.778971
10.1055/s-0031-1273425
10.1007/s00213-018-4950-4
10.1017/S0033291715002743
10.1016/j.neuroscience.2015.10.023
10.1371/journal.pbio.1002282
10.1016/j.fct.2010.06.020
10.3389/fncel.2017.00305
10.1155/2017/6871089
10.1016/j.pbb.2006.11.005
10.1186/s12974-019-1475-7
10.1016/j.brainres.2019.146392
10.1371/journal.pgen.1000489
10.1007/s00401-013-1223-5
10.1016/j.neuropharm.2010.01.012
10.1038/s41467-018-08154-1
10.1101/lm.179206
10.1017/S1092852915000449
10.1186/s13046-019-1212-1
10.1097/WNR.0000000000001180
10.1152/ajpcell.00284.2004
10.1371/journal.pone.0019859
10.1016/j.bbrc.2015.05.109
10.1038/mp.2010.98
10.1016/S0165-0327(02)00353-1
10.3390/molecules23092197
10.1016/j.semcdb.2003.12.022
10.1007/s00213-016-4357-z
10.1007/s11011-008-9114-5
10.1007/s00702-017-1709-8
10.1002/iub.209
10.1192/bjp.bp.115.180752
10.2174/157015911798376262
10.1016/j.bbrc.2006.03.196
10.1016/j.neuroscience.2012.09.073
10.1073/pnas.0800888106
10.3389/fpsyt.2014.00136
10.4103/1673-5374.211174
10.1038/ng.3552
10.1038/nrdp.2016.65
10.1016/j.pbb.2007.04.009
10.1016/j.psyneuen.2009.06.020
10.1248/bpb.29.2399
10.1016/j.jpsychires.2014.01.021
10.1503/jpn.170192
10.1016/j.euroneuro.2017.04.001
10.1176/appi.focus.20180030
10.3389/fncel.2018.00399
10.3389/fpsyt.2019.00423
10.1074/jbc.M007052200
10.1007/s11033-019-05129-3
10.1016/j.jad.2014.11.044
10.1007/400_2007_032
10.1093/cercor/bht203
10.3892/etm.2019.7633
10.1159/000374013
10.1016/j.neuropharm.2016.03.022
10.1038/sj.mp.4001791
10.1177/0269881107081521
10.1073/pnas.1102821108
10.1210/en.2009-1119
10.1111/j.1471-4159.2008.05489.x
10.1016/j.phymed.2012.03.012
10.1159/000366311
10.1097/FBP.0b013e3282ee2aa8
10.1038/npp.2011.151
10.1159/000113757
10.3389/fpsyt.2018.00334
10.1155/2017/1401790
10.4049/jimmunol.0803017
10.1042/BJ20130342
10.1093/ibd/izy158
10.1016/j.ygyno.2015.06.033
10.1074/jbc.M805055200
10.18632/oncotarget.5527
10.18632/oncotarget.7520
10.1159/000447885
10.4172/2167-1044.1000150
10.1159/000430380
10.3389/fnins.2019.01393
10.3892/ijmm.2016.2591
10.1038/s41588-018-0090-3
10.1038/nature11984
10.1016/j.neuint.2012.09.016
10.1172/JCI15696
10.1016/j.gene.2015.10.072
10.1248/bpb.34.253
10.1177/0269881118758304
10.1371/journal.pone.0080268
10.1038/srep30951
10.1159/000363000
10.1016/j.lfs.2004.04.014
10.1016/j.mehy.2015.10.012
10.1126/science.aaa5619
10.1016/j.pnpbp.2010.04.011",<Element 'PubmedArticle' at 0x7f05deb41ef0>
196,32810514,"Naringin attenuates Bisphenol-A mediated neurotoxicity in hypertensive rats by abrogation of cerebral nucleotide depletion, oxidative damage and neuroinflammation.","We examined whether active fruit naringin can reduce the risk of BPA-mediated neurotoxicity in L-NAME induced hypertensive rats and whether the modulation could be linked to improvement of brain NO signaling. Male albino rats were randomly distributed into eight (n = 7) groups. Group I was control animals, Group II was orally-treated with L-NAME, Group III was orally treated with 100 mg/kg BPA, Group IV was orally-treated with L-NAME +100 mg/kg BPA. Group V was orally-administered with L-NAME +80 mg/kg NAR. Group VI was orally-administered with 100 mg/kg BPA +80 mg/kg NAR. Group VII was orally-administered with L-NAME+100 mg/kg BPA +80 mg/kg NAR. Lastly, group VIII was orally-treated with 80 mg/kg NAR. The treatment lasted for 14 days. Sub-acute exposure to L-NAME and BPA induced hypertension and mediated-neuroinflammation at CA-2 and CA-4 of hippocampus cells. It was evident by increase in PDE-5","['ATP hydrolysis', 'Apoptosis', 'Bisphenol-A', 'L-NAME', 'Naringin', 'neuro-inflammation']",Neurotoxicology,2020-08-19,"[{'lastname': 'Akintunde', 'firstname': 'J K', 'initials': 'JK', 'affiliation': 'Applied Biochemistry and Molecular Toxicology Research Group, Department of Biochemistry, College of Biosciences, Federal University of Agriculture, Abeokuta, Nigeria. Electronic address: akintundejacob@yahoo.com.'}, {'lastname': 'Akintola', 'firstname': 'T E', 'initials': 'TE', 'affiliation': 'Applied Biochemistry and Molecular Toxicology Research Group, Department of Biochemistry, College of Biosciences, Federal University of Agriculture, Abeokuta, Nigeria.'}, {'lastname': 'Adenuga', 'firstname': 'G O', 'initials': 'GO', 'affiliation': 'Applied Biochemistry and Molecular Toxicology Research Group, Department of Biochemistry, College of Biosciences, Federal University of Agriculture, Abeokuta, Nigeria.'}, {'lastname': 'Odugbemi', 'firstname': 'Z A', 'initials': 'ZA', 'affiliation': 'Applied Biochemistry and Molecular Toxicology Research Group, Department of Biochemistry, College of Biosciences, Federal University of Agriculture, Abeokuta, Nigeria; Department of Physiology and Biochemistry, College of Veterinary Medicine, Federal University of Agriculture, Abeokuta, Nigeria.'}, {'lastname': 'Adetoye', 'firstname': 'R O', 'initials': 'RO', 'affiliation': 'Applied Biochemistry and Molecular Toxicology Research Group, Department of Biochemistry, College of Biosciences, Federal University of Agriculture, Abeokuta, Nigeria.'}, {'lastname': 'Akintunde', 'firstname': 'O G', 'initials': 'OG', 'affiliation': 'Department of Physiology and Biochemistry, College of Veterinary Medicine, Federal University of Agriculture, Abeokuta, Nigeria.'}]",,,,Copyright © 2020 Elsevier B.V. All rights reserved.,10.1016/j.neuro.2020.08.001,<Element 'PubmedArticle' at 0x7f05dea76360>
197,32798553,Behavioural and molecular effects of cannabidiolic acid in mice.,"Cannabidiolic acid (CBDA) is one of the most abundant phytocannabinoid acids in the Cannabis sativa plant. It has been shown that it is able to exert some therapeutic effects such as antiemetic, anti-inflammatory, anxiolytic or antidepressant, although some of them remain under debate. In the present study we aim to assess the potential behavioural effects of CBDA as well as its modulation of neuroinflammatory markers in the prefrontal cortex (PFC).
The effects of acute and repeated CBDA (0.001-1 mg/kg i.p.) treatments were evaluated on cognitive, emotional, motivational and nociceptive behaviours in male CD1 mice. For this, Y-maze and elevated plus maze paradigms, spontaneous locomotor activity, social interaction, hot-plate, formalin and tail suspension tests were used. We also studied the effects of CBDA on the rewarding responses of cocaine in the conditioned place preference (CPP) paradigm. Finally, PFC was dissected after acute and repeated CBDA treatments to evaluate inflammatory markers.
Acute CBDA treatment induced antinociceptive responses in the hot-plate test. A 10-day CBDA treatment reduced despair-like behaviour in the tail suspension test. CBDA did not alter the results of the remaining behavioural tests assayed, including cocaine-induced reward in the CPP. Regarding the biochemical analysis, repeated CBDA treatment diminished the level of peroxisome proliferator-activated receptor gamma (PPAR-γ) and increased that of interleukin-6 (IL-6) protein in PFC.
These results show that CBDA has limited in vivo effects on the modulation of mice behaviour, supporting the current skepticism regarding its therapeutic potential.","['Cannabidiolic acid', 'Cocaine', 'Despair-like behaviour', 'Neuroinflammation', 'Nociception']",Life sciences,2020-08-18,"[{'lastname': 'Alegre-Zurano', 'firstname': 'Laia', 'initials': 'L', 'affiliation': 'Neurobiology of Behaviour Research Group (GReNeC-NeuroBio), Department of Experimental and Health Sciences, Universitat Pompeu Fabra, Barcelona, Spain.'}, {'lastname': 'Martín-Sánchez', 'firstname': 'Ana', 'initials': 'A', 'affiliation': 'Neurobiology of Behaviour Research Group (GReNeC-NeuroBio), Department of Experimental and Health Sciences, Universitat Pompeu Fabra, Barcelona, Spain; Neuroscience Research Programme, IMIM-Hospital del Mar Research Institute, Barcelona, Spain.'}, {'lastname': 'Valverde', 'firstname': 'Olga', 'initials': 'O', 'affiliation': 'Neurobiology of Behaviour Research Group (GReNeC-NeuroBio), Department of Experimental and Health Sciences, Universitat Pompeu Fabra, Barcelona, Spain; Neuroscience Research Programme, IMIM-Hospital del Mar Research Institute, Barcelona, Spain. Electronic address: olga.valverde@upf.edu.'}]",,,,Copyright © 2020 Elsevier Inc. All rights reserved.,10.1016/j.lfs.2020.118271,<Element 'PubmedArticle' at 0x7f05dea89720>
198,32784004,Sodium orthovanadate improves learning and memory in intracerebroventricular-streptozotocin rat model of Alzheimer's disease through modulation of brain insulin resistance induced tau pathology.,"Sporadic Alzheimer's disease (sAD) is the most common type of dementia and progressive neurodegenerative disease. To establish the sAD model, intracerebroventricular (ICV) streptozotocin (STZ) at a dose of 3 mg/kg was administered bilaterally in rats on a stereotaxic apparatus. Behavioral tests such as Morris water maze (MWM), novel object recognition (NOR) and open field test were performed to evaluate cognitive and locomotor functions. Two treatment doses (5 mg/kg and 10 mg/kg) of sodium orthovanadate (SOV) and rivastigmine (2 mg/kg) were given orally to ICV-STZ induced rats for 21 days. Cortical and hippocampal tissues were dissected. Estimation of oxidative stress, mitochondrial dysfunction as complex I, II, III, IV activity, cholinergic function as acetylcholinesterase activity, ELISA for phosphorylated tau protein and insulin degrading enzyme (IDE), neuroinflammation as NF-κB gene expression and insulin signaling functioning as Q-RT-PCR for IR, IRS-1, PI3K, AKT, GSK-3β gene expression were performed. Behavioral results with SOV and rivastigmine treatment revealed decreased escape latency and increased discrimination index in MWM and NOR respectively. Treatment results with SOV also demonstrated attenuation of oxidative imbalance, improved mitochondrial activity, and reversed IDE and tau pathology. SOV treatment upregulated gene expression of IR, IRS-1, PI3K, and AKT, and downregulated that of GSK-3β. SOV results were compared with standard drug rivastigmine. Conclusively, the memory enhancement by SOV was mediated through oxidative balance, mitochondrial enzyme complex activation, and improved insulin signaling regulation. However, the primary mechanism of SOV remained attenuation of tau pathology by the upregulation of IRS-1/PI3K/AKT/GSK-3β pathway and reversal of insulin resistance in terms of IDE. Hence, in sAD paradigm, SOV contributed to memory improvement evident with the findings of behavioral studies, which can further potentially have clinical significance in AD.","['Alzheimer’s disease', 'ICV-STZ', 'Insulin resistance', 'Mitochondrial dysfunction', 'Oxidative stress', 'Sodium orthovanadate']",Brain research bulletin,2020-08-14,"[{'lastname': 'Akhtar', 'firstname': 'Ansab', 'initials': 'A', 'affiliation': 'Pharmacology Division, University Institute of Pharmaceutical Sciences, Panjab University, Chandigarh 160014, India.'}, {'lastname': 'Bishnoi', 'firstname': 'Mahendra', 'initials': 'M', 'affiliation': 'National Agri-Food Biotechnology Institute (NABI), Sector-81, SAS Nagar, Mohali 140306, Punjab, India.'}, {'lastname': 'Sah', 'firstname': 'Sangeeta Pilkhwal', 'initials': 'SP', 'affiliation': 'Pharmacology Division, University Institute of Pharmaceutical Sciences, Panjab University, Chandigarh 160014, India. Electronic address: spilkhwal@rediffmail.com.'}]",,,,Copyright © 2020 Elsevier Inc. All rights reserved.,10.1016/j.brainresbull.2020.08.001,<Element 'PubmedArticle' at 0x7f05dea954f0>
199,"32772307
27152411
26692007
26184078
26893170
25611054
32314850
10982334
20178748
27513702
8988899
29701146
16217132
32720486
32007143
33551947
32171193
32251729
25281913
9091795
15141376
10969042
16527442
26310920
32615182
26359987
32328364
30670284
27496941
32295727
15688296
15649582
32142785
32109013
26008214
32294339
32142651
25926900
31986264
20070490
32325383
32385132
31887664
32238438
15582288
16007097
18070603
15030709
20544829
26486634
32104915
32079150
32291797
26514204
31697951
28596733
10792199
30254716
32165426
32275288
32192578
8283386
27503577
32251791
32246784
28478550
21480979
22656125
32690910
30088946
18763235
32314810
24350834
32228363
15230868
32199615
32307298
28065781
19876062
7285872
32024428
24553808
32274570
14675124
22252235
32125452
11068941
32347747
30756405
24090288
22245784
15816940
27590243
21358966
25262626
30962427
31247931
18594966
24920061
31996437
32031570
0
0
20424953
32142773
32094336
16163626
32009228
30349079
32283294
26514093
32600350
32217117
32246917
32015507
32194980
32170560",Coronavirus Disease 2019 (COVID-19) and Its Neuroinvasive Capacity: Is It Time for Melatonin?,"The world faces an exceptional new public health concern caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), subsequently termed the coronavirus disease 2019 (COVID-19) by the World Health Organization (WHO). Although the clinical symptoms mostly have been characterized, the scientific community still doesn´t know how SARS-CoV-2 successfully reaches and spreads throughout the central nervous system (CNS) inducing brain damage. The recent detection of SARS-CoV-2 in the cerebrospinal fluid (CSF) and in frontal lobe sections from postmortem examination has confirmed the presence of the virus in neural tissue. This finding reveals a new direction in the search for a neurotherapeutic strategy in the COVID-19 patients with underlying diseases. Here, we discuss the COVID-19 outbreak in a neuroinvasiveness context and suggest the therapeutic use of high doses of melatonin, which may favorably modulate the immune response and neuroinflammation caused by SARS-CoV-2. However, clinical trials elucidating the efficacy of melatonin in the prevention and clinical management in the COVID-19 patients should be actively encouraged.","['COVID-19', 'Central nervous system', 'Melatonin', 'Neuroinvasion', 'Neuroprotection', 'SARS-CoV-2']",Cellular and molecular neurobiology,2020-08-11,"[{'lastname': 'Romero', 'firstname': 'Alejandro', 'initials': 'A', 'affiliation': 'Department of Pharmacology and Toxicology, Faculty of Veterinary Medicine, Complutense University of Madrid, Avda. Puerta de Hierro s/n, 28040, Madrid, Spain. manarome@ucm.es.'}, {'lastname': 'Ramos', 'firstname': 'Eva', 'initials': 'E', 'affiliation': 'Department of Pharmacology and Toxicology, Faculty of Veterinary Medicine, Complutense University of Madrid, Avda. Puerta de Hierro s/n, 28040, Madrid, Spain.'}, {'lastname': 'López-Muñoz', 'firstname': 'Francisco', 'initials': 'F', 'affiliation': 'Faculty of Health Sciences, University Camilo José Cela, C/ Castillo de Alarcón 49, 28692, Villanueva de la Cañada, Madrid, Spain.\nNeuropsychopharmacology Unit, Hospital 12 de Octubre Research Institute (i+12), Avda. Córdoba, s/n, 28041, Madrid, Spain.\nPortucalense Institute of Neuropsychology and Cognitive and Behavioural Neurosciences (INPP), Portucalense University, R. Dr. António Bernardino de Almeida 541, 4200-072, Porto, Portugal.\nThematic Network for Cooperative Health Research (RETICS), Addictive Disorders Network, Health Institute Carlos III, MICINN and FEDER, Madrid, Spain.'}, {'lastname': 'Gil-Martín', 'firstname': 'Emilio', 'initials': 'E', 'affiliation': 'Nutrition and Food Science Group, Department of Biochemistry, Genetics and Immunology, Faculty of Biology, University of Vigo, 36310, Vigo, Spain.'}, {'lastname': 'Escames', 'firstname': 'Germaine', 'initials': 'G', 'affiliation': 'Biomedical Research Center, Health Sciences Technology Park, University of Granada, 18016, Granada, Spain.\nDepartment of Physiology, University of Granada, 18016, Granada, Spain.\nCentro de Investigación Biomédica en Red de Fragilidad y Envejecimiento Saludable, Instituto de Investigación Biosanitaria CIBERFES, IBS. Granada, Granada Hospital Complex, 18016, Granada, Spain.'}, {'lastname': 'Reiter', 'firstname': 'Russel J', 'initials': 'RJ', 'affiliation': 'Department of Cellular and Structural Biology, University of Texas Health Science at San Antonio, San Antonio, TX, 78229, USA.'}]",,,,"© 2020. Springer Science+Business Media, LLC, part of Springer Nature.","10.1007/s10571-020-00938-8
10.1371/journal.pone.0154427
10.1007/s40261-015-0368-5
10.1002/jcph.592
10.1186/s40360-016-0052-2
10.1002/jmv.24130
10.1002/rmv.2109
10.1128/jvi.74.19.8913-8921.2000
10.1016/j.cell.2010.01.024
10.1002/14651858.CD006967.pub4
10.1056/NEJM199701163360306
10.2174/1381612824666180426112832
10.1385/ENDO:27:2:189
10.32388/FXGQSB
10.1016/S0140-6736(20)30211-7
10.1101/2020.04.07.030650
10.23812/CONTI-E
10.1016/j.hjc.2020.03.002
10.1016/j.virusres.2014.09.011
10.1056/NEJM199704033361418
10.1002/path.1560
10.32794/mr11250065
10.1161/01.res.87.5.e1
10.1016/j.biopha.2006.01.002
10.2174/0929867322666150827093730
10.1016/j.ejphar.2020.173329
10.1016/j.cell.2015.08.025
10.7759/cureus.7352
10.1016/j.ctim.2018.11.003
10.1093/ageing/afw123
10.1016/j.acra.2020.04.002
10.1086/427816
10.1016/j.pneurobio.2004.09.006
10.1053/j.gastro.2020.02.054
10.1056/NEJMoa2002032
10.1007/s00228-015-1873-4
10.1056/NEJMc2008597
10.1016/j.cell.2020.02.052
10.2174/1874364101509010028
10.1016/S0140-6736(20)30183-5
10.1111/j.1600-079X.2009.00733.x
10.1016/j.psychres.2020.112954
10.1136/svn-2020-000382
10.1016/j.isci.2019.100765
10.1124/molpharm.120.000014
10.1016/j.exger.2004.04.012
10.5812/ircmj.102828
10.1038/nm1267
10.1016/j.febslet.2007.11.085
10.1101/2020.04.06.027318
10.3201/eid1002.030638
10.1002/jnr.22430
10.1093/infdis/jiv499
10.1002/jmv.25728
10.3390/jcm9020538
10.1002/mds.28084
10.1146/annurev-pharmtox-010814-124742
10.1016/j.lfs.2019.117036
10.3389/fnagi.2017.00165
10.1046/j.1365-2125.2000.00195.x
10.1155/2018/9286458
10.1136/bmj.m1036
10.1001/jamaneurol.2020.1127
10.1016/S0140-6736(20)30628-0
10.1111/j.1600-079x.1993.tb00511.x
10.1177/2040206616660851
10.1016/j.ijid.2020.03.062
10.1002/jmv.25826
10.1007/s00429-017-1439-6
10.1111/j.1600-079X.2011.00854.x
10.3109/10715762.2012.697626
10.1038/s41569-020-0413-9
10.1152/ajpregu.00099.2018
10.1002/hup.980
10.1002/jmv.25915
10.1111/jpi.12113
10.32794/mr11250049
10.1148/radiol.2020201187
10.1111/j.1600-079X.2004.00135.x
10.1016/j.bbrc.2020.03.044
10.1016/j.jocn.2020.04.054
10.1016/j.freeradbiomed.2017.01.005
10.1038/hr.2009.174
10.1210/endo-109-4-1295
10.32794/mr11250047
10.1152/physiol.00034.2019
10.1007/s00429-014-0719-7
10.1007/s00395-020-0791-5
10.1046/j.1600-079x.2003.00092.x
10.1038/jcbfm.2011.197
10.1007/s00134-020-05991-x
10.1034/j.1600-0633.2002.290401.x
10.1080/08830185.2020.1756284
10.1111/nyas.14005
10.1186/1824-7288-39-61
10.1016/j.mce.2012.01.004
10.1111/j.0013-9580.2005.30204.x
10.1007/s11010-016-2808-9
10.32794/mr11250052
10.2174/157015910792246263
10.1111/jpi.12186
10.32794/mr11250011
10.1038/s41419-019-1556-7
10.3390/antiox8070198
10.1007/s11064-008-9766-x
10.1007/s00018-014-1659-3
10.1128/JVI.00127-20
10.1001/jama.2020.1585
10.1101/2020.03.14.988345
10.21203/rs.3.rs-22850/v1
10.1007/s11906-010-0105-7
10.1053/j.gastro.2020.02.055
10.1038/s41368-020-0074-x
10.1086/444461
10.1007/s11427-020-1637-5
10.1038/s41598-018-34011-8
10.1016/j.bbi.2020.04.017
10.1055/s-0035-1565083
10.1186/s13000-020-00994-0
10.1016/j.lfs.2020.117583
10.1016/S1474-4422(20)30109-5
10.1038/s41586-020-2012-7
10.1038/s41421-020-0153-3
10.1007/s11684-020-0754-0",<Element 'PubmedArticle' at 0x7f05deaa2bd0>
200,"32727084
32150953
29077871
24500412
31871494
28432601
26944242
22550578
28205574
16632328
12850213
23711480
29032407
28375916
30690165
17237663
25142459
19723945
32485058
29930500
23794642
16478686
24948120
29462012
30571942
29913939
22176142
23758741
32219147
31077796
23547920
31029798
31787711
29416128
26813032
24047529
15895084
19766105
28154473
21783017
18504511
28746078
24847207
21466443
30878800
32407956
28275350
27504140
15041446
25245374
21242699
21788310
23364963
22019843
27573801
32150935
30686732
27811267
24032675
18220622
29447138
27377722
22745251
25663667
17122042
25339862
31015277
23997430
27916979
31079836
21194394
20650402
24899808
23474509
10870748
25575710
29178034
27401055
30637713
23642658
20818832
27411937
18072813
20194146
27822619
29431402
24941666
26892406
25568646
26744882
19577851
21156893
30522140
26471248
27935242
28631063
27329171
7505999
19413995
23394523
21601562
26055231
22697514
23000428
29879374
27599446
25164769
24952959
13539486
31396087
8931279
31514292
12505702
32560159
27220803
28265364
27539936
30288203
20096327
14634025
20736084
15465922
17876302
22178921
18695637
11485574
11463796
15000462
26844976
27402190
29552727
22469754
25934566
28611664
31950563
31569558
29656363
31244434
28634464
28610993
25981305
28676456
27790149
30668378
28768536
25548106
30687006
11700558
25997585
28254531
25314940
16099397
17449181
26272430
18429935
17631786
23181761
15723097
25205418
27625036
29800607
26639824
30190675
31853615
27955699
32660140
30653511
31779692
30255058
12052036
28214084
24861964
29740093
24686507
21679434
27245980
29615912
15140616
18602217
23394519
14527707
17011598
26260027
23796633
30266286
30217164
32429243
30949911
1464245
32190420
31290436
24615439
31344333
15910891
26039098
24728618
32471028
14523789
27608657
25794224
32649294
24519701
30121836
32174618
29684510
17084977
26785976
30044864
16046173
28299455
24771836
29754321
32675390
31788391
24645812
25806902
29364513
21483401
29676237
16188428
24178954
22845893
22084787
22229320
24804094
24967102
29258432
30827269
22811766
26815246",ALIAmides Update: Palmitoylethanolamide and Its Formulations on Management of Peripheral Neuropathic Pain.,"Neuropathic pain results from lesions or diseases of the somatosensory nervous system and it remains largely difficult to treat. Peripheral neuropathic pain originates from injury to the peripheral nervous system (PNS) and manifests as a series of symptoms and complications, including allodynia and hyperalgesia. The aim of this review is to discuss a novel approach on neuropathic pain management, which is based on the knowledge of processes that underlie the development of peripheral neuropathic pain; in particular highlights the role of glia and mast cells in pain and neuroinflammation. ALIAmides (autacoid local injury antagonist amides) represent a group of endogenous bioactive lipids, including palmitoylethanolamide (PEA), which play a central role in numerous biological processes, including pain, inflammation, and lipid metabolism. These compounds are emerging thanks to their anti-inflammatory and anti-hyperalgesic effects, due to the down-regulation of activation of mast cells. Collectively, preclinical and clinical studies support the idea that ALIAmides merit further consideration as therapeutic approach for controlling inflammatory responses, pain, and related peripheral neuropathic pain.","['ALIAmides', 'neuroinflammation', 'palmitoylethanolamide', 'peripheral neuropathic pain']",International journal of molecular sciences,2020-07-31,"[{'lastname': ""D'Amico"", 'firstname': 'Ramona', 'initials': 'R', 'affiliation': ""Department of Chemical, Biological, Pharmaceutical and Environmental Sciences, University of Messina, Viale Ferdinando Stagno D'Alcontres 31, 98166 Messina, Italy.""}, {'lastname': 'Impellizzeri', 'firstname': 'Daniela', 'initials': 'D', 'affiliation': ""Department of Chemical, Biological, Pharmaceutical and Environmental Sciences, University of Messina, Viale Ferdinando Stagno D'Alcontres 31, 98166 Messina, Italy.""}, {'lastname': 'Cuzzocrea', 'firstname': 'Salvatore', 'initials': 'S', 'affiliation': ""Department of Chemical, Biological, Pharmaceutical and Environmental Sciences, University of Messina, Viale Ferdinando Stagno D'Alcontres 31, 98166 Messina, Italy.\nDepartment of Pharmacological and Physiological Science, Saint Louis University School of Medicine, 1402 South Grand Blvd, St Louis, MO 63104, USA.""}, {'lastname': 'Di Paola', 'firstname': 'Rosanna', 'initials': 'R', 'affiliation': ""Department of Chemical, Biological, Pharmaceutical and Environmental Sciences, University of Messina, Viale Ferdinando Stagno D'Alcontres 31, 98166 Messina, Italy.""}]",,,,,"10.3390/ijms21155330
10.3390/molecules25051171
10.1093/pm/pnx108
10.1136/bmj.f7656
10.1155/2019/8685954
10.1007/s11916-017-0629-5
10.1016/j.mayocp.2016.01.017
10.1155/2012/348043
10.1038/nrdp.2017.2
10.1016/j.jpain.2006.01.444
10.1016/S0959-4388(03)00074-6
10.1016/j.pain.2013.05.037
10.1007/s00415-017-8641-6
10.1212/CON.0000000000000462
10.1016/j.jpain.2019.01.009
10.1097/01.ajp.0000210956.31997.89
10.1016/S1474-4422(14)70102-4
10.14219/jada.archive.2009.0339
10.1111/jcmm.15427
10.3389/fncel.2018.00158
10.1093/bja/aet128
10.1016/S1359-6446(05)03637-8
10.1038/nrd4334
10.1097/ALN.0000000000002130
10.1016/j.neuron.2018.11.009
10.1016/j.sjpain.2010.01.007
10.1111/j.1529-8027.2011.00362.x
10.1111/imm.12134
10.1155/2020/9231452
10.1016/j.semcdb.2019.05.004
10.1186/1742-2094-10-43
10.1016/j.bbi.2019.04.037
10.1248/bpb.b19-00715
10.1038/nrn.2018.2
10.1111/jdi.12379
10.2174/18715273113126660168
10.1038/nn1472
10.1016/j.ejphar.2009.09.030
10.1155/2017/5048616
10.1016/S0929-6646(11)60074-0
10.1017/S1740925X08000100
10.1097/j.pain.0000000000000982
10.3389/fncel.2014.00121
10.2174/138920111798357465
10.1016/j.coph.2019.02.001
10.1016/j.phrs.2020.104875
10.3389/fphar.2017.00048
10.1155/2016/6153215
10.1016/j.lfs.2004.01.007
10.2174/0929867321666140915143040
10.1159/000323141
10.1213/ANE.0b013e31822827a2
10.3349/ymj.2013.54.2.321
10.1016/j.pnpbp.2011.10.007
10.2174/1871527315666160829105533
10.3390/antiox9030216
10.1016/j.neuron.2019.01.012
10.1126/science.aaf8924
10.1111/imm.12170
10.2174/157339906776818569
10.1097/j.pain.0000000000001122
10.1098/rstb.2015.0428
10.1126/science.1222381
10.1101/cshperspect.a020370
10.1523/JNEUROSCI.2289-06.2006
10.3389/fnins.2014.00315
10.15252/emmm.201810248
10.1155/2013/480739
10.1038/nri.2016.123
10.1016/j.bja.2019.03.023
10.1185/03007995.2010.545813
10.1016/S1474-4422(10)70143-5
10.2147/NDT.S61492
10.1097/00002508-200006001-00017
10.1016/S1474-4422(14)70251-0
10.1007/s40122-017-0091-4
10.1016/j.neuroscience.2016.06.057
10.1007/s40273-018-00761-6
10.1016/j.tips.2013.04.001
10.2165/11536200-000000000-00000
10.1007/s00228-016-2092-3
10.2165/00023210-200822010-00003
10.4065/mcp.2009.0649
10.1007/s40122-016-0060-3
10.1002/14651858.CD007393.pub4
10.1007/978-3-0348-0828-6_4
10.1186/s12871-015-0150-5
10.11138/ccmbm/2014.11.3.165
10.1016/j.psyneuen.2009.06.004
10.1055/s-0038-1673679
10.1002/ejp.811
10.1111/aap.12051
10.1007/s40122-017-0075-4
10.1111/aap.12039
10.1007/BF01972748
10.1016/j.bcp.2009.04.024
10.2174/1871527311312010013
10.1016/j.bcp.2011.05.004
10.1007/s12035-015-9253-8
10.1016/j.bbalip.2012.08.019
10.1096/fj.201800107R
10.1016/j.bcp.2016.09.001
10.1186/s12974-014-0136-0
10.1016/j.drudis.2014.06.007
10.3389/fphar.2019.00821
10.1016/S0166-2236(96)10058-8
10.3390/nu11092175
10.1016/S0009-3084(02)00158-5
10.3390/vetsci7020078
10.1111/bcp.13020
10.1002/fsn3.392
10.1111/bph.13580
10.1186/s41232-018-0086-5
10.1016/j.biochi.2010.01.006
10.1074/jbc.M306642200
10.1016/j.bbalip.2010.08.010
10.1124/mol.104.006353
10.1038/sj.bjp.0707460
10.1016/j.ejphar.2011.11.034
10.1038/bjp.2008.324
10.1042/bj3580249
10.1074/jbc.M106261200
10.1081/PDT-120027417
10.1097/SHK.0000000000000578
10.1016/j.phrs.2016.07.010
10.1007/s12035-018-0959-2
10.1189/jlb.0911485
10.1016/j.ejphar.2015.04.025
10.3389/fphar.2017.00308
10.1096/fj.201901584RR
10.3390/ijms20194845
10.1007/s12035-018-1064-2
10.2174/1871527318666190617162041
10.3389/fneur.2017.00233
10.1016/j.taap.2017.06.005
10.1016/j.ejphar.2015.05.010
10.1016/j.phrs.2017.06.014
10.3389/fphar.2016.00382
10.1016/j.phymed.2018.09.191
10.1186/s12917-017-1151-z
10.1093/ijnp/pyu111
10.3389/fnmol.2018.00490
10.1038/35102582
10.1016/j.prostaglandins.2015.05.001
10.1016/j.physbeh.2017.02.034
10.1007/s11745-014-3960-1
10.1016/j.prostaglandins.2004.09.008
10.1016/j.pain.2007.03.008
10.1016/j.bbagen.2015.08.004
10.1111/j.1582-4934.2008.00353.x
10.1186/1746-6148-8-230
10.1038/sj.bjp.0706112
10.1111/bph.12907
10.1124/mol.116.105668
10.1016/j.phrs.2018.05.013
10.1016/j.tvjl.2015.10.060
10.3389/fphar.2018.00871
10.1007/s00210-019-01785-1
10.1186/s13075-016-1189-5
10.3390/antiox9070601
10.1371/journal.pone.0208730
10.1186/s13075-019-2048-y
10.1016/j.ijvsm.2017.09.006
10.1054/plef.2001.0358
10.1016/j.pathophys.2017.02.005
10.1016/j.maturitas.2014.04.015
10.1038/s41598-018-25581-8
10.1038/nrrheum.2014.47
10.1186/1471-2474-12-134
10.1186/s12974-016-0595-6
10.3389/fphar.2018.00249
10.1016/j.jns.2004.03.008
10.1016/j.pain.2008.06.003
10.2174/1871527311312010008
10.1016/S0304-3959(03)00261-6
10.1016/j.neuropharm.2006.08.011
10.1186/s13041-015-0139-5
10.1016/j.nlm.2013.06.008
10.1016/j.nbd.2018.09.023
10.1186/s12974-018-1303-5
10.3390/ijms21103509
10.1007/s12020-019-01917-w
10.2337/diacare.15.12.1902
10.1212/CPJ.0000000000000671
10.4103/1673-5374.259603
10.1093/ilar/ilt052
10.1096/fj.201900538R
10.1016/j.neuropharm.2005.01.001
10.1371/journal.pone.0128080
10.1007/s00520-014-2242-z
10.3390/cancers12061370
10.1016/S0093-7754(03)00399-3
10.1124/jpet.116.236182
10.1515/jbcpp-2019-0274
10.1177/0333102414521510
10.1007/s00011-018-1179-y
10.4103/aam.aam_23_19
10.1016/j.jpain.2018.03.018
10.1016/j.pain.2006.09.008
10.1186/s12974-015-0472-8
10.1371/journal.pone.0201501
10.1016/j.jbspin.2005.03.003
10.1007/s10195-017-0453-z
10.3399/bjgp14X679903
10.1007/s10787-018-0493-x
10.3233/BMR-201843
10.7759/cureus.5934
10.2217/pmt.12.5
10.2217/pmt.15.5
10.1002/jcph.1070
10.2174/1871527317666180420143830
10.1016/j.ijom.2005.07.010
10.1007/s10787-013-0191-7
10.1111/j.1526-4637.2012.01432.x
10.5402/2011/917350
10.2174/187152711799219307
10.1155/2014/849623
10.1155/2014/854560
10.1186/s12871-017-0461-9
10.2174/1871527318666190227205359
10.5001/omj.2012.44",<Element 'PubmedArticle' at 0x7f05de9f3810>
201,32653559,Prolactin treatment reduces kainic acid-induced gliosis in the hippocampus of ovariectomized female rats.,"Neuroinflammation involves a set of responses occurring as a result of brain damage including astro- and microgliosis. In previous studies, we showed that treatment with prolactin (PRL) decreased neuronal loss induced by kainic acid (KA) in the hippocampus of female rats. This effect correlated with a decrease in astrogliosis. Here, we investigate whether treatment with PRL decreases astro- and microgliosis in the dorsal hippocampus, and how it modulates the expression of some important inflammatory factors such as TNFα, iNOS, IL-6, IL-10 and IL-4 after an excitotoxic lesion. For this, ovariectomized female rats were treated chronically with PRL (0.1 mg / day for 4 days, SC). On the third day of treatment, they received a KA injection (7.5 mg / kg, IP) and were sacrificed 24 or 48 h later. Chronic treatment with PRL reduced the astro- and micro-gliosis in CA4, CA3, and CA1 hippocampal subfields induced by KA. Morphometric analysis in CA4 showed that PRL reduced microglial activation. The analysis for anti- and pro-inflammatory cytokines revealed an increase of IL-10 and IL-4 in neurons due to treatment with PRL, accompanied by a decrease in the expression of TNFα and iNOS in lesioned rats. These results indicate that PRL has anti-inflammatory actions in the hippocampus, both by decreasing the astrogliosis and microglial activation and by reducing the level of pro-inflammatory cytokines probably through the upregulation of neuronal IL-10 and IL-4.","['GFAP', 'IL10', 'IL4', 'Microglia', 'TNFα', 'iNOS']",Brain research,2020-07-13,"[{'lastname': 'Reyes-Mendoza', 'firstname': 'Julio', 'initials': 'J', 'affiliation': 'Departamento de Neurobiología Celular y Molecular, Instituto de Neurobiología, Universidad Nacional Autónoma de México, Querétaro, Qro. 76230, Mexico.'}, {'lastname': 'Morales', 'firstname': 'Teresa', 'initials': 'T', 'affiliation': 'Departamento de Neurobiología Celular y Molecular, Instituto de Neurobiología, Universidad Nacional Autónoma de México, Querétaro, Qro. 76230, Mexico. Electronic address: marter@unam.mx.'}]",,,,Copyright © 2020 Elsevier B.V. All rights reserved.,10.1016/j.brainres.2020.147014,<Element 'PubmedArticle' at 0x7f05de978270>
202,32651843,Phoenixin-20 Ameliorates Lipopolysaccharide-Induced Activation of Microglial NLRP3 Inflammasome.,"Injury associated with neuroinflammation has been linked with several kinds of neurodegenerative diseases. The activation of the NLRP3 inflammasome plays an important role in microglia-mediated inflammation. Phoenixin (PNX)-20 is a newly discovered neuropeptide with pleiotropic effects involved in the regulation of reproductive and cognitive function, depression, and food uptake. This study investigated whether PNX-20 possesses a protective effect against lipopolysaccharide (LPS)-induced activation of the NLRP3 inflammasome in microglia. Firstly, our results show that the PNX-20 treatment significantly prevented LPS-induced expression of NADPH oxidase 4 (NOX-4) and the generation of reactive oxygen species (ROS). Secondly, PNX-20 mitigated LPS-induced upregulation of TxNIP, an upstream regulator of NLRP3 inflammasome activation. Thirdly, further evaluation of the major components of the NLRP3 inflammasome revealed that PNX-20 inhibited LPS-mediated upregulation of NLRP3, ASC, and cleaved caspase-1 (P10). Notably, based on our results, the inhibitory effect of PNX-20 on the NLRP3 inflammasome results in the inhibition of IL-1β and IL-18 secretions. Finally, we found that PNX-20 ameliorated the reduction in SIRT1 expression induced by LPS. When microglial SIRT1 was inhibited by nicotine, PNX-20 lost its suppressive effect on the expression of NLRP3, ASC, and caspase-1, as well as the secretion of IL-1β and IL-18. As a result of these findings, we draw the conclusion that the neuroprotective effect of PNX-20 is dependent on SIRT1. Collectively, the study shows that PNX-20 has a regulatory effect via modulation of neuroinflammation.","['Microglia', 'NLRP3 inflammasome', 'Neuroinflammation', 'Phoenixin 20', 'SIRT1']",Neurotoxicity research,2020-07-12,"[{'lastname': 'Zeng', 'firstname': 'Xiangliang', 'initials': 'X', 'affiliation': 'Department of Neurology, First Affiliated Hospital, Hunan University of Medicine, Huaihua, No.225, Yushi Road, Hecheng District, Huaihua City, 418000, Hunan Province, China.'}, {'lastname': 'Li', 'firstname': 'Yanchun', 'initials': 'Y', 'affiliation': 'Department of Neurology, First Affiliated Hospital, Hunan University of Medicine, Huaihua, No.225, Yushi Road, Hecheng District, Huaihua City, 418000, Hunan Province, China. liyanchun026@163.com.'}, {'lastname': 'Ma', 'firstname': 'Sicong', 'initials': 'S', 'affiliation': 'Department of Neurology, First Affiliated Hospital, Hunan University of Medicine, Huaihua, No.225, Yushi Road, Hecheng District, Huaihua City, 418000, Hunan Province, China.'}, {'lastname': 'Tang', 'firstname': 'Yidan', 'initials': 'Y', 'affiliation': 'Department of Neurology, First Affiliated Hospital, Hunan University of Medicine, Huaihua, No.225, Yushi Road, Hecheng District, Huaihua City, 418000, Hunan Province, China.'}, {'lastname': 'Li', 'firstname': 'Hanwen', 'initials': 'H', 'affiliation': 'Department of Neurology, First Affiliated Hospital, Hunan University of Medicine, Huaihua, No.225, Yushi Road, Hecheng District, Huaihua City, 418000, Hunan Province, China.'}]",,,,,10.1007/s12640-020-00225-w,<Element 'PubmedArticle' at 0x7f05de983bd0>
203,32629237,N-3 PUFA improved pup separation-induced postpartum depression via serotonergic pathway regulated by miRNA.,"Stress and ovarian hormone fluctuation are risk factors for postpartum depression (PPD). Previous studies suggested antidepressant-like effects of n-3 polyunsaturated fatty acids (PUFA), but their effect on dam animal with additional stress were not clear. The purpose of the present study was to investigate the hypothesis that n-3 PUFA improved PPD through the serotonergic and glutamatergic pathways by modulating miRNA. Rats were fed n-3 PUFA or control diet from gestation, with pup separation (PS) on postpartum days 2-14 and non-PS controls. N-3 PUFA reversed PS-induced depressive behaviors, including increased immobility, latencies to contact first pup and retrieve all pups, and decreased sucrose preference. N-3 PUFA also modulated the hypothalamic-pituitary-adrenal (HPA) axis by decreasing circulating levels of adrenocorticotropic hormone and corticosterone and expression of hypothalamic corticotrophin releasing factor and hippocampal miRNA-218 but increasing the hippocampal expression of glucocorticoid receptor. N-3 PUFA inhibited neuroinflammation by decreasing circulating levels of prostaglandin E","['MiRNA', 'N-3 PUFA', 'NMDA receptor', 'Postpartum depression', 'Rats', 'Serotonin']",The Journal of nutritional biochemistry,2020-07-07,"[{'lastname': 'Choi', 'firstname': 'Jeong-Eun', 'initials': 'JE', 'affiliation': 'Department of Food and Nutrition, Hanyang University, 222 Wangsimni-ro, Seongdong-gu, Seoul, 04763, Republic of Korea.'}, {'lastname': 'Kim', 'firstname': 'Eun-Young', 'initials': 'EY', 'affiliation': 'Department of Food and Nutrition, Hanyang University, 222 Wangsimni-ro, Seongdong-gu, Seoul, 04763, Republic of Korea.'}, {'lastname': 'Park', 'firstname': 'Yongsoon', 'initials': 'Y', 'affiliation': 'Department of Food and Nutrition, Hanyang University, 222 Wangsimni-ro, Seongdong-gu, Seoul, 04763, Republic of Korea. Electronic address: yongsoon@hanyang.ac.kr.'}]",,,,Copyright © 2020 Elsevier Inc. All rights reserved.,10.1016/j.jnutbio.2020.108417,<Element 'PubmedArticle' at 0x7f05de990810>
204,32623398,"Effects of Palmitoylethanolamide Combined with Luteoline on Frontal Lobe Functions, High Frequency Oscillations, and GABAergic Transmission in Patients with Frontotemporal Dementia.","Frontotemporal dementia (FTD) is a presenile neurodegenerative disease for which there is no effective pharmacological treatment. Recently, a link has been proposed between neuroinflammation and FTD.
Here, we aim to investigate the effects of palmitoylethanolamide (PEA) combined with luteoline (PEA-LUT), an endocannabinoid with anti-inflammatory and neuroprotective effects, on behavior, cognition, and cortical activity in a sample of FTD patients.
Seventeen patients with a diagnosis of probable FTD were enrolled. Cognitive and neurophysiological evaluations were performed at baseline and after 4 weeks of PEA-LUT 700 mg×2/day. Cognitive effects were assessed by Neuropsychiatric Inventory (NPI), Mini-Mental State Examination, Frontal Assessment Battery (FAB), Screening for Aphasia in Neurodegeneration, Activities of Daily Living-Instrumental Activities of Daily Living, and Frontotemporal Lobar Degeneration-modified Clinical Dementia Rating scale. To investigate in vivo neurophysiological effects of PEA-LUT, we used repetitive and paired-pulse transcranial magnetic stimulation (TMS) protocols assessing LTP-like cortical plasticity, short-interval intracortical inhibition, long-interval intracortical inhibition (LICI), and short-latency afferent inhibition. Moreover, we used TMS combined with EEG to evaluate the effects on frontal lobe cortical oscillatory activity.
Treatment with PEA-LUT was associated with an improvement in NPI and FAB scores. Neurophysiological evaluation showed a restoration of LICI, in particular at ISI 100 ms, suggesting a modulation of GABA(B) activity. TMS-EEG showed a remarkable increase of TMS-evoked frontal lobe activity and of high-frequency oscillations in the beta/gamma range.
PEA-LUT could reduce behavioral disturbances and improve frontal lobe functions in FTD patients through the modulation of cortical oscillatory activity and GABA(B)ergic transmission.","['Brain inflammation', 'EEG', 'GABA activity', 'behavioral symptoms', 'executive functions', 'frontotemporal dementia', 'transcranial magnetic stimulation']",Journal of Alzheimer's disease : JAD,2020-07-06,"[{'lastname': 'Assogna', 'firstname': 'Martina', 'initials': 'M', 'affiliation': 'Santa Lucia Foundation, IRCCS, Rome, Italy.\nTor Vergata Policlinic, Rome, Italy.'}, {'lastname': 'Casula', 'firstname': 'Elias Paolo', 'initials': 'EP', 'affiliation': 'Santa Lucia Foundation, IRCCS, Rome, Italy.\nDepartment of Clinical and Movement Neurosciences, University College London, United Kingdom.'}, {'lastname': 'Borghi', 'firstname': 'Ilaria', 'initials': 'I', 'affiliation': 'Santa Lucia Foundation, IRCCS, Rome, Italy.'}, {'lastname': 'Bonnì', 'firstname': 'Sonia', 'initials': 'S', 'affiliation': 'Santa Lucia Foundation, IRCCS, Rome, Italy.'}, {'lastname': 'Samà', 'firstname': 'Domenico', 'initials': 'D', 'affiliation': 'Tor Vergata Policlinic, Rome, Italy.'}, {'lastname': 'Motta', 'firstname': 'Caterina', 'initials': 'C', 'affiliation': 'Santa Lucia Foundation, IRCCS, Rome, Italy.'}, {'lastname': 'Di Lorenzo', 'firstname': 'Francesco', 'initials': 'F', 'affiliation': 'Santa Lucia Foundation, IRCCS, Rome, Italy.'}, {'lastname': ""D'Acunto"", 'firstname': 'Alessia', 'initials': 'A', 'affiliation': 'Santa Lucia Foundation, IRCCS, Rome, Italy.'}, {'lastname': 'Porrazzini', 'firstname': 'Francesco', 'initials': 'F', 'affiliation': 'Santa Lucia Foundation, IRCCS, Rome, Italy.'}, {'lastname': 'Minei', 'firstname': 'Marilena', 'initials': 'M', 'affiliation': 'Santa Lucia Foundation, IRCCS, Rome, Italy.'}, {'lastname': 'Caltagirone', 'firstname': 'Carlo', 'initials': 'C', 'affiliation': 'Santa Lucia Foundation, IRCCS, Rome, Italy.'}, {'lastname': 'Martorana', 'firstname': 'Alessandro', 'initials': 'A', 'affiliation': 'Tor Vergata Policlinic, Rome, Italy.'}, {'lastname': 'Koch', 'firstname': 'Giacomo', 'initials': 'G', 'affiliation': 'Santa Lucia Foundation, IRCCS, Rome, Italy.\neCampus University, Novedrate, Italy.'}]",,PEA-LUT could reduce behavioral disturbances and improve frontal lobe functions in FTD patients through the modulation of cortical oscillatory activity and GABA(B)ergic transmission.,"Treatment with PEA-LUT was associated with an improvement in NPI and FAB scores. Neurophysiological evaluation showed a restoration of LICI, in particular at ISI 100 ms, suggesting a modulation of GABA(B) activity. TMS-EEG showed a remarkable increase of TMS-evoked frontal lobe activity and of high-frequency oscillations in the beta/gamma range.",,10.3233/JAD-200426,<Element 'PubmedArticle' at 0x7f05de999db0>
205,32592061,Filtered air intervention reduces inflammation and hypothalamus-pituitary-adrenal axis activation in adult male and female rats after PM 2.5 exposure.,"Previous studies have indicated that particulate matter 2.5 (PM2.5) exposure stimulates systemic inflammation and activates the hypothalamus-pituitary-adrenal (HPA) axis, both of which are associated with stroke incidence and mortality. However, whether filtered air (FA) intervention modulates inflammation and HPA axis activation is still largely unknown. For FA group and PM2.5 group, adult Sprague-Dawley male and female rats were exposed to FA or PM2.5 for 6 months, respectively. For PM2.5 + 15 days FA group, the rats were achieved by receiving 15 days FA after PM2.5 exposure for 6 months. The immune cells and inflammatory biomarker levels in the blood and brain were analyzed by flow cytometry, ELISA, and qRT-PCR. To assess HPA axis activation, the levels of hormones in the blood were also analyzed by ELISA. FA intervention increased the percentage of CD4 T cells and T cells in the blood, which had decreased after PM2.5 exposure in both male and female rats. The ELISA and qRT-PCR results showed that FA intervention significantly reduced the levels of inflammatory biomarkers in the peripheral blood, and alleviated neuroinflammation in the cortex, hippocampus, and striatum. In addition, FA intervention also inhibited the inflammation in the hypothalamus and pituitary and adrenal glands, and decreased the levels of HPA axis hormones. Our results indicate that FA intervention exerts a protective effect on the brain by decreasing inflammation and HPA axis activation after PM2.5 exposure in both male and female rats.","['Filtered air intervention', 'Hypothalamus–pituitary–adrenal axis', 'Inflammatory response', 'Neuroinflammation', 'Particulate matter']",Environmental science and pollution research international,2020-06-28,"[{'lastname': 'Liu', 'firstname': 'Cuiying', 'initials': 'C', 'affiliation': 'China-America Institute of Neuroscience, Beijing Luhe Hospital, Capital Medical University, Beijing, China. liucy@mail.ccmu.edu.cn.'}, {'lastname': 'Yang', 'firstname': 'Jian', 'initials': 'J', 'affiliation': 'China-America Institute of Neuroscience, Beijing Luhe Hospital, Capital Medical University, Beijing, China.'}, {'lastname': 'Guan', 'firstname': 'Longfei', 'initials': 'L', 'affiliation': 'China-America Institute of Neuroscience, Beijing Luhe Hospital, Capital Medical University, Beijing, China.'}, {'lastname': 'Zhu', 'firstname': 'Yuequan', 'initials': 'Y', 'affiliation': 'China-America Institute of Neuroscience, Beijing Luhe Hospital, Capital Medical University, Beijing, China.'}, {'lastname': 'Geng', 'firstname': 'Xiaokun', 'initials': 'X', 'affiliation': 'China-America Institute of Neuroscience, Beijing Luhe Hospital, Capital Medical University, Beijing, China. xgeng@ccmu.edu.cn.\nDepartment of Neurology, Beijing Luhe Hospital, Capital Medical University, Beijing, China. xgeng@ccmu.edu.cn.'}]",,,,,"10.1007/s11356-020-09564-9
10.1016/j.neuro.2012.02.016
10.1016/j.yfrne.2016.07.001
10.1016/j.tins.2009.05.009
10.1161/CIR.0b013e3181dbece1
10.1016/j.neurol.2015.10.008
10.1161/STROKEAHA.111.673442
10.1016/j.jacc.2015.03.553
10.1186/s12974-016-0743-z
10.1016/j.redox.2018.08.009
10.1080/15287390801997732
10.1161/STROKEAHA.116.014242
10.1002/jnr.23784
10.18632/oncotarget.23347
10.1016/j.toxlet.2013.07.012
10.1016/j.envint.2018.05.031
10.1539/joh.45.321
10.1186/1476-069X-12-116
10.1186/s12989-017-0215-3
10.1016/j.neuron.2013.04.005
10.5853/jos.2017.02894
10.1007/s11356-015-5222-z
10.1161/CIRCULATIONAHA.116.026796
10.1016/j.bbi.2014.05.015
10.1016/j.envint.2018.06.027
10.1161/CIRCRESAHA.116.309279
10.1016/j.ecoenv.2019.02.086
10.1001/jama.294.23.3003
10.1186/s12974-018-1178-5
10.1016/j.freeradbiomed.2016.08.021
10.1289/ehp.1307151
10.1007/s10753-018-0732-8",<Element 'PubmedArticle' at 0x7f05de9a9900>
206,"32572760
31478128
30693424
29480757
26493445
27910074
30834805
24089194
28099414
22553043
25884014
30277602
25112680
26219651
29305854
27703142
25550365
25367879
26111628
30710529
24203677
27027288
28636962
29135354
30461327
31250377
21068831
15846805
28816095
26984740
17090684
24161035
22744646
26518242
31242047
22679224
25743218
29546590
10422759
18957080
12024206
15976302
22960406
18064003
15548611
19607967
16113687
27140692
30391355
26477583
22431614
25542238
11359521
18421008
25831128
30659573
26573918
25190938
27637674",Roles of Prokineticin 2 in Subarachnoid Hemorrhage-Induced Early Brain Injury via Regulation of Phenotype Polarization in Astrocytes.,"Previous studies have postulated that neuroinflammation can induce two different types of reactive astrocytes, A1 and A2. A1 astrocytes may be harmful, whereas A2 astrocytes may be protective. Specifically, prokineticin 2 (PK2) has been shown to regulate neuron-astrocyte signaling mechanism by promoting an alternative A2-protective phenotype in astrocytes. This study aimed to examine the role of PK2 in early brain injury (EBI) caused by subarachnoid hemorrhage (SAH). SAH-induced astrocytic activation was confirmed by Western blotting. We confirmed C3 and PTX3 as appropriate reactivity markers for discriminating A1 and A2 astrocytes, respectively. We also observed SAH-induced astrocytic activation in SAH patients. The increase of PK2 in neurons after SAH in both humans and rats suggested a possible relationship between PK2 and SAH pathology. PK2 knockdown promoted an A1 astrocytic phenotype with upregulation of neurodegenerative indicators, while intravascular injection of recombinant PK2 (rPK2) promoted A2 astrocytic phenotype and reduced SAH-induced neuronal injury and behavioral dysfunction. Finally, we identified that tumor necrosis factor alpha (TNF-α) was sufficient to elevate the protein level of PK2 in neurons and enhance astrocytic activation in vitro. Moreover, rPK2 selectively promoted astrocytic polarization to an A2 phenotype under a TNF-α stimulus and induced phosphorylation of signal transducer and activator of transcription 3 (STAT3), suggesting that SAH-induced increases in PK2 may function as an endogenous mechanism for self-repair. Collectively, our findings support that enhancing PK2 expression or administration of rPK2 may induce a selective modulation of astrocytic polarization to a protective phenotype following SAH-like stimuli.","['Astrocytes', 'Early brain injury', 'Phenotype polarization', 'Prokineticin 2', 'Subarachnoid hemorrhage']",Molecular neurobiology,2020-06-24,"[{'lastname': 'Ma', 'firstname': 'Mian', 'initials': 'M', 'affiliation': 'Department of Neurosurgery & Brain and Nerve Research Laboratory, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu Province, China.\nDepartment of Neurosurgery, Suzhou Municipal Hospital, Suzhou, Jiangsu Province, China.'}, {'lastname': 'Li', 'firstname': 'Haiying', 'initials': 'H', 'affiliation': 'Department of Neurosurgery & Brain and Nerve Research Laboratory, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu Province, China.'}, {'lastname': 'Wu', 'firstname': 'Jiang', 'initials': 'J', 'affiliation': 'Department of Neurosurgery & Brain and Nerve Research Laboratory, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu Province, China.'}, {'lastname': 'Zhang', 'firstname': 'Yunhai', 'initials': 'Y', 'affiliation': 'Jiangsu Key Laboratory of Medical Optics, Suzhou Institute of Biomedical Engineering and Technology, Chinese Academy of Sciences, Suzhou, China.'}, {'lastname': 'Shen', 'firstname': 'Haitao', 'initials': 'H', 'affiliation': 'Department of Neurosurgery & Brain and Nerve Research Laboratory, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu Province, China.'}, {'lastname': 'Li', 'firstname': 'Xiang', 'initials': 'X', 'affiliation': 'Department of Neurosurgery & Brain and Nerve Research Laboratory, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu Province, China.'}, {'lastname': 'Wang', 'firstname': 'Zhong', 'initials': 'Z', 'affiliation': 'Department of Neurosurgery & Brain and Nerve Research Laboratory, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu Province, China. nju_neurosurgery@163.com.\nDepartment of Neurosurgery, The First Affiliated Hospital of Soochow University, 188 Shizi Street, Suzhou, 215006, China. nju_neurosurgery@163.com.'}, {'lastname': 'Chen', 'firstname': 'Gang', 'initials': 'G', 'affiliation': 'Department of Neurosurgery & Brain and Nerve Research Laboratory, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu Province, China. nju_neurosurgery@163.com.\nDepartment of Neurosurgery, The First Affiliated Hospital of Soochow University, 188 Shizi Street, Suzhou, 215006, China. nju_neurosurgery@163.com.'}]",,,,,"10.1007/s12035-020-01990-7
10.1007/s12975-019-00726-7
10.1007/s12975-019-0689-4
10.1177/0271678X18760954
10.1016/j.bbadis.2015.10.013
10.1007/s12975-016-0512-4
10.1177/0271678X19830791
10.4049/jimmunol.1301637
10.1038/nature21029
10.1523/JNEUROSCI.6221-11.2012
10.1212/NXI.0000000000000095
10.1002/glia.23467
10.1371/journal.pbio.1000412
10.1007/s12035-014-8846-y
10.1161/STROKEAHA.115.009729
10.1016/j.bcp.2017.12.023
10.1038/ncomms12932
10.1161/STROKEAHA.114.007265
10.1007/s12035-014-8939-7
10.1007/s12035-015-9304-1
10.1016/j.expneurol.2019.01.018
10.1007/s12035-013-8579-3
10.1038/nature17623
10.1016/j.immuni.2017.06.006
10.1177/0271678X17742792
10.1177/0271678X18814614
10.1007/s12975-019-00708-9
10.1038/nature09612
10.1002/glia.20207
10.1177/0271678X17724681
10.1007/s12035-016-9833-2
10.1073/pnas.0602841103
10.1016/j.semnephrol.2013.08.001
10.1161/STROKEAHA.112.660340
10.1016/j.neulet.2015.10.056
10.1177/0271678X19859381
10.1242/dmm.008557
10.1016/j.expneurol.2015.02.031
10.1007/s12035-018-1006-z
10.1016/s0014-2999(99)00229-0
10.1186/1471-2172-9-60
10.1038/417405a
10.1126/science.1112103
10.1016/j.regpep.2012.08.003
10.1038/nature06348
10.1073/pnas.0407697101
10.1016/S0074-7742(09)85011-3
10.1038/sj.bjp.0706376
10.1016/j.neuropharm.2016.04.043
10.1016/j.mcn.2018.10.004
10.1038/srep15301
10.1073/pnas.1113363109
10.1007/s11064-014-1506-9
10.1046/j.1460-9568.2001.01549.x
10.1161/ATVBAHA.108.162404
10.1371/journal.pone.0121027
10.1001/jamaneurol.2019.0006
10.1007/s12975-015-0434-6
10.4103/0970-9185.137261
10.1016/S0140-6736(16)30668-7",<Element 'PubmedArticle' at 0x7f05de93aa90>
207,32513838,Shaping Microglial Phenotypes Through Estrogen Receptors: Relevance to Sex-Specific Neuroinflammatory Responses to Brain Injury and Disease.,"In mammals, 17",[],The Journal of pharmacology and experimental therapeutics,2020-06-10,"[{'lastname': 'Acosta-Martínez', 'firstname': 'Maricedes', 'initials': 'M', 'affiliation': 'Department of Physiology and Biophysics, Stony Brook Medicine, Stony Brook, New York Maricedes.acosta@stonybrook.edu.'}]",,,,Copyright © 2020 by The American Society for Pharmacology and Experimental Therapeutics.,10.1124/jpet.119.264598,<Element 'PubmedArticle' at 0x7f05de969e00>
208,32512571,"Involvement of Testosterone Signaling in the Integrity of the Neurovascular Unit in the Male: Review of Evidence, Contradictions, and Hypothesis.","Age-related central nervous system function decline and increased susceptibility of females compared to males with respect to prevalence of several neurodegenerative and neuropsychiatric diseases are both based on the principle that hormonal factors could be involved. These cerebral disorders are characterized by an alteration of blood-brain barrier (BBB) properties and chronic neuroinflammation, which lead to disease progression. Neuroinflammation, in turn, contributes to BBB dysfunction. The BBB and its environment, called the neurovascular unit (NVU), are crucial for cerebral homeostasis and neuronal function. Interestingly, sex steroids influence BBB properties and modulate neuroinflammatory responses. To date however, the majority of work reported has focused on the effects of estrogens on BBB function and neuroinflammation in female mammals. In contrast, the effects of testosterone signaling on the NVU in males are still poorly studied. The aim of this review was to summarize and discuss the literature, providing insights and contradictions to highlight hypothesis and the need for further investigations.","['Adult male brain', 'Blood-brain barrier', 'Neuroinflammation', 'Neurovascular unit', 'Testosterone']",Neuroendocrinology,2020-06-09,"[{'lastname': 'Ahmadpour', 'firstname': 'Delnia', 'initials': 'D', 'affiliation': 'Sorbonne Université, INSERM U1130, CNRS UMR 8246, Neuroscience Paris-Seine, Institut de Biologie Paris-Seine, Paris, France.'}, {'lastname': 'Grange-Messent', 'firstname': 'Valérie', 'initials': 'V', 'affiliation': 'Sorbonne Université, INSERM U1130, CNRS UMR 8246, Neuroscience Paris-Seine, Institut de Biologie Paris-Seine, Paris, France, valerie.messent@sorbonne-universite.fr.'}]",,,,"© 2020 S. Karger AG, Basel.",10.1159/000509218,<Element 'PubmedArticle' at 0x7f05de8f2c20>
209,32507541,Tibolone as Hormonal Therapy and Neuroprotective Agent.,"Tibolone (TIB), a selective tissue estrogenic activity regulator (STEAR) in clinical use by postmenopausal women, activates hormonal receptors in a tissue-specific manner. Estrogenic activity is present mostly in the brain, vagina, and bone, while the inactive forms predominate in the endometrium and breast. Conflicting literature on TIB's actions has been observed. While it has benefits for vasomotor symptoms, bone demineralization, and sexual health, a higher relative risk of hormone-sensitive cancer has been reported. In the brain, TIB can improve mood and cognition, neuroinflammation, and reactive gliosis. This review aims to discuss the systemic effects of TIB on peri- and post-menopausal women and its role in the brain. We suggest that TIB is a hormonal therapy with promising neuroprotective properties.","['breast', 'central nervous system', 'hormonal therapy', 'neuroprotection', 'tibolone', 'uterus']",Trends in endocrinology and metabolism: TEM,2020-06-09,"[{'lastname': 'Del Río', 'firstname': 'Juan Pablo', 'initials': 'JP', 'affiliation': 'Reproductive Health Research Institute, Santiago, Chile; Translational Psychiatry Laboratory, Clínica Psiquiátrica Universitaria, Hospital Clínico, Universidad de Chile, Santiago, Chile; Millennium Nucleus to Improve the Mental Health of Adolescents and Youths (Imhay), Santiago, Chile.'}, {'lastname': 'Molina', 'firstname': 'Santiago', 'initials': 'S', 'affiliation': 'Tallahassee Community College, Tallahassee, FL, USA.'}, {'lastname': 'Hidalgo-Lanussa', 'firstname': 'Oscar', 'initials': 'O', 'affiliation': 'Departamento de Nutrición y Bioquímica, Pontificia Universidad Javeriana, Bogotá, Colombia.'}, {'lastname': 'Garcia-Segura', 'firstname': 'Luis Miguel', 'initials': 'LM', 'affiliation': 'Instituto Cajal, CSIC, Madrid, Spain; Centro de Investigación Biomédica en Red Fragilidad y Envejecimiento Saludable (CIBERFES), Instituto de Salud Carlos III, Madrid, Spain.'}, {'lastname': 'Barreto', 'firstname': 'George E', 'initials': 'GE', 'affiliation': 'Department of Biological Sciences, School of Natural Sciences, University of Limerick, Limerick, Ireland; Health Research Institute, University of Limerick, Limerick, Ireland. Electronic address: George.Barreto@ul.ie.'}]",,,,Copyright © 2020 Elsevier Ltd. All rights reserved.,10.1016/j.tem.2020.04.007,<Element 'PubmedArticle' at 0x7f05de8fbcc0>
210,32433011,Oxytocin Signaling Pathway: From Cell Biology to Clinical Implications.,"In addition to the well-known role played in lactation and parturition, Oxytocin (OT) and OT receptor (OTR) are involved in many other aspects such as the control of maternal and social behavior, the regulation of the growth of the neocortex, the maintenance of blood supply to the cortex, the stimulation of limbic olfactory area to mother-infant recognition bond, and the modulation of the autonomic nervous system via the vagal pathway. Moreover, OT and OTR show antiinflammatory, anti-oxidant, anti-pain, anti-diabetic, anti-dyslipidemic and anti-atherogenic effects.
The aim of this narrative review is to summarize the main data coming from the literature dealing with the role of OT and OTR in physiology and pathologic conditions focusing on the most relevant aspects.
Appropriate keywords and MeSH terms were identified and searched in Pubmed. Finally, references of original articles and reviews were examined.
We report the most significant and updated data on the role played by OT and OTR in physiology and different clinical contexts.
Emerging evidence indicates the involvement of OT system in several pathophysiological mechanisms influencing brain anatomy, cognition, language, sense of safety and trust and maternal behavior, with the possible use of exogenous administered OT in the treatment of specific neuropsychiatric conditions. Furthermore, it modulates pancreatic β-cell responsiveness and lipid metabolism leading to possible therapeutic use in diabetic and dyslipidemic patients and for limiting and even reversing atherosclerotic lesions.","['Oxytocin', 'atherosclerosis', 'autism', 'bipolar disorder', 'depression', 'maternal behavior', 'metabolic homeostasis', 'neuroinflammation', 'oxytocin receptor', 'pain', 'schizophrenia', 'social behavior']","Endocrine, metabolic & immune disorders drug targets",2020-05-21,"[{'lastname': 'Iovino', 'firstname': 'Michele', 'initials': 'M', 'affiliation': 'Interdisciplinary Department of Medicine-Section of Internal Medicine, Geriatrics, Endocrinology and Rare Diseases. University of Bari ""Aldo Moro"", School of Medicine, Policlinico, Piazza Giulio Cesare 11, 70124, Bari, Italy.'}, {'lastname': 'Messana', 'firstname': 'Tullio', 'initials': 'T', 'affiliation': 'Infantile Neuropsychiatry, IRCCS - Institute of Neurological Sciences, Bologna, Italy.'}, {'lastname': 'Tortora', 'firstname': 'Anna', 'initials': 'A', 'affiliation': 'Interdisciplinary Department of Medicine-Section of Internal Medicine, Geriatrics, Endocrinology and Rare Diseases. University of Bari ""Aldo Moro"", School of Medicine, Policlinico, Piazza Giulio Cesare 11, 70124, Bari, Italy.'}, {'lastname': 'Giusti', 'firstname': 'Consuelo', 'initials': 'C', 'affiliation': 'Interdisciplinary Department of Medicine-Section of Internal Medicine, Geriatrics, Endocrinology and Rare Diseases. University of Bari ""Aldo Moro"", School of Medicine, Policlinico, Piazza Giulio Cesare 11, 70124, Bari, Italy.'}, {'lastname': 'Lisco', 'firstname': 'Giuseppe', 'initials': 'G', 'affiliation': 'Hospital Unit of Endocrinology, Perrino Hospital, Brindisi, Italy.'}, {'lastname': 'Giagulli', 'firstname': 'Vito Angelo', 'initials': 'VA', 'affiliation': 'Interdisciplinary Department of Medicine-Section of Internal Medicine, Geriatrics, Endocrinology and Rare Diseases. University of Bari ""Aldo Moro"", School of Medicine, Policlinico, Piazza Giulio Cesare 11, 70124, Bari, Italy.'}, {'lastname': 'Guastamacchia', 'firstname': 'Edoardo', 'initials': 'E', 'affiliation': 'Interdisciplinary Department of Medicine-Section of Internal Medicine, Geriatrics, Endocrinology and Rare Diseases. University of Bari ""Aldo Moro"", School of Medicine, Policlinico, Piazza Giulio Cesare 11, 70124, Bari, Italy.'}, {'lastname': 'De Pergola', 'firstname': 'Giovanni', 'initials': 'G', 'affiliation': 'Clinical Nutrition Unit, Medical Oncology, Department of Internal Medicine and Clinical Oncology, University of Bari, School of Medicine, Policlinico, Piazza Giulio Cesare 11, 70124, Bari, Italy.'}, {'lastname': 'Triggiani', 'firstname': 'Vincenzo', 'initials': 'V', 'affiliation': 'Interdisciplinary Department of Medicine-Section of Internal Medicine, Geriatrics, Endocrinology and Rare Diseases. University of Bari ""Aldo Moro"", School of Medicine, Policlinico, Piazza Giulio Cesare 11, 70124, Bari, Italy.'}]",,"Emerging evidence indicates the involvement of OT system in several pathophysiological mechanisms influencing brain anatomy, cognition, language, sense of safety and trust and maternal behavior, with the possible use of exogenous administered OT in the treatment of specific neuropsychiatric conditions. Furthermore, it modulates pancreatic β-cell responsiveness and lipid metabolism leading to possible therapeutic use in diabetic and dyslipidemic patients and for limiting and even reversing atherosclerotic lesions.",We report the most significant and updated data on the role played by OT and OTR in physiology and different clinical contexts.,"Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.",10.2174/1871530320666200520093730,<Element 'PubmedArticle' at 0x7f05de906360>
211,"32429243
15140616
9669787
17651722
16438952
22109525
16960492
26965148
1470919
7505999
31878942
23394519
23394524
14527707
26055231
27227691
30217164
31344333
29417759
24804094
29615912
7891882
18684881
8131840
28112808
22654713
30414938
23306840
24508519
11746349
26572258
23337437
31583353
24965534
11058224
2111020
28722693
25635831
16393343
11918652
14871450
15182944
15042580
15836625
14697327
11279274
25374594
22446192
25025489
23638296
25164769
3340425
16939637
29656363
29367208
29287688
30668378
27790086
31914916
21592995","Ultramicronized Palmitoylethanolamide and Paracetamol, a New Association to Relieve Hyperalgesia and Pain in a Sciatic Nerve Injury Model in Rat.","Inflammation is known to be an essential trigger of the pathological changes that have a critical impact on nerve repair and regeneration; moreover, damage to peripheral nerves can cause a loss of sensory function and produces persistent neuropathic pain. To date, various potential approaches for neuropathic pain have focused on controlling neuroinflammation. The aim of this study was to investigate the neuroprotective effects of a new association of ultramicronized Palmitoylethanolamide (PEAum), an Autacoid Local Injury Antagonist Amide (ALIAmide) with analgesic and anti-inflammatory properties, with Paracetamol, a common analgesic, in a rat model of sciatic nerve injury (SNI). The association of PEAum-Paracetamol, in a low dose (5 mg/kg + 30 mg/kg), was given by oral gavage daily for 14 days after SNI. PEAum-Paracetamol association was able to reduce hyperalgesia, mast cell activation, c-Fos and nerve growth factor (NGF) expression, neural histological damage, cytokine release, and apoptosis. Furthermore, the analgesic action of PEAum-Paracetamol could act in a synergistic manner through the inhibition of the NF-κB pathway, which leads to a decrease of cyclooxygenase 2-dependent prostaglandin E","['inflammation', 'palmitoylethanolamide', 'paracetamol', 'sciatic nerve injury']",International journal of molecular sciences,2020-05-21,"[{'lastname': 'Peritore', 'firstname': 'Alessio Filippo', 'initials': 'AF', 'affiliation': 'Department of Chemical, Biological, Pharmaceutical and Environmental Science, University of Messina, 98165 Messina, Italy.'}, {'lastname': 'Siracusa', 'firstname': 'Rosalba', 'initials': 'R', 'affiliation': 'Department of Chemical, Biological, Pharmaceutical and Environmental Science, University of Messina, 98165 Messina, Italy.'}, {'lastname': 'Fusco', 'firstname': 'Roberta', 'initials': 'R', 'affiliation': 'Department of Chemical, Biological, Pharmaceutical and Environmental Science, University of Messina, 98165 Messina, Italy.'}, {'lastname': 'Gugliandolo', 'firstname': 'Enrico', 'initials': 'E', 'affiliation': 'Department of Chemical, Biological, Pharmaceutical and Environmental Science, University of Messina, 98165 Messina, Italy.'}, {'lastname': ""D'Amico"", 'firstname': 'Ramona', 'initials': 'R', 'affiliation': 'Department of Chemical, Biological, Pharmaceutical and Environmental Science, University of Messina, 98165 Messina, Italy.'}, {'lastname': 'Cordaro', 'firstname': 'Marika', 'initials': 'M', 'affiliation': 'Department of Biomedical and Dental Sciences and Morphofunctional Imaging, University of Messina, 98165 Messina, Italy.'}, {'lastname': 'Crupi', 'firstname': 'Rosalia', 'initials': 'R', 'affiliation': 'Department of Veterinary Science, University of Messina, 98165 Messina, Italy.'}, {'lastname': 'Genovese', 'firstname': 'Tiziana', 'initials': 'T', 'affiliation': 'Department of Chemical, Biological, Pharmaceutical and Environmental Science, University of Messina, 98165 Messina, Italy.'}, {'lastname': 'Impellizzeri', 'firstname': 'Daniela', 'initials': 'D', 'affiliation': 'Department of Chemical, Biological, Pharmaceutical and Environmental Science, University of Messina, 98165 Messina, Italy.'}, {'lastname': 'Cuzzocrea', 'firstname': 'Salvatore', 'initials': 'S', 'affiliation': 'Department of Chemical, Biological, Pharmaceutical and Environmental Science, University of Messina, 98165 Messina, Italy.\nDepartment of Pharmacological and Physiological Science, Saint Louis University School of Medicine, St. Louis, MO 63104, USA.'}, {'lastname': 'Di Paola', 'firstname': 'Rosanna', 'initials': 'R', 'affiliation': 'Department of Chemical, Biological, Pharmaceutical and Environmental Science, University of Messina, 98165 Messina, Italy.'}]",,,,,"10.3390/ijms21103509
10.1016/j.jns.2004.03.008
10.1001/jama.280.2.147
10.1016/j.ejphar.2007.07.012
10.1016/j.ejphar.2005.12.015
10.1038/ncomms1559
10.1097/01.aco.0000245285.30282.70
10.1016/j.plipres.2016.02.002
10.1126/science.1470919
10.1007/BF01972748
10.1186/s12974-019-1671-5
10.2174/1871527311312010008
10.2174/1871527311312010009
10.1016/S0304-3959(03)00261-6
10.1007/s12035-015-9253-8
10.1097/j.pain.0000000000000623
10.1186/s12974-018-1303-5
10.1096/fj.201900538R
10.1002/prp2.367
10.1155/2014/849623
10.3389/fphar.2018.00249
10.1016/0304-3940(94)90191-0
10.1182/blood-2007-11-078097
10.1016/0014-5793(94)80132-0
10.1111/imm.12717
10.2174/157015911798376208
10.1016/j.bcp.2018.11.006
10.1007/s10620-012-2510-z
10.1016/j.ejphar.2014.01.057
10.1002/jnr.10013
10.3892/mmr.2015.4551
10.1254/jphs.12R14CP
10.1097/PR9.0000000000000738
10.2176/nmc.oa.2013-0321
10.1002/1096-9861(20001204)428:1<45::AID-CNE5>3.0.CO;2-A
10.1073/pnas.87.10.3899
10.1097/j.pain.0000000000000959
10.1186/1471-2377-6-1
10.1046/j.1460-9568.2002.01940.x
10.1111/j.1085-9489.2004.09104.x
10.1016/j.neulet.2004.03.040
10.1002/glia.10349
10.1111/j.1471-4159.2005.03050.x
10.1016/j.expneurol.2003.09.015
10.1046/j.1471-4159.2001.t01-1-00216.x
10.1016/j.neulet.2012.03.011
10.1089/neu.2014.3491
10.1186/s12974-014-0136-0
10.1016/0304-3959(88)90026-7
10.1111/j.1601-183X.2006.00268.x
10.21769/BioProtoc.1933
10.1007/s12035-018-1064-2
10.4049/jimmunol.1701280
10.1016/j.phrs.2017.12.022
10.1016/j.phymed.2018.09.191
10.3389/fnins.2016.00458
10.2174/1871527319666200107094732
10.1093/infdis/jir163",<Element 'PubmedArticle' at 0x7f05de912400>
212,"32409991
1382099
16305804
27400930
25622053
11037977
25025081
21586124
18615177
23983983
20590558
22160724
16923851
15332430
22129319
17106878
19093962
19858202
8508790
16796601
23435298
19152719
25144219
25502752
23711587
11789671
16352578
31490211
25505958
30581433
24691121
17715237
19565660
16023222
20363604
21673720
25106425
9416506
26307548
17475889
26903403
16436595
18849484
25939377
18373432
18780233
11704885
22342642
1460427
7686224
10068581
12714572
15630430
24814848
20374632
19950429
21174240
30026298
20523897
21108462
24155746
25449672
17712819
31161980
28861514
24362405
15509740
25253356
19265479
12001996
22569268
22363505
1279376
11309629
16410796
25517826
16507898
3003204
1850002
10843702
29683852
11196644
25810377
12667820
11284554
30472104
18195140
21562161
25896633
12052031
21198668
26090232
22291932
29471387
2165569
17641667
27373505
23078780
15085359
18178718
7689702
16103765
8063421
27398989
29688777
24292902
11282546
10469884
16596770
1592433
9078201
21750421
23997430
25157027
20495440
8903853
31136945
29194121
25980325
25614186
1950778
26124979
22025055
21252259
19321791
26965674
9070350
25719800
28383502
15181567
22406268
24096630
23880787
25891508
20012068
18722389
21641584
16519660
26160613
24078559
24862332
11801654
8566032
19505450
24587966
9548456
22391814
17356465
25877930
22551810
22925532
15739098
17197822
23002014
26189763
8921966
3018755
24862333
25340088
23922698
24562630
11304551
26452565
21715683
25821806
23389619
12446015
9858507
17135573",Targeting Cannabinoid Receptor 2 on Peripheral Leukocytes to Attenuate Inflammatory Mechanisms Implicated in HIV-Associated Neurocognitive Disorder.,"HIV infection affects an estimated 38 million people. Approximately 50% of HIV patients exhibit neurocognitive dysfunction termed HIV-Associated Neurocognitive Disorder (HAND). HAND is a consequence of chronic low-level neuroinflammation due to HIV entry into the brain. Initially, monocytes become activated in circulation and traffic to the brain. Monocytes, when activated, become susceptible to infection by HIV and can then carry the virus across the blood brain barrier. Once in the brain, activated monocytes secrete chemokines, which recruit virus-specific CD8","['AIDS', 'Anti-inflammatory', 'Cannabinoid', 'Cannabinoid receptor 2', 'Cannabis', 'HIVassociated neurocognitive disorders', 'Neuroinflammation']",Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology,2020-05-16,"[{'lastname': 'Rizzo', 'firstname': 'Michael D', 'initials': 'MD', 'affiliation': 'Michigan State University, East Lansing, MI, USA.\nCell & Molecular Biology Program, Michigan State University, East Lansing, MI, USA.\nInstitute for Integrative Toxicology, Michigan State University, East Lansing, MI, USA.'}, {'lastname': 'Henriquez', 'firstname': 'Joseph E', 'initials': 'JE', 'affiliation': 'Michigan State University, East Lansing, MI, USA.\nInstitute for Integrative Toxicology, Michigan State University, East Lansing, MI, USA.\nDepartment of Pharmacology & Toxicology, Michigan State University, East Lansing, MI, USA.'}, {'lastname': 'Blevins', 'firstname': 'Lance K', 'initials': 'LK', 'affiliation': 'Michigan State University, East Lansing, MI, USA.\nInstitute for Integrative Toxicology, Michigan State University, East Lansing, MI, USA.'}, {'lastname': 'Bach', 'firstname': 'Anthony', 'initials': 'A', 'affiliation': 'Michigan State University, East Lansing, MI, USA.\nCenter for Research on Ingredient Safety, Michigan State University, East Lansing, MI, USA.'}, {'lastname': 'Crawford', 'firstname': 'Robert B', 'initials': 'RB', 'affiliation': 'Michigan State University, East Lansing, MI, USA.\nInstitute for Integrative Toxicology, Michigan State University, East Lansing, MI, USA.'}, {'lastname': 'Kaminski', 'firstname': 'Norbert E', 'initials': 'NE', 'affiliation': 'Michigan State University, East Lansing, MI, USA. kamins11@msu.edu.\nInstitute for Integrative Toxicology, Michigan State University, East Lansing, MI, USA. kamins11@msu.edu.\nDepartment of Pharmacology & Toxicology, Michigan State University, East Lansing, MI, USA. kamins11@msu.edu.\nCenter for Research on Ingredient Safety, Michigan State University, East Lansing, MI, USA. kamins11@msu.edu.'}]",,,,,10.1007/s11481-020-09918-7,<Element 'PubmedArticle' at 0x7f05de883860>
213,32375205,Melatonin prevents neuroinflammation and relieves depression by attenuating autophagy impairment through FOXO3a regulation.,"Major depressive disorder (MDD) is a life-threatening illness characterized by mood changes and high rates of suicide. Although the role of neuroinflammation in MMD has been studied, the mechanistic interplay between antidepressants, neuroinflammation, and autophagy is yet to be investigated. The present study investigated the effect of melatonin on LPS-induced neuroinflammation, depression, and autophagy impairment. Our results showed that in mice, lipopolysaccharide (LPS) treatment induced depressive-like behaviors and caused autophagy impairment by dysregulating ATG genes. Moreover, LPS treatment significantly increased the levels of cytokines (TNFα, IL-1β, IL-6), enhanced NF-ᴋB phosphorylation, caused glial (astrocytes and microglia) cell activation, dysregulated FOXO3a expression, increased the levels of redox signaling molecules such as ROS/TBARs, and altered expression of Nrf2, SOD2, and HO-1. Melatonin treatment significantly abolished the effects of LPS, as demonstrated by improved depressive-like behaviors, normalized autophagy-related gene expression, and reduced levels of cytokines. Further, we investigated the role of autophagy in LPS-induced depressive-like behavior and neuroinflammation using autophagy inhibitors 3-MA and Ly294002. Interestingly, inhibitor treatment significantly abolished and reversed the anti-depressive, pro-autophagy, and anti-inflammatory effects of melatonin. The present study concludes that the anti-depressive effects of melatonin in LPS-induced depression might be mediated via autophagy modulation through FOXO3a signaling.","['anti-depressive Agents', 'autophagy', 'depression', 'inflammation', 'lipopolysaccharides', 'melatonin']",Journal of pineal research,2020-05-07,"[{'lastname': 'Ali', 'firstname': 'Tahir', 'initials': 'T', 'affiliation': 'State Key Laboratory of Oncogenomics, School of Chemical Biology and Biotechnology, Peking University Shenzhen Graduate School, Shenzhen, China.'}, {'lastname': 'Rahman', 'firstname': 'Shafiq Ur', 'initials': 'SU', 'affiliation': 'State Key Laboratory of Oncogenomics, School of Chemical Biology and Biotechnology, Peking University Shenzhen Graduate School, Shenzhen, China.\nDepartment of Pharmacy, Shaheed Benazir Bhutto University, Sheringal Dir, Pakistan.'}, {'lastname': 'Hao', 'firstname': 'Qiang', 'initials': 'Q', 'affiliation': 'State Key Laboratory of Oncogenomics, School of Chemical Biology and Biotechnology, Peking University Shenzhen Graduate School, Shenzhen, China.'}, {'lastname': 'Li', 'firstname': 'Weifen', 'initials': 'W', 'affiliation': 'State Key Laboratory of Oncogenomics, School of Chemical Biology and Biotechnology, Peking University Shenzhen Graduate School, Shenzhen, China.'}, {'lastname': 'Liu', 'firstname': 'Zizhen', 'initials': 'Z', 'affiliation': 'State Key Laboratory of Oncogenomics, School of Chemical Biology and Biotechnology, Peking University Shenzhen Graduate School, Shenzhen, China.'}, {'lastname': 'Ali Shah', 'firstname': 'Fawad', 'initials': 'F', 'affiliation': 'State Key Laboratory of Oncogenomics, School of Chemical Biology and Biotechnology, Peking University Shenzhen Graduate School, Shenzhen, China.\nRiphah Institute of Pharmaceutical Sciences, Riphah International University, Islamabad., Islamabad, Pakistan.'}, {'lastname': 'Murtaza', 'firstname': 'Iram', 'initials': 'I', 'affiliation': 'Signal Transduction Lab, Department of Biochemistry, Faculty of Biological Sciences, Quaid-I-Azam University, Islamabad, Pakistan.'}, {'lastname': 'Zhang', 'firstname': 'Zaijun', 'initials': 'Z', 'affiliation': 'International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Development of Chinese Ministry of Education (MOE), Jinan University College of Pharmacy, Guangzhou, China.'}, {'lastname': 'Yang', 'firstname': 'Xifei', 'initials': 'X', 'affiliation': 'Key Laboratory of Modern Toxicology of Shenzhen, Shenzhen Center for Disease Control and Prevention, Shenzhen, China.'}, {'lastname': 'Liu', 'firstname': 'Gongping', 'initials': 'G', 'affiliation': 'Department of Pathophysiology, School of Basic Medicine and the Collaborative Innovation Center for Brain Science, Key Laboratory of Ministry of Education of China and Hubei Province for Neurological Disorders, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.\nCo-innovation Center of Neuroregeneration, Nantong University, Nantong, China.'}, {'lastname': 'Li', 'firstname': 'Shupeng', 'initials': 'S', 'affiliation': 'State Key Laboratory of Oncogenomics, School of Chemical Biology and Biotechnology, Peking University Shenzhen Graduate School, Shenzhen, China.\nDepartment of Psychiatry, University of Toronto, Toronto, ON, Canada.'}]",,,,© 2020 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.,10.1111/jpi.12667,<Element 'PubmedArticle' at 0x7f05de85d220>
214,"32370224
11214935
15980141
17561271
20444991
12783912
17980667
8337941
16903141
16281905
7904883
8101989
12511861
24274755
20029438
30724769
27540165
7539162
22735515
23526370
27046083
28455699
24962261
8208340
8705276
8790403
9168844
11024157
14736847
23392676
27616557
16287689
22821398
24931403
25635871
26857744
29642165
30650564
26655603
28300322
31689427
26992135
17965659
18066056
27185853
29769333
18286612
21458888
28714865
89602
6686005
12621436
9920279
27052459
15313429
31771051
16943563
4209742
18198391
19589092
17555867
26298620
1301388
19139829
19840546
22265268
17657667
9626555
9528963
24184413
29891009
15452406
21072600
14568361
25724812
21245284
27880767
10858586
25125026
31520182
8760445
2125393
19187059
26108478
25220544
28502648
12045736
20967131
28752628
31915845
27445981
19302036
23252647
25257319
15954124
8745240
25136317
26470014
26990767
28690540
19765548
21633390
28636962
28099414
28476157
27654300
28838664
12270689
19679126
15465279
19066177
821790
6813384
18223273
14729865",Assessment of Glial Activation Response in the Progress of Natural Scrapie after Chronic Dexamethasone Treatment.,"Neuroinflammation has been correlated with the progress of neurodegeneration in many neuropathologies. Although glial cells have traditionally been considered to be protective, the concept of them as neurotoxic cells has recently emerged. Thus, a major unsolved question is the exact role of astroglia and microglia in neurodegenerative disorders. On the other hand, it is well known that glucocorticoids are the first choice to regulate inflammation and, consequently, neuroglial inflammatory activity. The objective of this study was to determine how chronic dexamethasone treatment influences the host immune response and to characterize the beneficial or detrimental role of glial cells. To date, this has not been examined using a natural neurodegenerative model of scrapie. With this aim, immunohistochemical expression of glial markers, prion protein accumulation, histopathological lesions and clinical evolution were compared with those in a control group. The results demonstrated how the complex interaction between glial populations failed to compensate for brain damage in natural conditions, emphasizing the need for using natural models. Additionally, the data showed that modulation of neuroinflammation by anti-inflammatory drugs might become a research focus as a potential therapeutic target for prion diseases, similar to that considered previously for other neurodegenerative disorders classified as prion-like diseases.","['astrocytes', 'dexamethasone', 'microglia', 'neuroinflammation', 'prion diseases', 'scrapie']",International journal of molecular sciences,2020-05-07,"[{'lastname': 'Guijarro', 'firstname': 'Isabel M', 'initials': 'IM', 'affiliation': 'Research Centre for Encephalopathies and Transmissible Emerging Diseases-Institute for Health Research Aragón (IIS), University of Zaragoza, C/Miguel Servet 155, 50013 Zaragoza, Spain.'}, {'lastname': 'Garcés', 'firstname': 'Moisés', 'initials': 'M', 'affiliation': 'Research Centre for Encephalopathies and Transmissible Emerging Diseases-Institute for Health Research Aragón (IIS), University of Zaragoza, C/Miguel Servet 155, 50013 Zaragoza, Spain.'}, {'lastname': 'Andrés-Benito', 'firstname': 'Pol', 'initials': 'P', 'affiliation': ""Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, 08908 Barcelona, Spain.""}, {'lastname': 'Marín', 'firstname': 'Belén', 'initials': 'B', 'affiliation': 'Research Centre for Encephalopathies and Transmissible Emerging Diseases-Institute for Health Research Aragón (IIS), University of Zaragoza, C/Miguel Servet 155, 50013 Zaragoza, Spain.'}, {'lastname': 'Otero', 'firstname': 'Alicia', 'initials': 'A', 'affiliation': 'Research Centre for Encephalopathies and Transmissible Emerging Diseases-Institute for Health Research Aragón (IIS), University of Zaragoza, C/Miguel Servet 155, 50013 Zaragoza, Spain.'}, {'lastname': 'Barrio', 'firstname': 'Tomás', 'initials': 'T', 'affiliation': 'Research Centre for Encephalopathies and Transmissible Emerging Diseases-Institute for Health Research Aragón (IIS), University of Zaragoza, C/Miguel Servet 155, 50013 Zaragoza, Spain.'}, {'lastname': 'Carmona', 'firstname': 'Margarita', 'initials': 'M', 'affiliation': ""Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, 08908 Barcelona, Spain.""}, {'lastname': 'Ferrer', 'firstname': 'Isidro', 'initials': 'I', 'affiliation': ""Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, 08908 Barcelona, Spain.""}, {'lastname': 'Badiola', 'firstname': 'Juan J', 'initials': 'JJ', 'affiliation': 'Research Centre for Encephalopathies and Transmissible Emerging Diseases-Institute for Health Research Aragón (IIS), University of Zaragoza, C/Miguel Servet 155, 50013 Zaragoza, Spain.'}, {'lastname': 'Monzón', 'firstname': 'Marta', 'initials': 'M', 'affiliation': 'Research Centre for Encephalopathies and Transmissible Emerging Diseases-Institute for Health Research Aragón (IIS), University of Zaragoza, C/Miguel Servet 155, 50013 Zaragoza, Spain.'}]",,,,,"10.3390/ijms21093231
10.1136/vr.156.26.846-b
10.1016/j.jneuroim.2007.05.006
10.1099/vir.0.021311-0
10.1001/jama.289.21.2819
10.1016/S1474-4422(07)70270-3
10.1007/BF00334672
10.1111/j.1365-2990.2005.00697.x
10.1097/00019052-199312000-00008
10.1073/pnas.90.14.6449
10.1038/nrn1007
10.1146/annurev-genet-110711-155524
10.1038/nrn2786
10.1097/WCO.0000000000000672
10.1126/science.aag2590
10.1620/tjem.174.295
10.1038/nn.3120
10.1007/s12031-013-0002-z
10.1371/journal.ppat.1005551
10.1007/s12035-017-0522-6
10.1038/nri3705
10.1111/j.1365-2990.1994.tb00956.x
10.1073/pnas.93.18.9754
10.1006/exnr.1997.6424
10.1128/JVI.74.21.10245-10248.2000
10.1523/JNEUROSCI.4303-03.2004
10.1523/JNEUROSCI.4440-12.2013
10.1016/j.it.2016.08.001
10.1080/13550280500187583
10.1007/s00441-012-1461-1
10.1007/s00441-014-1928-3
10.1371/journal.pone.0115351
10.1038/srep20762
10.1097/MD.0000000000010320
10.3390/v11010065
10.1016/j.bbadis.2015.11.014
10.1002/glia.23136
10.1016/j.mad.2019.111176
10.1002/glia.22963
10.1038/nn1997
10.1038/nn2028
10.1084/jem.20151000
10.1128/JVI.00549-18
10.1002/glia.20644
10.1016/j.neurobiolaging.2011.02.011
10.1172/JCI90605
10.1016/S0140-6736(79)91654-4
10.1007/BF01310854
10.1038/nature01457
10.1016/S0006-2952(98)00214-7
10.1007/s00204-016-1702-2
10.1016/j.intimp.2004.05.006
10.3233/JAD-190444
10.1523/JNEUROSCI.2797-06.2006
10.1038/249855a0
10.1099/vir.0.83281-0
10.1517/13543780903066780
10.1016/j.mce.2007.03.007
10.18632/aging.100797
10.1016/0303-7207(92)90091-J
10.1007/s10787-008-8046-3
10.1016/j.neuron.2009.09.032
10.1016/j.berh.2011.11.002
10.1080/03009740701340263
10.1210/er.19.3.269
10.1210/endo.139.4.5917
10.1016/j.physbeh.2013.10.035
10.1186/s40425-018-0371-5
10.1159/000080213
10.1007/s10787-010-0056-2
10.1016/S0301-0082(03)00114-X
10.1007/s00418-015-1314-6
10.1177/0300985810395784
10.1371/journal.pbio.1002579
10.1016/S0197-4580(00)00124-X
10.1177/1073858414547132
10.1007/s00424-019-02310-2
10.1099/0022-1317-77-8-1935
10.1007/BF01625735
10.1111/j.1365-2990.2008.00979.x
10.1186/s40478-015-0214-2
10.1002/glia.22751
10.1016/j.brainresbull.2017.05.003
10.1097/00019052-200206000-00020
10.1042/AN20100024
10.1111/cei.13018
10.1007/s00210-019-01775-3
10.3389/fendo.2016.00078
10.1146/annurev.immunol.021908.132528
10.1111/nan.12011
10.1186/s40478-014-0142-6
10.1002/jnr.20562
10.1111/j.1365-2990.1995.tb01097.x
10.3389/fnagi.2014.00198
10.1002/glia.22930
10.1111/jnc.13607
10.3389/fnagi.2017.00207
10.1016/j.bcp.2009.09.014
10.1038/cddis.2011.50
10.1016/j.immuni.2017.06.006
10.1038/nature21029
10.1186/s12974-017-0871-0
10.1128/JVI.01592-16
10.1006/nbdi.2002.0487
10.1016/j.expneurol.2009.07.032
10.1016/j.ijdevneu.2004.07.017
10.1136/ard.2008.100008
10.1093/infdis/146.5.657
10.1136/vr.162.4.130-c
10.1177/002215540405200201",<Element 'PubmedArticle' at 0x7f05de7b33b0>
215,"32370112
18865105
22896675
23635358
26431936
24861635
29916142
29896429
25752446
27230456
24144733
28179807
26343475
23406909
26839463
27870435
8122913
14432658
4399057
18195084
21068160
19028515
29307297
28642689
10880816
16255008
3975621
23407936
30827729
20966214
29881376
26441990
26134003
25193935
10567732
10433904
17043238
27196727
21778362
28931944
8193937
17965659
15831717
24860431
23100431
24871624
28618077
22182318
30184509
31743527
29139169
28341582
29924994
30481522
12426043
27102938
2089275
29239126
17357150
29275859
28620294
29096243
22497984
28219988
26246072
24434477
27197831
29426702
23994069
26037411
15111734
24623176
29801024
9343467
26441134
29194444
22837036
28270169
26120961
26472019
19056393
8552246
18853427
27145006
12480129
9952422
30962951
28888963
31992325
11872940
22450870
25373903
27717807
18258827
32058038
21745355
19682425
28848398
30108586
15042586
10221782
27634048
21527731
15895084
29439605
24761998
23999718
23711349
16049180
20681951
17299767
31831638
17351623
21209080
24047524
17410128
26099306
18951638
19443728
16732273
9724801
10805752
12125082
25426022
15993821
24175290
19302484
15728241
24990881
28442216
26941262
23238794
25663667
21435432
29526689
4945394
27092050
11283751
10322493
23307741
29712572
24270812
29316776
17960134
20584912
25680832
26403789
14993061
21208471
25380660
20012068
32044129
28099414
19782411
25668562
20946934
29717413
29728852
24462092
29269757
24733756
27983926
20427645
28607171
18614693
31105589
14999065
18567623
14559357
23348042
14634144
22435710
11040417
29755342
20392807
22396398
22981653
27530684
19505496
30386297
10077336
11136970
11295570
27789681
26303083
21907136
28980042
30635056
24730418
29259445
21680538
12209854
11850023
30570746
11245665
15896872
29158945
24447465
23804112
20404154
23429294
8084376
22645130
29114202
11014219
18286612
23401502
15798185
20351193
11149664
15256495
27127723
31435854
18522863
29311911
21564348
9890493
28974386
25423896
18829137
22581460
17462607
28041951
10973303
18460549
19533603
24999330
24722370
24637260
25305410
20169039
17186017
19447561
1893376
15528115
10564741
15337241
11384882
15337246
12207627
17113982
9106616
29582398
25086299
27250720
28948468",Microglial and Astrocytic Function in Physiological and Pathological Conditions: Estrogenic Modulation.,"There are sexual differences in the onset, prevalence, and outcome of numerous neurological diseases. Thus, in Alzheimer's disease, multiple sclerosis, and major depression disorder, the incidence in women is higher than in men. In contrast, men are more likely to present other pathologies, such as amyotrophic lateral sclerosis, Parkinson's disease, and autism spectrum. Although the neurological contribution to these diseases has classically always been studied, the truth is that neurons are not the only cells to be affected, and there are other cells, such as glial cells, that are also involved and could be key to understanding the development of these pathologies. Sexual differences exist not only in pathology but also in physiological processes, which shows how cells are differentially regulated in males and females. One of the reasons these sexual differences may occur could be due to the different action of sex hormones. Many studies have shown an increase in aromatase levels in the brain, which could indicate the main role of estrogens in modulating proinflammatory processes. This review will highlight data about sex differences in glial physiology and how estrogenic compounds, such as estradiol and tibolone, could be used as treatment in neurological diseases due to their anti-inflammatory effects and the ability to modulate glial cell functions.","['brain injury', 'estradiol', 'glial cells', 'neuroinflammation', 'phagocytosis', 'sex differences', 'tibolone']",International journal of molecular sciences,2020-05-07,"[{'lastname': 'Crespo-Castrillo', 'firstname': 'Andrea', 'initials': 'A', 'affiliation': 'Instituto Cajal, Consejo Superior de Investigaciones Científicas (CSIC), Avenida Doctor Arce, 37, 28002 Madrid, Spain.'}, {'lastname': 'Arevalo', 'firstname': 'Maria-Angeles', 'initials': 'MA', 'affiliation': 'Instituto Cajal, Consejo Superior de Investigaciones Científicas (CSIC), Avenida Doctor Arce, 37, 28002 Madrid, Spain.\nCentro de Investigación Biomédica en Red Fragilidad y Envejecimiento Saludables (CIBERFES), Instituto de Salud Carlos III, 28029 Madrid, Spain.'}]",,,,,"10.3390/ijms21093219
10.1126/scitranslmed.3003748
10.1186/1479-5876-11-107
10.1016/j.it.2015.08.006
10.1111/jnc.12755
10.1007/s12035-018-1183-9
10.14336/AD.2017.0926
10.1111/bph.13125
10.5213/inj.1632604.302
10.1016/j.neures.2013.10.004
10.1016/j.comppsych.2015.07.002
10.1097/WCO.0b013e32835ee548
10.1155/2015/676531
10.1002/jnr.23884
10.1146/annurev.ge.27.120193.000443
10.1210/endo-65-3-369
10.1098/rstb.1970.0052
10.1152/physrev.00010.2007
10.1210/en.2010-0607
10.1016/j.yfrne.2008.11.001
10.1177/1352458517737394
10.3389/fnsys.2017.00042
10.1016/S0149-7634(00)00018-X
10.1002/cne.20784
10.1126/science.3975621
10.1523/JNEUROSCI.1268-12.2013
10.1016/j.neuron.2019.02.006
10.1126/science.1194637
10.3389/fimmu.2018.01014
10.3389/fimmu.2015.00486
10.1101/cshperspect.a020537
10.4049/jimmunol.1400716
10.1016/S0165-3806(99)00113-3
10.1073/pnas.0607423103
10.1210/er.2016-1007
10.1126/science.1202529
10.1038/nrn.2017.110
10.1016/0361-9230(94)90189-9
10.1038/nn1997
10.1126/science.1110647
10.3389/fncel.2014.00129
10.1523/JNEUROSCI.1167-12.2012
10.1177/1073858414536468
10.1002/glia.23176
10.1111/j.1471-4159.2011.07630.x
10.1016/j.celrep.2018.08.001
10.1002/glia.23753
10.1002/glia.23263
10.1016/j.bbi.2017.03.010
10.1016/j.celrep.2018.05.048
10.20517/2347-8659.2019.31
10.1016/j.yfrne.2018.11.003
10.1016/S0006-8993(02)03475-3
10.1016/j.ygcen.2016.04.018
10.1016/0306-4522(90)90229-W
10.1002/dneu.22568
10.1002/glia.20500
10.1016/j.cell.2017.11.042
10.3389/fnsyn.2017.00010
10.1016/j.conb.2017.10.007
10.1016/j.psyneuen.2012.02.018
10.1523/JNEUROSCI.2906-16.2017
10.1007/s11011-015-9714-9
10.1016/j.expneurol.2014.01.003
10.1111/jnc.13590
10.1016/j.immuni.2018.01.011
10.1016/j.expneurol.2013.08.011
10.1002/glia.22867
10.1093/ilar.45.2.147
10.1002/ana.24135
10.1001/jamaneurol.2018.0821
10.1001/jama.1997.03550160069041
10.1016/j.bbi.2015.10.003
10.1371/journal.pone.0187631
10.1038/nn.3155
10.1186/s13041-017-0289-8
10.1038/nn.4053
10.1016/j.bbi.2015.10.006
10.1016/j.yhbeh.2008.10.016
10.1016/0306-4522(95)00250-M
10.1002/cne.21859
10.1210/en.2015-2012
10.1016/S0165-3806(02)00541-2
10.1523/JNEUROSCI.19-04-01464.1999
10.1038/s41420-019-0166-6
10.1016/j.neuint.2017.09.003
10.1186/s12974-020-1719-6
10.1159/000048726
10.1007/s10571-012-9829-z
10.1016/j.celrep.2014.09.025
10.1016/j.neuroscience.2016.09.047
10.1161/STROKEAHA.107.501460
10.1016/j.bbi.2020.02.001
10.1186/2042-6410-2-7
10.1016/j.yhbeh.2009.02.012
10.3389/fncel.2017.00235
10.3389/fimmu.2018.01753
10.1002/glia.10362
10.1016/S0301-0082(98)00069-0
10.1002/glia.23046
10.1152/physrev.00011.2010
10.1038/nn1472
10.1089/neu.2017.5530
10.1186/1742-2094-11-82
10.6091/ibj.1213.2013
10.1016/j.jneuroim.2013.04.008
10.1523/JNEUROSCI.5171-04.2005
10.1111/j.1471-4159.2010.06937.x
10.1002/glia.20489
10.1126/science.aax6752
10.1038/nm1555
10.1074/jbc.M110.169342
10.2174/18715273113126660173
10.1038/nature05704
10.1007/s12035-015-9282-3
10.1016/j.jneuroim.2008.09.010
10.1167/iovs.08-3357
10.1038/nn1715
10.1073/pnas.95.18.10896
10.1128/MCB.20.11.4106-4114.2000
10.1002/jnr.10304
10.3389/fncel.2014.00360
10.1016/j.jpain.2005.02.001
10.1155/2013/480702
10.1111/j.1471-4159.2009.06042.x
10.1084/jem.20041611
10.1126/scitranslmed.3009093
10.1016/j.molmed.2017.03.008
10.15252/emmm.201506123
10.1007/s11481-012-9427-3
10.1101/cshperspect.a020370
10.1016/j.ajpath.2010.12.051
10.1016/j.neuroscience.2018.02.048
10.1002/cne.901430405
10.3389/fnins.2016.00149
10.1038/35067582
10.1016/S0166-2236(98)01349-6
10.1126/science.1226740
10.1186/s13064-018-0104-y
10.1038/nature12776
10.4062/biomolther.2017.133
10.1038/nature06329
10.1083/jcb.201004096
10.1101/cshperspect.a020396
10.1007/s00018-015-2050-8
10.1196/annals.1286.027
10.1186/2042-6410-1-7
10.1101/cshperspect.a020420
10.1007/s00401-009-0619-8
10.1016/j.tins.2020.01.003
10.1038/nature21029
10.1016/j.tins.2009.08.002
10.1097/NEN.0000000000000165
10.1016/j.pneurobio.2010.09.005
10.1007/s13311-018-0631-6
10.1007/s13311-018-0630-7
10.1016/j.neuron.2013.12.034
10.1038/s41593-017-0033-9
10.1002/glia.22675
10.3727/096368916X693824
10.1523/JNEUROSCI.0137-10.2010
10.1523/JNEUROSCI.3351-16.2017
10.1523/JNEUROSCI.1709-08.2008
10.3389/fphys.2019.00486
10.1523/JNEUROSCI.3547-03.2004
10.1093/brain/awn109
10.1016/S0169-328X(03)00339-5
10.1016/j.molmed.2012.12.007
10.4049/jimmunol.171.11.6267
10.1089/neu.2011.2274
10.1016/S0301-0082(00)00025-3
10.3389/fnagi.2018.00124
10.1124/pr.109.002071
10.1523/JNEUROSCI.5372-11.2012
10.1016/j.yfrne.2012.08.004
10.5483/BMBRep.2016.49.9.141
10.1016/j.yfrne.2009.05.006
10.3389/fendo.2018.00610
10.1016/S0306-4522(98)00340-6
10.1016/S0092-8674(00)00188-4
10.1016/S1043-2760(01)00377-0
10.1124/jpet.116.237412
10.1016/j.beem.2015.04.008
10.1016/j.cmet.2011.08.005
10.1007/978-3-319-56895-9_6
10.1186/s13293-019-0219-9
10.1111/jne.12152
10.1002/rmb2.12006
10.1210/er.2010-0016
10.1002/cne.10325
10.1016/S0047-6374(01)00406-7
10.1111/jnc.14648
10.1523/JNEUROSCI.21-06-01809.2001
10.1016/j.molbrainres.2004.10.043
10.1038/sigtrans.2017.23
10.1016/j.mce.2014.01.010
10.1523/JNEUROSCI.0886-13.2013
10.1073/pnas.0910627107
10.1038/cddis.2013.30
10.1159/000126702
10.1074/jbc.M112.341867
10.3389/fnmol.2017.00330
10.1210/endo.141.10.7693
10.1002/glia.20644
10.1073/pnas.1300313110
10.1128/MCB.25.8.2957-2968.2005
10.4049/jimmunol.0903463
10.1097/00004647-200101000-00002
10.1210/en.2004-0619
10.1002/brb3.449
10.1007/s12311-019-01071-z
10.1016/j.yfrne.2008.04.001
10.3389/fnagi.2017.00430
10.1111/j.1365-2826.2011.02156.x
10.1097/00003072-199901000-00010
10.1016/j.yfrne.2017.09.002
10.1038/nrn3856
10.1016/j.neurobiolaging.2008.08.014
10.1210/en.2011-1859
10.1016/j.brainres.2007.03.082
10.1016/j.steroids.2016.12.011
10.1038/79637
10.1677/JOE-07-0294
10.1002/glia.20904
10.3389/fnagi.2014.00132
10.1371/journal.pone.0094320
10.1016/j.brainres.2014.03.002
10.1016/j.jsbmb.2014.10.002
10.2147/CIA.S6083
10.1038/nrc2048
10.1016/j.psyneuen.2009.04.012
10.1016/j.neuroimage.2004.07.036
10.1016/S0006-8993(99)02062-4
10.1016/j.maturitas.2004.02.013
10.1016/S0960-0760(01)00044-9
10.1016/j.maturitas.2004.02.012
10.1046/j.1365-2125.2002.01619.x
10.1016/j.jsbmb.2006.09.037
10.1124/mol.51.4.535
10.1007/s12035-018-1008-x
10.1016/j.jsbmb.2014.07.009
10.1016/j.mce.2016.05.024
10.1007/s12035-017-0777-y",<Element 'PubmedArticle' at 0x7f05de73b590>
216,32360838,Females are more susceptible than male mice to thermal hypernociceptive behavior induced by early-life bisphenol-A exposure: Effectiveness of diphenyl diselenide.,"Humans are ubiquitously exposed to bisphenol A (BPA), one of the most used synthetic monomers for manufacturing polycarbonate plastics. BPA exposure leads to abnormal nociceptive perception and neuroinflammation in rodents. This study investigated whether diphenyl diselenide (PhSe)","['Bisphenol a', 'Early-life', 'Hypernociception', 'Selenium', 'Sex']",European journal of pharmacology,2020-05-04,"[{'lastname': 'Jardim', 'firstname': 'Natália S', 'initials': 'NS', 'affiliation': 'Laboratório de Síntese, Reatividade e Avaliação Farmacológica e Toxicológica de Organocalcogênios, Centro de Ciências Naturais e Exatas, Universidade Federal de Santa Maria, Santa Maria, CEP 97105-900, RS, Brazil.'}, {'lastname': 'Müller', 'firstname': 'Sabrina G', 'initials': 'SG', 'affiliation': 'Laboratório de Síntese, Reatividade e Avaliação Farmacológica e Toxicológica de Organocalcogênios, Centro de Ciências Naturais e Exatas, Universidade Federal de Santa Maria, Santa Maria, CEP 97105-900, RS, Brazil.'}, {'lastname': 'Sari', 'firstname': 'Marcel H M', 'initials': 'MHM', 'affiliation': 'Laboratório de Síntese, Reatividade e Avaliação Farmacológica e Toxicológica de Organocalcogênios, Centro de Ciências Naturais e Exatas, Universidade Federal de Santa Maria, Santa Maria, CEP 97105-900, RS, Brazil.'}, {'lastname': 'Nogueira', 'firstname': 'Cristina W', 'initials': 'CW', 'affiliation': 'Laboratório de Síntese, Reatividade e Avaliação Farmacológica e Toxicológica de Organocalcogênios, Centro de Ciências Naturais e Exatas, Universidade Federal de Santa Maria, Santa Maria, CEP 97105-900, RS, Brazil. Electronic address: criswn@ufsm.br.'}]",,,,Copyright © 2020 Elsevier B.V. All rights reserved.,10.1016/j.ejphar.2020.173156,<Element 'PubmedArticle' at 0x7f05de68ab80>
217,32344037,"Delayed behavioral and genomic responses to acute combined stress in zebrafish, potentially relevant to PTSD and other stress-related disorders: Focus on neuroglia, neuroinflammation, apoptosis and epigenetic modulation.","Stress is a common trigger of stress-related illnesses, such as anxiety, phobias, depression and post-traumatic stress disorder (PTSD). Various animal models successfully reproduce core behaviors of these clinical conditions. Here, we develop a novel zebrafish model of stress (potentially relevant to human stress-related disorders), based on delayed persistent behavioral, endocrine and genomic responses to an acute severe 'combined' stressor. Specifically, one week after adult zebrafish were exposed to a complex combined 90-min stress, we assessed their behaviors in the novel tank and the light-dark box tests, as well as whole-body cortisol and brain gene expression, focusing on genomic biomarkers of microglia, astrocytes, neuroinflammation, apoptosis and epigenetic modulation. Overall, stressed fish displayed persistent anxiety-like behavior, elevated whole-body cortisol, as well as upregulated brain mRNA expression of genes encoding the glucocorticoid receptor, neurotrophin BDNF and its receptors (TrkB and P75), CD11b (a general microglial biomarker), COX-2 (an M1-microglial biomarker), CD206 (an M2-microglial biomarker), GFAP (a general astrocytal biomarker), C3 (an A1-astrocytal biomarker), S100α","['Acute stress', 'Apoptosis', 'Astrocytes', 'Epigenetics', 'Microglia', 'Zebrafish']",Behavioural brain research,2020-04-29,"[{'lastname': 'Yang', 'firstname': 'LongEn', 'initials': 'L', 'affiliation': 'School of Pharmacy, Southwest University, Chongqing, China.'}, {'lastname': 'Wang', 'firstname': 'Jingtao', 'initials': 'J', 'affiliation': 'School of Pharmacy, Southwest University, Chongqing, China.'}, {'lastname': 'Wang', 'firstname': 'Dongmei', 'initials': 'D', 'affiliation': 'School of Pharmacy, Southwest University, Chongqing, China.'}, {'lastname': 'Hu', 'firstname': 'Guojun', 'initials': 'G', 'affiliation': 'School of Pharmacy, Southwest University, Chongqing, China.'}, {'lastname': 'Liu', 'firstname': 'ZiYuan', 'initials': 'Z', 'affiliation': 'School of Pharmacy, Southwest University, Chongqing, China.'}, {'lastname': 'Yan', 'firstname': 'Dongni', 'initials': 'D', 'affiliation': 'School of Pharmacy, Southwest University, Chongqing, China.'}, {'lastname': 'Serikuly', 'firstname': 'Nazar', 'initials': 'N', 'affiliation': 'School of Pharmacy, Southwest University, Chongqing, China.'}, {'lastname': 'Alpyshov', 'firstname': 'Erik T', 'initials': 'ET', 'affiliation': 'School of Pharmacy, Southwest University, Chongqing, China; Granov Russian Scientific Center of Radiology and Surgical Technologies, Ministry of Healthcare of Russian Federation, St. Petersburg, Russia; Scientific Research Institute of Physiology and Basic Medicine, Novosibirsk, Russia; Institute of Medicine and Psychology, Novosibirsk State University, Novosibirsk, Russia.'}, {'lastname': 'Demin', 'firstname': 'Konstantin A', 'initials': 'KA', 'affiliation': 'Institute of Experimental Medicine, Almazov Medical Research Center, Ministy of Healthcare of Russian Federation, St. Petersburg, Russia.'}, {'lastname': 'Strekalova', 'firstname': 'Tatyana', 'initials': 'T', 'affiliation': 'I.M. Sechenov First Moscow State Medical University, Moscow, Russia; Maastricht University, Maastricht, the Netherlands; Research Institute of General Pathology and Pathophysiology, Moscow, Russia.'}, {'lastname': 'de Abreu', 'firstname': 'Murilo S', 'initials': 'MS', 'affiliation': 'Bioscience Institute, University of Passo Fundo, Passo Fundo, Brazil.'}, {'lastname': 'Song', 'firstname': 'Cai', 'initials': 'C', 'affiliation': 'Institute for Marine Drugs and Nutrition, Marine Medicine Development Center, Shenzhen Institute, Guangdong Ocean University, Zhanjiang, China.'}, {'lastname': 'Kalueff', 'firstname': 'Allan V', 'initials': 'AV', 'affiliation': 'School of Pharmacy, Southwest University, Chongqing, China; Ural Federal University, Ekaterinburg, Russia. Electronic address: avkalueff@gmail.com.'}]",,,,Copyright © 2020 Elsevier B.V. All rights reserved.,10.1016/j.bbr.2020.112644,<Element 'PubmedArticle' at 0x7f05de699f90>
218,"32340112
23993280
28418490
30496104
19351294
28848491
25060574
30692128
30496105
30954305
31333085
29065932
30254236
18296325
24757497
22492529
31212755
30275700
22293292
22133808
29218451
26140821
29671359
30843443
27431367
19238764
17066209
26005400
26086182
25681666
22349682
22012276
29738500
30326796
24440038
28532353
31013492
27304506
29936138
20723551
31539673
29299044
23168220
26758201
20186711
30568608
31671606
30359863
30206280
28852308
31315227
30561288
27793225
29902436
29754286
30747307
25415497
30292888
25078296
23222853
29134359
30023410
27148273
28343167
29797564
24065880
24690880
29483895
22794138
30468210
31694297
31914208
31241945
31861125
27417321
22401879
20408856
22674585
28691768
26786147
24655719
31379879
22814704
29438781
28523126
29950699
28419913
26228057
27421909
32053758",Diet and Mental Health: Review of the Recent Updates on Molecular Mechanisms.,"Over the last decades, there has been a substantial increase in the prevalence of mental health disorders, including an increased prevalence of depression, anxiety, cognitive, and sleep disorders. Diet and its bioactive components have been recognized among the modifiable risk factors, possibly influencing their pathogenesis. This review aimed to summarize molecular mechanisms underlying the putative beneficial effects toward brain health of different dietary factors, such as micro- and macronutrient intake and habits, such as feeding time and circadian rhythm. The role of hormonal homeostasis in the context of glucose metabolism and adiponectin regulation and its impact on systemic and neuro-inflammation has also been considered and deepened. In addition, the effect of individual bioactive molecules exerting antioxidant activities and acting as anti-inflammatory agents, such as omega-3 fatty acids and polyphenols, considered beneficial for the central nervous system via modulation of adult neurogenesis, synaptic and neuronal plasticity, and microglia activation has been summarized. An overview of the regulation of the gut-brain axis and its effect on the modulation of systemic inflammation and oxidative stress has been provided. Finally, the impact of bioactive molecules on inflammation and oxidative stress and its association with brain health has been summarized.","['brain', 'depression', 'diet', 'inflammation', 'mental health', 'neuronal plasticity', 'neurons', 'oxidative stress', 'polyphenols', 'sleep']","Antioxidants (Basel, Switzerland)",2020-04-29,"[{'lastname': 'Godos', 'firstname': 'Justyna', 'initials': 'J', 'affiliation': 'Oasi Research Institute-IRCCS, 94018 Troina, Italy.'}, {'lastname': 'Currenti', 'firstname': 'Walter', 'initials': 'W', 'affiliation': 'Department of Biomedical and Biotechnological Sciences, University of Catania, 95123 Catania, Italy.'}, {'lastname': 'Angelino', 'firstname': 'Donato', 'initials': 'D', 'affiliation': 'Faculty of Bioscience and Technology for Food, Agriculture and Environment, University of Teramo, 64100 Teramo, Italy.'}, {'lastname': 'Mena', 'firstname': 'Pedro', 'initials': 'P', 'affiliation': 'Human Nutrition Unit, Department of Food and Drugs, University of Parma, 43125 Parma, Italy.'}, {'lastname': 'Castellano', 'firstname': 'Sabrina', 'initials': 'S', 'affiliation': 'Department of Educational Sciences, University of Catania, 95124 Catania, Italy.'}, {'lastname': 'Caraci', 'firstname': 'Filippo', 'initials': 'F', 'affiliation': 'Oasi Research Institute-IRCCS, 94018 Troina, Italy.\nDepartment of Drug Sciences, University of Catania, 95125 Catania, Italy.'}, {'lastname': 'Galvano', 'firstname': 'Fabio', 'initials': 'F', 'affiliation': 'Department of Biomedical and Biotechnological Sciences, University of Catania, 95123 Catania, Italy.'}, {'lastname': 'Del Rio', 'firstname': 'Daniele', 'initials': 'D', 'affiliation': 'School of Advanced Studies on Food and Nutrition, University of Parma, 43125 Parma, Italy.\nDepartment of Veterinary Medicine, University of Parma, 43125 Parma, Italy.'}, {'lastname': 'Ferri', 'firstname': 'Raffaele', 'initials': 'R', 'affiliation': 'Oasi Research Institute-IRCCS, 94018 Troina, Italy.'}, {'lastname': 'Grosso', 'firstname': 'Giuseppe', 'initials': 'G', 'affiliation': 'Department of Biomedical and Biotechnological Sciences, University of Catania, 95123 Catania, Italy.'}]",,,,,"10.3390/antiox9040346
10.1016/S0140-6736(13)61611-6
10.1001/jama.2017.3826
10.1016/S0140-6736(18)32279-7
10.5694/j.1326-5377.2009.tb02471.x
10.3389/fneur.2017.00393
10.1186/1880-6805-33-22
10.1136/bmj.l296
10.1016/S0140-6736(18)32225-6
10.1016/S0140-6736(19)30041-8
10.2174/1381612825666190722110458
10.1017/S0029665117003974
10.1038/s41380-018-0237-8
10.1155/2014/313570
10.2337/db11-1521
10.3390/nu11061315
10.1177/1178646918802282
10.1254/jphs.11R04FM
10.1016/j.neulet.2011.11.024
10.1007/s13679-017-0291-6
10.1016/j.biopsych.2015.05.014
10.1080/09637486.2018.1462309
10.1080/09637486.2019.1580682
10.1146/annurev-nutr-071715-050947
10.2174/1574362410666150205165504
10.1016/j.jalz.2015.04.011
10.1016/j.jalz.2014.11.009
10.3233/JAD-2012-111799
10.1007/s12263-011-0255-5
10.3390/nu10050580
10.1080/1028415X.2018.1533199
10.1016/j.cmet.2013.12.008
10.1146/annurev-vision-111815-114558
10.1159/000500071
10.1016/j.cmet.2016.06.001
10.1016/j.ebiom.2018.06.013
10.1016/j.physbeh.2010.08.006
10.1016/j.jad.2019.09.050
10.2174/1745017901713010213
10.1016/j.cmet.2012.08.012
10.3109/07853890.2015.1131327
10.1002/dneu.20758
10.3389/fpsyt.2018.00669
10.3390/nu11112602
10.1016/j.jnutbio.2018.09.013
10.1038/s41598-018-31855-y
10.3748/wjg.v23.i30.5486
10.3390/nu11071613
10.1017/S0029665118002719
10.1016/bs.irn.2016.08.009
10.1016/j.chom.2018.05.012
10.1007/s00125-018-4632-0
10.1007/s11883-019-0772-z
10.1097/YCO.0000000000000117
10.1016/j.cgh.2018.10.002
10.1016/j.bbr.2014.07.027
10.1097/MED.0b013e32835bc703
10.1007/s13311-017-0585-0
10.1016/j.jcmgh.2018.04.003
10.3389/fimmu.2016.00154
10.1515/revneuro-2016-0088
10.1111/acer.13781
10.3389/fnins.2013.00169
10.4161/gmic.28683
10.3389/fendo.2018.00021
10.1089/ars.2012.4581
10.1039/C8NP00062J
10.3390/nu11112678
10.1002/mnfr.201900890
10.1021/acs.jafc.9b02155
10.3390/antiox8120650
10.1007/s40263-016-0370-3
10.1016/j.metabol.2012.01.017
10.1111/j.1365-2249.2010.04150.x
10.1002/glia.22350
10.1002/ajmg.b.32567
10.2174/1570159X14666160119094646
10.1186/1742-2094-11-51
10.3389/fimmu.2019.01696
10.1016/B978-0-12-398314-5.00001-5
10.1016/j.phrs.2018.02.007
10.1038/cti.2017.9
10.1038/s41598-018-28048-y
10.1016/j.psyneuen.2017.02.035
10.1017/S0007114515002093
10.1016/j.mam.2016.07.002
10.1080/09637486.2020.1725961",<Element 'PubmedArticle' at 0x7f05de6a97c0>
219,32334263,Bisphenol A induces DNA damage in cells exerting immune surveillance functions at peripheral and central level.,"Bisphenol A (BPA) is a synthetic xenoestrogen diffused worldwide. Humans are chronically exposed to low doses of BPA from food and drinks, thus BPA accumulates in tissues posing human health risk. In this study, we investigated the effects of BPA on peripheral blood mononuclear cells (PBMC) from human healthy donors, and in glia and microglia of rat offspring at postnatal day 17 (17PND) from pregnant females who received BPA soon after coupling and during lactation and weaning. Results indicated that BPA affected Phytoemagglutinin (PHA) stimulated PBMC proliferation causing an S-phase cell cycle accumulation at nanomolar concentrations while BPA was almost ineffective in resting PBMC. Furthermore, BPA induced chromosome aberrations and the appearance of shattered cells characterized by high number of fragmented and pulverized chromosomes, suggesting that the compound could cause a massive genomic rearrangement by inducing catastrophic events. The BPA-induced DNA damage was observed mainly in TCD4+ and TCD8+ subsets of T lymphocytes and was mediated by the increase of ERK1/2 phosphorylation, p21/Waf1 and PARP1 protein expression. Intriguingly, we observed for the first time that BPA-induced effects were associated to a sex specific modulation of ERα and ERβ in human PBMC. Immunofluorescence analysis of rat hippocampus corroborated in vitro findings showing that BPA induced ɣH2AX phosphorylation in microglia and astrocytosis by decreasing ERα expression within the dentate gyrus. Overall these results suggest that BPA can alter immune surveillance functions at both peripheral and central level with a potential risk for cancer, neuroinflammation and neurodegeneration.","['Astrocytosis', 'Bisphenol a', 'Developmental neurotoxicity', 'Genotoxicity', 'Hippocampus', 'Human lymphocytes']",Chemosphere,2020-04-26,"[{'lastname': 'Di Pietro', 'firstname': 'Paola', 'initials': 'P', 'affiliation': 'Department of Medicine, Surgery and Dentistry, ""Scuola Medica Salernitana"", University of Salerno, 84081, Baronissi, SA, Italy.'}, {'lastname': ""D'Auria"", 'firstname': 'Raffaella', 'initials': 'R', 'affiliation': 'Department of Medicine, Surgery and Dentistry, ""Scuola Medica Salernitana"", University of Salerno, 84081, Baronissi, SA, Italy.'}, {'lastname': 'Viggiano', 'firstname': 'Andrea', 'initials': 'A', 'affiliation': 'Department of Medicine, Surgery and Dentistry, ""Scuola Medica Salernitana"", University of Salerno, 84081, Baronissi, SA, Italy.'}, {'lastname': 'Ciaglia', 'firstname': 'Elena', 'initials': 'E', 'affiliation': 'Department of Medicine, Surgery and Dentistry, ""Scuola Medica Salernitana"", University of Salerno, 84081, Baronissi, SA, Italy.'}, {'lastname': 'Meccariello', 'firstname': 'Rosaria', 'initials': 'R', 'affiliation': 'Department of Movement Sciences and Wellbeing, Parthenope University of Naples, 80133, Naples, Italy.'}, {'lastname': 'Russo', 'firstname': 'Rossana Dello', 'initials': 'RD', 'affiliation': 'Department of Medicine, Surgery and Dentistry, ""Scuola Medica Salernitana"", University of Salerno, 84081, Baronissi, SA, Italy.'}, {'lastname': 'Puca', 'firstname': 'Annibale Alessandro', 'initials': 'AA', 'affiliation': 'Department of Medicine, Surgery and Dentistry, ""Scuola Medica Salernitana"", University of Salerno, 84081, Baronissi, SA, Italy; Cardiovascular Research Unit, IRCCS MultiMedica, 20138, Milan, Italy.'}, {'lastname': 'Vecchione', 'firstname': 'Carmine', 'initials': 'C', 'affiliation': 'Department of Medicine, Surgery and Dentistry, ""Scuola Medica Salernitana"", University of Salerno, 84081, Baronissi, SA, Italy; IRCCS Neuromed, Department of Vascular Physiopathology, 86077, Pozzilli, IS, Italy.'}, {'lastname': 'Nori', 'firstname': 'Stefania Lucia', 'initials': 'SL', 'affiliation': 'Department of Pharmacy, University of Salerno, 84084, Fisciano, SA, Italy.'}, {'lastname': 'Santoro', 'firstname': 'Antonietta', 'initials': 'A', 'affiliation': 'Department of Medicine, Surgery and Dentistry, ""Scuola Medica Salernitana"", University of Salerno, 84081, Baronissi, SA, Italy. Electronic address: ansantoro@unisa.it.'}]",,,,Copyright © 2020 Elsevier Ltd. All rights reserved.,10.1016/j.chemosphere.2020.126819,<Element 'PubmedArticle' at 0x7f05de662310>
220,"32244957
18286612
15891777
28862266
28634266
1770174
2998738
29428549
1711170
24828611
29339091
2902493
10384258
18354017
25435336
21613497
30374595
27637496
18558855
27662896
24806746
15055464
21616601
26384616
22895667
27002803
2859366
28982330
28584278
25622751
30003950
27034847
30459541
16613897
23886782
26363495
26539077
9191978
27571131
20558160
24565565
29890290
24349357
21876068
23325230
30796905
27507764
20398732
27219275
30082335
25228100
31078691
30143908
31394203
19361551
27445981
26439001
29523415
30173378
3211285
15974908
8977391
23312564
23049985
29580890
20149549
18784648
23613579
26990179
24530653
27459932
28866130
26305887
26830012
31726042
19917131
17196331
25344935
22562723
29158945
30206330
24744759
28012291
20940427
20225930",Insights into the Therapeutic Potential of Glucocorticoid Receptor Modulators for Neurodegenerative Diseases.,"Glucocorticoids are crucial for stress-coping, resilience, and adaptation. However, if the stress hormones become dysregulated, the vulnerability to stress-related diseases is enhanced. In this brief review, we discuss the role of glucocorticoids in the pathogenesis of neurodegenerative disorders in both human and animal models, and focus in particular on amyotrophic lateral sclerosis (ALS). For this purpose, we used the Wobbler animal model, which mimics much of the pathology of ALS including a dysfunctional hypothalamic-pituitary-adrenal axis. We discuss recent studies that demonstrated that the pathological cascade characteristic for motoneuron degeneration of ALS is mimicked in the genetically selected Wobbler mouse and can be attenuated by treatment with the selective glucocorticoid receptor antagonist (GRA) CORT113176. In long-term treatment (3 weeks) GRA attenuated progression of the behavioral, inflammatory, excitatory, and cell-death-signaling pathways while increasing the survival signal of serine-threonine kinase (pAkt). The action mechanism of the GRA may be either by interfering with GR deactivation or by restoring the balance between pro- and anti-inflammatory signaling pathways driven by the complementary mineralocorticoid receptor (MR)- and GR-mediated actions of corticosterone. Accordingly, GR antagonism may have clinical relevance for the treatment of neurodegenerative diseases.","['Wobbler mouse', 'amyotrophic lateral sclerosis', 'glucocorticoid receptor antagonist', 'neurodegeneration', 'neuroinflammation']",International journal of molecular sciences,2020-04-05,"[{'lastname': 'De Nicola', 'firstname': 'Alejandro F', 'initials': 'AF', 'affiliation': 'Laboratory of Neuroendocrine Biochemistry, Instituto de Biologia y Medicina Experimental-CONICET, Obligado 2490, 1428 Buenos Aires, Argentina.\nDept. of Human Biochemistry, Faculty of Medicine, University of Buenos Aires, Paraguay 2155, 1425 Buenos Aires, Argentina.'}, {'lastname': 'Meyer', 'firstname': 'Maria', 'initials': 'M', 'affiliation': 'Laboratory of Neuroendocrine Biochemistry, Instituto de Biologia y Medicina Experimental-CONICET, Obligado 2490, 1428 Buenos Aires, Argentina.'}, {'lastname': 'Guennoun', 'firstname': 'Rachida', 'initials': 'R', 'affiliation': 'U1195 Inserm and University Paris-Sud and University Paris Saclay 80 rue du Général Leclerc, 94276 Kremlin-Bicêtre, France.'}, {'lastname': 'Schumacher', 'firstname': 'Michael', 'initials': 'M', 'affiliation': 'U1195 Inserm and University Paris-Sud and University Paris Saclay 80 rue du Général Leclerc, 94276 Kremlin-Bicêtre, France.'}, {'lastname': 'Hunt', 'firstname': 'Hazel', 'initials': 'H', 'affiliation': 'CORCEPT Therapeutics, 149 Commonwealth Dr, Menlo Park, CA 94025, USA.'}, {'lastname': 'Belanoff', 'firstname': 'Joseph', 'initials': 'J', 'affiliation': 'CORCEPT Therapeutics, 149 Commonwealth Dr, Menlo Park, CA 94025, USA.'}, {'lastname': 'de Kloet', 'firstname': 'E Ronald', 'initials': 'ER', 'affiliation': 'Division of Endocrinology, Dept. of Internal Medicine, Leiden University Medical Center, Albinusdreef 2, 2333 ZA Leiden, The Netherlands.'}, {'lastname': 'Gonzalez Deniselle', 'firstname': 'Maria Claudia', 'initials': 'MC', 'affiliation': 'Laboratory of Neuroendocrine Biochemistry, Instituto de Biologia y Medicina Experimental-CONICET, Obligado 2490, 1428 Buenos Aires, Argentina.\nDept. of Physiology, Faculty of Medicine, University of Buenos Aires, Paraguay 2155, 1425 Buenos Aires, Argentina.'}]",,,,,"10.3390/ijms21062137
10.1002/glia.20644
10.1038/nrn1683
10.1038/nrendo.2017.97
10.1530/JOE-16-0660
10.1002/cne.903130312
10.1210/endo-117-6-2505
10.1016/j.yfrne.2018.02.003
10.1016/0306-4522(90)90244-X
10.1210/en.2014-1048
10.1016/j.yfrne.2018.01.001
10.1016/S0016-5085(51)80143-4
10.1016/S0140-6736(88)90742-8
10.1023/A:1006980301382
10.1523/JNEUROSCI.5547-07.2008
10.4172/2155-9929.1000277
10.1016/j.neurobiolaging.2014.10.031
10.1523/JNEUROSCI.0730-11.2011
10.1007/s00702-018-1947-4
10.1016/j.neubiorev.2016.09.006
10.1146/annurev.neuro.30.051606.094313
10.1007/s11910-016-0700-3
10.1055/s-0034-1371891
10.1007/BF03349149
10.1016/j.psyneuen.2011.04.013
10.1016/j.jns.2015.09.011
10.1161/ATVBAHA.112.252759
10.1016/j.jsbmb.2016.03.023
10.1016/0022-3956(85)90068-8
10.2174/1567202614666171005122925
10.3934/medsci.2017.1.1
10.1038/s41598-017-03016-0
10.1038/npp.2015.25
10.1016/j.nbd.2018.07.001
10.1155/2016/6391686
10.3389/fnins.2018.00739
10.1093/hmg/ddl094
10.1016/j.bbi.2013.07.003
10.1016/j.expneurol.2015.09.002
10.3389/fnins.2015.00381
10.1016/S0960-0760(96)00193-8
10.1210/en.2016-1244
10.1016/j.expneurol.2010.06.008
10.1016/j.jsbmb.2014.02.007
10.1016/j.neuroscience.2018.05.042
10.1371/journal.pone.0082767
10.1096/fj.11-190819
10.1523/JNEUROSCI.3314-12.2013
10.1016/j.cbi.2019.02.018
10.1002/dmrr.2842
10.1016/j.mce.2010.04.005
10.1210/en.2015-1604
10.1530/JME-18-0152
10.1159/000367849
10.1016/j.bbi.2019.05.014
10.1007/s10735-018-9786-z
10.1016/j.nbd.2019.104568
10.1016/j.bbi.2009.04.001
10.3389/fendo.2016.00078
10.4158/EP15888.OR
10.1016/j.biopsych.2018.01.008
10.1007/s10571-018-0614-5
10.1159/000125046
10.2174/1567205053585954
10.1210/endo.138.1.4835
10.1016/j.biopsych.2012.12.003
10.1371/journal.pone.0046224
10.1016/j.bbr.2018.03.033
10.1016/j.psyneuen.2010.01.011
10.1038/npp.2008.136
10.1073/pnas.1219411110
10.1111/bph.13477
10.1016/j.yhbeh.2014.02.002
10.1016/j.neurobiolaging.2016.05.018
10.1016/j.bbr.2017.08.045
10.1210/en.2015-1390
10.1038/ijo.2016.13
10.1016/j.brainres.2019.146551
10.1186/1750-1326-4-47
10.1016/j.neulet.2006.10.063
10.1093/intimm/dxu099
10.2119/molmed.2012.00020
10.1038/sigtrans.2017.23
10.1038/s41583-018-0055-7
10.3389/fimmu.2014.00136
10.1016/j.psyneuen.2016.11.036
10.1126/scisignal.2001077
10.3109/17482961003610853",<Element 'PubmedArticle' at 0x7f05de66eae0>
221,"32235333
15340387
16968947
29277082
27584586
24204649
26502112
28445557
29567626
28686820
28291877
29414461
29367012
24180513
24524317
24845238
2848184
2165569
28120229
16209908
22163051
21350020
22739983
27768570
25701682
27573936
27865421
27418880
27296152
28680401
27214593
27733830
26856781
27147666
28813226
26738731
28454984
27267376
28861504
21595653
21079038
28884750
12037135
18615177
23471521
16570099
16596770
1470919
7605349
7575630
20166927
31158514
24971285
18781977
26408161
24588819
28905873
17627561
28826540
28237318
29218644
28263083
17619859
30877436
27719666
28120232
26845349
31706993
31752240
28826544
25269802
31368508
17157480
31497013
27160412
26218440
29940172
30687364
30230028
30810595
31523814
29069647
28673718
28355238
30221908
27696789
16973189
27534132
28003841
26893742
28729222
21356367
18574142
24892832
28368293
17559833
27316720
28393689
31559333
18072821
30891583
23665426
31875578
28091830
20934418
30668410
30729524
17603156
24661285
29288755
32044019
31254955
31545255
30405369
28235543
27956800
27251985
22790217
30646402
27231091
31869648
22380944
30540974
29902764
27081466
27803783
16926492
24947163
28510844
28782167
30368137
25522550
30187618
20651334
22049156
26227501
26434142
26214608
30833968
29912150
23220159
23296806
21905822
26132854
27224271
26773165
29864906
24584866
19969046
27573669
25340185
20197260
30096653
26434146
31467573
29234406
30292828
30521868
28724214
31482864
30473536
30152861
26721216
31234360
30406586
29186788
22867633
25771248
30576910
19653195
30675711
25870747
30430938
11897574
22634841
25454145
31084880
30965237
31342604
28588670
29467906
30333873
25333415
23267129
28440434
27182439
18442668
28337141
19513519
25280609
31214786
31118562
31052317
24042437
31213838
28962084
31741856
20399285
28703755
31708938
26348780
15325732
30972667
29190597
28634795
29792346
29691607
28482935
30890467
28666754
28093813
31715307
28903178
31520598
31541628
31313346
30627539
12118288
6592593
25237707
30928500
28807850
21950160
31762649
30112023
30166094
23969579
29931585
30401578
22073270
22155310
10716613
23099255
22613837
26143011
32029170
27415761
30108565
28899514
25250053
31985261
31948627
29038058
31766432
31867219
31880247
25281205
25242268
24069362
31085246
26658749
20656057
32150408
28088731
21052946
28351318
29078261
30733560
29501481
30385373
29079437
30737440
31492037
31515079
27592281
29312812
29568932
28841022
31374350
27671821
32054336
31957323
11513350
32041250
19549173
21402700
27484716
20211007
25818165
14519971
27144550
31022663
24293411
21786165
16909005
24700193
31991334
20206138
29945666
30420908
19136982
29248425
30413188
30154767
28197615
31540047
29391738
27413711
20651736
21716177
2426995
21628989
9873822
17767808
12423414
25882312
2035468
23135605
29615341
20354680
28975684
22913292
19001155
16213533
22817868
28158929
30314288
29496608
25265540
22911847
22075021
26907190
29377443
31461637
27690011
19422370
20372879
25107591
31192780
28219707
28133450
26040667
20590562
31715269
29496166
29188362
29655682
30909600
30045773
27044819
26718323
29254887
31396402
30221728
29197639
27123073
23370361
28766683
29238202
24603988
25997419
27581969
26259389
25175770
24877026
25233414
31818359
31015365
26284139
29278704
26854718
23255929
31508364
30854080
25509983
21707486
17541980
29552150
25308129
23435916","Terpenoids, Cannabimimetic Ligands, beyond the ",Medicinal use of ,"['Cannabis plant', 'cannabinoid receptors', 'endocannabinoids', 'inflammation.', 'phytocannabinoid', 'terpenoids']","Molecules (Basel, Switzerland)",2020-04-03,"[{'lastname': 'Gonçalves', 'firstname': 'Elaine C D', 'initials': 'ECD', 'affiliation': 'Laboratory of Autoimmunity and Immunopharmacology (LAIF), Department of Health Sciences, Campus Araranguá, Universidade Federal de Santa Catarina, Araranguá 88906-072, Brazil.\nGraduate Program of Neuroscience, Center of Biological Sciences, Campus Florianópolis, Universidade Federal de Santa Catarina, Florianópolis 88040-900, Brazil.'}, {'lastname': 'Baldasso', 'firstname': 'Gabriela M', 'initials': 'GM', 'affiliation': 'Laboratory of Autoimmunity and Immunopharmacology (LAIF), Department of Health Sciences, Campus Araranguá, Universidade Federal de Santa Catarina, Araranguá 88906-072, Brazil.'}, {'lastname': 'Bicca', 'firstname': 'Maíra A', 'initials': 'MA', 'affiliation': 'Neurosurgery Department, Neurosurgery Pain Research institute, Johns Hopkins School of Medicine, Baltimore, MD 21287, USA.'}, {'lastname': 'Paes', 'firstname': 'Rodrigo S', 'initials': 'RS', 'affiliation': 'Laboratory of Autoimmunity and Immunopharmacology (LAIF), Department of Health Sciences, Campus Araranguá, Universidade Federal de Santa Catarina, Araranguá 88906-072, Brazil.'}, {'lastname': 'Capasso', 'firstname': 'Raffaele', 'initials': 'R', 'affiliation': 'Department of Agricultural Sciences, University of Naples Federico II, 80,055 Portici, Italy.'}, {'lastname': 'Dutra', 'firstname': 'Rafael C', 'initials': 'RC', 'affiliation': 'Laboratory of Autoimmunity and Immunopharmacology (LAIF), Department of Health Sciences, Campus Araranguá, Universidade Federal de Santa Catarina, Araranguá 88906-072, Brazil.\nGraduate Program of Neuroscience, Center of Biological Sciences, Campus Florianópolis, Universidade Federal de Santa Catarina, Florianópolis 88040-900, Brazil.'}]",,,,,"10.3390/molecules25071567
10.1038/nrd1495
10.1124/pr.58.3.2
10.1016/j.drugpo.2017.11.008
10.15585/mmwr.ss6511a1
10.1371/journal.pone.0076635
10.1001/jamapsychiatry.2015.1858
10.1001/jamapsychiatry.2017.0724
10.1016/j.drugalcdep.2018.01.022
10.4088/JCP.16m10948
10.1001/jama.2016.19706
10.1016/j.drugpo.2017.12.018
10.1111/add.12355
10.1111/add.12481
10.1001/jama.2014.6175
10.1038/346561a0
10.1016/j.mehy.2005.08.026
10.1371/journal.pone.0028668
10.1124/mol.111.071290
10.1038/cddis.2012.71
10.7812/TPP/16-005
10.1016/j.bbr.2015.02.023
10.2337/dc16-0650
10.1016/j.cellimm.2016.11.006
10.1186/s12950-016-0129-0
10.1038/npp.2016.93
10.3389/fphar.2017.00391
10.1055/s-0042-106303
10.3389/fphar.2016.00343
10.1016/j.schres.2016.02.004
10.1523/JNEUROSCI.3387-15.2016
10.1056/NEJMoa1611618
10.1007/s12031-015-0703-6
10.1016/j.pediatrneurol.2017.02.009
10.1093/brain/aww129
10.1089/can.2016.0037
10.1111/j.1476-5381.2011.01497.x
10.1124/pr.110.003004
10.1038/nrneurol.2017.122
10.1124/pr.54.2.161
10.2174/157015907780866884
10.1007/s11481-013-9445-9
10.1038/sj.ijo.0803272
10.1007/3-540-26573-2_1
10.1126/science.1470919
10.1016/0006-2952(95)00109-D
10.1006/bbrc.1995.2437
10.2174/092986710790980050
10.1016/j.drudis.2019.05.023
10.5812/ijhrba.9222
10.2174/138161208785740090
10.2174/1381612820666140130212957
10.1038/nrcardio.2017.130
10.2174/157016107781024109
10.1016/j.yebeh.2017.01.031
10.1007/s40119-017-0102-x
10.1139/cjpp-2016-0346
10.1007/s00213-007-0861-5
10.1007/s00425-019-03138-x
10.2174/1389557516666161004162133
10.1016/j.phrs.2016.01.033
10.1016/j.neuropharm.2019.107808
10.3390/medicina55110747
10.1093/carcin/bgu205
10.1111/bph.14815
10.1016/j.jdermsci.2006.10.009
10.3389/fimmu.2019.01921
10.1159/000445943
10.1111/bph.13250
10.1016/j.bcp.2018.06.025
10.3389/fpls.2018.01969
10.1111/fcp.12416
10.1590/0004-282x20180147
10.1111/jphp.13164
10.1159/000479863
10.1016/j.neuroscience.2017.06.037
10.1371/journal.pone.0173911
10.1002/cam4.816
10.1016/j.phytochem.2006.08.003
10.1177/1934578X1601100637
10.3892/ol.2015.4050
10.1016/j.neuropharm.2017.07.015
10.1016/j.ajpath.2010.11.052
10.1073/pnas.0803601105
10.1016/j.jep.2014.05.044
10.3390/ijms18040691
10.1016/j.ejphar.2007.04.059
10.1007/s11010-016-2733-y
10.2174/0929867324666170404150351
10.1089/can.2019.0016
10.1002/ame2.12039
10.1016/j.lfs.2013.04.013
10.1248/bpb.b19-00495
10.1007/s10753-016-0496-y
10.1016/j.phymed.2018.09.027
10.1002/jsfa.9629
10.1248/bpb.30.1217
10.1179/1476830514Y.0000000119
10.1016/j.fct.2017.12.053
10.1016/j.enzmictec.2019.109462
10.1016/j.intimp.2019.105706
10.1016/j.biopha.2019.109295
10.3389/fnbeh.2018.00241
10.1016/j.lfs.2017.02.010
10.3748/wjg.v22.i44.9765
10.1039/C6PP00075D
10.2220/biomedres.33.175
10.1055/a-0828-8387
10.1016/j.cbi.2016.05.029
10.1016/j.foodchem.2019.126010
10.1016/j.biopha.2018.11.131
10.1016/j.biopha.2018.06.027
10.1271/bbb.50608
10.1007/s00011-014-0749-x
10.1186/s40529-015-0116-4
10.1002/ptr.5880
10.1016/j.ecoenv.2018.10.062
10.1177/1934578X1400901028
10.1002/cbdv.201800354
10.1177/1082013211398803
10.1055/s-0035-1557790
10.1177/1934578X1501000837
10.1515/znc-2014-4138
10.1155/2019/5979546
10.3390/nu10060783
10.1016/j.ejphar.2012.11.040
10.1002/ptr.4686
10.1139/y11-067
10.1055/s-0035-1546169
10.1055/s-0042-107799
10.1016/j.exppara.2016.01.004
10.1016/j.biopha.2018.04.096
10.1016/j.fitote.2009.11.010
10.1124/mol.116.105080
10.1002/ptr.5105
10.2478/v10001-009-0032-5
10.1016/j.ejmech.2018.07.076
10.1177/1934578X1501000841
10.1155/2019/2745453
10.1155/2017/4926815
10.1016/j.lfs.2018.10.004
10.1016/j.lfs.2018.12.003
10.1016/j.biopha.2017.06.031
10.12659/MSM.916419
10.1042/BSR20180980
10.1111/iej.13006
10.1016/j.jep.2015.12.039
10.3390/molecules24122302
10.1007/s11356-018-3562-1
10.3390/molecules22122052
10.1016/j.jep.2012.07.026
10.1016/j.lfs.2015.02.021
10.1016/j.bioorg.2018.12.010
10.1002/ptr.2955
10.1007/s11356-019-04278-z
10.2174/1568026618666181115103104
10.1128/AAC.46.4.947-957.2002
10.3390/molecules17066305
10.1016/j.chroma.2014.10.045
10.1016/j.plantsci.2019.03.022
10.1016/j.biopha.2019.108812
10.1002/ptr.6436
10.3892/etm.2017.4350
10.3892/or.2014.3490
10.3892/or.2017.5593
10.1039/C4TB01764A
10.1016/j.canlet.2008.01.049
10.3389/fphar.2017.00105
10.3892/or_00000420
10.1016/j.colsurfb.2014.09.029
10.1007/s11095-019-2656-x
10.2147/DDDT.S198003
10.3390/molecules24091697
10.1038/labinvest.2013.111
10.2147/OTT.S196910
10.1016/j.biopha.2017.08.092
10.18240/ijo.2019.11.05
10.1016/j.intimp.2010.04.003
10.3390/molecules22071148
10.3389/fpls.2019.01265
10.1111/bcpt.12488
10.1016/j.jep.2004.05.021
10.1007/s11356-019-05035-y
10.1016/j.ecoenv.2017.11.044
10.1007/s11356-017-9490-7
10.1080/14786419.2018.1478829
10.1007/s00210-018-1504-6
10.1017/S0031182017000452
10.1016/j.bbamem.2019.03.006
10.1016/j.ijantimicag.2017.06.005
10.1002/ptr.5770
10.1016/j.fct.2019.110958
10.1016/j.biopha.2017.09.008
10.1016/j.lfs.2019.116867
10.1016/j.ejphar.2019.172666
10.1002/ddr.21564
10.1155/2018/1691428
10.1590/S0074-02762002000400017
10.1073/pnas.81.18.5896
10.1002/bmc.3151
10.1016/j.jep.2019.03.041
10.1016/j.jep.2017.08.005
10.1515/znc-2011-7-807
10.1016/j.sjbs.2018.08.005
10.3892/etm.2018.6244
10.1016/j.phymed.2018.04.055
10.3892/mmr.2013.1650
10.1007/s10637-018-0620-y
10.1016/j.pathophys.2018.10.003
10.1371/journal.pone.0027122
10.1016/j.bcp.2011.11.026
10.1211/0022357001773607
10.1016/j.ejphar.2012.10.019
10.1016/j.neuropharm.2012.05.008
10.1016/j.neuroscience.2015.06.051
10.1016/j.psj.2019.10.036
10.1371/journal.pone.0159006
10.3389/fmicb.2018.01708
10.1016/j.phymed.2017.08.016
10.1155/2014/378280
10.1089/fpd.2019.2751
10.1016/j.fm.2019.103386
10.1016/j.micpath.2017.10.013
10.3390/molecules24234237
10.1016/j.toxrep.2019.11.002
10.2174/1573406416666191227111106
10.1016/j.ejphar.2014.09.040
10.3402/ljm.v9.25431
10.1371/journal.pone.0074871
10.1016/j.lfs.2019.05.026
10.1007/s10753-015-0292-0
10.1016/j.bbalip.2010.07.004
10.1021/acs.jnatprod.9b01134
10.1016/j.biopha.2016.12.104
10.1007/s12272-010-1020-9
10.1177/1010428317695914
10.1016/j.biopha.2017.10.038
10.1038/s41598-018-38214-x
10.1016/j.biochi.2018.02.013
10.1016/j.ijpharm.2018.10.065
10.1016/j.ijbiomac.2017.10.143
10.1038/s41598-018-38217-8
10.3390/molecules24183241
10.1016/j.tips.2019.08.002
10.1016/j.molonc.2016.08.004
10.7717/peerj.3916
10.3892/ijo.2018.4314
10.1021/acs.molpharmaceut.7b00652
10.1016/j.jphotobiol.2019.111565
10.1080/21691401.2020.1725025
10.1002/cam4.2719
10.1016/S0278-5846(01)00192-0
10.3390/ijms21031084
10.1111/j.1365-2362.2009.02186.x
10.1074/jbc.M111.226365
10.3892/mmr.2016.5570
10.1186/1742-2094-7-17
10.1016/j.yexmp.2015.03.031
10.1271/bbb.67.1883
10.3390/molecules21050574
10.1016/j.phymed.2018.12.028
10.1093/carcin/bgt395
10.1007/s10495-011-0629-6
10.1159/000090364
10.1007/s12192-014-0508-5
10.1016/j.ejmech.2020.112081
10.1016/j.bcp.2010.02.015
10.1186/s13104-018-3527-y
10.1155/2018/3153527
10.1038/ijo.2008.233
10.1016/j.ejphar.2017.12.028
10.1186/s12929-018-0483-8
10.3389/fmicb.2018.01835
10.1039/C7FO00110J
10.3390/nu11092223
10.4103/jomfp.JOMFP_132_16
10.21037/tlcr.2016.06.07
10.1038/nrc2887
10.3390/molecules16075561
10.1097/00000542-198608000-00017
10.1248/yakushi.131.993
10.1038/emm.1998.7
10.1179/016164107X228697
10.1034/j.1600-0536.2002.470210_5.x
10.1016/j.jep.2015.04.004
10.1093/ajcn/53.6.1404
10.1007/s00213-012-2912-9
10.1016/j.bmcl.2018.03.029
10.1007/s00213-010-1827-6
10.1002/ejp.1120
10.1186/1744-8069-8-60
10.1124/jpet.108.145342
10.1016/j.lfs.2005.09.008
10.1016/j.biopsych.2012.06.012
10.1002/ejp.1002
10.3390/molecules23102602
10.1016/j.neulet.2018.02.056
10.1016/j.bcp.2014.09.018
10.1371/journal.pone.0041724
10.1213/ANE.0b013e31823a5d36
10.1016/j.brainres.2016.02.024
10.1111/micc.12442
10.1016/j.expneurol.2019.113045
10.3390/ijms17101413
10.1111/j.1476-5381.2009.00230.x
10.1007/s00213-010-1836-5
10.1016/j.neuropharm.2014.07.016
10.1177/0269881119849821
10.1016/j.ejphar.2017.02.031
10.3389/fphar.2016.00525
10.1111/bph.13212
10.1111/j.1476-5381.2010.00745.x
10.1016/j.taap.2019.114813
10.1007/s00432-017-2548-6
10.1016/j.phymed.2018.03.033
10.3390/cancers11030414
10.1186/s12943-018-0856-3
10.1016/j.biopha.2016.02.003
10.3892/or.2015.4457
10.1016/S2468-1253(17)30394-1
10.1038/s41420-019-0208-0
10.3892/mmr.2018.9488
10.1016/j.phrs.2017.11.027
10.3892/ol.2016.4335
10.1248/bpb.b12-00685
10.3892/ijo.2017.4079
10.2147/OTT.S150071
10.3892/ijo.2014.2325
10.3892/or.2015.3989
10.1186/s12885-016-2730-2
10.3892/ijo.2014.2561
10.4172/2157-2518.S6-005
10.1042/BST20140160
10.5483/BMBRep.2019.52.12.234
10.1042/BSR20182389
10.7150/jca.11735
10.1016/j.bbrc.2017.12.145
10.1016/j.canlet.2016.01.055
10.3892/ol.2012.982
10.3389/fonc.2019.00800
10.3892/ol.2019.9903
10.2174/187152011797655050
10.1002/jcb.21399
10.3892/ol.2018.7936
10.1016/j.clim.2014.09.014
10.1007/s12272-013-0054-1",<Element 'PubmedArticle' at 0x7f05de628900>
222,32196442,Implications of VIP and PACAP in Parkinson's Disease: What do we Know So Far?,"Parkinson's disease is one of the most common neurodegenerative disorders and although its aetiology is not yet fully understood, neuroinflammation has been identified as a key factor in the progression of the disease. Vasoactive intestinal peptide and pituitary adenylate-cyclase activating polypeptide are two neuropeptides that exhibit anti-inflammatory and neuroprotective properties, modulating the production of cytokines and chemokines and the behaviour of immune cells. However, the role of chemokines and cytokines modulated by the endogenous receptors of the peptides varies according to the stage of the disease.
We present an overview of the relationship between some cytokines and chemokines with vasoactive intestinal peptide, pituitary adenylate cyclase activating polypeptide and their endogenous receptors in the context of Parkinson's disease neuroinflammation and oxidative stress, as well as the modulation of microglial cells by the peptides in this context.
The two peptides exhibit neuroprotective and anti-inflammatory properties in models of Parkinson's disease, as they ameliorate cognitive functions, decrease the level of neuroinflammation and promote dopaminergic neuronal survival. The peptides have been tested in a variety of in vivo and in vitro models of Parkinson's disease, demonstrating the potential for therapeutic application.
More studies are needed to establish the clinical use of vasoactive intestinal peptide and pituitary adenylate cyclase activating polypeptide as safe candidates for treating Parkinson's disease, as the use of the peptides in different stages of the disease could produce different results concerning effectiveness.","[""Parkinson's\ndisease"", 'Vasoactive intestinal peptide (VIP)', 'neurodegenerative disease', 'neuroinflammation', 'neuropeptides', 'oxidative stress', 'pituitary adenylate-cyclase activating polypeptide (PACAP)']",Current medicinal chemistry,2020-03-21,"[{'lastname': 'de Souza', 'firstname': 'Filipe Resende Oliveira', 'initials': 'FRO', 'affiliation': 'Laboratory of Immunology and Microbiology, Department of Natural Sciences, Federal University of Sao Joao Del Rei, Praca Dom Helvecio, n. 74, Fabricas, 36301160, Sao Joao Del Rei, MG, Brazil.'}, {'lastname': 'Ribeiro', 'firstname': 'Fabiola Mara', 'initials': 'FM', 'affiliation': 'Laboratory of Neurobiochemistry, Department of Biochemistry and Immunology, Federal University of Minas Gerais, MG, Brazil.'}, {'lastname': 'Lima', 'firstname': ""Patrícia Maria d'Almeida"", 'initials': 'PMD', 'affiliation': 'Laboratory of Immunology and Microbiology, Department of Natural Sciences, Federal University of Sao Joao Del Rei, Praca Dom Helvecio, n. 74, Fabricas, 36301160, Sao Joao Del Rei, MG, Brazil.'}]",,"More studies are needed to establish the clinical use of vasoactive intestinal peptide and pituitary adenylate cyclase activating polypeptide as safe candidates for treating Parkinson's disease, as the use of the peptides in different stages of the disease could produce different results concerning effectiveness.","The two peptides exhibit neuroprotective and anti-inflammatory properties in models of Parkinson's disease, as they ameliorate cognitive functions, decrease the level of neuroinflammation and promote dopaminergic neuronal survival. The peptides have been tested in a variety of in vivo and in vitro models of Parkinson's disease, demonstrating the potential for therapeutic application.","Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.",10.2174/0929867327666200320162436,<Element 'PubmedArticle' at 0x7f05de4fcbd0>
223,"32184899
29128343
28556875
22348642
27535978
28485526
30439857
28925891
25005489
31212946
18562439
28450152
20981346
25773933
24587147
24797227
23271002
16521036
26178418
30075193
28453574
28515684
26959336
29879031
29286104
28583576
21935740
26684921
24878979
28848427
23440470
19264329
26813337
22677142
26507800
23486926
24481565
26773400
24064362
30459541
28932185
28129719
24035860
24946684
18521089
26827643
28056920","Jieyu Anshen Granule, a Chinese Herbal Formulation, Exerts Effects on Poststroke Depression in Rats.","Jieyu Anshen granule (JY) is a traditional Chinese medicine formula for treating depression and anxiety. The aim of the study was to observe the effects of JY on poststroke depression (PSD) and investigate the underlying mechanism. PSD rat model was developed by middle cerebral artery occlusion following chronic unpredictable mild stress in conjunction with isolation rearing. We performed behavioral tests, Western blot, ELISA, and BrdU/NeuN staining. Treatment with JY showed significant antidepressant effect in open-field and sucrose preference tests, as well as significant improvement in beam-walking, cylinder, grip strength, and water maze tests. In addition, treatment with JY could restore the levels of neurotransmitters and decrease the levels of hormone and inflammation cytokines in serum and brain. Treatment with JY also showed significant regulation in the expression of neurotransmitter receptors and NF-",[],Evidence-based complementary and alternative medicine : eCAM,2020-03-19,"[{'lastname': 'Du', 'firstname': 'Yuan', 'initials': 'Y', 'affiliation': 'Key Laboratory of Molecular Pharmacology and Drug Evaluation (Ministry of Education of China), School of Pharmacy, Yantai University, Yantai 264005, China.'}, {'lastname': 'Ruan', 'firstname': 'Jian', 'initials': 'J', 'affiliation': 'Yantai Center for Food and Drug Control, Yantai 264000, China.'}, {'lastname': 'Zhang', 'firstname': 'Leiming', 'initials': 'L', 'affiliation': 'Key Laboratory of Molecular Pharmacology and Drug Evaluation (Ministry of Education of China), School of Pharmacy, Yantai University, Yantai 264005, China.'}, {'lastname': 'Fu', 'firstname': 'Fenghua', 'initials': 'F', 'affiliation': 'Key Laboratory of Molecular Pharmacology and Drug Evaluation (Ministry of Education of China), School of Pharmacy, Yantai University, Yantai 264005, China.'}]",,,,Copyright © 2020 Yuan Du et al.,"10.1155/2020/7469068
10.1016/j.pharmthera.2017.11.005
10.3928/19404921-20170524-02
10.1111/j.1582-4934.2012.01555.x
10.1124/jpet.116.233841
10.1111/jmwh.12607
10.1038/srep05632
10.3390/nu11061361
10.1177/0269881108089814
10.1016/j.neures.2017.04.012
10.1155/2010/506952
10.1016/j.jcjd.2014.11.006
10.1371/journal.pone.0089953
10.1111/jcmm.12297
10.1016/j.phymed.2012.11.016
10.1007/s00213-005-0206-1
10.1017/s1041610215000988
10.1016/j.nlm.2018.07.014
10.1371/journal.pone.0176725
10.3389/fnbeh.2017.00075
10.1016/j.neubiorev.2016.03.004
10.1097/md.0000000000010919
10.3892/mmr.2017.8339
10.1016/j.pbb.2017.06.002
10.1007/s12529-011-9195-0
10.1176/appi.ajp.2015.15030363
10.3389/fnagi.2017.00270
10.1098/rstb.2012.0536
10.1016/j.jns.2009.02.334
10.1111/epi.13321
10.1016/j.expneurol.2012.05.016
10.5056/jnm15064
10.3389/fendo.2013.00026
10.1007/s00213-013-3415-z
10.1016/j.psyneuen.2015.12.021
10.1210/en.2013-1652
10.3389/fnins.2018.00739
10.3389/fnmol.2017.00287
10.1089/ars.2016.6706
10.1016/j.fitote.2013.09.001
10.1186/1742-2094-11-112
10.1038/mp.2008.58
10.1016/j.neurobiolaging.2015.10.021
10.1186/s12906-016-1516-z",<Element 'PubmedArticle' at 0x7f05de5069a0>
224,32165136,Oxidation-reduction mechanisms in psychiatric disorders: A novel target for pharmacological intervention.,"While neurotransmitter dysfunction represents a key component in mental illnesses, there is now a wide agreement for a central pathophysiological hub that includes hormones, neuroinflammation, redox mechanisms as well as oxidative stress. With respect to oxidation-reduction (redox) mechanisms, preclinical and clinical evidence suggests that an imbalance in the pro/anti-oxidative homeostasis toward the increased production of substances with oxidizing potential may contribute to the etiology and manifestation of different psychiatric disorders. The substantial and continous demand for energy renders the brain highly susceptible to disturbances in its energy supply, especially following exposure to stressful events, which may lead to overproduction of reactive oxygen and nitrogen species under conditions of perturbed antioxidant defenses. This will eventually induce different molecular alterations, including extensive protein and lipid peroxidation, increased blood-brain barrier permeability and neuroinflammation, which may contribute to the changes in brain function and morphology observed in mental illnesses. This view may also reconcile different key concepts for psychiatric disorders, such as the neurodevelopmental origin of these diseases, as well as the vulnerability of selective cellular populations that are critical for specific functional abnormalities. The possibility to pharmacologically modulate the redox system is receiving increasing interest as a novel therapeutic strategy to counteract the detrimental effects of the unbalance in brain oxidative mechanisms. This review will describe the main mechanisms and mediators of the redox system and will examine the alterations of oxidative stress found in animal models of psychiatric disorders as well as in patients suffering from mental illnesses, such as schizophrenia and major depressive disorder. In addition, it will discuss studies that examined the effects of psychotropic drugs, including antipsychotics and antidepressants, on the oxidative balance as well as studies that investigated the effectiveness of a direct modulation of oxidative mechanisms in counteracting the behavioral and functional alterations associated with psychiatric disorders, which supports the promising role of the redox system as a novel therapeutic target for the improved treatment of brain disorders.","['Animal models', 'Antidepressants', 'Antipsychotics', 'Major depressive disorder', 'Redox balance', 'Schizophrenia']",Pharmacology & therapeutics,2020-03-14,"[{'lastname': 'Rossetti', 'firstname': 'Andrea Carlo', 'initials': 'AC', 'affiliation': 'Central Institute of Mental Health, Medical Faculty Mannheim, Heidelberg University, Heidelberg, Germany; HITBR Hector Institute for Translational Brain Research GmbH, Mannheim, Germany; German Cancer Research Center (DKFZ), Heidelberg, Germany.'}, {'lastname': 'Paladini', 'firstname': 'Maria Serena', 'initials': 'MS', 'affiliation': 'Department of Medical Biotechnology and Translational Medicine, University of Milan, Italy; Department of Pharmacological and Biomolecular Sciences, University of Milan, Italy.'}, {'lastname': 'Riva', 'firstname': 'Marco Andrea', 'initials': 'MA', 'affiliation': 'Department of Pharmacological and Biomolecular Sciences, University of Milan, Italy. Electronic address: M.Riva@unimi.it.'}, {'lastname': 'Molteni', 'firstname': 'Raffaella', 'initials': 'R', 'affiliation': 'Department of Medical Biotechnology and Translational Medicine, University of Milan, Italy.'}]",,,,Copyright © 2020 Elsevier Inc. All rights reserved.,10.1016/j.pharmthera.2020.107520,<Element 'PubmedArticle' at 0x7f05de526c20>
225,32087283,Neuroprotection by dihydrotestosterone in LPS-induced neuroinflammation.,"Microglia-induced neuroinflammation plays a vital role in the etiology and progression of neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease and multiple sclerosis. The neuroprotective role of androgens, including testosterone and its metabolite dihydrotestosterone (DHT), has been increasingly demonstrated in these diseases, but few studies investigated the effects of androgen on neuroinflammation. This study investigated the role of DHT in lipopolysaccharide (LPS)-induced neuroinflammation, neuronal damage and behavioral dysfunction, as well as underlying mechanisms. We showed that DHT inhibited LPS-induced release of proinflammatory factors, including TNF-α, IL-1β, IL-6; iNOS, COX-2, NO, and PGE2 in BV2 cells and primary microglia by suppressing the TLR4-mediated NF-κB and MAPK p38 signaling pathways, thus protecting SH-SY5Y neurons from inflammatory damage induced by activated microglia. In an LPS-induced neuroinflammation mouse model, endogenous DHT depletion by castration exacerbated inflammatory responses by upregulating the levels of TNF-α, IL-1β, IL-6, iNOS, and COX-2 in the serum and brain by increasing the LR4-mediated NF-κB and MAPK pathway activation, but these effects were restored by exogenous DHT supplementation. Moreover, DHT also regulated the mRNA levels of the anti-inflammatory cytokines IL-10 and IL-13 in the brain. In addition, DHT modulated the expression of Aβ, the apoptotic proteins caspase-3, Bcl-2, and Bax, and synaptophysin, as well as neuronal damage in LPS-treated mouse brains. Further behavioral tests revealed that DHT ameliorated LPS-induced spatial and learning impairment and motor incoordination, and partly improved the locomotor activity in LPS-injected mice. Therefore, this study suggests that DHT exerts anti-neuroinflammatory and neuroprotective effects; thus, androgen replacement therapy is a potential therapeutic strategy for improving cognitive and behavioral function in neuroinflammation-related diseases.","['Cognitive impairment', 'Dihydrotestosterone', 'Lipopolysaccharide', 'Neuroinflammation', 'Sickness behavior']",Neurobiology of disease,2020-02-23,"[{'lastname': 'Yang', 'firstname': 'Lei', 'initials': 'L', 'affiliation': ""Department of Urology, Jing'an District Central Hospital, Fudan University, Shanghai 200040, China.""}, {'lastname': 'Zhou', 'firstname': 'Renyuan', 'initials': 'R', 'affiliation': ""Department of Urology, Tianjin Medical University General Hospital, Tianjin Medical University 300070 Tianjin, China; Department of Urology, Jing'an District Central Hospital, Fudan University, Shanghai 200040, China.""}, {'lastname': 'Tong', 'firstname': 'Yu', 'initials': 'Y', 'affiliation': ""Department of Urology, Jing'an District Central Hospital, Fudan University, Shanghai 200040, China.""}, {'lastname': 'Chen', 'firstname': 'Pengfei', 'initials': 'P', 'affiliation': ""Department of Urology, Jing'an District Central Hospital, Fudan University, Shanghai 200040, China.""}, {'lastname': 'Shen', 'firstname': 'Yu', 'initials': 'Y', 'affiliation': ""Department of Urology, Jing'an District Central Hospital, Fudan University, Shanghai 200040, China.""}, {'lastname': 'Miao', 'firstname': 'Shuai', 'initials': 'S', 'affiliation': ""Department of Urology, Jing'an District Central Hospital, Fudan University, Shanghai 200040, China. Electronic address: msdiyi@163.com.""}, {'lastname': 'Liu', 'firstname': 'Xiaoqiang', 'initials': 'X', 'affiliation': 'Department of Urology, Tianjin Medical University General Hospital, Tianjin Medical University 300070 Tianjin, China. Electronic address: 15233367861@163.com.'}]",,,,Copyright © 2020. Published by Elsevier Inc.,10.1016/j.nbd.2020.104814,<Element 'PubmedArticle' at 0x7f05de4b1db0>
226,"32065105
7990962
9285589
8373432
18096503
18429637
2308954
1504787
9472392
12752773
28101004
30553404
29533978
11301030
11301031
11279497
23040807
30288203
15100161
28862250
25195527
26157003
19307565
23372698
28625718
27133464
22579668
27679556
16472786
9349813
21076423
24650503
27899885
11916961
12951660
25568329
14976257
25130621
18367089
20920795
27282393
22385967
29953913
16364651
16847339
20720046
7898667
22442067
28210207
15354183
12405999
20381618
17194743
25225093
20439721
17641734
15454346
10696506
11179069
1669702
11260702
21851608
8632061
7541057
16691023
21216016
24055259
16543970
25651941
18073512
25598354
26090232
30210289
19476641
26483037
22653796
26565024
23296125
9748581
22827915
11883716
25524120
21690345
30114280
20468046
24036373
19805493
19457065
16472958
15755672
14526074
21459826
21546126
14657172
15728830
24189376
22763024
28721267
16343349
24030360
22233683
16732431
22891244
22163051
22248049
23831388
23515018
16837132
22451318
21364345
19370677
15477546
24571856
20461809
15064146
7906042
17636069
19120438
11860478
15894565
21459482
20939059
19419794
25863279
19490092
21323909
20980074
15837565
15372606
28735833
11739835
15190231
22342378
23892791
24911431
19815071
21406188
28713377
21449980
30582962
17401376
24342422
14615106
26585799
17692344
25466252
25488672
22830043
21300939
19124693
19710634
15994343
22776900
27528659
30042304
19188531
20015486
16633105
16399150
21878486
25711936
19285266
30929760
11470906
15157693
22727500
27806235
9685157
17179944
17630726
17558404
10462067
19005077
17551020
31097758
12871657
15317842
16316653
14610224
16553616
21079038
17876302
18445684
17765871
19723626
28800762
10691292
14623770
9556149
6329417
12617697
17579562
17349697
12052051
19070372
25222270
26343051
10980258
17682128
12834914
17132851
15987634
17724132
17565008
16997973
18625459
25818503
19226257",Endocannabinoid Receptors in the CNS: Potential Drug Targets for the Prevention and Treatment of Neurologic and Psychiatric Disorders.,"The endocannabinoid system participates in the regulation of CNS homeostasis and functions, including neurotransmission, cell signaling, inflammation and oxidative stress, as well as neuronal and glial cell proliferation, differentiation, migration and survival. Endocannabinoids are produced by multiple cell types within the CNS and their main receptors, CB1 and CB2, are expressed in both neurons and glia. Signaling through these receptors is implicated in the modulation of neuronal and glial alterations in neuroinflammatory, neurodegenerative and psychiatric conditions, including Alzheimer's, Parkinson's and Huntington's disease, multiple sclerosis, amyotrophic lateral sclerosis, stroke, epilepsy, anxiety and depression. The therapeutic potential of endocannabinoid receptors in neurological disease has been hindered by unwelcome side effects of current drugs used to target them; however, due to their extensive expression within the CNS and their involvement in physiological and pathological process in nervous tissue, they are attractive targets for drug development. The present review highlights the potential applications of the endocannabinoid system for the prevention and treatment of neurologic and psychiatric disorders.","['Endocannabinoids', 'drug\ntargets', 'endocannabinoid receptors', 'neurodegeneration', 'neuroinflammation', 'psychiatric disease']",Current neuropharmacology,2020-02-18,"[{'lastname': 'Estrada', 'firstname': 'José Antonio', 'initials': 'JA', 'affiliation': 'Neurochemistry Laboratory, Faculty of Medicine, Universidad Autónoma del Estado de México, Toluca, Mexico.'}, {'lastname': 'Contreras', 'firstname': 'Irazú', 'initials': 'I', 'affiliation': 'Neurochemistry Laboratory, Faculty of Medicine, Universidad Autónoma del Estado de México, Toluca, Mexico.'}]",,,,"Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.","10.2174/1570159X18666200217140255
10.1038/372686a0
10.1038/42015
10.1016/0006-2952(93)90486-G
10.1016/j.chembiol.2007.11.006
10.1021/cr0782067
10.1073/pnas.87.5.1932
10.1016/0006-8993(92)90428-C
10.1016/S0306-4522(96)00428-9
10.1046/j.1460-9568.2003.02599.x
10.3389/fncel.2016.00294
10.1016/j.plefa.2018.11.016
10.3390/ijms19030833
10.1016/S0896-6273(01)00246-X
10.1016/S0896-6273(01)00247-1
10.1038/35069076
10.1016/j.neuron.2012.09.020
10.1186/s41232-018-0086-5
10.1038/sj.bjp.0705726
10.1038/npp.2017.206
10.1016/j.toxlet.2014.09.002
10.1523/JNEUROSCI.4112-14.2015
10.1073/pnas.0901515106
10.1371/journal.pone.0054271
10.1016/j.neuropharm.2017.06.017
10.1016/j.neuron.2016.03.034
10.1016/j.neuropharm.2012.04.024
10.3389/fnins.2016.00406
10.1016/j.brainres.2005.11.035
10.1038/39807
10.1038/nn.2684
10.1016/j.conb.2013.12.006
10.3389/fnbeh.2016.00211
10.1074/jbc.M110813200
10.1002/glia.10270
10.15252/embr.201439668
10.1073/pnas.0306707101
10.1002/glia.22742
10.1016/j.neuron.2008.01.029
10.1016/j.neuron.2010.08.043
10.1093/cercor/bhw172
10.1016/j.cell.2012.01.037
10.1016/j.brainresbull.2018.06.012
10.1016/j.nbd.2005.11.004
10.1128/MCB.00397-06
10.2967/jnumed.110.077156
10.1016/0306-4522(94)90511-8
10.1523/JNEUROSCI.4628-11.2012
10.3389/fnins.2017.00030
10.1038/sj.npp.1300558
10.1046/j.1460-9568.2002.02192.x
10.1016/j.nbd.2010.03.020
10.1210/en.2005-1649
10.1098/rstb.2013.0599
10.1073/pnas.0914661107
10.1155/2007/52908
10.1016/j.lfs.2004.06.006
10.1023/A:1007074420772
10.1152/ajpheart.2001.280.3.H1241
10.1111/j.1750-3639.1991.tb00646.x
10.1038/35068632
10.1186/1742-2094-8-102
10.1016/0165-5728(95)00174-3
10.1016/0165-5728(95)00023-U
10.1159/000093243
10.1016/j.jneuroim.2010.12.005
10.1016/j.ajpath.2013.07.033
10.1160/TH05-06-0413
10.1111/bph.13106
10.1159/000110644
10.1007/s12035-014-9070-5
10.1155/2015/130639
10.3389/fnmol.2018.00295
10.1186/1744-8069-5-25
10.1007/s00213-015-4105-9
10.1002/glia.22366
10.1074/jbc.M115.683615
10.1007/s00018-012-1253-5
10.1016/S0925-4439(98)00042-8
10.1186/1471-2202-13-87
10.1016/S0024-3205(01)01516-8
10.1038/nrn3876
10.1073/pnas.1016442108
10.1371/journal.pone.0202566
10.1002/glia.20983
10.1016/j.neuroscience.2013.09.005
10.1093/brain/awp239
10.1111/j.1471-4159.2009.06181.x
10.1016/j.ijdevneu.2005.11.014
10.1016/j.nbd.2004.12.013
10.1126/science.1088208
10.1093/brain/awr046
10.1016/j.neurobiolaging.2011.03.012
10.1523/JNEUROSCI.23-35-11136.2003
10.1523/JNEUROSCI.4540-04.2005
10.1016/j.euroneuro.2013.10.002
10.1016/j.neurobiolaging.2012.06.005
10.1038/npjamd.2016.12
10.1186/1742-2094-2-29
10.1007/s10571-013-9984-x
10.1016/j.neuro.2011.12.015
10.1007/s00018-006-6037-3
10.1074/jbc.M112.350678
10.1371/journal.pone.0028668
10.1186/1742-2094-9-8
10.1016/j.mcn.2013.06.004
10.3233/JAD-130137
10.1016/j.neulet.2006.06.012
10.3233/JAD-2012-111862
10.1097/JCP.0b013e31820e861c
10.1212/01.WNL.0000140288.48796.8E
10.1177/1073858414524632
10.1002/mds.23014
10.1016/j.brainres.2004.02.016
10.1016/0091-3057(93)90230-Q
10.1212/01.wnl.0000267407.79757.75
10.1111/j.1460-9568.2008.06551.x
10.1046/j.0953-816x.2001.01812.x
10.1096/fj.04-3010fje
10.1016/j.neurobiolaging.2011.02.009
10.1002/syn.20807
10.1016/j.neurobiolaging.2009.03.017
10.1016/j.pnpbp.2015.03.017
10.1111/j.1460-9568.2009.06764.x
10.1111/j.1476-5381.2011.01278.x
10.1016/j.neurobiolaging.2010.09.012
10.1016/j.nbd.2004.11.009
10.1002/mds.20111
10.1016/j.ctim.2017.07.002
10.1212/WNL.57.11.2108
10.1097/00002826-200405000-00003
10.1016/j.neuropharm.2012.01.030
10.1007/s11481-013-9493-1
10.3109/08830185.2014.921165
10.1016/j.nbd.2009.09.020
10.1016/j.brainres.2011.03.020
10.3389/fimmu.2017.00753
10.1111/j.1476-5381.2011.01379.x
10.1016/j.bbi.2018.12.013
10.1038/nm1561
10.1016/j.cellimm.2013.11.002
10.1016/S0140-6736(03)14738-1
10.1038/nrn4036
10.1016/j.neuropharm.2007.06.024
10.1016/j.celrep.2014.11.001
10.1517/17460441.2014.966680
10.5402/2012/276902
10.1001/archgenpsychiatry.2011.5
10.1001/archgenpsychiatry.2008.519
10.1038/npp.2009.114
10.1210/en.2005-0610
10.1038/mp.2012.90
10.1073/pnas.1525066113
10.3390/molecules23081836
10.1097/PSY.0b013e3181907c1b
10.1016/j.biopsych.2009.09.033
10.1097/01.mcg.0000210099.36500.fe
10.1016/S0140-6736(05)67763-X
10.1093/cercor/bhr229
10.1016/j.neuroscience.2015.02.028
10.1016/j.beem.2008.09.003
10.1016/j.bja.2019.02.019
10.1073/pnas.161191698
10.1016/j.pain.2004.01.022
10.1016/j.pain.2012.04.020
10.1056/NEJMoa1604221
10.1038/28393
10.1038/sj.bjp.0706990
10.1021/jm070317a
10.1038/nn1916
10.1016/S0024-3205(99)00289-1
10.1523/JNEUROSCI.3400-08.2008
10.1073/pnas.0610811104
10.1038/s41598-019-43858-4
10.1016/S0028-3908(03)00195-3
10.1152/jn.00886.2003
10.1016/j.ejphar.2005.10.020
10.1124/jpet.103.060079
10.1111/j.1460-9568.2006.04684.x
10.1124/pr.110.003004
10.1038/sj.bjp.0707460
10.1242/jcs.020958
10.1016/j.bbrc.2007.08.078
10.1074/jbc.M109.050187
10.1186/s13041-017-0318-7
10.1385/JMN:13:1-2:55
10.1038/sj.bjp.0705577
10.1248/bpb.21.224
10.1016/0006-8993(82)91016-2
10.2165/00023210-200317030-00004
10.1146/annurev.biochem.75.103004.142819
10.1016/j.pharmthera.2007.01.005
10.1054/plef.2001.0349
10.1016/j.tips.2008.10.008
10.3390/cells3030914
10.1186/s13075-015-0743-x
10.1016/S0014-2999(00)00396-4
10.1124/jpet.107.125336
10.1016/S0006-8993(03)02808-7
10.1124/pr.58.4.5
10.1016/j.ejphar.2005.05.032
10.1084/jem.20070828
10.1124/jpet.107.123265
10.1124/jpet.106.111385
10.1016/j.nurt.2008.05.003
10.3233/JAD-142349
10.1111/j.1476-5381.2008.00048.x",<Element 'PubmedArticle' at 0x7f05de4c21d0>
227,"32063838
17431955
19179431
19951300
25689818
24215262
23832579
11114882
17127267
21266194
15961886
23468969
21803120
17595227
15218320
20619468
24588018
18550183
10878378
22316499
17222895
16289890
18940959
26695754
25787746
21402143
18394710
18828796
9620667
10784467
16631170
29567966
16565490
31840601
29113896
17952633
9305459
10486285
16254026
10816638
18190912
20553781
12753073
12792022
10415402
10364447
28420969
19864562
21034794
10721495
10225218
23792540
22713514
10397283
23245609
19453942
8158274
9581648
15548669
21812870
21222258
16154641
16414147
18162070
14698676
21332528
18001327
21036393
24917782
28424592
16899727
2308348
12379439
18348728
17203472
15528006
2174518
9045742
21769024
12113951
11137155
17850217
17095023
24635847
24881324
21946115
25975524
15961554
9581763
15904720
11704927
8971834
19765190
15251891
23993280
9326743
12796784
28778220
20201932",Activation of Melanocortin-4 Receptor Inhibits Both Neuroinflammation Induced by Early Exposure to Ethanol and Subsequent Voluntary Alcohol Intake in Adulthood in Animal Models: Is BDNF the Key Mediator?,"The concept that neuroinflammation induced by excessive alcohol intake in adolescence triggers brain mechanisms that perpetuate consumption has strengthened in recent years. The melanocortin system, composed of the melanocortin 4 receptor (MC4R) and its ligand α-melanocyte-stimulating hormone (α-MSH), has been implicated both in modulation of alcohol consumption and in ethanol-induced neuroinflammation decrease. Chronic alcohol consumption in adolescent rats causes a decrease in an α-MSH release by the hypothalamus, while the administration of synthetic agonists of MC4R causes a decrease in neuroinflammation and a decrease in voluntary alcohol consumption. However, the mechanism that connects the activation of MC4R with the decrease of both neuroinflammation and voluntary alcohol consumption has not been elucidated. Brain-derived neurotrophic factor (BDNF) has been implicated in alcohol drinking motivation, dependence and withdrawal, and its levels are reduced in alcoholics. Deficiencies in BDNF levels increased ethanol self-administration in rats. Further, BDNF triggers important anti-inflammatory effects in the brain, and this could be one of the mechanisms by which BDNF reduces chronic alcohol intake. Interestingly, MC4R signaling induces BDNF expression through the activation of the cAMP-responsive element-binding protein (CREB). We hypothesize that ethanol exposure during adolescence decreases the expression of α-MSH and hence MC4R signaling in the hippocampus, leading to a lower BDNF activity that causes dramatic changes in the brain (e.g., neuroinflammation and decreased neurogenesis) that predispose to maintain alcohol abuse until adulthood. The activation of MC4R either by α-MSH or by synthetic agonist peptides can induce the expression of BDNF, which would trigger several processes that lead to lower alcohol consumption.","['MC4R', 'alcohol use disorder', 'alcoholism', 'brain-derived neurotrophic factor', 'melanocyte-stimulating hormone', 'α-MSH']",Frontiers in cellular neuroscience,2020-02-18,"[{'lastname': 'Flores-Bastías', 'firstname': 'Osvaldo', 'initials': 'O', 'affiliation': 'Institute of Biomedical Sciences, Faculty of Health Sciences, Universidad Autónoma de Chile, Santiago, Chile.\nResearch Center for the Study of Alcohol Drinking Behavior in Adolescents, Universidad Autónoma de Chile, Santiago, Chile.'}, {'lastname': 'Adriasola-Carrasco', 'firstname': 'Alfredo', 'initials': 'A', 'affiliation': 'Institute of Biomedical Sciences, Faculty of Health Sciences, Universidad Autónoma de Chile, Santiago, Chile.'}, {'lastname': 'Karahanian', 'firstname': 'Eduardo', 'initials': 'E', 'affiliation': 'Institute of Biomedical Sciences, Faculty of Health Sciences, Universidad Autónoma de Chile, Santiago, Chile.\nResearch Center for the Study of Alcohol Drinking Behavior in Adolescents, Universidad Autónoma de Chile, Santiago, Chile.'}]",,,,"Copyright © 2020 Flores-Bastías, Adriasola-Carrasco and Karahanian.","10.3389/fncel.2020.00005
10.1016/s1470-2045(07)70099-2
10.1210/en.2008-1184
10.1111/j.1530-0277.2009.01084.x
10.1016/j.pnpbp.2015.02.006
10.1111/adb.12106
10.1002/glia.22504
10.1101/gad.841400
10.2741/2259
10.1016/j.bbi.2011.01.008
10.1152/ajpgi.00383.2004
10.1371/journal.pone.0057313
10.1016/j.mce.2011.07.036
10.1210/en.2007-0366
10.1159/000079321
10.1016/j.jneuroim.2010.06.013
10.1038/nrn3657
10.1016/j.tins.2008.04.002
10.4049/jimmunol.165.2.1013
10.1016/j.pharmthera.2012.01.008
10.1016/j.pbb.2006.12.001
10.1016/j.neuroscience.2005.08.090
10.1093/alcalc/agn079
10.1007/s00213-015-3906-1
10.1016/j.bbi.2011.03.003
10.1016/j.pharmthera.2008.01.003
10.1111/j.1530-0277.2008.00806.x
10.1002/jlb.63.6.740
10.1176/appi.ajp.157.5.745
10.1016/j.expneurol.2006.03.001
10.1038/s41598-018-22750-7
10.2353/ajpath.2006.050617
10.2174/138161282566619121614515
10.1016/j.neuropharm.2017.11.003
10.1007/s12031-007-0019-2
10.1016/s0741-8329(96)00209-1
10.1006/bbrc.1999.1276
10.1210/en.2005-0692
10.1111/j.1749-6632.1999.tb08662.x
10.1016/j.expneurol.2007.11.017
10.1016/j.pnpbp.2010.05.025
10.1046/j.1471-4159.2003.01748.x
10.1073/pnas.1230907100
10.1016/s0006-8993(99)01584-x
10.1006/exnr.1999.7064
10.3389/fnbeh.2017.00057
10.1523/JNEUROSCI.2243-09.2009
10.1016/j.neuroscience.2010.10.054
10.1016/s0272-7358(99)00027-6
10.1089/neu.1999.16.323
10.1016/j.pbb.2013.06.006
10.1016/j.bbr.2012.06.006
10.1097/00000374-199906000-00006
10.1016/S0140-6736(12)61766-8
10.1111/j.1471-4159.2009.06073.x
10.1523/JNEUROSCI.14-04-02377.1994
10.1111/j.1530-0277.1998.tb03668.x
10.1523/JNEUROSCI.3714-04.2004
10.1111/j.1369-1600.2011.00357.x
10.1007/978-1-4419-6354-3_3
10.1016/j.jneuroim.2005.07.024
10.1016/j.peptides.2005.12.002
10.1111/j.1530-0277.2007.00578.x
10.1016/j.npep.2003.10.003
10.1111/j.1530-0277.2011.01438.x
10.1111/j.1365-2826.2007.01610.x
10.1016/s0140-6736(10)61462-6
10.3389/fnins.2014.00128
10.3389/fncel.2017.00090
10.1523/JNEUROSCI.4988-05.2006
10.15288/jsa.1990.51.114
10.1016/s0361-9230(02)00844-4
10.1186/1742-2094-5-10
10.1002/glia.20467
10.1016/s0741-8329(04)00097-7
10.1016/0143-4179(90)90145-o
10.1523/JNEUROSCI.17-06-02181.1997
10.1097/ADM.0b013e3181e1299d
10.1016/s0006-8993(02)02619-7
10.1016/s0166-2236(00)01672-6
10.1111/j.1530-0277.2007.00510.x
10.1016/j.neuropharm.2006.08.015
10.1111/adb.12126
10.1016/j.ejphar.2011.09.015
10.1111/adb.12264
10.1210/en.2005-0562
10.1016/s0896-6273(00)81010-7
10.1016/j.bbr.2005.01.016
10.1086/324467
10.1097/00006123-199701000-00028
10.1111/j.1471-4159.2009.06389.x
10.1196/annals.1308.026
10.1016/S0140-6736(13)61611-6
10.1159/000097313
10.1038/nn1073
10.1186/s12974-017-0930-6
10.1111/j.1530-0277.2010.01150.x",<Element 'PubmedArticle' at 0x7f05de43f590>
228,32018209,Rhodiola rosea L. modulates inflammatory processes in a CRH-activated BV2 cell model.,"Rhodiola rosea L. (Crassulaceae) has been used for years in the traditional medicine of several countries as an adaptogen drug, able to preserve homeostasis in response to stress stimuli. Currently R. rosea roots and rhizome are classified as a traditional herbal medicinal product for temporary relief of symptoms of stress, such as fatigue and sensation of weakness by the European Medicines Agency.
Increasing evidences suggest the involvement of neuroinflammation in response to stress. However, whether the modulation of neuroinflammatory parameters could be involved in the anti-stress effect of R. rosea has been barely studied. Thus, the aim of this work is to investigate the possible modulation of molecular inflammatory processes elicited by a R. rosea roots and rhizome ethanolic extract in an in vitro model of corticotropin releasing hormone (CRH)-stimulated BV2 microglial cells.
BV2 cells were stimulated with CRH 100 nM and changes in cell viability, cytokines production and heat shock protein 70 (HSP70) levels were evaluated. Intracellular pathways related to inflammation, such as nuclear factor kappa-light-chain enhancer of activated B cells (NF-κB) nuclear translocation and mitogen-activated protein kinases (MAPK) activation were also analyzed.
We found that R. rosea extract (2.7% m/m rosavin and 1% m/m salidroside) 20 µg/ml was able to counteract the neuroinflammatory effect of CRH by inhibiting NF-κB nuclear translocation with a mechanism of action involving the modulation of mitogen-activated protein kinase-activated protein kinase 2 (MKK2), extracellular signal-regulated kinase 1/2 (ERK 1/2) and c-Jun n-terminal kinase (JNK), resulting in a reduction of HSP70 expression.
This work expands the knowledge of the intracellular mechanisms involved in R. rosea anti-stress activity and may be useful for the study of other adaptogen drugs.","['CRH', 'HSP70', 'MAPK', 'NF-κB', 'Rhodiola rosea L.', 'microglia']",Phytomedicine : international journal of phytotherapy and phytopharmacology,2020-02-06,"[{'lastname': 'Borgonetti', 'firstname': 'Vittoria', 'initials': 'V', 'affiliation': 'Department of Neuroscience, Psychology, Pharmacology and Child Health (NEUROFARBA), University of Florence, Florence, Italy.'}, {'lastname': 'Governa', 'firstname': 'Paolo', 'initials': 'P', 'affiliation': 'Department of Biotechnology, Chemistry and Pharmacy - Department of Excellence 2018-2022, University of Siena, Siena, Italy.'}, {'lastname': 'Biagi', 'firstname': 'Marco', 'initials': 'M', 'affiliation': 'Department of Physical Sciences, Earth and Environment, University of Siena, Strada Laterina, 8 Siena 53100, Italy. Electronic address: biagi4@unisi.it.'}, {'lastname': 'Dalia', 'firstname': 'Pasquale', 'initials': 'P', 'affiliation': 'Department of Life Sciences, University of Modena and Reggio Emilia, Modena, Italy.'}, {'lastname': 'Corsi', 'firstname': 'Lorenzo', 'initials': 'L', 'affiliation': 'Department of Life Sciences, University of Modena and Reggio Emilia, Modena, Italy.'}]",,This work expands the knowledge of the intracellular mechanisms involved in R. rosea anti-stress activity and may be useful for the study of other adaptogen drugs.,"We found that R. rosea extract (2.7% m/m rosavin and 1% m/m salidroside) 20 µg/ml was able to counteract the neuroinflammatory effect of CRH by inhibiting NF-κB nuclear translocation with a mechanism of action involving the modulation of mitogen-activated protein kinase-activated protein kinase 2 (MKK2), extracellular signal-regulated kinase 1/2 (ERK 1/2) and c-Jun n-terminal kinase (JNK), resulting in a reduction of HSP70 expression.",Copyright © 2019 Elsevier GmbH. All rights reserved.,10.1016/j.phymed.2019.153143,<Element 'PubmedArticle' at 0x7f05de3bc590>
229,"31992325
11788614
28191467
11063905
11799344
19412477
18001721
22067260
24704246
25052429
24819940
28948468
25086299
28667487
30822454
27250720
29582398
15337246
17113982
18001325
21555578
30391959
3192762
29316776
24270812
27559087
21199938
28539349
28007993
28642575
28099414
26477569
31297095
10987824
21745355
27717807
26037411
27283249
25843666
30227622
28888963
23584859
11384882
10433246
29162485
16736049
16787981
29178139
11222926
23238794
26818951
29139169
28341582
27546235
1562533
12239082
26153859
7144917
11108858
21125645
28552663
19777158
17707846
20495459
21118039
21208397
26343475
24444786
21767382
23819447
23795693",The synthetic steroid tibolone exerts sex-specific regulation of astrocyte phagocytosis under basal conditions and after an inflammatory challenge.,"Tibolone is a synthetic steroid used in clinical practice for the treatment of climacteric symptoms and osteoporosis. Active metabolites of tibolone, generated in target tissues, have an affinity for estrogen and androgen receptors. Astrocytes are direct targets for estrogenic compounds and previous studies have shown that tibolone protects brain cortical neurons in association with a reduction in reactive astrogliosis in a mouse model of traumatic brain injury. Since phagocytosis is a crucial component of the neuroprotective function exerted by astrocytes, in the present study, we have assessed whether tibolone regulates phagocytosis in primary astrocytes incubated with brain-derived cellular debris.
Male and female astrocyte cell cultures were obtained from newborn (P0-P2) female and male Wistar rats. Astrocytic phagocytosis was first characterized using carboxylate beads, Escherichia coli particles, or brain-derived cellular debris. Then, the effect of tibolone on the phagocytosis of Cy3-conjugated cellular debris was quantified by measuring the intensity of Cy3 dye-emitted fluorescence in a given GFAP immunoreactive area. Before the phagocytosis assays, astrocytes were incubated with tibolone in the presence or absence of estrogen or androgen receptor antagonists or an inhibitor of the enzyme that synthesizes estradiol. The effect of tibolone on phagocytosis was analyzed under basal conditions and after inflammatory stimulation with lipopolysaccharide.
Tibolone stimulated phagocytosis of brain-derived cellular debris by male and female astrocytes, with the effect being more pronounced in females. The effect of tibolone in female astrocytes was blocked by a selective estrogen receptor β antagonist and by an androgen receptor antagonist. None of these antagonists affected tibolone-induced phagocytosis in male astrocytes. In addition, the inhibition of estradiol synthesis in the cultures enhanced the stimulatory effect of tibolone on phagocytosis in male astrocytes but blocked the effect of the steroid in female cells under basal conditions. However, after inflammatory stimulation, the inhibition of estradiol synthesis highly potentiated the stimulation of phagocytosis by tibolone, particularly in female astrocytes.
Tibolone exerts sex-specific regulation of phagocytosis in astrocytes of both sexes, both under basal conditions and after inflammatory stimulation.","['Androgen receptor', 'Astrocytes', 'Cellular debris', 'Estrogen receptor', 'LPS', 'Phagocytosis', 'Sex differences', 'Tibolone']",Journal of neuroinflammation,2020-01-30,"[{'lastname': 'Crespo-Castrillo', 'firstname': 'Andrea', 'initials': 'A', 'affiliation': 'Instituto Cajal, Consejo Superior de Investigaciones Científicas (CSIC), Madrid, Spain.'}, {'lastname': 'Garcia-Segura', 'firstname': 'Luis-Miguel', 'initials': 'LM', 'affiliation': 'Instituto Cajal, Consejo Superior de Investigaciones Científicas (CSIC), Madrid, Spain.\nCentro de Investigación Biomédica en Red Fragilidad y Envejecimiento Saludables (CIBERFES), Instituto de Salud Carlos III, Madrid, Spain.'}, {'lastname': 'Arevalo', 'firstname': 'Maria-Angeles', 'initials': 'MA', 'affiliation': 'Instituto Cajal, Consejo Superior de Investigaciones Científicas (CSIC), Madrid, Spain. arevalo@cajal.csic.es.\nCentro de Investigación Biomédica en Red Fragilidad y Envejecimiento Saludables (CIBERFES), Instituto de Salud Carlos III, Madrid, Spain. arevalo@cajal.csic.es.'}]",,,"Tibolone stimulated phagocytosis of brain-derived cellular debris by male and female astrocytes, with the effect being more pronounced in females. The effect of tibolone in female astrocytes was blocked by a selective estrogen receptor β antagonist and by an androgen receptor antagonist. None of these antagonists affected tibolone-induced phagocytosis in male astrocytes. In addition, the inhibition of estradiol synthesis in the cultures enhanced the stimulatory effect of tibolone on phagocytosis in male astrocytes but blocked the effect of the steroid in female cells under basal conditions. However, after inflammatory stimulation, the inhibition of estradiol synthesis highly potentiated the stimulation of phagocytosis by tibolone, particularly in female astrocytes.",,"10.1186/s12974-020-1719-6
10.1210/jcem.87.1.8141
10.1155/2017/8630764
10.1016/S0378-5122(00)00147-X
10.1097/00004714-200202000-00010
10.2147/nedt.2006.2.3.299
10.1016/j.fertnstert.2007.05.061
10.1016/j.yhbeh.2011.10.005
10.1016/j.nrl.2014.03.002
10.1007/s11064-014-1385-0
10.1007/s12035-017-0777-y
10.1016/j.jsbmb.2014.07.009
10.1016/j.mce.2019.02.017
10.1016/j.mce.2016.05.024
10.1007/s12035-018-1008-x
10.1016/j.maturitas.2004.02.012
10.1016/j.jsbmb.2006.09.037
10.1111/j.1365-2826.2007.01611.x
10.1073/pnas.1103833108
10.1159/000495078
10.1002/cne.902760109
10.4062/biomolther.2017.133
10.1038/nature12776
10.1073/pnas.1609896113
10.1073/pnas.1013965108
10.1523/JNEUROSCI.3981-16.2017
10.1093/brain/aww298
10.1038/s41467-017-00037-1
10.1038/nature21029
10.1038/srep15224
10.3389/fendo.2019.00420
10.1046/j.1471-4159.2000.0751447.x
10.1186/2042-6410-2-7
10.1016/j.neuroscience.2016.09.047
10.1002/glia.22867
10.1016/j.pneurobio.2016.06.002
10.1016/j.nbd.2015.03.028
10.3390/ijms19092793
10.1016/j.neuint.2017.09.003
10.1210/en.2012-2137
10.1016/S0960-0760(01)00044-9
10.1210/endo.140.8.6907
10.1016/j.neuint.2017.11.007
10.1038/sj.jcbfm.9600331
10.1210/jc.2006-0462
10.1002/glia.23270
10.1016/S0197-0186(00)00090-5
10.1007/s11481-012-9427-3
10.1186/s12974-016-0477-y
10.1002/glia.23263
10.1016/j.bbi.2017.03.010
10.1038/nri.2016.90
10.1016/0960-0760(92)90394-X
10.1210/en.2002-211438
10.1038/nature14583
10.1038/300648a0
10.1016/S0039-128X(00)00112-4
10.1002/glia.21094
10.1016/j.yfrne.2017.05.003
10.1007/s00011-009-0026-6
10.1016/S1550-8579(07)80026-X
10.1097/YCO.0b013e3283399b86
10.2217/WHE.10.69
10.1186/2042-6410-2-1
10.1016/j.comppsych.2015.07.002
10.1016/j.mce.2014.01.009
10.1186/1742-2094-8-81
10.1089/neu.2013.2951
10.1111/jne.12067",<Element 'PubmedArticle' at 0x7f05de3ce130>
230,"31962288
20369906
22732773
24600223
31119452
28916533
18090425
17187353
22420316
22348647
16862116
16862115
30326935
28778989
29382817
22733568
20026663
20667979
30925302
29478591
17596718
25575133
28845019
28070672
24240737
21326809
25578179
21047645
22890097
23609919
26820675
25261995
19557827
28473694
17291356
22859297
20946666
22781549
24800652
22062772
24046442
24619111
22608501
20522652
28903038
25022663
23830905
28073925
23201826
28404863
28379303
28438992
27114033
21933710
26701296
23835471
22869752
27721502
28647554
29149899
19649643
29378861
30696728
18559255
21092856
21698296
29555433
21087763
26370502
28640985
28541286
27356620
28453791
25664864
25056957
21289198
28379303
30180904
31122931
25398946
22449108
30237248
19348680
19571141
23086309
22872701
18957508
17023659
25155018
26391226
25126728
27888204
25498145
27864321
26038556
21148290
23781020
23023224
20604899
11208108
24105262
29466794
20543840
17947579
19574390
21300889
24914048
22238144
24498420
23303181
27337104
26157142
30185813
17403894
17704799
24719561
27301639
21878357
21979464
22123826
23199899
22432061
19934398
21338643
29383696
19553463
20736318
26892362
25393765
15961763
15718306
15774780
19047126
17062684
17363531
15867239
16832603
17363532
19088048
27129177
25368984
25625276
22246440
31375314",Approaches to develop therapeutics to treat frontotemporal dementia.,"Frontotemporal degeneration (FTD) is a complex disease presenting as a spectrum of clinical disorders with progressive degeneration of frontal and temporal brain cortices and extensive neuroinflammation that result in personality and behavior changes, and eventually, death. There are currently no effective therapies for FTD. While 60-70% of FTD patients are sporadic cases, the other 30-40% are heritable (familial) cases linked to mutations in several known genes. We focus here on FTD caused by mutations in the GRN gene, which encodes a secreted protein, progranulin (PGRN), that has diverse roles in regulating cell survival, immune responses, and autophagy and lysosome function in the brain. FTD-linked mutations in GRN reduce brain PGRN levels that lead to autophagy and lysosome dysfunction, TDP43 accumulation, excessive microglial activation, astrogliosis, and neuron death through still poorly understood mechanisms. PGRN insufficiency has also been linked to Alzheimer's disease (AD), and so the development of therapeutics for GRN-linked FTD that restore PGRN levels and function may have broader application for other neurodegenerative diseases. This review focuses on a strategy to increase PGRN to functional, healthy levels in the brain by identifying novel genetic and chemical modulators of neuronal PGRN levels. This article is part of the special issue entitled 'The Quest for Disease-Modifying Therapies for Neurodegenerative Disorders'.","['AD', 'FTD', 'Lysosome', 'Neurodegenerative', 'Progranulin', 'Therapeutics']",Neuropharmacology,2020-01-22,"[{'lastname': 'Elia', 'firstname': 'Lisa P', 'initials': 'LP', 'affiliation': 'Center for Systems and Therapeutics and Taube/Koret Center for Neurodegenerative Disease Research, San Francisco, CA, USA; The J. David Gladstone Institutes, San Francisco, CA, USA. Electronic address: lisa.elia@gladstone.ucsf.edu.'}, {'lastname': 'Reisine', 'firstname': 'Terry', 'initials': 'T', 'affiliation': 'Independent Scientific Consultant, Santa Cruz, CA, USA.'}, {'lastname': 'Alijagic', 'firstname': 'Amela', 'initials': 'A', 'affiliation': 'Center for Systems and Therapeutics and Taube/Koret Center for Neurodegenerative Disease Research, San Francisco, CA, USA; The J. David Gladstone Institutes, San Francisco, CA, USA.'}, {'lastname': 'Finkbeiner', 'firstname': 'Steven', 'initials': 'S', 'affiliation': 'Center for Systems and Therapeutics and Taube/Koret Center for Neurodegenerative Disease Research, San Francisco, CA, USA; The J. David Gladstone Institutes, San Francisco, CA, USA; Departments of Neurology and Physiology, UCSF, San Francisco, CA, USA. Electronic address: steve.finkbeiner@gladstone.ucsf.edu.'}]",,,,Copyright © 2020 Elsevier Ltd. All rights reserved.,10.1016/j.neuropharm.2020.107948,<Element 'PubmedArticle' at 0x7f05de380040>
231,"31897636
23733364
12432041
11792040
19774497
11874820
9821083
1342197
17213414
22083882
16151706
12690042
23008735
20138011
17881267
23093976
21734248",Methylprednisolone pulse therapy as an adjuvant treatment of Streptococcus pneumoniae meningitis complicated by cerebral infarction-a case report and review of the literature.,"The role of methylprednisolone pulse therapy as adjuvant treatment of Streptococcus pneumoniae meningitis complicated by cerebral infarction has rarely been reported.
We reported a case report and also performed a systematic literature review.
A 1-year 2-month-old boy who presented with high fever, status epilepticus, and septic shock was diagnosed with cerebral infarction caused by Streptococcus pneumoniae meningitis on magnetic resonance imaging (MRI). He was treated with methylprednisolone pulse therapy and his clinical condition gradually improved thereafter. At the follow-up visit 1 year after discharge, he was able to sit without support, but he had moderate delays in speech and developmental milestones and epilepsy sequelae.
In severe cases, the use of high-dose methylprednisolone should be considered to modulate the inflammatory response in patients with severe cerebral infarction caused by Streptococcus pneumoniae meningitis.","['Cerebral infarction', 'Meningitis', 'Methylprednisolone', 'Streptococcus pneumoniae']",Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery,2020-01-04,"[{'lastname': 'Chan', 'firstname': 'Oi-Wa', 'initials': 'OW', 'affiliation': ""Division of Pediatric Critical Care Medicine and Pediatric Neurocritical Care Center, Chang Gung Children's Hospital and Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Taoyuan, Taiwan.""}, {'lastname': 'Lin', 'firstname': 'Jainn-Jim', 'initials': 'JJ', 'affiliation': ""Division of Pediatric Critical Care Medicine and Pediatric Neurocritical Care Center, Chang Gung Children's Hospital and Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Taoyuan, Taiwan. lin0227@adm.cgmh.org.tw.\nDivision of Pediatric Neurology, Chang Gung Children's Hospital and Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Taoyuan, Taiwan. lin0227@adm.cgmh.org.tw.\nGraduate Institute of Clinical Medical Sciences, College of Medicine, Chang Gung University, Taoyuan, Taiwan. lin0227@adm.cgmh.org.tw.""}, {'lastname': 'Hsia', 'firstname': 'Shao-Hsuan', 'initials': 'SH', 'affiliation': ""Division of Pediatric Critical Care Medicine and Pediatric Neurocritical Care Center, Chang Gung Children's Hospital and Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Taoyuan, Taiwan.""}, {'lastname': 'Lin', 'firstname': 'Chia-Ying', 'initials': 'CY', 'affiliation': ""Division of Pediatric Critical Care Medicine and Pediatric Neurocritical Care Center, Chang Gung Children's Hospital and Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Taoyuan, Taiwan.""}, {'lastname': 'Lin', 'firstname': 'Kung-Lin', 'initials': 'KL', 'affiliation': ""Division of Pediatric Neurology, Chang Gung Children's Hospital and Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Taoyuan, Taiwan.""}]",,"In severe cases, the use of high-dose methylprednisolone should be considered to modulate the inflammatory response in patients with severe cerebral infarction caused by Streptococcus pneumoniae meningitis.","A 1-year 2-month-old boy who presented with high fever, status epilepticus, and septic shock was diagnosed with cerebral infarction caused by Streptococcus pneumoniae meningitis on magnetic resonance imaging (MRI). He was treated with methylprednisolone pulse therapy and his clinical condition gradually improved thereafter. At the follow-up visit 1 year after discharge, he was able to sit without support, but he had moderate delays in speech and developmental milestones and epilepsy sequelae.",,10.1007/s00381-019-04485-6,<Element 'PubmedArticle' at 0x7f05de308450>
232,31849284,The Renin-Angiotensin System and the Cerebrovascular Diseases: Experimental and Clinical Evidence.,"Cerebrovascular Diseases (CVD) comprise a wide spectrum of disorders, all sharing an acquired or inherited alteration of the cerebral vasculature. CVD have been associated with important changes in systemic and tissue Renin-Angiotensin System (RAS). The aim of this review was to summarize and to discuss recent findings related to the modulation of RAS components in CVD. The role of RAS axes is more extensively studied in experimentally induced stroke. By means of AT1 receptors in the brain, Ang II hampers cerebral blood flow and causes tissue ischemia, inflammation, oxidative stress, cell damage and apoptosis. On the other hand, Ang-(1-7) by stimulating Mas receptor promotes angiogenesis in brain tissue, decreases oxidative stress, neuroinflammation, and improves cognition, cerebral blood flow, neuronal survival, learning and memory. In regard to clinical studies, treatment with Angiotensin Converting Enzyme (ACE) inhibitors and AT1 receptor antagonists exerts preventive and therapeutic effects on stroke. Besides stroke, studies support a similar role of RAS molecules also in traumatic brain injury and cerebral aneurysm. The literature supports a beneficial role for the alternative RAS axis in CVD. Further studies are necessary to investigate the therapeutic potential of ACE2 activators and/or Mas receptor agonists in patients with CVD.","['Renin angiotensin system', 'angiotensin peptides', 'cerebral\naneurysm', 'cerebrovascular disease', 'stroke', 'traumatic brain injury.']",Protein and peptide letters,2019-12-19,"[{'lastname': 'Kangussu', 'firstname': 'Lucas M', 'initials': 'LM', 'affiliation': 'Department of Morphology - Biological Science Institute, Federal University of Minas Gerais, Belo Horizonte, MG, Brazil.'}, {'lastname': 'Marzano', 'firstname': 'Lucas Alexandre Santos', 'initials': 'LAS', 'affiliation': 'Interdisciplinary Laboratory of Medical Investigation - Faculty of Medicine, Federal University of Minas Gerais, Belo Horizonte, MG, Brazil.'}, {'lastname': 'Souza', 'firstname': 'Cássio Ferraz', 'initials': 'CF', 'affiliation': 'Interdisciplinary Laboratory of Medical Investigation - Faculty of Medicine, Federal University of Minas Gerais, Belo Horizonte, MG, Brazil.'}, {'lastname': 'Dantas', 'firstname': 'Carolina Couy', 'initials': 'CC', 'affiliation': 'Interdisciplinary Laboratory of Medical Investigation - Faculty of Medicine, Federal University of Minas Gerais, Belo Horizonte, MG, Brazil.'}, {'lastname': 'Miranda', 'firstname': 'Aline Silva', 'initials': 'AS', 'affiliation': 'Department of Morphology - Biological Science Institute, Federal University of Minas Gerais, Belo Horizonte, MG, Brazil.\nInterdisciplinary Laboratory of Medical Investigation - Faculty of Medicine, Federal University of Minas Gerais, Belo Horizonte, MG, Brazil.'}, {'lastname': 'Simões E Silva', 'firstname': 'Ana Cristina', 'initials': 'AC', 'affiliation': 'Interdisciplinary Laboratory of Medical Investigation - Faculty of Medicine, Federal University of Minas Gerais, Belo Horizonte, MG, Brazil.'}]",,,,"Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.",10.2174/0929866527666191218091823,<Element 'PubmedArticle' at 0x7f05de313e50>
233,31841076,Folate and vitamin B-12 deficiencies additively impaire memory function and disturb the gut microbiota in amyloid-β infused rats.,,"['folate', 'insulin resistance', 'insulin signaling', 'memory impairment', 'vitamin B12']",International journal for vitamin and nutrition research. Internationale Zeitschrift fur Vitamin- und Ernahrungsforschung. Journal international de vitaminologie et de nutrition,2019-12-17,"[{'lastname': 'Park', 'firstname': 'Sunmin', 'initials': 'S', 'affiliation': 'Dept. of Food and Nutrition, Obesity/Diabetes Research Center, Hoseo University, Asan, South Korea.'}, {'lastname': 'Kang', 'firstname': 'Sunna', 'initials': 'S', 'affiliation': 'Dept. of Food and Nutrition, Obesity/Diabetes Research Center, Hoseo University, Asan, South Korea.'}, {'lastname': 'Sol Kim', 'firstname': 'Da', 'initials': 'D', 'affiliation': 'Dept. of Food and Nutrition, Obesity/Diabetes Research Center, Hoseo University, Asan, South Korea.'}]",,,,,10.1024/0300-9831/a000624,<Element 'PubmedArticle' at 0x7f05de31f770>
234,31840601,Activation of Melanocortin-4 Receptor by a Synthetic Agonist Inhibits Ethanolinduced Neuroinflammation in Rats.,"High ethanol intake induces a neuroinflammatory response resulting in the subsequent maintenance of chronic alcohol consumption. The melanocortin system plays a pivotal role in the modulation of alcohol consumption. Interestingly, it has been shown that the activation of melanocortin-4 receptor (MC4R) in the brain decreases the neuroinflammatory response in models of brain damage other than alcohol consumption, such as LPS-induced neuroinflammation, cerebral ischemia, glutamate excitotoxicity, and spinal cord injury.
In this work, we aimed to study whether MC4R activation by a synthetic MC4R-agonist peptide prevents ethanol-induced neuroinflammation, and if alcohol consumption produces changes in MC4R expression in the hippocampus and hypothalamus.
Ethanol-preferring Sprague Dawley rats were selected offering access to 20% ethanol on alternate days for 4 weeks (intermittent access protocol). After this time, animals were i.p. administered an MC4R agonist peptide in the last 2 days of the protocol. Then, the expression of the proinflammatory cytokines interleukin 6 (IL-6), interleukin 1-beta (IL-1β), and tumor necrosis factor-alpha (TNF-α) were measured in the hippocampus, hypothalamus and prefrontal cortex. It was also evaluated if ethanol intake produces alterations in the expression of MC4R in the hippocampus and the hypothalamus.
Alcohol consumption increased the expression of MC4R in the hippocampus and the hypothalamus. The administration of the MC4R agonist reduced IL-6, IL-1β and TNF-α levels in hippocampus, hypothalamus and prefrontal cortex, to those observed in control rats that did not drink alcohol.
High ethanol consumption produces an increase in the expression of MC4R in the hippocampus and hypothalamus. The administration of a synthetic MC4R-agonist peptide prevents neuroinflammation induced by alcohol consumption in the hippocampus, hypothalamus, and prefrontal cortex. These results could explain the effect of α-MSH and other synthetic MC4R agonists in decreasing alcohol intake through the reduction of the ethanol-induced inflammatory response in the brain.","['MC4R', 'alcohol use disorder', 'hypothalamus', 'melanocortin', 'neuroinflammation', 'α-MSH.']",Current pharmaceutical design,2019-12-17,"[{'lastname': 'Flores-Bastías', 'firstname': 'Osvaldo', 'initials': 'O', 'affiliation': 'Instituto de Ciencias Biomédicas, Facultad de Ciencias de la Salud, Universidad Autónoma de Chile, Chile.\nResearch Center for the Study of Alcohol Drinking Behavior in Adolescents, Santiago, Chile.'}, {'lastname': 'Gómez', 'firstname': 'Gonzalo I', 'initials': 'GI', 'affiliation': 'Instituto de Ciencias Biomédicas, Facultad de Ciencias de la Salud, Universidad Autónoma de Chile, Chile.\nResearch Center for the Study of Alcohol Drinking Behavior in Adolescents, Santiago, Chile.'}, {'lastname': 'Orellana', 'firstname': 'Juan A', 'initials': 'JA', 'affiliation': 'Research Center for the Study of Alcohol Drinking Behavior in Adolescents, Santiago, Chile.\nDepartamento de Neurología, Escuela de Medicina and Centro Interdisciplinario de Neurociencias, Facultad de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile.'}, {'lastname': 'Karahanian', 'firstname': 'Eduardo', 'initials': 'E', 'affiliation': 'Instituto de Ciencias Biomédicas, Facultad de Ciencias de la Salud, Universidad Autónoma de Chile, Chile.\nResearch Center for the Study of Alcohol Drinking Behavior in Adolescents, Santiago, Chile.'}]",,"High ethanol consumption produces an increase in the expression of MC4R in the hippocampus and hypothalamus. The administration of a synthetic MC4R-agonist peptide prevents neuroinflammation induced by alcohol consumption in the hippocampus, hypothalamus, and prefrontal cortex. These results could explain the effect of α-MSH and other synthetic MC4R agonists in decreasing alcohol intake through the reduction of the ethanol-induced inflammatory response in the brain.","Alcohol consumption increased the expression of MC4R in the hippocampus and the hypothalamus. The administration of the MC4R agonist reduced IL-6, IL-1β and TNF-α levels in hippocampus, hypothalamus and prefrontal cortex, to those observed in control rats that did not drink alcohol.","Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.",10.2174/1381612825666191216145153,<Element 'PubmedArticle' at 0x7f05de32a360>
235,"31838720
28332351
29563239
28739265
21598254
29671630
29129775
29404958
28731040
30026855
27268025
27302362
21149712
29562511
24356899
30876953
24931035
27567882
28520620
26207957
29843466
21499987
29955663
23485579
22892813
23582316
1566067
28582855
17902624
25237037
24672477
29688074
24957018
17029828
23924004
28754350
26942887
24334722
25792098
28739640
25882496
27567931
14654748
27689985
22333133
28197094
23925758
29024348
28393248
26898424
25689033
29945734
27986603
16624814
23660953
30468210
27591966
23933749
29562518
24249045
27844057
21906355
22225636
28040599
19601831
28646794
27660271
29242277
25318545
22959056
19885299
1763432
29377010
24931033
26282939
28642806
28703214
28793924
29209211
21694462
9311619
24858405
26643169
15295589
25381575
29169962
26728181",Epigallocatechin-3-Gallate (EGCG) Improves Cognitive Deficits Aggravated by an Obesogenic Diet Through Modulation of Unfolded Protein Response in APPswe/PS1dE9 Mice.,"Epigallocatechin-3-gallate (EGCG), a catechin found in green tea, has been previously investigated for its neuroprotective effects in vitro and in vivo. In the present study, we aimed to evaluate its possible beneficial effects in a well-established preclinical mixed model of familial Alzheimer's disease (AD) and type 2 diabetes mellitus (T2DM) based on the use of transgenic APPswe/PS1dE9 (APP/PS1) mice fed with a high fat diet (HFD). C57BL/6 wild-type (WT) and APP/PS1 mice were used in this study. APP/PS1 mice were fed with a palmitic acid-enriched HFD (APP/PS1 HFD) containing 45% of fat mainly from hydrogenated coconut oil. Intraperitoneal glucose tolerance tests (IP-GTT) and insulin tolerance tests (IP-ITT) were performed. Western blot analyses were performed to analyse protein expression, and water maze and novel object recognition test were done to evaluate the cognitive process. EGCG treatment improves peripheral parameters such as insulin sensitivity or liver insulin pathway signalling, as well as central memory deficits. It also markedly increased synaptic markers and cAMP response element binding (CREB) phosphorylation rates, as a consequence of a decrease in the unfolded protein response (UPR) activation through the reduction in the activation factor 4 (ATF4) levels and posterior downregulation of protein tyrosine phosphatase 1B (PTP1B). Moreover, EGCG significantly decreased brain amyloid β (Aβ) production and plaque burden by increasing the levels of α-secretase (ADAM10). Also, it led to a reduction in neuroinflammation, as suggested by the decrease in astrocyte reactivity and toll-like receptor 4 (TLR4) levels. Collectively, evidence suggests that chronic EGCG prevents distinct neuropathological AD-related hallmarks. This study also provides novel insights into the metabolic and neurobiological mechanisms of EGCG against cognitive loss through its effects on UPR function, suggesting that this compound may be a promising disease-modifying treatment for neurodegenerative diseases.","['APPswe/PS1dE9 mice', 'Cognitive deficits', 'Epigallocatechin-3-gallate', 'Hippocampus', 'Obesity', 'Unfolded protein response']",Molecular neurobiology,2019-12-16,"[{'lastname': 'Ettcheto', 'firstname': 'Miren', 'initials': 'M', 'affiliation': 'Departament of Pharmacology, Toxicology and Therapeutic Chemistry, Faculty of Pharmacy and Food Science, University of Barcelona, Barcelona, Spain.\nDepartment of Biochemistry and Biotechnology, Faculty of Medicine and Life Science, University Rovira i Virgili, Reus, Spain.\nBiomedical Research Networking Centre in Neurodegenerative Diseases (CIBERNED), Madrid, Spain.\nInstitute of Neuroscience, University of Barcelona, Barcelona, Spain.'}, {'lastname': 'Cano', 'firstname': 'Amanda', 'initials': 'A', 'affiliation': 'Biomedical Research Networking Centre in Neurodegenerative Diseases (CIBERNED), Madrid, Spain.\nInstitute of Nanoscience and Nanotechnology (IN2UB), University of Barcelona, Barcelona, Spain.\nDepartment of Pharmacy, Pharmaceutical Technology and Physical Chemistry, Faculty of Pharmacy and Food Science, University of Barcelona, Barcelona, Spain.'}, {'lastname': 'Manzine', 'firstname': 'Patricia R', 'initials': 'PR', 'affiliation': 'Department of Gerontology, Federal University of São Carlos (UFSCar), São Carlos, 13565-905, Brazil.'}, {'lastname': 'Busquets', 'firstname': 'Oriol', 'initials': 'O', 'affiliation': 'Departament of Pharmacology, Toxicology and Therapeutic Chemistry, Faculty of Pharmacy and Food Science, University of Barcelona, Barcelona, Spain.\nDepartment of Biochemistry and Biotechnology, Faculty of Medicine and Life Science, University Rovira i Virgili, Reus, Spain.\nBiomedical Research Networking Centre in Neurodegenerative Diseases (CIBERNED), Madrid, Spain.\nInstitute of Neuroscience, University of Barcelona, Barcelona, Spain.'}, {'lastname': 'Verdaguer', 'firstname': 'Ester', 'initials': 'E', 'affiliation': 'Biomedical Research Networking Centre in Neurodegenerative Diseases (CIBERNED), Madrid, Spain.\nInstitute of Neuroscience, University of Barcelona, Barcelona, Spain.\nDepartment of Cellular Biology, Physiology and Immunology, Faculty of Biology, University of Barcelona, Barcelona, Spain.'}, {'lastname': 'Castro-Torres', 'firstname': 'Rubén Dario', 'initials': 'RD', 'affiliation': 'Departament of Pharmacology, Toxicology and Therapeutic Chemistry, Faculty of Pharmacy and Food Science, University of Barcelona, Barcelona, Spain.\nDepartment of Biochemistry and Biotechnology, Faculty of Medicine and Life Science, University Rovira i Virgili, Reus, Spain.\nBiomedical Research Networking Centre in Neurodegenerative Diseases (CIBERNED), Madrid, Spain.\nInstitute of Neuroscience, University of Barcelona, Barcelona, Spain.\nDepartment of Cellular Biology, Physiology and Immunology, Faculty of Biology, University of Barcelona, Barcelona, Spain.\nDepartment of Cellular and Molecular Biology, Neuroscience Division, C.U.C.B.A., University of Guadalajara, Sierra Mojada, Col. Independencia, Guadalajara, Jalisco, México.'}, {'lastname': 'García', 'firstname': 'Maria Luisa', 'initials': 'ML', 'affiliation': 'Institute of Nanoscience and Nanotechnology (IN2UB), University of Barcelona, Barcelona, Spain.\nDepartment of Pharmacy, Pharmaceutical Technology and Physical Chemistry, Faculty of Pharmacy and Food Science, University of Barcelona, Barcelona, Spain.'}, {'lastname': 'Beas-Zarate', 'firstname': 'Carlos', 'initials': 'C', 'affiliation': 'Department of Cellular and Molecular Biology, Neuroscience Division, C.U.C.B.A., University of Guadalajara, Sierra Mojada, Col. Independencia, Guadalajara, Jalisco, México.'}, {'lastname': 'Olloquequi', 'firstname': 'Jordi', 'initials': 'J', 'affiliation': 'Laboratory of Cellular and Molecular Pathology, Facultad de Ciencias de la Salud, Instituto de Ciencias Biomédicas, Universidad Autónoma de Chile, Talca, Chile.'}, {'lastname': 'Auladell', 'firstname': 'Carme', 'initials': 'C', 'affiliation': 'Biomedical Research Networking Centre in Neurodegenerative Diseases (CIBERNED), Madrid, Spain.\nInstitute of Neuroscience, University of Barcelona, Barcelona, Spain.\nDepartment of Cellular Biology, Physiology and Immunology, Faculty of Biology, University of Barcelona, Barcelona, Spain.'}, {'lastname': 'Folch', 'firstname': 'Jaume', 'initials': 'J', 'affiliation': 'Department of Biochemistry and Biotechnology, Faculty of Medicine and Life Science, University Rovira i Virgili, Reus, Spain.\nBiomedical Research Networking Centre in Neurodegenerative Diseases (CIBERNED), Madrid, Spain.'}, {'lastname': 'Camins', 'firstname': 'Antoni', 'initials': 'A', 'affiliation': ""Departament of Pharmacology, Toxicology and Therapeutic Chemistry, Faculty of Pharmacy and Food Science, University of Barcelona, Barcelona, Spain. camins@ub.edu.\nBiomedical Research Networking Centre in Neurodegenerative Diseases (CIBERNED), Madrid, Spain. camins@ub.edu.\nInstitute of Neuroscience, University of Barcelona, Barcelona, Spain. camins@ub.edu.\nLaboratory of Cellular and Molecular Pathology, Facultad de Ciencias de la Salud, Instituto de Ciencias Biomédicas, Universidad Autónoma de Chile, Talca, Chile. camins@ub.edu.\nUnitat de Farmacologia i Farmacognòsia, Facultat de Farmàcia i Ciències de l'Alimentació, Universitat de Barcelona, Av. Joan XXIII 27/31, E-08028, Barcelona, Spain. camins@ub.edu.""}]",,,,,10.1007/s12035-019-01849-6,<Element 'PubmedArticle' at 0x7f05de273d10>
236,"31812985
15905876
23108405
19455173
26404712
19291319
20447436
19560279
18417116
27646262
18511949
17078938
18752720
23942837
22539004
16214171
25770831
25084759
26423115
27796749
22871521
22197970
23169346
19805148
10908618
11279616
19576919
24717328
29863004
23579271
29596965
24636912
25574819
11846609
25046624
15113710
25916883
28860968
18391224
6606682
28095363
16024125
24040820
18052970
18675469
17638387
26657646
18784648
26491229
25316305
11015810
19193712
20012068
18412998
29063347
17462537
11677273
20418481
22701758
22254000
27221032
9147382
27551466
25587858
22923091
17074364
28396009
29373584
24103812",Naturally Derived Polyphenols Protect Against Corticosterone-Induced Changes in Primary Cortical Neurons.,"Polyphenols are phytochemicals that have been associated with therapeutic effects in stress-related disorders. Indeed, studies suggest that polyphenols exert significant neuroprotection against multiple neuronal injuries, including oxidative stress and neuroinflammation, but the mechanisms are unclear. Evidence indicates that polyphenol neuroprotection may be mediated by activation of Nrf2, a transcription factor associated with antioxidant and cell survival responses. On the other hand, in stress-linked disorders, Fkbp5 is a novel molecular target for treatment because of its capacity to regulate glucocorticoid receptor sensitivity. However, it is not clear the role Fkbp5 plays in polyphenol-mediated stress modulation. In this study, the neuroprotective effects and mechanisms of the naturally derived polyphenols xanthohumol and quercetin against cytotoxicity induced by corticosterone were investigated in primary cortical cells.
Primary cortical cells containing both neurons and astrocytes were pre-incubated with different concentrations of quercetin and xanthohumol to examine the neuroprotective effects of polyphenols on cell viability, morphology, and gene expression following corticosterone insult.
Both polyphenols tested prevented the reduction of cell viability and alterations of neuronal/astrocytic numbers due to corticosterone exposure. Basal levels of Bdnf mRNA were also decreased after corticosterone insult; however, this was reversed by both polyphenol treatments. Interestingly, the Nrf2 inhibitor blocked xanthohumol but not quercetin-mediated neuroprotection. In contrast, we found that Fkbp5 expression is exclusively modulated by quercetin.
These results suggest that naturally derived polyphenols protect cortical cells against corticosterone-induced cytotoxicity and enhance cell survival via modulation of the Nrf2 pathway and expression of Fkbp5.","['cortical neurons', 'corticosterone', 'polyphenols', 'stress']",The international journal of neuropsychopharmacology,2019-12-10,"[{'lastname': 'Donoso', 'firstname': 'Francisco', 'initials': 'F', 'affiliation': 'APC Microbiome Ireland.\nDepartment of Psychiatry and Neurobehavioral Science, University College Cork, Cork, Ireland.'}, {'lastname': 'Ramírez', 'firstname': 'Valerie T', 'initials': 'VT', 'affiliation': 'APC Microbiome Ireland.'}, {'lastname': 'Golubeva', 'firstname': 'Anna V', 'initials': 'AV', 'affiliation': 'APC Microbiome Ireland.\nDepartment of Anatomy and Neuroscience, University College Cork, Cork, Ireland.'}, {'lastname': 'Moloney', 'firstname': 'Gerard M', 'initials': 'GM', 'affiliation': 'APC Microbiome Ireland.\nDepartment of Anatomy and Neuroscience, University College Cork, Cork, Ireland.'}, {'lastname': 'Stanton', 'firstname': 'Catherine', 'initials': 'C', 'affiliation': 'APC Microbiome Ireland.\nTeagasc Food Research Centre, Moorepark, Fermoy, Co. Cork, Ireland.'}, {'lastname': 'Dinan', 'firstname': 'Timothy G', 'initials': 'TG', 'affiliation': 'APC Microbiome Ireland.\nDepartment of Psychiatry and Neurobehavioral Science, University College Cork, Cork, Ireland.'}, {'lastname': 'Cryan', 'firstname': 'John F', 'initials': 'JF', 'affiliation': 'APC Microbiome Ireland.\nDepartment of Anatomy and Neuroscience, University College Cork, Cork, Ireland.'}]",,,"Both polyphenols tested prevented the reduction of cell viability and alterations of neuronal/astrocytic numbers due to corticosterone exposure. Basal levels of Bdnf mRNA were also decreased after corticosterone insult; however, this was reversed by both polyphenol treatments. Interestingly, the Nrf2 inhibitor blocked xanthohumol but not quercetin-mediated neuroprotection. In contrast, we found that Fkbp5 expression is exclusively modulated by quercetin.",© The Author(s) 2019. Published by Oxford University Press on behalf of CINP.,10.1093/ijnp/pyz052,<Element 'PubmedArticle' at 0x7f05de29d5e0>
237,"31779639
27637674
29554978
25385337
25956409
26011640
19063914
24704258
18329265
20153425
26600009
28894299
12422368
14973190
17264205
21541365
24300521
25264773
27459405
28747667
29775591
20729857
24212761
28260801
1603325
16436770
16482081
22414893
26851161
28524175
25022952
30983988
11070493
25993987
17923864
29227285
24291544",DHEA Attenuates Microglial Activation via Induction of JMJD3 in Experimental Subarachnoid Haemorrhage.,"Microglia are resident immune cells in the central nervous system and central to the innate immune system. Excessive activation of microglia after subarachnoid haemorrhage (SAH) contributes greatly to early brain injury, which is responsible for poor outcomes. Dehydroepiandrosterone (DHEA), a steroid hormone enriched in the brain, has recently been found to regulate microglial activation. The purpose of this study was to address the role of DHEA in SAH.
We used in vivo models of endovascular perforation and in vitro models of haemoglobin exposure to illustrate the effects of DHEA on microglia in SAH.
In experimental SAH mice, exogenous DHEA administration increased DHEA levels in the brain and modulated microglial activation. Ameliorated neuronal damage and improved neurological outcomes were also observed in the SAH mice pretreated with DHEA, suggesting neuronal protective effects of DHEA. In cultured microglia, DHEA elevated the mRNA and protein levels of Jumonji d3 (JMJD3, histone 3 demethylase) after haemoglobin exposure, downregulated the H3K27me3 level, and inhibited the transcription of proinflammatory genes. The devastating proinflammatory microglia-mediated effects on primary neurons were also attenuated by DHEA; however, specific inhibition of JMJD3 abolished the protective effects of DHEA. We next verified that DHEA-induced JMJD3 expression, at least in part, through the tropomyosin-related kinase A (TrkA)/Akt signalling pathway.
DHEA has a neuroprotective effect after SAH. Moreover, DHEA increases microglial JMJD3 expression to regulate proinflammatory/anti-inflammatory microglial activation after haemoglobin exposure, thereby suppressing inflammation.","['Dehydroepiandrosterone', 'Inflammation', 'JMJD3', 'Microglia', 'Subarachnoid haemorrhage']",Journal of neuroinflammation,2019-11-30,"[{'lastname': 'Tao', 'firstname': 'Tao', 'initials': 'T', 'affiliation': 'Department of Neurosurgery, Nanjing Drum Tower Hospital Clinical College of Nanjing Medical University, Nanjing, 210008, Jiangsu, China.'}, {'lastname': 'Liu', 'firstname': 'Guang-Jie', 'initials': 'GJ', 'affiliation': 'Department of Neurosurgery, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, 210008, Jiangsu, China.'}, {'lastname': 'Shi', 'firstname': 'Xuan', 'initials': 'X', 'affiliation': 'Department of Neurology, Jinling Hospital, Nanjing Medical University, Nanjing, China.'}, {'lastname': 'Zhou', 'firstname': 'Yan', 'initials': 'Y', 'affiliation': 'Department of Neurosurgery, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, 210008, Jiangsu, China.'}, {'lastname': 'Lu', 'firstname': 'Yue', 'initials': 'Y', 'affiliation': 'Department of Neurosurgery, Nanjing Drum Tower Hospital Clinical College of Nanjing Medical University, Nanjing, 210008, Jiangsu, China.\nDepartment of Neurosurgery, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, 210008, Jiangsu, China.'}, {'lastname': 'Gao', 'firstname': 'Yong-Yue', 'initials': 'YY', 'affiliation': 'Department of Neurosurgery, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, 210008, Jiangsu, China.'}, {'lastname': 'Zhang', 'firstname': 'Xiang-Sheng', 'initials': 'XS', 'affiliation': 'Department of Neurosurgery, Beijing Friendship Hospital, Capital Medical University, Beijing, 100032, China.'}, {'lastname': 'Wang', 'firstname': 'Han', 'initials': 'H', 'affiliation': 'Department of Neurosurgery, Nanjing Drum Tower Hospital Clinical College of Nanjing Medical University, Nanjing, 210008, Jiangsu, China.'}, {'lastname': 'Wu', 'firstname': 'Ling-Yun', 'initials': 'LY', 'affiliation': 'Department of Neurosurgery, Nanjing Drum Tower Hospital Clinical College of Nanjing Medical University, Nanjing, 210008, Jiangsu, China.\nDepartment of Neurosurgery, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, 210008, Jiangsu, China.'}, {'lastname': 'Chen', 'firstname': 'Chun-Lei', 'initials': 'CL', 'affiliation': 'Department of Neurosurgery, Nanjing Drum Tower Hospital Clinical College of Nanjing Medical University, Nanjing, 210008, Jiangsu, China.\nDepartment of Neurosurgery, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, 210008, Jiangsu, China.'}, {'lastname': 'Zhuang', 'firstname': 'Zong', 'initials': 'Z', 'affiliation': 'Department of Neurosurgery, Nanjing Drum Tower Hospital Clinical College of Nanjing Medical University, Nanjing, 210008, Jiangsu, China.\nDepartment of Neurosurgery, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, 210008, Jiangsu, China.'}, {'lastname': 'Li', 'firstname': 'Wei', 'initials': 'W', 'affiliation': 'Department of Neurosurgery, Nanjing Drum Tower Hospital Clinical College of Nanjing Medical University, Nanjing, 210008, Jiangsu, China. lwxzlw@126.com.\nDepartment of Neurosurgery, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, 210008, Jiangsu, China. lwxzlw@126.com.'}, {'lastname': 'Hang', 'firstname': 'Chun-Hua', 'initials': 'CH', 'affiliation': 'Department of Neurosurgery, Nanjing Drum Tower Hospital Clinical College of Nanjing Medical University, Nanjing, 210008, Jiangsu, China. hang_neurosurgery@163.com.\nDepartment of Neurosurgery, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, 210008, Jiangsu, China. hang_neurosurgery@163.com.'}]",,,"In experimental SAH mice, exogenous DHEA administration increased DHEA levels in the brain and modulated microglial activation. Ameliorated neuronal damage and improved neurological outcomes were also observed in the SAH mice pretreated with DHEA, suggesting neuronal protective effects of DHEA. In cultured microglia, DHEA elevated the mRNA and protein levels of Jumonji d3 (JMJD3, histone 3 demethylase) after haemoglobin exposure, downregulated the H3K27me3 level, and inhibited the transcription of proinflammatory genes. The devastating proinflammatory microglia-mediated effects on primary neurons were also attenuated by DHEA; however, specific inhibition of JMJD3 abolished the protective effects of DHEA. We next verified that DHEA-induced JMJD3 expression, at least in part, through the tropomyosin-related kinase A (TrkA)/Akt signalling pathway.",,"10.1186/s12974-019-1641-y
10.1016/S0140-6736(16)30668-7
10.1186/s12974-018-1118-4
10.1038/nrneurol.2014.207
10.1007/s00401-015-1440-1
10.1172/JCI78443
10.1016/j.yfrne.2008.11.002
10.1016/j.jsbmb.2014.03.008
10.1016/j.jsbmb.2007.12.013
10.1016/j.jsbmb.2010.02.007
10.1016/j.psyneuen.2015.11.005
10.1038/mp.2017.167
10.1002/syn.10145
10.1073/pnas.0307325101
10.1073/pnas.0610898104
10.1371/journal.pbio.1001051
10.1038/nmeth.3125
10.1038/nn.4338
10.1038/s41598-017-06914-5
10.1016/j.cell.2018.05.003
10.1038/ni.1920
10.1038/cdd.2013.159
10.1038/aps.2016.162
10.1016/0306-4522(92)90500-2
10.1056/NEJMra052732
10.1038/sj.jcbfm.9600283
10.1016/j.pneurobio.2012.02.003
10.1016/j.pneurobio.2016.01.005
10.1038/nrneurol.2017.69
10.1007/s40265-014-0259-8
10.3389/fnagi.2019.00061
10.1002/1097-4547(20001115)62:4<503::AID-JNR4>3.0.CO;2-A
10.1186/s13054-015-0954-1
10.1038/cr.2007.83
10.1172/JCI95946
10.1016/j.pneurobio.2013.11.003",<Element 'PubmedArticle' at 0x7f05de1b5ea0>
238,31734263,Neuroinflammation induced by lipopolysaccharide leads to memory impairment and alterations in hippocampal leptin signaling.,"Peripheral inflammation promotes immune-to-brain communication, mediated by cytokines that affect brain activity. Lipopolysaccharide (LPS) has been widely used to mimic systemic inflammation, and the adipokine leptin, released in this condition, modulates hypothalamic leptin receptors (ObR), contributing to sickness behavior. In this study, we used the intracerebroventricular (ICV) route for LPS administration in an attempt to evaluate an acute and direct of this pathogen-associated molecular pattern on leptin-mediated signaling in the hippocampus, where ObR has been implicated in modulating cognitive response. We used bilateral ICV injection of LPS (25 μg/ventricle) in 60-day-old male Wistar rats and the analysis were performed 48 h after surgery. Neuroinflammation was characterized in the LPS group by an increase in concentration of IL-1β, COX-2 and TLR4 in the hippocampus as well as glial fibrillary acidic protein (GFAP), indicating an astrocyte commitment. Cognitive damage was observed in the animals of the LPS group by an inability to increase the recognition index during the object recognition test. We observed an increase in the concentration of leptin receptors in the hippocampus, which was unaccompanied by changes in the proteins involved in leptin intracellular signaling (p-STAT3 and SOCS3). Moreover, we found a decrease in leptin concentration in the serum of the animals in the LPS group accompanied by an increase in TNF-α levels. Our results showed that neuroinflammation, even in an acute state, can lead to cognitive impairment and may be associated with leptin signaling disturbances in the hippocampus.","['Astrocytes', 'Hippocampus', 'Leptin', 'Lipopolysaccharide', 'Memory', 'Neuroinflammation']",Behavioural brain research,2019-11-18,"[{'lastname': 'Da Ré', 'firstname': 'Carollina', 'initials': 'C', 'affiliation': 'Departamento de Bioquímica, Instituto de Ciências Básicas da Saúde, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil. Electronic address: carollinafdare@gmail.com.'}, {'lastname': 'Souza', 'firstname': 'Jéssica Maria', 'initials': 'JM', 'affiliation': 'Departamento de Bioquímica, Instituto de Ciências Básicas da Saúde, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil. Electronic address: souza.jessicams@gmail.com.'}, {'lastname': 'Fróes', 'firstname': 'Fernanda', 'initials': 'F', 'affiliation': 'Departamento de Bioquímica, Instituto de Ciências Básicas da Saúde, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil. Electronic address: fernandatellesfroes@hotmail.com.'}, {'lastname': 'Taday', 'firstname': 'Jéssica', 'initials': 'J', 'affiliation': 'Departamento de Bioquímica, Instituto de Ciências Básicas da Saúde, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil. Electronic address: jessicataday@hotmail.com.'}, {'lastname': 'Dos Santos', 'firstname': 'João Paulo', 'initials': 'JP', 'affiliation': 'Departamento de Bioquímica, Instituto de Ciências Básicas da Saúde, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil. Electronic address: jpadossantos@gmail.com.'}, {'lastname': 'Rodrigues', 'firstname': 'Letícia', 'initials': 'L', 'affiliation': 'Departamento de Bioquímica, Instituto de Ciências Básicas da Saúde, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil. Electronic address: letigues@gmail.com.'}, {'lastname': 'Sesterheim', 'firstname': 'Patrícia', 'initials': 'P', 'affiliation': 'Instituto de Cardiologia - Fundação Universitária de Cardiologia, Porto Alegre, Brazil. Electronic address: patriciasester@gmail.com.'}, {'lastname': 'Gonçalves', 'firstname': 'Carlos Alberto', 'initials': 'CA', 'affiliation': 'Departamento de Bioquímica, Instituto de Ciências Básicas da Saúde, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil. Electronic address: casg@ufrgs.br.'}, {'lastname': 'Leite', 'firstname': 'Marina Concli', 'initials': 'MC', 'affiliation': 'Departamento de Bioquímica, Instituto de Ciências Básicas da Saúde, Universidade Federal do Rio Grande do Sul, Porto Alegre, Brazil. Electronic address: marina.leite@ufrgs.br.'}]",,,,Copyright © 2019 Elsevier B.V. All rights reserved.,10.1016/j.bbr.2019.112360,<Element 'PubmedArticle' at 0x7f05de1deea0>
239,31730796,Palmitate and Nitric Oxide Regulate the Expression of Spexin and Galanin Receptors 2 and 3 in Hypothalamic Neurons.,"Spexin (SPX) is a novel satiety factor that putatively binds the galanin receptors R2 and R3 (GalR2/R3). SPX reduces body weight, and circulating SPX is decreased in obesity. It is unknown how SPX and its receptors are regulated in the hypothalamus, critical for energy homeostasis. We therefore examined the regulation of hypothalamic Spx, GalR2 and GalR3 gene expression in mouse primary and immortalized hypothalamic neurons. We report that Spx, GalR2 and GalR3 mRNA levels were regulated by acute treatments of palmitate, a dietary saturated fatty acid, as well as the nitric oxide (NO) donor sodium nitroprusside (SNP), but through a pathway independent of cyclic GMP and protein kinase G. Additionally, the palmitate- and NO-mediated induction of Spx and galanin receptors was blocked with the PKC inhibitor k252c. Furthermore, palmitate induced mRNA levels of endoplasmic reticulum (ER) stress markers, including Chop, Grp78 and Bax/Bcl2, as well as C/ebp-β, whereas SNP induced Bax/Bcl2 and C/ebp-β. Transcriptional changes in Spx, GalR2, GalR3, C/ebp-β and ER stress marker mRNAs were blocked by pre-treatment with at least one of the chemical chaperones PBA or TUDCA. We also describe the presence of OCT-1 and C/EBP-β response elements in the 5' regulatory region of Spx and demonstrate that SNP increases binding of C/EBP-β to this region, but not Oct-1 mRNA nor OCT-1 binding. Our findings suggest an acute modulation of anorexigenic SPX signaling by palmitate and NO. Furthermore, ER stress and C/EBP-β appear to mediate the changes in Spx, GalR2 and GalR3 in hypothalamic neurons.","['anorexigen', 'cell biology', 'hypothalamus', 'neuroendocrinology', 'neuroinflammation', 'neuropeptide']",Neuroscience,2019-11-16,"[{'lastname': 'Tran', 'firstname': 'Andy', 'initials': 'A', 'affiliation': 'Departments of Physiology, University of Toronto, Toronto, ON, Canada.'}, {'lastname': 'Loganathan', 'firstname': 'Neruja', 'initials': 'N', 'affiliation': 'Departments of Physiology, University of Toronto, Toronto, ON, Canada.'}, {'lastname': 'McIlwraith', 'firstname': 'Emma K', 'initials': 'EK', 'affiliation': 'Departments of Physiology, University of Toronto, Toronto, ON, Canada.'}, {'lastname': 'Belsham', 'firstname': 'Denise D', 'initials': 'DD', 'affiliation': 'Departments of Physiology, University of Toronto, Toronto, ON, Canada; Departments of Obstetrics and Gynaecology, University of Toronto, Toronto, ON, Canada; Departments of Medicine, University of Toronto, Toronto, ON, Canada. Electronic address: d.belsham@utoronto.ca.'}]",,,,Copyright © 2019 IBRO. Published by Elsevier Ltd. All rights reserved.,10.1016/j.neuroscience.2019.10.028,<Element 'PubmedArticle' at 0x7f05de16ea40>
240,"31680842
29364586
26851597
30640362
29843254
28781108
28258522
30673988
17803225
29331730
31256135
22476196
22262078
24583037
29175324
26666230
23485579
30946847
23158895
30222190
12960095
30024276
31474827
16306348
18466898
27252647
30863012
26497034
31327392
27421117
25869785
18492290
5959122
25904081
27186358
25556713
12867498
25728442
29305122
25195184
19297401
19164583
26141845
30826352
26183127
23254291
23973293
26205827
12007541
22776039
18479783
27871675
30643288
20871975
10202534
28062257
23536825
31139316
27131827
18948395
25834231
28342971
31002893
26386291
21356520
29050859
27715341
10657518
25008180
29223528
29916537
29598932
30017231
30741689",Glucagon-Like Peptide-1: A Focus on Neurodegenerative Diseases.,"Diabetes mellitus is one of the major risk factors for cognitive dysfunction. The pathogenesis of brain impairment caused by chronic hyperglycemia is complex and includes mitochondrial dysfunction, neuroinflammation, neurotransmitters' alteration, and vascular disease, which lead to cognitive impairment, neurodegeneration, loss of synaptic plasticity, brain aging, and dementia. Glucagon-like peptide-1 (GLP-1), a gut released hormone, is attracting attention as a possible link between metabolic and brain impairment. Several studies have shown the influence of GPL-1 on neuronal functions such as thermogenesis, blood pressure control, neurogenesis, neurodegeneration, retinal repair, and energy homeostasis. Moreover, modulation of GLP-1 activity can influence amyloid β peptide aggregation in Alzheimer's disease (AD) and dopamine (DA) levels in Parkinson's disease (PD). GLP-1 receptor agonists (GLP-1RAs) showed beneficial actions on brain ischemia in animal models, such as the reduction of cerebral infarct area and the improvement of neurological deficit, acting mainly through inhibition of oxidative stress, inflammation, and apoptosis. They might also exert a beneficial effect on the cognitive impairment induced by diabetes or obesity improving learning and memory by modulating synaptic plasticity. Moreover, GLP-1RAs reduced hippocampal neurodegeneration. Besides this, there are growing evidences on neuroprotective effects of these agonists in animal models of neurodegenerative diseases, regardless of diabetes. In PD animal models, GPL-1RAs were able to protect motor activity and dopaminergic neurons whereas in AD models, they seemed to improve nearly all neuropathological features and cognitive functions. Although further clinical studies of GPL-1RAs in humans are needed, they seem to be a promising therapy for diabetes-associated cognitive decline.","['Alzheimer’s disease', 'GLP-1 receptor agonists', 'Parkinson’s disease', 'glucagon-like peptide-1', 'neurodegenerative diseases', 'type 2 diabetes']",Frontiers in neuroscience,2019-11-05,"[{'lastname': 'Grieco', 'firstname': 'Maddalena', 'initials': 'M', 'affiliation': 'Department of Biochemical Sciences, Faculty of Pharmacy and Medicine, Sapienza University of Rome, Rome, Italy.'}, {'lastname': 'Giorgi', 'firstname': 'Alessandra', 'initials': 'A', 'affiliation': 'Department of Biochemical Sciences, Faculty of Pharmacy and Medicine, Sapienza University of Rome, Rome, Italy.'}, {'lastname': 'Gentile', 'firstname': 'Maria Cristina', 'initials': 'MC', 'affiliation': 'Department of Experimental Medicine, Faculty of Medicine and Dentistry, Sapienza University of Rome, Rome, Italy.'}, {'lastname': ""d'Erme"", 'firstname': 'Maria', 'initials': 'M', 'affiliation': 'Department of Biochemical Sciences, Faculty of Pharmacy and Medicine, Sapienza University of Rome, Rome, Italy.'}, {'lastname': 'Morano', 'firstname': 'Susanna', 'initials': 'S', 'affiliation': 'Department of Experimental Medicine, Faculty of Medicine and Dentistry, Sapienza University of Rome, Rome, Italy.'}, {'lastname': 'Maras', 'firstname': 'Bruno', 'initials': 'B', 'affiliation': 'Department of Biochemical Sciences, Faculty of Pharmacy and Medicine, Sapienza University of Rome, Rome, Italy.'}, {'lastname': 'Filardi', 'firstname': 'Tiziana', 'initials': 'T', 'affiliation': 'Department of Experimental Medicine, Faculty of Medicine and Dentistry, Sapienza University of Rome, Rome, Italy.'}]",,,,"Copyright © 2019 Grieco, Giorgi, Gentile, d’Erme, Morano, Maras and Filardi.","10.3389/fnins.2019.01112
10.1111/dom.13162
10.1016/j.drudis.2016.01.013
10.1001/jamaneurol.2018.4304
10.3233/JPD-181329
10.1016/S0140-6736(17)31585-4
10.1007/s10787-017-0331-6
10.1007/s12640-019-9998-3
10.1002/jnr.21483
10.1016/j.neurobiolaging.2017.12.009
10.3233/JAD-190237
10.1172/JCI57256
10.1900/RDS.2011.8.418
10.1016/j.neuroscience.2014.02.022
10.1016/j.bbrc.2017.11.114
10.1007/s40263-015-0301-8
10.1172/JCI64595
10.1016/j.neuropharm.2019.03.035
10.1002/ddr.21439
10.1210/en.2003-323
10.1177/1479164118788079
10.3389/fnins.2019.00868
10.2337/diabetes.54.12.3343
10.1016/j.ejphar.2008.03.025
10.3389/fnagi.2016.00108
10.2147/DDDT.S165372
10.1007/s12035-015-9494-6
10.1016/j.jalz.2019.06.001
10.1371/journal.pone.0158205
10.3233/JAD-143090
10.1186/1742-2094-5-19
10.1007/bf00577838
10.1016/S0140-6736(14)61393-3
10.1111/jdi.12464
10.1111/micc.12186
10.1523/jneurosci.23-15-06163.2003
10.1016/S1474-4422(14)70249-2
10.1016/j.neuropharm.2018.01.001
10.1016/j.peptides.2014.08.014
10.1093/hmg/ddp012
10.1073/pnas.0806720106
10.1016/j.neuroscience.2015.06.054
10.1016/j.brainres.2019.02.030
10.1111/jnc.13248
10.1038/cddis.2012.189
10.1016/j.neuropharm.2013.08.005
10.1016/j.bbr.2015.07.024
10.1016/s0014-2999(02)01434-6
10.1111/j.1463-1326.2012.01663.x
10.1016/j.neurobiolaging.2008.04.002
10.1016/j.tem.2016.10.001
10.1038/s41591-018-0297-y
10.1007/s00125-010-1896-4
10.1146/annurev.neuro.22.1.123
10.1016/j.bbr.2017.01.004
10.1371/journal.pone.0058784
10.4239/wjd.v10.i5.291
10.1016/j.ejphar.2016.04.052
10.1210/en.2008-1221
10.1152/physrev.00013.2014
10.1016/j.bbr.2017.03.032
10.1016/j.neuint.2019.04.010
10.1016/j.ejphar.2015.09.024
10.1016/j.cmet.2011.02.002
10.1016/j.brainres.2017.10.012
10.1080/14737175.2017.1246183
10.1054/npep.1999.0053
10.2337/db14-0375
10.1016/j.neuropharm.2017.11.048
10.3892/mmr.2018.9180
10.1016/j.dsx.2018.03.002
10.1016/j.npep.2018.07.003
10.3233/JPD-181503",<Element 'PubmedArticle' at 0x7f05de17a9f0>
241,31675255,Bacterial meningitis: new treatment options to reduce the risk of brain damage.,,"['Bacterial meningitis', 'corticosteroid', 'daptomycin', 'glycerol', 'meningitis', 'metalloproteinase modulator']",Expert opinion on pharmacotherapy,2019-11-02,"[{'lastname': 'Principi', 'firstname': 'Nicola', 'initials': 'N', 'affiliation': 'Emeritus of Pediatrics, Università degli Studi di Milano, Milan, Italy.'}, {'lastname': 'Esposito', 'firstname': 'Susanna', 'initials': 'S', 'affiliation': ""Pietro Barilla Children's Hospital, Department of Medicine and Surgery, University of Parma, Parma, Italy.""}]",,,,,10.1080/14656566.2019.1685497,<Element 'PubmedArticle' at 0x7f05de12a2c0>
242,31646669,"Angiotensin II modulates amphetamine-induced glial and brain vascular responses, and attention deficit via angiotensin type 1 receptor: Evidence from brain regional sensitivity to amphetamine.","Amphetamine-induced neuroadaptations involve vascular damage, neuroinflammation, a hypo-functioning prefrontal cortex (PFC), and cognitive alterations. Brain angiotensin II, through angiotensin type 1 receptor (AT","['astrocytes', 'attention deficit', 'brain microvessels', 'microglia', 'prefrontal cortex']",The European journal of neuroscience,2019-10-28,"[{'lastname': 'Marchese', 'firstname': 'Natalia Andrea', 'initials': 'NA', 'affiliation': 'Departamento de Farmacología, Facultad de Ciencias Químicas, Instituto de Farmacología Experimental Córdoba (IFEC-CONICET), Universidad Nacional de Córdoba, Córdoba, Argentina.'}, {'lastname': 'Occhieppo', 'firstname': 'Victoria Belén', 'initials': 'VB', 'affiliation': 'Departamento de Farmacología, Facultad de Ciencias Químicas, Instituto de Farmacología Experimental Córdoba (IFEC-CONICET), Universidad Nacional de Córdoba, Córdoba, Argentina.'}, {'lastname': 'Basmadjian', 'firstname': 'Osvaldo Martin', 'initials': 'OM', 'affiliation': 'Departamento de Farmacología, Facultad de Ciencias Químicas, Instituto de Farmacología Experimental Córdoba (IFEC-CONICET), Universidad Nacional de Córdoba, Córdoba, Argentina.'}, {'lastname': 'Casarsa', 'firstname': 'Brenda Solange', 'initials': 'BS', 'affiliation': 'Laboratorio de Neurofarmacología, (IIBYT-CONICET), Facultad de Ciencias Químicas, Universidad Nacional de Córdoba, Universidad Católica de Córdoba, Córdoba, Argentina.'}, {'lastname': 'Baiardi', 'firstname': 'Gustavo', 'initials': 'G', 'affiliation': 'Laboratorio de Neurofarmacología, (IIBYT-CONICET), Facultad de Ciencias Químicas, Universidad Nacional de Córdoba, Universidad Católica de Córdoba, Córdoba, Argentina.'}, {'lastname': 'Bregonzio', 'firstname': 'Claudia', 'initials': 'C', 'affiliation': 'Departamento de Farmacología, Facultad de Ciencias Químicas, Instituto de Farmacología Experimental Córdoba (IFEC-CONICET), Universidad Nacional de Córdoba, Córdoba, Argentina.'}]",,,,© 2019 Federation of European Neuroscience Societies and John Wiley & Sons Ltd.,10.1111/ejn.14605,<Element 'PubmedArticle' at 0x7f05de130db0>
243,31639435,"Intranasal insulin treatment modulates the neurotropic, inflammatory, and oxidant mechanisms in the cortex and hippocampus in a low-grade inflammation model.","The inflammatory process plays a critical role in the development of neurodegenerative diseases. Insulin is used in preclinical and clinical studies of neurological disorders. Its intranasal (IN) administration directly in the brain allows for its peripheral metabolic effects to be avoided. Swiss male mice were injected with lipopolysaccharide (LPS) (0.1 mg/kg) to induce low-grade inflammation. IN insulin treatment was initiated 4 h later at a dose of 1.7 IU once daily for 5 days. LPS induced cognitive deficits, which the IN insulin treatment reversed. LPS significantly decreased, whereas IN insulin significantly increased the levels of brain-derived neurotrophic factor (BDNF) and nerve growth factor-β in the cortex. In the hippocampus, IN insulin significantly decreased the BDNF level. LPS significantly increased the interleukin (IL)-6 levels in the cortex, while IN Insulin significantly decreased its levels in the hippocampus. The tumor necrosis factor-α levels were significantly decreased by IN insulin both in the cortex and hippocampus. Moreover, IN insulin significantly increased the IL-10 levels in the cortex. The levels of oxidative and nitrosative stress were significantly higher in the LPS-treated mice; however, IN insulin had a modulatory effect on both. LPS significantly increased the antioxidant enzyme activity both in the cortex and hippocampus, whereas IN insulin significantly increased the activity of both superoxide dismutase and catalase in the hippocampus and that of catalase in the cortex. The hydrogen peroxide levels revealed that LPS significantly affected the electron transport chain. Therefore, IN insulin could be useful in the treatment of neuroinflammatory diseases.","['Brain metabolism', 'Drugs delivery', 'Learning and memory', 'Neuroinflammation', 'Oxidative stress']",Peptides,2019-10-23,"[{'lastname': 'Simon', 'firstname': 'Kellen Ugioni', 'initials': 'KU', 'affiliation': 'Programa de Pós-Graduação em Ciências da Saúde, Universidade do Extremo Sul Catarinense (UNESC), 88806-00 Criciúma, SC, Brazil.'}, {'lastname': 'Neto', 'firstname': 'Elias Wiggers', 'initials': 'EW', 'affiliation': 'Programa de Pós-Graduação em Ciências da Saúde, Universidade do Extremo Sul Catarinense (UNESC), 88806-00 Criciúma, SC, Brazil.'}, {'lastname': 'Tramontin', 'firstname': 'Natalia Dos Santos', 'initials': 'NDS', 'affiliation': 'Programa de Pós-Graduação em Ciências da Saúde, Universidade do Extremo Sul Catarinense (UNESC), 88806-00 Criciúma, SC, Brazil.'}, {'lastname': 'Canteiro', 'firstname': 'Paula Bortoluzzi', 'initials': 'PB', 'affiliation': 'Programa de Pós-Graduação em Ciências da Saúde, Universidade do Extremo Sul Catarinense (UNESC), 88806-00 Criciúma, SC, Brazil.'}, {'lastname': 'Pereira', 'firstname': 'Barbara da Costa', 'initials': 'BDC', 'affiliation': 'Programa de Pós-Graduação em Ciências da Saúde, Universidade do Extremo Sul Catarinense (UNESC), 88806-00 Criciúma, SC, Brazil.'}, {'lastname': 'Zaccaron', 'firstname': 'Rubya Pereira', 'initials': 'RP', 'affiliation': 'Programa de Pós-Graduação em Ciências da Saúde, Universidade do Extremo Sul Catarinense (UNESC), 88806-00 Criciúma, SC, Brazil.'}, {'lastname': 'Silveira', 'firstname': 'Paulo Cesar Lock', 'initials': 'PCL', 'affiliation': 'Programa de Pós-Graduação em Ciências da Saúde, Universidade do Extremo Sul Catarinense (UNESC), 88806-00 Criciúma, SC, Brazil.'}, {'lastname': 'Muller', 'firstname': 'Alexandre Pastoris', 'initials': 'AP', 'affiliation': 'Programa de Pós-Graduação em Ciências da Saúde, Universidade do Extremo Sul Catarinense (UNESC), 88806-00 Criciúma, SC, Brazil; Programa de Pós-Graduação em Farmacologia, Universidade Federal de Santa Catarina (UFSC), 88040-900 Florianópolis, SC, Brazil. Electronic address: alexandrep.muller@gmail.com.'}]",,,,Copyright © 2019. Published by Elsevier Inc.,10.1016/j.peptides.2019.170175,<Element 'PubmedArticle' at 0x7f05de149c20>
244,31626364,Neurochemical regulation of the expression and function of glial fibrillary acidic protein in astrocytes.,"Glial fibrillary acidic protein (GFAP), a type III intermediate filament, is a marker of mature astrocytes. The expression of GFAP gene is regulated by many transcription factors (TFs), mainly Janus kinase-2/signal transducer and activator of transcription 3 cascade and nuclear factor κ-light-chain-enhancer of activated B cell signaling. GFAP expression is also modulated by protein kinase and other signaling molecules that are elicited by neuronal activity and hormones. Abnormal expression of GFAP proteins occurs in neuroinflammation, neurodegeneration, brain edema-eliciting diseases, traumatic brain injury, psychiatric disorders and others. GFAP, mainly in α-isoform, is the major component of cytoskeleton and the scaffold of astrocytes, which is essential for the maintenance of astrocytic structure and shape. GFAP also has highly morphological plasticity because of its quick changes in assembling and polymerizing states in response to environmental challenges. This plasticity and its corresponding cellular morphological changes endow astrocytes the functions of physical barrier between adjacent neurons and stabilizer of extracellular environment. Moreover, GFAP colocalizes and even molecularly associates with many functional molecules. This feature allows GFAP to function as a platform for direct interactions between different molecules. Last, GFAP involves transportation and localization of other functional proteins and thus serves as a protein transport guide in astrocytes. This guiding role of GFAP involves an elastic retraction and extension cytoskeletal network that couples with GFAP reassembling, transporting, and membrane protein recycling machinery. This paper reviews our current understanding of the expression and functions of GFAP as well as their regulation.","['astrocyte', 'expression', 'function', 'glial fibrillary acidic protein', 'regulation']",Glia,2019-10-19,"[{'lastname': 'Li', 'firstname': 'Dongyang', 'initials': 'D', 'affiliation': 'Department of Physiology, Harbin Medical University, Harbin, China.'}, {'lastname': 'Liu', 'firstname': 'Xiaoyu', 'initials': 'X', 'affiliation': 'Department of Physiology, Harbin Medical University, Harbin, China.'}, {'lastname': 'Liu', 'firstname': 'Tianming', 'initials': 'T', 'affiliation': 'Department of Physiology, Harbin Medical University, Harbin, China.'}, {'lastname': 'Liu', 'firstname': 'Haitao', 'initials': 'H', 'affiliation': 'Department of Physiology, Harbin Medical University, Harbin, China.'}, {'lastname': 'Tong', 'firstname': 'Li', 'initials': 'L', 'affiliation': 'Department of Physiology, Harbin Medical University, Harbin, China.'}, {'lastname': 'Jia', 'firstname': 'Shuwei', 'initials': 'S', 'affiliation': 'Department of Physiology, Harbin Medical University, Harbin, China.'}, {'lastname': 'Wang', 'firstname': 'Yu-Feng', 'initials': 'YF', 'affiliation': 'Department of Physiology, Harbin Medical University, Harbin, China.'}]",,,,"© 2019 Wiley Periodicals, Inc.",10.1002/glia.23734,<Element 'PubmedArticle' at 0x7f05de15c450>
245,31560883,The inflammatory event of birth: How oxytocin signaling may guide the development of the brain and gastrointestinal system.,"The role of oxytocin (OT) as a neuropeptide that modulates social behavior has been extensively studied and reviewed, but beyond these functions, OT's adaptive functions at birth are quite numerous, as OT coordinates many physiological processes in the mother and fetus to ensure a successful delivery. In this review we explore in detail the potential adaptive roles of oxytocin as an anti-inflammatory, protective molecule at birth for the developing fetal brain and gastrointestinal system based on evidence that birth is a potent inflammatory/immune event. We discuss data with relevance for a number of neurodevelopmental disorders, as well as the emerging role of the gut-brain axis for health and disease. Finally, we discuss the potential relevance of sex differences in OT signaling present at birth in the increased male vulnerability to neurodevelopmental disabilities.","['Autism spectrum disorder', 'Gut-brain', 'Microbiome', 'Microglia', 'Neuroinflammation', 'Neuroprotection', 'Pregnancy', 'Resilience']",Frontiers in neuroendocrinology,2019-09-29,"[{'lastname': 'Kingsbury', 'firstname': 'Marcy A', 'initials': 'MA', 'affiliation': 'Department of Pediatrics, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA 02129, United States. Electronic address: makingsbury@mgh.harvard.edu.'}, {'lastname': 'Bilbo', 'firstname': 'Staci D', 'initials': 'SD', 'affiliation': 'Department of Pediatrics, Massachusetts General Hospital and Harvard Medical School, Charlestown, MA 02129, United States; Department of Psychology and Neuroscience, Duke University, Durham, NC 27708, United States.'}]",,,,Copyright © 2019 Elsevier Inc. All rights reserved.,10.1016/j.yfrne.2019.100794,<Element 'PubmedArticle' at 0x7f05de105180>
246,"31539547
26398331
24952959
9129987
20561356
24384256
18615177
22451318
24634659
18657708
24148086
24571443
7498464
29695817
14657172
15758162
30503633
16571781
18096503
23512546
20590555
10785540
21684528
19152719
15044630
28027345
20855465
16501580
16641999
12925275
23122958
30067909
28894217
21450051
22448282
8900284
28963716
28481031
15765806
21518335
22342378
1470919
9881850
18481028
25524120
19343058
12824792
12770562
18067139
16343349
20175693
30589476
26902320
26203149
21735070
11152748
21111767
16472786
10779390
20549374
28213089
29053063
29541929
21076424
21203567
22508047
29259753
15778874
8411021
11259648
9375218
21135382
19575681
1992016
30114402
12037135
24147028
22727500
27394666
27531971
26577751
30380982
29503395
19126760
25169670
17545313
27806235
21670103
19502530
21740924
21145341
12813001
21449980
19370677
22814532
16938887
21145178
21035522
23633327
25474204
8371711
16596779
26090232
30171986
20657592
10594647
14526074
8440779
8232935
26086345
7605349
27775719
17880375
12427829
12878687
28007597
16908411
25888232
26244281
17360910
10191316
22270809
25486617
18367089
20920795
25225093
25033180
30159798
22021672
15266552
21531987
24747340
15749716
17142782
27808576
25967266
29688777
19805493
11586361
25504894
21079038
25927213
22813736
1666930
28880480
27482533
25015040
24742657
15728830
17019571
19476641
14517174
17412883
11502933
25869205
30260791
30453998
11588122
21418147
26965674
19184452
20729846
21600985
20590577
24911644
25417929
8699243
9730904
10873554
17241118
7651369
31254249
18488142
30831402
27452464
9915812
10617657
16678907
23151067
24937045
20980074
8751088
29171003
26694807
16131310
9460749
10214976
28574961
21191673
28596366
26362942
25917763
26212325
26779719
24897085
25796567
25123336
28327340
24886384
12598628
14757702
28086980
26189763
29310667
7898667
15778743
24562630
22860205
28625720
28733129
26928013
23578284
21251115
29061509
24281562",Druggable targets of the endocannabinoid system: Implications for the treatment of HIV-associated neurocognitive disorder.,"HIV-associated neurocognitive disorder (HAND) affects nearly half of all HIV-infected individuals. Synaptodendritic damage correlates with neurocognitive decline in HAND, and many studies have demonstrated that HIV-induced neuronal injury results from excitotoxic and inflammatory mechanisms. The endocannabinoid (eCB) system provides on-demand protection against excitotoxicity and neuroinflammation. Here, we discuss evidence of the neuroprotective and anti-inflammatory properties of the eCB system from in vitro and in vivo studies. We examine the pharmacology of the eCB system and evaluate the therapeutic potential of drugs that modulate eCB signaling to treat HAND. Finally, we provide perspective on the need for additional studies to clarify the role of the eCB system in HIV neurotoxicity and speculate that strategies that enhance eCB signaling might slow cognitive decline in HAND.","['2-Arachidonoylglycerol', 'Anandamide', 'Cannabinoid receptor', 'Fatty acid amide hydrolase', 'HIV-1', 'Monoacylglycerol lipase']",Brain research,2019-09-21,"[{'lastname': 'Wu', 'firstname': 'Mariah M', 'initials': 'MM', 'affiliation': 'Graduate Program in Neuroscience, University of Minnesota Medical School, Minneapolis, MN 55455, USA. Electronic address: mmwu@umn.edu.'}, {'lastname': 'Zhang', 'firstname': 'Xinwen', 'initials': 'X', 'affiliation': 'Department of Pharmacology, University of Minnesota Medical School, Minneapolis, MN 55455, USA. Electronic address: zhan3619@umn.edu.'}, {'lastname': 'Asher', 'firstname': 'Melissa J', 'initials': 'MJ', 'affiliation': 'Graduate Program in Neuroscience, University of Minnesota Medical School, Minneapolis, MN 55455, USA. Electronic address: asher024@umn.edu.'}, {'lastname': 'Thayer', 'firstname': 'Stanley A', 'initials': 'SA', 'affiliation': 'Graduate Program in Neuroscience, University of Minnesota Medical School, Minneapolis, MN 55455, USA; Department of Pharmacology, University of Minnesota Medical School, Minneapolis, MN 55455, USA. Electronic address: sathayer@umn.edu.'}]",,,,Copyright © 2019 Elsevier B.V. All rights reserved.,10.1016/j.brainres.2019.146467,<Element 'PubmedArticle' at 0x7f05de10f130>
247,"31534953
8787671
9537324
10766253
21386802
23275931
20035790
24075719
26603190
26814590
28499988
15856065
16002529
18854155
20472136
28855891
19144836
24892821
28760600
27016501
2788034
2261637
25898198
9716487
30865890
20966214
22025055
30524228
32694719
25497089
28377875
25409701
29980196
24975592
17905568
21314736
29528526
26870797
26431692
10378877
17433555
26453898
26342944
26254332
29789127
11579142
20483490
17617622
20808781
28845299
26327363
29628394
24501362
12857678
30595477
30453385
17344397
11786910
21435392
12533608
26431939",Interleukin-6 Expression by Hypothalamic Microglia in Multiple Inflammatory Contexts: A Systematic Review.,"Interleukin-6 (IL-6) is a unique cytokine that can play both pro- and anti-inflammatory roles depending on the anatomical site and conditions under which it has been induced. Specific neurons of the hypothalamus provide important signals to control food intake and energy expenditure. In individuals with obesity, a microglia-dependent inflammatory response damages the neural circuits responsible for maintaining whole-body energy homeostasis, resulting in a positive energy balance. However, little is known about the role of IL-6 in the regulation of hypothalamic microglia. In this systematic review, we asked what types of conditions and stimuli could modulate microglial IL-6 expression in murine model. We searched the PubMed and Web of Science databases and analyzed 13 articles that evaluated diverse contexts and study models focused on IL-6 expression and microglia activation, including the effects of stress, hypoxia, infection, neonatal overfeeding and nicotine exposure, lipopolysaccharide stimulus, hormones, exercise protocols, and aging. The results presented in this review emphasized the role of ""injury-like"" stimuli, under which IL-6 acts as a proinflammatory cytokine, concomitant with marked microglial activation, which drive hypothalamic neuroinflammation. Emerging evidence indicates an important correlation of basal IL-6 levels and microglial function with the maintenance of hypothalamic homeostasis. Advances in our understanding of these different contexts will lead to the development of more specific pharmacological approaches for the management of acute and chronic conditions, like obesity and metabolic diseases, without disturbing the homeostatic functions of IL-6 and microglia in the hypothalamus.",[],BioMed research international,2019-09-20,"[{'lastname': 'Bobbo', 'firstname': 'Vanessa C D', 'initials': 'VCD', 'affiliation': 'Faculty of Nursing, University of Campinas, SP 13083-887, Brazil.\nLaboratory of Cell Signaling, Obesity and Comorbidities Research Center, University of Campinas, SP 13083-864, Brazil.'}, {'lastname': 'Jara', 'firstname': 'Carlos P', 'initials': 'CP', 'affiliation': 'Faculty of Nursing, University of Campinas, SP 13083-887, Brazil.\nLaboratory of Cell Signaling, Obesity and Comorbidities Research Center, University of Campinas, SP 13083-864, Brazil.'}, {'lastname': 'Mendes', 'firstname': 'Natália F', 'initials': 'NF', 'affiliation': 'Faculty of Nursing, University of Campinas, SP 13083-887, Brazil.\nLaboratory of Cell Signaling, Obesity and Comorbidities Research Center, University of Campinas, SP 13083-864, Brazil.'}, {'lastname': 'Morari', 'firstname': 'Joseane', 'initials': 'J', 'affiliation': 'Laboratory of Cell Signaling, Obesity and Comorbidities Research Center, University of Campinas, SP 13083-864, Brazil.'}, {'lastname': 'Velloso', 'firstname': 'Lício A', 'initials': 'LA', 'affiliation': 'Laboratory of Cell Signaling, Obesity and Comorbidities Research Center, University of Campinas, SP 13083-864, Brazil.'}, {'lastname': 'Araújo', 'firstname': 'Eliana P', 'initials': 'EP', 'affiliation': 'Faculty of Nursing, University of Campinas, SP 13083-887, Brazil.\nLaboratory of Cell Signaling, Obesity and Comorbidities Research Center, University of Campinas, SP 13083-864, Brazil.'}]",,,,,"10.1155/2019/1365210
10.1172/JCI118891
10.1038/32911
10.1038/35007534
10.1038/ijo.2011.56
10.1016/j.bbr.2009.12.024
10.1016/j.coph.2013.09.010
10.1016/j.cmet.2015.09.026
10.1038/nn.4202
10.1016/j.bbadis.2017.05.007
10.1038/nn1455
10.1210/en.2004-1520
10.1016/j.cell.2008.07.043
10.1523/JNEUROSCI.2760-08.2009
10.1210/en.2014-1090
10.1016/j.mce.2017.07.029
10.1016/j.bbamcr.2016.03.018
10.1016/0092-8674(89)90438-8
10.1016/0092-8674(90)90411-7
10.1038/ni.3153
10.1042/bj3340297
10.1016/j.celrep.2019.02.044
10.1126/science.1194637
10.1038/nri3086
10.1038/s42255-019-0040-0
10.1016/j.celrep.2014.11.018
10.2337/db14-0645
10.1186/s12974-018-1234-1
10.1016/j.bbi.2014.06.014
10.1016/j.bbi.2007.08.007
10.1111/j.1365-2826.2011.02113.x
10.1113/EP086780
10.1016/j.ebiom.2015.09.044
10.1016/j.bbi.2015.09.017
10.1016/S0165-5728(98)00217-3
10.1016/j.neuroscience.2007.02.043
10.1111/jne.12328
10.1016/j.bbi.2015.08.011
10.1152/ajpheart.00349.2015
10.1016/j.plefa.2018.04.003
10.1046/j.1471-4159.2001.00514.x
10.1016/j.tips.2010.04.001
10.4049/jimmunol.179.2.1292
10.1371/journal.pbio.1000465
10.1038/cddiscovery.2017.54
10.1016/j.neuroscience.2015.08.055
10.1016/j.stemcr.2018.03.008
10.1523/JNEUROSCI.1619-13.2014
10.1152/ajpendo.00074.2003
10.2139/ssrn.3254906
10.1002/glia.23505
10.1523/JNEUROSCI.5360-06.2007
10.1038/nm0102-75
10.1016/j.bbi.2011.03.012
10.1523/JNEUROSCI.23-02-00481.2003
10.1016/j.it.2015.08.003",<Element 'PubmedArticle' at 0x7f05de0719f0>
248,31465975,Cannabinoids Δ,"The neurodegeneration, neuro-inflammation and mitochondrial dysfunction which occur by methamphetamine (METH) abuse or administration are serious and motivation therapeutic approaches for inhibition of these types of neurodegeneration. As we know, METH through Toll-like receptors (TLRs), specially type 4, and NF-κB signaling pathway causes neuro-inflammation and mitochondrial dysfunction. Neuroprotective approach for management of METH-induced neurodegeneration, inflammation and mitochondrial dysfunction, through a novel neuroprotective agent is continuously being superior to any kind of other therapeutic strategy. Therefore, the clarification, introduction and development of efficacious novel neuroprotective agent are demanded. During recent years, using new neuroprotective agent with therapeutic probability for treatment of METH-induced neuro-inflammation and mitochondrial dysfunction has been astoundingly increased. Previous studies have stated the neuroprotective and anti-inflammatory roles ofcannabinoid derivate such as cannabidiol (CBD) and delta-9-tetrahydrocannabinol (Δ","['Cannabinoids', 'Methamphetamine', 'Neuro-inflammation']",Medical hypotheses,2019-08-30,"[{'lastname': 'Majdi', 'firstname': 'Fatemeh', 'initials': 'F', 'affiliation': 'Department of Pharmaceutical Chemistry, Faculty of Pharmaceutical Chemistry, Pharmaceutical Sciences Branch, Islamic Azad University (IUAPS), Tehran, Iran.'}, {'lastname': 'Taheri', 'firstname': 'Fereshteh', 'initials': 'F', 'affiliation': 'Research Center for Addiction and Risky Behaviors (ReCARB), Iran Psychiatric Center, Iran University of Medical Sciences, Tehran, Iran.'}, {'lastname': 'Salehi', 'firstname': 'Pegah', 'initials': 'P', 'affiliation': 'Research Center for Addiction and Risky Behaviors (ReCARB), Iran Psychiatric Center, Iran University of Medical Sciences, Tehran, Iran.'}, {'lastname': 'Motaghinejad', 'firstname': 'Majid', 'initials': 'M', 'affiliation': 'Research Center for Addiction and Risky Behaviors (ReCARB), Iran Psychiatric Center, Iran University of Medical Sciences, Tehran, Iran. Electronic address: Dr.motaghinejad6@gmail.com.'}, {'lastname': 'Safari', 'firstname': 'Sepideh', 'initials': 'S', 'affiliation': 'Razi Drug Research Center, Iran University of Medical Sciences, Tehran, Iran.'}]",,,,Copyright © 2019 Elsevier Ltd. All rights reserved.,10.1016/j.mehy.2019.109371,<Element 'PubmedArticle' at 0x7f05de09cef0>
249,"31430865
23636330
11089981
15031734
31141884
22399429
23794102
15946658
23783559
12160938
30625984
16707226
16707173
19735715
16710848
27421686
23104101
19641587
10521401
18662547
19286518
24011076
19995796
21930182
22706308
21912480
30591661
22681685
30987251
25423896
9924747
20685874
8650195
20303880
30478761
30884890
30756299
28466267
31117242
27821173
30618542
31091792
31096703
24481440
29088310
26738855
12270690
19416735
30563298
31052241
31216749
26134520
27457926
21961718
20133359
30654525
17385716
16081535
18329384
28196366
30423928
24690200
10531052
31108937
16938404
29782911
16469811
23471411
18423418
17447894
24755072
19558452
23549616
25892055
26261574",17β-Estradiol Modulates SIRT1 and Halts Oxidative Stress-Mediated Cognitive Impairment in a Male Aging Mouse Model.,"Oxidative stress has been considered the main mediator in neurodegenerative disease and in normal aging processes. Several studies have reported that the accumulation of reactive oxygen species (ROS), elevated oxidative stress, and neuroinflammation result in cellular malfunction. These conditions lead to neuronal cell death in aging-related neurodegenerative disorders such as Alzheimer's disease (AD) and Parkinson's disease. Chronic administration of d-galactose (d-gal) for a period of 10 weeks causes ROS generation and neuroinflammation, ultimately leading to cognitive impairment. In this study, we evaluated the estrogen receptor α (ERα)/silent mating type information regulation 2 homolog 1 (SIRT1)-dependent antioxidant efficacy of 17β-estradiol against d-gal-induced oxidative damage-mediated cognitive dysfunction in a male mouse model. The results indicate that 17β-estradiol, by stimulating ERα/SIRT1, halts d-gal-induced oxidative stress-mediated JNK/NF-ҡB overexpression, neuroinflammation and neuronal apoptosis. Moreover, 17β-estradiol ameliorated d-gal-induced AD-like pathophysiology, synaptic dysfunction and memory impairment in adult mouse brains. Interestingly, inhibition of SIRT1 with Ex527 (a potent and selective SIRT1 inhibitor) further enhanced d-gal-induced toxicity and abolished the beneficial effect of 17β-estradiol. Most importantly, for the first time, our molecular docking study reveals that 17β-estradiol allosterically increases the expression of SIRT1 and abolishes the inhibitory potential of d-ga. In summary, we can conclude that 17β-estradiol, in an ERα/SIRT1-dependent manner, abrogates d-gal-induced oxidative stress-mediated memory impairment, neuroinflammation, and neurodegeneration in adult mice.","['17β-Estradiol', 'ROS', 'SIRT1', 'd-galactose', 'neuroinflammation neurodegeneration']",Cells,2019-08-23,"[{'lastname': 'Khan', 'firstname': 'Mehtab', 'initials': 'M', 'affiliation': 'Division of Life sciences and Applied Life Science (BK 21plus), College of Natural Science, Gyeongsang National University, Jinju 52828, Korea.'}, {'lastname': 'Ullah', 'firstname': 'Rahat', 'initials': 'R', 'affiliation': 'Division of Life sciences and Applied Life Science (BK 21plus), College of Natural Science, Gyeongsang National University, Jinju 52828, Korea.'}, {'lastname': 'Rehman', 'firstname': 'Shafiq Ur', 'initials': 'SU', 'affiliation': 'Division of Life sciences and Applied Life Science (BK 21plus), College of Natural Science, Gyeongsang National University, Jinju 52828, Korea.'}, {'lastname': 'Shah', 'firstname': 'Shahid Ali', 'initials': 'SA', 'affiliation': 'Division of Life sciences and Applied Life Science (BK 21plus), College of Natural Science, Gyeongsang National University, Jinju 52828, Korea.'}, {'lastname': 'Saeed', 'firstname': 'Kamran', 'initials': 'K', 'affiliation': 'Division of Life sciences and Applied Life Science (BK 21plus), College of Natural Science, Gyeongsang National University, Jinju 52828, Korea.'}, {'lastname': 'Muhammad', 'firstname': 'Tahir', 'initials': 'T', 'affiliation': 'Division of Life sciences and Applied Life Science (BK 21plus), College of Natural Science, Gyeongsang National University, Jinju 52828, Korea.'}, {'lastname': 'Park', 'firstname': 'Hyun Young', 'initials': 'HY', 'affiliation': 'Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience (MHeNS), Medical Center (MUMC+), Faculty of Health, Medicine and Life Sciences, Maastricht University, European Graduate School of Neuroscience (EURON), 6229ER Maastricht, The Netherlands.'}, {'lastname': 'Jo', 'firstname': 'Myeung Hoon', 'initials': 'MH', 'affiliation': 'Division of Life sciences and Applied Life Science (BK 21plus), College of Natural Science, Gyeongsang National University, Jinju 52828, Korea.'}, {'lastname': 'Choe', 'firstname': 'Kyonghwan', 'initials': 'K', 'affiliation': 'Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience (MHeNS), Medical Center (MUMC+), Faculty of Health, Medicine and Life Sciences, Maastricht University, European Graduate School of Neuroscience (EURON), 6229ER Maastricht, The Netherlands.'}, {'lastname': 'Rutten', 'firstname': 'Bart P F', 'initials': 'BPF', 'affiliation': 'Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience (MHeNS), Medical Center (MUMC+), Faculty of Health, Medicine and Life Sciences, Maastricht University, European Graduate School of Neuroscience (EURON), 6229ER Maastricht, The Netherlands.'}, {'lastname': 'Kim', 'firstname': 'Myeong Ok', 'initials': 'MO', 'affiliation': 'Division of Life sciences and Applied Life Science (BK 21plus), College of Natural Science, Gyeongsang National University, Jinju 52828, Korea. mokim@gnu.ac.kr.'}]",,,,,"10.3390/cells8080928
10.1038/nature12143
10.1038/35041687
10.1038/nrd1330
10.3390/nu11061195
10.1007/978-94-007-2869-1_14
10.1007/s00709-013-0515-x
10.1016/j.cccn.2005.03.028
10.1007/s12035-013-8483-x
10.1016/S0891-5849(02)00914-0
10.3390/cells8010028
10.1016/j.psyneuen.2006.03.004
10.1016/j.bbr.2006.03.043
10.1016/j.exger.2009.08.011
10.1002/jnr.20899
10.1111/cns.12588
10.1016/j.freeradbiomed.2012.10.525
10.1038/nature08197
10.1101/gad.13.19.2570
10.1016/j.cell.2008.07.002
10.1126/science.1170803
10.1016/j.cmet.2013.07.013
10.1093/carcin/bgp308
10.1016/j.pneurobio.2011.09.001
10.1172/JCI45785
10.1155/2011/368276
10.3390/cells8010011
10.1016/j.neuron.2012.03.035
10.3390/cells8040310
10.1038/nrn3856
10.1016/S0306-4530(98)00071-7
10.1210/en.2010-0371
10.1073/pnas.93.12.5925
10.1016/j.cell.2010.02.016
10.1007/s11481-018-9824-3
10.3390/nu11030648
10.1007/s12035-019-1512-7
10.1007/s12035-017-0520-8
10.3390/ijms20102504
10.1186/s12974-016-0752-y
10.3389/fnins.2018.00888
10.3390/jcm8050680
10.3390/nu11051082
10.1038/cddis.2013.538
10.1093/cercor/bhx164
10.1007/s12035-015-9604-5
10.1006/nbdi.2002.0515
10.1016/j.yfrne.2009.04.011
10.3390/cells7120250
10.3390/cells8050400
10.3390/cells8060612
10.1038/ncomms8645
10.1073/pnas.1604558113
10.1016/j.ogc.2011.05.007
10.1093/cercor/bhq002
10.3390/cells8010059
10.1002/jnr.21252
10.1073/pnas.0504759102
10.1016/j.bbrc.2008.02.151
10.1159/000455866
10.3390/cells7110203
10.1016/j.brainres.2014.03.036
10.1126/science.286.5440.735
10.3390/cells8050474
10.1016/j.neuroscience.2006.07.021
10.1016/j.bbi.2018.05.013
10.1210/en.2005-1330
10.1126/science.1231097
10.1016/j.bbapap.2008.03.004
10.1042/BJ20070140
10.1016/j.bbrc.2014.04.066
10.1111/j.1471-4159.2009.06228.x
10.1007/s13238-013-2124-z
10.1111/jphp.12413",<Element 'PubmedArticle' at 0x7f05ddfec860>
250,"31422380
22617385
26540176
23489470
23663781
22226359
27874859
21886162
11746539
23572301
8203364
28935952
24915299
14645852
26003168
25194569
26657143
26042088
16957738
17717515
12008039
16957735
16957737
15716955
16123807
8604047
18371391
10195220
8423066
28251674
28671124
25470401
22024433
23026377
28761082
22160349
27578257
22048312
26840489
25447026
24522534
25485497
30425188
27182558
23421352
19482229
19369205
21467543
24244818
25133536
20970492
27375431
26001832
16799084
16794634
7490128
27789842
25855157
27699227
29608139
28340339
25499914","Rejuvenation of brain, liver and muscle by simultaneous pharmacological modulation of two signaling determinants, that change in opposite directions with age.","We hypothesize that altered intensities of a few morphogenic pathways account for most/all the phenotypes of aging. Investigating this has revealed a novel approach to rejuvenate multiple mammalian tissues by defined pharmacology. Specifically, we pursued the simultaneous youthful in vivo calibration of two determinants: TGF-beta which activates ALK5/pSmad 2,3 and goes up with age, and oxytocin (OT) which activates MAPK and diminishes with age. The dose of Alk5 inhibitor (Alk5i) was reduced by 10-fold and the duration of treatment was shortened (to minimize overt skewing of cell-signaling pathways), yet the positive outcomes were broadened, as compared with our previous studies. Alk5i plus OT quickly and robustly enhanced neurogenesis, reduced neuro-inflammation, improved cognitive performance, and rejuvenated livers and muscle in old mice. Interestingly, the combination also diminished the numbers of cells that express the CDK inhibitor and marker of senescence p16 in vivo. Summarily, simultaneously re-normalizing two pathways that change with age in opposite ways (up vs. down) synergistically reverses multiple symptoms of aging.","['TGF-beta', 'cognition', 'liver health', 'muscle repair', 'neuro-inflammation', 'neurogenesis', 'oxytocin']",Aging,2019-08-20,"[{'lastname': 'Mehdipour', 'firstname': 'Melod', 'initials': 'M', 'affiliation': 'Department of Bioengineering and QB3 Institute, University of California, Berkeley, Berkeley, CA 94720, USA.'}, {'lastname': 'Etienne', 'firstname': 'Jessy', 'initials': 'J', 'affiliation': 'Department of Bioengineering and QB3 Institute, University of California, Berkeley, Berkeley, CA 94720, USA.'}, {'lastname': 'Chen', 'firstname': 'Chia-Chien', 'initials': 'CC', 'affiliation': 'Department of Molecular, Cell and Developmental Biology, University of California, Santa Cruz, Santa Cruz, CA 95064, USA.'}, {'lastname': 'Gathwala', 'firstname': 'Ranveer', 'initials': 'R', 'affiliation': 'Department of Bioengineering and QB3 Institute, University of California, Berkeley, Berkeley, CA 94720, USA.'}, {'lastname': 'Rehman', 'firstname': 'Maryam', 'initials': 'M', 'affiliation': 'Department of Bioengineering and QB3 Institute, University of California, Berkeley, Berkeley, CA 94720, USA.'}, {'lastname': 'Kato', 'firstname': 'Cameron', 'initials': 'C', 'affiliation': 'Department of Bioengineering and QB3 Institute, University of California, Berkeley, Berkeley, CA 94720, USA.'}, {'lastname': 'Liu', 'firstname': 'Chao', 'initials': 'C', 'affiliation': 'Department of Bioengineering and QB3 Institute, University of California, Berkeley, Berkeley, CA 94720, USA.'}, {'lastname': 'Liu', 'firstname': 'Yutong', 'initials': 'Y', 'affiliation': 'Department of Bioengineering and QB3 Institute, University of California, Berkeley, Berkeley, CA 94720, USA.'}, {'lastname': 'Zuo', 'firstname': 'Yi', 'initials': 'Y', 'affiliation': 'Department of Molecular, Cell and Developmental Biology, University of California, Santa Cruz, Santa Cruz, CA 95064, USA.'}, {'lastname': 'Conboy', 'firstname': 'Michael J', 'initials': 'MJ', 'affiliation': 'Department of Bioengineering and QB3 Institute, University of California, Berkeley, Berkeley, CA 94720, USA.'}, {'lastname': 'Conboy', 'firstname': 'Irina M', 'initials': 'IM', 'affiliation': 'Department of Bioengineering and QB3 Institute, University of California, Berkeley, Berkeley, CA 94720, USA.'}]",,,,,"10.18632/aging.102148
10.4161/cc.20437
10.18632/aging.100819
10.1111/acel.12065
10.1016/j.cell.2013.04.015
10.1016/j.stem.2011.11.019
10.1038/ncomms13363
10.1038/nature10357
10.1002/jca.1024
10.5603/AIT.2013.0002
10.1016/S0272-6386(12)80135-1
10.1038/s41467-017-00698-y
10.1038/ncomms5082
10.1126/science.1087573
10.18632/oncotarget.3851
10.1038/nm.3655
10.1038/nm.4010
10.3389/fendo.2015.00079
10.1038/nature05091
10.1038/nrm2241
10.1016/S0165-2478(02)00023-8
10.1038/nature05159
10.1038/nature05092
10.1038/nature03260
10.1038/sj.onc.1208928
10.1523/JNEUROSCI.16-06-02027.1996
10.1016/j.stem.2007.09.002
10.1038/6368
10.1002/glia.440070114
10.1002/glia.23135
10.3233/JAD-170239
10.2174/1871527313666141130224206
10.1016/j.bbr.2011.10.009
10.1016/j.bbr.2012.09.044
10.1038/mp.2017.159
10.1007/s10339-011-0430-z
10.1007/s11357-016-9938-6
10.1038/nature10600
10.1038/nature16932
10.1002/stem.1908
10.1038/nature13013
10.4161/15384101.2014.965072
10.18632/aging.101646
10.1172/jci.insight.85608
10.1037/a0031581
10.1073/pnas.0901890106
10.1182/blood-2011-01-330142
10.4062/biomolther.2013.072
10.1371/journal.pone.0103677
10.1016/j.bbi.2010.10.015
10.3389/fncel.2016.00144
10.1186/s12974-015-0324-6
10.1513/pats.200601-008AW
10.1038/nrc1926
10.1126/science.aaf6659
10.1038/jid.2015.108
10.1172/jci.insight.87732
10.1172/JCI95147
10.1016/j.cell.2017.02.031
10.1016/j.devcel.2014.11.012",<Element 'PubmedArticle' at 0x7f05de17f680>
251,"31421410
23076408
28515690
24827941
28523794
27517478
28664398
27960152
28772270
23608137
25033060
25319470
29410737
27150190
28607392
15225806
25533012
27401255
30076526
26448556
29138801
28119569
25157786
27085714
26767952
22726353
24685992
24448902
29993274
28579120
28043680
24222043
22267242
24072555
29748075
20693391
20616348
29351514
29802210
21542804
23757400
30826386",Vitamin D receptor activation regulates microglia polarization and oxidative stress in spontaneously hypertensive rats and angiotensin II-exposed microglial cells: Role of renin-angiotensin system.,"Hypertension is one of the major predisposing factors for neurodegenerative disease characterized with activated renin-angiotensin system (RAS) in both periphery and brain. Vitamin D (VitD) is recently recognized as a pleiotropic hormone with strong neuroprotective properties. While multiple lines of evidence suggest that VitD can act on RAS, the evidence concerning the crosstalk between VitD and RAS in the brain is limited. Therefore, this study aims to evaluate whether VitD can modulate brain RAS to trigger neuroprotective actions in the brain of spontaneously hypertensive rats (SHR). Our data showed that calcitriol treatment induced VDR expression and inhibited neural death in the prefrontal cortex of SHR. Sustained calcitriol administration also inhibited microglia M1 polarization, but enhanced M2 polarization, accompanied with decreased expression of proinflammatory cytokines. We then further explored the potential mechanisms and showed that SHR exhibited overactivated classical RAS with increased expression of angiotensin II (Ang II) receptor type 1 (AT1), angiotensin converting enzyme (ACE) and Ang II production, whereas the counteracting arm of traditional RAS, ACE2/Ang(1-7)/MasR, was impaired in the SHR brain. Calcitriol nonsignificantly suppressed AT1 and ACE but markedly reduced Ang II formation. Intriguingly, calcitriol exerted pronouncedly impact on ACE2/Ang(1-7)/MasR axis with enhanced expression of ACE2, MasR and Ang(1-7) generation. Meanwhile, calcitriol ameliorated the overactivation of NADPH-oxidase (Nox), the downstream of RAS, in SHR, and also mitigated oxidative stress. In microglial (BV2) cells, we further found that calcitriol induced ACE2 and MasR with no significant impact on ACE and AT1. In accordance, calcitriol also attenuated Ang II-induced Nox activation and ROS production, and shifted the microglia polarization from M1 to M2 phenotype. However, co-treatment with A779, a specific MasR antagonist, abrogated the antioxidant and neuroimmune modulating actions of VitD. These findings strongly indicate the involvement of ACE2/Ang(1-7)/MasR pathway in the neuroprotective mechanisms of VitD in the hypertensive brain.","['ACE2/Ang(1–7)/MasR axis', 'Neuroinflammation', 'Oxidative stress', 'Renin-angiotensin system', 'Vitamin D']",Redox biology,2019-08-20,"[{'lastname': 'Cui', 'firstname': 'Changmeng', 'initials': 'C', 'affiliation': 'Affiliated Hospital of Jining Medical University, Jining Medical University, Jining, China.'}, {'lastname': 'Xu', 'firstname': 'Pengfei', 'initials': 'P', 'affiliation': ""Jining First People's Hospital, Jining Medical University, Jining, China.""}, {'lastname': 'Li', 'firstname': 'Gongying', 'initials': 'G', 'affiliation': 'Department of Mental Health, Jining Medical University, Jining, China.'}, {'lastname': 'Qiao', 'firstname': 'Yi', 'initials': 'Y', 'affiliation': 'Department of Public Health, Jining Medical University, Jining, China.'}, {'lastname': 'Han', 'firstname': 'Wenxiu', 'initials': 'W', 'affiliation': ""Jining First People's Hospital, Jining Medical University, Jining, China.""}, {'lastname': 'Geng', 'firstname': 'Chunmei', 'initials': 'C', 'affiliation': ""Jining First People's Hospital, Jining Medical University, Jining, China.""}, {'lastname': 'Liao', 'firstname': 'Dehua', 'initials': 'D', 'affiliation': 'Hunan Cancer Hospital, Central South University, Changsha, China.'}, {'lastname': 'Yang', 'firstname': 'Mengqi', 'initials': 'M', 'affiliation': ""Jining First People's Hospital, Jining Medical University, Jining, China.""}, {'lastname': 'Chen', 'firstname': 'Dan', 'initials': 'D', 'affiliation': ""Jining First People's Hospital, Jining Medical University, Jining, China.""}, {'lastname': 'Jiang', 'firstname': 'Pei', 'initials': 'P', 'affiliation': ""Jining First People's Hospital, Jining Medical University, Jining, China; Department of Precision Medicine, Tengzhou Central People's Hospital, Tengzhou, China. Electronic address: jiangpeicsu@sina.com.""}]",,,,Copyright © 2019 The Authors. Published by Elsevier B.V. All rights reserved.,10.1016/j.redox.2019.101295,<Element 'PubmedArticle' at 0x7f05de334810>
252,31408628,The prokineticin receptor antagonist PC1 rescues memory impairment induced by β amyloid administration through the modulation of prokineticin system.,"Growing evidences demonstrate that chemokines and chemokine receptors are up-regulated in resident central nervous system cells during Alzheimer's disease contributing to neuroinflammation and neurodegeneration. Prokineticin 2 belongs to a new family of chemokines which recently emerged as a critical player in immune system and inflammatory diseases. Since pharmacological blockade in vitro of the prokineticin system is able to antagonize Amyloid β-induced neurotoxicity, the aim of the present study was to investigate in vivo effects of prokineticin receptor antagonist PC1 on memory impairment in a rodent model of Alzheimer's disease. Rats were intracerebroventricular infused with Aβ","[""Alzheimer's disease"", 'Amyloid β', 'Animal model', 'Neurogenesis', 'Neuroprotection', 'Prokineticin 2', 'Prokineticin receptor antagonist', 'Prokineticin receptors']",Neuropharmacology,2019-08-14,"[{'lastname': 'Maftei', 'firstname': 'Daniela', 'initials': 'D', 'affiliation': 'Department of Physiology and Pharmacology ""Vittorio Erspamer"", Sapienza University of Rome, P.le A. Moro 5, 00185, Rome, Italy.'}, {'lastname': 'Ratano', 'firstname': 'Patrizia', 'initials': 'P', 'affiliation': 'Department of Physiology and Pharmacology ""Vittorio Erspamer"", Sapienza University of Rome, P.le A. Moro 5, 00185, Rome, Italy; Nanotechnology Institute, CNR-Nanotechnology Institute (CNR-NANOTEC), Sapienza University of Rome, P.le A. Moro 5, 00185, Rome, Italy.'}, {'lastname': 'Fusco', 'firstname': 'Ilaria', 'initials': 'I', 'affiliation': 'Department of Physiology and Pharmacology ""Vittorio Erspamer"", Sapienza University of Rome, P.le A. Moro 5, 00185, Rome, Italy.'}, {'lastname': 'Marconi', 'firstname': 'Veronica', 'initials': 'V', 'affiliation': 'Department of Physiology and Pharmacology ""Vittorio Erspamer"", Sapienza University of Rome, P.le A. Moro 5, 00185, Rome, Italy.'}, {'lastname': 'Squillace', 'firstname': 'Silvia', 'initials': 'S', 'affiliation': 'Department of Physiology and Pharmacology ""Vittorio Erspamer"", Sapienza University of Rome, P.le A. Moro 5, 00185, Rome, Italy.'}, {'lastname': 'Negri', 'firstname': 'Lucia', 'initials': 'L', 'affiliation': 'Department of Physiology and Pharmacology ""Vittorio Erspamer"", Sapienza University of Rome, P.le A. Moro 5, 00185, Rome, Italy.'}, {'lastname': 'Severini', 'firstname': 'Cinzia', 'initials': 'C', 'affiliation': 'Institute of Cell Biology and Neurobiology, CNR, Sense organs Department, Sapienza University of Rome, Viale del Policlinico 155, 00161, Rome, Italy.'}, {'lastname': 'Balboni', 'firstname': 'Gianfranco', 'initials': 'G', 'affiliation': 'Department of Life and Environmental Sciences, Unit of Pharmaceutical, Pharmacological and Nutraceutical Sciences, University of Cagliari, Via Ospedale 72, 09124, Cagliari, Italy.'}, {'lastname': 'Steardo', 'firstname': 'Luca', 'initials': 'L', 'affiliation': 'Department of Physiology and Pharmacology ""Vittorio Erspamer"", Sapienza University of Rome, P.le A. Moro 5, 00185, Rome, Italy.'}, {'lastname': 'Bronzuoli', 'firstname': 'Maria Rosanna', 'initials': 'MR', 'affiliation': 'Department of Physiology and Pharmacology ""Vittorio Erspamer"", Sapienza University of Rome, P.le A. Moro 5, 00185, Rome, Italy.'}, {'lastname': 'Scuderi', 'firstname': 'Caterina', 'initials': 'C', 'affiliation': 'Department of Physiology and Pharmacology ""Vittorio Erspamer"", Sapienza University of Rome, P.le A. Moro 5, 00185, Rome, Italy.'}, {'lastname': 'Campolongo', 'firstname': 'Patrizia', 'initials': 'P', 'affiliation': 'Department of Physiology and Pharmacology ""Vittorio Erspamer"", Sapienza University of Rome, P.le A. Moro 5, 00185, Rome, Italy.'}, {'lastname': 'Lattanzi', 'firstname': 'Roberta', 'initials': 'R', 'affiliation': 'Department of Physiology and Pharmacology ""Vittorio Erspamer"", Sapienza University of Rome, P.le A. Moro 5, 00185, Rome, Italy. Electronic address: roberta.lattanzi@uniroma1.it.'}]",,,,Copyright © 2019. Published by Elsevier Ltd.,10.1016/j.neuropharm.2019.107739,<Element 'PubmedArticle' at 0x7f05ddf44cc0>
253,"31403472
17660530
21833088
986024
25690592
24550311
18443225
22450508
22580585
16702550
30967673
8538762
9499428
12900543
18434530
20363980
17178841
23249737
18003914
20300060
25870930
19028515
12900543
20573260
20363980
12023983
15978012
21614513
25785854
19542428
18388297
21551360
29073101
25101834
26999603
17851529
24798337
14670982
26328764
28284523
25531312
25840993
19561615
29740925
19494326
26943960
10084932
25417205
19910308
27999654
21677750
19525957
22968824
21555578
14662901
29279367
29228214
24695404
22178198
20651746",The X-linked histone demethylase Kdm6a in CD4+ T lymphocytes modulates autoimmunity.,"Multiple sclerosis (MS) is a putative T cell-mediated autoimmune disease. As with many autoimmune diseases, females are more susceptible than males. Sexual dimorphisms may be due to differences in sex hormones, sex chromosomes, or both. Regarding sex chromosome genes, a small percentage of X chromosome genes escape X inactivation and have higher expression in females (XX) compared with males (XY). Here, high-throughput gene expression analysis in CD4+ T cells showed that the top sexually dimorphic gene was Kdm6a, a histone demethylase on the X chromosome. There was higher expression of Kdm6a in females compared with males in humans and mice, and the four core genotypes (FCG) mouse model showed higher expression in XX compared with XY. Deletion of Kdm6a in CD4+ T cells ameliorated clinical disease and reduced neuropathology in the classic CD4+ T cell-mediated autoimmune disease experimental autoimmune encephalomyelitis (EAE). Global transcriptome analysis in CD4+ T cells from EAE mice with a specific deletion of Kdm6a showed upregulation of Th2 and Th1 activation pathways and downregulation of neuroinflammation signaling pathways. Together, these data demonstrate that the X escapee Kdm6a regulates multiple immune response genes, providing a mechanism for sex differences in autoimmune disease susceptibility.","['Autoimmune diseases', 'Autoimmunity', 'Genetics', 'Multiple sclerosis', 'T cells']",The Journal of clinical investigation,2019-08-14,"[{'lastname': 'Itoh', 'firstname': 'Yuichiro', 'initials': 'Y', 'affiliation': 'Department of Neurology, David Geffen School of Medicine, UCLA, Los Angeles, California, USA.'}, {'lastname': 'Golden', 'firstname': 'Lisa C', 'initials': 'LC', 'affiliation': 'Department of Neurology, David Geffen School of Medicine, UCLA, Los Angeles, California, USA.\nMolecular Biology Institute, UCLA, Los Angeles, California, USA.'}, {'lastname': 'Itoh', 'firstname': 'Noriko', 'initials': 'N', 'affiliation': 'Department of Neurology, David Geffen School of Medicine, UCLA, Los Angeles, California, USA.'}, {'lastname': 'Matsukawa', 'firstname': 'Macy Akiyo', 'initials': 'MA', 'affiliation': 'Department of Neurology, David Geffen School of Medicine, UCLA, Los Angeles, California, USA.'}, {'lastname': 'Ren', 'firstname': 'Emily', 'initials': 'E', 'affiliation': 'Department of Neurology, David Geffen School of Medicine, UCLA, Los Angeles, California, USA.'}, {'lastname': 'Tse', 'firstname': 'Vincent', 'initials': 'V', 'affiliation': 'Department of Neurology, David Geffen School of Medicine, UCLA, Los Angeles, California, USA.'}, {'lastname': 'Arnold', 'firstname': 'Arthur P', 'initials': 'AP', 'affiliation': 'Department of Integrative Biology and Physiology, UCLA, Los Angeles, California, USA.'}, {'lastname': 'Voskuhl', 'firstname': 'Rhonda R', 'initials': 'RR', 'affiliation': 'Department of Neurology, David Geffen School of Medicine, UCLA, Los Angeles, California, USA.'}]",,,,,"10.1172/JCI126250
10.1056/NEJMoa073493
10.1038/nature10251
10.1212/WNL.26.9.821
10.1073/pnas.1307091111
10.1084/jem.20070850
10.1038/nrneurol.2012.43
10.1136/annrheumdis-2011-201246
10.1073/pnas.0600536103
10.1038/d41586-019-01141-6
10.1038/379131a0
10.1093/hmg/7.4.737
10.1159/000071572
10.1523/JNEUROSCI.5382-07.2008
10.1101/gr.103200.109
10.1128/MCB.01506-06
10.1101/gad.203356.112
10.1073/pnas.0707292104
10.1038/emboj.2010.37
10.1016/j.yfrne.2008.11.001
10.1159/000071572
10.1186/gb-2010-11-6-213
10.1101/gr.103200.109
10.1093/hmg/11.12.1409
10.1111/j.1460-9568.2005.04134.x
10.1007/s00439-011-1011-z
10.1371/journal.pgen.1005079
10.4049/jimmunol.0802325
10.1189/jlb.1107752
10.4049/jimmunol.1004043
10.1073/pnas.1705011114
10.1371/journal.pgen.1004507
10.1172/JCI83239
10.1038/nature06192
10.1074/jbc.M114.555052
10.1210/en.2003-1504
10.1016/j.jaut.2017.02.007
10.1093/jmcb/mjv022
10.1038/ni.1747
10.1111/acel.12772
10.4049/jimmunol.0803563
10.1016/j.jneuroim.2016.01.014
10.1126/science.283.5406.1277
10.1093/bioinformatics/btu781
10.1093/bioinformatics/btp616
10.1038/nature10163
10.1038/nmeth.1342
10.1007/s00335-012-9422-2
10.1073/pnas.1103833108
10.4049/jimmunol.171.12.6936
10.1073/pnas.1716032115
10.1093/bioinformatics/btu170
10.1016/j.jaut.2011.11.012
10.1038/nri2815",<Element 'PubmedArticle' at 0x7f05ddf5a9a0>
254,31401069,Cervical sympathectomy modulates the neurogenic inflammatory neuropeptides following experimental subarachnoid hemorrhage in rats.,"Neuroinflammation is implicated in cerebral vasospasm and brain injuries after subarachnoid hemorrhage (SAH). In addition to classical neuroinflammation with increased inflammatory cytokines, a sterile neurogenic inflammation characterized by release of potent vasoactive neuropeptides may be responsible for brain injuries after SAH. Sympathetic discharges from superior cervical ganglion contribute to vasoconstriction of cerebral arteries Thus, we investigated the effects of surgical cervical sympathectomy on the neurogenic inflammatory neuropeptides shortly after SAH induction in a model of SAH in rats.
Male Wistar rats were divided into 4 groups: control; was not touched, saline group; 300 μl of saline was injected into prechiasmatic cistern, SAH+Sham group; 300 μl of autologous blood was injected to induce subarachnoid hemorrhage into prechiasmatic cistern; SAH+Symp group; the left cervical sympathetic branch was surgically removed after the induction of SAH. Levels of neuropeptides CGRP, SP and VIP which are responsible for neurogenic inflammation, in plasma, trigeminal ganglion, brainstem and brain tissue were measured by ELISA. In addition, c-fos expression as a marker of neuronal activation in the trigeminal nucleus caudalis (TNC) was determined by immunohistochemical staining.
SAH significantly increased c-fos expression in the TNC, as well as CGRP, SP and VIP concentrations in plasma and trigeminal ganglion neurons, and also CGRP and SP concentrations in the brainstem. Cervical sympathectomy application significantly reduced the increases in these parameters induced by SAH.
Our findings suggest that cervical sympathectomy treatment may prevent early brain injury by modulating SAH-induced neurogenic inflammatory neuropeptides such as CGRP, SP and VIP, and improve the quality of life in survivors following SAH.","['Cervical sympathectomy', 'Neurogenic inflammation', 'Neuropeptides', 'Subarachnoid hemorrhage', 'Trigeminovascular system']",Brain research,2019-08-12,"[{'lastname': 'Dagistan', 'firstname': 'Yasar', 'initials': 'Y', 'affiliation': 'Abant Izzet Baysal University, Medical Faculty, Department of Neurosurgery, Bolu, Turkey.'}, {'lastname': 'Kilinc', 'firstname': 'Erkan', 'initials': 'E', 'affiliation': 'Abant Izzet Baysal University, Medical Faculty, Department of Physiology, Bolu, Turkey. Electronic address: erkankilinc@ibu.edu.tr.'}, {'lastname': 'Balci', 'firstname': 'Cemre Nur', 'initials': 'CN', 'affiliation': 'Abant Izzet Baysal University, Institute of Health Sciences, Department of Histology and Embryology, Bolu, Turkey.'}]",,,"SAH significantly increased c-fos expression in the TNC, as well as CGRP, SP and VIP concentrations in plasma and trigeminal ganglion neurons, and also CGRP and SP concentrations in the brainstem. Cervical sympathectomy application significantly reduced the increases in these parameters induced by SAH.",Copyright © 2019 Elsevier B.V. All rights reserved.,10.1016/j.brainres.2019.146366,<Element 'PubmedArticle' at 0x7f05ddf0b2c0>
255,"31383729
26084020
25622053
11037977
23983983
20206137
17906678
17726158
19152719
25175866
25144219
28210207
31490211
24788318
26935478
28872464
8021507
25667414
27443914
16023222
25106425
26903403
11704885
22723794
1460427
15630430
8413264
26502112
16624285
29487124
17712819
24920309
16908594
22442063
22569268
23152191
21873455
21789506
26876387
16410796
27611972
28092376
19910459
25810377
17185040
22019906
29471387
17401376
27597805
12130702
20737475
26152369
9336020
23209411
19457575
31136945
29194121
23471521
25614186
28383502
17703415
25417929
23408483
15390091
8164509
25891508
20012068
30314877
28741645
29248000
20153077
23244217
25877930
25639489
24862333
24562630
11304551
22430559
17950393
29940353
25821806
9694974
12566094",Δ,"Cannabis is widely used in the United States, with an estimated prevalence of 9.5%. Certain cannabinoids in ",[],The Journal of pharmacology and experimental therapeutics,2019-08-07,"[{'lastname': 'Rizzo', 'firstname': 'Michael D', 'initials': 'MD', 'affiliation': 'Cell and Molecular Biology Program (M.D.R.), Institute for Integrative Toxicology (M.D.R., R.B.C., N.E.K.), Center for Research on Ingredient Safety (A.B., N.E.K.), and Departments of Microbiology and Molecular Genetics (A.A.), Osteopathic Medicine (A.A.), and Pharmacology and Toxicology (S.S., N.E.K.), Michigan State University, East Lansing, Michigan.'}, {'lastname': 'Crawford', 'firstname': 'Robert B', 'initials': 'RB', 'affiliation': 'Cell and Molecular Biology Program (M.D.R.), Institute for Integrative Toxicology (M.D.R., R.B.C., N.E.K.), Center for Research on Ingredient Safety (A.B., N.E.K.), and Departments of Microbiology and Molecular Genetics (A.A.), Osteopathic Medicine (A.A.), and Pharmacology and Toxicology (S.S., N.E.K.), Michigan State University, East Lansing, Michigan.'}, {'lastname': 'Bach', 'firstname': 'Anthony', 'initials': 'A', 'affiliation': 'Cell and Molecular Biology Program (M.D.R.), Institute for Integrative Toxicology (M.D.R., R.B.C., N.E.K.), Center for Research on Ingredient Safety (A.B., N.E.K.), and Departments of Microbiology and Molecular Genetics (A.A.), Osteopathic Medicine (A.A.), and Pharmacology and Toxicology (S.S., N.E.K.), Michigan State University, East Lansing, Michigan.'}, {'lastname': 'Sermet', 'firstname': 'Sera', 'initials': 'S', 'affiliation': 'Cell and Molecular Biology Program (M.D.R.), Institute for Integrative Toxicology (M.D.R., R.B.C., N.E.K.), Center for Research on Ingredient Safety (A.B., N.E.K.), and Departments of Microbiology and Molecular Genetics (A.A.), Osteopathic Medicine (A.A.), and Pharmacology and Toxicology (S.S., N.E.K.), Michigan State University, East Lansing, Michigan.'}, {'lastname': 'Amalfitano', 'firstname': 'Andrea', 'initials': 'A', 'affiliation': 'Cell and Molecular Biology Program (M.D.R.), Institute for Integrative Toxicology (M.D.R., R.B.C., N.E.K.), Center for Research on Ingredient Safety (A.B., N.E.K.), and Departments of Microbiology and Molecular Genetics (A.A.), Osteopathic Medicine (A.A.), and Pharmacology and Toxicology (S.S., N.E.K.), Michigan State University, East Lansing, Michigan.'}, {'lastname': 'Kaminski', 'firstname': 'Norbert E', 'initials': 'NE', 'affiliation': 'Cell and Molecular Biology Program (M.D.R.), Institute for Integrative Toxicology (M.D.R., R.B.C., N.E.K.), Center for Research on Ingredient Safety (A.B., N.E.K.), and Departments of Microbiology and Molecular Genetics (A.A.), Osteopathic Medicine (A.A.), and Pharmacology and Toxicology (S.S., N.E.K.), Michigan State University, East Lansing, Michigan kamins11@msu.edu.'}]",,,,Copyright © 2019 by The American Society for Pharmacology and Experimental Therapeutics.,"10.1124/jpet.119.260661
10.1097/QAD.0000000000002296",<Element 'PubmedArticle' at 0x7f05ddf15f40>
256,"31361008
19015862
17579875
16718704
19204154
19455346
17021754
21644037
17279000
17003490
17071926
18379440
17278999
16950801
16983677
17436289
16862116
16862115
2268320
1542665
2236009
12928786
24800652
21813674
18378771
20026663
23041626
19649643
29044416
11708987
19924424
11310619
14561797
21810890
21514250
22101365
21707362
27693922
24423638
16930776
2300243
9630473
10980247
11327303
26001591
10192781
2818255
19860916
21204008
21813674
22781549
22062772
22509390
27114033
22608501
21051630",FTLD-TDP With and Without GRN Mutations Cause Different Patterns of CA1 Pathology.,"Heterozygous loss-of-function mutations in the GRN gene lead to progranulin (PGRN) haploinsufficiency and cause frontotemporal lobar degeneration with TDP-43 pathology type A (FTLD-TDP type A). PGRN is a highly conserved, secreted glycoprotein and functions in the central nervous system as a key modulator of microglial function. Hence, altered microglial function caused by PGRN deficiency may be tied to the pathogenesis of FTLD-TDP. Our previous studies showed that haploinsufficiency of GRN mutations extends to microglial PGRN expression in the hippocampal CA1 region. In this study, we found that the CA1 sector was associated with less neuronal loss and more frequent TDP-43 inclusions in FTLD-TDP type A cases with GRN mutations than in sporadic cases. In addition, the CA1 region in GRN mutation cases contained more rod-like microglia, which also had reduced PGRN expression. These findings suggest that the profile of TDP-43 inclusions, neuronal number, and microgliosis in the CA1 sector of FTLD-TDP type A cases may be influenced by GRN gene expression status.","['Frontotemporal lobar degeneration', 'Hippocampal sclerosis', 'Microglia', 'Neuroinflammation', 'Progranulin', 'TAR DNA-binding protein 43']",Journal of neuropathology and experimental neurology,2019-07-31,"[{'lastname': 'Mao', 'firstname': 'Qinwen', 'initials': 'Q', 'affiliation': 'Department of Pathology, Northwestern University Feinberg School of Medicine, Chicago, Illinois.'}, {'lastname': 'Zheng', 'firstname': 'Xiaojing', 'initials': 'X', 'affiliation': ""Laboratory of Gene Therapy, Department of Biochemistry, College of Life Sciences, Shaanxi Normal University, Xi'an, Shaanxi, P.R. China.""}, {'lastname': 'Gefen', 'firstname': 'Tamar', 'initials': 'T', 'affiliation': ""Mesulam Center for Cognitive Neurology and Alzheimer's Disease, Northwestern University Feinberg School of Medicine, Chicago, Illinois.""}, {'lastname': 'Rogalski', 'firstname': 'Emily', 'initials': 'E', 'affiliation': ""Mesulam Center for Cognitive Neurology and Alzheimer's Disease, Northwestern University Feinberg School of Medicine, Chicago, Illinois.""}, {'lastname': 'Spencer', 'firstname': 'Callen L', 'initials': 'CL', 'affiliation': ""Mesulam Center for Cognitive Neurology and Alzheimer's Disease, Northwestern University Feinberg School of Medicine, Chicago, Illinois.""}, {'lastname': 'Rademakers', 'firstname': 'Rosa', 'initials': 'R', 'affiliation': 'Department of Neuroscience, Mayo Clinic, Jacksonville, Florida.'}, {'lastname': 'Fought', 'firstname': 'Angela J', 'initials': 'AJ', 'affiliation': 'Division of Biostatistics, Department of Preventive Medicine, Northwestern University Feinberg School of Medicine.'}, {'lastname': 'Kohler', 'firstname': 'Missia', 'initials': 'M', 'affiliation': 'Cook County Medical Examiner, Chicago, Illinois.'}, {'lastname': 'Weintraub', 'firstname': 'Sandra', 'initials': 'S', 'affiliation': ""Mesulam Center for Cognitive Neurology and Alzheimer's Disease, Northwestern University Feinberg School of Medicine, Chicago, Illinois.""}, {'lastname': 'Xia', 'firstname': 'Haibin', 'initials': 'H', 'affiliation': ""Laboratory of Gene Therapy, Department of Biochemistry, College of Life Sciences, Shaanxi Normal University, Xi'an, Shaanxi, P.R. China.""}, {'lastname': 'Mesulam', 'firstname': 'Marek-Marsel', 'initials': 'MM', 'affiliation': ""Mesulam Center for Cognitive Neurology and Alzheimer's Disease, Northwestern University Feinberg School of Medicine, Chicago, Illinois.""}, {'lastname': 'Bigio', 'firstname': 'Eileen H', 'initials': 'EH', 'affiliation': ""Department of Pathology, Northwestern University Feinberg School of Medicine, Chicago, Illinois.\nMesulam Center for Cognitive Neurology and Alzheimer's Disease, Northwestern University Feinberg School of Medicine, Chicago, Illinois.""}]",,,,"© 2019 American Association of Neuropathologists, Inc. All rights reserved.",10.1093/jnen/nlz059,<Element 'PubmedArticle' at 0x7f05dde82b30>
257,"31359117
26123902
22333520
10599770
30274602
27908969
25755630
25524788
30718548
28867281
24782009
16272115
25750611
27713470
2125712
28216088
22492304
10938051
25698781
12450640
15817524
18374402
26733805
18199994
17289656
15576057
21334376
16978590
21163445
18073775
26176590
17504139
24700968
28289215
19376240
26896670
19297307
26291403
29551356
26552591
29985474
12297606
10036289
16585466
26004162
28892126
18533059
12872204
25486982
20071507
25249929
28179814
30030541
15724877
25585035
26529616
19161177
25742202
11489254
11457488
16810666
25976322
26435451
10680851
11726071
20955776
16772530
20853920
3050629
4815174
20221300
18805677
27991897
19188531
21818124
25113601
23410758
7527406
21084640
20980632
23998664
16139959
25309543
12912762
19531277
19751761
26111720
10940438
27546235
10022424
12577943
25682174
12823087
11070092
27856392
25898329
29760681
20160162
27872957
21570260
21234098
28089638
29889554
21442309
19747114
2063480
22289042
11905821
18650913
24495551
30457060
21977998
20008426
22494534
19150053
1697776
12697714
10401474
25598426
31103547
24308926
27155772
28744200
16491133
23638342
25564524
25016200
26979965
17700646
24793874
28445888
23127296
21040743
30293097
16946190
21482187
1347506
15626482
19298363
23153795
11397831
15697325
16316783
22945416
27232630
24898155
21508345
24522912
21119734
20439828
25074638
21359227
23206327
31068711
15250815
22096248
25629589
28804509
11444439
25449576
27761055
30236597
23853742
24417575
29016550
20357895
20083138
20679216
21470621
25086307
30912589
1330501
17475444
16557263
17640948
15465075
9729388
16492687
24676756
25988703
26907213
22305766
23291110
25139892
12377295
16399150
22967776
15546155
11245665
28912144
23921781
27196727
22832816
15857271
23406909
10084932
18704021
15944074
7550285
10657556
29199875
20406665","Stress, sex hormones, inflammation, and major depressive disorder: Extending Social Signal Transduction Theory of Depression to account for sex differences in mood disorders.","Social Signal Transduction Theory of Depression is a biologically plausible, multi-level theory that describes neural, physiologic, molecular, and genomic mechanisms that link experiences of social-environmental adversity with internal biological processes that drive depression pathogenesis, maintenance, and recurrence. Central to this theory is the hypothesis that interpersonal stressors involving social threat (e.g., social conflict, evaluation, rejection, isolation, and exclusion) upregulate inflammatory processes that can induce several depressive symptoms, including sad mood, anhedonia, fatigue, psychomotor retardation, and social-behavioral withdrawal. The original article describing this formulation (Psychol Bull 140:774-815, 2014) addressed critical questions involving depression onset and recurrence, as well as why depression is strongly predicted by early life stress and comorbid with anxiety disorders and certain physical disease conditions, such as asthma, rheumatoid arthritis, chronic pain, and cardiovascular disease. Here, we extend the theory to help explain sex differences in depression prevalence, which is a defining feature of this disorder. Central to this extension is research demonstrating that ovarian hormone fluctuations modulate women's susceptibility to stress, brain structure and function, and inflammatory activity and reactivity. These effects are evident at multiple levels and are highly context-dependent, varying as a function of several factors including sex, age, reproductive state, endogenous versus exogenous hormones, and hormone administration mode and dose. Together, these effects help explain why women are at greater risk for developing inflammation-related depressed mood and other neuropsychiatric, neurodevelopmental, and neurodegenerative disorders during the reproductive years, especially for those already at heightened risk for depression or in the midst of a hormonal transition period.","['Cytokines', 'Depression', 'Disease', 'Inflammation', 'Life stress', 'Neuroinflammation', 'Risk', 'Sex differences', 'Sex hormones', 'Social threat']",Psychopharmacology,2019-07-31,"[{'lastname': 'Slavich', 'firstname': 'George M', 'initials': 'GM', 'affiliation': 'Cousins Center for Psychoneuroimmunology and Department of Psychiatry and Biobehavioral Sciences, University of California, Los Angeles, UCLA Medical Plaza 300, Room 3156, Los Angeles, CA, 90095-7076, USA. gslavich@mednet.ucla.edu.'}, {'lastname': 'Sacher', 'firstname': 'Julia', 'initials': 'J', 'affiliation': 'Emotion NeuroimaGinG (EGG)-Lab and Department of Neurology, Max Planck Institute for Cognitive and Brain Sciences, Stephanstrasse 1a, 04103, Leipzig, Germany.'}]",,,,,10.1007/s00213-019-05326-9,<Element 'PubmedArticle' at 0x7f05dde27e50>
258,"31354896
15096404
20457954
21330902
21203440
21800103
23902750
23792284
22956581
29506535
22462664
18177640
11293804
15780868
24140886
16355225
17974036
12734393
12917686
22638776
20880510
20948535
18946042
17222529
20566001
22050959
22086103
15813646
11399676
11323130
16316653
16045490
20304807
21550725
20705215
16204639
18040791
25876735
29482740
17624463
12552021
28445708
24098399
21371995
10652440
16343349
20098669
17401376
17276894
16503355
23824763
14741442
18040842
15390091
24147028
25160710
17994110
20849866
24853387
18664590
27398024
12598628
29166835",Antiallodynic Effects of Cannabinoid Receptor 2 (CB,The most common neurological complication in patients receiving successful combination antiretroviral therapy (cART) is peripheral neuropathic pain. Data show that distal symmetric polyneuropathy (DSP) also develops along with murine acquired immunodeficiency syndrome (MAIDS) after infection with the LP-BM5 murine retrovirus mixture. Links between cannabinoid receptor 2 (CB,[],Pain research & management,2019-07-30,"[{'lastname': 'Sheng', 'firstname': 'Wen S', 'initials': 'WS', 'affiliation': 'Neurovirology Laboratory, Department of Medicine, University of Minnesota, Minneapolis, MN 55455, USA.'}, {'lastname': 'Chauhan', 'firstname': 'Priyanka', 'initials': 'P', 'affiliation': 'Neurovirology Laboratory, Department of Medicine, University of Minnesota, Minneapolis, MN 55455, USA.'}, {'lastname': 'Hu', 'firstname': 'Shuxian', 'initials': 'S', 'affiliation': 'Neurovirology Laboratory, Department of Medicine, University of Minnesota, Minneapolis, MN 55455, USA.'}, {'lastname': 'Prasad', 'firstname': 'Sujata', 'initials': 'S', 'affiliation': 'Neurovirology Laboratory, Department of Medicine, University of Minnesota, Minneapolis, MN 55455, USA.'}, {'lastname': 'Lokensgard', 'firstname': 'James R', 'initials': 'JR', 'affiliation': 'Neurovirology Laboratory, Department of Medicine, University of Minnesota, Minneapolis, MN 55455, USA.'}]",,,,,"10.1155/2019/1260353
10.1001/archneur.61.4.546
10.1001/archneurol.2010.76
10.1097/qad.0b013e328345889d
10.1371/journal.pone.0014433
10.1007/s13365-011-0042-5
10.1186/1742-2094-10-98
10.1016/j.pain.2013.06.022
10.4049/jimmunol.1201313
10.1186/s12974-018-1107-7
10.1111/j.1529-8027.2012.00373.x
10.1016/j.expneurol.2007.06.015
10.1046/j.1529-8027.2001.006001021.x
10.1016/j.virol.2005.01.027
10.1016/j.lfs.2013.10.005
10.1038/nature04223
10.1186/1744-8069-3-33
10.1124/jpet.103.052407
10.1038/nature01786
10.1007/s11064-012-0801-6
10.1016/j.nurt.2010.05.016
10.1038/nm.2234
10.1073/pnas.0801793105
10.1016/j.bbi.2006.11.011
10.1017/s1740925x10000098
10.1016/j.brainres.2011.10.016
10.2165/00023210-200519040-00005
10.1038/sj.bjp.0704110
10.1016/s0304-3959(00)00474-7
10.1016/j.ejphar.2005.10.020
10.1111/j.1460-9568.2005.04206.x
10.1182/blood-2010-01-260372
10.1016/j.pain.2011.03.038
10.1016/j.pain.2010.06.019
10.1189/jlb.0405216
10.1007/s11481-005-9007-x
10.1007/s11481-015-9603-3
10.1016/j.ejim.2018.01.020
10.1016/j.virusres.2007.05.022
10.1128/jvi.77.4.2775-2778.2003
10.1016/j.jneumeth.2017.04.012
10.1371/journal.pone.0075804
10.1093/brain/awr025
10.1002/(sici)1098-1136(20000215)29:4<293::aid-glia1>3.3.co;2-1
10.1186/1742-2094-2-29
10.1371/journal.pone.0008688
10.1038/nm1561
10.1016/j.intimp.2006.11.008
10.1016/j.molimm.2006.01.005
10.1007/s11481-013-9485-1
10.1016/j.jneuroim.2003.10.026
10.1007/s11481-006-9040-4
10.1002/glia.20108
10.1371/journal.pone.0077577
10.1007/s11916-014-0451-2
10.1038/sj.bjp.0707568
10.1016/j.neuropharm.2010.09.004
10.1016/j.biopsych.2014.04.009
10.1124/jpet.108.141994
10.4137/pmc.s32171
10.1523/jneurosci.23-04-01398.2003
10.1177/1744806917747425",<Element 'PubmedArticle' at 0x7f05dde072c0>
259,"31354401
19371742
9445346
28259722
7694279
9890428
29059593
28302915
28069909
21625615
17640823
25309326
11274341
27686844
25359225
21738161
11108754
16135580
20130219
24524551
21960564
8703181
25549183
22490926
19919699
9428305
17397044
23674483
19169263
25475834
12728267
19248774
16056254
9361344
20670828
15111734
23579082
16709809
28645895
8515904
16860801
11240037
29970193
28669797
21984070
27870437
9760699
12598900
16713598
23848237
25433215
8266365
27075756",Nursing Markedly Protects Postpartum Mice From Stroke: Associated Central and Peripheral Neuroimmune Changes and a Role for Oxytocin.,"Recent studies demonstrate significant neuroimmune changes in postpartum females, a period that also carries an increased risk of stroke. Oxytocin, a major hormone upregulated in the brains of nursing mothers, has been shown to both modulate neuroinflammation and protect against stroke. In the present study we assessed whether and how nursing modulates the neuroimmune response and injury after stroke. We observed that postpartum nursing mice were markedly protected from 1 h of transient middle cerebral artery occlusion (MCAO) relative to either non-pregnant/non-postpartum or non-nursing (pups removed) postpartum females. Nursing mice also expressed reduced levels of pro-inflammatory cytokines, had decreased migration of blood leukocytes into the brain following MCAO, and displayed peripheral neuroimmune changes characterized by increased spleen weight and increased fraction of spleen monocytes. Intranasal oxytocin treatment in non-pregnant females in part recapitulated the protective and anti-inflammatory effects associated with nursing. In summary, the results of the present study demonstrate that nursing in the postpartum period provides relative protection against transient ischemic stroke associated with decreased brain leukocytes and increased splenic monocytes. These effects appear to be regulated, at least in part, by oxytocin.","['FACS', 'MCAO', 'adaptive', 'cytokine', 'focal ischemia', 'inflammation', 'innate', 'ischemia']",Frontiers in neuroscience,2019-07-30,"[{'lastname': 'Stary', 'firstname': 'Creed M', 'initials': 'CM', 'affiliation': 'Department of Anesthesiology, Perioperative and Pain Medicine, Stanford, CA, United States.'}, {'lastname': 'Xu', 'firstname': 'Lijun', 'initials': 'L', 'affiliation': 'Department of Anesthesiology, Perioperative and Pain Medicine, Stanford, CA, United States.'}, {'lastname': 'Voloboueva', 'firstname': 'Ludmilla A', 'initials': 'LA', 'affiliation': 'Department of Anesthesiology, Perioperative and Pain Medicine, Stanford, CA, United States.'}, {'lastname': 'Alcántara-Hernández', 'firstname': 'Marcela', 'initials': 'M', 'affiliation': 'Department of Microbiology and Immunology, Stanford, CA, United States.\nProgram in Immunology, Stanford University School of Medicine, Stanford, CA, United States.'}, {'lastname': 'Arvola', 'firstname': 'Oiva J', 'initials': 'OJ', 'affiliation': 'Department of Anesthesiology, Perioperative and Pain Medicine, Stanford, CA, United States.'}, {'lastname': 'Idoyaga', 'firstname': 'Juliana', 'initials': 'J', 'affiliation': 'Department of Microbiology and Immunology, Stanford, CA, United States.\nProgram in Immunology, Stanford University School of Medicine, Stanford, CA, United States.'}, {'lastname': 'Giffard', 'firstname': 'Rona G', 'initials': 'RG', 'affiliation': 'Department of Anesthesiology, Perioperative and Pain Medicine, Stanford, CA, United States.'}]",,,,,"10.3389/fnins.2019.00609
10.1016/j.expneurol.2009.03.044
10.1016/j.pnpbp.2017.02.022
10.1073/pnas.90.21.10061
10.1002/(sici)1097-4547(19990101)55:1<1::aid-jnr1>3.0.co;2-9
10.1016/j.neurobiolaging.2017.09.022
10.1042/CS20160841
10.1093/qjmed/hcw222
10.1371/journal.pone.0019046
10.1016/j.psyneuen.2007.05.012
10.1152/physrev.2001.81.2.629
10.1016/j.bbi.2016.09.026
10.1111/ejn.12752
10.1038/nm.2399
10.1161/01.str.31.12.2948
10.1097/01.aog.0000172428.78411.b0
10.1189/jlb.1109766
10.1056/NEJMoa1311485
10.1161/STROKEAHA.111.628008
10.1096/fj.11-197384
10.1186/1479-5876-7-97
10.1097/00004647-199801000-00005
10.1002/hipo.20278
10.1002/ana.23815
10.1038/nm.1927
10.1111/cns.12361
10.1016/j.brainres.2009.02.029
10.1038/nri1669
10.1016/j.neuron.2010.07.002
10.1093/ilar.45.2.147
10.1016/j.psyneuen.2013.03.003
10.4049/jimmunol.176.11.6523
10.1073/pnas.1607002114
10.1016/s0149-7634(05)80152-6
10.1016/j.yhbeh.2006.05.006
10.1016/s0165-5728(00)00433-1
10.1186/s12974-018-1239-9
10.1016/j.bbi.2017.06.016
10.1038/nri3070
10.1002/jnr.23855
10.1016/s0301-0082(98)00034-3
10.1038/nn1023
10.1016/j.expneurol.2006.03.017
10.1111/ane.12165
10.1016/j.expneurol.2014.11.007
10.1161/01.str.25.1.165
10.1186/s12974-016-0541-7",<Element 'PubmedArticle' at 0x7f05dddb45e0>
260,"31297095
19538962
23731522
23196064
21767382
11351342
10200510
11113609
11014219
11245665
15748951
16369558
21900578
19595678
27020098
9826735
22493082
26101324
25512512
17372018
23277546
20962261
21836070
17283243
22897118
2110186
12475898
18338796
7181105
26321046
21348832
22403545
19104500
30381249
28974386
29985474
24607811
20392807
26891883
28862638
25002752
27196727
28861714
29125686
24762434
21900603
28810246
30017543
30001721
27127723
18262660
28964927
25105782
23881706
26659872
29654072
19536048
21774811
21127968
28620274
21277368
24163150
29202771",Estrogen Promotes Pro-resolving Microglial Behavior and Phagocytic Cell Clearance Through the Actions of Annexin A1.,"Local production of estrogen rapidly follows brain tissue injury, but the role this hormone plays in regulating the response to neural damage or in the modulation of mediators regulating inflammation is in many ways unclear. Using the murine BV2 microglia model as well as primary microglia from wild-type and annexin A1 (AnxA1) null mice, we have identified two related mechanisms whereby estradiol can modulate microglial behavior in a receptor specific fashion. Firstly, estradiol, via estrogen receptor β (ERβ), enhanced the phagocytic clearance of apoptotic cells, acting through increased production and release of the protein AnxA1. Secondly, stimulation of either ERβ or the G protein coupled estrogen receptor GPER promoted the adoption of an anti-inflammatory/pro-resolving phenotype, an action similarly mediated through AnxA1. Together, these data suggest the hypothesis that locally produced estrogen acts through AnxA1 to exert powerful pro-resolving actions, controlling and limiting brain inflammation and ultimately protecting this highly vulnerable organ. Given the high degree of receptor selectivity in evoking these responses, we suggest that the use of selective estrogen receptor ligands may hold therapeutic promise in the treatment of neuroinflammation, avoiding unwanted generalized effects.","['annexin A1', 'estrogen', 'microglia', 'phagocytosis', 'resolution']",Frontiers in endocrinology,2019-07-13,"[{'lastname': 'Loiola', 'firstname': 'Rodrigo Azevedo', 'initials': 'RA', 'affiliation': ""John Vane Science Centre, Barts and The London School of Medicine and Dentistry, William Harvey Research Institute, Queen Mary University of London, London, United Kingdom.\nLaboratoire de la Barrière Hémato-Encéphalique, Faculty Jean Perrin, EA 2465, Université d'Artois, Arras, France.""}, {'lastname': 'Wickstead', 'firstname': 'Edward S', 'initials': 'ES', 'affiliation': 'School of Life Sciences, College of Liberal Arts & Sciences, University of Westminster, London, United Kingdom.\nBarts and The London School of Medicine and Dentistry, Institute of Dentistry, Blizard Institute, Queen Mary University of London, London, United Kingdom.'}, {'lastname': 'Solito', 'firstname': 'Egle', 'initials': 'E', 'affiliation': 'John Vane Science Centre, Barts and The London School of Medicine and Dentistry, William Harvey Research Institute, Queen Mary University of London, London, United Kingdom.\nDipartimento di Medicina Molecolare e Biotecnologie Mediche, Universitá degli Studi di Napoli Federico II, Naples, Italy.'}, {'lastname': 'McArthur', 'firstname': 'Simon', 'initials': 'S', 'affiliation': 'Barts and The London School of Medicine and Dentistry, Institute of Dentistry, Blizard Institute, Queen Mary University of London, London, United Kingdom.'}]",,,,,"10.3389/fendo.2019.00420
10.1016/j.yhbeh.2009.06.002
10.1016/j.coph.2013.05.007
10.1016/j.jsbmb.2012.11.006
10.1186/1742-2094-8-81
10.1002/neu.1038
10.1038/sj.cdd.4400407
10.1016/S0531-5565(00)00161-3
10.1210/endo.141.10.7693
10.1523/JNEUROSCI.21-06-01809.2001
10.1016/j.jneuroim.2004.12.016
10.1038/ni1276
10.1523/JNEUROSCI.2102-11.2011
10.1016/j.brainres.2009.06.097
10.1038/nrd.2016.39
10.1073/pnas.95.24.14535
10.1189/jlb.0112008
10.4049/jimmunol.1500733
10.1073/pnas.1410938111
10.4049/jimmunol.178.7.4595
10.1073/pnas.1209362110
10.4049/jimmunol.1001095
10.1161/ATVBAHA.111.235176
10.1677/JOE-06-0132
10.1111/j.1476-5381.2012.02146.x
10.1016/0165-5728(90)90073-V
10.1096/fj.02-0239fje
10.1002/glia.20663
10.1016/0003-2697(82)90118-X
10.1016/j.bbi.2015.08.020
10.2174/138161211795049732
10.3389/fphar.2012.00027
10.1038/nri2470
10.1016/j.jsbmb.2018.10.015
10.1016/j.yfrne.2017.09.002
10.1038/s41582-018-0032-9
10.1016/j.jsbmb.2014.02.018
10.1124/pr.109.002071
10.1016/j.pneurobio.2015.12.008
10.1172/JCI90606
10.1084/jem.20132477
10.1210/er.2016-1007
10.1007/s10495-017-1413-z
10.1111/febs.14323
10.1172/JCI59901
10.1073/pnas.1104533108
10.1159/000478908
10.1016/j.cjtee.2018.04.003
10.1186/s12974-018-1246-x
10.1002/brb3.449
10.1016/j.tips.2007.12.003
10.1016/j.jsbmb.2017.09.019
10.1210/en.2014-1158
10.1007/s11481-013-9490-4
10.1007/s12035-015-9593-4
10.1530/JOE-18-0129
10.1097/SHK.0b013e3181b0ebcb
10.1186/1742-2094-8-82
10.1007/s11064-010-0336-7
10.3389/fnins.2017.00306
10.1016/j.bbi.2011.01.013
10.1007/s12031-013-0137-y
10.1186/s12974-017-1011-6",<Element 'PubmedArticle' at 0x7f05dddd3e50>
261,31256135,Exenatide Reverts the High-Fat-Diet-Induced Impairment of BDNF Signaling and Inflammatory Response in an Animal Model of Alzheimer's Disease.,"Alzheimer's disease (AD) is a multifactorial condition in which, along with amyloid-β (Aβ) and tau-related pathology, the synergistic activity of co-morbidity factors promote the onset and progression of the disease. Epidemiological evidence indicates that glucose intolerance, deficits in insulin secretion, or type-2 diabetes mellitus (T2DM) participate in increasing cognitive impairment or dementia risk. Insulin plays a pivotal role in the process as the hormone critically regulates brain functioning. GLP-1, the glucagon-like peptide 1, facilitates insulin signaling, regulates glucose homeostasis, and modulates synaptic plasticity. Exenatide is a synthetic GLP-1 analog employed in T2DM. However, exenatide has also been shown to affect the signaling of the brain-derived neurotrophic factor (BDNF), synaptic plasticity, and cognitive performances in animal models. In this study, we tested whether exenatide exerts neuroprotection in a preclinical AD model set to mimic the clinical complexity of the human disease. We investigated the effects of exenatide treatment in 3xTg-AD mice challenged with a high-fat diet (HFD). Endpoints of the study were variations in systemic metabolism, insulin and neurotrophic signaling, neuroinflammation, Aβ and tau pathology, and cognitive performances. Results of the study indicate that exenatide reverts the adverse changes of BDNF signaling and the neuroinflammation status of 3xTg-AD mice undergoing HFD without affecting systemic metabolism or promoting changes in cognitive performances.","['Aging', 'BDNF', 'T2DM', 'dementia', 'diabetes', 'exendin-4', 'insulin', 'insulin resistance', 'neurotrophic factors']",Journal of Alzheimer's disease : JAD,2019-07-01,"[{'lastname': 'Bomba', 'firstname': 'Manuela', 'initials': 'M', 'affiliation': ""Center of Excellence on Aging and Translational Medicine - CeSI-MeT, University G. d'Annunzio of Chieti-Pescara, Italy.\nDepartment of Neuroscience, Imaging, and Clinical Sciences, University G. d'Annunzio of Chieti-Pescara, Italy.""}, {'lastname': 'Granzotto', 'firstname': 'Alberto', 'initials': 'A', 'affiliation': ""Center of Excellence on Aging and Translational Medicine - CeSI-MeT, University G. d'Annunzio of Chieti-Pescara, Italy.\nDepartment of Neuroscience, Imaging, and Clinical Sciences, University G. d'Annunzio of Chieti-Pescara, Italy.""}, {'lastname': 'Castelli', 'firstname': 'Vanessa', 'initials': 'V', 'affiliation': ""Department of Life, Health and Environmental Sciences, University of L'Aquila, Italy.""}, {'lastname': 'Onofrj', 'firstname': 'Marco', 'initials': 'M', 'affiliation': ""Center of Excellence on Aging and Translational Medicine - CeSI-MeT, University G. d'Annunzio of Chieti-Pescara, Italy.\nDepartment of Neuroscience, Imaging, and Clinical Sciences, University G. d'Annunzio of Chieti-Pescara, Italy.""}, {'lastname': 'Lattanzio', 'firstname': 'Rossano', 'initials': 'R', 'affiliation': ""Center of Excellence on Aging and Translational Medicine - CeSI-MeT, University G. d'Annunzio of Chieti-Pescara, Italy.\nDepartment of Medical, Oral, and Biotechnological Sciences, University G. d'Annunzio of Chieti-Pescara, Italy.""}, {'lastname': 'Cimini', 'firstname': 'Annamaria', 'initials': 'A', 'affiliation': ""Department of Life, Health and Environmental Sciences, University of L'Aquila, Italy.\nSbarro Institute for Cancer Research and Molecular Medicine and Center for Biotechnology, Temple University, Philadelphia, PA, USA.\nNational Institute for Nuclear Physics (INFN), Gran Sasso National Laboratory (LNGS), Assergi, Italy.""}, {'lastname': 'Sensi', 'firstname': 'Stefano L', 'initials': 'SL', 'affiliation': ""Center of Excellence on Aging and Translational Medicine - CeSI-MeT, University G. d'Annunzio of Chieti-Pescara, Italy.\nDepartment of Neuroscience, Imaging, and Clinical Sciences, University G. d'Annunzio of Chieti-Pescara, Italy.\nDepartments of Neurology and Pharmacology, Institute for Mind Impairments and Neurological Disorders - iMIND, University of California - Irvine, Irvine, CA, USA.""}]",,,,,10.3233/JAD-190237,<Element 'PubmedArticle' at 0x7f05ddc7c5e0>
262,31238131,Direct and indirect effects of lipids on microglia function.,"Microglia are key players in brain function by maintaining brain homeostasis across lifetime. They participate to brain development and maturation through their ability to release neurotrophic factors, to remove immature synapses or unnecessary neural progenitors. They modulate neuronal activity in healthy adult brains and they also orchestrate the neuroinflammatory response in various pathophysiological contexts such as aging and neurodegenerative diseases. One of the main features of microglia is their high sensitivity to environmental factors, partly via the expression of a wide range of receptors. Recent data pinpoint that dietary fatty acids modulate microglia function. Both the quantity and the type of fatty acid are potent modulators of microglia physiology. The present review aims at dissecting the current knowledge on the direct and indirect mechanisms (focus on gut microbiota and hormones) through which fatty acids influence microglial physiology. We summarize main discoveries from in vitro and in vivo models on fatty acid-mediated microglial modulation. All these studies represent a promising field of research that could promote using nutrition as a novel therapeutic or preventive tool in diseases involving microglia dysfunctions.","['Fatty acids', 'Gut microbiota', 'Hormones', 'Inflammation', 'Microglia', 'Obesity']",Neuroscience letters,2019-06-27,"[{'lastname': 'Leyrolle', 'firstname': 'Q', 'initials': 'Q', 'affiliation': 'INRA, Nutrition et Neurobiologie Intégrée, UMR 1286, 33076 Bordeaux, France; Univ. Bordeaux, Nutrition et Neurobiologie Intégrée, UMR 1286, 33076 Bordeaux, France.'}, {'lastname': 'Layé', 'firstname': 'S', 'initials': 'S', 'affiliation': 'INRA, Nutrition et Neurobiologie Intégrée, UMR 1286, 33076 Bordeaux, France; Univ. Bordeaux, Nutrition et Neurobiologie Intégrée, UMR 1286, 33076 Bordeaux, France.'}, {'lastname': 'Nadjar', 'firstname': 'A', 'initials': 'A', 'affiliation': 'INRA, Nutrition et Neurobiologie Intégrée, UMR 1286, 33076 Bordeaux, France; Univ. Bordeaux, Nutrition et Neurobiologie Intégrée, UMR 1286, 33076 Bordeaux, France. Electronic address: agnes.nadjar@u-bordeaux.fr.'}]",,,,Copyright © 2019 Elsevier B.V. All rights reserved.,10.1016/j.neulet.2019.134348,<Element 'PubmedArticle' at 0x7f05ddc8c090>
263,31231832,Melatonin for prevention of placental malperfusion and fetal compromise associated with intrauterine inflammation-induced oxidative stress in a mouse model.,"Melatonin has been shown to reduce oxidative stress and mitigate hypercoagulability. We hypothesized that maternally administered melatonin may reduce placental oxidative stress and hypercoagulability associated with exposure to intrauterine inflammation (IUI) and consequently improve fetoplacental blood flow and fetal sequelae. Mice were randomized to the following groups: control (C), melatonin (M), lipopolysaccharide (LPS; a model of IUI) (L), and LPS with melatonin (ML). The expression of antioxidant mediators in the placenta was significantly decreased, while that of pro-inflammatory mediators was significantly increased in L compared to C and ML. The systolic/diastolic ratio, resistance index, and pulsatility index in uterine artery (UtA) and umbilical artery (UA) were significantly increased in L compared with other groups when analyzed by Doppler ultrasonography. The expression of antioxidant mediators in the placenta was significantly decreased, while that of pro-inflammatory mediators was significantly increased in L compared to C and ML. Vascular endothelial damage and thrombi formation, as evidenced by fibrin deposits, were similarly increased in L compared to other groups. Maternal pretreatment with melatonin appears to modulate maternal placental malperfusion, fetal cardiovascular compromise, and fetal neuroinflammation induced by IUI through its antioxidant properties.","['Doppler ultrasonography', 'intrauterine inflammation', 'melatonin', 'mice', 'placenta', 'placental insufficiency', 'pregnancy']",Journal of pineal research,2019-06-25,"[{'lastname': 'Lee', 'firstname': 'Ji Yeon', 'initials': 'JY', 'affiliation': 'Integrated Research Center for Fetal Medicine, Department of Gynecology and Obstetrics, Johns Hopkins University School of Medicine, Baltimore, MD, USA.\nDepartment of Obstetrics and Gynecology, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam, Korea.'}, {'lastname': 'Li', 'firstname': 'Su', 'initials': 'S', 'affiliation': 'Integrated Research Center for Fetal Medicine, Department of Gynecology and Obstetrics, Johns Hopkins University School of Medicine, Baltimore, MD, USA.'}, {'lastname': 'Shin', 'firstname': 'Na E', 'initials': 'NE', 'affiliation': 'Integrated Research Center for Fetal Medicine, Department of Gynecology and Obstetrics, Johns Hopkins University School of Medicine, Baltimore, MD, USA.'}, {'lastname': 'Na', 'firstname': 'Quan', 'initials': 'Q', 'affiliation': 'Integrated Research Center for Fetal Medicine, Department of Gynecology and Obstetrics, Johns Hopkins University School of Medicine, Baltimore, MD, USA.'}, {'lastname': 'Dong', 'firstname': 'Jie', 'initials': 'J', 'affiliation': 'Integrated Research Center for Fetal Medicine, Department of Gynecology and Obstetrics, Johns Hopkins University School of Medicine, Baltimore, MD, USA.'}, {'lastname': 'Jia', 'firstname': 'Bei', 'initials': 'B', 'affiliation': 'Integrated Research Center for Fetal Medicine, Department of Gynecology and Obstetrics, Johns Hopkins University School of Medicine, Baltimore, MD, USA.'}, {'lastname': 'Jones-Beatty', 'firstname': 'Kimberly', 'initials': 'K', 'affiliation': 'Integrated Research Center for Fetal Medicine, Department of Gynecology and Obstetrics, Johns Hopkins University School of Medicine, Baltimore, MD, USA.'}, {'lastname': 'McLane', 'firstname': 'Michael W', 'initials': 'MW', 'affiliation': 'Integrated Research Center for Fetal Medicine, Department of Gynecology and Obstetrics, Johns Hopkins University School of Medicine, Baltimore, MD, USA.'}, {'lastname': 'Ozen', 'firstname': 'Maide', 'initials': 'M', 'affiliation': 'Integrated Research Center for Fetal Medicine, Department of Gynecology and Obstetrics, Johns Hopkins University School of Medicine, Baltimore, MD, USA.\nDivision of Neonatology, Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, MD, USA.'}, {'lastname': 'Lei', 'firstname': 'Jun', 'initials': 'J', 'affiliation': 'Integrated Research Center for Fetal Medicine, Department of Gynecology and Obstetrics, Johns Hopkins University School of Medicine, Baltimore, MD, USA.'}, {'lastname': 'Burd', 'firstname': 'Irina', 'initials': 'I', 'affiliation': 'Integrated Research Center for Fetal Medicine, Department of Gynecology and Obstetrics, Johns Hopkins University School of Medicine, Baltimore, MD, USA.\nDepartment of Neurology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.'}]",,,,© 2019 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.,10.1111/jpi.12591,<Element 'PubmedArticle' at 0x7f05ddc93ea0>
264,"31159306
30498474
28731040
26355342
29921793
24630989
30288079
28197094
27095436
27939990
30524237
25619431
30301953
30259418
25451977
28119132
27075756
26520666
28254441
16122875
16978784
29454840
21810933
31036637
26603489
28904023
12759443
24771982
15826936
23354059
23850759
28696286
29854017
30517945
25956016
31052203",Oxytocin Suppresses Inflammatory Responses Induced by Lipopolysaccharide through Inhibition of the eIF-2-ATF4 Pathway in Mouse Microglia.,"Microglia maintain brain homeostasis and modulate neuroinflammation and are implicated in the pathogenesis of various neurological diseases such as Alzheimer's disease. In this study, we found that in lipopolysaccharide (LPS)-stimulated microglia, the endoplasmic reticulum (ER) stress-related eIF-2-ATF4 pathway plays significant roles in TNF- and IL-6 production, as well as in the inflammasome-mediated production of IL-1. Furthermore, our analysis revealed that oxytocin (OT), a nonapeptide synthesized in the hypothalamus, suppressed the production of these proinflammatory cytokines by inhibiting activation of the eIF-2-ATF4 pathway. Our findings therefore suggest a novel anti-inflammatory axis of OT in activated microglia, which would be helpful for developing the novel effective strategies for regulating microglia-associated neuroinflammation.","['endoplasmic reticulum stress', 'inflammasome', 'inflammation', 'microglia', 'oxytocin']",Cells,2019-06-05,"[{'lastname': 'Inoue', 'firstname': 'Takayuki', 'initials': 'T', 'affiliation': 'Department of Endocrinology, Metabolism, and Hypertension Research, Clinical Research Institute, National Hospital Organization Kyoto Medical Center, Kyoto 612-8555, Japan. taka2015.www@gmail.com.'}, {'lastname': 'Yamakage', 'firstname': 'Hajime', 'initials': 'H', 'affiliation': 'Department of Endocrinology, Metabolism, and Hypertension Research, Clinical Research Institute, National Hospital Organization Kyoto Medical Center, Kyoto 612-8555, Japan. yamakage@satista.jp.'}, {'lastname': 'Tanaka', 'firstname': 'Masashi', 'initials': 'M', 'affiliation': 'Department of Endocrinology, Metabolism, and Hypertension Research, Clinical Research Institute, National Hospital Organization Kyoto Medical Center, Kyoto 612-8555, Japan. masashi.7.tanaka@gmail.com.\nDepartment of Physical Therapy, Health Science University, Yamanashi 401-0380, Japan. masashi.7.tanaka@gmail.com.'}, {'lastname': 'Kusakabe', 'firstname': 'Toru', 'initials': 'T', 'affiliation': 'Department of Endocrinology, Metabolism, and Hypertension Research, Clinical Research Institute, National Hospital Organization Kyoto Medical Center, Kyoto 612-8555, Japan. kusakabe@kuhp.kyoto-u.ac.jp.'}, {'lastname': 'Shimatsu', 'firstname': 'Akira', 'initials': 'A', 'affiliation': 'Clinical Research Institute, National Hospital Organization Kyoto Medical Center, Kyoto 612-8555, Japan. ashimats@kyotolan.hosp.go.jp.'}, {'lastname': 'Satoh-Asahara', 'firstname': 'Noriko', 'initials': 'N', 'affiliation': 'Department of Endocrinology, Metabolism, and Hypertension Research, Clinical Research Institute, National Hospital Organization Kyoto Medical Center, Kyoto 612-8555, Japan. nsatoh@kuhp.kyoto-u.ac.jp.'}]",,,,,"10.3390/cells8060527
10.4172/2161-0460.1000380
10.3389/fneur.2018.00978
10.1038/nrneurol.2017.99
10.1038/cddis.2015.248
10.3390/cells7060063
10.1016/j.celrep.2014.02.015
10.2147/JIR.S141220
10.3389/fnagi.2017.00007
10.1186/s12974-016-0545-3
10.1016/j.ejphar.2016.12.014
10.3389/fncel.2018.00404
10.1016/j.psychres.2014.11.048
10.1038/s41583-018-0072-6
10.1007/s12640-018-9962-7
10.1016/j.mce.2014.11.008
10.1016/j.mce.2017.01.034
10.1186/s12974-016-0541-7
10.1016/j.bbagen.2015.10.025
10.1016/j.bbalip.2017.02.010
10.1016/j.bbagen.2005.08.001
10.1016/j.neulet.2006.08.044
10.1016/j.neuropharm.2018.02.007
10.1152/ajpendo.00029.2011
10.1073/pnas.1901659116
10.1038/srep17192
10.1096/fj.201700273R
10.4049/jimmunol.170.11.5630
10.1155/2014/352371
10.1074/jbc.M501759200
10.1007/s00018-012-1252-6
10.1016/j.bbamcr.2013.06.028
10.1073/pnas.1705521114
10.1155/2018/1849794
10.1159/000494761
10.1016/j.arr.2015.04.006
10.3390/ijms20092139",<Element 'PubmedArticle' at 0x7f05ddc28c20>
265,31131935,Administration of melatonin for prevention of preterm birth and fetal brain injury associated with premature birth in a mouse model.,"Maternal inflammation leads to preterm birth and perinatal brain injury. Melatonin, through its anti-inflammatory effects, has been shown to be protective against inflammation-induced perinatal adverse effects. However, the immunomodulatory effects of melatonin on preterm birth and prematurity-related morbidity remain unknown. We wanted to investigate the effects of maternally administered melatonin on preterm birth and perinatal brain injury in a mouse model of maternal inflammation.
A model of maternal inflammation employing lipopolysaccharide (LPS) was used to mimic the most common clinical scenario of preterm birth, that of maternal inflammation. Mice were randomly divided into the following groups: control, LPS, and LPS with melatonin pre-treatment. Doppler ultrasonography was used to obtain fetal and maternal hemodynamic measurements in utero. Placenta and fetal brains were harvested and analyzed for proinflammatory markers and signs of perinatal brain injury, respectively. Surviving offspring were assessed for neuromotor outcomes.
Melatonin pre-treatment lowered the level of proinflammatory cytokines in the uterus and the placenta, significantly improved LPS-induced acute fetal neuroinflammation and perinatal brain injury, as well as significantly upregulated the SIRT1/Nrf2 signaling pathway to reduce LPS-induced inflammation. Melatonin also prevented adverse neuromotor outcomes in offspring exposed to maternal inflammation.
Maternally administered melatonin modulated immune responses to maternal inflammation and decreased preterm birth and perinatal brain injury. These results suggest that melatonin, a safe treatment during pregnancy, may be used as an experimental therapeutic in clinical trials.","['maternal inflammation', 'melatonin', 'mouse', 'perinatal brain injury', 'preterm birth', 'preterm labor']","American journal of reproductive immunology (New York, N.Y. : 1989)",2019-05-28,"[{'lastname': 'Lee', 'firstname': 'Ji Yeon', 'initials': 'JY', 'affiliation': 'Department of Obstetrics and Gynecology, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam, Korea.\nDepartment of Gynecology and Obstetrics, Integrated Research Center for Fetal Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland.'}, {'lastname': 'Song', 'firstname': 'Haengseok', 'initials': 'H', 'affiliation': 'Department of Biomedical Science, College of Life Science, CHA University, Seongnam, Korea.'}, {'lastname': 'Dash', 'firstname': 'Oyunbileg', 'initials': 'O', 'affiliation': 'Department of Obstetrics and Gynecology, CHA Bundang Medical Center, CHA University School of Medicine, Seongnam, Korea.'}, {'lastname': 'Park', 'firstname': 'Mira', 'initials': 'M', 'affiliation': 'Department of Biomedical Science, College of Life Science, CHA University, Seongnam, Korea.'}, {'lastname': 'Shin', 'firstname': 'Na E', 'initials': 'NE', 'affiliation': 'Department of Gynecology and Obstetrics, Integrated Research Center for Fetal Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland.'}, {'lastname': 'McLane', 'firstname': 'Michael W', 'initials': 'MW', 'affiliation': 'Department of Gynecology and Obstetrics, Integrated Research Center for Fetal Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland.'}, {'lastname': 'Lei', 'firstname': 'Jun', 'initials': 'J', 'affiliation': 'Department of Gynecology and Obstetrics, Integrated Research Center for Fetal Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland.'}, {'lastname': 'Hwang', 'firstname': 'Jong Yun', 'initials': 'JY', 'affiliation': 'Department of Obstetrics and Gynecology, Kangwon National University School of Medicine, Chuncheon, Korea.'}, {'lastname': 'Burd', 'firstname': 'Irina', 'initials': 'I', 'affiliation': 'Department of Gynecology and Obstetrics, Integrated Research Center for Fetal Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland.'}]",,"Maternally administered melatonin modulated immune responses to maternal inflammation and decreased preterm birth and perinatal brain injury. These results suggest that melatonin, a safe treatment during pregnancy, may be used as an experimental therapeutic in clinical trials.","Melatonin pre-treatment lowered the level of proinflammatory cytokines in the uterus and the placenta, significantly improved LPS-induced acute fetal neuroinflammation and perinatal brain injury, as well as significantly upregulated the SIRT1/Nrf2 signaling pathway to reduce LPS-induced inflammation. Melatonin also prevented adverse neuromotor outcomes in offspring exposed to maternal inflammation.",© 2019 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.,10.1111/aji.13151,<Element 'PubmedArticle' at 0x7f05ddc4acc0>
266,"31081340
23348013
11031087
8114936
27713036
23627751
26894890
26595641
24915640
26462756
16244482
12226541
19251056
24819789
15665417
19128208
24418058
29018822
29562518
11170733
10527802
27037234
19273747
22936011
22337830
25088942
27988872
19777393
24380887
27802237
15750214
15196466
10812969
22500228
28716886
10670781
19744960
20176597
23519767
17448147
23299523
18546284
7852995
8215046
23999914
11520916
18656473
15695781
15728305
27701410
18612850
16033782
17034818
25323961
21863317
16179614
9546296
17442827
24361004
19018247
11578774
10672236
26888921
19828530
18780965
28374141
28767196
24046442
23400497
8898237
21207049
14602830
21810890
22368970
16340083
23142262
27676333
10383122
7666203
29867188
23848536
27617773
25354497
15750215
24640977
22476197
21881402
22970712
19276553
17985145
23920254
21605064
15758069
25708826
26869919
27054030",Altered Brain Expression of Insulin and Insulin-Like Growth Factors in Frontotemporal Lobar Degeneration: Another Degenerative Disease Linked to Dysregulation of Insulin Metabolic Pathways.,"Frontotemporal lobar degeneration (FTLD) is the third most common dementing neurodegenerative disease with nearly 80% having no known etiology.
Growing evidence that neurodegeneration can be linked to dysregulated metabolism prompted us to measure a panel of trophic factors, receptors, and molecules that modulate brain metabolic function in FTLD.
Postmortem frontal (Brodmann's area [BA]8/9 and BA24) and temporal (BA38) lobe homogenates were used to measure immunoreactivity to Tau, phosphorylated tau (pTau), ubiquitin, 4-hydroxynonenal (HNE), transforming growth factor-beta 1 (TGF-β1) and its receptor (TGF-β1R), brain-derived neurotrophic factor (BDNF), nerve growth factor, neurotrophin-3, neurotrophin-4, tropomyosin receptor kinase, and insulin and insulin-like growth factor-1 (IGF-1) and insulin-like growth factor-2 (IGF-2) and their receptors by direct-binding enzyme-linked immunosorbent assay.
FTLD brains had significantly elevated pTau, ubiquitin, TGF-β1, and HNE immunoreactivity relative to control. In addition, BDNF and neurotrophin-4 were respectively reduced in BA8/9 and BA38, while neurotrophin-3 and nerve growth factor were upregulated in BA38, and tropomyosin receptor kinase was elevated in BA24. Lastly, insulin and insulin receptor expressions were elevated in the frontal lobe, IGF-1 was increased in BA24, IGF-1R was upregulated in all three brain regions, and IGF-2 receptor was reduced in BA24 and BA38.
Aberrantly increased levels of pTau, ubiquitin, HNE, and TGF-β1, marking neurodegeneration, oxidative stress, and neuroinflammation, overlap with altered expression of insulin/IGF signaling ligand and receptors in frontal and temporal lobe regions targeted by FTLD. Dysregulation of insulin-IGF signaling networks could account for brain hypometabolism and several characteristic neuropathologic features that characterize FTLD but overlap with Alzheimer's disease, Parkinson's disease, and Dementia with Lewy Body Disease.","['neurodegenerative diseases', 'neurodevelopmental disorders', 'neuropathology']",ASN neuro,2019-05-14,"[{'lastname': 'Liou', 'firstname': 'Connie J', 'initials': 'CJ', 'affiliation': '1 Warren Alpert Medical School of Brown University, Providence, RI, USA.'}, {'lastname': 'Tong', 'firstname': 'Ming', 'initials': 'M', 'affiliation': '1 Warren Alpert Medical School of Brown University, Providence, RI, USA.\n2 Division of Neuropathology, Departments of Pathology, Medicine, Neurology, and Neurosurgery, Rhode Island Hospital, Providence, RI, USA.\n3 Department of Pathology and Laboratory Medicine, the Providence VA Medical Center, Providence, RI, USA.'}, {'lastname': 'Vonsattel', 'firstname': 'Jean P', 'initials': 'JP', 'affiliation': '4 New York Brain Bank, Taub Institute, Columbia University, New York, NY, USA.'}, {'lastname': 'de la Monte', 'firstname': 'Suzanne M', 'initials': 'SM', 'affiliation': '1 Warren Alpert Medical School of Brown University, Providence, RI, USA.\n2 Division of Neuropathology, Departments of Pathology, Medicine, Neurology, and Neurosurgery, Rhode Island Hospital, Providence, RI, USA.\n3 Department of Pathology and Laboratory Medicine, the Providence VA Medical Center, Providence, RI, USA.'}]",,,"FTLD brains had significantly elevated pTau, ubiquitin, TGF-β1, and HNE immunoreactivity relative to control. In addition, BDNF and neurotrophin-4 were respectively reduced in BA8/9 and BA38, while neurotrophin-3 and nerve growth factor were upregulated in BA38, and tropomyosin receptor kinase was elevated in BA24. Lastly, insulin and insulin receptor expressions were elevated in the frontal lobe, IGF-1 was increased in BA24, IGF-1R was upregulated in all three brain regions, and IGF-2 receptor was reduced in BA24 and BA38.",,10.1177/1759091419839515,<Element 'PubmedArticle' at 0x7f05ddc5ecc0>
267,"31057350
28108113
4160990
5320674
29957479
29970404
28859567
18396135
1671433
3329873
27001642
20388498
24112880
24391555
27388987
9322969
29381090
20127869
25657248
27208860
29538761
16002529
23579662
30127290
27288959
30646396
26667832
22074059
28617414
20116047
15129161
22248073
10195157
9873206
21976235
18232017
20226259
27154450
13852002
28389249
28179656
27558207
20348917
11108296
19808018
27021215
25208824
17637800
27400763
15465430
30254156
18240931
29857041
23682342
29914028
29017175
6154939
16254186
26264408
20023526
28481350
24155246
29660453
28972096
14473206
19144836
23407652
24840801
25872650
17277730
23168021
25197963
15788264
17012341
23231991
29361753
4607100
20643155
28695871
19046419
29948953
29462432
29107504
17596422
30030085
23562618
25560696
16801154
23237885
19025237
29296618
22201683
28592656
29388475
26296674
28683286
25497089
25668019
26110109
11210998
30064320
22844271
21208604
23667214
30064311
23560573
19852539
24177464
24424063
27548245
18854155
7984236",Deep Brain Stimulation for Obesity: A Review and Future Directions.,"The global prevalence of obesity has been steadily increasing. Although pharmacotherapy and bariatric surgeries can be useful adjuvants in the treatment of morbid obesity, they may lose long-term effectiveness. Obesity result largely from unbalanced energy homeostasis. Palatable and densely caloric foods may affect the brain overlapped circuits involved with homeostatic hypothalamus and hedonic feeding. Deep brain stimulation (DBS) consists of delivering electrical impulses to specific brain targets to modulate a disturbed neuronal network. In selected patients, DBS has been shown to be safe and effective for movement disorders. We review all the cases reports and series of patients treated with DBS for obesity using a PubMed search and will address the following obesity-related issues: (i) the hypothalamic regulation of homeostatic feeding; (ii) the reward mesolimbic circuit and hedonic feeding; (iii) basic concepts of DBS as well as the rationale for obesity treatment; (iv) perspectives and challenges in obesity DBS. The small number of cases provides preliminary evidence for the safety and the tolerability of a potential DBS approach. The ventromedial (","['deep brain stimulation', 'hypothalamus', 'metabolic disorders', 'neuroinflammation', 'nucleus accumbens', 'obesity']",Frontiers in neuroscience,2019-05-07,"[{'lastname': 'Formolo', 'firstname': 'Douglas A', 'initials': 'DA', 'affiliation': 'Center for Applied Neuroscience, University Hospital, Federal University of Santa Catarina, Florianópolis, Brazil.\nGraduate Program in Neuroscience, Federal University of Santa Catarina, Florianópolis, Brazil.'}, {'lastname': 'Gaspar', 'firstname': 'Joana M', 'initials': 'JM', 'affiliation': 'Laboratory of Bioenergetics and Oxidative Stress, Department of Biochemistry, Federal University of Santa Catarina, Florianópolis, Brazil.\nGraduate Program in Biochemistry, Department of Biochemistry, Federal University of Santa Catarina, Florianópolis, Brazil.'}, {'lastname': 'Melo', 'firstname': 'Hiago M', 'initials': 'HM', 'affiliation': 'Center for Applied Neuroscience, University Hospital, Federal University of Santa Catarina, Florianópolis, Brazil.\nGraduate Program in Neuroscience, Federal University of Santa Catarina, Florianópolis, Brazil.'}, {'lastname': 'Eichwald', 'firstname': 'Tuany', 'initials': 'T', 'affiliation': 'Laboratory of Bioenergetics and Oxidative Stress, Department of Biochemistry, Federal University of Santa Catarina, Florianópolis, Brazil.\nGraduate Program in Biochemistry, Department of Biochemistry, Federal University of Santa Catarina, Florianópolis, Brazil.'}, {'lastname': 'Zepeda', 'firstname': 'Ramiro Javier', 'initials': 'RJ', 'affiliation': ""Department of Neuroscience, Faculty of Medicine, Chile University and Health Science Institute, O'Higgins University, Santiago, Chile.""}, {'lastname': 'Latini', 'firstname': 'Alexandra', 'initials': 'A', 'affiliation': 'Laboratory of Bioenergetics and Oxidative Stress, Department of Biochemistry, Federal University of Santa Catarina, Florianópolis, Brazil.\nGraduate Program in Biochemistry, Department of Biochemistry, Federal University of Santa Catarina, Florianópolis, Brazil.'}, {'lastname': 'Okun', 'firstname': 'Michael S', 'initials': 'MS', 'affiliation': 'Fixel Institute for Neurological Diseases, Department of Neurology, University of Florida, Gainesville, FL, United States.'}, {'lastname': 'Walz', 'firstname': 'Roger', 'initials': 'R', 'affiliation': 'Center for Applied Neuroscience, University Hospital, Federal University of Santa Catarina, Florianópolis, Brazil.\nGraduate Program in Neuroscience, Federal University of Santa Catarina, Florianópolis, Brazil.\nFixel Institute for Neurological Diseases, Department of Neurology, University of Florida, Gainesville, FL, United States.\nGraduate Program in Medical Sciences, Federal University of Santa Catarina, Florianópolis, Brazil.\nDepartment of Internal Medicine, University Hospital, Federal University of Santa Catarina, Florianópolis, Brazil.'}]",,,,,"10.3389/fnins.2019.00323
10.1016/j.tins.2016.12.003
10.1016/0013-4694(66)90020-4
10.3171/jns.1965.23.2.0174
10.1016/j.jad.2018.05.028
10.1212/WNL.0000000000005956
10.3171/2017.6.FOCUS17256
10.1016/j.cmet.2008.01.006
10.1016/0140-6736(91)91175-T
10.1159/000100803
10.1038/ijo.2016.9
10.1016/j.brainres.2010.04.003
10.1016/B978-0-444-53497-2.00001-2
10.3389/fnsys.2013.00112
10.1038/nrendo.2016.107
10.1210/endo.138.10.5570
10.1089/dia.2017.0142
10.1002/hbm.20948
10.1126/science.1260776
10.1016/j.neuroimage.2016.05.044
10.1093/neuros/nyy024
10.1210/en.2004-1520
10.1038/496159a
10.3390/brainsci8080158
10.1016/j.jad.2016.05.064
10.1001/jamanetworkopen.2018.5275
10.1021/acschemneuro.5b00240
10.1111/j.1463-1326.2011.01534.x
10.1038/nrdp.2017.34
10.1016/j.biopsych.2009.11.028
10.1097/00001756-200405190-00011
10.1111/j.1471-4159.2012.07660.x
10.1038/1082
10.1159/000054392
10.1007/s00701-011-1166-3
10.1002/ana.21295
10.1016/j.neuroimage.2010.03.009
10.1016/j.pjnns.2016.01.014
10.1093/brain/83.2.337
10.1002/ar.1090780203
10.1016/j.physbeh.2017.04.001
10.1038/nature21363
10.1002/oby.21607
10.1038/nn.2519
10.1210/endo.141.12.7920
10.1016/j.cmet.2009.08.013
10.1016/j.neubiorev.2016.02.016
10.1186/1745-6215-15-356
10.1038/nrn2196
10.1002/mds.26703
10.1016/j.clinph.2004.05.031
10.1073/pnas.1800171115
10.3171/JNS/2008/108/2/0336
10.1016/j.neulet.2018.05.041
10.4103/2152-7806.110667
10.3233/JAD-180121
10.1159/000480665
10.1073/pnas.77.4.1880
10.1126/science.1115524
10.1016/j.conb.2015.07.005
10.1227/01.NEU.0000360570.40339.64
10.1038/nn.4559
10.1002/erv.2256
10.1016/j.metabol.2018.04.005
10.1136/jnnp-2016-315504
10.3171/jns.1962.19.1.0071
10.1523/JNEUROSCI.2760-08.2009
10.1001/2013.jamaneurol.45
10.1038/nrn3745
10.1111/jne.12285
10.1016/S1474-4422(12)70264-8
10.1056/NEJMp1408779
10.1080/13554790490507632
10.1136/jnnp.2006.095315
10.1109/RBME.2012.2197745
10.3390/brainsci8010019
10.1007/BF01405759
10.1016/j.physbeh.2010.07.005
10.4103/jpgm.JPGM_712_16
10.1186/1743-7075-5-35
10.1007/s12035-018-1175-9
10.1093/neuros/nyx630
10.1016/j.cmet.2017.09.021
10.1152/jn.00230.2007
10.1016/j.yebeh.2018.06.041
10.1016/j.biopsych.2013.01.034
10.5483/BMBRep.2015.48.4.272
10.1080/13554790600646995
10.1016/j.neubiorev.2012.12.001
10.1037/a0013600
10.1002/acn3.466
10.1172/JCI59660
10.1242/dmm.026609
10.1080/13554794.2018.1431678
10.1016/j.pneurobio.2015.08.001
10.1016/j.cmet.2017.05.015
10.1016/j.celrep.2014.11.018
10.1146/annurev-physiol-021014-071656
10.1016/j.nicl.2015.03.016
10.1016/S0140-6736(00)03643-6
10.3171/2018.5.FOCUS18163
10.1155/2012/847246
10.1016/j.ejphar.2010.10.107
10.1136/jnnp-2012-304396
10.3171/2018.4.FOCUS18141
10.3171/2013.2.JNS12903
10.3171/2009.9.JNS09577
10.1172/JCI68341
10.1210/en.2013-1831
10.1038/nn.4372
10.1016/j.cell.2008.07.043
10.1038/372425a0",<Element 'PubmedArticle' at 0x7f05ddbccf40>
268,"31040362
19857543
27815155
16723530
22522470
23251153
24796878
20133768
16597735
19840546
19444307
24871874
23291597
11286782
21255614
25662900
20233111
22513513
22220738
26887636
23886782
22466658
17298600
20616573
20929574
23255172
12920152
20303880
26611548
10869055
16361444
25227506
30081343
18391224
27445981
28093219
19007738
23508132
24604362
27881856
25680941
24076635
26171219
27429358
29111458
29608944
27066884
28321184
11224546
15556287
25442113
24553014
29987524
22699511
24263092
90544
942051
30316912
2429581
16206910",High dose of dexamethasone protects against EAE-induced motor deficits but impairs learning/memory in C57BL/6 mice.,"Multiple sclerosis (MS) is an autoimmune and neuroinflammatory disease characterized by demyelination of the Central Nervous System. Immune cells activation and release of pro-inflammatory cytokines play a crucial role in the disease modulation, decisively contributing to the neurodegeneration observed in MS and the experimental autoimmune encephalomyelitis (EAE), the widely used MS animal model. Synthetic glucocorticoids, commonly used to treat the MS attacks, have controversial effects on neuroinflammation and cognition. We sought to verify the influence of dexamethasone (DEX) on the EAE progression and on EAE-induced cognitive deficits. In myelin oligodendrocyte glycoprotein peptide (MOG35-55)-induced EAE female mice, treated once with DEX (50 mg/kg) or not, on the day of immunization, DEX decreased EAE-induced motor clinical scores, infiltrating cells in the spinal cord and delayed serum corticosterone peak. At the asymptomatic phase (8-day post-immunization), DEX did not protected from the EAE-induced memory consolidation deficits, which were accompanied by increased glucocorticoid receptor (GR) activity and decreased EGR-1 expression in the hippocampus. Blunting hippocampal GR genomic activation with DnGR vectors prevented DEX effects on EAE-induced memory impairment. These data suggest that, although DEX improves clinical signs, it decreases cognitive and memory capacity by diminishing neuronal activity and potentiating some aspects of neuroinflammation in EAE.",[],Scientific reports,2019-05-02,"[{'lastname': 'Dos Santos', 'firstname': 'Nilton', 'initials': 'N', 'affiliation': 'Department of Pharmacology, Institute of Biomedical Science, University of São Paulo, São Paulo, 05508-000, Brazil.'}, {'lastname': 'Novaes', 'firstname': 'Leonardo S', 'initials': 'LS', 'affiliation': 'Department of Pharmacology, Institute of Biomedical Science, University of São Paulo, São Paulo, 05508-000, Brazil.'}, {'lastname': 'Dragunas', 'firstname': 'Guilherme', 'initials': 'G', 'affiliation': 'Department of Pharmacology, Institute of Biomedical Science, University of São Paulo, São Paulo, 05508-000, Brazil.'}, {'lastname': 'Rodrigues', 'firstname': 'Jennifer R', 'initials': 'JR', 'affiliation': 'Department of Pharmacology, Institute of Biomedical Science, University of São Paulo, São Paulo, 05508-000, Brazil.'}, {'lastname': 'Brandão', 'firstname': 'Wesley', 'initials': 'W', 'affiliation': 'Department of Immunology, Institute of Biomedical Science, University of São Paulo, São Paulo, 05508-000, Brazil.'}, {'lastname': 'Camarini', 'firstname': 'Rosana', 'initials': 'R', 'affiliation': 'Department of Pharmacology, Institute of Biomedical Science, University of São Paulo, São Paulo, 05508-000, Brazil.'}, {'lastname': 'Peron', 'firstname': 'Jean Pierre Schatzmann', 'initials': 'JPS', 'affiliation': 'Department of Immunology, Institute of Biomedical Science, University of São Paulo, São Paulo, 05508-000, Brazil.'}, {'lastname': 'Munhoz', 'firstname': 'Carolina Demarchi', 'initials': 'CD', 'affiliation': 'Department of Pharmacology, Institute of Biomedical Science, University of São Paulo, São Paulo, 05508-000, Brazil. cdmunhoz@usp.br.'}]",,,,,"10.1038/s41598-019-43217-3
10.1016/j.pneurobio.2009.10.018
10.1016/j.neuropharm.2016.10.026
10.1523/JNEUROSCI.0474-06.2006
10.1016/j.neuroscience.2012.04.021
10.1155/2012/417017
10.1016/j.brainres.2014.04.034
10.1073/pnas.0910658107
10.1523/JNEUROSCI.4398-05.2006
10.1016/j.neuron.2009.09.032
10.1038/nri2550
10.1212/WNL.0000000000000560
10.1038/ni.2513
10.1016/S1471-4914(00)01909-2
10.1016/j.bbr.2011.01.018
10.1016/S1474-4422(14)70250-9
10.3109/09540261003589323
10.1517/14656566.2012.647767
10.1038/srep20926
10.1016/j.bbi.2013.07.003
10.1172/JCI58644
10.1111/j.1460-9568.2007.05335.x
10.1159/000314736
10.1186/1742-2094-7-60
10.1002/eji.201242613
10.1210/er.2002-0006
10.1016/j.cell.2010.02.016
10.1093/brain/123.7.1431
10.1073/pnas.0507572102
10.1159/000362724
10.1016/j.psyneuen.2018.07.031
10.1073/pnas.0705615105
10.3389/fendo.2016.00078
10.1016/j.physbeh.2017.01.020
10.1016/S1474-4422(08)70259-X
10.3389/fnins.2013.00025
10.1590/0004-282X20130216
10.1038/nrn.2016.155
10.1016/j.nbd.2015.01.006
10.1038/ni.2730
10.1002/prp2.135
10.1111/bph.13557
10.1016/j.toxlet.2017.10.020
10.1016/j.neuroscience.2018.03.038
10.1016/j.brainresbull.2016.04.004
10.3389/fnbeh.2017.00035
10.1038/85138
10.1016/j.pneurobio.2004.05.007
10.1016/j.neurobiolaging.2014.08.028
10.1016/S1734-1140(13)71527-5
10.1007/s11011-018-0283-6
10.1073/pnas.1201836109
10.1038/nprot.2013.155
10.1016/0006-8993(79)91013-8
10.1016/j.neuroscience.2018.09.037
10.1016/0003-2697(86)90263-0
10.2144/05393PS01",<Element 'PubmedArticle' at 0x7f05ddb96310>
269,"31020912
20691635
19770513
22057439
17964877
22868200
23088438
19770517
21253619
19521398
31131346
22006831
742764
15301397
2764374
23268610
29396833
18388796
28039405
26266827
23306702
25614040
29920340
29802242
24925765
25010302
22024324
26312544
8786732
26805770
27986521
29335474
25467821",B Cell-Activating Factor Is Associated with Testosterone and Smoking Status in Non-Ambulatory Men with Chronic Spinal Cord Injury.,"B cell-mediated autoimmunity may contribute to poor neurological outcomes after spinal cord injury (SCI). B cell-activating factor (BAFF) is a key cytokine involved in B cell development, proliferation, activation, and survival whose expression is elevated in men with chronic SCI. The aim of this study was to assess factors associated with circulating BAFF in non-ambulatory males with chronic SCI. We assessed the association between clinical and demographic factors, health habits, and circulating BAFF levels in a convenience sample of 43 non-ambulatory men with chronic spinal cord injury (≥ 1 year post-injury). Serum BAFF and total testosterone levels were quantified by enzyme-linked immunosorbent assay. Body composition was determined by whole body dual-energy X-ray absorptiometry. In multivariable models, active smokers had significantly greater BAFF levels than former/nonsmokers (871 pg/mL vs. 665 pg/ml, ","['B cell–activating factor (BAFF)', 'biomarker', 'rehabilitation medicine', 'spinal cord injury', 'testosterone']",Journal of neurotrauma,2019-04-26,"[{'lastname': 'Battaglino', 'firstname': 'Ricardo A', 'initials': 'RA', 'affiliation': 'Department of Rehabilitation Medicine, University of Minnesota, Minneapolis, Minnesota.'}, {'lastname': 'Nguyen', 'firstname': 'Nguyen', 'initials': 'N', 'affiliation': 'Department of Rehabilitation Medicine, University of Minnesota, Minneapolis, Minnesota.'}, {'lastname': 'Summers', 'firstname': 'Megan', 'initials': 'M', 'affiliation': 'Rocky Mountain Regional Spinal Injury System, Craig Rehabilitation Hospital, Englewood, Colorado.'}, {'lastname': 'Morse', 'firstname': 'Leslie R', 'initials': 'LR', 'affiliation': 'Department of Rehabilitation Medicine, University of Minnesota, Minneapolis, Minnesota.\nRocky Mountain Regional Spinal Injury System, Craig Rehabilitation Hospital, Englewood, Colorado.'}]",,,,,10.1089/neu.2018.6221,<Element 'PubmedArticle' at 0x7f05ddb02400>
270,31014564,Synthesis of andrographolide analogues and their neuroprotection and neurite outgrowth-promoting activities.,"Alzheimer's disease (AD) is the most prevalent neurodegenerative disease and remains incurable. Currently, neuronal injury and synapse loss have been considered to be main features in the pathophysiology of AD. Thus, modulation of neuronal survival and neurite outgrowth may represent an efficient strategy for the treatment of AD. Based on the isolates from the traditional medicine Andrographis paniculata, a series of andrographolide analogues were prepared and evaluated for the neuroprotection and neurotrophic activity. Two compounds (3 and 12) could effectively inhibit LPS-induced NO production and iNOS expression as well as proinflammatory cytokines TNF-α and IL-6. Moreover, pretreatment with 3 and 12 could protect neurons against microglia-mediated neurotoxicity. Further, H","['Alzheimer’s disease', 'Andrographolide', 'Neurite outgrowth', 'Neuroinflammation', 'Oxidative stress', 'mAChRs']",Bioorganic & medicinal chemistry,2019-04-25,"[{'lastname': 'Xu', 'firstname': 'Yuanzhen', 'initials': 'Y', 'affiliation': 'Shaanxi Key Laboratory of Natural Products & Chemical Biology, College of Chemistry & Pharmacy, Northwest A&F University, Yangling 712100, China.'}, {'lastname': 'Wei', 'firstname': 'Hongbo', 'initials': 'H', 'affiliation': 'Shaanxi Key Laboratory of Natural Products & Chemical Biology, College of Chemistry & Pharmacy, Northwest A&F University, Yangling 712100, China.'}, {'lastname': 'Wang', 'firstname': 'Jianping', 'initials': 'J', 'affiliation': 'Shaanxi Key Laboratory of Natural Products & Chemical Biology, College of Chemistry & Pharmacy, Northwest A&F University, Yangling 712100, China.'}, {'lastname': 'Wang', 'firstname': 'Weiwei', 'initials': 'W', 'affiliation': 'Shaanxi Key Laboratory of Natural Products & Chemical Biology, College of Chemistry & Pharmacy, Northwest A&F University, Yangling 712100, China.'}, {'lastname': 'Gao', 'firstname': 'Jinming', 'initials': 'J', 'affiliation': 'Shaanxi Key Laboratory of Natural Products & Chemical Biology, College of Chemistry & Pharmacy, Northwest A&F University, Yangling 712100, China. Electronic address: jinminggao@nwsuaf.edu.cn.'}]",,,,Copyright © 2019 Elsevier Ltd. All rights reserved.,10.1016/j.bmc.2019.04.025,<Element 'PubmedArticle' at 0x7f05ddb18ae0>
271,31006904,Melatonin improves functional recovery in female rats after acute spinal cord injury by modulating polarization of spinal microglial/macrophages.,"Spinal cord injury (SCI) is a devastating neurological disorder, but few drugs have proven to be effective for its treatment. Neuroinflammation exaggerates the secondary injury subsequent to trauma. Emerging evidence suggests that melatonin may help protect neural tissue against secondary injury after SCI, but the underlying mechanisms remain elusive. Microglial/macrophages polarization plays an important role in regulating immune responses. To examine whether melatonin exerts neuroprotective effects after acute SCI by regulating microglial/macrophages polarization in the spinal cord, we administered intraperitoneal injections of melatonin (50 mg/kg) in female rats immediately after SCI and then daily for seven consecutive days (n = 6). Compared with the vehicle-treated group (n = 6), the melatonin-treated group exhibited a greater Basso, Beattie, and Bresnahan locomotor rating score, smaller spinal cavity, and less cleaved caspase 3 immunofluorescence staining in the injured spinal segments. Real-time PCR data revealed decreases in the expression levels of M1 microglia phenotypic markers and increases in M2 markers in the spinal cord of melatonin-treated SCI rats, as compared to levels in the vehicle-treated group. Melatonin increased the number of CD206","['macrophage', 'melatonin', 'microglia', 'neuroinflammation', 'spinal cord injury']",Journal of neuroscience research,2019-04-23,"[{'lastname': 'Zhang', 'firstname': 'Yan', 'initials': 'Y', 'affiliation': 'Central Laboratory, Beijing Luhe Hospital, Capital Medical University, Beijing, China.'}, {'lastname': 'Liu', 'firstname': 'Zongjian', 'initials': 'Z', 'affiliation': 'Central Laboratory, Beijing Luhe Hospital, Capital Medical University, Beijing, China.\nResearch Department, Beijing Rehabilitation Hospital, Capital Medical University, Beijing, China.'}, {'lastname': 'Zhang', 'firstname': 'Wenxiu', 'initials': 'W', 'affiliation': 'Central Laboratory, Beijing Luhe Hospital, Capital Medical University, Beijing, China.'}, {'lastname': 'Wu', 'firstname': 'Qichao', 'initials': 'Q', 'affiliation': 'Department of Orthopedics, Beijing Luhe Hospital, Capital Medical University, Beijing, China.'}, {'lastname': 'Zhang', 'firstname': 'Yanjun', 'initials': 'Y', 'affiliation': 'Department of Orthopedics, Beijing Luhe Hospital, Capital Medical University, Beijing, China.'}, {'lastname': 'Liu', 'firstname': 'Yadong', 'initials': 'Y', 'affiliation': 'Department of Orthopedics, Beijing Luhe Hospital, Capital Medical University, Beijing, China.'}, {'lastname': 'Guan', 'firstname': 'Yun', 'initials': 'Y', 'affiliation': 'Department of Anesthesiology and Critical Care Medicine, Johns Hopkins University, Baltimore, Maryland.\nDepartment of Neurological Surgery, Johns Hopkins University, Baltimore, Maryland.'}, {'lastname': 'Chen', 'firstname': 'Xueming', 'initials': 'X', 'affiliation': 'Central Laboratory, Beijing Luhe Hospital, Capital Medical University, Beijing, China.\nDepartment of Orthopedics, Beijing Luhe Hospital, Capital Medical University, Beijing, China.'}]",,,,"© 2019 Wiley Periodicals, Inc.",10.1002/jnr.24409,<Element 'PubmedArticle' at 0x7f05dda69e50>
272,31002914,Insulin treatment protects the brain against neuroinflammation by reducing cerebral cytokines and modulating mitochondrial function.,"In the central nervous system, glial cells protect the brain against neuronal stress by inducing inflammatory responses; namely, intracellular signaling and cytokine production. However, chronic inflammation is often associated with degenerative diseases that can damage hormone signaling and mitochondrial function. Lipopolysaccharide (LPS) induces neuroinflammation by stimulating the production of interleukin-1beta (IL-1β) and tumor necrosis factor-alpha (TNF-α); moreover, it generates oxidative stress and impairs cognitive functions. The aim of the present study was to assess the therapeutic efficacy of intracerebroventricular (i.c.v.) injections of insulin against neuroinflammation. Inflammation was first induced in male Wistar rats (60 days old, n = 12/group) through an intraperitoneal injection of 0.1 mg/kg LPS. The i.c.v. insulin treatment at a 0.5 mU dose was initiated 4 h later and administered once a day for 5 days. Thereafter, the spatial memory of the rats was assessed, and the hippocampus and cortex were later dissected for biochemical analyses. Our results showed that LPS induced cognitive function impairments, but the insulin treatment reversed these effects. Whereas the levels of brain-derived neurotrophic factor and beta-nerve growth factor in the hippocampus were not altered by LPS, they were decreased in the cortex by insulin. The IL-1β and TNF-α levels were increased in the cortex and hippocampus following exposure to LPS, but insulin reversed these effects. Evaluation of the H","['Brain metabolism', 'Inflammation', 'Learning and memory', 'Oxidative stress']",Brain research bulletin,2019-04-20,"[{'lastname': 'Canteiro', 'firstname': 'Paula Bortoluzzi', 'initials': 'PB', 'affiliation': 'Programa de Pós-Graduação em Ciências da Saúde, Universidade do Extremo Sul Catarinense, 88806-00 Criciúma, SC, Brazil.'}, {'lastname': 'Antero', 'firstname': 'Daniel Casagrande', 'initials': 'DC', 'affiliation': 'Programa de Pós-Graduação em Ciências da Saúde, Universidade do Extremo Sul Catarinense, 88806-00 Criciúma, SC, Brazil.'}, {'lastname': 'Tramontin', 'firstname': 'Natalia Dos Santos', 'initials': 'NDS', 'affiliation': 'Programa de Pós-Graduação em Ciências da Saúde, Universidade do Extremo Sul Catarinense, 88806-00 Criciúma, SC, Brazil.'}, {'lastname': 'Simon', 'firstname': 'Kellen Ugioni', 'initials': 'KU', 'affiliation': 'Programa de Pós-Graduação em Ciências da Saúde, Universidade do Extremo Sul Catarinense, 88806-00 Criciúma, SC, Brazil.'}, {'lastname': 'Mendes', 'firstname': 'Carolini', 'initials': 'C', 'affiliation': 'Programa de Pós-Graduação em Ciências da Saúde, Universidade do Extremo Sul Catarinense, 88806-00 Criciúma, SC, Brazil.'}, {'lastname': 'Anastácio Borges Correa', 'firstname': 'Maria Eduarda', 'initials': 'ME', 'affiliation': 'Programa de Pós-Graduação em Ciências da Saúde, Universidade do Extremo Sul Catarinense, 88806-00 Criciúma, SC, Brazil.'}, {'lastname': 'Silveira', 'firstname': 'Paulo Cesar Lock', 'initials': 'PCL', 'affiliation': 'Programa de Pós-Graduação em Ciências da Saúde, Universidade do Extremo Sul Catarinense, 88806-00 Criciúma, SC, Brazil.'}, {'lastname': 'Muller', 'firstname': 'Alexandre Pastoris', 'initials': 'AP', 'affiliation': 'Programa de Pós-Graduação em Ciências da Saúde, Universidade do Extremo Sul Catarinense, 88806-00 Criciúma, SC, Brazil. Electronic address: alexandrep.muller@gmail.com.'}]",,,,Copyright © 2019 Elsevier Inc. All rights reserved.,10.1016/j.brainresbull.2019.04.011,<Element 'PubmedArticle' at 0x7f05dda77b30>
273,"30993381
9553964
17584152
2458546
18467433
16613757
23170013
16361024
2110186
1578513
10467263
28192415
24013726
2100318
23899562
17132977
6482428
9626555
24534266
17504139
9786892
11532427
18639741
12009767
25173821
20544861
18191113
834144
15033922
21114597
14993069
21815060
22130242
12898537
25878270
12138205
19864556
2884353
27450702
15773051
11846609
14907713
24752617
2387261
7603649
17615115
17175109
18572315
24622783
21820034
6124308
37781
14992820
24327952
27459405
21194965
18387603
19861158
6053726
24294985
9000459
17329931
3697698
16197805
23478947
17555867
15520847
15094077
5027747
14794711
26216003
21144857
14679177
22649228
19559078","In vitro models to study insulin and glucocorticoids modulation of trimethyltin (TMT)-induced neuroinflammation and neurodegeneration, and in vivo validation in db/db mice.","Brain susceptibility to a neurotoxic insult may be increased in a compromised health status, such as metabolic syndrome. Both metabolic syndrome and exposure to trimethyltin (TMT) are known to promote neurodegeneration. In combination the two factors may elicit additive or compensatory/regulatory mechanisms. Combined effects of TMT exposure (0.5-1 μM) and mimicked metabolic syndrome-through modulation of insulin and glucocorticoid (GC) levels-were investigated in three models: tridimensional rat brain cell cultures for neuron-glia effects; murine microglial cell line BV-2 for a mechanistic analysis of microglial reactivity; and db/db mice as an in vivo model of metabolic syndrome. In 3D cultures, low insulin condition significantly exacerbated TMT's effect on GABAergic neurons and promoted TMT-induced neuroinflammation, with increased expression of cytokines and of the regulator of intracellular GC activity, 11β-hydroxysteroid dehydrogenase 1 (11β-Hsd1). Microglial reactivity increased upon TMT exposure in medium combining low insulin and high GC. These results were corroborated in BV-2 microglial cells where lack of insulin exacerbated the TMT-induced increase in 11β-Hsd1 expression. Furthermore, TMT-induced microglial reactivity seems to depend on mineralocorticoid receptor activation. In diabetic BKS db mice, a discrete exacerbation of TMT neurotoxic effects on GABAergic neurons was observed, together with an increase of interleukin-6 (IL-6) and of basal 11β-Hsd1 expression as compared to controls. These results suggest only minor additive effects of the two brain insults, neurotoxicant TMT exposure and metabolic syndrome conditions, where 11β-Hsd1 appears to play a key role in the regulation of neuroinflammation and of its protective or neurodegenerative consequences.","['11β-Hydroxysteroid dehydrogenase (11β-hsd1)', 'Astrocyte', 'Glucocorticoid', 'Insulin', 'Interleukin-6 (IL-6)', 'Microglial cell', 'Neuron', 'Trimethyltin (TMT)']",Archives of toxicology,2019-04-18,"[{'lastname': 'Sandström', 'firstname': 'Jenny', 'initials': 'J', 'affiliation': 'Department of Physiology, Faculty of Biology and Medicine, University of Lausanne, Rue du Bugnon 7, 1005, Lausanne, Switzerland.\nSwiss Centre for Applied Human Toxicology, Basel, Switzerland.'}, {'lastname': 'Kratschmar', 'firstname': 'Denise V', 'initials': 'DV', 'affiliation': 'Division of Molecular and Systems Toxicology, Department of Pharmaceutical Sciences, University of Basel, Basel, Switzerland.\nSwiss Centre for Applied Human Toxicology, Basel, Switzerland.'}, {'lastname': 'Broyer', 'firstname': 'Alexandra', 'initials': 'A', 'affiliation': 'Department of Physiology, Faculty of Biology and Medicine, University of Lausanne, Rue du Bugnon 7, 1005, Lausanne, Switzerland.'}, {'lastname': 'Poirot', 'firstname': 'Olivier', 'initials': 'O', 'affiliation': 'Department of Medical Genetics, University of Lausanne, Lausanne, Switzerland.'}, {'lastname': 'Marbet', 'firstname': 'Philippe', 'initials': 'P', 'affiliation': 'Division of Molecular and Systems Toxicology, Department of Pharmaceutical Sciences, University of Basel, Basel, Switzerland.'}, {'lastname': 'Chantong', 'firstname': 'Boonrat', 'initials': 'B', 'affiliation': 'Division of Molecular and Systems Toxicology, Department of Pharmaceutical Sciences, University of Basel, Basel, Switzerland.'}, {'lastname': 'Zufferey', 'firstname': 'Fanny', 'initials': 'F', 'affiliation': 'Department of Physiology, Faculty of Biology and Medicine, University of Lausanne, Rue du Bugnon 7, 1005, Lausanne, Switzerland.\nSwiss Centre for Applied Human Toxicology, Basel, Switzerland.'}, {'lastname': 'Dos Santos', 'firstname': 'Tania', 'initials': 'T', 'affiliation': 'Department of Physiology, Faculty of Biology and Medicine, University of Lausanne, Rue du Bugnon 7, 1005, Lausanne, Switzerland.'}, {'lastname': 'Boccard', 'firstname': 'Julien', 'initials': 'J', 'affiliation': 'Swiss Centre for Applied Human Toxicology, Basel, Switzerland.\nSchool of Pharmaceutical Sciences, University of Geneva, Geneva, Switzerland.'}, {'lastname': 'Chrast', 'firstname': 'Roman', 'initials': 'R', 'affiliation': 'Department of Medical Genetics, University of Lausanne, Lausanne, Switzerland.\nDepartment of Neuroscience and Department of Clinical Neuroscience, Karolinska Institute, Stockholm, Sweden.'}, {'lastname': 'Odermatt', 'firstname': 'Alex', 'initials': 'A', 'affiliation': 'Division of Molecular and Systems Toxicology, Department of Pharmaceutical Sciences, University of Basel, Basel, Switzerland.\nSwiss Centre for Applied Human Toxicology, Basel, Switzerland.'}, {'lastname': 'Monnet-Tschudi', 'firstname': 'Florianne', 'initials': 'F', 'affiliation': 'Department of Physiology, Faculty of Biology and Medicine, University of Lausanne, Rue du Bugnon 7, 1005, Lausanne, Switzerland. Florianne.Tschudi-Monnet@unil.ch.\nSwiss Centre for Applied Human Toxicology, Basel, Switzerland. Florianne.Tschudi-Monnet@unil.ch.'}]",,,,,"10.1007/s00204-019-02455-0
10.1038/sj.ijo.0803677
10.2174/187153007780832082
10.1016/0306-4522(88)90150-9
10.1210/en.2008-0088
10.1212/WNL.0b013e3182752eef
10.1016/S1474-4422(05)70284-2
10.1016/0165-5728(90)90073-V
10.1002/jnr.490310405
10.1002/(SICI)1097-4547(19990915)57:6<916::AID-JNR17>3.0.CO;2-J
10.1038/nri.2017.1
10.1038/cdd.2013.108
10.2131/jts.15.SupplementIV_125
10.1186/1742-2094-9-260
10.1152/physrev.00020.2012
10.1186/1742-2094-3-27
10.1097/01.wad.0000213866.86934.7e
10.1016/0022-4731(84)90380-7
10.1210/edrv.19.3.0331
10.1016/j.jneuroim.2014.01.013
10.2174/092986707780597961
10.1074/jbc.273.44.28897
10.1016/S0006-8993(01)02675-0
10.1016/j.brainresbull.2008.02.029
10.1006/exnr.2002.7866
10.1016/j.steroids.2014.08.014
10.1002/glia.21007
10.1016/j.brainres.2007.11.076
10.1016/0026-0495(77)90128-7
10.1096/fj.03-0978fje
10.1111/j.1463-1326.2010.01305.x
10.1196/annals.1286.035
10.1007/978-1-61779-077-5_5
10.1007/978-1-61779-170-3_6
10.1248/bpb.34.1856
10.1002/jnr.10653
10.1523/JNEUROSCI.4668-14.2015
10.1128/MCB.22.16.5962-5974.2002
10.1523/jneurosci.3257-09.2009
10.1016/0165-0270(87)90041-0
10.1186/1742-2094-9-151
10.1016/j.brainresbull.2016.07.010
10.1016/j.neures.2004.12.005
10.1006/meth.2001.1262
10.1371/journal.pone.0095760
10.1210/endo-127-3-1450
10.1016/0006-8993(95)00509-O
10.1177/0960327107074589
10.1016/j.neuroscience.2006.10.054
10.1016/j.neulet.2008.05.100
10.1515/revneuro-2013-0050
10.1016/j.mce.2011.07.020
10.1016/0165-3806(82)90091-8
10.1186/1742-2094-8-174
10.1016/0003-2697(79)90793-0
10.1016/j.molbrainres.2003.12.001
10.1016/j.molmet.2013.09.005
10.1038/nn.4338
10.1016/j.cyto.2010.11.015
10.1016/j.ejphar.2008.02.050
10.1016/j.cellsig.2009.10.006
10.1111/j.1471-4159.1967.tb09509.x
10.1111/j.1365-2826.2011.02161.x
10.1021/jm4014746
10.1006/frne.1996.0143
10.1248/yakushi.127.451
10.1016/0006-8993(86)91590-8
10.1007/s00128-013-0975-x
10.1016/j.mce.2007.03.007
10.1172/JCI23506
10.1016/j.ejphar.2004.02.048
10.1007/978-1-4939-2895-8_16
10.1016/j.yfrne.2010.12.001
10.1172/JCI19451
10.1523/jneurosci.0719-12.2012
10.1016/j.brainresbull.2009.06.008",<Element 'PubmedArticle' at 0x7f05dda86900>
274,30950095,The emergence of melatonin in oncology: Focus on colorectal cancer.,"Within the last few decades, melatonin has increasingly emerged in clinical oncology as a naturally occurring bioactive molecule with substantial anticancer properties and a pharmacological profile optimal for joining the currently available pharmacopeia. In addition, extensive experimental data shows that this chronobiotic agent exerts oncostatic effects throughout all stages of tumor growth, from initial cell transformation to mitigation of malignant progression and metastasis; additionally, melatonin alleviates the side effects and improves the welfare of radio/chemotherapy-treated patients. Thus, the support of clinicians and oncologists for the use of melatonin in both the treatment and proactive prevention of cancer is gaining strength. Because of its epidemiological importance and symptomatic debut in advanced stages of difficult clinical management, colorectal cancer (CRC) is a preferential target for testing new therapies. In this regard, the development of effective forms of clinical intervention for the improvement of CRC outcome, specifically metastatic CRC, is urgent. At the same time, the need to reduce the costs of conventional anti-CRC therapy results is also imperative. In light of this status quo, the therapeutic potential of melatonin, and the direct and indirect critical processes of CRC malignancy it modulates, have aroused much interest. To illuminate the imminent future on CRC research, we focused our attention on the molecular mechanisms underlying the multiple oncostatic actions displayed by melatonin in the onset and evolution of CRC and summarized epidemiological evidence, as well as in vitro, in vivo and clinical findings that support the broadly protective potential demonstrated by melatonin.","['angiogenesis', 'apoptosis', 'circadian rhythms', 'colorectal cancer', 'epigenetics', 'inflammation', 'melatonin']",Medicinal research reviews,2019-04-06,"[{'lastname': 'Gil-Martín', 'firstname': 'Emilio', 'initials': 'E', 'affiliation': ""Department of Biochemistry, Genetics and Immunology, Biomedical Research Center (CINBIO, 'Centro Singular de Investigación de Galicia'), University of Vigo, Vigo, Spain.""}, {'lastname': 'Egea', 'firstname': 'Javier', 'initials': 'J', 'affiliation': 'Molecular Neuroinflammation and Neuronal Plasticity Laboratory, Research Unit, Hospital Universitario Santa Cristina, Madrid, Spain.\nServicio de Farmacología Clínica, Instituto de Investigación Sanitaria, Hospital Universitario de la Princesa, Madrid, Spain.\nDepartamento de Farmacología y Terapéutica, Instituto-Fundación Teófilo Hernando, Universidad Autónoma de Madrid, Madrid, Spain.'}, {'lastname': 'Reiter', 'firstname': 'Russel J', 'initials': 'RJ', 'affiliation': 'Department of Cellular and Structural Biology, UT Health Science Center, San Antonio, Texas, USA.'}, {'lastname': 'Romero', 'firstname': 'Alejandro', 'initials': 'A', 'affiliation': 'Department of Pharmacology and Toxicology, Faculty of Veterinary Medicine, Complutense University of Madrid, Madrid, Spain.'}]",,,,"© 2019 Wiley Periodicals, Inc.",10.1002/med.21582,<Element 'PubmedArticle' at 0x7f05dda3f310>
275,"30862089
30040716
27582220
29296624
30530798
30501591
25644018
28435163
29053785
29744576
27114033
2268320
12524533
16862116
16950801
17168647
22608501
27515686
20065792
17949857
24680777
22890097
19625741
25261995
26248158
8912679
16873554
10066447
11137762
22665040
20933034
24604062
20479936
20884628
22032330
26879559
23830905
27341800
1417868
8471244
22859297
26109656
28828399
21092856
22028881
24186875
22509390
24222922
12526812
24046442
23364791
26973102
18551524
10858277
23741441
8243292
27505256
26892362
27527809
23887054
23847387
20737593
20962456
19946692
23041626
30326935
24669294
28602351
29775591
10397269
30454027
30378010
29340960
27220888
27088855
30482868
26682689
28651064
30099848
30118483
29176029
27941174
21613335
19683260
23383391
25777512
22647257
26971930
29146050
27760429
19321167
23959579
30228207
21953639
21393509
24896343
23699531
29740434
26408020
25387791
24803297
27830341
21497117
21698296
27903606
18022721
19046946
23972823
17764761
20522652
20667979
22062772
21107132
29149899
30448285
28379303
25132502
27198084
28438992
24742461
26921617
23296467
24684749
19557827
26124111
19776335
17291356
28070672
28845019
21224065
25575133
27356620
29690919
25178404
30076830
26370502
28640985
30180904
24619111
17071926
17458552
27421577
30362531
28404863
28743268
28728022
29378861
28073925
21178100
28126008
28837568
24804730
30559071
17024494
19649643
25578179
23398167
30474172
29731673",Microglial Progranulin: Involvement in Alzheimer's Disease and Neurodegenerative Diseases.,"Neurodegenerative diseases such as Alzheimer's disease have proven resistant to new treatments. The complexity of neurodegenerative disease mechanisms can be highlighted by accumulating evidence for a role for a growth factor, progranulin (PGRN). PGRN is a glycoprotein encoded by the GRN/Grn gene with multiple cellular functions, including neurotrophic, anti-inflammatory and lysosome regulatory properties. Mutations in the GRN gene can lead to frontotemporal lobar degeneration (FTLD), a cause of dementia, and neuronal ceroid lipofuscinosis (NCL), a lysosomal storage disease. Both diseases are associated with loss of PGRN function resulting, amongst other features, in enhanced microglial neuroinflammation and lysosomal dysfunction. PGRN has also been implicated in Alzheimer's disease (AD). Unlike FTLD, increased expression of PGRN occurs in brains of human AD cases and AD model mice, particularly in activated microglia. How microglial PGRN might be involved in AD and other neurodegenerative diseases will be discussed. A unifying feature of PGRN in diseases might be its modulation of lysosomal function in neurons and microglia. Many experimental models have focused on consequences of PGRN gene deletion: however, possible outcomes of increasing PGRN on microglial inflammation and neurodegeneration will be discussed. We will also suggest directions for future studies on PGRN and microglia in relation to neurodegenerative diseases.","['amyloid', 'anti-inflammatory', 'growth factor', 'mutation', 'neurodegeneration', 'neuroinflammation']",Cells,2019-03-14,"[{'lastname': 'Mendsaikhan', 'firstname': 'Anarmaa', 'initials': 'A', 'affiliation': 'Molecular Neuroscience Research Center, Shiga University of Medical Science, Otsu 520-2192, Japan. anarmaa@belle.shiga-med.ac.jp.'}, {'lastname': 'Tooyama', 'firstname': 'Ikuo', 'initials': 'I', 'affiliation': 'Molecular Neuroscience Research Center, Shiga University of Medical Science, Otsu 520-2192, Japan. kinchan@belle.shiga-med.ac.jp.'}, {'lastname': 'Walker', 'firstname': 'Douglas G', 'initials': 'DG', 'affiliation': 'Molecular Neuroscience Research Center, Shiga University of Medical Science, Otsu 520-2192, Japan. walkerdg@gmail.com.'}]",,,,,"10.3390/cells8030230
10.3233/JAD-180145
10.1038/nature19323
10.1002/acn3.469
10.1212/WNL.0000000000006745
10.2174/0929867326666181203124102
10.1007/s40266-015-0239-z
10.1038/nrn.2017.36
10.1093/brain/awx198
10.1007/s00401-018-1861-8
10.1016/j.cell.2016.04.001
10.1016/S0006-291X(05)80908-8
10.1038/nm816
10.1038/nature05016
10.1093/hmg/ddl241
10.2174/156720506779025251
10.1126/scitranslmed.aah5642
10.1016/j.ajhg.2012.04.021
10.1016/j.ebiom.2016.08.004
10.1097/NRL.0b013e3181b1d5c6
10.1016/j.neurobiolaging.2007.08.022
10.1016/j.gene.2014.03.041
10.3233/JAD-2012-120946
10.3233/JAD-2009-1170
10.1038/nm.3672
10.1371/journal.pone.0133749
10.1042/bj3190441
10.1152/ajpregu.00616.2005
10.1006/bbrc.1999.0253
10.1016/S0304-3940(00)01699-2
10.1097/IGC.0b013e318253499c
10.1016/j.neuint.2010.09.008
10.3892/mmr.2014.2016
10.1371/journal.pone.0010551
10.1158/0008-5472.CAN-10-1684
10.1186/1471-2164-12-527
10.1038/srep21260
10.1016/j.neuroscience.2013.06.049
10.1186/s13024-016-0114-3
10.1016/0006-291X(92)92349-3
10.1002/mrd.1080340302
10.1074/jbc.R112.399170
10.1523/JNEUROSCI.4808-14.2015
10.1523/ENEURO.0100-17.2017
10.1016/j.neuron.2010.09.034
10.1371/journal.pone.0026454
10.1152/ajplung.00221.2013
10.1371/journal.pone.0035115
10.11648/j.ab.20130103.11
10.1016/S0092-8674(02)01141-8
10.1242/jcs.132076
10.1074/jbc.M112.441949
10.1016/j.neurobiolaging.2016.01.001
10.1002/ana.21397
10.1177/002215540004800713
10.1371/journal.pone.0064989
10.1210/endo.133.6.8243292
10.1111/nyas.13191
10.1038/srep21115
10.1016/j.cyto.2016.08.007
10.1016/j.brainres.2013.07.023
10.1093/cvr/cvt178
10.1002/cne.22430
10.1262/jrd.10-116S
10.1007/s00401-009-0616-y
10.1172/JCI63113
10.1186/s13024-018-0288-y
10.12703/P6-13
10.1016/j.cell.2017.05.018
10.1016/j.cell.2018.05.003
10.1186/s13058-018-1060-5
10.1007/s12253-018-0520-7
10.1007/s11060-017-2742-z
10.18632/oncotarget.9556
10.1038/ncb3340
10.15252/emmm.201809712
10.3233/JAD-150746
10.1016/j.drudis.2017.06.006
10.1111/crj.12952
10.1371/journal.pone.0202149
10.1515/jpem-2017-0321
10.1515/jpem-2016-0378
10.1177/1352458511406164
10.1016/j.jns.2009.07.011
10.3233/JAD-150069
10.3233/JAD-2012-112120
10.2174/1567205013666160314151247
10.1016/j.neurobiolaging.2017.10.016
10.1159/000448896
10.1016/j.atherosclerosis.2009.02.017
10.1007/s11481-013-9495-z
10.1136/thoraxjnl-2018-211916
10.1002/eji.201142056
10.1126/science.1199214
10.2741/4274
10.1523/JNEUROSCI.5336-12.2013
10.3389/fimmu.2018.00793
10.1007/s13238-015-0213-x
10.1038/srep07023
10.1007/s10753-014-9911-4
10.1007/s10067-016-3467-7
10.1016/j.immuni.2011.01.018
10.1371/journal.pone.0021023
10.1083/jcb.201603079
10.1016/j.neures.2007.09.010
10.1016/j.brainres.2008.10.021
10.1186/1742-2094-10-105
10.1016/j.bbr.2007.07.020
10.2353/ajpath.2010.090915
10.1096/fj.10-161471
10.1016/j.nbd.2011.10.016
10.1097/NEN.0b013e3181fc9aea
10.1186/s12974-017-1000-9
10.1016/j.nbd.2018.11.011
10.1093/brain/awx060
10.1002/glia.22727
10.1002/eji.201646437
10.1073/pnas.1700477114
10.1016/j.neuron.2014.02.040
10.1093/brain/aww016
10.1084/jem.20120412
10.1186/alzrt247
10.1002/path.2580
10.1073/pnas.1510329112
10.1177/1533317509346209
10.1186/1742-2094-4-7
10.1007/s00401-017-1668-z
10.1538/expanim.17-0060
10.1016/j.ajpath.2010.11.002
10.1097/NEN.0000000000000158
10.1038/ncomms11992
10.1186/s13195-018-0370-2
10.1186/s40478-014-0101-2
10.1016/j.expneurol.2018.07.016
10.1083/jcb.201502029
10.1111/jnc.14110
10.1186/s13024-018-0281-5
10.1007/s00401-014-1262-6
10.1093/brain/awl271
10.1007/s00401-007-0223-8
10.1016/j.arr.2016.07.002
10.1002/jcp.27588
10.1126/scitranslmed.aah5642
10.1186/s13024-017-0196-6
10.1016/j.neuron.2017.06.026
10.1523/JNEUROSCI.3081-17.2018
10.1093/hmg/ddx011
10.1212/WNL.0b013e31820a0e3b
10.1186/s40478-017-0412-1
10.1371/journal.pone.0182896
10.1371/journal.pone.0097032
10.1016/j.ymthe.2018.11.013
10.1007/s00401-006-0148-7
10.1007/s00401-009-0576-2
10.1007/s00415-014-7630-2
10.1111/ene.12090
10.1111/ejn.14290
10.5607/en.2018.27.2.77",<Element 'PubmedArticle' at 0x7f05dda499f0>
276,"30804990
8274921
11836303
14717652
15034122
25783782
28571876
29291495
21807071
26881096
28229104
16965544
19489049
19950194
16554481
16598704
17049888
17320196
22155932
25749097
15582111
21151368
22634506
23541001
22564440
26279160
18478112
3000518
2439913
9106754
17923095
17425584
20128952
26136654
1322219
23615548
25300466
7823121
9065522
27666383
14975588
16723527
16597735
19125209
19647070
19286276
21525267
10899938
10995825
12782338
17459425
20519534
7549035
12359175
15893410
18407425
19825412
21088683
8361683
23756184
15189770
7503324
27086968
20231476
22883210
22738723
3774900
2838856
7920600
9761216
11150568
8239251
17194565
25214446
26596563
7568031
9704996
23239421
6228698
1449247
3453748
12633144
12176079
16165282
16386803
16452658
9526014
22520439
25193603",Immune Challenge Alters Reactivity of Hippocampal Noradrenergic System in Prenatally Stressed Aged Mice.,Prenatal stress (PS) has long-term sequelae for the morphological and functional status of the central nervous system of the progeny. A PS-induced proinflammatory status of the organism may result in an impairment of both hippocampal synaptic plasticity and hippocampus-dependent memory formation in adults. We addressed here the question of how PS-induced alterations in the immune response in young and old mice may contribute to changes in hippocampal function in aging. Immune stimulation (via ,[],Neural plasticity,2019-02-26,"[{'lastname': 'Grigoryan', 'firstname': 'Gayane', 'initials': 'G', 'affiliation': 'Division of Cellular Neurobiology, Zoological Institute, Technical University of Braunschweig, Braunschweig 38106, Germany.'}, {'lastname': 'Lonnemann', 'firstname': 'Niklas', 'initials': 'N', 'affiliation': 'Division of Cellular Neurobiology, Zoological Institute, Technical University of Braunschweig, Braunschweig 38106, Germany.'}, {'lastname': 'Korte', 'firstname': 'Martin', 'initials': 'M', 'affiliation': 'Division of Cellular Neurobiology, Zoological Institute, Technical University of Braunschweig, Braunschweig 38106, Germany.\nNeuroinflammation and Neurodegeneration Group, Helmholtz Centre for Infection Research, Braunschweig 38126, Germany.'}]",,,,,"10.1155/2019/3152129
10.1136/bmj.307.6918.1524
10.1210/jcem.87.2.8233
10.1037/0033-2909.130.1.115
10.1113/jphysiol.2003.056911
10.1002/dev.21297
10.1016/j.neubiorev.2017.05.021
10.1016/j.psyneuen.2017.12.014
10.1016/j.neuroscience.2011.07.048
10.1155/2016/2540462
10.1016/j.ynstr.2016.08.004
10.1111/j.1460-9568.2006.05024.x
10.1002/syn.20664
10.1002/dneu.20766
10.1523/JNEUROSCI.3850-05.2006
10.1002/hipo.20181
10.1016/j.nlm.2006.09.001
10.1016/j.bbr.2007.01.018
10.1113/jphysiol.2011.222042
10.1371/journal.pone.0119407
10.1016/j.bbr.2004.05.030
10.3389/fnbeh.2010.00173
10.1016/j.neuroscience.2012.05.040
10.1016/j.biopsych.2013.02.003
10.1016/j.neuropharm.2012.04.013
10.1159/000437302
10.1371/journal.pone.0002170
10.1016/0006-8993(85)90981-3
10.1038/327620a0
10.1097/00001756-199702100-00028
10.1016/j.cell.2007.09.017
10.1111/j.1460-9568.2007.05376.x
10.1017/S1461145709991131
10.3389/fnins.2015.00220
10.1016/0006-8993(92)90809-N
10.1152/jn.00834.2012
10.1016/j.bbr.2014.09.047
10.1523/JNEUROSCI.15-01-00110.1995
10.1523/jneurosci.17-07-02626.1997
10.1016/j.ijdevneu.2016.09.010
10.1016/j.jneuroim.2003.11.009
10.1523/JNEUROSCI.0802-06.2006
10.1523/JNEUROSCI.4398-05.2006
10.1016/j.bbi.2009.07.008
10.1016/j.neurobiolaging.2009.01.012
10.1523/JNEUROSCI.0450-11.2011
10.1523/JNEUROSCI.20-18-06811.2000
10.1016/S0304-3940(03)00440-3
10.1016/j.neuropharm.2007.03.006
10.1523/JNEUROSCI.5172-09.2010
10.1006/brbi.1995.1012
10.1006/exnr.2002.7966
10.1016/j.neurobiolaging.2005.03.010
10.1016/j.psyneuen.2008.02.013
10.1016/j.bbi.2009.10.002
10.1038/nri2873
10.1016/j.neuroscience.2013.05.061
10.1016/j.ejphar.2004.04.011
10.1152/ajpregu.1995.269.5.R969
10.1016/j.brainres.2016.04.032
10.1073/pnas.0909586107
10.1016/j.biopsych.2012.06.013
10.1016/j.neurobiolaging.2012.05.012
10.4172/2155-9562.1000271
10.1016/0031-9384(86)90172-1
10.1016/0031-9384(88)90273-9
10.1111/j.1365-2826.1994.tb00591.x
10.1016/S0031-9384(98)00056-0
10.1016/S0031-9384(00)00351-6
10.7326/0003-4819-119-12-199312150-00007
10.1016/j.bbi.2006.11.006
10.1002/hipo.22363
10.1016/j.lfs.2015.10.025
10.1073/pnas.92.19.8856
10.1016/S0028-3908(98)00035-5
10.1002/jnr.23172
10.1016/0047-6374(83)90100-8
10.1002/ana.410320510
10.1097/00002093-198701040-00005
10.1001/archneur.60.3.337
10.1016/S0197-0186(02)00049-9
10.1016/j.neuroscience.2005.06.090
10.1016/j.jneuroim.2005.11.021
10.1523/JNEUROSCI.4236-05.2006
10.1523/JNEUROSCI.18-08-02974.1998
10.1186/1742-2094-9-71
10.1016/j.brainres.2014.08.040",<Element 'PubmedArticle' at 0x7f05dd9abb80>
277,"30740047
18648635
19567371
26056061
21354648
12393603
26639457
16293609
9430225
27445981
19647070
22832853
28238753
22539300
19570680
22889165
26656793
23573276
10658955
27013966
25146427
25890375
10856322
22309794
24860090
20026014
17203472
19720084
8282004
12671681
27764084
21965677
27889894
27034847
9266546
17574218
25894679",Glucocorticoid Induced Leucine Zipper in Lipopolysaccharide Induced Neuroinflammation.,"Glucocorticoids (GCs) are steroid hormones secreted as the end-product of the neuroendocrine stress cascade. Both absence and elevated GC mediate neurotoxic responses, suggesting that a narrow window ranging from physiological to slightly high GC mediate protective responses. The beneficial effects of GC are attributed to the transactivation of regulatory proteins and inhibition mediated by glucocorticoid receptor (GR) interactions with other co-factors. The glucocorticoid induced leucine zipper (GILZ) is a gene strongly upregulated by GC and mediates many of the anti-inflammatory and anti-proliferative effects of GC. Although GILZ is constitutively expressed in many tissues including the brain, the expression has been shown to occur with varying dynamics suggesting that the local milieu modulates its expression with consequent effects on cellular responses. Here we investigated the expression profile of GILZ in lipopolysaccharide (LPS) mediated neuroinflammation model of Alzheimer's disease (AD). Our data suggest that the GILZ expression is downregulated in neuroinflammation correlating inversely with the pro-inflammatory cytokines and innate immune responses.","['Alzheimer’s disease', 'cytokines', 'glucocorticoid induced leucine zipper', 'neuroinflammation', 'toll like receptor-4']",Frontiers in aging neuroscience,2019-02-12,"[{'lastname': 'Witek', 'firstname': 'Emily', 'initials': 'E', 'affiliation': 'Laboratory Animal Resources and Center, Department of Internal Medicine, Indiana University School of Medicine, Indianapolis, IN, United States.'}, {'lastname': 'Hickman', 'firstname': 'Debra', 'initials': 'D', 'affiliation': 'Laboratory Animal Resources and Center, Department of Internal Medicine, Indiana University School of Medicine, Indianapolis, IN, United States.'}, {'lastname': 'Lahiri', 'firstname': 'Debomoy K', 'initials': 'DK', 'affiliation': 'Department of Psychiatry, Stark Neuroscience Research Institute, Indiana University School of Medicine, Indianapolis, IN, United States.'}, {'lastname': 'Srinivasan', 'firstname': 'Mythily', 'initials': 'M', 'affiliation': 'Department of Oral Pathology, Medicine and Radiology, Indiana University School of Dentistry and Indiana University-Purdue University Indianapolis, Indiana University School of Medicine, Indianapolis, IN, United States.'}]",,,,,"10.3389/fnagi.2018.00432
10.2203/dose-response.004.01.004.abraham
10.1096/fj.09-134684
10.14814/phy2.12382
10.1016/j.ejcb.2011.01.001
10.1182/blood-2002-02-0538
10.2174/1570159x14666151204122017
10.1182/blood-2005-07-2760
10.1016/s1074-7613(00)80398-2
10.3389/fendo.2016.00078
10.1016/j.bbi.2009.07.008
10.1038/tp.2012.14
10.1016/j.exer.2017.02.011
10.1002/eji.201142081
10.1016/j.jocn.2008.12.026
10.1186/1742-2094-9-197
10.1016/j.neubiorev.2015.11.009
10.1371/journal.pone.0060705
10.1515/revneuro.1999.10.2.117
10.3389/fnmol.2016.00019
10.1111/cns.12315
10.1186/s12974-015-0291-y
10.1136/thorax.55.7.603
10.1016/j.neulet.2012.01.052
10.1074/jbc.M113.535237
10.1016/j.brainres.2009.12.014
10.1002/glia.20467
10.1016/j.jneumeth.2009.08.018
10.1016/0922-4106(93)90072-h
10.1038/sj.embor.embor805
10.1371/journal.pone.0160314
10.1074/jbc.M111.279257
10.1007/s12035-016-0277-5
10.1155/2016/6391686
10.1159/000097295
10.1016/j.brainres.2007.05.024
10.1007/s11064-015-1567-4",<Element 'PubmedArticle' at 0x7f05dd921d10>
278,"30695999
27173592
27874975
22121477
28757677
25432899
29856066
28082452
27217403
26433058
25566544
27818384
25948533
18957951
19100239
18178625
29951057
30127734
29078813
23365075
20870176
19104149
28607129
15975516
11923495
21798372
28035084
22534621
22668972
27002656
29335605
29915582
29402868
17161343
20584883
19339255
29166603
28911981
29402847
25084739
25501574
23054369
17875676
27841763
16285007
14737169
18787560
20026661
26129975
12943676
14702348
24825162
21576386
16151014
15715670
17325039
25871850
25797575
29422891
10579204
22385963
27098703
26576074
29066950
30258056",T-Cell Accumulation in the Hypertensive Brain: A Role for Sphingosine-1-Phosphate-Mediated Chemotaxis.,"Hypertension is considered the major modifiable risk factor for the development of cognitive impairment. Because increased blood pressure is often accompanied by an activation of the immune system, the concept of neuro-inflammation gained increasing attention in the field of hypertension-associated neurodegeneration. Particularly, hypertension-associated elevated circulating T-lymphocyte populations and target organ damage spurred the interest to understanding mechanisms leading to inflammation-associated brain damage during hypertension. The present study describes sphingosine-1-phosphate (S1P) as major contributor to T-cell chemotaxis to the brain during hypertension-associated neuro-inflammation and cognitive impairment. Using Western blotting, flow cytometry and mass spectrometry approaches, we show that hypertension stimulates a sphingosine kinase 1 (SphK1)-dependent increase of cerebral S1P concentrations in a mouse model of angiotensin II (AngII)-induced hypertension. The development of a distinct S1P gradient between circulating blood and brain tissue associates to elevated CD3+ T-cell numbers in the brain. Inhibition of S1P₁-guided T-cell chemotaxis with the S1P receptor modulator FTY720 protects from augmentation of brain CD3 expression and the development of memory deficits in hypertensive WT mice. In conclusion, our data highlight a new approach to the understanding of hypertension-associated inflammation in degenerative processes of the brain during disease progression.","['T-cell chemotaxis', 'cognitive impairment', 'hypertension', 'inflammation', 'sphingosine-1-phosphate']",International journal of molecular sciences,2019-01-31,"[{'lastname': 'Don-Doncow', 'firstname': 'Nicholas', 'initials': 'N', 'affiliation': 'Department of Experimental Science, Lund University, 22 184 Lund, Sweden. nicholas.don-doncow@med.lu.se.'}, {'lastname': 'Vanherle', 'firstname': 'Lotte', 'initials': 'L', 'affiliation': 'Department of Experimental Science, Lund University, 22 184 Lund, Sweden. lotte.vanherle.8386@med.lu.se.'}, {'lastname': 'Zhang', 'firstname': 'Yun', 'initials': 'Y', 'affiliation': 'Department of Experimental Science, Lund University, 22 184 Lund, Sweden. yun.zhang@med.lu.se.'}, {'lastname': 'Meissner', 'firstname': 'Anja', 'initials': 'A', 'affiliation': 'Department of Experimental Science, Lund University, 22 184 Lund, Sweden. anja.meissner@med.lu.se.\nWallenberg Center for Molecular Medicine, Lund University, 22 184 Lund, Sweden. anja.meissner@med.lu.se.'}]",,,,,"10.3390/ijms20030537
10.1159/000446082
10.1111/jnc.13905
10.1155/2012/320648
10.1155/2017/7146290
10.1007/s11906-014-0507-z
10.1111/bph.14381
10.1093/cvr/cvw256
10.1161/HYPERTENSIONAHA.116.07237
10.1016/j.imlet.2015.09.015
10.1212/NXI.0000000000000054
10.1093/brain/aww270
10.1161/JAHA.115.001920
10.1038/tpj.2008.15
10.1016/j.bbrc.2008.12.023
10.1073/pnas.0708092105
10.3389/fimmu.2018.01302
10.3389/fnagi.2018.00236
10.1186/s13024-017-0222-8
10.4049/jimmunol.1200947
10.1016/j.immuni.2010.08.018
10.1172/JCI36470
10.1161/HYPERTENSIONAHA.117.09200
10.1016/j.chembiol.2005.04.019
10.1126/science.1070238
10.1016/j.intimp.2011.07.004
10.4062/biomolther.2016.160
10.1161/CIRCULATIONAHA.111.047316
10.1161/CIRCULATIONAHA.111.039644
10.1007/s00011-016-0939-9
10.1038/s41593-017-0059-z
10.3389/fimmu.2018.01213
10.1159/000486809
10.1016/j.atherosclerosissup.2018.04.298
10.1016/j.intimp.2006.07.030
10.1084/jem.20091343
10.1093/brain/awp070
10.1016/j.celrep.2017.10.094
10.1016/j.bbi.2017.09.006
10.1159/000486200
10.1016/j.jneuroim.2014.07.009
10.1371/journal.pone.0114895
10.1007/s11481-012-9402-z
10.1084/jem.20070657
10.1172/JCI86950
10.1002/eji.200526218
10.1038/nature02284
10.1038/nri2400
10.1084/jem.20091619
10.1161/CIRCRESAHA.115.306901
10.1016/S0006-291X(03)01551-1
10.1074/jbc.M307046200
10.1002/eji.201344158
10.1084/jem.20102551
10.1126/science.1113640
10.1111/j.1471-4159.2004.02955.x
10.1128/MCB.01465-06
10.1210/me.2014-1388
10.1016/j.expneurol.2015.03.012
10.3389/fimmu.2017.01905
10.1016/S0306-4522(99)00288-2
10.1016/j.cell.2012.01.038
10.1523/JNEUROSCI.3588-15.2016
10.1155/2015/492659
10.3389/fnmol.2017.00317
10.1038/s41467-018-06234-w",<Element 'PubmedArticle' at 0x7f05dd93e0e0>
279,"30666561
12572519
14528680
15099705
15303649
15763571
16417781
17401570
19766184
20107219
20387225
21852788
22229116
22500399
24113920
24648308
24728946
24971874
26048653
26135675
26165866
26408046
26793098
26971524
27229883
27255958
27448766
28137413
28347832
28359852
28581010
28767069
28946859
29181847
29274586
29306052
29310862
29352921
5950056",Steroid-Enriched Fraction of Achyranthes bidentata Protects Amyloid β Peptide 1-40-Induced Cognitive Dysfunction and Neuroinflammation in Rats.,"The roots of Achyranthes bidentata Blume (AB) is commonly used in the treatment of osteoporosis and dementia in traditional Chinese medicine. Pharmacological reports evidenced that AB possessed anti-osteoarthritis effects. However, there is little literature about the anti-dementia activities of AB. The present study was designed to prepare steroid-enriched fraction of AB (ABS) and investigate whether ABS can protect from cognitive dysfunction and neuroinflammation against Aβ 1-40-induced Alzheimer's disease (AD) model in rats. ABS only contained 135.11 ± 4.28 mg of ecdysterone per gram. ABS (50 mg/kg) reversed the dysfunction of exploratory activity and memory function on plus-maze and Morris water maze caused by Aβ 1-40 in rats. ABS (50 mg/kg) also decreased amyloid deposition, neurofibrillary tangle, neural damage, activated astrocyte, and microglial caused by Aβ 1-40. Furthermore, ABS reversed the phenomenon of neural oxidative damage and neuroinflammation, including the higher levels of MDA and cytokines, and the lower activities of antioxidant enzymes and GSH levels caused by Aβ 1-40 in rat cortex and hippocampus. Finally, ABS restored the activation of ERK pathway and decreased NF-κB phosphorylation and translocation altered by Aβ 1-40. ABS alone (50 mg/kg) promoted cognitive function, activated brain antioxidant defense system, and decreased brain TNF-α levels in sham group. Therefore, ABS has the cognition-promoting and antidementia potential. Steroids especial ecdysterone are major active components of AB. The action mechanism is due to decreasing oxidative stress and neuroinflammation through modulating ERK pathway, NF-κB phosphorylation, and translocation in Aβ 1-40-induced AD rat model.","['Achyranthes bidentata', 'Aβ 1–40', 'ERK/NF-κB pathway', 'Ecdysterone', 'Hippocampus', 'Neuroinflammation', 'Oxidative stress']",Molecular neurobiology,2019-01-23,"[{'lastname': 'Lin', 'firstname': 'Li-Wei', 'initials': 'LW', 'affiliation': 'School of Chinese Medicines for Post-Baccalaureate, I-Shou University, Kaohsiung, 82445, Taiwan.'}, {'lastname': 'Tsai', 'firstname': 'Fan-Hsuan', 'initials': 'FH', 'affiliation': 'School of Chinese Medicines for Post-Baccalaureate, I-Shou University, Kaohsiung, 82445, Taiwan.'}, {'lastname': 'Lan', 'firstname': 'Wan-Cheng', 'initials': 'WC', 'affiliation': 'Department of Chinese Pharmaceutical Sciences and Chinese Medicine Resources, China Medical University, Taichung, 40402, Taiwan.'}, {'lastname': 'Cheng', 'firstname': 'Yih-Dih', 'initials': 'YD', 'affiliation': 'Department of Pharmacy, China Medical University Hospital, Taichung, 40402, Taiwan.'}, {'lastname': 'Lee', 'firstname': 'Sheng-Chi', 'initials': 'SC', 'affiliation': 'Pintung Branch, Kaohsiung Veterans General Hospital, Pitung, 91245, Taiwan. osclee.tw@msa.hinet.net.'}, {'lastname': 'Wu', 'firstname': 'Chi-Rei', 'initials': 'CR', 'affiliation': 'Department of Chinese Pharmaceutical Sciences and Chinese Medicine Resources, China Medical University, Taichung, 40402, Taiwan. crw@mail.cmu.edu.tw.'}]",,,,,10.1007/s12035-018-1436-7,<Element 'PubmedArticle' at 0x7f05dd8ef270>
280,30655633,Multidisciplinary approach to prostatitis.,"The modern clinical research on prostatitis started with the work of Stamey and coworkers who developed the basic principles we are still using. They established the segmented culture technique for localizing the infections in the males to the urethra, the bladder, or the prostate and to differentiate the main categories of prostatitis. Such categories with slight modifications are still used according to the NIH classification: acute bacterial prostatitis, chronic bacterial prostatitis, Chronic Pelvic Pain Syndrome (CPPS) and asymptomatic prostatitis. Prostatic inflammation is considered an important factor in influencing both prostatic growth and progression of symptoms of benign prostatic hyperplasia and prostatitis. Chronic inflammation/neuroinflammation is a result of a deregulated acute phase response of the innate immune system affecting surrounding neural tissue at molecular, structural and functional levels. Clinical observations suggest that chronic inflammation correlates with chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) and benign prostatic hyperplasia (BPH) and an history of clinical chronic prostatitis significantly increases the odds for prostate cancer. The NIHNIDDK classification based on the use of the microbiological 4- glasses localization test or simplified 2-glasses test, is currently accepted worldwide. The UPOINT system identifies groups of clinicians with homogeneous clinical presentation and is used to recognize phenotypes to be submitted to specific treatments. The UPOINTS algorithm implemented the original UPOINT adding to the urinary domains (U), psycho-social (P), organspecific (O), infection (I), neurological (N), muscle tension and tenderness (T) a further domain related to sexuality (S). In fact sexual dysfunction (erectile, ejaculatory, libido loss) has been described in 46-92% of cases with a high impact on the quality of life of patients with CP/CPPS. Prostatic ultrasound represents the most popular imaging test in the work-up of either acute and chronic prostatitis although no specific hypo-hyperechoic pattern has been clearly associated with chronic bacterial prostatitis and CPPS. Use of a digital-processing software to calculate the extension of prostatic calcification area at ultrasound demonstrated a higher percentage of prostatic calcification in patients with chronic bacterial prostatitis. Multiparametric Magnetic Resonance Imaging (mpMRI) is the current state-of-the art imaging modality in the assessment of patients with prostate cancer although a variety of benign conditions, including inflammation, may mimic prostate cancer and act as confounding factors in the discrimination between neoplastic and non-neoplastic lesions. Bacteria can infect prostate gland by: ascending the urethra, reflux of urine into the prostatic ducts, direct inoculation of bacteria through inserted biopsy needles or hematogenous seeding. Enterobacteriaceae are the predominant pathogens in acute and chronic bacterial prostatitis, but an increasing role of Enterococci has been reported. Many strains of these uropathogens exhibit the ability to form biofilm and multidrug- resistance. Sexually Transmitted Infections (STI) agents, in particular Chlamydia trachomatis and Mycoplasma genitalium, have been also considered as causative pathogens of chronic bacterial prostatitis. On the contrary the effective role in genital diseases of other ""genital mycoplasmas"" is still a much debated issue. Sexually Transmitted Infections agents should be investigated by molecular methods in both patient and sexual partner. ""Next generation"" investigations, such as cytokine analysis, cytological typing of immune cells could help stratifying the immune response. Epigenetic dysregulation of inflammatory factors should be investigated according to systemic and compartment-specific signals. The search for biomarkers should also include evaluation of hormonal pathways, as measurement of estrogen levels in semen. Antimicrobials are the first line agents for the treatment of bacterial prostatitis. The success of antimicrobial treatment depends on the antibacterial activity and the pharmacokinetic characteristics of the drug which must reach high concentrations in prostate secretion and prostate tissue. Acute bacterial prostatitis can be a serious infection with a potential risk for urosepsis For iInitial treatment of severely ill patients, intravenous administration of high doses of bactericidal antimicrobials, such as broad-spectrum penicillins, third-generation cephalosporins or fluoroquinolones, is recommended in combination with an aminoglycoside. Use of piperacillin-tazobactam and meropenem is justified in presence of multiresistant gramnegative pathogens. The antibiotic treatment of chronic prostatitis is currently based on the use of fluoroquinolones that, given for 2 to 4 weeks, cured about 70% of men with chronic bacterial prostatitis. For the treatment of Chlamydial prostatitis macrolides were shown to be more effective than fluoroquinolones, whereas no differences were observed in microbiological and clinical efficacy between macrolides and tetracyclines for the treatment of infections caused by intracellular pathogens. Aminoglycosides and fosfomycin could be considered as a therapeutic alternative for the treatment of quinolone resistant prostatitis. Use of alpha-blockers in CP/CPPS patients with urinary symptoms and analgesics +/- non steroidal anti-inflammatory drugs (NSAID), in presence of pain demonstrated a reduction of symptoms reduction and an improvement of quality of life, although long term use of NSAID is limited by side effect profile. However, the multimodal therapeutic regimen by contemporary use of alphablockers, antibiotics and anti-inflammatory showed a better control of prostatitis symptoms than single drug treatment. Novel therapeutic substances for the treatment of pain, such as the cannabinoid anandamide would be highly interesting to test. An alternative for the treatment of chronic prostatitis/chronic pelvic pain syndrome is phytotherapy, as primary therapy or in association with other drugs. Quercetin, pollen extract, extract of Serenoa repens and other mixtures of herbal extracts showed a positive effect on symptoms and quality of life without side effects. The association of CP/CPPS with alterations of intestinal function has been described. Diet has its effects on inflammation by regulation of the composition of intestinal flora and direct action on the intestinal cells (sterile inflammation). Intestinal bacteria (microbiota) interacts with food influencing the metabolic, immune and inflammatory response of the organism. The intestinal microbiota has protective function against pathogenic bacteria, metabolic function by synthesis of vitamins, decomposition of bile acids and production of trophic factors (butyrate), and modulation of the intestinal immune system. The alteration of the microbiota is called ""dysbiosis"" causing invasive intestinal diseases pathologies (leaky gut syndrome and food intolerances, irritable bowel syndrome or chronic inflammatory bowel diseases) and correlating with numerous systemic diseases including acute and chronic prostatitis. Administration of live probiotics bacteria can be used to regulate the balance if intestinal flora. Sessions of hydrocolontherapy can represent an integration to this therapeutic approach. Finally, microbiological examination of sexual partners can offer supplementary information for treatment.",[],"Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica",2019-01-19,"[{'lastname': 'Magri', 'firstname': 'Vittorio', 'initials': 'V', 'affiliation': 'ASST Nord Milano. alberto.trinchieri@gmail.com.'}, {'lastname': 'Boltri', 'firstname': 'Matteo', 'initials': 'M', 'affiliation': None}, {'lastname': 'Cai', 'firstname': 'Tommaso', 'initials': 'T', 'affiliation': None}, {'lastname': 'Colombo', 'firstname': 'Roberto', 'initials': 'R', 'affiliation': None}, {'lastname': 'Cuzzocrea', 'firstname': 'Salvatore', 'initials': 'S', 'affiliation': None}, {'lastname': 'De Visschere', 'firstname': 'Pieter', 'initials': 'P', 'affiliation': None}, {'lastname': 'Giuberti', 'firstname': 'Rosanna', 'initials': 'R', 'affiliation': None}, {'lastname': 'Granatieri', 'firstname': 'Clara Maria', 'initials': 'CM', 'affiliation': None}, {'lastname': 'Latino', 'firstname': 'Maria Agnese', 'initials': 'MA', 'affiliation': None}, {'lastname': 'Larganà', 'firstname': 'Gaetano', 'initials': 'G', 'affiliation': None}, {'lastname': 'Leli', 'firstname': 'Christian', 'initials': 'C', 'affiliation': None}, {'lastname': 'Maierna', 'firstname': 'Giorgio', 'initials': 'G', 'affiliation': None}, {'lastname': 'Marchese', 'firstname': 'Valentina', 'initials': 'V', 'affiliation': None}, {'lastname': 'Massa', 'firstname': 'Elisabetta', 'initials': 'E', 'affiliation': None}, {'lastname': 'Matteelli', 'firstname': 'Alberto', 'initials': 'A', 'affiliation': None}, {'lastname': 'Montanari', 'firstname': 'Emanuele', 'initials': 'E', 'affiliation': None}, {'lastname': 'Morgia', 'firstname': 'Giuseppe', 'initials': 'G', 'affiliation': None}, {'lastname': 'Naber', 'firstname': 'Kurt G', 'initials': 'KG', 'affiliation': None}, {'lastname': 'Papadouli', 'firstname': 'Vaia', 'initials': 'V', 'affiliation': None}, {'lastname': 'Perletti', 'firstname': 'Gianpaolo', 'initials': 'G', 'affiliation': None}, {'lastname': 'Rekleiti', 'firstname': 'Nektaria', 'initials': 'N', 'affiliation': None}, {'lastname': 'Russo', 'firstname': 'Giorgio I', 'initials': 'GI', 'affiliation': None}, {'lastname': 'Sensini', 'firstname': 'Alessandra', 'initials': 'A', 'affiliation': None}, {'lastname': 'Stamatiou', 'firstname': 'Konstantinos', 'initials': 'K', 'affiliation': None}, {'lastname': 'Trinchieri', 'firstname': 'Alberto', 'initials': 'A', 'affiliation': None}, {'lastname': 'Wagenlehner', 'firstname': 'Florian M E', 'initials': 'FME', 'affiliation': None}]",,,,,10.4081/aiua.2018.4.227,<Element 'PubmedArticle' at 0x7f05dd90c3b0>
281,"30647133
15583024
21195129
16984997
11744095
20488256
23681668
26433186
24385629
24813893
15415436
17806403
21005001
14841244
16236742
18374402
25080336
16537405
23955365
29222167
16751103
16415872
15381688
1499722
8901021
25672248
17180163
21997792
17012295
22198949
17982277
26173988
27061018
12430718
28007303
17475877
21685327
20534434
23630275
21356739
20110936",The neurosteroid pregnenolone promotes degradation of key proteins in the innate immune signaling to suppress inflammation.,"Pregnenolone is a steroid hormone precursor that is synthesized in various steroidogenic tissues, in the brain, and in lymphocytes. In addition to serving as the precursor for other steroid hormones, pregnenolone exerts its own effect as an anti-inflammatory molecule to maintain immune homeostasis in various inflammatory conditions. Pregnenolone and its metabolic derivatives have been shown to have beneficial effects in the brain, including enhancing memory and learning, reversing depressive disorders, and modulating cognitive functions. A decreased level of pregnenolone has been observed in neuroinflammatory diseases, which emphasizes its role in neuroprotection and neuroregeneration. Although the anti-inflammatory property of pregnenolone was recognized several decades ago, its mechanism of action remains unknown. Here we report that pregnenolone promotes ubiquitination and degradation of the TLR2/4 adaptor protein TIRAP and TLR2 in macrophages and microglial cells. Pregnenolone and its metabolites suppressed the secretion of tumor necrosis factor α and interleukin-6 mediated through TLR2 and TLR4 signaling. Pregnenolone has been reported to induce activation of cytoplasmic linker protein 170, and this protein has recently been shown to promote targeted degradation of TIRAP. We observed enhanced degradation of TIRAP and TLR4 suppression by cytoplasmic linker protein 170 in the presence of pregnenolone. Our experimental data reveal novel nongenomic targets of pregnenolone and provide important leads to understand its role in restoring immune homeostasis in various inflammatory conditions.","['Toll-like receptor (TLR)', 'immunosuppression', 'inflammation', 'innate immunity', 'ubiquitylation (ubiquitination)']",The Journal of biological chemistry,2019-01-17,"[{'lastname': 'Murugan', 'firstname': 'Subathra', 'initials': 'S', 'affiliation': 'From the Laboratory of Immunology and Microbial Pathogenesis, National Institute of Animal Biotechnology, Hyderabad, Telangana 500032, India and.'}, {'lastname': 'Jakka', 'firstname': 'Padmaja', 'initials': 'P', 'affiliation': 'From the Laboratory of Immunology and Microbial Pathogenesis, National Institute of Animal Biotechnology, Hyderabad, Telangana 500032, India and.\nGraduate Studies, Manipal Academy of Higher Education, Manipal, Karnataka 576104, India.'}, {'lastname': 'Namani', 'firstname': 'Swapna', 'initials': 'S', 'affiliation': 'From the Laboratory of Immunology and Microbial Pathogenesis, National Institute of Animal Biotechnology, Hyderabad, Telangana 500032, India and.\nGraduate Studies, Manipal Academy of Higher Education, Manipal, Karnataka 576104, India.'}, {'lastname': 'Mujumdar', 'firstname': 'Varadendra', 'initials': 'V', 'affiliation': 'From the Laboratory of Immunology and Microbial Pathogenesis, National Institute of Animal Biotechnology, Hyderabad, Telangana 500032, India and.'}, {'lastname': 'Radhakrishnan', 'firstname': 'Girish', 'initials': 'G', 'affiliation': 'From the Laboratory of Immunology and Microbial Pathogenesis, National Institute of Animal Biotechnology, Hyderabad, Telangana 500032, India and girish@niab.org.in.'}]",,,,© 2019 Murugan et al.,"10.1074/jbc.RA118.005543
10.1210/er.2003-0030
10.1016/j.mce.2010.12.017
10.1073/pnas.0606544103
10.1016/S0165-0173(01)00135-7
10.1016/j.bbalip.2010.05.006
10.1002/emmm.201202124
10.1016/j.jsbmb.2015.09.030
10.1126/science.1243985
10.1016/j.celrep.2014.04.011
10.1210/jcem-10-4-455
10.1126/science.100.2587.63
10.1097/00006842-194511000-00004
10.1210/jcem-11-6-559
10.1056/NEJMra050541
10.1016/j.yfrne.2008.02.001
10.1371/journal.pone.0103969
10.1073/pnas.0600113103
10.1038/nchembio.1321
10.4049/jimmunol.1601559
10.1016/j.cell.2006.03.047
10.1038/ni1299
10.1083/jcb.200402082
10.1016/0014-5793(92)81261-J
10.1016/0014-2999(95)00840-3
10.1038/nrn2038
10.1038/nri3073
10.1093/brain/awl251
10.4049/jimmunol.1101121
10.1159/000110455
10.1002/eji.201545655
10.1111/ejn.13257
10.1093/jnen/61.11.1013
10.1016/j.jneuroim.2016.12.004
10.4049/jimmunol.178.10.6476
10.4049/jimmunol.1001992
10.1073/pnas.1006496107
10.1073/pnas.1216671110
10.3791/1488",<Element 'PubmedArticle' at 0x7f05dd919810>
282,30616867,Recent advances in the therapeutic development for Huntington disease.,"Huntington disease (HD) is a rare genetic neurodegenerative condition. The availability of a genetic diagnosis makes HD an attractive model for the development of therapies that can delay or, at best, halt the progression of neurodegenerative conditions. Tetrabenazine and deutetrabenazine are the only treatment options with a formal indication (chorea) for this patient population.
Literature review on HD and clinical trials using the medical databases Pubmed, Web of Science, and clinical trial registries. Recent clinical trials conducted with the goal of disease-modification or new symptomatic treatment indications were included. Non-pharmacological interventions were excluded.
Therapeutic approaches aiming at disease-modification include huntingtin-lowering strategies, the modulation of huntingtin homeostasis and neuroinflammation. Huntingtin-lowering strategies are of particular interest by targeting the mRNA of the huntingtin (HTT) gene at the core of HD biology. Antisense oligonucleotides (ASO) are the only huntingtin-lowering strategies in clinical development. The initial results suggest that the first non-allele specific ASO was safe and associated with a reduction in the levels of mutated huntingtin protein (mHTT). Other clinical trials for disease-modification in HD have generated negative results or are ongoing. Assays to measure CSF mHTT and brain nuclear imaging specific to HD can support the rational development of these therapies. Novel symptomatic treatment indications explored in clinical trials include motor disability, irritability and apathy.
The years ahead are promising for novel and revolutionary therapies aimed at core disease mechanisms in HD. Clinical research platforms such as Enroll-HD are expected to potentiate the conduction of clinical trials in HD.","['Disease-modifying therapies', 'Huntingtin', 'Huntington disease', 'Immunotherapy', 'Symptomatic treatment']",Parkinsonism & related disorders,2019-01-09,"[{'lastname': 'Mestre', 'firstname': 'Tiago A', 'initials': 'TA', 'affiliation': ""Parkinson's Disease and Movement Disorders Center, Division of Neurology, Department of Medicine, The Ottawa Hospital Research Institute, The University of Ottawa Brain and Mind Institute, Canada. Electronic address: tmestre@toh.ca.""}]",,,"Therapeutic approaches aiming at disease-modification include huntingtin-lowering strategies, the modulation of huntingtin homeostasis and neuroinflammation. Huntingtin-lowering strategies are of particular interest by targeting the mRNA of the huntingtin (HTT) gene at the core of HD biology. Antisense oligonucleotides (ASO) are the only huntingtin-lowering strategies in clinical development. The initial results suggest that the first non-allele specific ASO was safe and associated with a reduction in the levels of mutated huntingtin protein (mHTT). Other clinical trials for disease-modification in HD have generated negative results or are ongoing. Assays to measure CSF mHTT and brain nuclear imaging specific to HD can support the rational development of these therapies. Novel symptomatic treatment indications explored in clinical trials include motor disability, irritability and apathy.",Copyright © 2018 Elsevier Ltd. All rights reserved.,10.1016/j.parkreldis.2018.12.003,<Element 'PubmedArticle' at 0x7f05dd8b8b30>
283,"30607903
10336536
10374817
10380075
10559890
11514075
11810404
11882652
11905991
11956956
11976437
11992015
12225874
12384227
12388547
12585679
12657697
12761548
12861385
14579249
14580312
15123736
15229237
15306158
15374226
15451022
15644984
15657046
15728830
15750214
15750215
15882358
16120783
16412093
16627931
16732431
16837132
16864698
17056790
17123555
17140550
17220545
17404373
17494993
17952652
17982898
18040888
18057555
18088381
18291574
1834965
18354008
19365734
19628748
19648913
19661616
19745037
19827303
20304978
20353781
21195590
21277873
21420365
21646525
2165569
22233683
22248049
22451318
22776349
22886150
22921433
23108544
2424016
24333387
24380887
24401760
24529521
24719136
24933620
25009698
25187358
25299754
25503661
25524120
25645684
25684318
25698444
25989217
26092091
26298663
27321914
28130308
2881207
29134561
29533978
30149447
6606682
7181105
7686508
7689702
7897397
8856836
8922409
9405284
9720972
9829797",Cannabinoid Receptor Type 1 Agonist ACEA Improves Cognitive Deficit on STZ-Induced Neurotoxicity Through Apoptosis Pathway and NO Modulation.,"The cannabinoid system has the ability to modulate cellular and molecular mechanisms, including excitotoxicity, oxidative stress, apoptosis, and inflammation, acting as a neuroprotective agent, by its relationship with signaling pathways associated to the control of cell proliferation, differentiation, and survival. Recent reports have raised new perspectives on the possible role of cannabinoid system in neurodegenerative diseases like Alzheimer disease's (AD). AD is a neurodegenerative disorder characterized by the presence of amyloid plaques, neurofibrillary tangles, neuronal death, and progressive cognitive loss, which could be caused by energy metabolism impairment, changes in insulin signaling, chronic oxidative stress, neuroinflammation, Tau hyperphosphorylation, and Aβ deposition in the brain. Thus, we investigated the presumptive protective effect of the cannabinoid type 1 (CB1)-selective receptor agonist arachidonyl-2'-chloroethylamide (ACEA) against streptozotocin (STZ) exposure stimuli in an in vitro neuronal model (Neuro-2a neuroblastoma cells) and in vivo model (intracerebroventricular STZ injection), experimental models of sporadic AD. Our results demonstrated that ACEA treatment reversed cognitive impairment and increased activity of Akt and ERK triggered by STZ, and increased IR expression and increased the anti-apoptotic proteins levels, Bcl-2. In the in vitro model, ACEA was able to rescue cells from STZ-triggered death and modulated the NO release by STZ. Our study has demonstrated a participation of the cannabinoid system in cellular survival, involving the CB1 receptor, which occurs by positive regulation of the anti-apoptotic proteins, suggesting the participation of this system in neurodegenerative processes. Our data suggest that the cannabinoid system is an interesting therapeutic target for the treatment of neurodegenerative diseases.","['ACEA', 'Agonist CB1', 'Alzheimer’s disease', 'Neurodegeneration', 'Neuroprotection', 'Streptozotocin']",Neurotoxicity research,2019-01-05,"[{'lastname': 'Crunfli', 'firstname': 'Fernanda', 'initials': 'F', 'affiliation': 'Department of Physiology and Biophysics, Institute of Biomedical Sciences, University of São Paulo, Av. Prof. Lineu Prestes, 1524, São Paulo, SP, 05508-000, Brazil. fernandacrunfli@gmail.com.'}, {'lastname': 'Vrechi', 'firstname': 'Talita A', 'initials': 'TA', 'affiliation': 'Department of Physiology and Biophysics, Institute of Biomedical Sciences, University of São Paulo, Av. Prof. Lineu Prestes, 1524, São Paulo, SP, 05508-000, Brazil.'}, {'lastname': 'Costa', 'firstname': 'Andressa P', 'initials': 'AP', 'affiliation': 'Department of Physiology and Biophysics, Institute of Biomedical Sciences, University of São Paulo, Av. Prof. Lineu Prestes, 1524, São Paulo, SP, 05508-000, Brazil.'}, {'lastname': 'Torrão', 'firstname': 'Andréa S', 'initials': 'AS', 'affiliation': 'Department of Physiology and Biophysics, Institute of Biomedical Sciences, University of São Paulo, Av. Prof. Lineu Prestes, 1524, São Paulo, SP, 05508-000, Brazil.'}]",,,,,10.1007/s12640-018-9991-2,<Element 'PubmedArticle' at 0x7f05dd8c2db0>
284,"30537997
24997032
19404271
25689247
21677746
26600970
23384445
21988661
23023166
22801555
24075718
11076888
23541470
24744759
27889451
22688187
10085047
20303872
7494493
22832610
19890268
26090491
21228220
28683149
26755160
28328972
27793227
26469024
26805875
27392632
25411471
26030851
20705860
23828891
26451344
29878576
29169241
23063970
19910123
29173525
20155849
16984660
22816728
16890594
11837726
12883111
21856139
28743984
22907164
30319571
25171511
25083050
24415853
30239343
27056723
29081213
28612842
9575574
11901203
11781274
18639629
21368716
26462538
17919507
16216887
24280877
29173520
23216550
21205640
25042861
28325746
25115840
26513610
26368297
24732573
24906568
26361415
25784930
27694934
27413153
27060191
19246945
28859865
25613713
27019327
27056982
28166278
26733300
23568206
23966110
24047867
20453760
26399249",Bidirectional gut-brain-microbiota axis as a potential link between inflammatory bowel disease and ischemic stroke.,"Emerging evidence suggests that gut-brain-microbiota axis (GBMAx) may play a pivotal role linking gastrointestinal and neuronal disease. In this review, we summarize the latest advances in studies of GBMAx in inflammatory bowel disease (IBD) and ischemic stroke. A more thorough understanding of the GBMAx could advance our knowledge about the pathophysiology of IBD and ischemic stroke and help to identify novel therapeutic targets via modulation of the GBMAx.","['Adrenocorticotropic hormone', 'Gut-brain-microbiota axis', 'Inflammatory', 'Inflammatory bowel disease', 'Ischemic stroke']",Journal of neuroinflammation,2018-12-13,"[{'lastname': 'Zhao', 'firstname': 'Liang', 'initials': 'L', 'affiliation': 'Department of Gastroenterology, Renmin Hospital of Wuhan University, Wuhan, China.'}, {'lastname': 'Xiong', 'firstname': 'Qiutang', 'initials': 'Q', 'affiliation': 'Diabetes Research Center, Renmin Hospital of Wuhan University, Wuhan, China.'}, {'lastname': 'Stary', 'firstname': 'Creed M', 'initials': 'CM', 'affiliation': 'Department of Anesthesiology, Perioperative and Pain Medicine, Stanford University School of Medicine, Stanford, CA, 94305, USA.'}, {'lastname': 'Mahgoub', 'firstname': 'Omer Kamal', 'initials': 'OK', 'affiliation': 'Central Laboratory, Renmin Hospital of Wuhan University, Wuhan, China.'}, {'lastname': 'Ye', 'firstname': 'Yingze', 'initials': 'Y', 'affiliation': 'Central Laboratory, Renmin Hospital of Wuhan University, Wuhan, China.'}, {'lastname': 'Gu', 'firstname': 'Lijuan', 'initials': 'L', 'affiliation': 'Central Laboratory, Renmin Hospital of Wuhan University, Wuhan, China.'}, {'lastname': 'Xiong', 'firstname': 'Xiaoxing', 'initials': 'X', 'affiliation': 'Central Laboratory, Renmin Hospital of Wuhan University, Wuhan, China. xiaoxingxiong@whu.edu.cn.\nDepartment of Neurosurgery, Renmin Hospital of Wuhan University, 99 Zhang Zhidong Rd, Wuhan, 430060, Hubei, China. xiaoxingxiong@whu.edu.cn.'}, {'lastname': 'Zhu', 'firstname': 'Shengmei', 'initials': 'S', 'affiliation': 'Department of Anesthesiology, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, 310000, Zhejiang, China. smzhu20088@zju.edu.cn.'}]",,,,,"10.1186/s12974-018-1382-3
10.1007/978-1-4939-0897-4_6
10.1038/nrgastro.2009.35
10.1172/JCI76304
10.1038/nature10208
10.4291/wjgp.v6.i4.124
10.1016/j.tins.2013.01.005
10.1111/j.1365-2982.2011.01796.x
10.1016/j.autneu.2015.07.270
10.1038/embor.2012.96
10.1016/j.coph.2013.09.008
10.1136/gut.47.6.861
10.1016/j.jnutbio.2013.01.006
10.3389/fimmu.2014.00136
10.1016/j.molcel.2016.10.025
10.1038/mp.2012.77
10.1016/j.cell.2010.01.022
10.1111/j.1348-0421.1995.tb02242.x
10.1038/tp.2011.37
10.1038/mi.2009.124
10.1155/2015/489821
10.1096/fj.10-172205
10.1371/journal.pone.0180025
10.1128/IAI.01374-15
10.1371/journal.pone.0172914
10.1016/bs.irn.2016.08.005
10.1038/526312a
10.3390/nu8010056
10.1016/j.neuropharm.2016.07.002
10.1126/scitranslmed.3009759
10.1038/nn.4030
10.1126/science.1241165
10.1080/21688370.2015.1039691
10.1111/nmo.13366
10.1053/j.gastro.2012.10.003
10.1016/j.psyneuen.2009.10.004
10.1016/j.gtc.2017.08.006
10.1002/ibd.21215
10.1186/1745-0179-2-24
10.1186/1471-230X-12-93
10.1053/j.gastro.2006.05.017
10.1023/A:1013256629600
10.1097/01.PSY.0000074759.71084.AB
10.1016/j.coi.2011.07.010
10.1038/nrgastro.2012.152
10.3389/fmicb.2018.02247
10.1097/MIB.0000000000000174
10.3748/wjg.v20.i1.6
10.1152/ajpgi.00086.2016
10.1038/mi.2017.49
10.1084/jem.20011714
10.1053/gast.2002.30770
10.1016/j.bbi.2008.06.011
10.1097/SHK.0b013e3182168d56
10.1124/jpet.115.228205
10.1053/j.gastro.2007.08.061
10.1084/jem.20042397
10.1097/01.MIB.0000437495.30052.be
10.1111/jgh.12073
10.1126/science.1198469
10.1038/ijo.2014.124
10.1136/gutjnl-2016-313099
10.1007/s11239-014-1129-7
10.1097/MEG.0000000000000495
10.1097/MCG.0000000000000408
10.1016/j.atherosclerosis.2014.03.023
10.1016/j.ejim.2014.05.009
10.3748/wjg.v21.i33.9688
10.1016/S1873-9946(13)60020-3
10.1155/2015/672460
10.1038/nm.4194
10.1523/JNEUROSCI.1114-16.2016
10.1016/j.bbi.2016.04.003
10.1159/000205514
10.1016/j.neulet.2017.08.061
10.1186/s12974-014-0231-2
10.1038/nm.4068
10.1161/STROKEAHA.115.011800
10.1371/journal.pone.0171521
10.1016/j.neulet.2015.12.047
10.4014/jmb.1205.05018
10.3390/nu5083299
10.1177/0148607113501881
10.1097/TA.0b013e3181d87373
10.1007/s12028-015-0203-0",<Element 'PubmedArticle' at 0x7f05dd7e8f40>
285,30506969,Oxytocin receptor agonist reduces perinatal brain damage by targeting microglia.,"Prematurity and fetal growth restriction (FGR) are frequent conditions associated with adverse neurocognitive outcomes. We have previously identified early deregulation of genes controlling neuroinflammation as a putative mechanism linking FGR and abnormal trajectory of the developing brain. While the oxytocin system was also found to be impaired following adverse perinatal events, its role in the modulation of neuroinflammation in the developing brain is still unknown. We used a double-hit rat model of perinatal brain injury induced by gestational low protein diet (LPD) and potentiated by postnatal injections of subliminal doses of interleukin-1β (IL1β) and a zebrafish model of neuroinflammation. Effects of the treatment with carbetocin, a selective, long lasting, and brain diffusible oxytocin receptor agonist, have been assessed using a combination of histological, molecular, and functional tools in vivo and in vitro. In the double-hit model, white matter inflammation, deficient myelination, and behavioral deficits have been observed and the oxytocin system was impaired. Early postnatal supplementation with carbetocin alleviated microglial activation at both transcriptional and cellular levels and provided long-term neuroprotection. The central anti-inflammatory effects of carbetocin have been shown in vivo in rat pups and in a zebrafish model of early-life neuroinflammation and reproduced in vitro on stimulated sorted primary microglial cell cultures from rats subjected to LPD. Carbetocin treatment was associated with beneficial effects on myelination, long-term intrinsic brain connectivity and behavior. Targeting oxytocin signaling in the developing brain may be an effective approach to prevent neuroinflammation - induced brain damage of perinatal origin.","['microglia', 'myelination', 'neuroprotection', 'oxytocin', 'perinatal stress']",Glia,2018-12-07,"[{'lastname': 'Mairesse', 'firstname': 'Jérôme', 'initials': 'J', 'affiliation': ""PROTECT, Inserm U1141, Université Paris Diderot, Paris, France.\nDivision of Neonatology and Pediatric Intensive Care, Children's University Hospital of Geneva, Geneva, Switzerland.\nLaboratory of Child Growth and Development, University of Geneva, Geneva, Switzerland.""}, {'lastname': 'Zinni', 'firstname': 'Manuela', 'initials': 'M', 'affiliation': 'PROTECT, Inserm U1141, Université Paris Diderot, Paris, France.'}, {'lastname': 'Pansiot', 'firstname': 'Julien', 'initials': 'J', 'affiliation': 'PROTECT, Inserm U1141, Université Paris Diderot, Paris, France.'}, {'lastname': 'Hassan-Abdi', 'firstname': 'Rahma', 'initials': 'R', 'affiliation': 'PROTECT, Inserm U1141, Université Paris Diderot, Paris, France.'}, {'lastname': 'Demene', 'firstname': 'Charlie', 'initials': 'C', 'affiliation': 'Institut Langevin, CNRS UMR 7587, Inserm U979, ESPCI Paris, PSL Research University, Paris, France.'}, {'lastname': 'Colella', 'firstname': 'Marina', 'initials': 'M', 'affiliation': 'PROTECT, Inserm U1141, Université Paris Diderot, Paris, France.'}, {'lastname': 'Charriaut-Marlangue', 'firstname': 'Christiane', 'initials': 'C', 'affiliation': 'PROTECT, Inserm U1141, Université Paris Diderot, Paris, France.'}, {'lastname': 'Rideau Batista Novais', 'firstname': 'Aline', 'initials': 'A', 'affiliation': 'PROTECT, Inserm U1141, Université Paris Diderot, Paris, France.'}, {'lastname': 'Tanter', 'firstname': 'Mickael', 'initials': 'M', 'affiliation': 'Institut Langevin, CNRS UMR 7587, Inserm U979, ESPCI Paris, PSL Research University, Paris, France.'}, {'lastname': 'Maccari', 'firstname': 'Stefania', 'initials': 'S', 'affiliation': 'International Associated Laboratory (LIA) ""Prenatal Stress and Neurodegenerative Diseases, University of Lille 1 - CNRS UMR8576 Lille, France and Sapienza University of Rome - IRCCS Neuromed, Rome, Italy.'}, {'lastname': 'Gressens', 'firstname': 'Pierre', 'initials': 'P', 'affiliation': 'PROTECT, Inserm U1141, Université Paris Diderot, Paris, France.\nPremUP Foundation, Paris, France.'}, {'lastname': 'Vaiman', 'firstname': 'Daniel', 'initials': 'D', 'affiliation': 'PremUP Foundation, Paris, France.\nInstitut Cochin, Inserm U1016, UMR8104 CNRS, Paris, France.'}, {'lastname': 'Soussi-Yanicostas', 'firstname': 'Nadia', 'initials': 'N', 'affiliation': 'PROTECT, Inserm U1141, Université Paris Diderot, Paris, France.'}, {'lastname': 'Baud', 'firstname': 'Olivier', 'initials': 'O', 'affiliation': ""PROTECT, Inserm U1141, Université Paris Diderot, Paris, France.\nDivision of Neonatology and Pediatric Intensive Care, Children's University Hospital of Geneva, Geneva, Switzerland.\nLaboratory of Child Growth and Development, University of Geneva, Geneva, Switzerland.\nPremUP Foundation, Paris, France.""}]",,,,"© 2018 Wiley Periodicals, Inc.",10.1002/glia.23546,<Element 'PubmedArticle' at 0x7f05dd7a3bd0>
286,30500621,"On the role of corticosterone in behavioral disorders, microbiota composition alteration and neuroimmune response in adult male mice subjected to maternal separation stress.","Experiencing psychosocial adversities in early life such as maternal separation (MS) increases the risk of psychiatric disorders. Immune-inflammatory responses have imperative roles in the pathophysiology of psychiatric disorders. MS relatively changes the composition of intestinal microbiota leading to an overactivation of the hypothalamic-pituitary-adrenal (HPA) axis, and subsequently increases the corticosterone level. In this study, we aimed to evaluate the role of corticosterone in behavioral changes and microbiota modifications in a mouse model of MS afflicted neuroinflammatory response in the hippocampus. For this purpose, 180 min of MS stress was applied to mice at postnatal day (PND) 2-14 followed by behavioral tests including forced swimming test (FST), splash test, open field test (OFT) and elevated plus maze (EPM) at PND 50-52. For evaluating the role of corticosterone, mice were subjected to adrenalectomy. Using real-time RT-PCR, the expression of inflammatory genes was determined in the hippocampus and colon tissues. We found that MS provoked depressive- and anxiety-like behaviors in adult male mice. In addition, MS was able to active a neuroimmune response in the hippocampus, motivate inflammation and histopathologic changes in the colon tissue and modify the composition of gut microbiota as well. Interestingly, our findings showed that adrenalectomy (decline in the corticosterone level), could modulate the above-mentioned negative effects of MS. In conclusion, our results demonstrated that overactivation of HPA axis and the subsequent increased level of corticosterone could act, possibly, as the deleterious effects of MS on behavior, microbiota composition changes and activation of neuroimmune response.","['Adrenalectomy', 'HPA axis', 'Maternal separation', 'Microbiota', 'Neuroinflammation', 'Psychiatric disorders']",International immunopharmacology,2018-12-01,"[{'lastname': 'Amini-Khoei', 'firstname': 'Hossein', 'initials': 'H', 'affiliation': 'Medical Plants Research Center, Basic Health Sciences Institute, Shahrekord University of Medical Sciences, Shahrekord, Iran. Electronic address: aminikhoyi@gmail.com.'}, {'lastname': 'Haghani-Samani', 'firstname': 'Elaheh', 'initials': 'E', 'affiliation': 'Medical Plants Research Center, Basic Health Sciences Institute, Shahrekord University of Medical Sciences, Shahrekord, Iran.'}, {'lastname': 'Beigi', 'firstname': 'Masoumeh', 'initials': 'M', 'affiliation': 'Medical Plants Research Center, Basic Health Sciences Institute, Shahrekord University of Medical Sciences, Shahrekord, Iran.'}, {'lastname': 'Soltani', 'firstname': 'Amin', 'initials': 'A', 'affiliation': 'Medical Plants Research Center, Basic Health Sciences Institute, Shahrekord University of Medical Sciences, Shahrekord, Iran.'}, {'lastname': 'Mobini', 'firstname': 'Gholam Reza', 'initials': 'GR', 'affiliation': 'Cellular and Molecular Research Center, Basic Health Sciences Institute, Shahrekord University of Medical Sciences, Shahrekord, Iran.'}, {'lastname': 'Balali-Dehkordi', 'firstname': 'Shima', 'initials': 'S', 'affiliation': 'Department of Basic Sciences, Faculty of Veterinary Medicine, Shahid Chamran University of Ahvaz, Ahvaz, Iran.'}, {'lastname': 'Haj-Mirzaian', 'firstname': 'Arvin', 'initials': 'A', 'affiliation': 'Experimental Medicine Research Center, Tehran University of Medical Sciences, Tehran, Iran.'}, {'lastname': 'Rafieian-Kopaei', 'firstname': 'Mahmoud', 'initials': 'M', 'affiliation': 'Medical Plants Research Center, Basic Health Sciences Institute, Shahrekord University of Medical Sciences, Shahrekord, Iran.'}, {'lastname': 'Alizadeh', 'firstname': 'Akram', 'initials': 'A', 'affiliation': 'Cellular and Molecular Research Center, Basic Health Sciences Institute, Shahrekord University of Medical Sciences, Shahrekord, Iran.'}, {'lastname': 'Hojjati', 'firstname': 'Mohammad Reza', 'initials': 'MR', 'affiliation': 'Department of Physiology and Pharmacology, School of Medicine, Shahrekord University of Medical Sciences, Shahrekord, Iran.'}, {'lastname': 'Validi', 'firstname': 'Majid', 'initials': 'M', 'affiliation': 'Department of Medical Laboratory Sciences, School of Allied Medical Sciences, Shahrekord University of Medical Sciences, Shahrekord, Iran.'}]",,,,Copyright © 2018. Published by Elsevier B.V.,10.1016/j.intimp.2018.11.037,<Element 'PubmedArticle' at 0x7f05dd7ba540>
287,30496754,Oleoylethanolamide restores alcohol-induced inhibition of neuronal proliferation and microglial activity in striatum.,"Previous findings demonstrate a homeostatic role for oleoylethanolamide (OEA) signaling in the ethanol-related neuroinflammation and behavior. However, extensive research is still required in order to unveil the effects of OEA on a number of neurobiological functions such as adult neurogenesis, cell survival and resident neuroimmunity that become notably altered by alcohol. Daily consumption of ethanol (10%) for 2 weeks (6.3&#x202F;±&#x202F;1.1&#x202F;g/kg/day during last 5 days) caused hypolocomotor activity in rats. This effect appears to rely on central signaling mechanisms given that alcohol increased the OEA levels, the gene expression of OEA-synthesizing enzyme Nape-pld and the number of PPARα-immunoreactive neurons in the striatum. Ethanol-related neurobiological alterations such as a reduction in the number of microglial cells expressing iNOS (a cytokine-inducible immune defense) and in adult neural stem/progenitor cell (NSPC) proliferation (phospho-H3 and BrdU) and maturation (BrdU/β3-tubulin), as well as an increase in damage cell activity (FosB) and apoptosis (cleaved caspase 3) were also observed in the rat striatum. Pharmacological administration of OEA (10 mg/kg) for 5 days during ethanol exposure exacerbated ethanol-induced hypolocomotion and cell apoptosis in the striatum. Interestingly, OEA abrogated the impaired effects of ethanol on PPARα-positive cell population and NSPC proliferation and maturation. OEA also decreased astrocyte-related vimentin immunoreactivity and increased microglial cell population (Iba-1, iNOS) in the striatum. These results suggest that OEA-PPARα signaling modulates glial activation, cell apoptosis and NSPC proliferation and maturation in response to striatal-specific neurobiological alterations induced by prolonged ethanol intake in rats.","['Alcohol', 'Locomotion', 'Microglia', 'Neurogenesis', 'PPARα', 'Striatum']",Neuropharmacology,2018-11-30,"[{'lastname': 'Rivera', 'firstname': 'Patricia', 'initials': 'P', 'affiliation': 'Department of Endocrinology, Fundación Investigación Biomédica del Hospital Infantil Universitario Niño Jesús, Madrid, Spain.'}, {'lastname': 'Silva-Peña', 'firstname': 'Daniel', 'initials': 'D', 'affiliation': 'Instituto de Investigación Biomédica de Málaga (IBIMA), UGC Salud Mental, Universidad de Málaga, Hospital Universitario Regional de Málaga, Málaga, Spain.'}, {'lastname': 'Blanco', 'firstname': 'Eduardo', 'initials': 'E', 'affiliation': 'Institute of Biomedical Research of Lleida (IRB Lleida), University of Lleida, Lleida, Spain.'}, {'lastname': 'Vargas', 'firstname': 'Antonio', 'initials': 'A', 'affiliation': 'Instituto de Investigación Biomédica de Málaga (IBIMA), UGC Salud Mental, Universidad de Málaga, Hospital Universitario Regional de Málaga, Málaga, Spain.'}, {'lastname': 'Arrabal', 'firstname': 'Sergio', 'initials': 'S', 'affiliation': 'Instituto de Investigación Biomédica de Málaga (IBIMA), UGC Salud Mental, Universidad de Málaga, Hospital Universitario Regional de Málaga, Málaga, Spain.'}, {'lastname': 'Serrano', 'firstname': 'Antonia', 'initials': 'A', 'affiliation': 'Instituto de Investigación Biomédica de Málaga (IBIMA), UGC Salud Mental, Universidad de Málaga, Hospital Universitario Regional de Málaga, Málaga, Spain.'}, {'lastname': 'Pavón', 'firstname': 'Francisco Javier', 'initials': 'FJ', 'affiliation': 'Instituto de Investigación Biomédica de Málaga (IBIMA), UGC Salud Mental, Universidad de Málaga, Hospital Universitario Regional de Málaga, Málaga, Spain.'}, {'lastname': 'Bindila', 'firstname': 'Laura', 'initials': 'L', 'affiliation': 'Institute of Physiological Chemistry, University Medical Center of the Johannes Gutenberg-University of Mainz, German Resilience Center (DRZ), Mainz, Germany.'}, {'lastname': 'Lutz', 'firstname': 'Beat', 'initials': 'B', 'affiliation': 'Institute of Physiological Chemistry, University Medical Center of the Johannes Gutenberg-University of Mainz, German Resilience Center (DRZ), Mainz, Germany.'}, {'lastname': 'Rodríguez de Fonseca', 'firstname': 'Fernando', 'initials': 'F', 'affiliation': 'Instituto de Investigación Biomédica de Málaga (IBIMA), UGC Salud Mental, Universidad de Málaga, Hospital Universitario Regional de Málaga, Málaga, Spain. Electronic address: fernando.rodriguez@ibima.eu.'}, {'lastname': 'Suárez', 'firstname': 'Juan', 'initials': 'J', 'affiliation': 'Instituto de Investigación Biomédica de Málaga (IBIMA), UGC Salud Mental, Universidad de Málaga, Hospital Universitario Regional de Málaga, Málaga, Spain. Electronic address: juan.suarez@ibima.eu.'}]",,,,Copyright © 2018 Elsevier Ltd. All rights reserved.,10.1016/j.neuropharm.2018.11.037,<Element 'PubmedArticle' at 0x7f05dd7c4cc0>
288,30466987,Novel molecular mechanisms for the adaptogenic effects of herbal extracts on isolated brain cells using systems biology.,"Adaptogens are natural compounds or plant extracts that increase adaptability and survival of organisms under stress. Adaptogens stimulate cellular and organismal defense systems by activating intracellular and extracellular signaling pathways and expression of stress-activated proteins and neuropeptides. The effects adaptogens on mediators of adaptive stress response and longevity signaling pathways have been reported, but their stress-protective mechanisms are still not fully understood.
The aim of this study was to identify key molecular mechanisms of adaptogenic plants traditionally used to treat stress and aging-related disorders, i.e., Rhodiola rosea, Eleutherococcus senticosus, Withania somnifera, Rhaponticum carthamoides, and Bryonia alba.
To investigate the underlying molecular mechanisms of adaptogens, we conducted RNA sequencing to profile gene expression alterations in T98G neuroglia cells upon treatment of adaptogens and analyzed the relevance of deregulated genes to adaptive stress-response signaling pathways using in silico pathway analysis software.
At least 88 of the 3516 genes regulated by adaptogens were closely associated with adaptive stress response and adaptive stress-response signaling pathways (ASRSPs), including neuronal signaling related to corticotropin-releasing hormone, cAMP-mediated, protein kinase A, and CREB; pathways related to signaling involving CXCR4, melatonin, nitric oxide synthase, GP6, Gαs, MAPK, neuroinflammation, neuropathic pain, opioids, renin-angiotensin, AMPK, calcium, and synapses; and pathways associated with dendritic cell maturation and G-coupled protein receptor-mediated nutrient sensing in enteroendocrine cells. All samples tested showed significant effects on the expression of genes encoding neurohormones CRH, GNRH, UCN, G-protein-coupled and other transmembrane receptors TLR9, PRLR, CHRNE, GP1BA, PLXNA4, a ligand-dependent nuclear receptor RORA, transmembrane channels, transcription regulators FOS, FOXO6, SCX, STAT5A, ZFPM2, ZNF396, ZNF467, protein kinases MAPK10, MAPK13, MERTK, FLT1, PRKCH, ROS1, TTN), phosphatases PTPRD, PTPRR, peptidases, metabolic enzymes, a chaperone (HSPA6), and other proteins, all of which modulate numerous life processes, playing key roles in several canonical pathways involved in defense response and regulation of homeostasis in organisms. It is for the first time we report that the molecular mechanism of actions of melatonin and plant adaptogens are alike, all adaptogens tested activated the melatonin signaling pathway by acting through two G-protein-coupled membrane receptors MT1 and MT2 and upregulation of the ligand-specific nuclear receptor RORA, which plays a role in intellectual disability, neurological disorders, retinopathy, hypertension, dyslipidemia, and cancer, which are common in aging. Furthermore, melatonin activated adaptive signaling pathways and upregulated expression of UCN, GNRH1, TLR9, GP1BA, PLXNA4, CHRM4, GPR19, VIPR2, RORA, STAT5A, ZFPM2, ZNF396, FLT1, MAPK10, MERTK, PRKCH, and TTN, which were commonly regulated by all adaptogens tested. We conclude that melatonin is an adaptation hormone playing an important role in regulation of homeostasis. Adaptogens presumably worked as eustressors (""stress-vaccines"") to activate the cellular adaptive system by inducing the expression of ASRSPs, which then reciprocally protected cells from damage caused by distress. Functional investigation by interactive pathways analysis demonstrated that adaptogens activated ASRSPs associated with stress-induced and aging-related disorders such as chronic inflammation, cardiovascular health, neurodegenerative cognitive impairment, metabolic disorders, and cancer.
This study has elucidated the genome-wide effects of several adaptogenic herbal extracts in brain cells culture. These data highlight the consistent activation of ASRSPs by adaptogens in T98G neuroglia cells. The extracts affected many genes playing key roles in modulation of adaptive homeostasis, indicating their ability to modify gene expression to prevent stress-induced and aging-related disorders. Overall, this study provides a comprehensive look at the molecular mechanisms by which adaptogens exerts stress-protective effects.","['Adaptogen', 'Melatonin', 'Pathway analysis', 'RNA sequencing', 'Rhodiola', 'Withania']",Phytomedicine : international journal of phytotherapy and phytopharmacology,2018-11-24,"[{'lastname': 'Panossian', 'firstname': 'Alexander', 'initials': 'A', 'affiliation': 'EuroPharma USA Inc., Green Bay, WI, USA; Phytomed AB, Vaxtorp, Sweden. Electronic address: apanossian@europharmausa.com.'}, {'lastname': 'Seo', 'firstname': 'Ean-Jeong', 'initials': 'EJ', 'affiliation': 'Department of Pharmaceutical Biology, Institute of Pharmacy and Biochemistry, Johannes Gutenberg University, Staudinger Weg 5, Mainz 55128, Germany.'}, {'lastname': 'Efferth', 'firstname': 'Thomas', 'initials': 'T', 'affiliation': 'Department of Pharmaceutical Biology, Institute of Pharmacy and Biochemistry, Johannes Gutenberg University, Staudinger Weg 5, Mainz 55128, Germany. Electronic address: efferth@uni-mainz.de.'}]",,"This study has elucidated the genome-wide effects of several adaptogenic herbal extracts in brain cells culture. These data highlight the consistent activation of ASRSPs by adaptogens in T98G neuroglia cells. The extracts affected many genes playing key roles in modulation of adaptive homeostasis, indicating their ability to modify gene expression to prevent stress-induced and aging-related disorders. Overall, this study provides a comprehensive look at the molecular mechanisms by which adaptogens exerts stress-protective effects.",,Copyright © 2018 The Authors. Published by Elsevier GmbH.. All rights reserved.,10.1016/j.phymed.2018.09.204,<Element 'PubmedArticle' at 0x7f05dd7de680>
289,30414958,Cannabinoid Type 2 Receptor System Modulates Paclitaxel-Induced Microglial Dysregulation and Central Sensitization in Rats.,"Paclitaxel induces microglial activation and production of proinflammatory mediators in the dorsal horn, which contribute to the development and maintenance of central sensitization and pain behavior. MDA7, 1-([3-benzyl-3-methyl-2,3-dihydro-1-benzofuran-6-yl]carbonyl) piperidine, is a novel highly selective cannabinoid type 2 (CB2) agonist. We tested the hypothesis that activation of CB2 receptor by MDA7 modulates microglial dysregulation, suppresses the overexpression of brain-derived neurotrophic factor (BDNF) in microglia in the dorsal horn, and attenuates the central sensitization and pain behavior induced by paclitaxel. For 4 consecutice days, groups of rats randomly received saline or 1.0 mg/kg of paclitaxel daily intraperitoneally for a total cumulative dose of 4 mg/kg. MDA7 15 mg/kg intraperitoneally or vehicle were administered 15 min before administering paclitaxel for 4 days and then continued for another 10 days. Behavioral and molecular studies were performed. Paclitaxel induced the expression of CB2 receptors and production of interleukin (IL)-6 in microglia in the dorsal horn. MDA7 attenuated the expression of IL-6 and promoted the expression of IL-10. Paclitaxel induced epigenetic upregulation of IRF8 and P2X purinoceptor 4 (P2X4) in microglia and subsequently increased the expression of alpha isoform of calcium/calmodulin-dependent protein kinase II (CaMKIIα), transcriptional factors p-CREB and ΔFosB, leading to the overproduction of BDNF in microglia. Paclitaxel also upregulated the expression of glutamate receptor subunits GluR1 and NR2B, decreased the expression of K","['Paclitaxel', 'cannabinoid type 2 (CB2) receptor', 'microglia', 'neuroinflammation', 'neuropathic pain']",The journal of pain,2018-11-12,"[{'lastname': 'Wu', 'firstname': 'Jiang', 'initials': 'J', 'affiliation': 'Anesthesiology Institute, Cleveland Clinic, and Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, Ohio.'}, {'lastname': 'Hocevar', 'firstname': 'Mark', 'initials': 'M', 'affiliation': 'Brown University, Providence, Rhode Island.'}, {'lastname': 'Bie', 'firstname': 'Bihua', 'initials': 'B', 'affiliation': 'Anesthesiology Institute, Cleveland Clinic, and Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, Ohio.'}, {'lastname': 'Foss', 'firstname': 'Joseph F', 'initials': 'JF', 'affiliation': 'Anesthesiology Institute, Cleveland Clinic, and Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, Ohio.'}, {'lastname': 'Naguib', 'firstname': 'Mohamed', 'initials': 'M', 'affiliation': 'Anesthesiology Institute, Cleveland Clinic, and Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, Ohio. Electronic address: naguibm@ccf.org.'}]",,,,Copyright © 2018 the American Pain Society. Published by Elsevier Inc. All rights reserved.,10.1016/j.jpain.2018.10.007,<Element 'PubmedArticle' at 0x7f05dd767cc0>
290,"30361800
26857201
26516628
23290630
19028830
28634006
27501960
29297041
19308306
26498263
27951522
23019265
25635258
28382320
23133550
28104256
29720546
12535003
29788256
29027539
27802825
29374079
26250739
29576504
15503099
17502467
20639385
18022700
23597832
28283101
27920282
26894206
12822056
10929279
26092914
29465257
29572931
25690593
25821844
28018943
27355107
25635259
27113605
28255575
29228214
29892608
25340086
30048919
27458601
28642888
24142147
28105459
27371488
27758954
28054001
30186620
29637999
28572277
26185772
27546235
28928747
22577216
27466467
23973225
25774787
29695592
28684532
27788675
29378942
19170744
26537743
24272588
29131884
29114566
19426994
29707611
26906964
28778445
20651746
26810718
24550311
27164713
8017890
24384647
21952097
20437582
29549225
27800532
29436488
22260418
26251845
29724224
22281844
29272336
24793874
20398859
12615637
24713508
16275834
12225904
26773723
24634831
17052660
26046348
8910077
29564373
29490181
24415568
2043940
18332247
18671877
27144216
29307297
29142145
24099751
7836963
7783875
29670575
25921037",Sex differences in autoimmune disorders of the central nervous system.,"Stronger adaptive immune responses in females can be observed in different mammals, resulting in better control of infections compared to males. However, this presumably evolutionary difference likely also drives higher incidence of autoimmune diseases observed in humans. Here, we summarize sex differences in the most common autoimmune diseases of the central nervous system (CNS) and discuss recent advances in the understanding of possible underlying immunological and CNS intrinsic mechanisms. In multiple sclerosis (MS), the most common inflammatory disease of the CNS, but also in rarer conditions, such as neuromyelitis optica spectrum disorders (NMOSD) or neuronal autoantibody-mediated autoimmune encephalitis (AE), sex is one of the top risk factors, with women being more often affected than men. Immunological mechanisms driving the sex bias in autoimmune CNS diseases are complex and include hormonal as well as genetic and epigenetic effects, which could also be exerted indirectly via modulation of the microbiome. Furthermore, CNS intrinsic differences could underlie the sex bias in autoimmunity by differential responses to injury. The strong effects of sex on incidence and possibly also activity and progression of autoimmune CNS disorders suggest that treatments need to be tailored to each sex to optimize efficacy. To date, however, due to a lack of systematic studies on treatment responses in males versus females, evidence in this area is still sparse. We argue that studies taking sex differences into account could pave the way for sex-specific and therefore personalized treatment.",[],Seminars in immunopathology,2018-10-27,"[{'lastname': 'Gold', 'firstname': 'Stefan M', 'initials': 'SM', 'affiliation': 'Institute of Neuroimmunology and Multiple Sclerosis (INIMS), Center for Molecular Neurobiology Hamburg (ZMNH), University Medical Center Hamburg Eppendorf, Hamburg, Germany.\nDepartment of Psychiatry, Charité - Universitätsmedizin Berlin, Cooperate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Campus Benjamin Franklin, Hindenburgdamm 30, 12203, Berlin, Germany.'}, {'lastname': 'Willing', 'firstname': 'Anne', 'initials': 'A', 'affiliation': 'Institute of Neuroimmunology and Multiple Sclerosis (INIMS), Center for Molecular Neurobiology Hamburg (ZMNH), University Medical Center Hamburg Eppendorf, Hamburg, Germany.'}, {'lastname': 'Leypoldt', 'firstname': 'Frank', 'initials': 'F', 'affiliation': 'Department of Neurology, Christian-Albrechts-University Kiel, Kiel, Germany.\nNeuroimmunology Section, Institute of Clinical Chemistry, University Hospital Schleswig-Holstein Kiel/Lübeck, Kiel/Lübeck, Germany.'}, {'lastname': 'Paul', 'firstname': 'Friedemann', 'initials': 'F', 'affiliation': 'NeuroCure Clinical Research Center, Charité - Universitätsmedizin Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Charitéplatz 1, 10117, Berlin, Germany.\nExperimental and Clinical Research Center, Max Delbrueck Center for Molecular Medicine and Charité - Universitätsmedizin Berlin, Berlin, Germany.'}, {'lastname': 'Friese', 'firstname': 'Manuel A', 'initials': 'MA', 'affiliation': 'Institute of Neuroimmunology and Multiple Sclerosis (INIMS), Center for Molecular Neurobiology Hamburg (ZMNH), University Medical Center Hamburg Eppendorf, Hamburg, Germany. manuel.friese@zmnh.uni-hamburg.de.'}]",,,,,10.1007/s00281-018-0723-8,<Element 'PubmedArticle' at 0x7f05dd7776d0>
291,30314601,Molecular Imaging of the Cannabinoid System in Idiopathic Parkinson's Disease.,"The endocannabinoid system is a modulator of neurotransmitter release and is involved in several physiological functions. Hence, it has been increasingly studied as a potential pharmacologic target of Parkinson's disease. Several preclinical and clinical studies evidenced a substantial rearrangement of the endocannabinoid system in the basal ganglia circuit following dopamine depletion. The endocannabinoid system has been additionally implicated in the regulation of neuroinflammation and neuroprotection through the activation of CB2 receptors, suggesting a potential target for disease modifying therapies in Parkinson's disease. In this chapter, current pharmacological and physiological knowledge on the role of the endocannabinoid system will be reviewed, focusing on preclinical studies animal models and clinical studies in patients with idiopathic Parkinson's disease. The main strategies for imaging the brain cannabinoid system will be summarized to finally focus on in vivo imaging of patients with Parkinson's disease.","['Cannabinoids', 'Endocannabinoid system', 'PET', ""Parkinson's disease"", 'Receptor imaging']",International review of neurobiology,2018-10-14,"[{'lastname': 'Cilia', 'firstname': 'Roberto', 'initials': 'R', 'affiliation': 'Parkinson Institute, ASST Gaetano Pini-CTO, Milan, Italy. Electronic address: roberto.cilia@gmail.com.'}]",,,,© 2018 Elsevier Inc. All rights reserved.,10.1016/bs.irn.2018.08.004,<Element 'PubmedArticle' at 0x7f05dd7a0860>
292,30260321,The role of inflammation on the functionality of intracortical microelectrodes.,"Neuroinflammation has long been associated with the performance decline of intracortical microelectrodes (IMEs). Consequently, several strategies, including the use of anti-inflammatories, have been employed to mitigate the inflammation surrounding IMEs. However, these strategies have had limited success towards achieving a chronically viable cortical neural interface, questioning the efficacy of anti-inflammatory approach.
Herein, we conducted a systematic study in rats implanted with functional devices by modulating inflammation via systemic injection of lipopolysaccharide (LPS), dexamethasone (DEX), a combination of both, or none to assess the degree of inflammation on device functionality. We hypothesized that implanted rats treated with LPS will have a negative impact, and rats treated with DEX will have a positive impact on functionality IMEs and histological outcome.
Contrary to our hypothesis, we did not observe adverse effects in recording metrics among different groups with LPS and/or DEX treatment despite alterations in initial pro-inflammatory markers. We also did not observe any functional benefit of anti-inflammatory treatment. Regardless of the treatment conditions, the recording quality degraded at chronic time points. In end-point histology, implanted rats that received LPS had significantly lower NeuN density and higher levels of CD68 surrounding the implant site, indicative of the pro-inflammatory effect of LPS, which, however, contradicted with the recorded results.
Collectively, our results suggest that acute inflammatory events may not be the key driver for functional degradation of IMEs. Future intervention strategies geared towards improving the functional longevity of intracortical devices may benefit using multi-modal approaches rather than a single approach, such as controlling the initial inflammatory response.",[],Journal of neural engineering,2018-09-28,"[{'lastname': 'Gaire', 'firstname': 'Janak', 'initials': 'J', 'affiliation': 'Department of Neuroscience, University of Florida, Gainesville, FL, United States of America.'}, {'lastname': 'Lee', 'firstname': 'Heui Chang', 'initials': 'HC', 'affiliation': None}, {'lastname': 'Hilborn', 'firstname': 'Nicholas', 'initials': 'N', 'affiliation': None}, {'lastname': 'Ward', 'firstname': 'Ray', 'initials': 'R', 'affiliation': None}, {'lastname': 'Regan', 'firstname': 'Mary', 'initials': 'M', 'affiliation': None}, {'lastname': 'Otto', 'firstname': 'Kevin J', 'initials': 'KJ', 'affiliation': None}]",,,,,10.1088/1741-2552/aae4b6,<Element 'PubmedArticle' at 0x7f05dd729a90>
293,"30256928
11057423
12089760
20042893
22581460
16815634
19428444
23211559
17261780
24681088
24440641
20001955
17895061
11680444
16702472
20577047
26891883
9388012
10683408
22495674
10732320
12372846
14708019
17916740
21343284
25762980
22305144
17785421
11074057
27324789
28489296
26122289
10537181
16306086
17024710
28457941
27552247
23443267
27221711
17218540
15207546
21241678
26463920
22782509
26303850
27006446
15764676
24485041
26286136
25668489
20526754
28945526
19265055
15271491
19563606
25883987
17592774
24685383
15539555
20479872
22975197
21763529
20304826
25682174
21108469
27843532
26955967
20940729
22572084
29373810
29106594",Selective Nonnuclear Estrogen Receptor Activation Decreases Stroke Severity and Promotes Functional Recovery in Female Mice.,"Estrogens provide neuroprotection in animal models of stroke, but uterotrophic effects and cancer risk limit translation. Classic estrogen receptors (ERs) serve as transcription factors, whereas nonnuclear ERs govern numerous cell processes and exert beneficial cardiometabolic effects without uterine or breast cancer growth in mice. Here, we determined how nonnuclear ER stimulation with pathway-preferential estrogen (PaPE)-1 affects stroke outcome in mice. Ovariectomized female mice received vehicle, estradiol (E2), or PaPE-1 before and after transient middle cerebral artery occlusion (tMCAo). Lesion severity was assessed with MRI, and poststroke motor function was evaluated through 2 weeks after tMCAo. Circulating, spleen, and brain leukocyte subpopulations were quantified 3 days after tMCAo by flow cytometry, and neurogenesis and angiogenesis were evaluated histologically 2 weeks after tMCAo. Compared with vehicle, E2 and PaPE-1 reduced infarct volumes at 3 days after tMCAo, though only PaPE-1 reduced leukocyte infiltration into the ischemic brain. Unlike E2, PaPE-1 had no uterotrophic effect. Both interventions had negligible effect on long-term poststroke neuronal or vascular plasticity. All mice displayed a decline in motor performance at 2 days after tMCAo, and vehicle-treated mice did not improve thereafter. In contrast, E2 and PaPE-1 treatment afforded functional recovery at 6 days after tMCAo and beyond. Thus, the selective activation of nonnuclear ER by PaPE-1 decreased stroke severity and improved functional recovery in mice without undesirable uterotrophic effects. The beneficial effects of PaPE-1 are also associated with attenuated neuroinflammation in the brain. PaPE-1 and similar molecules may warrant consideration as efficacious ER modulators providing neuroprotection without detrimental effects on the uterus or cancer risk.",[],Endocrinology,2018-09-27,"[{'lastname': 'Selvaraj', 'firstname': 'Uma Maheswari', 'initials': 'UM', 'affiliation': 'Department of Neurology and Neurotherapeutics, University of Texas Southwestern Medical Center, Dallas, Texas.'}, {'lastname': 'Zuurbier', 'firstname': 'Kielen R', 'initials': 'KR', 'affiliation': 'Department of Neurology and Neurotherapeutics, University of Texas Southwestern Medical Center, Dallas, Texas.'}, {'lastname': 'Whoolery', 'firstname': 'Cody W', 'initials': 'CW', 'affiliation': 'Department of Neurology and Neurotherapeutics, University of Texas Southwestern Medical Center, Dallas, Texas.'}, {'lastname': 'Plautz', 'firstname': 'Erik J', 'initials': 'EJ', 'affiliation': 'Department of Neurology and Neurotherapeutics, University of Texas Southwestern Medical Center, Dallas, Texas.'}, {'lastname': 'Chambliss', 'firstname': 'Ken L', 'initials': 'KL', 'affiliation': 'Center for Pulmonary and Vascular Biology, Department of Pediatrics, University of Texas Southwestern Medical Center, Dallas, Texas.'}, {'lastname': 'Kong', 'firstname': 'Xiangmei', 'initials': 'X', 'affiliation': 'Department of Neurology and Neurotherapeutics, University of Texas Southwestern Medical Center, Dallas, Texas.'}, {'lastname': 'Zhang', 'firstname': 'Shanrong', 'initials': 'S', 'affiliation': 'Advanced Imaging Research Center, University of Texas Southwestern Medical Center, Dallas, Texas.'}, {'lastname': 'Kim', 'firstname': 'Sung Hoon', 'initials': 'SH', 'affiliation': 'Department of Chemistry, University of Illinois at Urbana-Champaign, Urbana, Illinois.'}, {'lastname': 'Katzenellenbogen', 'firstname': 'Benita S', 'initials': 'BS', 'affiliation': 'Department of Molecular and Integrative Physiology, University of Illinois at Urbana-Champaign, Urbana, Illinois.'}, {'lastname': 'Katzenellenbogen', 'firstname': 'John A', 'initials': 'JA', 'affiliation': 'Department of Chemistry, University of Illinois at Urbana-Champaign, Urbana, Illinois.'}, {'lastname': 'Mineo', 'firstname': 'Chieko', 'initials': 'C', 'affiliation': 'Center for Pulmonary and Vascular Biology, Department of Pediatrics, University of Texas Southwestern Medical Center, Dallas, Texas.'}, {'lastname': 'Shaul', 'firstname': 'Philip W', 'initials': 'PW', 'affiliation': 'Center for Pulmonary and Vascular Biology, Department of Pediatrics, University of Texas Southwestern Medical Center, Dallas, Texas.'}, {'lastname': 'Stowe', 'firstname': 'Ann M', 'initials': 'AM', 'affiliation': 'Department of Neurology and Neurotherapeutics, University of Texas Southwestern Medical Center, Dallas, Texas.\nDepartment of Neurology, University of Kentucky, Lexington, Kentucky.'}]",,,,,10.1210/en.2018-00600,<Element 'PubmedArticle' at 0x7f05dd737860>
294,30221582,Activating Adiponectin Signaling with Exogenous AdipoRon Reduces Myelin Lipid Accumulation and Suppresses Macrophage Recruitment after Spinal Cord Injury.,"Myelin-laden macrophages (mye-MΦ), resulting primarily from internalization of myelin debris by infiltrating bone marrow-derived macrophages in spinal cord injury (SCI), trigger inflammatory responses that largely contribute to secondary injury. Adiponectin, which is secreted from adipose tissue, is an important hormone that modulates macrophage inflammation. In the present study, we examined the role of adiponectin on macrophage-mediated neuroinflammation after SCI. We found that in vitro activation of adiponectin receptors (AdipoRs) by their agonist AdipoRon suppressed myelin lipid accumulation in mye-MΦ through APPL1/PPARγ/LXRα/ABCA1-mediated lipid efflux, subsequently inhibiting inflammation and restoring normal function to mye-MΦ. In vivo data further confirmed that intravenous administration of AdipoRon after SCI dampened recruitment of macrophages and reduced myelin lipid accumulation. Accordingly, AdipoRon treatment ameliorated post-SCI tissue damage and astrogliosis, resulting in improved motor function. Although there was no significant pathological exacerbation in adiponectin-null mice subjected to SCI, our work reveals a functional link between adiponectin and hematogenous macrophages in the context of SCI, suggesting that activation of adiponectin signaling is a promising therapeutic approach to mitigate mye-MΦ-mediated neuroinflammation in neurological disorders involving demyelination.","['adiponectin', 'chemotaxis', 'myelin lipid accumulation', 'myelin-laden macrophage', 'neuroinflammation', 'spinal cord injury']",Journal of neurotrauma,2018-09-18,"[{'lastname': 'Zhou', 'firstname': 'Qishuang', 'initials': 'Q', 'affiliation': ""1 Institute of Inflammation and Diseases, First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.\n4 Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, China.""}, {'lastname': 'Xiang', 'firstname': 'Hongkai', 'initials': 'H', 'affiliation': ""1 Institute of Inflammation and Diseases, First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.\n4 Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, China.""}, {'lastname': 'Li', 'firstname': 'Ang', 'initials': 'A', 'affiliation': '2 Guangdong-Hong Kong-Macau Institute of CNS Regeneration, Joint International Research Laboratory of CNS Regeneration Ministry of Education, Jinan University, Guangzhou, China.\n5 Academician Workstation for Spinal Cord Injury, Kunming Tongren Hospital, Kunming, China.'}, {'lastname': 'Lin', 'firstname': 'Wu', 'initials': 'W', 'affiliation': '1 Institute of Inflammation and Diseases, First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.'}, {'lastname': 'Huang', 'firstname': 'Zhaoshui', 'initials': 'Z', 'affiliation': '1 Institute of Inflammation and Diseases, First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.'}, {'lastname': 'Guo', 'firstname': 'Junxiu', 'initials': 'J', 'affiliation': '2 Guangdong-Hong Kong-Macau Institute of CNS Regeneration, Joint International Research Laboratory of CNS Regeneration Ministry of Education, Jinan University, Guangzhou, China.'}, {'lastname': 'Wang', 'firstname': 'Pingjie', 'initials': 'P', 'affiliation': '2 Guangdong-Hong Kong-Macau Institute of CNS Regeneration, Joint International Research Laboratory of CNS Regeneration Ministry of Education, Jinan University, Guangzhou, China.'}, {'lastname': 'Chi', 'firstname': 'Yijie', 'initials': 'Y', 'affiliation': '1 Institute of Inflammation and Diseases, First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.'}, {'lastname': 'Xiang', 'firstname': 'Ke', 'initials': 'K', 'affiliation': '2 Guangdong-Hong Kong-Macau Institute of CNS Regeneration, Joint International Research Laboratory of CNS Regeneration Ministry of Education, Jinan University, Guangzhou, China.'}, {'lastname': 'Xu', 'firstname': 'Yunsheng', 'initials': 'Y', 'affiliation': '1 Institute of Inflammation and Diseases, First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.'}, {'lastname': 'Zhou', 'firstname': 'Libing', 'initials': 'L', 'affiliation': '2 Guangdong-Hong Kong-Macau Institute of CNS Regeneration, Joint International Research Laboratory of CNS Regeneration Ministry of Education, Jinan University, Guangzhou, China.'}, {'lastname': 'So', 'firstname': 'Kwok-Fai', 'initials': 'KF', 'affiliation': '2 Guangdong-Hong Kong-Macau Institute of CNS Regeneration, Joint International Research Laboratory of CNS Regeneration Ministry of Education, Jinan University, Guangzhou, China.\n5 Academician Workstation for Spinal Cord Injury, Kunming Tongren Hospital, Kunming, China.'}, {'lastname': 'Chen', 'firstname': 'Xiaoming', 'initials': 'X', 'affiliation': '1 Institute of Inflammation and Diseases, First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.'}, {'lastname': 'Sun', 'firstname': 'Xin', 'initials': 'X', 'affiliation': '2 Guangdong-Hong Kong-Macau Institute of CNS Regeneration, Joint International Research Laboratory of CNS Regeneration Ministry of Education, Jinan University, Guangzhou, China.'}, {'lastname': 'Ren', 'firstname': 'Yi', 'initials': 'Y', 'affiliation': '1 Institute of Inflammation and Diseases, First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.\n2 Guangdong-Hong Kong-Macau Institute of CNS Regeneration, Joint International Research Laboratory of CNS Regeneration Ministry of Education, Jinan University, Guangzhou, China.\n3 Department of Biomedical Sciences, Florida State University College of Medicine, Tallahassee, Florida.'}]",,,,,10.1089/neu.2018.5783,<Element 'PubmedArticle' at 0x7f05dd7608b0>
295,"30208760
23007702
22260389
23840238
25008549
23354834
20411441
26254059
25773147
28086065
29025968
28921554
21723251
18006683
15077152
20959619
17362839
21979913
20811354
21884931
28334843
23191986
25888640
25899084
20548331
21801009
15798367
11038174
11060023
15355958
16286508
26799652
22342941
22441107
28928406
23516279
29246612
27704281
21460614
24009854
27281615
23372817
24036151
24401604
26165754
25485521
27803889
22078875
22449030
20104028
22248718
24084739
26505221
25417929
26120731
27624289
17487163",Mir223 restrains autophagy and promotes CNS inflammation by targeting ATG16L1.,"Microglia are innate immune cells in the central nervous system (CNS), that supplies neurons with key factors for executing autophagosomal/lysosomal functions. Macroautophagy/autophagy is a cellular catabolic process that maintains cell balance in response to stress-related stimulation. Abnormal autophagy occurs with many pathologies, such as cancer, and autoimmune and neurodegenerative diseases. Hence, clarification of the mechanisms of autophagy regulation is of utmost importance. Recently, researchers presented microRNAs (miRNAs) as novel and potent modulators of autophagic activity. Here, we found that Mir223 deficiency significantly ameliorated CNS inflammation, demyelination and the clinical symptoms of experimental autoimmune encephalomyelitis (EAE) and increased resting microglia and autophagy in brain microglial cells. In contrast, the autophagy inhibitor 3-methylademine (3-MA) aggravated the clinical symptoms of EAE in wild-type (WT) and Mir223-deficienct mice. Furthermore, it was confirmed that Mir223 deficiency in mice increased the protein expression of ATG16L1 (autophagy related 16-like 1 [S. cerevisiae]) and LC3-II in bone marrow-derived macrophage cells compared with cells from WT mice. Indeed, the cellular level of Atg16l1 was decreased in BV2 cells upon Mir223 overexpression and increased following the introduction of antagomirs. We also showed that the 3' UTR of Atg16l1 contained functional Mir223-responsive sequences and that overexpression of ATG16L1 returned autophagy to normal levels even in the presence of Mir223 mimics. Collectively, these data indicate that Mir223 is a novel and important regulator of autophagy and that Atg16l1 is a Mir223 target in this process, which may have implications for improving our understanding of the neuroinflammatory process of EAE. Abbreviations: 3-MA: 3-methylademine; ACTB/β-actin: actin, beta; ATG: autophagy related; ATG16L1: autophagy related 16-like 1 (S. cerevisiae); BECN1: beclin 1, autophagy related; CNR2: cannabinoid receptor 2 (macrophage); CNS: central nervous system; CQ: chloroquine; EAE: experimental autoimmune encephalomyelitis; FOXO3: forkhead box O3; GAPDH: glyceraldehyde-3-phosphate dehydrogenase; H&E: hematoxylin and eosin; ITGAM: integrin alpha M; LPS: lipoplysaccharide; MAP1LC3/LC3: microtubule-associated protein 1 light chain 3; miRNAs: microRNAs; MS: multiple sclerosis; PPARG: peroxisome proliferator activated receptor gamma; PTPRC: protein tyrosine phosphatase, receptor type, C; RA: rheumatoid arthritis; SQSTM1: sequestosome 1; TB: tuberculosis; TIMM23: translocase of inner mitochondrial membrane 23; TLR: toll-like receptor.","['ATG16L1', 'CNS inflammation', 'autophagy', 'experimental autoimmune encephalomyelitis', 'microglia']",Autophagy,2018-09-14,"[{'lastname': 'Li', 'firstname': 'Yan', 'initials': 'Y', 'affiliation': 'a Laboratory of Immunology and Inflammation, Department of Immunology, Key Laboratory of Immune Microenvironment and Diseases of Educational Ministry of China, Tianjin Key Laboratory of Cellular and Molecular Immunology, Key Laboratory of Hormones and Development (Ministry of Health) , Tianjin Medical University , Tianjin , China.'}, {'lastname': 'Zhou', 'firstname': 'Dongmei', 'initials': 'D', 'affiliation': 'a Laboratory of Immunology and Inflammation, Department of Immunology, Key Laboratory of Immune Microenvironment and Diseases of Educational Ministry of China, Tianjin Key Laboratory of Cellular and Molecular Immunology, Key Laboratory of Hormones and Development (Ministry of Health) , Tianjin Medical University , Tianjin , China.'}, {'lastname': 'Ren', 'firstname': 'Yinghui', 'initials': 'Y', 'affiliation': 'b Tianjin Key Laboratory of Lung Cancer Metastasis and Tumor Microenvironment, Tianjin Lung Cancer Institute , Tianjin Medical University General Hospital , Tianjin , China.'}, {'lastname': 'Zhang', 'firstname': 'Zimu', 'initials': 'Z', 'affiliation': 'a Laboratory of Immunology and Inflammation, Department of Immunology, Key Laboratory of Immune Microenvironment and Diseases of Educational Ministry of China, Tianjin Key Laboratory of Cellular and Molecular Immunology, Key Laboratory of Hormones and Development (Ministry of Health) , Tianjin Medical University , Tianjin , China.'}, {'lastname': 'Guo', 'firstname': 'Xiangdong', 'initials': 'X', 'affiliation': 'a Laboratory of Immunology and Inflammation, Department of Immunology, Key Laboratory of Immune Microenvironment and Diseases of Educational Ministry of China, Tianjin Key Laboratory of Cellular and Molecular Immunology, Key Laboratory of Hormones and Development (Ministry of Health) , Tianjin Medical University , Tianjin , China.'}, {'lastname': 'Ma', 'firstname': 'MingKun', 'initials': 'M', 'affiliation': 'a Laboratory of Immunology and Inflammation, Department of Immunology, Key Laboratory of Immune Microenvironment and Diseases of Educational Ministry of China, Tianjin Key Laboratory of Cellular and Molecular Immunology, Key Laboratory of Hormones and Development (Ministry of Health) , Tianjin Medical University , Tianjin , China.\nc Second Affiliated Hospital of Tianjin University of Traditional Chinese Medicine , Tianjin , China.'}, {'lastname': 'Xue', 'firstname': 'Zhenyi', 'initials': 'Z', 'affiliation': 'a Laboratory of Immunology and Inflammation, Department of Immunology, Key Laboratory of Immune Microenvironment and Diseases of Educational Ministry of China, Tianjin Key Laboratory of Cellular and Molecular Immunology, Key Laboratory of Hormones and Development (Ministry of Health) , Tianjin Medical University , Tianjin , China.'}, {'lastname': 'Lv', 'firstname': 'Jienv', 'initials': 'J', 'affiliation': 'a Laboratory of Immunology and Inflammation, Department of Immunology, Key Laboratory of Immune Microenvironment and Diseases of Educational Ministry of China, Tianjin Key Laboratory of Cellular and Molecular Immunology, Key Laboratory of Hormones and Development (Ministry of Health) , Tianjin Medical University , Tianjin , China.\nd Hexi Women & Children Healthcare and Family Planning Service Center , Tianjin , China.'}, {'lastname': 'Liu', 'firstname': 'Hongkun', 'initials': 'H', 'affiliation': 'a Laboratory of Immunology and Inflammation, Department of Immunology, Key Laboratory of Immune Microenvironment and Diseases of Educational Ministry of China, Tianjin Key Laboratory of Cellular and Molecular Immunology, Key Laboratory of Hormones and Development (Ministry of Health) , Tianjin Medical University , Tianjin , China.'}, {'lastname': 'Xi', 'firstname': 'Qing', 'initials': 'Q', 'affiliation': 'a Laboratory of Immunology and Inflammation, Department of Immunology, Key Laboratory of Immune Microenvironment and Diseases of Educational Ministry of China, Tianjin Key Laboratory of Cellular and Molecular Immunology, Key Laboratory of Hormones and Development (Ministry of Health) , Tianjin Medical University , Tianjin , China.'}, {'lastname': 'Jia', 'firstname': 'Long', 'initials': 'L', 'affiliation': 'a Laboratory of Immunology and Inflammation, Department of Immunology, Key Laboratory of Immune Microenvironment and Diseases of Educational Ministry of China, Tianjin Key Laboratory of Cellular and Molecular Immunology, Key Laboratory of Hormones and Development (Ministry of Health) , Tianjin Medical University , Tianjin , China.'}, {'lastname': 'Zhang', 'firstname': 'Lijuan', 'initials': 'L', 'affiliation': 'a Laboratory of Immunology and Inflammation, Department of Immunology, Key Laboratory of Immune Microenvironment and Diseases of Educational Ministry of China, Tianjin Key Laboratory of Cellular and Molecular Immunology, Key Laboratory of Hormones and Development (Ministry of Health) , Tianjin Medical University , Tianjin , China.'}, {'lastname': 'Liu', 'firstname': 'Ying', 'initials': 'Y', 'affiliation': 'a Laboratory of Immunology and Inflammation, Department of Immunology, Key Laboratory of Immune Microenvironment and Diseases of Educational Ministry of China, Tianjin Key Laboratory of Cellular and Molecular Immunology, Key Laboratory of Hormones and Development (Ministry of Health) , Tianjin Medical University , Tianjin , China.'}, {'lastname': 'Zhang', 'firstname': 'Qi', 'initials': 'Q', 'affiliation': 'e Institute of Integrative Medicines for Acute Abdominal Diseases , Nankai Hospital , Tianjin , China.'}, {'lastname': 'Yan', 'firstname': 'Jun', 'initials': 'J', 'affiliation': 'f Tianjin Institute of Animal husbandry and veterinary , Tianjin , China.'}, {'lastname': 'Da', 'firstname': 'Yurong', 'initials': 'Y', 'affiliation': 'a Laboratory of Immunology and Inflammation, Department of Immunology, Key Laboratory of Immune Microenvironment and Diseases of Educational Ministry of China, Tianjin Key Laboratory of Cellular and Molecular Immunology, Key Laboratory of Hormones and Development (Ministry of Health) , Tianjin Medical University , Tianjin , China.'}, {'lastname': 'Gao', 'firstname': 'Fei', 'initials': 'F', 'affiliation': 'g State Key Laboratory of Reproductive Biology, Institute of Zoology , Chinese Academy of Sciences , Beijing , China.'}, {'lastname': 'Yue', 'firstname': 'Jianbo', 'initials': 'J', 'affiliation': 'h Department of Biomedical Sciences , City University of Hong Kong , Hong Kong , China.'}, {'lastname': 'Yao', 'firstname': 'Zhi', 'initials': 'Z', 'affiliation': 'a Laboratory of Immunology and Inflammation, Department of Immunology, Key Laboratory of Immune Microenvironment and Diseases of Educational Ministry of China, Tianjin Key Laboratory of Cellular and Molecular Immunology, Key Laboratory of Hormones and Development (Ministry of Health) , Tianjin Medical University , Tianjin , China.'}, {'lastname': 'Zhang', 'firstname': 'Rongxin', 'initials': 'R', 'affiliation': 'a Laboratory of Immunology and Inflammation, Department of Immunology, Key Laboratory of Immune Microenvironment and Diseases of Educational Ministry of China, Tianjin Key Laboratory of Cellular and Molecular Immunology, Key Laboratory of Hormones and Development (Ministry of Health) , Tianjin Medical University , Tianjin , China.\ni Guangdong Province Key Laboratory for Biotechnology Drug Candidates, School of Life Sciences and Biopharmaceutics , Guangdong Pharmaceutical University , Guangzhou , China.'}]",,,,,"10.1080/15548627.2018.1522467
10.1002/eji.201646375",<Element 'PubmedArticle' at 0x7f05dd6efd10>
296,30193877,Palmitoylethanolamide counteracts autistic-like behaviours in BTBR T+tf/J mice: Contribution of central and peripheral mechanisms.,"Autism spectrum disorders (ASD) are a group of heterogeneous neurodevelopmental conditions characterized by impaired social interaction, and repetitive stereotyped behaviours. Interestingly, functional and inflammatory gastrointestinal diseases are often reported as a comorbidity in ASDs, indicating gut-brain axis as a novel emerging approach. Recently, a central role for peroxisome-proliferator activated receptor (PPAR)-α has been addressed in neurological functions, associated with the behaviour. Among endogenous lipids, palmitoylethanolamide (PEA), a PPAR-α agonist, has been extensively studied for its anti-inflammatory effects both at central and peripheral level. Based on this background, the aim of this study was to investigate the pharmacological effects of PEA on autistic-like behaviour of BTBR T+tf/J mice and to shed light on the contributing mechanisms. Our results showed that PEA reverted the altered behavioural phenotype of BTBR mice, and this effect was contingent to PPAR-α activation. Moreover, PEA was able to restore hippocampal BDNF signalling pathway, and improve mitochondrial dysfunction, both pathological aspects, known to be consistently associated with ASDs. Furthermore, PEA reduced the overall inflammatory state of BTBR mice, reducing the expression of pro-inflammatory cytokines at hippocampal, serum, and colonic level. The analysis of gut permeability and the expression of colonic tight junctions showed a reduction of leaky gut in PEA-treated BTBR mice. This finding together with PEA effect on gut microbiota composition suggests an involvement of microbiota-gut-brain axis. In conclusion, our results demonstrated a therapeutic potential of PEA in limiting ASD symptoms, through its pleiotropic mechanism of action, supporting neuroprotection, anti-inflammatory effects, and the modulation of gut-brain axis.","['Autism spectrum disorder (ASD)', 'BDNF signalling pathway', 'Behaviour', 'Cytokines', 'Microbiota-gut brain axis', 'Neuroinflammation', 'Peroxisome-proliferator activated receptor (PPAR)-α']","Brain, behavior, and immunity",2018-09-09,"[{'lastname': 'Cristiano', 'firstname': 'Claudia', 'initials': 'C', 'affiliation': 'Department of Pharmacy, University of Naples ""Federico II"", 80131 Naples, Italy.'}, {'lastname': 'Pirozzi', 'firstname': 'Claudio', 'initials': 'C', 'affiliation': 'Department of Pharmacy, University of Naples ""Federico II"", 80131 Naples, Italy.'}, {'lastname': 'Coretti', 'firstname': 'Lorena', 'initials': 'L', 'affiliation': 'Task Force on Microbiome Studies, University of Naples ""Federico II"", 80131 Naples, Italy; Institute for Experimental Endocrinology and Oncology, IEOS, Consiglio Nazionale delle Ricerche CNR, Via S. Pansini, 5, 80131, Naples, Italy.'}, {'lastname': 'Cavaliere', 'firstname': 'Gina', 'initials': 'G', 'affiliation': 'Department of Biology, University of Naples ""Federico II"", 80131 Naples, Italy.'}, {'lastname': 'Lama', 'firstname': 'Adriano', 'initials': 'A', 'affiliation': 'Department of Pharmacy, University of Naples ""Federico II"", 80131 Naples, Italy; Task Force on Microbiome Studies, University of Naples ""Federico II"", 80131 Naples, Italy.'}, {'lastname': 'Russo', 'firstname': 'Roberto', 'initials': 'R', 'affiliation': 'Department of Pharmacy, University of Naples ""Federico II"", 80131 Naples, Italy.'}, {'lastname': 'Lembo', 'firstname': 'Francesca', 'initials': 'F', 'affiliation': 'Department of Pharmacy, University of Naples ""Federico II"", 80131 Naples, Italy; Task Force on Microbiome Studies, University of Naples ""Federico II"", 80131 Naples, Italy.'}, {'lastname': 'Mollica', 'firstname': 'Maria Pina', 'initials': 'MP', 'affiliation': 'Department of Biology, University of Naples ""Federico II"", 80131 Naples, Italy.'}, {'lastname': 'Meli', 'firstname': 'Rosaria', 'initials': 'R', 'affiliation': 'Department of Pharmacy, University of Naples ""Federico II"", 80131 Naples, Italy.'}, {'lastname': 'Calignano', 'firstname': 'Antonio', 'initials': 'A', 'affiliation': 'Department of Pharmacy, University of Naples ""Federico II"", 80131 Naples, Italy.'}, {'lastname': 'Mattace Raso', 'firstname': 'Giuseppina', 'initials': 'G', 'affiliation': 'Department of Pharmacy, University of Naples ""Federico II"", 80131 Naples, Italy; Task Force on Microbiome Studies, University of Naples ""Federico II"", 80131 Naples, Italy. Electronic address: mattace@unina.it.'}]",,,,Copyright © 2018 The Author(s). Published by Elsevier Inc. All rights reserved.,10.1016/j.bbi.2018.09.003,<Element 'PubmedArticle' at 0x7f05dd71a6d0>
297,"30134818
2957436
25702943
27114901
26000145
22571715
21619669
21777306
27594784
23890115
11389472
11698225
23514202
22961981
7978722
20861159
15550678
26032326
24084011
27227024
3904772
20163522
22451665
26381393
27098723
26029488
23576883
10229704
2166084
12787756
12672827
18801465
16297163
27099524
27854251
21071612
17406516
12093668
27727448
27245705
18269338
17368864
19043430
15824111
24756716
27161226
12838338
28247021
23487023
19061922
23220009
27123773
28661067
1999813
16731230
25596273
20828570
23190005
23511953
26517445
18425107
16408004
15576364
25998963
21555074
18978782
17606539
28549569",Loss of Transient Receptor Potential Melastatin 3 ion channel function in natural killer cells from Chronic Fatigue Syndrome/Myalgic Encephalomyelitis patients.,"Chronic Fatigue Syndrome (CFS)/ Myalgic Encephalomyelitis (ME) is a debilitating disorder that is accompanied by reduced cytotoxic activity in natural killer (NK) cells. NK cells are an essential innate immune cell, responsible for recognising and inducing apoptosis of tumour and virus infected cells. Calcium is an essential component in mediating this cellular function. Transient Receptor Potential Melastatin 3 (TRPM3) cation channels have an important regulatory role in mediating calcium influx to help maintain cellular homeostasis. Several single nucleotide polymorphisms have been reported in TRPM3 genes from isolated peripheral blood mononuclear cells, NK and B cells in patients with CFS/ME and have been proposed to correlate with illness presentation. Moreover, a significant reduction in both TRPM3 surface expression and intracellular calcium mobilisation in NK cells has been found in CFS/ME patients compared with healthy controls. Despite the functional importance of TRPM3, little is known about the ion channel function in NK cells and the epiphenomenon of CFS/ME. The objective of the present study was to characterise the TRPM3 ion channel function in NK cells from CFS/ME patients in comparison with healthy controls using whole cell patch-clamp techniques.
NK cells were isolated from 12 age- and sex-matched healthy controls and CFS patients. Whole cell electrophysiology recording has been used to assess TRPM3 ion channel activity after modulation with pregnenolone sulfate and ononetin.
We report a significant reduction in amplitude of TRPM3 current after pregnenolone sulfate stimulation in isolated NK cells from CFS/ME patients compared with healthy controls. In addition, we found pregnenolone sulfate-evoked ionic currents through TRPM3 channels were significantly modulated by ononetin in isolated NK cells from healthy controls compared with CFS/ME patients.
TRPM3 activity is impaired in CFS/ME patients suggesting changes in intracellular Ca","['Calcium', 'Chronic fatigue syndrome/Myalgic encephalomyelitis', 'Flow cytometry', 'Natural killer cells', 'Patch-clamp', 'Transient receptor potential Melastatin 3']","Molecular medicine (Cambridge, Mass.)",2018-08-24,"[{'lastname': 'Cabanas', 'firstname': 'Hélène', 'initials': 'H', 'affiliation': 'School of Medical Science, Griffith University, Gold Coast, QLD, Australia. h.cabanas@griffith.edu.au.\nThe National Centre for Neuroimmunology and Emerging Diseases, Menzies Health Institute Queensland, Griffith University, Gold Coast, QLD, Australia. h.cabanas@griffith.edu.au.'}, {'lastname': 'Muraki', 'firstname': 'Katsuhiko', 'initials': 'K', 'affiliation': 'Laboratory of Cellular Pharmacology, School of Pharmacy, Aichi-Gakuin University, Chikusa, Nagoya, Japan.'}, {'lastname': 'Eaton', 'firstname': 'Natalie', 'initials': 'N', 'affiliation': 'School of Medical Science, Griffith University, Gold Coast, QLD, Australia.\nThe National Centre for Neuroimmunology and Emerging Diseases, Menzies Health Institute Queensland, Griffith University, Gold Coast, QLD, Australia.'}, {'lastname': 'Balinas', 'firstname': 'Cassandra', 'initials': 'C', 'affiliation': 'School of Medical Science, Griffith University, Gold Coast, QLD, Australia.\nThe National Centre for Neuroimmunology and Emerging Diseases, Menzies Health Institute Queensland, Griffith University, Gold Coast, QLD, Australia.'}, {'lastname': 'Staines', 'firstname': 'Donald', 'initials': 'D', 'affiliation': 'School of Medical Science, Griffith University, Gold Coast, QLD, Australia.\nThe National Centre for Neuroimmunology and Emerging Diseases, Menzies Health Institute Queensland, Griffith University, Gold Coast, QLD, Australia.'}, {'lastname': 'Marshall-Gradisnik', 'firstname': 'Sonya', 'initials': 'S', 'affiliation': 'School of Medical Science, Griffith University, Gold Coast, QLD, Australia.\nThe National Centre for Neuroimmunology and Emerging Diseases, Menzies Health Institute Queensland, Griffith University, Gold Coast, QLD, Australia.'}]",,,"We report a significant reduction in amplitude of TRPM3 current after pregnenolone sulfate stimulation in isolated NK cells from CFS/ME patients compared with healthy controls. In addition, we found pregnenolone sulfate-evoked ionic currents through TRPM3 channels were significantly modulated by ononetin in isolated NK cells from healthy controls compared with CFS/ME patients.",,"10.1186/s10020-018-0046-1
10.1002/nbm.3261
10.1016/j.nicl.2016.03.017
10.1007/s13317-013-0051-x
10.1186/1479-5876-10-88
10.1186/1479-5876-9-81
10.1111/j.1365-2796.2011.02428.x
10.1016/B978-0-12-407870-3.00007-X
10.1038/35077544
10.1016/S1471-4906(01)02060-9
10.1186/1479-5876-11-68
10.1074/jbc.M112.396663
10.7326/0003-4819-121-12-199412150-00009
10.1124/mol.104.006734
10.3390/molecules181012012
10.4161/23328940.2014.988524
10.1146/annurev.iy.03.040185.000335
10.1111/j.1471-4159.2010.06644.x
10.1074/jbc.M112.350686
10.1111/sji.12388
10.1080/21642850.2015.1014489
10.2147/CLEP.S39876
10.1289/ehp.99107s125
10.1016/S0952-7915(03)00039-6
10.1074/jbc.M211232200
10.1016/j.autrev.2008.08.003
10.2147/TACG.S99405
10.1182/blood-2010-09-303057
10.1038/nprot.2006.340
10.1111/cei.12882
10.1186/s40659-016-0087-2
10.1517/14728222.12.3.281
10.1016/j.bbadis.2007.02.002
10.1038/ncb1208-1383
10.1074/jbc.M503092200
10.1007/978-3-642-54215-2_17
10.1007/978-3-319-26974-0_5
10.1038/nrm1150
10.1007/s00429-017-1380-8
10.1182/blood-2012-04-425397
10.1016/j.bbamcr.2008.11.001
10.1016/j.bbamcr.2012.11.016
10.1002/jmri.25283
10.1177/014107689108400224
10.1016/j.jpsychores.2006.03.001
10.3324/haematol.2014.116053
10.1016/j.febslet.2010.08.047
10.1111/bph.12076
10.1530/JME-12-0237
10.1080/19336950.2015.1113719
10.1038/ni1582
10.1038/nchembio0705-85
10.1074/jbc.M413303200
10.1038/nri3839
10.1016/j.neuron.2011.02.051
10.1038/ncb1801
10.1542/peds.2006-2759
10.1016/j.ceca.2017.05.002",<Element 'PubmedArticle' at 0x7f05dd6a9b30>
298,30098312,Pharmacological blockade of fatty acid amide hydrolase (FAAH) by URB597 improves memory and changes the phenotype of hippocampal microglia despite ethanol exposure.,"Changes in endogenous cannabinoid homeostasis are associated with both ethanol-related neuroinflammation and memory decline. Extensive research is still required to unveil the role of endocannabinoid signaling activation on hippocampal microglial cells after ethanol exposure. Either microglial morphology, phenotype and recruitment may become notably altered after chronic alcohol-related neurodegeneration. Here, we evaluated the pharmacological effects of fatty-acid amide-hydrolase (FAAH) inhibitor URB597 (0.3 mg/kg), oleoylethanolamide (OEA, 10 mg/kg), arachidonoylethanolamide (AEA, 10 mg/kg), the CB1 receptor agonist ACEA (3 mg/kg) and the CB2 receptor agonist JWH133 (0.2 mg/kg) administered for 5 days in a rat model of subchronic (2 weeks) ethanol diet (11% v/v) exposure. URB597 turned to be the most effective treatment. URB597 increased microglial (IBA-1+) cell population, and changed morphometric features (cell area and perimeter, roughness, fractal dimension, lacunarity) associated with activated microglia in the hippocampus of ethanol-exposed rats. Regarding innate immune activity, URB597 specifically increased mRNA levels of toll-like receptor 4 (TLR4), glial fibrillary acidic protein (Gfap) and the chemokine stromal cell-derived factor 1 (SDF-1α/CXCL12), and elevated the cell population expressing the chemokine receptors CX3CR1, CCR2 and CCR4 in the ethanol-exposed rat hippocampus. Contrary to ethanol effect, URB597 reduced mRNA levels of Iba-1, Tnfα, IL-6 and the monocyte chemoattractant protein-1 (MCP-1/CCL2), as well as cell population expressing iNOS. URB597 effects on hippocampal immune system were accompanied by changes in short and long-term visual recognition memory. These results suggest that FAAH inhibition may modulates hippocampal microglial recruitment and activation that can be associated with improved hippocampal-dependent memory despite ethanol exposure.","['Alcohol', 'FAAH', 'Hippocampus', 'Memory, microglia']",Biochemical pharmacology,2018-08-12,"[{'lastname': 'Rivera', 'firstname': 'Patricia', 'initials': 'P', 'affiliation': 'UGC Salud Mental, Instituto de Investigación Biomédica de Málaga (IBIMA), Universidad de Málaga, Hospital Universitario Regional de Málaga, Málaga, Spain; Department of Endocrinology, Fundación Investigación Biomédica del Hospital Infantil Universitario Niño Jesús, Madrid, Spain.'}, {'lastname': 'Fernández-Arjona', 'firstname': 'María Del Mar', 'initials': 'MDM', 'affiliation': 'Departamento de Biología Celular, Genética y Fisiología, IBIMA, Universidad de Málaga, Málaga, Spain.'}, {'lastname': 'Silva-Peña', 'firstname': 'Daniel', 'initials': 'D', 'affiliation': 'UGC Salud Mental, Instituto de Investigación Biomédica de Málaga (IBIMA), Universidad de Málaga, Hospital Universitario Regional de Málaga, Málaga, Spain.'}, {'lastname': 'Blanco', 'firstname': 'Eduardo', 'initials': 'E', 'affiliation': 'Institute of Biomedical Research of Lleida (IRB Lleida), Universitat de Lleida, Lleida, Spain.'}, {'lastname': 'Vargas', 'firstname': 'Antonio', 'initials': 'A', 'affiliation': 'UGC Salud Mental, Instituto de Investigación Biomédica de Málaga (IBIMA), Universidad de Málaga, Hospital Universitario Regional de Málaga, Málaga, Spain.'}, {'lastname': 'López-Ávalos', 'firstname': 'María Dolores', 'initials': 'MD', 'affiliation': 'Departamento de Biología Celular, Genética y Fisiología, IBIMA, Universidad de Málaga, Málaga, Spain.'}, {'lastname': 'Grondona', 'firstname': 'Jesús M', 'initials': 'JM', 'affiliation': 'Departamento de Biología Celular, Genética y Fisiología, IBIMA, Universidad de Málaga, Málaga, Spain.'}, {'lastname': 'Serrano', 'firstname': 'Antonia', 'initials': 'A', 'affiliation': 'UGC Salud Mental, Instituto de Investigación Biomédica de Málaga (IBIMA), Universidad de Málaga, Hospital Universitario Regional de Málaga, Málaga, Spain.'}, {'lastname': 'Pavón', 'firstname': 'Francisco Javier', 'initials': 'FJ', 'affiliation': 'UGC Salud Mental, Instituto de Investigación Biomédica de Málaga (IBIMA), Universidad de Málaga, Hospital Universitario Regional de Málaga, Málaga, Spain.'}, {'lastname': 'Rodríguez de Fonseca', 'firstname': 'Fernando', 'initials': 'F', 'affiliation': 'UGC Salud Mental, Instituto de Investigación Biomédica de Málaga (IBIMA), Universidad de Málaga, Hospital Universitario Regional de Málaga, Málaga, Spain. Electronic address: fernando.rodriguez@ibima.eu.'}, {'lastname': 'Suárez', 'firstname': 'Juan', 'initials': 'J', 'affiliation': 'UGC Salud Mental, Instituto de Investigación Biomédica de Málaga (IBIMA), Universidad de Málaga, Hospital Universitario Regional de Málaga, Málaga, Spain. Electronic address: juan.suarez@ibima.eu.'}]",,,,Copyright © 2018 Elsevier Inc. All rights reserved.,10.1016/j.bcp.2018.08.005,<Element 'PubmedArticle' at 0x7f05dd6d92c0>
299,30093243,Autoimmune Encephalopathy Beyond Anti-NMDAR Encephalitis: The Case of an Adolescent Male with AntiAcetylcholine Receptor Ganglionic Neuronal Antibody Encephalitis.,,[],Psychosomatics,2018-08-11,"[{'lastname': 'Osuagwu', 'firstname': 'Ferdnand C', 'initials': 'FC', 'affiliation': 'Division of Child and Adolescent Psychiatry, Department of Psychiatry, University of Michigan Medical School, MI. Electronic address: oferdnan@med.umich.edu.'}, {'lastname': 'Mohiuddin', 'firstname': 'Sarah S', 'initials': 'SS', 'affiliation': 'Division of Child and Adolescent Psychiatry, Department of Psychiatry, University of Michigan Medical School, MI.'}, {'lastname': 'Malas', 'firstname': 'Nasuh', 'initials': 'N', 'affiliation': 'Division of Child and Adolescent Psychiatry, Department of Psychiatry, University of Michigan Medical School, MI; Department of Pediatrics and Communicable Diseases, University of Michigan Medical School, MI.'}]",,,,,10.1016/j.psym.2018.07.007,<Element 'PubmedArticle' at 0x7f05dd66dbd0>
300,"30084008
16580076
4065042
25452021
27530684
9053779
25863445
19565659
21749911
28789972
18601693
9442349
29605635
7083185
25423896
9169111
27861893
17229096
29237239
17142999
16579833
27573712
19815003
15582747
20116395
22699893
15211466
22365983
22085911
11264718
19589866
28324066
19718764
21622487
29047208
28093793
25038582
17206614
18436308
16566897
21767382
9370199
11997208
18331884
28942480
14724248
24612124
28259043
26661058
9314579
29771302
26321384
21115103
27801959
24265837
11668648
27178577
28902684
28202255
27683901
28758205
15555924
19838799
24151456
20798479
23873366
16191621
29078716
20842717
15896953
2357545
11351342
19185610
21208470
25105782
17669643
15101089
24508640
2009554
19710328
24105482
21143665
21068160
22510730
9578823
16426763
3332938
29381778
28649695
15818556
27553191
17018237
23180279
28583855
19555289
28314822
25683735
24939838
26231585
14694190
14611865
12963100
27911748
5138326
26456904
20045216
18820691
29284502
21320576
5009066
28414121
16736049
29555375
20097718
24423637
11698605
14645116
10077336
24508637
10622413
28032117
29031551
18402929
16029903
17443767
15245494
14993062
12884966
26223010
25620703
10221449
10731101
26074768
29054014
12699330
28755863
15229239
7626466
24646567
28028198",Non-reproductive Functions of Aromatase in the Central Nervous System Under Physiological and Pathological Conditions.,"The modulation of brain function and behavior by steroid hormones was classically associated with their secretion by peripheral endocrine glands. The discovery that the brain expresses the enzyme aromatase, which produces estradiol from testosterone, expanded this traditional concept. One of the best-studied roles of brain estradiol synthesis is the control of reproductive behavior. In addition, there is increasing evidence that estradiol from neural origin is also involved in a variety of non-reproductive functions. These include the regulation of neurogenesis, neuronal development, synaptic transmission, and plasticity in brain regions not directly related with the control of reproduction. Central aromatase is also involved in the modulation of cognition, mood, and non-reproductive behaviors. Furthermore, under pathological conditions aromatase is upregulated in the central nervous system. This upregulation represents a neuroprotective and likely also a reparative response by increasing local estradiol levels in order to maintain the homeostasis of the neural tissue. In this paper, we review the non-reproductive functions of neural aromatase and neural-derived estradiol under physiological and pathological conditions. We also consider the existence of sex differences in the role of the enzyme in both contexts.","['Astrocytes', 'Neuroinflammation', 'Neuroprotection', 'Radial glia', 'Sex differences', 'Synapses']",Cellular and molecular neurobiology,2018-08-08,"[{'lastname': 'Brocca', 'firstname': 'Maria Elvira', 'initials': 'ME', 'affiliation': 'Instituto Cajal, Consejo Superior de Investigaciones Científicas (CSIC), Madrid, Spain. m.brocca@cajal.csic.es.'}, {'lastname': 'Garcia-Segura', 'firstname': 'Luis Miguel', 'initials': 'LM', 'affiliation': 'Instituto Cajal, Consejo Superior de Investigaciones Científicas (CSIC), Madrid, Spain.\nCentro de Investigación Biomédica en Red Fragilidad y Envejecimiento Saludable (CIBERFES), Instituto de Salud Carlos III, Madrid, Spain.'}]",,,,,10.1007/s10571-018-0607-4,<Element 'PubmedArticle' at 0x7f05dd67a040>
301,"30075820
19877496
22618691
22553021
27885636
24666367
21801442
21707791
9613558
20657592
21079038
21256197
18534982
19027877
14963641
25304184
23951176
11242034
22535895
19150373
24349124
26088684
25752945
20468046
11891798
19839937
17274532
11331425
8526880
16596771
6248568
26335034
21193003
7535770
26643508
26188416
17715343",2-arachidonyl glycerol modulates astrocytic glutamine synthetase via p38 and ERK1/2 pathways.,"The glutamine synthetase (GS), an astrocyte-specific enzyme, is involved in lipopolysaccharide (LPS)-induced inflammation which activates the mitogen-activated protein kinase (MAPK) signaling. Endocannabinoid 2-arachidonyl glycerol (2-AG) has been described to serve as an endogenous mediator of analgesia and neuroprotection. However, whether 2-AG can directly influence astrocytic GS and MAPK expressions remains unknown.
In the present study, the effects of 2-AG on astrocytic GS expression, p38 and ERK1/2 expression, cell viability, and apoptosis following LPS exposure were investigated.
The results revealed that LPS exposure increased GS expression with p38 activation in the early phase and decreased GS expression with activation of ERK1/2, decrease of cell viability, and increase of apoptosis in the late phase. Inhibition of p38 reversed GS increase in the early phase while inhibition of ERK1/2 reversed GS decrease in the late phase induced by LPS exposure. 2-AG protected astrocytes from increase of apoptosis and decrease of cell viability induced by the late phase of LPS exposure. In the early phase of LPS exposure, 2-AG could suppress the increase of GS expression and activation of p38 signaling. In the late phase of LPS exposure, 2-AG could reverse the decrease of GS expression and activation of ERK1/2 induced by LPS.
These findings suggest that 2-AG could maintain the GS expression in astrocytes to a relatively stable level through modulating MAPK signaling and protect astrocytes from LPS exposure.","['2-AG', 'Astrocyte', 'ERK', 'Glutamine synthetase', 'MAPK', 'p38']",Journal of neuroinflammation,2018-08-05,"[{'lastname': 'Wang', 'firstname': 'Shenghong', 'initials': 'S', 'affiliation': ""Key Laboratory of Orthopaedics Disease of Gansu Province, Lanzhou University Second Hospital, No.82 Cuiyingmen Street, Lanzhou, Gansu, 730030, People's Republic of China.""}, {'lastname': 'Zhang', 'firstname': 'Hua', 'initials': 'H', 'affiliation': ""Key Laboratory of Orthopaedics Disease of Gansu Province, Lanzhou University Second Hospital, No.82 Cuiyingmen Street, Lanzhou, Gansu, 730030, People's Republic of China.""}, {'lastname': 'Geng', 'firstname': 'Bin', 'initials': 'B', 'affiliation': ""Key Laboratory of Orthopaedics Disease of Gansu Province, Lanzhou University Second Hospital, No.82 Cuiyingmen Street, Lanzhou, Gansu, 730030, People's Republic of China.\nDepartment of Orthopaedics, Lanzhou University Second Hospital, No.82 Cuiyingmen Street, Lanzhou, Gansu, 730030, People's Republic of China.""}, {'lastname': 'Xie', 'firstname': 'Qiqi', 'initials': 'Q', 'affiliation': ""Key Laboratory of Orthopaedics Disease of Gansu Province, Lanzhou University Second Hospital, No.82 Cuiyingmen Street, Lanzhou, Gansu, 730030, People's Republic of China.""}, {'lastname': 'Li', 'firstname': 'Wenzhou', 'initials': 'W', 'affiliation': ""Key Laboratory of Orthopaedics Disease of Gansu Province, Lanzhou University Second Hospital, No.82 Cuiyingmen Street, Lanzhou, Gansu, 730030, People's Republic of China.""}, {'lastname': 'Deng', 'firstname': 'Yajun', 'initials': 'Y', 'affiliation': ""Key Laboratory of Orthopaedics Disease of Gansu Province, Lanzhou University Second Hospital, No.82 Cuiyingmen Street, Lanzhou, Gansu, 730030, People's Republic of China.""}, {'lastname': 'Shi', 'firstname': 'Weidong', 'initials': 'W', 'affiliation': ""Key Laboratory of Orthopaedics Disease of Gansu Province, Lanzhou University Second Hospital, No.82 Cuiyingmen Street, Lanzhou, Gansu, 730030, People's Republic of China.""}, {'lastname': 'Pan', 'firstname': 'Yunyan', 'initials': 'Y', 'affiliation': ""Clinical Laboratory, Lanzhou University Second Hospital, No.82 Cuiyingmen Street, Lanzhou, Gansu, 730030, People's Republic of China.""}, {'lastname': 'Kang', 'firstname': 'Xuewen', 'initials': 'X', 'affiliation': ""Key Laboratory of Orthopaedics Disease of Gansu Province, Lanzhou University Second Hospital, No.82 Cuiyingmen Street, Lanzhou, Gansu, 730030, People's Republic of China.\nDepartment of Orthopaedics, Lanzhou University Second Hospital, No.82 Cuiyingmen Street, Lanzhou, Gansu, 730030, People's Republic of China.""}, {'lastname': 'Wang', 'firstname': 'Jing', 'initials': 'J', 'affiliation': ""Key Laboratory of Orthopaedics Disease of Gansu Province, Lanzhou University Second Hospital, No.82 Cuiyingmen Street, Lanzhou, Gansu, 730030, People's Republic of China. wang_jing@lzu.edu.cn.""}]",,These findings suggest that 2-AG could maintain the GS expression in astrocytes to a relatively stable level through modulating MAPK signaling and protect astrocytes from LPS exposure.,"The results revealed that LPS exposure increased GS expression with p38 activation in the early phase and decreased GS expression with activation of ERK1/2, decrease of cell viability, and increase of apoptosis in the late phase. Inhibition of p38 reversed GS increase in the early phase while inhibition of ERK1/2 reversed GS decrease in the late phase induced by LPS exposure. 2-AG protected astrocytes from increase of apoptosis and decrease of cell viability induced by the late phase of LPS exposure. In the early phase of LPS exposure, 2-AG could suppress the increase of GS expression and activation of p38 signaling. In the late phase of LPS exposure, 2-AG could reverse the decrease of GS expression and activation of ERK1/2 induced by LPS.",,"10.1186/s12974-018-1254-x
10.1007/s11064-012-0803-4
10.1523/JNEUROSCI.6343-11.2012
10.1007/978-3-319-45096-4_13
10.1111/ejn.12562
10.1186/1750-1326-6-55
10.1111/j.1460-9568.2011.07747.x
10.1111/j.1600-0404.1998.tb05956.x
10.1038/nn.2601
10.1124/pr.110.003004
10.1016/j.neuroscience.2011.01.024
10.1074/jbc.M800524200
10.1016/j.bbalip.2008.10.007
10.1007/s00210-004-0871-3
10.1016/j.phrs.2014.09.008
10.1371/journal.pone.0071500
10.1038/35065000
10.1152/physrev.00028.2011
10.1016/j.brainresrev.2008.12.011
10.1371/journal.pone.0081747
10.1007/s11064-015-1636-8
10.1002/jcp.24981
10.1002/glia.20983
10.1002/jnr.10165
10.2174/187152709789824660
10.1046/j.1471-4159.2001.00333.x
10.1042/bj3120637
10.1007/3-540-26573-2_2
10.1083/jcb.85.3.890
10.1016/j.etap.2015.08.010
10.1016/j.neuint.2010.12.018
10.1074/jbc.270.13.7420
10.1002/ptr.5538
10.1007/s10571-015-0238-y
10.1523/JNEUROSCI.2260-07.2007",<Element 'PubmedArticle' at 0x7f05dd622400>
302,30063850,Anti-inflammatory potential of thymosin β4 in the central nervous system: implications for progressive neurodegenerative diseases.,"The actin-sequestering thymosin beta4 (Tβ4) is the most abundant member of the β-thymosins, and is widely expressed in the central nervous system (CNS), but its functions in the healthy and diseased brain are poorly understood. The expression of Tβ4 in neurons and microglia, the resident immune cells of the brain, suggests that it can play a role in modulating behavioral processes and immunological mechanisms in the brain. The purpose of this review is to shed lights on the role of Tβ4 in CNS function and diseases without antecedent autoimmune inflammation or injury, and to question its therapeutic potential for neurodegenerative disorders such as Alzheimer's disease.
This review presents the evidence supporting a role for Tβ4 in behaviors that are affected in CNS disorders, as well as studies linking Tβ4 upregulation in microglia to neuroinflammatory processes associated with these disorders. Finally, the implication of Tβ4 in the process of microglial activation and the mechanisms underlying its ability to suppress pro-inflammatory signaling in microglia are discussed.
Tβ4 has the potential to control inflammatory processes in the brain, opening avenues for new therapeutic applications to a range of neurodegenerative conditions.","['Thymosin β4', 'central nervous system disorders', 'microglia', 'neuroinflammation']",Expert opinion on biological therapy,2018-08-01,"[{'lastname': 'Pardon', 'firstname': 'Marie-Christine', 'initials': 'MC', 'affiliation': 'a School of Life Sciences, Division of Physiology, Pharmacology and Neuroscience, Queens Medical Centre , The University of Nottingham Medical School , Nottingham , UK.'}]",,,,,10.1080/14712598.2018.1486817,<Element 'PubmedArticle' at 0x7f05dd645360>
303,"30058012
23813098
28669034
3228475
15084437
29410360
25548106
27423516
22141465
26295827
29150085
19007820
24389395
24409127
19416833
23046519
11031087
29182481
24606520
25735211
15730864
28579484
26578900
29408270
22056833
18823959
16764943
1402908
29149808
29022083
1561686
29102164
19647106
28706574
29352997
12048174
27539936
19962408
25748831
22645692
26567045
16046840
26416672
25497453
29382825
29194585
12955147
29725299
29436743
22480617
22414817
16931063
24825105
23880066
17264450
22912680
12944505
25601829
29137683
18695637
28886007
25210802
20060020
21640811
22147192
20206165
25638390
10719080
28495306
17073815
28210782
28730283
23394521
23425575
19413995
29394934
28336953
21085899
24434477
21255263
22569153
29355822
20470384
26341391
21788999","Palmitoylethanolamide prevents neuroinflammation, reduces astrogliosis and preserves recognition and spatial memory following induction of neonatal anoxia-ischemia.","Neonatal anoxia-ischemia (AI) particularly affects the central nervous system. Despite the many treatments that have been tested, none of them has proven to be completely successful. Palmitoylethanolamide (PEA) and oleoylethanolamide (OEA) are acylethanolamides that do not bind to CB1 or CB2 receptors and thus they do not present cannabinoid activity. These molecules are agonist compounds of peroxisome proliferator-activator receptor alpha (PPARα), which modulates the expression of different genes that are related to glucose and lipid metabolism, inflammation, differentiation and proliferation.
In the present study, we analyzed the effects that the administration of PEA or OEA, after a neonatal AI event, has over different areas of the hippocampus.
To this end, 7-day-old rats were subjected to AI and then treated with vehicle, OEA (2 or 10 mg/kg) or PEA (2 or 10 mg/kg). At 30 days of age, animals were subjected to behavioral tests followed by immunohistochemical studies.
Results showed that neonatal AI was associated with decreased locomotion, as well as recognition and spatial memory impairments. Furthermore, these deficits were accompanied with enhanced neuroinflammation and astrogliosis, as well as a decreased PPARα expression. PEA treatment was able to prevent neuroinflammation, reduce astrogliosis and preserve cognitive functions.
These results indicate that the acylethanolamide PEA may play an important role in the mechanisms underlying neonatal AI, and it could be a good candidate for further studies regarding neonatal AI treatments.","['Astrogliosis', 'Memory impairment', 'Neonatal anoxia-ischemia', 'Neuroinflammation', 'Oleoylethanolamide', 'Palmitoylethanolamide']",Psychopharmacology,2018-07-31,"[{'lastname': 'Holubiec', 'firstname': 'Mariana I', 'initials': 'MI', 'affiliation': 'Unidad de Gestión Clínica de Salud Mental, Instituto de Investigación Biomédica de Málaga (IBIMA), Hospital Regional Universitario de Málaga, Avenida Carlos Haya 82, 29010, Málaga, Spain.\nInstituto de Investigaciones Bioquímicas de Buenos Aires (IIBBA), Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Av. Patricias Argentinas 435, C1405BWE, Ciudad Autónoma de Buenos Aires, Argentina.'}, {'lastname': 'Romero', 'firstname': 'Juan I', 'initials': 'JI', 'affiliation': 'Unidad de Gestión Clínica de Salud Mental, Instituto de Investigación Biomédica de Málaga (IBIMA), Hospital Regional Universitario de Málaga, Avenida Carlos Haya 82, 29010, Málaga, Spain.\nInstituto de Investigaciones Bioquímicas de Buenos Aires (IIBBA), Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Av. Patricias Argentinas 435, C1405BWE, Ciudad Autónoma de Buenos Aires, Argentina.'}, {'lastname': 'Suárez', 'firstname': 'Juan', 'initials': 'J', 'affiliation': 'Unidad de Gestión Clínica de Salud Mental, Instituto de Investigación Biomédica de Málaga (IBIMA), Hospital Regional Universitario de Málaga, Avenida Carlos Haya 82, 29010, Málaga, Spain.'}, {'lastname': 'Portavella', 'firstname': 'Manuel', 'initials': 'M', 'affiliation': 'Laboratorio de Conducta Animal y Neurociencia, Departamento de Psicología Experimental, Facultad de Psicología, Universidad de Sevilla, C/Camilo José Cela s/n, 41018, Sevilla, Spain.'}, {'lastname': 'Fernández-Espejo', 'firstname': 'Emilio', 'initials': 'E', 'affiliation': 'Laboratorio de Neurofisiología y Neurología Molecular, Departamento de Fisiología Médica y Biofísica, Facultad de Medicina, Universidad de Sevilla, Av. Sánchez Pizjuán 4, 41009, Sevilla, Spain.'}, {'lastname': 'Blanco', 'firstname': 'Eduardo', 'initials': 'E', 'affiliation': 'Lleida Institute for Biomedical Research, Dr. Pifarré Foundation (IRBLleida), University of Lleida, Av. Alcalde Rovira Roure 80, 25198, Lleida, Spain.'}, {'lastname': 'Galeano', 'firstname': 'Pablo', 'initials': 'P', 'affiliation': 'Unidad de Gestión Clínica de Salud Mental, Instituto de Investigación Biomédica de Málaga (IBIMA), Hospital Regional Universitario de Málaga, Avenida Carlos Haya 82, 29010, Málaga, Spain. pgaleano@leloir.org.ar.\nInstituto de Investigaciones Bioquímicas de Buenos Aires (IIBBA), Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Av. Patricias Argentinas 435, C1405BWE, Ciudad Autónoma de Buenos Aires, Argentina. pgaleano@leloir.org.ar.'}, {'lastname': 'de Fonseca', 'firstname': 'Fernando Rodríguez', 'initials': 'FR', 'affiliation': 'Unidad de Gestión Clínica de Salud Mental, Instituto de Investigación Biomédica de Málaga (IBIMA), Hospital Regional Universitario de Málaga, Avenida Carlos Haya 82, 29010, Málaga, Spain. fernando.rodriguez@ibima.eu.'}]",,,"Results showed that neonatal AI was associated with decreased locomotion, as well as recognition and spatial memory impairments. Furthermore, these deficits were accompanied with enhanced neuroinflammation and astrogliosis, as well as a decreased PPARα expression. PEA treatment was able to prevent neuroinflammation, reduce astrogliosis and preserve cognitive functions.",,10.1007/s00213-018-4982-9,<Element 'PubmedArticle' at 0x7f05dd64af90>
304,"29983634
17617647
18801465
7978722
21946893
12562565
15699087
8014482
11722149
2166084
24959566
26516304
19237251
10367610
7480560
20403505
12944327
12700181
11288761
18675469
18368033
26983566
21315796
1659582
18160468
12461200
14754825
9669518
17803834
11914448
17276605
11585638
9466535
26230484
16610957
16740143
18573538
9713562
15471616
19701493
19124690
17192580
10873181
8728570
10634215
9201656
19122123
12006334
20693261
20157190
12615092
8148458
12892658
22774788
26365173
20231081
11274650
11268418
19300594
24343193
15220929
19234457
18923511
29392095
28231836",Reduction of Glucocorticoid Receptor Function in Chronic Fatigue Syndrome.,"Glucocorticoid receptor (GR) function may have aetiopathogenic significance in chronic fatigue syndrome (CFS), via its essential role in mediating inflammatory responses as well as in hypothalamic-pituitary-adrenal axis regulation. GR function can be estimated ex vivo by measuring dexamethasone (dex) modulation of cytokine response to lipopolysaccharide (LPS), and ",[],Mediators of inflammation,2018-07-10,"[{'lastname': 'Lynn', 'firstname': 'Megan', 'initials': 'M', 'affiliation': 'Institute of Neuroscience, Newcastle University, Newcastle upon Tyne, UK.'}, {'lastname': 'Maclachlan', 'firstname': 'Laura', 'initials': 'L', 'affiliation': 'Department of Public Health and Community Medicine, University of Gothenburg, Gothenburg, Sweden.'}, {'lastname': 'Finkelmeyer', 'firstname': 'Andreas', 'initials': 'A', 'affiliation': 'Institute of Neuroscience, Newcastle University, Newcastle upon Tyne, UK.'}, {'lastname': 'Clark', 'firstname': 'James', 'initials': 'J', 'affiliation': 'Institute of Neuroscience, Newcastle University, Newcastle upon Tyne, UK.'}, {'lastname': 'Locke', 'firstname': 'James', 'initials': 'J', 'affiliation': 'Institute of Cellular Medicine and NIHR Newcastle Biomedical Research Centre, Newcastle University, Newcastle upon Tyne, UK.'}, {'lastname': 'Todryk', 'firstname': 'Stephen', 'initials': 'S', 'affiliation': 'Institute of Cellular Medicine and NIHR Newcastle Biomedical Research Centre, Newcastle University, Newcastle upon Tyne, UK.\nFaculty of Health and Life Sciences, Northumbria University, Newcastle upon Tyne, UK.'}, {'lastname': 'Ng', 'firstname': 'Wan-Fai', 'initials': 'WF', 'affiliation': 'Institute of Cellular Medicine and NIHR Newcastle Biomedical Research Centre, Newcastle University, Newcastle upon Tyne, UK.\nNewcastle Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK.'}, {'lastname': 'Newton', 'firstname': 'Julia L', 'initials': 'JL', 'affiliation': 'Institute of Cellular Medicine and NIHR Newcastle Biomedical Research Centre, Newcastle University, Newcastle upon Tyne, UK.\nNewcastle Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK.'}, {'lastname': 'Watson', 'firstname': 'Stuart', 'initials': 'S', 'affiliation': 'Institute of Neuroscience, Newcastle University, Newcastle upon Tyne, UK.\nNorthumberland, Tyne and Wear NHS Foundation Trust, Newcastle upon Tyne, UK.'}]",,,,,"10.1155/2018/3972104
10.1093/qjmed/hcm057
10.1016/j.autrev.2008.08.003
10.7326/0003-4819-121-12-199412150-00009
10.1038/nrendo.2011.153
10.1176/appi.ajp.160.2.221
10.1093/occmed/kqi013
10.1093/infdis/170.1.1
10.1155/2013/784520
10.7150/ijms.12399
10.1016/j.mehy.2008.11.044
10.1097/00006842-199905000-00009
10.1097/00006842-199507000-00002
10.1016/j.jpsychores.2009.12.004
10.1176/appi.ajp.160.9.1554
10.1210/er.2002-0014
10.2310/6650.2001.34047
10.1016/j.tins.2008.06.006
10.1038/npp.2008.44
10.1034/j.1601-5215.2003.00033.x
10.1016/j.biopsycho.2011.02.002
10.1210/jcem-73-6-1224
10.1210/jc.2007-1747
10.1097/01.psy.0000038937.67401.61
10.1192/bjp.184.2.136
10.1111/j.1600-0447.1998.tb10030.x
10.1017/S0033291707001444
10.1097/00006842-200203000-00015
10.1016/j.psyneuen.2006.12.005
10.1016/S0165-5728(01)00400-3
10.1086/517373
10.1097/PSY.0000000000000224
10.2217/14622416.7.3.475
10.1111/j.1601-183X.2006.00244.x
10.1016/j.jad.2008.05.001
10.1046/j.1365-2265.1998.00418.x
10.1016/j.psyneuen.2004.06.008
10.1111/j.1751-9861.2008.00033.x
10.1001/archgenpsychiatry.2008.508
10.1196/annals.1366.014
10.1093/qjmed/93.6.323
10.1016/0091-3057(95)02127-2
10.1023/A:1020558917955
10.1016/S0022-3956(96)00063-5
10.1176/appi.psy.49.6.470
10.1136/ard.61.6.554
10.1093/rheumatology/keq240
10.1093/occmed/kqp180
10.1016/S0145-2134(02)00541-0
10.1093/clinids/18.Supplement_1.S79
10.1016/S0306-4530(02)00108-7
10.1037/a0029146
10.1016/j.pneurobio.2015.09.001
10.1016/j.euroneuro.2010.02.006
10.1016/S0006-3223(00)01088-X
10.1111/j.1749-6632.2000.tb05453.x
10.1177/0004867413516681
10.1038/nn1276
10.1038/nn.2270
10.1038/nature07455
10.1080/21641846.2018.1384095
10.1186/s12920-017-0248-3",<Element 'PubmedArticle' at 0x7f05dd5b45e0>
305,"29948851
21851230
25729548
15177383
11393256
9729336
17285186
26220842
14977568
11170729
21185611
19214153
29602490
17682949
10547095
16303916
18267965
24780430
12815713
12442313
16181084
18246008
8742041
17111361
19966907
16873930
15359610
22186333
29441625
21731081
15484662
17241284
11181507
26170828
20517941
7783230
27686494
15840993
29359704
16774470
12111861
15048924
25326018
12128278
25635633
22561613",Coenzyme Q10 Influences on the Levels of TNF-α and IL-10 and the Ratio of Bax/Bcl2 in a Menopausal Rat Model Following Lumbar Spinal Cord Injury.,"The roles of the immune response and apoptosis as potential mediators of secondary damage in spinal cord injury (SCI) are being investigated. Research is also being done to determine the effects of female gonadal steroids, which decrease during menopause, and antioxidants, such as coenzyme Q10 (CoQ10) on SCI. We hypothesized that in the absence of female gonadal steroids, which provide protection following an SCI, CoQ10 could modulate the expression of cytokines, such as tumor necrosis factor (TNF)-α and interleukin (IL)-10, besides aquaporin-4 (AQP4) water channels in the CNS, which participate in neuroinflammation, as well as the Bax and Bcl2 proteins that are involved in apoptosis at the site of injury. The spinal cord was compressed at the level of the T10 vertebrae and rats were treated by 10 mg/kg/day CoQ10 for 3 weeks after surgery. The TNF-α and IL-10 expressions were studied using an ELISA. Western blot was used to investigate the Bax/Bcl-2 ratio, AQP4. The level of TNF-α significantly decreased following the administration of CoQ10 compared with the level of IL-10. When the treatment group was compared with the OVX-SCI group, the ratio of Bax/Bcl2 significantly decreased in the groups (P < 0.01). Based on our findings, CoQ10 could be used to compensate for the absence of the neuroprotection effects provided by female gonadal steroids via reducing the inappropriate effects of the two main pathways of secondary damage in SCI apoptosis.","['Coenzyme Q10', 'IL-10', 'Ovariectomy', 'Spinal cord injury', 'TNF-α']",Journal of molecular neuroscience : MN,2018-06-28,"[{'lastname': 'Hassanzadeh', 'firstname': 'Sajad', 'initials': 'S', 'affiliation': 'Neuroscience Research Center (NRC), Iran University of Medical Sciences, Tehran, Iran.\nDepartment of Anatomy, Faculty of Medicine, Iran University of Medical Sciences, Tehran, Iran.'}, {'lastname': 'Jameie', 'firstname': 'Seyed Behnamedin', 'initials': 'SB', 'affiliation': 'Neuroscience Research Center (NRC), Iran University of Medical Sciences, Tehran, Iran.\nDepartment of Medical Basic Sciences, Faculty of Allied Medicine, Iran University of Medical Sciences, Tehran, Iran.'}, {'lastname': 'Soleimani', 'firstname': 'Maryam', 'initials': 'M', 'affiliation': 'Neuroscience Research Center (NRC), Iran University of Medical Sciences, Tehran, Iran. Ma.soleimani@uswr.ac.ir.\nDepartment of Medical Basic Sciences, University of Social Welfare and Rehabilitation Sciences, Tehran, Iran. Ma.soleimani@uswr.ac.ir.'}, {'lastname': 'Farhadi', 'firstname': 'Mona', 'initials': 'M', 'affiliation': 'Neuroscience Research Center (NRC), Iran University of Medical Sciences, Tehran, Iran.\nDepartment of Microbiology, Islamic Azad University, Karaj, Iran.'}, {'lastname': 'Kerdari', 'firstname': 'Mahdieh', 'initials': 'M', 'affiliation': 'Neuroscience Research Center (NRC), Iran University of Medical Sciences, Tehran, Iran.'}, {'lastname': 'Danaei', 'firstname': 'Navid', 'initials': 'N', 'affiliation': 'Department of Pediatric, Semnan University of Medical Sciences, Semnan, Iran.'}]",,,,,10.1007/s12031-018-1090-6,<Element 'PubmedArticle' at 0x7f05dd562f40>
306,29913427,Formononetin inhibits neuroinflammation and increases estrogen receptor beta (ERβ) protein expression in BV2 microglia.,"Formononetin is a bioactive non-steroidal polyphenol found in a variety of plants. In this study we evaluated the effects of formononetin on neuroinflammation in LPS-stimulated BV2 microglia. Results showed that formononetin significantly reduced the production of TNF-α, IL-6 and IL-1β, nitrite and PGE","['ERβ', 'Formononetin', 'NF-κB', 'Neuroinflammation']",International immunopharmacology,2018-06-19,"[{'lastname': 'El-Bakoush', 'firstname': 'Abdelmeniem', 'initials': 'A', 'affiliation': 'Department of Pharmacy, School of Applied Sciences, University of Huddersfield, Huddersfield HD1 3DH, United Kingdom.'}, {'lastname': 'Olajide', 'firstname': 'Olumayokun A', 'initials': 'OA', 'affiliation': 'Department of Pharmacy, School of Applied Sciences, University of Huddersfield, Huddersfield HD1 3DH, United Kingdom. Electronic address: o.a.olajide@hud.ac.uk.'}]",,,,Copyright © 2018 Elsevier B.V. All rights reserved.,10.1016/j.intimp.2018.06.016,<Element 'PubmedArticle' at 0x7f05dd57cf40>
307,29911915,Targeting glucose-dependent insulinotropic polypeptide receptor for neurodegenerative disorders.,"Incretin hormones, glucose-dependent insulinotropic polypeptide (GIP), and glucagon-like peptide-1 (GLP-1) exert pleiotropic effects on endocrine pancreas and nervous system. Expression of GIP and GIP receptor (GIPR) in neurons, their roles in neurogenesis, synaptic plasticity, neurotransmission, and neuromodulation uniquely position GIPR for therapeutic applications in neurodegenerative disorders. GIP analogs acting as GIPR agonists attenuate neurobehavioral and neuropathological sequelae of neurodegenerative disorders in preclinical models, e.g. Alzheimer's disease (AD), Parkinson's disease (PD), and cerebrovascular disorders. Modulation of GIPR signaling offers an unprecedented approach for disease modification by arresting neuronal viability decline, enabling neuronal regeneration, and reducing neuroinflammation. Growth-promoting effects of GIP signaling and broad-based neuroprotection highlight the therapeutic potential of GIPR agonists. Areas covered: This review focuses on the role of GIPR-mediated signaling in the central nervous system in neurophysiological and neuropathological conditions. In context of neurodegeneration, the article summarizes potential of targeting GIPR signaling for neurodegenerative conditions such as AD, PD, traumatic brain injury, and cerebrovascular disorders. Expert opinion: GIPR represents a validated therapeutic target for neurodegenerative disorders. GIPR agonists impart symptomatic improvements, slowed neurodegeneration, and enhanced neuronal regenerative capacity in preclinical models. Modulation of GIPR signaling is potentially a viable therapeutic approach for disease modification in neurodegenerative disorders.","['Alzheimer’s disease', 'Parkinson’s disease', 'glucose-dependent insulinotropic polypeptide', 'neurodegeneration', 'stroke']",Expert opinion on therapeutic targets,2018-06-19,"[{'lastname': 'Verma', 'firstname': 'Mahip K', 'initials': 'MK', 'affiliation': 'a Department of Pharmacology, Novel Drug Discovery and Development , Lupin Limited , Pune , India.'}, {'lastname': 'Goel', 'firstname': 'Rajan', 'initials': 'R', 'affiliation': 'a Department of Pharmacology, Novel Drug Discovery and Development , Lupin Limited , Pune , India.'}, {'lastname': 'Krishnadas', 'firstname': 'Nandakumar', 'initials': 'N', 'affiliation': 'b Department of Pharmacology , Manipal College of Pharmaceutical Sciences, Manipal Academy of Higher Education (MAHE) , Manipal , India.'}, {'lastname': 'Nemmani', 'firstname': 'Kumar V S', 'initials': 'KVS', 'affiliation': 'a Department of Pharmacology, Novel Drug Discovery and Development , Lupin Limited , Pune , India.'}]",,,,,10.1080/14728222.2018.1487952,<Element 'PubmedArticle' at 0x7f05dd58b090>
308,"29882317
18026097
24744759
22982535
28848398
27234350
22925833
28671693
26780511
28027926
25471682
23746838
2998738
26207921
18286612
14730714
28414331
26431938",Glucocorticoid-mediated modulation of morphological changes associated with aging in microglia.,"Microglia dynamically adapt their morphology and function during increasing age. However, the mechanisms behind these changes are to date poorly understood. Glucocorticoids (GCs) are long known and utilized for their immunomodulatory actions and endogenous GC levels are described to alter with advancing age. We here tested the hypothesis that age-associated elevations in GC levels implicate microglia function and morphology. Our data indicate a decrease in microglial complexity and a concomitant increase in GC levels during aging. Interestingly, enhancing GC levels in young mice enhanced microglial ramifications, while the knockdown of the glucocorticoid receptor expression in old mice aggravated age-associated microglial amoebification. These data suggest that GCs increase ramification of hippocampal microglia and may modulate age-associated changes in microglial morphology.","['glucocorticoid receptor', 'glucocorticoids', 'hippocampus', 'inflammaging', 'microglia', 'neuroimmunology', 'neuroinflammation']",Aging cell,2018-06-09,"[{'lastname': 'van Olst', 'firstname': 'Lynn', 'initials': 'L', 'affiliation': 'Department of Molecular Cell Biology and Immunology, VU University Medical Center, Amsterdam Neuroscience, Amsterdam, The Netherlands.'}, {'lastname': 'Bielefeld', 'firstname': 'Pascal', 'initials': 'P', 'affiliation': 'Neuroscience Program, Swammerdam Institute for Life Sciences, University of Amsterdam, Amsterdam, The Netherlands.'}, {'lastname': 'Fitzsimons', 'firstname': 'Carlos P', 'initials': 'CP', 'affiliation': 'Neuroscience Program, Swammerdam Institute for Life Sciences, University of Amsterdam, Amsterdam, The Netherlands.'}, {'lastname': 'de Vries', 'firstname': 'Helga E', 'initials': 'HE', 'affiliation': 'Department of Molecular Cell Biology and Immunology, VU University Medical Center, Amsterdam Neuroscience, Amsterdam, The Netherlands.'}, {'lastname': 'Schouten', 'firstname': 'Marijn', 'initials': 'M', 'affiliation': 'Department of Molecular Cell Biology and Immunology, VU University Medical Center, Amsterdam Neuroscience, Amsterdam, The Netherlands.'}]",,,,© 2018 The Authors. Aging Cell published by the Anatomical Society and John Wiley & Sons Ltd.,"10.1111/acel.12790
10.1038/nn2014
10.3389/fimmu.2014.00136
10.1016/j.yfrne.2012.08.006
10.3389/fncel.2017.00235
10.1016/j.yfrne.2016.05.001
10.1038/mp.2012.123
10.1038/nn.4597
10.1038/nn.4222
10.1016/j.bbi.2016.12.023
10.1159/000367692
10.1016/j.cell.2013.05.039
10.1210/endo-117-6-2505
10.1038/srep12448
10.1002/glia.20644
10.1002/glia.10319
10.1038/nn.4547
10.1016/j.it.2015.08.008",<Element 'PubmedArticle' at 0x7f05dd594450>
309,"29796990
10206339
10381209
10501190
10662535
11063054
11149664
11258671
11433375
11532975
11535291
11834296
12016909
12171246
12203394
12456489
12465042
1322737
14578353
15240011
15304253
16364377
16805774
16987013
17015177
17192562
17352382
17982091
18189315
18240315
18315570
18929509
19420298
19836631
21134288
22155530
22182832
22507553
22584352
23176293
23307413
24455696
24825463
26360782
26526842
26643608
27959401
7554139
7682018
7891077
8426746
8597452
8784058
9218249
9498303",Neuroprotective Effects of Dehydroepiandrosterone Sulfate Through Inhibiting Expression of Matrix Metalloproteinase-9 from Bradykinin-Challenged Astroglia.,"Dehydroepiandrosterone sulfate (DHEAS), one of the most important neuroactive steroids, is produced in the adrenals and the brain. DHEAS is believed to play a critical role in modulating different forms of cellular control, including processes associated with human neural systems. Its production rate and level in serum, adrenals, and brain gradually decrease with advancing age. The decline of DHEAS level was associated with age-related neuronal dysfunction and degeneration, most probably because the steroids protect the central nervous system (CNS) neurons against neurotoxic challenges. Moreover, increasing studies show that matrix metalloproteinases (MMPs), MMP-9 especially, are upregulated by proinflammatory mediators in the CNS disorders. The increased MMP-9 as an inflammatory biomarker of several CNS disorders that may participate in the CNS inflammation and neurodegeneration. Herein, we investigate the effects of DHEAS on brain inflammation by the model we have defined of bradykinin (BK)-induced MMP-9 expression in rat brain astrocyte (RBA) and its mechanism. The results showed that DHEAS significantly reduce MMP-9 induced by BK. Pretreatment with DHEAS can inhibit BK-stimulated phosphorylation of c-Src and PYK2. Moreover, DHEAS attenuated BK-stimulated NADPH oxidase (Nox)-derived reactive oxygen species (ROS) production, suggesting that DHEAS has an antioxidative effect. We further demonstrated that DHEAS blocked activation of ERK1/2, Akt, and c-Fos/AP-1 by BK. Finally, DHEAS decreased MMP-9-related events including RBA migration and neuronal apoptosis. The results will provide new insights into the anti-inflammatory action of DHEAS, supporting that DHEAS may have a neuroprotective effect in the improvement of the CNS disorders by reducing neuroinflammation.","['Anti-inflammation', 'Bradykinin', 'Brain astrocytes', 'Dehydroepiandrosterone sulfate', 'Matrix metalloproteinase-9', 'Neuroprotection']",Molecular neurobiology,2018-05-26,"[{'lastname': 'Liou', 'firstname': 'Chian-Jiun', 'initials': 'CJ', 'affiliation': 'Department of Nursing, Division of Basic Medical Sciences, Research Center for Chinese Herbal Medicine, and Graduate Institute of Health Industry Technology, Chang Gung University of Science and Technology, Tao-Yuan, Taiwan.\nDivision of Allergy, Asthma, and Rheumatology, Department of Pediatrics, Chang Gung Memorial Hospital, Gui-Shan, Taoyuan, Taiwan.'}, {'lastname': 'Yang', 'firstname': 'Chuen-Mao', 'initials': 'CM', 'affiliation': 'Department of Physiology and Pharmacology and Health Ageing Research Center, College of Medicine, Chang Gung University, Tao-Yuan, Taiwan.'}, {'lastname': 'Lee', 'firstname': 'Tsong-Hai', 'initials': 'TH', 'affiliation': 'Stroke Center and Stroke Section, Department of Neurology, Chang Gung Memorial Hospital, Linkou Medical Center and Chang Gung University College of Medicine, Tao-Yuan, Taiwan.'}, {'lastname': 'Liu', 'firstname': 'Pei-Shan', 'initials': 'PS', 'affiliation': 'Department of Microbiology, Soochow University, Taipei, Taiwan.'}, {'lastname': 'Hsieh', 'firstname': 'Hsi-Lung', 'initials': 'HL', 'affiliation': 'Department of Nursing, Division of Basic Medical Sciences, Research Center for Chinese Herbal Medicine, and Graduate Institute of Health Industry Technology, Chang Gung University of Science and Technology, Tao-Yuan, Taiwan. hlhsieh@mail.cgust.edu.tw.\nDepartment of Neurology, Chang Gung Memorial Hospital, Tao-Yuan, Taiwan. hlhsieh@mail.cgust.edu.tw.'}]",,,,,10.1007/s12035-018-1125-6,<Element 'PubmedArticle' at 0x7f05dd5289f0>
310,"29786066
18023876
22875882
25242587
16946190
24424390
23360282
24952646
24062448
21525267
24858659
11353685
24439304
28373688
22386198
15036934
19748076
27375619
28454621
28061971
23670490
17641734
27373505
22804774
21918506
24953427
21111767
29195684
25618404
23966702
25701613
24523548
27223094
27065163
22722024
9402037
23487769
29382712
8864538
21110319
18334483
22204398
26470014
24508064
16337411
23948212
22434220
12152079
19050159
19017533
23035099
11166076
25430780
23433741","Repeated social defeat-induced neuroinflammation, anxiety-like behavior and resistance to fear extinction were attenuated by the cannabinoid receptor agonist WIN55,212-2.","Psychosocial stress contributes to the development of psychiatric disorders. Repeated social defeat (RSD) is a murine stressor that causes a release of inflammatory monocytes into circulation. Moreover, RSD-induced anxiety-like behavior is dependent on the recruitment of these monocytes to the brain. Activation of the endocannabinoid (ECB) system may modulate both neuroendocrine and inflammatory responses mediated by stress. Therefore, we hypothesized that a cannabinoid receptor agonist would attenuate RSD-induced inflammation, anxiety, and stress sensitization. To test this hypothesis, mice received an injection of the synthetic cannabinoid",[],Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology,2018-05-23,"[{'lastname': 'Lisboa', 'firstname': 'Sabrina Francesca', 'initials': 'SF', 'affiliation': 'Department of Pharmacology, University of Sao Paulo (USP), Ribeirão Preto, São Paulo, 14049900, Brazil. sa_lisboa@hotmail.com.\nCenter for Interdisciplinary Research on Applied Neurosciences (NAPNA), Medical School of Ribeirão Preto, University of Sao Paulo (USP), Ribeirão Preto, São Paulo, 14049900, Brazil. sa_lisboa@hotmail.com.'}, {'lastname': 'Niraula', 'firstname': 'Anzela', 'initials': 'A', 'affiliation': 'Division of Biosciences, Ohio State University, Columbus, OH, 43210, USA.'}, {'lastname': 'Resstel', 'firstname': 'Leonardo Barbosa', 'initials': 'LB', 'affiliation': 'Department of Pharmacology, University of Sao Paulo (USP), Ribeirão Preto, São Paulo, 14049900, Brazil.\nCenter for Interdisciplinary Research on Applied Neurosciences (NAPNA), Medical School of Ribeirão Preto, University of Sao Paulo (USP), Ribeirão Preto, São Paulo, 14049900, Brazil.'}, {'lastname': 'Guimaraes', 'firstname': 'Francisco Silveira', 'initials': 'FS', 'affiliation': 'Department of Pharmacology, University of Sao Paulo (USP), Ribeirão Preto, São Paulo, 14049900, Brazil.\nCenter for Interdisciplinary Research on Applied Neurosciences (NAPNA), Medical School of Ribeirão Preto, University of Sao Paulo (USP), Ribeirão Preto, São Paulo, 14049900, Brazil.'}, {'lastname': 'Godbout', 'firstname': 'Jonathan P', 'initials': 'JP', 'affiliation': 'Division of Biosciences, Ohio State University, Columbus, OH, 43210, USA.\nDepartment of Neuroscience, Ohio State University, Columbus, OH, 43210, USA.\nCenter for Brain and Spinal Cord Repair, Ohio State University, Columbus, OH, 43210, USA.'}, {'lastname': 'Sheridan', 'firstname': 'John F', 'initials': 'JF', 'affiliation': 'Division of Biosciences, Ohio State University, Columbus, OH, 43210, USA.\nDepartment of Neuroscience, Ohio State University, Columbus, OH, 43210, USA.\nInstitute for Behavioral Medicine Research, Ohio State University, Columbus, OH, 43210, USA.'}]",,,,,"10.1038/s41386-018-0064-2
10.1016/j.neubiorev.2007.08.007
10.1189/jlb.0212100
10.1016/j.bbi.2014.05.016
10.1176/ajp.2006.163.9.1630
10.1038/tp.2013.118
10.1186/1471-244X-13-40
10.1038/nm.3589
10.1073/pnas.1310655110
10.1523/JNEUROSCI.0450-11.2011
10.1016/j.bbi.2014.05.007
10.1152/ajpregu.2001.280.6.R1799
10.1016/j.biopsych.2013.11.029
10.1016/j.psyneuen.2012.02.003
10.1016/j.neubiorev.2003.12.001
10.1016/j.biopsych.2009.06.026
10.1016/j.biopsych.2017.03.007
10.1016/bs.vh.2016.09.006
10.1038/mp.2013.61
10.1155/2007/52908
10.1016/j.pharmthera.2016.06.011
10.1146/annurev-psych-113011-143739
10.1038/npp.2011.204
10.1016/j.bbi.2014.06.007
10.1016/j.pnpbp.2010.11.027
10.1016/j.jneuroim.2017.11.008
10.1523/JNEUROSCI.1671-13.2013
10.1016/j.bbi.2015.01.016
10.1523/JNEUROSCI.3723-13.2014
10.1016/j.bbi.2016.05.008
10.1002/cphy.c150015
10.1016/j.neuropharm.2012.06.003
10.1007/PL00005093
10.1073/pnas.1218573110
10.1523/JNEUROSCI.2568-17.2018
10.1111/j.1476-5381.1996.tb15639.x
10.1002/eji.201040667
10.1074/jbc.M707960200
10.1186/1478-811X-9-33
10.1002/glia.22930
10.1016/j.nlm.2014.01.018
10.1016/j.nlm.2005.10.005
10.1016/j.bbr.2013.08.010
10.1038/npp.2012.36
10.1038/nature00839
10.1101/lm.1081908
10.1016/j.yfrne.2008.10.001
10.1523/JNEUROSCI.1515-12.2012
10.1016/S0149-7634(00)00048-8
10.1038/npp.2014.317
10.1016/j.psyneuen.2013.01.014",<Element 'PubmedArticle' at 0x7f05dd546810>
311,"29781146
24554058
28737885
29055034
29055040
29055032
23891641
26692007
19706469
26081146
14715909
12120282
21459362
14623297
29399045
12444602
15060979
26603284
18194201
18855662
25697044
29149325
19862561
11171037
10989282
26321907
293720
21790776
22569208
27280380
15009509
26732138
19221418
16262633
26514204
25475041
22771380
12242084
15164945
28478550
17081983
14675124
24628077
15617532
22443683
19879837
15099019
27974994
28874589
12662348
15498938
20031277
21884551
1982956
11682063
12595746
8813989
15748895
23937612
20434483
14659528",Modulation of serine/threonine phosphatases by melatonin: therapeutic approaches in neurodegenerative diseases.,"Melatonin is an endogenous hormone produced by the pineal gland as well as many other tissues and organs. The natural decline in melatonin levels with ageing contributes significantly to the development of neurodegenerative disorders. Neurodegenerative diseases share common mechanisms of toxicity such as proteinopathy, mitochondrial dysfunction, metal dyshomeostasis, oxidative stress, neuroinflammation and an imbalance in the phosphorylation/dephosphorylation ratio. Several reports have proved the usefulness of melatonin in counteracting the events that lead to a neurodegenerative scenario. In this review, we have focused on the fact that melatonin could rectify the altered phosphorylation/dephosphorylation rate found in some neurodegenerative diseases by influencing the activity of phosphoprotein phosphatases. We analyse whether melatonin offers any protective activity towards these enzymes through a direct interaction. LINKED ARTICLES: This article is part of a themed section on Recent Developments in Research of Melatonin and its Potential Therapeutic Applications. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v175.16/issuetoc.",[],British journal of pharmacology,2018-05-22,"[{'lastname': 'Arribas', 'firstname': 'Raquel L', 'initials': 'RL', 'affiliation': 'Instituto-Fundación Teófilo Hernando, Departamento de Farmacología y Terapéutica, Universidad Autónoma de Madrid, Madrid, Spain.'}, {'lastname': 'Romero', 'firstname': 'Alejandro', 'initials': 'A', 'affiliation': 'Department of Pharmacology & Toxicology, Faculty of Veterinary Medicine, Complutense University of Madrid, Madrid, Spain.'}, {'lastname': 'Egea', 'firstname': 'Javier', 'initials': 'J', 'affiliation': 'Instituto-Fundación Teófilo Hernando, Departamento de Farmacología y Terapéutica, Universidad Autónoma de Madrid, Madrid, Spain.\nMolecular Neuroinflammation and Neuronal Plasticity Laboratory, Research Unit, Hospital Universitario Santa Cristina, Madrid, Spain.\nInstituto de Investigación Sanitaria, Hospital Universitario de la Princesa, Madrid, Spain.'}, {'lastname': 'de Los Ríos', 'firstname': 'Cristóbal', 'initials': 'C', 'affiliation': 'Instituto-Fundación Teófilo Hernando, Departamento de Farmacología y Terapéutica, Universidad Autónoma de Madrid, Madrid, Spain.\nInstituto de Investigación Sanitaria, Hospital Universitario de la Princesa, Madrid, Spain.'}]",,,,© 2018 The British Pharmacological Society.,10.1111/bph.14365,<Element 'PubmedArticle' at 0x7f05dd4f1ea0>
312,"29760681
11459116
21673906
26988999
4815174
14432658
18195084
15583024
27530684
16684650
558037
10746941
17013392
17222505
11444439
18374402
28144231
23357432
19401209
10328986
17596438
9030643
11113338
9925890
11751611
25511993
11978836
17266735
639042
24882635
8341652
23322319
8603038
15313771
10882835
19458217
12808104
16971528
19828812
22072656
12960034
18323418
12086642
10027289
23123886
17600562
25307223
15073041
8298194
20224563
9890981
9688926
10924060
10512927
11641386
11029403
15496504
2277354
19664713
9227446
20460386
22391220
17065532
12167775
16371946
19847447
26698019
15711064
15001666
1562533
26538779
19393685
25092805
5861717
6474166
2643827
11826092
20354534
21929623
15313799
26032719
17282988
11283751
21609825
25074747
9437023
23433260
25253853
28625813
9809557
23746839
29625071
29513649
26170290
8962152
7560271
9182802
12122071
9658334
3419503
3411349
20187140
26330519
10413781
20156817
17348018
2045885
7972037
22262875
15593136
15888646
8058723
12218180
14694190
973554
17196590
27364569
17261778
20966214
15831717
20887954
11099416
24772353
24713688
22933588
23872599
23942366
24607811
21277368
8808786
10359581
9517572
26745968
12390516
15798185
11245665
22497984
29243403
17356684
20012068
24231735
1279865
10732996
11340204
21292979
16388306
22152301
15254070
11158678
24270812
11701765
16310865
10941153
15731004
19759299
21143654
12106687
15389604
19797123
8313156
18328572
19031445
10501189
17850464
19533603
7996194
10077336
15818556
11264718
21767382
17823932
22561337
22825593
8841321
21911834
1148661
15188374
20351193
15353495
12852833
16797503
18322171
15294932
21304144
14581618
14615545
21787860
17823975
18172772
16977605
16420418
16297637
19714501
11784794
21983279
19557094
18635871
14664813
15211466
17565708
22983209
26606999
19539954
19853640
15845917
16793889
21555578
23401502
22985767
23690824
27871670
18522863
22189676
16337092
28757878
21564348
27115998
21198642
26862926
27074377
26952870
28826723
27524440
28362944
10838594
15749165
9087894
10632615
11500839
19458226
19013173
8058721
17875989
18614682
15967447
19357283
26747664
21595047
13756296
9710521
10630192
22007133
23138980
22824261","Sex Steroids, Adult Neurogenesis, and Inflammation in CNS Homeostasis, Degeneration, and Repair.","Sex steroidal hormones coordinate the development and maintenance of tissue architecture in many organs, including the central nervous systems (CNS). Within the CNS, sex steroids regulate the morphology, physiology, and behavior of a wide variety of neural cells including, but not limited to, neurons, glia, endothelial cells, and immune cells. Sex steroids spatially and temporally control distinct molecular networks, that, in turn modulate neural activity, synaptic plasticity, growth factor expression and function, nutrient exchange, cellular proliferation, and apoptosis. Over the last several decades, it has become increasingly evident that sex steroids, often in conjunction with neuroinflammation, have profound impact on the occurrence and severity of neuropsychiatric and neurodegenerative disorders. Here, I review the foundational discoveries that established the regulatory role of sex steroids in the CNS and highlight recent advances toward elucidating the complex interaction between sex steroids, neuroinflammation, and CNS regeneration through adult neurogenesis. The majority of recent work has focused on neuroinflammatory responses following acute physical damage, chronic degeneration, or pharmacological insult. Few studies directly assess the role of immune cells in regulating adult neurogenesis under healthy, homeostatic conditions. As such, I also introduce tractable, non-traditional models for examining the role of neuroimmune cells in natural neuronal turnover, seasonal plasticity of neural circuits, and extreme CNS regeneration.","['apoptosis', 'astrocyte', 'microglia', 'neural homeostasis', 'neural plasticity', 'neurodegenerative', 'neurogenesis', 'steroidal hormone']",Frontiers in endocrinology,2018-05-16,"[{'lastname': 'Larson', 'firstname': 'Tracy A', 'initials': 'TA', 'affiliation': 'Department of Biology, University of Virginia, Charlottesville, VA, United States.'}]",,,,,"10.3389/fendo.2018.00205
10.1254/jjp.86.137
10.3390/ijms12031533
10.1016/j.yfrne.2016.03.002
10.1210/jcem-38-3-476
10.1210/endo-65-3-369
10.1152/physrev.00010.2007
10.1210/er.2003-0030
10.5483/BMBRep.2016.49.9.141
10.1080/03602530600569877
10.1016/0006-8993(77)90624-2
10.1093/toxsci/54.1.138
10.1038/ng1901
10.1016/j.mce.2006.12.010
10.1385/ENDO:14:3:407
10.1016/j.yfrne.2008.02.001
10.3389/fendo.2017.00002
10.1016/j.steroids.2013.01.003
10.1016/j.yfrne.2009.04.007
10.1006/frne.1999.0177
10.1523/JNEUROSCI.0909-07.2007
10.1523/JNEUROSCI.17-05-01848.1997
10.1016/S0306-4522(00)00439-5
10.1111/j.1469-7793.1999.209ad.x
10.1210/endo.143.1.8582
10.1016/j.brainres.2014.12.011
10.1111/j.1471-4159.2006.04264.x
10.1016/j.yfrne.2014.05.003
10.1073/pnas.90.14.6439
10.1007/s10571-012-9903-6
10.1016/0960-0760(95)00234-0
10.1196/annals.1298.013
10.1016/S0891-0618(00)00051-X
10.1523/JNEUROSCI.0638-09.2009
10.1128/MCB.23.13.4649-4662.2003
10.1523/JNEUROSCI.1443-06.2006
10.1523/JNEUROSCI.3059-09.2009
10.1523/JNEUROSCI.4097-11.2011
10.1210/en.2003-0724
10.1126/science.1152677
10.1016/S0896-6273(02)00722-5
10.1016/S0896-6273(00)80678-9
10.1016/j.neuroscience.2012.09.023
10.1111/j.1440-1681.2007.04683.x
10.1016/bs.apha.2014.06.018
10.1161/01.RES.0000127719.13255.81
10.1091/mbc.4.10.973
10.1038/nprot.2010.6
10.1074/jbc.274.4.2185
10.1152/ajpheart.2000.279.2.H610
10.1161/01.STR.30.10.2186
10.1152/jappl.2001.91.5.2391
10.1161/01.RES.87.8.677
10.1124/mol.104.004465
10.1113/jphysiol.1990.sp018243
10.1016/j.nbd.2009.07.030
10.1124/jpet.110.168930
10.3233/JAD-2012-112189
10.1167/iovs.06-0322
10.1097/00001756-200208070-00024
10.1038/nrn1826
10.1007/s00401-009-0601-5
10.1016/j.neubiorev.2015.11.016
10.1159/000082141
10.1210/me.2003-0441
10.1016/0960-0760(92)90394-X
10.1016/j.yfrne.2009.04.004
10.1002/glia.22736
10.1002/cne.901240303
10.1126/science.6474166
10.1038/scientificamerican0289-74
10.1038/nrn2822
10.1111/j.1460-9568.2011.07851.x
10.1196/annals.1298.024
10.1101/cshperspect.a019000
10.1098/rstb.2006.2015
10.1038/35067582
10.1016/j.neuron.2011.05.001
10.1038/jcbfm.2014.130
10.1523/JNEUROSCI.18-03-01020.1998
10.1186/1749-8104-8-3
10.1523/JNEUROSCI.3316-13.2014
10.1016/j.bcp.2017.06.116
10.1038/3305
10.1016/j.cell.2013.05.002
10.1016/j.stem.2018.03.015
10.1038/nature25975
10.1073/pnas.1508545112
10.1073/pnas.93.25.14895
10.1002/cne.903560411
10.1016/S0896-6273(00)80317-7
10.1523/JNEUROSCI.22-14-06106.2002
10.1002/(SICI)1097-4695(199807)36:1<1::AID-NEU1>3.0.CO;2-6
10.1038/335353a0
10.1523/JNEUROSCI.08-08-02707.1988
10.1002/cne.22281
10.1101/cshperspect.a018812
10.1002/(SICI)1096-9861(19990830)411:3<487::AID-CNE10>3.0.CO;2-M
10.1098/rstb.2009.0220
10.1002/cne.21296
10.1523/JNEUROSCI.11-06-01756.1991
10.1073/pnas.91.23.11217
10.1523/JNEUROSCI.3434-11.2012
10.1002/cne.20385
10.1523/JNEUROSCI.4520-04.2005
10.1073/pnas.91.17.7854
10.1073/pnas.192308799
10.1073/pnas.2630225100
10.1111/j.1600-0404.1976.tb04363.x
10.1016/j.exer.2006.11.008
10.7554/eLife.19109
10.1196/annals.1386.035
10.1126/science.1194637
10.1126/science.1110647
10.1016/j.stem.2010.08.014
10.1126/science.290.5497.1768
10.1155/2014/610343
10.1038/nrn3722
10.1161/STROKEAHA.112.659656
10.1038/nn.3469
10.1038/jcbfm.2013.146
10.1016/j.jsbmb.2014.02.018
10.1016/j.bbi.2011.01.013
10.1016/0197-0186(95)00141-7
10.1084/jem.189.11.1777
10.1002/(SICI)1098-1136(199804)22:4<401::AID-GLIA9>3.0.CO;2-5
10.1007/s12640-015-9592-2
10.1046/j.1471-4159.2002.01122.x
10.1128/MCB.25.8.2957-2968.2005
10.1523/JNEUROSCI.21-06-01809.2001
10.1016/j.psyneuen.2012.02.018
10.1002/dneu.22569
10.1017/S1740925X06000202
10.1007/s00401-009-0619-8
10.1016/j.neuroscience.2013.10.050
10.1016/0166-2236(92)90191-A
10.1016/S0197-0186(99)00137-0
10.1126/science.1059162
10.1126/science.1197598
10.1038/nn1623
10.1016/j.cmet.2011.08.016
10.1194/jlr.R400004-JLR200
10.1126/science.291.5504.657
10.1038/nature12776
10.1046/j.1471-4159.2001.00595.x
10.1016/j.tips.2005.11.002
10.1002/1098-1136(200009)31:3<267::AID-GLIA80>3.0.CO;2-N
10.1242/jcs.01658
10.1523/JNEUROSCI.1514-09.2009
10.1111/j.1460-9568.2010.07516.x
10.1016/S0169-328X(02)00379-0
10.1002/neu.20043
10.1210/en.2009-0352
10.1016/0006-8993(93)90964-O
10.1016/j.jneuroim.2008.01.006
10.1002/glia.20806
10.1046/j.1471-4159.1999.0731453.x
10.1111/j.1365-2826.2007.01588.x
10.1002/glia.20904
10.1523/JNEUROSCI.14-12-07541.1994
10.1016/S0306-4522(98)00340-6
10.1002/neu.20147
10.1046/j.1365-2826.2001.00647.x
10.1186/1742-2094-8-81
10.1002/dneu.20548
10.1016/j.yhbeh.2012.04.007
10.1007/s00401-012-1018-0
10.1161/01.STR.27.10.1739
10.1182/blood-2011-03-340281
10.1136/bmj.2.5969.473
10.1002/art.20309
10.4049/jimmunol.0903463
10.1161/01.CIR.0000142050.19488.C7
10.1016/j.cardiores.2006.05.015
10.4049/jimmunol.180.6.3661
10.4049/jimmunol.173.4.2227
10.1176/appi.neuropsych.23.1.90
10.1073/pnas.2234031100
10.1126/science.1088417
10.1016/j.bbi.2011.07.225
10.1002/glia.20571
10.1007/s12031-007-9028-4
10.1002/glia.20419
10.1111/j.1460-9568.2005.04539.x
10.1016/j.mcn.2005.10.006
10.1007/s12035-009-8081-0
10.1523/JNEUROSCI.22-02-00486.2002
10.1016/j.bbi.2011.09.012
10.1634/stemcells.2008-0116
10.1016/S1044-7431(03)00218-5
10.1002/cne.20157
10.1002/dneu.20564
10.1038/nn.3212
10.1016/j.neuron.2015.10.037
10.1016/j.jns.2009.05.028
10.1016/j.neulet.2009.10.051
10.1677/joe.1.06063
10.1523/JNEUROSCI.0453-06.2006
10.1073/pnas.1103833108
10.1073/pnas.1300313110
10.1016/j.bbi.2012.09.003
10.1155/2013/608654
10.1016/j.biopsych.2016.10.004
10.1016/j.yfrne.2008.04.001
10.1007/s10571-011-9783-1
10.1016/j.neuroscience.2005.07.060
10.1155/2017/4653936
10.1111/j.1365-2826.2011.02156.x
10.1371/journal.pone.0154022
10.1111/j.1471-4159.2010.07168.x
10.1056/NEJMoa1600651
10.1056/NEJMsr1604338
10.1016/j.stem.2016.02.016
10.1016/j.stem.2017.07.014
10.1016/j.stem.2016.07.019
10.1093/cid/ciw878
10.1016/S0166-2236(00)01558-7
10.1016/j.tins.2005.01.004
10.1002/(SICI)1097-4695(199704)32:4<426::AID-NEU6>3.0.CO;2-8
10.1523/JNEUROSCI.20-02-00854.2000
10.1002/neu.1055
10.1523/JNEUROSCI.5571-08.2009
10.1016/j.yhbeh.2008.10.006
10.1073/pnas.91.17.7844
10.1073/pnas.0707239104
10.1523/JNEUROSCI.0663-08.2008
10.1016/j.yhbeh.2005.04.009
10.1523/JNEUROSCI.5423-08.2009
10.1101/cshperspect.a019018
10.1002/dneu.20918
10.1006/exnr.1998.6853
10.1006/exnr.1999.7182
10.1242/dev.072587
10.1126/science.1228773
10.1186/1749-8104-7-27",<Element 'PubmedArticle' at 0x7f05dd513ef0>
313,29751000,2-Arachidonoylglycerol: A signaling lipid with manifold actions in the brain.,2-Arachidonoylglycerol (2-AG) is a signaling lipid in the central nervous system that is a key regulator of neurotransmitter release. 2-AG is an endocannabinoid that activates the cannabinoid CB,[],Progress in lipid research,2018-05-12,"[{'lastname': 'Baggelaar', 'firstname': 'Marc P', 'initials': 'MP', 'affiliation': 'Department of Molecular Physiology, Leiden Institute of Chemistry, Leiden University, Einsteinweg 55, 2333 CC Leiden, The Netherlands.'}, {'lastname': 'Maccarrone', 'firstname': 'Mauro', 'initials': 'M', 'affiliation': 'Department of Medicine, Campus Bio-Medico University of Rome, Via Alvaro del Portillo 21, 00128 Rome, Italy; European Centre for Brain Research/IRCCS Santa Lucia Foundation, via del Fosso del Fiorano 65, 00143 Rome, Italy.'}, {'lastname': 'van der Stelt', 'firstname': 'Mario', 'initials': 'M', 'affiliation': 'Department of Molecular Physiology, Leiden Institute of Chemistry, Leiden University, Einsteinweg 55, 2333 CC Leiden, The Netherlands.. Electronic address: m.van.der.stelt@chem.leidenuniv.nl.'}]",,,,Copyright © 2018 The Authors. Published by Elsevier Ltd.. All rights reserved.,10.1016/j.plipres.2018.05.002,<Element 'PubmedArticle' at 0x7f05dd499f40>
314,"29684507
26637556
15847852
17096009
17406976
26084692
28219987
12879863
19342823
24829996
18479218
15927699
15475532
11668089
24023412
27539920
18550427
24951624
19486591
18689429
25217656
19352056
19457890
18469338
21135513
18487441
20678996
19463813
22016534
7620610
9344632
8103642
11846609
22160544
15089972
12901335
18190523
22933020
11168839
22466658
20547972
28637815
27698069
14693687
25362113
25009217
27163380
23225134
29167166
25776070
18574076
18768402
23877628
28710070
26801309
23438934
20142564
22083161
10330245",Angiotensin II Type 1a Receptors in the Subfornical Organ Modulate Neuroinflammation in the Hypothalamic Paraventricular Nucleus in Heart Failure Rats.,"Inflammation in the hypothalamic paraventricular nucleus (PVN) contributes to neurohumoral excitation and its adverse consequences in systolic heart failure (HF). The stimuli that trigger inflammation in the PVN in HF are not well understood. Angiotensin II (AngII) has pro-inflammatory effects, and circulating levels of AngII increase in HF. The subfornical organ (SFO), a circumventricular structure that lacks an effective blood-brain barrier and senses circulating AngII, contains PVN-projecting neurons. We hypothesized that activation of AngII type 1a receptors (AT","['arginine vasopressin', 'forebrain', 'proinflammatory cytokines', 'renin-angiotensin system', 'sympathetic nerve activity']",Neuroscience,2018-04-24,"[{'lastname': 'Yu', 'firstname': 'Yang', 'initials': 'Y', 'affiliation': 'Department of Internal Medicine, University of Iowa Carver College of Medicine, 200 Hawkins Drive, Iowa City, IA, USA. Electronic address: yang-yu@uiowa.edu.'}, {'lastname': 'Wei', 'firstname': 'Shun-Guang', 'initials': 'SG', 'affiliation': 'Department of Internal Medicine, University of Iowa Carver College of Medicine, 200 Hawkins Drive, Iowa City, IA, USA. Electronic address: shunguang-wei@uiowa.edu.'}, {'lastname': 'Weiss', 'firstname': 'Robert M', 'initials': 'RM', 'affiliation': 'Department of Internal Medicine, University of Iowa Carver College of Medicine, 200 Hawkins Drive, Iowa City, IA, USA. Electronic address: robert-weiss@uiowa.edu.'}, {'lastname': 'Felder', 'firstname': 'Robert B', 'initials': 'RB', 'affiliation': 'Department of Internal Medicine, University of Iowa Carver College of Medicine, 200 Hawkins Drive, Iowa City, IA, USA; Research Service, Veterans Affairs Medical Center, 601 Highway 6 West, Iowa City, IA, USA. Electronic address: robert-felder@uiowa.edu.'}]",,,,Copyright © 2018 IBRO. Published by Elsevier Ltd. All rights reserved.,10.1016/j.neuroscience.2018.04.012,<Element 'PubmedArticle' at 0x7f05dd4277c0>
315,"29667931
27493973
27540165
27179961
23318001
28189498
29338785
28303137
23644076
24445162
26341532
17106878
21945916
18414822
20055710
23488800
26963721
25089563
23753417
22817481
19247832
28261874
12468568
26448556
26067058
27094468
24368090
26044748
23997755
24355101
19439822
23835908
22492304
11378049
24047617
26576561
27670763
26780455
24342611
23499735
26802771
24824997
26364736","AVE0991, a nonpeptide analogue of Ang-(1-7), attenuates aging-related neuroinflammation.","During the aging process, chronic neuroinflammation induced by microglia is detrimental for the brain and contributes to the etiology of several aging-related neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease. As a newly identified axis of renin-angiotensin system, ACE2/Ang-(1-7)/MAS1 axis plays a crucial role in modulating inflammatory responses under various pathological conditions. However, its relationship with aging-related neuroinflammation is less studied so far. In this study, by using SAMP8 mice, an animal model of accelerated aging, we revealed that the neuroinflammation in the aged brain might be attributed to a decreased level of Ang-(1-7). More importantly, we provided evidence that AVE0991, a nonpeptide analogue of Ang-(1-7), attenuated the aging-related neuroinflammation via suppression of microglial-mediated inflammatory response through a MAS1 receptor-dependent manner. Meanwhile, this protective effect might be ascribed to the M2 activation of microglia induced by AVE0991. Taken together, these findings reveal the association of Ang-(1-7) with the inflammatory response in the aged brain and uncover the potential of its nonpeptide analogue AVE0991 in attenuation of aging-related neuroinflammation.","['AVE0991', 'angiotensin-(1-7)', 'microglia', 'neuroinflammation', 'renin-angiotensin system']",Aging,2018-04-19,"[{'lastname': 'Jiang', 'firstname': 'Teng', 'initials': 'T', 'affiliation': 'Department of Neurology, Nanjing First Hospital Nanjing Medical University, Nanjing, PR China.'}, {'lastname': 'Xue', 'firstname': 'Liu-Jun', 'initials': 'LJ', 'affiliation': ""Department of Neurology, Nanjing First Hospital Nanjing Medical University, Nanjing, PR China.\nDepartment of Neurology, Huai'an First People's Hospital, Nanjing Medical University, Huai'an, PR China.""}, {'lastname': 'Yang', 'firstname': 'Yang', 'initials': 'Y', 'affiliation': 'Department of Neurology, Nanjing First Hospital Nanjing Medical University, Nanjing, PR China.'}, {'lastname': 'Wang', 'firstname': 'Qing-Guang', 'initials': 'QG', 'affiliation': 'Department of Neurology, Nanjing First Hospital Nanjing Medical University, Nanjing, PR China.'}, {'lastname': 'Xue', 'firstname': 'Xiao', 'initials': 'X', 'affiliation': 'Department of Neurology, Nanjing First Hospital Nanjing Medical University, Nanjing, PR China.'}, {'lastname': 'Ou', 'firstname': 'Zhou', 'initials': 'Z', 'affiliation': 'Department of Neurology, Nanjing First Hospital Nanjing Medical University, Nanjing, PR China.'}, {'lastname': 'Gao', 'firstname': 'Qing', 'initials': 'Q', 'affiliation': 'Department of Neurology, Nanjing First Hospital Nanjing Medical University, Nanjing, PR China.'}, {'lastname': 'Shi', 'firstname': 'Jian-Quan', 'initials': 'JQ', 'affiliation': 'Department of Neurology, Nanjing First Hospital Nanjing Medical University, Nanjing, PR China.'}, {'lastname': 'Wu', 'firstname': 'Liang', 'initials': 'L', 'affiliation': 'Department of Neurology, Nanjing First Hospital Nanjing Medical University, Nanjing, PR China.'}, {'lastname': 'Zhang', 'firstname': 'Ying-Dong', 'initials': 'YD', 'affiliation': 'Department of Neurology, Nanjing First Hospital Nanjing Medical University, Nanjing, PR China.'}]",,,,,"10.18632/aging.101419
10.1155/2016/8426874
10.1126/science.aag2590
10.1016/j.jalz.2016.02.010
10.1016/j.molmed.2012.12.003
10.1016/j.nbd.2017.02.001
10.1186/s12974-018-1060-5
10.3389/fimmu.2017.00198
10.1016/j.pharmthera.2013.04.013
10.1016/j.bcp.2014.01.008
10.1016/j.brainres.2015.08.031
10.1002/glia.20459
10.1016/j.peptides.2011.09.010
10.1007/s00109-008-0336-0
10.1146/annurev.pharmtox.010909.105610
10.1111/bph.12159
10.1371/journal.pone.0150861
10.1089/ars.2013.5818
10.1161/HYPERTENSIONAHA.111.00919
10.1111/j.1476-5381.2012.02105.x
10.1007/s11064-009-9923-x
10.1111/neup.12373
10.1161/01.HYP.0000037979.53963.8F
10.1111/jnc.13386
10.1016/j.pneurobio.2015.05.003
10.1016/j.exger.2016.03.014
10.1016/j.neurobiolaging.2013.11.026
10.1007/s12035-015-9260-9
10.2174/1570159X11311020007
10.1016/j.peptides.2013.12.006
10.1097/01.hjh.0000467659.31038.0f
10.1038/mp.2013.83
10.1210/en.2011-1925
10.1016/S0090-4295(01)01124-4
10.3233/JAD-131148
10.1007/s00401-015-1504-2
10.1007/s00401-016-1622-5
10.1007/s12035-016-9704-x
10.1016/j.bbrc.2013.12.051
10.1016/j.phrs.2013.03.001
10.1016/j.neuropharm.2016.01.028
10.1111/bph.12770
10.1016/j.neurobiolaging.2015.08.019",<Element 'PubmedArticle' at 0x7f05dd44bcc0>
316,29627302,Inhibitive Effect of Resveratrol on the Inflammation in Cultured Astrocytes and Microglia Induced by Aβ,"Astrocytes and microglia appear central to the initiation and progression of neuroinflammation in Alzheimer's disease (AD). In this study, inflammation was mimicked by Aβ","[""Alzheimer's disease"", 'astrocytes', 'inflammation', 'microglia', 'nuclear factor-κB', 'resveratrol']",Neuroscience,2018-04-09,"[{'lastname': 'Zhao', 'firstname': 'Haifeng', 'initials': 'H', 'affiliation': 'Department of Nutrition and Food Hygiene, School of Public Health, Shanxi Medical University, Taiyuan, Shanxi 030001, PR China. Electronic address: haifengzao75@163.com.'}, {'lastname': 'Wang', 'firstname': 'Qian', 'initials': 'Q', 'affiliation': 'Department of Nutrition and Food Hygiene, School of Public Health, Shanxi Medical University, Taiyuan, Shanxi 030001, PR China.'}, {'lastname': 'Cheng', 'firstname': 'Xuejiao', 'initials': 'X', 'affiliation': 'Department of Nutrition and Food Hygiene, School of Public Health, Shanxi Medical University, Taiyuan, Shanxi 030001, PR China.'}, {'lastname': 'Li', 'firstname': 'Xuemin', 'initials': 'X', 'affiliation': 'Center for Disease Control and Prevention in Shanxi Province, Taiyuan, Shanxi 030012, PR China.'}, {'lastname': 'Li', 'firstname': 'Na', 'initials': 'N', 'affiliation': 'Department of Nutrition and Food Hygiene, School of Public Health, Shanxi Medical University, Taiyuan, Shanxi 030001, PR China.'}, {'lastname': 'Liu', 'firstname': 'Tiantian', 'initials': 'T', 'affiliation': 'Department of Nutrition and Food Hygiene, School of Public Health, Shanxi Medical University, Taiyuan, Shanxi 030001, PR China.'}, {'lastname': 'Li', 'firstname': 'Jing', 'initials': 'J', 'affiliation': 'Department of Nutrition and Food Hygiene, School of Public Health, Shanxi Medical University, Taiyuan, Shanxi 030001, PR China.'}, {'lastname': 'Yang', 'firstname': 'Qian', 'initials': 'Q', 'affiliation': 'Department of Nutrition and Food Hygiene, School of Public Health, Shanxi Medical University, Taiyuan, Shanxi 030001, PR China.'}, {'lastname': 'Dong', 'firstname': 'Ruirui', 'initials': 'R', 'affiliation': 'Department of Nutrition and Food Hygiene, School of Public Health, Shanxi Medical University, Taiyuan, Shanxi 030001, PR China.'}, {'lastname': 'Zhang', 'firstname': 'Yusen', 'initials': 'Y', 'affiliation': 'Department of Nutrition and Food Hygiene, School of Public Health, Shanxi Medical University, Taiyuan, Shanxi 030001, PR China.'}, {'lastname': 'Zhang', 'firstname': 'Luping', 'initials': 'L', 'affiliation': 'Department of Nutrition and Food Hygiene, School of Public Health, Shanxi Medical University, Taiyuan, Shanxi 030001, PR China.'}]",,,,Copyright © 2018 IBRO. Published by Elsevier Ltd. All rights reserved.,10.1016/j.neuroscience.2018.03.047,<Element 'PubmedArticle' at 0x7f05dd3f11d0>
317,"29579222
19389627
15172174
17543500
24952959
16499883
9854452
10922080
16386803
19464360
25004388
15068390
28192415
17882254
12114258
25653586
26607104
19655259
17194743
20398732
17565008
16723527
20654654
9646173
28234213
11520904
16647243
22041296
15820709
18079203
20184396
24845457
19710634
21775596
12096891
15184902
23458502
11790511
10557108
11301286
20375198
27077495
16968947
15331569
23374874
15020765
16018870
22777139
25870539
10696570
14659696
17244613
19840546
26881836
21238488
18653287
18722389
17433555
19111355
21115202
21173796
24937045
19931610
19620237
22960592
17030030
21525267
15528042",Inhibition of Fatty Acid Amide Hydrolase by PF-3845 Alleviates the Nitrergic and Proinflammatory Response in Rat Hippocampus Following Acute Stress.,"Long-term exposure to stress has been demonstrated to cause neuroinflammation through a sustained overproduction of free radicals, including nitric oxide, via an increased inducible nitric oxide synthase activity. We previously demonstrated that inducible nitric oxide synthase activity and mRNA are significantly upregulated in the rat hippocampus following just 4 hours of restraint stress. Similar to nitric oxide, endocannabinoids are synthesized on demand, with preclinical observations suggesting that cannabinoid receptor agonists and endocannabinoid enhancers inhibit nitrergic activity. Specifically, previous work has shown that enhancement of endocannabinoids via inhibition of fatty acid amide hydrolase with PF-3845 reduced inducible nitric oxide synthase-expressing microglia following traumatic brain injury. However, this describes cannabinoid modulation following physical injury, and therefore the present study aimed to examine the effects of PF-3845 in the modulation of nitrergic and inflammatory-related genes within the hippocampus after acute stress exposure.
Following vehicle or PF-3845 injections (5 mg/kg; i.p.), male Wistar rats were exposed to 0 (control), 60, 240, or 360 minutes of restraint stress after which plasma and dorsal hippocampus were isolated for further biochemical and gene expression analysis.
The results demonstrate that pretreatment with PF-3845 rapidly ameliorates plasma corticosterone release at 60 minutes of stress. An increase in endocannabinoid signalling also induces an overall attenuation in inducible nitric oxide synthase, tumor necrosis factor-alpha convertase, interleukin-6, cyclooxygenase-2, peroxisome proliferator-activated receptor gamma mRNA, and the transactivation potential of nuclear factor kappa-light-chain-enhancer of activated B cells in the hippocampus.
These results suggest that enhanced endocannabinoid levels in the dorsal hippocampus have an overall antinitrosative and antiinflammatory effect following acute stress exposure.","['acute stress', 'endocannabinoids', 'fatty acid amide hydrolase inhibitor', 'inducible nitric oxide synthase', 'neuroinflammatory response']",The international journal of neuropsychopharmacology,2018-03-27,"[{'lastname': 'Chen', 'firstname': 'Hsiao-Jou Cortina', 'initials': 'HC', 'affiliation': 'School of Biomedical Sciences, The University of Queensland, St Lucia, Australia.'}, {'lastname': 'Spiers', 'firstname': 'Jereme G', 'initials': 'JG', 'affiliation': 'MRC Toxicology Unit, University of Leicester, Leicester, United Kingdom.'}, {'lastname': 'Sernia', 'firstname': 'Conrad', 'initials': 'C', 'affiliation': 'School of Biomedical Sciences, The University of Queensland, St Lucia, Australia.'}, {'lastname': 'Lavidis', 'firstname': 'Nickolas A', 'initials': 'NA', 'affiliation': 'School of Biomedical Sciences, The University of Queensland, St Lucia, Australia.'}]",,,"The results demonstrate that pretreatment with PF-3845 rapidly ameliorates plasma corticosterone release at 60 minutes of stress. An increase in endocannabinoid signalling also induces an overall attenuation in inducible nitric oxide synthase, tumor necrosis factor-alpha convertase, interleukin-6, cyclooxygenase-2, peroxisome proliferator-activated receptor gamma mRNA, and the transactivation potential of nuclear factor kappa-light-chain-enhancer of activated B cells in the hippocampus.",© The Author(s) 2018. Published by Oxford University Press on behalf of CINP.,10.1093/ijnp/pyy033,<Element 'PubmedArticle' at 0x7f05dd403310>
318,29548998,mTORC1 pathway disruption abrogates the effects of the ciliary neurotrophic factor on energy balance and hypothalamic neuroinflammation.,"Ciliary neurotrophic factor (CNTF) potently decreases food intake and body weight in diet-induced obese mice by acting through neuronal circuits and pathways located in the arcuate nucleus (ARC) of the hypothalamus. CNTF also exerts pro-inflammatory actions within the brain. Here we tested whether CNTF modifies energy balance by inducing inflammatory responses in the ARC and whether these effects depend upon the mechanistic target of rapamycin complex 1 (mTORC1) pathway, which regulates both energy metabolism and inflammation. To this purpose, chow- and high fat diet (HFD)- fed mice lacking the S6 kinase 1 (S6K1","['CNTF', 'Glia cells', 'Hypothalamus', 'Inflammation', 'Microglia', 'Obesity', 'S6K1', 'mTOR']","Brain, behavior, and immunity",2018-03-20,"[{'lastname': 'André', 'firstname': 'Caroline', 'initials': 'C', 'affiliation': 'INSERM, Neurocentre Magendie, Physiopathologie de la Plasticité Neuronale, U1215, F-33000 Bordeaux, France; University of Bordeaux, Neurocentre Magendie, Physiopathologie de la Plasticité Neuronale, U1215, F-33000 Bordeaux, France.'}, {'lastname': 'Catania', 'firstname': 'Caterina', 'initials': 'C', 'affiliation': 'INSERM, Neurocentre Magendie, Physiopathologie de la Plasticité Neuronale, U1215, F-33000 Bordeaux, France; University of Bordeaux, Neurocentre Magendie, Physiopathologie de la Plasticité Neuronale, U1215, F-33000 Bordeaux, France.'}, {'lastname': 'Remus-Borel', 'firstname': 'Julie', 'initials': 'J', 'affiliation': 'INRA, Nutrition et Neurobiologie Intégrée, UMR 1286, F-33076 Bordeaux, France; University of Bordeaux, Nutrition et Neurobiologie Intégrée, UMR 1286, F-33076 Bordeaux, France.'}, {'lastname': 'Ladeveze', 'firstname': 'Elodie', 'initials': 'E', 'affiliation': 'INSERM, Neurocentre Magendie, Physiopathologie de la Plasticité Neuronale, U1215, F-33000 Bordeaux, France; University of Bordeaux, Neurocentre Magendie, Physiopathologie de la Plasticité Neuronale, U1215, F-33000 Bordeaux, France.'}, {'lastname': 'Leste-Lasserre', 'firstname': 'Thierry', 'initials': 'T', 'affiliation': 'INSERM, Neurocentre Magendie, Physiopathologie de la Plasticité Neuronale, U1215, F-33000 Bordeaux, France; University of Bordeaux, Neurocentre Magendie, Physiopathologie de la Plasticité Neuronale, U1215, F-33000 Bordeaux, France.'}, {'lastname': 'Mazier', 'firstname': 'Wilfrid', 'initials': 'W', 'affiliation': 'INSERM, Neurocentre Magendie, Physiopathologie de la Plasticité Neuronale, U1215, F-33000 Bordeaux, France; University of Bordeaux, Neurocentre Magendie, Physiopathologie de la Plasticité Neuronale, U1215, F-33000 Bordeaux, France.'}, {'lastname': 'Binder', 'firstname': 'Elke', 'initials': 'E', 'affiliation': 'INSERM, Neurocentre Magendie, Physiopathologie de la Plasticité Neuronale, U1215, F-33000 Bordeaux, France; University of Bordeaux, Neurocentre Magendie, Physiopathologie de la Plasticité Neuronale, U1215, F-33000 Bordeaux, France.'}, {'lastname': 'Gonzales', 'firstname': 'Delphine', 'initials': 'D', 'affiliation': 'INSERM, Neurocentre Magendie, Physiopathologie de la Plasticité Neuronale, U1215, F-33000 Bordeaux, France; University of Bordeaux, Neurocentre Magendie, Physiopathologie de la Plasticité Neuronale, U1215, F-33000 Bordeaux, France.'}, {'lastname': 'Clark', 'firstname': 'Samantha', 'initials': 'S', 'affiliation': 'INSERM, Neurocentre Magendie, Physiopathologie de la Plasticité Neuronale, U1215, F-33000 Bordeaux, France; University of Bordeaux, Neurocentre Magendie, Physiopathologie de la Plasticité Neuronale, U1215, F-33000 Bordeaux, France.'}, {'lastname': 'Guzman-Quevedo', 'firstname': 'Omar', 'initials': 'O', 'affiliation': 'INSERM, Neurocentre Magendie, Physiopathologie de la Plasticité Neuronale, U1215, F-33000 Bordeaux, France; University of Bordeaux, Neurocentre Magendie, Physiopathologie de la Plasticité Neuronale, U1215, F-33000 Bordeaux, France.'}, {'lastname': 'Abrous', 'firstname': 'Djoher Nora', 'initials': 'DN', 'affiliation': 'INSERM, Neurocentre Magendie, Physiopathologie de la Plasticité Neuronale, U1215, F-33000 Bordeaux, France; University of Bordeaux, Neurocentre Magendie, Physiopathologie de la Plasticité Neuronale, U1215, F-33000 Bordeaux, France.'}, {'lastname': 'Layé', 'firstname': 'Sophie', 'initials': 'S', 'affiliation': 'INRA, Nutrition et Neurobiologie Intégrée, UMR 1286, F-33076 Bordeaux, France; University of Bordeaux, Nutrition et Neurobiologie Intégrée, UMR 1286, F-33076 Bordeaux, France.'}, {'lastname': 'Cota', 'firstname': 'Daniela', 'initials': 'D', 'affiliation': 'INSERM, Neurocentre Magendie, Physiopathologie de la Plasticité Neuronale, U1215, F-33000 Bordeaux, France; University of Bordeaux, Neurocentre Magendie, Physiopathologie de la Plasticité Neuronale, U1215, F-33000 Bordeaux, France. Electronic address: daniela.cota@inserm.fr.'}]",,,,Copyright © 2018 Elsevier Inc. All rights reserved.,10.1016/j.bbi.2018.03.014,<Element 'PubmedArticle' at 0x7f05dd3ada40>
319,29526318,A comparative study of melatonin and immunomodulatory therapy with interferon beta and glatiramer acetate in a mouse model of multiple sclerosis.,"Multiple sclerosis (MS) is a chronic, demyelinating, autoimmune disease of the central nervous system causing neuroinflammation. Experimental autoimmune encephalitis (EAE) is a model of the disease. MS is classically treated with interferon beta (IFN-β) and glatiramer acetate (GA). Melatonin (MLT) has been reported to modulate immune system responses. The aim of the present study is to analyse the effects of MLT administration in comparison with the first-line treatments for MS (IFN-β and GA).
EAE was induced in male Sprague-Dawley rats; the animals subsequently received either IFN-β, GA, or MLT. Cerebrospinal fluid (CSF) samples were analysed by multiplex assay to determine the levels of proinflammatory cytokines. The neurological evaluation of EAE was also recorded.
All immunised animals developed EAE. We evaluated the first relapse-remission cycle, observing that IFN-β and GA had better results than MLT in the clinical evaluation. Neither EAE nor any of the treatments administered modified CSF IL-1β and IL-12p70 concentrations. However, IFN-β and MLT did decrease CSF TNF-α concentrations.
Further studies are needed to evaluate the molecular mechanisms involved in the behaviour of MLT in EAE, and to quantify other cytokines in different biological media in order for MLT to be considered an anti-inflammatory agent capable of regulating MS.","['Acetato de glatirámero', 'EAE', 'Encefalitis autoinmune experimental', 'Esclerosis múltiple', 'Glatiramer acetate', 'Immunomodulators', 'Inmunomoduladores', 'Interferon beta', 'Interferón beta', 'Melatonin', 'Melatonina', 'Multiple sclerosis']",Neurologia,2018-03-13,"[{'lastname': 'Ramos González', 'firstname': 'E J', 'initials': 'EJ', 'affiliation': 'Departamento de Fisiología, Centro Universitario Ciencias de la Salud, Universidad de Guadalajara, Guadalajara, Jalisco, México; División de Neurociencias, Centro de Investigación Biomédica de Occidente, Instituto Mexicano del Seguro Social, Guadalajara, Jalisco, México.'}, {'lastname': 'Ramirez Jirano', 'firstname': 'L J', 'initials': 'LJ', 'affiliation': 'División de Neurociencias, Centro de Investigación Biomédica de Occidente, Instituto Mexicano del Seguro Social, Guadalajara, Jalisco, México.'}, {'lastname': 'García Martínez', 'firstname': 'D Z', 'initials': 'DZ', 'affiliation': 'División de Investigación Quirúrgica, Centro de Investigación Biomédica de Occidente, Instituto Mexicano del Seguro Social, Guadalajara, Jalisco, México.'}, {'lastname': 'Ortiz', 'firstname': 'G G', 'initials': 'GG', 'affiliation': 'División de Neurociencias, Centro de Investigación Biomédica de Occidente, Instituto Mexicano del Seguro Social, Guadalajara, Jalisco, México.'}, {'lastname': 'Jave Suárez', 'firstname': 'L F', 'initials': 'LF', 'affiliation': 'División de Inmunología, Centro de Investigación Biomédica de Occidente, Instituto Mexicano del Seguro Social, Guadalajara, Jalisco, México.'}, {'lastname': 'Leal Cortes', 'firstname': 'C A', 'initials': 'CA', 'affiliation': 'División de Investigación Quirúrgica, Centro de Investigación Biomédica de Occidente, Instituto Mexicano del Seguro Social, Guadalajara, Jalisco, México.'}, {'lastname': 'Bitzer Quintero', 'firstname': 'O K', 'initials': 'OK', 'affiliation': 'División de Neurociencias, Centro de Investigación Biomédica de Occidente, Instituto Mexicano del Seguro Social, Guadalajara, Jalisco, México. Electronic address: neuronim26@yahoo.com.'}]",,,"All immunised animals developed EAE. We evaluated the first relapse-remission cycle, observing that IFN-β and GA had better results than MLT in the clinical evaluation. Neither EAE nor any of the treatments administered modified CSF IL-1β and IL-12p70 concentrations. However, IFN-β and MLT did decrease CSF TNF-α concentrations.","Copyright © 2018 Sociedad Española de Neurología. Publicado por Elsevier España, S.L.U. All rights reserved.",10.1016/j.nrl.2018.01.007,<Element 'PubmedArticle' at 0x7f05dd3bee00>
320,"29506554
19369037
8174519
11262734
12644744
8985696
22957234
12151121
20618423
1743148
17442304
17113938
22396881
12821374
18177363
18226170
19774666
20880506
20837059
19615761
25732035
21925173
16116433
25765328
25716834
24355813
10947836
15987264
14678765
17521344
23298414
14616295
27352343
21423669
21970823
19360884
9427511
18454941
19110011
10335522
26720702
20004858
22171792
24333865
18550176
11864735
12955493
2777930
12209121
28444637
11549943
18178255
17303248
9495576
603028
16621450
18003843
22101060
24169149
26684336
19288274
23142267
16563220
21446052
9126873
15195687
10467263
21859125
19812958
20672003
21464890
22488332
25350774
6140073
9751175
15752349
19850449
21915647
23922547
21724913
17007911
1331416
24446952
7952267
22240205
23339567",Effects of dexamethasone on the Li-pilocarpine model of epilepsy: protection against hippocampal inflammation and astrogliosis.,"Temporal lobe epilepsy (TLE) is the most common form of partial epilepsy and is accompanied, in one third of cases, by resistance to antiepileptic drugs (AED). Most AED target neuronal activity modulated by ionic channels, and the steroid sensitivity of these channels has supported the use of corticosteroids as adjunctives to AED. Assuming the importance of astrocytes in neuronal activity, we investigated inflammatory and astroglial markers in the hippocampus, a key structure affected in TLE and in the Li-pilocarpine model of epilepsy.
Initially, hippocampal slices were obtained from sham rats and rats subjected to the Li-pilocarpine model of epilepsy, at 1, 14, and 56 days after status epilepticus (SE), which correspond to the acute, silent, and chronic phases. Dexamethasone was added to the incubation medium to evaluate the secretion of S100B, an astrocyte-derived protein widely used as a marker of brain injury. In the second set of experiments, we evaluated the in vivo effect of dexamethasone, administrated at 2 days after SE, on hippocampal inflammatory (COX-1/2, PGE2, and cytokines) and astroglial parameters: GFAP, S100B, glutamine synthetase (GS) and water (AQP-4), and K
Basal S100B secretion and S100B secretion in high-K
Changes in astroglial parameters emphasize the importance of these cells for understanding alterations and mechanisms of epileptic disorders in this model. In vivo dexamethasone administration prevented most of the parameters analyzed, reinforcing the importance of anti-inflammatory steroid therapy in the Li-pilocarpine model and possibly in other epileptic conditions in which neuroinflammation is present.","['Astrocytes', 'Dexamethasone', 'Epilepsy', 'Neuroinflammation', 'S100B']",Journal of neuroinflammation,2018-03-07,"[{'lastname': 'Vizuete', 'firstname': 'Adriana Fernanda K', 'initials': 'AFK', 'affiliation': 'Department of Biochemistry, Instituto de Ciências Básicas da Saúde, Universidade Federal do Rio Grande do Sul, Ramiro Barcelos, 2600-Anexo, Porto Alegre, RS, 90035-003, Brazil. adrianavizuete@gmail.com.'}, {'lastname': 'Hansen', 'firstname': 'Fernanda', 'initials': 'F', 'affiliation': 'Department of Biochemistry, Instituto de Ciências Básicas da Saúde, Universidade Federal do Rio Grande do Sul, Ramiro Barcelos, 2600-Anexo, Porto Alegre, RS, 90035-003, Brazil.'}, {'lastname': 'Negri', 'firstname': 'Elisa', 'initials': 'E', 'affiliation': 'Department of Biochemistry, Instituto de Ciências Básicas da Saúde, Universidade Federal do Rio Grande do Sul, Ramiro Barcelos, 2600-Anexo, Porto Alegre, RS, 90035-003, Brazil.'}, {'lastname': 'Leite', 'firstname': 'Marina Concli', 'initials': 'MC', 'affiliation': 'Department of Biochemistry, Instituto de Ciências Básicas da Saúde, Universidade Federal do Rio Grande do Sul, Ramiro Barcelos, 2600-Anexo, Porto Alegre, RS, 90035-003, Brazil.'}, {'lastname': 'de Oliveira', 'firstname': 'Diogo Losch', 'initials': 'DL', 'affiliation': 'Department of Biochemistry, Instituto de Ciências Básicas da Saúde, Universidade Federal do Rio Grande do Sul, Ramiro Barcelos, 2600-Anexo, Porto Alegre, RS, 90035-003, Brazil.'}, {'lastname': 'Gonçalves', 'firstname': 'Carlos-Alberto', 'initials': 'CA', 'affiliation': 'Department of Biochemistry, Instituto de Ciências Básicas da Saúde, Universidade Federal do Rio Grande do Sul, Ramiro Barcelos, 2600-Anexo, Porto Alegre, RS, 90035-003, Brazil.'}]",,,Basal S100B secretion and S100B secretion in high-K,,"10.1186/s12974-018-1109-5
10.1016/j.eplepsyres.2009.03.003
10.1097/00019052-200104000-00009
10.1097/00019052-200304000-00008
10.1016/S0920-1211(96)00043-5
10.1016/S0920-1211(02)00072-4
10.1111/j.1528-1167.2010.02632.x
10.1111/j.1528-1157.1991.tb05533.x
10.1016/j.expneurol.2007.03.008
10.1016/j.brainresbull.2006.08.009
10.1016/S0014-4886(03)00086-4
10.1111/j.1528-1167.2007.01484.x
10.1111/j.1528-1167.2008.01491.x
10.1016/j.nurt.2010.08.002
10.1016/j.brainresrev.2010.09.002
10.1016/j.tins.2009.05.001
10.1101/cshperspect.a022434
10.1016/j.expneurol.2011.08.024
10.1038/nm1277
10.1093/brain/awv067
10.1523/JNEUROSCI.1574-14.2015
10.1016/j.tins.2013.11.002
10.1046/j.1460-9568.2000.00140.x
10.1111/j.1528-1167.2005.01006.x
10.1016/j.nbd.2003.08.001
10.1111/j.1528-1167.2007.01135.x
10.1016/j.tins.2012.11.008
10.1034/j.1600-0404.2003.00159.x
10.1007/s12013-015-0683-8
10.1371/journal.ppat.1001315
10.1186/1742-2094-8-128
10.1002/jnr.22083
10.1016/S0169-328X(97)00221-0
10.1016/j.clinbiochem.2008.04.003
10.1016/j.bbamcr.2008.11.009
10.1177/135245859900500210
10.1016/j.yebeh.2015.10.003
10.1139/y11-096
10.1016/j.nbd.2013.12.001
10.1016/j.jneumeth.2008.04.019
10.1016/S0166-4328(01)00417-X
10.1007/s00441-003-0751-z
10.1038/jcbfm.1989.83
10.1038/nrn920
10.1007/s11064-017-2276-y
10.1023/A:1017585308255
10.1016/j.jneumeth.2007.11.021
10.1016/j.jneumeth.2007.01.001
10.1016/S0009-8981(97)00173-3
10.1016/0003-2697(77)90043-4
10.1016/j.eplepsyres.2006.02.004
10.1523/JNEUROSCI.4141-07.2007
10.1016/j.expneurol.2011.10.028
10.1016/j.clineuro.2013.09.035
10.1101/cshperspect.a022699
10.1007/s11064-009-9949-0
10.1016/j.brainres.2012.10.065
10.1111/j.1582-4934.2006.tb00289.x
10.1016/S0024-3205(97)00104-5
10.1081/CEH-120034137
10.1002/(SICI)1097-4547(19990915)57:6<916::AID-JNR17>3.0.CO;2-J
10.1021/ac200782h
10.1007/978-3-211-98811-4_46
10.1155/2010/790431
10.1371/journal.pone.0018200
10.1007/s11064-012-0766-5
10.1111/ejn.12756
10.1016/0165-3806(83)90123-2
10.1046/j.1471-4159.1998.71041436.x
10.1111/j.1742-4658.2004.04537.x
10.1016/j.eplepsyres.2009.09.020
10.1007/s10072-011-0774-2
10.3389/fncel.2013.00104
10.1167/iovs.11-7675
10.1016/j.acthis.2006.07.003
10.1111/epi.12461
10.1111/j.1750-3639.1994.tb00841.x
10.1186/1742-2094-10-11",<Element 'PubmedArticle' at 0x7f05dd3d1130>
321,29498843,Discovery of Trifluoromethyl Glycol Carbamates as Potent and Selective Covalent Monoacylglycerol Lipase (MAGL) Inhibitors for Treatment of Neuroinflammation.,"Monoacylglycerol lipase (MAGL) inhibition provides a potential treatment approach to neuroinflammation through modulation of both the endocannabinoid pathway and arachidonoyl signaling in the central nervous system (CNS). Herein we report the discovery of compound 15 (PF-06795071), a potent and selective covalent MAGL inhibitor, featuring a novel trifluoromethyl glycol leaving group that confers significant physicochemical property improvements as compared with earlier inhibitor series with more lipophilic leaving groups. The design strategy focused on identifying an optimized leaving group that delivers MAGL potency, serine hydrolase selectivity, and CNS exposure while simultaneously reducing log  D, improving solubility, and minimizing chemical lability. Compound 15 achieves excellent CNS exposure, extended 2-AG elevation effect in vivo, and decreased brain inflammatory markers in response to an inflammatory challenge.",[],Journal of medicinal chemistry,2018-03-03,"[{'lastname': 'McAllister', 'firstname': 'Laura A', 'initials': 'LA', 'affiliation': 'Pfizer Worldwide Research and Development , 610 Main Street , Cambridge , Massachusetts 02139 , United States.'}, {'lastname': 'Butler', 'firstname': 'Christopher R', 'initials': 'CR', 'affiliation': 'Pfizer Worldwide Research and Development , 610 Main Street , Cambridge , Massachusetts 02139 , United States.'}, {'lastname': 'Mente', 'firstname': 'Scot', 'initials': 'S', 'affiliation': 'Pfizer Worldwide Research and Development , 610 Main Street , Cambridge , Massachusetts 02139 , United States.'}, {'lastname': ""O'Neil"", 'firstname': 'Steven V', 'initials': 'SV', 'affiliation': 'Pfizer Worldwide Research and Development , 445 Eastern Point Road , Groton , Connecticut 06340 , United States.'}, {'lastname': 'Fonseca', 'firstname': 'Kari R', 'initials': 'KR', 'affiliation': 'Pfizer Worldwide Research and Development , 610 Main Street , Cambridge , Massachusetts 02139 , United States.'}, {'lastname': 'Piro', 'firstname': 'Justin R', 'initials': 'JR', 'affiliation': 'Pfizer Worldwide Research and Development , 610 Main Street , Cambridge , Massachusetts 02139 , United States.'}, {'lastname': 'Cianfrogna', 'firstname': 'Julie A', 'initials': 'JA', 'affiliation': 'Pfizer Worldwide Research and Development , 445 Eastern Point Road , Groton , Connecticut 06340 , United States.'}, {'lastname': 'Foley', 'firstname': 'Timothy L', 'initials': 'TL', 'affiliation': 'Pfizer Worldwide Research and Development , 445 Eastern Point Road , Groton , Connecticut 06340 , United States.'}, {'lastname': 'Gilbert', 'firstname': 'Adam M', 'initials': 'AM', 'affiliation': 'Pfizer Worldwide Research and Development , 445 Eastern Point Road , Groton , Connecticut 06340 , United States.'}, {'lastname': 'Harris', 'firstname': 'Anthony R', 'initials': 'AR', 'affiliation': 'Pfizer Worldwide Research and Development , 445 Eastern Point Road , Groton , Connecticut 06340 , United States.'}, {'lastname': 'Helal', 'firstname': 'Christopher J', 'initials': 'CJ', 'affiliation': 'Pfizer Worldwide Research and Development , 445 Eastern Point Road , Groton , Connecticut 06340 , United States.'}, {'lastname': 'Johnson', 'firstname': 'Douglas S', 'initials': 'DS', 'affiliation': 'Pfizer Worldwide Research and Development , 610 Main Street , Cambridge , Massachusetts 02139 , United States.'}, {'lastname': 'Montgomery', 'firstname': 'Justin I', 'initials': 'JI', 'affiliation': 'Pfizer Worldwide Research and Development , 445 Eastern Point Road , Groton , Connecticut 06340 , United States.'}, {'lastname': 'Nason', 'firstname': 'Deane M', 'initials': 'DM', 'affiliation': 'Pfizer Worldwide Research and Development , 445 Eastern Point Road , Groton , Connecticut 06340 , United States.'}, {'lastname': 'Noell', 'firstname': 'Stephen', 'initials': 'S', 'affiliation': 'Pfizer Worldwide Research and Development , 445 Eastern Point Road , Groton , Connecticut 06340 , United States.'}, {'lastname': 'Pandit', 'firstname': 'Jayvardhan', 'initials': 'J', 'affiliation': 'Pfizer Worldwide Research and Development , 445 Eastern Point Road , Groton , Connecticut 06340 , United States.'}, {'lastname': 'Rogers', 'firstname': 'Bruce N', 'initials': 'BN', 'affiliation': 'Pfizer Worldwide Research and Development , 610 Main Street , Cambridge , Massachusetts 02139 , United States.'}, {'lastname': 'Samad', 'firstname': 'Tarek A', 'initials': 'TA', 'affiliation': 'Pfizer Worldwide Research and Development , 610 Main Street , Cambridge , Massachusetts 02139 , United States.'}, {'lastname': 'Shaffer', 'firstname': 'Christopher L', 'initials': 'CL', 'affiliation': 'Pfizer Worldwide Research and Development , 610 Main Street , Cambridge , Massachusetts 02139 , United States.'}, {'lastname': 'da Silva', 'firstname': 'Rafael G', 'initials': 'RG', 'affiliation': 'Pfizer Worldwide Research and Development , 445 Eastern Point Road , Groton , Connecticut 06340 , United States.'}, {'lastname': 'Uccello', 'firstname': 'Daniel P', 'initials': 'DP', 'affiliation': 'Pfizer Worldwide Research and Development , 445 Eastern Point Road , Groton , Connecticut 06340 , United States.'}, {'lastname': 'Webb', 'firstname': 'Damien', 'initials': 'D', 'affiliation': 'Pfizer Worldwide Research and Development , 610 Main Street , Cambridge , Massachusetts 02139 , United States.'}, {'lastname': 'Brodney', 'firstname': 'Michael A', 'initials': 'MA', 'affiliation': 'Pfizer Worldwide Research and Development , 610 Main Street , Cambridge , Massachusetts 02139 , United States.'}]",,,,,10.1021/acs.jmedchem.8b00070,<Element 'PubmedArticle' at 0x7f05dd38b220>
322,29484707,2-AG limits Theiler's virus induced acute neuroinflammation by modulating microglia and promoting MDSCs.,"The innate immune response is mediated by primary immune modulators such as cytokines and chemokines that together with immune cells and resident glia orchestrate CNS immunity and inflammation. Growing evidence supports that the endocannabinoid 2-arachidonoylglycerol (2-AG) exerts protective actions in CNS injury models. Here, we used the acute phase of Theiler's virus induced demyelination disease (TMEV-IDD) as a model of acute neuroinflammation to investigate whether 2-AG modifies the brain innate immune responses to TMEV and CNS leukocyte trafficking. 2-AG or the inhibition of its hydrolysis diminished the reactivity and number of microglia at the TMEV injection site reducing their morphological complexity and modulating them towards an anti-inflammatory state via CB2 receptors. Indeed, 2-AG dampened the infiltration of immune cells into the CNS and inhibited their egress from the spleen, resulting in long-term beneficial effects at the chronic phase of the disease. Intriguingly, it is not a generalized action over leukocytes since 2-AG increased the presence and suppressive potency of myeloid derived suppressor cells (MDSCs) in the brain resulting in higher apoptotic CD4","['2-AG', 'CB receptors', 'MAGL', 'MDSCs', 'TMEV', 'inflammation', 'microglia']",Glia,2018-02-28,"[{'lastname': 'Mecha', 'firstname': 'Miriam', 'initials': 'M', 'affiliation': 'Departamento de Neurobiología Funcional y de Sistemas, Grupo de Neuroinmunología, Instituto Cajal, CSIC, Madrid, Spain.'}, {'lastname': 'Feliú', 'firstname': 'Ana', 'initials': 'A', 'affiliation': 'Departamento de Neurobiología Funcional y de Sistemas, Grupo de Neuroinmunología, Instituto Cajal, CSIC, Madrid, Spain.'}, {'lastname': 'Machín', 'firstname': 'Isabel', 'initials': 'I', 'affiliation': 'Laboratorio de Neuroinmuno-Reparación, Hospital Nacional de Parapléjicos-SESCAM Finca ""La Peraleda"" s/n, Toledo, Spain.'}, {'lastname': 'Cordero', 'firstname': 'Cesar', 'initials': 'C', 'affiliation': 'Departamento de Neurobiología Funcional y de Sistemas, Grupo de Neuroinmunología, Instituto Cajal, CSIC, Madrid, Spain.'}, {'lastname': 'Carrillo-Salinas', 'firstname': 'Francisco', 'initials': 'F', 'affiliation': 'Departamento de Neurobiología Funcional y de Sistemas, Grupo de Neuroinmunología, Instituto Cajal, CSIC, Madrid, Spain.'}, {'lastname': 'Mestre', 'firstname': 'Leyre', 'initials': 'L', 'affiliation': 'Departamento de Neurobiología Funcional y de Sistemas, Grupo de Neuroinmunología, Instituto Cajal, CSIC, Madrid, Spain.'}, {'lastname': 'Hernández-Torres', 'firstname': 'Gloria', 'initials': 'G', 'affiliation': 'Departamento de Química Orgánica, Facultad de Químicas, Universidad Complutense de Madrid, Madrid, Spain.'}, {'lastname': 'Ortega-Gutiérrez', 'firstname': 'Silvia', 'initials': 'S', 'affiliation': 'Departamento de Química Orgánica, Facultad de Químicas, Universidad Complutense de Madrid, Madrid, Spain.'}, {'lastname': 'López-Rodríguez', 'firstname': 'María L', 'initials': 'ML', 'affiliation': 'Departamento de Química Orgánica, Facultad de Químicas, Universidad Complutense de Madrid, Madrid, Spain.'}, {'lastname': 'de Castro', 'firstname': 'Fernando', 'initials': 'F', 'affiliation': 'Departamento de Neurobiología Funcional y de Sistemas, Grupo de Neurobiología del Desarrollo. Instituto Cajal, CSIC, Madrid, Spain.'}, {'lastname': 'Clemente', 'firstname': 'Diego', 'initials': 'D', 'affiliation': 'Laboratorio de Neuroinmuno-Reparación, Hospital Nacional de Parapléjicos-SESCAM Finca ""La Peraleda"" s/n, Toledo, Spain.'}, {'lastname': 'Guaza', 'firstname': 'Carmen', 'initials': 'C', 'affiliation': 'Departamento de Neurobiología Funcional y de Sistemas, Grupo de Neuroinmunología, Instituto Cajal, CSIC, Madrid, Spain.'}]",,,,"© 2018 Wiley Periodicals, Inc.",10.1002/glia.23317,<Element 'PubmedArticle' at 0x7f05dd39b9a0>
323,29458118,Neuroprotective effect of melatonin against lipopolysaccharide-induced depressive-like behavior in mice.,"Accumulating evidence indicates an interaction between inflammation and depression since increased levels of pro-inflammatory cytokines are associated with depression-related symptoms. Melatonin is a hormone synthesized and secreted by the pineal gland with antioxidant, anti-inflammatory and antidepressant-like effects. In this way, it would be interesting to evaluate the putative antidepressant-like effect of melatonin treatment in an acute inflammation mice model of depression. The present study aimed to investigate the effect of melatonin treatment on lipopolysaccharide (LPS) induced depressive-like behavior, neuroinflammation, oxidative stress and alteration on brain-derived neurotrophic fator (BDNF) levels. Mice were treated with melatonin (10 mg/kg, i.p.) 30 min before LPS (0.5 mg/kg, i.p.) injection. Twenty-four hours after LPS infusion, mice were submitted to the behavioral tests and, thereafter, biochemical determinations were performed. Melatonin treatment prevented LPS-induced depressive-like behavior in the forced swim and tail suspension tests with no alterations in locomotor activity evaluated in the open field test. Melatonin attenuated LPS-induced increase in tumor necrosis factor-α (TNF-α) and reduction of BDNF levels in the hippocampus. Treatment with melatonin also prevented LPS-induced increase in lipid peroxidation and the reduction of glutathione levels in the hippocampus. In conclusion, the present study suggests that melatonin treatment exerted neuroprotective effects against LPS-induced depressive-like behavior which may be related to reduction of TNF-α release, oxidative stress and modulation of BDNF expression.","['Brain-derived neurotrophic factor', 'Depression', 'Lipopolysaccharide', 'Melatonin', 'Oxidative stress', 'Tumor necrosis factor-α']",Physiology & behavior,2018-02-20,"[{'lastname': 'Taniguti', 'firstname': 'E H', 'initials': 'EH', 'affiliation': 'Laboratório de Fisiologia, Departamento de Ciências Básicas em Saúde, Faculdade de Medicina, Universidade Federal de Mato Grosso, Boa Esperança, 78060900 Cuiabá, MT, Brazil.'}, {'lastname': 'Ferreira', 'firstname': 'Y S', 'initials': 'YS', 'affiliation': 'Laboratório de Fisiologia, Departamento de Ciências Básicas em Saúde, Faculdade de Medicina, Universidade Federal de Mato Grosso, Boa Esperança, 78060900 Cuiabá, MT, Brazil.'}, {'lastname': 'Stupp', 'firstname': 'I J V', 'initials': 'IJV', 'affiliation': 'Laboratório de Fisiologia, Departamento de Ciências Básicas em Saúde, Faculdade de Medicina, Universidade Federal de Mato Grosso, Boa Esperança, 78060900 Cuiabá, MT, Brazil; Laboratório de Imunologia, Departamento de Ciências Básicas em Saúde, Faculdade de Medicina, Universidade Federal de Mato Grosso, Boa Esperança, 78060900 Cuiabá, MT, Brazil.'}, {'lastname': 'Fraga-Junior', 'firstname': 'E B', 'initials': 'EB', 'affiliation': 'Laboratório de Fisiologia, Departamento de Ciências Básicas em Saúde, Faculdade de Medicina, Universidade Federal de Mato Grosso, Boa Esperança, 78060900 Cuiabá, MT, Brazil.'}, {'lastname': 'Mendonça', 'firstname': 'C B', 'initials': 'CB', 'affiliation': 'Laboratório de Imunologia, Departamento de Ciências Básicas em Saúde, Faculdade de Medicina, Universidade Federal de Mato Grosso, Boa Esperança, 78060900 Cuiabá, MT, Brazil.'}, {'lastname': 'Rossi', 'firstname': 'F L', 'initials': 'FL', 'affiliation': 'Laboratório de Imunologia, Departamento de Ciências Básicas em Saúde, Faculdade de Medicina, Universidade Federal de Mato Grosso, Boa Esperança, 78060900 Cuiabá, MT, Brazil.'}, {'lastname': 'Ynoue', 'firstname': 'H N', 'initials': 'HN', 'affiliation': 'Laboratório de Imunologia, Departamento de Ciências Básicas em Saúde, Faculdade de Medicina, Universidade Federal de Mato Grosso, Boa Esperança, 78060900 Cuiabá, MT, Brazil.'}, {'lastname': 'Doneda', 'firstname': 'D L', 'initials': 'DL', 'affiliation': 'Laboratório de Fisiologia, Departamento de Ciências Básicas em Saúde, Faculdade de Medicina, Universidade Federal de Mato Grosso, Boa Esperança, 78060900 Cuiabá, MT, Brazil.'}, {'lastname': 'Lopes', 'firstname': 'L', 'initials': 'L', 'affiliation': 'Laboratório de Fisiologia, Departamento de Ciências Básicas em Saúde, Faculdade de Medicina, Universidade Federal de Mato Grosso, Boa Esperança, 78060900 Cuiabá, MT, Brazil.'}, {'lastname': 'Lima', 'firstname': 'E', 'initials': 'E', 'affiliation': 'Laboratório de Fisiologia, Departamento de Ciências Básicas em Saúde, Faculdade de Medicina, Universidade Federal de Mato Grosso, Boa Esperança, 78060900 Cuiabá, MT, Brazil.'}, {'lastname': 'Buss', 'firstname': 'Z S', 'initials': 'ZS', 'affiliation': 'Laboratório de Imunologia, Departamento de Ciências Básicas em Saúde, Faculdade de Medicina, Universidade Federal de Mato Grosso, Boa Esperança, 78060900 Cuiabá, MT, Brazil.'}, {'lastname': 'Vandresen-Filho', 'firstname': 'S', 'initials': 'S', 'affiliation': 'Laboratório de Fisiologia, Departamento de Ciências Básicas em Saúde, Faculdade de Medicina, Universidade Federal de Mato Grosso, Boa Esperança, 78060900 Cuiabá, MT, Brazil. Electronic address: samuelvandresen@yahoo.com.br.'}]",,,,Copyright © 2018 Elsevier Inc. All rights reserved.,10.1016/j.physbeh.2018.02.034,<Element 'PubmedArticle' at 0x7f05dd32d270>
324,"29417177
14279267
19767575
25403565
24029244
21879347
14581618
15717009
25614742
24101490
26768693
28509260
25146023
24565523
28658409
16049170
17617407
11031095
23402507
27309476
25673840
22133879
28638997
28306359
23502599
28288940
26341974
23238858
25182840
24721734
25421645
28224125
15711542
23872599
28008279
24529943
25584044
25660362
20637060
12149426
22233298
25979862
26283909
28085005
24747011
24772245
21905956
15567326
24582777
23899655
24352035
24126226
23603407
25386818
24232253
27781140
25426252
25088370",Stem cells from human apical papilla decrease neuro-inflammation and stimulate oligodendrocyte progenitor differentiation via activin-A secretion.,"Secondary damage following spinal cord injury leads to non-reversible lesions and hampering of the reparative process. The local production of pro-inflammatory cytokines such as TNF-α can exacerbate these events. Oligodendrocyte death also occurs, followed by progressive demyelination leading to significant tissue degeneration. Dental stem cells from human apical papilla (SCAP) can be easily obtained at the removal of an adult immature tooth. This offers a minimally invasive approach to re-use this tissue as a source of stem cells, as compared to biopsying neural tissue from a patient with a spinal cord injury. We assessed the potential of SCAP to exert neuroprotective effects by investigating two possible modes of action: modulation of neuro-inflammation and oligodendrocyte progenitor cell (OPC) differentiation. SCAP were co-cultured with LPS-activated microglia, LPS-activated rat spinal cord organotypic sections (SCOS), and LPS-activated co-cultures of SCOS and spinal cord adult OPC. We showed for the first time that SCAP can induce a reduction of TNF-α expression and secretion in inflamed spinal cord tissues and can stimulate OPC differentiation via activin-A secretion. This work underlines the potential therapeutic benefits of SCAP for spinal cord injury repair.","['Dental stem cells', 'Differentiation', 'Inflammation', 'Oligodendrocyte progenitor cells', 'Spinal cord']",Cellular and molecular life sciences : CMLS,2018-02-09,"[{'lastname': 'De Berdt', 'firstname': 'Pauline', 'initials': 'P', 'affiliation': 'Louvain Drug Research Institute (LDRI), Advanced Drug Delivery and Biomaterials (ADDB), Université Catholique de Louvain, Avenue E. Mounier 73, B1 73.12, 1200, Brussels, Belgium.'}, {'lastname': 'Bottemanne', 'firstname': 'Pauline', 'initials': 'P', 'affiliation': 'Louvain Drug Research Institute, Bioanalysis and Pharmacology of Bioactive Lipids Research Group (BPBL), Université Catholique de Louvain, Avenue E. Mounier 73, B1 72.01, 1200, Brussels, Belgium.'}, {'lastname': 'Bianco', 'firstname': 'John', 'initials': 'J', 'affiliation': 'Louvain Drug Research Institute (LDRI), Advanced Drug Delivery and Biomaterials (ADDB), Université Catholique de Louvain, Avenue E. Mounier 73, B1 73.12, 1200, Brussels, Belgium.'}, {'lastname': 'Alhouayek', 'firstname': 'Mireille', 'initials': 'M', 'affiliation': 'Louvain Drug Research Institute, Bioanalysis and Pharmacology of Bioactive Lipids Research Group (BPBL), Université Catholique de Louvain, Avenue E. Mounier 73, B1 72.01, 1200, Brussels, Belgium.'}, {'lastname': 'Diogenes', 'firstname': 'Anibal', 'initials': 'A', 'affiliation': 'Department of Endodontics, University of Texas Health Science Center at San Antonio, San Antonio, Texas, USA.'}, {'lastname': 'Lloyd', 'firstname': 'Amy', 'initials': 'A', 'affiliation': None}, {'lastname': 'Llyod', 'firstname': 'Amy', 'initials': 'A', 'affiliation': ""MRC Center for Reproductive Health, The Queen's Medical Research Institute, The University of Edinburgh, Edinburgh, UK.""}, {'lastname': 'Gerardo-Nava', 'firstname': 'Jose', 'initials': 'J', 'affiliation': 'Institute of Neuropathology, Uniklinik RWTH Aachen, Pauwelsstraße 30, 52074, Aachen, Germany.'}, {'lastname': 'Brook', 'firstname': 'Gary A', 'initials': 'GA', 'affiliation': 'Institute of Neuropathology, Uniklinik RWTH Aachen, Pauwelsstraße 30, 52074, Aachen, Germany.'}, {'lastname': 'Miron', 'firstname': 'Véronique', 'initials': 'V', 'affiliation': ""MRC Center for Reproductive Health, The Queen's Medical Research Institute, The University of Edinburgh, Edinburgh, UK.""}, {'lastname': 'Muccioli', 'firstname': 'Giulio G', 'initials': 'GG', 'affiliation': 'Louvain Drug Research Institute, Bioanalysis and Pharmacology of Bioactive Lipids Research Group (BPBL), Université Catholique de Louvain, Avenue E. Mounier 73, B1 72.01, 1200, Brussels, Belgium.'}, {'lastname': 'Rieux', 'firstname': 'Anne des', 'initials': 'AD', 'affiliation': 'Louvain Drug Research Institute (LDRI), Advanced Drug Delivery and Biomaterials (ADDB), Université Catholique de Louvain, Avenue E. Mounier 73, B1 73.12, 1200, Brussels, Belgium. anne.desrieux@uclouvain.be.'}]",,,,,10.1007/s00018-018-2764-5,<Element 'PubmedArticle' at 0x7f05dd340bd0>
325,"29357308
15832099
10858586
16681555
18245760
20600995
11467904
22695063
17192785
21843630
25130658
24836855
19004525
16033812
20589103
24523541
19835956
27086703
23134888
19605830
20373343
20980669
20375505
17167157
24474665
7920638
7874780
9931268
16530430
10751265
26857805
24952993
20944075
21282661
20573574
21997383
12634421
24848386
11293693
11832223
9931269
24548606
19853041
12192226
1669507
25267715
11306609
21818123
26340961
23150934
15557505
25792098
20715081
21460840
19584447
23018453
20074603
23959201
22474610
23150908
25376331
27636853
18395201
22888310
19595974
8086986
17332786
18768414
20693633
14568808
12566948
27777039
18514163
25882911
19667321
20061650
6610841
21088973
25822631
11192058
25393045
20124113
16545583
21177953
17374720
17242490
26821081
19662657
15703252
17210814
9708558
11282915
10733371
8482924
11692019
25990058
21825241
22169231
22357713
24204343
12210786
15093872
15219578
17427739
9617910
19297430
18223623
748370
12507782
12821592
17716081
15623693
22213409
11532280
26082010
26104658
20352396
26130946
25917100","Systemic inflammation as a predictor of brain aging: Contributions of physical activity, metabolic risk, and genetic risk.","Inflammatory processes may contribute to risk for Alzheimer's disease (AD) and age-related brain degeneration. Metabolic and genetic risk factors, and physical activity may, in turn, influence these inflammatory processes. Some of these risk factors are modifiable, and interact with each other. Understanding how these processes together relate to brain aging will help to inform future interventions to treat or prevent cognitive decline. We used brain magnetic resonance imaging (MRI) to scan 335 older adult humans (mean age 77.3 ± 3.4 years) who remained non-demented for the duration of the 9-year longitudinal study. We used structural equation modeling (SEM) in a subset of 226 adults to evaluate whether measures of baseline peripheral inflammation (serum C-reactive protein levels; CRP), mediated the baseline contributions of genetic and metabolic risk, and physical activity, to regional cortical thickness in AD-relevant brain regions at study year 9. We found that both baseline metabolic risk and AD risk variant apolipoprotein E ε4 (APOE4), modulated baseline serum CRP. Higher baseline CRP levels, in turn, predicted thinner regional cortex at year 9, and mediated an effect between higher metabolic risk and thinner cortex in those regions. A higher polygenic risk score composed of variants in immune-associated AD risk genes (other than APOE) was associated with thinner regional cortex. However, CRP levels did not mediate this effect, suggesting that other mechanisms may be responsible for the elevated AD risk. We found interactions between genetic and environmental factors and structural brain health. Our findings support the role of metabolic risk and peripheral inflammation in age-related brain decline.","['AD', ""Alzheimer's disease"", 'Brain structure', 'Brain volume', 'C-reactive protein', 'CRP', 'Cholesterol', 'Cognitive aging', 'Cortical thickness', 'Gene', 'Genetic risk', 'Inflammation', 'Insulin', 'Metabolic risk', 'Neuroinflammation', 'Obesity', 'Physical activity', 'Polygenic risk score']",NeuroImage,2018-01-23,"[{'lastname': 'Corlier', 'firstname': 'Fabian', 'initials': 'F', 'affiliation': 'Imaging Genetics Center, Mark and Mary Stevens Neuroimaging and Informatics Institute, Keck School of Medicine, University of Southern California, Marina del Rey, CA 90292, USA.'}, {'lastname': 'Hafzalla', 'firstname': 'George', 'initials': 'G', 'affiliation': 'Imaging Genetics Center, Mark and Mary Stevens Neuroimaging and Informatics Institute, Keck School of Medicine, University of Southern California, Marina del Rey, CA 90292, USA.'}, {'lastname': 'Faskowitz', 'firstname': 'Joshua', 'initials': 'J', 'affiliation': 'Imaging Genetics Center, Mark and Mary Stevens Neuroimaging and Informatics Institute, Keck School of Medicine, University of Southern California, Marina del Rey, CA 90292, USA.'}, {'lastname': 'Kuller', 'firstname': 'Lewis H', 'initials': 'LH', 'affiliation': 'Department of Epidemiology, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA 15261, USA.'}, {'lastname': 'Becker', 'firstname': 'James T', 'initials': 'JT', 'affiliation': 'Departments of Neurology, Psychiatry, and Psychology, University of Pittsburgh, Pittsburgh, PA 15139, USA.'}, {'lastname': 'Lopez', 'firstname': 'Oscar L', 'initials': 'OL', 'affiliation': 'Department of Neurology, University of Pittsburgh, Pittsburgh, PA 15213, USA.'}, {'lastname': 'Thompson', 'firstname': 'Paul M', 'initials': 'PM', 'affiliation': 'Imaging Genetics Center, Mark and Mary Stevens Neuroimaging and Informatics Institute, Keck School of Medicine, University of Southern California, Marina del Rey, CA 90292, USA; Depts. of Neurology, Psychiatry, Engineering, Radiology, & Ophthalmology, Keck/USC School of Medicine, University of Southern California, Los Angeles, CA 90033, USA.'}, {'lastname': 'Braskie', 'firstname': 'Meredith N', 'initials': 'MN', 'affiliation': 'Imaging Genetics Center, Mark and Mary Stevens Neuroimaging and Informatics Institute, Keck School of Medicine, University of Southern California, Marina del Rey, CA 90292, USA. Electronic address: meredith.braskie@ini.usc.edu.'}]",,,,Copyright © 2018 Elsevier Inc. All rights reserved.,"10.1016/j.neuroimage.2017.12.027
10.1016/S0197-4580(00)00124-X
10.1111/j.1464-5491.2006.01858.x
10.1016/j.neuroimage.2010.06.025
10.1006/nimg.2001.0848
10.1186/1742-2094-9-125
10.1038/ng1934
10.1016/j.bbi.2011.07.240
10.1016/j.jalz.2014.02.009
10.1016/j.neuroscience.2014.05.005
10.1016/j.neurobiolaging.2008.09.012
10.1189/jlb.0505247
10.3389/fnagi.2010.00023
10.1523/JNEUROSCI.2830-13.2014
10.1016/j.bbadis.2009.10.004
10.1080/14737175.2016.1179582
10.3945/ajcn.112.043240
10.1056/NEJMoa0809437
10.1002/ana.21955
10.1212/WNL.0b013e3181ffe4d1
10.1159/000285166
10.1093/gerona/61.11.1166
10.1177/2150131913520328
10.1038/ng0694-180
10.1006/nimg.1998.0395
10.1016/j.neuroimage.2006.01.021
10.1212/WNL.54.7.1492
10.1002/jcla.21920
10.1016/j.neurobiolaging.2014.03.034
10.1212/WNL.0b013e3181f88359
10.1073/pnas.1015950108
10.1016/j.neulet.2010.05.092
10.1007/s00018-011-0840-1
10.1073/pnas.0230450100
10.1109/42.906426
10.1016/S0896-6273(02)00569-X
10.1006/nimg.1998.0396
10.1016/j.pneurobio.2014.02.004
10.1016/j.neuroimage.2009.10.043
10.1016/1047-2797(91)90005-W
10.1016/j.jalz.2014.05.1756
10.1038/nri3041
10.1177/1533317515602087
10.1056/NEJMoa1211851
10.1212/01.WNL.0000141850.47773.5F
10.1016/S1474-4422(15)70016-5
10.3132/dvdr.2007.019
10.1002/hbm.21113
10.1038/ng.803
10.3233/JAD-2009-1163
10.1159/000343302
10.1016/j.humimm.2010.01.008
10.1016/j.neuroimage.2013.08.022
10.1101/cshperspect.a006213
10.1056/NEJMoa1211103
10.1056/NEJMoa1211103
10.1007/s11682-014-9330-z
10.3233/JAD-160665
10.1016/j.ejphar.2008.02.049
10.1016/j.jalz.2007.01.008
10.1136/bmj.309.6955.636
10.1139/h06-113
10.1001/jama.300.9.1027
10.3233/JAD-2010-100201
10.1001/archneur.60.10.1385
10.1159/000067110
10.1016/j.arr.2016.10.001
10.1016/j.biopsych.2008.04.016
10.1016/j.bbi.2015.03.015
10.1212/WNL.0b013e3181b16431
10.3233/JAD-2010-1219
10.1212/WNL.34.7.939
10.1007/s00421-010-1724-z
10.1001/jamaneurol.2014.4477
10.1080/10705511.2014.935842
10.1007/s004210000312
10.1016/j.soard.2014.06.010
10.1001/archgenpsychiatry.2009.193
10.1016/j.neuroimage.2006.01.047
10.1242/jeb.048074
10.1073/pnas.0611721104
10.1080/00273170701341316
10.1002/hbm.20870
10.1093/cercor/bhi044
10.1001/archneur.64.1.93
10.1002/ana.410440226
10.1161/01.CIR.103.13.1813
10.1056/NEJM200003233421202
10.1631/jzus.B1400219
10.1001/archneurol.2011.167
10.1093/cercor/bhr348
10.1212/WNL.0b013e318248e50f
10.3389/fnagi.2013.00064
10.1002/ana.10265
10.1016/j.jacc.2003.10.061
10.1002/(SICI)1096-8652(199707)55:3<134::AID-AJH3>3.0.CO;2-T/abstract
10.1109/TMI.2006.887364
10.1109/42.668698
10.3945/jn.108.098251
10.1016/0021-9681(78)90058-9
10.1016/S0165-5728(02)00398-3
10.1161/01.ATV.0000089628.63625.D4
10.1146/annurev.clinpsy.1.102803.144239
10.1212/01.WNL.0000147474.29994.35
10.1001/archneurol.2011.670
10.1016/S0161-5890(01)00042-6
10.1038/jcbfm.2015.125
10.1161/JAHA.114.001140
10.1007/s12640-010-9175-1
10.3346/jkms.2015.30.7.860
10.4049/jimmunol.1402909
10.1086/651257",<Element 'PubmedArticle' at 0x7f05dd35fb30>
326,29331881,Ameliorative role of genistein against age-dependent chronic arsenic toxicity in murine brains via the regulation of oxidative stress and inflammatory signaling cascades.,"Brain is highly prone to oxidative damage due to its huge lipid content and extensive energy requirements. Exogenous insult in brain via oxidative injury can lead to severe pathophysiological conditions. Age-dependent deterioration of normal brain functions is also noteworthy. Genistein, a polyphenolic isoflavonoid, obtained from the soy plant, is well known to protect against several diseased conditions. Here, in this study chronic brain toxicity model was developed using oral administration of arsenic for 90 days in adult and aged murines. We observed that intraperitoneal administration of genistein improved the arsenic induced behavioral abnormalities in the rats. It was also evident from the histopathological studies that the extent of tissue damage due to arsenic exposure was more in aged rats compared to the adults. Evaluation of different stress markers, intracellular ROS level and mitochondrial membrane potential revealed the involvement of oxidative stress and mitochondrial dysfunction in inducing brain damage in arsenic exposed murines. It was observed that genistein can significantly ameliorate the stressed condition in both the animal groups but the protective effect of genistein was more significant in the adult animals. The underlying signalling mechanism behind the cytotoxicity of arsenic was investigated and revealed that genistein exhibited neuroprotection significantly by modulating the JNK3 mediated apoptosis, ERK1/2 mediated autophagy and TNFα associated inflammatory pathways. Overall study infers that genistein has significant ameliorative effect of against age-dependent cytotoxicity of arsenic in murine brains.","['Apoptosis', 'Arsenic', 'Autophagy', 'Brain', 'Genistein', 'Inflammation', 'Oxidative stress']",The Journal of nutritional biochemistry,2018-01-15,"[{'lastname': 'Saha', 'firstname': 'Sukanya', 'initials': 'S', 'affiliation': 'Division of Molecular Medicine, Bose Institute, P-1/12, CIT Scheme VII M, Kolkata, 700054, India.'}, {'lastname': 'Sadhukhan', 'firstname': 'Pritam', 'initials': 'P', 'affiliation': 'Division of Molecular Medicine, Bose Institute, P-1/12, CIT Scheme VII M, Kolkata, 700054, India.'}, {'lastname': 'Mahalanobish', 'firstname': 'Sushweta', 'initials': 'S', 'affiliation': 'Division of Molecular Medicine, Bose Institute, P-1/12, CIT Scheme VII M, Kolkata, 700054, India.'}, {'lastname': 'Dutta', 'firstname': 'Sayanta', 'initials': 'S', 'affiliation': 'Division of Molecular Medicine, Bose Institute, P-1/12, CIT Scheme VII M, Kolkata, 700054, India.'}, {'lastname': 'Sil', 'firstname': 'Parames C', 'initials': 'PC', 'affiliation': 'Division of Molecular Medicine, Bose Institute, P-1/12, CIT Scheme VII M, Kolkata, 700054, India. Electronic address: parames@jcbose.ac.in.'}]",,,,Copyright © 2017 Elsevier Inc. All rights reserved.,10.1016/j.jnutbio.2017.11.010,<Element 'PubmedArticle' at 0x7f05dd2b0c20>
327,29274997,Electroconvulsive therapy enhances the anti-ageing hormone Klotho in the cerebrospinal fluid of geriatric patients with major depression.,"Klotho is a humoral factor with pleiotropic effects. Most notably, Klotho deficiency is associated with a phenotype comprising organ manifestations accompanying aging including atherosclerosis and cognitive impairment. Research on the role of Klotho in affective disorder is scarce, which is surprising in light of the fact that depression is associated with accelerated cellular aging as well as aging-related phenotypes and comorbidity observed in Klotho deficiency. On these grounds we investigated Klotho levels in the cerebrospinal fluid (CSF) and serum of eight geriatric patients undergoing electroconvulsive therapy (ECT) for severe depression. We hypothesize that ECT as a highly effective antidepressant treatment leads enhances Klotho levels. We found a significant difference between pre- and post-ECT CSF Klotho (792.5pg/ml vs. 991.3pg/ml, p=0.0020), but no difference in serum Klotho (602.5 vs. 594.3, p=0.32). Moreover, CSF Klotho increase positively correlated with the number of single ECT sessions that were performed in each patient (F1, 6)=7.84, p=0.031). Conjointly, the results of our exploratory study with a small sample size suggest a central nervous system-specific impact of ECT on Klotho, which may in turn partake in mediating the antidepressant effect of ECT. We suggest the modulation of neuroinflammatory processes, which have been ascribed pathophysiological relevance within the conceptual framework of the neuroinflammation hypothesis of depression, through ECT as a potential mechanism by which Klotho is enhanced in response to treatment. Further preclinical and clinical investigation should aim for a precise identification of the role of Klotho in depressive disorder.","['Cerebrospinal fluid', 'Depression', 'ECT', 'Electroconvulsive therapy', 'Klotho']",European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology,2017-12-25,"[{'lastname': 'Hoyer', 'firstname': 'Carolin', 'initials': 'C', 'affiliation': 'Department of Neurology, University Medical Centre Mannheim, Mannheim, Germany.'}, {'lastname': 'Sartorius', 'firstname': 'Alexander', 'initials': 'A', 'affiliation': 'Department of Psychiatry and Psychotherapy, Central Institute of Mental Health, Medical Faculty Mannheim/Heidelberg University, Mannheim, Germany.'}, {'lastname': 'Aksay', 'firstname': 'Suna Su', 'initials': 'SS', 'affiliation': 'Department of Psychiatry and Psychotherapy, Central Institute of Mental Health, Medical Faculty Mannheim/Heidelberg University, Mannheim, Germany.'}, {'lastname': 'Bumb', 'firstname': 'Jan Malte', 'initials': 'JM', 'affiliation': 'Department of Addictive Behavior and Addiction Medicine, Central Institute of Mental Health, Medical Faculty Mannheim/Heidelberg University, Mannheim, Germany.'}, {'lastname': 'Janke', 'firstname': 'Christoph', 'initials': 'C', 'affiliation': 'Department of Anesthesiology and Critical Care Medicine, University Medical Centre Mannheim, Mannheim, Germany.'}, {'lastname': 'Thiel', 'firstname': 'Manfred', 'initials': 'M', 'affiliation': 'Department of Anesthesiology and Critical Care Medicine, University Medical Centre Mannheim, Mannheim, Germany.'}, {'lastname': 'Haffner', 'firstname': 'Dieter', 'initials': 'D', 'affiliation': 'Department of Pediatric Kidney, Liver and Metabolic Diseases, Hannover Medical School, Hannover, Germany.'}, {'lastname': 'Leifheit-Nestler', 'firstname': 'Maren', 'initials': 'M', 'affiliation': 'Department of Pediatric Kidney, Liver and Metabolic Diseases, Hannover Medical School, Hannover, Germany.'}, {'lastname': 'Kranaster', 'firstname': 'Laura', 'initials': 'L', 'affiliation': 'Department of Psychiatry and Psychotherapy, Central Institute of Mental Health, Medical Faculty Mannheim/Heidelberg University, Mannheim, Germany. Electronic address: laura.kranaster@zi-mannheim.de.'}]",,,,Copyright © 2017 Elsevier B.V. and ECNP. All rights reserved.,10.1016/j.euroneuro.2017.12.012,<Element 'PubmedArticle' at 0x7f05dd2bde50>
328,29266208,"Potential neuroprotective effect of androst-5-ene-3β, 17β-diol (ADIOL) on the striatum, and substantia nigra in Parkinson's disease rat model.","Parkinson's disease (PD) is a progressive neurodegenerative disorder with behavioral and motor abnormalities. Androst-5-ene-3β, 17β-diol (ADIOL), an estrogen receptor (ER) β agonist, was found to mediate a transrepressive mechanism that selectively modulates the extent of neuroinflammation and, in turn, neurodegeneration. In consensus, ERβ polymorphism was more frequently detected in early-onset PD patients. Thus, in an approach to elucidate the role of ERβ agonists on PD, our study was designed to investigate the possible neuroprotective effect of ADIOL, in three dose levels (0.35, 3.5, 35 mg/kg/day), against rotenone (ROT)-induced PD rat model. Amelioration in striatal dopamine (DA), nuclear factor-kappa B (NF-κB), and the expression of down-stream inflammatory mediators, as well as apoptotic markers were observed in the striatum and substantia nigra (SN) upon pre-treatment with the three doses of ADIOL. Similarly, light microscopy (LM) examination revealed declined degeneration of neurons upon pretreatment with ADIOL. Significant improvement in nigral tyrosine hydroxylase (TH) and reduction of nigral α-synuclein densities were also detected after ADIOL pre-treatment with better results frequently achieved with the middle dose (3.5 mg/kg/day). The middle dose of ADIOL showed behavioral improvement, with elevation in the ATP level, which was emphasized by the improvement in mitochondrial integrity observed upon electron microscopy (EM) examination. In conclusion, the present study confirmed for the first time the ability of ADIOL to protect against neuroinflammation and, in turn, neurodegeneration process and motor dysfunction in PD animal model, which was more obviously observed with the middle dose.","['17β-diol', 'Androst-5-ene-3β', ""Parkinson's disease"", 'estrogen receptor', 'neurodegeneration', 'neuroinflammation', 'rotenone']",Journal of cellular physiology,2017-12-22,"[{'lastname': 'Salama', 'firstname': 'Rania M', 'initials': 'RM', 'affiliation': 'Faculty of Pharmacy, Department of Pharmacology and Toxicology, Misr International University (MIU), Cairo, Egypt.'}, {'lastname': 'Tadros', 'firstname': 'Mariane G', 'initials': 'MG', 'affiliation': 'Faculty of Pharmacy, Department of Pharmacology and Toxicology, Ain Shams University, Cairo, Egypt.'}, {'lastname': 'Schaalan', 'firstname': 'Mona F', 'initials': 'MF', 'affiliation': 'Faculty of Pharmacy, Department of Biochemistry, Misr International University (MIU), Cairo, Egypt.'}, {'lastname': 'Bahaa', 'firstname': 'Nevine', 'initials': 'N', 'affiliation': 'Faculty of Medicine, Department of Histology and Cell Biology, Ain Shams University, Cairo, Egypt.'}, {'lastname': 'Abdel-Tawab', 'firstname': 'Ahmed M', 'initials': 'AM', 'affiliation': 'Faculty of Medicine, Department of Pharmacology, Ain Shams University, Cairo, Egypt.'}, {'lastname': 'Khalifa', 'firstname': 'Amani E', 'initials': 'AE', 'affiliation': 'Faculty of Pharmacy, Department of Pharmacology and Toxicology, Ain Shams University, Cairo, Egypt.'}]",,,,"© 2017 Wiley Periodicals, Inc.",10.1002/jcp.26412,<Element 'PubmedArticle' at 0x7f05dd2cb130>
329,29215318,Therapeutic potential of silymarin in chronic unpredictable mild stress induced depressive-like behavior in mice.,"Silymarin, a plant-derived polyphenolic flavonoid of Silybum marianum, elicited significant antidepressant-like activity in an acute restraint stress model of depression. It improved monoamines, mainly 5-hydroxytryptamine (5-HT) levels in the cortex, dopamine (DA) and norepinephrine (NE) in the cerebellum in mice. The present study was undertaken to explore the antidepressant potential of silymarin in chronic unpredictable mild stress (CUMS) induced depressive-like behavior in mice, and to find out its probable mechanism(s) of action, mainly neurogenesis, neuroinflammation, and/or oxidative stress. The mice were subjected to CUMS for 28 days (4 weeks) and administered with silymarin (100 mg/kg and 200 mg/kg), or fluoxetine or vehicle from days 8 to 28 (3 weeks simultaneously). Animals were evaluated for behavioral changes, such as anhedonia by sucrose preference test, behavioral despair by forced swim test, and exploratory behaviors by an open field test. In addition, neurobiochemical alterations, mainly monoamines, 5-HT, NE, DA, neurotrophic factor BDNF, and cytokines, IL-6, TNF-α, oxidant-antioxidant parameters by determining the malondialdehyde formation (an index of lipid peroxidation process), superoxide dismutase (SOD) and catalase (CAT) activity in hippocampus and cerebral cortex along with serum corticosterone were investigated. Our findings reveal that mice subjected to CUMS exhibited lower sucrose preference, increase immobility time without affecting general locomotion of the animals, and reduce BDNF, 5-HT, NE, and DA level, increased serum corticosterone, IL-6 and TNF-α along with an oxidant-antioxidant imbalance in the hippocampus and cerebral cortex. Silymarin significantly reversed the CUMS-induced changes in the hippocampus and cerebral cortex in mice. Thus, the possible mechanism involved in the antidepressant-like activity of silymarin is correlated to the alleviation of monoaminergic, neurogenesis (enhancing 5-HT, NE, and BDNF levels), and attenuation of inflammatory cytokines system and oxidative stress by modulation of corticosterone response, restoration of antioxidant defense system in cerebral cortex and hippocampus.","['Silymarin', 'antidepressant activity', 'chronic unpredictable mild stress', 'neurobiochemical alterations', 'oxidative stress']","Journal of psychopharmacology (Oxford, England)",2017-12-08,"[{'lastname': 'Thakare', 'firstname': 'Vishnu N', 'initials': 'VN', 'affiliation': '1 Department of Pharmacology, Sinhgad Institute of Pharmaceutical Sciences, Lonavala, India.\n4 Department of Pharmacology, Institute of Pharmacy, Nirma University, Ahmedabad, India.'}, {'lastname': 'Patil', 'firstname': 'Rajesh R', 'initials': 'RR', 'affiliation': '1 Department of Pharmacology, Sinhgad Institute of Pharmaceutical Sciences, Lonavala, India.'}, {'lastname': 'Oswal', 'firstname': 'Rajesh J', 'initials': 'RJ', 'affiliation': '1 Department of Pharmacology, Sinhgad Institute of Pharmaceutical Sciences, Lonavala, India.'}, {'lastname': 'Dhakane', 'firstname': 'Valmik D', 'initials': 'VD', 'affiliation': '2 Research and Development, Astec Life Sciences, Mumbai, India.'}, {'lastname': 'Aswar', 'firstname': 'Manoj K', 'initials': 'MK', 'affiliation': '3 Department of Pharmacology, Sinhgad Institute of Pharmacy, Nerhe, Pune, India.'}, {'lastname': 'Patel', 'firstname': 'Bhoomika M', 'initials': 'BM', 'affiliation': '4 Department of Pharmacology, Institute of Pharmacy, Nirma University, Ahmedabad, India.'}]",,,,,10.1177/0269881117742666,<Element 'PubmedArticle' at 0x7f05dd2d8ea0>
330,29180108,"Palmitate induces neuroinflammation, ER stress, and Pomc mRNA expression in hypothalamic mHypoA-POMC/GFP neurons through novel mechanisms that are prevented by oleate.","Dietary fats can modulate brain function. How free fatty acids (FFAs) alter hypothalamic pro-opiomelanocortin (POMC) neurons remain undefined. The saturated FFA, palmitate, increased neuroinflammatory and ER stress markers, as well as Pomc mRNA levels, but did not affect insulin signaling, in mHypoA-POMC/GFP-2 neurons. This effect was mediated through the MAP kinases JNK and ERK. Further, the increase in Pomc was dependent on palmitoyl-coA synthesis, but not de novo ceramide synthesis, as inhibition of SPT enhanced palmitate-induced Pomc expression, while methylpalmitate had no effect. While palmitate concomitantly induces neuroinflammation and ER stress, these effects were independent of changes in Pomc expression. Palmitate thus has direct acute effects on Pomc, which appears to be important for negative feedback, but not directly related to neuroinflammation. The monounsaturated FFA oleate completely blocked the palmitate-mediated increase in neuroinflammation, ER stress, and Pomc mRNAs. This study provides insight into the complex central metabolic regulation by FFAs.","['ER stress', 'Hypothalamus', 'JNK', 'Neuroinflammation', 'Oleate', 'POMC', 'Palmitate']",Molecular and cellular endocrinology,2017-11-29,"[{'lastname': 'Tse', 'firstname': 'Erika K', 'initials': 'EK', 'affiliation': 'Department of Physiology, Faculty of Medicine, University of Toronto, Toronto, ON M5S 1A8, Canada.'}, {'lastname': 'Belsham', 'firstname': 'Denise D', 'initials': 'DD', 'affiliation': 'Department of Physiology, Faculty of Medicine, University of Toronto, Toronto, ON M5S 1A8, Canada; Departments of Medicine and Obstetrics and Gynaecology, Faculty of Medicine, University of Toronto, Toronto, ON M5S 1A8, Canada. Electronic address: d.belsham@utoronto.ca.'}]",,,,Copyright © 2017 Elsevier B.V. All rights reserved.,10.1016/j.mce.2017.11.017,<Element 'PubmedArticle' at 0x7f05dd224c20>
331,"29176951
6095858
6203594
11016826
17222167
21565248
19325075
15837822
12771599
8543010
23761677
27350568
7593202
28192415
5570193
26439835
25535255
2477295
21514687
23774137
21772669
3091487
25294233
12732588
15895164
20614158
9336389
9030200
21757727
24120988
6196032
28905075
26362341
16712803
25265888
22410004
16322748
23207724
1648735
9682908
22183064
6329386
12504785
23052777
319841
22006678
25551197
1279653
28493895
23435331
28292945
22323544
11516627
4382231
8033829
7626063
9039134
26078492
4685360
25001271
17717539
20148682
9427610
24137350
73437
25062123
19050443
20226856
18795974
26825542
12756273
3236314
9315538
10704258
24050624
18650913
20303867
25609892
12490957
19837951
25275046
57130
7806435
9653513
26909067
24486056
20422450
11403834
9306153
23874694
24778633
5659654
9245487
3019770
18703152
19236338
16741678
12818356
8586810
15009217
21296109
9422732
16139690
12027881
17610345
21195808
17139451
20039297
25866790
22763713
28287106
9130001
22136168
18070001
27199985
7718605
19559678
18021769
24904197
25288301
8396262
19365146
26471775
24850053
11546672
4315650
12027880
14993422
16210605
17892975
9952158",Much More than a Cardiotonic Steroid: Modulation of Inflammation by Ouabain.,"Since the discovery of ouabain as a cardiotonic steroid hormone present in higher mammals, research about it has progressed rapidly and several of its physiological and pharmacological effects have been described. Ouabain can behave as a stress hormone and adrenal cortex is its main source. Direct effects of ouabain are originated due to the binding to its receptor, the Na","['cell migration', 'cytokines', 'immune system', 'neuroinflammation', 'ouabain', 'peripheral inflammation']",Frontiers in physiology,2017-11-28,"[{'lastname': 'Cavalcante-Silva', 'firstname': 'Luiz H A', 'initials': 'LHA', 'affiliation': 'Programa de Pós-Graduação em Produtos Naturais e Sintéticos Bioativos, Laboratório de Imunobiotecnologia, Centro de Ciências da Saúde, Universidade Federal da Paraíba, João Pessoa, Brazil.'}, {'lastname': 'Lima', 'firstname': 'Éssia de Almeida', 'initials': 'ÉA', 'affiliation': 'Programa de Pós-Graduação em Biotecnologia, Laboratório de Imunobiotecnologia, Centro de Biotecnologia, Universidade Federal da Paraíba, João Pessoa, Brazil.'}, {'lastname': 'Carvalho', 'firstname': 'Deyse C M', 'initials': 'DCM', 'affiliation': 'Programa Multicêntrico de Pós-graduação em Ciências Fisiológicas, Laboratório de Imunobiotecnologia, Centro de Biotecnologia, Universidade Federal da Paraíba, João Pessoa, Brazil.'}, {'lastname': 'de Sales-Neto', 'firstname': 'José M', 'initials': 'JM', 'affiliation': 'Programa de Pós-Graduação em Produtos Naturais e Sintéticos Bioativos, Laboratório de Imunobiotecnologia, Centro de Ciências da Saúde, Universidade Federal da Paraíba, João Pessoa, Brazil.'}, {'lastname': 'Alves', 'firstname': 'Anne K de Abreu', 'initials': 'AKA', 'affiliation': 'Programa de Pós-Graduação em Biotecnologia, Laboratório de Imunobiotecnologia, Centro de Biotecnologia, Universidade Federal da Paraíba, João Pessoa, Brazil.'}, {'lastname': 'Galvão', 'firstname': 'José G F M', 'initials': 'JGFM', 'affiliation': 'Programa de Pós-Graduação em Produtos Naturais e Sintéticos Bioativos, Laboratório de Imunobiotecnologia, Centro de Ciências da Saúde, Universidade Federal da Paraíba, João Pessoa, Brazil.'}, {'lastname': 'da Silva', 'firstname': 'Juliane S de França', 'initials': 'JSF', 'affiliation': 'Programa de Pós-Graduação em Produtos Naturais e Sintéticos Bioativos, Laboratório de Imunobiotecnologia, Centro de Ciências da Saúde, Universidade Federal da Paraíba, João Pessoa, Brazil.'}, {'lastname': 'Rodrigues-Mascarenhas', 'firstname': 'Sandra', 'initials': 'S', 'affiliation': 'Programa de Pós-Graduação em Produtos Naturais e Sintéticos Bioativos, Laboratório de Imunobiotecnologia, Centro de Ciências da Saúde, Universidade Federal da Paraíba, João Pessoa, Brazil.\nPrograma de Pós-Graduação em Biotecnologia, Laboratório de Imunobiotecnologia, Centro de Biotecnologia, Universidade Federal da Paraíba, João Pessoa, Brazil.\nPrograma Multicêntrico de Pós-graduação em Ciências Fisiológicas, Laboratório de Imunobiotecnologia, Centro de Biotecnologia, Universidade Federal da Paraíba, João Pessoa, Brazil.'}]",,,,,"10.3389/fphys.2017.00895
10.1016/0006-2952(84)90152-7
10.1111/j.1476-5381.1984.tb10777.x
10.1291/hypres.23.Supplement_S93
10.1111/j.1365-2796.2006.01745.x
10.1016/j.mce.2011.04.019
10.1124/pr.108.000711
10.1161/01.HYP.0000165024.47728.f7
10.1097/01.CCM.0000059721.57219.C3
10.1016/0014-5793(95)01301-6
10.1152/ajprenal.00248.2013
10.1113/JP272419
10.1002/jcp.1041650205
10.1038/nri.2017.1
10.1007/BF00572268
10.1016/j.imbio.2015.09.020
10.15252/emmm.201404797
10.1016/j.imbio.2011.03.002
10.1016/j.neuropharm.2013.06.006
10.1155/2011/912925
10.1681/ASN.2014020130
10.1161/01.HYP.0000072801.90600.C2
10.1590/S0001-37652005000200008
10.1007/s00018-010-0444-1
10.1161/01.HYP.30.4.886
10.1016/S0167-4889(96)00116-4
10.1074/jbc.M111.247767
10.1016/j.brainres.2013.09.052
10.1016/0006-2952(83)90215-0
10.1007/s00011-017-1092-9
10.1007/s00232-015-9840-7
10.1016/j.biopsych.2005.12.021
10.1186/s12931-014-0093-2
10.1016/j.bcp.2012.02.023
10.1038/nri1733
10.1097/MNH.0b013e32835b36ec
10.1073/pnas.88.14.6259
10.3109/10641969809053230
10.1097/CRD.0b013e31823c835c
10.1111/j.1476-5381.1984.tb16450.x
10.1016/S0014-2999(02)02813-3
10.1007/s00436-012-3146-9
10.1016/0304-4165(77)90320-8
10.1002/jnr.22745
10.1186/s12974-014-0218-z
10.1111/j.1600-0773.1992.tb00499.x
10.1371/journal.pone.0176676
10.1038/nri3399
10.1189/jlb.3MR0117-024R
10.4049/jimmunol.1101987
10.1016/S0898-6568(01)00169-3
10.1038/213840b0
10.1210/endo.135.2.8033829
10.1006/bbrc.1995.1996
10.1161/01.HYP.29.1.401
10.1155/2015/265798
10.1016/0014-4827(73)90403-5
10.1161/HYPERTENSIONAHA.114.03919
10.1038/nri2156
10.1146/annurev-physiol-021909-135725
10.1038/nm0198-078
10.3892/ol.2013.1406
10.1016/j.coph.2014.07.004
10.1097/HJH.0b013e32831cf2c6
10.1016/j.bbadis.2010.03.001
10.1186/1753-6561-8-S4-P260
10.1111/j.1365-2567.2008.02933.x
10.1016/j.ejphar.2016.01.010
10.1124/jpet.103.052977
10.1161/01.CIR.96.5.1501
10.1006/cyto.1999.0555
10.1146/annurev-pathol-020712-164023
10.1038/nature07201
10.1016/j.cell.2010.03.006
10.1155/2014/494956
10.1038/nature01320
10.1152/ajpheart.00734.2009
10.1016/0091-6749(76)90061-0
10.1016/0192-0561(94)90097-3
10.1023/A:1022259832207
10.3389/fendo.2016.00010
10.1016/j.smim.2014.01.003
10.1007/s10495-010-0494-8
10.1016/S0140-6736(00)04904-7
10.1016/S0192-0561(96)00070-7
10.1371/journal.pone.0068623
10.3389/fimmu.2014.00143
10.1038/219198a0
10.1006/cyto.1997.0206
10.1016/0014-5793(86)80980-2
10.1016/j.cellbi.2008.07.012
10.1111/j.1749-6632.2008.03969.x
10.1007/s10540-006-9012-1
10.1016/S0024-3205(03)00377-1
10.1097/00004872-199510000-00013
10.1111/j.1432-1033.2004.04012.x
10.1016/j.bbamcr.2011.01.034
10.1074/jbc.273.2.784
10.1016/j.semnephrol.2005.03.010
10.1046/j.1432-1033.2002.02911.x
10.2165/00129784-200707030-00004
10.1016/j.autrev.2010.12.006
10.1007/s11010-006-9180-0
10.1002/eji.200939613
10.1155/2015/537136
10.1002/cbf.2856
10.1038/nri.2017.10
10.1016/S0162-3109(96)00159-2
10.1146/annurev-immunol-100311-102839
10.1111/j.1365-2796.2007.01883.x
10.3389/fimmu.2016.00160
10.1016/0005-2736(94)00297-3
10.1016/j.jpain.2007.07.006
10.1016/j.ejphar.2007.10.049
10.1155/2014/760368
10.1016/j.jneuroim.2014.09.007
10.1073/pnas.90.17.8189
10.1159/000212383
10.1038/nri3908
10.1111/nyas.12445
10.1016/0024-3205(70)90180-3
10.1046/j.1432-1033.2002.02910.x
10.1124/mi.3.3.157
10.4049/jimmunol.175.8.5024
10.1016/j.bcp.2009.06.027
10.1097/00000542-199902000-00026",<Element 'PubmedArticle' at 0x7f05dd2355e0>
332,29141189,Role of Cyclooxygenase Inhibitors in Diminution of Dissimilar Stress-induced Depressive Behavior and Memory Impairment in Rats.,"Memory functions can be considerably affected by various life events and stress has shown to be a chief regulator. Different stress patterns have distinct effects on the overall functioning of the brain. Stress provokes inflammation not only in the periphery but also in the brain. Neuroinflammation causes alterations in neuronal structure and function, which eventually progress to the development of neurodegenerative diseases. Inflammatory reactions are modulated through communication between the nervous, endocrine and immune systems. An excessive release of stress hormones and changes in the neurotransmission system may cause cognitive impairments. The present study investigated dissimilar stress-related memory deficits and their diminution by non-steroidal anti-inflammatory drugs (NSAIDs). Treatment with cyclooxygenase inhibitors, which inhibit prostaglandin synthesis, has enhanced memory functions in a number of neuroinflammatory states. In this study, rats were exposed to a series of dissimilar stressors and behavioral parameters for depression and memory functions were examined. Corticosterone, serotonin (5-HT) and dopamine (DA) levels were also estimated. Results from the forced swim test, elevated plus maze test and Morris water maze test showed significant effects of NSAIDs. A significant decrease in plasma corticosterone and increased DA and 5-HT levels were observed in NSAID-treated dissimilar-stressed rats. This study demonstrates the therapeutic potential of NSAIDs for dissimilar stress-induced depressive behaviors and impaired memory functions and related hormonal and neurochemical changes in the rat brain.","['NSAIDs', 'depression', 'dopamine', 'memory', 'serotonin', 'stress']",Neuroscience,2017-11-16,"[{'lastname': 'Perveen', 'firstname': 'Tahira', 'initials': 'T', 'affiliation': 'Neurochemistry and Biochemical Neuropharmacology Research Unit, Department of Biochemistry, University of Karachi, Pakistan. Electronic address: tahiraatiq@hotmail.com.'}, {'lastname': 'Emad', 'firstname': 'Shaista', 'initials': 'S', 'affiliation': 'Neurochemistry and Biochemical Neuropharmacology Research Unit, Department of Biochemistry, University of Karachi, Pakistan; Department of Biochemistry, Jinnah Medical & Dental College, Karachi, Pakistan.'}, {'lastname': 'Haider', 'firstname': 'Saida', 'initials': 'S', 'affiliation': 'Neurochemistry and Biochemical Neuropharmacology Research Unit, Department of Biochemistry, University of Karachi, Pakistan.'}, {'lastname': 'Sadaf', 'firstname': 'Sana', 'initials': 'S', 'affiliation': 'Neurochemistry and Biochemical Neuropharmacology Research Unit, Department of Biochemistry, University of Karachi, Pakistan.'}, {'lastname': 'Qadeer', 'firstname': 'Sara', 'initials': 'S', 'affiliation': 'Neurochemistry and Biochemical Neuropharmacology Research Unit, Department of Biochemistry, University of Karachi, Pakistan.'}, {'lastname': 'Batool', 'firstname': 'Zehra', 'initials': 'Z', 'affiliation': 'Neurochemistry and Biochemical Neuropharmacology Research Unit, Department of Biochemistry, University of Karachi, Pakistan.'}, {'lastname': 'Sarfaraz', 'firstname': 'Yousra', 'initials': 'Y', 'affiliation': 'Neurochemistry and Biochemical Neuropharmacology Research Unit, Department of Biochemistry, University of Karachi, Pakistan.'}, {'lastname': 'Sheikh', 'firstname': 'Sheeza', 'initials': 'S', 'affiliation': 'Neurochemistry and Biochemical Neuropharmacology Research Unit, Department of Biochemistry, University of Karachi, Pakistan.'}]",,,,Copyright © 2017 IBRO. Published by Elsevier Ltd. All rights reserved.,10.1016/j.neuroscience.2017.11.014,<Element 'PubmedArticle' at 0x7f05dd180590>
333,29102164,Soy isoflavone genistein attenuates lipopolysaccharide-induced cognitive impairments in the rat via exerting anti-oxidative and anti-inflammatory effects.,"Systemic inflammation during infectious disorders usually accompanies chronic complications including cognitive dysfunction. Neuroinflammation and cognitive deficit are also observed in some debilitating neurological disorders like Alzheimer's and Parkinson's diseases. Genistein is a soy isoflavone with multiple beneficial effects including anti-inflammatory, anti-oxidative, and protective properties. In this research study, the effect of genistein in prevention of lipopolysaccharide (LPS)-induced cognitive dysfunction was investigated. LPS was given i.p. (500 μg/kg/day) and genistein was orally given (10, 50, or 100 mg/kg) for one week. Findings showed that genistein could dose-dependently attenuate spatial recognition, discrimination, and memory deficits. Additionally, genistein treatment of LPS-challenged group lowered hippocampal level of malondialdehyde (MDA) and increased activity of superoxide dismutase (SOD) and catalase and glutathione (GSH) level. Furthermore, genistein ameliorated hippocampal acetylcholinesterase (AChE) activity in LPS-challenged rats. Furthermore, genistein administration to LPS-injected group lowered hippocampal level of interleukin 6 (IL-6), nuclear factor-kappaB (NF-κB) p65, toll-like receptor 4 (TLR4), tumor necrosis factor α (TNFα), cyclooxygenase-2 (COX2), inducible nitric oxide synthase (iNOS), glial fibrillary acidic protein (GFAP), and increased hippocampal level of antioxidant element nuclear factor (erythroid-derived 2)-like 2 (Nrf2). In conclusion, genistein alleviated LPS-induced cognitive dysfunctions and neural inflammation attenuation of oxidative stress and AChE activity and appropriate modulation of Nrf2/NF-κB/IL-6/TNFα/COX2/iNOS/TLR4/GFAP.","['Cognition', 'Genistein', 'Learning and memory', 'Lipopolysaccharide', 'Neuroinflammation', 'Oxidative stress']",Cytokine,2017-11-06,"[{'lastname': 'Mirahmadi', 'firstname': 'Seyed-Mohamad-Sadegh', 'initials': 'SM', 'affiliation': 'School of Medicine, Iran University of Medical Sciences, Tehran, Iran.'}, {'lastname': 'Shahmohammadi', 'firstname': 'Alireza', 'initials': 'A', 'affiliation': 'School of Medicine, Iran University of Medical Sciences, Tehran, Iran.'}, {'lastname': 'Rousta', 'firstname': 'Ali-Mohammad', 'initials': 'AM', 'affiliation': 'School of Medicine, Iran University of Medical Sciences, Tehran, Iran.'}, {'lastname': 'Azadi', 'firstname': 'Mohammad-Reza', 'initials': 'MR', 'affiliation': 'School of Medicine, Iran University of Medical Sciences, Tehran, Iran.'}, {'lastname': 'Fahanik-Babaei', 'firstname': 'Javad', 'initials': 'J', 'affiliation': 'Neuroscience Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.'}, {'lastname': 'Baluchnejadmojarad', 'firstname': 'Tourandokht', 'initials': 'T', 'affiliation': 'Department of Physiology, School of Medicine, Iran University of Medical Sciences, Tehran, Iran. Electronic address: baluchnejadmojarad.t@iums.ac.ir.'}, {'lastname': 'Roghani', 'firstname': 'Mehrdad', 'initials': 'M', 'affiliation': 'Neurophysiology Research Center, Shahed University, Tehran, Iran. Electronic address: mroghani@shahed.ac.ir.'}]",,,,Copyright © 2017 Elsevier Ltd. All rights reserved.,10.1016/j.cyto.2017.10.008,<Element 'PubmedArticle' at 0x7f05dd18ed10>
334,"29079998
15611276
11885968
17406592
26133302
25042403
13678674
27093924
18356270
25384416
18414499
24515442
22457547
10970434
27601160
12007417
18032778
23860568
25573647
12824464
23762086
22326887
16864697
19182524
16796807
16131021
21420027
24667331
16192374
20698820
24410883
21253592
23305936
22809665
19525918
24693424
24932387
20344885
24244697
24680857
25360394
11675008
27966331
26984336
27104958
16177180
24351865
25834699
16720574
23840908
3751752
19516017
22959056
23190711
25103178
21097505
14744438
7569976
16423918",Role of 3-Acetyl-11-Keto-Beta-Boswellic Acid in Counteracting LPS-Induced Neuroinflammation via Modulation of miRNA-155.,"Neuroinflammation is one of the most important mechanisms underlying neurodegeneration. Lipopolysaccharide (LPS) is a potent inflammogen which causes cognitive dysfunction. Boswellia serrata is known since many years as a powerful anti-inflammatory herbal drug. Its beneficial effect mainly arises from inhibition of 5-lipoxygenase (5-LO) enzyme. 3-acetyl-11-keto-β-boswellic acid (AKBA) is the most potent 5-LO inhibitor extracted from the oleo-gum-resin of Boswellia serrata. The aim of the present work is to study the molecular mechanisms underlying the anti-inflammatory and neuroprotective effects of AKBA and dexamethasone (DEX) in LPS-induced neuroinflammatory model. A single intraperitoneal (i.p.) dose of LPS (0.8 mg/kg) was injected to induce cognitive dysfunction. The LPS-treated mice were administered for 7 days with either AKBA or DEX at intraperitoneal doses of 5 and 1 mg/kg, respectively. Cognitive, locomotor functions, and anxiety level were first examined. The level of the phosphorylated inhibitory protein for NF-κB, IκB-α (P-IκB-α), was measured, and the expression levels of the inflammatory microRNA-155 (miR-155) and its target gene, suppressor of cytokine signaling-1 (SOCS-1), were determined in the brain. Moreover, the level of carbonyl proteins as a measure of oxidative stress and several cytokines as well as markers for apoptosis and amyloidogenesis was detected. Results showed that AKBA and DEX reversed the behavioral dysfunction induced by LPS. AKBA decreased P-IκB-α, miRNA-155 expression level, and carbonyl protein content. It restored normal cytokine level and increased SOCS-1 expression level. It also showed anti-apoptotic and anti-amyloidogenic effects in LPS-injected mice. These findings suggest AKBA as a therapeutic drug for alleviating the symptoms of neuroinflammatory disorders.","['AKBA', 'DEX', 'Inflammatory markers', 'LPS', 'Molecular markers']",Molecular neurobiology,2017-10-29,"[{'lastname': 'Sayed', 'firstname': 'Aya Shoukry', 'initials': 'AS', 'affiliation': 'Department of Pharmaceutical Biology, Faculty of Pharmacy and Biotechnology, German University in Cairo, Main Entrance of Al Tagamoa Al Khames, New Cairo City, 11835, Egypt.'}, {'lastname': 'Gomaa', 'firstname': 'Iman Emam Omar', 'initials': 'IEO', 'affiliation': 'Biotechnology Sector, Faculty of Pharmacy and Biotechnology, German University in Cairo, Cairo, Egypt. igomaa@nu.edu.eg.\nSchool of Engineering and Applied Sciences, Nile University, Cairo, Egypt. igomaa@nu.edu.eg.\nNano Science and Technology Institute, Kafr El-Sheikh University, Kafr El-Sheikh, Egypt. igomaa@nu.edu.eg.\n, Juhayna Square, Sheik Zayed District, 6 October City, Giza, Cairo, 12588, Egypt. igomaa@nu.edu.eg.'}, {'lastname': 'Bader', 'firstname': 'Michael', 'initials': 'M', 'affiliation': 'Max-Delbrück-Center for Molecular Medicine (MDC), Robert-Rössle-Strasse 10, 13125, Berlin, Germany.'}, {'lastname': 'El Sayed', 'firstname': 'Nesrine Salah El Dine', 'initials': 'NSED', 'affiliation': 'Department of Pharmacology and Toxicology, Faculty of Pharmacy, Cairo University, Giza, 12613, Egypt.\nDepartment of Pharmacology and Toxicology, Faculty of Pharmacy and Biotechnology, German University in Cairo, Main Entrance of Al Tagamoa Al Khames, New Cairo City, 11835, Egypt.'}]",,,,,10.1007/s12035-017-0801-2,<Element 'PubmedArticle' at 0x7f05dd19c860>
335,29049934,Molecular changes associated with escitalopram response in a stress-based model of depression.,"Converging evidence points at hypothalamus-pituitary-adrenal (HPA) axis hyperactivity and neuroinflammation as important factors involved in the etiopathogenesis of major depressive disorder (MDD) and in therapeutic efficacy of antidepressants. In this study, we examined the molecular effects associated with a response to a week-long treatment with escitalopram in the chronic escape deficit (CED) model, a validated model of depression based on the induction of an escape deficit after exposure of rats to an unavoidable stress. We confirmed our previous result that a treatment with escitalopram (10mg/kg) was effective after 7days in reverting the stress-induced escape deficit in approximately 50% of the animals, separating responders from non-responders. Expression of markers of HPA axis functionality as well as several inflammatory mediators were evaluated in the hypothalamus, a key structure integrating signals from the neuro, immune, endocrine systems. In the hypothalamus of responder animals we observed a decrease in the expression of CRH and its receptors and an increase in GR protein in total and nuclear extracts; this effect was accompanied by a significant decrease in circulating corticosterone in the same cohort. Hypothalamic IL-1β and TNFα expression were increased in stressed animals, while CXCL2, IL-6, and ADAM17 mRNA levels were decreased in escitalopram treated rats regardless of the treatment response. These data suggest that efficacy of a one week treatment with escitalopram may be partially mediated by a decrease HPA axis activity, while in the hypothalamus the drug-induced effects on the expression of immune modulators did not correlate with the behavioural outcome.","['Corticosterone', 'Escitalopram', 'HPA axis', 'Hypothalamus', 'Neuroinflammation', 'Treatment-resistant depression']",Psychoneuroendocrinology,2017-10-20,"[{'lastname': 'Benatti', 'firstname': 'Cristina', 'initials': 'C', 'affiliation': 'Department of Life Sciences, University of Modena and Reggio Emilia, Via Campi 287, 41125, Modena, Italy; Center for Neuroscience and Neurotechnology University of Modena and Reggio Emilia, Modena, Italy. Electronic address: cristina.benatti@unimore.it.'}, {'lastname': 'Alboni', 'firstname': 'Silvia', 'initials': 'S', 'affiliation': 'Department of Life Sciences, University of Modena and Reggio Emilia, Via Campi 287, 41125, Modena, Italy.'}, {'lastname': 'Blom', 'firstname': 'Joan M C', 'initials': 'JMC', 'affiliation': 'Center for Neuroscience and Neurotechnology University of Modena and Reggio Emilia, Modena, Italy; Department of Education and Human Sciences, University of Modena and Reggio Emilia, Viale Antonio Allegri 9, 42121, Reggio Emilia, Italy.'}, {'lastname': 'Mendlewicz', 'firstname': 'Julien', 'initials': 'J', 'affiliation': 'Department of Psychiatry, University Clinics of Brussels, Erasme Hospital, Free University of Brussels, 808 Route de Lennik, Brussels, Belgium.'}, {'lastname': 'Tascedda', 'firstname': 'Fabio', 'initials': 'F', 'affiliation': 'Department of Life Sciences, University of Modena and Reggio Emilia, Via Campi 287, 41125, Modena, Italy; Center for Neuroscience and Neurotechnology University of Modena and Reggio Emilia, Modena, Italy.'}, {'lastname': 'Brunello', 'firstname': 'Nicoletta', 'initials': 'N', 'affiliation': 'Department of Life Sciences, University of Modena and Reggio Emilia, Via Campi 287, 41125, Modena, Italy; Center for Neuroscience and Neurotechnology University of Modena and Reggio Emilia, Modena, Italy.'}]",,,,Copyright © 2017 Elsevier Ltd. All rights reserved.,10.1016/j.psyneuen.2017.10.011,<Element 'PubmedArticle' at 0x7f05dd136720>
336,29031551,Neuroinflammation and neurosteroidogenesis: Reciprocal modulation during injury to the adult zebra finch brain.,Estrogens like estradiol (E,"['Estrogen', 'Songbird', 'TBI']",Physiology & behavior,2017-10-17,"[{'lastname': 'Pedersen', 'firstname': 'Alyssa L', 'initials': 'AL', 'affiliation': 'Department of Biology, American University, Washington, DC, United States; Center for Behavioral Neuroscience, American University, Washington, DC, United States.'}, {'lastname': 'Brownrout', 'firstname': 'Jenna L', 'initials': 'JL', 'affiliation': 'Department of Biology, American University, Washington, DC, United States; Center for Behavioral Neuroscience, American University, Washington, DC, United States.'}, {'lastname': 'Saldanha', 'firstname': 'Colin J', 'initials': 'CJ', 'affiliation': 'Department of Biology, American University, Washington, DC, United States; Center for Behavioral Neuroscience, American University, Washington, DC, United States. Electronic address: saldanha@american.edu.'}]",,,,Copyright © 2017 Elsevier Inc. All rights reserved.,10.1016/j.physbeh.2017.10.013,<Element 'PubmedArticle' at 0x7f05dd143ea0>
337,"28913358
13940299
3800971
27396447
27166279
23668691
23325217
22201683
16557263
17826030
17890752
23074226
20110366
23775687
27330055
21499269
24075847
23334579
10567732
26187728
25497089
19648648
22766885
19265148
25447767
19144836
19228962
28319103
19633658
19536194
22224781
22325453
25606824
26260210
20145655
21376175
24750819
27677851
28377412
22224776
26732544
25712734
25169121
23348416
22381575
23478176
24055259
27207308
28154473
18178058
22136135
25844479
16815803
12556347
18996199
17014957
18625277
20619468
10505977
23881919
27447824
17228030
10604470
25801577
28198428
22465905
26138507
26042199
19773372
28625043
19280057
24381790
26856650
26645250
23454172
23864339
22379116
25309797
21925262
19384567
26872221
19620309
25658305
23813326
22040697
28285098
27288847
16751422
19922787
27534878
24166765
25220417
26339623
22279596
24074743
24978197
21663979
28446241
26417688
24997608
19251743
23396211
28683283
23299855
26441834
28134508",Central Modulation of Neuroinflammation by Neuropeptides and Energy-Sensing Hormones during Obesity.,"Central nervous system (CNS) senses energy homeostasis by integrating both peripheral and autonomic signals and responding to them by neurotransmitters and neuropeptides release. Although it is previously considered an immunologically privileged organ, we now know that this is not so. Cells belonging to the immune system, such as B and T lymphocytes, can be recruited into the CNS to face damage or infection, in addition to possessing resident immunological cells, called microglia. In this way, positive energy balance during obesity promotes an inflammatory state in the CNS. Saturated fatty acids from the diet have been pointed out as powerful candidates to trigger immune response in peripheral system and in the CNS. However, how central immunity communicates to peripheral immune response remains to be clarified. Recently there has been a great interest in the neuropeptides, POMC derived peptides, ghrelin, and leptin, due to their capacity to suppress or induce inflammatory responses in the brain, respectively. These may be potential candidates to treat different pathologies associated with autoimmunity and inflammation. In this review, we will discuss the role of lipotoxicity associated with positive energy balance during obesity in proinflammatory response in microglia, B and T lymphocytes, and its modulation by neuropeptides.",[],BioMed research international,2017-09-16,"[{'lastname': 'Maldonado-Ruiz', 'firstname': 'Roger', 'initials': 'R', 'affiliation': 'Laboratory of Virology and Immunology, Faculty of Life Sciences, Autonomous University of Nuevo Leon, San Nicolás de los Garza, NL, Mexico.\nNeurometabolism Unit, Center for Research and Development in Health Sciences, Autonomous University of Nuevo Leon, San Nicolás de los Garza, NL, Mexico.'}, {'lastname': 'Fuentes-Mera', 'firstname': 'Lizeth', 'initials': 'L', 'affiliation': 'Biochemistry Department, Faculty of Medicine, Autonomous University of Nuevo Leon, San Nicolás de los Garza, NL, Mexico.'}, {'lastname': 'Camacho', 'firstname': 'Alberto', 'initials': 'A', 'affiliation': 'Neurometabolism Unit, Center for Research and Development in Health Sciences, Autonomous University of Nuevo Leon, San Nicolás de los Garza, NL, Mexico.\nBiochemistry Department, Faculty of Medicine, Autonomous University of Nuevo Leon, San Nicolás de los Garza, NL, Mexico.'}]",,,,,"10.1155/2017/7949582
10.1083/jcb.17.3.487
10.1042/bj2390121
10.1038/nri.2016.70
10.1152/ajpendo.00012.2016
10.1017/S0029665113001031
10.1038/nature11862
10.1172/jci59660
10.1038/nri1810
10.1016/j.bbi.2007.07.004
10.1093/ndt/gfm517
10.1074/jbc.M112.413500
10.1074/jbc.M109.077610
10.1007/978-94-007-6331-9-1
10.1194/jlr.R066514
10.1038/nm.2353
10.1016/j.bbi.2013.09.011
10.1038/nn.3318
10.1016/S0165-3806(99)00113-3
10.1101/cshperspect.a020545
10.1016/j.celrep.2014.11.018
10.1074/jbc.M109.044065
10.1194/jlr.D029546
10.4049/jimmunol.0802217
10.1016/j.neuint.2015.03.003
10.1523/JNEUROSCI.2760-08.2009
10.1523/jneurosci.3567-08.2009
10.1038/nutd.2017.10
10.1038/nm.1964
10.1038/ni.1760
10.1146/annurev.immunol.25.022106.141623
10.1016/j.molimm.2012.01.005
10.1038/ncomms7074
10.1016/j.molimm.2015.07.024
10.1038/jcbfm.2010.14
10.1016/j.yexcr.2010.12.017
10.1186/1742-2094-11-80
10.1186/s12974-016-0729-x
10.1126/scisignal.aai7696
10.1146/annurev-immunol-020711-074934
10.3389/fimmu.2015.00636
10.1002/ana.24387
10.1111/cei.12444
10.1038/nri3383
10.1242/dmm.009464
10.1016/j.cyto.2013.02.009
10.1016/j.ajpath.2013.07.033
10.1186/s12974-016-0582-y
10.1155/2017/5048616
10.1016/j.bbi.2007.11.009
10.1186/1742-2094-8-169
10.1371/journal.pone.0122211
10.1098/rstb.2006.1861
10.1152/ajpendo.00434.2002
10.1016/j.phrs.2008.10.005
10.1016/j.neulet.2006.09.034
10.1016/j.peptides.2008.06.009
10.1016/j.jneuroim.2010.06.013
10.1016/S0165-5728(99)00122-8
10.1530/JME-13-0064
10.1371/journal.pone.0159724
10.1038/oby.2007.525
10.1038/45230
10.1016/j.npep.2015.02.002
10.1038/srep42706
10.1016/j.nut.2011.11.021
10.1016/j.npep.2015.06.003
10.1016/j.molmet.2015.03.005
10.1530/EJE-09-0375
10.1093/abbs/gmp001
10.1155/2013/518909
10.1016/j.nut.2015.12.034
10.1530/JOE-15-0330
10.1016/j.peptides.2013.02.011
10.1530/EJE-13-0347
10.1530/EJE-11-0982
10.3803/enm.2014.29.3.371
10.1016/j.bbi.2011.08.009
10.1007/s12640-009-9037-x
10.1111/jnc.13576
10.4049/jimmunol.0803362
10.1371/journal.pone.0117081
10.1007/s10753-013-9667-2
10.1016/j.mam.2011.10.012
10.1016/j.cytogfr.2017.03.001
10.1016/j.dci.2016.06.006
10.4049/jimmunol.176.12.7745
10.1016/j.bbi.2009.11.003
10.1152/ajpregu.00258.2016
10.1002/glia.22580
10.1038/onc.2014.283
10.1155/2015/581469
10.1371/journal.pone.0030571
10.1016/j.nutres.2013.07.004
10.1210/me.2014-1011
10.1016/j.tips.2011.04.004
10.1186/s12974-017-0869-7
10.1016/j.bbrc.2015.09.130
10.1038/nm.3614
10.1677/JOE-08-0276
10.1038/nm.3082
10.1016/j.cmet.2017.06.006
10.1096/fj.12-221143
10.3389/fendo.2015.00144
10.1021/acs.biochem.6b01008",<Element 'PubmedArticle' at 0x7f05dd151400>
338,28884751,Tuberculous meningitis.,"Tuberculosis remains a global health problem, with an estimated 10.4 million cases and 1.8 million deaths resulting from the disease in 2015. The most lethal and disabling form of tuberculosis is tuberculous meningitis (TBM), for which more than 100,000 new cases are estimated to occur per year. In patients who are co-infected with HIV-1, TBM has a mortality approaching 50%. Study of TBM pathogenesis is hampered by a lack of experimental models that recapitulate all the features of the human disease. Diagnosis of TBM is often delayed by the insensitive and lengthy culture technique required for disease confirmation. Antibiotic regimens for TBM are based on those used to treat pulmonary tuberculosis, which probably results in suboptimal drug levels in the cerebrospinal fluid, owing to poor blood-brain barrier penetrance. The role of adjunctive anti-inflammatory, host-directed therapies - including corticosteroids, aspirin and thalidomide - has not been extensively explored. To address this deficit, two expert meetings were held in 2009 and 2015 to share findings and define research priorities. This Review summarizes historical and current research into TBM and identifies important gaps in our knowledge. We will discuss advances in the understanding of inflammation in TBM and its potential modulation; vascular and hypoxia-mediated tissue injury; the role of intensified antibiotic treatment; and the importance of rapid and accurate diagnostics and supportive care in TBM.",[],Nature reviews. Neurology,2017-09-09,"[{'lastname': 'Wilkinson', 'firstname': 'Robert J', 'initials': 'RJ', 'affiliation': 'Department of Medicine, Imperial College London, Norfolk Place, London W2 1PG, UK.\nThe Francis Crick Institute, Midland Road, London NW1 2AT, UK.\nWellcome Centre for Infectious Diseases Research in Africa, Institute of Infectious Disease and Molecular Medicine and Department of Medicine, University of Cape Town, Republic of South Africa.'}, {'lastname': 'Rohlwink', 'firstname': 'Ursula', 'initials': 'U', 'affiliation': 'Division of Neurosurgery, University of Cape Town, Anzio Road, Observatory 7925, Republic of South Africa.'}, {'lastname': 'Misra', 'firstname': 'Usha Kant', 'initials': 'UK', 'affiliation': 'Department of Neurology, Sanjay Gandhi Postgraduate Institute of Medical Sciences, Rae Bareli Road, Lucknow, Uttar Pradesh 226014, India.'}, {'lastname': 'van Crevel', 'firstname': 'Reinout', 'initials': 'R', 'affiliation': 'Radboud University Medical Center, Geert Grooteplein Zuid 10, 6525 GA Nijmegen, The Netherlands.'}, {'lastname': 'Mai', 'firstname': 'Nguyen Thi Hoang', 'initials': 'NTH', 'affiliation': 'Oxford University Clinical Research Unit, 764 Vo Van Kiet, Quan 5, Ho Chi Minh City, Vietnam.'}, {'lastname': 'Dooley', 'firstname': 'Kelly E', 'initials': 'KE', 'affiliation': 'Johns Hopkins University School of Medicine, The Johns Hopkins Hospital, 1800 Orleans Street, Baltimore, Maryland 21287, USA.'}, {'lastname': 'Caws', 'firstname': 'Maxine', 'initials': 'M', 'affiliation': 'Liverpool School of Tropical Medicine, Pembroke Place, Liverpool L3 5QA, UK.'}, {'lastname': 'Figaji', 'firstname': 'Anthony', 'initials': 'A', 'affiliation': 'Division of Neurosurgery, University of Cape Town, Anzio Road, Observatory 7925, Republic of South Africa.'}, {'lastname': 'Savic', 'firstname': 'Rada', 'initials': 'R', 'affiliation': 'UCSF School of Pharmacy, Department, Bioengineering, 1700 4th Street, San Francisco, California 94158, UA.'}, {'lastname': 'Solomons', 'firstname': 'Regan', 'initials': 'R', 'affiliation': 'Faculty of Health Sciences, Stellenbosch University, Tygerberg Hospital, Francie van Zijl Drive, Tygerberg 7505, Cape Town, Republic of South Africa.'}, {'lastname': 'Thwaites', 'firstname': 'Guy E', 'initials': 'GE', 'affiliation': 'Oxford University Clinical Research Unit, 764 Vo Van Kiet, Quan 5, Ho Chi Minh City, Vietnam.\nCentre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Old Road, Oxford OX3 9FZ, UK.'}, {'lastname': None, 'firstname': None, 'initials': None, 'affiliation': None}]",,,,,10.1038/nrneurol.2017.120,<Element 'PubmedArticle' at 0x7f05dd1149a0>
339,"28853159
27514452
18303850
26650443
26650439
17462987
20929960
9237266
15038601
19395593
26362846
21907283
22849356
26114403
27430371
20600638
12379255
26260390
25042014
25938459
17264176
10748014
7815073
22244763
24705063
23373812
23602910
23129362
20649561
24336050
25579849
7768881
27159993
15606779
25964986
28861508
22571976
25246934
25173986
27578922
23889598
20660395
25311884
24874548
26464438
18518822
11092756
25252936
23640460
16504929
25083916
28861498
26659605",Tetrahydrocannabinolic acid is a potent PPARγ agonist with neuroprotective activity.,"Phytocannabinoids are produced in Cannabis sativa L. in acidic form and are decarboxylated upon heating, processing and storage. While the biological effects of decarboxylated cannabinoids such as Δ
The effects of six phytocannabinoids on PPARγ binding and transcriptional activity were investigated. The effect of Δ
Cannabinoid acids bind and activate PPARγ with higher potency than their decarboxylated products. Δ
Δ",[],British journal of pharmacology,2017-08-31,"[{'lastname': 'Nadal', 'firstname': 'Xavier', 'initials': 'X', 'affiliation': 'Phytoplant Research SL, Córdoba, Spain.'}, {'lastname': 'Del Río', 'firstname': 'Carmen', 'initials': 'C', 'affiliation': 'Instituto Maimónides de Investigación Biomédica de Córdoba, Departamento de Biología Celular, Fisiología e Inmunología, Hospital Universitario Reina Sofía, Universidad de Córdoba, Córdoba, Spain.'}, {'lastname': 'Casano', 'firstname': 'Salvatore', 'initials': 'S', 'affiliation': 'Phytoplant Research SL, Córdoba, Spain.'}, {'lastname': 'Palomares', 'firstname': 'Belén', 'initials': 'B', 'affiliation': 'Instituto Maimónides de Investigación Biomédica de Córdoba, Departamento de Biología Celular, Fisiología e Inmunología, Hospital Universitario Reina Sofía, Universidad de Córdoba, Córdoba, Spain.'}, {'lastname': 'Ferreiro-Vera', 'firstname': 'Carlos', 'initials': 'C', 'affiliation': 'Phytoplant Research SL, Córdoba, Spain.'}, {'lastname': 'Navarrete', 'firstname': 'Carmen', 'initials': 'C', 'affiliation': 'Vivacell Biotechnology SL, Córdoba, Spain.'}, {'lastname': 'Sánchez-Carnerero', 'firstname': 'Carolina', 'initials': 'C', 'affiliation': 'Phytoplant Research SL, Córdoba, Spain.'}, {'lastname': 'Cantarero', 'firstname': 'Irene', 'initials': 'I', 'affiliation': 'Instituto Maimónides de Investigación Biomédica de Córdoba, Departamento de Biología Celular, Fisiología e Inmunología, Hospital Universitario Reina Sofía, Universidad de Córdoba, Córdoba, Spain.'}, {'lastname': 'Bellido', 'firstname': 'Maria Luz', 'initials': 'ML', 'affiliation': 'Vivacell Biotechnology SL, Córdoba, Spain.'}, {'lastname': 'Meyer', 'firstname': 'Stefan', 'initials': 'S', 'affiliation': 'Phytoplant Research SL, Córdoba, Spain.'}, {'lastname': 'Morello', 'firstname': 'Gaetano', 'initials': 'G', 'affiliation': 'Emerald Health Pharmaceuticals, San Diego, CA, USA.'}, {'lastname': 'Appendino', 'firstname': 'Giovanni', 'initials': 'G', 'affiliation': 'Dipartimento di Scienze del Farmaco, Università del Piemonte Orientale, Novara, Italy.'}, {'lastname': 'Muñoz', 'firstname': 'Eduardo', 'initials': 'E', 'affiliation': 'Instituto Maimónides de Investigación Biomédica de Córdoba, Departamento de Biología Celular, Fisiología e Inmunología, Hospital Universitario Reina Sofía, Universidad de Córdoba, Córdoba, Spain.'}]",,,,© 2017 The British Pharmacological Society.,10.1111/bph.14019,<Element 'PubmedArticle' at 0x7f05dd11e860>
340,"28828399
20522652
27021778
22028881
16862116
26595641
2268320
8486624
23136129
27126638
24779634
21289198
21087763
25519158
23825679
23342160
19649643
22895706
23699531
25578179
16862115
25373145
19158106
21178100
16950801
18768919
22348647
22123177
24619111
26124111
27341800
8784346
21092856
20142525
18568075
23239020
20731760
16145712
19267410
21212639
14657016
27114033
28466142
26968346
23398167
11371512
27703466
25261995
20021345
24925315
27543298
23742080
27356620
21497117
23185029
27009575
27997711
19860916
26109656
26869920
11445546
21617040
24680777
2236009
19288468
22608501
23393155
20188224
15773042
25066864
22509390
22652185
25022663
18359860
27595404
25613900
20154673
24804730
28404863
22733568
20667979
26687838
21698296
26370502
12526812","Intracellular Proteolysis of Progranulin Generates Stable, Lysosomal Granulins that Are Haploinsufficient in Patients with Frontotemporal Dementia Caused by ",Homozygous or heterozygous mutations in the ,"[""Alzheimer's disease"", ""Parkinson's disease"", 'amyotophic lateral sclerosis', 'autophagy', 'cathepsin L', 'frontotemporal dementia', 'granulins', 'lysosomal storage disease', 'neurodegeneration', 'neuroinflammation', 'neuronal ceroid lipofuscinosis', 'progranulin ']",eNeuro,2017-08-23,"[{'lastname': 'Holler', 'firstname': 'Christopher J', 'initials': 'CJ', 'affiliation': 'Department of Pharmacology, Emory University School of Medicine, Atlanta, GA 30322.'}, {'lastname': 'Taylor', 'firstname': 'Georgia', 'initials': 'G', 'affiliation': 'Department of Pharmacology, Emory University School of Medicine, Atlanta, GA 30322.'}, {'lastname': 'Deng', 'firstname': 'Qiudong', 'initials': 'Q', 'affiliation': 'Department of Pharmacology, Emory University School of Medicine, Atlanta, GA 30322.\nDepartment of Biochemistry, Emory University School of Medicine, Atlanta, GA 30322.'}, {'lastname': 'Kukar', 'firstname': 'Thomas', 'initials': 'T', 'affiliation': 'Department of Pharmacology, Emory University School of Medicine, Atlanta, GA 30322.\nCenter for Neurodegenerative Disease, Emory University School of Medicine, Atlanta, GA 30322.\nDepartment of Neurology, Emory University School of Medicine, Atlanta, GA 30322.'}]",,,,,"10.1523/ENEURO.0100-17.2017
10.2353/ajpath.2010.090915
10.1016/j.neurobiolaging.2016.02.019
10.1371/journal.pone.0026454
10.1038/nature05016
10.1016/S0140-6736(15)00461-4
10.1093/hmg/dds475
10.1093/hmg/ddw127
10.1111/epi.12632
10.1523/JNEUROSCI.5757-10.2011
10.1016/j.ajhg.2010.11.002
10.14670/HH-30.647
10.1371/journal.pone.0067680
10.1371/journal.pone.0054448
10.1007/s00401-009-0576-2
10.1523/JNEUROSCI.0521-12.2012
10.1523/JNEUROSCI.5336-12.2013
10.1007/s00415-014-7630-2
10.1038/nature05017
10.1101/gr.177220.114
10.1093/brain/awn352
10.1212/WNL.0b013e31820a0e3b
10.1093/hmg/ddl241
10.1212/01.wnl.0000325058.10218.fc
10.1007/s00401-014-1262-6
10.1073/pnas.1510329112
10.1186/s13024-016-0114-3
10.1016/j.neuron.2010.09.034
10.1001/archneurol.2010.113
10.1172/JCI34694
10.1007/s12035-012-8380-8
10.1111/j.1471-4159.2010.06961.x
10.1002/pmic.200401247
10.1002/ajmg.a.32712
10.1159/000322538
10.1093/emboj/cdg629
10.1016/j.cell.2016.04.001
10.1007/s00401-017-1716-8
10.1016/j.tins.2016.02.002
10.1111/ene.12090
10.1093/hmg/10.11.1191
10.1159/000447738
10.1038/nm.3672
10.1093/hmg/ddu299
10.1007/s00401-016-1610-9
10.1111/jnc.12329
10.1038/ncomms11992
10.1016/j.immuni.2011.01.018
10.1083/jcb.201208152
10.1111/bpa.12480
10.1186/1471-2202-10-130
10.1523/JNEUROSCI.4808-14.2015
10.3389/fnagi.2016.00011
10.1126/science.1204592
10.1016/j.gene.2014.03.041
10.1002/ana.21621
10.1016/j.ajhg.2012.04.021
10.1093/hmg/ddt052
10.1016/j.jprot.2010.02.013
10.1016/j.mcn.2014.07.006
10.1371/journal.pone.0035115
10.1016/j.ymgme.2012.04.024
10.1186/s40478-014-0078-x
10.1110/ps.073295308
10.1038/nmeth.3995
10.1126/science.1260419
10.1038/ng.536
10.1371/journal.pone.0097032
10.1002/path.4043
10.1096/fj.10-161471
10.1371/journal.pone.0021023
10.1083/jcb.201502029",<Element 'PubmedArticle' at 0x7f05dd0cc400>
341,"28751457
12684434
20156559
6435883
16086023
24695702
25130621
16374793
11796850
23076662
18970977
12697742
25383388
17229577
25703008
25857324
20230193
12209119
26239536
17222456
19487649
20878765
21480865
25900077
21767322
20880511
25298214
21300122
27115988
25470046
11286782
23034914
978224
10374717
19815071
21406188
22739983
24148569
27671734
16870736
12427829
10594662
21496013
23588220
12235363
25927213
16367798
12876144
18715114
21848846
21596037
14735117
11764092
18466224
10841576
23839053
25152470",2-Arachidonoylglycerol Reduces Proteoglycans and Enhances Remyelination in a Progressive Model of Demyelination.,"The failure to undergo remyelination is a critical impediment to recovery in multiple sclerosis. Chondroitin sulfate proteoglycans (CSPGs) accumulate at demyelinating lesions creating a nonpermissive environment that impairs axon regeneration and remyelination. Here, we reveal a new role for 2-arachidonoylglycerol (2-AG), the major CNS endocannabinoid, in the modulation of CSPGs deposition in a progressive model of multiple sclerosis, the Theiler's murine encephalomyelitis virus-induced demyelinating disease. Treatment with a potent reversible inhibitor of the enzyme monoacylglycerol lipase, which accounts for 85% of the 2-AG degradation in the mouse CNS, modulates neuroinflammation and reduces CSPGs accumulation and astrogliosis around demyelinated lesions in the spinal cord of Theiler's murine encephalomyelitis virus-infected mice. Inhibition of 2-AG hydrolysis augments the number of mature oligodendrocytes and increases MBP, leading to remyelination and functional recovery of mice. Our findings establish a mechanism for 2-AG promotion of remyelination with implications in axonal repair in CNS demyelinating pathologies.","['2-AG', 'TMEV-IDD', 'chondroitin sulfate proteoglycans', 'neuroinflammation', 'oligodendrocytes', 'remyelination']",The Journal of neuroscience : the official journal of the Society for Neuroscience,2017-07-29,"[{'lastname': 'Feliú', 'firstname': 'Ana', 'initials': 'A', 'affiliation': 'Functional and Systems Neurobiology Department, Neuroimmunology Group, Instituto Cajal, 28002 Madrid, Spain.'}, {'lastname': 'Bonilla Del Río', 'firstname': 'Itziar', 'initials': 'I', 'affiliation': 'Department of Neurosciences, University of the Basque Country UPV/EHU, E-48940 Leioa, Spain.\nAchucarro Basque Center for Neuroscience Bizkaia, Science and Technology Park, E-48170 Zamudio, Spain, and.'}, {'lastname': 'Carrillo-Salinas', 'firstname': 'Francisco Javier', 'initials': 'FJ', 'affiliation': 'Functional and Systems Neurobiology Department, Neuroimmunology Group, Instituto Cajal, 28002 Madrid, Spain.'}, {'lastname': 'Hernández-Torres', 'firstname': 'Gloria', 'initials': 'G', 'affiliation': 'Department of Organic Chemistry I, Universidad Complutense de Madrid 28040 Madrid, Spain.'}, {'lastname': 'Mestre', 'firstname': 'Leyre', 'initials': 'L', 'affiliation': 'Functional and Systems Neurobiology Department, Neuroimmunology Group, Instituto Cajal, 28002 Madrid, Spain.'}, {'lastname': 'Puente', 'firstname': 'Nagore', 'initials': 'N', 'affiliation': 'Department of Neurosciences, University of the Basque Country UPV/EHU, E-48940 Leioa, Spain.\nAchucarro Basque Center for Neuroscience Bizkaia, Science and Technology Park, E-48170 Zamudio, Spain, and.'}, {'lastname': 'Ortega-Gutiérrez', 'firstname': 'Silvia', 'initials': 'S', 'affiliation': 'Department of Organic Chemistry I, Universidad Complutense de Madrid 28040 Madrid, Spain.'}, {'lastname': 'López-Rodríguez', 'firstname': 'Maria L', 'initials': 'ML', 'affiliation': 'Department of Organic Chemistry I, Universidad Complutense de Madrid 28040 Madrid, Spain.'}, {'lastname': 'Grandes', 'firstname': 'Pedro', 'initials': 'P', 'affiliation': 'Department of Neurosciences, University of the Basque Country UPV/EHU, E-48940 Leioa, Spain.\nAchucarro Basque Center for Neuroscience Bizkaia, Science and Technology Park, E-48170 Zamudio, Spain, and.\nDivision of Medical Sciences, University of Victoria, Victoria, British Columbia V8P 5C2, Canada.'}, {'lastname': 'Mecha', 'firstname': 'Miriam', 'initials': 'M', 'affiliation': 'Functional and Systems Neurobiology Department, Neuroimmunology Group, Instituto Cajal, 28002 Madrid, Spain, miriammecha@cajal.csic.es cgjb@cajal.csic.es.'}, {'lastname': 'Guaza', 'firstname': 'Carmen', 'initials': 'C', 'affiliation': 'Functional and Systems Neurobiology Department, Neuroimmunology Group, Instituto Cajal, 28002 Madrid, Spain, miriammecha@cajal.csic.es cgjb@cajal.csic.es.'}]",,,,Copyright © 2017 the authors 0270-6474/17/378385-14$15.00/0.,"10.1523/JNEUROSCI.2900-16.2017
10.1016/j.nbd.2010.02.002
10.1016/0092-8674(84)90276-9
10.1038/nm1279
10.1523/JNEUROSCI.4369-13.2014
10.1002/glia.22742
10.1002/cne.20822
10.1056/NEJMoa010994
10.1002/ana.23693
10.1016/S0140-6736(08)61620-7
10.1172/JCI200317652
10.1016/j.mcn.2006.12.005
10.1002/stem.1979
10.1111/bph.13159
10.1517/14728221003709792
10.1038/nrn917
10.1002/ana.24497
10.1016/j.brainresrev.2006.09.006
10.1212/WNL.0b013e3181a8260a
10.1002/glia.21061
10.1111/j.1476-5381.2011.01414.x
10.1007/s11481-015-9609-x
10.1111/j.1750-3639.2011.00518.x
10.1016/j.nurt.2010.07.003
10.1002/anie.201407807
10.1016/j.neuint.2011.01.017
10.1038/ncomms11312
10.1038/nature13974
10.1016/S1471-4914(00)01909-2
10.1002/ana.23599
10.1016/0022-510X(76)90267-7
10.1016/S0014-2999(99)00187-9
10.1016/j.nbd.2009.09.020
10.1016/j.brainres.2011.03.020
10.1038/cddis.2012.71
10.1016/j.expneurol.2013.10.011
10.7554/eLife.18246
10.1523/JNEUROSCI.1299-06.2006
10.1046/j.1460-9568.1999.00873.x
10.1111/j.1469-7580.2010.01330.x
10.1016/j.expneurol.2013.04.003
10.1073/pnas.192314199
10.1186/s12974-015-0305-9
10.1111/j.1469-7580.2005.00454.x
10.1093/brain/awg224
10.1371/journal.pmed.0050171
10.1111/j.1471-4159.2011.07370.x
10.1016/j.expneurol.2011.05.002
10.1038/nrn1326
10.1093/jnen/60.12.1198
10.1111/j.1365-2990.2008.00956.x
10.1073/pnas.97.12.6820
10.1007/s12264-013-1359-2
10.1016/j.brainres.2014.08.048",<Element 'PubmedArticle' at 0x7f05dcfc9180>
342,28734673,Somatostatin protects human retinal pericytes from inflammation mediated by microglia.,"Diabetic retinopathy (DR) is usually considered a microvascular disease. However, involvement of the neuroretina in the early stages of DR has recently gained major credit. Inflammatory processes, leading to glial activation and neuronal apoptosis, develop early in the retina of diabetic subjects. Pericytes constitute a link between the vascular and the neural retina, play a central role in blood-retinal barrier maintenance, and may influence neuroinflammation. Somatostatin (SST) is a potent neuroprotective factor, which is down-regulated during early DR. In this paper, we have investigated the effects of the inflammatory signals triggered by the activation of microglia on inflammation and apoptosis/survival pathways in pericytes. Microglia cells (Bv-2) were stimulated with lipopolysaccharide (LPS) and/or SST. Human retinal pericytes (HRP) were exposed to conditioned media (CM) collected from Bv-2 cells in physiological conditions and in the settings described above. A panel of inflammation, apoptosis and survival mediators was analyzed. HRP treated with LPS-CM showed a significant increase of pro-inflammatory (iNos and TNFα) and pro-apoptotic mediators (FasL, active caspase-8, tBid and Bax), and a concomitant decrease in pro-survival factors (BclxL and pAkt). SST added to LPS was able to counteract these effects in all conditions. In conclusion, SST is able to modulate apoptosis/survival pathways in HRP during microglia-mediated inflammation. These results demonstrate a crosstalk between microglia and retinal pericytes, evidencing a possible defensive role of microglia in the early phases of DR.","['Apoptosis', 'Diabetic retinopathy', 'Inflammation', 'Microglia', 'Pericyte', 'Somatostatin']",Experimental eye research,2017-07-25,"[{'lastname': 'Mazzeo', 'firstname': 'Aurora', 'initials': 'A', 'affiliation': 'Dept of Medical Sciences, University of Turin, Corso AM Dogliotti 14, 10126 Torino, Italy. Electronic address: aurora.mazzeo@unito.it.'}, {'lastname': 'Arroba', 'firstname': 'Ana I', 'initials': 'AI', 'affiliation': 'Alberto Sols Biomedical Research Institute (IIBm) (CSIC/UAM), C/Arturo Duperier 4, 28029 Madrid, Spain; Spanish Biomedical Research Centre in Diabetes and Associated Metabolic Disorders (CIBERdem), ISCIII, Instituto de Salud Carlos III, C/ Monforte de Lemos 3-5, 28029 Madrid, Spain. Electronic address: aarroba@iib.uam.es.'}, {'lastname': 'Beltramo', 'firstname': 'Elena', 'initials': 'E', 'affiliation': 'Dept of Medical Sciences, University of Turin, Corso AM Dogliotti 14, 10126 Torino, Italy. Electronic address: elena.beltramo@unito.it.'}, {'lastname': 'Valverde', 'firstname': 'Angela M', 'initials': 'AM', 'affiliation': 'Alberto Sols Biomedical Research Institute (IIBm) (CSIC/UAM), C/Arturo Duperier 4, 28029 Madrid, Spain; Spanish Biomedical Research Centre in Diabetes and Associated Metabolic Disorders (CIBERdem), ISCIII, Instituto de Salud Carlos III, C/ Monforte de Lemos 3-5, 28029 Madrid, Spain. Electronic address: avalverde@iib.uam.es.'}, {'lastname': 'Porta', 'firstname': 'Massimo', 'initials': 'M', 'affiliation': 'Dept of Medical Sciences, University of Turin, Corso AM Dogliotti 14, 10126 Torino, Italy. Electronic address: massimo.porta@unito.it.'}]",,,,Copyright © 2017 Elsevier Ltd. All rights reserved.,10.1016/j.exer.2017.07.011,<Element 'PubmedArticle' at 0x7f05dcf75d10>
343,"28724382
21151735
19225398
20626359
20818791
22190370
23077050
20970492
23471521
17934510
14657172
25863279
16512913
17329437
22795792
26032254
22248049
19884325
17982478
26408163
21949506
21838753
25814137
23796670
21317632
22728316
24517920
21041647
23426204
24162463
20022387
18664380
24589481
22368036
23314110
23261685
19126760
1470919
7605349
16099396
12052034
21684528
19804829
18362605
24198365",Activation of cannabinoid receptor type 2 attenuates surgery-induced cognitive impairment in mice through anti-inflammatory activity.,"Neuroinflammation plays a major role in postoperative cognitive dysfunction (POCD). Accumulated evidence indicates that cannabinoid receptor type 2 (CB2R) can mediate anti-inflammatory and immunomodulatory effects in part by controlling microglial activity. However, the impact of CB2R on postoperative cognition has not been investigated. We hypothesized that CB2R is involved in surgery-induced cognitive impairment in adult mice.
Adult C57BL/6 mice were subjected to intramedullary fixation surgery for tibial fracture under isoflurane anesthesia and CB2R agonist (JWH133) or CB2R antagonist (AM630) treatment. The mice were trained 24 h prior to surgery using a fear conditioning protocol and assessed in a novel context on postoperative days 1, 3, and 7 to evaluate cognitive function. Open-field testing was performed to evaluate the locomotor activity of the mice. The expression levels of IL-1β, TNF-α, MCP-1, and CB2R in the hippocampus and prefrontal cortex were assessed by Western blotting; the expression of microglial marker CD11b in the CA1 area of the hippocampus and medial prefrontal cortex was assessed by immunostaining.
The mice displayed no changes in locomotor activity after surgery and drug treatments. The mice exhibited impaired hippocampal-dependent memory accompanied by an increased expression of proinflammatory factors in the hippocampus and prefrontal cortex 1, 3, and 7 days after surgery, while hippocampal-independent memory remained unaffected at the same time points. JWH133 treatment attenuated surgery-induced memory loss, while AM630 treatment aggravated surgery-induced memory loss, paralleled by a decreased or increased expression of proinflammatory factors in the hippocampus and prefrontal cortex. The expression of CB2R in the hippocampus and prefrontal cortex was upregulated following surgery; however, it was downregulated by postoperative treatment with JWH133. Similarly, the expression of CD11b in the CA1 area of the hippocampus and medial prefrontal cortex was upregulated following surgery and downregulated by postoperative treatment with JWH133.
These findings indicate that CB2R may modulate the neuroinflammatory and cognitive impairment in a mouse model of orthopedic surgery, and the activation of CB2R may effectively ameliorate the hippocampal-dependent memory loss of mice in the early postoperative stage.","['Cannabinoid receptor type 2', 'Neuroinflammation', 'Postoperative cognitive dysfunction']",Journal of neuroinflammation,2017-07-21,"[{'lastname': 'Sun', 'firstname': 'Lingling', 'initials': 'L', 'affiliation': 'Department of Anesthesiology, Zhongnan Hospital of Wuhan University, 169, Donghu Road, Wuhan, 430071, Hubei, China.'}, {'lastname': 'Dong', 'firstname': 'Rui', 'initials': 'R', 'affiliation': 'Department of Anesthesiology, Zhongnan Hospital of Wuhan University, 169, Donghu Road, Wuhan, 430071, Hubei, China.'}, {'lastname': 'Xu', 'firstname': 'Xin', 'initials': 'X', 'affiliation': 'Department of Anesthesiology, Zhongnan Hospital of Wuhan University, 169, Donghu Road, Wuhan, 430071, Hubei, China.'}, {'lastname': 'Yang', 'firstname': 'Xi', 'initials': 'X', 'affiliation': 'Department of Anesthesiology, Zhongnan Hospital of Wuhan University, 169, Donghu Road, Wuhan, 430071, Hubei, China.'}, {'lastname': 'Peng', 'firstname': 'Mian', 'initials': 'M', 'affiliation': 'Department of Anesthesiology, Zhongnan Hospital of Wuhan University, 169, Donghu Road, Wuhan, 430071, Hubei, China. sophie_pm@msn.com.'}]",,,"The mice displayed no changes in locomotor activity after surgery and drug treatments. The mice exhibited impaired hippocampal-dependent memory accompanied by an increased expression of proinflammatory factors in the hippocampus and prefrontal cortex 1, 3, and 7 days after surgery, while hippocampal-independent memory remained unaffected at the same time points. JWH133 treatment attenuated surgery-induced memory loss, while AM630 treatment aggravated surgery-induced memory loss, paralleled by a decreased or increased expression of proinflammatory factors in the hippocampus and prefrontal cortex. The expression of CB2R in the hippocampus and prefrontal cortex was upregulated following surgery; however, it was downregulated by postoperative treatment with JWH133. Similarly, the expression of CD11b in the CA1 area of the hippocampus and medial prefrontal cortex was upregulated following surgery and downregulated by postoperative treatment with JWH133.",,"10.1186/s12974-017-0913-7
10.1016/j.aan.2010.09.003
10.1097/ALN.0b013e318195b569
10.1111/j.1399-6576.2010.02268.x
10.1002/ana.22082
10.1002/ana.22664
10.1523/JNEUROSCI.2173-12.2012
10.1016/j.bbi.2010.10.015
10.1007/s11481-013-9445-9
10.1038/sj.bjp.0707505
10.1016/j.pnpbp.2015.03.017
10.1186/1471-2377-6-12
10.1523/JNEUROSCI.4814-06.2007
10.1016/j.neurobiolaging.2012.06.011
10.1016/j.lfs.2015.05.005
10.1186/1742-2094-9-8
10.1096/fj.09-141275
10.1038/sj.bjp.0707523
10.3389/fnbeh.2011.00057
10.1111/j.1476-5381.2011.01625.x
10.1007/s00213-015-3917-y
10.1016/j.neuropharm.2013.05.034
10.1097/ALN.0b013e31820ad3ce
10.1016/j.bbi.2012.06.004
10.1016/j.bbi.2014.02.002
10.1073/pnas.1014557107
10.1097/ALN.0b013e3182834d94
10.1097/ALN.0000000000000045
10.1016/j.jneuroim.2009.11.011
10.1016/j.bbi.2008.07.002
10.1097/ALN.0000000000000191
10.1002/ana.23536
10.1097/ALN.0b013e3182834d77
10.1016/j.pharmthera.2012.12.002
10.1152/physrev.00019.2008
10.1126/science.1470919
10.1016/0006-2952(95)00109-D
10.1016/j.prostaglandins.2004.09.007
10.1054/plef.2001.0356
10.1016/j.biopsych.2011.04.022
10.1016/j.nbd.2009.09.021
10.1097/ALN.0b013e318167af74
10.1523/JNEUROSCI.2049-13.2013",<Element 'PubmedArticle' at 0x7f05dcf81f90>
344,"28714753
7896671
22935553
9699708
10596252
25957806
15730904
22534626
27188830
25325534
24184556
27110222
26657857
18537653
18258663
25695943
25695942
15968928
20230803
14973249
25117419
24561489
26304458
26809245
15911817
22245284
25314221
26559389
2516000
16638499
26325561
7661914
9464208
8464654
2912267
18035153
16225742
25301689
19668249",Pediatric Acute-Onset Neuropsychiatric Syndrome Response to Oral Corticosteroid Bursts: An Observational Study of Patients in an Academic Community-Based PANS Clinic.,"Sudden-onset severe obsessive-compulsive symptoms and/or severely restrictive food intake with at least two coinciding, similarly debilitating neuropsychiatric symptoms define Pediatric Acute-onset Neuropsychiatric Syndrome (PANS). When associated with Group A Streptococcus, the syndrome is labeled Pediatric Autoimmune Neuropsychiatric Disorder Associated with Streptococcal infections (PANDAS). An abnormal immune response to infection and subsequent neuroinflammation is postulated to play an etiologic role. Most patients have a relapsing-remitting course. Treatment outcome data for youth with PANS and PANDAS are limited.
One hundred seventy-eight consecutive patients were seen in the Stanford PANS clinic between September 1, 2012 and January 15, 2016, of whom 98 met PANS or PANDAS criteria, had a single episode of PANS or relapsing/remitting course, and collectively experienced 403 flares. Eighty-five flares were treated with 102 total courses of oral corticosteroids of either short (4-5 days) or long (5 days-8 weeks) duration. Response to treatment was assessed within 14 days of initiating a short burst of corticosteroids and at the end of a long burst based on clinician documentation and patient questionnaires. Data were analyzed by using multilevel random-effects models.
Patients experienced shorter flares when treated with oral corticosteroids (6.4 ± 5.0 weeks vs. 11.4 ± 8.6 weeks) than when not treated (p < 0.001), even after controlling for presumed confounding variables, including age at flare, weeks since onset of PANS illness, sex, antibiotic treatment, prophylactic antibiotics, previous immunomodulatory treatment, maintenance anti-inflammatory therapy, psychiatric medications, and cognitive behavioral therapy (p < 0.01). When corticosteroids were given for the initial PANS episode, flares tended to be shorter (10.3 ± 5.7 weeks) than when not treated (16.5 ± 9.6 weeks) (p = 0.06). This difference was statistically significant after controlling for the relevant confounding variables listed earlier (p < 0.01). Earlier use of corticosteroids was associated with shorter flare durations (p < 0.001). Longer courses of corticosteroids were associated with a more enduring impact on the duration of neuropsychiatric symptom improvement (p = 0.014).
Corticosteroids may be a helpful treatment intervention in patients with new-onset and relapsing/remitting PANS and PANDAS, hastening symptom improvement or resolution. When corticosteroids are given earlier in a disease flare, symptoms improve more quickly and patients achieve clinical remission sooner. Longer courses of corticosteroids may result in more durable remissions. A double-blind placebo-controlled clinical trial of corticosteroids in PANS is warranted to formally assess treatment efficacy.","['PANDAS', 'PANS', 'corticosteroids', 'immune modulation', 'obsessive-compulsive disorder', 'tics']",Journal of child and adolescent psychopharmacology,2017-07-18,"[{'lastname': 'Brown', 'firstname': 'Kayla', 'initials': 'K', 'affiliation': ""1 Division of Pediatrics, Department of Allergy, Immunology, and Rheumatology, Stanford University School of Medicine , Palo Alto, California.\n2 Stanford PANS Clinic and Research Program at Lucile Packard Children's Hospital, Stanford University School of Medicine , Palo Alto, California.""}, {'lastname': 'Farmer', 'firstname': 'Cristan', 'initials': 'C', 'affiliation': '3 Intramural Research Program, National Institute of Mental Health , Bethesda, Maryland.'}, {'lastname': 'Farhadian', 'firstname': 'Bahare', 'initials': 'B', 'affiliation': ""2 Stanford PANS Clinic and Research Program at Lucile Packard Children's Hospital, Stanford University School of Medicine , Palo Alto, California.""}, {'lastname': 'Hernandez', 'firstname': 'Joseph', 'initials': 'J', 'affiliation': ""1 Division of Pediatrics, Department of Allergy, Immunology, and Rheumatology, Stanford University School of Medicine , Palo Alto, California.\n2 Stanford PANS Clinic and Research Program at Lucile Packard Children's Hospital, Stanford University School of Medicine , Palo Alto, California.""}, {'lastname': 'Thienemann', 'firstname': 'Margo', 'initials': 'M', 'affiliation': ""2 Stanford PANS Clinic and Research Program at Lucile Packard Children's Hospital, Stanford University School of Medicine , Palo Alto, California.\n4 Division of Pediatrics, Department of Child and Adolescent Psychiatry, Stanford University School of Medicine , Palo Alto, California.""}, {'lastname': 'Frankovich', 'firstname': 'Jennifer', 'initials': 'J', 'affiliation': ""1 Division of Pediatrics, Department of Allergy, Immunology, and Rheumatology, Stanford University School of Medicine , Palo Alto, California.\n2 Stanford PANS Clinic and Research Program at Lucile Packard Children's Hospital, Stanford University School of Medicine , Palo Alto, California.""}]",,"Corticosteroids may be a helpful treatment intervention in patients with new-onset and relapsing/remitting PANS and PANDAS, hastening symptom improvement or resolution. When corticosteroids are given earlier in a disease flare, symptoms improve more quickly and patients achieve clinical remission sooner. Longer courses of corticosteroids may result in more durable remissions. A double-blind placebo-controlled clinical trial of corticosteroids in PANS is warranted to formally assess treatment efficacy.","Patients experienced shorter flares when treated with oral corticosteroids (6.4 ± 5.0 weeks vs. 11.4 ± 8.6 weeks) than when not treated (p < 0.001), even after controlling for presumed confounding variables, including age at flare, weeks since onset of PANS illness, sex, antibiotic treatment, prophylactic antibiotics, previous immunomodulatory treatment, maintenance anti-inflammatory therapy, psychiatric medications, and cognitive behavioral therapy (p < 0.01). When corticosteroids were given for the initial PANS episode, flares tended to be shorter (10.3 ± 5.7 weeks) than when not treated (16.5 ± 9.6 weeks) (p = 0.06). This difference was statistically significant after controlling for the relevant confounding variables listed earlier (p < 0.01). Earlier use of corticosteroids was associated with shorter flare durations (p < 0.001). Longer courses of corticosteroids were associated with a more enduring impact on the duration of neuropsychiatric symptom improvement (p = 0.014).",,"10.1089/cap.2016.0139
10.1089/cap.2016.0151
10.1089/cap.2016.0148",<Element 'PubmedArticle' at 0x7f05dcf2c220>
345,"28698257
19566837
21196131
9016301
17875676
11380825
21403086
26254332
20547972
20142564
25302502
26056339
25470051
27776109
23334579
24360280
22632727
26040959
24316888
27294511
24313777
24859199
14687548
27893460
20407134
9231833
18390891
23968981
26134639
17490814
2828236
14534577
16702209
23906810
24712567
22391036
11840268
24270184
26485285
20937129",Brain Transforming Growth Factor-β Resists Hypertension Via Regulating Microglial Activation.,"Hypertension is the major risk factor for stroke. Recent work unveiled that hypertension is associated with chronic neuroinflammation; microglia are the major players in neuroinflammation, and the activated microglia elevate sympathetic nerve activity and blood pressure. This study is to understand how brain homeostasis is kept from hypertensive disturbance and microglial activation at the onset of hypertension.
Hypertension was induced by subcutaneous delivery of angiotensin II, and blood pressure was monitored in conscious animals. Microglial activity was analyzed by flow cytometry and immunohistochemistry. Antibody, pharmacological chemical, and recombinant cytokine were administered to the brain through intracerebroventricular infusion. Microglial depletion was performed by intracerebroventricular delivering diphtheria toxin to CD11b-diphtheria toxin receptor mice. Gene expression profile in sympathetic controlling nucleus was analyzed by customized qRT-PCR array.
Transforming growth factor-β (TGF-β) is constitutively expressed in the brains of normotensive mice. Removal of TGF-β or blocking its signaling before hypertension induction accelerated hypertension progression, whereas supplementation of TGF-β1 substantially suppressed neuroinflammation, kidney norepinephrine level, and blood pressure. By means of microglial depletion and adoptive transfer, we showed that the effects of TGF-β on hypertension are mediated through microglia. In contrast to the activated microglia in established hypertension, the resting microglia are immunosuppressive and important in maintaining neural homeostasis at the onset of hypertension. Further, we profiled the signature molecules of neuroinflammation and neuroplasticity associated with hypertension and TGF-β by qRT-PCR array.
Our results identify that TGF-β-modulated microglia are critical to keeping brain homeostasis responding to hypertensive disturbance.","['blood pressure', 'diphtheria toxin', 'hypertension', 'microglia', 'stroke']",Stroke,2017-07-13,"[{'lastname': 'Li', 'firstname': 'You', 'initials': 'Y', 'affiliation': 'From the School of Life Science and Technology, Tongji University, Shanghai, China (Y.L., T.V.Z., J.F.); The Second Affiliated Hospital of Zhejiang University (P.S.), Institute of Translational Medicine (P.S.), and Department of Physiology (X.Z.S.), Zhejiang University School of Medicine, Hangzhou, China; Department of Neurology (Y.L., L.L., P.L., P.S.) and Department of Biomedical Science (T.V.Z., K.E.B.), Cedars-Sinai Medical Center, Los Angeles, CA; and Pharmacological and Brain Sciences, University of Iowa (A.K.J.).'}, {'lastname': 'Shen', 'firstname': 'Xiao Z', 'initials': 'XZ', 'affiliation': 'From the School of Life Science and Technology, Tongji University, Shanghai, China (Y.L., T.V.Z., J.F.); The Second Affiliated Hospital of Zhejiang University (P.S.), Institute of Translational Medicine (P.S.), and Department of Physiology (X.Z.S.), Zhejiang University School of Medicine, Hangzhou, China; Department of Neurology (Y.L., L.L., P.L., P.S.) and Department of Biomedical Science (T.V.Z., K.E.B.), Cedars-Sinai Medical Center, Los Angeles, CA; and Pharmacological and Brain Sciences, University of Iowa (A.K.J.).'}, {'lastname': 'Li', 'firstname': 'Liang', 'initials': 'L', 'affiliation': 'From the School of Life Science and Technology, Tongji University, Shanghai, China (Y.L., T.V.Z., J.F.); The Second Affiliated Hospital of Zhejiang University (P.S.), Institute of Translational Medicine (P.S.), and Department of Physiology (X.Z.S.), Zhejiang University School of Medicine, Hangzhou, China; Department of Neurology (Y.L., L.L., P.L., P.S.) and Department of Biomedical Science (T.V.Z., K.E.B.), Cedars-Sinai Medical Center, Los Angeles, CA; and Pharmacological and Brain Sciences, University of Iowa (A.K.J.).'}, {'lastname': 'Zhao', 'firstname': 'Tuantuan V', 'initials': 'TV', 'affiliation': 'From the School of Life Science and Technology, Tongji University, Shanghai, China (Y.L., T.V.Z., J.F.); The Second Affiliated Hospital of Zhejiang University (P.S.), Institute of Translational Medicine (P.S.), and Department of Physiology (X.Z.S.), Zhejiang University School of Medicine, Hangzhou, China; Department of Neurology (Y.L., L.L., P.L., P.S.) and Department of Biomedical Science (T.V.Z., K.E.B.), Cedars-Sinai Medical Center, Los Angeles, CA; and Pharmacological and Brain Sciences, University of Iowa (A.K.J.).'}, {'lastname': 'Bernstein', 'firstname': 'Kenneth E', 'initials': 'KE', 'affiliation': 'From the School of Life Science and Technology, Tongji University, Shanghai, China (Y.L., T.V.Z., J.F.); The Second Affiliated Hospital of Zhejiang University (P.S.), Institute of Translational Medicine (P.S.), and Department of Physiology (X.Z.S.), Zhejiang University School of Medicine, Hangzhou, China; Department of Neurology (Y.L., L.L., P.L., P.S.) and Department of Biomedical Science (T.V.Z., K.E.B.), Cedars-Sinai Medical Center, Los Angeles, CA; and Pharmacological and Brain Sciences, University of Iowa (A.K.J.).'}, {'lastname': 'Johnson', 'firstname': 'Alan K', 'initials': 'AK', 'affiliation': 'From the School of Life Science and Technology, Tongji University, Shanghai, China (Y.L., T.V.Z., J.F.); The Second Affiliated Hospital of Zhejiang University (P.S.), Institute of Translational Medicine (P.S.), and Department of Physiology (X.Z.S.), Zhejiang University School of Medicine, Hangzhou, China; Department of Neurology (Y.L., L.L., P.L., P.S.) and Department of Biomedical Science (T.V.Z., K.E.B.), Cedars-Sinai Medical Center, Los Angeles, CA; and Pharmacological and Brain Sciences, University of Iowa (A.K.J.).'}, {'lastname': 'Lyden', 'firstname': 'Patrick', 'initials': 'P', 'affiliation': 'From the School of Life Science and Technology, Tongji University, Shanghai, China (Y.L., T.V.Z., J.F.); The Second Affiliated Hospital of Zhejiang University (P.S.), Institute of Translational Medicine (P.S.), and Department of Physiology (X.Z.S.), Zhejiang University School of Medicine, Hangzhou, China; Department of Neurology (Y.L., L.L., P.L., P.S.) and Department of Biomedical Science (T.V.Z., K.E.B.), Cedars-Sinai Medical Center, Los Angeles, CA; and Pharmacological and Brain Sciences, University of Iowa (A.K.J.).'}, {'lastname': 'Fang', 'firstname': 'Jianmin', 'initials': 'J', 'affiliation': 'From the School of Life Science and Technology, Tongji University, Shanghai, China (Y.L., T.V.Z., J.F.); The Second Affiliated Hospital of Zhejiang University (P.S.), Institute of Translational Medicine (P.S.), and Department of Physiology (X.Z.S.), Zhejiang University School of Medicine, Hangzhou, China; Department of Neurology (Y.L., L.L., P.L., P.S.) and Department of Biomedical Science (T.V.Z., K.E.B.), Cedars-Sinai Medical Center, Los Angeles, CA; and Pharmacological and Brain Sciences, University of Iowa (A.K.J.).'}, {'lastname': 'Shi', 'firstname': 'Peng', 'initials': 'P', 'affiliation': 'From the School of Life Science and Technology, Tongji University, Shanghai, China (Y.L., T.V.Z., J.F.); The Second Affiliated Hospital of Zhejiang University (P.S.), Institute of Translational Medicine (P.S.), and Department of Physiology (X.Z.S.), Zhejiang University School of Medicine, Hangzhou, China; Department of Neurology (Y.L., L.L., P.L., P.S.) and Department of Biomedical Science (T.V.Z., K.E.B.), Cedars-Sinai Medical Center, Los Angeles, CA; and Pharmacological and Brain Sciences, University of Iowa (A.K.J.). ship@zju.edu.cn jfang@tongji.edu.cn.'}]",,,"Transforming growth factor-β (TGF-β) is constitutively expressed in the brains of normotensive mice. Removal of TGF-β or blocking its signaling before hypertension induction accelerated hypertension progression, whereas supplementation of TGF-β1 substantially suppressed neuroinflammation, kidney norepinephrine level, and blood pressure. By means of microglial depletion and adoptive transfer, we showed that the effects of TGF-β on hypertension are mediated through microglia. In contrast to the activated microglia in established hypertension, the resting microglia are immunosuppressive and important in maintaining neural homeostasis at the onset of hypertension. Further, we profiled the signature molecules of neuroinflammation and neuroplasticity associated with hypertension and TGF-β by qRT-PCR array.","© 2017 American Heart Association, Inc.",10.1161/STROKEAHA.117.017370,<Element 'PubmedArticle' at 0x7f05dcf4f220>
346,28698092,"Spasticity in multiple sclerosis: Contribution of inflammation, autoimmune mediated neuronal damage and therapeutic interventions.","In contrast to other diseases that go along with spasticity (e.g. spinal cord injury), spasticity in chronic autoimmune diseases involving the CNS is complicated by the ongoing damage of neuronal networks that leads to permanent changes in the clinical picture of spasticity. Multiple sclerosis (MS) is the most frequent autoimmune disease of the central nervous system (CNS) and spasticity is one of the most disabling symptoms. It occurs in more than 80% MS patients at some point of the disease and is associated with impaired ambulation, pain and the development of contractures. Besides causing cumulative structural damage, neuroinflammation occurring in MS leads to dynamic changes in motor circuit function and muscle tone that are caused by cytokines, prostaglandins, reactive oxygen species and stress hormones that affect neuronal circuits and thereby spasticity. The situation is complicated further by the fact that therapeutics used for the immunotherapy of MS may worsen spasticity and drugs used for the symptomatic treatment of spasticity have been shown to have the potential to alter immune cell function and CNS autoimmunity itself. This review summarizes the current knowledge on the immunologic pathways that are involved in the development, maintenance, dynamic changes and pharmacological modulation of spasticity in MS.","['Cytokines', 'Multiple sclerosis', 'Neurodegeneration', 'Neuroinflammation', 'Spasticity']",Autoimmunity reviews,2017-07-13,"[{'lastname': 'Patejdl', 'firstname': 'Robert', 'initials': 'R', 'affiliation': 'University of Rostock, Department of Physiology, Germany. Electronic address: robert.patejdl@uni-rostock.de.'}, {'lastname': 'Zettl', 'firstname': 'Uwe K', 'initials': 'UK', 'affiliation': 'University of Rostock, Department of Neurology, Division of Neuroimmunology, Germany.'}]",,,,Copyright © 2017 Elsevier B.V. All rights reserved.,10.1016/j.autrev.2017.07.004,<Element 'PubmedArticle' at 0x7f05dceef270>
347,"28667487
17074507
9845273
25343964
11384882
17229941
18482593
27283249
20012068
28332151
25423896
20566663
8690915
21486251
11465996
24054992
15448158
27250720
20561356
24819940
21982954
24183692
17562483
24732014
19150053
24744400
17117171
22940431
25414643
25224590
21929682
23831150
21595013
18358090
15337246
24444786
22248073
25448601
11604225
16879163
27443914
19094079
25516121
24727365
24918290
18775356
27148048
17908174
17023425
11788422
19087328
15694366
18001325
19690763
20880511
24704246
22833869
25927064
25052429
1478729
27445795
25477778
16888643
21994399
22975659
25086299
17822540
11746774
18386154
10037689
11165240
11788415
25443742
27680512
19904605",Tibolone Preserves Mitochondrial Functionality and Cell Morphology in Astrocytic Cells Treated with Palmitic Acid.,"Obesity has been associated with increased chronic neuroinflammation and augmented risk of neurodegeneration. This is worsened during the normal aging process when the levels of endogenous gonadal hormones are reduced. In this study, we have assessed the protective actions of tibolone, a synthetic steroid with estrogenic actions, on T98G human astrocytic cells exposed to palmitic acid, a saturated fatty acid used to mimic obesity in vitro. Tibolone improved cell survival, and preserved mitochondrial membrane potential in palmitic acid-treated astrocytic cells. Although we did not find significant actions of tibolone on free radical production, it modulated astrocytic morphology after treatment with palmitic acid. These data suggest that tibolone protects astrocytic cells by preserving both mitochondrial functionality and morphological complexity.","['Astrocytes', 'Mitochondria', 'Morphology', 'Palmitic acid', 'Tibolone']",Molecular neurobiology,2017-07-02,"[{'lastname': 'González-Giraldo', 'firstname': 'Yeimy', 'initials': 'Y', 'affiliation': 'Departamento de Nutrición y Bioquímica, Facultad de Ciencias, Pontificia Universidad Javeriana, Bogotá D.C., Colombia.'}, {'lastname': 'Garcia-Segura', 'firstname': 'Luis Miguel', 'initials': 'LM', 'affiliation': 'Instituto Cajal, CSIC, Madrid, Spain.\nCIBER de Investigación Biomédica en Red de Fragilidad y Envejecimiento Saludable (CIBERFES), Instituto de Salud Carlos III, Madrid, Spain.'}, {'lastname': 'Echeverria', 'firstname': 'Valentina', 'initials': 'V', 'affiliation': 'Fac. Cs de la Salud, Universidad San Sebastián, Lientur 1457, 4080871, Concepción, Chile.\nBay Pines VA Health Care System, 10,000 Bay Pines Blvd, Bldg 23, Rm 123, Bay Pines, FL, 33744, USA.'}, {'lastname': 'Barreto', 'firstname': 'George E', 'initials': 'GE', 'affiliation': 'Departamento de Nutrición y Bioquímica, Facultad de Ciencias, Pontificia Universidad Javeriana, Bogotá D.C., Colombia. gesbarreto@gmail.com.\nInstituto de Ciencias Biomédicas, Universidad Autónoma de Chile, Santiago, Chile. gesbarreto@gmail.com.'}]",,,,,10.1007/s12035-017-0667-3,<Element 'PubmedArticle' at 0x7f05dcef9310>
348,28665507,Participation of hypothalamic CB1 receptors in reproductive axis disruption during immune challenge.,"Immune challenge inhibits reproductive function and endocannabinoids (eCB) modulate sexual hormones. However, no studies have been performed to assess whether the eCB system mediates the inhibition of hormones that control reproduction as a result of immune system activation during systemic infections. For that reason, we evaluated the participation of the hypothalamic cannabinoid receptor CB1 on the hypothalamic-pituitary-gonadal (HPG) axis activity in rats submitted to immune challenge. Male adult rats were treated i.c.v. administration with a CB1 antagonist/inverse agonist (AM251) (500 ng/5 μL), followed by an i.p. injection of lipopolysaccharide (LPS) (5 mg/kg) 15 minutes later. Plasmatic, hypothalamic and adenohypophyseal pro-inflammatory cytokines, hormones and neuropeptides were assessed 90 or 180 minutes post-LPS. The plasma concentration of tumour necrosis factor α and adenohypophyseal mRNA expression of Tnfα and Il1β increased 90 and 180 minutes post i.p. administration of LPS. However, cytokine mRNA expression in the hypothalamus increased only 180 minutes post-LPS, suggesting an inflammatory delay in this organ. CB1 receptor blockade with AM251 increased LPS inflammatory effects, particularly in the hypothalamus. LPS also inhibited the HPG axis by decreasing gonadotrophin-releasing hormone hypothalamic content and plasma levels of luteinising hormone and testosterone. These disruptor effects were accompanied by decreased hypothalamic Kiss1 mRNA expression and prostaglandin E2 content, as well as by increased gonadotrophin-inhibitory hormone (Rfrp3) mRNA expression. All these disruptive effects were prevented by the presence of AM251. In summary, our results suggest that, in male rats, eCB mediate immune challenge-inhibitory effects on reproductive axis at least partially via hypothalamic CB1 activation. In addition, this receptor also participates in homeostasis recovery by modulating the inflammatory process taking place after LPS administration.","['endocannabinoid system', 'immune challenge', 'reproductive axis']",Journal of neuroendocrinology,2017-07-01,"[{'lastname': 'Surkin', 'firstname': 'P N', 'initials': 'PN', 'affiliation': 'Facultad de Odontología, Universidad de Buenos Aires, Buenos Aires, Argentina.\nConsejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Buenos Aires, Argentina.'}, {'lastname': 'Di Rosso', 'firstname': 'M E', 'initials': 'ME', 'affiliation': 'Pontificia Universidad Católica Argentina (UCA), Consejo Nacional de Investigaciones Científicas y Técnicas, Instituto de Investigaciones Biomédicas (BIOMED), Buenos Aires, Argentina.'}, {'lastname': 'Correa', 'firstname': 'F', 'initials': 'F', 'affiliation': 'Facultad de Medicina, Centro de Estudios Farmacológicos y Botánicos, Universidad de Buenos Aires, Consejo Nacional de Investigaciones Científicas y Técnicas, Buenos Aires, Argentina.'}, {'lastname': 'Elverdin', 'firstname': 'J C', 'initials': 'JC', 'affiliation': 'Facultad de Odontología, Universidad de Buenos Aires, Buenos Aires, Argentina.'}, {'lastname': 'Genaro', 'firstname': 'A M', 'initials': 'AM', 'affiliation': 'Pontificia Universidad Católica Argentina (UCA), Consejo Nacional de Investigaciones Científicas y Técnicas, Instituto de Investigaciones Biomédicas (BIOMED), Buenos Aires, Argentina.\nFacultad de Medicina, Universidad de Buenos Aires, Buenos Aires, Argentina.'}, {'lastname': 'De Laurentiis', 'firstname': 'A', 'initials': 'A', 'affiliation': 'Facultad de Odontología, Universidad de Buenos Aires, Buenos Aires, Argentina.\nFacultad de Medicina, Centro de Estudios Farmacológicos y Botánicos, Universidad de Buenos Aires, Consejo Nacional de Investigaciones Científicas y Técnicas, Buenos Aires, Argentina.'}, {'lastname': 'Fernández-Solari', 'firstname': 'J', 'initials': 'J', 'affiliation': 'Facultad de Odontología, Universidad de Buenos Aires, Buenos Aires, Argentina.\nConsejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Buenos Aires, Argentina.'}]",,,,© 2017 British Society for Neuroendocrinology.,10.1111/jne.12499,<Element 'PubmedArticle' at 0x7f05dcf15a90>
349,28648389,Stress primes microglial polarization after global ischemia: Therapeutic potential of progesterone.,"Despite the fact that stress is associated with increased risk of stroke and worsened outcome, most preclinical studies have ignored this comorbid factor, especially in the context of testing neuroprotective treatments. Preclinical research suggests that stress primes microglia, resulting in an enhanced reactivity to a subsequent insult and potentially increasing vulnerability to stroke. Ischemia-induced activated microglia can be polarized into a harmful phenotype, M1, which produces pro-inflammatory cytokines, or a protective phenotype, M2, which releases anti-inflammatory cytokines and neurotrophic factors. Selective modulation of microglial polarization by inhibiting M1 or stimulating M2 may be a potential therapeutic strategy for treating cerebral ischemia. Our laboratory and others have shown progesterone to be neuroprotective against ischemic stroke in rodents, but it is not known whether it will be as effective under a comorbid condition of chronic stress. Here we evaluated the neuroprotective effect of progesterone on the inflammatory response in the hippocampus after exposure to stress followed by global ischemia. We focused on the effects of microglial M1/M2 polarization and pro- and anti-inflammatory mediators in stressed ischemic animals. Male Sprague-Dawley rats were exposed to 8 consecutive days of social defeat stress and then subjected to global ischemia or sham surgery. The rats received intraperitoneal injections of progesterone (8mg/kg) or vehicle at 2h post-ischemia followed by subcutaneous injections at 6h and once every 24h post-injury for 7days. The animals were killed at 7 and 14days post-ischemia, and brains were removed and processed to assess outcome measures using histological, immunohistochemical and molecular biology techniques. Pre-ischemic stress (1) exacerbated neuronal loss and neurodegeneration as well as microglial activation in the selectively vulnerable CA1 hippocampal region, (2) dysregulated microglial polarization, leading to upregulation of both M1 and M2 phenotype markers, (3) increased pro-inflammatory cytokine expression, and (4) reduced anti-inflammatory cytokine and neurotrophic factor expression in the ischemic hippocampus. Treatment with progesterone significantly attenuated stress-induced microglia priming by modulating polarized microglia and the inflammatory environment in the hippocampus, the area most vulnerable to ischemic injury. Our findings can be taken to suggest that progesterone holds potential as a candidate for clinical testing in ischemic stroke where high stress may be a contributing factor.","['Global ischemia', 'Inflammation', 'M1/M2 polarization', 'Microglia', 'Neuroprotection', 'Progesterone', 'Stress']","Brain, behavior, and immunity",2017-06-27,"[{'lastname': 'Espinosa-Garcia', 'firstname': 'Claudia', 'initials': 'C', 'affiliation': 'Department of Emergency Medicine, Emory University, Atlanta, GA 30322, USA. Electronic address: claudia.espinosa-garcia@emory.edu.'}, {'lastname': 'Sayeed', 'firstname': 'Iqbal', 'initials': 'I', 'affiliation': 'Department of Emergency Medicine, Emory University, Atlanta, GA 30322, USA. Electronic address: isayeed@emory.edu.'}, {'lastname': 'Yousuf', 'firstname': 'Seema', 'initials': 'S', 'affiliation': 'Department of Emergency Medicine, Emory University, Atlanta, GA 30322, USA. Electronic address: syousu2@emory.edu.'}, {'lastname': 'Atif', 'firstname': 'Fahim', 'initials': 'F', 'affiliation': 'Department of Emergency Medicine, Emory University, Atlanta, GA 30322, USA. Electronic address: fatif@emory.edu.'}, {'lastname': 'Sergeeva', 'firstname': 'Elena G', 'initials': 'EG', 'affiliation': 'Department of Emergency Medicine, Emory University, Atlanta, GA 30322, USA. Electronic address: elena.sergeeva@emory.edu.'}, {'lastname': 'Neigh', 'firstname': 'Gretchen N', 'initials': 'GN', 'affiliation': 'Department of Psychiatry and Behavioral Sciences, Emory University, Atlanta, GA 30322, USA. Electronic address: gretchen.neigh@emory.edu.'}, {'lastname': 'Stein', 'firstname': 'Donald G', 'initials': 'DG', 'affiliation': 'Department of Emergency Medicine, Emory University, Atlanta, GA 30322, USA. Electronic address: dstei04@emory.edu.'}]",,,,Copyright © 2017 Elsevier Inc. All rights reserved.,10.1016/j.bbi.2017.06.012,<Element 'PubmedArticle' at 0x7f05dcea6450>
350,28634006,Testosterone Differentially Affects T Cells and Neurons in Murine and Human Models of Neuroinflammation and Neurodegeneration.,"The high female-to-male sex ratio of multiple sclerosis (MS) prevalence has continuously confounded researchers, especially in light of male patients' accelerated disease course at later stages of MS. Although multiple studies have concentrated on estrogenic mechanisms of disease modulation, fairly little attention has been paid to androgenic effects in a female system, and even fewer studies have attempted to dissociate hormonal effects on the neurodegenerative and neuroinflammatory processes of MS. Herein, we demonstrate the differential effects of hormone treatment on the acute inflammatory and chronic neurodegenerative phases of murine experimental autoimmune encephalomyelitis. Although s.c. treatment with testosterone and aromatase inhibitor applied beginning on the day of immunization ameliorated initial course of disease, similar treatment administered therapeutically exacerbated chronic disease course. Spinal cord analyses of axonal densities reflected the clinical scores of the chronic phase. In vitro, testosterone treatment not only decreased Th1 and Th17 differentiation in an aromatase-independent fashion, but also exacerbated cell death in induced pluripotent stem cell-derived primary human neurons under oxidative stress conditions in an aromatase inhibitor-dependent manner. Thus, through the alleviation of inflammatory processes and the exacerbation of neurodegenerative processes, androgens may contribute to the epidemiologic sex differentials observed in MS prevalence and course.",[],The American journal of pathology,2017-06-22,"[{'lastname': 'Massa', 'firstname': 'Megan G', 'initials': 'MG', 'affiliation': 'Department of Neurology, Ruhr University-Bochum, Bochum, Germany.'}, {'lastname': 'David', 'firstname': 'Christina', 'initials': 'C', 'affiliation': 'Department of Neurology, Ruhr University-Bochum, Bochum, Germany.'}, {'lastname': 'Jörg', 'firstname': 'Stefanie', 'initials': 'S', 'affiliation': 'Department of Neurology, Friedrich-Alexander University-Erlangen-Nuremberg, Erlangen, Germany.'}, {'lastname': 'Berg', 'firstname': 'Johannes', 'initials': 'J', 'affiliation': 'Department of Neurology, Ruhr University-Bochum, Bochum, Germany.'}, {'lastname': 'Gisevius', 'firstname': 'Barbara', 'initials': 'B', 'affiliation': 'Department of Neurology, Ruhr University-Bochum, Bochum, Germany.'}, {'lastname': 'Hirschberg', 'firstname': 'Sarah', 'initials': 'S', 'affiliation': 'Department of Neurology, Ruhr University-Bochum, Bochum, Germany.'}, {'lastname': 'Linker', 'firstname': 'Ralf A', 'initials': 'RA', 'affiliation': 'Department of Neurology, Friedrich-Alexander University-Erlangen-Nuremberg, Erlangen, Germany.'}, {'lastname': 'Gold', 'firstname': 'Ralf', 'initials': 'R', 'affiliation': 'Department of Neurology, Ruhr University-Bochum, Bochum, Germany.'}, {'lastname': 'Haghikia', 'firstname': 'Aiden', 'initials': 'A', 'affiliation': 'Department of Neurology, Ruhr University-Bochum, Bochum, Germany. Electronic address: aiden.haghikia@rub.de.'}]",,,,Copyright © 2017 American Society for Investigative Pathology. Published by Elsevier Inc. All rights reserved.,10.1016/j.ajpath.2017.03.006,<Element 'PubmedArticle' at 0x7f05dceb3630>
351,28618070,Morin Suppresses Astrocyte Activation and Regulates Cytokine Release in Bone Cancer Pain Rat Models.,"As inflammatory and immune responses are involved in pathophysiology of debilitating neuropathic pain, reagents that can modulate these two responses may have therapeutic potential. Morin, derived from the moraceae family of plants, benefits inflammation-related diseases, but its antinociceptive effects on cancer pain remain elusive. In the present study, we investigated antinociceptive effects of morin on bone cancer pain using a rat model, where rats were subject to implantation of Walker 256 mammary gland carcinoma cells into the tibia. Morin (5-20 mg/kg) dose-dependently attenuated behavioral hypersensitivities, including mechanical allodynia and free movement pain, which was accompanied by downregulation of astrocyte marker glial fibrillary acidic protein in the spinal cord in cancer-bearing rats. Treatment with morin also induced reduction of pro-inflammatory cytokines TNF-α, IL-1β, and IL-6 and upregulation of an antiinflammatory cytokine IL-10. Furthermore, intrathecal injection of AM630 (an antagonist of cannabinoid receptor 2, CB","['CB2', 'bone cancer pain', 'cytokine', 'morin']",Phytotherapy research : PTR,2017-06-16,"[{'lastname': 'Jiang', 'firstname': 'Wei', 'initials': 'W', 'affiliation': 'Shandong Provincial Hospital, Affiliated to Shandong University, No. 324 Jingwuweiqi Road, Jinan, 250021, Shandong Province, China.'}, {'lastname': 'Wang', 'firstname': 'Ying', 'initials': 'Y', 'affiliation': 'Shandong Provincial Hospital, Affiliated to Shandong University, No. 324 Jingwuweiqi Road, Jinan, 250021, Shandong Province, China.'}, {'lastname': 'Sun', 'firstname': 'Wei', 'initials': 'W', 'affiliation': 'Shandong Provincial Hospital, Affiliated to Shandong University, No. 324 Jingwuweiqi Road, Jinan, 250021, Shandong Province, China.'}, {'lastname': 'Zhang', 'firstname': 'Mengyuan', 'initials': 'M', 'affiliation': 'Shandong Provincial Hospital, Affiliated to Shandong University, No. 324 Jingwuweiqi Road, Jinan, 250021, Shandong Province, China.'}]",,,,"Copyright © 2017 John Wiley & Sons, Ltd.",10.1002/ptr.5849,<Element 'PubmedArticle' at 0x7f05dcebf9a0>
352,"28544365
8880734
24078816
24439723
7510610
8707928
18832152
21822589
26512331
16024755
1650522
17666053
24245565
25711529
24517230
16212944
20424564
22396865
26244935
16552414
21613996
15964248
10537031
17578509
20974732
24341993
25373903
16988703
16580998
7723929
23039106
15757637
26780286
10089130
21935936
15486815
22560222
25907790
26268661
22182318
18631321
27312235
16445986
20573720
22201683
24590317
10378877
27314003
23636330
26394137
19894723",Anti-aging drugs reduce hypothalamic inflammation in a sex-specific manner.,"Aging leads to hypothalamic inflammation, but does so more slowly in mice whose lifespan has been extended by mutations that affect GH/IGF-1 signals. Early-life exposure to GH by injection, or to nutrient restriction in the first 3 weeks of life, also modulate both lifespan and the pace of hypothalamic inflammation. Three drugs extend lifespan of UM-HET3 mice in a sex-specific way: acarbose (ACA), 17-α-estradiol (17αE2), and nordihydroguaiaretic acid (NDGA), with more dramatic longevity increases in males in each case. In this study, we examined the effect of these anti-aging drugs on neuro-inflammation in hypothalamus and hippocampus. We found that age-associated hypothalamic inflammation is reduced in males but not in females at 12 months of age by ACA and 17αE2 and at 22 months of age in NDGA-treated mice. The three drugs blocked indices of hypothalamic reactive gliosis associated with aging, such as Iba-1-positive microglia and GFAP-positive astrocytes, as well as age-associated overproduction of TNF-α. This effect was not observed in drug-treated female mice or in the hippocampus of the drug-treated animals. On the other hand, caloric restriction (CR; an intervention that extends the lifespan in both sexes) significantly reduced hypothalamic microglia and TNF-α in both sexes at 12 months of age. Together, these results suggest that the extent of drug-induced changes in hypothalamic inflammatory processes is sexually dimorphic in a pattern that parallels the effects of these agents on mouse longevity and that mimics the changes seen, in both sexes, of long-lived nutrient restricted or mutant mice.","['\nNDGA\n', '17-α Estradiol', 'Acarbose', 'aging', 'hypothalamus', 'inflammation', 'longevity', 'sexual dimorphism']",Aging cell,2017-05-26,"[{'lastname': 'Sadagurski', 'firstname': 'Marianna', 'initials': 'M', 'affiliation': 'Division of Geriatric and Palliative Medicine, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA.'}, {'lastname': 'Cady', 'firstname': 'Gillian', 'initials': 'G', 'affiliation': 'Department of Pathology and Geriatrics Center, University of Michigan, Ann Arbor, MI, USA.'}, {'lastname': 'Miller', 'firstname': 'Richard A', 'initials': 'RA', 'affiliation': 'Department of Pathology and Geriatrics Center, University of Michigan, Ann Arbor, MI, USA.'}]",,,,© 2017 The Authors. Aging Cell published by the Anatomical Society and John Wiley & Sons Ltd.,10.1111/acel.12590,<Element 'PubmedArticle' at 0x7f05dcecf1d0>
353,"28528968
24239383
21630409
20309983
11124442
17504894
9663454
7475950
8282104
12941771
15476930
10385705
7564878
20005808
8932539
9755090
22646481
23593132
25146704
21818468
9491937
23530509
22500019
23219578
9753619
10907112
24169554
2529544
12130773
26071095
18640458
23125202
7929617
15292279
23794448
21224052
21947943
22474610
27255958
23197731
26768593
11979402
23552370
12719630
18654087
2668077
22862822
20835230
2251906
17316162
8245987
22908189
3670729
20541952
21802388
28059785
7472513
8076756
9406927
10719219
2608057
9623635
17614161
19866952
10208278
25430817
9361021
22129618
20226802
24520345
9830016
25120481
21482827
3263583
27021820
23183359
2874657
21115952
22135135
25813842
20153100
19150656
17051221
25149184
9356260
21248787
20962049
24019897
8090221
8306873
9808328
26340637
27911303
17762886
3035556
9209829
23713771
17203498
23956012
10693932
16492554
16492540
27743934
28503657
24614496
28363773
23943781",Amylin and its G-protein-coupled receptor: A probable pathological process and drug target for Alzheimer's disease.,"G-protein-coupled receptors (GPCRs) are shown to be involved in Alzheimer's disease (AD) pathogenesis. However, because GPCRs include a large family of membrane receptors, it is unclear which specific GPCR or pathway with rational ligands can become effective therapeutic targets for AD. Amylin receptor (AmR) is a GPCR that mediates several activities, such as improving glucose metabolism, relaxing cerebrovascular structure, modulating inflammatory reactions and potentially enhancing neural regeneration. Recent studies show that peripheral treatments with amylin or its clinical analog, pramlintide, reduced several components of AD pathology, including amyloid plaques, tauopathy, neuroinflammation and other components in the brain, corresponding with improved learning and memory in AD mouse models. Because amylin shares a similar secondary structure with amyloid-β peptide (Aβ), I propose that the AmR/GPCR pathway is disturbed by a large amount of Aβ in the AD brain, leading to tau phosphorylation, neuroinflammation and neuronal death in the pathological cascade. Amylin-type peptides, readily crossing the blood-brain barrier (BBB), are the rational ligands to enhance this GPCR pathway and may exhibit utility as novel therapeutic agents for treating AD.","['Alzheimer’s disease', 'G-protein-coupled receptors (GPCRs)', 'amylin', 'amylin receptor (AmR)', 'therapeutics']",Neuroscience,2017-05-23,"[{'lastname': 'Qiu', 'firstname': 'Wei Qiao', 'initials': 'WQ', 'affiliation': ""Department of Psychiatry, Boston University School of Medicine, United States; Department of Pharmacology & Experimental Therapeutics, Boston University School of Medicine, United States; Alzheimer's Disease Center, Boston University School of Medicine, United States. Electronic address: wqiu67@bu.edu.""}]",,,,Copyright © 2017 IBRO. Published by Elsevier Ltd. All rights reserved.,10.1016/j.neuroscience.2017.05.024,<Element 'PubmedArticle' at 0x7f05dce73630>
354,28526435,"The bidirectional gut-brain-microbiota axis as a potential nexus between traumatic brain injury, inflammation, and disease.","As head injuries and their sequelae have become an increasingly salient matter of public health, experts in the field have made great progress elucidating the biological processes occurring within the brain at the moment of injury and throughout the recovery thereafter. Given the extraordinary rate at which our collective knowledge of neurotrauma has grown, new insights may be revealed by examining the existing literature across disciplines with a new perspective. This article will aim to expand the scope of this rapidly evolving field of research beyond the confines of the central nervous system (CNS). Specifically, we will examine the extent to which the bidirectional influence of the gut-brain axis modulates the complex biological processes occurring at the time of traumatic brain injury (TBI) and over the days, months, and years that follow. In addition to local enteric signals originating in the gut, it is well accepted that gastrointestinal (GI) physiology is highly regulated by innervation from the CNS. Conversely, emerging data suggests that the function and health of the CNS is modulated by the interaction between 1) neurotransmitters, immune signaling, hormones, and neuropeptides produced in the gut, 2) the composition of the gut microbiota, and 3) integrity of the intestinal wall serving as a barrier to the external environment. Specific to TBI, existing pre-clinical data indicates that head injuries can cause structural and functional damage to the GI tract, but research directly investigating the neuronal consequences of this intestinal damage is lacking. Despite this void, the proposed mechanisms emanating from a damaged gut are closely implicated in the inflammatory processes known to promote neuropathology in the brain following TBI, which suggests the gut-brain axis may be a therapeutic target to reduce the risk of Chronic Traumatic Encephalopathy and other neurodegenerative diseases following TBI. To better appreciate how various peripheral influences are implicated in the health of the CNS following TBI, this paper will also review the secondary biological injury mechanisms and the dynamic pathophysiological response to neurotrauma. Together, this review article will attempt to connect the dots to reveal novel insights into the bidirectional influence of the gut-brain axis and propose a conceptual model relevant to the recovery from TBI and subsequent risk for future neurological conditions.","['Chronic Traumatic Encephalopathy', 'Concussion', 'Gut', 'Gut-brain axis', 'Intestinal dysfunction', 'Microbiota', 'Microglia', 'Neurodegenerative disease', 'Neuroinflammation', 'Traumatic Brain Injury']","Brain, behavior, and immunity",2017-05-21,"[{'lastname': 'Sundman', 'firstname': 'Mark H', 'initials': 'MH', 'affiliation': 'Department of Psychology, University of Arizona, Tucson, AZ, USA. Electronic address: marksundman@email.arizona.edu.'}, {'lastname': 'Chen', 'firstname': 'Nan-Kuei', 'initials': 'NK', 'affiliation': 'Department of Biomedical Engineering, University of Arizona, Tucson, AZ, USA.'}, {'lastname': 'Subbian', 'firstname': 'Vignesh', 'initials': 'V', 'affiliation': 'Department of Biomedical Engineering, University of Arizona, Tucson, AZ, USA; Department of Systems and Industrial Engineering, University of Arizona, Tucson, AZ, USA.'}, {'lastname': 'Chou', 'firstname': 'Ying-Hui', 'initials': 'YH', 'affiliation': 'Department of Psychology, University of Arizona, Tucson, AZ, USA; Cognitive Science Program, University of Arizona, Tucson, AZ, USA; Arizona Center on Aging, University of Arizona, Tucson, AZ, USA.'}]",,,,Copyright © 2017 Elsevier Inc. All rights reserved.,10.1016/j.bbi.2017.05.009,<Element 'PubmedArticle' at 0x7f05dcda74f0>
355,28479389,Involvement of progranulin in modulating neuroinflammatory responses but not neurogenesis in the hippocampus of aged mice.,"It is well established that adult neurogenesis in the hippocampus declines with age. Our previous studies have suggested that progranulin (PGRN) has a facilitative effect on hippocampal neurogenesis. We have also shown that PGRN plays a role in suppressing excessive neuroinflammatory responses in the cortex and thalamus after brain injury and aging, respectively. However, the roles of PGRN in modulating neurogenesis and neuroinflammatory responses in the hippocampus of aged animals are not yet understood. In the present study, we investigated neurogenesis and neuroinflammation-related responses in the hippocampus of young (15-week-old) and old (135-week-old) wild-type and PGRN-deficient male mice. Neurogenesis in the dentate gyrus of the hippocampus markedly declined with age, and there was no significant difference between the genotype. The number of CD68-positive activated microglia and the expression of lysosomal genes in the hippocampus were significantly increased with age, and PGRN deficiency further increased them. The expression of pro-inflammatory genes was also increased with age, and PGRN deficiency significantly enhanced some of them. These results suggest that PGRN deficiency exacerbates neuroinflammatory responses related to activated microglia in aged animals, while PGRN may not counteract the decline of hippocampal neurogenesis with age.","['Aging', 'Hippocampus', 'Neurogenesis', 'Neuroinflammation', 'Progranulin']",Experimental gerontology,2017-05-10,"[{'lastname': 'Ma', 'firstname': 'Yanbo', 'initials': 'Y', 'affiliation': 'Department of Veterinary Physiology, Graduate School of Agricultural and Life Sciences, The University of Tokyo, Tokyo 113-8657, Japan; Department of Animal Physiology, College of Animal Science, Henan University of Science and Technology, Luoyang 471003, China.'}, {'lastname': 'Matsuwaki', 'firstname': 'Takashi', 'initials': 'T', 'affiliation': 'Department of Veterinary Physiology, Graduate School of Agricultural and Life Sciences, The University of Tokyo, Tokyo 113-8657, Japan.'}, {'lastname': 'Yamanouchi', 'firstname': 'Keitaro', 'initials': 'K', 'affiliation': 'Department of Veterinary Physiology, Graduate School of Agricultural and Life Sciences, The University of Tokyo, Tokyo 113-8657, Japan.'}, {'lastname': 'Nishihara', 'firstname': 'Masugi', 'initials': 'M', 'affiliation': 'Department of Veterinary Physiology, Graduate School of Agricultural and Life Sciences, The University of Tokyo, Tokyo 113-8657, Japan. Electronic address: amnishi@mail.ecc.u-tokyo.ac.jp.'}]",,,,Copyright © 2017 Elsevier Inc. All rights reserved.,10.1016/j.exger.2017.05.003,<Element 'PubmedArticle' at 0x7f05dcdb1770>
356,28477436,Brain inflammasomes in stroke and depressive disorders: Regulation by oestrogen.,"Neuroinflammation is a devastating pathophysiological process that results in brain damage and neuronal death. Pathogens, cell fragments and cellular dysfunction trigger inflammatory responses. Irrespective of the cause, inflammasomes are key intracellular multiprotein signalling platforms that sense neuropathological conditions. The activation of inflammasomes leads to the auto-proteolytic cleavage of caspase-1, resulting in the proteolysis of the pro-inflammatory cytokines interleukin (IL)1β and IL18 into their bioactive forms. It also initiates pyroptosis, a type of cell death. The two cytokines contribute to the pathogenesis in acute and chronic brain diseases and also play a central role in human aging and psychiatric disorders. Sex steroids, in particular oestrogens, are well-described neuroprotective agents in the central nervous system. Oestrogens improve the functional outcome after ischaemia and traumatic brain injury, reduce neuronal death in Parkinson's and Alzheimer's disease, as well as in amyotrophic lateral sclerosis, attenuate glutamate excitotoxicity and the formation of radical oxygen species, and lessen the spread of oedema after damage. Moreover, oestrogens alleviate menopause-related depressive symptoms and have a positive influence on depressive disorders probably by influencing growth factor production and serotonergic brain circuits. Recent evidence also suggests that inflammasome signalling affects anxiety- and depressive-like behaviour and that oestrogen ameliorates depression-like behaviour through the suppression of inflammasomes. In the present review, we highlight the most recent findings demonstrating that oestrogens selectively suppress the activation of the neuroinflammatory cascade in the brain in acute and chronic brain disease models. Furthermore, we aim to describe putative regulatory signalling pathways involved in the control of inflammasomes. Finally, we consider that psychiatric disorders such as depression also contain an inflammatory component that could be modulated by oestrogen.","['depressive disorder', 'inflammasome', 'ischaemia', 'neuroinflammation', 'oestrogen']",Journal of neuroendocrinology,2017-05-10,"[{'lastname': 'Slowik', 'firstname': 'A', 'initials': 'A', 'affiliation': 'Medical Faculty, Institute of Neuroanatomy, RWTH Aachen, Aachen, Germany.'}, {'lastname': 'Lammerding', 'firstname': 'L', 'initials': 'L', 'affiliation': 'Medical Faculty, Institute of Neuroanatomy, RWTH Aachen, Aachen, Germany.'}, {'lastname': 'Hoffmann', 'firstname': 'S', 'initials': 'S', 'affiliation': 'Department of Psychiatry, Psychotherapy and Psychosomatics, Medical Faculty, RWTH Aachen, Aachen, Germany.\nJARA - Translational Brain Medicine, Aachen, Germany.'}, {'lastname': 'Beyer', 'firstname': 'C', 'initials': 'C', 'affiliation': 'Medical Faculty, Institute of Neuroanatomy, RWTH Aachen, Aachen, Germany.\nJARA - Translational Brain Medicine, Aachen, Germany.'}]",,,,© 2017 British Society for Neuroendocrinology.,10.1111/jne.12482,<Element 'PubmedArticle' at 0x7f05dcdbe900>
357,28385651,Intranasal telmisartan ameliorates brain pathology in five familial Alzheimer's disease mice.,"The renin-angiotensin system (RAS) is a major circulative system engaged in homeostasis modulation. Angiotensin II (Ang II) serves as its main effector hormone upon binding to its primary receptor, Ang II receptor type 1 (AT","['Alzheimer’s disease', 'Angiotensin II', 'Glial inflammation', 'Microglia', 'Telmisartan']","Brain, behavior, and immunity",2017-04-08,"[{'lastname': 'Torika', 'firstname': 'Nofar', 'initials': 'N', 'affiliation': 'Department of Clinical Biochemistry and Pharmacology, Ben-Gurion University of the Negev, Beer-Sheva P.O.B 653, Israel.'}, {'lastname': 'Asraf', 'firstname': 'Keren', 'initials': 'K', 'affiliation': 'Department of Clinical Biochemistry and Pharmacology, Ben-Gurion University of the Negev, Beer-Sheva P.O.B 653, Israel.'}, {'lastname': 'Cohen', 'firstname': 'Hagit', 'initials': 'H', 'affiliation': 'Anxiety and Stress Research Unit, Beer-Sheva Mental Health Center, Ministry of Health, Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel; Department of Psychology, Ben-Gurion University of the Negev, Beer-Sheva, Israel.'}, {'lastname': 'Fleisher-Berkovich', 'firstname': 'Sigal', 'initials': 'S', 'affiliation': 'Department of Clinical Biochemistry and Pharmacology, Ben-Gurion University of the Negev, Beer-Sheva P.O.B 653, Israel. Electronic address: fleisher@bgu.ac.il.'}]",,,,Copyright © 2017 Elsevier Inc. All rights reserved.,10.1016/j.bbi.2017.04.001,<Element 'PubmedArticle' at 0x7f05dcdc8bd0>
358,"28368293
26339480
11596130
7536402
15710469
10595504
7880387
16200070
16200068
18922831
23378325
18970977
26965491
24930711
18574142
27379721
27628733
27508987
22224308
26010666
25556061
24443833
17446019
24263433
27232720
27051430
27234712
25171128
24488604
24210682
23414569
22326488
27364363
27086601
26876387
26758668
26289248
25356432
20153077
12182963
20541836
20829244
12876144
28107775
26883973
26827298
21356367
16343349
10822068
7556170
9064327
27988430
25417010
26819091
25194788
21931637","(-)-β-Caryophyllene, a CB2 Receptor-Selective Phytocannabinoid, Suppresses Motor Paralysis and Neuroinflammation in a Murine Model of Multiple Sclerosis.","(-)-β-caryophyllene (BCP), a cannabinoid receptor type 2 (CB2)-selective phytocannabinoid, has already been shown in precedent literature to exhibit both anti-inflammatory and analgesic effects in mouse models of inflammatory and neuropathic pain. Herein, we endeavored to investigate the therapeutic potential of BCP on experimental autoimmune encephalomyelitis (EAE), a murine model of multiple sclerosis (MS). Furthermore, we sought to demonstrate some of the mechanisms that underlie the modulation BCP exerts on autoimmune activated T cells, the pro-inflammatory scenery of the central nervous system (CNS), and demyelination. Our findings demonstrate that BCP significantly ameliorates both the clinical and pathological parameters of EAE. In addition, data hereby presented indicates that mechanisms underlying BCP immunomodulatory effect seems to be linked to its ability to inhibit microglial cells, CD4+ and CD8+ T lymphocytes, as well as protein expression of pro-inflammatory cytokines. Furthermore, it diminished axonal demyelination and modulated Th1/Treg immune balance through the activation of CB2 receptor. Altogether, our study represents significant implications for clinical research and strongly supports the effectiveness of BCP as a novel molecule to target in the development of effective therapeutic agents for MS.","['(−)-β-caryophyllene', 'CB2 receptor', 'experimental autoimmune encephalomyelitis', 'multiple sclerosis', 'neuroinflammation', 'phytocannabinoid']",International journal of molecular sciences,2017-04-04,"[{'lastname': 'Alberti', 'firstname': 'Thaís Barbosa', 'initials': 'TB', 'affiliation': 'Laboratory of Autoimmunity and Immunopharmacology (LAIF), Department of Health Sciences, Center of Araranguá, Federal University of Santa Catarina, Araranguá 88906-072, Brazil. alberti.thais@gmail.com.'}, {'lastname': 'Barbosa', 'firstname': 'Wagner Luiz Ramos', 'initials': 'WL', 'affiliation': 'Faculty of Pharmaceutical Sciences, Federal University of Pará, Belém 66075-740, Brazil. zweigw@gmail.com.'}, {'lastname': 'Vieira', 'firstname': 'José Luiz Fernandes', 'initials': 'JL', 'affiliation': 'Faculty of Pharmaceutical Sciences, Federal University of Pará, Belém 66075-740, Brazil. jvieira@ufpa.br.'}, {'lastname': 'Raposo', 'firstname': 'Nádia Rezende Barbosa', 'initials': 'NR', 'affiliation': 'Research and Innovation in Health Sciences (NUPICS), Federal University of Juiz de Fora, Juiz de Fora 36036-900, Brazil. nadiacritt@gmail.com.'}, {'lastname': 'Dutra', 'firstname': 'Rafael Cypriano', 'initials': 'RC', 'affiliation': 'Laboratory of Autoimmunity and Immunopharmacology (LAIF), Department of Health Sciences, Center of Araranguá, Federal University of Santa Catarina, Araranguá 88906-072, Brazil. rafaelcdutra@gmail.com.'}]",,,,,"10.3390/ijms18040691
10.12688/f1000research.6378.1
10.1002/glia.1111
10.1002/ana.410370404
10.1016/j.jneuroim.2004.11.011
10.1016/S0896-6273(00)81107-1
10.1016/0167-5699(95)80068-9
10.1038/ni1254
10.1038/ni1261
10.1177/1352458508096687
10.1002/ana.23758
10.1016/S0140-6736(08)61620-7
10.1016/j.physbeh.2014.06.003
10.1073/pnas.0803601105
10.1007/s00011-016-0969-3
10.5650/jos.ess16038
10.1590/0001-3765201620140050
10.1002/cbdv.201400255
10.1016/S1875-5364(14)60133-3
10.1080/14786419.2013.873435
10.1016/j.jep.2007.03.005
10.1007/BF00982102
10.1016/j.scitotenv.2016.05.034
10.1002/mnfr.201600197
10.1159/000362689
10.1007/s12031-014-0243-5
10.1016/j.euroneuro.2013.10.008
10.1016/j.ajpath.2012.11.024
10.1016/j.freeradbiomed.2012.01.014
10.2174/1574884711666160418105339
10.1016/j.autrev.2016.02.008
10.2174/1389450117666160112113703
10.1007/s13311-015-0383-5
10.1002/acn3.84
10.1016/j.imbio.2009.12.005
10.1016/S0163-7258(02)00255-3
10.1016/j.imbio.2010.03.009
10.1177/1352458510378020
10.1093/brain/awg224
10.1111/bph.13722
10.1016/j.lfs.2016.02.049
10.1016/j.yebeh.2015.12.040
10.1016/j.ajpath.2010.11.052
10.1186/1742-2094-2-29
10.1016/S0014-2999(00)00211-9
10.1111/j.1432-1033.1995.tb20780.x
10.1084/jem.184.3.1101
10.1016/j.autrev.2016.12.011
10.1007/s11064-014-1474-0
10.1186/s12974-016-0484-z
10.1016/j.neuroscience.2014.08.043
10.1371/journal.pone.0024034",<Element 'PubmedArticle' at 0x7f05dcdd4e00>
359,28295567,Melatonin reverses H,"Autophagy, a degradation mechanism that plays a major role in maintaining cellular homeostasis and diminishes in aging, is considered an aging characteristic. Melatonin is an important hormone that plays a wide range of physiological functions, including the anti-aging effect, potentially via the regulation of the Sirtuin1 (SIRT1) pathway. The deacetylation ability of SIRT1 is important for controlling the function of several transcription factors, including nuclear factor kappa B (NF-ĸB). Apart from inflammation, NF-ĸB can regulate autophagy by inhibiting Beclin1, an initiator of autophagy. Although numerous studies have revealed the role of melatonin in regulating autophagy, very limited experiments have shown that melatonin can increase autophagic activity via SIRT1 in a senescent model. This study focuses on the effect of melatonin on autophagy via the deacetylation activity of SIRT1 on RelA/p65, a subunit of NF-ĸB, to determine whether melatonin can attenuate the aging condition. SH-SY5Y cells were treated with H","['aging', 'autophagy', 'epigenetic', 'melatonin', 'neuroinflammation', 'sirtuin 1']",Journal of pineal research,2017-03-16,"[{'lastname': 'Nopparat', 'firstname': 'Chutikorn', 'initials': 'C', 'affiliation': 'Research Center for Neuroscience, Institute of Molecular Biosciences, Mahidol University, Nakhon Pathom, Thailand.'}, {'lastname': 'Sinjanakhom', 'firstname': 'Puritat', 'initials': 'P', 'affiliation': 'Research Center for Neuroscience, Institute of Molecular Biosciences, Mahidol University, Nakhon Pathom, Thailand.'}, {'lastname': 'Govitrapong', 'firstname': 'Piyarat', 'initials': 'P', 'affiliation': 'Research Center for Neuroscience, Institute of Molecular Biosciences, Mahidol University, Nakhon Pathom, Thailand.\nCenter for Neuroscience and Department of Pharmacology, Faculty of Science, Mahidol University, Bangkok, Thailand.\nChulabhorn Graduate Institute, Chulabhorn Royal Academy, Bangkok, Thailand.'}]",,,,© 2017 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.,10.1111/jpi.12407,<Element 'PubmedArticle' at 0x7f05dcd38e00>
360,"28265898
18083844
20117131
26781879
17292584
19146875
22466130
22466126
8662823
19553445
17989304
12808141
16174730
16524371
27312666
17989304
18554968
24948120
22222817
19474321
17174525
26752644
24919967
19339605
15995722
27670299
3340425
21159431
24531553
22565312
11801370
27538456
20554014
23686636
18480275
21068766
20817353
21068766
23979158
25467445
21443797
24833289
15497039
12808141
19553445
14624855
22016541
25467445
20383154
10570489
11356865
23359671
23946399
27934764","Spinal CCL2 Promotes Central Sensitization, Long-Term Potentiation, and Inflammatory Pain via CCR2: Further Insights into Molecular, Synaptic, and Cellular Mechanisms.","Mounting evidence supports an important role of chemokines, produced by spinal cord astrocytes, in promoting central sensitization and chronic pain. In particular, CCL2 (C-C motif chemokine ligand 2) has been shown to enhance N-methyl-D-aspartate (NMDA)-induced currents in spinal outer lamina II (IIo) neurons. However, the exact molecular, synaptic, and cellular mechanisms by which CCL2 modulates central sensitization are still unclear. We found that spinal injection of the CCR2 antagonist RS504393 attenuated CCL2- and inflammation-induced hyperalgesia. Single-cell RT-PCR revealed CCR2 expression in excitatory vesicular glutamate transporter subtype 2-positive (VGLUT2","['Chemokines', 'C–C motif chemokine ligand 2 (CCL2)', 'Monocyte chemoattractant protein 1 (MCP-1)', 'Neuron–glial interaction']",Neuroscience bulletin,2017-03-08,"[{'lastname': 'Xie', 'firstname': 'Rou-Gang', 'initials': 'RG', 'affiliation': ""Department of Neurobiology and Collaborative Innovation Center for Brain Science, The Fourth Military Medical University, Xi'an, 710032, China. rgxie@fmmu.edu.cn.\nDepartment of Anesthesiology, Duke University Medical Center, Durham, NC, 27710, USA. rgxie@fmmu.edu.cn.""}, {'lastname': 'Gao', 'firstname': 'Yong-Jing', 'initials': 'YJ', 'affiliation': 'Pain Research Laboratory, Institute of Nautical Medicine, Jiangsu Key laboratory of Neuroregeneration, Nantong University, Nantong, 226001, China.'}, {'lastname': 'Park', 'firstname': 'Chul-Kyu', 'initials': 'CK', 'affiliation': 'Department of Physiology, College of Medicine, Gachon University, Incheon, 21999, Republic of Korea.'}, {'lastname': 'Lu', 'firstname': 'Ning', 'initials': 'N', 'affiliation': 'Institutes of Brain Science and State Key Laboratory of Medical Neurobiology, Collaborative Innovation Center for Brain Science, Fudan University, Shanghai, 200032, China.'}, {'lastname': 'Luo', 'firstname': 'Ceng', 'initials': 'C', 'affiliation': ""Department of Neurobiology and Collaborative Innovation Center for Brain Science, The Fourth Military Medical University, Xi'an, 710032, China.""}, {'lastname': 'Wang', 'firstname': 'Wen-Ting', 'initials': 'WT', 'affiliation': ""Department of Neurobiology and Collaborative Innovation Center for Brain Science, The Fourth Military Medical University, Xi'an, 710032, China.""}, {'lastname': 'Wu', 'firstname': 'Sheng-Xi', 'initials': 'SX', 'affiliation': ""Department of Neurobiology and Collaborative Innovation Center for Brain Science, The Fourth Military Medical University, Xi'an, 710032, China.""}, {'lastname': 'Ji', 'firstname': 'Ru-Rong', 'initials': 'RR', 'affiliation': 'Department of Anesthesiology, Duke University Medical Center, Durham, NC, 27710, USA. ru-rong.ji@duke.edu.\nDepartment of Neurobiology, Duke University Medical Center, Durham, NC, 27710, USA. ru-rong.ji@duke.edu.'}]",,,,,"10.1007/s12264-017-0106-5
10.1073/pnas.0709250104
10.1016/j.pharmthera.2010.01.002
10.1007/s12264-015-0007-4
10.1016/j.bbi.2006.12.003
10.1016/j.brainresrev.2008.12.002
10.1007/s12264-012-1218-6
10.1007/s12264-012-1208-8
10.1074/jbc.271.20.11603
10.1523/JNEUROSCI.0485-09.2009
10.1523/JNEUROSCI.3016-07.2007
10.1073/pnas.1331358100
10.1073/pnas.0503496102
10.1111/j.1471-4159.2006.03746.x
10.1038/srep28188
10.1523/JNEUROSCI.3016-07.2007
10.1016/j.ejpain.2008.04.017
10.1038/nrd4334
10.1007/s11302-011-9288-x
10.1523/JNEUROSCI.0828-09.2009
10.1016/j.bbi.2006.11.003
10.1172/JCI81950
10.1093/brain/awu140
10.1523/JNEUROSCI.3623-08.2009
10.1038/nrn1701
10.1038/srep34356
10.1016/0304-3959(88)90026-7
10.1016/j.pain.2010.11.014
10.1172/JCI72230
10.1172/JCI45414
10.1016/S0306-4522(01)00459-6
10.1038/ncomms12531
10.1016/j.bbi.2010.06.001
10.1002/ana.23928
10.1523/JNEUROSCI.3338-07.2008
10.1038/nrn2947
10.1016/j.pain.2010.08.008
10.1038/nrn2947
10.1172/JCI70026
10.1016/j.cell.2014.11.003
10.1186/1744-8069-7-20
10.1016/j.tins.2014.04.002
10.1073/pnas.1331358100
10.1523/JNEUROSCI.0485-09.2009
10.1016/j.tins.2003.09.017
10.1523/JNEUROSCI.2443-11.2011
10.1016/j.cell.2014.11.003
10.1038/16040
10.1113/jphysiol.2012.250522
10.1523/JNEUROSCI.0454-13.2013
10.1126/science.aah5715",<Element 'PubmedArticle' at 0x7f05dcd4b900>
361,28259722,Oxytocin mitigated the depressive-like behaviors of maternal separation stress through modulating mitochondrial function and neuroinflammation.,"Mother-infant contact has a critical role on brain development and behavior. Experiencing early-life adversities (such as maternal separation stress or MS in rodents) results in adaptations of neurotransmission systems, which may subsequently increase the risk of depression symptoms later in life. In this study, we show that Oxytocin (OT) exerted antioxidant and anti-inflammatory properties. Previous studies indicate that neuroinflammation and mitochondrial dysfunction are associated with the pathophysiology of depression. To investigate the antidepressant-like effects of OT, we applied MS paradigm (as a valid animal model of depression) to male mice at postnatal day (PND) 2 to PND 14 (3h daily, 9AM to 12AM) and investigated the depressive-like behaviors of these animals at PND 60 in different groups. Animals in this work were divided into 4 experimental groups: 1) saline-treated, 2) OT-treated, 3) atosiban (OT antagonist)-treated and, 4) OT+ atosiban-treated mice. We used forced swimming test (FST), splash test, sucrose preference test (SPT) and open field test (OFT) for behavioral assessment. Additionally, we used another set of animals to investigate the effects of MS and different treatments on mitochondrial function and the expression of the relevant genes for neuroinflammation. Our results showed that MS provoked depressive- like behaviors in the FST, SPT and splash test. In addition, our molecular findings revealed that MS is capable of inducing abnormal mitochondrial function and immune-inflammatory response in the hippocampus. Further, we observed that treating stressed animals with OT (intracerebroventricular, i.c.v. injection) attenuated the MS-induced depressive-like behaviors through improving mitochondrial function and decreasing the hippocampal expression of immune-inflammatory genes. In conclusion, we showed that MS-induced depressive-like behaviors in adult male mice are associated with abnormal mitochondrial function and immune-inflammatory responses in the hippocampus, and activation of OTergic system has protective effects against negative effects of MS on brain and behavior of animals.","['Depression', 'Maternal separation stress', 'Mitochondrial function', 'Neuroinflammation', 'Oxytocin']",Progress in neuro-psychopharmacology & biological psychiatry,2017-03-06,"[{'lastname': 'Amini-Khoei', 'firstname': 'Hossein', 'initials': 'H', 'affiliation': 'Medical Plants Research Center, Shahrekord University of Medical Sciences, Shahrekord, Iran; Department of Physiology and Pharmacology, School of Medicine, Shahrekord University of Medical Sciences, Shahrekord, Iran.'}, {'lastname': 'Mohammadi-Asl', 'firstname': 'Ali', 'initials': 'A', 'affiliation': 'Experimental Medicine Research Center, Tehran University of Medical Sciences, Tehran, Iran; Department of Pharmacology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.'}, {'lastname': 'Amiri', 'firstname': 'Shayan', 'initials': 'S', 'affiliation': 'Experimental Medicine Research Center, Tehran University of Medical Sciences, Tehran, Iran; Regenerative Medicine Program, Department of Biochemistry and Medical Genetics, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, MB, Canada.'}, {'lastname': 'Hosseini', 'firstname': 'Mir-Jamal', 'initials': 'MJ', 'affiliation': 'Zanjan Applied Pharmacology Research Center, Zanjan University of Medical sciences, Zanjan, Iran; Department of Pharmacology and Toxicology, School of Pharmacy, Zanjan University of Medical Sciences, Zanjan, Iran.'}, {'lastname': 'Momeny', 'firstname': 'Majid', 'initials': 'M', 'affiliation': 'Hematology/Oncology and Stem Cell Transplantation Research Center, Shariati Hospital, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.'}, {'lastname': 'Hassanipour', 'firstname': 'Mahsa', 'initials': 'M', 'affiliation': 'Department of Physiology and Pharmacology, School of Medicine, Rafsanjan University of Medical Sciences, Kerman, Iran; Physiology-Pharmacology Research Center, Rafsanjan University of Medical Sciences, Rafsanjan, Iran.'}, {'lastname': 'Rastegar', 'firstname': 'Mojgan', 'initials': 'M', 'affiliation': 'Regenerative Medicine Program, Department of Biochemistry and Medical Genetics, Max Rady College of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, MB, Canada.'}, {'lastname': 'Haj-Mirzaian', 'firstname': 'Arya', 'initials': 'A', 'affiliation': 'Experimental Medicine Research Center, Tehran University of Medical Sciences, Tehran, Iran; Department of Pharmacology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.'}, {'lastname': 'Mirzaian', 'firstname': 'Arvin Haj-', 'initials': 'AH', 'affiliation': 'Experimental Medicine Research Center, Tehran University of Medical Sciences, Tehran, Iran; Department of Pharmacology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.'}, {'lastname': 'Sanjarimoghaddam', 'firstname': 'Hossein', 'initials': 'H', 'affiliation': 'Experimental Medicine Research Center, Tehran University of Medical Sciences, Tehran, Iran.'}, {'lastname': 'Mehr', 'firstname': 'Shahram Ejtemaei', 'initials': 'SE', 'affiliation': 'Experimental Medicine Research Center, Tehran University of Medical Sciences, Tehran, Iran; Department of Pharmacology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran.'}, {'lastname': 'Dehpour', 'firstname': 'Ahmad Reza', 'initials': 'AR', 'affiliation': 'Experimental Medicine Research Center, Tehran University of Medical Sciences, Tehran, Iran; Department of Pharmacology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran. Electronic address: Dehpour@yahoo.com.'}]",,,,Copyright © 2017 Elsevier Inc. All rights reserved.,10.1016/j.pnpbp.2017.02.022,<Element 'PubmedArticle' at 0x7f05dcc7c9a0>
362,28192111,Effects of progesterone administered after MPTP on dopaminergic neurons of male mice.,"Progesterone neuroprotection of striatal dopamine (DA) in male mice lesioned with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) was previously reported when administered before MPTP or an hour after. A dose of MPTP to induce a partial lesion was used to model early stages or prodromal Parkinson. We hypothesized that brain DA can be restored by progesterone administered early (24 h) or later (5 days) after MPTP. Male mice received 4 injections of MPTP (8 mg/kg) and progesterone (8 mg/kg) once daily for 5 days started 24 h or 5 days after MPTP. The lesion decreased striatal DA and its metabolites but not serotonin contents. MPTP mice treated with progesterone starting 24 h but not 5 days after MPTP had higher striatal DA and its metabolites content than vehicle-treated MPTP mice. Striatal DA transporter (DAT) and vesicular monoamine transporter 2 (VMAT2) specific binding decreased in lesioned mice and were corrected with progesterone treatment starting 24 h but not 5 days after MPTP. Striatal glial fibrillary acidic protein (GFAP) levels, a marker of activated astrocytes, were elevated by the MPTP lesion and were corrected with progesterone treatment starting 24 h after MPTP. Striatal brain derived neurotrophic factor (BDNF) levels were decreased by the MPTP lesion and were prevented by progesterone treatments whereas no change of Akt, GSK3β, ERK1 and 2 and their phosphorylated forms were observed. Thus, progesterone administered after MPTP in mice protected dopaminergic neurons through modulation of neuroinflammation and BDNF. In humans, progesterone could possibly be used as a disease-modifying drug in prodromal Parkinson.","['BDNF', 'GFAP', 'Neuroinflammation', ""Parkinson's disease"", 'Progesterone', 'Striatum']",Neuropharmacology,2017-02-14,"[{'lastname': 'Litim', 'firstname': 'Nadhir', 'initials': 'N', 'affiliation': 'Neuroscience Research Unit, Centre Hospitalier Universitaire de Québec, CHUL, Quebec City, Canada; Faculty of Pharmacy, Laval University, Quebec City, Canada.'}, {'lastname': 'Morissette', 'firstname': 'Marc', 'initials': 'M', 'affiliation': 'Neuroscience Research Unit, Centre Hospitalier Universitaire de Québec, CHUL, Quebec City, Canada.'}, {'lastname': 'Di Paolo', 'firstname': 'Thérèse', 'initials': 'T', 'affiliation': 'Neuroscience Research Unit, Centre Hospitalier Universitaire de Québec, CHUL, Quebec City, Canada; Faculty of Pharmacy, Laval University, Quebec City, Canada. Electronic address: Therese.Dipaolo@crchul.ulaval.ca.'}]",,,,Copyright © 2017 Elsevier Ltd. All rights reserved.,10.1016/j.neuropharm.2017.02.007,<Element 'PubmedArticle' at 0x7f05dcc8a400>
363,"28154473
26067058
12915048
8866675
12220687
23690824
23792284
17974036
23792284
16355225
15836971
16624951
20418178
23111678
16307586
17307159
26881105
17904651
24504982
11023702
24588018
15001661
22566831
9045742
9620667
7544012
8603997
10486285
16647700
17588564
16414116
23940690
18625277
8415620
7854347
9120297
12817018
10358199
12384937
16293345
10233018
15787746
15699165
16371321
10702221
23468969
15833358
27359332
14572638
9743348
11239505
1490338
20965575
9152411
25105291
8755601
20959451
23211819
10804204
12112366
9757047
20937084
11113362
11857684
25170632
8926038
8846399
21803157
17419800
17617622
12684452
11786404
12796468
23386811
11169794
22290798
21703408
24009773
23689030
12798410
3017502
15026153
9878783
14559360
15617771
11050135
20081244
17915196
19306358
8112823
24719110
26363192
25176008
7560019
24664661
12427855
16403466
17919885
12359508
15337367
24184719
22007767
22805317
18495419
25206918
17353067
17239992
22136135
17976913
17194506
5450698
25422088
2872248
6571696
2803320
19805477
22289055
19109992
23517078
15985713
12525573
12372411
17826030
12054537
15194876
15476707
12754213
12020953
9916753
9973433
25653374
12923064
25550371
22643083
23720065
18442091
22328918
16891616
12666096
12626429
15584490
10431211
16202621
10457173
10337915
11029467
9813054
10433861
18325491
19552966
22509294
25777539
23935251
16764934
8622767
18374474
11227737
12915402
15823563
20063038
21388399
12684217
12519865
16537513
16492802
17151007
21940421
23918980
24333694
23371349
20883741
24382888
11062498
12383518
11874202
8808790
9187934
7678597
11438168
15100316
18523290
26604896
974776
16449797
25209287
22724132
26386297
12950462
20398373
18790011
20609516
22825006
25871534
15342200
22384199
18660829
6283379
14615490
8387282
3535798
3317417
15269340
9620797
15576460
12749828
15047974
10980200
18498438
12145288
17981883
15070851
16025744
9328930
19568255
16039904
24321213
24746422
15486424
22145886
25707377
20804799
19299480
20691540
25305050
7489415
8616722
8801538
10579368
15634336
10867658
19350671
9392508
8603777
9927310
20399755
15122202
8996253
8621806
15388782
16842830
10873603
24166765
19922787
25142458
23895348
24780498
19139561
19620723
22536415
10604470
11243865
11272130
25107984
11162448
9379845
11196643
17634369
20444938
25309797
26079709
20351014
22416219
19384567
19620309
21983104
15176951
19382238
24513955","Neuropeptides and Microglial Activation in Inflammation, Pain, and Neurodegenerative Diseases.","Microglial cells are responsible for immune surveillance within the CNS. They respond to noxious stimuli by releasing inflammatory mediators and mounting an effective inflammatory response. This is followed by release of anti-inflammatory mediators and resolution of the inflammatory response. Alterations to this delicate process may lead to tissue damage, neuroinflammation, and neurodegeneration. Chronic pain, such as inflammatory or neuropathic pain, is accompanied by neuroimmune activation, and the role of glial cells in the initiation and maintenance of chronic pain has been the subject of increasing research over the last two decades. Neuropeptides are small amino acidic molecules with the ability to regulate neuronal activity and thereby affect various functions such as thermoregulation, reproductive behavior, food and water intake, and circadian rhythms. Neuropeptides can also affect inflammatory responses and pain sensitivity by modulating the activity of glial cells. The last decade has witnessed growing interest in the study of microglial activation and its modulation by neuropeptides in the hope of developing new therapeutics for treating neurodegenerative diseases and chronic pain. This review summarizes the current literature on the way in which several neuropeptides modulate microglial activity and response to tissue damage and how this modulation may affect pain sensitivity.",[],Mediators of inflammation,2017-02-06,"[{'lastname': 'Carniglia', 'firstname': 'Lila', 'initials': 'L', 'affiliation': 'INBIOMED (Instituto de Investigaciones Biomédicas), UBA-CONICET, Facultad de Medicina, Universidad de Buenos Aires, Paraguay 2155, Ciudad Autónoma de Buenos Aires, Argentina.'}, {'lastname': 'Ramírez', 'firstname': 'Delia', 'initials': 'D', 'affiliation': 'INBIOMED (Instituto de Investigaciones Biomédicas), UBA-CONICET, Facultad de Medicina, Universidad de Buenos Aires, Paraguay 2155, Ciudad Autónoma de Buenos Aires, Argentina.'}, {'lastname': 'Durand', 'firstname': 'Daniela', 'initials': 'D', 'affiliation': 'INBIOMED (Instituto de Investigaciones Biomédicas), UBA-CONICET, Facultad de Medicina, Universidad de Buenos Aires, Paraguay 2155, Ciudad Autónoma de Buenos Aires, Argentina.'}, {'lastname': 'Saba', 'firstname': 'Julieta', 'initials': 'J', 'affiliation': 'INBIOMED (Instituto de Investigaciones Biomédicas), UBA-CONICET, Facultad de Medicina, Universidad de Buenos Aires, Paraguay 2155, Ciudad Autónoma de Buenos Aires, Argentina.'}, {'lastname': 'Turati', 'firstname': 'Juan', 'initials': 'J', 'affiliation': 'INBIOMED (Instituto de Investigaciones Biomédicas), UBA-CONICET, Facultad de Medicina, Universidad de Buenos Aires, Paraguay 2155, Ciudad Autónoma de Buenos Aires, Argentina.'}, {'lastname': 'Caruso', 'firstname': 'Carla', 'initials': 'C', 'affiliation': 'INBIOMED (Instituto de Investigaciones Biomédicas), UBA-CONICET, Facultad de Medicina, Universidad de Buenos Aires, Paraguay 2155, Ciudad Autónoma de Buenos Aires, Argentina.'}, {'lastname': 'Scimonelli', 'firstname': 'Teresa N', 'initials': 'TN', 'affiliation': 'IFEC-CONICET, Depto. Farmacología, Facultad de Ciencias Químicas, Universidad Nacional de Córdoba, Córdoba, Argentina.'}, {'lastname': 'Lasaga', 'firstname': 'Mercedes', 'initials': 'M', 'affiliation': 'INBIOMED (Instituto de Investigaciones Biomédicas), UBA-CONICET, Facultad de Medicina, Universidad de Buenos Aires, Paraguay 2155, Ciudad Autónoma de Buenos Aires, Argentina.'}]",,,,,"10.1155/2017/5048616
10.1016/j.pneurobio.2015.05.003
10.1016/S0165-6147(03)00176-7
10.1016/0165-0173(95)00011-9
10.1016/s0022-510x(02)00207-1
10.1155/2013/608654
10.1016/j.pain.2013.06.022
10.1186/1744-8069-3-33
10.1016/j.pain.2013.06.022
10.1038/nature04223
10.1016/j.pain.2005.02.009
10.1523/jneurosci.0003-06.2006
10.1016/j.jpain.2010.02.010
10.1007/s13105-012-0217-4
10.1111/j.1460-9568.2005.04451.x
10.1016/j.ejphar.2007.01.013
10.1155/2016/3276383
10.1016/j.tins.2007.07.007
10.1002/glia.22633
10.1006/phrs.2000.0725
10.1038/nrn3657
10.1124/pr.56.1.1
10.3389/fimmu.2011.00041
10.1073/pnas.92.17.8016
10.1006/bbrc.1999.1276
10.1016/j.ejphar.2006.03.038
10.1016/j.ejphar.2007.05.025
10.1016/j.npep.2005.10.006
10.1371/journal.pone.0071056
10.1016/j.peptides.2008.06.009
10.5772/32672
10.1073/pnas.90.19.8856
10.1210/me.8.10.1298
10.4049/jimmunol.171.1.353
10.1002/art.10526
10.1016/j.peptides.2005.01.031
10.1111/j.1365-3083.2005.01565.x
10.4049/jimmunol.174.4.2297
10.1007/bf03033980
10.1074/jbc.275.10.6695
10.1371/journal.pone.0057313
10.1016/j.jneuroim.2005.01.008
10.1371/journal.pone.0158564
10.1016/S0014-5793(03)01029-9
10.1016/s0006-2952(00)00583-9
10.3109/02713689208999545
10.1016/j.jneuroim.2010.09.025
10.1371/journal.pone.0104420
10.1073/pnas.93.15.8051
10.1074/jbc.m110.164020
10.1167/iovs.12-10776
10.1002/glia.10098
10.1016/S0169-328X(98)00184-3
10.1186/1742-2094-7-61
10.1016/s0306-4522(00)00398-5
10.1002/glia.10034
10.1159/000363041
10.1002/glia.440150408
10.1139/y95-148
10.1016/j.mcn.2011.07.006
10.1111/j.1471-4159.2007.04559.x
10.4049/jimmunol.179.2.1292
10.1016/s0002-9440(10)64354-4
10.1084/jem.20021546
10.3389/fncel.2013.00006
10.1002/1098-1136(20010101)33:1<87::aid-glia1008>3.0.co;2-s
10.1002/glia.22298
10.1016/j.ajpath.2011.03.042
10.1371/journal.pone.0074488
10.1016/j.jneuroim.2013.04.019
10.1016/S0024-3205(03)00349-7
10.1016/0006-8993(86)90283-0
10.1016/j.neulet.2003.12.096
10.1016/s0169-328x(98)00291-5
10.1016/j.molbrainres.2003.08.001
10.1016/j.bbr.2004.06.008
10.1016/s1734-1140(09)70171-9
10.1016/j.brainres.2007.08.054
10.1002/glia.20871
10.1002/glia.440090408
10.1523/jneurosci.4703-13.2014
10.1016/j.neuropharm.2015.09.010
10.1111/bph.12895
10.1016/0165-5728(95)00089-K
10.1002/j.1532-2149.2014.493.x
10.1016/j.brainres.2005.11.066
10.1016/j.bbi.2007.07.014
10.1054/npep.2002.0897
10.1016/j.npep.2004.06.002
10.1016/j.pneurobio.2013.10.002
10.1111/j.1471-4159.2011.07541.x
10.1111/j.1460-9568.2012.08232.x
10.1016/j.bbi.2008.03.009
10.4103/1673-5374.133140
10.1016/j.neuint.2007.01.010
10.1016/j.peptides.2006.07.029
10.1186/1742-2094-8-169
10.1016/j.pain.2007.09.016
10.1016/j.peptides.2006.09.029
10.1126/science.169.3951.1217
10.1111/apha.12427
10.1007/BF03348097
10.1038/304547a0
10.1016/0006-291X(89)91757-9
10.1124/pr.109.001370
10.1111/j.1476-5381.2012.01871.x
10.1016/j.pharmthera.2008.11.006
10.1111/bph.12181
10.1189/jlb.0702372
10.1016/S0006-291X(02)02305-7
10.1016/S0006-291X(02)00283-8
10.1097/01.wnr.0000130541.29635.6f
10.1016/j.brainres.2004.08.017
10.1074/jbc.m303199200
10.1016/S0165-5728(02)00059-0
10.1523/JNEUROSCI.4058-14.2015
10.1096/fj.02-1029fje
10.1161/strokeaha.114.006864
10.1179/1743132812Y.0000000028
10.1007/s12031-013-0017-5
10.1002/glia.20681
10.1371/journal.pone.0029790
10.1124/jpet.106.102236
10.1002/ana.10483
10.1191/1352458504ms1096oa
10.1016/s0165-6147(99)01340-1
10.1016/j.mcn.2005.08.016
10.1046/j.1460-9568.1999.00693.x
10.1016/s0165-5728(99)00023-5
10.1074/jbc.m006923200
10.1074/jbc.273.47.31427
10.1006/frne.1999.0183
10.1016/j.ejphar.2008.02.025
10.1016/j.jneuroim.2009.05.016
10.1371/journal.pone.0034376
10.3892/mmr.2015.3494
10.1155/2013/952375
10.1016/j.pharmthera.2006.04.010
10.1038/381242a0
10.1016/j.mce.2007.12.014
10.1007/BF03343800
10.1074/jbc.m302456200
10.1016/j.bbrc.2005.03.088
10.1007/s00018-009-0240-y
10.1111/j.1749-6632.2011.05985.x
10.1152/ajpendo.00048.2003
10.1210/jc.2002-020950
10.1073/pnas.0508997103
10.1084/jem.20052017
10.1136/ard.2006.062703
10.1093/infdis/jir608
10.4049/jimmunol.1300384
10.1016/j.nbd.2013.11.022
10.1002/art.37877
10.1016/j.peptides.2010.09.018
10.1152/physrev.00031.2013
10.1038/80826
10.1016/S0378-1119(02)00861-2
10.1023/A:1013911205494
10.1016/0197-0186(95)00140-9
10.1016/0165-5728(93)90212-H
10.1016/S0165-5728(01)00295-8
10.4049/jimmunol.172.9.5707
10.4049/jimmunol.180.12.8241
10.4103/1673-5374.165505
10.1016/0006-8993(76)90907-0
10.1096/fj.05-4553com
10.1523/JNEUROSCI.2238-14.2014
10.1016/j.ejphar.2012.03.025
10.1016/j.neuroscience.2015.09.036
10.1046/j.1471-4159.2003.01969.x
10.1186/1742-2094-7-27
10.1016/j.neulet.2008.09.009
10.1016/j.pain.2010.06.017
10.1097/WNR.0b013e3283572206
10.1016/j.ajpath.2015.02.011
10.1016/j.jneuroim.2004.06.005
10.1371/journal.pone.0032268
10.1038/bjp.2008.301
10.1038/298240a0
10.1074/jbc.m305332200
10.1006/bbrc.1993.1451
10.1016/0006-291X(86)90708-4
10.1073/pnas.84.23.8628
10.1152/physrev.00037.2003
10.1038/30666
10.1210/en.2004-1080
10.1016/s1094-5539(03)00049-x
10.1074/jbc.M006512200
10.1111/j.1471-4159.2008.05494.x
10.1074/jbc.m204619200
10.1093/ndt/gfm600
10.1210/en.2003-1583
10.1291/hypres.28.165
10.1038/ki.1997.413
10.1038/jcbfm.2009.92
10.1016/j.it.2005.07.004
10.1016/j.bbi.2013.11.021
10.1016/j.jneuroim.2014.03.008
10.1152/jn.00339.2004
10.1186/1744-8069-7-94
10.1002/art.39082
10.1016/j.peptides.2010.08.020
10.1096/fj.08-128348
10.1016/j.pain.2010.07.006
10.1016/j.metabol.2014.09.010
10.1038/nm1295-1311
10.1038/nm0596-589
10.1016/0196-9781(96)00025-3
10.1210/endo.140.12.7288
10.1111/j.1432-1033.2004.04391.x
10.1002/1096-9861(20000724)423:2<261::aid-cne6>3.0.co;2-6
10.1002/cne.22025
10.2337/diab.46.12.2119
10.2337/diab.45.4.531
10.1210/en.140.2.814
10.1016/j.brainres.2010.04.011
10.1038/nri1350
10.1084/jem.185.1.171
10.1172/JCI118653
10.1113/jphysiol.2004.074351
10.1016/j.physbeh.2006.05.016
10.1006/bbrc.2000.2937
10.1002/glia.22580
10.1016/j.bbi.2009.11.003
10.1016/s1474-4422(14)70085-7
10.1111/jnc.12380
10.1016/j.nbd.2014.04.012
10.1172/JCI36785
10.1073/pnas.0903524106
10.1371/journal.pone.0035594
10.1038/45230
10.1006/bbrc.2001.4518
10.2337/diabetes.50.2.227
10.1124/pr.113.008433
10.1006/bbrc.2000.4039
10.1016/S0169-328X(97)00071-5
10.1038/35051587
10.1523/jneurosci.1661-07.2007
10.1210/en.2009-1416
10.3803/enm.2014.29.3.371
10.1016/j.nbd.2015.06.002
10.1677/JOE-10-0040
10.4196/kjpp.2012.16.1.43
10.1007/s12640-009-9037-x
10.4049/jimmunol.0803362
10.1016/j.peptides.2011.09.019
10.1042/bj20040036
10.1002/jnr.22088
10.1097/aap.0000000000000050",<Element 'PubmedArticle' at 0x7f05dcc9b590>
364,"28153013
11450660
18097481
8514412
7853849
10908149
19706181
19944760
3574672
12531061
9219316
25892509
23866773
26700298
18832582
18694963
22524232
11254661
17403137
8534264
19911057
15453089
21898139
21831262
26295288
12011030
12810490
12458049
12225362
23945160
23997430
26922073
24390634
15698718
27598389
17938219
17645739
15125785
17255352
17143528
12551744
25889406",Effects of dexamethasone and meloxicam on Borrelia burgdorferi-induced inflammation in glial and neuronal cells of the central nervous system.,"Lyme neuroborreliosis (LNB), caused by the spirochete Borrelia burgdorferi (Bb), affects both the central and peripheral nervous systems. Previously, we reported that in a model of acute LNB in rhesus monkeys, treatment with the anti-inflammatory drug dexamethasone significantly reduced both pleocytosis and levels of cerebrospinal fluid (CSF) immune mediators that were induced by Bb. Dexamethasone also inhibited the formation of inflammatory, neurodegenerative, and demyelinating lesions in the brain and spinal cord of these animals. In contrast, these signs were evident in the infected animals that were left untreated or in those that were treated with meloxicam, a non-steroidal anti-inflammatory drug.
To address the differential anti-inflammatory effects of dexamethasone and meloxicam in the central nervous system (CNS), we evaluated the potential of these drugs to alter the levels of Bb-induced inflammatory mediators in culture supernatants of rhesus frontal cortex (FC) explants, primary rhesus astrocytes and microglia, and human oligodendrocytes. We also ascertained the potential of dexamethasone to modulate Bb-induced apoptosis in rhesus FC explants. As meloxicam is a known COX-2 inhibitor, we evaluated whether meloxicam altered the levels of COX-2 as induced by live Bb in cell lysates of primary rhesus astrocytes and microglia.
Dexamethasone but not meloxicam significantly reduced the levels of several Bb-induced immune mediators in culture supernatants of FC explants, astrocytes, microglia, and oligodendrocytes. Dexamethasone also had a protective effect on Bb-induced neuronal and oligodendrocyte apoptosis in rhesus FC explants. Further, meloxicam significantly reduced the levels of Bb-induced COX-2 in microglia, while both Bb and meloxicam were unable to alter the constitutive levels of COX-2 in astrocytes.
These data indicate that dexamethasone and meloxicam have differential anti-inflammatory effects on Bb-induced inflammation in glial and neuronal cells of the CNS and help explain the in vivo findings of significantly reduced inflammatory mediators in the CSF and lack of inflammatory neurodegenerative lesions in the brain and spinal cord of Bb-infected animals that were treated with dexamethasone but not meloxicam. Signaling cascades altered by dexamethasone could serve as possible therapeutic targets for limiting CNS inflammation and tissue damage in LNB.","['Apoptosis', 'Borrelia burgdorferi', 'Dexamethasone', 'Inflammation', 'Lyme neuroborreliosis', 'Meloxicam']",Journal of neuroinflammation,2017-02-06,"[{'lastname': 'Ramesh', 'firstname': 'Geeta', 'initials': 'G', 'affiliation': 'Division of Bacteriology and Parasitology, Tulane National Primate Research Center, Covington, LA, USA.'}, {'lastname': 'Martinez', 'firstname': 'Alejandra N', 'initials': 'AN', 'affiliation': 'Division of Bacteriology and Parasitology, Tulane National Primate Research Center, Covington, LA, USA.'}, {'lastname': 'Martin', 'firstname': 'Dale S', 'initials': 'DS', 'affiliation': 'Division of Bacteriology and Parasitology, Tulane National Primate Research Center, Covington, LA, USA.'}, {'lastname': 'Philipp', 'firstname': 'Mario T', 'initials': 'MT', 'affiliation': 'Division of Bacteriology and Parasitology, Tulane National Primate Research Center, Covington, LA, USA. philipp@tulane.edu.\nDepartment of Microbiology and Immunology, Tulane University Medical School, New Orleans, LA, USA. philipp@tulane.edu.'}]",,,"Dexamethasone but not meloxicam significantly reduced the levels of several Bb-induced immune mediators in culture supernatants of FC explants, astrocytes, microglia, and oligodendrocytes. Dexamethasone also had a protective effect on Bb-induced neuronal and oligodendrocyte apoptosis in rhesus FC explants. Further, meloxicam significantly reduced the levels of Bb-induced COX-2 in microglia, while both Bb and meloxicam were unable to alter the constitutive levels of COX-2 in astrocytes.",,"10.1186/s12974-017-0806-9
10.1056/NEJM200107123450207
10.1038/labinvest.3780109
10.1186/1742-2094-6-23
10.1016/j.nbd.2009.11.016
10.1212/WNL.37.5.749
10.1016/S0049-0172(97)80049-2
10.1016/j.ajpath.2015.01.024
10.1186/1742-2094-10-88
10.1186/s12974-015-0461-y
10.2353/ajpath.2008.080483
10.1128/IAI.00394-08
10.1172/JCI12484
10.1111/j.1471-4159.2007.04535.x
10.1016/0006-2952(95)02111-6
10.1371/journal.ppat.1000659
10.1093/jnen/63.9.901
10.1007/s00415-011-6221-8
10.1186/1471-2334-11-215
10.17305/bjbms.2015.594
10.1128/IAI.70.6.3300-3303.2002
10.1001/archneur.60.6.849
10.1016/S0165-5728(02)00255-2
10.1046/j.1365-2567.2002.01500.x
10.1128/CVI.00353-13
10.1007/s11011-016-9812-3
10.1007/s00296-013-2923-9
10.1016/j.diagmicrobio.2004.04.022
10.1128/IAI.00856-07
10.1111/j.1574-695X.2007.00293.x
10.1186/1471-2199-5-2
10.1182/blood-2006-10-048215
10.1016/S0024-3205(02)02446-3
10.1186/s12974-015-0274-z",<Element 'PubmedArticle' at 0x7f05dcb35b80>
365,28095731,N-Palmitoylethanolamine-Oxazoline as a New Therapeutic Strategy to Control Neuroinflammation: Neuroprotective Effects in Experimental Models of Spinal Cord and Brain Injury.,"Modulation of N-acylethanolamine-hydrolyzing acid amidase (NAAA) represents a potential alternative strategy in the treatment of neuroinflammation. Recent studies showed that pharmacological modulation of NAAA could be achieved with the oxazoline of palmitoylethanolamide (PEA; PEA-OXA). The aim of this study was to evaluate the neuroprotective effects of PEA-OXA in the secondary neuroinflammatory events induced by spinal and brain trauma in mice. Animals were subjected to spinal cord and brain injury models and PEA-OXA (10 mg/kg) was administered both intraperitoneally and orally 1 h and 6 h after trauma. PEA-OXA treatment markedly reduced the histological alterations induced by spinal cord injury (SCI) and traumatic brain injury (TBI) and ameliorated the motor function and behavioral deficits, as well. In addition, the expression of neurotrophic factors, such as glial cell line-derived neurotrophic factor, brain-derived neurotrophic factor, and neurotrophin-3 were increased by PEA-OXA treatment. Moreover, PEA-OXA also significantly decreased glial fibrillary acidic protein hyperexpression, the nuclear translocation of nuclear factor (NF)-κB, phosphorylation of Ser536 on the NF-κB subunit p65, and degradation of IκB-α, as well as diminished the expression of pro-inflammatory mediators such as cyclooxygenase-2 (COX-2), inducible nitric oxide synthase, tumor necrosis factor (TNF)-α and interleukin (IL)-1β. The modulation of intracellular NAAA by PEA-OXA treatment could thus represent a novel therapy to control neuroinflammatory conditions associated with SCI and TBI.","['ALIAmide', 'central nervous system', 'cytokines', 'inflammation', 'neurotrophic factors']",Journal of neurotrauma,2017-01-18,"[{'lastname': 'Impellizzeri', 'firstname': 'Daniela', 'initials': 'D', 'affiliation': '1 Department of Chemical, Biological, Pharmaceutical, and Environmental Sciences, University of Messina , Messina, Italy .'}, {'lastname': 'Cordaro', 'firstname': 'Marika', 'initials': 'M', 'affiliation': '1 Department of Chemical, Biological, Pharmaceutical, and Environmental Sciences, University of Messina , Messina, Italy .'}, {'lastname': 'Bruschetta', 'firstname': 'Giuseppe', 'initials': 'G', 'affiliation': '1 Department of Chemical, Biological, Pharmaceutical, and Environmental Sciences, University of Messina , Messina, Italy .'}, {'lastname': 'Siracusa', 'firstname': 'Rosalba', 'initials': 'R', 'affiliation': '1 Department of Chemical, Biological, Pharmaceutical, and Environmental Sciences, University of Messina , Messina, Italy .'}, {'lastname': 'Crupi', 'firstname': 'Rosalia', 'initials': 'R', 'affiliation': '1 Department of Chemical, Biological, Pharmaceutical, and Environmental Sciences, University of Messina , Messina, Italy .'}, {'lastname': 'Esposito', 'firstname': 'Emanuela', 'initials': 'E', 'affiliation': '1 Department of Chemical, Biological, Pharmaceutical, and Environmental Sciences, University of Messina , Messina, Italy .'}, {'lastname': 'Cuzzocrea', 'firstname': 'Salvatore', 'initials': 'S', 'affiliation': '1 Department of Chemical, Biological, Pharmaceutical, and Environmental Sciences, University of Messina , Messina, Italy .\n2 Manchester Biomedical Research Centre, Manchester Royal Infirmary, School of Medicine, University of Manchester , United Kingdom .'}]",,,,,10.1089/neu.2016.4808,<Element 'PubmedArticle' at 0x7f05dcb57f40>
366,28087250,Pharmacology of cannabinoids in the treatment of epilepsy.,"The use of cannabis products in the treatment of epilepsy has long been of interest to researchers and clinicians alike; however, until recently very little published data were available to support its use. This article summarizes the available scientific data of pharmacology from human and animal studies on the major cannabinoids which have been of interest in the treatment of epilepsy, including ∆9-tetrahydrocannabinol (∆9-THC), cannabidiol (CBD), ∆9-tetrahydrocannabivarin (∆9-THCV), cannabidivarin (CBDV), and ∆9-tetrahydrocannabinolic acid (Δ9-THCA). It has long been known that ∆9-THC has partial agonist activity at the endocannabinoid receptors CB1 and CB2, though it also binds to other targets which may modulate neuronal excitability and neuroinflammation. The actions of Δ9-THCV and Δ9-THCA are less well understood. In contrast to ∆9-THC, CBD has low affinity for CB1 and CB2 receptors and other targets have been investigated to explain its anticonvulsant properties including TRPV1, voltage gated potassium and sodium channels, and GPR55, among others. We describe the absorption, distribution, metabolism, and excretion of each of the above mentioned compounds. Cannabinoids as a whole are very lipophilic, resulting in decreased bioavailability, which presents challenges in optimal drug delivery. Finally, we discuss the limited drug-drug interaction data available on THC and CBD. As cannabinoids and cannabis-based products are studied for efficacy as anticonvulsants, more investigation is needed regarding the specific targets of action, optimal drug delivery, and potential drug-drug interactions. This article is part of a Special Issue titled Cannabinoids and Epilepsy.","['Cannabidivarin', 'Cannabinoids', 'Pharmacology', 'Tetrahydrocannabinol', 'Tetrahydrocannabinolic acid', 'Tetrahydrocannabivarin']",Epilepsy & behavior : E&B,2017-01-15,"[{'lastname': 'Gaston', 'firstname': 'Tyler E', 'initials': 'TE', 'affiliation': 'Department of Neurology, Division of Epilepsy, University of Alabama at Birmingham, Birmingham, AL, USA. Electronic address: tegaston@uabmc.edu.'}, {'lastname': 'Friedman', 'firstname': 'Daniel', 'initials': 'D', 'affiliation': 'Comprehensive Epilepsy Center, Department of Neurology, NYU Langone Medical Center, New York, NY, USA.'}]",,,,Published by Elsevier Inc.,10.1016/j.yebeh.2016.11.016,<Element 'PubmedArticle' at 0x7f05dca684f0>
367,"28086928
16369558
9466977
12391014
15753205
16424216
18437155
23484005
22802419
22171045
22538616
22499990
22844113
23349501
15836891
19340313
19144836
18854155
16002529
25811237
22201683
24892821
19858212
22279596
26512023
23415177
25375037
26195725
18223605
17055291
22326217
9660946
11445068
24074867
24074868
22285542
25786112
21386802
20383154
24530025
25450447
20080636
20808781
20045008
12914723
24048027
22522614
21257748
19996183",Resolvin RvD2 reduces hypothalamic inflammation and rescues mice from diet-induced obesity.,"Diet-induced hypothalamic inflammation is an important mechanism leading to dysfunction of neurons involved in controlling body mass. Studies have shown that polyunsaturated fats can reduce hypothalamic inflammation. Here, we evaluated the presence and function of RvD2, a resolvin produced from docosahexaenoic acid, in the hypothalamus of mice.
Male Swiss mice were fed either chow or a high-fat diet. RvD2 receptor and synthetic enzymes were evaluated by real-time PCR and immunofluorescence. RvD2 was determined by mass spectrometry. Dietary and pharmacological approaches were used to modulate the RvD2 system in the hypothalamus, and metabolic phenotype consequences were determined.
All enzymes involved in the synthesis of RvD2 were detected in the hypothalamus and were modulated in response to the consumption of dietary saturated fats, leading to a reduction of hypothalamic RvD2. GPR18, the receptor for RvD2, which was detected in POMC and NPY neurons, was also modulated by dietary fats. The substitution of saturated by polyunsaturated fats in the diet resulted in increased hypothalamic RvD2, which was accompanied by reduced body mass and improved glucose tolerance. The intracerebroventricular treatment with docosahexaenoic acid resulted in increased expression of the RvD2 synthetic enzymes, increased expression of anti-inflammatory cytokines and improved metabolic phenotype. Finally, intracerebroventricular treatment with RvD2 resulted in reduced adiposity, improved glucose tolerance and increased hypothalamic expression of anti-inflammatory cytokines.
Thus, RvD2 is produced in the hypothalamus, and its receptor and synthetic enzymes are modulated by dietary fats. The improved metabolic outcomes of RvD2 make this substance an attractive approach to treat obesity.","['Brain', 'Hypothalamus', 'Lipid', 'Metabolism', 'Nutrient']",Journal of neuroinflammation,2017-01-15,"[{'lastname': 'Pascoal', 'firstname': 'Livia B', 'initials': 'LB', 'affiliation': 'Obesity and Comorbidities Research Center, Laboratory of Cell Signaling, University of Campinas, Campinas, SP, 13084-761, Brazil.'}, {'lastname': 'Bombassaro', 'firstname': 'Bruna', 'initials': 'B', 'affiliation': 'Obesity and Comorbidities Research Center, Laboratory of Cell Signaling, University of Campinas, Campinas, SP, 13084-761, Brazil.'}, {'lastname': 'Ramalho', 'firstname': 'Albina F', 'initials': 'AF', 'affiliation': 'Obesity and Comorbidities Research Center, Laboratory of Cell Signaling, University of Campinas, Campinas, SP, 13084-761, Brazil.'}, {'lastname': 'Coope', 'firstname': 'Andressa', 'initials': 'A', 'affiliation': 'Obesity and Comorbidities Research Center, Laboratory of Cell Signaling, University of Campinas, Campinas, SP, 13084-761, Brazil.'}, {'lastname': 'Moura', 'firstname': 'Rodrigo F', 'initials': 'RF', 'affiliation': 'Obesity and Comorbidities Research Center, Laboratory of Cell Signaling, University of Campinas, Campinas, SP, 13084-761, Brazil.'}, {'lastname': 'Correa-da-Silva', 'firstname': 'Felipe', 'initials': 'F', 'affiliation': 'Obesity and Comorbidities Research Center, Laboratory of Cell Signaling, University of Campinas, Campinas, SP, 13084-761, Brazil.'}, {'lastname': 'Ignacio-Souza', 'firstname': 'Leticia', 'initials': 'L', 'affiliation': 'Obesity and Comorbidities Research Center, Laboratory of Cell Signaling, University of Campinas, Campinas, SP, 13084-761, Brazil.'}, {'lastname': 'Razolli', 'firstname': 'Daniela', 'initials': 'D', 'affiliation': 'Obesity and Comorbidities Research Center, Laboratory of Cell Signaling, University of Campinas, Campinas, SP, 13084-761, Brazil.'}, {'lastname': 'de Oliveira', 'firstname': 'Diogo', 'initials': 'D', 'affiliation': 'Faculty of Pharmaceutical Sciences, University of Campinas, Campinas, Brazil.'}, {'lastname': 'Catharino', 'firstname': 'Rodrigo', 'initials': 'R', 'affiliation': 'Faculty of Pharmaceutical Sciences, University of Campinas, Campinas, Brazil.'}, {'lastname': 'Velloso', 'firstname': 'Licio A', 'initials': 'LA', 'affiliation': 'Obesity and Comorbidities Research Center, Laboratory of Cell Signaling, University of Campinas, Campinas, SP, 13084-761, Brazil. lavelloso.unicamp@gmail.com.'}]",,,"All enzymes involved in the synthesis of RvD2 were detected in the hypothalamus and were modulated in response to the consumption of dietary saturated fats, leading to a reduction of hypothalamic RvD2. GPR18, the receptor for RvD2, which was detected in POMC and NPY neurons, was also modulated by dietary fats. The substitution of saturated by polyunsaturated fats in the diet resulted in increased hypothalamic RvD2, which was accompanied by reduced body mass and improved glucose tolerance. The intracerebroventricular treatment with docosahexaenoic acid resulted in increased expression of the RvD2 synthetic enzymes, increased expression of anti-inflammatory cytokines and improved metabolic phenotype. Finally, intracerebroventricular treatment with RvD2 resulted in reduced adiposity, improved glucose tolerance and increased hypothalamic expression of anti-inflammatory cytokines.",,"10.1186/s12974-016-0777-2
10.1038/ni1276
10.1172/JCI1578
10.1084/jem.20020760
10.1084/jem.20042031
10.4049/jimmunol.176.3.1848
10.1038/nri2294
10.1371/journal.pone.0058258
10.4049/jimmunol.1101665
10.1523/JNEUROSCI.4192-11.2011
10.1038/nature11042
10.1161/ATVBAHA.112.249508
10.4049/jimmunol.1201272
10.2337/db12-0828
10.1016/S0140-6736(05)66378-7
10.1371/journal.pone.0005045
10.1523/JNEUROSCI.2760-08.2009
10.1016/j.cell.2008.07.043
10.1210/en.2004-1520
10.1210/er.2014-1100
10.1172/JCI59660
10.1210/en.2014-1090
10.1074/jbc.M109.030874
10.1371/journal.pone.0030571
10.1017/S0007114512005090
10.1210/en.2014-1552
10.1084/jem.20150225
10.1038/oby.2007.14
10.1016/j.jasms.2006.09.002
10.1016/j.cmet.2012.01.002
10.1016/S1097-2765(00)80062-3
10.1016/S0014-5793(01)02591-1
10.1016/j.cell.2013.09.003
10.1016/j.cell.2013.09.004
10.1016/j.cmet.2011.12.016
10.1371/journal.pone.0119850
10.1038/ijo.2011.56
10.1038/nm.2123
10.1016/j.jalz.2013.12.024
10.1016/j.bbalip.2014.10.009
10.1073/pnas.0907342107
10.1016/j.neuropharm.2009.12.016
10.1016/S1096-6374(03)00051-0
10.1073/pnas.1306799110
10.2337/db11-0390
10.1074/jbc.M110.173021
10.1210/en.2009-0865",<Element 'PubmedArticle' at 0x7f05dca733b0>
368,"27918427
24438352
19444307
18970977
25772897
20398859
9682040
25781857
22363612
25462579
20008670
19506118
15130950
20008671
20679640
18057139
9626554
19535262
22577091
10857555
26567005
12511652
20453850
22973440
19211889
21785216
20570717
26874070
24478366
17314279
11802212
15234536
18248819
10809956
11721699
1502189
12698200
23885109
11826263
24317118
22159143
22129255
1940367
8200135
12531884
16849443
24612525
20236233
22341909
26236110
22155203
19957009
9316698
8874591
7688676
8137548
17487163
16153891
1859183
8190833
25889599
10556797
17289576
24130130
8058071
8015553
24029242
26000330",Prolactin: Friend or Foe in Central Nervous System Autoimmune Inflammation?,"The higher prevalence of multiple sclerosis (MS) in females, along with the modulation of disease activity observed during pregnancy and the post-partum period, has suggested a hormonal influence in MS. Even if prolactin (PRL) does not belong to the sex hormones family, its crucial role in female reproduction and lactation has prompted great efforts to understand if PRL could represent a gender factor in the pathogenesis of MS and experimental autoimmune encephalomyelitis (EAE), the animal model for this disease. Extensive literature has documented a remarkable immune-stimulating potential for this hormone, indicating PRL as a disease-promoting factor in MS and EAE. However, recent work has pointed out that PRL is endowed with important neuroprotective and remyelinating properties and has encouraged a reinterpretation of the involvement of this hormone in MS. In this review we summarize both the protective functions that PRL exerts in central nervous system tissue as well as the inflammatory activity of this hormone in the context of autoimmune responses against myelin. Last, we draw future lines of research that might help to better clarify the impact of PRL on MS pathology.","['experimental autoimmune encephalomyelitis', 'multiple sclerosis', 'neuroinflammation', 'neuroprotection', 'prolactin']",International journal of molecular sciences,2016-12-06,"[{'lastname': 'Costanza', 'firstname': 'Massimo', 'initials': 'M', 'affiliation': 'Department of Clinical Neuroscience, Neurological Institute Foundation IRCCS Carlo Besta, 20133 Milan, Italy. Massimo.Costanza@istituto-besta.it.'}, {'lastname': 'Pedotti', 'firstname': 'Rosetta', 'initials': 'R', 'affiliation': 'Department of Clinical Neuroscience, Neurological Institute Foundation IRCCS Carlo Besta, 20133 Milan, Italy. Rosetta.Pedotti@istituto-besta.it.'}]",,,,,"10.3390/ijms17122026
10.1146/annurev-immunol-032713-120227
10.1038/nri2550
10.1016/S0140-6736(08)61620-7
10.1016/S1474-4422(14)70256-X
10.1016/S1474-4422(10)70064-8
10.1056/NEJM199807303390501
10.1038/nrendo.2015.36
10.1371/journal.pone.0031305
10.1016/j.autrev.2014.11.005
10.1001/archneurol.2009.281
10.1001/archneurol.2009.132
10.1093/brain/awh152
10.1001/archneurol.2009.280
10.1212/WNL.0b013e3181eb5860
10.1210/er.2007-0017
10.1210/edrv.19.3.0334
10.1016/j.tem.2009.03.001
10.1210/er.2011-1040
10.1210/er.21.3.292
10.1096/fj.15-276519
10.1126/science.1076647
10.1038/nn.2550
10.1371/journal.pone.0044371
10.1523/JNEUROSCI.3178-08.2009
10.1172/JCI46276
10.1016/j.neuroscience.2010.05.074
10.1016/j.brainres.2016.02.011
10.1523/JNEUROSCI.2452-13.2014
10.1523/JNEUROSCI.4441-06.2007
10.1002/ijc.1624
10.1016/j.imlet.2004.03.009
10.1016/j.cyto.2007.11.007
10.1046/j.1365-2567.2000.00996.x
10.1191/096120301717164967
10.1073/pnas.89.16.7713
10.1038/sj.bjc.6600860
10.4049/jimmunol.1301128
10.1146/annurev.physiol.64.081501.131049
10.1038/nm.3411
10.1530/JME-11-0040
10.1056/NEJMra1100359
10.1006/clin.1994.1095
10.1172/JCI200316530
10.4049/jimmunol.177.3.1401
10.1016/j.jneuroim.2014.02.007
10.1111/j.1365-2826.2010.01972.x
10.1016/j.jocn.2011.07.032
10.1155/2015/732539
10.1016/j.autrev.2011.11.009
10.1007/s11060-009-0076-1
10.1097/00002826-199410000-00011
10.1111/j.1600-0404.1996.tb00036.x
10.1111/j.1365-2249.1993.tb07966.x
10.1111/j.1365-2249.1994.tb07028.x
10.1038/nprot.2006.285
10.1016/j.it.2005.08.014
10.1002/ana.410290514
10.1016/0306-4530(94)90003-5
10.1186/s12974-015-0278-8
10.1002/(SICI)1521-4141(199911)29:11<3432::AID-IMMU3432>3.0.CO;2-2
10.1016/j.cell.2006.12.036
10.1530/JME-13-0220
10.1210/en.2013-1476
10.1002/acn3.194",<Element 'PubmedArticle' at 0x7f05dc9a32c0>
369,27911310,Cholinergic Modification of Neurogenesis and Gliosis Improves the Memory of AβPPswe/PSEN1dE9 Alzheimer's Disease Model Mice Fed a High-Fat Diet.,"We previously reported that neuroinflammation contributes to the amnesia of AβPPswe/PSEN1dE9 Alzheimer's disease model mice fed a high-fat diet to induce type-2 diabetes (T2DM-AD mice), but the underlying mechanism for the memory decline remained unclear. Recent studies have suggested that cholinergic modulation is involved in neuroinflammatory cellular reactions including neurogenesis and gliosis, and in memory improvement. In this study, we administered a broad-spectrum cholinesterase inhibitor, rivastigmine (2 mg/kg/day, s.c.), into T2DM-AD mice for 6 weeks, and evaluated their memory performance, neurogenesis, and neuroinflammatory reactions. By two hippocampal-dependent memory tests, the Morris water maze and contextual fear conditioning, rivastigmine improved the memory deterioration of the T2DM-AD mice (n = 8, p < 0.01). The number of newborn neurons in the hippocampal dentate gyrus was 1138±324 (Ave±SEM) in wild-type littermates, 2573±442 in T2DM-AD-Vehicle, and 2165±300 in T2DM-AD-Rivastigmine mice, indicating that neurogenesis was accelerated in the two T2DM-AD groups (n = 5, p < 0.05). The dendritic maturation of new neurons in T2DM-AD-Vehicle mice was severely abrogated, and rivastigmine treatment reversed this retarded maturation. In addition, the hippocampus of T2DM-AD-Vehicle mice showed increased proinflammatory cytokines IL-1β and TNF-α and gliosis, and rivastigmine treatment blocked these inflammatory reactions. Rivastigmine did not change the insulin abnormality or amyloid pathology in these mice. Thus, cholinergic modulation by rivastigmine treatment led to enhanced neurogenesis and the suppression of gliosis, which together ameliorated the memory decline in T2DM-AD model mice.","['Acetylcholinesterase', 'Alzheimer’s disease', 'gliosis', 'high-fat diet', 'inflammation', 'memory', 'neurogenesis', 'rivastigmine', 'type 2 diabetes mellitus']",Journal of Alzheimer's disease : JAD,2016-12-03,"[{'lastname': 'Matsuda', 'firstname': 'Takeshi', 'initials': 'T', 'affiliation': None}, {'lastname': 'Hisatsune', 'firstname': 'Tatsuhiro', 'initials': 'T', 'affiliation': None}]",,,,,10.3233/JAD-160761,<Element 'PubmedArticle' at 0x7f05dc9cb5e0>
370,27870397,Sex differences in neuroimmunity and pain.,"Differences in the prevalence of chronic pain in women vs. men are well known, and decades of laboratory experimentation have demonstrated that women are more sensitive to pain than are men. Attention has thus shifted to investigating mechanisms underlying such differences. Recent evidence suggests that neuroimmune modulation of pain may represent an important cause of sex differences. The current Review examines the evidence for gonadal hormone modulation of the immune system, immune system modulation of pain, and interactions that might help to explain sex differences in pain. © 2016 Wiley Periodicals, Inc.","['IL-1β', 'IL-6', 'T cells', 'TNF-α', 'estrogen', 'immune system', 'inflammation', 'macrophages', 'microglia', 'pain', 'progesterone', 'sex differences', 'testosterone']",Journal of neuroscience research,2016-11-22,"[{'lastname': 'Rosen', 'firstname': 'Sarah', 'initials': 'S', 'affiliation': 'Department of Psychology and Alan Edwards Centre for Research on Pain, McGill University, Montreal, Quebec, Canada.'}, {'lastname': 'Ham', 'firstname': 'Boram', 'initials': 'B', 'affiliation': 'Department of Psychology and Alan Edwards Centre for Research on Pain, McGill University, Montreal, Quebec, Canada.'}, {'lastname': 'Mogil', 'firstname': 'Jeffrey S', 'initials': 'JS', 'affiliation': 'Department of Psychology and Alan Edwards Centre for Research on Pain, McGill University, Montreal, Quebec, Canada.'}]",,,,"© 2016 Wiley Periodicals, Inc.",10.1002/jnr.23831,<Element 'PubmedArticle' at 0x7f05dc9d96d0>
371,"27758118
19037001
17339406
21737777
9106073
17892496
9166739
12379909
12160938
21536110
24889886
15535133
12366822
19203575
2882529
27074429
17097745
17003354
12788509
23791709
10708854
17372191
1346137
19917131
17317010
7835247
15015004
18684473
12744474
16912070
7181105
22248144
20140959
7595501
15665833
7539914
21195648
15948188
18832333
18304357
21852960
16807899
22155370
6137484
23121979
10762723
24089628
17200717
14400
25681623
24966471
25451225
25917893
16925588
11698255
1969723
11526952
7890330
7890329
1683703
22024597
15750215
22476197
20599704
20678471
19721819
12769187
16339510
9916881
22820375
11494408
25846981
10490282
9058007
24656144
23055521
23590975
21687761",Blockade of Glutamine Synthetase Enhances Inflammatory Response in Microglial Cells.,"Microglial cells are brain-resident macrophages engaged in surveillance and maintained in a constant state of relative inactivity. However, their involvement in autoimmune diseases indicates that in pathological conditions microglia gain an inflammatory phenotype. The mechanisms underlying this change in the microglial phenotype are still unclear. Since metabolism is an important modulator of immune cell function, we focused our attention on glutamine synthetase (GS), a modulator of the response to lipopolysaccharide (LPS) activation in other cell types, which is expressed by microglia.
GS inhibition enhances release of inflammatory mediators of LPS-activated microglia in vitro, leading to perturbation of the redox balance and decreased viability of cocultured neurons. GS inhibition also decreases insulin-mediated glucose uptake in microglia. In vivo, microglia-specific GS ablation enhances expression of inflammatory markers upon LPS treatment. In the spinal cords from experimental autoimmune encephalomyelitis (EAE), GS expression levels and glutamine/glutamate ratios are reduced.
Recently, metabolism has been highlighted as mediator of immune cell function through the discovery of mechanisms that (behind these metabolic changes) modulate the inflammatory response. The present study shows for the first time a metabolic mechanism mediating microglial response to a proinflammatory stimulus, pointing to GS activity as a master modulator of immune cell function and thus unraveling a potential therapeutic target.
Our study highlights a new role of GS in modulating immune response in microglia, providing insights into the pathogenic mechanisms associated with inflammation and new strategies of therapeutic intervention. Antioxid. Redox Signal. 26, 351-363.","['glutamine', 'glutamine synthetase', 'insulin resistance', 'microglia', 'neuroinflammation']",Antioxidants & redox signaling,2016-11-03,"[{'lastname': 'Palmieri', 'firstname': 'Erika M', 'initials': 'EM', 'affiliation': '1 Department of Biosciences, Biotechnologies and Biopharmaceutics, University of Bari , Bari, Italy .'}, {'lastname': 'Menga', 'firstname': 'Alessio', 'initials': 'A', 'affiliation': ""2 National Cancer Research Center, Istituto Tumori 'Giovanni Paolo II,' Bari, Italy .""}, {'lastname': 'Lebrun', 'firstname': 'Aurore', 'initials': 'A', 'affiliation': '3 Department of Cancer Biology, Thomas Jefferson University , Philadelphia, Pennsylvania.\n4 Department of Neurological Surgery, Thomas Jefferson University , Philadelphia, Pennsylvania.'}, {'lastname': 'Hooper', 'firstname': 'Douglas C', 'initials': 'DC', 'affiliation': '3 Department of Cancer Biology, Thomas Jefferson University , Philadelphia, Pennsylvania.\n4 Department of Neurological Surgery, Thomas Jefferson University , Philadelphia, Pennsylvania.'}, {'lastname': 'Butterfield', 'firstname': 'D Allan', 'initials': 'DA', 'affiliation': '5 Department of Chemistry, University of Kentucky , Lexington, Kentucky.\n6 Sanders-Brown Center on Aging, University of Kentucky , Lexington, Kentucky.'}, {'lastname': 'Mazzone', 'firstname': 'Massimiliano', 'initials': 'M', 'affiliation': '7 Laboratory of Tumor Inflammation and Angiogenesis, Department of Oncology, University of Leuven , Leuven, Belgium .\n8 Laboratory of Tumor Inflammation and Angiogenesis, Vesalius Research Center, VIB, Leuven, Belgium .'}, {'lastname': 'Castegna', 'firstname': 'Alessandra', 'initials': 'A', 'affiliation': ""1 Department of Biosciences, Biotechnologies and Biopharmaceutics, University of Bari , Bari, Italy .\n2 National Cancer Research Center, Istituto Tumori 'Giovanni Paolo II,' Bari, Italy .""}]",,,"GS inhibition enhances release of inflammatory mediators of LPS-activated microglia in vitro, leading to perturbation of the redox balance and decreased viability of cocultured neurons. GS inhibition also decreases insulin-mediated glucose uptake in microglia. In vivo, microglia-specific GS ablation enhances expression of inflammatory markers upon LPS treatment. In the spinal cords from experimental autoimmune encephalomyelitis (EAE), GS expression levels and glutamine/glutamate ratios are reduced.",,10.1089/ars.2016.6715,<Element 'PubmedArticle' at 0x7f05dc9625e0>
372,27206668,Vinpocetine and Vasoactive Intestinal Peptide Attenuate Manganese-Induced Toxicity in NE-4C Cells.,"Increased concentration of manganese (Mn) in the brain is known to be associated with excitotoxicity and neuroinflammation. Vinpocetine, an alkaloid derived from the plant Vinca minor L., basically shows its effect via phosphodiesterase inhibition and voltage-dependent Na","['Apoptosis', 'Manganese', 'NE-4C cells', 'Vasoactive intestinal peptide', 'Vinpocetine']",Biological trace element research,2016-11-03,"[{'lastname': 'Bora', 'firstname': 'Saylav', 'initials': 'S', 'affiliation': 'Department of Physiology, School of Medicine, Faculty of Medicine, Ege University, 35100, Bornova, Izmir, Turkey. saylavbora@hotmail.com.'}, {'lastname': 'Erdogan', 'firstname': 'Mumin Alper', 'initials': 'MA', 'affiliation': 'Department of Physiology, School of Medicine, Faculty of Medicine, Ege University, 35100, Bornova, Izmir, Turkey.'}, {'lastname': 'Armagan', 'firstname': 'Güliz', 'initials': 'G', 'affiliation': 'Department of Biochemistry, Faculty of Pharmacy, Ege University, 35100, Bornova, Izmir, Turkey.'}, {'lastname': 'Sevgili', 'firstname': 'Elvin', 'initials': 'E', 'affiliation': 'Department of Biochemistry, Faculty of Pharmacy, Ege University, 35100, Bornova, Izmir, Turkey.'}, {'lastname': 'Dagcı', 'firstname': 'Taner', 'initials': 'T', 'affiliation': 'Department of Physiology, School of Medicine, Faculty of Medicine, Ege University, 35100, Bornova, Izmir, Turkey.'}]",,,,,10.1007/s12011-016-0742-z,<Element 'PubmedArticle' at 0x7f05dc990810>
373,27693335,Investigation of the effects of vanilloids in chronic fatigue syndrome.,"To assess the effectiveness of TRPV1 modulators in animal model of Chronic fatigue syndrome (CFS). To assess central and peripheral behavioral activity of TRPV1 modulators.
CFS was induced by forcing the rats to swim for 10min for 21 consecutive days. The rats were treated with capsaicin (TRPV1 agonist, 2.5mg/kg) and n-tert-butylcyclohexanol (TRPV1 antagonist, 10mg/kg) for 21days 30min before the exposure to stress procedure. The behavioral consequence of CFS was measured in terms of immobility time, grip strength, locomotor activity, and anxiety level using Rota rod, Actophotometer, and Elevated plus maze model respectively. The other parameters include Plasma corticosterone, adrenal gland and spleen weight, complete blood count, blood urea niterogen (BUN), Lactate dehydrogenase (LDH), Lipid peroxidation, catalase and reduced glutathione (GSH).
TRPV1 modulators reversed (p<0.05) the increase in immobility period, anxiety, spleen weight, BUN and LDH levels, and MDA levels along with decrease in grip strength, locomotor activity, plasma corticosterone, adrenal gland weight, catalase, and GSH. There was also significant increase in total WBC count when compared with the disease control group. The reversal was attributed to modulation of HPA axis, oxidative stress, anaerobic respiration product, muscle degradation product.
The present study reveals the effectiveness of n-tert-butylcyclohexanol and capsaicin against chronic fatigue syndrome. The mechanism of action can be attributed to inhibition of TRPV1 channel and thereby modulating pain perception, neuroendocrine function, oxidative stress and immune function.","['Chronic fatigue syndrome', 'Fatigue', 'Forced swimming test', 'TRPV1 channel', 'Vanilloids']",Brain research bulletin,2016-10-28,"[{'lastname': 'Sarvaiya', 'firstname': 'Kuldeep', 'initials': 'K', 'affiliation': 'Department of Pharmacology, L.M. College of Pharmacy, Ahmedabad, 380009 Gujarat, India. Electronic address: Sarvaiyakuldeep5393@gmail.com.'}, {'lastname': 'Goswami', 'firstname': 'Sunita', 'initials': 'S', 'affiliation': 'Department of Pharmacology, L.M. College of Pharmacy, Ahmedabad, 380009 Gujarat, India.'}]",,"The present study reveals the effectiveness of n-tert-butylcyclohexanol and capsaicin against chronic fatigue syndrome. The mechanism of action can be attributed to inhibition of TRPV1 channel and thereby modulating pain perception, neuroendocrine function, oxidative stress and immune function.",,Copyright © 2016 Elsevier Inc. All rights reserved.,10.1016/j.brainresbull.2016.09.015,<Element 'PubmedArticle' at 0x7f05dc99af90>
374,27106168,Ketamine modulates hippocampal neurogenesis and pro-inflammatory cytokines but not stressor induced neurochemical changes.,"Considerable recent attention has focused on the rapid antidepressant effects observed in treatment resistant patients produced by the NMDA receptor antagonist, ketamine. Surprisingly, the effects of ketamine in the context of stressor exposure, as well as the consequences of its chronic use are unclear. Thus, we assessed the impact of acute and repeated ketamine treatment together with acute [restraint or lipopolysaccharide (LPS)] or chronic (unpredictable different psychogenic challenges) stressor exposure. Importantly, acute ketamine treatment did provoke an antidepressant-like effect in a forced swim test (FST) and this effect lasted for 8 days following repeated exposure to the drug. Although acute restraint and LPS individually provoked the expected elevation of plasma corticosterone and brain-region specific monoamine variations, ketamine had no influence on corticosterone and had, at best, sparse effects on the monoamine changes. Similarly, ketamine did not appreciably influence the stressor induced neurochemical and sucrose preference alterations, it did however, dose-dependently reverse the LPS induced elevation of the pro-inflammatory cytokines, interleukin-1β (IL-1β) and tumor necrosis factor-α (TNF-α). Likewise, repeated ketamine administration increased adult hippocampal neurogenesis. These data indicate that repeated ketamine administration had greater behavioral consequences than acute treatment and that the drug might be imparting antidepressant effects through its effects on neuroplasticity and inflammatory processes rather than the typical neurochemical/hormonal factors affected by stressors. This article is part of the Special Issue entitled 'Ionotropic glutamate receptors'.","['Cytokine', 'Depression', 'Ketamine', 'LPS', 'Neurogenesis', 'Stressor']",Neuropharmacology,2016-10-25,"[{'lastname': 'Clarke', 'firstname': 'Melanie', 'initials': 'M', 'affiliation': 'Department of Neuroscience, Carleton University, 1125 Colonel By Drive, Ottawa, Ontario K1S 5B6, Canada.'}, {'lastname': 'Razmjou', 'firstname': 'Sara', 'initials': 'S', 'affiliation': 'Department of Neuroscience, Carleton University, 1125 Colonel By Drive, Ottawa, Ontario K1S 5B6, Canada.'}, {'lastname': 'Prowse', 'firstname': 'Natalie', 'initials': 'N', 'affiliation': 'Department of Neuroscience, Carleton University, 1125 Colonel By Drive, Ottawa, Ontario K1S 5B6, Canada.'}, {'lastname': 'Dwyer', 'firstname': 'Zach', 'initials': 'Z', 'affiliation': 'Department of Neuroscience, Carleton University, 1125 Colonel By Drive, Ottawa, Ontario K1S 5B6, Canada.'}, {'lastname': 'Litteljohn', 'firstname': 'Darcy', 'initials': 'D', 'affiliation': 'Department of Neuroscience, Carleton University, 1125 Colonel By Drive, Ottawa, Ontario K1S 5B6, Canada.'}, {'lastname': 'Pentz', 'firstname': 'Rowan', 'initials': 'R', 'affiliation': 'Department of Neuroscience, Carleton University, 1125 Colonel By Drive, Ottawa, Ontario K1S 5B6, Canada.'}, {'lastname': 'Anisman', 'firstname': 'Hymie', 'initials': 'H', 'affiliation': 'Department of Neuroscience, Carleton University, 1125 Colonel By Drive, Ottawa, Ontario K1S 5B6, Canada.'}, {'lastname': 'Hayley', 'firstname': 'Shawn', 'initials': 'S', 'affiliation': 'Department of Neuroscience, Carleton University, 1125 Colonel By Drive, Ottawa, Ontario K1S 5B6, Canada. Electronic address: shawn_hayley@carleton.ca.'}]",,,,Copyright © 2016 Elsevier Ltd. All rights reserved.,10.1016/j.neuropharm.2016.04.021,<Element 'PubmedArticle' at 0x7f05dc929c20>
375,27616549,Palmitoylethanolamide protects mice against 6-OHDA-induced neurotoxicity and endoplasmic reticulum stress: In vivo and in vitro evidence.,"Several pathogenetic factors have been involved in the onset and progression of Parkinson's disease (PD), including inflammation, oxidative stress, unfolded protein accumulation, and apoptosis. Palmitoylethanolamide (PEA), an endogenous N-acylethanolamine, has been shown to be a neuroprotective and anti-inflammatory molecule, acting as a peroxisome proliferator activated receptor (PPAR)-α agonist. In this study we investigated the effects of PEA on behavioral alterations and the underlying pathogenic mechanisms in the 6-hydroxydopamine (6-OHDA)-induced model of PD in male mice. Additionally, we showed the involvement of PPAR-α in PEA protective effect on SH-SY5Y neuroblastoma against 6-OHDA damage. Here, we report that PEA (3-30mg/kg/days.c.) improved behavioral impairments induced by unilateral intrastriatal injection of 6-OHDA. This effect was accompanied by a significant increase in tyrosine hydroxylase expression at striatal level, indicating PEA preserving effect on dopaminergic neurons. Moreover, we found a reduction in the expression of pro-inflammatory enzymes, i.e. inducible nitric oxide synthase and cyclooxygenase-2, a modulation between pro- and anti-apoptotic markers, suggestive of PEA capability in controlling neuroinflammation and cell death. Interestingly, PEA also showed protective scavenging effect, through superoxide dismutase induction, and dampened unfolding protein response, interfering on glucose-regulated protein 78 expression and PERK-eIF2α pathway. Similar data were found in in vitro studies, where PEA treatment was found to rescue SH-SY5Y neuroblastoma cells from 6-OHDA-induced damage and death, partly by inhibiting endoplasmic reticulum stress detrimental response. Therefore, PEA, counteracting the pathogenetic aspects involved in the development of PD, showed its therapeutic potential, possibly integrating current treatments correcting dopaminergic deficits and motor dysfunction.","['Apoptosis', 'Endoplasmic reticulum stress', 'Oxidative stress', 'PPAR-α', 'Palmitoylethanolamide', ""Parkinson's disease""]",Pharmacological research,2016-10-21,"[{'lastname': 'Avagliano', 'firstname': 'Carmen', 'initials': 'C', 'affiliation': 'Department of Pharmacy, University of Naples ""Federico II"", 80131, Naples, Italy.'}, {'lastname': 'Russo', 'firstname': 'Roberto', 'initials': 'R', 'affiliation': 'Department of Pharmacy, University of Naples ""Federico II"", 80131, Naples, Italy.'}, {'lastname': 'De Caro', 'firstname': 'Carmen', 'initials': 'C', 'affiliation': 'Department of Pharmacy, University of Naples ""Federico II"", 80131, Naples, Italy.'}, {'lastname': 'Cristiano', 'firstname': 'Claudia', 'initials': 'C', 'affiliation': 'Department of Pharmacy, University of Naples ""Federico II"", 80131, Naples, Italy.'}, {'lastname': 'La Rana', 'firstname': 'Giovanna', 'initials': 'G', 'affiliation': 'Department of Pharmacy, University of Naples ""Federico II"", 80131, Naples, Italy.'}, {'lastname': 'Piegari', 'firstname': 'Giuseppe', 'initials': 'G', 'affiliation': 'Department of Veterinary Medicine and Animal Production, University of Naples ""Federico II"", 80137 Naples, Italy.'}, {'lastname': 'Paciello', 'firstname': 'Orlando', 'initials': 'O', 'affiliation': 'Department of Veterinary Medicine and Animal Production, University of Naples ""Federico II"", 80137 Naples, Italy.'}, {'lastname': 'Citraro', 'firstname': 'Rita', 'initials': 'R', 'affiliation': 'Department of Health Sciences, School of Medicine, University of Catanzaro ""Magna Graecia"", Catanzaro, Italy.'}, {'lastname': 'Russo', 'firstname': 'Emilio', 'initials': 'E', 'affiliation': 'Department of Health Sciences, School of Medicine, University of Catanzaro ""Magna Graecia"", Catanzaro, Italy.'}, {'lastname': 'De Sarro', 'firstname': 'Giovambattista', 'initials': 'G', 'affiliation': 'Department of Health Sciences, School of Medicine, University of Catanzaro ""Magna Graecia"", Catanzaro, Italy.'}, {'lastname': 'Meli', 'firstname': 'Rosaria', 'initials': 'R', 'affiliation': 'Department of Pharmacy, University of Naples ""Federico II"", 80131, Naples, Italy.'}, {'lastname': 'Mattace Raso', 'firstname': 'Giuseppina', 'initials': 'G', 'affiliation': 'Department of Pharmacy, University of Naples ""Federico II"", 80131, Naples, Italy. Electronic address: mattace@unina.it.'}, {'lastname': 'Calignano', 'firstname': 'Antonio', 'initials': 'A', 'affiliation': 'Department of Pharmacy, University of Naples ""Federico II"", 80131, Naples, Italy.'}]",,,,Copyright © 2016 Elsevier Ltd. All rights reserved.,10.1016/j.phrs.2016.09.004,<Element 'PubmedArticle' at 0x7f05dc93a180>
376,"27717401
16618472
25142459
10371588
17920770
16856116
18443635
24758595
26629597
23448470
12894165
21969325
20870295
22710756
21234811
17250968
10779657
11150554
26984186
19029990
22378047
17681149
22910418
23707273
17928570
24499354
21979425
21490083
25630024
27139929
19139563
21307767
24278116
20613859
19016445
23967058
26699615
19864556
18770762
25523105
26867675
22923332
7990513
20385224
23820126
26453963
21518571
11086074
25366967
23781069
16189277
15491976
23077543
24669294
22419372
27123124
26089604
20511666
19574425
23515178
24521472
19710468
21248152
19636355
15220792
24928142
12808141
26598697
15561377
19233260
21458249
24793056
25476600
9662373",Adoptive transfer of M2 macrophages reduces neuropathic pain via opioid peptides.,"During the inflammation which occurs following nerve damage, macrophages are recruited to the site of injury. Phenotypic diversity is a hallmark of the macrophage lineage and includes pro-inflammatory M1 and anti-inflammatory M2 populations. Our aim in this study was to investigate the ability of polarized M0, M1, and M2 macrophages to secrete opioid peptides and to examine their relative contribution to the modulation of neuropathic pain.
Mouse bone marrow-derived cells were cultured as unstimulated M0 macrophages or were stimulated into an M1 phenotype using lipopolysaccharide and interferon-γ or into an M2 phenotype using interleukin-4. The macrophage phenotypes were verified using flow cytometry for surface marker analysis and cytokine bead array for cytokine profile assessment. Opioid peptide levels were measured by radioimmunoassay and enzyme immunoassay. As a model of neuropathic pain, a chronic constriction injury (CCI) of the sciatic nerve was employed. Polarized M0, M1, and M2 macrophages (5 × 10
Compared to M0 and M1 cells, M2 macrophages contained and released higher amounts of opioid peptides, including Met-enkephalin, dynorphin A (1-17), and β-endorphin. M2 cells transferred perineurally at the nerve injury site reduced mechanical, but not heat hypersensitivity following the second injection. The analgesic effect was reversed by the perineurally applied opioid receptor antagonist naloxone methiodide. M2 cells did not affect sensitivity following sham surgery. Neither M0 nor M1 cells altered mechanical and heat sensitivity in CCI or sham-operated animals. Tracing the fluorescently labeled M0, M1, and M2 cells ex vivo showed that they remained in the nerve and preserved their phenotype.
Perineural transplantation of M2 macrophages resulted in opioid-mediated amelioration of neuropathy-induced mechanical hypersensitivity, while M1 macrophages did not exacerbate pain. Therefore, rather than focusing on macrophage-induced pain generation, promoting opioid-mediated M2 actions may be more relevant for pain control.","['Analgesia', 'Dynorphin', 'Endorphin', 'Enkephalin', 'Macrophage', 'Neuropathic pain']",Journal of neuroinflammation,2016-10-09,"[{'lastname': 'Pannell', 'firstname': 'Maria', 'initials': 'M', 'affiliation': 'Department of Anesthesiology and Critical Care Medicine, Charité-Universitätsmedizin Berlin, Campus Benjamin Franklin, Hindenburgdamm 30, 12203, Berlin, Germany.'}, {'lastname': 'Labuz', 'firstname': 'Dominika', 'initials': 'D', 'affiliation': 'Department of Anesthesiology and Critical Care Medicine, Charité-Universitätsmedizin Berlin, Campus Benjamin Franklin, Hindenburgdamm 30, 12203, Berlin, Germany.'}, {'lastname': 'Celik', 'firstname': 'Melih Ö', 'initials': 'MÖ', 'affiliation': 'Department of Anesthesiology and Critical Care Medicine, Charité-Universitätsmedizin Berlin, Campus Benjamin Franklin, Hindenburgdamm 30, 12203, Berlin, Germany.'}, {'lastname': 'Keye', 'firstname': 'Jacqueline', 'initials': 'J', 'affiliation': 'Medizinische Klinik für Gastroenterologie, Infektiologie und Rheumatologie, Charité-Universitätsmedizin Berlin, Campus Benjamin Franklin, Hindenburgdamm 30, 12203, Berlin, Germany.'}, {'lastname': 'Batra', 'firstname': 'Arvind', 'initials': 'A', 'affiliation': 'Medizinische Klinik für Gastroenterologie, Infektiologie und Rheumatologie, Charité-Universitätsmedizin Berlin, Campus Benjamin Franklin, Hindenburgdamm 30, 12203, Berlin, Germany.'}, {'lastname': 'Siegmund', 'firstname': 'Britta', 'initials': 'B', 'affiliation': 'Medizinische Klinik für Gastroenterologie, Infektiologie und Rheumatologie, Charité-Universitätsmedizin Berlin, Campus Benjamin Franklin, Hindenburgdamm 30, 12203, Berlin, Germany.'}, {'lastname': 'Machelska', 'firstname': 'Halina', 'initials': 'H', 'affiliation': 'Department of Anesthesiology and Critical Care Medicine, Charité-Universitätsmedizin Berlin, Campus Benjamin Franklin, Hindenburgdamm 30, 12203, Berlin, Germany. halina.machelska@charite.de.'}]",,,"Compared to M0 and M1 cells, M2 macrophages contained and released higher amounts of opioid peptides, including Met-enkephalin, dynorphin A (1-17), and β-endorphin. M2 cells transferred perineurally at the nerve injury site reduced mechanical, but not heat hypersensitivity following the second injection. The analgesic effect was reversed by the perineurally applied opioid receptor antagonist naloxone methiodide. M2 cells did not affect sensitivity following sham surgery. Neither M0 nor M1 cells altered mechanical and heat sensitivity in CCI or sham-operated animals. Tracing the fluorescently labeled M0, M1, and M2 cells ex vivo showed that they remained in the nerve and preserved their phenotype.",,"10.1186/s12974-016-0735-z
10.1016/j.jpain.2005.11.008
10.1016/S1474-4422(14)70102-4
10.1016/S0140-6736(99)01307-0
10.1016/j.pain.2007.08.033
10.1056/NEJMp1402780
10.1016/j.coph.2015.11.004
10.2174/138161281942140105163727
10.1038/nm908
10.1124/pr.110.003145
10.1016/j.jneuroim.2010.08.013
10.1016/S1474-4422(12)70134-5
10.1007/s00005-010-0106-x
10.1016/j.pain.2006.11.017
10.1016/S0304-3959(99)00306-1
10.1016/S0031-9384(00)00333-4
10.1093/brain/aww038
10.1038/nri2448
10.1172/JCI59643
10.1016/j.cmet.2007.06.010
10.1016/j.bbrc.2012.08.039
10.1016/j.pain.2013.04.039
10.1124/jpet.107.126045
10.1186/1744-8069-10-10
10.1097/WNR.0b013e32834cd76a
10.1213/ANE.0b013e31821b220c
10.1097/j.pain.0000000000000097
10.1016/j.bbi.2016.04.018
10.1172/JCI36246C1
10.1097/ALN.0b013e31820b8b1e
10.1371/journal.pone.0079099
10.1371/journal.pbio.1000412
10.1371/journal.pone.0069421
10.1371/journal.pone.0145342
10.1523/JNEUROSCI.3257-09.2009
10.1007/s00429-014-0962-y
10.1186/s12974-016-0503-0
10.1096/fj.12-208678
10.1016/0165-0270(94)90144-9
10.1016/j.bbi.2010.04.001
10.1124/jpet.113.205344
10.1016/j.neuropharm.2015.10.003
10.4049/jimmunol.165.11.6364
10.1084/jem.20140283
10.1128/mBio.00264-13
10.1182/blood-2005-03-1014
10.1309/QHD6YFN81KQXUUH6
10.1371/journal.pone.0047045
10.12703/P6-13
10.1007/s00262-012-1240-6
10.3324/haematol.2010.023879
10.2353/ajpath.2009.081011
10.1016/j.biomaterials.2013.02.065
10.1111/sji.12162
10.4049/jimmunol.0900864
10.1189/jlb.0710409
10.1371/journal.pmed.1000113
10.1097/00000542-200407000-00031
10.1186/1744-8069-10-36
10.1073/pnas.1331358100
10.1073/pnas.1501372112
10.1016/j.pain.2004.08.029
10.1016/j.bbi.2009.02.007
10.1016/j.aanat.2011.02.011
10.1016/j.jpain.2014.01.491
10.1016/j.bbi.2014.11.007
10.1038/nm0798-814",<Element 'PubmedArticle' at 0x7f05dc94c360>
377,27513198,Is the Wnt/β-catenin pathway involved in the anti-inflammatory activity of glucocorticoids in spinal cord injury?,"The Wnt canonical or the Wnt/β-catenin pathway has been implicated in the regulation of several physiopathological pathways such as inflammation. Glucocorticoids (GCs) are administered widely to treat inflammation in several diseases, including spinal cord injury (SCI). The aim of this study was to evaluate whether the Wnt canonical pathway is involved in experimental SCI and whether it is implicated in the anti-inflammatory activity of two different GCs: the methylprednisolone sodium succinate (MPSS), considered the standard treatment for acute SCI, and mometasone furoate (MF), mainly administered for the treatment of airway and skin diseases. Experimental SCI was induced in mice by surgical spinal cord compression at the T6-T7 level. Then, mice were treated with MPSS (6 mg/kg) or MF (0.1 mg/kg) for 7 days until they were killed. Both GCs were found to modulate the Wnt canonical pathway, but in particular, the MF treatment was shown to restore completely the downregulated pathway in SCI. The MF treatment also significantly increased peroxisome proliferator-activated receptor-γ, a Wnt target gene with anti-inflammatory properties, compared with MPSS, and it also inhibited the levels of the proinflammatory cytokines interleukin 1β and tumor necrosis factor-α. Here, we suggest that MF has more efficacy than MPSS in inhibiting inflammation in an SCI experimental model and we propose the β-catenin/peroxisome proliferator-activated receptor-γ axis as the mechanism by which MF exerts these beneficial effects.",[],Neuroreport,2016-08-12,"[{'lastname': 'Libro', 'firstname': 'Rosaliana', 'initials': 'R', 'affiliation': ""IRCCS Centro Neurolesi 'Bonino-Pulejo', Contrada Casazza, Messina, Italy.""}, {'lastname': 'Giacoppo', 'firstname': 'Sabrina', 'initials': 'S', 'affiliation': None}, {'lastname': 'Bramanti', 'firstname': 'Placido', 'initials': 'P', 'affiliation': None}, {'lastname': 'Mazzon', 'firstname': 'Emanuela', 'initials': 'E', 'affiliation': None}]",,,,,10.1097/WNR.0000000000000663,<Element 'PubmedArticle' at 0x7f05dc882770>
378,27459932,New selective glucocorticoid receptor modulators reverse amyloid-β peptide-induced hippocampus toxicity.,"In Alzheimer's disease (AD), cognitive deficits and psychological symptoms are associated with an early deregulation of the hypothalamic-pituitary-adrenal axis. Here, in an acute model of AD, we investigated if antiglucocorticoid strategies with selective glucocorticoid receptor (GR) modulators (CORT108297 and CORT113176) that combine antagonistic and agonistic GR properties could offer an interesting therapeutic approach in the future. We confirm the expected properties of the nonselective GR antagonist (mifepristone) because in addition to restoring basal circulating glucocorticoids levels, mifepristone totally reverses synaptic deficits and hippocampal apoptosis processes. However, mifepristone only partially reverses cognitive deficit, effects of the hippocampal amyloidogenic pathway, and neuroinflammatory processes, suggesting limits in its efficacy. By contrast, selective GR modulators CORT108297 and CORT113176 at a dose of 20 and 10 mg/kg, respectively, reverse hippocampal amyloid-β peptide generation, neuroinflammation, and apoptotic processes, restore the hippocampal levels of synaptic markers, re-establish basal plasma levels of glucocorticoids, and improve cognitive function. In conclusion, selective GR modulators are particularly attractive and may pave the way to new strategies for AD treatment.","[""Alzheimer's disease"", 'Amyloid-β peptide', 'Aβ(25–35) peptide', 'Glucocorticoid receptors', 'HPA axis', 'Hippocampus', 'Rat', 'Selective GR modulator']",Neurobiology of aging,2016-07-28,"[{'lastname': 'Pineau', 'firstname': 'Fanny', 'initials': 'F', 'affiliation': 'Molecular Mechanisms in Neurodegenerative Dementia Laboratory, Inserm U1198, Montpellier, France; University of Montpellier, Montpellier, France; EPHE, Paris, France.'}, {'lastname': 'Canet', 'firstname': 'Geoffrey', 'initials': 'G', 'affiliation': 'Molecular Mechanisms in Neurodegenerative Dementia Laboratory, Inserm U1198, Montpellier, France; University of Montpellier, Montpellier, France; EPHE, Paris, France.'}, {'lastname': 'Desrumaux', 'firstname': 'Catherine', 'initials': 'C', 'affiliation': 'Molecular Mechanisms in Neurodegenerative Dementia Laboratory, Inserm U1198, Montpellier, France; University of Montpellier, Montpellier, France; EPHE, Paris, France.'}, {'lastname': 'Hunt', 'firstname': 'Hazel', 'initials': 'H', 'affiliation': 'Corcept Therapeutics, Menlo Park, CA, USA.'}, {'lastname': 'Chevallier', 'firstname': 'Nathalie', 'initials': 'N', 'affiliation': 'Molecular Mechanisms in Neurodegenerative Dementia Laboratory, Inserm U1198, Montpellier, France; University of Montpellier, Montpellier, France; EPHE, Paris, France.'}, {'lastname': 'Ollivier', 'firstname': 'Matthias', 'initials': 'M', 'affiliation': 'Molecular Mechanisms in Neurodegenerative Dementia Laboratory, Inserm U1198, Montpellier, France; University of Montpellier, Montpellier, France; EPHE, Paris, France.'}, {'lastname': 'Belanoff', 'firstname': 'Joseph K', 'initials': 'JK', 'affiliation': 'Corcept Therapeutics, Menlo Park, CA, USA.'}, {'lastname': 'Givalois', 'firstname': 'Laurent', 'initials': 'L', 'affiliation': 'Molecular Mechanisms in Neurodegenerative Dementia Laboratory, Inserm U1198, Montpellier, France; University of Montpellier, Montpellier, France; EPHE, Paris, France. Electronic address: lgivalois@univ-montp2.fr.'}]",,,,Copyright © 2016 Elsevier Inc. All rights reserved.,10.1016/j.neurobiolaging.2016.05.018,<Element 'PubmedArticle' at 0x7f05dc88af40>
379,27423516,PEA and luteolin synergistically reduce mast cell-mediated toxicity and elicit neuroprotection in cell-based models of brain ischemia.,"The combination of palmitoylethanolamide (PEA), an endogenous fatty acid amide belonging to the family of the N-acylethanolamines, and the flavonoid luteolin has been found to exert neuroprotective activities in a variety of mouse models of neurological disorders, including brain ischemia. Indirect findings suggest that the two molecules can reduce the activation of mastocytes in brain ischemia, thus modulating crucial cells that trigger the inflammatory cascade. Though, no evidence exists about a direct effect of PEA and luteolin on mast cells in experimental models of brain ischemia, either used separately or in combination. In order to fill this gap, we developed a novel cell-based model of severe brain ischemia consisting of primary mouse cortical neurons and cloned mast cells derived from mouse fetal liver (MC/9 cells) subjected to oxygen and glucose deprivation (OGD). OGD exposure promoted both mast cell degranulation and the release of lactate dehydrogenase (LDH) in a time-dependent fashion. MC/9 cells exacerbated neuronal damage in neuron-mast cells co-cultures exposed to OGD. Likewise, the conditioned medium derived from OGD-exposed MC/9 cells induced significant neurotoxicity in control primary neurons. PEA and luteolin pre-treatment synergistically prevented the OGD-induced degranulation of mast cells and reduced the neurotoxic potential of MC/9 cells conditioned medium. Finally, the association of the two drugs promoted a direct synergistic neuroprotection even in pure cortical neurons exposed to OGD. In summary, our results indicate that mast cells release neurotoxic factors upon OGD-induced activation. The association PEA-luteolin actively reduces mast cell-mediated neurotoxicity as well as pure neurons susceptibility to OGD.","['Brain ischemia', 'Luteolin', 'Mast cells', 'Neuroinflammation', 'Neurons', 'PEA']",Brain research,2016-07-18,"[{'lastname': 'Parrella', 'firstname': 'Edoardo', 'initials': 'E', 'affiliation': 'Division of Pharmacology, Department of Molecular and Translational Medicine, National Institute of Neuroscience, University of Brescia, Italy. Electronic address: edoardo.parrella@unibs.it.'}, {'lastname': 'Porrini', 'firstname': 'Vanessa', 'initials': 'V', 'affiliation': 'Division of Pharmacology, Department of Molecular and Translational Medicine, National Institute of Neuroscience, University of Brescia, Italy. Electronic address: v.porrini@unibs.it.'}, {'lastname': 'Iorio', 'firstname': 'Rosa', 'initials': 'R', 'affiliation': 'Division of Pharmacology, Department of Molecular and Translational Medicine, National Institute of Neuroscience, University of Brescia, Italy. Electronic address: rosa91i@hotmail.it.'}, {'lastname': 'Benarese', 'firstname': 'Marina', 'initials': 'M', 'affiliation': 'Division of Pharmacology, Department of Molecular and Translational Medicine, National Institute of Neuroscience, University of Brescia, Italy. Electronic address: marina.benarese@unibs.it.'}, {'lastname': 'Lanzillotta', 'firstname': 'Annamaria', 'initials': 'A', 'affiliation': 'Division of Pharmacology, Department of Molecular and Translational Medicine, National Institute of Neuroscience, University of Brescia, Italy. Electronic address: annamaria.lanzillotta@unibs.it.'}, {'lastname': 'Mota', 'firstname': 'Mariana', 'initials': 'M', 'affiliation': 'Division of Pharmacology, Department of Molecular and Translational Medicine, National Institute of Neuroscience, University of Brescia, Italy. Electronic address: m.coelhodamota@unibs.it.'}, {'lastname': 'Fusco', 'firstname': 'Mariella', 'initials': 'M', 'affiliation': 'Epitech Group s.r.l., Saccolongo, Padova, Italy. Electronic address: mariella.fusco@epitech.it.'}, {'lastname': 'Tonin', 'firstname': 'Paolo', 'initials': 'P', 'affiliation': 'IRCCS San Camillo, Venezia, Italy. Electronic address: paolo.tonin@ospedalesancamillo.net.'}, {'lastname': 'Spano', 'firstname': 'PierFranco', 'initials': 'P', 'affiliation': 'Division of Pharmacology, Department of Molecular and Translational Medicine, National Institute of Neuroscience, University of Brescia, Italy; IRCCS San Camillo, Venezia, Italy. Electronic address: pierfranco.spano@unibs.it.'}, {'lastname': 'Pizzi', 'firstname': 'Marina', 'initials': 'M', 'affiliation': 'Division of Pharmacology, Department of Molecular and Translational Medicine, National Institute of Neuroscience, University of Brescia, Italy; IRCCS San Camillo, Venezia, Italy. Electronic address: marina.pizzi@unibs.it.'}]",,,,Copyright © 2016 Elsevier B.V. All rights reserved.,10.1016/j.brainres.2016.07.014,<Element 'PubmedArticle' at 0x7f05dc89d180>
380,27364363,Endocannabinoid System in Neurological Disorders.,"Several studies support the evidence that the endocannabinoid system and cannabimimetic drugs might have therapeutic potential in numerous pathologies. These pathologies range from neurological disorders, atherosclerosis, stroke, cancer to obesity/metabolic syndrome and others.
In this paper we review the endocannabinoid system signaling and its alteration in neurodegenerative disorders like multiple sclerosis, Alzheimer's disease, Parkinson's disease and Huntington's disease and discuss the main findings about the use of cannabinoids in the therapy of these pathologies.
Despite different etiologies, neurodegenerative disorders exhibit similar mechanisms like neuro-inflammation, excitotoxicity, deregulation of intercellular communication, mitochondrial dysfunction and disruption of brain tissue homeostasis. Current treatments ameliorate the symptoms but are not curative. Interfering with the endocannabinoid signaling might be a valid therapeutic option in neuro-degeneration. To this aim, pharmacological intervention to modulate the endocannabinoid system and the use of natural and synthetic cannabimimetic drugs have been assessed. CB1 and CB2 receptor signaling contributes to the control of Ca2+ homeostasis, trophic support, mitochondrial activity, and inflammatory conditions.
Several studies and patents suggest that the endocannabinoid system has neuro-protective properties and might be a target in neurodegenerative diseases.",[],Recent patents on CNS drug discovery,2016-07-02,"[{'lastname': 'Ranieri', 'firstname': 'Roberta', 'initials': 'R', 'affiliation': None}, {'lastname': 'Laezza', 'firstname': 'Chiara', 'initials': 'C', 'affiliation': None}, {'lastname': 'Bifulco', 'firstname': 'Maurizio', 'initials': 'M', 'affiliation': None}, {'lastname': 'Marasco', 'firstname': 'Daniela', 'initials': 'D', 'affiliation': None}, {'lastname': 'Malfitano', 'firstname': 'Anna M', 'initials': 'AM', 'affiliation': 'Department of Medicine and Surgery, University of Salerno, Via Salvatore Allende, Baronissi, 84081 Salerno, Italy and Department of Pharmacy, University of Salerno, Via Giovanni Paolo II 84084 Fisciano (Salerno)- Italy. annamaria.malfitano@unina.it.'}]",,Several studies and patents suggest that the endocannabinoid system has neuro-protective properties and might be a target in neurodegenerative diseases.,"Despite different etiologies, neurodegenerative disorders exhibit similar mechanisms like neuro-inflammation, excitotoxicity, deregulation of intercellular communication, mitochondrial dysfunction and disruption of brain tissue homeostasis. Current treatments ameliorate the symptoms but are not curative. Interfering with the endocannabinoid signaling might be a valid therapeutic option in neuro-degeneration. To this aim, pharmacological intervention to modulate the endocannabinoid system and the use of natural and synthetic cannabimimetic drugs have been assessed. CB1 and CB2 receptor signaling contributes to the control of Ca2+ homeostasis, trophic support, mitochondrial activity, and inflammatory conditions.",,10.2174/1574889810999160719105433,<Element 'PubmedArticle' at 0x7f05dc82af40>
381,27300756,Interleukin-21-dependent modulation of T cell antigen receptor reactivity towards low affinity peptide ligands in autoreactive CD8(+) T lymphocytes.,"IL-21 promotes autoimmune type-1 diabetes (T1D) in NOD mice by facilitating CD4(+) T cell help to CD8(+) T cells. IL-21 also enables autoreactive CD8(+) T cells to respond to weak TCR ligands and induce T1D. Here, we assessed whether IL-21 is essential for T1D induction in a mouse model where the disease can occur independently of CD4 help. In this model, which expresses lymphocytic choriomeningitis virus (LCMV) glycoprotein (GP) antigen under the rat insulin promoter (RIP-GP), LCMV infection activates CD8(+) T cells reactive to the GP-derived GP33 peptide that attack pancreatic islets and cause T1D. We show that IL-21 deficiency in RIP-GP mice did not impair T1D induction by LCMV expressing the wildtype GP33 peptide. Surprisingly, LCMV-L6F, expressing a weak peptide mimic of GP33, induced T1D more efficiently in Il21(-/-)RIP-GP mice than in controls. However, LCMV-C4Y expressing a very weak peptide mimic of GP33 did not induce T1D in Il21(-/-) mice, but T cells from the infected mice caused disease in lymphopenic RIP-GP mice upon adoptive transfer. Using Nur77(GFP) reporter mice, we show that CD8(+) T cells from Il21(-/-) mice expressing the GP33-specific transgenic P14 TCR showed increased reactivity towards low affinity TCR ligands. Collectively, our findings show that IL-21 is not always required for T1D induction by autoreactive CD8(+) T cells, and suggest that IL-21 may play an important role in regulating CD8(+) T cell reactivity towards low affinity TCR ligands.","['Altered peptide ligand', 'Autoimmune diabetes', 'CD8(+) T cells', 'Interleukin-21', 'TCR']",Cytokine,2016-06-15,"[{'lastname': 'Bobbala', 'firstname': 'Diwakar', 'initials': 'D', 'affiliation': 'Department of Pediatrics, Immunology Division, Faculty of Medicine and Health Sciences, Université de Sherbrooke, Sherbrooke J1H 5N4, Québec, Canada.'}, {'lastname': 'Orkhis', 'firstname': 'Sakina', 'initials': 'S', 'affiliation': 'Department of Pediatrics, Immunology Division, Faculty of Medicine and Health Sciences, Université de Sherbrooke, Sherbrooke J1H 5N4, Québec, Canada.'}, {'lastname': 'Kandhi', 'firstname': 'Rajani', 'initials': 'R', 'affiliation': 'Department of Pediatrics, Immunology Division, Faculty of Medicine and Health Sciences, Université de Sherbrooke, Sherbrooke J1H 5N4, Québec, Canada.'}, {'lastname': 'Ramanathan', 'firstname': 'Sheela', 'initials': 'S', 'affiliation': 'Department of Pediatrics, Immunology Division, Faculty of Medicine and Health Sciences, Université de Sherbrooke, Sherbrooke J1H 5N4, Québec, Canada. Electronic address: Sheela.Ramanathan@USherbrooke.ca.'}, {'lastname': 'Ilangumaran', 'firstname': 'Subburaj', 'initials': 'S', 'affiliation': 'Department of Pediatrics, Immunology Division, Faculty of Medicine and Health Sciences, Université de Sherbrooke, Sherbrooke J1H 5N4, Québec, Canada. Electronic address: Subburaj.Ilangumaran@Usherbrooke.ca.'}]",,,,Copyright © 2016 Elsevier Ltd. All rights reserved.,10.1016/j.cyto.2016.06.011,<Element 'PubmedArticle' at 0x7f05dc834d10>
382,27268413,Melatonin promotes blood-brain barrier integrity in methamphetamine-induced inflammation in primary rat brain microvascular endothelial cells.,"Melatonin is a neurohormone and has high potent of antioxidant that is widely reported to be active against methamphetamine (METH)-induced toxicity to neuron, glial cells, and brain endothelial cells. However, the role of melatonin on the inflammatory responses which are mostly caused by blood-brain barrier (BBB) impairment by METH administration has not been investigated. This study used the primary rat brain microvascular endothelial cells (BMVECs) to determine the protective mechanism of melatonin on METH-induced inflammatory responses in the BBB via nuclear factor-ĸB (NF-κB) and nuclear factor erythroid 2-related factor-2 (Nrf2) signaling. Herein, we demonstrated that melatonin reduced the level of the inflammatory mediators, including intercellular adhesion molecules (ICAM)-1, vascular cell adhesion molecules (VCAM)-1, matrix metallopeptidase (MMP)-9, inducible nitric oxide synthase (iNOS), and nitric oxide (NO) caused by METH. These responses were related to the decrease of the expression and translocation of the NF-κB p65 subunit and the activity of NADPH oxidase (NOX)-2. In addition, melatonin promoted the antioxidant processes, modulated the expression and translocation of Nrf2, and also increased the level of heme oxygenase (HO)-1, NAD (P) H: quinone oxidoreductase (NQO)-1, γ-glutamylcysteine synthase (γ-GCLC), and the activity of superoxide dismutase (SOD) through NOX2 mechanism. In addition, we found that the protective role of melatonin in METH-induced inflammatory responses in the BBB was mediated through melatonin receptors (MT1/2). We concluded that the interaction of melatonin with its receptor prevented METH-induced inflammatory responses by suppressing the NF-κB signaling and promoting the Nrf2 signaling before BBB impairment.","['Blood–brain barrier', 'Melatonin', 'Methamphetamine', 'Nf-κb', 'Nrf2']",Brain research,2016-06-09,"[{'lastname': 'Jumnongprakhon', 'firstname': 'Pichaya', 'initials': 'P', 'affiliation': 'Department of Anatomy, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand.'}, {'lastname': 'Govitrapong', 'firstname': 'Piyarat', 'initials': 'P', 'affiliation': 'Research Center for Neuroscience, Institute of Molecular Biosciences, Mahidol University, Bangkok, Thailand; Center for Neuroscience and Department of Pharmacology, Faculty of Science, Mahidol University, Bangkok, Thailand.'}, {'lastname': 'Tocharus', 'firstname': 'Chainarong', 'initials': 'C', 'affiliation': 'Department of Anatomy, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand.'}, {'lastname': 'Tocharus', 'firstname': 'Jiraporn', 'initials': 'J', 'affiliation': 'Department of Physiology, Faculty of Medicine, Chiang Mai University, Chiang Mai 50200, Thailand. Electronic address: jtocharus@gmail.com.'}]",,,,Copyright © 2016 Elsevier B.V. All rights reserved.,10.1016/j.brainres.2016.05.049,<Element 'PubmedArticle' at 0x7f05dc8443b0>
383,27265346,Acute bacterial meningitis in adults.,"Over the past several decades, the incidence of bacterial meningitis in children has decreased but there remains a significant burden of disease in adults, with a mortality of up to 30%. Although the pathogenesis of bacterial meningitis is not completely understood, knowledge of bacterial invasion and entry into the CNS is improving. Clinical features alone cannot determine whether meningitis is present and analysis of cerebrospinal fluid is essential for diagnosis. Newer technologies, such as multiplex PCR, and novel diagnostic platforms that incorporate proteomics and genetic sequencing, might help provide a quicker and more accurate diagnosis. Even with appropriate antimicrobial therapy, mortality is high and so attention has focused on adjunctive therapies; adjunctive corticosteroids are beneficial in certain circumstances. Any further improvements in outcome are likely to come from either modulation of the host response or novel approaches to therapy, rather than new antibiotics. Ultimately, the best hope to reduce the disease burden is with broadly protective vaccines.",[],"Lancet (London, England)",2016-06-07,"[{'lastname': 'McGill', 'firstname': 'Fiona', 'initials': 'F', 'affiliation': 'Institute of Infection and Global Health, University of Liverpool, Liverpool, UK; NIHR Health Protection Research Unit in Emerging and Zoonotic Infections, Liverpool, UK; Leeds University Hospitals NHS Trust, Leeds, UK; Royal Liverpool and Broadgreen University Hospitals NHS Trust, Liverpool, UK.'}, {'lastname': 'Heyderman', 'firstname': 'Robert S', 'initials': 'RS', 'affiliation': 'Malawi-Liverpool-Wellcome Trust, Clinical Research Programme, University of Malawi College of Medicine, Blantyre, Malawi; Division of Infection and Immunity, University College London, London, UK.'}, {'lastname': 'Panagiotou', 'firstname': 'Stavros', 'initials': 'S', 'affiliation': 'Institute of Infection and Global Health, University of Liverpool, Liverpool, UK.'}, {'lastname': 'Tunkel', 'firstname': 'Allan R', 'initials': 'AR', 'affiliation': 'Warren Alpert Medical School, Brown University, Providence, RI, USA.'}, {'lastname': 'Solomon', 'firstname': 'Tom', 'initials': 'T', 'affiliation': 'Institute of Infection and Global Health, University of Liverpool, Liverpool, UK; The Walton Centre NHS Foundation Trust, Liverpool, UK; NIHR Health Protection Research Unit in Emerging and Zoonotic Infections, Liverpool, UK; Royal Liverpool and Broadgreen University Hospitals NHS Trust, Liverpool, UK. Electronic address: tsolomon@liv.ac.uk.'}]",,,,Copyright © 2016 Elsevier Ltd. All rights reserved.,10.1016/S0140-6736(16)30654-7,<Element 'PubmedArticle' at 0x7f05dc851e50>
384,27242078,Estrogen-induced neuroprotective and anti-inflammatory effects are dependent on the brain areas of middle-aged female rats.,"Reproductive aging in females is characterized by fluctuations and precipitous decline in estrogen levels, which may lead to reduction in cognitive function and age-associated neurodegenerative disorders. The nature of estrogen-mediated neuronal plasticity is unknown during reproductive aging. We hypothesize that estrogen treatment of early middle-aged ovariectomized rats may exert specific effects in the brain by modulating signaling pathways regulating metabolic enzymes, inflammatory markers, antioxidant status, cholinergic function and survival signals.
To investigate the mechanisms of estrogen-induced effects on neuroprotection and neuroinflammation through the involvement of intracellular signaling pathways in brain areas of ovariectomized (OVX) middle-aged (MA) female rats.
Ovariectomized early MA female Sprague-Dawley rats (n=8/group) were implanted with 17β-estradiol (E2) 30-day release pellets (0.6μg and 300μg). At the end of the treatment period, frontal cortex (FC), striatum (STR), medial basal hypothalamus (MBH), and hippocampus (HP) were isolated and examined for the expression of tyrosine hydroxylase (p-TH), nerve growth factor (NGF), p-NF-κB (p50 and p65)and p-ERK, p-CREB, p-Akt, and activities of cholinesterases and antioxidant enzymes, key regulatory enzymes of metabolic pathways, and nitric oxide production.
E2 enhanced p-TH expression in FC and HP, reduced NGF expression in HP, and suppressed p-NF-κB expression in FC and STR. It also increased the expression of molecular markers (p-ERK, p-CREB and p-Akt), and nitric oxide production in various brain areas, while differentially regulating the activities of metabolic enzymes and cholinesterases.
Estrogen modulates the neural and inflammatory factors, and intracellular markers depending on the brain areas that may influence differential remodeling of neuronal circuitry which can be used to develop therapeutic strategies in cognitive impairment and neurodegenerative disorders in aging.","['Akt', 'CREB', 'Cholinesterase', 'ERK', 'Nerve growth factor', 'Tyrosine hydroxylase']",Brain research bulletin,2016-06-01,"[{'lastname': 'Pratap', 'firstname': 'Uday P', 'initials': 'UP', 'affiliation': 'Integrative Medicine Laboratory, Department of Biotechnology, School of Bioengineering, SRM University, Kattankulathur 603203, Tamil Nadu, India.'}, {'lastname': 'Patil', 'firstname': 'Anushree', 'initials': 'A', 'affiliation': 'Integrative Medicine Laboratory, Department of Biotechnology, School of Bioengineering, SRM University, Kattankulathur 603203, Tamil Nadu, India.'}, {'lastname': 'Sharma', 'firstname': 'Himanshu R', 'initials': 'HR', 'affiliation': 'Integrative Medicine Laboratory, Department of Biotechnology, School of Bioengineering, SRM University, Kattankulathur 603203, Tamil Nadu, India.'}, {'lastname': 'Hima', 'firstname': 'Lalgi', 'initials': 'L', 'affiliation': 'Integrative Medicine Laboratory, Department of Biotechnology, School of Bioengineering, SRM University, Kattankulathur 603203, Tamil Nadu, India.'}, {'lastname': 'Chockalingam', 'firstname': 'Ramanathan', 'initials': 'R', 'affiliation': 'Integrative Medicine Laboratory, Department of Biotechnology, School of Bioengineering, SRM University, Kattankulathur 603203, Tamil Nadu, India.'}, {'lastname': 'Hariharan', 'firstname': 'Murali M', 'initials': 'MM', 'affiliation': 'Integrative Medicine Laboratory, Department of Biotechnology, School of Bioengineering, SRM University, Kattankulathur 603203, Tamil Nadu, India.'}, {'lastname': 'Shitoot', 'firstname': 'Sushrut', 'initials': 'S', 'affiliation': 'Integrative Medicine Laboratory, Department of Biotechnology, School of Bioengineering, SRM University, Kattankulathur 603203, Tamil Nadu, India.'}, {'lastname': 'Priyanka', 'firstname': 'Hannah P', 'initials': 'HP', 'affiliation': 'Integrative Medicine Laboratory, Department of Biotechnology, School of Bioengineering, SRM University, Kattankulathur 603203, Tamil Nadu, India.'}, {'lastname': 'ThyagaRajan', 'firstname': 'Srinivasan', 'initials': 'S', 'affiliation': 'Integrative Medicine Laboratory, Department of Biotechnology, School of Bioengineering, SRM University, Kattankulathur 603203, Tamil Nadu, India. Electronic address: thyagarajan.s@ktr.srmuniv.ac.in.'}]",,"Estrogen modulates the neural and inflammatory factors, and intracellular markers depending on the brain areas that may influence differential remodeling of neuronal circuitry which can be used to develop therapeutic strategies in cognitive impairment and neurodegenerative disorders in aging.","E2 enhanced p-TH expression in FC and HP, reduced NGF expression in HP, and suppressed p-NF-κB expression in FC and STR. It also increased the expression of molecular markers (p-ERK, p-CREB and p-Akt), and nitric oxide production in various brain areas, while differentially regulating the activities of metabolic enzymes and cholinesterases.",Copyright © 2016 Elsevier Inc. All rights reserved.,10.1016/j.brainresbull.2016.05.015,<Element 'PubmedArticle' at 0x7f05dc85b900>
385,27216917,Role of neuroinflammation and sex hormones in war-related PTSD.,"The susceptibility to develop posttraumatic stress disorder (PTSD) is greatly influenced by both innate and environmental risk factors. One of these factors is gender, with women showing higher incidence of trauma-related mental health disorders than their male counterparts. The evidence so far links these differences in susceptibility or resilience to trauma to the neuroprotective actions of sex hormones in reducing neuroinflammation after severe stress exposure. In this review, we discuss the impact of war-related trauma on the incidence of PTSD in civilian and military populations as well as differences associated to gender in the incidence and recovery from PTSD. In addition, the mutually influencing role of inflammation, genetic, and sex hormones in modulating the consequences derived from exposure to traumatic events are discussed in light of current evidence.","['Combat PTSD', 'Fear', 'Neuroinflammation', 'Sex hormones', 'Stress', 'Trauma']",Molecular and cellular endocrinology,2016-05-25,"[{'lastname': 'Mendoza', 'firstname': 'Cristhian', 'initials': 'C', 'affiliation': 'Neurobiology Laboratory, Facultad Ciencias de la Salud, Universidad San Sebastian, Lientur 1457, Concepción, 4080871, Chile.'}, {'lastname': 'Barreto', 'firstname': 'George E', 'initials': 'GE', 'affiliation': 'Departamento de Nutrición y Bioquímica, Facultad de Ciencias, Pontificia Universidad Javeriana, Bogotá D.C., Colombia; Center for Biomedical Research, Universidad Autónoma de Chile, Carlos Antúnez 1920, Providencia, Santiago, Chile.'}, {'lastname': 'Ávila-Rodriguez', 'firstname': 'Marco', 'initials': 'M', 'affiliation': 'Facultad de Ciencias de Salud, Universidad del Tolima, Ibagué, Colombia.'}, {'lastname': 'Echeverria', 'firstname': 'Valentina', 'initials': 'V', 'affiliation': 'Neurobiology Laboratory, Facultad Ciencias de la Salud, Universidad San Sebastian, Lientur 1457, Concepción, 4080871, Chile; Research and Development, Bay Pines VA Healthcare System, Bay Pines, FL, USA. Electronic address: echeverria.valentina@gmail.com.'}]",,,,Published by Elsevier Ireland Ltd.,10.1016/j.mce.2016.05.016,<Element 'PubmedArticle' at 0x7f05dc7ebe50>
386,"27215202
20581817
23830905
23239020
8471244
25206520
10202533
16988041
22343943
23041626
19401723
16862115
21611805
16411231
11606633
18662748
16115202
21609825
23609508
17203472
22187000
25184042
17764761
19721334
25689259
25110593
22192775
18178625
10858277
23458502
22915113
17978023
16903808
21540081
27308421
25579391
22766974
22500797
21934540
12853570
19656578
17938969
17179653
21742312
23407954
16862116
8891309
20965424
23201826
14615545
20962456
14660786
23650397
19309037
9501234
8294551
11260702",Progranulin Protects Hippocampal Neurogenesis via Suppression of Neuroinflammatory Responses Under Acute Immune Stress.,"Immune stress is well known to suppress adult neurogenesis in the hippocampus. We have demonstrated that progranulin (PGRN) has a mitogenic effect on neurogenesis under several experimental conditions. We have also shown that PGRN suppresses excessive neuroinflammatory responses after traumatic brain injury. However, the role of PGRN in modulating neurogenesis under acute immune stress is yet to be elucidated. In the present study, we evaluated the involvement of PGRN in neurogenesis and inflammatory responses in the hippocampus using a lipopolysaccharide (LPS)-induced immune stress model. Treatment of mice with LPS significantly increased the expression of PGRN in activated microglia and decreased neurogenesis in the dentate gyrus of the hippocampus. PGRN deficiency increased CD68-immunoreactive area and exacerbated suppression of neurogenesis following LPS treatment. The expression levels of lysosomal genes including lysozyme M, macrophage expressed gene 1, and cathepsin Z were higher in PGRN-deficient than in wild-type mice, while PGRN deficiency decreased mammalian target of rapamycin (mTOR) mRNA levels, suggesting that PGRN suppresses excessive lysosomal biogenesis by promoting mTOR signaling. LPS treatment also increased the expression of proinflammatory genes such as interleukin (IL)-1β, tumor necrosis factor-α, and microsomal prostaglandin E synthase-1 (mPGES-1) in the hippocampus, and PGRN deficiency further enhanced gene expression of IL-6 and mPGES-1. These results suggest that PGRN plays a protecting role in hippocampal neurogenesis at least partially by attenuating neuroinflammatory responses during LPS-induced acute immune stress.","['Immune stress', 'Microglia', 'Neurogenesis', 'Neuroinflammation', 'Progranulin']",Molecular neurobiology,2016-05-25,"[{'lastname': 'Ma', 'firstname': 'Yanbo', 'initials': 'Y', 'affiliation': 'Department of Veterinary Physiology, Graduate School of Agricultural and Life Sciences, The University of Tokyo, Tokyo, 113-8657, Japan.'}, {'lastname': 'Matsuwaki', 'firstname': 'Takashi', 'initials': 'T', 'affiliation': 'Department of Veterinary Physiology, Graduate School of Agricultural and Life Sciences, The University of Tokyo, Tokyo, 113-8657, Japan.'}, {'lastname': 'Yamanouchi', 'firstname': 'Keitaro', 'initials': 'K', 'affiliation': 'Department of Veterinary Physiology, Graduate School of Agricultural and Life Sciences, The University of Tokyo, Tokyo, 113-8657, Japan.'}, {'lastname': 'Nishihara', 'firstname': 'Masugi', 'initials': 'M', 'affiliation': 'Department of Veterinary Physiology, Graduate School of Agricultural and Life Sciences, The University of Tokyo, Tokyo, 113-8657, Japan. amnishi@mail.ecc.u-tokyo.ac.jp.'}]",,,,,10.1007/s12035-016-9939-6,<Element 'PubmedArticle' at 0x7f05dc7f7130>
387,27212623,Interfering with the CCL2-glycosaminoglycan axis as a potential approach to modulate neuroinflammation.,"Multiple Sclerosis, a chronic inflammatory demyelinating disease of the central nervous system, involves an increased expression of monocyte chemotactic protein 1 MCP1-/CCL2. For exerting its chemotactic effects, chemokine binding to glycosaminoglycans (GAGs) is required and therefore this interaction represents a potential target for therapeutic intervention. We have designed an anti-inflammatory decoy variant, Met-CCL2 (Y13A S21K Q23R), embodying increased affinity for GAGs as well as knocked-out GPCR activation properties. This non-signalling dominant-negative mutant is shown here to be able to displace wild type CCL2 from GAGs by which it is supposed to interfere with the chemokine-related inflammatory response. In vivo, the anti-inflammatory properties were successfully demonstrated in a murine model of zymosan-induced peritonitis as well as in an experimental autoimmune encephalomyelitis, a model relevant for multiple sclerosis, where the compound lead to significantly reduced clinical scores due to reduction of cellular infiltrates and demyelination in spinal cord and cerebellum. These findings indicate a promising potential for future therapeutic development.","['Anti-inflammatory', 'CCL2 decoy', 'Experimental autoimmune encephalomyelitis', 'Glycosaminoglycans', 'Multiple sclerosis']",Neuroscience letters,2016-05-24,"[{'lastname': 'Gschwandtner', 'firstname': 'Martha', 'initials': 'M', 'affiliation': 'Institute of Pharmaceutical Sciences, University of Graz, Schubertstraße 1/1, A- 8010 Graz, Austria.'}, {'lastname': 'Piccinini', 'firstname': 'Anna Maria', 'initials': 'AM', 'affiliation': 'ProtAffin Biotechnologie AG, A- 8020 Graz, Austria.'}, {'lastname': 'Gerlza', 'firstname': 'Tanja', 'initials': 'T', 'affiliation': 'ProtAffin Biotechnologie AG, A- 8020 Graz, Austria.'}, {'lastname': 'Adage', 'firstname': 'Tiziana', 'initials': 'T', 'affiliation': 'ProtAffin Biotechnologie AG, A- 8020 Graz, Austria.'}, {'lastname': 'Kungl', 'firstname': 'Andreas J', 'initials': 'AJ', 'affiliation': 'Institute of Pharmaceutical Sciences, University of Graz, Schubertstraße 1/1, A- 8010 Graz, Austria; ProtAffin Biotechnologie AG, A- 8020 Graz, Austria. Electronic address: andreas.kungl@uni-graz.at.'}]",,,,Copyright © 2016 Elsevier Ireland Ltd. All rights reserved.,10.1016/j.neulet.2016.05.037,<Element 'PubmedArticle' at 0x7f05dc810630>
388,"27209303
19577560
7667254
26018497
12832847
12066192
11035255
26886752
11579422
19548866
9130276
20536337
18477398
18775776
18503736
12160890
16312042
2864480
9231715
25064341
23468867
25037773
24552786
18564616
6727660
5749362
9766878
12324201
24300695
10408610
11720089
24947870
19526038
11489339
16697651
16698011
11704644
4399399
15337655
19172438
20723799
18415683
10557342
12883039
7763297
6650142
23967153
6606682
14292762
16298740
22547510
22698992
4623845
19172664
19747935
25492727
21421044
18160224
25274809
21763406
22197082
17150277
9932714
9495562
9483511
17609521
18506671
25446914
21703296
22821418
19387830
26471226
3693430
20433854
26057360
10706193
19716383
760819
25559957
21699081
10976232
17318212
24692838
26638996
17227439
11044350",Naringin and Sertraline Ameliorate Doxorubicin-Induced Behavioral Deficits Through Modulation of Serotonin Level and Mitochondrial Complexes Protection Pathway in Rat Hippocampus.,"The present study was designed to investigate the neuroprotective effect of naringin (NR) alone as well as its combination with sertraline (SRT) against doxorubicin (DOX)-induced neurobehavioral and neurochemical anomalies. DOX (15 mg/kg; i.p.) administration caused behavioral alterations, oxidative stress, neuroinflammation, mitochondrial dysfunction and monoamines alteration in male Wistar rats. NR (50 and 100 mg/kg; i.p.) and SRT (5 mg/kg; i.p.) treatment significantly attenuated DOX-induced anxiety and depressive-like behavior as evident from elevated plus maze (EPM) and modified forced swimming test (mFST), respectively. NR treatment significantly attenuated DOX-induced raised plasma corticosterone (CORT), tumor necrosis factor-alpha (TNF-α) and interleukin-1 beta (IL-1β) levels in the hippocampus (HC). Furthermore, we found that combination of NR and SRT regimen ameliorated DOX-induced behavioral anomalies through modulation of the 5-HT level and mitochondrial complexes protection pathway along with alleviation of oxidative stress in the HC region. Therefore, NR treatment alone or in combination with SRT could be beneficial against DOX-induced neurotoxicity.","['Doxorubicin', 'Mitochondrial complexes', 'Monoamines', 'Naringin', 'Oxidative stress', 'Sertraline']",Neurochemical research,2016-05-23,"[{'lastname': 'Kwatra', 'firstname': 'Mohit', 'initials': 'M', 'affiliation': 'Neurobehavioral Pharmacology Laboratory, Department of Pharmacology, Faculty of Pharmacy, Jamia Hamdard (Hamdard University), New Delhi, 110062, India. mohitpharmacology@gmail.com.\nDepartment of Pharmacology and Toxicology, National Institute of Pharmaceutical Education and Research Guwahati, Guwahati, Assam, 781032, India. mohitpharmacology@gmail.com.'}, {'lastname': 'Jangra', 'firstname': 'Ashok', 'initials': 'A', 'affiliation': 'Department of Pharmacology and Toxicology, National Institute of Pharmaceutical Education and Research Guwahati, Guwahati, Assam, 781032, India.'}, {'lastname': 'Mishra', 'firstname': 'Murli', 'initials': 'M', 'affiliation': 'Department of Toxicology and Cancer Biology, College of Medicine, University of Kentucky, Lexington, KY, 40536, USA.'}, {'lastname': 'Sharma', 'firstname': 'Yogita', 'initials': 'Y', 'affiliation': 'Department of Pharmacology and Toxicology, National Institute of Pharmaceutical Education and Research Guwahati, Guwahati, Assam, 781032, India.'}, {'lastname': 'Ahmed', 'firstname': 'Sahabuddin', 'initials': 'S', 'affiliation': 'Department of Pharmacology and Toxicology, National Institute of Pharmaceutical Education and Research Guwahati, Guwahati, Assam, 781032, India.'}, {'lastname': 'Ghosh', 'firstname': 'Pinaki', 'initials': 'P', 'affiliation': 'Department of Pharmacology, Poona College of Pharmacy, Bharati Vidyapeeth Deemed University, Erandwane, Pune, Maharashtra, 411038, India.'}, {'lastname': 'Kumar', 'firstname': 'Vikas', 'initials': 'V', 'affiliation': 'Neurobehavioral Pharmacology Laboratory, Department of Pharmacology, Faculty of Pharmacy, Jamia Hamdard (Hamdard University), New Delhi, 110062, India.'}, {'lastname': 'Vohora', 'firstname': 'Divya', 'initials': 'D', 'affiliation': 'Neurobehavioral Pharmacology Laboratory, Department of Pharmacology, Faculty of Pharmacy, Jamia Hamdard (Hamdard University), New Delhi, 110062, India.'}, {'lastname': 'Khanam', 'firstname': 'Razia', 'initials': 'R', 'affiliation': 'Neurobehavioral Pharmacology Laboratory, Department of Pharmacology, Faculty of Pharmacy, Jamia Hamdard (Hamdard University), New Delhi, 110062, India.\nDepartment of Pharmacology, Gulf Medical University, Ajman, United Arab Emirates.'}]",,,,,10.1007/s11064-016-1949-2,<Element 'PubmedArticle' at 0x7f05ddfef5e0>
389,27033055,Glucagon-Like Peptide-1-Mediated Modulation of Inflammatory Pathways in the Diabetic Brain: Relevance to Alzheimer's Disease.,"Neuroinflammation has emerged as an important cause of cognitive decline during aging and in Alzheimer's disease (AD). Chronic low-grade inflammation is observed in obesity and diabetes, which are important risk factors for AD. Therefore, we examined the markers of inflammation in the brain hippocampal samples of Zucker diabetic fatty (ZDF) rats. Pathway-specific gene expression profiling revealed significant increases in the expression of oxidative stress and inflammatory genes. Western blot analysis further showed the activation of NF-kB, defective CREB phosphorylation, and decreases in the levels of neuroprotective CREB target proteins, including Bcl-2, BDNF, and BIRC3 in the diabetic rat brain samples, all of which are related to AD pathology. As therapies based on glucagon-like peptide-1 (GLP-1) are effective in controlling blood glucose levels in type 2 diabetic patients, we tested the in vivo actions of GLP-1 in the diabetic brain by a 10-wk treatment of ZDF rats with alogliptin, an inhibitor of dipeptidyl peptidase. Alogliptin increased the circulating levels of GLP-1 by 125% and decreased blood glucose in diabetic rats by 59%. Normalization of defective signaling to CREB in the hippocampal samples of treated diabetic rats resulted in the increased expression of CREB targets. Dual actions of GLP-1 in the pancreatic beta cells and in the brain suggest that incretin therapies may reduce cognitive decline in the aging diabetic patients and also have the potential to be used in treating Alzheimer's patients.",[],Current Alzheimer research,2016-04-02,"[{'lastname': 'Qin', 'firstname': 'LiMei', 'initials': 'L', 'affiliation': None}, {'lastname': 'Chong', 'firstname': 'Thomas', 'initials': 'T', 'affiliation': None}, {'lastname': 'Rodriguez', 'firstname': 'Richard', 'initials': 'R', 'affiliation': None}, {'lastname': 'Pugazhenthi', 'firstname': 'Subbiah', 'initials': 'S', 'affiliation': 'Department of Medicine, University of Colorado School of Medicine, Anschutz Medical Campus, Mail Stop 8106, 12801 E 17th Ave, Aurora, CO 80045, USA. subbiah.pugazhenthi@ucdenver.edu.'}]",,,,,10.2174/1567205013666160401114751,<Element 'PubmedArticle' at 0x7f05dc7bc540>
390,"27030717
20948531
20650402
19712899
11476884
25582579
18786633
20581331
10714678
17291188
20117131
24948120
18083844
21722132
18177992
9634237
22694179
17292584
11438578
24735601
21332278
19674450
20127490
26168219
24263070
25119456
25393328
26353174
2837713
15494189
20675053
25994587
12935942
22820168
13502156
16215299
18471878
16011832
20180838
20880510
16325578
24024042
21893056
18480275
11426226
15597059
15836971
19285061
19837031
11698029
25588373
24593954
22049432",Crosstalk between astrocytic CXCL12 and microglial CXCR4 contributes to the development of neuropathic pain.,"Chemokine axis chemokine C-X-C motif ligand 12/C-X-C chemokine receptor type 4 (CXCL12/CXCR4) is an emerging pain modulator, but mechanisms for its involvement in neuropathic pain remain unclear. Here, we aimed to study whether CXCL12/CXCR4 axis modulated the development of neuropathic pain via glial mechanisms. In this study, two mouse models of neuropathic pain, namely partial sciatic nerve ligation (pSNL) model and chronic post-ischemia pain (CPIP) model, were used.
In the dorsal horn of L3-L5 segment of spinal cord, CXCL12 and CXCR4 were expressed in both astrocyte and microglia in normal mice. In the pSNL or CPIP model, the expression level of CXCL12 in the ipsilateral L3-L5 segment of mice spinal cord was increased in an astrocyte-dependent manner on post-operative day (POD) 3. Intrathecal administration of CXCL12 with AMD3100 (CXCR4 antagonist) or minocycline (microglia activation inhibitor), but not fluorocitrate (astrocyte activation inhibitor), reversed CXCL12-indued mechanical allodynia in naïve mice. In these models, AMD3100 and AMD3465 (CXCR4 antagonist), administered daily from 1 h before surgery and up to POD 3, attenuated the development of mechanical allodynia. Moreover, AMD3100 administered daily from 1 h before surgery and up to POD 3 downregulated mRNA levels of tumor necrosis factor alpha, interleukin 1β, and interleukin 6 in the ipsilateral L3-L5 segment of spinal cord in the pSNL and CPIP models on POD 3.
This study demonstrates the crosstalk between astrocytic CXCL12 and microglial CXCR4 in the pathogenesis of neuropathic pain using pSNL and CPIP models. Our results offer insights for the future research on CXCL12/CXCR4 axis and neuropathic pain therapy.","['CXCL12/CXCR4 axis', 'glial–glial crosstalk', 'neuroinflammation', 'neuropathic pain']",Molecular pain,2016-04-01,"[{'lastname': 'Luo', 'firstname': 'Xin', 'initials': 'X', 'affiliation': 'Department of Anaesthesiology, The University of Hong Kong, HKSAR, China Laboratory and Clinical Research Institute for Pain, The University of Hong Kong, HKSAR, China.'}, {'lastname': 'Tai', 'firstname': 'Wai L', 'initials': 'WL', 'affiliation': 'Department of Anaesthesiology, The University of Hong Kong, HKSAR, China Laboratory and Clinical Research Institute for Pain, The University of Hong Kong, HKSAR, China.'}, {'lastname': 'Sun', 'firstname': 'Liting', 'initials': 'L', 'affiliation': 'Department of Anaesthesiology, The University of Hong Kong, HKSAR, China Laboratory and Clinical Research Institute for Pain, The University of Hong Kong, HKSAR, China.'}, {'lastname': 'Pan', 'firstname': 'Zhiqiang', 'initials': 'Z', 'affiliation': 'Department of Anesthesiology, Xuzhou Medical University, Jiangsu Province, China.'}, {'lastname': 'Xia', 'firstname': 'Zhengyuan', 'initials': 'Z', 'affiliation': 'Department of Anaesthesiology, The University of Hong Kong, HKSAR, China Research Center of Heart, Brain, Hormone and Healthy Aging, The University of Hong Kong, HKSAR, China.'}, {'lastname': 'Chung', 'firstname': 'Sookja K', 'initials': 'SK', 'affiliation': 'Laboratory and Clinical Research Institute for Pain, The University of Hong Kong, HKSAR, China Research Center of Heart, Brain, Hormone and Healthy Aging, The University of Hong Kong, HKSAR, China Department of Anatomy, The University of Hong Kong, HKSAR, China.'}, {'lastname': 'Cheung', 'firstname': 'Chi Wai', 'initials': 'CW', 'affiliation': 'Department of Anaesthesiology, The University of Hong Kong, HKSAR, China Research Center of Heart, Brain, Hormone and Healthy Aging, The University of Hong Kong, HKSAR, China Department of Anatomy, The University of Hong Kong, HKSAR, China cheucw@hku.hk.'}]",,This study demonstrates the crosstalk between astrocytic CXCL12 and microglial CXCR4 in the pathogenesis of neuropathic pain using pSNL and CPIP models. Our results offer insights for the future research on CXCL12/CXCR4 axis and neuropathic pain therapy.,"In the dorsal horn of L3-L5 segment of spinal cord, CXCL12 and CXCR4 were expressed in both astrocyte and microglia in normal mice. In the pSNL or CPIP model, the expression level of CXCL12 in the ipsilateral L3-L5 segment of mice spinal cord was increased in an astrocyte-dependent manner on post-operative day (POD) 3. Intrathecal administration of CXCL12 with AMD3100 (CXCR4 antagonist) or minocycline (microglia activation inhibitor), but not fluorocitrate (astrocyte activation inhibitor), reversed CXCL12-indued mechanical allodynia in naïve mice. In these models, AMD3100 and AMD3465 (CXCR4 antagonist), administered daily from 1 h before surgery and up to POD 3, attenuated the development of mechanical allodynia. Moreover, AMD3100 administered daily from 1 h before surgery and up to POD 3 downregulated mRNA levels of tumor necrosis factor alpha, interleukin 1β, and interleukin 6 in the ipsilateral L3-L5 segment of spinal cord in the pSNL and CPIP models on POD 3.",© The Author(s) 2016.,10.1177/1744806916636385,<Element 'PubmedArticle' at 0x7f05dc7cc0e0>
391,26972291,Stroke and Neuroinflamation: Role of Sexual Hormones.,"Inflammatory response in the nervous system, called neuroinflammation, is a common process of several neurodegenerative diseases and brain disorders. To understand the underlying mechanism of this brain response to damage would be interesting to identify new common therapy targets to neurodegenerative processes. Ischemic stroke has an important socioeconomic impact being the second cause of mortality and the first cause of long-term disability in the world. Until now, there is not any pharmacological treatment to reduce the brain damage induced. In this review, we will expose recent evidences about neuroinflammation after stroke in animal models and in human. We summarize the most relevant information about the inflammatory-cellular component: microglia/ astrocytes response and peripheral blood cells infiltration to the brain describing the key adhesion molecules implicated in this process. Also, we review the inflammatory-molecular response including the beneficial/detrimental role of chemokines and cytokines after ischemia. Currently, female sexual hormones (estradiol and progesterone) are considered as neuroprotective agents. We and others laboratories demonstrated anti-inflammatory actions of these hormones after stroke, modulating not only the cellular response (reducing the reactive gliosis), but also the immune response. Here, we will present the current data about the neuroprotective role of estradiol and progesterone after ischemic injury focused in their anti-inflammatory action. Additionally, we will review the recent information about the mechanism of action of both hormones, including different receptors and signaling pathways. Finally, we will discuss the synergistic or antagonic therapeutic effects when they are administered together.",[],Current pharmaceutical design,2016-03-15,"[{'lastname': 'Perez-Alvarez', 'firstname': 'Maria Jose', 'initials': 'MJ', 'affiliation': None}, {'lastname': 'Wandosell', 'firstname': 'Francisco', 'initials': 'F', 'affiliation': 'Centro de Biologia Molecular ""Severo Ochoa"", (CSIC-UAM & CIBERNED), Universidad Autonoma Madrid, C/ Nicolas Cabrera 1, 28049 Madrid, Spain. fwandosell@cbm.csic.es.'}]",,,,,10.2174/138161282210160304112834,<Element 'PubmedArticle' at 0x7f05dc76c630>
392,"26963472
17775725
6163211
6396714
25168757
25110187
16918306
20478440
14623515
19401955
25222364
20144613
21623961
19401952
21622487
21535249
11351342
10077336
11264718
15211466
21767382
23795693
15818556
15271060
17955551
20878945
25187205
25017891
22024597
24025052
23459929
20479749
11510884
21508345
22187483
24901329
12462413
25017893
25165433
11844745
2052592
21911834
20685874
15459880
15967447
22789464
22414444
9637400
19797123
17561817
10221674
8313156
19395682
21909323
18820691
20925573
8207243
15156148
22512254
16997132
21564348
24607811",Centrally Synthesized Estradiol Is a Potent Anti-Inflammatory in the Injured Zebra Finch Brain.,"In homeotherms, injury to the brain, such as a penetrating wound, increases microglial cytokine expression and astroglial aromatase (estrogen synthase). In songbirds, injury-induced synthesis of estrogens is neuroprotective as aromatase inhibition and replacement with estradiol (E2) exacerbates and mitigates the extent of damage, respectively. The influence of induced aromatization on inflammation, however, remains unstudied. We hypothesized that injury-induced aromatization, via E2 synthesis, may affect neuroinflammation after a penetrating brain injury. Using adult zebra finches, we first documented an increase in the transcription of cytokines but not aromatase, 2 hours after the injury. Twenty-four hours after the injury, however, aromatase was dramatically elevated and cytokine expression had returned to baseline, suggesting that aromatization may be involved in the decrease of cytokines and neuroinflammation. In two subsequent experiments, we tested the influence of the inhibition of induced aromatization and aromatase inhibition with concomitant central E2 replacement on the transcription of the cytokines TNF-α, IL-1β, and IL-6, the enzyme cyclooxygenase-2 (cox-2), and its product prostaglandin E2 (PGE2). Administration of fadrozole, an aromatase inhibitor, caused a sustained elevation of IL-1β in females and TNF-α, cox-2, and PGE2 in both sexes. This prolonged neuroinflammation appears to be due to a failure to synthesize E2 locally because intracranial E2 replacement lowered IL-1β in females, TNF-α in males, and cox-2 and PGE2 in both sexes. IL-6 was not affected by injury, aromatase inhibition, or E2 replacement in either sex. These data suggest that E2 synthesis after a penetrating brain injury is a potent and inducible anti-inflammatory signal, with specific modulation of discrete cytokine signaling.",[],Endocrinology,2016-03-11,"[{'lastname': 'Pedersen', 'firstname': 'Alyssa L', 'initials': 'AL', 'affiliation': 'Department of Biology, Behavior, Cognition, and Neuroscience Program and The Center for Behavioral Neuroscience, American University, Washington, DC 20016.'}, {'lastname': 'Nelson', 'firstname': 'Lars H', 'initials': 'LH', 'affiliation': 'Department of Biology, Behavior, Cognition, and Neuroscience Program and The Center for Behavioral Neuroscience, American University, Washington, DC 20016.'}, {'lastname': 'Saldanha', 'firstname': 'Colin J', 'initials': 'CJ', 'affiliation': 'Department of Biology, Behavior, Cognition, and Neuroscience Program and The Center for Behavioral Neuroscience, American University, Washington, DC 20016.'}]",,,,,10.1210/en.2015-1991,<Element 'PubmedArticle' at 0x7f05dc775180>
393,26928197,NLRP3 inflammasome activation mediates estrogen deficiency-induced depression- and anxiety-like behavior and hippocampal inflammation in mice.,"Decline of estrogen level is associated with an increase in mood disturbances such as depression and anxiety. Our previous study showed that increased levels of inflammatory cytokines in hippocampus contribute to estrogen deficiency-induced depression-like behavior in rodents. Since the nucleotide binding and oligomerization domain-like receptor family pyrin domain-containing 3 (NLRP3) inflammasome plays a critical role in various inflammatory diseases, we explored whether NLRP3 inflammasome is involved in affective disorders caused by estrogen deficiency. It was found that ovariectomy increased the levels of IL-1β and IL-18, NLRP3 expression and active caspase-1 in hippocampus of female mice. Ovariectomy also resulted in an increase in the level of TLR-2 and TLR-4, active NF-κB, pro-IL-1β and pro-IL-18. Treatment of ovariectomized (OVX) mice with inflammasome inhibitor VX-765 ameliorated depression- and anxiety-like behavior and reversed increased levels of IL-1β and IL-18 in hippocampus. Ovariectomy-induced depression- and anxiety-like behavior and increased inflammatory indicators were reversed by administration of 17β-estradiol (E2) and estrogen receptor (ER)β agonist but not ERα agonist. In addition, ovariectomy led to increased expression of P2X7 receptor (P2X7R), which was also reversed by E2 and ERβ agonist. Our study suggests that estrogen deficiency results in NLRP3 inflammasome activation, thereby leading to neuroinflammation in hippocampus and depression and anxiety. Estrogen modulation of inflammation in hippocampus and depression- and anxiety-like behavior is ERβ dependent. NLRP3 inflammasome could be the potential therapeutic target for estrogen deficiency-related affective disorders.","['Anxiety', 'Depression', 'Estrogen', 'Hippocampus', 'Inflammation', 'NLRP3 inflammasome']","Brain, behavior, and immunity",2016-03-02,"[{'lastname': 'Xu', 'firstname': 'Yongjun', 'initials': 'Y', 'affiliation': 'Department of Physiology, Second Military Medical University, Shanghai 200433, China.'}, {'lastname': 'Sheng', 'firstname': 'Hui', 'initials': 'H', 'affiliation': 'Department of Physiology, Second Military Medical University, Shanghai 200433, China.'}, {'lastname': 'Bao', 'firstname': 'Qingyue', 'initials': 'Q', 'affiliation': 'Department of Physiology, Second Military Medical University, Shanghai 200433, China.'}, {'lastname': 'Wang', 'firstname': 'Yujun', 'initials': 'Y', 'affiliation': 'School of Kinesiology, The Key Laboratory of Exercise and Health Sciences of Ministry of Education, Shanghai University of Sport, Shanghai 200438, China.'}, {'lastname': 'Lu', 'firstname': 'Jianqiang', 'initials': 'J', 'affiliation': 'School of Kinesiology, The Key Laboratory of Exercise and Health Sciences of Ministry of Education, Shanghai University of Sport, Shanghai 200438, China.'}, {'lastname': 'Ni', 'firstname': 'Xin', 'initials': 'X', 'affiliation': 'Department of Physiology, Second Military Medical University, Shanghai 200433, China. Electronic address: nixin@smmu.edu.cn.'}]",,,,Copyright © 2016 Elsevier Inc. All rights reserved.,10.1016/j.bbi.2016.02.022,<Element 'PubmedArticle' at 0x7f05dc798ef0>
394,"26928013
25984581
23932184
23422663
12051555
15513908
19716187
22332151
20681434
14573722
19395695
20019914
24148924
14732621
17317458
24599114
17029828
18537667
22778499
22832605
18812633
24571856
22021672
23122958
22813736
18534982
17767011
23332364
18349428
25462318
21168897
25791864
16957004
15944180
22015313
25036434
15527881
18458226
21104383
21256197
21501147
20107219",NO2 inhalation promotes Alzheimer's disease-like progression: cyclooxygenase-2-derived prostaglandin E2 modulation and monoacylglycerol lipase inhibition-targeted medication.,"Air pollution has been reported to be associated with increased risks of cognitive impairment and neurodegenerative diseases. Because NO2 is a typical primary air pollutant and an important contributor to secondary aerosols, NO2-induced neuronal functional abnormalities have attracted greater attention, but the available experimental evidence, modulating mechanisms, and targeting medications remain ambiguous. In this study, we exposed C57BL/6J and APP/PS1 mice to dynamic NO2 inhalation and found for the first time that NO2 inhalation caused deterioration of spatial learning and memory, aggravated amyloid β42 (Aβ42) accumulation, and promoted pathological abnormalities and cognitive defects related to Alzheimer's disease (AD). The microarray and bioinformation data showed that the cyclooxygenase-2 (COX-2)-mediated arachidonic acid (AA) metabolism of prostaglandin E2 (PGE2) played a key role in modulating this aggravation. Furthermore, increasing endocannabinoid 2-arachidonoylglycerol (2-AG) by inhibiting monoacylglycerol lipase (MAGL) prevented PGE2 production, neuroinflammation-associated Aβ42 accumulation, and neurodegeneration, indicating a therapeutic target for relieving cognitive impairment caused by NO2 exposure.",[],Scientific reports,2016-03-02,"[{'lastname': 'Yan', 'firstname': 'Wei', 'initials': 'W', 'affiliation': 'College of Environment and Resources, Research Center of Environment and Health, Shanxi University, Taiyuan, Shanxi 030006, PR China.'}, {'lastname': 'Yun', 'firstname': 'Yang', 'initials': 'Y', 'affiliation': 'College of Environment and Resources, Research Center of Environment and Health, Shanxi University, Taiyuan, Shanxi 030006, PR China.'}, {'lastname': 'Ku', 'firstname': 'Tingting', 'initials': 'T', 'affiliation': 'College of Environment and Resources, Research Center of Environment and Health, Shanxi University, Taiyuan, Shanxi 030006, PR China.'}, {'lastname': 'Li', 'firstname': 'Guangke', 'initials': 'G', 'affiliation': 'College of Environment and Resources, Research Center of Environment and Health, Shanxi University, Taiyuan, Shanxi 030006, PR China.'}, {'lastname': 'Sang', 'firstname': 'Nan', 'initials': 'N', 'affiliation': 'College of Environment and Resources, Research Center of Environment and Health, Shanxi University, Taiyuan, Shanxi 030006, PR China.'}]",,,,,10.1038/srep22429,<Element 'PubmedArticle' at 0x7f05dc727e00>
395,"26869995
25487257
24570244
21219177
8866547
7584987
11743140
11771681
12679442
19932865
20100379
12183482
12562868
17911005
9603719
15840860
17167471
19526743
22889634
26689763
19773713
21427699
24440038
8680439
20579529
6351077
9293156
9809193
12543259
17569758
19127293
20096034
23382817
1932370
19849845
19840546
22221653
24744759
1958562
10969176
11932204
15265777
23953592
23384835
1659887
10666132
3259257
2783450
1900940
1504369
10092810
12843254
16723527
20943909
4035356
12562515
25228100
16597735
14641004
19769617
22207707
21745355
25224590
11932280
18003947
11389183
22596080
22209870
22498877
16469811
11063824
11245665
17621558
15256495
26342753
8313156
19797123
15389604
16564034
19948157
25135305
19533603
21555578
22554613
23190172
22878846
21851230
24508637
12369809
12885581
25510908
15798185
21774811
20124437
23454542
26143538
24791714
9435533
20212497
12221198
20573720
25721737
16271821
3527687
2170594
9526844
12920152
4287854
17116226
12088740
12770552
18560126
12566944
15123342
16293343
24686304
14698750
24662056
24667364
20413889
22634281
23999121
11454984
24847262
9427435
2294222
1666318
3024478
3104646
2543203
8625075
10617994
11448594
9024261
21745038
22079780
25886196
26081124
8055855
2200312
18162444
6368214
11795526
12087131
15717011
23565247
8532119
3035995
7545529
7874583
10759363
11524440
1890278
17054664
20368473
3011836
468975
12023257
25238021
909626
9473772
3396527
12527850
12446991
23244540
24570826
24268369
14763916
7665373
6386779
8964797
7845058
10467254
2362589
11085908
24886300
21525175
24440143
11481408
20097433
13993953
5061300
8420637
12325034
12807724
1423856
8625440
15746164
10858586
17563030
10381209
12928047
18203962
9894871
20186857
24805069
7777138
8780008
10691302
1494214
9730874
12060495
15284365
19700036
12392776
20921964",The Role of Steroid Hormones in the Modulation of Neuroinflammation by Dietary Interventions.,"Steroid hormones, such as sex hormones and glucocorticoids, have been demonstrated to play a role in different cellular processes in the central nervous system, ranging from neurodevelopment to neurodegeneration. Environmental factors, such as calorie intake or fasting frequency, may also impact on such processes, indicating the importance of external factors in the development and preservation of a healthy brain. The hypothalamic-pituitary-adrenal axis and glucocorticoid activity play a role in neurodegenerative processes, including in disorders such as in Alzheimer's and Parkinson's diseases. Sex hormones have also been shown to modulate cognitive functioning. Inflammation is a common feature in neurodegenerative disorders, and sex hormones/glucocorticoids can act to regulate inflammatory processes. Intermittent fasting can protect the brain against cognitive decline that is induced by an inflammatory stimulus. On the other hand, obesity increases susceptibility to inflammation, while metabolic syndromes, such as diabetes, are associated with neurodegeneration. Consequently, given that gonadal and/or adrenal steroids may significantly impact the pathophysiology of neurodegeneration, via their effect on inflammatory processes, this review focuses on how environmental factors, such as calorie intake and intermittent fasting, acting through their modulation of steroid hormones, impact on inflammation that contributes to cognitive and neurodegenerative processes.","['dietary energy restriction', 'glucocorticoids', 'high-fat diet', 'neuroinflammation', 'sex hormones']",Frontiers in endocrinology,2016-02-13,"[{'lastname': 'Vasconcelos', 'firstname': 'Andrea Rodrigues', 'initials': 'AR', 'affiliation': 'Laboratory of Molecular Neuropharmacology, Department of Pharmacology, Institute of Biomedical Science, University of São Paulo, São Paulo, Brazil; Laboratory of Molecular and Functional Neurobiology, Department of Pharmacology, Institute of Biomedical Science, University of São Paulo, São Paulo, Brazil.'}, {'lastname': 'Cabral-Costa', 'firstname': 'João Victor', 'initials': 'JV', 'affiliation': 'Laboratory of Molecular and Functional Neurobiology, Department of Pharmacology, Institute of Biomedical Science, University of São Paulo , São Paulo , Brazil.'}, {'lastname': 'Mazucanti', 'firstname': 'Caio Henrique', 'initials': 'CH', 'affiliation': 'Laboratory of Molecular Neuropharmacology, Department of Pharmacology, Institute of Biomedical Science, University of São Paulo , São Paulo , Brazil.'}, {'lastname': 'Scavone', 'firstname': 'Cristoforo', 'initials': 'C', 'affiliation': 'Laboratory of Molecular Neuropharmacology, Department of Pharmacology, Institute of Biomedical Science, University of São Paulo , São Paulo , Brazil.'}, {'lastname': 'Kawamoto', 'firstname': 'Elisa Mitiko', 'initials': 'EM', 'affiliation': 'Laboratory of Molecular and Functional Neurobiology, Department of Pharmacology, Institute of Biomedical Science, University of São Paulo , São Paulo , Brazil.'}]",,,,,"10.3389/fendo.2016.00009
10.1016/j.bpobgyn.2014.10.002
10.1001/jama.2014.732
10.1146/annurev-immunol-031210-101322
10.2337/diab.45.11.1455
10.1038/nm1195-1155
10.1080/07315724.2001.10719162
10.1210/jc.2002-021262
10.1016/j.nutres.2009.10.013
10.1017/S000711450999359X
10.1152/japplphysiol.00224.2002
10.1194/jlr.M200318-JLR200
10.1016/j.jnutbio.2007.08.001
10.1126/science.280.5368.1371
10.1001/jama.293.15.1861
10.1038/nature05482
10.1016/j.jand.2012.03.034
10.1080/13607863.2015.1124837
10.1038/ijo.2011.65
10.1016/j.cmet.2013.12.008
10.1111/j.1365-2826.1993.tb00537.x
10.1016/j.nutres.2010.05.001
10.1079/PNS19830021
10.1016/S0167-5699(97)01111-0
10.1111/j.1440-1681.1998.tb02301.x
10.1016/S0531-5565(02)00146-8
10.1210/en.2007-0161
10.1371/journal.pone.0004146
10.1111/j.1474-9726.2010.00553.x
10.1371/journal.pone.0052416
10.1186/1742-2094-6-30
10.1016/j.neuron.2009.09.032
10.1016/j.maturitas.2011.12.007
10.3389/fimmu.2014.00136
10.1016/0960-0760(91)90285-D
10.1016/S0165-5728(00)00297-6
10.1677/jme.0.0280069
10.1196/annals.1321.009
10.1016/j.tips.2013.07.003
10.1210/en.2012-2045
10.1016/0960-0760(91)90284-C
10.1084/jem.167.5.1708
10.1084/jem.169.2.431
10.1073/pnas.88.6.2274
10.1016/0889-1591(92)90015-G
10.1523/JNEUROSCI.0802-06.2006
10.1523/JNEUROSCI.0303-09.2010
10.1126/science.4035356
10.1046/j.1471-4159.2003.01604.x
10.1159/000367849
10.1523/JNEUROSCI.4398-05.2006
10.1530/eje.0.1490601
10.1111/j.1365-2265.2009.03713.x
10.2164/jandrol.111.015065
10.1186/2042-6410-2-7
10.1186/s12974-014-0162-y
10.1210/jcem.87.4.8397
10.1095/biolreprod.107.063545
10.1046/j.1471-4159.2001.00345.x
10.1097/WAD.0b013e318258cd63
10.1016/j.yfrne.2011.12.001
10.1016/j.lfs.2012.03.009
10.1210/en.2005-1330
10.1016/S0165-5728(00)00386-6
10.1177/0968051907080428
10.1210/en.2004-0619
10.1016/j.expneurol.2015.08.018
10.1016/0006-8993(93)90964-O
10.1210/en.2009-0352
10.1002/neu.20043
10.1016/j.brainres.2006.02.029
10.1016/j.brainres.2009.11.044
10.1007/s11357-014-9707-3
10.1002/glia.20904
10.1073/pnas.1103833108
10.1016/j.freeradbiomed.2012.03.005
10.1111/jne.12007
10.1007/s12640-012-9347-2
10.1089/neu.2010.1686
10.1016/j.mce.2013.12.019
10.1037/0735-7044.116.5.902
10.1016/S0197-4580(02)00193-8
10.1186/s12974-014-0171-x
10.1128/MCB.25.8.2957-2968.2005
10.1186/1742-2094-8-82
10.1096/fj.09-144014
10.1016/j.neuroscience.2013.02.044
10.1016/j.psyneuen.2015.06.012
10.1016/j.neuroscience.2014.04.012
10.1038/ijo.2010.34
10.1210/en.2010-0336
10.1016/j.bbr.2015.02.036
10.1016/j.pnpbp.2005.08.006
10.1210/edrv-7-3-284
10.1016/S0165-5728(97)00186-0
10.1210/er.2002-0006
10.1111/j.1468-1331.2006.01500.x
10.1016/S0306-4522(02)00123-9
10.1016/S0306-4522(03)00154-4
10.1159/000067581
10.1016/S0197-4580(03)00090-3
10.1016/j.peptides.2005.10.006
10.1016/j.nbd.2014.03.011
10.1016/j.neuroscience.2003.09.020
10.1016/j.bbi.2014.03.005
10.1016/j.bbr.2014.02.040
10.3233/JAD-2010-091414
10.1016/j.physbeh.2012.05.015
10.1016/j.neuroscience.2013.08.044
10.1038/labinvest.3780307
10.3389/fnagi.2014.00088
10.1023/A:1018476631561
10.1093/jnci/82.2.129
10.1002/1097-0142(19951215)76:12<2491::AID-CNCR2820761213>3.0.CO;2-R
10.1016/S0899-9007(01)00576-7
10.1210/jcem.82.2.3783
10.1080/01635581.2011.589957
10.1016/j.yfrne.2011.10.001
10.1371/journal.pone.0120775
10.1007/s10815-015-0506-2
10.1037/0278-6133.13.3.195
10.1097/00000542-199008000-00020
10.1016/j.arr.2007.08.007
10.1210/edrv-5-1-25
10.1111/j.1749-6632.2001.tb05633.x
10.1152/physrev.00004.2002
10.1602/neurorx.1.1.111
10.1371/journal.pone.0060437
10.1016/0197-4580(95)00072-M
10.1159/000177254
10.1093/gerona/50A.5.B288
10.1093/gerona/50A.2.B78
10.1258/002367700780578028
10.1093/gerona/56.9.B391
10.1093/geronj/46.5.B171
10.1111/j.1474-9726.2006.00236.x
10.1097/PSY.0b013e3181d9523c
10.1210/jcem-63-1-133
10.1210/jcem-49-3-406
10.1093/gerona/57.6.B211
10.3109/10253890.2014.967677
10.1159/000122669
10.1002/(SICI)1098-2744(199801)21:1<62::AID-MC8>3.3.CO;2-8
10.1159/000066446
10.1016/j.nutres.2012.06.021
10.1016/j.metabol.2013.10.007
10.1530/eje.0.1500185
10.1097/00004647-199607000-00008
10.1016/0047-6374(94)90002-7
10.1002/(SICI)1097-4547(19990915)57:6<830::AID-JNR8>3.3.CO;2-U
10.1006/exnr.2000.7512
10.1186/1742-2094-11-85
10.1152/ajpregu.00057.2011
10.1016/j.bbi.2014.01.005
10.1016/j.tips.2009.11.004
10.1016/0361-9230(93)90033-8
10.1002/mc.10073
10.1093/carcin/bgg077
10.1093/carcin/13.10.1925
10.1093/carcin/17.2.209
10.1093/carcin/bgi051
10.1016/S0197-4580(00)00124-X
10.1001/archinte.167.11.1195
10.1016/S0891-5849(98)00293-7
10.1016/S0197-4580(03)00005-8
10.1177/011542650802300135
10.1002/1531-8249(199901)45:1<8::AID-ART4>3.3.CO;2-M
10.1002/ana.21798
10.1016/j.expneurol.2014.04.017
10.1016/0197-4580(94)00159-6
10.1046/j.1471-4159.1996.66051836.x
10.1385/JMN:13:1-2:159
10.1177/0148607192016006561
10.1165/ajrcmb.19.3.3114
10.1089/10799900252982043
10.1016/j.nutres.2009.06.010
10.1016/S0197-4580(02)00017-9
10.1038/ijo.2010.171",<Element 'PubmedArticle' at 0x7f05dc74a4f0>
396,26815246,"Palmitoylethanolamide, a Special Food for Medical Purposes, in the Treatment of Chronic Pain: A Pooled Data Meta-analysis.","A growing body of evidence suggests that neuroinflammation, which is characterized by infiltration of immune cells, activation of mast cells and glial cells, and production of inflammatory mediators in the peripheral and central nervous systems, has an important role in the induction and maintenance of chronic pain. These findings support the notion that new therapeutic opportunities for chronic pain might be based on anti-inflammatory and pro-resolving mediators that act on immune cells, in particular mast cells and glia, to mitigate or abolish neuroinflammation. Among anti-inflammatory and pro-resolving lipid mediators, palmitoylethanolamide (PEA) has been reported to down-modulate mast cell activation and to control glial cell behaviors.
The aim of this study was to perform a pooled meta-analysis to evaluate the efficacy and safety of micronized and ultra-micronized palmitoylethanolamide (PEA) on pain intensity in patients suffering from chronic and/or neuropathic pain.
Pooled data analysis consisting of double-blind, controlled, and open-label clinical trials.
Double-blind, controlled, and open-label clinical trials were selected consulting the PubMed, Google Scholar, and Cochrane databases, and proceedings of neuroscience meetings. The terms chronic pain, neuropathic pain, and micronized and ultra-micronized PEA were used for the search. Selection criteria included availability of raw data and comparability between tools used to diagnose and assess pain intensity. Raw data obtained by authors were pooled in one database and analyzed by the Generalized Linear Mixed Model. The changes in pain over time, measured by comparable tools, were also assessed by linear regression post-hoc analysis and the Kaplan-Meier estimate. Twelve studies were included in the pooled meta-analysis, 3 of which were double-blind trials comparing active comparators vs placebo, 2 were open-label trials vs standard therapies, and 7 were open-label trials without comparators.
Results showed that PEA elicits a progressive reduction of pain intensity significantly higher than control. The magnitude of reduction equals 1.04 points every 2 weeks with a 35% response variance explained by the linear model. In contrast, in the control group pain, reduction intensity equals 0.20 points every 2 weeks with only 1% of the total variance explained by the regression. The Kaplan-Meier estimator showed a pain score = 3 in 81% of PEA treated patients compared to only 40.9% in control patients by day 60 of treatment. PEA effects were independent of patient age or gender, and not related to the type of chronic pain.
Noteworthy, serious adverse events related to PEA were not registered and/or reported in any of the studies.
These results confirm that PEA might represent an exciting, new therapeutic strategy to manage chronic and neuropathic pain associated with neuroinflammation.",[],Pain physician,2016-01-28,"[{'lastname': 'Paladini', 'firstname': 'Antonella', 'initials': 'A', 'affiliation': ""Assistant Professor, Department of Anesthesia and Pain Medicine, MESVA, University of L'Aquila, L'Aquila, Italy.""}, {'lastname': 'Fusco', 'firstname': 'Mariella', 'initials': 'M', 'affiliation': 'Scientific Information and Documentation Center, Epitech Group, 35030 Saccolongo, Padua, Italy.'}, {'lastname': 'Cenacchi', 'firstname': 'Teresa', 'initials': 'T', 'affiliation': 'Clinical Research Advisor, Epitech Research Group, Via Luigi Einaudi 13, Padova, Italy.'}, {'lastname': 'Schievano', 'firstname': 'Carlo', 'initials': 'C', 'affiliation': 'Adjunct Professor of Statistics, Department of Comparative Biomedicine, University of Padova, Padova, Italy.'}, {'lastname': 'Piroli', 'firstname': 'Alba', 'initials': 'A', 'affiliation': ""Assistant Professor, Department of Anesthesia and Pain Medicine, MESVA, University of L'Aquila, L'Aquila, Italy.""}, {'lastname': 'Varrassi', 'firstname': 'Giustino', 'initials': 'G', 'affiliation': ""University of L'Aquila, and Paolo Procacci Foundation, Via Tacito 7, 00193 Roma, Italy.""}]",,"These results confirm that PEA might represent an exciting, new therapeutic strategy to manage chronic and neuropathic pain associated with neuroinflammation.","Results showed that PEA elicits a progressive reduction of pain intensity significantly higher than control. The magnitude of reduction equals 1.04 points every 2 weeks with a 35% response variance explained by the linear model. In contrast, in the control group pain, reduction intensity equals 0.20 points every 2 weeks with only 1% of the total variance explained by the regression. The Kaplan-Meier estimator showed a pain score = 3 in 81% of PEA treated patients compared to only 40.9% in control patients by day 60 of treatment. PEA effects were independent of patient age or gender, and not related to the type of chronic pain.",,,<Element 'PubmedArticle' at 0x7f05dc636d10>
397,26765997,Suppressor of cytokine signaling 2 modulates the immune response profile and development of experimental cerebral malaria.,"Plasmodium falciparum infection results in severe malaria in humans, affecting various organs, including the liver, spleen and brain, and resulting in high morbidity and mortality. The Plasmodium berghei ANKA (PbA) infection in mice closely recapitulates many aspects of human cerebral malaria (CM); thus, this model has been used to investigate the pathogenesis of CM. Suppressor of cytokine signaling 2 (SOCS2), an intracellular protein induced by cytokines and hormones, modulates the immune response, neural development, neurogenesis and neurotrophic pathways. However, the role of SOCS2 during CM remains unknown. SOCS2 knockout (SOCS2(-/-)) mice infected with PbA show an initial resistance to infection with reduced parasitemia and production of TNF, TGF-β, IL-12 and IL-17 in the brain. Interestingly, in the late phase of infection, SOCS2(-/-) mice display increased parasitemia and reduced Treg cell infiltration, associated with enhanced levels of Th1 and Th17 cells and related cytokines IL-17, IL-6, and TGF-β in the brain. A significant reduction in protective neurotrophic factors, such as glial cell line-derived neurotrophic factor (GDNF) and brain-derived neurotrophic factor (BDNF), was also observed. Moreover, the molecular alterations in the brain of infected SOCS2(-/-) mice were associated with anxiety-related behaviors and cognition impairment. Mechanistically, these results revealed enhanced nitric oxide (NO) production in PbA-infected SOCS2(-/-) mice, and the inhibition of NO synthesis through l-NAME led to a marked decrease in survival, the disruption of parasitemia control and more pronounced anxiety-like behavior. Treatment with l-NAME also shifted the levels of Th1, Th7 and Treg cells in the brains of infected SOCS2(-/-) mice to the background levels observed in infected WT, with remarkable exception of increased CD8(+)IFN(+) T cells and inflammatory monocytes. These results indicate that SOCS2 plays a dual role during PbA infection, being detrimental in the control of the parasite replication but crucial in the regulation of the immune response and production of neurotrophic factors. Here, we provided strong evidence of a critical relationship between SOCS2 and NO in the orchestration of the immune response and development of CM during PbA infection.","['BDNF', 'Cerebral malaria', 'GDNF', 'Immune regulation', 'Neuroimmune response', 'Neuroinflammation', 'Neurotrophic factors', 'Nitric oxide', 'SOCS2', 'l-NAME']","Brain, behavior, and immunity",2016-01-15,"[{'lastname': 'Brant', 'firstname': 'Fatima', 'initials': 'F', 'affiliation': 'Program in Health Sciences: Infectious Diseases and Tropical Medicine, School of Medicine, Federal University of Minas Gerais, Belo Horizonte, MG, Brazil; Department of Biochemistry and Immunology, Institute of Biological Science, Federal University of Minas Gerais, Belo Horizonte, MG, Brazil.'}, {'lastname': 'Miranda', 'firstname': 'Aline S', 'initials': 'AS', 'affiliation': 'Program in Health Sciences: Infectious Diseases and Tropical Medicine, School of Medicine, Federal University of Minas Gerais, Belo Horizonte, MG, Brazil; Department of Biochemistry and Immunology, Institute of Biological Science, Federal University of Minas Gerais, Belo Horizonte, MG, Brazil.'}, {'lastname': 'Esper', 'firstname': 'Lisia', 'initials': 'L', 'affiliation': 'Program in Health Sciences: Infectious Diseases and Tropical Medicine, School of Medicine, Federal University of Minas Gerais, Belo Horizonte, MG, Brazil; Department of Biochemistry and Immunology, Institute of Biological Science, Federal University of Minas Gerais, Belo Horizonte, MG, Brazil.'}, {'lastname': 'Gualdrón-López', 'firstname': 'Melisa', 'initials': 'M', 'affiliation': 'Department of Biochemistry and Immunology, Institute of Biological Science, Federal University of Minas Gerais, Belo Horizonte, MG, Brazil.'}, {'lastname': 'Cisalpino', 'firstname': 'Daniel', 'initials': 'D', 'affiliation': 'Department of Microbiology, Institute of Biological Science, Federal University of Minas Gerais, Belo Horizonte, MG, Brazil.'}, {'lastname': 'de Souza', 'firstname': 'Danielle da Gloria', 'initials': 'DDG', 'affiliation': 'Department of Microbiology, Institute of Biological Science, Federal University of Minas Gerais, Belo Horizonte, MG, Brazil.'}, {'lastname': 'Rachid', 'firstname': 'Milene Alvarenga', 'initials': 'MA', 'affiliation': 'Department of Pathology, Institute of Biological Science, Federal University of Minas Gerais, Belo Horizonte, MG, Brazil.'}, {'lastname': 'Tanowitz', 'firstname': 'Herbert B', 'initials': 'HB', 'affiliation': 'Department of Pathology and Medicine, Albert Einstein College of Medicine, Bronx, NY, USA.'}, {'lastname': 'Teixeira', 'firstname': 'Mauro Martins', 'initials': 'MM', 'affiliation': 'Program in Health Sciences: Infectious Diseases and Tropical Medicine, School of Medicine, Federal University of Minas Gerais, Belo Horizonte, MG, Brazil; Department of Biochemistry and Immunology, Institute of Biological Science, Federal University of Minas Gerais, Belo Horizonte, MG, Brazil.'}, {'lastname': 'Teixeira', 'firstname': 'Antônio Lucio', 'initials': 'AL', 'affiliation': 'Program in Health Sciences: Infectious Diseases and Tropical Medicine, School of Medicine, Federal University of Minas Gerais, Belo Horizonte, MG, Brazil; Department of Biochemistry and Immunology, Institute of Biological Science, Federal University of Minas Gerais, Belo Horizonte, MG, Brazil.'}, {'lastname': 'Machado', 'firstname': 'Fabiana Simão', 'initials': 'FS', 'affiliation': 'Program in Health Sciences: Infectious Diseases and Tropical Medicine, School of Medicine, Federal University of Minas Gerais, Belo Horizonte, MG, Brazil; Department of Biochemistry and Immunology, Institute of Biological Science, Federal University of Minas Gerais, Belo Horizonte, MG, Brazil. Electronic address: machadofs@icb.ufmg.br.'}]",,,,Copyright © 2016 Elsevier Inc. All rights reserved.,10.1016/j.bbi.2016.01.002,<Element 'PubmedArticle' at 0x7f05dc6441d0>
398,"26730729
15952441
7753119
10670912
12577253
23242694
25846618
21050844
15135924
20870295
22136937
16687502
24902717
15908459
16299550
18957080
25685780
25434589
20649560
23680671
19006379
19667192
17900807
17023558
24744434
10706871
1326755
18337473
21466441
23548897
22528488
20961685
12690707
9696468
12122079
12088745
10340299
15470478
9384494
17198690
22431614
22710756
24294006
14668051
24743146
25317247
23323860
19200057
16268804
15548611
25884014
19077468
21820405
24152983
25273317
19441010
19595641
19733151",Antagonism of the Prokineticin System Prevents and Reverses Allodynia and Inflammation in a Mouse Model of Diabetes.,"Neuropathic pain is a severe diabetes complication and its treatment is not satisfactory. It is associated with neuroinflammation-related events that participate in pain generation and chronicization. Prokineticins are a new family of chemokines that has emerged as critical players in immune system, inflammation and pain. We investigated the role of prokineticins and their receptors as modulators of neuropathic pain and inflammatory responses in experimental diabetes. In streptozotocin-induced-diabetes in mice, the time course expression of prokineticin and its receptors was evaluated in spinal cord and sciatic nerves, and correlated with mechanical allodynia. Spinal cord and sciatic nerve pro- and anti-inflammatory cytokines were measured as protein and mRNA, and spinal cord GluR subunits expression studied. The effect of preventive and therapeutic treatment with the prokineticin receptor antagonist PC1 on behavioural and biochemical parameters was evaluated. Peripheral immune activation was assessed measuring macrophage and T-helper cytokine production. An up-regulation of the Prokineticin system was present in spinal cord and nerves of diabetic mice, and correlated with allodynia. Therapeutic PC1 reversed allodynia while preventive treatment blocked its development. PC1 normalized prokineticin levels and prevented the up-regulation of GluN2B subunits in the spinal cord. The antagonist restored the pro-/anti-inflammatory cytokine balance altered in spinal cord and nerves and also reduced peripheral immune system activation in diabetic mice, decreasing macrophage proinflammatory cytokines and the T-helper 1 phenotype. The prokineticin system contributes to altered sensitivity in diabetic neuropathy and its inhibition blocked both allodynia and inflammatory events underlying disease.",[],PloS one,2016-01-06,"[{'lastname': 'Castelli', 'firstname': 'Mara', 'initials': 'M', 'affiliation': 'Dipartimento di Scienze Farmacologiche e Biomolecolari, Università degli Studi di Milano, Milano, Italy.'}, {'lastname': 'Amodeo', 'firstname': 'Giada', 'initials': 'G', 'affiliation': 'Dipartimento di Scienze Farmacologiche e Biomolecolari, Università degli Studi di Milano, Milano, Italy.'}, {'lastname': 'Negri', 'firstname': 'Lucia', 'initials': 'L', 'affiliation': ""Department of Physiology and Pharmacology 'Vittorio Erspamer', University of Rome, Roma, Italy.""}, {'lastname': 'Lattanzi', 'firstname': 'Roberta', 'initials': 'R', 'affiliation': ""Department of Physiology and Pharmacology 'Vittorio Erspamer', University of Rome, Roma, Italy.""}, {'lastname': 'Maftei', 'firstname': 'Daniela', 'initials': 'D', 'affiliation': ""Department of Physiology and Pharmacology 'Vittorio Erspamer', University of Rome, Roma, Italy.""}, {'lastname': 'Gotti', 'firstname': 'Cecilia', 'initials': 'C', 'affiliation': 'Consiglio Nazionale delle Ricerche, Institute of Neuroscience, Milano, Italy.'}, {'lastname': 'Pistillo', 'firstname': 'Francesco', 'initials': 'F', 'affiliation': 'Consiglio Nazionale delle Ricerche, Institute of Neuroscience, Milano, Italy.'}, {'lastname': 'Onnis', 'firstname': 'Valentina', 'initials': 'V', 'affiliation': 'Department of Life and Environmental Sciences, Unit of Pharmaceutical, Pharmacological and Nutraceutical Sciences, University of Cagliari, Cagliari, Italy.'}, {'lastname': 'Congu', 'firstname': 'Cenzo', 'initials': 'C', 'affiliation': 'Department of Life and Environmental Sciences, Unit of Pharmaceutical, Pharmacological and Nutraceutical Sciences, University of Cagliari, Cagliari, Italy.'}, {'lastname': 'Panerai', 'firstname': 'Alberto E', 'initials': 'AE', 'affiliation': 'Dipartimento di Scienze Farmacologiche e Biomolecolari, Università degli Studi di Milano, Milano, Italy.'}, {'lastname': 'Sacerdote', 'firstname': 'Paola', 'initials': 'P', 'affiliation': 'Dipartimento di Scienze Farmacologiche e Biomolecolari, Università degli Studi di Milano, Milano, Italy.'}, {'lastname': 'Franchi', 'firstname': 'Silvia', 'initials': 'S', 'affiliation': 'Dipartimento di Scienze Farmacologiche e Biomolecolari, Università degli Studi di Milano, Milano, Italy.'}]",,,,,"10.1371/journal.pone.0146259
10.1007/s11481-012-9428-2
10.1007/978-3-662-46450-2_8
10.1016/j.ejphar.2010.10.060
10.1016/j.jneuroim.2010.08.013
10.1016/j.coph.2011.10.023
10.1111/bph.12793
10.1186/1471-2172-9-60
10.1016/j.phrs.2014.11.004
10.1111/j.1476-5381.2010.00873.x
10.1016/j.biocel.2013.05.004
10.1021/jm800854e
10.1073/pnas.0903720106
10.1189/jlb.3HI0713-406RR
10.1124/mol.108.045203
10.1074/jbc.M113.450049
10.1074/jbc.M111.326801
10.1016/j.pain.2010.09.030
10.1073/pnas.1113363109
10.1016/S1474-4422(12)70134-5
10.1172/JCI71389
10.4239/wjd.v5.i5.697
10.1111/j.1749-6632.2012.06826.x
10.1159/000178888
10.1016/j.bbrc.2011.07.077
10.1161/JAHA.113.000411
10.1007/s12020-014-0437-1
10.1002/ptr.2806
10.1016/j.jpain.2009.04.003
10.1016/j.bbrc.2009.08.171",<Element 'PubmedArticle' at 0x7f05dc654450>
399,26701296,Core neuropathological abnormalities in progranulin-deficient mice are penetrant on multiple genetic backgrounds.,"Loss-of-function mutations in the progranulin gene (GRN) are a common cause of familial frontotemporal lobar degeneration (FTLD). A high degree of heterogeneity in the age-of-onset, duration of disease, and clinical presentation of FTLD, even among families carrying the same GRN mutation, suggests that additional modifying genes may be important to pathogenesis. Progranulin-knockout mice display subtle behavioral abnormalities and progressive neuropathological changes, as well as altered dendritic morphology and synaptic deficits in the hippocampus. In this study we evaluated multiple neuropathological endpoints in aged progranulin knockout mice and their wild-type littermates on two different genetic backgrounds: C57Bl/6 and 129/SvImJ. We find that in most brain regions, both strains are susceptible to progranulin-mediated neuropathological phenotypes, including astrogliosis, microgliosis, and highly accelerated deposition of the aging pigment lipofuscin. Neuroinflammation due to progranulin deficiency is exaggerated in the B6 strain and present, but less pronounced, in the 129 strain. Differences between the strains in hippocampal neuron counts and neuronal morphology suggest a complex role for progranulin in the hippocampus. We conclude that core progranulin-mediated neurodegenerative phenotypes are penetrant on multiple inbred mouse strains, but that genetic background modulates progranulin's role in neuroinflammation and hippocampal biology.","['frontotemporal lobar degeneration', 'genetic background', 'neuropathology', 'progranulin', 'progranulin-knockout mice']",Neuroscience,2015-12-25,"[{'lastname': 'Petkau', 'firstname': 'T L', 'initials': 'TL', 'affiliation': ""Center for Molecular Medicine & Therapeutics, Department of Medical Genetics, University of British Columbia, and Children's and Women's Hospital, 980 West 28th Avenue, Vancouver, BC V5Z 4H4, Canada.""}, {'lastname': 'Hill', 'firstname': 'A', 'initials': 'A', 'affiliation': ""Center for Molecular Medicine & Therapeutics, Department of Medical Genetics, University of British Columbia, and Children's and Women's Hospital, 980 West 28th Avenue, Vancouver, BC V5Z 4H4, Canada.""}, {'lastname': 'Leavitt', 'firstname': 'B R', 'initials': 'BR', 'affiliation': ""Center for Molecular Medicine & Therapeutics, Department of Medical Genetics, University of British Columbia, and Children's and Women's Hospital, 980 West 28th Avenue, Vancouver, BC V5Z 4H4, Canada; Division of Neurology, Department of Medicine, University of British Columbia Hospital, S192, 2211 Wesbrook Mall, Vancouver, BC V6T 2B5, Canada; Brain Research Centre, University of British Columbia, Vancouver, BC V6T 1Z3, Canada. Electronic address: bleavitt@cmmt.ubc.ca.""}]",,,,Copyright © 2015 IBRO. Published by Elsevier Ltd. All rights reserved.,10.1016/j.neuroscience.2015.12.006,<Element 'PubmedArticle' at 0x7f05dc5fc3b0>
400,"26700298
11450660
18830214
21903253
19944760
21831262
24365431
449663
2682960
7870120
3574672
12725846
19078675
25728308
23396928
16119630
15534758
20621802
9166956
18097481
3670609
2168778
19451535
8514412
7853849
9728541
10908149
19706181
9066359
12531061
9219316
25892509
23866773
17403137
8534264
15893422
12938230
22524232
18832582
23997430
20870295
19233564
11698032
19720751
25354724
21878126
10580813
12495638
19486649
26264608
19441045
25576332
23931802
7572274
15891419
11566042
9364409
8936779
8933206
23313123
15698718
11238200
10720533
17645739
16880258",Anti-inflammatory effects of dexamethasone and meloxicam on Borrelia burgdorferi-induced inflammation in neuronal cultures of dorsal root ganglia and myelinating cells of the peripheral nervous system.,"Lyme neuroborreliosis (LNB), caused by the spirochete Borrelia burgdorferi (Bb), could result in cognitive impairment, motor dysfunction, and radiculoneuritis. We hypothesized that inflammation is a key factor in LNB pathogenesis and recently evaluated the effects of dexamethasone, a steroidal anti-inflammatory drug, and meloxicam a non-steroidal anti-inflammatory drug (NSAID), in a rhesus monkey model of acute LNB. Dexamethasone treatment significantly reduced the levels of immune mediators, and prevented inflammatory and/or neurodegenerative lesions in the central and peripheral nervous systems, and apoptosis in the dorsal root ganglia (DRG). However, infected animals treated with meloxicam showed levels of inflammatory mediators, inflammatory lesions, and DRG cell apoptosis that were similar to that of the infected animals that were left untreated.
To address the differential anti-inflammatory effects of dexamethasone and meloxicam on neuronal and myelinating cells of the peripheral nervous system (PNS), we evaluated the potential of these drugs to alter the levels of Bb-induced inflammatory mediators in rhesus DRG cell cultures and primary human Schwann cells (HSC), using multiplex enzyme-linked immunosorbent assays (ELISA). We also ascertained the ability of these drugs to modulate cell death as induced by live Bb in HSC using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) viability assay and the potential of dexamethasone to modulate Bb-induced apoptosis in HSC by the TUNEL assay.
Earlier, we reported that dexamethasone significantly reduced Bb-induced immune mediators and apoptosis in rhesus DRG cell cultures. Here, we report that dexamethasone but not meloxicam significantly reduces the levels of several cytokines and chemokines as induced by live Bb, in HSC and DRG cell cultures. Further, meloxicam does not significantly alter Bb-induced cell death in HSC, while dexamethasone protects HSC against Bb-induced cell death.
These data help further explain our in vivo findings of significantly reduced levels of inflammatory mediators, DRG-apoptosis, and lack of inflammatory neurodegenerative lesions in the nerve roots and DRG of Bb-infected animals that were treated with dexamethasone, but not meloxicam. Evaluating the role of the signaling mechanisms that contribute to the anti-inflammatory potential of dexamethasone in the context of LNB could serve to identify therapeutic targets for limiting radiculitis and axonal degeneration in peripheral LNB.",[],Journal of neuroinflammation,2015-12-25,"[{'lastname': 'Ramesh', 'firstname': 'Geeta', 'initials': 'G', 'affiliation': 'Division of Bacteriology and Parasitology, Tulane National Primate Research Center, Covington, LA, USA. gramesh@tulane.edu.'}, {'lastname': 'Meisner', 'firstname': 'Olivia C', 'initials': 'OC', 'affiliation': 'Department of Neuroscience and Behavioral Biology, Emory College of Arts and Sciences, Atlanta, GA, USA. omeisne@emory.edu.'}, {'lastname': 'Philipp', 'firstname': 'Mario T', 'initials': 'MT', 'affiliation': 'Division of Bacteriology and Parasitology, Tulane National Primate Research Center, Covington, LA, USA. philipp@tulane.edu.\nDepartment of Microbiology and Immunology, Tulane University Medical School, New Orleans, LA, USA. philipp@tulane.edu.'}]",,,"Earlier, we reported that dexamethasone significantly reduced Bb-induced immune mediators and apoptosis in rhesus DRG cell cultures. Here, we report that dexamethasone but not meloxicam significantly reduces the levels of several cytokines and chemokines as induced by live Bb, in HSC and DRG cell cultures. Further, meloxicam does not significantly alter Bb-induced cell death in HSC, while dexamethasone protects HSC against Bb-induced cell death.",,"10.1186/s12974-015-0461-y
10.1056/NEJM200107123450207
10.1016/S0140-6736(11)60103-7
10.1016/j.nbd.2009.11.016
10.1186/1471-2334-11-215
10.1016/B978-0-7020-4088-7.00099-7
10.1097/00005792-197907000-00001
10.1093/clinids/11.Supplement_6.S1482
10.1002/mus.880180319
10.1212/WNL.37.5.749
10.1016/S1090-3801(02)00121-0
10.1097/00131402-200206000-00006
10.1016/j.annemergmed.2015.01.011
10.1055/s-2004-821174
10.1016/j.jns.2010.05.009
10.1055/s-2008-1040909
10.1212/WNL.37.11.1700
10.1093/brain/113.4.1207
10.1212/WNL.0b013e3181a60a89
10.1086/515357
10.1038/labinvest.3780109
10.1186/1742-2094-6-23
10.1002/ana.410410313
10.1016/S0049-0172(97)80049-2
10.1016/j.ajpath.2015.01.024
10.1186/1742-2094-10-88
10.1111/j.1471-4159.2007.04535.x
10.1016/0006-2952(95)02111-6
10.1016/j.neulet.2005.04.069
10.1002/eji.200323872
10.2353/ajpath.2008.080483
10.1016/j.jneuroim.2010.08.013
10.1016/j.pain.2009.02.001
10.1016/S0014-2999(01)01311-5
10.1124/mi.9.4.7
10.1111/cei.12479
10.1186/1742-2094-8-110
10.1016/S0165-5728(99)00132-0
10.1016/S1044-5323(02)00125-2
10.1016/j.bbi.2009.01.012
10.1007/s00401-015-1466-4
10.1002/mus.21289
10.1016/B978-0-444-52902-2.00032-1
10.1016/0736-5748(95)00018-C
10.1097/01.wco.0000169752.54191.97
10.1053/bega.2001.0236
10.1111/j.2042-7158.1997.tb06030.x
10.1016/0192-0561(96)00031-8
10.1016/j.amjoto.2012.11.009
10.1016/j.diagmicrobio.2004.04.022
10.1086/315340
10.1111/j.1574-695X.2007.00293.x
10.1084/jem.20060336",<Element 'PubmedArticle' at 0x7f05dc609630>
401,26698019,Female sex steroids and glia cells: Impact on multiple sclerosis lesion formation and fine tuning of the local neurodegenerative cellular network.,"Multiple sclerosis (MS) is a chronic inflammatory and demyelinating disease that shows a female-to-male gender prevalence and alleviation of disease activity during late stage pregnancy. In MS-related animal models, sex steroids ameliorate symptoms and protect from demyelination and neuronal damage. Underlying mechanisms of these protective avenues are continuously discovered, in part by using novel transgenic animal models. In this review article, we highlight the regulation of glia cell function by female sex steroids. We specifically focus on the relevance of glia cells for immune cell recruitment into the central nervous system and show how estrogen and progesterone can modulate these cell-cell communication pathways. Since MS is considered to have a strong neurodegenerative component, principal neuroprotective mechanisms, exerted by sex-steroids will be discussed as well. Activation of steroid receptors might not just act as immunosuppressant but at the same time harmonize brain-intrinsic networks to dampen neurodegeneration and, thus, disease progression in MS.","['Astroglia', 'Estrogen', 'Immune cells', 'Inflammation', 'Invasion', 'Microglia', 'Multiple sclerosis', 'Neuroinflammation', 'Neuroprotection', 'Progesterone']",Neuroscience and biobehavioral reviews,2015-12-25,"[{'lastname': 'Kipp', 'firstname': 'Markus', 'initials': 'M', 'affiliation': 'Department of Neuroanatomy, Ludwig-Maximilians-University of Munich, Munich, Germany. Electronic address: markus.kipp@med.uni-muenchen.de.'}, {'lastname': 'Hochstrasser', 'firstname': 'Tanja', 'initials': 'T', 'affiliation': 'Department of Neuroanatomy, Ludwig-Maximilians-University of Munich, Munich, Germany.'}, {'lastname': 'Schmitz', 'firstname': 'Christoph', 'initials': 'C', 'affiliation': 'Department of Neuroanatomy, Ludwig-Maximilians-University of Munich, Munich, Germany.'}, {'lastname': 'Beyer', 'firstname': 'Cordian', 'initials': 'C', 'affiliation': 'Institute of Neuroanatomy, Faculty of Medicine, RWTH Aachen University, 52074 Aachen, Germany.'}]",,,,Copyright © 2015 Elsevier Ltd. All rights reserved.,10.1016/j.neubiorev.2015.11.016,<Element 'PubmedArticle' at 0x7f05dc537ae0>
402,"26661058
6163211
6436161
17775725
9370200
7499563
10880992
8885196
7996194
10077336
11264718
15271060
17955551
11351342
14993062
11040417
15818556
14611865
20878945
18363824
17565708
25770855
20010956
10616799
22401743
10215039
12390866
12209854
23819447
19207827
21734295
17949721
21909323
18820691
17443767
22414444
23795693
9073501
7968362
20925573
10683277
17949414
17643555
14670998
20619320
23196064
10819775
8084376
10493767
24447465","A Quantification of the Injury-Induced Changes in Central Aromatase, Oestrogenic Milieu and Steroid Receptor Expression in the Zebra Finch.","In songbirds and mammals, brain injury results in the up-regulation of aromatase (oestrogen synthase) expression in astroglia. The resulting presumed synthesis of neural oestradiol (E2 ) has neuroprotective effects including a decrease in neurodegeneration, neuroinflammation and apoptosis. The development of therapeutic tools that exploit oestrogenic neuroprotection in the treatment of neurotrauma requires a precise quantification of the endogenous changes in neural aromatase and E2 following brain injury. Surprisingly, the expected increase in neural oestrogens following brain injury has not been demonstrated. Furthermore, we are just beginning to unravel the mechanisms behind the protective effects of centrally synthesised E2 . In the present study, levels of aromatase immunoprotein, neural E2 and steroid receptor mRNA were quantified in adult male and female zebra finches 48 h following a unilateral penetrating brain injury. Both aromatase and E2 were up-regulated in the injured hemisphere of the brain compared to the uninjured hemisphere, demonstrating for the first time a robust increase in neural E2 levels following injury. We did not detect an effect of injury on mRNA expression of the oestrogen receptors (ER)-α, ER-β or GPER-1, but observed a significant decrease in androgen receptor transcription in the injured lobe relative to the contralateral uninjured hemisphere. We conclude that mechanical damage causes a dramatic increase in local aromatisation, and the resultant high levels of central E2 are available to modulate steroid sensitive targets. Studies using alternate methods of receptor detection and/or time points may be necessary to understand the complete suite of mechanisms underlying the neuroprotective effects of induced oestrogen synthesis in this animal model.","['aromatisation', 'neuroprotection', 'steroid receptor', 'traumatic brain injury']",Journal of neuroendocrinology,2015-12-15,"[{'lastname': 'Mehos', 'firstname': 'C J', 'initials': 'CJ', 'affiliation': 'Department of Biology and Center for Behavioral Neuroscience, American University, Washington, DC, USA.'}, {'lastname': 'Nelson', 'firstname': 'L H', 'initials': 'LH', 'affiliation': 'Department of Biology and Center for Behavioral Neuroscience, American University, Washington, DC, USA.'}, {'lastname': 'Saldanha', 'firstname': 'C J', 'initials': 'CJ', 'affiliation': 'Department of Biology and Center for Behavioral Neuroscience, American University, Washington, DC, USA.'}]",,,,© 2015 British Society for Neuroendocrinology.,10.1111/jne.12348,<Element 'PubmedArticle' at 0x7f05dc540e50>
403,"26647069
26469771
23746838
20157523
23425777
16006669
23936746
14615299
8790433
12379605
16944320
16007092
25553802
25553648
21483034
23265946
9597130
16623771
16397579
11983155
10964953
10487715
10969176
9105673
10935546
16597735
20943909
11048732
9005851
11399427
9812896
23316192
6249596
7686508
15189333
11035810
19298762
22643085
23320155
23879250
17081971
15473860
22952392
15084453
11940574
25789082
21282632
26460008
7720076
10507837
12384700
14734535
7720076
15720724
20006983
21736545
24642411
11809808
17693123
23636330
9143018
14766800
22396894
17964225
23786653
9605921
11244051
11942558
19840546
18650913
25961830
17678955
14614955
25341517
26328016
22388478
20409609
17643369
17143299
17517621
9790190
12154096
15314234
25309941
22580404
21686046
20006983
23396967
17569865
21183076
15143170
24183784
25717070
25443287
17049865
24886300
25818175
2429581
8764593
942051
17497670
25429903
23320155
16944320",Age-related neuroinflammation and changes in AKT-GSK-3β and WNT/ β-CATENIN signaling in rat hippocampus.,"Aging is a multifactorial process associated with an increased susceptibility to neurodegenerative disorders which can be related to chronic inflammation. Chronic inflammation, however, can be characterized by the persistent elevated glucocorticoid (GCs) levels, activation of the proinflammatory transcription factor NF-кB, as well as an increase in cytokines. Interestingly, both NF-кB and cytokines can be even modulated by Glycogen Synthase Kinase 3 beta (GSK-3β) activity, which is a key protein that can intermediate inflammation and metabolism, once it has a critical role in AKT signaling pathway, and can also intermediate WNT/β-CATENIN signaling pathway. The aim of this study was to verify age-related changes in inflammatory status, as well as in the AKT and WNT signaling pathways. Results showed an age-related increase in neuroinflammation as indicated by NF-кB activation, TNF-α and GCs increased levels, a decrease in AKT activation and an increase in GSK-3β activity in both 12- and 24- month old animals. Aging also seems to induce a progressive decrease in canonical WNT/β-CATENIN signaling pathway once there is a decrease in DVL-2 levels and in the transcription of Axin2 gene. Little is known about the DVL-2 regulation as well as its roles in WNT signaling pathway, but for the first time it was suggested that DVL-2 expression can be changed along aging.","['AKT', 'GCs', 'GSK-3β', 'NF-κB', 'β-catenin']",Aging,2015-12-10,"[{'lastname': 'Orellana', 'firstname': 'Ana Maria Marques', 'initials': 'AM', 'affiliation': 'Department of Pharmacology, Institute of Biomedical Sciences, University of São Paulo, 05508-900 São Paulo, Brazil.'}, {'lastname': 'Vasconcelos', 'firstname': 'Andrea Rodrigues', 'initials': 'AR', 'affiliation': 'Department of Pharmacology, Institute of Biomedical Sciences, University of São Paulo, 05508-900 São Paulo, Brazil.'}, {'lastname': 'Leite', 'firstname': 'Jacqueline Alves', 'initials': 'JA', 'affiliation': 'Department of Pharmacology, Institute of Biomedical Sciences, University of São Paulo, 05508-900 São Paulo, Brazil.'}, {'lastname': 'de Sá Lima', 'firstname': 'Larissa', 'initials': 'L', 'affiliation': 'Department of Pharmacology, Institute of Biomedical Sciences, University of São Paulo, 05508-900 São Paulo, Brazil.'}, {'lastname': 'Andreotti', 'firstname': 'Diana Zukas', 'initials': 'DZ', 'affiliation': 'Department of Pharmacology, Institute of Biomedical Sciences, University of São Paulo, 05508-900 São Paulo, Brazil.'}, {'lastname': 'Munhoz', 'firstname': 'Carolina Demarchi', 'initials': 'CD', 'affiliation': 'Department of Pharmacology, Institute of Biomedical Sciences, University of São Paulo, 05508-900 São Paulo, Brazil.'}, {'lastname': 'Kawamoto', 'firstname': 'Elisa Mitiko', 'initials': 'EM', 'affiliation': 'Department of Pharmacology, Institute of Biomedical Sciences, University of São Paulo, 05508-900 São Paulo, Brazil.'}, {'lastname': 'Scavone', 'firstname': 'Cristoforo', 'initials': 'C', 'affiliation': 'Department of Pharmacology, Institute of Biomedical Sciences, University of São Paulo, 05508-900 São Paulo, Brazil.'}]",,,,,"10.18632/aging.100853
10.1111/bcp.12804
10.1186/1742-4933-1110-1124
10.13188/12327-13204X.1000001
10.1155/2012/752563",<Element 'PubmedArticle' at 0x7f05dc55cb30>
404,26620836,Lipopolysaccharide induced anxiety- and depressive-like behaviour in mice are prevented by chronic pre-treatment of esculetin.,"Inflammation and oxidative stress are involved in the pathophysiology of anxiety and depression. Esculetin (ESC), a coumarin derived potent antioxidant, also possessing anti-inflammatory and neuroprotective activity. This study investigated the effect of ESC in lipopolysaccharide (LPS)-induced anxiety- and depressive-like behaviour in mice. ESC (25 and 50mg/kg, p.o.) was administered daily for 14 days, and challenged with saline or LPS (0.83mg/kg; i.p.) on the 15th day. Behavioural paradigms such as elevated plus maze (EPM), open field test (OFT), forced swim test (FST) and tail suspension test (TST) were employed to assess anxiety- and depressive-like behaviour in mice post-LPS injection. Hippocampal cytokines, MDA and GSH level, and plasma corticosterone (CORT) were measured. ESC pre-treatment significantly (P<0.05) attenuated LPS-induced anxiety-like behaviour by modulating EPM and OFT parameters. Moreover, LPS-induced increase in immobility time in FST and TST were also prevented significantly (P<0.05) by ESC (50mg/kg). ESC pre-treatment ameliorated LPS-induced neuroinflammation by attenuating brain IL-1β, IL-6, TNF-α level, and oxidative stress as well as plasma CORT level. In conclusion, the results suggest that ESC prevented LPS-induced anxiety- and depressive-like behaviour which may be governed by inhibition of cytokine production, oxidative stress and plasma CORT level. The results support the potential usefulness of ESC in the treatment of psychiatric disorders associated with inflammation and oxidative stress.","['Anxiety', 'Depression', 'Esculetin', 'Lipopolysaccharide', 'Neuroinflammation', 'Oxidative stress']",Neuroscience letters,2015-12-02,"[{'lastname': 'Sulakhiya', 'firstname': 'Kunjbihari', 'initials': 'K', 'affiliation': 'Laboratory of Neuroscience, Department of Pharmacology and Toxicology, National Institute of Pharmaceutical Education and Research (NIPER), Guwahati, Assam 781032, India. Electronic address: niperkunj@gmail.com.'}, {'lastname': 'Keshavlal', 'firstname': 'Gohil Pratik', 'initials': 'GP', 'affiliation': 'Laboratory of Neuroscience, Department of Pharmacology and Toxicology, National Institute of Pharmaceutical Education and Research (NIPER), Guwahati, Assam 781032, India.'}, {'lastname': 'Bezbaruah', 'firstname': 'Babul B', 'initials': 'BB', 'affiliation': 'Department of Pharmacology, Gauhati Medical College, Guwahati, Assam 781032, India.'}, {'lastname': 'Dwivedi', 'firstname': 'Shubham', 'initials': 'S', 'affiliation': 'Laboratory of Neuroscience, Department of Pharmacology and Toxicology, National Institute of Pharmaceutical Education and Research (NIPER), Guwahati, Assam 781032, India.'}, {'lastname': 'Gurjar', 'firstname': 'Satendra Singh', 'initials': 'SS', 'affiliation': 'Department of Biotechnology, National Institute of Pharmaceutical Education and Research (NIPER), Guwahati, Assam 781032, India.'}, {'lastname': 'Munde', 'firstname': 'Nitin', 'initials': 'N', 'affiliation': 'Laboratory of Neuroscience, Department of Pharmacology and Toxicology, National Institute of Pharmaceutical Education and Research (NIPER), Guwahati, Assam 781032, India.'}, {'lastname': 'Jangra', 'firstname': 'Ashok', 'initials': 'A', 'affiliation': 'Laboratory of Neuroscience, Department of Pharmacology and Toxicology, National Institute of Pharmaceutical Education and Research (NIPER), Guwahati, Assam 781032, India.'}, {'lastname': 'Lahkar', 'firstname': 'Mangala', 'initials': 'M', 'affiliation': 'Department of Pharmacology, Gauhati Medical College, Guwahati, Assam 781032, India.'}, {'lastname': 'Gogoi', 'firstname': 'Ranadeep', 'initials': 'R', 'affiliation': 'Department of Biotechnology, National Institute of Pharmaceutical Education and Research (NIPER), Guwahati, Assam 781032, India.'}]",,,,Copyright © 2015 Elsevier Ireland Ltd. All rights reserved.,10.1016/j.neulet.2015.11.031,<Element 'PubmedArticle' at 0x7f05dc518310>
405,26562172,Progesterone Improves Neurobehavioral Outcome in Models of Intracerebral Hemorrhage.,"In models of acute brain injury, progesterone improves recovery through several mechanisms including modulation of neuroinflammation. Secondary injury from neuroinflammation is a potential therapeutic target after intracerebral hemorrhage (ICH). For potential translation of progesterone as a clinical acute ICH therapeutic, the present study sought to define efficacy of exogenous progesterone administration in ICH-relevant experimental paradigms. Young and aged C57BL/6 male, female, and ovariectomized (OVX) mice underwent left intrastriatal collagenase (0.05-0.075 U) or autologous whole blood (35 μl) injection. Progesterone at varying doses (4-16 mg/kg) was administered at 2, 5, 24, 48, and 72 h after injury. Rotarod and Morris water maze latencies were measured on days 1-7 and days 28-31 after injury, respectively. Hematoma volume, brain water content (cerebral edema), complementary immunohistochemistry, multiplex cytokine arrays, and inflammatory proteins were assessed at prespecified time points after injury. Progesterone (4 mg/kg) administration improved rotarod and water maze latencies (p < 0.01), and decreased cerebral edema (p < 0.05), microglial proliferation, and neuronal loss (p < 0.01) in young and aged male, young OVX, and aged female mice. Brain concentration of proinflammatory cytokines and Toll-like receptor-associated proteins were also decreased after progesterone (4 mg/kg) treatment (p < 0.01). Progesterone-treated young female mice showed no detectable effects. Exogenous progesterone improved short- and long-term neurobehavioral recovery and modulated neuroinflammation in male and OVX mice after ICH. Future studies should validate these findings, and address timing and length of administration before translation to clinical trial.",[],Neuroendocrinology,2015-11-13,"[{'lastname': 'Lei', 'firstname': 'Beilei', 'initials': 'B', 'affiliation': 'Multidisciplinary Neuroprotection Laboratories, Duke University, Durham, N.C., USA.'}, {'lastname': 'Wang', 'firstname': 'Haichen', 'initials': 'H', 'affiliation': None}, {'lastname': 'Jeong', 'firstname': 'Seongtae', 'initials': 'S', 'affiliation': None}, {'lastname': 'Hsieh', 'firstname': 'Justin T', 'initials': 'JT', 'affiliation': None}, {'lastname': 'Majeed', 'firstname': 'Mohammed', 'initials': 'M', 'affiliation': None}, {'lastname': 'Dawson', 'firstname': 'Hana', 'initials': 'H', 'affiliation': None}, {'lastname': 'Sheng', 'firstname': 'Huaxin', 'initials': 'H', 'affiliation': None}, {'lastname': 'Warner', 'firstname': 'David S', 'initials': 'DS', 'affiliation': None}, {'lastname': 'James', 'firstname': 'Michael L', 'initials': 'ML', 'affiliation': None}]",,,,"© 2015 S. Karger AG, Basel.",10.1159/000442204,<Element 'PubmedArticle' at 0x7f05dc469270>
406,26535964,Stress-induced anhedonia is associated with the activation of the inflammatory system in the rat brain: Restorative effect of pharmacological intervention.,"Major depression is a complex disease that originates from the interaction between a genetic background of susceptibility and environmental factors such as stress. At molecular level, it is characterized by dysfunctions of multiple systems including neurotransmitters, hormones, signalling pathways, neurotrophic and neuroplastic molecules and - more recently - inflammatory mediators. Accordingly, in the present study we used the chronic mild stress (CMS) paradigm in the rat to elucidate to what extent brain inflammation may contribute to the development and/or the maintenance of an anhedonic phenotype and how pharmacological intervention may interfere with such behavioral and molecular stress-induced alterations. To this aim, adult male rats were exposed to CMS for 2 weeks and the cerebral expression of several mediators of the inflammatory system was evaluated in the hippocampus and prefrontal cortex of both stressed and control animals in parallel with the sucrose intake. Next, the animals that showed a decreased sucrose consumption were exposed to five further weeks of CMS and treated with the antidepressants imipramine or agomelatine, or the antipsychotic lurasidone. Our results demonstrate that only the stressed animals that were characterized by a deficit in sucrose intake showed increased expression of the pro-inflammatory cytokines IL-1β, IL-6 and up-regulation of markers and mediators of microglia activation such as CD11b, CX3CL1 and its receptor CX3CR1 in comparison with stress-resilient animals. Some of these molecular alterations persisted also after longer stress exposure and were modulated, similarly to the behavioral effects of CMS, by chronic pharmacological treatment. These data suggest that neuroinflammation may have a key role in the pathological consequences of stress exposure, thus contributing to the subject's vulnerability for depression.","['Agomelatine: N-[2-(7-methoxynaphthalen-1-yl) ethyl]acetamide', 'Antidepressant', 'Chronic mild stress', 'Cytokines', 'Differential susceptibility', 'Imipramine: 3-(10,11-dihydro-5H-dibenzo[b,f]azepin-5-yl)-N,N-dimethylpropan-1-amine', 'Lurasidone: (3aR,4S,7R,7aS)-2-{(1R,2R)-2-[4-(1,2-benzisothiazol-3-yl) piperazin-1-ylmethyl] cyclohexylmethyl} hexahydro-4,7-methano-2H-isoindole-1,3-dione', 'Microglia activation', 'Sucrose intake']",Pharmacological research,2015-11-05,"[{'lastname': 'Rossetti', 'firstname': 'Andrea C', 'initials': 'AC', 'affiliation': 'Dipartimento di Scienze Farmacologiche e Biomolecolari, Università degli Studi di Milano, Milan, Italy. Electronic address: andreacarlo.rossetti@unimi.it.'}, {'lastname': 'Papp', 'firstname': 'Mariusz', 'initials': 'M', 'affiliation': 'Institute of Pharmacology, Polish Academy of Sciences, Kracow, Poland. Electronic address: nfpapp@cyfronet.pl.'}, {'lastname': 'Gruca', 'firstname': 'Piotr', 'initials': 'P', 'affiliation': 'Institute of Pharmacology, Polish Academy of Sciences, Kracow, Poland. Electronic address: gruca@if-pan.krakow.pl.'}, {'lastname': 'Paladini', 'firstname': 'Maria Serena', 'initials': 'MS', 'affiliation': 'Dipartimento di Scienze Farmacologiche e Biomolecolari, Università degli Studi di Milano, Milan, Italy. Electronic address: mariaserena.paladini@studenti.unimi.it.'}, {'lastname': 'Racagni', 'firstname': 'Giorgio', 'initials': 'G', 'affiliation': 'Dipartimento di Scienze Farmacologiche e Biomolecolari, Università degli Studi di Milano, Milan, Italy. Electronic address: giorgio.racagni@unimi.it.'}, {'lastname': 'Riva', 'firstname': 'Marco A', 'initials': 'MA', 'affiliation': 'Dipartimento di Scienze Farmacologiche e Biomolecolari, Università degli Studi di Milano, Milan, Italy. Electronic address: m.riva@unimi.it.'}, {'lastname': 'Molteni', 'firstname': 'Raffaella', 'initials': 'R', 'affiliation': 'Dipartimento di Scienze Farmacologiche e Biomolecolari, Università degli Studi di Milano, Milan, Italy. Electronic address: raffaella.molteni@unimi.it.'}]",,,,Copyright © 2015 Elsevier Ltd. All rights reserved.,10.1016/j.phrs.2015.10.022,<Element 'PubmedArticle' at 0x7f05dc474040>
407,"26530284
18973581
14872203
17627270
18982002
20128854
19606083
10706215
18844212
9671339
18718470
22216301
18073775
19477151
8539342
20227680
11082065
22513055
23778854
19693780
20152109
24223526
20006974
3546309
11027914
17123470
20133768
9891013
25330740
16360222
17179037
23219884
8816705
1365858
12419546
9016908
17955054
9758169
18059411
4055897
17049169
12907793
3746406
9570806
10347793
21736899
15522247
16900104
17401725
11298800
23691371
21481538
9452163
16037678",Enzymatic Depletion of the Polysialic Acid Moiety Associated with the Neural Cell Adhesion Molecule Inhibits Antidepressant Efficacy.,"Antidepressant drugs are too often ineffective, the exact mechanism of efficacy is still ambiguous, and there has been a paucity of novel targets for pharmacotherapy. In an attempt to understand the pathogenesis of depression and subsequently develop more efficacious antidepressant drugs, multiple theories have been proposed, including the modulation of neurotransmission, the upregulation of neurogenesis and neurotrophic factors, normalizing hypothalamic-pituitary-adrenal reactivity, and the reduction of neuroinflammation; all of which have supporting lines of evidence. Therefore, an ideal molecular target for novel pharmaceutical intervention would function at the confluence of these theories. The polysialylated form of the neural cell adhesion molecule (PSA-NCAM) functions broadly, serving to mediate synaptic plasticity, neurogenesis, neurotrophic factor signaling, and inflammatory signaling throughout the brain; all of which are associated with the pathophysiology and treatment of depression. Moreover, the expression of PSA-NCAM is reduced by depression, and conversely enhanced by antidepressant treatment, particularly within the hippocampus. Here we demonstrate that selectively cleaving the polysialic acid moiety, using the bacteriophage-derived enzyme endoneuraminidase N, completely inhibits the antidepressant efficacy of the selective-serotonin reuptake inhibitor fluoxetine (FLX) in a chronic unpredictable stress model of depression. We also observe a corresponding attenuation of FLX-induced hippocampal neuroplasticity, including decreased hippocampal neurogenesis, synaptic density, and neural activation. These data indicate that PSA-NCAM-mediated neuroplasticity is necessary for antidepressant action; therefore PSA-NCAM represents an interesting, and novel, target for pharmacotherapy.",[],Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology,2015-11-05,"[{'lastname': 'Wainwright', 'firstname': 'Steven R', 'initials': 'SR', 'affiliation': 'Graduate Program in Neuroscience, University of British Columbia, Vancouver, British Columbia, Canada.'}, {'lastname': 'Barha', 'firstname': 'Cindy K', 'initials': 'CK', 'affiliation': 'Department of Psychology, University of British Columbia, Vancouver, British Columbia, Canada.'}, {'lastname': 'Hamson', 'firstname': 'Dwayne K', 'initials': 'DK', 'affiliation': 'Department of Psychology, University of British Columbia, Vancouver, British Columbia, Canada.'}, {'lastname': 'Epp', 'firstname': 'Jonathan R', 'initials': 'JR', 'affiliation': 'Program in Neurosciences and Mental Health, Hospital for Sick Children, Toronto, Ontario, Canada.'}, {'lastname': 'Chow', 'firstname': 'Carmen', 'initials': 'C', 'affiliation': 'Department of Psychology, University of British Columbia, Vancouver, British Columbia, Canada.'}, {'lastname': 'Lieblich', 'firstname': 'Stephanie E', 'initials': 'SE', 'affiliation': 'Department of Psychology, University of British Columbia, Vancouver, British Columbia, Canada.'}, {'lastname': 'Rutishauser', 'firstname': 'Urs', 'initials': 'U', 'affiliation': 'Department of Cell Biology, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.'}, {'lastname': 'Galea', 'firstname': 'Liisa Am', 'initials': 'LA', 'affiliation': 'Graduate Program in Neuroscience, University of British Columbia, Vancouver, British Columbia, Canada.\nDepartment of Psychology, University of British Columbia, Vancouver, British Columbia, Canada.\nBrain Research Centre, University of British Columbia, Vancouver, British Columbia, Canada.'}]",,,,,10.1038/npp.2015.337,<Element 'PubmedArticle' at 0x7f05dc484b80>
408,26452467,Experimental study of cerebrospinal fluid tumor necrosis factor-alpha release in penicillin- and cephalosporin-resistant pneumococcal meningitis treated with different antibiotic schedules.,"To measure the inflammatory response in terms of tumor necrosis factor-alpha (TNF-α) levels in cerebrospinal fluid (CSF), using bacteriolytic versus nonbacteriolytic antibiotic therapy and adjunctive treatment with dexamethasone in an experimental rabbit model of pneumococcal meningitis.
In a rabbit model of pneumococcal meningitis, we tested CSF TNF-α levels in several samples from rabbits infected with the HUB 2349 strain and treated with ceftriaxone 100 mg/kg/d, ceftriaxone plus vancomycin 30 mg/kg/d, or daptomycin at 15 mg/kg or 25 mg/kg. Daptomycin schedules were compared with the same doses in combination with dexamethasone at 0.125 mg/kg every 12 hours over a 26-hour period.
The ceftriaxone group had the highest levels of TNF-α. TNF-α levels were significantly higher after ceftriaxone administration than in both daptomycin groups. The high-dose daptomycin group presented the lowest inflammatory levels in CSF samples. Adjunctive treatment with dexamethasone in this group modulated the inflammatory response, bringing down CSF TNF-α levels.
CSF TNF-α levels were significantly lower in rabbits treated with daptomycin than in rabbits treated with ceftriaxone. Daptomycin avoided the inflammatory peak after administration observed in ceftriaxone-treated rabbits. The use of daptomycin plus dexamethasone achieved a significantly larger reduction in CSF TNF-α levels.","['Streptococcus pneumoniae', 'ceftriaxone', 'cytokines', 'daptomycin', 'dexamethasone']","Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi",2015-10-11,"[{'lastname': 'Vivas', 'firstname': 'M', 'initials': 'M', 'affiliation': ""Laboratory of Experimental Infection, Infectious Diseases Department, IDIBELL-Hospital Universitari de Bellvitge, Feixa Llarga s/n, 08907 L'Hospitalet de Llobregat, Barcelona, Spain. Electronic address: mireiavivas@gmail.com.""}, {'lastname': 'Force', 'firstname': 'E', 'initials': 'E', 'affiliation': ""Laboratory of Experimental Infection, Infectious Diseases Department, IDIBELL-Hospital Universitari de Bellvitge, Feixa Llarga s/n, 08907 L'Hospitalet de Llobregat, Barcelona, Spain.""}, {'lastname': 'El Haj', 'firstname': 'C', 'initials': 'C', 'affiliation': ""Laboratory of Experimental Infection, Infectious Diseases Department, IDIBELL-Hospital Universitari de Bellvitge, Feixa Llarga s/n, 08907 L'Hospitalet de Llobregat, Barcelona, Spain.""}, {'lastname': 'Tubau', 'firstname': 'F', 'initials': 'F', 'affiliation': ""Microbiology Department, IDIBELL-Hospital Universitari de Bellvitge and CIBERES ISCIII, Feixa Llarga s/n, 08907 L'Hospitalet de Llobregat, Barcelona, Spain.""}, {'lastname': 'Ariza', 'firstname': 'J', 'initials': 'J', 'affiliation': ""Laboratory of Experimental Infection, Infectious Diseases Department, IDIBELL-Hospital Universitari de Bellvitge, Feixa Llarga s/n, 08907 L'Hospitalet de Llobregat, Barcelona, Spain.""}, {'lastname': 'Cabellos', 'firstname': 'C', 'initials': 'C', 'affiliation': ""Laboratory of Experimental Infection, Infectious Diseases Department, IDIBELL-Hospital Universitari de Bellvitge, Feixa Llarga s/n, 08907 L'Hospitalet de Llobregat, Barcelona, Spain.""}]",,CSF TNF-α levels were significantly lower in rabbits treated with daptomycin than in rabbits treated with ceftriaxone. Daptomycin avoided the inflammatory peak after administration observed in ceftriaxone-treated rabbits. The use of daptomycin plus dexamethasone achieved a significantly larger reduction in CSF TNF-α levels.,"The ceftriaxone group had the highest levels of TNF-α. TNF-α levels were significantly higher after ceftriaxone administration than in both daptomycin groups. The high-dose daptomycin group presented the lowest inflammatory levels in CSF samples. Adjunctive treatment with dexamethasone in this group modulated the inflammatory response, bringing down CSF TNF-α levels.",Copyright © 2015. Published by Elsevier B.V.,10.1016/j.jmii.2015.07.014,<Element 'PubmedArticle' at 0x7f05dc423f40>
409,"26417153
10442165
16316783
10442175
10464374
11751035
10869498
9400897
3889509
19427367
11374330
17700577
11122355
9164599
2119829
2200823
8345201
9057644
10843735
8163473
8872612
4559710
11595215",IL-4 Inhibits IL-1β-Induced Depressive-Like Behavior and Central Neurotransmitter Alterations.,"It has been known that activation of the central innate immune system or exposure to stress can disrupt balance of anti-/proinflammatory cytokines. The aim of the present study was to investigate the role of pro- and anti-inflammatory cytokines in the modulation of depressive-like behaviors, the hormonal and neurotransmitter systems in rats. We investigated whether centrally administered IL-1β is associated with activation of CNS inflammatory pathways and behavioral changes and whether treatment with IL-4 could modulate IL-1β-induced depressive-like behaviors and central neurotransmitter systems. Infusion of IL-4 significantly decreased IL-1β-induced anhedonic responses and increased social exploration and total activity. Treatment with IL-4 markedly blocked IL-1β-induced increase in PGE2 and CORT levels. Also, IL-4 reduced IL-1β-induced 5-HT levels by inhibiting tryptophan hydroxylase (TPH) mRNA and activating serotonin transporter (SERT) in the hippocampus, and levels of NE were increased by activating tyrosine hydroxylase (TH) mRNA expression. These results demonstrate that IL-4 may locally contribute to the regulation of noradrenergic and serotonergic neurotransmission and may inhibit IL-1β-induced behavioral and immunological changes. The present results suggest that IL-4 modulates IL-1β-induced depressive behavior by inhibiting IL-1β-induced central glial activation and neurotransmitter alterations. IL-4 reduced central and systemic mediatory inflammatory activation, as well as reversing the IL-1β-induced alterations in neurotransmitter levels. The present findings contribute a biochemical pathway regulated by IL-4 that may have therapeutic utility for treatment of IL-1β-induced depressive behavior and neuroinflammation which warrants further study.",[],Mediators of inflammation,2015-09-30,"[{'lastname': 'Park', 'firstname': 'Hyun-Jung', 'initials': 'HJ', 'affiliation': 'Acupuncture and Meridian Science Research Center (AMSRC), Department of Science in Korean Medicine, Graduate School, College of Korean Medicine, Kyung Hee University, 1 Hoegi-dong, Dongdaemun-gu, Seoul 130-701, Republic of Korea ; Department of Psychology and Center for Neuroscience, Brigham Young University, Provo, UT 84602, USA.'}, {'lastname': 'Shim', 'firstname': 'Hyun-Soo', 'initials': 'HS', 'affiliation': 'Acupuncture and Meridian Science Research Center (AMSRC), Department of Science in Korean Medicine, Graduate School, College of Korean Medicine, Kyung Hee University, 1 Hoegi-dong, Dongdaemun-gu, Seoul 130-701, Republic of Korea ; Department of Neuroscience and Cell Biology, University of Texas Medical Branch, Galveston, TX 77551, USA.'}, {'lastname': 'An', 'firstname': 'Kyungeh', 'initials': 'K', 'affiliation': 'Department of Adult Health and Nursing Systems, School of Nursing, Virginia Commonwealth University, Richmond, VA 23298-0567, USA.'}, {'lastname': 'Starkweather', 'firstname': 'Angela', 'initials': 'A', 'affiliation': 'Center for Advancement in Managing Pain, School of Nursing, University of Connecticut, Storrs, CT 06269, USA.'}, {'lastname': 'Kim', 'firstname': 'Kyung Soo', 'initials': 'KS', 'affiliation': 'Department of Integrative Medicine and Research Center of Behavioral Medicine, College of Medicine, The Catholic University of Korea, Seoul 137-701, Republic of Korea.'}, {'lastname': 'Shim', 'firstname': 'Insop', 'initials': 'I', 'affiliation': 'Acupuncture and Meridian Science Research Center (AMSRC), Department of Science in Korean Medicine, Graduate School, College of Korean Medicine, Kyung Hee University, 1 Hoegi-dong, Dongdaemun-gu, Seoul 130-701, Republic of Korea.'}]",,,,,"10.1155/2015/941413
10.1007/978-0-585-37970-8_2
10.1016/j.it.2005.11.006
10.1007/978-0-585-37970-8_12
10.1002/(sici)1096-9861(19991011)413:160;113::aid-cne862;3.0.co;2-b
10.1016/s0893-133x(01)00305-0
10.1016/s0006-8993(00)02398-2
10.1016/0165-0270(85)90026-3
10.1016/j.neulet.2009.05.008
10.1007/s002130100687
10.1038/sj.mp.4002055
10.1046/j.1460-9568.2000.01348.x
10.1016/s0091-3057(96)00335-8
10.1006/cyto.1999.0622
10.1002/(sici)1097-4644(199609)62:3lt;411::aid-jcb11>3.0.co;2-l
10.1016/0006-8993(72)90398-8
10.1016/s0006-8993(01)02910-9",<Element 'PubmedArticle' at 0x7f05dc435540>
410,"26384348
18373985
22811431
25907989
25805970
14976264
20089851
23542362
24602889
23941528
15022260
17976862
23417962
23888142
24507186
17147953
16183991
25589773
20554604
23224511
22949090
18579222
15599669
19197138
22569962
25934099
18499466
19245663
20940627
22407459
16621167
17224059
21975039
20888078
24529758
25071471
23925977
24298267
15744310
15126506
20385619
16817860
24144549
15072572
7699989
11642401
16939484
18805010
22189567
22356806
23774254
20361959
16182554
15668962
17573824
24597893
25377425
24272709
22284404
18599449
15152190
23422569
24184051
12072154
11705464
16608241
2789141
1356145
16354677
23840057
10082752
15034006
12969123
23271700
20011043
21551343
20580712
11846609
11328886",Reciprocal regulation between sirtuin-1 and angiotensin-II in the substantia nigra: implications for aging and neurodegeneration.,"Local angiotensin II (AII) and sirtuin 1 (SIRT1) play a major role in the modulation of neuroinflammation, oxidative stress and aging-related dopaminergic vulnerability to damage. However, it is not known whether the modulation is related to reciprocal regulation between SIRT1 and AII. In the present study, a single intraventricular injection of AII increased nigral SIRT1 levels in young adult rats. Although AII activity is known to be increased in aged rats, levels of SIRT1 were significantly lower than in young controls. Treatment with the SIRT1-activating compound resveratrol increased nigral SIRT1 levels in aged rats. Levels of SIRT1 were significantly higher in aged wild type mice than in AII type-1 receptor (AT1) deficient mice. In cell culture studies, treatment with AII also induced a transitory increase in levels of SIRT1 in the MES 23.5 dopaminergic neuron and the N9 microglial cell lines. In aged rats, treatment with resveratrol induced a significant decrease in the expression of AT1 receptors and markers of NADPH-oxidase activation (p47phox). In aged transgenic mice over-expressing SIRT1, levels of AT1 and p47 phox were lower than in aged wild type controls. In vitro, the inhibitory effects of resveratrol on AII/AT1/NADPH-oxidase activity were confirmed in primary mesencephalic cultures, the N9 microglial cell line, and the dopaminergic neuron cell line MES 23.5, and they were blocked by the SIRT1 specific inhibitor EX527. The present findings show that SIRT1 and the axis AII/AT1/NADPH-oxidase regulate each other. This is impaired in aged animals and may be mitigated with sirtuin-activating compounds.","['Gerotarget', 'Parkinson', 'dopamine', 'longevity', 'neuroinflammation', 'resveratrol']",Oncotarget,2015-09-19,"[{'lastname': 'Diaz-Ruiz', 'firstname': 'Carmen', 'initials': 'C', 'affiliation': 'Laboratory of Neuroanatomy and Experimental Neurology, Dept. of Morphological Sciences, CIMUS, University of Santiago de Compostela, Santiago de Compostela, Spain.\nNetworking Research Center on Neurodegenerative Diseases (CIBERNED), Madrid, Spain.'}, {'lastname': 'Rodriguez-Perez', 'firstname': 'Ana I', 'initials': 'AI', 'affiliation': 'Laboratory of Neuroanatomy and Experimental Neurology, Dept. of Morphological Sciences, CIMUS, University of Santiago de Compostela, Santiago de Compostela, Spain.\nNetworking Research Center on Neurodegenerative Diseases (CIBERNED), Madrid, Spain.'}, {'lastname': 'Beiroa', 'firstname': 'Daniel', 'initials': 'D', 'affiliation': 'Department of Physiology, CIMUS, University of Santiago de Compostela, Santiago de Compostela, Spain.\nCIBER Fisiopatología de la Obesidad y Nutrición (CIBERobn), Spain.'}, {'lastname': 'Rodriguez-Pallares', 'firstname': 'Jannette', 'initials': 'J', 'affiliation': 'Laboratory of Neuroanatomy and Experimental Neurology, Dept. of Morphological Sciences, CIMUS, University of Santiago de Compostela, Santiago de Compostela, Spain.\nNetworking Research Center on Neurodegenerative Diseases (CIBERNED), Madrid, Spain.'}, {'lastname': 'Labandeira-Garcia', 'firstname': 'Jose L', 'initials': 'JL', 'affiliation': 'Laboratory of Neuroanatomy and Experimental Neurology, Dept. of Morphological Sciences, CIMUS, University of Santiago de Compostela, Santiago de Compostela, Spain.\nNetworking Research Center on Neurodegenerative Diseases (CIBERNED), Madrid, Spain.'}]",,,,,10.18632/oncotarget.5596,<Element 'PubmedArticle' at 0x7f05dc44e4f0>
411,26363665,"Sickness: From the focus on cytokines, prostaglandins, and complement factors to the perspectives of neurons.","Systemic inflammation leads to a variety of physiological (e.g. fever) and behavioral (e.g. anorexia, immobility, social withdrawal, depressed mood, disturbed sleep) responses that are collectively known as sickness. While these phenomena have been studied for the past few decades, the neurobiological mechanisms by which sickness occurs remain unclear. In this review, we first revisit how the body senses and responds to infections and injuries by eliciting systemic inflammation. Next, we focus on how peripheral inflammatory molecules such as cytokines, prostaglandins, and activated complement factors communicate with the brain to trigger neuroinflammation and sickness. Since depression also involves inflammation, we further elaborate on the interrelationship between sickness and depression. Finally, we discuss how immune activation can modulate neurons in the brain, and suggest future perspectives to help unravel how changes in neuronal functions relate to sickness responses.","['Complement factors', 'Cytokines', 'Depression', 'Neurohormones', 'Neuroinflammation', 'Prostaglandins', 'Sickness response', 'Systemic inflammation']",Neuroscience and biobehavioral reviews,2015-09-14,"[{'lastname': 'Poon', 'firstname': 'David Chun-Hei', 'initials': 'DC', 'affiliation': 'Laboratory of Neurodegenerative Diseases, School of Biomedical Sciences, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region.'}, {'lastname': 'Ho', 'firstname': 'Yuen-Shan', 'initials': 'YS', 'affiliation': 'School of Nursing, Faculty of Health and Social Sciences, The Hong Kong Polytechnic University, Hung Hom, Kowloon, Hong Kong Special Administrative Region.'}, {'lastname': 'Chiu', 'firstname': 'Kin', 'initials': 'K', 'affiliation': 'Laboratory of Retina Brain Research, Department of Ophthalmology, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region.'}, {'lastname': 'Wong', 'firstname': 'Hoi-Lam', 'initials': 'HL', 'affiliation': 'Laboratory of Neurodegenerative Diseases, School of Biomedical Sciences, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region.'}, {'lastname': 'Chang', 'firstname': 'Raymond Chuen-Chung', 'initials': 'RC', 'affiliation': 'Laboratory of Neurodegenerative Diseases, School of Biomedical Sciences, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region; Research Centre of Heart, Brain, Hormone and Healthy Aging, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong Special Administrative Region; State Key Laboratory of Brain and Cognitive Sciences, The University of Hong Kong, Hong Kong Special Administrative Region. Electronic address: rccchang@hku.hk.'}]",,,,Copyright © 2015 Elsevier Ltd. All rights reserved.,10.1016/j.neubiorev.2015.07.015,<Element 'PubmedArticle' at 0x7f05dc3f89a0>
412,26348582,Inflammatory transcription factors as activation markers and functional readouts in immune-to-brain communication.,"Immune-to-brain communication pathways involve humoral mediators, including cytokines, central modulation by neuronal afferents and immune cell trafficking to the brain. During systemic inflammation these pathways contribute to mediating brain-controlled sickness symptoms including fever. Experimentally, activation of these signaling pathways can be mimicked and studied when injecting animals with pathogen associated molecular patterns (PAMPS). One central component of the brain inflammatory response, which leads, for example, to fever induction, is transcriptional activation of brain cells via cytokines and PAMPS. We and others have studied the spatiotemporal activation and the physiological significance of transcription factors for the induction of inflammation within the brain and the manifestation of fever. Evidence has revealed a role of nuclear factor (NF)κB in the initiation, signal transducer and activator of transcription (STAT)3 in the maintenance and NF-interleukin (IL)6 in the maintenance or even termination of brain-inflammation and fever. Moreover, psychological stressors, such as exposure to a novel environment, leads to increased body core temperature and genomic NF-IL6-activation, suggesting a potential use of NF-IL6-immunohistochemistry as a multimodal brain cell activation marker and a role for NF-IL6 for differential brain activity. In addition, the nutritional status, as reflected by circulating levels of the cytokine-like hormone leptin, influence immune-to-brain communication and age-dependent changes in LPS-induced fever. Overall, transcription factors remain therapeutically important targets for the treatment of brain-inflammation and fever induction during infectious/non-infectious inflammatory and psychological stress. However, the exact physiological role and significance of these transcription factors requires to be further investigated.","['Brain-inflammation', 'Cytokines', 'Fever', 'Immune-to-brain signaling', 'Leptin', 'Nuclear factor interleukin 6', 'Nuclear factor kappa B', 'Pathogen-associated molecular pattern', 'Prostaglandins', 'Signal transducer and activator of transcription 3']","Brain, behavior, and immunity",2015-09-09,"[{'lastname': 'Rummel', 'firstname': 'Christoph', 'initials': 'C', 'affiliation': 'Institute of Veterinary Physiology and Biochemistry, Justus-Liebig-University Giessen, 35392 Giessen, Germany. Electronic address: Christoph.D.Rummel@vetmed.uni-giessen.de.'}]",,,,Copyright © 2015 Elsevier Inc. All rights reserved.,10.1016/j.bbi.2015.09.003,<Element 'PubmedArticle' at 0x7f05dc4050e0>
413,"26321913
1711170
1630584
19969022
3253099
2987634
16154792
12446609
8136039
7595641
11488380
8138969
12498954
19104149
21217155
21940629
12600714
12603843
9580157
12067227
9517856
23433314
23383169
8808788
11701929
22033462
12971891
8252612
3327424
24565378
15625078
16723527
20201008
12562515
24259593
10922518
25297066
19286276
16901708
19283469
24113652
24529917
17209801
15480844
19412960
16647243
24485491
19647070
25816800
21635199
11278753
22431735
14614955
16162857
8903847
24504409
25451151
12446003
20711177
24722204
9263193
22001159
15143169
18047562
10964613
21878486
19296921
11099416
9836646
42834
21927881
12096891
12399247
15283957
23225525
23821370
7196554
22776046
10934283
17495632
18304357
4376244
19328213
11072751
9462735
11093760
1951377
20026420
2089275
22544647
9705986
23526723
25728499
23384604
17129618
16022865
25610370
8719510
3411354
22825468
18172548
10202533
12893096
17615391
3399080
12052540
10453354
21051678
16176362
11239978
8071868
15964248
14630699
16957086
17414942
18335161
6368214
16597735
20052403
12843254
16278020
23485736
8071867
10711949
18279483
9197268
11173288
23427326
10781595
23800361
15939444
1930727
20602449
21467220
18571778
19943124
15350242
2239475
17008564
25684748
3746406
12052541
12034786
5865993
828106
21025115
14593171
12526994
18412632
15013364
3935041
19619638
18692253
19840546
17194565
1560229
8597390
9145302
25589262
19752299
21908876
15163680
15207276
15772982
20153418
8255412
9882535
25586882
19442825
25300681
11425308
17562931
23500798
25568124
12631585
21525267
10391435
17192953
25594175
14755719
18343932
23950648",Relevance of chronic stress and the two faces of microglia in Parkinson's disease.,"This review is aimed to highlight the importance of stress and glucocorticoids (GCs) in modulating the inflammatory response of brain microglia and hence its potential involvement in Parkinson's disease (PD). The role of inflammation in PD has been reviewed extensively in the literature and it is supposed to play a key role in the course of the disease. Historically, GCs have been strongly associated as anti-inflammatory hormones. However, accumulating evidence from the peripheral and central nervous system have clearly revealed that, under specific conditions, GCs may promote brain inflammation including pro-inflammatory activation of microglia. We have summarized relevant data linking PD, neuroinflamamation and chronic stress. The timing and duration of stress response may be critical for delineating an immune response in the brain thus probably explain the dual role of GCs and/or chronic stress in different animal models of PD.","['Parkinson’s disease', 'corticosterone', 'glucocorticoids', 'microglia', 'neurodegeneration', 'neuroinflammation', 'stress']",Frontiers in cellular neuroscience,2015-09-01,"[{'lastname': 'Herrera', 'firstname': 'Antonio J', 'initials': 'AJ', 'affiliation': 'Departamento de Bioquímica y Biología Molecular, Facultad de Farmacia and Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla Sevilla, Spain.'}, {'lastname': 'Espinosa-Oliva', 'firstname': 'Ana M', 'initials': 'AM', 'affiliation': 'Departamento de Bioquímica y Biología Molecular, Facultad de Farmacia and Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla Sevilla, Spain.'}, {'lastname': 'Carrillo-Jiménez', 'firstname': 'Alejandro', 'initials': 'A', 'affiliation': 'Departamento de Bioquímica y Biología Molecular, Facultad de Farmacia and Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla Sevilla, Spain.'}, {'lastname': 'Oliva-Martín', 'firstname': 'María J', 'initials': 'MJ', 'affiliation': 'Departamento de Bioquímica y Biología Molecular, Facultad de Farmacia and Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla Sevilla, Spain.'}, {'lastname': 'García-Revilla', 'firstname': 'Juan', 'initials': 'J', 'affiliation': 'Departamento de Bioquímica y Biología Molecular, Facultad de Farmacia and Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla Sevilla, Spain.'}, {'lastname': 'García-Quintanilla', 'firstname': 'Alberto', 'initials': 'A', 'affiliation': 'Departamento de Bioquímica y Biología Molecular, Facultad de Farmacia and Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla Sevilla, Spain.'}, {'lastname': 'de Pablos', 'firstname': 'Rocío M', 'initials': 'RM', 'affiliation': 'Departamento de Bioquímica y Biología Molecular, Facultad de Farmacia and Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla Sevilla, Spain.'}, {'lastname': 'Venero', 'firstname': 'José L', 'initials': 'JL', 'affiliation': 'Departamento de Bioquímica y Biología Molecular, Facultad de Farmacia and Instituto de Biomedicina de Sevilla (IBiS), Hospital Universitario Virgen del Rocío/CSIC/Universidad de Sevilla Sevilla, Spain.'}]",,,,,"10.3389/fncel.2015.00312
10.1016/0306-4522(90)90244-x
10.1159/000126188
10.1016/j.neuro.2009.12.001
10.1016/0014-2999(88)90068-4
10.1016/0024-3205(85)90304-2
10.1016/j.parkreldis.2005.07.005
10.1210/en.2002-220598
10.1016/0166-4328(93)90096-9
10.1016/0022-510x(95)00108-e
10.1037/0033-295x.108.3.624
10.1016/s0197-4580(02)00065-9
10.1172/JCI36470
10.1136/jnnp.2010.213652
10.1074/jbc.M111.275370
10.1016/s0014-2999(03)01285-8
10.1046/j.1471-4159.2003.01634.x
10.1046/j.1471-4159.1998.70041584.x
10.1046/j.1471-4159.2002.00799.x
10.1111/j.1600-0404.1998.tb00614.x
10.1111/ene.12117
10.1371/journal.pone.0055375
10.1016/0197-0186(95)00139-5
10.1126/science.1063522
10.1016/S0896-6273(03)00568-3
10.1007/bf00711582
10.1111/j.1749-6632.1987.tb24973.x
10.1186/1742-2094-11-34
10.1096/fj.04-2153fje
10.1523/jneurosci.0802-06.2006
10.1002/eji.201040319
10.1046/j.1471-4159.2003.01604.x
10.1136/jnnp-2013-305911
10.1016/s0361-9230(00)00275-6
10.1002/mds.26048
10.1016/j.neurobiolaging.2009.01.012
10.1016/j.nbd.2006.06.013
10.1007/s10571-009-9375-5
10.1016/j.nlm.2013.09.017
10.1016/j.mehy.2014.01.026
10.1146/annurev.pharmtox.47.120505.105140
10.1007/s00702-003-0059-x
10.1002/mds.22473
10.1016/j.bbi.2006.03.005
10.1016/j.psyneuen.2013.11.006
10.1016/j.bbi.2009.07.008
10.1016/j.bbi.2015.03.010
10.1517/14656566.2011.587120
10.1074/jbc.m010809200
10.1074/jbc.m111.311589
10.1016/s0028-3908(03)00279-x
10.1212/01.wnl.0000180361.74060.70
10.1006/brbi.1995.1028
10.1038/nm.3457
10.1016/j.ajpath.2014.08.025
10.1016/s0165-5728(02)00357-0
10.1038/ng.642
10.1093/hmg/ddu170
10.1016/s0197-4580(97)80309-0
10.1016/j.expneurol.2011.09.035
10.1128/mcb.24.11.4743-4756.2004
10.1111/j.1471-4159.2007.05148.x
10.1006/nbdi.2000.0289
10.1093/cercor/bhr229
10.1016/S1474-4422(09)70062-6
10.1126/science.290.5497.1768
10.1126/science.282.5395.1914
10.1016/0024-3205(79)90414-4
10.1007/s10072-011-0770-6
10.1006/brbi.2001.0638
10.1152/ajpregu.00230.2002
10.1016/j.neuroscience.2004.05.046
10.1002/ana.23746
10.1007/s00702-013-1062-5
10.1016/0149-7634(81)90005-1
10.1111/j.1471-4159.2012.07864.x
10.1097/wco.0b013e3280adc943
10.1186/1742-2094-5-8
10.1016/j.brainresrev.2009.03.002
10.1007/s007020070078
10.1038/ng0298-106
10.1124/mol.58.6.1247
10.1016/0002-9343(91)90150-v
10.1016/j.biocel.2009.12.016
10.1016/0306-4522(90)90229-w
10.1007/s12035-012-8267-8
10.1111/j.1469-7793.1998.331bk.x
10.1002/ana.23894
10.1111/apha.12476
10.1093/brain/aws331
10.1016/j.bbr.2006.10.032
10.1016/j.expneurol.2005.02.021
10.3389/fncel.2014.00440
10.1016/0957-4271(95)00014-3
10.1038/cddis.2012.94
10.1172/JCI32806
10.1146/annurev.neuro.22.1.105
10.1016/s0006-3223(03)00177-x
10.1152/physrev.00041.2006
10.1212/wnl.38.8.1285
10.1016/s0304-3940(02)00300-2
10.1210/er.20.4.435
10.1176/appi.psy.51.6.474
10.1111/j.1460-9568.2005.04285.x
10.1016/s0031-9384(00)00371-1
10.1016/j.arr.2005.03.002
10.1096/fj.03-0501fje
10.1523/jneurosci.0519-06.2006
10.1097/01.wnf.0000240954.72186.91
10.1007/s00702-008-0018-7
10.1210/edrv-5-1-25
10.1523/jneurosci.4398-05.2006
10.1371/journal.pone.0008566
10.1016/j.jneuroim.2005.09.012
10.1016/j.neulet.2013.02.024
10.1016/s0140-6736(05)72455-7
10.1111/j.1600-0404.2007.00986.x
10.1126/science.276.5321.2045
10.1016/s1360-1385(00)01843-4
10.1212/WNL.0b013e31828727ba
10.1074/jbc.m002035200
10.1186/1750-1326-8-19
10.1016/j.physbeh.2005.05.003
10.1037/0735-7044.105.4.599
10.1002/mds.22850
10.1073/pnas.1017820108
10.1002/ana.21380
10.1007/s12017-009-8107-9
10.1016/j.tics.2004.07.009
10.2105/AJPH.96.10.1740
10.1016/j.neuroscience.2015.02.008
10.1016/s0304-3940(02)00301-4
10.1212/wnl.58.10.1501
10.1159/000127780
10.1016/0376-8716(76)90030-2
10.1210/jcem-6-2-117
10.1126/science.1090278
10.1016/s0031-9384(02)00939-3
10.1111/j.1460-9568.2008.06177.x
10.1016/s0022-4804(03)00300-7
10.1002/ana.410180506
10.1016/j.bbi.2009.07.003
10.1016/j.jneuroim.2008.06.019
10.1016/j.neuron.2009.09.032
10.1016/j.bbi.2006.11.006
10.1111/j.1471-4159.1992.tb10047.x
10.1111/j.1749-6632.1995.tb44666.x
10.1002/(sici)1098-1136(199705)20:1<23::aid-glia3>3.3.co;2-u
10.1002/cphy.c140007
10.1001/archneurol.2009.195
10.1093/brain/awr203
10.1124/jpet.104.070961
10.1016/j.nbd.2004.01.010
10.1002/jnr.20443
10.1016/j.bbi.2010.02.001
10.1159/000119002
10.1006/frne.1998.0172
10.1186/s12974-014-0228-x
10.1016/j.neuro.2009.02.011
10.1007/5584_2014_10
10.1021/bi0102398
10.1001/archneur.64.6.836
10.1016/j.bbi.2013.03.004
10.1523/JNEUROSCI.3561-14.2015
10.1096/fj.02-0314fje
10.1523/JNEUROSCI.0450-11.2011
10.1016/s0306-4522(98)00685-x
10.1002/ajmg.b.30435
10.1016/j.cell.2014.11.047
10.1002/ana.10795
10.1007/s00401-008-0361-7
10.2147/NDT.S48455",<Element 'PubmedArticle' at 0x7f05dc40e590>
414,"26215834
25197646
21691802
22348647
15094456
12928786
24462919
9771457
18378771
25431764
21184660
19776335
23041626
16862115
21611805
12526812
19625741
19016491
25435337
24795567
23609919
12655302
25374890
19860916
19907078
10728698
20846376
24627329
10858277
24680777
24070898
19557827
23959579
20026663
21813674
21393509
23463024
23276979
16950801
18568075
12889069
22859297
20737593
21471435
25575133
23316765
21224065
25261995
21212639
23706646
19388207
21531375
12524533
20667979
23089745
16862116
19339619
19158106
23201826
21512023
23516300
23737518
20387302
20955934
19288468
16983685
19795409
22890097",The Role of PGRN in Alzheimer's Disease.,"Progranulin (PGRN), a multifunctional growth factor expressed in various tissues, is involved in a diversity of physiologic and pathological processes, including cell proliferation, wound healing, and modulation of inflammation. Interest in the role of progranulin in the brain has increased dramatically since mutations in GRN, which encodes for the protein PGRN, are associated with the pathogenesis of Alzheimer's disease (AD). A great many of studies suggest that PGRN participates in AD pathogenesis through diverse pathways, including Aβ deposition and clearance, intraneuronal deposition of phosphorylated tau, neuroinflammation, and neuronal survival. Decreased GRN mRNA levels can be detected in the parietal lobe of patients clinically diagnosed with AD; more importantly, emerging data support that serum or plasma PGRN can act as a biomarker for AD. By understanding PGRN in a wider context, we may be better able to depict its role in AD and then provide a therapeutic strategy for AD.","['Alzheimer’s disease', 'Amyloid-β', 'PGRN', 'Pathogenesis', 'Therapy']",Molecular neurobiology,2015-07-29,"[{'lastname': 'Jing', 'firstname': 'Hua', 'initials': 'H', 'affiliation': 'Department of Neurology, Qingdao Municipal Hospital, School of Medicine, Qingdao University, Qingdao, China.'}, {'lastname': 'Tan', 'firstname': 'Meng-Shan', 'initials': 'MS', 'affiliation': 'Department of Neurology, Qingdao Municipal Hospital, School of Medicine, Qingdao University, Qingdao, China.'}, {'lastname': 'Yu', 'firstname': 'Jin-Tai', 'initials': 'JT', 'affiliation': 'Department of Neurology, Qingdao Municipal Hospital, School of Medicine, Qingdao University, Qingdao, China. yu-jintai@163.com.\nMemory and Aging Center, Department of Neurology, University of California, San Francisco, CA, USA. yu-jintai@163.com.'}, {'lastname': 'Tan', 'firstname': 'Lan', 'initials': 'L', 'affiliation': 'Department of Neurology, Qingdao Municipal Hospital, School of Medicine, Qingdao University, Qingdao, China. dr.tanlan@163.com.'}]",,,,,10.1007/s12035-015-9358-0,<Element 'PubmedArticle' at 0x7f05dc336f40>
415,26209559,Endogenous 2-Arachidonoylglycerol Alleviates Cyclooxygenases-2 Elevation-Mediated Neuronal Injury From SO2 Inhalation via PPARγ Pathway.,"Although the health effects of sulfur dioxide (SO2) pollution in the atmospheric environment are not new, epidemiological studies and parallel experimental investigations indicate that acute SO2 exposure causes glutamate-mediated excitotoxicity and even contributes to the outcome of cerebral ischemia. Additionally, the free radical-related inflammatory responses are responsible for neuronal insults and consequent brain disorders. However, few medications are available for preventing the inflammatory responses and relieving the subsequent harmful insults from SO2 inhalation. Here, we show that endocannabinoid 2-arachidonoylglycerol (2-AG) prevents neurotoxicity from SO2 inhalation by suppressing cyclooxygenase-2 (COX-2) overexpression, and this action appears to be mediated via cannabinoid receptor 1 (CB1)-dependent mitogen-activated protein kinase/nuclear factor κB (NF-κB) signaling pathways. Furthermore, CB1-dependent peroxisome proliferator activated receptor γ (PPARγ) expression was an important modulator of the 2-AG-mediated resolution on NF-κB-coupled COX-2 elevation in response to SO2 neuroinflammation. This finding provides evidence of a possible therapeutic effect of endogenous 2-AG regulation for protecting against neurological dysfunction from SO2 inhalation in polluted areas.","['cyclooxygenase-2 (COX-2)', 'endocannabinoid 2-arachidonoylglycerol (2-AG)', 'neuroinflammation', 'peroxisome proliferator activated receptor γ (PPARγ)', 'sulfur dioxide (SO2)']",Toxicological sciences : an official journal of the Society of Toxicology,2015-07-26,"[{'lastname': 'Li', 'firstname': 'Ben', 'initials': 'B', 'affiliation': ""College of Environment and Resource, Research Center of Environment and Health, Shanxi University, Taiyuan, Shanxi 030006, People's Republic of China.""}, {'lastname': 'Chen', 'firstname': 'Minjun', 'initials': 'M', 'affiliation': ""College of Environment and Resource, Research Center of Environment and Health, Shanxi University, Taiyuan, Shanxi 030006, People's Republic of China.""}, {'lastname': 'Guo', 'firstname': 'Lin', 'initials': 'L', 'affiliation': ""College of Environment and Resource, Research Center of Environment and Health, Shanxi University, Taiyuan, Shanxi 030006, People's Republic of China.""}, {'lastname': 'Yun', 'firstname': 'Yang', 'initials': 'Y', 'affiliation': ""College of Environment and Resource, Research Center of Environment and Health, Shanxi University, Taiyuan, Shanxi 030006, People's Republic of China.""}, {'lastname': 'Li', 'firstname': 'Guangke', 'initials': 'G', 'affiliation': ""College of Environment and Resource, Research Center of Environment and Health, Shanxi University, Taiyuan, Shanxi 030006, People's Republic of China.""}, {'lastname': 'Sang', 'firstname': 'Nan', 'initials': 'N', 'affiliation': ""College of Environment and Resource, Research Center of Environment and Health, Shanxi University, Taiyuan, Shanxi 030006, People's Republic of China sangnan@sxu.edu.cn.""}]",,,,"© The Author 2015. Published by Oxford University Press on behalf of the Society of Toxicology. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.",10.1093/toxsci/kfv147,<Element 'PubmedArticle' at 0x7f05dc350900>
416,26162711,Got worms? Perinatal exposure to helminths prevents persistent immune sensitization and cognitive dysfunction induced by early-life infection.,"The incidence of autoimmune and inflammatory diseases has risen dramatically in post-industrial societies. ""Biome depletion"" - loss of commensal microbial and multicellular organisms such as helminths (intestinal worms) that profoundly modulate the immune system - may contribute to these increases. Hyperimmune-associated disorders also affect the brain, especially neurodevelopment, and increasing evidence links early-life infection to cognitive and neurodevelopmental disorders. We have demonstrated previously that rats infected with bacteria as newborns display life-long vulnerabilities to cognitive dysfunction, a vulnerability that is specifically linked to long-term hypersensitivity of microglial cell function, the resident immune cells of the brain. Here, we demonstrate that helminth colonization of pregnant dams attenuated the exaggerated brain cytokine response of their offspring to bacterial infection, and that combined with post-weaning colonization of offspring with helminths (consistent with their mothers treatment) completely prevented enduring microglial sensitization and cognitive dysfunction in adulthood. Importantly, helminths had no overt impact on adaptive immune cell subsets, whereas exaggerated innate inflammatory responses in splenic macrophages were prevented. Finally, helminths altered the effect of neonatal infection on the gut microbiome; neonatal infection with Escherichia coli caused a shift from genera within the Actinobacteria and Tenericutes phyla to genera in the Bacteroidetes phylum in rats not colonized with helminths, but helminths attenuated this effect. In sum, these data point toward an inter-relatedness of various components of the biome, and suggest potential mechanisms by which this helminth might exert therapeutic benefits in the treatment of neuroinflammatory and cognitive disorders.","['Autoimmune', 'Cytokines', 'Developmental programming', 'Hygiene hypothesis', 'Microglia', 'Neurodevelopment']","Brain, behavior, and immunity",2015-07-15,"[{'lastname': 'Williamson', 'firstname': 'Lauren L', 'initials': 'LL', 'affiliation': 'Department of Psychology & Neuroscience, Duke Institute for Brain Sciences, Duke University, United States.'}, {'lastname': 'McKenney', 'firstname': 'Erin A', 'initials': 'EA', 'affiliation': 'Department of Biology, Duke University, United States.'}, {'lastname': 'Holzknecht', 'firstname': 'Zoie E', 'initials': 'ZE', 'affiliation': 'Department of Surgery, Duke University Medical Center, United States.'}, {'lastname': 'Belliveau', 'firstname': 'Christine', 'initials': 'C', 'affiliation': 'Department of Psychology & Neuroscience, Duke Institute for Brain Sciences, Duke University, United States.'}, {'lastname': 'Rawls', 'firstname': 'John F', 'initials': 'JF', 'affiliation': 'Department of Molecular Genetics and Microbiology, Duke University Medical Center, United States.'}, {'lastname': 'Poulton', 'firstname': 'Susan', 'initials': 'S', 'affiliation': 'Department of Surgery, Duke University Medical Center, United States.'}, {'lastname': 'Parker', 'firstname': 'William', 'initials': 'W', 'affiliation': 'Department of Surgery, Duke University Medical Center, United States.'}, {'lastname': 'Bilbo', 'firstname': 'Staci D', 'initials': 'SD', 'affiliation': 'Department of Psychology & Neuroscience, Duke Institute for Brain Sciences, Duke University, United States. Electronic address: staci.bilbo@duke.edu.'}]",,,,Copyright © 2015 Elsevier Inc. All rights reserved.,10.1016/j.bbi.2015.07.006,<Element 'PubmedArticle' at 0x7f05dc35c950>
417,26159205,Insulin Modulates In Vitro Secretion of Cytokines and Cytotoxins by Human Glial Cells.,"Alzheimer's disease (AD) is the most common form of dementia worldwide. Type 2 diabetes (T2D) has been implicated as a risk factor for AD. Since T2D is a peripheral inflammatory condition, and AD brains exhibit exacerbated neuroinflammation, we hypothesized that inflammatory mechanisms could contribute to the observed link between T2D and AD. Abnormal peripheral and brain insulin concentrations have been reported in both T2D and AD. The neurotrophic role of insulin has been described; however, this hormone can also regulate inflammatory responses in the periphery. Therefore we used in vitro human cell culture systems to elucidate the possible effects of insulin on neuroinflammation. We show that human astrocytes and microglia express both isoforms of the insulin receptor as well as the insulin-like growth factor (IGF)-1 receptor. They also express insulin receptor substrate (IRS)-1 and IRS-2, which are required for propagation of insulin/IGF- 1 signaling. We show that at low nanomolar concentrations, insulin could be pro-inflammatory by upregulating secretion of interleukin (IL)-6 and IL-8 from stimulated human astrocytes and secretion of IL-8 from stimulated human microglia. This effect dissipates at higher insulin concentrations. In contrast, insulin at a broader concentration range (10 pM - 1 μM) reduces the toxicity of stimulated human microglia and THP-1 monocytic cells towards SH-SY5Y neuronal cells. These data show that insulin may regulate the inflammatory status of glial cells by modulating their select functions, which in turn can influence the survival of neurons contributing to the observed link between T2D and AD.",[],Current Alzheimer research,2015-07-15,"[{'lastname': 'Spielman', 'firstname': 'Lindsay J', 'initials': 'LJ', 'affiliation': None}, {'lastname': 'Bahniwal', 'firstname': 'Manpreet', 'initials': 'M', 'affiliation': None}, {'lastname': 'Little', 'firstname': 'Jonathan P', 'initials': 'JP', 'affiliation': None}, {'lastname': 'Walker', 'firstname': 'Douglas G', 'initials': 'DG', 'affiliation': None}, {'lastname': 'Klegeris', 'firstname': 'Andis', 'initials': 'A', 'affiliation': 'Department of Biology, University of British Columbia Okanagan Campus, 3187 University Way, Kelowna, BC, Canada, V1V 1V7. andis.klegeris@ubc.ca.'}]",,,,,10.2174/1567205012666150710104428,<Element 'PubmedArticle' at 0x7f05dc2ea220>
418,26119836,Bacterial meningitis: insights into pathogenesis and evaluation of new treatment options: a perspective from experimental studies.,"Bacterial meningitis is associated with high mortality and morbidity rates. Bacterial components induce an overshooting inflammatory reaction, eventually leading to brain damage. Pathological correlates of neurofunctional deficits include cortical necrosis, damage of the inner ear and hippocampal apoptosis. The hippocampal dentate gyrus is important for memory acquisition and harbors a neuronal stem cell niche, thus being potentially well equipped for regeneration. Adjuvant therapies aimed at decreasing the inflammatory reaction, for example, dexamethasone, and those protecting the brain from injury have been evaluated in animal models of the disease. They include nonbacteriolytic antibiotics (e.g., daptomycin), metalloproteinase inhibitors and modulators of the immunological response, for example, granulocyte colony-stimulating factor. Increasing research interest has recently been focused on interventions aimed at supporting regenerative processes.","['Streptococcus pneumoniae', 'animal model', 'bacterial meningitis', 'brain injury', 'dentate gyrus', 'neurogenesis', 'neuroinfection', 'neuroinflammation']",Future microbiology,2015-06-30,"[{'lastname': 'Liechti', 'firstname': 'Fabian D', 'initials': 'FD', 'affiliation': 'Neuroinfection Laboratory, Institute for Infectious Diseases, University of Bern, Friedbühlstr. 51, CH-3010 Bern, Switzerland.'}, {'lastname': 'Grandgirard', 'firstname': 'Denis', 'initials': 'D', 'affiliation': 'Neuroinfection Laboratory, Institute for Infectious Diseases, University of Bern, Friedbühlstr. 51, CH-3010 Bern, Switzerland.'}, {'lastname': 'Leib', 'firstname': 'Stephen L', 'initials': 'SL', 'affiliation': 'Neuroinfection Laboratory, Institute for Infectious Diseases, University of Bern, Friedbühlstr. 51, CH-3010 Bern, Switzerland.\nBiology Division, Spiez Laboratory, Swiss Federal Office for Civil Protection, Austrasse, CH-3700 Spiez, Switzerland.'}]",,,,,10.2217/fmb.15.43,<Element 'PubmedArticle' at 0x7f05dc2f72c0>
419,26093305,"Recombinant tissue plasminogen activator promotes, and progesterone attenuates, microglia/macrophage M1 polarization and recruitment of microglia after MCAO stroke in rats.","Tissue plasminogen activator (tPA) is one of the few approved treatments for stroke, but its effects on the phenotype of microglia/macrophages are poorly understood. One of its side effects is an increase in the inflammatory response leading to neuronal cell damage and death in the ischemic cascade after stroke. Injury-induced activated microglia/macrophages can have dual functions as pro-inflammatory (M1) and anti-inflammatory (M2) factors in brain injury and repair. Recent studies show that progesterone (PROG) is a potent anti-inflammatory agent which affects microglia/macrophage expression after brain injury.
We examined the interaction of tPA-induced expression of microglia/macrophage phenotypes and PROG's anti-inflammatory effects.
tPA treatment increased the recruitment of microglia/macrophages, the polarity of M1 reactions, the expression of MIP-1α in neurons and capillaries, and the expression of MMP-3 compared to vehicle, and PROG modulated these effects.
PROG treatment attenuates tPA-induced inflammatory alterations in brain capillaries and microglia/macrophages both in vivo and in vitro and thus may be a useful adjunct therapy when tPA is given for stroke.","['M1/M2 polarization', 'MIP-1α', 'Macrophage', 'Microglia', 'Neuroinflammation', 'Progesterone', 'Recovery', 'Stroke', 'tPA']","Brain, behavior, and immunity",2015-06-21,"[{'lastname': 'Won', 'firstname': 'Soonmi', 'initials': 'S', 'affiliation': 'Department of Emergency Medicine, Emory University, Atlanta, GA 30322, USA.'}, {'lastname': 'Lee', 'firstname': 'Jae-Kyung', 'initials': 'JK', 'affiliation': 'Department of Physiology, Emory University, Atlanta, GA 30322, USA.'}, {'lastname': 'Stein', 'firstname': 'Donald G', 'initials': 'DG', 'affiliation': 'Department of Emergency Medicine, Emory University, Atlanta, GA 30322, USA. Electronic address: dstei04@emory.edu.'}]",,,"tPA treatment increased the recruitment of microglia/macrophages, the polarity of M1 reactions, the expression of MIP-1α in neurons and capillaries, and the expression of MMP-3 compared to vehicle, and PROG modulated these effects.",Copyright © 2015 Elsevier Inc. All rights reserved.,10.1016/j.bbi.2015.06.007,<Element 'PubmedArticle' at 0x7f05dc3015e0>
420,"26090232
21827663
21472005
21842586
16845890
19766105
25582579
8956110
8774799
8843602
22674585
23686747
22933588
25304927
25452009
19125256
10415142
23922379
7582491
17178196
16052037
20818416
21907912
15973410
11727767
9526841
11916961
17167081
11156943
15009671
15728830
15390105
25276817
2440339
18040786
7550361
22806180
14526074
16387640
16204639
17556587
19805493
18362605
19804829
19005077
11789671
16086683
16343349
19864556
24722970
10843702
16387633
10217305
20346144
14996418
17196262
9663559
23190582
10594923
18502582
19464294
22563843
25048571
21467997
24942731","Anandamide, Acting via CB2 Receptors, Alleviates LPS-Induced Neuroinflammation in Rat Primary Microglial Cultures.","Microglial activation is a polarized process divided into potentially neuroprotective phenotype M2 and neurotoxic phenotype M1, predominant during chronic neuroinflammation. Endocannabinoid system provides an attractive target to control the balance between microglial phenotypes. Anandamide as an immune modulator in the central nervous system acts via not only cannabinoid receptors (CB1 and CB2) but also other targets (e.g., GPR18/GPR55). We studied the effect of anandamide on lipopolysaccharide-induced changes in rat primary microglial cultures. Microglial activation was assessed based on nitric oxide (NO) production. Analysis of mRNA was conducted for M1 and M2 phenotype markers possibly affected by the treatment. Our results showed that lipopolysaccharide-induced NO release in microglia was significantly attenuated, with concomitant downregulation of M1 phenotypic markers, after pretreatment with anandamide. This effect was not sensitive to CB1 or GPR18/GPR55 antagonism. Administration of CB2 antagonist partially abolished the effects of anandamide on microglia. Interestingly, administration of a GPR18/GPR55 antagonist by itself suppressed NO release. In summary, we showed that the endocannabinoid system plays a crucial role in the management of neuroinflammation by dampening the activation of an M1 phenotype. This effect was primarily controlled by the CB2 receptor, although functional cross talk with GPR18/GPR55 may occur.",[],Neural plasticity,2015-06-20,"[{'lastname': 'Malek', 'firstname': 'Natalia', 'initials': 'N', 'affiliation': 'Laboratory of Pain Pathophysiology, Institute of Pharmacology, Polish Academy of Sciences, Smetna 12 Street, 31-343 Krakow, Poland ; Department of Pain Pharmacology, Institute of Pharmacology, Polish Academy of Sciences, Smetna 12 Street, 31-343 Krakow, Poland.'}, {'lastname': 'Popiolek-Barczyk', 'firstname': 'Katarzyna', 'initials': 'K', 'affiliation': 'Department of Pain Pharmacology, Institute of Pharmacology, Polish Academy of Sciences, Smetna 12 Street, 31-343 Krakow, Poland.'}, {'lastname': 'Mika', 'firstname': 'Joanna', 'initials': 'J', 'affiliation': 'Department of Pain Pharmacology, Institute of Pharmacology, Polish Academy of Sciences, Smetna 12 Street, 31-343 Krakow, Poland.'}, {'lastname': 'Przewlocka', 'firstname': 'Barbara', 'initials': 'B', 'affiliation': 'Department of Pain Pharmacology, Institute of Pharmacology, Polish Academy of Sciences, Smetna 12 Street, 31-343 Krakow, Poland.'}, {'lastname': 'Starowicz', 'firstname': 'Katarzyna', 'initials': 'K', 'affiliation': 'Laboratory of Pain Pathophysiology, Institute of Pharmacology, Polish Academy of Sciences, Smetna 12 Street, 31-343 Krakow, Poland ; Department of Pain Pharmacology, Institute of Pharmacology, Polish Academy of Sciences, Smetna 12 Street, 31-343 Krakow, Poland.'}]",,,,,"10.1155/2015/130639
10.1186/1742-2094-8-92
10.1139/y05-143
10.1016/j.ejphar.2009.09.030
10.1093/brain/awu377
10.1002/(SICI)1096-9861(19961216)376:3<447::AID-CNE7>3.0.CO;2-2
10.1016/0166-2236(96)10047-3
10.1002/glia.22350
10.1002/jnr.23242
10.1161/STROKEAHA.112.659656
10.1016/j.jneuroim.2014.09.020
10.1038/srep07279
10.1007/s00401-008-0476-x
10.1006/exnr.1999.7118
10.1189/jlb.0113043
10.1111/j.1476-5381.1995.tb14987.x
10.1016/j.neuroscience.2006.11.016
10.1385/nmm:7:1-2:037
10.1038/onc.2010.402
10.1038/nature03658
10.1016/s0165-5728(97)00181-1
10.1074/jbc.m110813200
10.1523/jneurosci.2531-06.2006
10.1046/j.1471-4159.2003.02244.x
10.1523/jneurosci.4540-04.2005
10.1002/glia.20092
10.1155/2014/762930
10.1007/s11481-005-9010-2
10.1016/0165-0173(94)00015-h
10.1007/s00109-012-0925-9
10.1126/science.1088208
10.1016/j.neuron.2005.11.027
10.1189/jlb.0405216
10.1126/science.1142265
10.1093/brain/awp239
10.1097/aln.0b013e318167af74
10.1016/j.nbd.2009.09.021
10.1523/jneurosci.3400-08.2008
10.1016/s1567-5769(01)00147-3
10.1111/j.1471-4159.2005.03380.x
10.1186/1742-2094-2-29
10.1523/jneurosci.3257-09.2009
10.1007/s00401-014-1274-2
10.4049/jimmunol.164.12.6461
10.1016/j.neuron.2005.12.004
10.1046/j.1471-4159.1999.0722215.x
10.1186/1471-2202-11-44
10.1016/j.intimp.2003.12.011
10.1016/j.jneuroim.2006.11.018
10.1016/S0165-5728(98)00027-7
10.1186/1479-5876-10-239
10.1002/(sici)1098-1136(20000101)29:1x003C;58::aid-glia6x0003e;3.0.co;2-w
10.1016/j.pain.2008.04.006
10.1016/j.febslet.2009.05.028
10.1111/j.1476-5381.2012.02019.x
10.1111/bph.12850
10.1074/jbc.m114.561761",<Element 'PubmedArticle' at 0x7f05dc30e6d0>
421,"26056339
19710497
20101001
16760914
12492778
20547972
24366083
19246475
17140851
20966214
24742461
23023392
24162652
24962261
21527731
25047355
24360280
10221782
12427977
16322748
15630444
24647951
23525041
12535154
24966471
23575851
19476542
23686171",Microglia participate in neurogenic regulation of hypertension.,"Hypertension is associated with neuroinflammation and increased sympathetic tone. Interference with neuroinflammation by an anti-inflammatory reagent or overexpression of interleukin-10 in the brain was found to attenuate hypertension. However, the cellular mechanism of neuroinflammation, as well as its impact on neurogenic regulation of blood pressure, is unclear. Here, we found that hypertension, induced by either angiotensin II or l-N(G)-nitro-l-arginine methyl ester, is accompanied by microglial activation as manifested by microgliosis and proinflammatory cytokine upregulation. Targeted depletion of microglia significantly attenuated neuroinflammation, glutamate receptor expression in the paraventricular nucleus, plasma vasopressin level, kidney norepinephrine concentration, and blood pressure. Furthermore, when microglia were preactivated and transferred into the brains of normotensive mice, there was a significantly prolonged pressor response to intracerebroventricular injection of angiotensin II, and inactivation of microglia eliminated these effects. These data demonstrate that microglia, the resident immune cells in the brain, are the major cellular factors in mediating neuroinflammation and modulating neuronal excitation, which contributes to the elevated blood pressure.","['angiotensin', 'hypertension', 'microglia', 'neuroimmunomodulation']","Hypertension (Dallas, Tex. : 1979)",2015-06-10,"[{'lastname': 'Shen', 'firstname': 'Xiao Z', 'initials': 'XZ', 'affiliation': 'From the Departments of Biomedical Sciences (X.Z.S., K.H.S., K.E.B.), Neurology (Y.L., L.L., P.L., P.S.), and Pathology and Laboratory Medicine (X.Z.S., K.E.B.), Cedars-Sinai Medical Center, Los Angeles, CA.'}, {'lastname': 'Li', 'firstname': 'You', 'initials': 'Y', 'affiliation': 'From the Departments of Biomedical Sciences (X.Z.S., K.H.S., K.E.B.), Neurology (Y.L., L.L., P.L., P.S.), and Pathology and Laboratory Medicine (X.Z.S., K.E.B.), Cedars-Sinai Medical Center, Los Angeles, CA.'}, {'lastname': 'Li', 'firstname': 'Liang', 'initials': 'L', 'affiliation': 'From the Departments of Biomedical Sciences (X.Z.S., K.H.S., K.E.B.), Neurology (Y.L., L.L., P.L., P.S.), and Pathology and Laboratory Medicine (X.Z.S., K.E.B.), Cedars-Sinai Medical Center, Los Angeles, CA.'}, {'lastname': 'Shah', 'firstname': 'Kandarp H', 'initials': 'KH', 'affiliation': 'From the Departments of Biomedical Sciences (X.Z.S., K.H.S., K.E.B.), Neurology (Y.L., L.L., P.L., P.S.), and Pathology and Laboratory Medicine (X.Z.S., K.E.B.), Cedars-Sinai Medical Center, Los Angeles, CA.'}, {'lastname': 'Bernstein', 'firstname': 'Kenneth E', 'initials': 'KE', 'affiliation': 'From the Departments of Biomedical Sciences (X.Z.S., K.H.S., K.E.B.), Neurology (Y.L., L.L., P.L., P.S.), and Pathology and Laboratory Medicine (X.Z.S., K.E.B.), Cedars-Sinai Medical Center, Los Angeles, CA.'}, {'lastname': 'Lyden', 'firstname': 'Patrick', 'initials': 'P', 'affiliation': 'From the Departments of Biomedical Sciences (X.Z.S., K.H.S., K.E.B.), Neurology (Y.L., L.L., P.L., P.S.), and Pathology and Laboratory Medicine (X.Z.S., K.E.B.), Cedars-Sinai Medical Center, Los Angeles, CA.'}, {'lastname': 'Shi', 'firstname': 'Peng', 'initials': 'P', 'affiliation': 'From the Departments of Biomedical Sciences (X.Z.S., K.H.S., K.E.B.), Neurology (Y.L., L.L., P.L., P.S.), and Pathology and Laboratory Medicine (X.Z.S., K.E.B.), Cedars-Sinai Medical Center, Los Angeles, CA. Peng.Shi@cshs.org.'}]",,,,"© 2015 American Heart Association, Inc.",10.1161/HYPERTENSIONAHA.115.05333,<Element 'PubmedArticle' at 0x7f05dc27d1d0>
422,"26055231
24669208
23218523
23547920
20573451
24473264
25164769
20087366
20337613
24713688
22950912
23203114
21765618
9006319
3023451
24795567
22515328
23197111
7517440
20022504
24403170
21639869
22916199
22542283
22516295
21062492
23806692
7514639
24760838
24638131
19926854
14001233
20889584
2261679
23844686
10627616
16605240
24297668
25056458
23845731
21410936
12379909
7690905
23758741
25470347
24607225
19857483
21521653
21738161
24286707
20303877
24052108
23834189
24599476
24032675
21713648
20117131
23307734
16968947
16006518
22885997
23425575
21354467
15000462
19439008
15799549
16478686
23880066
25106636
18249450
23108549
25046306",N-Palmitoylethanolamine and Neuroinflammation: a Novel Therapeutic Strategy of Resolution.,"Inflammation is fundamentally a protective cellular response aimed at removing injurious stimuli and initiating the healing process. However, when prolonged, it can override the bounds of physiological control and becomes destructive. Inflammation is a key element in the pathobiology of chronic pain, neurodegenerative diseases, stroke, spinal cord injury, and neuropsychiatric disorders. Glia, key players in such nervous system disorders, are not only capable of expressing a pro-inflammatory phenotype but respond also to inflammatory signals released from cells of immune origin such as mast cells. Chronic inflammatory processes may be counteracted by a program of resolution that includes the production of lipid mediators endowed with the capacity to switch off inflammation. These naturally occurring lipid signaling molecules include the N-acylethanolamines, N-arachidonoylethanolamine (an endocannabinoid), and its congener N-palmitoylethanolamine (palmitoylethanolamide or PEA). PEA may play a role in maintaining cellular homeostasis when faced with external stressors provoking, for example, inflammation. PEA is efficacious in mast cell-mediated models of neurogenic inflammation and neuropathic pain and is neuroprotective in models of stroke, spinal cord injury, traumatic brain injury, and Parkinson disease. PEA in micronized/ultramicronized form shows superior oral efficacy in inflammatory pain models when compared to naïve PEA. Intriguingly, while PEA has no antioxidant effects per se, its co-ultramicronization with the flavonoid luteolin is more efficacious than either molecule alone. Inhibiting or modulating the enzymatic breakdown of PEA represents a complementary therapeutic approach to treat neuroinflammation. This review is intended to discuss the role of mast cells and glia in neuroinflammation and strategies to modulate their activation based on leveraging natural mechanisms with the capacity for self-defense against inflammation.",[],Molecular neurobiology,2015-06-10,"[{'lastname': 'Skaper', 'firstname': 'Stephen D', 'initials': 'SD', 'affiliation': 'Department of Pharmaceutical and Pharmacological Sciences, University of Padua, Largo ""Egidio Meneghetti"" 2, 35131, Padua, Italy, stephen.skaper@unipd.it.'}, {'lastname': 'Facci', 'firstname': 'Laura', 'initials': 'L', 'affiliation': None}, {'lastname': 'Barbierato', 'firstname': 'Massimo', 'initials': 'M', 'affiliation': None}, {'lastname': 'Zusso', 'firstname': 'Morena', 'initials': 'M', 'affiliation': None}, {'lastname': 'Bruschetta', 'firstname': 'Giuseppe', 'initials': 'G', 'affiliation': None}, {'lastname': 'Impellizzeri', 'firstname': 'Daniela', 'initials': 'D', 'affiliation': None}, {'lastname': 'Cuzzocrea', 'firstname': 'Salvatore', 'initials': 'S', 'affiliation': None}, {'lastname': 'Giusti', 'firstname': 'Pietro', 'initials': 'P', 'affiliation': None}]",,,,,10.1007/s12035-015-9253-8,<Element 'PubmedArticle' at 0x7f05dc2947c0>
423,26047726,Inhibition of prolactin with bromocriptine for 28days increases blood-brain barrier permeability in the rat.,"The blood-brain barrier (BBB) is necessary for the proper function of the brain. Its maintenance is regulated by endogenous factors. Recent evidences suggest prolactin (PRL) regulates the BBB properties in vitro, nevertheless no evidence of these effects have been reported in vivo. The aim of this study was to evaluate the role of PRL in the maintenance of the BBB in the rat. Male Wistar rats were treated with Bromocriptine (Bromo) to inhibit PRL production for 28days in the absence or presence of lipopolysaccharide (LPS). BBB permeability was evaluated through the Evans Blue dye and fluorescein-dextran extravasation as well as through edema formation. The expression of claudin-5, occludin, glial fibrillary acidic protein (GFAP) and the PRL receptor (PRLR) was evaluated through western blot. Bromo reduced the physiological levels of PRL at 28days. At the same time, Bromo increased BBB permeability and edema formation associated with a decrement in claudin-5 and occludin and potentiated the increase in BBB permeability induced by LPS. However, no neuroinflammation was detected, since the expression of GFAP was unchanged, as well as the expression of the PRLR. These data provide the first evidence that inhibition of PRL with Bromo affects the maintenance of the BBB through modulating the expression of tight junction proteins in vivo.","['blood–brain barrier', 'lipopolysaccharide', 'permeability', 'prolactin', 'tight junctions']",Neuroscience,2015-06-07,"[{'lastname': 'Rosas-Hernandez', 'firstname': 'H', 'initials': 'H', 'affiliation': 'Laboratorio de Fisiologia Celular, Facultad de Ciencias Quimicas, Universidad Autonoma de San Luis Potosi, Av. Manuel Nava 6, Colonia Universitaria, San Luis Potosi, SLP 78210, Mexico.'}, {'lastname': 'Ramirez', 'firstname': 'M', 'initials': 'M', 'affiliation': 'Laboratorio de Fisiologia Celular, Facultad de Ciencias Quimicas, Universidad Autonoma de San Luis Potosi, Av. Manuel Nava 6, Colonia Universitaria, San Luis Potosi, SLP 78210, Mexico.'}, {'lastname': 'Ramirez-Lee', 'firstname': 'M A', 'initials': 'MA', 'affiliation': 'Laboratorio de Fisiologia Celular, Facultad de Ciencias Quimicas, Universidad Autonoma de San Luis Potosi, Av. Manuel Nava 6, Colonia Universitaria, San Luis Potosi, SLP 78210, Mexico.'}, {'lastname': 'Ali', 'firstname': 'S F', 'initials': 'SF', 'affiliation': 'Neurochemistry Laboratory, Division of Neurotoxicology, National Center for Toxicological Research, 3900 NCTR Road, Jefferson, AR 72079, USA.'}, {'lastname': 'Gonzalez', 'firstname': 'C', 'initials': 'C', 'affiliation': 'Laboratorio de Fisiologia Celular, Facultad de Ciencias Quimicas, Universidad Autonoma de San Luis Potosi, Av. Manuel Nava 6, Colonia Universitaria, San Luis Potosi, SLP 78210, Mexico. Electronic address: cgonzalez.uaslp@gmail.com.'}]",,,,Copyright © 2015 IBRO. All rights reserved.,10.1016/j.neuroscience.2015.05.066,<Element 'PubmedArticle' at 0x7f05dc2384f0>
424,26031312,Allosteric modulation of sigma-1 receptors by SKF83959 inhibits microglia-mediated inflammation.,"Recent studies have shown that sigma-1 receptor orthodox agonists can inhibit neuroinflammation. SKF83959 (3-methyl-6-chloro-7,8-hydroxy-1-[3-methylphenyl]-2,3,4,5-tetrahydro-1H-3-benzazepine), an atypical dopamine receptor-1 agonist, has been recently identified as a potent allosteric modulator of sigma-1 receptor. Here, we investigated the anti-inflammatory effects of SKF83959 in lipopolysaccharide (LPS)-stimulated BV2 microglia. Our results indicated that SKF83959 significantly suppressed the expression/release of the pro-inflammatory mediators, such as tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β), inducible nitric oxide synthase (iNOS), and inhibited the generation of reactive oxygen species. All of these responses were blocked by selective sigma-1 receptor antagonists (BD1047 or BD1063) and by ketoconazole (an inhibitor of enzyme cytochrome c17 to inhibit the synthesis of endogenous dehydroepiandrosterone, DHEA). Additionally, we found that SKF83959 promoted the binding activity of DHEA with sigma-1 receptors, and enhanced the inhibitory effects of DHEA on LPS-induced microglia activation in a synergic manner. Furthermore, in a microglia-conditioned media system, SKF83959 inhibited the cytotoxicity of conditioned medium generated by LPS-activated microglia toward HT-22 neuroblastoma cells. Taken together, our study provides the first evidence that allosteric modulation of sigma-1 receptors by SKF83959 inhibits microglia-mediated inflammation. SKF83959 is a potent allosteric modulator of sigma-1 receptor. Our results indicated that SKF83959 enhanced the activity of endogenous dehydroepiandrosterone (DHEA) in a synergic manner, and inhibited the activation of BV2 microglia and the expression/release of the pro-inflammatory mediators, such as tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β), inducible nitric oxide synthase (iNOS).","['SKF83959', 'allosteric modulation', 'dehydroepiandrosterone', 'microglia', 'neuroinflammation', 'sigma-1 receptor']",Journal of neurochemistry,2015-06-03,"[{'lastname': 'Wu', 'firstname': 'Zhuang', 'initials': 'Z', 'affiliation': 'Jiangsu Key laboratory of Translational Research and Therapy for Neuropsychiatric-disorders & Department of Pharmacology, College of Pharmaceutical Sciences, Soochow University, Suzhou, Jiangsu, China.'}, {'lastname': 'Li', 'firstname': 'Linlang', 'initials': 'L', 'affiliation': 'Jiangsu Key laboratory of Translational Research and Therapy for Neuropsychiatric-disorders & Department of Pharmacology, College of Pharmaceutical Sciences, Soochow University, Suzhou, Jiangsu, China.'}, {'lastname': 'Zheng', 'firstname': 'Long-Tai', 'initials': 'LT', 'affiliation': 'Jiangsu Key laboratory of Translational Research and Therapy for Neuropsychiatric-disorders & Department of Pharmacology, College of Pharmaceutical Sciences, Soochow University, Suzhou, Jiangsu, China.'}, {'lastname': 'Xu', 'firstname': 'Zhihong', 'initials': 'Z', 'affiliation': 'Jiangsu Huayi Technology Co, Changshu, Jiangsu, China.'}, {'lastname': 'Guo', 'firstname': 'Lin', 'initials': 'L', 'affiliation': 'Jiangsu Key laboratory of Translational Research and Therapy for Neuropsychiatric-disorders & Department of Pharmacology, College of Pharmaceutical Sciences, Soochow University, Suzhou, Jiangsu, China.'}, {'lastname': 'Zhen', 'firstname': 'Xuechu', 'initials': 'X', 'affiliation': 'Jiangsu Key laboratory of Translational Research and Therapy for Neuropsychiatric-disorders & Department of Pharmacology, College of Pharmaceutical Sciences, Soochow University, Suzhou, Jiangsu, China.'}]",,,,© 2015 International Society for Neurochemistry.,10.1111/jnc.13182,<Element 'PubmedArticle' at 0x7f05dc244310>
425,"25962384
21867920
22339795
22330831
25009704
22716035
25074039
19481465
24973566
24204944
12244105
11956198
20133390
14729864
22053353
22363560
8637870
20950588
22685343
18587449
24102214
23912944
24831513
22646533
25072877
25436483
11356949
7689702
23711022
17901198
19552692
16894349
21615724
23801328
22021672
10794511
20688501
22879589
10688632
9435190
22952224
16365309
24267894
21942629
23411724
22387618
21920367
11447235
25140003
19029917
20657592
21501147
22219191
18700152
15184902
21564090
21501091
23824979
18615177
20122289
23471521
20875047
23515018
24161403
17650315
25269445",4'-O-methylhonokiol increases levels of 2-arachidonoyl glycerol in mouse brain via selective inhibition of its COX-2-mediated oxygenation.,"4'-O-methylhonokiol (MH) is a natural product showing anti-inflammatory, anti-osteoclastogenic, and neuroprotective effects. MH was reported to modulate cannabinoid CB2 receptors as an inverse agonist for cAMP production and an agonist for intracellular [Ca2+]. It was recently shown that MH inhibits cAMP formation via CB2 receptors. In this study, the exact modulation of MH on CB2 receptor activity was elucidated and its endocannabinoid substrate-specific inhibition (SSI) of cyclooxygenase-2 (COX-2) and CNS bioavailability are described for the first time.
CB2 receptor modulation ([35S]GTPγS, cAMP, and β-arrestin) by MH was measured in hCB2-transfected CHO-K1 cells and native conditions (HL60 cells and mouse spleen). The COX-2 SSI was investigated in RAW264.7 cells and in Swiss albino mice by targeted metabolomics using LC-MS/MS.
MH is a CB2 receptor agonist and a potent COX-2 SSI. It induced partial agonism in both the [35S]GTPγS binding and β-arrestin recruitment assays while being a full agonist in the cAMP pathway. MH selectively inhibited PGE2 glycerol ester formation (over PGE2) in RAW264.7 cells and significantly increased the levels of 2-AG in mouse brain in a dose-dependent manner (3 to 20 mg kg(-1)) without affecting other metabolites. After 7 h from intraperitoneal (i.p.) injection, MH was quantified in significant amounts in the brain (corresponding to 200 to 300 nM).
LC-MS/MS quantification shows that MH is bioavailable to the brain and under condition of inflammation exerts significant indirect effects on 2-AG levels. The biphenyl scaffold might serve as valuable source of dual CB2 receptor modulators and COX-2 SSIs as demonstrated by additional MH analogs that show similar effects. The combination of CB2 agonism and COX-2 SSI offers a yet unexplored polypharmacology with expected synergistic effects in neuroinflammatory diseases, thus providing a rationale for the diverse neuroprotective effects reported for MH in animal models.",[],Journal of neuroinflammation,2015-05-13,"[{'lastname': 'Chicca', 'firstname': 'Andrea', 'initials': 'A', 'affiliation': 'Institute of Biochemistry and Molecular Medicine, NCCR TransCure, University of Bern, Bühlstrasse 28, CH-3012, Bern, Switzerland. chicca@ibmm.unibe.ch.'}, {'lastname': 'Gachet', 'firstname': 'Maria Salomé', 'initials': 'MS', 'affiliation': 'Institute of Biochemistry and Molecular Medicine, NCCR TransCure, University of Bern, Bühlstrasse 28, CH-3012, Bern, Switzerland. gachet@ibmm.unibe.ch.'}, {'lastname': 'Petrucci', 'firstname': 'Vanessa', 'initials': 'V', 'affiliation': 'Institute of Biochemistry and Molecular Medicine, NCCR TransCure, University of Bern, Bühlstrasse 28, CH-3012, Bern, Switzerland. petrucci@ibmm.unibe.ch.'}, {'lastname': 'Schuehly', 'firstname': 'Wolfgang', 'initials': 'W', 'affiliation': 'Institute of Zoology, Karl-Franzens-University Graz, Universitätsplatz 2, 8010, Graz, Austria. wolfgang.schuehly@uni-graz.at.'}, {'lastname': 'Charles', 'firstname': 'Roch-Philippe', 'initials': 'RP', 'affiliation': 'Institute of Biochemistry and Molecular Medicine, NCCR TransCure, University of Bern, Bühlstrasse 28, CH-3012, Bern, Switzerland. charles@ibmm.unibe.ch.'}, {'lastname': 'Gertsch', 'firstname': 'Jürg', 'initials': 'J', 'affiliation': 'Institute of Biochemistry and Molecular Medicine, NCCR TransCure, University of Bern, Bühlstrasse 28, CH-3012, Bern, Switzerland. gertsch@ibmm.unibe.ch.'}]",,,"MH is a CB2 receptor agonist and a potent COX-2 SSI. It induced partial agonism in both the [35S]GTPγS binding and β-arrestin recruitment assays while being a full agonist in the cAMP pathway. MH selectively inhibited PGE2 glycerol ester formation (over PGE2) in RAW264.7 cells and significantly increased the levels of 2-AG in mouse brain in a dose-dependent manner (3 to 20 mg kg(-1)) without affecting other metabolites. After 7 h from intraperitoneal (i.p.) injection, MH was quantified in significant amounts in the brain (corresponding to 200 to 300 nM).",,"10.1186/s12974-015-0307-7
10.1016/j.chembiol.2011.05.012
10.1186/1742-2094-9-35
10.4062/biomolther.2014.030
10.1186/1742-2094-9-135
10.1016/j.bmc.2009.05.018
10.1016/j.bbagen.2014.06.016
10.1371/journal.pone.0077739
10.1074/jbc.M206788200
10.1074/jbc.M201084200
10.1124/pr.109.001081
10.1194/jlr.M300475-JLR200
10.1038/nchembio.663
10.1371/journal.pone.0031111
10.1073/pnas.93.6.2317
10.1016/j.brainres.2010.10.019
10.1124/jpet.112.196451
10.1038/bjp.2008.142
10.1111/bph.12410
10.1038/nn.3480
10.1021/cb500177c
10.1111/j.1476-5381.2012.02059.x
10.1016/j.ejmech.2014.07.062
10.1016/j.jchromb.2014.11.001
10.1038/365061a0
10.1111/bph.12191
10.1124/mol.107.040352
10.1111/j.1476-5381.2009.00154.x
10.1038/sj.bjp.0706838
10.1111/j.1476-5381.2011.01503.x
10.1074/jbc.M113.489906
10.1126/science.1209200
10.1016/S0024-3205(99)00628-1
10.1016/j.jnutbio.2010.04.002
10.1074/jbc.M112.373241
10.1074/jbc.M112.382481
10.1073/pnas.0509588102
10.1016/j.cell.2013.10.042
10.1146/annurev.pharmtox.010909.105800
10.1038/nrd3954
10.1016/j.bcp.2012.02.014
10.1016/j.jim.2011.08.021
10.1074/jbc.M105854200
10.1124/mol.114.094284
10.1038/nchembio.129
10.1038/nn.2601
10.1111/j.1476-5381.2011.01444.x
10.1074/jbc.M111.327874
10.1016/j.pharmthera.2008.08.001
10.1038/nn1262
10.1111/j.1476-5381.2011.01486.x
10.1089/jmf.2010.1111
10.1002/ptr.5033
10.2174/157015907780866884
10.1186/alzrt24
10.1007/s11481-013-9445-9
10.1111/j.1755-5949.2010.00195.x
10.1016/j.brainres.2013.10.025
10.1186/1471-2202-8-54
10.15252/emmm.201404168",<Element 'PubmedArticle' at 0x7f05dc2586d0>
426,"25890304
15094071
10826997
16131630
10613344
15229476
9722981
15970280
3563497
17645240
3885223
21270887
8386530
23497056
22430016
12612639
15003389
12466191
23170013
8920958
10070049
19349193
16569464
17116217
11145584
11466439
15094076
9101135
11232005
18057344
18057338
10534146
8762726
15562401
23941777
21931374
24259252
23700046
24005315
24430534
21135382
20517932
17914061
24878635
23959579
22509390
20889566
20110184
19251055
15370374
15466497
15598782
12629086
22489249
20029798
23392468
18677023
18177247
21556959
24510686
10414596
23612635
23781310
21378090
24685003
23473966
16030122
18478565
9068598
1317782
10022425",Insulin-like growth factors and related proteins in plasma and cerebrospinal fluids of HIV-positive individuals.,"Clinically significant dysregulation of the insulin-like growth factor (IGF) family proteins occurs in HIV-infected individuals, but the details including whether the deficiencies in IGFs contribute to CNS dysfunction are unknown.
We measured the levels of IGF1, IGF2, IGFBP1, IGFBP2, and IGF2 receptor (IGF2R) in matching plasma and cerebrospinal fluid (CSF) samples of 107 HIV+ individuals from CNS HIV Antiretroviral Therapy Effects Research (CHARTER) and analyzed their associations with demographic and disease characteristics, as well as levels of several soluble inflammatory mediators (TNFα, IL-6, IL-10, IL-17, IP-10, MCP-1, and progranulin). We also determined whether IGF1 or IGF2 deficiency is associated with HIV-associated neurocognitive disorder (HAND) and whether the levels of soluble IGF2R (an IGF scavenging receptor, which we also have found to be a cofactor for HIV infection in vitro) correlate with HIV viral load (VL).
There was a positive correlation between the levels of IGF-binding proteins (IGFBPs) and those of inflammatory mediators: between plasma IGFBP1 and IL-17 (β coefficient 0.28, P = 0.009), plasma IGFBP2 and IL-6 (β coefficient 0.209, P = 0.021), CSF IGFBP1 and TNFα (β coefficient 0.394, P < 0.001), and CSF IGFBP2 and TNF-α (β coefficient 0.14, P < 0.001). As IGFBPs limit IGF availability, these results suggest that inflammation is a significant factor that modulates IGF protein expression/availability in the setting of HIV infection. However, there was no significant association between HAND and the reduced levels of plasma IGF1, IGF2, or CSF IGF1, suggesting a limited power of our study. Interestingly, plasma IGF1 was significantly reduced in subjects on non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy (ART) compared to protease inhibitor-based therapy (174.1 ± 59.8 vs. 202.8 ± 47.3 ng/ml, P = 0.008), suggesting a scenario in which ART regimen-related toxicity can contribute to HAND. Plasma IGF2R levels were positively correlated with plasma VL (β coefficient 0.37, P = 0.021) and inversely correlated with current CD4+ T cell counts (β coefficient -0.04, P = 0.021), supporting our previous findings in vitro.
Together, these results strongly implicate (1) an inverse relationship between inflammation and IGF growth factor availability and the contribution of IGF deficiencies to HAND and (2) the role of IGF2R in HIV infection and as a surrogate biomarker for HIV VL.",[],Journal of neuroinflammation,2015-04-19,"[{'lastname': 'Suh', 'firstname': 'Hyeon-Sook', 'initials': 'HS', 'affiliation': 'Department of Pathology, Albert Einstein College of Medicine, Bronx, NY, 10461, USA. hyeon-sook.suh@einstein.yu.edu.'}, {'lastname': 'Lo', 'firstname': 'Yungtai', 'initials': 'Y', 'affiliation': 'Department of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, NY, 10461, USA. yungtai.lo@einstein.yu.edu.'}, {'lastname': 'Choi', 'firstname': 'Namjong', 'initials': 'N', 'affiliation': 'Department of Pathology, Albert Einstein College of Medicine, Bronx, NY, 10461, USA. namjong.choi@einstein.yu.edu.'}, {'lastname': 'Letendre', 'firstname': 'Scott', 'initials': 'S', 'affiliation': 'Department of Neurology, University of California San Diego, 9500 Gilman Dr, La Jolla, CA, 92093, USA. sletendre@ucsd.edu.'}, {'lastname': 'Lee', 'firstname': 'Sunhee C', 'initials': 'SC', 'affiliation': 'Department of Pathology, Albert Einstein College of Medicine, Bronx, NY, 10461, USA. sunhee.lee@einstein.yu.edu.'}]",,,"There was a positive correlation between the levels of IGF-binding proteins (IGFBPs) and those of inflammatory mediators: between plasma IGFBP1 and IL-17 (β coefficient 0.28, P = 0.009), plasma IGFBP2 and IL-6 (β coefficient 0.209, P = 0.021), CSF IGFBP1 and TNFα (β coefficient 0.394, P < 0.001), and CSF IGFBP2 and TNF-α (β coefficient 0.14, P < 0.001). As IGFBPs limit IGF availability, these results suggest that inflammation is a significant factor that modulates IGF protein expression/availability in the setting of HIV infection. However, there was no significant association between HAND and the reduced levels of plasma IGF1, IGF2, or CSF IGF1, suggesting a limited power of our study. Interestingly, plasma IGF1 was significantly reduced in subjects on non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy (ART) compared to protease inhibitor-based therapy (174.1 ± 59.8 vs. 202.8 ± 47.3 ng/ml, P = 0.008), suggesting a scenario in which ART regimen-related toxicity can contribute to HAND. Plasma IGF2R levels were positively correlated with plasma VL (β coefficient 0.37, P = 0.021) and inversely correlated with current CD4+ T cell counts (β coefficient -0.04, P = 0.021), supporting our previous findings in vitro.",,"10.1186/s12974-015-0288-6
10.1016/j.ejphar.2004.02.042
10.1210/er.2004-0024
10.1038/nrc1387
10.1016/S1357-2725(98)00048-X
10.1016/j.cccn.2005.05.001
10.1126/science.3563497
10.1111/j.1440-1789.2007.00776.x
10.1073/pnas.82.7.2153
10.1038/nature09667
10.1016/0896-6273(93)90173-O
10.1186/1742-2094-10-37
10.1038/nrn3209
10.1038/nrm1050
10.1016/j.brainresrev.2003.11.002
10.1210/er.2001-0033
10.1212/WNL.0b013e3182752eef
10.1006/bbrc.1996.1705
10.1016/j.tem.2009.01.002
10.1016/j.neurobiolaging.2006.02.012
10.1111/j.1468-1331.2006.01503.x
10.1016/j.ejphar.2004.02.047
10.1210/edrv.18.2.0296
10.1056/NEJMe0707201
10.1056/NEJMoa072375
10.1097/00042560-199909010-00006
10.1046/j.1365-2265.1996.705526.x
10.1016/j.metabol.2004.06.025
10.1016/j.cyto.2013.07.018
10.1038/nrendo.2011.151
10.1007/s11481-013-9512-2
10.1007/s11154-013-9247-7
10.1530/EJE-13-0510
10.3851/IMP2721
10.1212/WNL.0b013e318200d727
10.1212/01.WNL.0000287431.88658.8b
10.1371/journal.pone.0098184
10.1007/s11481-013-9495-z
10.1371/journal.pone.0035115
10.2353/ajpath.2010.100399
10.1016/j.ghir.2009.12.005
10.1016/S0083-6729(08)00624-9
10.1080/13803390490509565
10.1093/aje/kwh289
10.1210/jc.2002-021380
10.1155/2012/467154
10.1002/jmv.21625
10.1097/QAI.0b013e318289bb7e
10.1001/jama.300.5.509
10.1086/524848
10.1007/s13365-011-0034-5
10.1007/s11481-013-9520-2
10.1002/(SICI)1098-2825(1999)13:4<166::AID-JCLA5>3.0.CO;2-X
10.1530/EC-12-0053
10.1530/EJE-11-0059
10.1186/1471-2377-14-64
10.1016/j.psyneuen.2013.02.006
10.1158/1055-9965.EPI-04-0803
10.1002/ijc.23558",<Element 'PubmedArticle' at 0x7f05dc1c9a40>
427,"25885968
24929952
23883676
22417477
15626687
19270192
23180053
21159555
23980069
20580712
22189567
10536259
22031787
22158645
22526820
24279649
18086951
24687998
25538205
22718804
21865264
18768402
22592638
19075092
22287496
25135355
22956998
21178125
23224511
22187625
10930194
12388241
21394088
22257799
18768398
21846363
23823602
14714584
16103268
24955935
25223692
17569888
20547972
23547236
21209001
19536048
19849845
15748951
24935937",Brain endogenous angiotensin II receptor type 2 (AT2-R) protects against DOCA/salt-induced hypertension in female rats.,"Recent studies demonstrate that there are sex differences in the expression of angiotensin receptor type 2 (AT2-R) in the kidney and that AT2-R plays an enhanced role in regulating blood pressure (BP) in females. Also, brain AT2-R activation has been reported to negatively modulate BP and sympathetic outflow. The present study investigated whether the central blockade of endogenous AT2-R augments deoxycorticosterone acetate (DOCA)/salt-induced hypertension in both male and female rats.
All rats were subcutaneously infused with DOCA combined with 1% NaCl solution as the sole drinking fluid. BP and heart rate (HR) were recorded by telemetric transmitters. To determine the effect of central AT2-R on DOCA/salt-induced hypertension, male and female rats were intracerebroventricularly (icv) infused with AT2-R antagonist, PD123,319, during DOCA/salt treatment. Subsequently, the paraventricular nucleus (PVN) of the hypothalamus, a key cardiovascular regulatory region of the brain, was analyzed by quantitative real-time PCR and Western blot.
DOCA/salt treatment elicited a greater increase in BP in male rats than that in females. Icv infusions of the AT2-R antagonist significantly augmented DOCA/salt pressor effects in females. However, this same treatment had no enhanced effect on DOCA/salt-induced increase in the BP in males. Real-time PCR and Western blot analysis of the female brain revealed that DOCA/salt treatment enhanced the mRNA and protein expression for both antihypertensive components including AT2-R, angiotensin-converting enzyme (ACE)-2, and interleukin (IL)-10 and hypertensive components including angiotensin receptor type 1 (AT1-R), ACE-1, tumor necrosis factor (TNF)-α, and IL-1β, but decreased mRNA expression of renin in the PVN. The central blockade of AT2-R reversed the changes in mRNA and protein expressions of ACE-2, IL-10, and renin, further increased the expressions of TNF-α and IL-1β, and kept higher the expressions of AT1-R, ACE-1, and AT2-R.
These results indicate that endogenous AT2-R activation in the brain plays an important protective role in the development of DOCA/salt-induced hypertension in females, but not in males. The protective effect of AT2-R in females involves regulating the expression of brain renin-angiotensin system components and proinflammatory cytokines.",[],Journal of neuroinflammation,2015-04-18,"[{'lastname': 'Dai', 'firstname': 'Shu-Yan', 'initials': 'SY', 'affiliation': 'Department of Obstetrics and Gynecology, Shengjing Hospital, China Medical University, 36, Sanhao Street, Shenyang, 110004, China. daishy2014@163.com.'}, {'lastname': 'Peng', 'firstname': 'Wei', 'initials': 'W', 'affiliation': 'Department of Physiology and Pathophysiology, Life Science Research Center, Hebei North University, Zhangjiakou City, Hebei, China. sun003@126.com.'}, {'lastname': 'Zhang', 'firstname': 'Yu-Ping', 'initials': 'YP', 'affiliation': 'Department of Physiology and Pathophysiology, Life Science Research Center, Hebei North University, Zhangjiakou City, Hebei, China. zhangeping@sina.com.'}, {'lastname': 'Li', 'firstname': 'Jian-Dong', 'initials': 'JD', 'affiliation': 'Department of Physiology and Pathophysiology, Life Science Research Center, Hebei North University, Zhangjiakou City, Hebei, China. djl999shengli@163.com.'}, {'lastname': 'Shen', 'firstname': 'Ying', 'initials': 'Y', 'affiliation': 'Department of Obstetrics and Gynecology, Shengjing Hospital, China Medical University, 36, Sanhao Street, Shenyang, 110004, China. daishy2014@163.com.'}, {'lastname': 'Sun', 'firstname': 'Xiao-Fei', 'initials': 'XF', 'affiliation': 'Department of Obstetrics and Gynecology, Shengjing Hospital, China Medical University, 36, Sanhao Street, Shenyang, 110004, China. daishy2014@163.com.'}]",,,"DOCA/salt treatment elicited a greater increase in BP in male rats than that in females. Icv infusions of the AT2-R antagonist significantly augmented DOCA/salt pressor effects in females. However, this same treatment had no enhanced effect on DOCA/salt-induced increase in the BP in males. Real-time PCR and Western blot analysis of the female brain revealed that DOCA/salt treatment enhanced the mRNA and protein expression for both antihypertensive components including AT2-R, angiotensin-converting enzyme (ACE)-2, and interleukin (IL)-10 and hypertensive components including angiotensin receptor type 1 (AT1-R), ACE-1, tumor necrosis factor (TNF)-α, and IL-1β, but decreased mRNA expression of renin in the PVN. The central blockade of AT2-R reversed the changes in mRNA and protein expressions of ACE-2, IL-10, and renin, further increased the expressions of TNF-α and IL-1β, and kept higher the expressions of AT1-R, ACE-1, and AT2-R.",,"10.1186/s12974-015-0261-4
10.1007/s11906-014-0458-4
10.1152/ajpregu.00222.2013
10.1186/2042-6410-3-7
10.1152/ajpheart.00969.2004
10.1152/ajpheart.01255.2008
10.1007/s11906-012-0319-y
10.1016/j.coph.2010.11.004
10.1161/HYPERTENSIONAHA.113.00922
10.1016/j.expneurol.2010.05.015
10.1093/brain/awr320
10.1016/S0006-8993(99)01815-6
10.1152/ajpregu.00256.2011
10.1161/HYPERTENSIONAHA.111.184986
10.1177/1470320312443720
10.1111/apha.12207
10.1161/HYPERTENSIONAHA.107.101717
10.1093/ajh/hpu044
10.1152/ajpregu.00046.2012
10.1152/ajprenal.00339.2011
10.1161/HYPERTENSIONAHA.108.113639
10.1152/ajprenal.00097.2012
10.1161/HYPERTENSIONAHA.108.124198
10.1177/1470320311432185
10.1016/j.neuroscience.2014.07.071
10.1371/journal.pone.0044121
10.1152/ajpregu.00222.2010
10.1007/s11906-012-0321-4
10.1155/2012/192567
10.1097/00004872-200018070-00018
10.1152/ajpheart.00515.2002
10.1038/ajh.2011.33
10.1097/MNH.0b013e328350261b
10.1161/HYPERTENSIONAHA.108.116228
10.1186/1750-1326-6-58
10.1038/ki.2013.193
10.1291/hypres.26.915
10.1161/01.HYP.0000178564.14464.80
10.1089/jir.2013.0159
10.1016/j.taap.2014.09.004
10.1161/CIRCRESAHA.107.148940
10.1161/HYPERTENSIONAHA.110.150409
10.1161/HYPERTENSIONAHA.111.00422
10.1152/ajprenal.00616.2010
10.1097/SHK.0b013e3181b0ebcb
10.1186/1742-2094-6-30
10.1016/j.jneuroim.2004.12.016
10.1161/HYPERTENSIONAHA.114.03189",<Element 'PubmedArticle' at 0x7f05dc1830e0>
428,"25875136
2308954
18482420
10650181
20468046
23012451
16547218
18196212
24530639
21707818
23935251
16402900
18792785
18781987
18172430
20632970
12052030
21735070
19355915
19226257
23934130
21345170
24204649
23515018
22321918
20562169
22159099
9238833
9610679
24744434
16918439
24962261
15864274
17011047
24427137
17023558
24509089
18782012
21831965
22079984
18037916
12640071
24070095
18617277
18426493
9916880
16081203
22940268
24897085
11106790
10843702
14757702
21768160
23117180
18597549",Exposure of Adolescent Mice to Delta-9-Tetrahydrocannabinol Induces Long-Lasting Modulation of Pro- and Anti-Inflammatory Cytokines in Hypothalamus and Hippocampus Similar to that Observed for Peripheral Macrophages.,"Cannabis use is frequent among adolescents. Its main component, delta-9-tetrahydrocannabinol (THC), affects the immune system. We recently demonstrated that chronic exposure of adolescent mice to THC suppressed immunity immediately after treatment but that after a washout period THC induced a long-lasting opposite modulation towards a proinflammatory and T-helper-1 phenotype in adulthood. The main objective of this study was to investigate whether the same effect was also present in brain regions such as the hypothalamus and hippocampus. Thirty-three-day-old adolescent and 80-day-old adult male mice were used. Acute THC administration induced a similar reduction of macrophage proinflammatory cytokines and an IL-10 increase in adult and adolescent mice. THC did not affect brain cytokines in adult mice, but a proinflammatory cytokine decrease was evident in the adolescent brain. A similar effect was present in the hypothalamus and hippocampus after 10 days' THC administration. In contrast, when brain cytokines were measured 47 days after the final THC administration, we observed an inverted effect in adult mice treated as adolescents, i.e., IL-1β and TNF-α increased and IL-10 decreased, indicating a shift toward neuroinflammation. These data suggest that THC exposure in adolescence has long-lasting effects on brain cytokines that parallel those present in the periphery. This modulation may affect vulnerability to immune and behavioural diseases in adulthood.",[],Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology,2015-04-16,"[{'lastname': 'Moretti', 'firstname': 'Sarah', 'initials': 'S', 'affiliation': 'Dipartimento di Scienze Farmacologiche e Biomolecolari, University of Milano, via Vanvitelli 32, 20129, Milan, Italy.'}, {'lastname': 'Franchi', 'firstname': 'Silvia', 'initials': 'S', 'affiliation': None}, {'lastname': 'Castelli', 'firstname': 'Mara', 'initials': 'M', 'affiliation': None}, {'lastname': 'Amodeo', 'firstname': 'Giada', 'initials': 'G', 'affiliation': None}, {'lastname': 'Somaini', 'firstname': 'Lorenzo', 'initials': 'L', 'affiliation': None}, {'lastname': 'Panerai', 'firstname': 'Alberto', 'initials': 'A', 'affiliation': None}, {'lastname': 'Sacerdote', 'firstname': 'Paola', 'initials': 'P', 'affiliation': None}]",,,,,10.1007/s11481-015-9592-2,<Element 'PubmedArticle' at 0x7f05dc0e89f0>
429,"25714473
16284108
18250205
23087666
20002528
15670654
17089881
11264318
18289174
12615622
12773326
18276944
12377837
16272771
15082065
21123558
16469926
22405498
12379243
16840748
11296300
18446826
15328027
15743533
24246910
17710531
23877747
24595452
16563441
20157238
19499323
17045262
21846086
24746483
22523540
24505383
20336662
20871647
22265820
22438957
22138659
19185773
18405964
24400114
24311876
15750040
21760595
21763611
16469705
14532003
17326836
17520191
15773902
18305250
20010695
22118713
17219050
14599483
19074266
20813126
11054421
23894366",Neuroprotective mechanism of Lycium barbarum polysaccharides against hippocampal-dependent spatial memory deficits in a rat model of obstructive sleep apnea.,"Chronic intermittent hypoxia (CIH) is a hallmark of obstructive sleep apnea (OSA), which induces hippocampal injuries mediated by oxidative stress. This study aims to examine the neuroprotective mechanism of Lycium barbarum polysaccharides (LBP) against CIH-induced spatial memory deficits. Adult Sprague-Dawley rats were exposed to hypoxic treatment resembling a severe OSA condition for a week. The animals were orally fed with LBP solution (1 mg/kg) daily 2 hours prior to hypoxia or in air for the control. The effect of LBP on the spatial memory and levels of oxidative stress, inflammation, endoplasmic reticulum (ER) stress, apoptosis and neurogenesis in the hippocampus was examined. There was a significant deficit in the spatial memory and an elevated level of malondialdehyde with a decreased expression of antioxidant enzymes (SOD, GPx-1) in the hypoxic group when compared with the normoxic control. In addition, redox-sensitive nuclear factor kappa B (NFКB) canonical pathway was activated with a translocation of NFКB members (p65, p50) and increased expression levels of NFКB-dependent inflammatory cytokines and mediator (TNFα, IL-1β, COX-2); also, a significantly elevated level of ER stress (GRP78/Bip, PERK, CHOP) and autophagic flux in the hypoxic group, leading to neuronal apoptosis in hippocampal subfields (DG, CA1, CA3). Remarkably, LBP administration normalized the elevated level of oxidative stress, neuroinflammation, ER stress, autophagic flux and apoptosis induced by hypoxia. Moreover, LBP significantly mitigated both the caspase-dependent intrinsic (Bax, Bcl2, cytochrome C, cleaved caspase-3) and extrinsic (FADD, cleaved caspase-8, Bid) signaling apoptotic cascades. Furthermore, LBP administration prevented the spatial memory deficit and enhanced the hippocampal neurogenesis induced by hypoxia. Our results suggest that LBP is neuroprotective against CIH-induced hippocampal-dependent spatial memory deficits by promoting hippocampal neurogenesis and negatively modulating the apoptotic signaling cascades activated by oxidative stress and inflammation.",[],PloS one,2015-02-26,"[{'lastname': 'Lam', 'firstname': 'Chun-Sing', 'initials': 'CS', 'affiliation': 'Department of Physiology, University of Hong Kong, Hong Kong, PR China.'}, {'lastname': 'Tipoe', 'firstname': 'George Lim', 'initials': 'GL', 'affiliation': 'Department of Anatomy, University of Hong Kong, Hong Kong, PR China; Research Centre of Heart, Brain, Hormone & Healthy Aging, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, PR China.'}, {'lastname': 'So', 'firstname': 'Kwok-Fai', 'initials': 'KF', 'affiliation': 'Department of Anatomy, University of Hong Kong, Hong Kong, PR China; Department of Ophthalmology, University of Hong Kong, Hong Kong, PR China; Research Centre of Heart, Brain, Hormone & Healthy Aging, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, PR China; State Key Laboratory of Brain and Cognitive Science, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, PR China; Guangdong-HongKong-Macau Institute of CNS Regeneration, Jinan University, Guangdong, PR China; Guangdong Key Laboratory of Brain Function and Diseases, Jinan University, Guangzhou 510632, China.'}, {'lastname': 'Fung', 'firstname': 'Man-Lung', 'initials': 'ML', 'affiliation': 'Department of Physiology, University of Hong Kong, Hong Kong, PR China; Research Centre of Heart, Brain, Hormone & Healthy Aging, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, PR China.'}]",,,,,"10.1371/journal.pone.0117990
10.1513/pats.200709-155MG
10.3389/fneur.2012.00139
10.1111/j.1471-4159.2009.06535.x
10.1111/j.1600-079X.2007.00514.x
10.1164/rccm.200701-110OC
10.1523/JNEUROSCI.2862-10.2010
10.1002/hipo.20439
10.1016/j.pbb.2013.11.009
10.1038/nutd.2013.22
10.1371/journal.pone.0090780
10.3233/JAD-2010-1280
10.1007/s10571-009-9419-x
10.1021/jf2021754
10.1016/j.jep.2014.04.013
10.1371/journal.pone.0033374
10.1371/journal.pone.0088076
10.1002/jcb.22539
10.1016/j.phymed.2011.11.011
10.1371/journal.pone.0033596
10.1016/j.jep.2011.11.033
10.1016/j.nutres.2008.11.005
10.1016/j.ijbiomac.2008.02.003
10.1371/journal.pone.0084800
10.1038/cdd.2011.96
10.1523/JNEUROSCI.5232-07.2008
10.1038/emboj.2009.369
10.1111/j.1742-7843.2011.00834.x
10.1073/pnas.0808036105
10.1016/j.ijbiomac.2010.08.016
10.1371/journal.pone.0068881",<Element 'PubmedArticle' at 0x7f05dc1014f0>
430,"25698740
22792024
15763581
19625512
12191816
15342202
11910117
10995847
15049508
17106878
10788757
16732273
15716415
14684243
18640811
22593065
18073775
15895084
15850652
9233643
12383243
12955300
17433456
22319481
19275930
17965659
11931741
17093901
21106836
16639403
16626814
12441055
15857621
10595516
10571232
12052905
12124424
11056157
24753224
12167678
18612067
8661250
9697854
10399941
15869941
12122150
17325196
22167804
8195155
25033184
10595426
20022933
11566478
9728920
21447397
14507968
23575840
8953500
15713269
20970492",Microglial activation enhances associative taste memory through purinergic modulation of glutamatergic neurotransmission.,"The cerebral innate immune system is able to modulate brain functioning and cognitive processes. During activation of the cerebral innate immune system, inflammatory factors produced by microglia, such as cytokines and adenosine triphosphate (ATP), have been directly linked to modulation of glutamatergic system on one hand and learning and memory functions on the other hand. However, the cellular mechanisms by which microglial activation modulates cognitive processes are still unclear. Here, we used taste memory tasks, highly dependent on glutamatergic transmission in the insular cortex, to investigate the behavioral and cellular impacts of an inflammation restricted to this cortical area in rats. We first show that intrainsular infusion of the endotoxin lipopolysaccharide induces a local inflammation and increases glutamatergic AMPA, but not NMDA, receptor expression at the synaptic level. This cortical inflammation also enhances associative, but not incidental, taste memory through increase of glutamatergic AMPA receptor trafficking. Moreover, we demonstrate that ATP, but not proinflammatory cytokines, is responsible for inflammation-induced enhancement of both associative taste memory and AMPA receptor expression in insular cortex. In conclusion, we propose that inflammation restricted to the insular cortex enhances associative taste memory through a purinergic-dependent increase of glutamatergic AMPA receptor expression at the synapse.","['AMPA', 'ATP', 'cytokines', 'lipopolysaccharide', 'neuroinflammation']",The Journal of neuroscience : the official journal of the Society for Neuroscience,2015-02-24,"[{'lastname': 'Delpech', 'firstname': 'Jean-Christophe', 'initials': 'JC', 'affiliation': 'INRA, Nutrition et Neurobiologie intégrée, Unité Mixte de Recherche 1286, Bordeaux, France, University of Bordeaux, Nutrition et Neurobiologie intégrée, Unité Mixte de Recherche 1286, Bordeaux, France.'}, {'lastname': 'Saucisse', 'firstname': 'Nicolas', 'initials': 'N', 'affiliation': 'INRA, Nutrition et Neurobiologie intégrée, Unité Mixte de Recherche 1286, Bordeaux, France, University of Bordeaux, Nutrition et Neurobiologie intégrée, Unité Mixte de Recherche 1286, Bordeaux, France.'}, {'lastname': 'Parkes', 'firstname': 'Shauna L', 'initials': 'SL', 'affiliation': ""INRA, Nutrition et Neurobiologie intégrée, Unité Mixte de Recherche 1286, Bordeaux, France, University of Bordeaux, Nutrition et Neurobiologie intégrée, Unité Mixte de Recherche 1286, Bordeaux, France, Centre National de la Recherche Scientifique, Institut de Neurosciences Cognitives et Intégratives d'Aquitaine, Unité Mixte de Recherche 5287, 33076 Bordeaux, France, Université de Bordeaux, Institut de Neurosciences Cognitives et Intégratives d'Aquitaine, 33076 Bordeaux, France.""}, {'lastname': 'Lacabanne', 'firstname': 'Chloe', 'initials': 'C', 'affiliation': 'INRA, Nutrition et Neurobiologie intégrée, Unité Mixte de Recherche 1286, Bordeaux, France, University of Bordeaux, Nutrition et Neurobiologie intégrée, Unité Mixte de Recherche 1286, Bordeaux, France.'}, {'lastname': 'Aubert', 'firstname': 'Agnes', 'initials': 'A', 'affiliation': 'INRA, Nutrition et Neurobiologie intégrée, Unité Mixte de Recherche 1286, Bordeaux, France, University of Bordeaux, Nutrition et Neurobiologie intégrée, Unité Mixte de Recherche 1286, Bordeaux, France.'}, {'lastname': 'Casenave', 'firstname': 'Fabrice', 'initials': 'F', 'affiliation': 'INRA, Nutrition et Neurobiologie intégrée, Unité Mixte de Recherche 1286, Bordeaux, France, University of Bordeaux, Nutrition et Neurobiologie intégrée, Unité Mixte de Recherche 1286, Bordeaux, France.'}, {'lastname': 'Coutureau', 'firstname': 'Etienne', 'initials': 'E', 'affiliation': ""Centre National de la Recherche Scientifique, Institut de Neurosciences Cognitives et Intégratives d'Aquitaine, Unité Mixte de Recherche 5287, 33076 Bordeaux, France, Université de Bordeaux, Institut de Neurosciences Cognitives et Intégratives d'Aquitaine, 33076 Bordeaux, France.""}, {'lastname': 'Sans', 'firstname': 'Nathalie', 'initials': 'N', 'affiliation': 'Institut National de la Santé et de la Recherche Médicale, U862 NeuroCentre Magendie, Planar Polarity and Plasticity Group, Bordeaux, France, and University of Bordeaux, U862 NeuroCentre Magendie, Bordeaux, France.'}, {'lastname': 'Layé', 'firstname': 'Sophie', 'initials': 'S', 'affiliation': 'INRA, Nutrition et Neurobiologie intégrée, Unité Mixte de Recherche 1286, Bordeaux, France, University of Bordeaux, Nutrition et Neurobiologie intégrée, Unité Mixte de Recherche 1286, Bordeaux, France.'}, {'lastname': 'Ferreira', 'firstname': 'Guillaume', 'initials': 'G', 'affiliation': 'INRA, Nutrition et Neurobiologie intégrée, Unité Mixte de Recherche 1286, Bordeaux, France, University of Bordeaux, Nutrition et Neurobiologie intégrée, Unité Mixte de Recherche 1286, Bordeaux, France, guillaume.ferreira@bordeaux.inra.fr agnes.nadjar@u-bordeaux.fr.'}, {'lastname': 'Nadjar', 'firstname': 'Agnes', 'initials': 'A', 'affiliation': 'INRA, Nutrition et Neurobiologie intégrée, Unité Mixte de Recherche 1286, Bordeaux, France, University of Bordeaux, Nutrition et Neurobiologie intégrée, Unité Mixte de Recherche 1286, Bordeaux, France, guillaume.ferreira@bordeaux.inra.fr agnes.nadjar@u-bordeaux.fr.'}]",,,,Copyright © 2015 the authors 0270-6474/15/353022-12$15.00/0.,"10.1523/JNEUROSCI.3028-14.2015
10.5607/en.2012.21.2.37
10.1016/j.physbeh.2005.01.006
10.1523/JNEUROSCI.5667-08.2009
10.1016/S0166-4328(02)00043-8
10.1016/j.jneuroim.2004.06.009
10.1126/science.1067859
10.1023/B:CEMN.0000012722.45805.c8
10.1002/glia.20459
10.1016/S0893-133X(99)00166-9
10.1038/nn1715
10.1523/JNEUROSCI.4268-04.2005
10.1016/S0166-4328(03)00181-5
10.1016/j.bbi.2008.05.007
10.1523/JNEUROSCI.0025-12.2012
10.1038/nrn2297
10.1038/nn1472
10.1016/j.brainresrev.2004.12.003
10.1046/j.1460-9568.2002.02174.x
10.1007/s00213-003-1554-3
10.1016/j.bbr.2007.03.021
10.3389/fnbeh.2011.00087
10.1016/j.bbi.2009.03.001
10.1038/nn1997
10.1016/S0896-6273(02)00638-4
10.1007/s10787-006-0006-1
10.1523/JNEUROSCI.1872-10.2010
10.1038/nn0506-593
10.1016/j.jneuroim.2006.03.001
10.1016/S0896-6273(02)01024-3
10.1016/j.neuropharm.2005.02.001
10.1016/S0896-6273(00)81119-8
10.1016/S0896-6273(00)80852-1
10.1146/annurev.neuro.25.112701.142758
10.1046/j.1471-4159.2002.00944.x
10.1074/jbc.M006814200
10.1002/hipo.22295
10.1073/pnas.182200499
10.1101/lm.964708
10.1006/nlme.1996.0042
10.1016/S0896-6273(00)80517-6
10.1016/S0896-6273(00)80786-2
10.1016/j.expneurol.2004.12.026
10.1113/jphysiol.2002.021956
10.1085/jgp.200609693
10.1073/pnas.1111098109
10.1016/j.neuron.2014.06.005
10.1016/S0166-4328(99)00098-4
10.1210/en.2009-0862
10.1016/S0149-7634(01)00021-5
10.1016/S0896-6273(00)80548-6
10.1016/j.nlm.2011.03.005
10.1523/JNEUROSCI.5107-12.2013
10.1111/j.2042-7158.1996.tb05891.x
10.1016/j.brainres.2004.11.018
10.1016/j.bbi.2010.10.015",<Element 'PubmedArticle' at 0x7f05dc0a8f40>
431,25697044,Melatonin and brain inflammaging.,"Melatonin is known to possess several properties of value for healthy aging, as a direct and indirect antioxidant, protectant and modulator of mitochondrial function, antiexcitotoxic agent, enhancer of circadian amplitudes, immune modulator and neuroprotectant. It is levels tend to decrease in the course of senescence and are more strongly reduced in several neurodegenerative disorders, especially Alzheimer's disease, and in diseases related to insulin resistance such as diabetes type 2. Although the role of melatonin in aging and age-related diseases has been repeatedly discussed, the newly emerged concept of inflammaging, that is, the contribution of low-grade inflammation to senescence progression has not yet been the focus of melatonin research. This review addresses the multiple protective actions of melatonin and its kynuramine metabolites that are relevant to the attenuation of inflammatory responses and progression of inflammaging in the brain, i.e. avoidance of excitotoxicity, reduction of free radical formation by support of mitochondrial electron flux, prevention of NADPH oxidase activation and suppression of inducible nitric oxide synthase, as well as downregulation of proinflammatory cytokines. The experimental evidence is primarily discussed on the basis of aging and senescence-accelerated animals, actions in the immune system, and the relationship between melatonin and sirtuins, having properties of aging suppressors. Sirtuins act either as accessory components or downstream factors of circadian oscillators, which are also under control by melatonin. Inflammaging is assumed to strongly contribute to neurodegeneration of the circadian master clock observed in advanced senescence and, even more, in Alzheimer's disease, a change that affects countless physiological functions.","['Aging', ""Alzheimer's disease"", 'Circadian', 'Mitochondria', 'Neuroinflammation', 'Neuroprotection']",Progress in neurobiology,2015-02-24,"[{'lastname': 'Hardeland', 'firstname': 'Rüdiger', 'initials': 'R', 'affiliation': 'Johann Friedrich Blumenbach Institute of Zoology and Anthropology, University of Goettingen, Berliner Str. 28, D-37073 Goettingen, Germany. Electronic address: rhardel@gwdg.de.'}, {'lastname': 'Cardinali', 'firstname': 'Daniel P', 'initials': 'DP', 'affiliation': 'BIOMED-UCA-CONICET, Faculty of Medical Sciences, Pontificia Universidad Católica Argentina, C1107AFD Buenos Aires, Argentina.'}, {'lastname': 'Brown', 'firstname': 'Gregory M', 'initials': 'GM', 'affiliation': 'Department of Psychiatry, Faculty of Medicine, University of Toronto, Centre for Addiction and Mental Health, 250 College Street, Toronto, ON M5T 1R8, Canada.'}, {'lastname': 'Pandi-Perumal', 'firstname': 'Seithikurippu R', 'initials': 'SR', 'affiliation': 'Center for Healthful Behavior Change (CHBC), Division of Health and Behavior, Department of Population Health, New York University Medical Center, Clinical & Translational Research Institute, 227 East 30th Street, New York, NY 10016, USA.'}]",,,,Copyright © 2015 Elsevier Ltd. All rights reserved.,10.1016/j.pneurobio.2015.02.001,<Element 'PubmedArticle' at 0x7f05dc0d9a40>
432,27259217,[Regulation of neurogenesis: factors affecting of new neurons formation in adult mammals brain].,"Neurogenesis is a complex and multi-step process of generating completely functional neurons. This process in adult brain is based on pluripotentional neuronal stem cells (NSC), which are able to proliferation and differentiation into mature neurons or glial cells. NSC are located in subgranular zone inside hippocampus and in subventricular zone. The new neurons formation depends on many endo- and exogenous factors which modulate each step of neurogenesis. This article describes the most important regulators of adult neurogenesis, mainly: neurotrophins, growth factors, hormones, neurotransmitters and microenvironment of NSC. Some drugs, especially antipsychotics, antidepressants and normothymics may affect the neurogenic properties of adult brain. Moreover pathological processes such as neuroinflammation, stroke or epilepsy are able to induce proliferation of NSC. The proneurogenic effects of psychotropic drugs and pathological processes are associated with their ability to increase some hormones and neurotrophins level, as well as with rising the expression of antiapoptotic Bcl-2 protein and metalloproteinase MMP-2. Additionaly, some drugs, for example haloperidol, are able to block prolactin and dopaminergic neuroblasts receptors. Down-regulation of adult neurogenesis is associated with alcohol abuse and high stress level. Negative effect of many drugs, such as cytostatics, COX-2 inhibitors and opioides was also observed. The proneurogenic effect of described factors suggest their broad therapeutic potential and gives a new perspective on an effective and modern treatment of many neuropsychiatric disorders. This effect can also help to clarify the pathogenesis of disorders associated with proliferation and degeneration of adult brain cells.",[],Postepy higieny i medycyny doswiadczalnej (Online),2015-01-01,"[{'lastname': 'Respondek', 'firstname': 'Michalina', 'initials': 'M', 'affiliation': 'Wydział Farmaceutyczny z Oddziałem Medycyny Laboratoryjnej w Sosnowcu, Śląski Uniwersytet Medyczny w Katowicach, Katedra i Zakład Chemii i Analizy Leków w Sosnowcu.'}, {'lastname': 'Buszman', 'firstname': 'Ewa', 'initials': 'E', 'affiliation': 'Wydział Farmaceutyczny z Oddziałem Medycyny Laboratoryjnej w Sosnowcu, Śląski Uniwersytet Medyczny w Katowicach, Katedra i Zakład Chemii i Analizy Leków w Sosnowcu.'}]",,,,,,<Element 'PubmedArticle' at 0x7f05dc023ae0>
433,"25548106
23046519
22884901
17272660
18261748
10321658
19618742
14284696
11156943
22498761
15009671
23163925
17664017
942051
23169348
1395659
24786329
23896215
8900284
19386271
3593597
17868306
8304529
23533304
24465540
17192570
24606520
12955147
22101642
19070629
18468686
10805525
19615459
24169105
24140894
18433869
11145976
3050629
23667516
19394765
21068301
14977603
20714818
21952131
11852148
14977594
12949078
15465922
16997973
22176740
11208916
22747645
20801430
19091987
23394525
23574441
16517404
23374874
20026014
14595399
20029832
17167086
11700558
24802360
9917869
12154273
4055775
2771659
19515980
21486787
17449181
17906680
23950538
3124165
8680860
22480617",Systemic administration of oleoylethanolamide protects from neuroinflammation and anhedonia induced by LPS in rats.,"The acylethanolamides oleoylethanolamide and palmitoylethanolamide are endogenous lipid mediators with proposed neuroprotectant properties in central nervous system (CNS) pathologies. The precise mechanisms remain partly unknown, but growing evidence suggests an antiinflammatory/antioxidant profile.
We tested whether oleoylethanolamide/palmitoylethanolamide (10 mg/kg, i.p.) attenuate neuroinflammation and acute phase responses (hypothalamus-pituitary-adrenal (HPA) stress axis stress axis activation, thermoregulation, and anhedonia) induced by lipopolysaccharide (0.5 mg/kg, i.p.) in rats.
Lipopolysaccharide increased mRNA levels of the proinflammatory cytokines tumor necrosis factor-α, interleukin-1β, and interleukin-6, nuclear transcription factor-κB activity, and the expression of its inhibitory protein IκBα in cytoplasm, the inducible isoforms of nitric oxide synthase and cyclooxygenase-2, microsomal prostaglandin E2 synthase mRNA, and proinflammatory prostaglandin E2 content in frontal cortex 150 minutes after administration. As a result, the markers of nitrosative/oxidative stress nitrites (NO2(-)) and malondialdehyde were increased. Pretreatment with oleoylethanolamide/ palmitoylethanolamide reduced plasma tumor necrosis factor-α levels after lipopolysaccharide, but only oleoylethanolamide significantly reduced brain tumor necrosis factor-α mRNA. Oleoylethanolamide and palmitoylethanolamide prevented lipopolysaccharide-induced nuclear transcription factor-κB (NF-κB)/IκBα upregulation in nuclear and cytosolic extracts, respectively, the expression of inducible isoforms of nitric oxide synthase, cyclooxygenase-2, and microsomal prostaglandin E2 synthase and the levels of prostaglandin E2. Additionally, both acylethanolamides reduced lipopolysaccharide-induced oxidative/nitrosative stress. Neither oleoylethanolamide nor palmitoylethanolamide modified plasma corticosterone levels after lipopolysaccharide, but both acylethanolamides reduced the expression of hypothalamic markers of thermoregulation interleukin-1β, cyclooxygenase-2, and prostaglandin E2, and potentiated the hypothermic response after lipopolysaccharide. Interestingly, only oleoylethanolamide disrupted lipopolysaccharide-induced anhedonia in a saccharine preference test.
Results indicate that oleoylethanolamide and palmitoylethanolamide have antiinflammatory/neuroprotective properties and suggest a role for these acylethanolamides as modulators of CNS pathologies with a neuroinflammatory component.","['OEA', 'PEA', 'anhedonia', 'lipopolysaccharide', 'neuroinflammation']",The international journal of neuropsychopharmacology,2014-12-31,"[{'lastname': 'Sayd', 'firstname': 'Aline', 'initials': 'A', 'affiliation': 'Department of Psychobiology, Faculty of Psychology, Complutense University, Complutense University of Madrid (UCM), Madrid, Spain (Ms Antón, and Drs Alén, Rodríguez de Fonseca and Orio); Department of Pharmacology, Faculty of Medicine, UCM, and Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM)), Madrid, Spain (Ms Sayd, and Drs Leza and García-Bueno); Department of Psychiatry, Faculty of Medicine, UCM, and Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Madrid, Spain (Dr Caso); UGC Salud Mental, Instituto de Investigación Biomédica de Málaga, Hospital Regional Universitario de Málaga-Universidad de Málaga, and Red de Trastornos Adictivos, Málaga, Spain (Drs Pavón and Rodríguez de Fonseca).'}, {'lastname': 'Antón', 'firstname': 'María', 'initials': 'M', 'affiliation': 'Department of Psychobiology, Faculty of Psychology, Complutense University, Complutense University of Madrid (UCM), Madrid, Spain (Ms Antón, and Drs Alén, Rodríguez de Fonseca and Orio); Department of Pharmacology, Faculty of Medicine, UCM, and Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM)), Madrid, Spain (Ms Sayd, and Drs Leza and García-Bueno); Department of Psychiatry, Faculty of Medicine, UCM, and Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Madrid, Spain (Dr Caso); UGC Salud Mental, Instituto de Investigación Biomédica de Málaga, Hospital Regional Universitario de Málaga-Universidad de Málaga, and Red de Trastornos Adictivos, Málaga, Spain (Drs Pavón and Rodríguez de Fonseca).'}, {'lastname': 'Alén', 'firstname': 'Francisco', 'initials': 'F', 'affiliation': 'Department of Psychobiology, Faculty of Psychology, Complutense University, Complutense University of Madrid (UCM), Madrid, Spain (Ms Antón, and Drs Alén, Rodríguez de Fonseca and Orio); Department of Pharmacology, Faculty of Medicine, UCM, and Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM)), Madrid, Spain (Ms Sayd, and Drs Leza and García-Bueno); Department of Psychiatry, Faculty of Medicine, UCM, and Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Madrid, Spain (Dr Caso); UGC Salud Mental, Instituto de Investigación Biomédica de Málaga, Hospital Regional Universitario de Málaga-Universidad de Málaga, and Red de Trastornos Adictivos, Málaga, Spain (Drs Pavón and Rodríguez de Fonseca).'}, {'lastname': 'Caso', 'firstname': 'Javier Rubén', 'initials': 'JR', 'affiliation': 'Department of Psychobiology, Faculty of Psychology, Complutense University, Complutense University of Madrid (UCM), Madrid, Spain (Ms Antón, and Drs Alén, Rodríguez de Fonseca and Orio); Department of Pharmacology, Faculty of Medicine, UCM, and Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM)), Madrid, Spain (Ms Sayd, and Drs Leza and García-Bueno); Department of Psychiatry, Faculty of Medicine, UCM, and Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Madrid, Spain (Dr Caso); UGC Salud Mental, Instituto de Investigación Biomédica de Málaga, Hospital Regional Universitario de Málaga-Universidad de Málaga, and Red de Trastornos Adictivos, Málaga, Spain (Drs Pavón and Rodríguez de Fonseca).'}, {'lastname': 'Pavón', 'firstname': 'Javier', 'initials': 'J', 'affiliation': 'Department of Psychobiology, Faculty of Psychology, Complutense University, Complutense University of Madrid (UCM), Madrid, Spain (Ms Antón, and Drs Alén, Rodríguez de Fonseca and Orio); Department of Pharmacology, Faculty of Medicine, UCM, and Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM)), Madrid, Spain (Ms Sayd, and Drs Leza and García-Bueno); Department of Psychiatry, Faculty of Medicine, UCM, and Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Madrid, Spain (Dr Caso); UGC Salud Mental, Instituto de Investigación Biomédica de Málaga, Hospital Regional Universitario de Málaga-Universidad de Málaga, and Red de Trastornos Adictivos, Málaga, Spain (Drs Pavón and Rodríguez de Fonseca).'}, {'lastname': 'Leza', 'firstname': 'Juan Carlos', 'initials': 'JC', 'affiliation': 'Department of Psychobiology, Faculty of Psychology, Complutense University, Complutense University of Madrid (UCM), Madrid, Spain (Ms Antón, and Drs Alén, Rodríguez de Fonseca and Orio); Department of Pharmacology, Faculty of Medicine, UCM, and Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM)), Madrid, Spain (Ms Sayd, and Drs Leza and García-Bueno); Department of Psychiatry, Faculty of Medicine, UCM, and Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Madrid, Spain (Dr Caso); UGC Salud Mental, Instituto de Investigación Biomédica de Málaga, Hospital Regional Universitario de Málaga-Universidad de Málaga, and Red de Trastornos Adictivos, Málaga, Spain (Drs Pavón and Rodríguez de Fonseca).'}, {'lastname': 'Rodríguez de Fonseca', 'firstname': 'Fernando', 'initials': 'F', 'affiliation': 'Department of Psychobiology, Faculty of Psychology, Complutense University, Complutense University of Madrid (UCM), Madrid, Spain (Ms Antón, and Drs Alén, Rodríguez de Fonseca and Orio); Department of Pharmacology, Faculty of Medicine, UCM, and Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM)), Madrid, Spain (Ms Sayd, and Drs Leza and García-Bueno); Department of Psychiatry, Faculty of Medicine, UCM, and Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Madrid, Spain (Dr Caso); UGC Salud Mental, Instituto de Investigación Biomédica de Málaga, Hospital Regional Universitario de Málaga-Universidad de Málaga, and Red de Trastornos Adictivos, Málaga, Spain (Drs Pavón and Rodríguez de Fonseca).'}, {'lastname': 'García-Bueno', 'firstname': 'Borja', 'initials': 'B', 'affiliation': 'Department of Psychobiology, Faculty of Psychology, Complutense University, Complutense University of Madrid (UCM), Madrid, Spain (Ms Antón, and Drs Alén, Rodríguez de Fonseca and Orio); Department of Pharmacology, Faculty of Medicine, UCM, and Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM)), Madrid, Spain (Ms Sayd, and Drs Leza and García-Bueno); Department of Psychiatry, Faculty of Medicine, UCM, and Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Madrid, Spain (Dr Caso); UGC Salud Mental, Instituto de Investigación Biomédica de Málaga, Hospital Regional Universitario de Málaga-Universidad de Málaga, and Red de Trastornos Adictivos, Málaga, Spain (Drs Pavón and Rodríguez de Fonseca). lorio@psi.ucm.es bgbueno@med.ucm.es.'}, {'lastname': 'Orio', 'firstname': 'Laura', 'initials': 'L', 'affiliation': 'Department of Psychobiology, Faculty of Psychology, Complutense University, Complutense University of Madrid (UCM), Madrid, Spain (Ms Antón, and Drs Alén, Rodríguez de Fonseca and Orio); Department of Pharmacology, Faculty of Medicine, UCM, and Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM)), Madrid, Spain (Ms Sayd, and Drs Leza and García-Bueno); Department of Psychiatry, Faculty of Medicine, UCM, and Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Madrid, Spain (Dr Caso); UGC Salud Mental, Instituto de Investigación Biomédica de Málaga, Hospital Regional Universitario de Málaga-Universidad de Málaga, and Red de Trastornos Adictivos, Málaga, Spain (Drs Pavón and Rodríguez de Fonseca). lorio@psi.ucm.es bgbueno@med.ucm.es.'}]",,,"Lipopolysaccharide increased mRNA levels of the proinflammatory cytokines tumor necrosis factor-α, interleukin-1β, and interleukin-6, nuclear transcription factor-κB activity, and the expression of its inhibitory protein IκBα in cytoplasm, the inducible isoforms of nitric oxide synthase and cyclooxygenase-2, microsomal prostaglandin E2 synthase mRNA, and proinflammatory prostaglandin E2 content in frontal cortex 150 minutes after administration. As a result, the markers of nitrosative/oxidative stress nitrites (NO2(-)) and malondialdehyde were increased. Pretreatment with oleoylethanolamide/ palmitoylethanolamide reduced plasma tumor necrosis factor-α levels after lipopolysaccharide, but only oleoylethanolamide significantly reduced brain tumor necrosis factor-α mRNA. Oleoylethanolamide and palmitoylethanolamide prevented lipopolysaccharide-induced nuclear transcription factor-κB (NF-κB)/IκBα upregulation in nuclear and cytosolic extracts, respectively, the expression of inducible isoforms of nitric oxide synthase, cyclooxygenase-2, and microsomal prostaglandin E2 synthase and the levels of prostaglandin E2. Additionally, both acylethanolamides reduced lipopolysaccharide-induced oxidative/nitrosative stress. Neither oleoylethanolamide nor palmitoylethanolamide modified plasma corticosterone levels after lipopolysaccharide, but both acylethanolamides reduced the expression of hypothalamic markers of thermoregulation interleukin-1β, cyclooxygenase-2, and prostaglandin E2, and potentiated the hypothermic response after lipopolysaccharide. Interestingly, only oleoylethanolamide disrupted lipopolysaccharide-induced anhedonia in a saccharine preference test.",© The Author 2015. Published by Oxford University Press on behalf of CINP.,10.1093/ijnp/pyu111,<Element 'PubmedArticle' at 0x7f05dc02acc0>
434,"25489058
19700514
24014829
21178125
12456490
15192025
14707156
21818366
18768926
22124756
21952934
23691105
20547972
19926873
18258853
17325232
15317910
19095631
22371360
24014677
12093889
7488043
23389111
22043205
16775508
21126972
16766857
17496209
15084475
15851630
20194308
21971354
12623955
21263123
19923158
16870827
23535237
16151022
19901158
21833043
12484518
20807798
22958438
24014678",Brain-targeted angiotensin-converting enzyme 2 overexpression attenuates neurogenic hypertension by inhibiting cyclooxygenase-mediated inflammation.,"Overactivity of the renin-angiotensin system, oxidative stress, and cyclooxygenases (COX) in the brain are implicated in the pathogenesis of hypertension. We previously reported that angiotensin-converting enzyme 2 (ACE2) overexpression in the brain attenuates the development of deoxycorticosterone acetate-salt hypertension, a neurogenic hypertension model with enhanced brain renin-angiotensin system and sympathetic activity. To elucidate the mechanisms involved, we investigated whether oxidative stress, mitogen-activated protein kinase signaling and cyclooxygenase (COX) activation in the brain are modulated by ACE2 in neurogenic hypertension. Deoxycorticosterone acetate-salt hypertension significantly increased expression of Nox-2 (+61±5%), Nox-4 (+50±13%), and nitrotyrosine (+89±32%) and reduced activity of the antioxidant enzymes, catalase (-29±4%) and superoxide dismutase (-31±7%), indicating increased oxidative stress in the brain of nontransgenic mice. This increased oxidative stress was attenuated in transgenic mice overexpressing ACE2 in the brain. Deoxycorticosterone acetate-salt-induced reduction of neuronal nitric oxide synthase expression (-26±7%) and phosphorylated endothelial nitric oxide synthase/total endothelial nitric oxide synthase (-30±3%), and enhanced phosphorylation of protein kinase B and extracellular signal-regulated kinase 1/2 in the paraventricular nucleus, were reversed by ACE2 overexpression. In addition, ACE2 overexpression blunted the hypertension-mediated increase in gene and protein expression of COX-1 and COX-2 in the paraventricular nucleus. Furthermore, gene silencing of either COX-1 or COX-2 in the brain, reduced microglial activation and accompanied neuroinflammation, ultimately attenuating Deoxycorticosterone acetate-salt hypertension. Together, these data provide evidence that brain ACE2 overexpression reduces oxidative stress and COX-mediated neuroinflammation, improves antioxidant and nitric oxide signaling, and thereby attenuates the development of neurogenic hypertension.","['angiotensin-converting enzyme 2', 'cyclooxygenases', 'hypertension', 'paraventricular nucleus', 'renin-angiotensin system']","Hypertension (Dallas, Tex. : 1979)",2014-12-10,"[{'lastname': 'Sriramula', 'firstname': 'Srinivas', 'initials': 'S', 'affiliation': 'Department of Pharmacology and Experimental Therapeutics, Neurosciences and Cardiovascular Center of Excellence, Louisiana State University Health Sciences Center, New Orleans.'}, {'lastname': 'Xia', 'firstname': 'Huijing', 'initials': 'H', 'affiliation': 'Department of Pharmacology and Experimental Therapeutics, Neurosciences and Cardiovascular Center of Excellence, Louisiana State University Health Sciences Center, New Orleans.'}, {'lastname': 'Xu', 'firstname': 'Ping', 'initials': 'P', 'affiliation': 'Department of Pharmacology and Experimental Therapeutics, Neurosciences and Cardiovascular Center of Excellence, Louisiana State University Health Sciences Center, New Orleans.'}, {'lastname': 'Lazartigues', 'firstname': 'Eric', 'initials': 'E', 'affiliation': 'Department of Pharmacology and Experimental Therapeutics, Neurosciences and Cardiovascular Center of Excellence, Louisiana State University Health Sciences Center, New Orleans. elazar@lsuhsc.edu.'}]",,,,"© 2014 American Heart Association, Inc.",10.1161/HYPERTENSIONAHA.114.04691,<Element 'PubmedArticle' at 0x7f05dbfa39a0>
435,"25484899
22807925
23201149
11456467
17201934
24920943
20624414
17948033
24808825
18579287
16671092
22683307
20484021
24904289
21423242
23108246
16311407
16328521
17291188
24549061
20018651
18177271
22698181
24218476
15246055
19038344
22079531
25002861
15246052
20427692
17883327
21376175
10415611
10582593
16025454
9689100
9634238
19429788
22689506
16702540
18177992
21722132
12183377
15843601
16964252
16971524
16262623
18272682
21289183
12832536
24154522
17197241
16940167
23153575
18267076
20531309
20161793
22736769
16107333
19380869
19641136
20162608
20388803
20197403
18057003
20686112
21730065
17804806
22989616
21220099
21990345
22300987
24991762
18442043
19794961
18615560
18533280
21220100
23344887
21300915
15542430
24718993
22976302
24174685
22116388
19283075
22355073
17337880
17509912
15677762
19917287
23994027
22704957
24157575
18081553
17339401
20616489
19844112
21917845
1532025
2407518
3263120
2460095
2556147
11095488
19041259
10022962
9439931
24770895
10926317
1664173
2544414
2097644
1406045
8419142
16137855
23700204
8828513
8037707
17339398
17234709
19901009
24770897
11024545
12431218
14511338
17901225
16258074
18753332
18698020
23244149
19302186
16061624
17959712
15921680
22797070
19830694
11157475
16038794
17913342
11579215
1350382
17981589
23476673
15987445
10656438
18711432
16621164
12702590
14595012
17108064
17384278
21316111
16046252
12586845
11242036
11431324
22036649
24124379
22417013
19646861
15844659
12839981
20049170
19859817
17634424
16638848
22152016
19637976
22119203
19620247
12089357
20451543
21285319
15947113
18356276
20117169
16452215
18712678
15281349
14971737
21069582
18318996
21810944
22020338
20616490
19437356
18673444
21918831
22009797
12792878
21822544
22541998
22822048
21753072
23933118
19890024
19208779
21647843
8881450
10069660
10747307
21658592
19280118
19473177
23895705
15837989
12602530
12539178
20309720
17384283
24102412
21147876
18509006",Emerging Targets in Pituitary Adenomas: Role of the CXCL12/CXCR4-R7 System.,"Chemokines are chemotactic regulators of immune surveillance in physiological and pathological conditions such as inflammation, infection, and cancer. Several chemokines and cognate receptors are constitutively expressed in the central nervous system, not only in glial and endothelial cells but also in neurons, controlling neurogenesis, neurite outgrowth, and axonal guidance during development. In particular, the chemokine CXCL12 and its receptors, CXCR4 and CXCR7, form a functional network that controls plasticity in different brain areas, influencing neurotransmission, neuromodulation, and cell migration, and the dysregulation of this chemokinergic axis is involved in several neurodegenerative, neuroinflammatory, and malignant diseases. CXCR4 primarily mediates the transduction of proliferative signals, while CXCR7 seems to be mainly responsible for scavenging CXCL12. Importantly, the multiple intracellular signalling generated by CXCL12 interaction with its receptors influences hypothalamic modulation of neuroendocrine functions, although a direct modulation of pituitary functioning via autocrine/paracrine mechanisms was also reported. Both CXCL12 and CXCR4 are constitutively overexpressed in pituitary adenomas and their signalling induces cell survival and proliferation, as well as hormonal hypersecretion. In this review we focus on the physiological and pathological functions of immune-related cyto- and chemokines, mainly focusing on the CXCL12/CXCR4-7 axis, and their role in pituitary tumorigenesis. Accordingly, we discuss the potential targeting of CXCR4 as novel pharmacological approach for pituitary adenomas.",[],International journal of endocrinology,2014-12-09,"[{'lastname': 'Barbieri', 'firstname': 'Federica', 'initials': 'F', 'affiliation': 'Department of Internal Medicine and Medical Specialties and Center of Excellence for Biomedical Research (CEBR), University of Genova, Viale Benedetto XV, 2-16132 Genova, Italy.'}, {'lastname': 'Thellung', 'firstname': 'Stefano', 'initials': 'S', 'affiliation': 'Department of Internal Medicine and Medical Specialties and Center of Excellence for Biomedical Research (CEBR), University of Genova, Viale Benedetto XV, 2-16132 Genova, Italy.'}, {'lastname': 'Würth', 'firstname': 'Roberto', 'initials': 'R', 'affiliation': 'Department of Internal Medicine and Medical Specialties and Center of Excellence for Biomedical Research (CEBR), University of Genova, Viale Benedetto XV, 2-16132 Genova, Italy.'}, {'lastname': 'Gatto', 'firstname': 'Federico', 'initials': 'F', 'affiliation': 'Department of Internal Medicine and Medical Specialties and Center of Excellence for Biomedical Research (CEBR), University of Genova, Viale Benedetto XV, 2-16132 Genova, Italy.'}, {'lastname': 'Corsaro', 'firstname': 'Alessandro', 'initials': 'A', 'affiliation': 'Department of Internal Medicine and Medical Specialties and Center of Excellence for Biomedical Research (CEBR), University of Genova, Viale Benedetto XV, 2-16132 Genova, Italy.'}, {'lastname': 'Villa', 'firstname': 'Valentina', 'initials': 'V', 'affiliation': 'Department of Internal Medicine and Medical Specialties and Center of Excellence for Biomedical Research (CEBR), University of Genova, Viale Benedetto XV, 2-16132 Genova, Italy.'}, {'lastname': 'Nizzari', 'firstname': 'Mario', 'initials': 'M', 'affiliation': 'Department of Internal Medicine and Medical Specialties and Center of Excellence for Biomedical Research (CEBR), University of Genova, Viale Benedetto XV, 2-16132 Genova, Italy.'}, {'lastname': 'Albertelli', 'firstname': 'Manuela', 'initials': 'M', 'affiliation': 'Department of Internal Medicine and Medical Specialties and Center of Excellence for Biomedical Research (CEBR), University of Genova, Viale Benedetto XV, 2-16132 Genova, Italy.'}, {'lastname': 'Ferone', 'firstname': 'Diego', 'initials': 'D', 'affiliation': 'Department of Internal Medicine and Medical Specialties and Center of Excellence for Biomedical Research (CEBR), University of Genova, Viale Benedetto XV, 2-16132 Genova, Italy.'}, {'lastname': 'Florio', 'firstname': 'Tullio', 'initials': 'T', 'affiliation': 'Department of Internal Medicine and Medical Specialties and Center of Excellence for Biomedical Research (CEBR), University of Genova, Viale Benedetto XV, 2-16132 Genova, Italy.'}]",,,,,"10.1155/2014/753524
10.3389/fimmu.2012.00175
10.1016/j.ygcen.2012.11.010
10.1006/frne.2001.0214
10.1186/gb-2006-7-12-243
10.3389/fncel.2014.00154
10.1016/j.yfrne.2010.07.001
10.1038/nrn2255
10.3389/fncel.2014.00115
10.1016/j.canlet.2008.04.050
10.1002/ijc.22024
10.1016/j.ejca.2012.05.005
10.3389/fncel.2014.00144
10.1038/nrendo.2011.40
10.1097/WCO.0b013e3283587bed
10.1385/ENDO:28:1:027
10.1007/s00401-005-1100-y
10.1146/annurev.immunol.24.021605.090529
10.1038/ni.2812
10.1073/pnas.0912852107
10.1042/BJ20071493
10.1016/j.imlet.2012.04.004
10.1124/pr.113.007724
10.1016/j.semcancer.2003.10.006
10.1016/j.semcancer.2008.11.001
10.1016/j.bbcan.2011.10.008
10.3389/fimmu.2014.00277
10.1016/j.semcancer.2003.10.003
10.1124/pr.109.002436
10.1146/annurev.pharmtox.48.121806.154841
10.1016/j.yexcr.2010.12.017
10.1111/j.1749-6632.1999.tb07640.x
10.1046/j.1471-4159.1999.0732348.x
10.1002/cne.20598
10.1073/pnas.95.16.9448
10.1038/31269
10.1242/dev.032276
10.1002/dneu.22041
10.1073/pnas.0602620103
10.1016/j.pneurobio.2007.11.003
10.1111/j.1471-4159.2011.07371.x
10.1523/JNEUROSCI.4631-04.2005
10.1038/nn1764
10.1523/JNEUROSCI.2575-06.2006
10.1111/j.1460-9568.2005.04378.x
10.1523/JNEUROSCI.4651-07.2008
10.1523/JNEUROSCI.3118-10.2011
10.1242/dev.098145
10.1016/j.molmed.2006.12.003
10.1084/jem.20052144
10.1016/j.molmed.2012.10.004
10.1016/j.cell.2007.12.034
10.1038/onc.2010.212
10.1371/journal.pone.0009175
10.1074/jbc.M111.335679
10.1074/jbc.M508234200
10.1182/blood-2008-12-196618
10.4049/jimmunol.0900269
10.1002/ijc.25245
10.1158/0008-5472.CAN-09-3642
10.1242/jcs.062810
10.1074/jbc.M707465200
10.1073/pnas.1008461107
10.1074/jbc.M111.277038
10.1073/pnas.0702229104
10.1016/j.cytogfr.2012.08.007
10.1016/j.neuron.2010.12.005
10.1073/pnas.1101133108
10.1016/j.biocel.2012.01.007
10.1038/cddis.2014.269
10.1002/dvg.20387
10.1593/neo.09724
10.1002/cne.21780
10.1016/j.jneuroim.2008.04.020
10.1016/j.neuron.2010.12.006
10.1007/s10545-012-9574-y
10.1084/jem.20102010
10.1016/j.ccr.2004.09.027
10.1242/dev.104224
10.1242/jcs.101675
10.1523/JNEUROSCI.0857-13.2013
10.1159/000330857
10.1371/journal.pone.0004815
10.1210/en.2011-1937
10.1159/000100278
10.1016/j.semcdb.2007.04.006
10.1210/en.2004-1209
10.1016/j.ygcen.2009.11.007
10.1016/j.mce.2013.08.018
10.1016/j.drudis.2012.06.001
10.1016/j.tox.2013.10.003
10.1111/j.1365-2826.2007.01616.x
10.1677/JME-06-0014
10.1159/000318488
10.1159/000245928
10.1530/ERC-11-0066
10.1210/endo-126-3-1435
10.1016/S0006-291X(88)81252-X
10.1016/S0006-291X(88)81253-1
10.1016/0006-291X(89)91097-8
10.1210/jc.85.11.4411
10.1016/j.cyto.2008.08.005
10.1007/s004410051248
10.1055/s-0029-1211777
10.1007/s00441-014-1861-5
10.1055/s-2000-7887
10.1210/endo-125-1-575
10.1016/0024-3205(92)90012-E
10.1210/en.132.1.459
10.1016/j.domaniend.2005.07.008
10.1210/en.137.10.4503
10.1006/bbrc.1994.1906
10.1677/JME-06-0035
10.1210/en.2006-1390
10.1677/JOE-09-0333
10.1007/s00441-014-1864-2
10.1016/S0165-5728(00)00338-6
10.1046/j.1460-9568.2002.02237.x
10.1046/j.1460-9568.2003.02893.x
10.1210/en.2007-1097
10.1124/mol.105.015255
10.1677/JOE-08-0250
10.1158/1078-0432.CCR-07-4717
10.7314/APJCP.2012.13.10.5281
10.1111/j.1365-2826.2009.01867.x
10.1158/0008-5472.CAN-04-1303
10.1124/mol.107.039974
10.1016/j.yexcr.2005.04.024
10.1038/onc.2012.280
10.1002/ijc24964
10.1182/blood.V97.3.608
10.1016/j.cellsig.2004.12.009
10.1016/j.mce.2007.08.012
10.1126/science.256.5060.1215
10.2741/2723
10.1155/2013/926295
10.1186/bcr1022
10.1038/ni.f.207
10.1016/j.neuint.2006.03.003
10.1073/pnas.2235846100
10.1215/15228517-2006-023
10.1196/annals.1378.037
10.1016/j.jneuroim.2011.01.006
10.1016/j.canlet.2005.06.021
10.1210/me.2002-0438
10.1038/35065016
10.1016/j.yexcr.2011.10.012
10.2147/OTT.S36109
10.1186/1746-6148-8-27
10.1016/j.ejca.2009.06.026
10.1155/2010/426956
10.1007/s10585-009-9294-3
10.1158/1541-7786.MCR-06-0368
10.1158/1078-0432.CCR-05-1940
10.1186/bcr3074
10.1517/14728220903170675
10.1016/j.ejca.2011.11.002
10.1677/ERC-09-0101
10.1210/me.16.7.1638
10.1016/j.yfrne.2010.04.002
10.1210/en.2010-1077
10.1677/erc.1.00949
10.1210/en.2007-1696
10.1016/j.mce.2010.01.033
10.1158/0008-5472.CAN-05-1189
10.1159/000079047
10.1023/B:PITU.0000011173.04191.37
10.1007/s12020-010-9407-4
10.1038/cmi.2008.8
10.1210/en.2011-1216
10.1038/onc.2011.458
10.1159/000318489
10.1080/08820530902805651
10.1111/j.1440-1789.2008.00937.x
10.1007/s11102-011-0346-8
10.1530/ERC-11-0211
10.3892/or.2011.1416
10.1016/j.ando.2012.04.003
10.1530/JME-12-0113
10.1530/EJE-11-0304
10.1016/j.mce.2013.08.002
10.1210/jc.2009-1360
10.1677/JME-09-0009
10.1007/s12022-011-9167-6
10.1046/j.1365-2265.1996.d01-1554.x
10.1530/eje.0.1400155
10.1016/j.ghir.2011.03.005
10.1007/s11060-009-9835-2
10.1111/j.1365-2265.2009.03629.x
10.2174/1876528901104010064
10.3967/0895-3988.2013.07.011
10.1200/JCO.2005.07.078
10.1007/BF03345118
10.1002/jemt.10262
10.1007/s11060-010-0152-6
10.1196/annals.1378.042
10.1021/cb400521b
10.1210/en.2010-0642
10.1677/ERC-07-0271",<Element 'PubmedArticle' at 0x7f05dbfc5d10>
436,"25416141
19033832
16983222
22747709
21436875
11831551
23118733
12098511
17513784
20637752
18262323
24889886
24761998
19152719
18037916
10822068
21735070
7689702
19805493
21332427
19332079
17245417
21970496
22903455
22020035
19490092
16204639
19476641
15542269
20880501
23039106
3193461
22568499
11961073
19255856
16751414
20166927
25042014
18615177
22442067
22573182
19081024
24773520
21530945
22901764
15716856
19663686
16230799
19889224
18829442
12958415
21331083
18040800
10996217
14757702
18178718
15821753
17185040
16086683
21707587
21538668
20590558
23960212","Cannabinoid receptor type-2 stimulation, blockade, and deletion alter the vascular inflammatory responses to traumatic brain injury.","Immunomodulatory therapies have been identified as interventions for secondary injury after traumatic brain injury (TBI). The cannabinoid receptor type-2 (CB2R) is proposed to play an important, endogenous role in regulating inflammation. The effects of CB2R stimulation, blockade, and deletion on the neurovascular inflammatory responses to TBI were assessed.
Wild-type C57BL/6 or CB2R knockout mice were randomly assigned to controlled cortical impact (CCI) injury or to craniotomy control groups. The effects of treatment with synthetic, selective CB2R agonists (0-1966 and JWH-133), a selective CB2R antagonist, or vehicle solution administered to CCI groups were assessed at 1-day after injury. Changes in TNF-α, intracellular adhesion molecule (ICAM-1), inducible nitric oxide synthase (iNOS), macrophage/microglial ionized calcium-binding adaptor molecule, and blood-brain-barrier (BBB) permeability were assessed using ELISA, quantitative RT-PCR, immunohistochemistry, and fluorometric analysis of sodium fluorescein uptake. CB2R knockouts and wild-type mice with CCI injury were treated with a CB2R agonist or vehicle treatment.
TNF-α mRNA increased at 6 hours and 1 to 3 days after CCI; a CB2R antagonist and genetic knockout of the CB2R exacerbated TNF-α mRNA expression. Treatment with a CB2R agonist attenuated TNF-α protein levels indicating post-transcriptional mechanisms. Intracellular adhesion molecule (ICAM-1) mRNA was increased at 6 hours, and at 1 to 2 days after CCI, reduced in mice treated with a CB2R agonist, and increased in CB2R knockout mice with CCI. Sodium fluorescein uptake was increased in CB2R knockouts after CCI, with and without a CB2R agonist. iNOS mRNA expression peaked early (6 hours) and remained increased from 1 to 3 days after injury. Treatment with a CB2R agonist attenuated increases in iNOS mRNA expression, while genetic deletion of the CB2R resulted in substantial increases in iNOS expression. Double label immunohistochemistry confirmed that iNOS was expressed by macrophage/microglia in the injured cortex.
Findings demonstrate that the endogenous cannabinoid system and CB2R play an important role in regulating inflammation and neurovascular responses in the traumatically injured brain. CB2R stimulation with two agonists (0-1966 and JWH-133) dampened post-traumatic inflammation, while blockade or deletion of the CB2R worsened inflammation. Findings support previous evidence that modulating the CB2R alters infiltrating macrophages and activated resident microglia. Further investigation into the role of the CB2R on specific immune cell populations in the injured brain is warranted.",[],Journal of neuroinflammation,2014-11-25,"[{'lastname': 'Amenta', 'firstname': 'Peter S', 'initials': 'PS', 'affiliation': 'Department of Neurological Surgery, Thomas Jefferson University Hospital, 1020 Locust Street, Thomas Jefferson University, Philadelphia, PA, 19107, USA. peter.amenta@gmail.com.'}, {'lastname': 'Jallo', 'firstname': 'Jack I', 'initials': 'JI', 'affiliation': 'Department of Neurological Surgery, Thomas Jefferson University Hospital, 1020 Locust Street, Thomas Jefferson University, Philadelphia, PA, 19107, USA. jack.jallo@jefferson.edu.'}, {'lastname': 'Tuma', 'firstname': 'Ronald F', 'initials': 'RF', 'affiliation': 'Department of Physiology, Temple University School of Medicine, 3500 N Broad St, Philadelphia, PA, 19140, USA. ronald.tuma@temple.edu.'}, {'lastname': 'Hooper', 'firstname': 'D Craig', 'initials': 'DC', 'affiliation': 'Department of Cancer Biology, Thomas Jefferson University Hospital, 1020 Locust Street, Thomas Jefferson University, Philadelphia, PA, 19107, USA. douglas.hooper@jefferson.edu.'}, {'lastname': 'Elliott', 'firstname': 'Melanie B', 'initials': 'MB', 'affiliation': 'Department of Neurological Surgery, Thomas Jefferson University Hospital, 1020 Locust Street, Thomas Jefferson University, Philadelphia, PA, 19107, USA. Melanie.elliott@jefferson.edu.'}]",,"Findings demonstrate that the endogenous cannabinoid system and CB2R play an important role in regulating inflammation and neurovascular responses in the traumatically injured brain. CB2R stimulation with two agonists (0-1966 and JWH-133) dampened post-traumatic inflammation, while blockade or deletion of the CB2R worsened inflammation. Findings support previous evidence that modulating the CB2R alters infiltrating macrophages and activated resident microglia. Further investigation into the role of the CB2R on specific immune cell populations in the injured brain is warranted.","TNF-α mRNA increased at 6 hours and 1 to 3 days after CCI; a CB2R antagonist and genetic knockout of the CB2R exacerbated TNF-α mRNA expression. Treatment with a CB2R agonist attenuated TNF-α protein levels indicating post-transcriptional mechanisms. Intracellular adhesion molecule (ICAM-1) mRNA was increased at 6 hours, and at 1 to 2 days after CCI, reduced in mice treated with a CB2R agonist, and increased in CB2R knockout mice with CCI. Sodium fluorescein uptake was increased in CB2R knockouts after CCI, with and without a CB2R agonist. iNOS mRNA expression peaked early (6 hours) and remained increased from 1 to 3 days after injury. Treatment with a CB2R agonist attenuated increases in iNOS mRNA expression, while genetic deletion of the CB2R resulted in substantial increases in iNOS expression. Double label immunohistochemistry confirmed that iNOS was expressed by macrophage/microglia in the injured cortex.",,"10.1186/s12974-014-0191-6
10.1097/01.HTR.0000341435.52004.ac
10.1097/00001199-200609000-00001
10.1186/1742-2094-9-150
10.1155/2011/765923
10.1385/MN:24:1-3:169
10.3389/fneur.2012.00155
10.1016/S0165-5728(02)00114-5
10.4049/jimmunol.178.11.7334
10.1016/j.expneurol.2010.07.005
10.1016/j.pneurobio.2007.12.001
10.1186/1742-2094-11-98
10.1186/1742-2094-11-82
10.1017/S1462399409000957
10.1038/sj.bjp.0707584
10.1016/S0014-2999(00)00211-9
10.1007/s11481-011-9291-6
10.1038/365061a0
10.1093/brain/awp239
10.1089/neu.2010.1672
10.1016/j.mvr.2009.03.005
10.1038/sj.jcbfm.9600447
10.1089/neu.2011.1853
10.1002/jnr.23114
10.1161/STROKEAHA.111.631044
10.1111/j.1460-9568.2009.06764.x
10.1189/jlb.0405216
10.1186/1744-8069-5-25
10.1016/j.forsciint.2004.06.027
10.1016/j.nurt.2010.07.002
10.1111/j.1365-2990.2012.01306.x
10.1089/neu.1988.5.1
10.1111/j.1526-4610.2012.02160.x
10.1124/jpet.301.2.679
10.1007/s11481-009-9148-4
10.4049/jimmunol.176.12.7666
10.2174/092986710790980050
10.1002/jnr.23452
10.2174/157015907780866884
10.1523/JNEUROSCI.4628-11.2012
10.1007/s00018-012-0987-4
10.1016/j.surg.2008.05.017
10.1089/neu.2013.2985
10.1016/j.brainres.2011.04.014
10.13172/2052-787X-1-1-477
10.1016/j.jpain.2012.05.013
10.1038/sj.jcbfm.9600068
10.1089/neu.2008.0747
10.4103/0028-3886.16930
10.1186/1742-2094-6-32
10.1073/pnas.0807656105
10.1038/nrn2995
10.1007/s11481-006-9025-3
10.1016/S0165-5728(00)00307-6
10.1038/sj.bjp.0705667
10.1152/ajpheart.01328.2007
10.1038/sj.bjp.0706215
10.1016/j.clim.2006.11.002
10.1111/j.1471-4159.2005.03380.x
10.1111/j.1476-5381.2010.01139.x
10.1002/hipo.20946
10.1111/j.1476-5381.2010.00729.x",<Element 'PubmedArticle' at 0x7f05dbe7f590>
437,25390799,The gut microbiota and its correlations with the central nervous system disorders.,"A mutual impact of gastrointestinal tract (GIT) and central nervous system (CNS) functions has been recognized since the mid-twentieth century. It is accepted that the so-called gut-brain axis provides a two-way homeostatic communication, through immunological, hormonal and neuronal signals. A dysfunction of this axis has been associated with the pathogenesis of some diseases both within and outside the GIT, that have shown an increase in incidence over the last decades. Studies comparing germ-free animals and animals exposed to pathogenic bacterial infections, probiotics or antibiotics suggest the participation of the microbiota in this communication and a role in host defense, regulation of immunity and autoimmune disease appearance. The GIT could represent a vulnerable area through which pathogens influence all aspects of physiology and even induce CNS neuro-inflammation. All those concepts may suggest the modulation of the gut microbiota as an achievable strategy for innovative therapies in complex disorders. Moving from this background, the present review discusses the relationship between intestinal microbiota and CNS and the effects in health and disease. We particularly look at how the commensal gut microbiota influences systemic immune response in some neurological disorders, highlighting its impact on pain and cognition in multiple sclerosis, Guillain-Barrè Syndrome, neurodevelopmental and behavioral disorders and Alzheimer's disease. In this review we discuss recent studies showing that the potential microbiota-gut-brain dialogue is implicated in neurodegenerative diseases. Gaining a better understanding of the relationship between microbiota and CNS could provide an insight on the pathogenesis and therapeutic strategies of these disorders.",[],Panminerva medica,2014-11-13,"[{'lastname': 'Catanzaro', 'firstname': 'R', 'initials': 'R', 'affiliation': 'Section of Gastroenterology, Department of Medical and Pediatric Sciences, Institute of Internal Medicine ""A. Francaviglia"", University of Catania, ""G. Rodolico"" Hospital, Catania, Italy - rcatanza@unict.it.'}, {'lastname': 'Anzalone', 'firstname': 'M', 'initials': 'M', 'affiliation': None}, {'lastname': 'Calabrese', 'firstname': 'F', 'initials': 'F', 'affiliation': None}, {'lastname': 'Milazzo', 'firstname': 'M', 'initials': 'M', 'affiliation': None}, {'lastname': 'Capuana', 'firstname': 'M', 'initials': 'M', 'affiliation': None}, {'lastname': 'Italia', 'firstname': 'A', 'initials': 'A', 'affiliation': None}, {'lastname': 'Occhipinti', 'firstname': 'S', 'initials': 'S', 'affiliation': None}, {'lastname': 'Marotta', 'firstname': 'F', 'initials': 'F', 'affiliation': None}]",,,,,,<Element 'PubmedArticle' at 0x7f05dbe2c450>
438,25305410,Selective estrogen-receptor modulators suppress microglial activation and neuronal cell death via an estrogen receptor-dependent pathway.,"Growing evidence shows that steroid hormones, especially 17β-estradiol (E2), protect neuronal cells by attenuating excess activation of microglia. However, the use of E2 in the clinic is controversial because of its peripheral actions in reproductive organs and its potential to increase risk for endometrial cancer and breast cancer. Selective estrogen-receptor modulators (SERMs) bind to estrogen receptors (ERs), but their effects as ER agonists or antagonists are dependent on the target tissue. SERMs pose very little cancer risk as a result of their anti-estrogen action in reproductive organs, but their action in the brain is not well understood. In this study, we investigated the effects of SERMs tamoxifen (Tam) and raloxifene (Rlx) on microglial activation and subsequent neuronal injury. Tam and Rlx suppressed the increases in proinflammatory cytokines and chemokine expression that were induced by lipopolysaccharide (LPS) in rat primary microglia cultures. The microglial-conditioned media pretreated with Tam or Rlx significantly attenuated cellular injury in SH-SY5Y cells elicited by microglial-conditioned media treated with LPS alone. Rat primary microglia expressed ERα and ERβ primarily in the nucleus, and thus we examined the involvement of ERs in the suppressive action of Tam and Rlx on microglial activation using a pure ER antagonist, ICI182,780. Pretreatment with ICI182,780 abolished the suppressive effects of SERMs on microglial activation, as well as their protective action on SH-SY5Y cells. A luciferase assay using a vector with three estrogen response elements (EREs) revealed that Tam and Rlx activated ERE-mediated transcription in rat primary microglia. Taken together, these results suggest that Tam and Rlx suppress microglial activation and subsequent neuronal cell death via an ER-mediated transcription pathway. SERMs could represent a novel therapeutic strategy for disorders of the central nervous system based on their ability to suppress neuroinflammation.","['Estrogen receptor', 'Microglia', 'Neuroinflammation', 'Raloxifene', 'Tamoxifen']",The Journal of steroid biochemistry and molecular biology,2014-10-12,"[{'lastname': 'Ishihara', 'firstname': 'Yasuhiro', 'initials': 'Y', 'affiliation': 'Laboratory of Molecular Brain Science, Graduate School of Integrated Arts and Sciences, Hiroshima University, Higashi-Hiroshima 739-8521, Japan. Electronic address: ishiyasu@hiroshima-u.ac.jp.'}, {'lastname': 'Itoh', 'firstname': 'Kouichi', 'initials': 'K', 'affiliation': 'Laboratory for Brain Science, Kagawa School of Pharmaceutical Sciences, Tokushima Bunri University, Kagawa 769-2193, Japan.'}, {'lastname': 'Ishida', 'firstname': 'Atsuhiko', 'initials': 'A', 'affiliation': 'Laboratory of Molecular Brain Science, Graduate School of Integrated Arts and Sciences, Hiroshima University, Higashi-Hiroshima 739-8521, Japan.'}, {'lastname': 'Yamazaki', 'firstname': 'Takeshi', 'initials': 'T', 'affiliation': 'Laboratory of Molecular Brain Science, Graduate School of Integrated Arts and Sciences, Hiroshima University, Higashi-Hiroshima 739-8521, Japan.'}]",,,,Copyright © 2014 Elsevier Ltd. All rights reserved.,10.1016/j.jsbmb.2014.10.002,<Element 'PubmedArticle' at 0x7f05dbe35400>
439,25287609,Prostaglandins and n-3 polyunsaturated fatty acids in the regulation of the hypothalamic-pituitary axis.,"The hypothalamic-pituitary (H-P) axis integrates complex physiological and environmental signals and responds to these cues by modulating the synthesis and secretion of multiple pituitary hormones to regulate peripheral tissues. Prostaglandins are a component of this regulatory system, affecting multiple hormone synthesis and secretion pathways in the H-P axis. The implications of these actions are that physiological processes or disease states that alter prostaglandin levels in the hypothalamus or pituitary can impinge on H-P axis function. Considering the role of prostaglandins in mediating inflammation, the potential for neuroinflammation to affect H-P axis function in this manner may be significant. In addition, the mitigating effects of n-3 polyunsaturated fatty acids (n-3 PUFA) on the inflammation-associated synthesis of prostaglandins and their role as substrates for pro-resolving lipid mediators may also include effects in the H-P axis. One context in which neuroinflammation may play a role is in the etiology of diet-induced obesity, which also correlates with altered pituitary hormone levels. This review will survey evidence for the actions of prostaglandins and other lipid mediators in the H-P axis, and will address the potential for obesity-associated inflammation and n-3 PUFA to impinge on these mechanisms.","['Hypothalamus', 'Neuroinflammation', 'Obesity', 'Pituitary', 'Prostaglandin', 'n-3 PUFA']","Prostaglandins, leukotrienes, and essential fatty acids",2014-10-08,"[{'lastname': 'Shewchuk', 'firstname': 'Brian M', 'initials': 'BM', 'affiliation': 'Department of Biochemistry and Molecular Biology, Brody School of Medicine, East Carolina University, Greenville, NC 27834, United States. Electronic address: shewchukb@ecu.edu.'}]",,,,Copyright © 2014 Elsevier Ltd. All rights reserved.,10.1016/j.plefa.2014.09.005,<Element 'PubmedArticle' at 0x7f05dbe41770>
440,"25245209
21731800
10924962
21564348
16603429
11087781
8841347
9658195
19797123
2005736
14987460
11160259
7488136
10408542
9721254
22387674
10214746
11009185
15665410
9338790
7812784
9582256
10024327
24512013
22245971
19533603
24157932
11488555
19086259
15246987
10368776
12764095
15210525
15968645
8848182
10447458
15748951
12388836
9809515
11172057
20738280
9398750
18297128
7746387
10817919
15520817
17452498
11745614
17615392
8080389
21354436
16710759
10779008
22521773
23333800
11418693
17274967
13957617
3324647
11896151
16873607
20617147
11923515
9191758
11278111
10214749
16580743
23483801
9861029
11739260
24348584
24228255
24205286
9921852
23771838
16938840
12135731
18328572
9768697
10938336
12353060
14662901
12271473
22492045
23085545
18338250
8248223
19253103
9579298
20631292
23774759
21152017
8710070
17997403
11239204
10732322
15256808
11043525
10430862
24637260
23362079
15778508
11581496
21776259
18693301
18539019
9671811
20096754
15246826
11101351
15020068
12834108
17762604
24424441
15294932
15184606
24896367
14500565
12738057
21373949
17689850
19461673
10833057
24846829
8450456
12208729
20633113
10227628
11454321
9927655
23500634
18976694
15509581
18408366
8072437
22204318
9388012
10662537
12325070
18286612
22888145
20012068
18078984
19389388
15662835
16130149
15994367
17640948
10202604
12538720
9927308
23362211
12878732
23089362
19759299
23536494
16614138
24662928
11406480
18541692
20298245
15144879
11141318
12065211
12383724
2399550
10700514
12413371
9518671
17803971
17696335
16269315
16951259
22525427",Estrogen receptor agonists for attenuation of neuroinflammation and neurodegeneration.,"Recent results from laboratory investigations and clinical trials indicate important roles for estrogen receptor (ER) agonists in protecting the central nervous system (CNS) from noxious consequences of neuroinflammation and neurodegeneration. Neurodegenerative processes in several CNS disorders including spinal cord injury (SCI), multiple sclerosis (MS), Parkinson's disease (PD), and Alzheimer's disease (AD) are associated with activation of microglia and astrocytes, which drive the resident neuroinflammatory response. During neurodegenerative processes, activated microglia and astrocytes cause deleterious effects on surrounding neurons. The inhibitory activity of ER agonists on microglia activation might be a beneficial therapeutic option for delaying the onset or progression of neurodegenerative injuries and diseases. Recent studies suggest that ER agonists can provide neuroprotection by modulation of cell survival mechanisms, synaptic reorganization, regenerative responses to axonal injury, and neurogenesis process. The anti-inflammatory and neuroprotective actions of ER agonists are mediated mainly via two ERs known as ERα and ERβ. Although some studies have suggested that ER agonists may be deleterious to some neuronal populations, the potential clinical benefits of ER agonists for augmenting cognitive function may triumph over the associated side effects. Also, understanding the modulatory activities of ER agonists on inflammatory pathways will possibly lead to the development of selective anti-inflammatory molecules with neuroprotective roles in different CNS disorders such as SCI, MS, PD, and AD in humans. Future studies should be concentrated on finding the most plausible molecular pathways for enhancing protective functions of ER agonists in treating neuroinflammatory and neurodegenerative injuries and diseases in the CNS.","['Estrogen receptor agonists', 'Inflammation', 'Neurodisorders', 'Neuroprotection']",Brain research bulletin,2014-09-24,"[{'lastname': 'Chakrabarti', 'firstname': 'Mrinmay', 'initials': 'M', 'affiliation': 'University of South Carolina School of Medicine, Department of Pathology, Microbiology, and Immunology, Columbia, SC 29209, USA.'}, {'lastname': 'Haque', 'firstname': 'Azizul', 'initials': 'A', 'affiliation': 'Department of Microbiology and Immunology, Hollings Cancer Center, Medical University of South Carolina, Charleston, SC 29425, USA.'}, {'lastname': 'Banik', 'firstname': 'Naren L', 'initials': 'NL', 'affiliation': 'Department of Neurosurgery and Neurology, Medical University of South Carolina, Charleston, SC 29425, USA.'}, {'lastname': 'Nagarkatti', 'firstname': 'Prakash', 'initials': 'P', 'affiliation': 'University of South Carolina School of Medicine, Department of Pathology, Microbiology, and Immunology, Columbia, SC 29209, USA.'}, {'lastname': 'Nagarkatti', 'firstname': 'Mitzi', 'initials': 'M', 'affiliation': 'University of South Carolina School of Medicine, Department of Pathology, Microbiology, and Immunology, Columbia, SC 29209, USA.'}, {'lastname': 'Ray', 'firstname': 'Swapan K', 'initials': 'SK', 'affiliation': 'University of South Carolina School of Medicine, Department of Pathology, Microbiology, and Immunology, Columbia, SC 29209, USA. Electronic address: swapan.ray@uscmed.sc.edu.'}]",,,,Copyright © 2014 Elsevier Inc. All rights reserved.,"10.1016/j.brainresbull.2014.09.004
10.1016/j.jsbmb.2014.05.005
10.1002/ptr.4928
10.1038/mp.2014.23",<Element 'PubmedArticle' at 0x7f05dbe4b7c0>
441,25150504,Effect of ovariectomy on inflammation induced by intermittent hypoxia in a mouse model of sleep apnea.,"Patient data report marked gender and pre-vs-postmenopausal differences in obstructive sleep apnea (OSA). However, no experimental data are available on how sexual hormones modulate OSA consequences. Here we report novel results on estrogen-modulated heart and brain inflammation in female mice subjected to intermittent hypoxia, a major injurious challenge in OSA. C57BL/6J (14-week old) intact and ovariectomized mice (n=6 each) were subjected to intermittent hypoxia (20 s at 5% and 40s at 21%, 60 cycles/h; 6 h/day). Identical intact and ovariectomized groups breathing room air were controls. After 30 days, the gene expressions of interleukins 6 and 8 (IL-6, IL-8) in the brain and heart tissues were measured. Whereas, compared with normoxia, intermittent hypoxia considerably increased IL-6 and IL-8 gene expressions in intact females, no change was found in ovariectomized mice when comparing normoxia and intermittent hypoxia. These data suggest that estrogens modulate the inflammatory effects of intermittent hypoxia and point to further studies on the role played by sex hormones in OSA.","['Inflammation', 'Intermittent hypoxia', 'Obstructive sleep apnea', 'Ovariectomy', 'Sexual hormones']",Respiratory physiology & neurobiology,2014-08-26,"[{'lastname': 'Torres', 'firstname': 'Marta', 'initials': 'M', 'affiliation': 'CIBER de Enfermedades Respiratorias, Madrid, Spain; Laboratori del Son, Hospital Clínic, Universitat de Barcelona-IDIBAPS, Spain.'}, {'lastname': 'Palomer', 'firstname': 'Xavier', 'initials': 'X', 'affiliation': 'CIBER de Diabetes y Enfermedades Metabólicas Asociadas, Madrid, Spain; Department de Farmacologia i Química Terapèutica, IBUB (Institut de Biomedicina de la Universitat de Barcelona), Facultat de Farmàcia, Universitat de Barcelona, Spain.'}, {'lastname': 'Montserrat', 'firstname': 'Josep M', 'initials': 'JM', 'affiliation': 'CIBER de Enfermedades Respiratorias, Madrid, Spain; Laboratori del Son, Hospital Clínic, Universitat de Barcelona-IDIBAPS, Spain.'}, {'lastname': 'Vázquez-Carrera', 'firstname': 'Manel', 'initials': 'M', 'affiliation': 'CIBER de Diabetes y Enfermedades Metabólicas Asociadas, Madrid, Spain; Department de Farmacologia i Química Terapèutica, IBUB (Institut de Biomedicina de la Universitat de Barcelona), Facultat de Farmàcia, Universitat de Barcelona, Spain.'}, {'lastname': 'Farré', 'firstname': 'Ramon', 'initials': 'R', 'affiliation': 'CIBER de Enfermedades Respiratorias, Madrid, Spain; Unitat Biofísica i Bioenginyeria, Facultat de Medicina, Universitat de Barcelona-IDIBAPS, Spain. Electronic address: rfarre@ub.edu.'}]",,,,Copyright © 2014 Elsevier B.V. All rights reserved.,10.1016/j.resp.2014.08.009,<Element 'PubmedArticle' at 0x7f05dbdd8ef0>
442,25149263,Acute treatment with valproic acid and l-thyroxine ameliorates clinical signs of experimental autoimmune encephalomyelitis and prevents brain pathology in DA rats.,"Multiple sclerosis (MS) is the most common chronic inflammatory demyelinating disease of the central nervous system (CNS) in young adults. Chronic treatments with histone deacetylase inhibitors (HDACis) have been reported to ameliorate experimental autoimmune encephalomyelitis (EAE), a rodent model of MS, by targeting immune responses. We have recently shown that the HDAC inhibition/knockdown in the presence of thyroid hormone (T3) can also promote oligodendrocyte (OL) differentiation and expression of myelin genes in neural stem cells (NSCs) and oligodendrocyte precursors (OPCs). In this study, we found that treatment with an HDACi, valproic acid (VPA), and T3, alone or in combination, directly affects encephalitogenic CD4+ T cells. VPA, but not T3, compromised their proliferation, while both molecules reduced the frequency of IL-17-producing cells. Transfer of T3, VPA and VPA/T3 treated encephalitogenic CD4+ T cells into naïve rats induced less severe EAE, indicating that the effects of these molecules are persistent and do not require their maintenance after the initial stimuli. Thus, we investigated the effect of acute treatment with VPA and l-thyroxine (T4), a precursor of T3, on myelin oligodendrocyte glycoprotein-induced EAE in Dark Agouti rats, a close mimic of MS. We found that a brief treatment after disease onset led to sustained amelioration of EAE and prevention of inflammatory demyelination in the CNS accompanied with a higher expression of myelin-related genes in the brain. Furthermore, the treatment modulated immune responses, reduced the number of CD4+ T cells and affected the Th1 differentiation program in the brain. Our data indicate that an acute treatment with VPA and T4 after the onset of EAE can produce persistent clinically relevant therapeutic effects by limiting the pathogenic immune reactions while promoting myelin gene expression.","['Epigenetics', 'Experimental autoimmune encephalomyelitis', 'Histone deacetylases', 'Immune system', 'Multiple sclerosis', 'Myelin', 'Neuroinflammation', 'Oligodendrocyte precursor', 'T cells', 'Thyroid hormone']",Neurobiology of disease,2014-08-26,"[{'lastname': 'Castelo-Branco', 'firstname': 'Gonçalo', 'initials': 'G', 'affiliation': 'Laboratory of Molecular Neurobiology, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden; Department of Neuroscience, Karolinska Institutet, Stockholm, Sweden. Electronic address: Goncalo.Castelo-Branco@ki.se.'}, {'lastname': 'Stridh', 'firstname': 'Pernilla', 'initials': 'P', 'affiliation': 'Department of Clinical Neuroscience, Center for Molecular Medicine, Karolinska Institutet, Stockholm, Sweden.'}, {'lastname': 'Guerreiro-Cacais', 'firstname': 'André Ortlieb', 'initials': 'AO', 'affiliation': 'Department of Clinical Neuroscience, Center for Molecular Medicine, Karolinska Institutet, Stockholm, Sweden.'}, {'lastname': 'Adzemovic', 'firstname': 'Milena Z', 'initials': 'MZ', 'affiliation': 'Department of Clinical Neuroscience, Center for Molecular Medicine, Karolinska Institutet, Stockholm, Sweden; Center for Brain Research, Vienna, Austria.'}, {'lastname': 'Falcão', 'firstname': 'Ana Mendanha', 'initials': 'AM', 'affiliation': 'Laboratory of Molecular Neurobiology, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden.'}, {'lastname': 'Marta', 'firstname': 'Monica', 'initials': 'M', 'affiliation': 'Department of Clinical Neuroscience, Center for Molecular Medicine, Karolinska Institutet, Stockholm, Sweden; Neuroscience, Blizard Institute, Queen Mary University London, London, UK.'}, {'lastname': 'Berglund', 'firstname': 'Rasmus', 'initials': 'R', 'affiliation': 'Department of Clinical Neuroscience, Center for Molecular Medicine, Karolinska Institutet, Stockholm, Sweden.'}, {'lastname': 'Gillett', 'firstname': 'Alan', 'initials': 'A', 'affiliation': 'Department of Clinical Neuroscience, Center for Molecular Medicine, Karolinska Institutet, Stockholm, Sweden.'}, {'lastname': 'Hamza', 'firstname': 'Kedir Hussen', 'initials': 'KH', 'affiliation': 'Laboratory of Molecular Neurobiology, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, Stockholm, Sweden.'}, {'lastname': 'Lassmann', 'firstname': 'Hans', 'initials': 'H', 'affiliation': 'Center for Brain Research, Vienna, Austria.'}, {'lastname': 'Hermanson', 'firstname': 'Ola', 'initials': 'O', 'affiliation': 'Department of Neuroscience, Karolinska Institutet, Stockholm, Sweden.'}, {'lastname': 'Jagodic', 'firstname': 'Maja', 'initials': 'M', 'affiliation': 'Department of Clinical Neuroscience, Center for Molecular Medicine, Karolinska Institutet, Stockholm, Sweden. Electronic address: Maja.Jagodic@ki.se.'}]",,,,Copyright © 2014. Published by Elsevier Inc.,10.1016/j.nbd.2014.08.019,<Element 'PubmedArticle' at 0x7f05dbca7d60>
443,"25135305
15967377
22492304
19394356
9464988
12048217
19299024
15970017
23028880
19533603
18455872
21778316
11248225
21357268
17993994
15748951
21564349
17276138
17403432
10911963
10942521
9218432
10213481
9633809
9724801
15694689
17350671
19836443
16949056
15734144
16628003
16247808
15925283
14568026
23272189
20552057
19501645
19584059
16343783
12509805
22227472
16226751
18925972
11069120
19632300
20660252
18411298
22537429
21071446
20738755
16773072
10709973
19361542
15885957
22143822
7285872
9416670
17470386
20394757
10532629
16399210
18342840
17980408
19538946
18714076
18298467
10408982
20450904
18031570
19627457
15145751
16978658
15152190
1328293",Melatonin and oestrogen treatments were able to improve neuroinflammation and apoptotic processes in dentate gyrus of old ovariectomized female rats.,"The aim of this study was to determine the outcomes of oestrogen and melatonin treatments following long-term ovarian hormone depletion on neuroinflammation and apoptotic processes in dentate gyrus of hippocampi. Forty-six female Wistar rats of 22 months of age were used. Twelve of them remained intact, and the other 34 were ovariectomized at 12 months of age. Ovariectomized animals were divided into three groups and treated for 10 weeks with oestrogens, melatonin or saline. All rats were killed by decapitation at 24 months of age, and dentate gyri were collected. A group of 2 month-old intact female rats was used as young control. The levels of pro-inflammatory cytokines and heat shock protein 70 (HSP 70) were analysed by ELISA. The expressions of TNFα, IL1β, GFAP, nNOS, iNOS, HO-1, NFκB, Bax, Bad, AIF, Bcl2 and SIRT1 genes were detected by real-time (RT)-PCR. Western blots were used to measure the protein expression of NFκB p65, NFκB p50/105, IκBα, IκBβ, p38 MAPK, MAP-2 and synapsin I. We have assessed the ability of 17β-oestradiol and melatonin administration to downregulate markers of neuroinflammation in the dentate gyrus of ovariectomized female rats. Results indicated that 17β-oestradiol and melatonin treatments were able to significantly decrease expression of pro-inflammatory cytokines, iNOS and HO-1 in the hippocampus when compared to non-treated animals. A similar age- and long-term ovarian hormone depletion- related increase in GFAP was also attenuated after both melatonin and oestradiol treatments. In a similar way to oestradiol, melatonin decreased the activation of p38 MAPK and NFκB pathways. The treatments enhanced the levels of synaptic molecules synapsin I and MAP-2 and have been shown to modulate the pro-antiapoptotic ratio favouring the second and to increase SIRT1 expression. These findings support the potential therapeutic role of melatonin and oestradiol as protective anti-inflammatory agents for the central nervous system during menopause.",[],"Age (Dordrecht, Netherlands)",2014-08-20,"[{'lastname': 'Kireev', 'firstname': 'Roman A', 'initials': 'RA', 'affiliation': 'Instituto de Investigación Biomédica de Vigo (IBIV), Xerencia de Xestión Integrada de Vigo, SERGAS, Biomedical Research Unit, Hospital Rebullón (CHUVI), Puxeiros s/n, 36415, MOS Pontevedra, Spain, rakireev@gmail.com.'}, {'lastname': 'Vara', 'firstname': 'Elena', 'initials': 'E', 'affiliation': None}, {'lastname': 'Viña', 'firstname': 'Jose', 'initials': 'J', 'affiliation': None}, {'lastname': 'Tresguerres', 'firstname': 'Jesus A F', 'initials': 'JA', 'affiliation': None}]",,,,,"10.1007/s11357-014-9707-3
10.1016/j.phrs.2005.03.002
10.1210/en.2011-1925
10.1016/j.yfrne.2009.04.003
10.1074/jbc.M204994200
10.1016/j.tips.2008.12.006
10.1258/136218005775544525
10.1371/journal.pone.0045250
10.1002/glia.20904
10.1016/j.neulet.2008.04.026
10.1016/S0009-2797(00)00319-7
10.4049/jimmunol.1002205
10.1097/gme.0b013e31812503f2
10.1016/j.jneuroim.2004.12.016
10.1111/j.1365-2826.2011.02157.x
10.1016/j.it.2007.01.005
10.1111/j.1749-6632.2000.tb06651.x
10.1002/1097-4652(200010)185:1<80::AID-JCP7>3.0.CO;2-W
10.1074/jbc.272.29.18033
10.1002/(SICI)1097-4547(19990401)56:1<99::AID-JNR13>3.0.CO;2-G
10.1002/(SICI)1098-1136(199807)23:3<249::AID-GLIA7>3.0.CO;2-#
10.1073/pnas.95.18.10896
10.1016/j.mehy.2004.06.035
10.1016/j.mad.2007.01.005
10.1016/j.exger.2009.10.006
10.1016/j.brainres.2006.07.105
10.1016/j.tem.2005.01.004
10.4161/cc.5.8.2690
10.1002/jnr.20671
10.1016/j.freeradbiomed.2005.02.033
10.1016/S0306-4522(03)00245-8
10.1371/journal.pone.0051911
10.3389/neuro.24.006.2009
10.1016/j.bbi.2009.05.060
10.1074/jbc.M109.000463
10.1016/j.neuroscience.2005.10.058
10.1002/glia.10168
10.1016/j.lfs.2011.12.006
10.1016/j.expneurol.2005.09.008
10.1186/1742-2094-5-45
10.1046/j.1365-2826.2000.00541.x
10.1016/j.neulet.2009.07.058
10.1523/JNEUROSCI.0027-10.2010
10.1128/MCB.00296-08
10.1186/1742-2094-9-79
10.1074/jbc.M110.169839
10.1111/j.1600-079X.2010.00805.x
10.1038/nrd2070
10.1034/j.1600-079X.2001.280207.x
10.1016/j.yfrne.2009.03.007
10.1016/j.exger.2005.03.003
10.1007/s10522-011-9367-y
10.1210/endo-109-4-1295
10.1016/S0166-2236(97)01139-9
10.1016/j.exger.2007.03.001
10.1016/j.lfs.2010.04.002
10.1097/00004647-199910000-00001
10.1016/j.neurobiolaging.2005.01.016
10.1016/j.brainres.2008.01.080
10.1016/j.yfrne.2007.08.002
10.1016/j.brainres.2009.06.029
10.1111/j.1600-079X.2008.00561.x
10.1016/S0165-5728(99)00053-3
10.1016/j.ejphar.2010.04.041
10.1111/j.1474-9726.2007.00356.x
10.1111/j.1600-079X.2009.00699.x
10.1016/j.brainres.2004.02.019
10.1016/j.lfs.2006.06.023
10.1038/sj.emboj.7600244
10.1172/JCI115980",<Element 'PubmedArticle' at 0x7f05dbcb92c0>
444,25131447,Interplay between brain stem angiotensins and monocyte chemoattractant protein-1 as a novel mechanism for pressor response after ischemic stroke.,"Pressor response after stroke commonly leads to early death or susceptibility to stroke recurrence, and detailed mechanisms are still lacking. We assessed the hypothesis that the renin-angiotensin system contributes to pressor response after stroke by differential modulation of the pro-inflammatory chemokine monocyte chemoattractant protein-1 (MCP-1) in the rostral ventrolateral medulla (RVLM), a key brain stem site that maintains blood pressure. We also investigated the beneficial effects of a novel renin inhibitor, aliskiren, against stroke-elicited pressor response. Experiments were performed in male adult Sprague-Dawley rats. Stroke induced by middle cerebral artery occlusion elicited significant pressor response, accompanied by activation of angiotensin II (Ang II)/type I receptor (AT1R) and AT2R signaling, depression of Ang-(1-7)/MasR and Ang IV/AT4R cascade, alongside augmentation of MCP-1/C-C chemokine receptor 2 (CCR2) signaling and neuroinflammation in the RVLM. Stroke-elicited pressor response was significantly blunted by antagonism of AT1R, AT2R or MCP-1/CCR2 signaling, and eliminated by applying Ang-(1-7) or Ang IV into the RVLM. Furthermore, stroke-activated MCP-1/CCR2 signaling was enhanced by AT1R and AT2R activation, and depressed by Ang-(1-7)/MasR and Ang IV/AT4R cascade. Aliskiren inhibited stroke-elicited pressor response via downregulating MCP-1/CCR2 activity and reduced neuroinflammation in the RVLM; these effects were potentiated by Ang-(1-7) or Ang IV. We conclude that whereas Ang II/AT1R or Ang II/AT2R signaling in the brain stem enhances, Ang-(1-7)/MasR or Ang IV/AT4R antagonizes pressor response after stroke by differential modulations of MCP-1 in the RVLM. Furthermore, combined administration of aliskiren and Ang-(1-7) or Ang IV into the brain stem provides more effective amelioration of stroked-induced pressor response.","['Aliskiren', 'Angiotensin isoforms and receptors', 'Ischemic stroke', 'Middle cerebral artery occlusion', 'Monocyte chemoattractant protein-1', 'Neuroinflammation', 'Pressor response after stroke', 'Rostral ventrolateral medulla']",Neurobiology of disease,2014-08-19,"[{'lastname': 'Chang', 'firstname': 'Alice Y W', 'initials': 'AY', 'affiliation': 'Center for Translational Research in Biomedical Sciences, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan, ROC; Department of Physiology, National Cheng Kung University, Tainan, Taiwan, ROC; Department of Pharmacology, Kaohsiung Medical University, Kaohsiung, Taiwan, ROC; Department of Biological Science, National Sun Yat-sen University, Kaohsiung, Taiwan, ROC. Electronic address: aywchang@mail.ncku.edu.tw.'}, {'lastname': 'Li', 'firstname': 'Faith C H', 'initials': 'FC', 'affiliation': 'Center for Translational Research in Biomedical Sciences, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan, ROC.'}, {'lastname': 'Huang', 'firstname': 'Chi-Wei', 'initials': 'CW', 'affiliation': 'Department of Biological Science, National Sun Yat-sen University, Kaohsiung, Taiwan, ROC; Department of Neurology, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan, ROC.'}, {'lastname': 'Wu', 'firstname': 'Julie C C', 'initials': 'JC', 'affiliation': 'Center for Translational Research in Biomedical Sciences, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan, ROC.'}, {'lastname': 'Dai', 'firstname': 'Kuang-Yu', 'initials': 'KY', 'affiliation': 'Center for Translational Research in Biomedical Sciences, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan, ROC.'}, {'lastname': 'Chen', 'firstname': 'Chang-Han', 'initials': 'CH', 'affiliation': 'Center for Translational Research in Biomedical Sciences, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan, ROC.'}, {'lastname': 'Li', 'firstname': 'Shau-Hsuan', 'initials': 'SH', 'affiliation': 'Department of Hematology and Oncology, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan, ROC.'}, {'lastname': 'Su', 'firstname': 'Chia-Hao', 'initials': 'CH', 'affiliation': 'Center for Translational Research in Biomedical Sciences, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan, ROC.'}, {'lastname': 'Wu', 'firstname': 'Re-Wen', 'initials': 'RW', 'affiliation': 'Department of Orthopedics, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan, ROC.'}]",,,,Copyright © 2014 Elsevier Inc. All rights reserved.,10.1016/j.nbd.2014.08.005,<Element 'PubmedArticle' at 0x7f05dbc26680>
445,25114100,Hepatocyte growth factor limits autoimmune neuroinflammation via glucocorticoid-induced leucine zipper expression in dendritic cells.,"Autoimmune neuroinflammation, including multiple sclerosis and its animal model, experimental autoimmune encephalomyelitis (EAE), a prototype for T cell-mediated autoimmunity, is believed to result from immune tolerance dysfunction leading to demyelination and substantial neurodegeneration. We previously showed that CNS-restricted expression of hepatocyte growth factor (HGF), a potent neuroprotective factor, reduced CNS inflammation and clinical deficits associated with EAE. In this study, we demonstrate that systemic HGF treatment ameliorates EAE through the development of tolerogenic dendritic cells (DCs) with high expression levels of glucocorticoid-induced leucine zipper (GILZ), a transcriptional repressor of gene expression and a key endogenous regulator of the inflammatory response. RNA interference-directed neutralization of GILZ expression by DCs suppressed the induction of tolerance caused by HGF. Finally, adoptive transfer of HGF-treated DCs from wild-type but not GILZ gene-deficient mice potently mediated functional recovery in recipient mice with established EAE through effective modulation of autoaggressive T cell responses. Altogether, these results show that by inducing GILZ in DCs, HGF reproduces the mechanism of immune regulation induced by potent immunomodulatory factors such as IL-10, TGF-β1, and glucocorticoids and therefore that HGF therapy may have potential in the treatment of autoimmune dysfunctions.",[],"Journal of immunology (Baltimore, Md. : 1950)",2014-08-13,"[{'lastname': 'Benkhoucha', 'firstname': 'Mahdia', 'initials': 'M', 'affiliation': 'Department of Pathology and Immunology, Faculty of Medicine, University of Geneva, 1211 Geneva, Switzerland; Unit of Neuroimmunology and Multiple Sclerosis, Division of Neurology, Department of Clinical Neurosciences, Geneva University Hospital, 1211 Geneva, Switzerland;'}, {'lastname': 'Molnarfi', 'firstname': 'Nicolas', 'initials': 'N', 'affiliation': 'Department of Pathology and Immunology, Faculty of Medicine, University of Geneva, 1211 Geneva, Switzerland; Unit of Neuroimmunology and Multiple Sclerosis, Division of Neurology, Department of Clinical Neurosciences, Geneva University Hospital, 1211 Geneva, Switzerland;'}, {'lastname': 'Dunand-Sauthier', 'firstname': 'Isabelle', 'initials': 'I', 'affiliation': 'Department of Pathology and Immunology, Faculty of Medicine, University of Geneva, 1211 Geneva, Switzerland;'}, {'lastname': 'Merkler', 'firstname': 'Doron', 'initials': 'D', 'affiliation': 'Department of Pathology and Immunology, Faculty of Medicine, University of Geneva, 1211 Geneva, Switzerland; Division of Clinical Pathology, Geneva University Hospital, 1211 Geneva, Switzerland; Institut für Neuropathologie, Universitätsmedizin Göttingen, Georg-August-Universität, 37099 Göttingen, Germany;'}, {'lastname': 'Schneiter', 'firstname': 'Gregory', 'initials': 'G', 'affiliation': 'Department of Pathology and Immunology, Faculty of Medicine, University of Geneva, 1211 Geneva, Switzerland; Unit of Neuroimmunology and Multiple Sclerosis, Division of Neurology, Department of Clinical Neurosciences, Geneva University Hospital, 1211 Geneva, Switzerland;'}, {'lastname': 'Bruscoli', 'firstname': 'Stefano', 'initials': 'S', 'affiliation': 'Section of Pharmacology, Department of Medicine, University of Perugia, 06132 Perugia, Italy;'}, {'lastname': 'Riccardi', 'firstname': 'Carlo', 'initials': 'C', 'affiliation': 'Section of Pharmacology, Department of Medicine, University of Perugia, 06132 Perugia, Italy;'}, {'lastname': 'Tabata', 'firstname': 'Yasuhiko', 'initials': 'Y', 'affiliation': 'Department of Biomaterials, Institute for Frontier Medical Sciences, Kyoto University, Kyoto 606-8507, Japan;'}, {'lastname': 'Funakoshi', 'firstname': 'Hiroshi', 'initials': 'H', 'affiliation': 'Center for Advanced Research and Education, Asahikawa Medical University, Asahikawa 078-8510, Japan;'}, {'lastname': 'Nakamura', 'firstname': 'Toshikazu', 'initials': 'T', 'affiliation': 'Neurogen Inc., Nakahozumi, Ibaraki, Osaka 567-0034, Japan; and.'}, {'lastname': 'Reith', 'firstname': 'Walter', 'initials': 'W', 'affiliation': 'Department of Pathology and Immunology, Faculty of Medicine, University of Geneva, 1211 Geneva, Switzerland;'}, {'lastname': 'Santiago-Raber', 'firstname': 'Marie-Laure', 'initials': 'ML', 'affiliation': 'Department of Pathology and Immunology, Faculty of Medicine, University of Geneva, 1211 Geneva, Switzerland;'}, {'lastname': 'Lalive', 'firstname': 'Patrice H', 'initials': 'PH', 'affiliation': 'Department of Pathology and Immunology, Faculty of Medicine, University of Geneva, 1211 Geneva, Switzerland; Unit of Neuroimmunology and Multiple Sclerosis, Division of Neurology, Department of Clinical Neurosciences, Geneva University Hospital, 1211 Geneva, Switzerland; Division of Laboratory Medicine, Department of Genetic and Laboratory Medicine, Geneva University Hospital, 1211 Geneva, Switzerland patrice.lalive@hcuge.ch.'}]",,,,"Copyright © 2014 by The American Association of Immunologists, Inc.",10.4049/jimmunol.1302338,<Element 'PubmedArticle' at 0x7f05dbc35e50>
446,"25092805
19031445
16651886
12054570
2776038
20625376
23065788
17557778
19318112
1282751
23026979
18061700
24638138
17692515
21736923
23231597
23153407
12887683
22283602
17715141
17956739
19109501
21828184
23365095
14720179
12403837
1995287
24191028
21467994
19763593
7770777
15649707
11108869
19053058
16652341
19356606
20943809
22635678
7557380
20672298
9213138
20404843
15111314
11145196
24121112
20857501
18558866
6889633
14507666
11835378
18490917
11487645
19660659
24172649
18286612
20933114
18349131
20544279
21555578
22033509
19746424
22583443
19302141
2713643
18720413
17616732
17011666
18447940
20153059
15629202
20381586",Progesterone and nestorone promote myelin regeneration in chronic demyelinating lesions of corpus callosum and cerebral cortex.,"Multiple Sclerosis affects mainly women and consists in intermittent or chronic damages to the myelin sheaths, focal inflammation, and axonal degeneration. Current therapies are limited to immunomodulators and antiinflammatory drugs, but there is no efficient treatment for stimulating the endogenous capacity of myelin repair. Progesterone and synthetic progestins have been shown in animal models of demyelination to attenuate myelin loss, reduce clinical symptoms severity, modulate inflammatory responses and partially reverse the age-dependent decline in remyelination. Moreover, progesterone has been demonstrated to promote myelin formation in organotypic cultures of cerebellar slices. In the present study, we show that progesterone and the synthetic 19-nor-progesterone derivative Nestorone® promote the repair of severe chronic demyelinating lesions induced by feeding cuprizone to female mice for up to 12 weeks. Progesterone and Nestorone increase the density of NG2(+) oligodendrocyte progenitor cells and CA II(+) mature oligodendrocytes and enhance the formation of myelin basic protein (MBP)- and proteolipid protein (PLP)-immunoreactive myelin. However, while demyelination in response to cuprizone was less marked in corpus callosum than in cerebral cortex, remyelination appeared earlier in the former. The remyelinating effect of progesterone was progesterone receptor (PR)-dependent, as it was absent in PR-knockout mice. Progesterone and Nestorone also decreased (but did not suppress) neuroinflammatory responses, specifically astrocyte and microglial cell activation. Therefore, some progestogens are promising therapeutic candidates for promoting the regeneration of myelin.","['cuprizone', 'oligodendrocytes', 'progesterone receptor', 'progestogens', 'remyelination']",Glia,2014-08-06,"[{'lastname': 'El-Etr', 'firstname': 'Martine', 'initials': 'M', 'affiliation': 'UMR 788 Inserm and University Paris-Sud, 94276, Kremlin-Bicêtre, France.'}, {'lastname': 'Rame', 'firstname': 'Marion', 'initials': 'M', 'affiliation': None}, {'lastname': 'Boucher', 'firstname': 'Celine', 'initials': 'C', 'affiliation': None}, {'lastname': 'Ghoumari', 'firstname': 'Abdel M', 'initials': 'AM', 'affiliation': None}, {'lastname': 'Kumar', 'firstname': 'Narender', 'initials': 'N', 'affiliation': None}, {'lastname': 'Liere', 'firstname': 'Philippe', 'initials': 'P', 'affiliation': None}, {'lastname': 'Pianos', 'firstname': 'Antoine', 'initials': 'A', 'affiliation': None}, {'lastname': 'Schumacher', 'firstname': 'Michael', 'initials': 'M', 'affiliation': None}, {'lastname': 'Sitruk-Ware', 'firstname': 'Regine', 'initials': 'R', 'affiliation': None}]",,,,"© 2014 Wiley Periodicals, Inc.",10.1002/glia.22736,<Element 'PubmedArticle' at 0x7f05dbc47540>
447,"25080336
9405705
17014900
18374402
22732134
18308838
18602498
24065876
22649404
8620923
9271001
15932748
16259981
17892409
20555409
10567046
10794300
11825624
15885907
19135987
21277368
21705427
21403869
23499999
17011666
18447940
17250675
17180163
20880501
22741103
9712833
9414121
15683737
21733175
1578513
19565166
21389984
1733727
10616793
23962089
15819693
20609516
19302050
18675321
18267068
7508926
18483177
9464988
9475517
12048217
15739188
24223607
16641245",Anti-inflammatory effects of progesterone in lipopolysaccharide-stimulated BV-2 microglia.,"Female sex is associated with improved outcome in experimental brain injury models, such as traumatic brain injury, ischemic stroke, and intracerebral hemorrhage. This implies female gonadal steroids may be neuroprotective. A mechanism for this may involve modulation of post-injury neuroinflammation. As the resident immunomodulatory cells in central nervous system, microglia are activated during acute brain injury and produce inflammatory mediators which contribute to secondary injury including proinflammatory cytokines, and nitric oxide (NO) and prostaglandin E2 (PGE2), mediated by inducible NO synthase (iNOS) and cyclooxygenase-2 (COX-2), respectively. We hypothesized that female gonadal steroids reduce microglia mediated neuroinflammation. In this study, the progesterone's effects on tumor necrosis factor alpha (TNF-α), iNOS, and COX-2 expression were investigated in lipopolysaccharide (LPS)-stimulated BV-2 microglia. Further, investigation included nuclear factor kappa B (NF-κB) and mitogen activated protein kinase (MAPK) pathways. LPS (30 ng/ml) upregulated TNF-α, iNOS, and COX-2 protein expression in BV-2 cells. Progesterone pretreatment attenuated LPS-stimulated TNF-α, iNOS, and COX-2 expression in a dose-dependent fashion. Progesterone suppressed LPS-induced NF-κB activation by decreasing inhibitory κBα and NF-κB p65 phosphorylation and p65 nuclear translocation. Progesterone decreased LPS-mediated phosphorylation of p38, c-Jun N-terminal kinase and extracellular regulated kinase MAPKs. These progesterone effects were inhibited by its antagonist mifepristone. In conclusion, progesterone exhibits pleiotropic anti-inflammatory effects in LPS-stimulated BV-2 microglia by down-regulating proinflammatory mediators corresponding to suppression of NF-κB and MAPK activation. This suggests progesterone may be used as a potential neurotherapeutic to treat inflammatory components of acute brain injury.",[],PloS one,2014-08-01,"[{'lastname': 'Lei', 'firstname': 'Beilei', 'initials': 'B', 'affiliation': 'Multidisciplinary Neuroprotection Laboratories, Duke University Medical Center, Durham, North Carolina, United States of America; Department of Anesthesiology, Duke University Medical Center, Durham, North Carolina, United States of America.'}, {'lastname': 'Mace', 'firstname': 'Brian', 'initials': 'B', 'affiliation': 'Department of Neurology, Duke University Medical Center, Durham, North Carolina, United States of America.'}, {'lastname': 'Dawson', 'firstname': 'Hana N', 'initials': 'HN', 'affiliation': 'Department of Neurology, Duke University Medical Center, Durham, North Carolina, United States of America.'}, {'lastname': 'Warner', 'firstname': 'David S', 'initials': 'DS', 'affiliation': 'Multidisciplinary Neuroprotection Laboratories, Duke University Medical Center, Durham, North Carolina, United States of America; Department of Anesthesiology, Duke University Medical Center, Durham, North Carolina, United States of America; Department of Neurobiology, Duke University Medical Center, Durham, North Carolina, United States of America.'}, {'lastname': 'Laskowitz', 'firstname': 'Daniel T', 'initials': 'DT', 'affiliation': 'Multidisciplinary Neuroprotection Laboratories, Duke University Medical Center, Durham, North Carolina, United States of America; Department of Anesthesiology, Duke University Medical Center, Durham, North Carolina, United States of America; Department of Neurology, Duke University Medical Center, Durham, North Carolina, United States of America; Department of Neurobiology, Duke University Medical Center, Durham, North Carolina, United States of America.'}, {'lastname': 'James', 'firstname': 'Michael L', 'initials': 'ML', 'affiliation': 'Multidisciplinary Neuroprotection Laboratories, Duke University Medical Center, Durham, North Carolina, United States of America; Department of Anesthesiology, Duke University Medical Center, Durham, North Carolina, United States of America; Department of Neurology, Duke University Medical Center, Durham, North Carolina, United States of America.'}]",,,,,10.1371/journal.pone.0103969,<Element 'PubmedArticle' at 0x7f05dbbeeef0>
448,"25049069
19022335
6668417
19253915
7978722
20863625
19124690
22417946
7480560
22718491
18160468
24636516
16700640
1159263
23916911
18697684
12892658
19607750
18937978
16042777","Stress management skills, cortisol awakening response, and post-exertional malaise in Chronic Fatigue Syndrome.","Chronic Fatigue Syndrome (CFS) is characterized in part by debilitating fatigue typically exacerbated by cognitive and/or physical exertion, referred to as post-exertional malaise (PEM). In a variety of populations, the cortisol awakening response (CAR) has stood out as a marker of endocrine dysregulation relevant to the experience of fatigue, and may therefore be particularly relevant in CFS. This is the first study to examine PEM and the CAR in a sample of individuals with CFS. The CAR has also been established as a stress-sensitive measure of HPA axis functioning. It follows that better management of stress could modulate the CAR, and in turn PEM. In this cross-sectional study, we hypothesized that greater Perceived Stress Management Skills (PSMS) would relate to lower reports of PEM, via the impact of PSMS on the CAR. A total of 117 adults (72% female) with a CFS diagnosis completed self-report measures of PSMS and PEM symptomatology and a two-day protocol of saliva collection. Cortisol values from awakening and 30 min post-awakening were used to compute the CAR. Regression analyses revealed that greater PSMS related to greater CAR and greater CAR related to less PEM severity. Bootstrapped analyses revealed an indirect effect of PSMS on PEM via the CAR, such that greater PSMS related to less PEM, via a greater CAR. Future research should examine these trends longitudinally and whether interventions directed at improving stress management skills are accompanied by improved cortisol regulation and less PEM in individuals with CFS.","['Chronic Fatigue Syndrome', 'Cortisol', 'HPA axis', 'Stress management']",Psychoneuroendocrinology,2014-07-23,"[{'lastname': 'Hall', 'firstname': 'Daniel L', 'initials': 'DL', 'affiliation': 'Department of Psychology, University of Miami, Coral Gables, FL, USA. Electronic address: dhall@psy.miami.edu.'}, {'lastname': 'Lattie', 'firstname': 'Emily G', 'initials': 'EG', 'affiliation': 'Department of Psychology, University of Miami, Coral Gables, FL, USA.'}, {'lastname': 'Antoni', 'firstname': 'Michael H', 'initials': 'MH', 'affiliation': 'Department of Psychology, University of Miami, Coral Gables, FL, USA.'}, {'lastname': 'Fletcher', 'firstname': 'Mary Ann', 'initials': 'MA', 'affiliation': 'Institute for Neuro Immune Medicine, Nova Southeastern University, Davie, FL, USA.'}, {'lastname': 'Czaja', 'firstname': 'Sara', 'initials': 'S', 'affiliation': 'Department of Psychiatry and Behavioral Sciences, University of Miami, Miami, FL, USA.'}, {'lastname': 'Perdomo', 'firstname': 'Dolores', 'initials': 'D', 'affiliation': 'Department of Psychiatry and Behavioral Sciences, University of Miami, Miami, FL, USA.'}, {'lastname': 'Klimas', 'firstname': 'Nancy G', 'initials': 'NG', 'affiliation': 'Institute for Neuro Immune Medicine, Nova Southeastern University, Davie, FL, USA.'}]",,,,Copyright © 2014 Elsevier Ltd. All rights reserved.,"10.1016/j.psyneuen.2014.06.021
10.1016/j.psyneuen.2014.01.017",<Element 'PubmedArticle' at 0x7f05dbc14040>
449,25042403,Dexamethasone reduces brain cell apoptosis and inhibits inflammatory response in rats with intracerebral hemorrhage.,"Spontaneous intracerebral hemorrhage (ICH) is associated with high rates of mortality and morbidity. Thus, the identification of novel therapeutic agents for preventing strokes and attenuating poststroke brain damage is crucial. Dexamethasone (DEX) is used clinically to reduce edema formation in patients with spinal cord injury and brain tumors. In this study, we sought to elucidate the effects of DEX treatment on apoptosis and inflammation following ICH in rats. A high dose of DEX (15 mg/kg) was administered immediately following ICH induction and again 3 days later. The inflammatory and apoptotic responses in the rat brains were evaluated by using hematoxylin-eosin, terminal deoxynucleotidyl transferase dUTP nick end labeling, Nissl, and neurofilament-H staining. Levels of phosphorylated neurofilaments and apoptosis-related proteins such as B-cell lymphoma 2 (Bcl-2), Bcl-2 associated X protein (Bax), caspase-3, and P53 were analyzed by Western blotting. This study shows that rats without ICH that received DEX treatment had a fourfold higher expression of Bcl-2 than sham-operated rats. ICH causes an increase in Bax, cleaved caspase-3, and P53 proteins from 4 hr to 7 days following ICH induction. In comparison with the ICH rats, the ICH/DEX rats showed significantly decreased apoptotic cell death and increased neuron survival and maintained neurofilament integrity in the perihematomal region. DEX increased the Bcl-2/Bax ratio and lowered the expression of cleaved caspase-3 at 12 hr and 5 days. The ICH rats were accompanied by activation of the inflammatory response, and DEX treatment modulated the expression of a variety of cell types and then decreased ICH-induced apoptosis.","['Bax', 'Bcl-2', 'P53', 'apoptosis', 'cleaved caspase-3', 'dexamethasone', 'inflammatory response', 'intracerebral hemorrhage']",Journal of neuroscience research,2014-07-22,"[{'lastname': 'Lee', 'firstname': 'I-Neng', 'initials': 'IN', 'affiliation': 'Department of Medical Research, Chang Gung Memorial Hospital, Chia-Yi, Taiwan.'}, {'lastname': 'Cheng', 'firstname': 'Wan-Chun', 'initials': 'WC', 'affiliation': None}, {'lastname': 'Chung', 'firstname': 'Chiu-Yen', 'initials': 'CY', 'affiliation': None}, {'lastname': 'Lee', 'firstname': 'Ming-Hsueh', 'initials': 'MH', 'affiliation': None}, {'lastname': 'Lin', 'firstname': 'Martin Hsiu-Chu', 'initials': 'MH', 'affiliation': None}, {'lastname': 'Kuo', 'firstname': 'Chia-Hui', 'initials': 'CH', 'affiliation': None}, {'lastname': 'Weng', 'firstname': 'Hsu-Huei', 'initials': 'HH', 'affiliation': None}, {'lastname': 'Yang', 'firstname': 'Jen-Tsung', 'initials': 'JT', 'affiliation': None}]",,,,"© 2014 Wiley Periodicals, Inc.",10.1002/jnr.23454,<Element 'PubmedArticle' at 0x7f05dbba5540>
450,24995391,Melatonin reduced microglial activation and alleviated neuroinflammation induced neuron degeneration in experimental traumatic brain injury: Possible involvement of mTOR pathway.,"This study was designed to detect the modulation manner of melatonin on microglial activation and explore herein possible involvement of mammalian target of rapamycin (mTOR) pathway following traumatic brain injury (TBI). ICR mice were divided into four groups: sham group, TBI group, TBI+sal group and TBI+Melatonin group. A weight-drop model was employed to cause TBI. Neurological severity score (NSS) tests were performed to measure behavioral outcomes. Nissl staining was conducted to observe the neuronal degeneration and wet-to-dry weight ratio indicated brain water content. Immunofluorescence was designed to investigate microglial activation. Enzyme-linked immunosorbent assay (ELISA) was employed to evaluate proinflammatory cytokine levels (interleukin-beta (IL-1β), tumor necrosis factor-alpha (TNF-α)). Western blotting was engaged to analyze the protein content of mammalian target of rapamycin (mTOR), p70 ribosomal S6 kinase (p70S6K) and S6 ribosomal protein (S6RP). Melatonin administration was associated with markedly restrained microglial activation, decreased release of proinflammatory cytokines and increased the number of surviving neurons at the site of peri-contusion. Meanwhile, melatonin administration resulted in dephosphorylated mTOR pathway. In conclusion, this study presents a new insight into the mechanisms responsible for the anti-neuroinflammation of melatonin, with possible involvement of mTOR pathway.","['Inflammation', 'Mammalian target of rapamycin', 'Melatonin', 'Microglia activation', 'Traumatic brain injury']",Neurochemistry international,2014-07-06,"[{'lastname': 'Ding', 'firstname': 'Ke', 'initials': 'K', 'affiliation': 'Department of Neurosurgery, Jinling Hospital, School of Medicine, Nanjing University, Nanjing, Jiangsu Province, China.'}, {'lastname': 'Wang', 'firstname': 'Handong', 'initials': 'H', 'affiliation': 'Department of Neurosurgery, Jinling Hospital, School of Medicine, Nanjing University, Nanjing, Jiangsu Province, China. Electronic address: njhdwang@hotmail.com.'}, {'lastname': 'Xu', 'firstname': 'Jianguo', 'initials': 'J', 'affiliation': 'Department of Neurosurgery, Jinling Hospital, School of Medicine, Nanjing University, Nanjing, Jiangsu Province, China.'}, {'lastname': 'Lu', 'firstname': 'Xinyu', 'initials': 'X', 'affiliation': 'Department of Neurosurgery, Jinling Hospital, School of Medicine, Nanjing University, Nanjing, Jiangsu Province, China.'}, {'lastname': 'Zhang', 'firstname': 'Li', 'initials': 'L', 'affiliation': 'Department of Neurosurgery, Jinling Hospital, School of Medicine, Nanjing University, Nanjing, Jiangsu Province, China.'}, {'lastname': 'Zhu', 'firstname': 'Lin', 'initials': 'L', 'affiliation': 'Department of Neurosurgery, Jinling Hospital, School of Medicine, Nanjing University, Nanjing, Jiangsu Province, China.'}]",,,,Copyright © 2014 Elsevier Ltd. All rights reserved.,10.1016/j.neuint.2014.06.015,<Element 'PubmedArticle' at 0x7f05dbbb2f90>
451,"24902717
19146875
24517644
19006379
24018757
2837713
6276474
7990513
16927269
22431614
22641053
15908459
18957080
20117131
20880510
19667192
17107623
6893963
20223588
20649561
15932929
16901473
22122547
15548611
16299550
17900807
20649560
20412858
21481532
21466441
22136937
18615143
16793879
17881008
18005070
24234439
22528488
21687716
23242694
19525966
18064003
21371995
16687502
12270950
20961685
19303429
23630344
17284183",Controlling the activation of the Bv8/prokineticin system reduces neuroinflammation and abolishes thermal and tactile hyperalgesia in neuropathic animals.,"Chemokines are involved in neuroinflammation and contribute to chronic pain processing. The new chemokine prokineticin 2 (PROK2) and its receptors (PKR1 and PKR2 ) have a role in inflammatory pain and immunomodulation. In the present study, we investigated the involvement of PROK2 and its receptors in neuropathic pain.
Effects of single, intrathecal, perineural and s.c. injections of the PKR antagonist PC1, or of 1 week s.c. treatment, on thermal hyperalgesia and tactile allodynia was evaluated in mice with chronic constriction of the sciatic nerve (CCI). Expression and localization of PROK2 and of its receptors at peripheral and central level was evaluated 10 days after CCI, following treatment for 1 week with saline or PC1. IL-1β and IL-10 levels, along with glia activation, were evaluated.
Subcutaneous, intrathecal and perineural PC1 acutely abolished the CCI-induced hyperalgesia and allodynia. At 10 days after CCI, PROK2 and its receptor PKR2 were up-regulated in nociceptors, in Schwann cells and in activated astrocytes of the spinal cord. Therapeutic treatment with PC1 (s.c., 1 week) alleviated established thermal hyperalgesia and allodynia, reduced the injury-induced overexpression of PROK2, significantly blunted nerve injury-induced microgliosis and astrocyte activation in the spinal cord and restored the physiological levels of proinflammatory and anti-inflammatory cytokines in periphery and in spinal cord.
The prokineticin system contributes to pain modulation via neuron-glia interaction. Sustained inhibition of the prokineticin system, at peripheral or central levels, blocked both pain symptoms and some events underlying disease progression.",[],British journal of pharmacology,2014-06-07,"[{'lastname': 'Maftei', 'firstname': 'D', 'initials': 'D', 'affiliation': ""Department of Physiology and Pharmacology 'Vittorio Erspamer', University of Rome, Rome, Italy.""}, {'lastname': 'Marconi', 'firstname': 'V', 'initials': 'V', 'affiliation': None}, {'lastname': 'Florenzano', 'firstname': 'F', 'initials': 'F', 'affiliation': None}, {'lastname': 'Giancotti', 'firstname': 'L A', 'initials': 'LA', 'affiliation': None}, {'lastname': 'Castelli', 'firstname': 'M', 'initials': 'M', 'affiliation': None}, {'lastname': 'Moretti', 'firstname': 'S', 'initials': 'S', 'affiliation': None}, {'lastname': 'Borsani', 'firstname': 'E', 'initials': 'E', 'affiliation': None}, {'lastname': 'Rodella', 'firstname': 'L F', 'initials': 'LF', 'affiliation': None}, {'lastname': 'Balboni', 'firstname': 'G', 'initials': 'G', 'affiliation': None}, {'lastname': 'Luongo', 'firstname': 'L', 'initials': 'L', 'affiliation': None}, {'lastname': 'Maione', 'firstname': 'S', 'initials': 'S', 'affiliation': None}, {'lastname': 'Sacerdote', 'firstname': 'P', 'initials': 'P', 'affiliation': None}, {'lastname': 'Negri', 'firstname': 'L', 'initials': 'L', 'affiliation': None}, {'lastname': 'Lattanzi', 'firstname': 'R', 'initials': 'R', 'affiliation': None}]",,,,© 2014 The British Pharmacological Society.,10.1111/bph.12793,<Element 'PubmedArticle' at 0x7f05dbbbee50>
452,"24722370
12797954
12325070
14634144
9682040
20021342
7895009
15845917
17785421
14662901
12584371
15294957
16872778
21555578
18516496
19234157
10453354
12528183
19050256
19305396
19234209
12794163
21689408
16632554
15926914
16872684
15905186
17655940
21236705
16888771
6248568
19273365
19031437
16793889
11106572
22319003
11596125
16470015
23210447
23850670
11641387
19533603
11562344
15798185",Raloxifene suppresses experimental autoimmune encephalomyelitis and NF-κB-dependent CCL20 expression in reactive astrocytes.,"Recent clinical data have led to the consideration of sexual steroids as new potential therapeutic tools for multiple sclerosis. Selective estrogen receptor modulators can exhibit neuroprotective effects like estrogen, with fewer systemic estrogen side effects than estrogen, offering a more promising therapeutic modality for multiple sclerosis. The important role of astrocytes in a proinflammatory effect mediated by CCL20 signaling on inflammatory cells has been documented. Their potential contribution to selective estrogen receptor modulator-mediated protection is still unknown. Using a mouse model of chronic neuroinflammation, we report that raloxifene, a selective estrogen receptor modulator, alleviated experimental autoimmune encephalomyelitis-an animal model of multiple sclerosis-and decreased astrocytic production of CCL20. Enzyme-linked immunosorbent assay, immunohistochemistry imaging and transwell migration assays revealed that reactive astrocytes express CCL20, which promotes Th17 cell migration. In cultured rodent astrocytes, raloxifene inhibited IL-1β-induced CCL20 expression and chemotaxis ability for Th17 migration, whereas the estrogen receptor antagonist ICI 182,780 blocked this effect. Western blotting further indicated that raloxifene suppresses IL-1β-induced NF-κB activation (phosphorylation of p65) and translocation but does not affect phosphorylation of IκB. In conclusion, these data demonstrate that raloxifene provides robust neuroprotection against experimental autoimmune encephalomyelitis, partially via an inhibitory action on CCL20 expression and NF-κB pathways in reactive astrocytes. Our results contribute to a better understanding of the critical roles of raloxifene in treating experimental autoimmune encephalomyelitis and uncover reactive astrocytes as a new target for the inhibitory action of estrogen receptors on chemokine CCL20 expression.",[],PloS one,2014-04-12,"[{'lastname': 'Li', 'firstname': 'Rui', 'initials': 'R', 'affiliation': 'Multiple Sclerosis Center, Department of Neurology, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, Guangdong Province, China.'}, {'lastname': 'Xu', 'firstname': 'Wen', 'initials': 'W', 'affiliation': 'Multiple Sclerosis Center, Department of Neurology, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, Guangdong Province, China.'}, {'lastname': 'Chen', 'firstname': 'Ying', 'initials': 'Y', 'affiliation': 'Multiple Sclerosis Center, Department of Neurology, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, Guangdong Province, China.'}, {'lastname': 'Qiu', 'firstname': 'Wei', 'initials': 'W', 'affiliation': 'Multiple Sclerosis Center, Department of Neurology, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, Guangdong Province, China.'}, {'lastname': 'Shu', 'firstname': 'Yaqing', 'initials': 'Y', 'affiliation': 'Multiple Sclerosis Center, Department of Neurology, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, Guangdong Province, China.'}, {'lastname': 'Wu', 'firstname': 'Aimin', 'initials': 'A', 'affiliation': 'Multiple Sclerosis Center, Department of Neurology, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, Guangdong Province, China.'}, {'lastname': 'Dai', 'firstname': 'Yongqiang', 'initials': 'Y', 'affiliation': 'Multiple Sclerosis Center, Department of Neurology, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, Guangdong Province, China.'}, {'lastname': 'Bao', 'firstname': 'Jian', 'initials': 'J', 'affiliation': 'Multiple Sclerosis Center, Department of Neurology, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, Guangdong Province, China.'}, {'lastname': 'Lu', 'firstname': 'Zhengqi', 'initials': 'Z', 'affiliation': 'Multiple Sclerosis Center, Department of Neurology, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, Guangdong Province, China.'}, {'lastname': 'Hu', 'firstname': 'Xueqiang', 'initials': 'X', 'affiliation': 'Multiple Sclerosis Center, Department of Neurology, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, Guangdong Province, China.'}]",,,,,10.1371/journal.pone.0094320,<Element 'PubmedArticle' at 0x7f05dbae4180>
453,24721689,Lack of interleukin-17 leads to a modulated micro-environment and amelioration of mechanical hypersensitivity after peripheral nerve injury in mice.,"Interleukin-17 (IL-17) is involved in a wide range of inflammatory disorders and in recruitment of inflammatory cells to injury sites. A recent study of IL-17 knock-out mice revealed that IL-17 contributes to neuroinflammation and neuropathic pain after peripheral nerve injury. Surprisingly, little is known of micro-environment modulation by IL-17 in injured sites and in pathologically related neuroinflammation and chronic neuropathic pain. Therefore, we investigated nociceptive sensitization, immune cell infiltration, myeloperoxidase (MPO) activity, and expression of multiple cytokines and opioid peptides in damaged nerves of wild-type (IL-17(+/+)) and IL-17 knock-out (IL-17(-/-)) mice after partial sciatic nerve ligation. Our results demonstrated that the IL-17(-/-) mice had less behavioral hypersensitivity after partial sciatic nerve ligation, and inflammatory cell infiltration and pro-inflammatory cytokine (tumor necrosis factor-α, IL-6, and interferon-γ) levels in damaged nerves were significantly decreased, with the levels of anti-inflammatory cytokines IL-10 and IL-13, and expressions of enkephalin, β-endorphin, and dynorphin were also decreased compared to those in wild-type control mice. In conclusion, we provided evidence that IL-17 modulates the micro-environment at the level of the peripheral injured nerve site and regulates progression of behavioral hypersensitivity in a murine chronic neuropathic pain model. The attenuated behavioral hypersensitivity in IL-17(-/-) mice could be a result of decreased inflammatory cell infiltration to the injured site, resulting in modulation of the pro- and anti-inflammatory cytokine milieu within the injured nerve. Therefore, IL-17 may be a critical component for neuropathic pain pathogenesis and a novel target for therapeutic intervention for this and other chronic pain states.","['Animal model', 'Inflammation', 'Interleukin-17', 'Nerve injury', 'Neuropathic pain']",Pain,2014-04-12,"[{'lastname': 'Day', 'firstname': 'Yuan-Ji', 'initials': 'YJ', 'affiliation': 'Department of Anesthesiology, Chang Gung Memorial Hospital, Linkou, Taiwan, ROC Transgenic & Molecular Immunogenetics Laboratory, Chang Gung Memorial Hospital, Linkou, Taiwan, ROC Department of Medical Research and Development, Chang Gung Memorial Hospital, Linkou, Taiwan, ROC Department of Medicine, Chang Gung University, Linkou, Taiwan, ROC Graduate Institutes of Clinical Medical Sciences, Chang Gung University, Linkou, Taiwan, ROC Department of Anesthesiology, National Defense Medical Center and Tri-Service General Hospital, Taipei, Taiwan, ROC.'}, {'lastname': 'Liou', 'firstname': 'Jiin-Tarng', 'initials': 'JT', 'affiliation': None}, {'lastname': 'Lee', 'firstname': 'Chiou-Mei', 'initials': 'CM', 'affiliation': None}, {'lastname': 'Lin', 'firstname': 'Yi-Chiao', 'initials': 'YC', 'affiliation': None}, {'lastname': 'Mao', 'firstname': 'Chih-Chieh', 'initials': 'CC', 'affiliation': None}, {'lastname': 'Chou', 'firstname': 'An-Hsun', 'initials': 'AH', 'affiliation': None}, {'lastname': 'Liao', 'firstname': 'Chia-Chih', 'initials': 'CC', 'affiliation': None}, {'lastname': 'Lee', 'firstname': 'Hung-Chen', 'initials': 'HC', 'affiliation': None}]",,,,Copyright © 2014 International Association for the Study of Pain. Published by Elsevier B.V. All rights reserved.,10.1016/j.pain.2014.04.004,<Element 'PubmedArticle' at 0x7f05dbb05b30>
454,"24709540
18076956
23488865
18081184
18037916
14519657
11516769
17868306
1317925
15340387
12136125
18291574
17141334
21545415
18751909
23441874
12843414
10204543
16352709
20074221
15252281
12405999
11169780
20166926
18814866
12461523
21145341
19897074
19328213
19245664
15837565
19029917
20570522
16751707
14526074
2165569
15952893
22804774
7605349
14715937
16762556
22571976
15456244
22481411
17709120
7689702
14999072
19481477
21447538
12203042
21079038
14595399
19490092
22431736
16796384
15892633
18509037
11000918
18414385
16805835
12660305
7751968
21849983
15930374
20143198
21595923
20067581
20174577
16052037
16224028
19357281
11229977
14757702
12598628
8640565
11279497
9765328
16043139
16165214",Prior stimulation of the endocannabinoid system prevents methamphetamine-induced dopaminergic neurotoxicity in the striatum through activation of CB2 receptors.,"Methamphetamine toxicity is associated with cell death and loss of dopamine neuron terminals in the striatum similar to what is found in some neurodegenerative diseases. Conversely, the endocannabinoid system (ECS) has been suggested to be neuroprotective in the brain, and new pharmacological tools have been developed to increase their endogenous tone. In this study, we evaluated whether ECS stimulation could reduce the neurotoxicity of high doses of methamphetamine on the dopamine system. We found that methamphetamine alters the levels of the major endocannabinoids, anandamide (AEA) and 2-arachidonoyl glycerol (2-AG) in the striatum, suggesting that the ECS participates in the brain responses to methamphetamine. Δ(9)-tetrahydrocannabinol (THC), a cannabis-derived agonist of both CB1 and CB2 cannabinoid receptors, or inhibitors of the main enzymes responsible for the degradation of AEA and 2-AG (URB597 and JZL184, respectively), blunted the decrease in striatal protein levels of tyrosine hydroxylase induced by methamphetamine. In addition, antagonists of CB2, but not of CB1, blocked the preventive effects of URB597 and JZL184, suggesting that only the former receptor subtype is engaged in neuroprotection exerted by ECS stimulation. Finally, we found that methamphetamine increases striatal levels of the cytokine tumor necrosis factor alpha, an effect that was blocked by ECS stimulation. Altogether, our results indicate that stimulation of ECS prior to the administration of an overdose of methamphetamine considerably reduces the neurotoxicity of the drug through CB2 receptor activation and highlight a protective function for the ECS against the toxicity induced by drugs and other external insults to the brain. This article is part of the Special Issue entitled 'CNS Stimulants'.","['Endocannabinoids', 'Methamphetamine', 'Neuroinflammation', 'Neuroprotection', 'Neurotoxicity', 'THC']",Neuropharmacology,2014-04-09,"[{'lastname': 'Nader', 'firstname': 'Joëlle', 'initials': 'J', 'affiliation': 'INSERM, U1084, Experimental and Clinical Neurosciences Laboratory, Neurobiology and Neuropharmacology of Addiction, F-86022 Poitiers, France; University of Poitiers, U1084, F-86022 Poitiers, France.'}, {'lastname': 'Rapino', 'firstname': 'Cinzia', 'initials': 'C', 'affiliation': 'Faculty of Veterinary Medicine, University of Teramo, Teramo, Italy.'}, {'lastname': 'Gennequin', 'firstname': 'Benjamin', 'initials': 'B', 'affiliation': 'INSERM, U1084, Experimental and Clinical Neurosciences Laboratory, Neurobiology and Neuropharmacology of Addiction, F-86022 Poitiers, France; University of Poitiers, U1084, F-86022 Poitiers, France.'}, {'lastname': 'Chavant', 'firstname': 'Francois', 'initials': 'F', 'affiliation': 'University of Poitiers, U1084, F-86022 Poitiers, France; Pharmacology Department, Poitiers University Hospital, Poitiers, France.'}, {'lastname': 'Francheteau', 'firstname': 'Maureen', 'initials': 'M', 'affiliation': 'INSERM, U1084, Experimental and Clinical Neurosciences Laboratory, Neurobiology and Neuropharmacology of Addiction, F-86022 Poitiers, France; University of Poitiers, U1084, F-86022 Poitiers, France.'}, {'lastname': 'Makriyannis', 'firstname': 'Alexandros', 'initials': 'A', 'affiliation': 'Center for Drug Discovery, Department of Pharmaceutical Sciences, and Chemistry and Chemical Biology, Northeastern University, Boston, USA.'}, {'lastname': 'Duranti', 'firstname': 'Andrea', 'initials': 'A', 'affiliation': 'Dipartimento di Scienze Biomolecolari, Università degli Studi di Urbino ""Carlo Bo"", Urbino, Italy.'}, {'lastname': 'Maccarrone', 'firstname': 'Mauro', 'initials': 'M', 'affiliation': 'Center of Integrated Research, Campus Bio-Medico University of Rome, Via Alvaro del Portillo 21, 00128 Rome, Italy; European Center for Brain Research/IRCCS Santa Lucia Foundation, Via del Fosso di Fiorano 35, 00146 Rome, Italy. Electronic address: m.maccarrone@unicampus.it.'}, {'lastname': 'Solinas', 'firstname': 'Marcello', 'initials': 'M', 'affiliation': 'INSERM, U1084, Experimental and Clinical Neurosciences Laboratory, Neurobiology and Neuropharmacology of Addiction, F-86022 Poitiers, France; University of Poitiers, U1084, F-86022 Poitiers, France.'}, {'lastname': 'Thiriet', 'firstname': 'Nathalie', 'initials': 'N', 'affiliation': 'INSERM, U1084, Experimental and Clinical Neurosciences Laboratory, Neurobiology and Neuropharmacology of Addiction, F-86022 Poitiers, France; University of Poitiers, U1084, F-86022 Poitiers, France. Electronic address: nathalie.thiriet@univ-poitiers.fr.'}]",,,,Copyright © 2014 Elsevier Ltd. All rights reserved.,10.1016/j.neuropharm.2014.03.014,<Element 'PubmedArticle' at 0x7f05dbb201d0>
455,24662962,Effects of naproxen on immune responses in a colchicine-induced rat model of Alzheimer's disease.,"The components of the immune system have been indicated to be linked with the neurotoxicity in Alzheimer's disease (AD). The participation of the immune system in the neurodegeneration in a rat model of colchicine-induced AD has not been explored.
In the present study, hippocampal neurodegeneration along with reactive oxygen species (ROS), nitrite and TNF-α in the hippocampus and some systemic immune responses were measured after 15 and 21 days of intracerebroventricular colchicine injection in rats and again after oral administration of different doses of the anti-inflammatory drug naproxen in AD rats.
Chromatolysis and amyloid plaques were found along with higher ROS, nitrite and TNF-α levels in the hippocampus of colchicine-induced AD rats, and these changes were prevented by naproxen in a dose-dependent manner. Alterations in immunological parameters [increased phagocytic activity of white blood cells and splenic polymorphonuclear cells (PMN), increased cytotoxicity and decreased leucocyte adhesive inhibition index (LAI) of splenic mononuclear cells (MNC)] were also observed in colchicine-injected rats, which showed a dose-dependent recovery after oral administration of naproxen in AD rats. The number of plaques, chromatolysis of Nissl granules, TNF-α, nitrite and ROS levels in the hippocampus, phagocytic activity of splenic PMN and LAI of splenic MNC in AD rats showed greater changes in the 21- than in the 15-day study, and the recovery of these parameters after administration of naproxen differed between the two study durations.
The present study shows that colchicine-induced neurodegeneration is time dependent and mediated by cyclooxygenase-induced neuroinflammation, which is reflected in the systemic immunological responses.",[],Neuroimmunomodulation,2014-03-26,"[{'lastname': 'Sil', 'firstname': 'Susmita', 'initials': 'S', 'affiliation': 'Neurophysiology Laboratory, Department of Physiology, University College of Science and Technology, University of Calcutta, Kolkata, India.'}, {'lastname': 'Goswami', 'firstname': 'Ananda Raj', 'initials': 'AR', 'affiliation': None}, {'lastname': 'Dutta', 'firstname': 'Goutam', 'initials': 'G', 'affiliation': None}, {'lastname': 'Ghosh', 'firstname': 'Tusharkanti', 'initials': 'T', 'affiliation': None}]",,"The present study shows that colchicine-induced neurodegeneration is time dependent and mediated by cyclooxygenase-induced neuroinflammation, which is reflected in the systemic immunological responses.","Chromatolysis and amyloid plaques were found along with higher ROS, nitrite and TNF-α levels in the hippocampus of colchicine-induced AD rats, and these changes were prevented by naproxen in a dose-dependent manner. Alterations in immunological parameters [increased phagocytic activity of white blood cells and splenic polymorphonuclear cells (PMN), increased cytotoxicity and decreased leucocyte adhesive inhibition index (LAI) of splenic mononuclear cells (MNC)] were also observed in colchicine-injected rats, which showed a dose-dependent recovery after oral administration of naproxen in AD rats. The number of plaques, chromatolysis of Nissl granules, TNF-α, nitrite and ROS levels in the hippocampus, phagocytic activity of splenic PMN and LAI of splenic MNC in AD rats showed greater changes in the 21- than in the 15-day study, and the recovery of these parameters after administration of naproxen differed between the two study durations.",,10.1159/000357735,<Element 'PubmedArticle' at 0x7f05dbad40e0>
456,24621884,Iptakalim confers an antidepressant effect in a chronic mild stress model of depression through regulating neuro-inflammation and neurogenesis.,"Depression is a serious mental disorder in the world, but the underlying mechanisms remain unclear and the effective cures are scarce. Iptakalim (Ipt), an ATP-sensitive potassium (K-ATP) channel opener that can cross the blood-brain barrier freely, has been demonstrated to inhibit neuro-inflammation and enhance adult hippocampal neurogenesis. But it is unknown whether Ipt is beneficial to therapy of depression by modulating neurogenesis and neuro-inflammation. This study aimed to determine the potential antidepressant efficacy of Ipt in a chronic mild stress (CMS) mouse model of depression. We showed that treatment with Ipt (10 mg/kg/day, i.p) for 4 wk restored the decrease of sucrose preference and shortened the immobile time in forced swimming tests (FST) and tail suspension tests (TST) in CMS model mice. We further found that Ipt reversed the CMS-induced reduction of the adult hippocampal neurogenesis and improved cerebral insulin signalling in the CMS mice. Furthermore, Ipt negatively regulated nod-like receptor protein 3 (NLRP3) expression and, in turn, inhibited microglia-mediated neuro-inflammation by suppressing the activation of NLRP3-inflammasome/caspase-1/interleukin 1β axis in the hippocampus of CMS mice. Taken together, our findings demonstrate that Ipt plays a potential antidepressant role in CMS model mice through regulating neuro-inflammation and neurogenesis, which will provide potential for Ipt in terms of opening up novel therapeutic avenues for depression.",[],The international journal of neuropsychopharmacology,2014-03-14,"[{'lastname': 'Lu', 'firstname': 'Ming', 'initials': 'M', 'affiliation': 'Jiangsu Key Laboratory of Neurodegeneration, Department of Pharmacology,Nanjing Medical University,Nanjing, Jiangsu,China.'}, {'lastname': 'Yang', 'firstname': 'Jing-Zhe', 'initials': 'JZ', 'affiliation': 'Jiangsu Key Laboratory of Neurodegeneration, Department of Pharmacology,Nanjing Medical University,Nanjing, Jiangsu,China.'}, {'lastname': 'Geng', 'firstname': 'Fan', 'initials': 'F', 'affiliation': 'Jiangsu Key Laboratory of Neurodegeneration, Department of Pharmacology,Nanjing Medical University,Nanjing, Jiangsu,China.'}, {'lastname': 'Ding', 'firstname': 'Jian-Hua', 'initials': 'JH', 'affiliation': 'Jiangsu Key Laboratory of Neurodegeneration, Department of Pharmacology,Nanjing Medical University,Nanjing, Jiangsu,China.'}, {'lastname': 'Hu', 'firstname': 'Gang', 'initials': 'G', 'affiliation': 'Jiangsu Key Laboratory of Neurodegeneration, Department of Pharmacology,Nanjing Medical University,Nanjing, Jiangsu,China.'}]",,,,,10.1017/S1461145714000285,<Element 'PubmedArticle' at 0x7f05db9a1090>
457,24606520,Neuroprotective properties of peroxisome proliferator-activated receptor alpha (PPARα) and its lipid ligands.,"Signalling lipids are known to control a wide array of cellular processes, including cell proliferation, apoptosis, migration, and energy metabolism. Fatty acids and their derivatives, eicosanoids, phosphoinositides, sphingolipids, some cannabinoid-like molecules bind and activate nuclear receptors, including peroxisome proliferator-activated receptors (PPARs). This subfamily of transcription factors comprises three isotypes - PPARα (NR1C1), PPAR β/δ (NR1C2), PPARγ (NR1C3) - which bind to specific DNA response elements, as heterodimers with retinoid X receptors. PPAR activity is modulated by post-translational modifications and cofactors, towards which they show differential affinity. The three PPARs mutually interact, being integrated in a complex system, leading to the concept of a ""PPAR triad"". Nevertheless, the isotypes also show distinct actions on cellular physiology and partially different tissue, ligand and target gene specificities. In the brain, while the functions of PPARγ and its ligands are being thoroughly investigated, the actual and potential roles of PPARα and β/δ are far from being clarified. PPARα appears especially intriguing, since it is selectively expressed in certain brain areas and neuronal/glial populations, and modulates antioxidant responses, neurotransmission, neuroinflammation, neurogenesis, and glial cell proliferation/differentiation. This receptor and its endogenous ligands, including oleoylethanoloamide (OEA) and palmitoylethanolamide (PEA), are involved in physiological and pathological responses, such as satiety, memory consolidation, and modulation of pain perception. The protective role of PPARα agonists in neurodegenerative diseases and in neuropsychiatric disorders makes manipulation of this pathway highly attractive as therapeutic strategy for neuropathological conditions. In this review, we focus on the pleiotropic functions of PPARα and its lipid ligands in the nervous tissue, devoting special attention to neuroprotection.",[],Current medicinal chemistry,2014-03-13,"[{'lastname': 'Fidaleo', 'firstname': 'Marco', 'initials': 'M', 'affiliation': None}, {'lastname': 'Fanelli', 'firstname': 'Francesca', 'initials': 'F', 'affiliation': None}, {'lastname': 'Ceru', 'firstname': 'Maria Paola', 'initials': 'MP', 'affiliation': None}, {'lastname': 'Moreno', 'firstname': 'Sandra', 'initials': 'S', 'affiliation': 'Dept. of Science, University ""Roma Tre"", viale Marconi 446, Rome 00146, Italy. sandra.moreno@uniroma3.it.'}]",,,,,10.2174/0929867321666140303143455,<Element 'PubmedArticle' at 0x7f05db9ad180>
458,24548522,Oral lichen planus and neurogenic inflammation: new observations and therapeutic implications from four clinical cases.,"Oral lichen planus (OLP) is a usually chronic and relapsing mucocutaneous disease with unknown etiology. Immunosuppressive treatment is sometimes unsatisfactory. We describe four cases of reticular OLP localized on the internal side of cheek, in the territory innervated by sensory free endings of the buccinator nerve, poorly responding to immunosuppressive treatment (topical/systemic corticosteroids, topical cyclosporin). Addition of prazepam 10 mg/day to standard therapy achieved significant improvement and clinical healing in 30-40 days. Because of the complex interplay between the nervous and immune systems, neuroinflammation, acting through conventional axon reflex and/or indirect reflex mechanism involving localized efferent vasodilatory parasympathetic fibers, could have an important pathogenic role in OLP. Such hypothesis could explain, at least partly, the spreading of lesions in OLP primarily triggered (and possibly sustained) by infections, irritants, or autoimmunity. Moreover, neuroinflammation could have a relevant role in OLP related to psychosomatic diseases, where the nervous component is the primary trigger and the main pathogen responsible for the lesions observed. Benzodiazepines modulate neuroinflammation through central, and, possibly, peripheral action. In OLP patients with mild/subclinical psychological conditions, low doses may effectively modulate neuroinflammatory pathways that are not always completely inhibited by immunosuppressive treatment and can contribute to the persistence of inflammation.","['benzodiazepines', 'neurogenic inflammation', 'oral lichen planus']",Dermatologic therapy,2014-02-20,"[{'lastname': 'Guarneri', 'firstname': 'Fabrizio', 'initials': 'F', 'affiliation': 'Department of Clinical and Experimental Medicine, University of Messina, Messina, Italy.'}, {'lastname': 'Guarneri', 'firstname': 'Claudio', 'initials': 'C', 'affiliation': None}, {'lastname': 'Marini', 'firstname': 'Herbert', 'initials': 'H', 'affiliation': None}]",,,,"© 2014 Wiley Periodicals, Inc.",10.1111/dth.12118,<Element 'PubmedArticle' at 0x7f05db9b7e50>
459,"24508637
17379265
22840752
22538356
22387674
9445346
16049426
15111734
12690218
18716201
9347981
9809515
12573724
9518671
16148753
14694190
21320576
22051040
18402929
21826442
18601693
19909788
7968362
10622413
20926671
14507969
15229239
16344155
17026534
21749911
22699893
15271060
17955551
11351342
23170794
16443127
37614
18716201
23474850
24015243
19889994
11896151
14993043
19815003
22072674
22510730",Brain-derived estrogen exerts anti-inflammatory and neuroprotective actions in the rat hippocampus.,"17β-estradiol (E2) has been implicated to play a critical role in neuroprotection, synaptic plasticity, and cognitive function. Classically, the role of gonadal-derived E2 in these events is well established, but the role of brain-derived E2 is less clear. To address this issue, we investigated the expression, localization, and modulation of aromatase and local E2 levels in the hippocampus following global cerebral ischemia (GCI) in adult ovariectomized rats. Immunohistochemistry (IHC) revealed that the hippocampal regions CA1, CA3 and dentate gyrus (DG) exhibited high levels of immunoreactive aromatase staining, with aromatase being co-localized primarily in neurons in non-ischemic animals. Following GCI, aromatase became highly expressed in GFAP-positive astrocytes in the hippocampal CA1 region at 2-3 days post GCI reperfusion. An ELISA for E2 and IHC for E2 confirmed the GCI-induced elevation of local E2 in the CA1 region and that the increase in local E2 occurred in astrocytes. Furthermore, central administration of aromatase antisense (AS) oligonucleotides, but not missense (MS) oligonucleotides, blocked the increase in aromatase and local E2 in astrocytes after GCI, and resulted in a significant increase in GCI-induced hippocampal CA1 region neuronal cell death and neuroinflammation. As a whole, these results suggest that brain-derived E2 exerts important neuroprotective and anti-inflammatory actions in the hippocampal CA1 region following GCI.","['Aromatase', 'Brain', 'Estrogen', 'Hippocampus', 'Neuroprotection']",Molecular and cellular endocrinology,2014-02-11,"[{'lastname': 'Zhang', 'firstname': 'Quan-Guang', 'initials': 'QG', 'affiliation': 'Institute of Molecular Medicine and Genetics, Medical College of Georgia at Georgia Regents University, Augusta, GA 30912, USA. Electronic address: qzhang@gru.edu.'}, {'lastname': 'Wang', 'firstname': 'Ruimin', 'initials': 'R', 'affiliation': 'Institute of Molecular Medicine and Genetics, Medical College of Georgia at Georgia Regents University, Augusta, GA 30912, USA; Neurobiology Institute of Medical Research Centre, Hebei United University, Tangshan, Hebei 063000, PR China.'}, {'lastname': 'Tang', 'firstname': 'Hui', 'initials': 'H', 'affiliation': 'Institute of Molecular Medicine and Genetics, Medical College of Georgia at Georgia Regents University, Augusta, GA 30912, USA; Neurobiology Institute of Medical Research Centre, Hebei United University, Tangshan, Hebei 063000, PR China.'}, {'lastname': 'Dong', 'firstname': 'Yan', 'initials': 'Y', 'affiliation': 'Institute of Molecular Medicine and Genetics, Medical College of Georgia at Georgia Regents University, Augusta, GA 30912, USA.'}, {'lastname': 'Chan', 'firstname': 'Alice', 'initials': 'A', 'affiliation': 'Institute of Molecular Medicine and Genetics, Medical College of Georgia at Georgia Regents University, Augusta, GA 30912, USA.'}, {'lastname': 'Sareddy', 'firstname': 'Gangadhara Reddy', 'initials': 'GR', 'affiliation': 'Department of Obstetrics and Gynecology, University of Texas Health Science Center, San Antonio, TX, USA.'}, {'lastname': 'Vadlamudi', 'firstname': 'Ratna K', 'initials': 'RK', 'affiliation': 'Department of Obstetrics and Gynecology, University of Texas Health Science Center, San Antonio, TX, USA.'}, {'lastname': 'Brann', 'firstname': 'Darrell W', 'initials': 'DW', 'affiliation': 'Institute of Molecular Medicine and Genetics, Medical College of Georgia at Georgia Regents University, Augusta, GA 30912, USA. Electronic address: dbrann@gru.edu.'}]",,,,Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.,10.1016/j.mce.2013.12.019,<Element 'PubmedArticle' at 0x7f05db9c3220>
460,24444786,Role of astrocytes in the neuroprotective actions of 17β-estradiol and selective estrogen receptor modulators.,"Neuroprotective actions of 17β-estradiol (estradiol) are in part mediated by direct actions on neurons. Astrocytes, which play an essential role in the maintenance of the homeostasis of neural tissue, express estrogen receptors and are also involved in the neuroprotective actions of estradiol in the brain. Estradiol controls gliosis and regulates neuroinflammation, edema and glutamate transport acting on astrocytes. In addition, the hormone regulates the release of neurotrophic factors and other neuroprotective molecules by astrocytes. In addition, reactive astrocytes are a local source of neuroprotective estradiol for the injured brain. Since estradiol therapy is not free from peripheral risks, alternatives for the hormone have been explored. Some selective estrogen receptor modulators (SERMs), which are already in use in clinical practice for the treatment of breast cancer, osteoporosis or menopausal symptoms, exert similar actions to estradiol on astrocytes. Therefore, SERMs represent therapeutic alternatives to estradiol for the activation of astroglia-mediated neuroprotective mechanisms.","['Brain edema', 'Glutamate transporters', 'Neuroglobin', 'Neuroinflammation', 'Neurotrophic factors', 'Reactive astrocytes']",Molecular and cellular endocrinology,2014-01-22,"[{'lastname': 'Acaz-Fonseca', 'firstname': 'Estefania', 'initials': 'E', 'affiliation': 'Instituto Cajal, CSIC, E-28002 Madrid, Spain.'}, {'lastname': 'Sanchez-Gonzalez', 'firstname': 'Rebeca', 'initials': 'R', 'affiliation': 'Instituto Cajal, CSIC, E-28002 Madrid, Spain.'}, {'lastname': 'Azcoitia', 'firstname': 'Iñigo', 'initials': 'I', 'affiliation': 'Departamento de Biología Celular, Facultad de Biología, Universidad Complutense de Madrid, E-28040 Madrid, Spain.'}, {'lastname': 'Arevalo', 'firstname': 'Maria Angeles', 'initials': 'MA', 'affiliation': 'Instituto Cajal, CSIC, E-28002 Madrid, Spain.'}, {'lastname': 'Garcia-Segura', 'firstname': 'Luis M', 'initials': 'LM', 'affiliation': 'Instituto Cajal, CSIC, E-28002 Madrid, Spain. Electronic address: lmgs@cajal.csic.es.'}]",,,,Copyright © 2014 Elsevier Ireland Ltd. All rights reserved.,10.1016/j.mce.2014.01.009,<Element 'PubmedArticle' at 0x7f05db9e0950>
461,"24358119
10816189
15251143
21697236
11159037
19503810
22920508
20664400
20877404
21054759
16856047
19605775
9212029
16489880
12517191
20961565
18381541
22334391
11695949
22652683
9369822
21421895
22399133
16697939
20036959
22693607
22160306
17513458
22962010
7631700
8727554
9794943
471183
15362718
23347579
19591903
11160401
16970848
10519896
11641451
9914589
2357788
18000831
9438210
22457757
18711727
17547892
11137749
16492993
19743455
19217590
22002627
22696578
15057942
23312823
12471018
21750107
9261164
19890091
17576036
21940629",Effects of intra-amniotic lipopolysaccharide and maternal betamethasone on brain inflammation in fetal sheep.,"Chorioamnionitis and antenatal glucocorticoids are common exposures for preterm infants and can affect the fetal brain, contributing to cognitive and motor deficits in preterm infants. The effects of antenatal glucocorticoids on the brain in the setting of chorioamnionitis are unknown. We hypothesized that antenatal glucocorticoids would modulate inflammation in the brain and prevent hippocampal and white matter injury after intra-amniotic lipopolysaccharide (LPS) exposure.
Time-mated ewes received saline (control), an intra-amniotic injection of 10 mg LPS at 106d GA or 113d GA, maternal intra-muscular betamethasone (0.5 mg/kg maternal weight) alone at 113d GA, betamethasone at 106d GA before LPS or betamethasone at 113d GA after LPS. Animals were delivered at 120d GA (term=150d). Brain structure volumes were measured on T2-weighted MRI images. The subcortical white matter (SCWM), periventricular white matter (PVWM) and hippocampus were analyzed for microglia, astrocytes, apoptosis, proliferation, myelin and pre-synaptic vesicles.
LPS and/or betamethasone exposure at different time-points during gestation did not alter brain structure volumes on MRI. Betamethasone alone did not alter any of the measurements. Intra-amniotic LPS at 106d or 113d GA induced inflammation as indicated by increased microglial and astrocyte recruitment which was paralleled by increased apoptosis and hypomyelination in the SCWM and decreased synaptophysin density in the hippocampus. Betamethasone before the LPS exposure at 113d GA prevented microglial activation and the decrease in synaptophysin. Betamethasone after LPS exposure increased microglial infiltration and apoptosis.
Intra-uterine LPS exposure for 7d or 14d before delivery induced inflammation and injury in the fetal white matter and hippocampus. Antenatal glucocorticoids aggravated the inflammatory changes in the brain caused by pre-existing intra-amniotic inflammation. Antenatal glucocorticoids prior to LPS reduced the effects of intra-uterine inflammation on the brain. The timing of glucocorticoid administration in the setting of chorioamnionitis can alter outcomes for the fetal brain.",[],PloS one,2013-12-21,"[{'lastname': 'Kuypers', 'firstname': 'Elke', 'initials': 'E', 'affiliation': 'Department of Pediatrics, School of Mental Health and Neuroscience, Maastricht University Medical Center, Maastricht, The Netherlands.'}, {'lastname': 'Jellema', 'firstname': 'Reint K', 'initials': 'RK', 'affiliation': 'Department of Pediatrics, School of Mental Health and Neuroscience, Maastricht University Medical Center, Maastricht, The Netherlands.'}, {'lastname': 'Ophelders', 'firstname': 'Daan R M G', 'initials': 'DR', 'affiliation': 'Department of Pediatrics, School of Mental Health and Neuroscience, Maastricht University Medical Center, Maastricht, The Netherlands.'}, {'lastname': 'Dudink', 'firstname': 'Jeroen', 'initials': 'J', 'affiliation': 'Department of Pediatrics, Erasmus Medical Center-Sophia, Rotterdam, The Netherlands.'}, {'lastname': 'Nikiforou', 'firstname': 'Maria', 'initials': 'M', 'affiliation': 'Department of Pediatrics, School of Mental Health and Neuroscience, Maastricht University Medical Center, Maastricht, The Netherlands.'}, {'lastname': 'Wolfs', 'firstname': 'Tim G A M', 'initials': 'TG', 'affiliation': 'Department of Pediatrics, School of Mental Health and Neuroscience, Maastricht University Medical Center, Maastricht, The Netherlands.'}, {'lastname': 'Nitsos', 'firstname': 'Ilias', 'initials': 'I', 'affiliation': ""School of Women's and Infants' Health, The University of Western Australia, Perth, Australia ; The Ritchie Centre, Monash Institute of Medical Research, Melbourne, Australia.""}, {'lastname': 'Pillow', 'firstname': 'J Jane', 'initials': 'JJ', 'affiliation': 'School of Anatomy, Physiology and Human Biology, The University of Western Australia, Perth, Australia.'}, {'lastname': 'Polglase', 'firstname': 'Graeme R', 'initials': 'GR', 'affiliation': ""School of Women's and Infants' Health, The University of Western Australia, Perth, Australia ; The Ritchie Centre, Monash Institute of Medical Research, Melbourne, Australia.""}, {'lastname': 'Kemp', 'firstname': 'Matthew W', 'initials': 'MW', 'affiliation': ""School of Women's and Infants' Health, The University of Western Australia, Perth, Australia.""}, {'lastname': 'Saito', 'firstname': 'Masatoshi', 'initials': 'M', 'affiliation': ""School of Women's and Infants' Health, The University of Western Australia, Perth, Australia.""}, {'lastname': 'Newnham', 'firstname': 'John P', 'initials': 'JP', 'affiliation': ""School of Women's and Infants' Health, The University of Western Australia, Perth, Australia.""}, {'lastname': 'Jobe', 'firstname': 'Alan H', 'initials': 'AH', 'affiliation': ""School of Women's and Infants' Health, The University of Western Australia, Perth, Australia ; Division of Pulmonary Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States of America.""}, {'lastname': 'Kallapur', 'firstname': 'Suhas G', 'initials': 'SG', 'affiliation': ""School of Women's and Infants' Health, The University of Western Australia, Perth, Australia ; Division of Pulmonary Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States of America.""}, {'lastname': 'Kramer', 'firstname': 'Boris W', 'initials': 'BW', 'affiliation': 'Department of Pediatrics, School of Mental Health and Neuroscience, Maastricht University Medical Center, Maastricht, The Netherlands.'}]",,Intra-uterine LPS exposure for 7d or 14d before delivery induced inflammation and injury in the fetal white matter and hippocampus. Antenatal glucocorticoids aggravated the inflammatory changes in the brain caused by pre-existing intra-amniotic inflammation. Antenatal glucocorticoids prior to LPS reduced the effects of intra-uterine inflammation on the brain. The timing of glucocorticoid administration in the setting of chorioamnionitis can alter outcomes for the fetal brain.,LPS and/or betamethasone exposure at different time-points during gestation did not alter brain structure volumes on MRI. Betamethasone alone did not alter any of the measurements. Intra-amniotic LPS at 106d or 113d GA induced inflammation as indicated by increased microglial and astrocyte recruitment which was paralleled by increased apoptosis and hypomyelination in the SCWM and decreased synaptophysin density in the hippocampus. Betamethasone before the LPS exposure at 113d GA prevented microglial activation and the decrease in synaptophysin. Betamethasone after LPS exposure increased microglial infiltration and apoptosis.,,"10.1371/journal.pone.0081644
10.1056/NEJM200005183422007
10.1016/j.siny.2003.09.005
10.1136/adc.2010.210187
10.1371/journal.pone.0005837
10.1097/AOG.0b013e3181e90046
10.1038/jp.2010.96
10.1111/j.1471-0528.2010.02751.x
10.1177/0883073809338066
10.1203/00006450-199707000-00001
10.1001/archpedi.157.1.26
10.1016/j.jpeds.2010.09.010
10.1542/peds.2007-2158
10.1002/ana.22620
10.1001/archpsyc.58.11.1032
10.1016/S0002-9378(97)70271-0
10.1177/1933719111398498
10.1007/s13311-012-0108-y
10.1016/j.jsgi.2006.02.011
10.1371/journal.pone.0038257
10.1152/ajplung.00338.2011
10.1152/ajplung.00003.2007
10.1152/ajplung.00280.2011
10.1016/0002-9378(95)90210-4
10.1063/1.362966
10.1542/peds.102.5.1116
10.1111/j.1365-2990.1979.tb00664.x
10.1186/1742-2094-10-13
10.1016/j.neuroscience.2009.07.009
10.1177/08830738060210070101
10.1056/NEJM199910143411604
10.1203/00006450-200111000-00008
10.1016/S0002-9378(99)70160-2
10.1016/0165-3806(90)90002-G
10.1002/dneu.20583
10.3109/14767059709162011
10.1371/journal.pone.0033369
10.1002/jnr.21825
10.1016/S0304-3940(00)01605-0
10.1203/01.pdr.0000182596.66175.ee
10.1002/ana.21713
10.1016/S0002-9378(09)00292-0
10.1002/ana.22480
10.1152/ajpregu.00216.2012
10.1002/bies.20012
10.1101/gr.118042.110
10.1074/jbc.272.34.21467
10.1210/er.2009-0013
10.1016/j.mce.2007.04.014
10.1074/jbc.M111.275370",<Element 'PubmedArticle' at 0x7f05db96e5e0>
462,24346217,Stimulation of insulin signaling and inhibition of JNK-AP1 activation protect cells from amyloid-β-induced signaling dysregulation and inflammatory response.,"One of the hallmarks of Alzheimer's disease (AD) is the accumulation and deposition of amyloid-β (Aβ) peptides in the brain and cerebral vasculature. Aβ evokes neuroinflammation and has been implicated in insulin signaling disruption and JNK-AP1 activation, contributing to AD neuropathologies including oxidative injury and vascular insufficiencies. In this study we aim to better understand the protective mechanisms of insulin signaling and JNK-AP1 inhibition on the adverse effects of Aβ. Four-hour treatment of hCMEC/D3, the immortalized human brain endothelial cells (iHBEC), with Aβ1-42 resulted in significant c-Jun phosphorylation, oxidative stress, and cell toxicity. Concurrent treatment with Aβ1-42 and insulin or Aβ1-42 and JNK inhibitor SP600125 significantly improved cell viability. Cytokine array on conditioned media showed that insulin and SP600125 strongly reduced all Aβ1-42-induced cytokines. ELISA confirmed the protective effect of insulin and SP600125 on Aβ-induced expression of interleukin (IL)-8 and Growth related oncogene-α (Gro-α). qRT-PCR revealed that insulin and SP600125 protected iHBEC from Aβ1-42-induced inflammatory gene expression. Transcription factor profiling showed that treatment of iHBEC with Aβ1-42, insulin, or SP600125 alone or in combination resulted in profound changes in modulating the activities of multiple transcription factors and relevant pathways, some of which were validated by western blot. Insulin treatment and JNK inhibition in vitro synergistically reduced c-Jun phosphorylation and thus JNK-AP1 signaling activation. The study suggests that activation of insulin and blocking of JNK-AP1 signaling inhibits Aβ-induced dysregulation of insulin signaling and inflammatory response.","[""Alzheimer's disease"", 'JNK-AP1 signaling', 'amyloid-β peptides', 'inflammatory response insulin signaling']",Journal of Alzheimer's disease : JAD,2013-12-19,"[{'lastname': 'Bamji-Mirza', 'firstname': 'Michelle', 'initials': 'M', 'affiliation': 'Human Health Therapeutics Portfolio, National Research Council Canada, Ottawa, ON, Canada Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada.'}, {'lastname': 'Callaghan', 'firstname': 'Debbie', 'initials': 'D', 'affiliation': 'Human Health Therapeutics Portfolio, National Research Council Canada, Ottawa, ON, Canada.'}, {'lastname': 'Najem', 'firstname': 'Dema', 'initials': 'D', 'affiliation': 'Human Health Therapeutics Portfolio, National Research Council Canada, Ottawa, ON, Canada Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada.'}, {'lastname': 'Shen', 'firstname': 'Shanshan', 'initials': 'S', 'affiliation': 'Human Health Therapeutics Portfolio, National Research Council Canada, Ottawa, ON, Canada Southeast University, Nanjing, China.'}, {'lastname': 'Hasim', 'firstname': 'Mohamed Shaad', 'initials': 'MS', 'affiliation': 'Human Health Therapeutics Portfolio, National Research Council Canada, Ottawa, ON, Canada Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada.'}, {'lastname': 'Yang', 'firstname': 'Ze', 'initials': 'Z', 'affiliation': 'Beijing Hospital & Beijing Institute of Geriatrics, Chinese Ministry of Health, Beijing, China.'}, {'lastname': 'Zhang', 'firstname': 'Wandong', 'initials': 'W', 'affiliation': 'Human Health Therapeutics Portfolio, National Research Council Canada, Ottawa, ON, Canada Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada Southeast University, Nanjing, China.'}]",,,,,10.3233/JAD-131949,<Element 'PubmedArticle' at 0x7f05db998220>
463,24333475,Role of neurosteroids in experimental 3-nitropropionic acid induced neurotoxicity in rats.,"Huntington's disease is an autosomal dominant, progressive, and fatal neurodegenerative disease characterized by motor and non-motor symptoms. Systemic administration of 3-nitropropionic acid, a complex II inhibitor of the electron transport chain induces selective striatal lesions in rodents. Neurosteroids are synthesized in central nervous system, able to modulate GABAA receptor function and has been reported to have neuroprotective action. The present study has been designed to investigate the role of neurosteroids such as progesterone and pregnenolone which are positive and negative modulators of GABA respectively against 3-nitropropionic acid induced experimental Huntington's disease. Systemic administration of 3-nitropropionic acid (10mg/kg i.p.) for 14 days significantly reduced body weight, locomotor activity, motor coordination, balance beam walk performance, antioxidant defense enzymes (reduced glutathione and catalase) and significantly increase oxidative stress markers (lipid peroxidation and nitrite level) in striatum and cortex. 3-Nitropropionic acid treatment also increases pro-inflammatory cytokines (TNF-α and IL-1β) level in striatum. Progesterone (10, 20mg/kg/day i.p.) treatments for 14 days significantly reversed the behavioral, antioxidant defense enzymes, oxidative stress marker and pro-inflammatory cytokines as compared to the 3-Nitropropionic acid treated group. Pregnenolone (1 and 2mg/kg i.p.), a negative modulator of GABAA pretreatment significantly reversed the protective effect of progesterone on behavioral and biochemical parameters. The results of the present study suggest that the positive GABAergic modulation may be beneficial for the treatment of motor disorder.","['Antioxidant', 'Inflammation', 'Neuroinflammation', 'Neurosteroids', 'Neurotoxicity', 'Oxidative stress']",European journal of pharmacology,2013-12-18,"[{'lastname': 'Kumar', 'firstname': 'Pushpender', 'initials': 'P', 'affiliation': 'Department of Pharmacology, I.S.F. College of Pharmacy, Ferozepur Road, Ghal Kalan, Moga 142001, Punjab, India.'}, {'lastname': 'Kumar', 'firstname': 'Puneet', 'initials': 'P', 'affiliation': 'Department of Pharmacology, I.S.F. College of Pharmacy, Ferozepur Road, Ghal Kalan, Moga 142001, Punjab, India. Electronic address: punnubansal79@gmail.com.'}, {'lastname': 'Khan', 'firstname': 'Aamir', 'initials': 'A', 'affiliation': 'Department of Pharmacology, I.S.F. College of Pharmacy, Ferozepur Road, Ghal Kalan, Moga 142001, Punjab, India.'}, {'lastname': 'Deshmukh', 'firstname': 'Rahul', 'initials': 'R', 'affiliation': 'Department of Pharmacology, I.S.F. College of Pharmacy, Ferozepur Road, Ghal Kalan, Moga 142001, Punjab, India.'}, {'lastname': 'Lal Sharma', 'firstname': 'Pyare', 'initials': 'P', 'affiliation': 'Department of Pharmacology, I.S.F. College of Pharmacy, Ferozepur Road, Ghal Kalan, Moga 142001, Punjab, India.'}]",,,,© 2013 Published by Elsevier B.V.,10.1016/j.ejphar.2013.11.036,<Element 'PubmedArticle' at 0x7f05db927590>
464,24290604,Genistein antagonizes inflammatory damage induced by β-amyloid peptide in microglia through TLR4 and NF-κB.,"Microglia activation and neuroinflammation have been associated with the pathogenesis of neurodegenerative disorders such as Alzheimer's disease (AD). Toll-like receptor 4 (TLR4) and nuclear factor (NF)-κB-mediated signal pathways exert key modulating roles in the inflammatory processes. The aim of the present study was to investigate whether genistein (Gen) has a neuroprotective effect against inflammatory damage induced by β-amyloid peptide25-35 (Aβ25-35) through the TLR4 and NF-κB-mediated signal pathways.
BV-2 microglia cells were preincubated with Gen for 2 h and then treated with 25 μM Aβ25-35 for another 24 h. The expression of inflammatory mediators, TLR4 and NF-κB and the activity of NF-κB were measured.
The results showed that Gen could attenuate the cytotoxicity and inflammatory damage induced by Aβ25-35. Gen also significantly reversed Aβ25-35-induced up-regulation of TLR4 and NF-κB expression and the DNA binding and transcriptional activities of NF-κB.
These results indicated that Gen could alleviate the inflammation caused by Aβ25-35 treatment, which might be associated with the regulation of the TLR4/NF-κB signal pathway.","['Genistein', 'NF-κB', 'Neuroinflammation', 'TLR4', 'β-amyloid peptides 25-35']","Nutrition (Burbank, Los Angeles County, Calif.)",2013-12-03,"[{'lastname': 'Zhou', 'firstname': 'Xin', 'initials': 'X', 'affiliation': 'Department of Nutrition and Food Hygiene, School of Public Health, Capital Medical University, Beijing, P.R. China; Department of Nutrition, Beijing Jishuitan Hospital, Beijing, P.R. China.'}, {'lastname': 'Yuan', 'firstname': 'Linhong', 'initials': 'L', 'affiliation': None}, {'lastname': 'Zhao', 'firstname': 'Xia', 'initials': 'X', 'affiliation': None}, {'lastname': 'Hou', 'firstname': 'Chengcheng', 'initials': 'C', 'affiliation': None}, {'lastname': 'Ma', 'firstname': 'Weiwei', 'initials': 'W', 'affiliation': None}, {'lastname': 'Yu', 'firstname': 'Huanling', 'initials': 'H', 'affiliation': None}, {'lastname': 'Xiao', 'firstname': 'Rong', 'initials': 'R', 'affiliation': None}]",,"These results indicated that Gen could alleviate the inflammation caused by Aβ25-35 treatment, which might be associated with the regulation of the TLR4/NF-κB signal pathway.",The results showed that Gen could attenuate the cytotoxicity and inflammatory damage induced by Aβ25-35. Gen also significantly reversed Aβ25-35-induced up-regulation of TLR4 and NF-κB expression and the DNA binding and transcriptional activities of NF-κB.,Copyright © 2014 Elsevier Inc. All rights reserved.,10.1016/j.nut.2013.06.006,<Element 'PubmedArticle' at 0x7f05db9364a0>
465,24210682,The cannabinoid CB₂ receptor-selective phytocannabinoid beta-caryophyllene exerts analgesic effects in mouse models of inflammatory and neuropathic pain.,"The widespread plant volatile beta-caryophyllene (BCP) was recently identified as a natural selective agonist of the peripherally expressed cannabinoid receptor 2 (CB₂). It is found in relatively high concentrations in many spices and food plants. A number of studies have shown that CB₂ is critically involved in the modulation of inflammatory and neuropathic pain responses. In this study, we have investigated the analgesic effects of BCP in animal models of inflammatory and neuropathic pain. We demonstrate that orally administered BCP reduced inflammatory (late phase) pain responses in the formalin test in a CB₂ receptor-dependent manner, while it had no effect on acute (early phase) responses. In a neuropathic pain model the chronic oral administration of BCP attenuated thermal hyperalgesia and mechanical allodynia, and reduced spinal neuroinflammation. Importantly, we found no signs of tolerance to the anti-hyperalgesic effects of BCP after prolonged treatment. Oral BCP was more effective than the subcutaneously injected synthetic CB₂ agonist JWH-133. Thus, the natural plant product BCP may be highly effective in the treatment of long lasting, debilitating pain states. Our results have important implications for the role of dietary factors in the development and modulation of chronic pain conditions.","['Beta-caryophyllene', 'CB(2)', 'Dietary cannabinoid', 'Inflammatory pain', 'Neuropathic pain']",European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology,2013-11-12,"[{'lastname': 'Klauke', 'firstname': 'A-L', 'initials': 'AL', 'affiliation': 'Institute of Molecular Psychiatry, University of Bonn, Sigmund-Freud-Straße 25, D-53127 Bonn, Germany.'}, {'lastname': 'Racz', 'firstname': 'I', 'initials': 'I', 'affiliation': 'Institute of Molecular Psychiatry, University of Bonn, Sigmund-Freud-Straße 25, D-53127 Bonn, Germany. Electronic address: iracz@uni-bonn.de.'}, {'lastname': 'Pradier', 'firstname': 'B', 'initials': 'B', 'affiliation': 'Institute of Molecular Psychiatry, University of Bonn, Sigmund-Freud-Straße 25, D-53127 Bonn, Germany.'}, {'lastname': 'Markert', 'firstname': 'A', 'initials': 'A', 'affiliation': 'Institute of Molecular Psychiatry, University of Bonn, Sigmund-Freud-Straße 25, D-53127 Bonn, Germany.'}, {'lastname': 'Zimmer', 'firstname': 'A M', 'initials': 'AM', 'affiliation': 'Institute of Molecular Psychiatry, University of Bonn, Sigmund-Freud-Straße 25, D-53127 Bonn, Germany.'}, {'lastname': 'Gertsch', 'firstname': 'J', 'initials': 'J', 'affiliation': 'Institute of Biochemistry and Molecular Medicine, NCCR TransCure, University of Bern, CH-3012 Bern, Switzerland.'}, {'lastname': 'Zimmer', 'firstname': 'A', 'initials': 'A', 'affiliation': 'Institute of Molecular Psychiatry, University of Bonn, Sigmund-Freud-Straße 25, D-53127 Bonn, Germany.'}]",,,,© 2013 Published by Elsevier B.V. and ECNP.,10.1016/j.euroneuro.2013.10.008,<Element 'PubmedArticle' at 0x7f05db944ef0>
466,"24184692
11596125
9287080
12732219
15316569
12084661
16952768
19125209
223373
1100363
16459196
15546500
15758200
17311007
19181453
11910117
16228195
20553666
21070752
11007552
8192550
2780868
19738918
21822589
17678443
23998680
12764712
19840552
8180493
8331373
21466807
8287639
15452348
3416813
21334376
7706984
19840551
11502077
18652593
12730370
17010099
11826131
17196373
3968250
21194878
8738124
14498812
22824372
12373778
15251869
19144219
15245494
19996051
17229839
9454673
12000023
18295201
16054404
9053778
18417120
19840550
9329052
2623060
1946732
19345235
21842958
22716225
18343048
11259646
8750036
23624153
4369747
22495674
12600701
8180786
11164524
21423522
11370915
3955380
10491603
9460086
20966214
16431027
2319307
14563697
19756668
15217982
21051630
20012873
12784938
15136206
23001904
12782226
3382961
8140154
12379902
17965659
15178148
11943575
9787259
7496395
22710611
22213434
22681685
427544
9336221
19180243
23550796
15642619
1972786
20977928
15301440
23218519
21376052
23036617
20561965
22044189
2036956
11390983
11861602
18395274
22036561
12580336
2062894
23064447
3361004
17904653
21855579
15939837
21527731
14625061
889997
15464412
22266677
11593044
7729817
19342614
19372198
19131570
10893321
18396007
22363256
1836980
12533625
15251876
14766964
16182315
8423067
9528939
18513207
22981654
9799625
20491737
8637636
8521507
11790402
5785179
5440182
9787243
11965354
18342957
20646174
9541747
22967838
23174754
12475728
15919386
17945360
11059796
22289042
10719670
688003
12422216
19150053
23460698
9044444
11716576
11853861
21045176
11581496
15831717
15584884
11154764
11413544
12766928
19770291
9832446
16373420
770154
9032138
21722643
18499302
19900508
11438369
16545402
19046994
22857738
16388117
11274650
175861
2029889
6889633
9039386
17398312
19002191
10082463
20803000
12563281
21788513
14432658
16356491
17065412
11604252
15005465
17592937
7805281
9811905
7144917
16165228
18511511
19302036
7969768
8931596
7033265
15645223
16410296
16423715
17505125
15103225
15741744
15313032
22814704
15019800
15215292
10696570
22829357
3994625
20100488
19857931
17449187
9435325
12764219
22182318
4615003
18385317
744147
8987135
9388012
8866117
2324335
15452575
16309736
2681349
21123560
23230441
23230443
11698594
10817843
9483198
15788779
16547515
18096163
18083105
22018180
20577641
2976393
15285801
10221782
18471802
14499305
1460092
19401208
12732232
17671613
18996135
18367262
18752645
16259628
22072657
16889944
16321169
15123493
19469025
22351060
16891615
16310967
4952008
5812988
18083219
20557401
12047726
1657578
8774455
17651767
21443935
21854839
12021416
11196285
19339593
11523856
11378181
15862182
19896524
19485563
15554900
22134008
7792821
2647464
22352791
9284067
10965508
18065159
21656765
22753124
12460592
16750837
19646508
15713269
11248111
18096161
9390761
11750181
12062475",Puberty and adolescence as a time of vulnerability to stressors that alter neurobehavioral processes.,"Puberty and adolescence are major life transitions during which an individual's physiology and behavior changes from that of a juvenile to that of an adult. Here we review studies documenting the effects of stressors during pubertal and adolescent development on the adult brain and behavior. The experience of complex or compound stressors during puberty/adolescence generally increases stress reactivity, increases anxiety and depression, and decreases cognitive performance in adulthood. These behavioral changes correlate with decreased hippocampal volumes and alterations in neural plasticity. Moreover, stressful experiences during puberty disrupt behavioral responses to gonadal hormones both in sexual performance and on cognition and emotionality. These behavioral changes correlate with altered estrogen receptor densities in some estrogen-concentrating brain areas, suggesting a remodeling of the brain's response to hormones. A hypothesis is presented that activation of the immune system results in chronic neuroinflammation that may mediate the alterations of hormone-modulated behaviors in adulthood.","['Anxiety', 'Cognitive function', 'Depression', 'Estradiol', 'Immune challenge', 'Progesterone', 'Sexual behavior', 'Stress', 'Stress reactivity']",Frontiers in neuroendocrinology,2013-11-05,"[{'lastname': 'Holder', 'firstname': 'Mary K', 'initials': 'MK', 'affiliation': 'Neuroscience and Behavior Program, Tobin Hall, University of Massachusetts, Amherst, MA 01003-9271, USA; Center for Neuroendocrine Studies, Tobin Hall, University of Massachusetts, Amherst, MA 01003-9271, USA. Electronic address: mkholder@cns.umass.edu.'}, {'lastname': 'Blaustein', 'firstname': 'Jeffrey D', 'initials': 'JD', 'affiliation': 'Neuroscience and Behavior Program, Tobin Hall, University of Massachusetts, Amherst, MA 01003-9271, USA; Center for Neuroendocrine Studies, Tobin Hall, University of Massachusetts, Amherst, MA 01003-9271, USA. Electronic address: blaustein@cns.umass.edu.'}]",,,,Copyright © 2013 Elsevier Inc. All rights reserved.,10.1016/j.yfrne.2013.10.004,<Element 'PubmedArticle' at 0x7f05db9589a0>
467,24184413,"The inflamed axis: the interaction between stress, hormones, and the expression of inflammatory-related genes within key structures comprising the hypothalamic-pituitary-adrenal axis.","Acute stress increases the expression of cytokines and other inflammatory-related factors in the CNS, plasma, and endocrine glands, and activation of inflammatory signaling pathways within the hypothalamic-pituitary-adrenal (HPA) axis may play a key role in later stress sensitization. In addition to providing a summary of stress effects on neuroimmune changes within the CNS, we present a series of experiments that characterize stress effects on members of the interleukin-1β (IL-1) super-family and other inflammatory-related genes in key structures comprising the HPA axis (PVN, pituitary and adrenal glands), followed by a series of experiments examining the impact of exogenous hormone administration (CRH and ACTH) and dexamethasone on the expression of inflammatory-related genes in adult male Sprague-Dawley rats. The results demonstrated robust, time-dependent, and asynchronous expression patterns for IL-1 and IL-1R2 in the PVN, with substantial increases in IL-6 and COX-2 in the adrenal glands emerging as key findings. The effects of exogenous CRH and ACTH were predominantly isolated within the adrenals. Finally, pretreatment with dexamethasone severely blunted neuroimmune changes in the adrenal glands, but not in the PVN. These findings provide novel insight into the relationship between stress, the expression of inflammatory signaling factors within key structures comprising the HPA axis, and their interaction with HPA hormones, and provide a foundation for better understanding the role of cytokines as modulators of hypothalamic, pituitary and adrenal sensitivity.","['ACTH', 'CRH', 'Corticosterone', 'Interleukin-1', 'Neuroinflammation', 'Stress']",Physiology & behavior,2013-11-05,"[{'lastname': 'Hueston', 'firstname': 'Cara M', 'initials': 'CM', 'affiliation': 'Behavioral Neuroscience Program, Department of Psychology, Binghamton University, Binghamton, NY 13902-6000, United States.'}, {'lastname': 'Deak', 'firstname': 'Terrence', 'initials': 'T', 'affiliation': None}]",,,,© 2013.,10.1016/j.physbeh.2013.10.035,<Element 'PubmedArticle' at 0x7f05db8dcbd0>
468,24184051,Brain angiotensin regulates iron homeostasis in dopaminergic neurons and microglial cells.,"Dysfunction of iron homeostasis has been shown to be involved in ageing, Parkinson's disease and other neurodegenerative diseases. Increased levels of labile iron result in increased reactive oxygen species and oxidative stress. Angiotensin II, via type-1 receptors, exacerbates oxidative stress, the microglial inflammatory response and progression of dopaminergic degeneration. Angiotensin activates the NADPH-oxidase complex, which produces superoxide. However, it is not known whether angiotensin affects iron homeostasis. In the present study, administration of angiotensin to primary mesencephalic cultures, the dopaminergic cell line MES23.5 and to young adult rats, significantly increased levels of transferrin receptors, divalent metal transporter-1 and ferroportin, which suggests an increase in iron uptake and export. In primary neuron-glia cultures and young rats, angiotensin did not induce significant changes in levels of ferritin or labile iron, both of which increased in neurons in the absence of glia (neuron-enriched cultures, dopaminergic cell line) and in the N9 microglial cell line. In aged rats, which are known to display high levels of angiotensin activity, ferritin levels and iron deposits in microglial cells were enhanced. Angiotensin-induced changes were inhibited by angiotensin type-1 receptor antagonists, NADPH-oxidase inhibitors, antioxidants and NF-kB inhibitors. The results demonstrate that angiotensin, via type-1 receptors, modulates iron homeostasis in dopaminergic neurons and microglial cells, and that glial cells play a major role in efficient regulation of iron homeostasis in dopaminergic neurons.","['2′,3′-cyclic nucleotide 3′-phosphodiesterase', 'AII', 'Ageing', 'Ammonium pyrrolidinedithiocarbamate', 'Ara-C', 'CNPase', 'DIV', 'DMT1', 'Dopamine', 'Fp1', 'IL-1 β', 'Interleucin 1 β', 'Microglia', 'N-acetyl-cysteine', 'NAC', 'NADPH-oxidase', 'NF-kB', 'Neuroinflammation', 'Oxidative stress', 'PD', 'PDTC', 'PG-SK', ""Parkinson's disease"", 'Phen Green-SK', 'RAS', 'ROS', 'Renin–angiotensin system', 'SN', 'SN compacta', 'SNc', 'TH', 'Tf', 'TfR', 'WB', 'angiotensin II', 'cytosine-β-d-arabino-furanoside', 'days in vitro', 'divalent metal transporter 1', 'ferroportin 1', 'reactive oxygen species', 'renin–angiotensin system', 'substantia nigra', 'transferrin', 'transferrin receptor', 'tyrosine hydroxylase', 'western blot']",Experimental neurology,2013-11-05,"[{'lastname': 'Garrido-Gil', 'firstname': 'Pablo', 'initials': 'P', 'affiliation': 'Laboratory of Neuroanatomy and Experimental Neurology, Department of Morphological Sciences, Faculty of Medicine, University of Santiago de Compostela, Santiago de Compostela, Spain; Networking Research Center on Neurodegenerative Diseases (CIBERNED), Spain.'}, {'lastname': 'Rodriguez-Pallares', 'firstname': 'Jannette', 'initials': 'J', 'affiliation': None}, {'lastname': 'Dominguez-Meijide', 'firstname': 'Antonio', 'initials': 'A', 'affiliation': None}, {'lastname': 'Guerra', 'firstname': 'Maria J', 'initials': 'MJ', 'affiliation': None}, {'lastname': 'Labandeira-Garcia', 'firstname': 'Jose L', 'initials': 'JL', 'affiliation': None}]",,,,© 2013.,10.1016/j.expneurol.2013.10.013,<Element 'PubmedArticle' at 0x7f05db86bcc0>
469,"24178954
22845893
19625089
11786493
11374613
23555989
12359622
21554431
16388853
19926854
6308001
22201038
23394519
16997973
20948535
23394527
23415738
16819765
22674585
21233218
23337437
11442148
21764514
19254044
22767065
15963531
8900284
19413995
19921464
16919265
21483401
23623250
22710756
22301508
22125609
22442754
22429572
22558609
24645812
16968947
17565008
23123446
21713658
21890273
22084787
21929436
22229320
20851058
16369558
14634025
18657182
16103691
23054979
17712833
23108549
22293560
19594844
22970839
22178921
19860689
15465922
13211905
22411529
12031775
23707281
23242694
23343704
20096327
23489748
9696473
18534634
17011598
20176435
14527707
23394524
11426841
12944505
21219627
14639155
22395856
23302980
19096368
11602256
8739213
17631917
21601979
23083124
18602217
9685157
22019552
7724569
23533304
23394521
12941436
21136068
16605240
9013571
24804094
23374874
18429637
23071955
23307734
23197111
23425575
21753876
22998903
12684477
20025063
22972997
20345619
23312640
23006799
19386271
22516295
23701652
22613992
22001158
20194146
20581331","Palmitoylethanolamide, a naturally occurring disease-modifying agent in neuropathic pain.","Persistent pain affects nearly half of all people seeking medical care in the US alone, and accounts for at least $80 billion worth of lost productivity each year. Among all types of chronic pain, neuropathic pain stands out: this is pain resulting from damage or disease of the somatosensory nervous system, and remains largely untreatable. With few available treatment options, neuropathic pain represents an area of significant and growing unmet medical need. Current treatment of peripheral neuropathic pain involves several drug classes, including opioids, gabapentinoids, antidepressants, antiepileptic drugs, local anesthetics and capsaicin. Even so, less than half of patients achieve partial relief. This review discusses a novel approach to neuropathic pain management, based on knowledge of: the role of glia and mast cells in pain and neuroinflammation; the body's innate mechanisms to maintain cellular homeostasis when faced with external stressors provoking, for example, inflammation. The discovery that palmitoylethanolamide, a member of the N-acylethanolamine family which is produced from the lipid bilayer on-demand, is capable of exerting anti-allodynic and anti-hyperalgesic effects by down-modulating both microglial and mast cell activity has led to the application of this fatty acid amide in several clinical studies of neuropathic pain, with beneficial outcome and no indication of adverse effects at pharmacological doses. Collectively, the findings presented here propose that palmitoylethanolamide merits further consideration as a disease-modifying agent for controlling inflammatory responses and related chronic and neuropathic pain.",[],Inflammopharmacology,2013-11-02,"[{'lastname': 'Skaper', 'firstname': 'Stephen D', 'initials': 'SD', 'affiliation': 'Department of Pharmaceutical and Pharmacological Sciences, University of Padua, Largo ""E. Meneghetti"" 2, 35131, Padua, Italy, stephen.skaper@unipd.it.'}, {'lastname': 'Facci', 'firstname': 'Laura', 'initials': 'L', 'affiliation': None}, {'lastname': 'Fusco', 'firstname': 'Mariella', 'initials': 'M', 'affiliation': None}, {'lastname': 'Della Valle', 'firstname': 'Maria Federica', 'initials': 'MF', 'affiliation': None}, {'lastname': 'Zusso', 'firstname': 'Morena', 'initials': 'M', 'affiliation': None}, {'lastname': 'Costa', 'firstname': 'Barbara', 'initials': 'B', 'affiliation': None}, {'lastname': 'Giusti', 'firstname': 'Pietro', 'initials': 'P', 'affiliation': None}]",,,,,10.1007/s10787-013-0191-7,<Element 'PubmedArticle' at 0x7f05db87b860>
470,"24132508
20664579
6471907
17321089
17430248
1557503
10790736
10753987
14729054
22189635
7886219
10461904
10760552
15824339
5964963
16115016
23691016
15070489
15852378
10442086
16530422
16269322
13650640
13561538
3908871
16037678
22465167
8944624
16095696
23596385
7181105
16103002
9636201
16629160
17276889
13726518
22735830
12150769
21884554
20487207
10385216
24422
20012873
22537595
20647027
23099054
2017440
7576227
23576971
21103031
18110453
14581933
20676609
12559837","Modulation of nitrergic signalling pathway by American ginseng attenuates chronic unpredictable stress-induced cognitive impairment, neuroinflammation, and biochemical alterations.","Prolonged stress causes extensive loss of neurons leading to deficits in cognitive performance. Increasing evidence indicates that accumulation of intercellular messenger, nitric oxide (NO), plays a crucial role in the pathogenesis of memory disorders. American ginseng (AG) is known to show protection in different animal models of neurological diseases; however, its exact mechanism of action is not clearly understood. Therefore, the current study was designed to investigate the interaction of AG against chronic unpredictable stress (CUS)-associated behavioral and biochemical alterations and the probable role of nitrergic pathway in this effect. Male Laca mice were exposed to a series of stressors along with drug/vehicle treatment daily for 28 days. CUS paradigm caused significant impairment in both acquisition and retention memory as measured in Morris water maze and elevated plus maze task. This was coupled with alterations in oxidative stress markers, mitochondrial enzyme complex activities, pro-inflammatory cytokine (TNF-α), and acetylcholinesterase levels in the hippocampus as compared with naïve group. Besides, there was a marked increase in serum corticosterone levels. AG (100, 200 mg/kg; p.o.) treatment significantly improved cognitive impairment; reduced TNF-α, acetylcholinesterase, and corticosterone levels; and attenuated oxidative-nitrergic stress. Furthermore, pre-treatment of L-arginine (100 mg/kg; i.p.), a nitric oxide donor, with subeffective dose of AG (100 mg/kg; p.o.) reversed its protective effects. However, L-NAME (10 mg/kg, i.p.), a non-specific NO synthase inhibitor, potentiated the effects of AG. Our findings suggest that modulation of nitrergic signalling cascade is involved in the protective effects of AG against CUS-induced cognitive dysfunction, oxidative stress, and neuroinflammation.",[],Naunyn-Schmiedeberg's archives of pharmacology,2013-10-18,"[{'lastname': 'Rinwa', 'firstname': 'Puneet', 'initials': 'P', 'affiliation': 'Pharmacology Division, University Institute of Pharmaceutical Sciences, UGC Centre of Advanced Study, Panjab University, Chandigarh, 160014, India.'}, {'lastname': 'Kumar', 'firstname': 'Anil', 'initials': 'A', 'affiliation': None}]",,,,,10.1007/s00210-013-0925-5,<Element 'PubmedArticle' at 0x7f05db821c70>
471,"24012919
22237781
21296855
23095829
17363520
19138050
12105305
16549835
19020040
22584394
18662748
19138045
10229119
12225870
18541537
11784794
21273577
16202616
22606284
12801933
11701758
22687052
20583976
16377409
19149566
20041759
19084353
23488800
22817481
21769868
23233095
20935211
17363603
22326709
20837666
18768926
22140049
9097077
18852043
22387176
15780134
22549954
22745251
15951342
22198171
20061544
14615545
2777795
23499837
19801103
20122169
20617366
22026649
22644942
21395552
19920106
22963500",Angiotensin-(1-7) prevents radiation-induced inflammation in rat primary astrocytes through regulation of MAP kinase signaling.,"About 500,000 new cancer patients will develop brain metastases in 2013. The primary treatment modality for these patients is partial or whole brain irradiation which leads to a progressive, irreversible cognitive impairment. Although the exact mechanisms behind this radiation-induced brain injury are unknown, neuroinflammation in glial populations is hypothesized to play a role. Blockers of the renin-angiotensin system (RAS) prevent radiation-induced cognitive impairment and modulate radiation-induced neuroinflammation. Recent studies suggest that RAS blockers may reduce inflammation by increasing endogenous concentrations of the anti-inflammatory heptapeptide angiotensin-(1-7) [Ang-(1-7)]. Ang-(1-7) binds to the AT(1-7) receptor and inhibits MAP kinase activity to prevent inflammation. This study describes the inflammatory response to radiation in astrocytes characterized by radiation-induced increases in (i) IL-1β and IL-6 gene expression; (ii) COX-2 and GFAP immunoreactivity; (iii) activation of AP-1 and NF-κB transcription factors; and (iv) PKCα, MEK, and ERK (MAP kinase) activation. Treatment with U-0126, a MEK inhibitor, demonstrates that this radiation-induced inflammation in astrocytes is mediated through the MAP kinase pathway. Ang-(1-7) inhibits radiation-induced inflammation, increases in PKCα, and MAP kinase pathway activation (phosphorylation of MEK and ERK). Additionally Ang-(1-7) treatment leads to an increase in dual specificity phosphatase 1 (DUSP1). Furthermore, treatment with sodium vanadate (Na3VO4), a phosphatase inhibitor, blocks Ang-(1-7) inhibition of radiation-induced inflammation and MAP kinase activation, suggesting that Ang-(1-7) alters phosphatase activity to inhibit radiation-induced inflammation. These data suggest that RAS blockers inhibit radiation-induced inflammation and prevent radiation-induced cognitive impairment not only by reducing Ang II but also by increasing Ang-(1-7) levels.","['ACEI', 'ARB', 'Ang', 'Angiotensin', 'Angiotensin converting enzyme inhibitor', 'Angiotensin receptor blocker', 'Angiotensin-(1–7)', 'COX-2', 'Cyclooxygenase-2', 'DUSP1', 'Dual specificity phosphatase 1', 'EMSA', 'ERK', 'Electromobility-shift assay', 'Extracellular signal-regulated kinase', 'Fractionated whole brain irradiation', 'GFAP', 'Glial fibrillary acidic protein', 'IL', 'Interleukin', 'MAP kinase signaling', 'MEK', 'Mitogen-activated protein erk kinase', 'RAS', 'Radiation-induced Inflammation', 'Rat primary astrocytes', 'Renin-angiotensin system', 'TNF-α', 'Tumor necrosis factor-α', 'fWBI']",Free radical biology & medicine,2013-09-10,"[{'lastname': 'Moore', 'firstname': 'Elizabeth D', 'initials': 'ED', 'affiliation': 'Department of Cancer Biology, Wake Forest School of Medicine, Winston-Salem, NC 27157, USA; Department of Radiation Oncology, Wake Forest School of Medicine, Winston-Salem, NC 27157, USA; Brain Tumor Center of Excellence, Wake Forest School of Medicine, Winston-Salem, NC 27157, USA. Electronic address: elmoore2@wakehealth.edu.'}, {'lastname': 'Kooshki', 'firstname': 'Mitra', 'initials': 'M', 'affiliation': 'Department of Radiation Oncology, Wake Forest School of Medicine, Winston-Salem, NC 27157, USA; Brain Tumor Center of Excellence, Wake Forest School of Medicine, Winston-Salem, NC 27157, USA.'}, {'lastname': 'Metheny-Barlow', 'firstname': 'Linda J', 'initials': 'LJ', 'affiliation': 'Department of Cancer Biology, Wake Forest School of Medicine, Winston-Salem, NC 27157, USA; Department of Radiation Oncology, Wake Forest School of Medicine, Winston-Salem, NC 27157, USA; Brain Tumor Center of Excellence, Wake Forest School of Medicine, Winston-Salem, NC 27157, USA.'}, {'lastname': 'Gallagher', 'firstname': 'Patricia E', 'initials': 'PE', 'affiliation': 'Hypertension and Vascular Research Center, Wake Forest School of Medicine, Winston-Salem, NC 27157, USA.'}, {'lastname': 'Robbins', 'firstname': 'Mike E', 'initials': 'ME', 'affiliation': 'Department of Cancer Biology, Wake Forest School of Medicine, Winston-Salem, NC 27157, USA; Department of Radiation Oncology, Wake Forest School of Medicine, Winston-Salem, NC 27157, USA; Brain Tumor Center of Excellence, Wake Forest School of Medicine, Winston-Salem, NC 27157, USA.'}]",,,,© 2013 Published by Elsevier Inc.,10.1016/j.freeradbiomed.2013.08.183,<Element 'PubmedArticle' at 0x7f05db83def0>
472,"23959579
17291356
20522652
21892962
7499961
7776981
12525699
16862116
19795409
1542665
23136129
3962603
16557302
19683260
21087763
22859297
9665274
22895706
19649643
18551524
21450051
17107594
21220649
16862115
10858277
21611805
19963041
8182347
17953663
19625741
19158106
22505994
23049970
23242157
18768919
16737445
21135382
20054825
21047645
21092856
23089745
9039268
11581411
22890097
22569268
21368173
19300249
22761921
1693470
12221085
8030755
11279269
23041626
20517932
10548097
20215705
16873554
21497117
16260393
20737593
21107132
21224065
18723524
7684756
12931033
12359436
18184915
19288468
21858182
22509390
20889566
23497056
16352738
23140401
23201826
21393509
22684309
21792312
22802426
21085476
10079180
18378771
20154673
21613335
20028451
22161130
18575609
21612671
22733568
14500651
20026663
19056610
12526812",Potential roles of microglial cell progranulin in HIV-associated CNS pathologies and neurocognitive impairment.,"Progranulin (PGRN) is a highly unusual molecule with both neuronal and microglial expression with two seemingly unrelated functions, i.e., as a neuronal growth factor and a modulator of neuroinflammation. Haploinsufficiency due to loss of function mutations lead to a fatal presenile dementing illness (frontotemporal lobar degeneration), indicating that adequate expression of PGRN is essential for successful aging. PGRN might be a particularly relevant factor in the pathogenesis of HIVencephalitis (HIVE) and HIV-associated neurocognitive disorders (HAND). We present emerging data and a review of the literature which show that cells of myeloid lineage such as macrophages and microglia are the primary sources of PGRN and that PGRN expression contributes to pathogenesis of CNS diseases. We also present evidence that PGRN is a macrophage antiviral cytokine. For example, PGRN mRNA and protein expression are significantly upregulated in brain specimens with HIVE, and in HIV infected microglia in vitro. Paradoxically, our preliminary CHARTER data analyses indicate that lower PGRN levels in CSF trended towards an association with HAND, particularly in those without detectable virus. Based upon these findings, we introduce the hypothesis that PGRN plays dual roles in modulating antiviral immunity and neuronal dysfunction in the context of HIV infection. In the presence of active viral replication, PGRN expression is increased functioning as an anti-viral factor as well as a neuroprotectant. In the absence of active HIV replication, ongoing inflammation or other stressors suppress PGRN production from macrophages/microglia contributing to neurocognitive dysfunction. We propose.",[],Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology,2013-08-21,"[{'lastname': 'Suh', 'firstname': 'Hyeon-Sook', 'initials': 'HS', 'affiliation': None}, {'lastname': 'Gelman', 'firstname': 'Benjamin B', 'initials': 'BB', 'affiliation': None}, {'lastname': 'Lee', 'firstname': 'Sunhee C', 'initials': 'SC', 'affiliation': None}]",,,,,10.1007/s11481-013-9495-z,<Element 'PubmedArticle' at 0x7f05db624720>
473,"23813098
22500269
19004805
11786493
19625089
20511559
21980200
8931279
7689770
1357565
14530364
12359622
19926854
21554431
19520991
12154273
12023948
15662442
21521653
21878486
2022965
21410936
21639869
16960575
17965659
1829107
22004612
20087366
22542283
9454764
11442148
17762205
19838177
22000153
10202538
8787137
23046519
22189915
22072381
11166964
21350020
19150373
22483302
2407920
21713648
8900284
9326296
8633002
12951563
12457181
22301508
21931491
10627616
22125609
15009671
15665833
12505419
16407564
20029625
16968947
17565008
8170980
22414817
21255263
17188755
21354467
11245916
18000063
12617561
7517440
11156943
21472005
22229320
12586432
14634025
21907261
6148726
8769879
18385539
22178921
16928856
15465922
11929922
10616793
13211905
11514078
9231736
3023451
22405189
7818259
12915048
16006518
20096327
18367664
9696473
22661311
7514639
20887872
14527707
15771708
21673720
23394524
16807890
15954124
10800968
11426841
16982866
11463796
12944505
21219627
18930143
9150253
11602256
8739213
17631917
18657868
21072242
18602217
22293457
17924984
22019552
7724569
12960758
9461251
9685157
16820801
11596126
20022504
23166447
11205147
10704463
12941436
21842586
8527732
22740789
20573451
12971891
15777864
2261679
21951367
22190366
12379909
19380799
22998138
17344397
18463248
19386271
22884901
22916199
22516295
17376966
19515262
22423088
20337613
22912680
16163296
21252104
20581331
22071848","Glia and mast cells as targets for palmitoylethanolamide, an anti-inflammatory and neuroprotective lipid mediator.","Glia are key players in a number of nervous system disorders. Besides releasing glial and neuronal signaling molecules directed to cellular homeostasis, glia respond also to pro-inflammatory signals released from immune-related cells, with the mast cell being of particular interest. A proposed mast cell-glia communication may open new perspectives for designing therapies to target neuroinflammation by differentially modulating activation of non-neuronal cells normally controlling neuronal sensitization-both peripherally and centrally. Mast cells and glia possess endogenous homeostatic mechanisms/molecules that can be upregulated as a result of tissue damage or stimulation of inflammatory responses. Such molecules include the N-acylethanolamines, whose principal family members are the endocannabinoid N-arachidonoylethanolamine (anandamide), and its congeners N-stearoylethanolamine, N-oleoylethanolamine, and N-palmitoylethanolamine (PEA). A key role of PEA may be to maintain cellular homeostasis when faced with external stressors provoking, for example, inflammation: PEA is produced and hydrolyzed by microglia, it downmodulates mast cell activation, it increases in glutamate-treated neocortical neurons ex vivo and in injured cortex, and PEA levels increase in the spinal cord of mice with chronic relapsing experimental allergic encephalomyelitis. Applied exogenously, PEA has proven efficacious in mast cell-mediated experimental models of acute and neurogenic inflammation. This fatty acid amide possesses also neuroprotective effects, for example, in a model of spinal cord trauma, in a delayed post-glutamate paradigm of excitotoxic death, and against amyloid β-peptide-induced learning and memory impairment in mice. These actions may be mediated by PEA acting through ""receptor pleiotropism,"" i.e., both direct and indirect interactions of PEA with different receptor targets, e.g., cannabinoid CB2 and peroxisome proliferator-activated receptor-alpha.",[],Molecular neurobiology,2013-07-03,"[{'lastname': 'Skaper', 'firstname': 'Stephen D', 'initials': 'SD', 'affiliation': 'Dipartimento di Scienze del Farmaco, Università degli Studi di Padova, Largo ""Egidio Meneghetti"" 2, 35131, Padova, Italy, stephen.skaper@unipd.it.'}, {'lastname': 'Facci', 'firstname': 'Laura', 'initials': 'L', 'affiliation': None}, {'lastname': 'Giusti', 'firstname': 'Pietro', 'initials': 'P', 'affiliation': None}]",,,,,10.1007/s12035-013-8487-6,<Element 'PubmedArticle' at 0x7f05db650ae0>
474,"23763366
9809515
7790416
10436119
10616799
9347981
11896151
19889994
17261780
9367266
11186229
10700514
10894176
17317017
17433554
9813255
9419067
14627632
14673006
11823716
14507969
16598173
16971488
15145751
23500634
16527848
11172057
10566973
10700513
12364742
12624540
17321521
11108769
10625733
11145565
15529016
17462607
20484627
18829137
19223913
17124377
15336580
12865482
12652183
17360245
2465607
11025411
21750148
9521273
11777539
9005851
1370886
11333359
8567948
7685573
16882007
15804507
10719091
17709900
19332057
14526226
19429053
20525067
17233289
14535942
19751099
15567334
21606872
21168500
20925481
11424959
15817823
10583912
14689453
7984152
15336232
12650718
12670715
18278798
22621285
19840235
21311966
12925018
17049974
20880502
19269277
14978360
17344397
23481567
20701773
15082232
9729323
8743420
8404686
15147770
15076729
23497056
22056294
21818353
21959174
21316352
21971527
19795501
18485335
12112378
12796722
19053043
22836271
22293437
10417663
8129600
1993062
10453051
16530273
23206327
21277368
16243607
18329265
21127968
16013043
18286612
18328572
23401502
21565615
15256495
12878732
15261308
19664827
21564348
20010956
15953991
19190654",Stroke neuroprotection: oestrogen and insulin-like growth factor-1 interactions and the role of microglia.,"Oestrogen has been shown to be neuroprotective for stroke and other neural injury models. Oestrogen promotes a neuroprotective phenotype through myriad actions, including stimulating neurogenesis, promoting neuronal differentiation and survival, suppressing neuroinflammation and maintaining the integrity of the blood-brain barrier. At the molecular level, oestrogen directly modulates genes that are beneficial for repair and regeneration via the canonical oestrogen receptor. Increasingly, evidence indicates that oestrogen acts in concert with growth factors to initiate neuroprotection. Oestrogen and insulin-like growth factor (IGF)-1 act cooperatively to influence cell survival, and combined steroid hormone/growth factor interaction has been well documented in the context of neurones and astrocytes. Here, we summarise the evidence that oestrogen-mediated neuroprotection is critically dependent on IGF-1 signalling, and specifically focus on microglia as the source of IGF-1 and the locus of oestrogen-IGF-1 interactions in stroke neuroprotection.","['IGF-1', 'growth factor', 'microglia', 'oestrogens', 'stroke']",Journal of neuroendocrinology,2013-06-15,"[{'lastname': 'Sohrabji', 'firstname': 'F', 'initials': 'F', 'affiliation': ""Women's Health in Neuroscience Program, Neuroscience and Experimental Therapeutics, TAMHSC College of Medicine, Bryan, TX, USA.""}, {'lastname': 'Williams', 'firstname': 'M', 'initials': 'M', 'affiliation': None}]",,,,© 2013 British Society for Neuroendocrinology.,10.1111/jne.12059,<Element 'PubmedArticle' at 0x7f05db6065e0>
475,23756243,Glucocorticoid-induced apoptosis in animal models of multiple sclerosis.,"Glucocorticoids (GCs) are highly potent anti-inflammatory and immunosuppressive agents. They exert influence on many cell types of the immune system and impact a plethora of processes such as cytokine production, leukocyte differentiation, migration and adhesion, apoptosis induction, and changes in morphology. Those that are most relevant for the modulation of neuroinflammatory diseases, however, are still under debate. In this review, we will elaborate on how GCs impact inflammatory responses in general and revisit the ambivalent role that apoptosis plays in animal models of multiple sclerosis. Furthermore, we will discuss arguments that speak in favor or against an essential function of GC-induced apoptosis in neuroinflammation. We anticipate that a better knowledge of the mechanisms that GCs employ will eventually find its way into clinical practice for the future benefit of afflicted patients.",[],Critical reviews in immunology,2013-06-13,"[{'lastname': 'Herold', 'firstname': 'Marco J', 'initials': 'MJ', 'affiliation': 'Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia.'}, {'lastname': 'Reichardt', 'firstname': 'Holger M', 'initials': 'HM', 'affiliation': None}]",,,,,10.1615/critrevimmunol.2013007415,<Element 'PubmedArticle' at 0x7f05db5c5040>
476,"23613781
20684422
15925697
3124165
18789657
20133768
9236543
907867
8759023
4146582
14672754
18766332
2991960
14680686
21253949
17273796
18420184
17022948
3917507
9619120
2195555
21052984
10447091
559941
5964963
7181105
13726518
18110453
10461904
9231715
10976232
13561538
15059690
7604147
6368214
15619113
19713693
19664321
17268845
19249910
11292519
7845373
17464095
16387899
18392456
11246099
9120760
19616038
16103002
9636201
14561818
21871566
19129380
18976114
6878484
12393461
18401724
12140770
21384104
12932852
15381772
696348
17289085
17418561
15531295
11083086
22205277",Suppression of neuroinflammatory and apoptotic signaling cascade by curcumin alone and in combination with piperine in rat model of olfactory bulbectomy induced depression.,"Bilateral destruction of the olfactory bulbs is known to cause behavioral changes analogous to symptoms of depression. Curcumin, a traditional Indian spice is currently being investigated in different psychiatric problems including depression. Dietary phytochemicals are currently used as an adjuvant therapy to accelerate their therapeutic efficacy. Therefore, the present study is an attempt to elucidate the neuroprotective mechanism of curcumin and its co-administration with piperine against olfactory bulbectomy induced depression in rats.
Rats undergone olfactory bulbs ablations were analyzed after post-surgical rehabilitation period of 2 weeks. Animals were then treated with different doses of curcumin (100, 200 and 400 mg/kg; p.o.), piperine (20 mg/kg; p.o.) and their combination daily for another 2 weeks. Imipramine (10 mg/kg; i.p.) served as a standard control. Various behavioral tests like forced swim test (FST), open field behaviour and sucrose preference test (SPT) were performed, followed by estimation of biochemical, mitochondrial, molecular and histopathological parameters in rat brain.
Ablation of olfactory bulbs caused depression-like symptoms as evidenced by increased immobility time in FST, hyperactivity in open field arena, and anhedonic like response in SPT along with alterations in mitochondrial enzyme complexes, increased serum corticosterone levels and oxidative damage. These deficits were integrated with increased inflammatory cytokines (TNF-α) and apoptotic factor (caspase-3) levels along with a marked reduction in neurogenesis factor (BDNF) in the brain of olfactory bulbectomized (OBX) rats. Curcumin treatment significantly and dose-dependently restored all these behavioral, biochemical, mitochondrial, molecular and histopathological alterations associated with OBX induced depression. Further, co-administration of piperine with curcumin significantly potentiated their neuroprotective effects as compared to their effects alone.
The present study highlights that curcumin along with piperine exhibits neuroprotection against olfactory bulbectomy induced depression possibly by modulating oxidative-nitrosative stress induced neuroinflammation and apoptosis.",[],PloS one,2013-04-25,"[{'lastname': 'Rinwa', 'firstname': 'Puneet', 'initials': 'P', 'affiliation': 'Pharmacology Division, University Institute of Pharmaceutical Sciences, UGC Centre of Advanced Study, Panjab University, Chandigarh, India.'}, {'lastname': 'Kumar', 'firstname': 'Anil', 'initials': 'A', 'affiliation': None}, {'lastname': 'Garg', 'firstname': 'Sukant', 'initials': 'S', 'affiliation': None}]",,,"Ablation of olfactory bulbs caused depression-like symptoms as evidenced by increased immobility time in FST, hyperactivity in open field arena, and anhedonic like response in SPT along with alterations in mitochondrial enzyme complexes, increased serum corticosterone levels and oxidative damage. These deficits were integrated with increased inflammatory cytokines (TNF-α) and apoptotic factor (caspase-3) levels along with a marked reduction in neurogenesis factor (BDNF) in the brain of olfactory bulbectomized (OBX) rats. Curcumin treatment significantly and dose-dependently restored all these behavioral, biochemical, mitochondrial, molecular and histopathological alterations associated with OBX induced depression. Further, co-administration of piperine with curcumin significantly potentiated their neuroprotective effects as compared to their effects alone.",,10.1371/journal.pone.0061052,<Element 'PubmedArticle' at 0x7f05db5cb130>
477,23578583,The potential role of T cell migration and chemotaxis as targets of glucocorticoids in multiple sclerosis and experimental autoimmune encephalomyelitis.,"Glucocorticoids (GCs) are the most commonly prescribed drugs for the treatment of acute disease bouts in multiple sclerosis (MS) patients. While T lymphocytes were shown to be essential targets of GC therapy, at least in animal models of MS, the mechanisms by which GCs modulate T cell function are less clear. Until now, apoptosis induction and repression of pro-inflammatory cytokines in T cells have been considered the most critical mechanisms in ameliorating disease symptoms. However, this notion is being challenged by increasing evidence that the control of T cell migration and chemotaxis by GCs might be even more important for the treatment of neuroinflammatory diseases. In this review we aim to provide an overview of how GCs impact the morphological alterations that T cells undergo during activation and migration as well as the influences that GCs have on the directed movement of T cells under the influence of chemokines. A deeper understanding of these processes should not only help to advance our understanding of how GCs exert their beneficial effects in MS therapy but may reveal future strategies to intervene in the pathogenesis of neuroinflammatory diseases.","['Chemokines', 'Glucocorticoids', 'Migration', 'Neuroinflammation', 'T cells']",Molecular and cellular endocrinology,2013-04-13,"[{'lastname': 'Fischer', 'firstname': 'Henrike J', 'initials': 'HJ', 'affiliation': 'Institute for Cellular and Molecular Immunology, University of Göttingen Medical School, Humboldtallee 34, 37073 Göttingen, Germany.'}, {'lastname': 'Schweingruber', 'firstname': 'Nils', 'initials': 'N', 'affiliation': None}, {'lastname': 'Lühder', 'firstname': 'Fred', 'initials': 'F', 'affiliation': None}, {'lastname': 'Reichardt', 'firstname': 'Holger M', 'initials': 'HM', 'affiliation': None}]",,,,Copyright © 2013 Elsevier Ireland Ltd. All rights reserved.,10.1016/j.mce.2013.04.001,<Element 'PubmedArticle' at 0x7f05db5334f0>
478,"23517078
21524252
12481158
20978211
6473167
14515353
15489032
18055122
9242621
9733069
9245931
9396054
18308299
17466601
17512639
17513014
16972896
15913892
17027094
20957078
17018277
15985713
18506634
10542221
10975815
11441105
9973433
10337915
10510358
11093139
15169929
15020654
22532442
15569266
17425606
18574733
16402407
8020059
15518900
8280921
16565493
12239106
12657686
12764228
9647867
22289055
18614693
22033933
10964933
18383383
22460784
15584490
10804204
1704221
17384649
8790779
9677397
21285140
21677142
9096398
10378876
11792830
7643128
2803320
7517435
9439840
17995938
7694477
21524256
23189073
22669509
17467231
21281617
22941903
16651528
16783372
14983478
12588810
9529258
18043584
15084446
21524257
19840545
12615050
21348830
6473166
21524249
10188950
8396727
17284589
20133634
17055439
8576167
17868305
17077178
7595475
16689670
19190179
20171991
20674737
8070162
19461672
22674051
21346763
11935374
19805477
8987738
20448827
18440632
7621745
12145407
11193816
19076367
19650041
8821745
9760129
10467267
22319466","VIP and PACAP: neuropeptide modulators of CNS inflammation, injury, and repair.","Inflammatory processes play both regenerative and destructive roles in multiple sclerosis, stroke, CNS trauma, amyotrophic lateral sclerosis and aging-related neurodegenerative diseases such as Alzheimer's, Parkinson's and Huntington's. Endogenous defence mechanisms against these pathologies include those that are directly neuroprotective, and those that modulate the expression of inflammatory mediators in microglia, astrocytes, and invading inflammatory cells. While a number of mechanisms and molecules have been identified that can directly promote neuronal survival, less is known about how the brain protects itself from harmful inflammation, and further, how it co-opts the healing function of the immune system to promote CNS repair. The two closely related neuroprotective peptides, vasoactive intestinal peptide (VIP) and pituitary adenylyl cyclase-activating peptide (PACAP), which are up-regulated in neurons and immune cells after injury and/or inflammation, are known to protect neurons, but also exert powerful in vivo immunomodulatory actions, which are primarily anti-inflammatory. These peptide actions are mediated by high-affinity receptors expressed not only on neurons, but also astrocytes, microglia and peripheral inflammatory cells. Well-established immunomodulatory actions of these peptides are to inhibit macrophage and microglia production and release of inflammatory mediators such as TNF-α and IFN-γ, and polarization of T-cell responses away from Th1 and Th17, and towards a Th2 phenotype. More recent studies have revealed that these peptides can also promote the production of both natural and inducible subsets of regulatory T-cells. The neuroprotective and immunomodulatory actions of VIP and PACAP suggest that receptors for these peptides may be therapeutic targets for neurodegenerative and neuroinflammatory diseases and other forms of CNS injury.",[],British journal of pharmacology,2013-03-23,"[{'lastname': 'Waschek', 'firstname': 'J A', 'initials': 'JA', 'affiliation': 'Department of Psychiatry and Semel Institute, University of California at Los Angeles, Los Angeles, CA 90095-7332, USA. jwaschek@mednet.ucla.edu'}]",,,,Published 2013.. This article is a U.S. Government work and is in the public domain in the USA.,10.1111/bph.12181,<Element 'PubmedArticle' at 0x7f05db53cd60>
479,"23509933
10604470
11057670
16491079
17060947
16601073
18577498
19931250
19906954
21565248
18291254
15232612
19620309
3399080
20962566
19450656
9870933
11102468
10725699
15569692
15117840
19384567
22416219
21181542
8809836
8787820",Ghrelin inhibits LPS-induced release of IL-6 from mouse dopaminergic neurones.,"Ghrelin is an orexigenic stomach hormone that acts centrally to increase mid-brain dopamine neurone activity, amplify dopamine signaling and protect against neurotoxin-induced dopamine cell death in the mouse substantia nigra pars compacta (SNpc). In addition, ghrelin inhibits the lipopolysaccharide (LPS)-induced release of pro-inflammatory cytokines from peripheral macrophages, T-cells and from LPS stimulated microglia. Here we sought to determine whether ghrelin attenuates pro-inflammatory cytokine release from dopaminergic neurones.
The dopaminergic SN4741 cell-line, which derives from the mouse substantia nigra (SN) and expresses the ghrelin-receptor (growth hormone secretagogue receptor (GHS-R)) and the ghrelin-O-acyl transferase (GOAT) enzyme, was used to determine the neuro-immunomodulatory action of ghrelin. We induced innate immune activation via LPS challenge (1 μg/ml) of SN4741 neurones that had been pre-cultured in the presence or absence of ghrelin (1, 10, 100 nM) for 4 h. After 24 h supernatants were collected for detection of IL-1 beta (IL-1β ), TNF alpha (TNF-α) and IL-6 cytokines via enzyme linked immunosorbent assay (ELISA) analysis. Nuclear translocation of the transcription factor nuclear factor kappa B (NF-κB) was analyzed by Western blotting, and to determine viability of treatments a cell viability assay and caspase-3 immunohistochemistry were performed.We provide evidence that while IL-1β and TNF-α were not detectable under any conditions, SN4741 neurones constitutively released IL-6 under basal conditions and treatment with LPS significantly increased IL-6 secretion. Pre-treatment of neurones with ghrelin attenuated LPS-mediated IL-6 release at 24 h, an affect that was inhibited by the GHS-R antagonist [D-Lys3]-GHRP-6. However, while ghrelin pre-treatment attenuated the LPS-mediated increase in NF-κB, there was no alteration in its nuclear translocation. Cell viability assay and caspase-3 immunocytochemistry demonstrated that the results were independent from activation of cytotoxic and/or apoptotic mechanisms in the neuronal population, respectively.
Our results provide evidence that the gut-hormone, ghrelin, attenuates IL-6 secretion to LPS challenge in mid-brain dopaminergic neurones. These data suggest that ghrelin may protect against dopaminergic SN nerve cell damage or death via modulation of the innate immune response.",[],Journal of neuroinflammation,2013-03-21,"[{'lastname': 'Beynon', 'firstname': 'Amy L', 'initials': 'AL', 'affiliation': 'Molecular Neuroscience, Swansea University, Swansea, SA28PP, UK.'}, {'lastname': 'Brown', 'firstname': 'M Rowan', 'initials': 'MR', 'affiliation': None}, {'lastname': 'Wright', 'firstname': 'Rhiannon', 'initials': 'R', 'affiliation': None}, {'lastname': 'Rees', 'firstname': 'Mark I', 'initials': 'MI', 'affiliation': None}, {'lastname': 'Sheldon', 'firstname': 'I Martin', 'initials': 'IM', 'affiliation': None}, {'lastname': 'Davies', 'firstname': 'Jeffrey S', 'initials': 'JS', 'affiliation': None}]",,"Our results provide evidence that the gut-hormone, ghrelin, attenuates IL-6 secretion to LPS challenge in mid-brain dopaminergic neurones. These data suggest that ghrelin may protect against dopaminergic SN nerve cell damage or death via modulation of the innate immune response.",,,"10.1186/1742-2094-10-40
10.1038/45230
10.1038/35038090
10.1038/nn1656
10.1172/JCI29867
10.1210/me.2005-0084
10.1016/j.expneurol.2008.05.006
10.1016/j.expneurol.2009.11.009
10.1523/JNEUROSCI.3890-09.2009
10.1016/j.mce.2011.04.019
10.1016/j.surg.2007.09.039
10.4049/jimmunol.0803362
10.1212/WNL.38.8.1285
10.3858/emm.2010.42.12.085
10.1016/j.neulet.2009.05.033
10.1161/01.CIR.0000127956.43874.F2
10.1007/s12640-009-9037-x
10.4196/kjpp.2012.16.1.43
10.1007/s00415-010-5864-1
10.1016/0304-3940(96)12706-3
10.1016/0304-3940(95)12192-7",<Element 'PubmedArticle' at 0x7f05db3f6360>
480,"23505367
15685144
9450233
6126663
18052527
1310525
15104793
22380481
19819030
16150122
19840542
15331418
19515766
8917593
10227422
10996215
16414999
8627232
7901429
21994755
20087684
12776209
16973541
12551996
12738000
11452126
4944396
9400592
17108044
21994441
20338162
18480436
12424690
4609903
17376910
16973548
16896148
16699014
18539532
21865385
10846095
22851595
17703415
17724202
9794439
22848506
20881186
17872438
21631323
18268036
6159568
6275339
6087775
1311911
10821506
9395863
19879801
22033878
18641350
9436789
9630473
14667577
10092810
17389906
12663804
18256681
2041662
9302246
18594939
2167378
8223263
11248669
11756505
20530674
19164857
16289840
9502816
22013124
21530661
20677593
18554795
10414517
18044205
888843
4113154
18322077
7605067
19561645
17507799
11063929
10976221
5970298
14567957
14473282
4101340
4761656
21144857
12587075
10786994
19124555
17272615
22013125
16280582
16571625
15496441
10375501
15183722
18353302
10027293
12441288
12381668
16322694
12777630
8595881
8790332
19692604
19862523
15555926
19800966
12925694
10529818
10101968
10876803
21728035
8815757
6324014
15127310
18551722
21820954
11679922",Glucocorticoid treatment of MCMV infected newborn mice attenuates CNS inflammation and limits deficits in cerebellar development.,"Infection of the developing fetus with human cytomegalovirus (HCMV) is a major cause of central nervous system disease in infants and children; however, mechanism(s) of disease associated with this intrauterine infection remain poorly understood. Utilizing a mouse model of HCMV infection of the developing CNS, we have shown that peripheral inoculation of newborn mice with murine CMV (MCMV) results in CNS infection and developmental abnormalities that recapitulate key features of the human infection. In this model, animals exhibit decreased granule neuron precursor cell (GNPC) proliferation and altered morphogenesis of the cerebellar cortex. Deficits in cerebellar cortical development are symmetric and global even though infection of the CNS results in a non-necrotizing encephalitis characterized by widely scattered foci of virus-infected cells with mononuclear cell infiltrates. These findings suggested that inflammation induced by MCMV infection could underlie deficits in CNS development. We investigated the contribution of host inflammatory responses to abnormal cerebellar development by modulating inflammatory responses in infected mice with glucocorticoids. Treatment of infected animals with glucocorticoids decreased activation of CNS mononuclear cells and expression of inflammatory cytokines (TNF-α, IFN-β and IFNγ) in the CNS while minimally impacting CNS virus replication. Glucocorticoid treatment also limited morphogenic abnormalities and normalized the expression of developmentally regulated genes within the cerebellum. Importantly, GNPC proliferation deficits were normalized in MCMV infected mice following glucocorticoid treatment. Our findings argue that host inflammatory responses to MCMV infection contribute to deficits in CNS development in MCMV infected mice and suggest that similar mechanisms of disease could be responsible for the abnormal CNS development in human infants infected in-utero with HCMV.",[],PLoS pathogens,2013-03-19,"[{'lastname': 'Kosmac', 'firstname': 'Kate', 'initials': 'K', 'affiliation': 'Department of Microbiology, University of Alabama at Birmingham, Birmingham, Alabama, United States of America. katek@uab.edu'}, {'lastname': 'Bantug', 'firstname': 'Glenn R', 'initials': 'GR', 'affiliation': None}, {'lastname': 'Pugel', 'firstname': 'Ester P', 'initials': 'EP', 'affiliation': None}, {'lastname': 'Cekinovic', 'firstname': 'Djurdjica', 'initials': 'D', 'affiliation': None}, {'lastname': 'Jonjic', 'firstname': 'Stipan', 'initials': 'S', 'affiliation': None}, {'lastname': 'Britt', 'firstname': 'William J', 'initials': 'WJ', 'affiliation': None}]",,,,,"10.1371/journal.ppat.1003200
10.1371/journal.ppat.0030149
10.1371/journal.pone.0041476",<Element 'PubmedArticle' at 0x7f05db40d180>
481,"23471521
17296917
22972984
19274719
16118055
21916860
17123706
22197668
1313866
11156943
17015679
16540272
17934510
15758162
17329437
9718090
8056
11789671
10869379
14996418
8662742
22421596
11786493
18848818
22448282
17284931
16288682
18500446
17538000
7544292
2848184
17229577
19052649
16387640
16039904
12509806
7760148
7565624
16864698
21735070
5538858
18574142
15548432
9653176
19596672
2560548
16596771
12037135
17712819
16889960
10722167
20943404
8831752
12538019
15582455
21142261
21670103
16781706
12813001
17478614
18221225
16513651
19961570
6145762
11448490
22973422
19496827
17185040
21735467
18941231
11020293
17401376
10594647
14526074
22248049
2165569
2175265
12130702
12091357
5879350
4879547
17712814
21951063
19059482
17982478
21830069
20874519
9738948
18178718
7689702
19884325
15266552
12606780
16968947
10926528
16364651
21397004
14741442
16478899
22420307
15866202
10594923
19005078
17660390
15728830
22442067
19457575
17114903
17712817
15620723
21420365
18199524
21456949
7962480
16081674
22763024
19408320
10051546
22491047
19525393
21470162
12598408
19357281
9618400
16260047
18289087
18761332
15550382
14517981
21104379
18725316
16512913
20696525
17245417
19332079
9694974
16924491
16612464
16401651",Cannabinoid receptor 2: potential role in immunomodulation and neuroinflammation.,"An accumulating body of evidence suggests that endocannabinoids and cannabinoid receptors type 1 and 2 (CB(1), CB(2)) play a significant role in physiologic and pathologic processes, including cognitive and immune functions. While the addictive properties of marijuana, an extract from the Cannabis plant, are well recognized, there is growing appreciation of the therapeutic potential of cannabinoids in multiple pathologic conditions involving chronic inflammation (inflammatory bowel disease, arthritis, autoimmune disorders, multiple sclerosis, HIV-1 infection, stroke, Alzheimer's disease to name a few), mainly mediated by CB(2) activation. Development of CB(2) agonists as therapeutic agents has been hampered by the complexity of their intracellular signaling, relative paucity of highly selective compounds and insufficient data regarding end effects in the target cells and organs. This review attempts to summarize recent advances in studies of CB(2) activation in the setting of neuroinflammation, immunomodulation and HIV-1 infection.",[],Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology,2013-03-09,"[{'lastname': 'Rom', 'firstname': 'Slava', 'initials': 'S', 'affiliation': 'Department of Pathology and Laboratory Medicine, Temple University School of Medicine, 3401 N. Broad St., Philadelphia, PA 19140, USA. srom@temple.edu'}, {'lastname': 'Persidsky', 'firstname': 'Yuri', 'initials': 'Y', 'affiliation': None}]",,,,,10.1007/s11481-013-9445-9,<Element 'PubmedArticle' at 0x7f05db3cf6d0>
482,"23435356
19488073
22241550
12511643
14563478
15663479
15163437
15247473
17972101
17868301
17613521
17984088
21884984
22958208
21712650
19344641
17768266
19181488
21156177
16115212
17622221
16989820
21071507
15194882
20938637
20215417
21112026
19033418
19863652
21907225
21320597
19368844
16483717
20130223
19015006
19120103
18701679
19647049
20816924
22917616
7536823
19577549
17595225
21299657
16044172
16116490
17335389
22693556
22835848
20628266
19162119
16146581
21257271
16847459
18593594
20059554
19900455
18394919
18971218
12930783
19006079
16148224
20398061
23007167
19520831
23336056
22832966
23139830
22826344
21182901
16458260
19046994
22488525
692746
10804232
17950541
19840776
22826223
18496129
19679166
21129470
20220017
18986658
21903025
18192499
20139991
11182535
20856248",Tryptophan hydroxylase-2: an emerging therapeutic target for stress disorders.,"Serotonin (5-HT) has been long recognized to modulate the stress response, and dysfunction of 5-HT has been implicated in numerous stress disorders. Accordingly, the 5-HT system has been targeted for the treatment of stress disorders. Tryptophan hydroxylase (TPH) is the rate-limiting enzyme in 5-HT synthesis, and the recent identification of a second, neuron-specific TPH isoform (TPH2) opened up a new area of research. With a decade of extensive investigation, it is now recognized that: (1) TPH2 exhibits a highly flexible gene expression that is modulated by an increasing number of internal and external environmental factors including the biological clock, stressors, endogenous hormones, and antidepressant therapies; and (2) genetically determined TPH2 activity is linked to a growing body of stress-related neuronal correlates and behavioral traits. These findings reveal an active role of TPH2 in the stress response and provide new insights into the long recognized but not yet fully understood 5-HT-stress interaction. As a major modulator of 5-HT neurotransmission and the stress response, TPH2 is of both pathophysiological and pharmacological significance, and is emerging as a new therapeutic target for the treatment of stress disorders. Given that numerous antidepressant therapies influence TPH2 gene expression, TPH2 is already inadvertently targeted for the treatment of stress disorders. With increased understanding of the regulation of TPH2 activity we can now purposely utilize TPH2 as a target to develop new or optimize current therapies, which are expected to greatly improve the prevention and treatment of a wide variety of stress disorders.",[],Biochemical pharmacology,2013-02-26,"[{'lastname': 'Chen', 'firstname': 'Guo-Lin', 'initials': 'GL', 'affiliation': 'Harvard Medical School, New England Primate Research Center, Division of Neuroscience, One Pine Hill Drive, Southborough, MA 01772-9102, USA. guo-lin_chen@hms.harvard.edu'}, {'lastname': 'Miller', 'firstname': 'Gregory M', 'initials': 'GM', 'affiliation': None}]",,,,Copyright © 2013 Elsevier Inc. All rights reserved.,10.1016/j.bcp.2013.02.018,<Element 'PubmedArticle' at 0x7f05db395130>
483,23394526,Neuroglial roots of neurodegenerative diseases: therapeutic potential of palmitoylethanolamide in models of Alzheimer's disease.,"The growth of knowledge about the molecular mechanisms underlying Alzheimer's disease (AD) has highlighted the role of neuroinflammation in the pathophysiology of this disorder. AD is classically characterized by the deposit of misfolded proteins: the extracellular accumulation of beta amyloid peptide (Aβ), and the formation of intracellular neurofibrillary tangles. However, it is clear that many other cellular dysfunctions occur. Among these, a prominent role is exerted by the inflammatory process which is a consequence of the over-activation of glial cells. Indeed, several models of AD have demonstrated that glia modify their functions, losing the physiological supportive role. These cells instead acquire a pro-inflammatory phenotype, thus contributing to exacerbate Aβ toxicity. The relationship between neurodegeneration and neuroinflammation is strictly interdependent, and research efforts are now addressed to antagonize both processes simultaneously. Along this line palmitoylethanolamide (PEA) has attracted much attention because of its numerous pharmacological properties, particularly those related to the modulation of peripheral inflammation through the peroxisome proliferator activated receptor-α involvement. In light of these considerations, we explored the antiinflammatory and neuroprotective effects of PEA in rat neuronal cultures and organotypic hippocampal slices challenged with Aβ, and treated with PEA in the presence or absence of a selective peroxisome proliferator activated receptor-α antagonist. The data indicate that PEA is able to blunt Aβ-induced astrocyte activation and to exert a marked protective effect on neurons. These findings highlight new pharmacological properties of PEA and suggest that this compound may provide an effective strategy for AD.",[],CNS & neurological disorders drug targets,2013-02-12,"[{'lastname': 'Scuderi', 'firstname': 'Caterina', 'initials': 'C', 'affiliation': 'Department of Physiology and Pharmacology ""Vittorio Erspamer"", SAPIENZA University of Rome, P.le Aldo Moro, 5, 00185 Rome, Italy.'}, {'lastname': 'Steardo', 'firstname': 'Luca', 'initials': 'L', 'affiliation': None}]",,,,,10.2174/1871527311312010011,<Element 'PubmedArticle' at 0x7f05db33f860>
484,"23383397
22330821
19595937
19674436
20175776
20061018
14973251
22002425
19450719
18793332
18310257
11514021
19090987
10234025
9951629
10028999
12943738
7752947
11821512
9435644
19811239
8994414
9931124
1661757
11530288
11861038
3047403
19142361
18456730
17699561
9631868
12810582
15158151
10537176
7945336
12075344
11390023
11882619
9283715
11805174
15189325
16868049
9374841
15036490
18083251
15550614
18679017
18296494
20955869
11788163
12117397
8732994
10334810
15699442
9222939
14734680
16990489
9453326
9740621
12372768
16075377
9890393
15388495
19942928
18522829
17121991
10867218
21035950
20870012
19127280
17673335
12676174
17324119
17096009
16533956
11378246
12374512
19597068
15837534
12584663
19796831
20627092
11604391
22964777
15917098
17362841
15929050
19782074
11445253
18363935
19956428
14561528
14578918
20068258
21709373
22412114
12972166
14742905
17591969
17098332
15308303
19897485
21382117
22784036
19956426
11507039
18192335
23990808",Interactions between oestrogen and the renin angiotensin system - potential mechanisms for gender differences in Alzheimer's disease.,"Interactions between oestrogen and the renin angiotensin system (RAS) are reviewed and explored from the perspective where these interactions may modulate risk of developing Alzheimer's disease (AD). AD is more prevalent in women than men, partly attributed to women's increased life expectancy; however underlying vascular differences may also contribute to AD risk. The RAS is a key regulator of blood pressure (BP). Pharmacological inhibition of angiotensin converting enzyme (ACE) and blockade of angiotensin II type 1 receptors (AT1R) are widely used to treat hypertension. Variation in components of the RAS such as ACE, neprilysin (NEP) and AT1R have been reported in AD, some of which may also directly alter AD neuropathology with changes in amyloid beta (Aβ) levels, cognitive decline and neuroinflammation. Recently, RAS inhibiting drugs have been shown to attenuate the incidence, progression and pathology of AD. Oestrogen is also thought to prevent hypertension by reducing the vasoconstrictive actions of the RAS. Reduced oestrogen levels in women during the menopausal transition may therefore increase their risk of hypertension and/or RAS-mediated changes to cerebrovascular or AD pathology. Specifically, oestrogen prevents the production and action of angiotensin II (Ang II), thought to exert harmful effects of the RAS in both hypertension and AD, while also potentially facilitating RAS-mediated Aβ degradation. These oestrogen-RAS interactions may partly explain current conflicting findings regarding oestrogen depletion and hormone therapy with respect to AD risk. Clinical trials targeting either the RAS or oestrogen systems for AD prevention and treatment should perhaps give closer attention to key biochemical components of these pathways as potential confounders to primary and secondary outcome measures.","['Alzheimer’s disease', 'Oestrogen', 'gender difference', 'renin angiotensin system (RAS)']",American journal of neurodegenerative disease,2013-02-06,"[{'lastname': ""O'Hagan"", 'firstname': 'Thomas Simon', 'initials': 'TS', 'affiliation': 'Dementia Research Group, John James Laboratories, School of Clinical Sciences, University of Bristol, Frenchay Hospital Bristol, BS16 1LE.'}, {'lastname': 'Wharton', 'firstname': 'Whitney', 'initials': 'W', 'affiliation': None}, {'lastname': 'Kehoe', 'firstname': 'Patrick Gavin', 'initials': 'PG', 'affiliation': None}]",,,,,,<Element 'PubmedArticle' at 0x7f05db349f40>
485,"23348027
9483683
19125209
21435391
22248083
12745313
17953161
19560279
21466807
22093902
22647578
11014219
18382067
1623570
19338700
16125862
18475514
10442180
18367364
15748951
23123920
19286276
10669189
16647243
19393683
22966132
18191534
21093579
21411230
6381037
10377371
18849120
12399247
19393685
14575731
19372198
19131570
19913969
17705097
22497984
12676570
16901532
2027540
21418338
9482808
15877314
8016286
17900830
19906234
21745355
22370490
21615563
21127968
19275906
15879140
18460549
17593929
20438720
11279849",Sex differences in the effects of adolescent stress on adult brain inflammatory markers in rats.,"Both basic and clinical research indicates that females are more susceptible to stress-related affective disorders than males. One of the mechanisms by which stress induces depression is via inflammatory signaling in the brain. Stress during adolescence, in particular, can also disrupt the activation and continued development of both the hypothalamic-pituitary-adrenal (HPA) and -gonadal (HPG) axes, both of which modulate inflammatory pathways and brain regions involved in affective behavior. Therefore, we tested the hypothesis that adolescent stress differentially alters brain inflammatory mechanisms associated with affective-like behavior into adulthood based on sex. Male and female Wistar rats underwent mixed-modality stress during adolescence (PND 37-48) and were challenged with lipopolysaccharide (LPS; 250μg/kg, i.p.) or saline 4.5weeks later (in adulthood). Hippocampal inflammatory marker gene expression and circulating HPA and HPG axes hormone concentrations were then determined. Despite previous studies indicating that adolescent stress induces affective-like behaviors in female rats only, this study demonstrated that adolescent stress increased hippocampal inflammatory responses to LPS in males only, suggesting that differences in neuroinflammatory signaling do not drive the divergent affective-like behaviors. The sex differences in inflammatory markers were not associated with differences in corticosterone. In females that experienced adolescent stress, LPS increased circulating estradiol. Estradiol positively correlated with hippocampal microglial gene expression in control female rats, whereas adolescent stress negated this relationship. Thus, estradiol in females may potentially protect against stress-induced increases in neuroinflammation.",[],"Brain, behavior, and immunity",2013-01-26,"[{'lastname': 'Pyter', 'firstname': 'Leah M', 'initials': 'LM', 'affiliation': 'Center for Wound Healing and Tissue Regeneration, College of Dentistry, University of Illinois at Chicago, Chicago, IL, USA.'}, {'lastname': 'Kelly', 'firstname': 'Sean D', 'initials': 'SD', 'affiliation': None}, {'lastname': 'Harrell', 'firstname': 'Constance S', 'initials': 'CS', 'affiliation': None}, {'lastname': 'Neigh', 'firstname': 'Gretchen N', 'initials': 'GN', 'affiliation': None}]",,,,Copyright © 2013 Elsevier Inc. All rights reserved.,10.1016/j.bbi.2013.01.075,<Element 'PubmedArticle' at 0x7f05db2fb360>
486,"23324534
22378659
15254934
22264765
21723456
18295728
10359578
22017435
15642740
17444957
17433868
18718031
18625522
21585290
15240667
18675552
12725798
22127692
20149932
21372118
21109310
19034695
19016524
20945608
21211990
16242914
15308519
17911457
17092341
19339060
22124120","BAFF/APRIL system in pediatric OMS: relation to severity, neuroinflammation, and immunotherapy.","B-cell dysregulation has been implicated but not fully characterized in pediatric opsoclonus-myoclonus syndrome (OMS), a neuroblastoma-associated neuroinflammatory disorder.
To assess the role of B-cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), two critical B cell-modulating cytokines, as potential biomarkers of disease activity and treatment biomarkers in OMS.
Soluble BAFF and APRIL were measured in cerebrospinal fluid (CSF) and serum by ELISA in 433 children (296 OMS, 109 controls, 28 other inflammatory neurological disorders (OIND)). BAFF-R receptors on circulating CD19+ B cells were measured by flow cytometry. A blinded scorer rated motor severity on the OMS Evaluation Scale. Immunotherapies were evaluated cross-sectionally and longitudinally.
The mean CSF BAFF concentration, which was elevated in untreated OMS and OIND, correlated with OMS severity category (P = 0.006), and reduction by adrenocorticotropic hormone or corticotropin (ACTH) (-61%) or corticosteroids (-38%) was seen at each level of severity. In contrast, CSF APRIL was normal in OMS and OIND and unaffected by immunotherapy. When the entire OMS dataset was dichotomized into 'high' versus 'normal' CSF BAFF concentration, the phenotype of the high group included greater motor severity and number of CSF oligoclonal bands, and a higher concentration of inflammatory chemokines CXCL13 and CXCL10 in CSF and CXCL9 and CCL21 in serum. Serum APRIL was 6.7-fold higher in the intravenous immunoglobulins (IVIg) group, whereas serum BAFF was 2.6-fold higher in the rituximab group. The frequency of B cell BAFF-R expression was similar in untreated and treated OMS. Longitudinal studies of CSF BAFF revealed a significant decline in ACTH-treated patients (with or without rituximab) (P < 0.0001). Longitudinal studies of serum APRIL showed a 2.9-fold increase after 1 to 2 g/kg IVIg monotherapy (P = 0.0003).
Striking distinctions in BAFF/APRIL signaling were found. OMS displayed heterogeneity in CSF BAFF expression, which met many but not all criteria as a potential biomarker of disease activity. We speculate that CSF BAFF may have more utility in a biomarker panel than as a stand-alone biomarker, and that the selective upregulation of both serum APRIL by IVIg and BAFF by rituximab, as well as downregulation of CSF BAFF by ACTH/steroids, may have utility as treatment biomarkers.",[],Journal of neuroinflammation,2013-01-18,"[{'lastname': 'Pranzatelli', 'firstname': 'Michael R', 'initials': 'MR', 'affiliation': 'Department of Neurology, National Pediatric Myoclonus Center and Neuroimmunology Laboratory, and Southern Illinois University School of Medicine, PO Box 19643, Springfield, IL 62794-9643, USA. mpranzatelli@siumed.edu'}, {'lastname': 'Tate', 'firstname': 'Elizabeth D', 'initials': 'ED', 'affiliation': None}, {'lastname': 'McGee', 'firstname': 'Nathan R', 'initials': 'NR', 'affiliation': None}, {'lastname': 'Travelstead', 'firstname': 'Anna L', 'initials': 'AL', 'affiliation': None}, {'lastname': 'Colliver', 'firstname': 'Jerry A', 'initials': 'JA', 'affiliation': None}, {'lastname': 'Ness', 'firstname': 'Jayne M', 'initials': 'JM', 'affiliation': None}, {'lastname': 'Ransohoff', 'firstname': 'Richard M', 'initials': 'RM', 'affiliation': None}]",,,"The mean CSF BAFF concentration, which was elevated in untreated OMS and OIND, correlated with OMS severity category (P = 0.006), and reduction by adrenocorticotropic hormone or corticotropin (ACTH) (-61%) or corticosteroids (-38%) was seen at each level of severity. In contrast, CSF APRIL was normal in OMS and OIND and unaffected by immunotherapy. When the entire OMS dataset was dichotomized into 'high' versus 'normal' CSF BAFF concentration, the phenotype of the high group included greater motor severity and number of CSF oligoclonal bands, and a higher concentration of inflammatory chemokines CXCL13 and CXCL10 in CSF and CXCL9 and CCL21 in serum. Serum APRIL was 6.7-fold higher in the intravenous immunoglobulins (IVIg) group, whereas serum BAFF was 2.6-fold higher in the rituximab group. The frequency of B cell BAFF-R expression was similar in untreated and treated OMS. Longitudinal studies of CSF BAFF revealed a significant decline in ACTH-treated patients (with or without rituximab) (P < 0.0001). Longitudinal studies of serum APRIL showed a 2.9-fold increase after 1 to 2 g/kg IVIg monotherapy (P = 0.0003).",,"10.1186/1742-2094-10-10
10.1177/0883073811428816
10.1002/mds.20125
10.1016/j.jneuroim.2011.12.014
10.1016/j.pediatrneurol.2011.02.012
10.1016/j.autrev.2007.05.002
10.1084/jem.189.11.1747
10.1111/j.1600-065X.2011.01067.x
10.1084/jem.20041674
10.1111/j.1365-3083.2007.01921.x
10.1016/j.coi.2007.04.008
10.1186/ar2484
10.1016/j.jneuroim.2008.06.006
10.3109/03009742.2010.550900
10.1016/j.cyto.2008.06.001
10.1016/S1046-2023(02)00355-9
10.1002/art.30599
10.1016/j.jneuroim.2010.01.011
10.1177/1352458511398887
10.1016/j.jneuroim.2010.10.027
10.1007/s12013-008-9036-1
10.1002/eji.200838640
10.1016/j.cyto.2010.12.004
10.1016/j.jaut.2005.08.004
10.1136/ard.2003.018663
10.1196/annals.1423.044
10.1186/ar2076
10.1016/j.jneuroim.2009.03.006
10.4049/jimmunol.1102321",<Element 'PubmedArticle' at 0x7f05db31b770>
487,23313345,Exogenous T3 administration provides neuroprotection in a murine model of traumatic brain injury.,"Traumatic brain injury (TBI) induces primary and secondary damage in both the endothelium and the brain parenchyma. While neurons die quickly by necrosis, a vicious cycle of secondary injury in endothelial cells exacerbates the initial injury. Thyroid hormones are reported to be decreased in patients with brain injury. Controlled cortical impact injury (CCI) is a widely used, clinically relevant model of TBI. Here, using CCI in adult male mice, we set to determine whether 3,5,3'-triiodothyronine (T3) attenuates posttraumatic neurodegeneration and neuroinflammation in an experimental model of TBI. Treatment with T3 (1.2μg/100g body weight, i.p.) 1h after TBI resulted in a significant improvement in motor and cognitive recovery after CCI, as well as in marked reduction of lesion volumes. Mouse model for brain injury showed reactive astrocytes with increased glial fibrillary acidic protein, and formation of inducible nitric oxide synthase (iNOS). Western blot analysis revealed the ability of T3 to reduce brain trauma through modulation of cytoplasmic-nuclear shuttling of nuclear factor-κB (NF-κB). Twenty-four hours after brain trauma, T3-treated mice also showed significantly lower number of TUNEL(+) apoptotic neurons and curtailed induction of Bax, compared to vehicle control. In addition, T3 significantly enhanced the post-TBI expression of the neuroprotective neurotrophins (BDNF and GDNF) compared to vehicle. Our data provide an additional mechanism for the anti-inflammatory effects of thyroid hormone with critical implications in immunopathology at the cross-roads of the immune-endocrine circuits.",[],Pharmacological research,2013-01-15,"[{'lastname': 'Crupi', 'firstname': 'Rosalia', 'initials': 'R', 'affiliation': 'Department of Biological and Environmental Sciences, University of Messina, Italy.'}, {'lastname': 'Paterniti', 'firstname': 'Irene', 'initials': 'I', 'affiliation': None}, {'lastname': 'Campolo', 'firstname': 'Michela', 'initials': 'M', 'affiliation': None}, {'lastname': 'Di Paola', 'firstname': 'Rosanna', 'initials': 'R', 'affiliation': None}, {'lastname': 'Cuzzocrea', 'firstname': 'Salvatore', 'initials': 'S', 'affiliation': None}, {'lastname': 'Esposito', 'firstname': 'Emanuela', 'initials': 'E', 'affiliation': None}]",,,,Copyright © 2013 Elsevier Ltd. All rights reserved.,10.1016/j.phrs.2012.12.009,<Element 'PubmedArticle' at 0x7f05db2b5cc0>
488,23196064,Neuroprotection by gonadal steroid hormones in acute brain damage requires cooperation with astroglia and microglia.,"The neuroactive steroids 17β-estradiol and progesterone control a broad spectrum of neural functions. Besides their roles in the regulation of classical neuroendocrine loops, they strongly influence motor and cognitive systems, behavior, and modulate brain performance at almost every level. Such a statement is underpinned by the widespread and lifelong expression pattern of all types of classical and non-classical estrogen and progesterone receptors in the CNS. The life-sustaining power of neurosteroids for tattered or seriously damaged neurons aroused interest in the scientific community in the past years to study their ability for therapeutic use under neuropathological challenges. Documented by excellent studies either performed in vitro or in adequate animal models mimicking acute toxic or chronic neurodegenerative brain disorders, both hormones revealed a high potency to protect neurons from damage and saved neural systems from collapse. Unfortunately, neurons, astroglia, microglia, and oligodendrocytes are comparably target cells for both steroid hormones. This hampers the precise assignment and understanding of neuroprotective cellular mechanisms activated by both steroids. In this article, we strive for a better comprehension of the mutual reaction between these steroid hormones and the two major glial cell types involved in the maintenance of brain homeostasis, astroglia and microglia, during acute traumatic brain injuries such as stroke and hypoxia. In particular, we attempt to summarize steroid-activated cellular signaling pathways and molecular responses in these cells and their contribution to dampening neuroinflammation and neural destruction. This article is part of a Special Issue entitled 'CSR 2013'.","['AD', 'AQP', 'ATP', ""Alzheimer's disease"", 'Astroglia', 'BBB', 'BSA', 'CNS', 'Ca(2+)/calmodulin-dependent protein kinases', 'CaMK', 'EAE', 'ER', 'ERK', 'Estrogen', 'G-protein coupled receptor 30', 'GFAP', 'GLAST', 'GLT-1', 'GPR30', 'ICI', 'ICI 182,780', 'IGF', 'IL', 'Ko', 'MAPK', 'MHC', 'MMP', 'MNAR', 'Microglia', 'NF-κB', 'PELP1', 'PI3K', 'PKA', 'PKC', 'Progesterone', 'RCEs', 'ROS', 'SERM', 'Src', 'TGF-β', 'TNF-α', 'VEGF', 'adenosine triphosphate', 'aquaporin', 'blood–brain barrier', 'bovine serum albumin', 'central nervous system', 'estrogen receptor', 'experimental autoimmune encephalomyelitis', 'extracellular signal-related kinase', 'glial fibrillary acidic protein', 'glutamate transporter-1', 'gutamate–aspartate transporter', 'iNOS', 'inducible nitric oxide synthase', 'insulin-like growth factor-1', 'interleukin', 'knockout', 'major histocompatibility complex', 'matrix metalloproteinase', 'mitogen-activated protein kinase', 'modulator of nongenomic activity of ER', 'nuclear factor-kappa B', 'phosphatidylinositol 3-kinases', 'proline, glutamate and leucine rich protein1', 'protein kinase A', 'protein kinase C', 'radical oxygen species', 'respiratory chain enzymes', 'sarcoma', 'selective estrogen receptor modulator', 'siRNA', 'small interfering RNA', 'tMCAO', 'transforming growth factor-beta', 'transient middle cerebral artery occlusion', 'tumor necrosis factor-alpha', 'vascular endothelial growth factor']",The Journal of steroid biochemistry and molecular biology,2012-12-01,"[{'lastname': 'Johann', 'firstname': 'Sonja', 'initials': 'S', 'affiliation': 'Institute of Neuroanatomy, RWTH Aachen University, D-52074 Aachen, Germany.'}, {'lastname': 'Beyer', 'firstname': 'Cordian', 'initials': 'C', 'affiliation': None}]",,,,Copyright © 2012 Elsevier Ltd. All rights reserved.,10.1016/j.jsbmb.2012.11.006,<Element 'PubmedArticle' at 0x7f05db2c4590>
489,"23190711
22326264
19776225
21945603
9626555
6482428
2998738
3443807
10696570
8603039
7825905
21820034
2902493
2845584
11350956
19909806
15199296
7670488
17555867
21198556
10760063
15153751
21736918
20544861
22155566
19565166
1578513
2110186
11846609
9786892
19022273
3224763
16759088
16103409
16087724
15062542
20600925
7715646
21646349
20456998
19482216
19296921
22166438
21467220",Mineralocorticoid and glucocorticoid receptors differentially regulate NF-kappaB activity and pro-inflammatory cytokine production in murine BV-2 microglial cells.,"Microglia, the resident macrophage-like cells in the brain, regulate innate immune responses in the CNS to protect neurons. However, excessive activation of microglia contributes to neurodegenerative diseases. Corticosteroids are potent modulators of inflammation and mediate their effects by binding to mineralocorticoid receptors (MR) and glucocorticoid receptors (GR). Here, the coordinated activities of GR and MR on the modulation of the nuclear factor-κB (NF-κB) pathway in murine BV-2 microglial cells were studied.
BV-2 cells were treated with different corticosteroids in the presence or absence of MR and GR antagonists. The impact of the glucocorticoid-activating enzyme 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) was determined by incubating cells with 11-dehydrocorticosterone, with or without selective inhibitors. Expression of interleukin-6 (IL-6), tumor necrosis factor receptor 2 (TNFR2), and 11β-HSD1 mRNA was analyzed by RT-PCR and IL-6 protein expression by ELISA. NF-κB activation and translocation upon treatment with various corticosteroids were visualized by western blotting, immunofluorescence microscopy, and translocation assays.
GR and MR differentially regulate NF-κB activation and neuroinflammatory parameters in BV-2 cells. By converting inactive 11-dehydrocorticosterone to active corticosterone, 11β-HSD1 essentially modulates the coordinated action of GR and MR. Biphasic effects were observed for 11-dehydrocorticosterone and corticosterone, with an MR-dependent potentiation of IL-6 and tumor necrosis factor-α (TNF-α) expression and NF-κB activation at low/moderate concentrations and a GR-dependent suppression at high concentrations. The respective effects were confirmed using the MR ligand aldosterone and the antagonist spironolactone as well as the GR ligand dexamethasone and the antagonist RU-486. NF-κB activation could be blocked by spironolactone and the inhibitor of NF-κB translocation Cay-10512. Moreover, an increased expression of TNFR2 was observed upon treatment with 11-dehydrocorticosterone and aldosterone, which was reversed by 11β-HSD1 inhibitors and/or spironolactone and Cay-10512.
A tightly coordinated GR and MR activity regulates the NF-κB pathway and the control of inflammatory mediators in microglia cells. The balance of GR and MR activity is locally modulated by the action of 11β-HSD1, which is upregulated by pro-inflammatory mediators and may represent an important feedback mechanism involved in resolution of inflammation.",[],Journal of neuroinflammation,2012-11-30,"[{'lastname': 'Chantong', 'firstname': 'Boonrat', 'initials': 'B', 'affiliation': 'Division of Molecular and Systems Toxicology, Department of Pharmaceutical Sciences, University of Basel, Klingelbergstrasse 50, CH-4056 Basel, Switzerland.'}, {'lastname': 'Kratschmar', 'firstname': 'Denise V', 'initials': 'DV', 'affiliation': None}, {'lastname': 'Nashev', 'firstname': 'Lyubomir G', 'initials': 'LG', 'affiliation': None}, {'lastname': 'Balazs', 'firstname': 'Zoltan', 'initials': 'Z', 'affiliation': None}, {'lastname': 'Odermatt', 'firstname': 'Alex', 'initials': 'A', 'affiliation': None}]",,,"GR and MR differentially regulate NF-κB activation and neuroinflammatory parameters in BV-2 cells. By converting inactive 11-dehydrocorticosterone to active corticosterone, 11β-HSD1 essentially modulates the coordinated action of GR and MR. Biphasic effects were observed for 11-dehydrocorticosterone and corticosterone, with an MR-dependent potentiation of IL-6 and tumor necrosis factor-α (TNF-α) expression and NF-κB activation at low/moderate concentrations and a GR-dependent suppression at high concentrations. The respective effects were confirmed using the MR ligand aldosterone and the antagonist spironolactone as well as the GR ligand dexamethasone and the antagonist RU-486. NF-κB activation could be blocked by spironolactone and the inhibitor of NF-κB translocation Cay-10512. Moreover, an increased expression of TNFR2 was observed upon treatment with 11-dehydrocorticosterone and aldosterone, which was reversed by 11β-HSD1 inhibitors and/or spironolactone and Cay-10512.",,"10.1186/1742-2094-9-260
10.1016/j.bbrc.2012.01.139
10.1152/ajpendo.00320.2009
10.1016/j.mce.2011.09.011
10.1210/er.19.3.269
10.1210/endo-117-6-2505
10.1677/joe.0.1150459
10.1210/er.21.1.55
10.1016/0960-0760(95)00235-9
10.1016/j.mce.2011.07.020
10.1126/science.2845584
10.1074/jbc.M100374200
10.1016/j.bbadis.2009.10.017
10.1097/01.mnh.0000133976.32559.b0
10.1038/ng0895-394
10.1016/j.mce.2007.03.007
10.1111/j.1476-5381.2010.01199.x
10.1046/j.1523-1755.2000.00971.x
10.1159/000078099
10.1016/j.mce.2011.06.020
10.1016/j.mce.2011.11.026
10.1002/jnr.490310405
10.1016/0165-5728(90)90073-V
10.1006/meth.2001.1262
10.1074/jbc.273.44.28897
10.1016/j.steroids.2008.10.010
10.1021/jm0600794
10.1084/jem.20050119
10.1677/jme.1.01736
10.1016/j.mce.2003.11.027
10.1016/j.mcn.2010.06.014
10.1056/NEJM199505183322008
10.1074/jbc.M110.212365
10.1016/j.cytogfr.2010.04.003
10.1016/S0140-6736(09)60326-3
10.1016/S1474-4422(09)70062-6
10.1073/pnas.1017820108",<Element 'PubmedArticle' at 0x7f05db2d6270>
490,"23108549
21881466
21931491
21969914
21827663
21771791
21562886
21472005
21842586
21951367
21878486
22500269
20117131
21801430
21081837
20029625
20573451
22000153
16259628
16006518
15662442
21713648
2261679
10627616
21521653
22190366
1357565
3023451
7689770
2022965
7517440
2407920
7818259
18657868
19906445
19004805
11166964
11514078
12617561
21907261
18463248
21441897
18337420
15777864
19515262
19150373
21816109
21639869
14527707
22019552
11929922
8170980
8931279
9326296
7514639
18385539
17188755
21527731
17965659
8787137
12838577
12586432
16807890
19520991
1829107
10616793
15678118
12457181
17762205
16163296
17924984
15771708
20087366
21980200
12676570
16647243
20153418
20361987
20176930
21525267
11146058
15954124
2145387
15665833
15649707
11834594
12951563
22072381
10704463
14530364
19380799
16960575
21350020
17376966
16260491
19838177
17351623
17344397
16820801
22293457
21072242
22423088
19625371
17916583
18087731
22516295
12672055
15241362
17355971
20599470
15809417
21620385
19921464
1388246
20127816
20025063
20798517
22613992
11169404
18435916
22204316
9006319
18559098
1370670
6148726
11596126
20511559
21410936
20581331
18622054
22189915
22004612
16407564
16968947
9461251
9150253
11245916
14634025
13211905
8739213
9685157
11442148
20096327
22483302
17631917
7724569
19625089
9231736
12944505
15009671
12154273
22125609
11156943
11786493
9696473
11426841
12359622
19386271
21219627
12941436
18602217
18930143
21354467
18367664
8769879
8633002
22414817
22405189
15465922
21554431
21255263
17565008
22178921
12023948
11602256
9454764
16982866
16928856
8900284
11463796
19926854
20022504
22542283
21673720
20337613
22229320
22301508",Mast cell-glia axis in neuroinflammation and therapeutic potential of the anandamide congener palmitoylethanolamide.,"Communication between the immune and nervous systems depends a great deal on pro-inflammatory cytokines. Both astroglia and microglia, in particular, constitute an important source of inflammatory mediators and may have fundamental roles in central nervous system (CNS) disorders from neuropathic pain and epilepsy to neurodegenerative diseases. Glial cells respond also to pro-inflammatory signals released from cells of immune origin. In this context, mast cells are of particular relevance. These immune-related cells, while resident in the CNS, are able to cross a compromised blood-spinal cord and blood-brain barrier in cases of CNS pathology. Emerging evidence suggests the possibility of mast cell-glia communication, and opens exciting new perspectives for designing therapies to target neuroinflammation by differentially modulating the activation of non-neuronal cells normally controlling neuronal sensitization-both peripherally and centrally. This review aims to provide an overview of recent progress relating to the pathobiology of neuroinflammation, the role of glia, neuro-immune interactions involving mast cells and the possibility that glia-mast cell interactions contribute to exacerbation of acute symptoms of chronic neurodegenerative disease and accelerated disease progression, as well as promotion of pain transmission pathways. Using this background as a starting point for discussion, we will consider the therapeutic potential of naturally occurring fatty acid ethanolamides, such as palmitoylethanolamide in treating systemic inflammation or blockade of signalling pathways from the periphery to the brain in such settings.",[],"Philosophical transactions of the Royal Society of London. Series B, Biological sciences",2012-10-31,"[{'lastname': 'Skaper', 'firstname': 'Stephen D', 'initials': 'SD', 'affiliation': ""Dipartimento di Scienze del Farmaco, Università degli Studi di Padova, Largo 'Egidio Meneghetti' 2, 35131 Padova, Italy. stephen.skaper@unipd.it""}, {'lastname': 'Facci', 'firstname': 'Laura', 'initials': 'L', 'affiliation': None}]",,,,,"10.1098/rstb.2011.0391
10.1016/S1569-2558(03)31042-2
10.1016/S1569-2558(03)31042-2
10.1016/S1537-5897(03)00044-2
10.1016/S1537-5897(03)00044-2
10.1097/NRL.0b013e31822aad04
10.1097/NRL.0b013e31822aad04
10.2147/NDT.S23721
10.2147/NDT.S23721
10.4061/2011/251517
10.4061/2011/251517
10.1186/1742-2094-8-92
10.1186/1742-2094-8-92
10.1074/jbc.M111.254268
10.1074/jbc.M111.254268
10.1007/s00401-011-0833-z
10.1007/s00401-011-0833-z
10.1038/cddis.2011.17
10.1038/cddis.2011.17
10.1111/j.1755-5949.2009.00113.x
10.1111/j.1755-5949.2009.00113.x
10.1093/cercor/bhr229
10.1093/cercor/bhr229
10.1016/j.pharmthera.2010.01.002
10.1016/j.pharmthera.2010.01.002
10.1186/1756-6606-4-31
10.1186/1756-6606-4-31
10.1254/jphs.10R04CP
10.1254/jphs.10R04CP
10.1155/2009/545263
10.1155/2009/545263
10.1016/j.pain.2010.05.031
10.1016/j.pain.2010.05.031
10.1016/j.jneuroim.2011.08.006
10.1016/j.jneuroim.2011.08.006
10.1186/1742-2094-2-24
10.1186/1742-2094-2-24
10.1073/pnas.0504197102
10.1073/pnas.0504197102
10.1038/ni1158
10.1038/ni1158
10.1038/ni1158
10.1038/ni1158
10.1016/0165-3806(90)90077-C
10.1016/0165-3806(90)90077-C
10.1016/j.bbi.2011.04.005
10.1016/j.bbi.2011.04.005
10.1002/ana.22550
10.1002/ana.22550
10.1007/BF00993271
10.1007/BF00993271
10.1172/JCI112765
10.1172/JCI112765
10.1016/0166-2236(93)90180-T
10.1016/0166-2236(93)90180-T
10.1097/00005072-199105000-00005
10.1097/00005072-199105000-00005
10.1016/0022-510X(94)90300-X
10.1016/0022-510X(94)90300-X
10.1016/0024-3205(90)90129-F
10.1016/0024-3205(90)90129-F
10.1002/ana.410370112
10.1002/ana.410370112
10.1016/j.jneuroim.2008.05.019
10.1016/j.jneuroim.2008.05.019
10.1016/j.jneuroim.2009.10.011
10.1016/j.jneuroim.2009.10.011
10.1073/pnas.0809479105
10.1073/pnas.0809479105
10.1016/S0304-3959(00)00490-5
10.1016/S0304-3959(00)00490-5
10.1016/S0304-3959(01)00359-1
10.1016/S0304-3959(01)00359-1
10.1016/j.pneurobio.2011.08.006
10.1016/j.pneurobio.2011.08.006
10.1523/JNEUROSCI.0323-08.2008
10.1523/JNEUROSCI.0323-08.2008
10.1038/emboj.2011.89
10.1038/emboj.2011.89
10.1523/JNEUROSCI.5589-07.2008
10.1523/JNEUROSCI.5589-07.2008
10.1016/j.pain.2005.01.002
10.1016/j.pain.2005.01.002
10.1186/1744-8069-5-28
10.1186/1744-8069-5-28
10.1016/j.brainresrev.2008.12.011
10.1016/j.brainresrev.2008.12.011
10.1186/1744-8069-7-57
10.1186/1744-8069-7-57
10.1186/1744-8069-7-42
10.1186/1744-8069-7-42
10.1016/S0304-3959(03)00261-6
10.1016/S0304-3959(03)00261-6
10.1016/j.bbi.2011.09.016
10.1016/j.bbi.2011.09.016
10.1152/jn.00593.2001
10.1152/jn.00593.2001
10.1073/pnas.91.9.3739
10.1073/pnas.91.9.3739
10.1016/S0166-2236(96)10058-8
10.1016/S0166-2236(96)10058-8
10.1046/j.1471-4159.1997.69041668.x
10.1046/j.1471-4159.1997.69041668.x
10.1254/jphs.FP0072181
10.1254/jphs.FP0072181
10.1016/j.jneuroim.2006.11.014
10.1016/j.jneuroim.2006.11.014
10.1152/physrev.00011.2010
10.1152/physrev.00011.2010
10.1038/nn1997
10.1038/nn1997
10.1016/0166-2236(96)81863-7
10.1016/0166-2236(96)81863-7
10.1002/neu.10220
10.1002/neu.10220
10.1016/S0165-3806(02)00613-2
10.1016/S0165-3806(02)00613-2
10.1002/mrdd.20102
10.1002/mrdd.20102
10.1161/STROKEAHA.109.549691
10.1161/STROKEAHA.109.549691
10.1084/jem.174.1.103
10.1084/jem.174.1.103
10.1097/00004647-200001000-00009
10.1097/00004647-200001000-00009
10.1038/sj.jcbfm.9600014
10.1038/sj.jcbfm.9600014
10.1038/nm1202-1363
10.1038/nm1202-1363
10.1159/000105478
10.1159/000105478
10.1038/sj.jcbfm.9600228
10.1038/sj.jcbfm.9600228
10.1111/j.1750-3639.2007.00092.x
10.1111/j.1750-3639.2007.00092.x
10.1111/j.1365-2990.2004.00622.x
10.1111/j.1365-2990.2004.00622.x
10.1038/jcbfm.2009.282
10.1038/jcbfm.2009.282
10.1161/STROKEAHA.111.632224
10.1161/STROKEAHA.111.632224
10.1016/S0889-1591(03)00032-1
10.1016/S0889-1591(03)00032-1
10.1016/j.bbi.2006.03.005
10.1016/j.bbi.2006.03.005
10.1016/j.bbi.2010.02.001
10.1016/j.bbi.2010.02.001
10.1016/j.neuropharm.2010.03.014
10.1016/j.neuropharm.2010.03.014
10.1073/pnas.0911515107
10.1073/pnas.0911515107
10.1523/JNEUROSCI.0450-11.2011
10.1523/JNEUROSCI.0450-11.2011
10.1016/S0006-8993(00)03026-2
10.1016/S0006-8993(00)03026-2
10.1002/jnr.20562
10.1002/jnr.20562
10.1084/jem.172.4.1025
10.1084/jem.172.4.1025
10.1038/nm1177
10.1038/nm1177
10.1016/j.nbd.2004.09.019
10.1016/j.nbd.2004.09.019
10.1093/brain/awf015
10.1093/brain/awf015
10.1038/nrn1195
10.1038/nrn1195
10.1002/glia.21266
10.1002/glia.21266
10.1084/jem.191.5.813
10.1084/jem.191.5.813
10.4049/jimmunol.0801485
10.4049/jimmunol.0801485
10.1038/nm1474
10.1038/nm1474
10.1124/mol.111.071290
10.1124/mol.111.071290
10.1523/JNEUROSCI.4371-06.2007
10.1523/JNEUROSCI.4371-06.2007
10.1084/jem.20051529
10.1084/jem.20051529
10.1038/nn.2432
10.1038/nn.2432
10.1038/nm1555
10.1038/nm1555
10.1523/JNEUROSCI.5360-06.2007
10.1523/JNEUROSCI.5360-06.2007
10.1038/sj.jcbfm.9600362
10.1038/sj.jcbfm.9600362
10.1186/1742-2094-9-27
10.1186/1742-2094-9-27
10.1371/journal.pbio.1000527
10.1371/journal.pbio.1000527
10.1523/JNEUROSCI.6394-11.2012
10.1523/JNEUROSCI.6394-11.2012
10.1189/jlb.0908517
10.1189/jlb.0908517
10.1093/hmg/ddm290
10.1093/hmg/ddm290
10.1007/s10048-007-0111-3
10.1007/s10048-007-0111-3
10.1096/fj.11-197194fj.11-197194
10.1096/fj.11-197194fj.11-197194
10.1002/eji.200323830
10.1002/eji.200323830
10.1016/j.jaci.2004.03.049
10.1016/j.jaci.2004.03.049
10.1074/jbc.M607277200
10.1074/jbc.M607277200
10.1016/j.neulet.2010.06.078
10.1016/j.neulet.2010.06.078
10.1073/pnas.0501634102
10.1073/pnas.0501634102
10.1016/j.cellimm.2011.05.001
10.1016/j.cellimm.2011.05.001
10.1007/s11302-009-9173-z
10.1007/s11302-009-9173-z
10.1038/359241a0
10.1038/359241a0
10.1002/jnr.22343
10.1002/jnr.22343
10.1002/jnr.22304
10.1002/jnr.22304
10.1159/000320556
10.1159/000320556
10.1159/000171029
10.1159/000171029
10.1002/1521-4141
10.1002/1521-4141
10.1016/j.bbrc.2008.04.055
10.1016/j.bbrc.2008.04.055
10.2174/138945012799201603
10.2174/138945012799201603
10.1186/1471-2172-9-29
10.1186/1471-2172-9-29
10.1016/0165-5728(92)90056-Q
10.1016/0165-5728(92)90056-Q
10.1016/0304-3940(84)90052-1
10.1016/0304-3940(84)90052-1
10.1002/glia.1107
10.1002/glia.1107
10.4049/jimmunol.1000991
10.4049/jimmunol.1000991
10.1186/1742-2094-8-25
10.1186/1742-2094-8-25
10.1177/1073858409360822
10.1177/1073858409360822
10.1007/s10787-011-0108-2
10.1007/s10787-011-0108-2
10.1016/j.ejphar.2011.10.001
10.1016/j.ejphar.2011.10.001
10.1523/JNEUROSCI.4652-05.2006
10.1523/JNEUROSCI.4652-05.2006
10.1124/pr.58.3.2
10.1124/pr.58.3.2
10.1016/S0005-2760(97)00132-X
10.1016/S0005-2760(97)00132-X
10.1016/S0005-2760(97)00009-X
10.1016/S0005-2760(97)00009-X
10.1016/S0169-328X(00)00290-4
10.1016/S0169-328X(00)00290-4
10.1074/jbc.M306642200
10.1074/jbc.M306642200
10.1084/jem.100.5.425
10.1084/jem.100.5.425
10.1021/ja01577a066
10.1021/ja01577a066
10.1016/0014-2999(96)00015-5
10.1016/0014-2999(96)00015-5
10.1038/28393
10.1038/28393
10.1046/j.1528-1157.2001.41499.x
10.1046/j.1528-1157.2001.41499.x
10.1016/j.biochi.2010.01.006
10.1016/j.biochi.2010.01.006
10.1016/j.neuropharm.2007.05.015
10.1016/j.neuropharm.2007.05.015
10.1073/pnas.92.8.3376
10.1073/pnas.92.8.3376
10.1016/j.vetimm.2009.06.011
10.1016/j.vetimm.2009.06.011
10.1046/j.1471-4159.1997.69020753.x
10.1046/j.1471-4159.1997.69020753.x
10.1046/j.1471-4159.2003.02244.x
10.1046/j.1471-4159.2003.02244.x
10.1161/01.STR.0000023491.63693.18
10.1161/01.STR.0000023491.63693.18
10.1371/journal.pone.0027257
10.1371/journal.pone.0027257
10.1096/fj.00-0399fje
10.1096/fj.00-0399fje
10.1038/sj.bjp.0704466
10.1038/sj.bjp.0704466
10.1016/S0304-3959(98)00041-4
10.1016/S0304-3959(98)00041-4
10.1016/S0014-2999(01)00988-8
10.1016/S0014-2999(01)00988-8
10.1038/sj.bjp.0704900
10.1038/sj.bjp.0704900
10.1016/j.ejphar.2009.04.022
10.1016/j.ejphar.2009.04.022
10.1186/1744-8069-7-3
10.1186/1744-8069-7-3
10.1016/S0024-3205(03)00651-9
10.1016/S0024-3205(03)00651-9
10.1016/j.pain.2008.06.003
10.1016/j.pain.2008.06.003
10.1016/j.nbd.2008.09.015
10.1016/j.nbd.2008.09.015
10.1016/j.bbi.2011.02.006
10.1016/j.bbi.2011.02.006
10.1124/jpet.108.136903
10.1124/jpet.108.136903
10.1046/j.1471-4159.1996.66031157.x
10.1046/j.1471-4159.1996.66031157.x
10.1073/pnas.93.9.3984
10.1073/pnas.93.9.3984
10.1038/npp.2012.25
10.1038/npp.2012.25
10.1186/1742-2094-9-21
10.1186/1742-2094-9-21
10.1124/mol.104.006353
10.1124/mol.104.006353
10.1111/j.1365-2826.2011.02152.x
10.1111/j.1365-2826.2011.02152.x
10.1111/j.1582-4934.2011.01267.x
10.1111/j.1582-4934.2011.01267.x
10.1124/jpet.107.123265
10.1124/jpet.107.123265
10.1016/j.ejphar.2011.11.034
10.1016/j.ejphar.2011.11.034
10.1038/sj.bjp.0704732
10.1038/sj.bjp.0704732
10.1016/S0014-5793(01)02934-9
10.1016/S0014-5793(01)02934-9
10.1523/JNEUROSCI.1771-06.2006
10.1523/JNEUROSCI.1771-06.2006
10.1038/384083a0
10.1038/384083a0
10.1074/jbc.M106261200
10.1074/jbc.M106261200
10.1073/pnas.0907417106
10.1073/pnas.0907417106
10.1016/j.bmcl.2009.11.134
10.1016/j.bmcl.2009.11.134
10.1016/j.bmc.2012.03.065
10.1016/j.bmc.2012.03.065
10.1038/nrn3053
10.1038/nrn3053
10.1111/j.1398-9995.2010.02350.x
10.1111/j.1398-9995.2010.02350.x
10.2174/187152711799219307
10.2174/187152711799219307
10.1136/acupmed-2011-010119
10.1136/acupmed-2011-010119
10.2174/1876386301205010012
10.2174/1876386301205010012",<Element 'PubmedArticle' at 0x7f05db27a860>
491,"23043675
22040146
21551239
11156943
18096503
21813022
11329626
21256197
17700715
12967941
9512456
12136125
21501147
12509806
14511339
19616342
21864979
11011050
20147530
21309057
21198549
15973410
16331291
20153076
21700474
21952131
20649561
19502530
20554481
21659471
8660583
19029917
19635411
21406188
14753451
10868955
20649560
7605349
16914119
20534007
20191092
22021672
21564082
22284189
11586361
15729296
16364651
21511917
7507507
17011047
18393970
16611855
17876302
21418147
21600985
10734163
18722389
15894565
16732431
21470205
17196262
17143303
21049984
21543155
18534982",The monoacylglycerol lipase inhibitor JZL184 attenuates LPS-induced increases in cytokine expression in the rat frontal cortex and plasma: differential mechanisms of action.,"JZL184 is a selective inhibitor of monoacylglycerol lipase (MAGL), the enzyme that preferentially catabolizes the endocannabinoid 2-arachidonoyl glycerol (2-AG). Here, we have studied the effects of JZL184 on inflammatory cytokines in the brain and plasma following an acute immune challenge and the underlying receptor and molecular mechanisms involved.
JZL184 and/or the CB₁ receptor antagonist, AM251 or the CB₂ receptor antagonist, AM630 were administered to rats 30 min before lipopolysaccharide (LPS). 2 h later cytokine expression and levels, MAGL activity, 2-AG, arachidonic acid and prostaglandin levels were measured in the frontal cortex, plasma and spleen.
JZL184 attenuated LPS-induced increases in IL-1β, IL-6, TNF-α and IL-10 but not the expression of the inhibitor of NFkB (IκBα) in rat frontal cortex. AM251 attenuated JZL184-induced decreases in frontal cortical IL-1β expression. Although arachidonic acid levels in the frontal cortex were reduced in JZL184-treated rats, MAGL activity, 2-AG, PGE₂ and PGD₂ were unchanged. In comparison, MAGL activity was inhibited and 2-AG levels enhanced in the spleen following JZL184. In plasma, LPS-induced increases in TNF-α and IL-10 levels were attenuated by JZL184, an effect partially blocked by AM251. In addition, AM630 blocked LPS-induced increases in plasma IL-1β in the presence, but not absence, of JZL184.
Inhibition of peripheral MAGL in rats by JZL184 suppressed LPS-induced circulating cytokines that in turn may modulate central cytokine expression. The data provide further evidence for the endocannabinoid system as a therapeutic target in treatment of central and peripheral inflammatory disorders.",[],British journal of pharmacology,2012-10-10,"[{'lastname': 'Kerr', 'firstname': 'D M', 'initials': 'DM', 'affiliation': 'Physiology, School of Medicine, National University of Ireland, Galway, Ireland.'}, {'lastname': 'Harhen', 'firstname': 'B', 'initials': 'B', 'affiliation': None}, {'lastname': 'Okine', 'firstname': 'B N', 'initials': 'BN', 'affiliation': None}, {'lastname': 'Egan', 'firstname': 'L J', 'initials': 'LJ', 'affiliation': None}, {'lastname': 'Finn', 'firstname': 'D P', 'initials': 'DP', 'affiliation': None}, {'lastname': 'Roche', 'firstname': 'M', 'initials': 'M', 'affiliation': None}]",,,,© 2012 The Authors. British Journal of Pharmacology © 2012 The British Pharmacological Society.,10.1111/j.1476-5381.2012.02237.x,<Element 'PubmedArticle' at 0x7f05db20bdb0>
492,22966132,"Neuroactive steroids, their metabolites, and neuroinflammation.","Neuroinflammation represents a common feature of many neurodegenerative diseases implicated both in their onset and progression. Neuroactive steroids act as physiological regulators and protective agents in the nervous system. Therefore, the attention of biomedical research has been recently addressed in evaluating whether neuroactive steroids, such as progestagens, androgens, and estrogens may also affect neuroinflammatory pathways. Observations so far obtained suggest a general anti-inflammatory effect with a beneficial relapse on several neurodegenerative experimental models, thus confirming the potentiality of a neuroprotective strategy based on neuroactive steroids. In this scenario, neuroactive steroid metabolism and the sophisticated machinery involved in their signaling are becoming especially attractive. In particular, because metabolism of neuroactive steroids as well as expression of their receptors is affected during the course of neurodegenerative events, a crucial role of progesterone and testosterone metabolites in modulating neuroinflammation and neurodegeneration may be proposed. In the present review, we will address this issue, providing evidence supporting the hypothesis that the efficacy of neuroactive steroids could be improved through the use of their metabolites.",[],Journal of molecular endocrinology,2012-09-12,"[{'lastname': 'Giatti', 'firstname': 'Silvia', 'initials': 'S', 'affiliation': 'Dipartimento di Scienze Farmacologiche e Biomolecolari, Center of Excellence on Neurodegenerative Diseases, Università degli Studi di Milano, Milano, Italy.'}, {'lastname': 'Boraso', 'firstname': 'Mariaserena', 'initials': 'M', 'affiliation': None}, {'lastname': 'Melcangi', 'firstname': 'Roberto Cosimo', 'initials': 'RC', 'affiliation': None}, {'lastname': 'Viviani', 'firstname': 'Barbara', 'initials': 'B', 'affiliation': None}]",,,,,10.1530/JME-12-0127,<Element 'PubmedArticle' at 0x7f05db1bf220>
493,"22947340
8857952
8610387
21427390
21473750
12682146
9003603
19752224
21777830
12486250
11994020
20195147
17431778
22257833
8892876
19367559
6246178
6307573
9708763
199755
9817887
1357442
15308099",CMV-associated encephalitis and antineuronal autoantibodies--a case report.,"Human cytomegalovirus (CMV) is an ubiquitous pathogen capable of modulating the host immune system. Immune dysfunction is common during CMV infection and includes autoimmune phenomena. Here we focus on a case of primary CMV infection associated with encephalopathy in a patient with a rudimentary spleen. We discuss diagnostic challenges and immunological aspects as well as the hypothesis that CMV may break tolerance and induce potentially encephalitogenic autoantibodies.
A 33-year-old woman was admitted with features of encephalitis, rapidly progressing into a catatonic state. The patient tested negative for presence of herpes simplex virus DNA in cerebrospinal fluid (CSF), and had elevated liver enzymes and hepatomegaly at computed tomography scan (CT) examination. CT scan and magnetic resonance imaging (MRI) showed only a rudimentary spleen. Initially, serum was negative for anti-CMV IgM, but borderline for anti-CMV IgG by enzyme-linked immunosorbent assay. However, a more sensitive assay resulted in a positive specific IgM Western blot profile and low IgG avidity, suggesting primary CMV infection. Further, CMV DNA was retrospectively detected in a CSF sample collected at admission. We also detected antineuronal autoantibodies, which stained GAD-positive neurons in the hippocampus. The patient was treated by a combination of prednisone, intravenous immunoglobulins (IVIg) and antivirals, which resulted in a dramatic amelioration of the patient's neurological status. One year after admission the patient exhibited a nearly complete recovery with mild deficits in attention and memory.
A possible reason for the critical course of CMV infection could be the lack of a functional spleen in this patient, a condition previously associated with severe CMV infection. Prompt treatment with antiviral drugs, steroids and IVIg was most likely important for the positive outcome in this case and should be considered for similar cases of severe primary CMV infection associated with immunopathological phenomena.",[],BMC neurology,2012-09-06,"[{'lastname': 'Xu', 'firstname': 'Xinling', 'initials': 'X', 'affiliation': 'Department of Medicine, Karolinska Institutet, Stockholm, Sweden.'}, {'lastname': 'Bergman', 'firstname': 'Peter', 'initials': 'P', 'affiliation': None}, {'lastname': 'Willows', 'firstname': 'Thomas', 'initials': 'T', 'affiliation': None}, {'lastname': 'Tammik', 'firstname': 'Charlotte', 'initials': 'C', 'affiliation': None}, {'lastname': 'Sund', 'firstname': 'Marie', 'initials': 'M', 'affiliation': None}, {'lastname': 'Hökfelt', 'firstname': 'Tomas', 'initials': 'T', 'affiliation': None}, {'lastname': 'Söderberg-Naucler', 'firstname': 'Cecilia', 'initials': 'C', 'affiliation': None}, {'lastname': 'Varani', 'firstname': 'Stefania', 'initials': 'S', 'affiliation': None}]",,,,,"10.1186/1471-2377-12-87
10.1046/j.1365-2141.1996.7592380.x
10.1097/00007890-199602270-00014
10.1093/cid/cir074
10.1186/2042-4280-2-6
10.1128/JCM.41.4.1565-1568.2003
10.4049/jimmunol.0803688
10.1016/S1474-4422(11)70096-5
10.1073/pnas.222658699
10.2165/00023210-200216050-00003
10.1007/s10620-006-9712-1
10.1016/j.jcv.2011.12.028
10.1002/rmv.609
10.1016/0090-1229(83)90187-3
10.1016/j.immuni.2004.07.011",<Element 'PubmedArticle' at 0x7f05db1c5bd0>
494,22771318,Shilajit attenuates behavioral symptoms of chronic fatigue syndrome by modulating the hypothalamic-pituitary-adrenal axis and mitochondrial bioenergetics in rats.,"Shilajit has been used as a rejuvenator for ages in Indian ancient traditional medicine and has been validated for a number of pharmacological activities.
The effect of processed shilajit which was standardized to dibenzo-α-pyrones (DBPs;0.43% w/w), DBP-chromoproteins (DCPs; 20.45% w/w) and fulvic acids (56.75% w/w) was evaluated in a rat model of chronic fatigue syndrome (CFS). The mitochondrial bioenergetics and the activity of hypothalamus-pituitary-adrenal (HPA) axis were evaluated for the plausible mechanism of action of shilajit.
CFS was induced by forcing the rats to swim for 15mins for 21 consecutive days. The rats were treated with shilajit (25, 50 and 100mg/kg) for 21 days before exposure to stress procedure. The behavioral consequence of CFS was measured in terms of immobility and the climbing period. The post-CFS anxiety level was assessed by elevated plus maze (EPM) test. Plasma corticosterone and adrenal gland weight were estimated as indices of HPA axis activity. Analysis of mitochondrial complex chain enzymes (Complex I, II, IV and V) and mitochondrial membrane potential (MMP) in prefrontal cortex (PFC) were performed to evaluate the mitochondrial bioenergetics and integrity respectively.
Shilajit reversed the CFS-induced increase in immobility period and decrease in climbing behavior as well as attenuated anxiety in the EPM test. Shilajit reversed CFS-induced decrease in plasma corticosterone level and loss of adrenal gland weight indicating modulation of HPA axis. Shilajit prevented CFS-induced mitochondrial dysfunction by stabilizing the complex enzyme activities and the loss of MMP. Shilajit reversed CFS-induced mitochondrial oxidative stress in terms of NO concentration and, LPO, SOD and catalase activities.
The results indicate that shilajit mitigates the effects of CFS in this model possibly through the modulation of HPA axis and preservation of mitochondrial function and integrity. The reversal of CFS-induced behavioral symptoms and mitochondrial bioenergetics by shilajit indicates mitochondria as a potential target for treatment of CFS.",[],Journal of ethnopharmacology,2012-07-10,"[{'lastname': 'Surapaneni', 'firstname': 'Dinesh Kumar', 'initials': 'DK', 'affiliation': 'Neurotherapeutics Lab, Department of Pharmaceutics, Indian Institute of Technology (Banaras Hindu University), Varanasi 221005 U.P., India.'}, {'lastname': 'Adapa', 'firstname': 'Sree Rama Shiva Shanker', 'initials': 'SR', 'affiliation': None}, {'lastname': 'Preeti', 'firstname': 'Kumari', 'initials': 'K', 'affiliation': None}, {'lastname': 'Teja', 'firstname': 'Gangineni Ravi', 'initials': 'GR', 'affiliation': None}, {'lastname': 'Veeraragavan', 'firstname': 'Muruganandam', 'initials': 'M', 'affiliation': None}, {'lastname': 'Krishnamurthy', 'firstname': 'Sairam', 'initials': 'S', 'affiliation': None}]",,The results indicate that shilajit mitigates the effects of CFS in this model possibly through the modulation of HPA axis and preservation of mitochondrial function and integrity. The reversal of CFS-induced behavioral symptoms and mitochondrial bioenergetics by shilajit indicates mitochondria as a potential target for treatment of CFS.,"Shilajit reversed the CFS-induced increase in immobility period and decrease in climbing behavior as well as attenuated anxiety in the EPM test. Shilajit reversed CFS-induced decrease in plasma corticosterone level and loss of adrenal gland weight indicating modulation of HPA axis. Shilajit prevented CFS-induced mitochondrial dysfunction by stabilizing the complex enzyme activities and the loss of MMP. Shilajit reversed CFS-induced mitochondrial oxidative stress in terms of NO concentration and, LPO, SOD and catalase activities.",Copyright © 2012 Elsevier Ireland Ltd. All rights reserved.,10.1016/j.jep.2012.06.002,<Element 'PubmedArticle' at 0x7f05db1dc270>
495,22765923,Updating the mild encephalitis hypothesis of schizophrenia.,"Schizophrenia seems to be a heterogeneous disorder. Emerging evidence indicates that low level neuroinflammation (LLNI) may not occur infrequently. Many infectious agents with low overall pathogenicity are risk factors for psychoses including schizophrenia and for autoimmune disorders. According to the mild encephalitis (ME) hypothesis, LLNI represents the core pathogenetic mechanism in a schizophrenia subgroup that has syndromal overlap with other psychiatric disorders. ME may be triggered by infections, autoimmunity, toxicity, or trauma. A 'late hit' and gene-environment interaction are required to explain major findings about schizophrenia, and both aspects would be consistent with the ME hypothesis. Schizophrenia risk genes stay rather constant within populations despite a resulting low number of progeny; this may result from advantages associated with risk genes, e.g., an improved immune response, which may act protectively within changing environments, although they are associated with the disadvantage of increased susceptibility to psychotic disorders. Specific schizophrenic symptoms may arise with instances of LLNI when certain brain functional systems are involved, in addition to being shaped by pre-existing liability factors. Prodrome phase and the transition to a diseased status may be related to LLNI processes emerging and varying over time. The variability in the course of schizophrenia resembles the varying courses of autoimmune disorders, which result from three required factors: genes, the environment, and the immune system. Preliminary criteria for subgrouping neurodevelopmental, genetic, ME, and other types of schizophrenias are provided. A rare example of ME schizophrenia may be observed in Borna disease virus infection. Neurodevelopmental schizophrenia due to early infections has been estimated by others to explain approximately 30% of cases, but the underlying pathomechanisms of transition to disease remain in question. LLNI (e.g. from reactivation related to persistent infection) may be involved and other pathomechanisms including dysfunction of the blood-brain barrier or the blood-CSF barrier, CNS-endogenous immunity and the volume transmission mode balancing wiring transmission (the latter represented mainly by synaptic transmission, which is often described as being disturbed in schizophrenia). Volume transmission is linked to CSF signaling; and together could represent a common pathogenetic link for the distributed brain dysfunction, dysconnectivity, and brain structural abnormalities observed in schizophrenia. In addition, CSF signaling may extend into peripheral tissues via the CSF outflow pathway along brain nerves and peripheral nerves, and it may explain the peripheral topology of neuronal dysfunctions found, like in olfactory dysfunction, dysautonomia, and even in peripheral tissues, i.e., the muscle lesions that were found in 50% of cases. Modulating factors in schizophrenia, such as stress, hormones, and diet, are also modulating factors in the immune response. Considering recent investigations of CSF, the ME schizophrenia subgroup may constitute approximately 40% of cases.",[],Progress in neuro-psychopharmacology & biological psychiatry,2012-07-07,"[{'lastname': 'Bechter', 'firstname': 'K', 'initials': 'K', 'affiliation': 'Ulm University, Clinic for Psychiatry and Psychotherapy II, Ludwig-Heilmeyer-Str. 2, D-89312 Günzburg, Germany. Karl.Bechter@bkh-guenzburg.de'}]",,,,Copyright © 2012 Elsevier Inc. All rights reserved.,10.1016/j.pnpbp.2012.06.019,<Element 'PubmedArticle' at 0x7f05db16be00>
496,"22659246
19482216
11861600
2354853
2783450
17322387
18523311
15546910
15145616
19064876
18573821
20086025
17657668
12137800
16083972
11381138
14966571
20621641
22455832
9844099
21555578
10084932
21039734
17976745
21615563
9682040
11459810
10537116
11371357
19676075
15033880
21335982
11353685
12667647
16567656
17911392",Dynamic development of glucocorticoid resistance during autoimmune neuroinflammation.,"Glucocorticoids (GC) are powerful endogenous and therapeutic modulators of inflammation and play a critical role for controlling autoimmunity. GC resistance can be seen in patients with cell-mediated autoimmune disorders, but it is unknown whether this represents a stable trait or a state.
The objective of the study was to determine whether GC resistance of T cell responses is dynamically regulated in experimental autoimmune encephalomyelitis (EAE) and multiple sclerosis (MS).
This was a translational observational study. PATIENTS AND ANIMALS: EAE was induced in C57BL/6 mice. A cross-sectional sample of 25 patients with relapsing-remitting MS was included as well as four MS patients during pregnancy and postpartum.
Outcome measures included GC sensitivity of T cell proliferation and GC-mediated apoptosis.
GC resistance was seen in both autoantigen-specific and nonspecific responses of T cells obtained from mice with EAE. GC resistance preceded clinical symptoms and central nervous system infiltration of immune cells. T cells obtained during EAE were resistant to GC-induced apoptosis, and this was linked to down-regulation of GC receptor-α expression. GC resistance in T cells was also seen in MS patients with radiological evidence for ongoing inflammation. GC resistance was absent in the MS patients during pregnancy, when relapse risk is decreased, but recurred postpartum, a time of increased relapse risk.
These data demonstrate that GC resistance during autoimmune neuroinflammation is dynamically regulated. This has implications for the timing of steroid treatments and provides a putative pathway to explain the observed association between psychological stress and exacerbation of autoimmune diseases.",[],The Journal of clinical endocrinology and metabolism,2012-06-05,"[{'lastname': 'Gold', 'firstname': 'Stefan M', 'initials': 'SM', 'affiliation': 'Center for Molecular Neurobiology, University Hospital Hamburg-Eppendorf, Falkenried 94, D-20251 Hamburg, Germany. stefan.gold@zmnh.uni-hamburg.de'}, {'lastname': 'Sasidhar', 'firstname': 'Manda V', 'initials': 'MV', 'affiliation': None}, {'lastname': 'Lagishetty', 'firstname': 'Venu', 'initials': 'V', 'affiliation': None}, {'lastname': 'Spence', 'firstname': 'Rory D', 'initials': 'RD', 'affiliation': None}, {'lastname': 'Umeda', 'firstname': 'Elizabeth', 'initials': 'E', 'affiliation': None}, {'lastname': 'Ziehn', 'firstname': 'Marina O', 'initials': 'MO', 'affiliation': None}, {'lastname': 'Krieger', 'firstname': 'Thorsten', 'initials': 'T', 'affiliation': None}, {'lastname': 'Schulz', 'firstname': 'Karl-Heinz', 'initials': 'KH', 'affiliation': None}, {'lastname': 'Heesen', 'firstname': 'Christoph', 'initials': 'C', 'affiliation': None}, {'lastname': 'Hewison', 'firstname': 'Martin', 'initials': 'M', 'affiliation': None}, {'lastname': 'Voskuhl', 'firstname': 'Rhonda R', 'initials': 'RR', 'affiliation': None}]",,,"GC resistance was seen in both autoantigen-specific and nonspecific responses of T cells obtained from mice with EAE. GC resistance preceded clinical symptoms and central nervous system infiltration of immune cells. T cells obtained during EAE were resistant to GC-induced apoptosis, and this was linked to down-regulation of GC receptor-α expression. GC resistance in T cells was also seen in MS patients with radiological evidence for ongoing inflammation. GC resistance was absent in the MS patients during pregnancy, when relapse risk is decreased, but recurred postpartum, a time of increased relapse risk.",,"10.1210/jc.2012-1294
10.1016/j.psyneuen.2012.03.001",<Element 'PubmedArticle' at 0x7f05db1734a0>
497,22656125,"Melatonin attenuated mediators of neuroinflammation and alpha-7 nicotinic acetylcholine receptor mRNA expression in lipopolysaccharide (LPS) stimulated rat astrocytoma cells, C6.","Melatonin has been known to affect a variety of astrocytes functions in many neurological disorders but its mechanism of action on neuroinflammatory cascade and alpha-7 nicotinic acetylcholine receptor (α7-nAChR) expression are still not properly understood. Present study demonstrated that treatment of C6 cells with melatonin for 24 hours significantly decreased lipopolysaccharide (LPS) induced nitrative and oxidative stress, expressions of cyclooxigenase-2 (COX-2), inducible nitric-oxide synthase (iNOS) and glial fibrillary acidic protein (GFAP). Melatonin also modulated LPS-induced mRNA expressions of α7-nAChR and inflammatory cytokine genes. Furthermore, melatonin reversed LPS-induced changes in C/EBP homologous protein 10 (CHOP), microsomal prostaglandin E synthase-1(mPGES-1) and phosphorylated p38 mitogen activated protein kinase (P-p38). Treatment with pyrrolidine dithiocarbamate (PDTC) inhibited α7-nAChR mRNA expression in LPS-induced C6 cells. Our findings explored anti-neuroinflammatory action of melatonin, which may suggests its beneficial roles in the neuroinflammation associated disorders.",[],Free radical research,2012-06-05,"[{'lastname': 'Niranjan', 'firstname': 'Rituraj', 'initials': 'R', 'affiliation': 'Division of Pharmacology, CSIR-Central Drug Research Institute, Lucknow, India.'}, {'lastname': 'Nath', 'firstname': 'Chandishwar', 'initials': 'C', 'affiliation': None}, {'lastname': 'Shukla', 'firstname': 'Rakesh', 'initials': 'R', 'affiliation': None}]",,,,,10.3109/10715762.2012.697626,<Element 'PubmedArticle' at 0x7f05db18cd10>
498,22647865,A life-threatening central nervous system-tuberculosis inflammatory reaction nonresponsive to corticosteroids and successfully controlled by infliximab in a young patient with a variant of juvenile idiopathic arthritis.,"We report a young patient with a variant of juvenile idiopathic arthritis, who, after 4 years of infliximab treatment, developed miliary tuberculosis (TB) with central nervous system involvement (meningitis and multiple tuberculomas). After anti-TB treatment, clinical and radiologic responses were observed, but severe cerebrospinal fluid and brain inflammatory reaction, nonresponsive to corticosteroids, persisted. It was considered a life-threatening paradoxical reaction based on initial cerebrospinal fluid isolation of Mycobacterium tuberculosis fully sensitive to primary anti-TB drugs. After 4 months in the hospital, infliximab was administered considering that infliximab is a potent tumor necrosis factor α inhibiting agent that participates in the formation and preservation of granulomas and may help to modulate the exaggerated cell-mediated immune response against mycobacterial antigens. Clinical complications associated to brain inflammation resolved, and after 3 years of follow-up, the patient remains self-sufficient without neurologic sequels.",[],Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases,2012-06-01,"[{'lastname': 'Jorge', 'firstname': 'Jaimes-Hernández', 'initials': 'JH', 'affiliation': 'Rheumatology Department, Centro Médico ISSEMYM, Toluca, México. jorjaimes@yahoo.com'}, {'lastname': 'Graciela', 'firstname': 'Cárdenas', 'initials': 'C', 'affiliation': None}, {'lastname': 'Pablo', 'firstname': 'Aranda-Pereira', 'initials': 'AP', 'affiliation': None}, {'lastname': 'Luis', 'firstname': 'Soto-Hernández José', 'initials': 'SH', 'affiliation': None}]",,,,,10.1097/RHU.0b013e318258b725,<Element 'PubmedArticle' at 0x7f05db19a450>
499,22507884,Treatment of γ-aminobutyric acid B receptor-antibody autoimmune encephalitis with oral corticosteroids.,"Autoimmune encephalitis is increasingly identified as a cause of nonviral, idiopathic encephalitis. Present treatment algorithms recommend costly immune-modulating treatments and do not identify a role for oral corticosteroids.
To present a patient with γ-aminobutyric acid(B) receptor-antibody encephalitis before and after treatment with oral corticosteroids.
Case report.
The inpatient course as well as outpatient follow-up is discussed.
A 43-year-old man with initial presentation of seizures and altered mental status.
Our patient was treated with an extended course of oral corticosteroids as an outpatient.
After treatment with oral corticosteroids, our patient had steady clinical improvement, achieved seizure freedom, and experienced improved mental status to within normal limits.
This case supports the use of low-cost oral corticosteroids in treating patients with γ-aminobutyric acid(B) receptor-antibody encephalitis.",[],Archives of neurology,2012-04-18,"[{'lastname': 'Goldenholz', 'firstname': 'Daniel M', 'initials': 'DM', 'affiliation': 'Department of Neurology, University of California, Davis Medical Center, Sacramento, 95817, USA. daniel.goldenholz@ucdmc.ucdavis.edu'}, {'lastname': 'Wong', 'firstname': 'Victoria S S', 'initials': 'VS', 'affiliation': None}, {'lastname': 'Bateman', 'firstname': 'Lisa M', 'initials': 'LM', 'affiliation': None}, {'lastname': 'Apperson', 'firstname': 'Michelle', 'initials': 'M', 'affiliation': None}, {'lastname': 'Oskarsson', 'firstname': 'Bjorn', 'initials': 'B', 'affiliation': None}, {'lastname': 'Akhtar', 'firstname': 'Shahrzad', 'initials': 'S', 'affiliation': None}, {'lastname': 'Wheelock', 'firstname': 'Vicki', 'initials': 'V', 'affiliation': None}]",,,"After treatment with oral corticosteroids, our patient had steady clinical improvement, achieved seizure freedom, and experienced improved mental status to within normal limits.",,10.1001/archneurol.2012.197,<Element 'PubmedArticle' at 0x7f05db1236d0>
